Datasets:

indsigt-ai

/

region_hovedstaden_text

like 0

Follow

indsigt.ai 2

Rigshospitalet_¥jensygdomme (HOC)_Præoperativ desinfektion af ¢je og ¢jenomgivelser.

Præoperativ desinfektion af øje og øjenomgivelser Målgrupper og anvendelsesområde Angiver retninglinjer for fremgangsmåde ved desinfektion af operationsfelt ved øjenoperation. Gældende for Afdeling for Øjensygdomme, Rigshospitalet. Definitioner Ingen Fremgangsmåde Forud for enhver øjenoperation desinficeres øje og øjenomgivelser på en af følgende måder, medmindre andet er ordineret, eller der foreligger kontraindikationer for eksempel: allergi, perforation eller ved infektion, hvor desinficerende midler vil sløre resultatet fra en prøve. Afrensning med Povidone iodid på konjunktiva og klorhexidin periorbitalt: - Make-up og andre urenheder fjernes - Øjet dryppes med dråber - Oxybuprocain 0,4 % - Øjet dryppes med minimum 5 dråber Povidone-jodid 5% - Cilierne renses med en non-Woven vatpid gennemvædet med Povidone-jodid 5% - Øjenomgivelser desinficeres med Klorhexidinsprit 0,5 % på ren gaze-tampon helt ned til cilierækken - Gentag punkt 3, 4 og 5 yderligere én gang Afrensning udelukkende med Povidone iodid: - Make-up og andre urenheder fjernes - Øjet dryppes med dråber - Oxybuprocain 0,4 % - Øjet dryppes med dråber - Betadine 5 %, evt. Povidone-iodine 5 % - Cilierne renses med en non-Woven vatpid vædet med dråber - Betadine 5 %, evt. Povidone-iodine 5 % - Gentag punkt 2,3 og 4 yderligere én gang Afrensning af øje udelukkende med klorhexidin: - Evt. make-up og andre urenheder fjernes - Øjet dryppes med Oxybuprokain 0,4 % - Øjet dryppes rigeligt med klorhexidin i vandig opløsning 0,05% = 0,5 mg/ml - Øjenomgivelser desinficeres med klorhexidinsprit 0,5% = 5 mg/ml på ren gaze-tampon med øjet lukket og der tørres hen over cilierne for at fjerne evt. cilieurenheder. - Punkt 4 gentages yderligere én gang - Inden operationen går i gang, skylles øjets overflade med skyllevæske Ansvar og organisering Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger. Afsnitsledende overlæger, afdelingssygeplejersker og ledende lægesekretærer, er ansvarlige for at instruksen udarbejdes, revideres og implementeres. Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen. Referencer, lovgivning og faglig evidens samt links hertil Bilag

<h1><div id="Afsnit#1699579029853">Præoperativ desinfektion af øje og øjenomgivelser</div></h1><div id="BodyWeb#1699579029853"><p>&nbsp;</p> <div class="collapsible-item" expandedstart="1"><a name="1699579029853Maalgrupper"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Målgrupper og anvendelsesområde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>Angiver retninglinjer for fremgangsmåde ved desinfektion af operationsfelt ved øjenoperation.</p> <p>Gældende for Afdeling for Øjensygdomme, Rigshospitalet.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579029853Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579029853Definitioner"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Definitioner</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>Ingen</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579029853Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579029853Fremgangsmaade"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Fremgangsmåde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm"><span style="background-color:white"><span style="color:#222222">Forud for enhver øjenoperation desinficeres øje og øjenomgivelser på en af følgende måder, medmindre andet er ordineret, eller der foreligger kontraindikationer for eksempel: allergi, perforation eller ved infektion, hvor desinficerende midler vil sløre resultatet fra en prøve.</span></span></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="background-color:white"><span style="color:#222222">Afrensning med Povidone iodid på konjunktiva og klorhexidin periorbitalt:</span></span></strong></p> <ol> <li><span style="background-color:white"><span style="color:#222222">Make-up og andre urenheder fjernes</span></span></li> <li><span style="background-color:white"><span style="color:#222222">Øjet dryppes med dråber - Oxybuprocain 0,4 %</span></span></li> <li><span style="background-color:white"><span style="color:#222222">Øjet dryppes med minimum 5 dråber&nbsp;Povidone-jodid 5%</span></span></li> <li><span style="background-color:white"><span style="color:#222222">Cilierne renses med en non-Woven vatpid gennemvædet med Povidone-jodid 5%</span></span></li> <li><span style="background-color:white"><span style="color:#222222">Øjenomgivelser desinficeres med Klorhexidinsprit 0,5 % på ren gaze-tampon helt ned til cilierækken</span></span></li> <li><span style="background-color:white"><span style="color:#222222">Gentag punkt 3, 4 og 5 yderligere én gang</span></span></li> </ol> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="background-color:white"><span style="color:#222222">Afrensning udelukkende med Povidone iodid:</span></span></strong></p> <ol> <li><span style="background-color:white"><span style="color:#222222">Make-up og andre urenheder fjernes</span></span></li> <li><span style="background-color:white"><span style="color:#222222">Øjet dryppes med dråber - Oxybuprocain 0,4 %</span></span></li> <li><span style="background-color:white"><span style="color:#222222">Øjet dryppes med dråber - Betadine 5 %, evt. Povidone-iodine 5 % </span></span></li> <li><span style="background-color:white"><span style="color:#222222">Cilierne renses med en non-Woven vatpid vædet med dråber - Betadine 5 %, evt. Povidone-iodine 5 % </span></span></li> <li><span style="background-color:white"><span style="color:#222222">Gentag punkt 2,3 og 4 yderligere én gang</span></span></li> </ol> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="background-color:white"><span style="color:#222222">Afrensning af øje udelukkende med klorhexidin:</span></span></strong></p> <ol> <li><span style="background-color:white"><span style="color:#222222">Evt. make-up og andre urenheder fjernes</span></span></li> <li><span style="background-color:white"><span style="color:#222222">Øjet dryppes med Oxybuprokain 0,4 %</span></span></li> <li><span style="background-color:white"><span style="color:#222222">Øjet dryppes rigeligt med klorhexidin i vandig opløsning </span></span><span style="background-color:white"><span style="color:black">0,05% = 0,5 mg/ml</span></span></li> <li><span style="background-color:white"><span style="color:#222222">Øjenomgivelser desinficeres med </span></span><span style="background-color:white"><span style="color:black">klorhexidinsprit 0,5% = 5 mg/ml </span></span><span style="background-color:white"><span style="color:#222222">på ren gaze-tampon med øjet lukket og der tørres hen over cilierne for at fjerne evt. cilieurenheder.</span></span></li> <li><span style="background-color:white"><span style="color:#222222">Punkt 4 gentages yderligere én gang</span></span></li> <li><span style="background-color:white"><span style="color:#222222">Inden operationen går i gang, skylles øjets overflade med skyllevæske</span></span></li> </ol> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579029853Ansvar"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Ansvar og organisering</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p><br> Afdelingsledelsen i Afdeling for Øjensygdomme,&nbsp;Rigshospitalet, er ansvarlig for at instruksen foreligger.<br> Afsnitsledende overlæger, afdelingssygeplejersker og ledende lægesekretærer, er ansvarlige for at instruksen udarbejdes, revideres og implementeres.<br> Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579029853Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579029853Referencer"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Referencer, lovgivning og faglig evidens samt links hertil</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579029853Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579029853Bilag"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Bilag</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579029853Top">Tilbage til top</a></p>

Rigshospitalet_¥jensygdomme (HOC)_PVK delegereret ret til anlæggelse.

PVK, delegereret ret til anlæggelse Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Bilag Målgrupper og anvendelsesområde Målgruppen for denne instruks er: - Optometrister, social- og sundhedsassistenter og sygeplejersker ansat ved Afdeling for Øjensygdomme, Rigshospitalet. Instruksen beskriver: - Delegation af lægeforbeheoldt virksomhed, krav om uddannelse og oplæring, tilsyn og kvalitetsmonitorering, dokumentation i personalesagen, samt praktisk udførelse af den delegerede opgave. Definitioner Lægeforbeholdt virksomhed: At foretage operative indgreb, som er defineret ved gennembrud af hud og væv og indførelse af visse former for apparatur i de naturlige legemsåbninger, undtaget er f.eks. termometer til temperaturmåling. Fremgangsmåde For delegeringen: Delegeringen omfatter: - Ved ordination af undersøgelse/behandling, hvor det er en forudsætning for udførelse eller iværksættelse, at perforation af hud er nødvendig, foreligger delegation for anlæggelse af PVK Personen opgaven delegeres til, skal have følgende kvalifikationer og kompetencer: - Autorisation som optometrist, sygeplejerske eller social- og sundhedsassisitent. - Gennemført nedenstående uddannelses- og oplæringsprogram. Uddannelse og oplæring For at få den delegerede ret til at anlægge PVK skal følgende e-learning kursus gennemføres: - E-learning. Anlæggelse af PVK - Sidemandsoplæring ved sygeplejerske Dokumentation i personalesagen Ved gennemført undervisning skal nedenstående kursusbevis opbevares i p-sagen: - Kursusbevis PVK.docx Praktisk udførelse af den delegerede opgave Nedenstående instrukser skal efterleves: - Perifert venekateter (PVK), anlæggelse og håndtering af Ansvar og organisering Afdelingsledelsen, er ansvarlig for - At instruksen foreligger. Afsnits- og/eller teamansvarlig overlæge, er fagligt ansvarlig for - At træffe beslutning om delegering - At den person, der bemyndiges til at varetage opgaven, er kompetent og uddannet hertil, så opgaven udføres på et tilfredsstillende fagligt niveau Personen, som har fået delegeringen, er ansvarlig for - At udføre opgaven ud fra gældende retningslinjer og instrukser - At holde sin viden ajour for den delegerede opgave - At frasige sig en opgave, som den pågældende ikke ser sig i stand til at udføre forsvarligt. Referencer, lovgivning og faglig evidens samt links hertil Perifert venekateter (PVK), anlæggelse og håndtering af E-learning. Anlæggelse af PVK https://hygiejne.ssi.dk/NIRivkatetre Bilag

<h1><div id="Afsnit#1699578943436">PVK, delegereret ret til anlæggelse</div></h1><div id="BodyWeb#1699578943436"><p><a name="1699578943436Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578943436Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578943436Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578943436Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578943436Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578943436Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578943436Bilag">Bilag</a><br> &nbsp;</h3> <h2>&nbsp;</h2> <div class="collapsible-item" expandedstart="1"><a name="1699578943436Maalgrupper"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Målgrupper og anvendelsesområde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0px; margin-right:0px; text-align:start">Målgruppen for denne instruks er:</p> <ul style="margin-left:40px; margin-right:0px"> <li>Optometrister, social- og sundhedsassistenter og sygeplejersker ansat ved Afdeling for Øjensygdomme, Rigshospitalet.</li> </ul> <p style="margin-left:0px; margin-right:0px; text-align:start">Instruksen beskriver:</p> <ul style="margin-left:40px; margin-right:0px"> <li>Delegation af lægeforbeheoldt virksomhed, krav om uddannelse og oplæring, tilsyn og kvalitetsmonitorering, dokumentation i personalesagen, samt praktisk udførelse af den delegerede opgave.</li> </ul> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578943436Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699578943436Definitioner"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Definitioner</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>Lægeforbeholdt virksomhed:&nbsp;<em>At foretage operative indgreb, som er defineret ved gennembrud af hud og væv og indførelse af visse former for apparatur i de naturlige legemsåbninger, undtaget er f.eks. termometer til temperaturmåling.</em></p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578943436Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699578943436Fremgangsmaade"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Fremgangsmåde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0px; margin-right:0px; text-align:start"><strong>For delegeringen:</strong></p> <p style="margin-left:0px; margin-right:0px; text-align:start">Delegeringen omfatter:</p> <ul style="margin-right:0px"> <li><span style="background-color:rgba(255, 255, 255, 0.85); color:#000000">Ved ordination af undersøgelse/behandling, hvor det er en forudsætning for udførelse eller iværksættelse, at perforation af hud er nødvendig, foreligger delegation for anlæggelse af PVK</span></li> </ul> <p style="margin-left:0px; margin-right:0px; text-align:start">Personen opgaven delegeres til, skal have følgende kvalifikationer og kompetencer:</p> <ul style="margin-right:0px"> <li>Autorisation som optometrist, sygeplejerske eller social- og sundhedsassisitent.</li> <li>Gennemført&nbsp;nedenstående uddannelses- og oplæringsprogram.</li> </ul> <p>&nbsp;</p> <p style="margin-left:0px; margin-right:0px; text-align:start"><strong>Uddannelse og oplæring</strong></p> <p style="margin-left:0px; margin-right:0px; text-align:start">For at få&nbsp;den delegerede ret til at anlægge PVK skal følgende e-learning kursus gennemføres:</p> <ul> <li style="text-align:start"><a href="https://kursusportalen.plan2learn.dk/KursusValg.aspx?id=36518" target="_blank">E-learning. Anlæggelse af PVK</a></li> <li style="text-align:start">Sidemandsoplæring ved sygeplejerske</li> </ul> <p style="text-align:start">&nbsp;</p> <p style="margin-left:0px; margin-right:0px; text-align:start"><strong>Dokumentation i personalesagen</strong></p> <p style="margin-left:0px; margin-right:0px; text-align:start">Ved gennemført undervisning skal nedenstående kursusbevis opbevares i p-sagen:</p> <ul> <li style="margin-left: 0px; margin-right: 0px; text-align: start;"><img src="/icons/vwicn005.gif" onclick="Ext.DMS.util.showImage(this);"><a href="###FOLDER###" target="_blank">Kursusbevis PVK.docx</a></li> </ul> <p style="margin-left:0px; margin-right:0px; text-align:start">&nbsp;</p> <p style="margin-left:0px; margin-right:0px; text-align:start"><strong>Praktisk udførelse af den delegerede opgave</strong></p> <p style="margin-left:0px; margin-right:0px; text-align:start">Nedenstående instrukser skal efterleves:</p> <ul> <li style="text-align:start"><a href="###FOLDER###" target="_blank">Perifert venekateter (PVK), anlæggelse og håndtering af</a></li> </ul> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578943436Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699578943436Ansvar"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Ansvar og organisering</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p><strong>Afdelingsledelsen,&nbsp;</strong>er ansvarlig for</p> <ul style="margin-left:40px; margin-right:0px"> <li><span style="background-color:#ffffff; color:#222222">At instruksen foreligger.</span></li> </ul> <p><strong>Afsnits- og/eller teamansvarlig overlæge,&nbsp;</strong>er fagligt ansvarlig for</p> <ul style="margin-left:40px; margin-right:0px"> <li>At træffe beslutning om delegering</li> <li>At den person, der bemyndiges til at varetage opgaven, er kompetent og uddannet hertil, så opgaven udføres på et tilfredsstillende fagligt niveau</li> </ul> <p><strong>Personen, som har fået delegeringen</strong>, er ansvarlig for</p> <ul style="margin-left:40px; margin-right:0px"> <li>At udføre opgaven ud fra gældende retningslinjer og instrukser</li> <li>At holde sin viden ajour for den delegerede opgave​​​​​​</li> <li><span style="background-color:#f9f9fb; color:#212529">At frasige sig en opgave, som den pågældende ikke ser sig i stand til at udføre forsvarligt.</span></li> </ul> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578943436Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699578943436Referencer"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Referencer, lovgivning og faglig evidens samt links hertil</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p><a href="https://vip.regionh.dk/VIP/Redaktoer/RH.nsf/XF61E2A17ABDF7E22C12580E90044BCCC?OpenDocument&amp;level=MAIN&amp;ref=internalVIP" style="color: blue; cursor: default; font-family: Calibri, Arial, Helvetica, sans-serif; font-size: 14.6667px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Perifert venekateter (PVK), anlæggelse og håndtering af</a></p> <p><a href="https://kursusportalen.plan2learn.dk/KursusValg.aspx?id=36518" target="_blank">E-learning. Anlæggelse af PVK</a></p> <p><a href="https://hygiejne.ssi.dk/NIRivkatetre" target="_blank">https://hygiejne.ssi.dk/NIRivkatetre</a></p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578943436Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699578943436Bilag"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Bilag</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578943436Top">Tilbage til top</a></p>

Rigshospitalet_¥jensygdomme (HOC)_Refraktions bestemmelse Afdeling for ¥jensygdomme Rigshospitalet.

Refraktions bestemmelse, Afdeling for Øjensygdomme, Rigshospitalet Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Målgrupper og anvendelsesområde Angiver retningslinjer for refraktions bestemmelse i Afdeling for Øjensygdomme, Rigshospitalet. Instruksen er gældende for læger og optikere ansat i Afdeling for Øjensygdomme, Rigshospitalet. Der er særlige retningslinjer hvis der indgår forskningsprotokoller. Definitioner Øjets brydning (refraktion) kan betragtes på 2 måder: - ved at følge hvor parallelt indfaldne lysstråler samles (fig 1a) - ved at følge hvor reflekterede lysstråler fra nethinden samles når de forlader øjet (fig 1b) Ved hypermetropi (langsynethed), emmetropi (normalt syn) og myopi (nærsynethed) dannes billedet henholdsvis bagved, på og foran nethinden (fig 1a). Ved astigmatisme (bygningsfejl) er brydningen uens i forskellige retninger og billeddannelsen ligger skråt foran, på eller bagved nethinden. Ved at anvende et cylinderglas som kun bryder i en retning (vinkelret på sin akse) kan billedet rettes op til at ligge i et plan. Ved myopi på f.eks. -3D dannes et uklart billede på nethinden og visus (se instruksen om Visus bestemmelse, Afdeling for Øjensygdomme, Rigshospitalet) måles til ca 6/46=0,13. I det i øvrigt normale øje kan visus med et brilleglas på -3D måles til 6/6=1,0. Ved hypermetropi på f.eks. +3D dannes også et uklart billede på nethinden, men den yngre patient kan med sin akkommodationsevne tildele øjet de manglende +3D så den målte synsstyrke er 6/6=1,0. Den ældre patient har ingen akkommodationsevne tilbage og man vil måle en nedsat synsstyrke på f.eks. 6/46 =0,13, som dog kan forbedres til 6/6=1,0 med et brilleglas på +3D, hvis øjet i øvrigt er normalt. De lysstråler der reflekteres fra nethinden vil forlade øjet henholdsvis divergerende, parallelt og konvergerende (fig 1b) De divergerende stråler ved hypermetropi kan forlænges til et punkt i afstanden (r) bagved øjet, de parallelle stråler ved emmetropi kan forlænges til et punkt beliggende uendeligt langt foran øjet og de konvergerende stråler ved myopi kan forlænges til et punkt i afstanden (–r) foran øjet. Punkterne i afstanden (–r) og r kaldes øjets fjernpunkt (FP) og 1/ r (målt i m) angiver den diopriske beliggenhed af øjets fjernpunkt og udtrykker øjets refraktion. Ligger fjernpunktet 0,5m bagved eller 0,5m foran øjet er dette henholdsvis +2 diopri hypermetropt eller -2 dioptri myopi. Øjets refraktion angives ved en sfærisk værdi (sf), en cylinder værdi (cyl) og dennes akse i i grader (0 til 180 gr). Det optiske princip ved korrektion af refraktionsanomalier er at bestemme den sfærocylindriske linse der i en brille eller kontaktlinse har fokalpunkter sammenfaldende med øjets fjernpunkter. (Et fokalpunkt (brændpunkt) er der hvor parallelt indfaldne lysstråler samles efter at have passeret en linse. Den reciprokke værdi af afstanden i m til focalpunktet angiver linsens dioptriske værdi). Jo længere en linse anbringes fra øjets fjernpunkt jo svagere skal den være. Dette forklarer hvorfor en kontaktlinse ved henholdsvis myopi og hypermetropi er svagere eller stærkere end brilleglaset. For at stimulere accomodationen mindst mulig anvendes ved myopi svageste minusglas og ved hypermetropi stærkeste plusglas der giver bedste synskomfort. Fremgangsmåde Objektiv bestemmelse af øjet refraktion Autorefraktor - Bygger på forskellige optiske principper, som hele tiden udvikles. Retino-/scia- skopi - Undersøgeren anbringer sit øje 0,5m (-2 D) foran patienten - Ved at skyde linser ind foran patientens øje flyttes øjets fjerpunkt til undersøgerens øje, hvorved hele patientens pupil ses fyldt med lys. - Har undersøgeren anbragt f.eks +4D linse foran øjet er øjets refraktion (+4D -2D)= +2D. Subjektiv bestemmelse af øjets refraktion Der kan anvendes elektronisk phoropter, manuel phoropter eller prøvebrille med glas fra brillekasse. Som start anvendes patientens brille værdier eller autorefraktor/retinoskopi værdier. Ved astigmatisme anvendes sædvanligvis minus cylinder. Udmål hvert øje for sig. - Sfærisk værdi. Tjek med 0, +0,25 og -0,25hvad der er bedst (ved nedsat visus anvendes evt +0,5 og -0,5) - Akse værdi. Brug krydscylinder (+- 0,25 eller +- 0,5) 45 grader fra cylinderaksen og drej aksen ved bedste indstilling mod krydscylinderens minus. - Cylinder værdi. Brug krydscylinder i cylinderaksen og øg eller svæk cylinderen afhængig af om – eller + på krydscylinderen foretrækkes. - Gennemgå de 3 punkter igen indtil der ikke er ændringer Udmål andet øje på samme måde - Binokulær afbalancering. - Begge øjne ser på tavlen - Adder +1,5 til den overfor udmålte refraktion (tavlen skal ses sløret) - Tildæk derefter skiftevis højre og venstre øje og øg evt. + på et øje til de ser lige sløret. - Derefter øges minus til bedste visus. - Til slut kan der finjusteres med rød/grøn tavle med -0,25 (rød klarest) og +0,25 (grøn klarest). Læsetillæg Som tommelfingerregel er læsetillæget til afstandskorrektionen - + 1D mellem 40 og 50 år - + 1,5D mellem 50 og 55 år - + 2 D mellem 55 og 60 år - + 2,5D over 60 år Juster ovennævnte ved at give patienten en læsetekst i hænderne i den afstand der foretrækkes. Nedsat visus Ved subjektiv refraktionering kan forskellige sfærocylindre give samme resultat, som derfor er mere usikkert. Læsetillægget kan øges så patienten får læseteksten tættere på og dermed en forstørrende effekt. Ansvar og organisering Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger. Afsnitsledende overlæger, afdelingssygeplejersker og ledende lægesekretærer, er ansvarlige for at instruksen udarbejdes, revideres og implementeres. Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen. Referencer, lovgivning og faglig evidens samt links hertil Visus bestemmelse, Afdeling for Øjensygdomme, Rigshospitalet - instruks fra HovedOrtoCentret-Afdeling for Øjensygdomme, Rigshospitalet Akkrediteringsstandarder Bilag

<h1><div id="Afsnit#1699578896929">Refraktions bestemmelse, Afdeling for Øjensygdomme, Rigshospitalet</div></h1><div id="BodyWeb#1699578896929"><p><a name="1699578896929Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578896929Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578896929Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578896929Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578896929Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578896929Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578896929Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578896929Bilag">Bilag</a><br> &nbsp;</h3> <h2><a name="1699578896929Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p>Angiver retningslinjer for&nbsp;refraktions bestemmelse i Afdeling for Øjensygdomme, Rigshospitalet.</p> <p>Instruksen er gældende for læger og optikere ansat i Afdeling for Øjensygdomme, Rigshospitalet.</p> <p>Der er særlige retningslinjer hvis der indgår forskningsprotokoller.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578896929Top">Tilbage til top</a></p> <h2><a name="1699578896929Definitioner"></a><br> Definitioner</h2> <p>Øjets brydning (refraktion) kan betragtes på 2 måder:</p> <ol> <li>ved at følge hvor parallelt indfaldne lysstråler samles (fig 1a)</li> <li>ved at følge hvor reflekterede lysstråler fra nethinden samles når de forlader øjet (fig 1b)</li> </ol> <p>Ved&nbsp;hypermetropi (langsynethed), emmetropi (normalt syn) og myopi (nærsynethed) dannes billedet henholdsvis bagved, på og foran nethinden (fig 1a). Ved astigmatisme (bygningsfejl) er brydningen uens i forskellige retninger og billeddannelsen ligger skråt foran, på eller bagved nethinden. Ved at anvende et cylinderglas som kun bryder i en retning (vinkelret på sin akse) kan billedet rettes op til at ligge i et plan.</p> <p>Ved&nbsp;myopi på f.eks. -3D dannes et uklart billede på nethinden og visus (se instruksen om <a href="###FOLDER###" target="_blank">Visus bestemmelse, Afdeling for Øjensygdomme, Rigshospitalet</a>) måles til ca 6/46=0,13. I det i øvrigt normale øje kan visus med et brilleglas på -3D måles til 6/6=1,0. Ved hypermetropi på f.eks. +3D dannes også et uklart billede på nethinden, men den yngre patient kan med sin akkommodationsevne tildele øjet de manglende +3D så den målte synsstyrke er 6/6=1,0. Den ældre patient har ingen akkommodationsevne tilbage og man vil måle en nedsat synsstyrke på f.eks. 6/46 =0,13, som dog kan forbedres til 6/6=1,0 med et brilleglas på +3D, hvis øjet i øvrigt er normalt.</p> <p>De&nbsp;lysstråler der reflekteres fra nethinden vil forlade øjet henholdsvis divergerende, parallelt og konvergerende (fig 1b) De divergerende stråler ved hypermetropi kan forlænges til et punkt i afstanden (r) bagved øjet, de parallelle stråler ved emmetropi kan forlænges til et punkt beliggende uendeligt langt foran øjet og de konvergerende stråler ved myopi kan forlænges til et punkt i afstanden (–r) foran øjet.</p> <p>Punkterne i afstanden (–r) og r kaldes øjets fjernpunkt (FP) og 1/ r (målt i m) angiver den diopriske beliggenhed af øjets fjernpunkt og udtrykker øjets refraktion. Ligger fjernpunktet 0,5m bagved eller 0,5m foran øjet er dette henholdsvis +2 diopri hypermetropt eller -2 dioptri myopi.</p> <p>&nbsp;</p> <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <img alt="" src="/VIP/Redaktoer/1301G3.nsf/vLookupUpload/ATTACH-RHAP-A5WHDA/$FILE/Refraktion, fig. 1.png" style="height:526px; width:563px" onclick="Ext.DMS.util.showImage(this);"></p> <p>&nbsp;</p> <p>&nbsp;</p> <p>Øjets refraktion angives ved en sfærisk værdi (sf), en cylinder værdi (cyl) og dennes akse i i grader (0 til 180 gr).</p> <p>Det optiske princip ved korrektion af refraktionsanomalier er at bestemme den sfærocylindriske linse der i en brille eller kontaktlinse har fokalpunkter sammenfaldende med øjets fjernpunkter. (Et fokalpunkt (brændpunkt) er der hvor parallelt indfaldne lysstråler samles efter at have passeret en linse. Den reciprokke værdi af afstanden i m til focalpunktet angiver linsens dioptriske værdi). Jo længere en linse anbringes fra øjets fjernpunkt jo svagere skal den være. Dette forklarer hvorfor en kontaktlinse ved henholdsvis myopi og hypermetropi er svagere eller stærkere end brilleglaset.</p> <p>For at stimulere accomodationen mindst mulig anvendes ved myopi svageste minusglas og ved hypermetropi stærkeste plusglas der giver bedste synskomfort.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578896929Top">Tilbage til top</a></p> <h2><a name="1699578896929Fremgangsmaade"></a><br> &nbsp;</h2> <h2>Fremgangsmåde</h2> <p><strong>Objektiv bestemmelse af øjet refraktion</strong></p> <p style="margin-left:40px">Autorefraktor</p> <ul> <li>Bygger på forskellige optiske principper, som hele tiden udvikles.</li> </ul> <p style="margin-left:40px">Retino-/scia- skopi</p> <ul> <li>Undersøgeren anbringer sit øje 0,5m (-2 D) foran patienten</li> <li>Ved at skyde linser ind foran patientens øje flyttes øjets fjerpunkt til undersøgerens øje, hvorved hele patientens pupil ses fyldt med lys.</li> <li>Har undersøgeren anbragt f.eks +4D linse foran øjet er øjets refraktion (+4D -2D)= +2D.</li> </ul> <h4>Subjektiv bestemmelse af øjets refraktion</h4> <p style="margin-left:40px">Der kan anvendes elektronisk phoropter, manuel phoropter eller prøvebrille med glas fra brillekasse.</p> <p style="margin-left:40px">Som start anvendes patientens brille værdier eller autorefraktor/retinoskopi værdier. Ved astigmatisme anvendes sædvanligvis minus cylinder. Udmål hvert øje for sig.</p> <ul> <li><strong>Sfærisk værdi</strong>. Tjek med 0, +0,25 og -0,25hvad der er bedst (ved nedsat visus anvendes evt +0,5 og -0,5)</li> <li><strong>Akse værdi</strong>. Brug krydscylinder (+- 0,25 eller +- 0,5) 45 grader fra cylinderaksen og drej aksen ved bedste indstilling mod krydscylinderens minus.<br> <br> <br> <img alt="" src="/VIP/Redaktoer/1301G3.nsf/vLookupUpload/ATTACH-RHAP-A5WHL9/$FILE/Refraktion, akse og cylinder.png" style="height:273px; width:420px" onclick="Ext.DMS.util.showImage(this);"><br> &nbsp;</li> <li><strong>Cylinder værdi</strong>. Brug krydscylinder i cylinderaksen og øg eller svæk cylinderen afhængig af om – eller + på krydscylinderen foretrækkes.</li> <li>Gennemgå de 3 punkter igen indtil der ikke er ændringer</li> </ul> <p style="margin-left:40px">Udmål andet øje på samme måde</p> <ul style="margin-left:40px"> <li><strong>Binokulær afbalancering. </strong> <ul> <li>Begge øjne ser på tavlen</li> <li>Adder +1,5 til den overfor udmålte refraktion (tavlen skal ses sløret)</li> <li>Tildæk derefter skiftevis højre og venstre øje og øg evt. + på et øje til de ser lige sløret.</li> <li>Derefter øges minus til bedste visus.</li> <li>Til slut kan der finjusteres med rød/grøn tavle med -0,25 (rød klarest) og +0,25 (grøn klarest).</li> </ul> </li> </ul> <p>&nbsp;</p> <p><strong>Læsetillæg</strong></p> <p style="margin-left:40px">Som tommelfingerregel er læsetillæget til afstandskorrektionen</p> <ul> <li>+ 1D mellem 40 og 50 år</li> <li>+ 1,5D mellem 50 og 55 år</li> <li>+ 2 D mellem 55 og 60 år</li> <li>+ 2,5D over 60 år</li> </ul> <p style="margin-left:40px">Juster ovennævnte ved at give patienten en læsetekst i hænderne i den afstand der foretrækkes.</p> <p><strong>Nedsat visus</strong></p> <p style="margin-left:40px">Ved subjektiv refraktionering kan forskellige sfærocylindre give samme resultat, som derfor er mere usikkert. Læsetillægget kan øges så patienten får læseteksten tættere på og dermed en forstørrende effekt.</p> <p style="margin-left:40px">&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578896929Top">Tilbage til top</a></p> <h2><a name="1699578896929Ansvar"></a><br> Ansvar og organisering</h2> <p style="margin-left:0cm; margin-right:0cm">Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger.<br> Afsnitsledende overlæger, afdelingssygeplejersker og ledende lægesekretærer, er ansvarlige for at instruksen udarbejdes, revideres og implementeres.<br> Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578896929Top">Tilbage til top</a></p> <h2><a name="1699578896929Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p><a href="###FOLDER###" target="_blank">Visus bestemmelse, Afdeling for Øjensygdomme, Rigshospitalet</a>&nbsp;- instruks fra HovedOrtoCentret-Afdeling for Øjensygdomme, Rigshospitalet</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578896929Top">Tilbage til top</a></p> <h2><a name="1699578896929Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578896929Top">Tilbage til top</a></p> <h2><a name="1699578896929Bilag"></a><br> Bilag</h2> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578896929Top">Tilbage til top</a></p>

Rigshospitalet_¥jensygdomme (HOC)_Refraktiv kirurgi Generel instruks.

Refraktiv kirurgi, Generel instruks Målgrupper og anvendelsesområde Angiver retningslinjer for forløb i Team for Brydningsfejl for patienter, der er henvist med refraktiv problemstilling til Afdeling for Øjensygdomme, Rigshospitalet Gældende for personalet i Team for Brydningsfejl, Afdeling for Øjensygdomme, Rigshospitalet. Definitioner ACD: Anterior Chamber Depth CCT: Central Corneal Thickness (corneas tyndeste punkt) CLE: Clear Lens Extraction (“kataraktoperation”) også kaldet RLE (Refractive Lens Exchange) CXL: Corneal Cross-Linking (UV lysbehandling af hornhinde ved keratoconus) CIRCLE:Anvendes som reoperation efter SMILE ICL: Implantable Collamer Lens (linseimplantat ml. iris og naturlig linse) LASIK: Laser Assisted In Situ Keratomileusis (laseroperation med corneal flap) PRK: Photorefractive Keratectomy (skrab af epithel efterfulgt af excimer-laser) SMILE: Small Incision Lenticule Extraction (laseroperation med fjernelse af vævsskive gn. tunnel) Fremgangsmåde Refraktive offentlige kriterier (når briller eller CL-korrektion er en ringere optisk løsning end operation) - Myopi > 6 D sf ou (sfærisk ækvivalent) - Hypermetropi > 6 D sf ou (sfærisk ækvivalent) - Anisometropi > 3 D - Astigmatisme > 3 D cyl. på bare ét øje - Andre refraktionsanomalier, hvor anvendelse af briller eller kontaktlinser ikke er en mulig foranstaltning på grund af medicinske eller fysiske forhold eller erhverv - Irregulær astigmatisme, som ikke kan korrigeres med briller eller kontaktlinser Behandlingsområder - LASIK: -10 D sf til +1,50 D Sf. Astigmatisme -5 D cyl. - PRK: -3 D sf til +1,5 D sf (uden MMC) og ned til -6.0 D sf (med MMC) - SMILE: -10 D sf til -0,5 D sf og -5 D cyl. SEQ i alt -12,5 D Operationstyper Der kan foretages laseroperationer med ablation/ekstraktion af cornealt væv (SMILE, LASIK og PRK): samt linseimplantatsoperationer (ICL, CLE): Hovedparten af operationerne udgøres af SMILE. Forundersøgelse Før konsultation - Fremsøg dagens lister i SP (Tidsplan > Afs.: (søgefelt) -> ”ØGA44RK”) - Forundersøgelser: smartphrase: ”økrkambfus; Læs henvisning - Kontroller: smartphrase: økrk1d, økrk1u, økrk1m; læs operationsnotat om der var komplikationer (”Oprforløb: 1” = ukompliceret), dertil evt. notat fra tidligere kontrol Under konsultation - Spørg som det første pt., om de har pauseret bløde kontaktlinser i 48 timer forud for undersøgelsen og evt. hårde kontaktlinser 1 uge før – hvis ikke, da aflys og ny tid! - Anamnese: - Refraktion: Stabil indenfor minimum 2 år? - Kontaktlinsebrug: intolerance? Kræves for egnethed til refraktiv kirurgi i off. Regi. - Tørre øjne? Hvor hyppigt dryppes der? - Erhverv: Kampsport? Militær? Alle former for fysisk vold/slag mod ansigt øger risiko for flap displacering/-læsion. - Endt amning/graviditet > 6 mdr - Obj: - Punktat tørhedskeratopati ved fluoresceinfarvning - Katarakt? Overvej CLE Refclient - Ref-client skal være gemt med alle data - Hvis indtastning foretages af uddannelsessøgende læge, skal refraktion, corneatykkelse og k-mål konfirmeres af optiker Information - Alle - Kan gå i bruser næste morgen med lukkede øjne - Undgå hav- og karbad i 4 uger - SMILE - Forudsigelighed: - Knap 80% når samme syn efter opr uden brille/cl, som før med bedste brille, - 98% af øjne ser 6/12 eller bedre) - 83% ligger inden for +-0,5D og 95% indenfor +-1D - Bygningsfejl over 1 cyl reduceres i gennemsnit med 80% - Forløb: - Tåget syn første døgn - Efter 1 måned kan brillestyrke bestemmes - Efter 1 uge status og afslutning - Risici: - 1-2 % taber 2 eller flere linier ved operation, men ingen falder dog under 0.3 - 1/4 klager over glare efter 1 md, men kun 5% efter 1 år) - Tørre øjne er en hyppig klage, som dog aftager med tiden, men få personer har selv efter et år forsat behov for at dryppe øjnene med kunstig tårevæske - Infektion under 1% kan medføre nedsat synsstyrke - LASIK/Circle - 2-5% risiko for at miste 2 linjer - Risiko for nattegener - 85% sandsynlighed for visus 1,0 binokulært uden korrektion - Relasik først muligt 6 mdr postoperativt - Hovedparten oplever midlertidigt tørre øjne i op til 6 måneder, 5% vedvarende (typisk dem med gener præoperativt), tørre øjne skyldes: nerver bliver beskadigede - 0,5 promille får en keratitis - Ved stor pupil: Større risiko for blændingsgener om natten - Sov med hårdt skjold 1 uge - PRK - 2-3 uger med ringe visus, ca. 1 uge med smerter, bandagelinse fjernes efter 1 uge Undersøgelsesprogram ved forundersøgelse Alle patienter - Pentacam - IOLMaster - Visus/refraktion: visus mec, cc, cycloplegisk reaktion primært v. hypermetrope < 30 år - Spaltelampe (inkl. funduskopi, efter dilatation) Hvis PRK/LASIK (hypermetropi) eller CIRCLE overvejes + Atlas Refraktionering (se særskilt instruks): - Tag udgangspunkt i habituel korrektion - Giv +0,5 sf eller -0,5 sf. Herefter +/- 0,25 sf indtil bedste visus opnås - Find den bedste akse med kryds cylinder - Find den bedste cylindriske styrke med kryds cylinderen - Til sidst afbalancerer man ved at give +1,5 sf for begge øjne - OBS: refraktionering foretaget af uddannelsessøgende læge skal konfirmeres af optiker Ved tvivl ved FUS. Få emailadresse og mobilnummer og konferér med senior læge Eksklusionskriterier Generelle: - Alder < 21 år - Alder > 50 for myope og SMILE - Ustabil refraktion indenfor seneste 2 år - Velfungerende kontaktlinser - Hypermetrope med > +1,50 med lille ACD og under 55 år - Oxford score > 1 Corneal refraktiv kirurgi (SMILE/LASIK/PRK): - Belin Ambrosio Score - Total: rød - Back: gul - Steepening - Inferior ≥ 1,5 D - Superior ≥ 2,0 D LASIK og ICL - Kontaktsport Generelt flowchart for refraktivt team - Hypermetropi - > 50 år: RLE monofokal (torisk IOL såfremt corneaastigm. ≥ 1,50 D) - < 50 år - Op til + 1,5 D: Lasik - > + 1,5 D: ICL (ACD ≥ 3,0 mm), alternativt multifokal RLE (< 40 år) - Myopi - > 55 år: RLE monofokal (torisk IOL såfremt corneaastigm. ≥ 1,50D) - < 50 år - Op til -12,5 SEQ D (op til -10 D sf og 5 D cyl): SMILE - > - 10 D: ICL (Intern ACD ≥ 3,0 mm) - ≥ 50 år – 55 år: Individuel vurdering – helst afvente behandling og fortsætte med CL/briller - Astigmatismer - SMILE/LASIK/PRK: op til 5.00 D (Bygningsfejl over 1 cyl reduceres i gennemsnit med 80%) Kontrolprogram SMILE - 1 uge: Pentacam, Visus/refraktion, spaltelampe LASIK/Circle - 1 dag: spaltelampe - 1 uge: Pentacam, visus/refraktion, spaltelampe PTK/PRK - 1 uge: spaltelampe - 1 md: Pentacam, visus/refraktion, spaltelampe, tryk ICL - 1 dag: visus/refraktion, spaltelampe, IOP - 3 uger: Casia, visus/refraktion, spaltelampe, IOP. Afsluttes til eøl for kontrolforløb; 6 mdr, 1 år, 2 år, 3 år, 4 år, 5 år. Ved spaltelampekontrol kontrollér følgende: - Flap in situ? - Interface inflammation? - Flap folder? - Infektion? - Debris i flap interface? - Epithelindvækst? - Vaulting af ICL Postoperativ medicin: SMILE/LASIK/CIRCLE/RELASIK, flapløft - Tobradex x 4 i 1 uge - Ukonserverede lubrikerende dråber x 4 – gerne i 2 mdr PRK/PTK - Tobradex x 4 i 4 uger - Voltabak x 3 i 3 dage - Ukonserverede lubrikerende dråber x 4 – gerne i 2 mdr Behandling af komplikationer Postoperativ keratit Der skal skelnes mellem tidlige (indenfor dage) og sene (indenfor uger) keratitter. De tidlige skyldes oftest gram positive bakterier og de sene som oftest atypiske mykobakterier og svamp. - Overvej flapløft, hvor der samtidig podes til eswap og skylles med Cefuroxim opløsning (samme koncentration som anvendes til kataraktkirurgi). Påfør på dyrkningsseddel: ”obs atypisk mykobakterie”. - Hvis der ikke foretages flapløft podes forsigtigt fra cornea. Hvis dette fravælges podes fra konjunktiva. Begge podninger med Eswap mhp dyrkning for svampe og bakterier. Påfør på dyrkningsseddel: ”obs atypisk mykobakterie”. - Seponer steroid - Antibakteriel behandling: - Tidlige infektioner: Ciloxan og kloramfenikol - Sene infektioner: Konf. mikrobiolog - Ved obs svamp: Natacyn fra Alcon Interface inflammation - Rp Maxidex x 8 i 1 uge, herefter x 4 i 1 uge - Giv tid til kontrol efter 2 uger, hvor der skal måles tryk Makrostriae: - Skal behandles hurtigst muligt - CGE99 Anden operation for vævsforandringer i hornhinde - Epithelet over folddannelserne - ca. 5 mm i diameter – fjernes - Flappen hydreres med alm. fysiologisk saltvand eller skyllevæske. - Folddannelserne udglattes ved at trække 90 grader på deres retning i hver sin ende med tørre spyd - CL påsættes og Tobradex x 4 i 1 uge, herefter fjernes CL og der fortsættes med dråber x 2 i 1 uge. Mikrostriae: - Foretag wet PTK: vand på cornea, indstil laser på 20 um dybde i 8 mm diameter Lenticule rester ved SMILE - Sprøjt ikke væske ind i interfacet, da det vil sløre oversigten - Udtag lenticule rester med 25 G VR pincet - Udvid pupillen og anvend retroillumination. Herved fremstår resterne meget tydeligt i operationsmikroskop Intraoperative suction loss (Ref: Titiyal et al: “Current concepts in refractive surgery”) ###TABEL_1### Diverse info PTK: - 8 mm zone i 65 um dybde inducerer 1 D hyperopi SMILE - Ved lenticule dissektion: Når man tydeligt kan se lenticulens kant, så er man i posterior plane (meniscus sign) CLE - Anterior optic capture -> 1,5 D højere styrke for linsen -> myopinisering Ansvar og organisering Afdelingsledelsen, Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger. Afsnitsledende overlæge, afdelingssygeplejersker og ledende lægesekretærer, er ansvarlig for at instruksen udarbejdes, revideres og implementeres. Den enkelte medarbejder i Afdeling for Øjensygdomme, er ansvarlig for at kende og følge instruksen Referencer, lovgivning og faglig evidens samt links hertil Bilag

<h1><div id="Afsnit#1699578972527">Refraktiv kirurgi, Generel instruks</div></h1><div id="BodyWeb#1699578972527"><p>&nbsp;</p> <div class="collapsible-item" expandedstart="1"><a name="1699578972527Maalgrupper"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Målgrupper og anvendelsesområde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm">Angiver retningslinjer for forløb i Team for Brydningsfejl for patienter, der er henvist&nbsp;med refraktiv problemstilling til Afdeling for Øjensygdomme, Rigshospitalet</p> <p style="margin-left:0cm; margin-right:0cm">Gældende for personalet i Team for Brydningsfejl, Afdeling for Øjensygdomme, Rigshospitalet.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578972527Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699578972527Definitioner"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Definitioner</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-right:0cm">ACD: Anterior Chamber Depth<br> CCT: Central Corneal Thickness (corneas tyndeste punkt)<br> CLE: Clear Lens Extraction (“kataraktoperation”) også kaldet RLE (Refractive Lens Exchange)<br> CXL: Corneal Cross-Linking (UV lysbehandling af hornhinde ved keratoconus)<br> CIRCLE:Anvendes som reoperation efter SMILE<br> ICL: Implantable Collamer Lens (linseimplantat ml. iris og naturlig linse)<br> LASIK:&nbsp;Laser Assisted In Situ Keratomileusis (laseroperation med corneal flap)<br> PRK: Photorefractive Keratectomy (skrab af epithel efterfulgt af excimer-laser)<br> SMILE: Small Incision Lenticule Extraction (laseroperation med fjernelse af vævsskive gn. tunnel)</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578972527Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699578972527Fremgangsmaade"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Fremgangsmåde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <h2 style="margin-left:0cm; margin-right:0cm"><span style="color:#2f5496">Refraktive offentlige kriterier </span></h2> <h2 style="margin-left:0cm; margin-right:0cm"><span style="color:#2f5496">(når briller eller CL-korrektion er en ringere optisk løsning end operation)</span></h2> <ul> <li>Myopi &gt; 6 D sf ou (sfærisk ækvivalent)</li> <li>Hypermetropi &gt; 6 D sf ou (sfærisk<strong> </strong>ækvivalent)</li> <li>Anisometropi &gt; 3 D</li> <li>Astigmatisme &gt; 3 D cyl. på bare ét øje</li> <li>Andre refraktionsanomalier, hvor anvendelse af briller eller kontaktlinser ikke er en<strong> </strong>mulig foranstaltning på grund af medicinske eller fysiske forhold eller erhverv</li> <li>Irregulær astigmatisme, som ikke kan korrigeres med<strong> </strong>briller eller kontaktlinser</li> </ul> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <h2 style="margin-left:0cm; margin-right:0cm"><span style="color:#2f5496">Behandlingsområder</span></h2> <ul> <li>LASIK: -10 D sf til +1,50 D Sf. Astigmatisme -5 D cyl.</li> <li>PRK: -3 D sf til +1,5 D sf (uden MMC) og ned til -6.0 D sf (med MMC)</li> <li>SMILE: -10 D sf til -0,5 D sf og -5 D cyl. SEQ i alt -12,5 D</li> </ul> <h2 style="margin-left:0cm; margin-right:0cm"><span style="color:#2f5496">Operationstyper</span></h2> <p style="margin-left:0cm; margin-right:0cm">Der kan foretages laseroperationer med ablation/ekstraktion af cornealt væv (SMILE, LASIK og PRK):</p> <p style="margin-left:0cm; margin-right:0cm"><img src="data:image/png;base64,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" style="height:250px; width:580px" onclick="Ext.DMS.util.showImage(this);"></p> <p style="margin-left:0cm; margin-right:0cm">samt linseimplantatsoperationer (ICL, CLE):</p> <p style="margin-left:0cm; margin-right:0cm"><img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAmMAAAEKCAYAAABe21JyAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAADsMAAA7DAcdvqGQAAP+lSURBVHhe7P1nkGVbdt8Hrsy8/t70Wb6e7dcWAAESRiMGGSFNiBIpfRkooKAYoQ8ToZgQRWqcIJERCn1QhL6MMJwYaWZEQprhSCHRgMJQAh1MwwNt0b7fa/dsvfImfeY1efNm5vx+a9+Tma+6utGQyG5Uo3bWqXPuOftsu8x/r732PjMnhHgWnoVn4Vl4Fp6FZ+FZeBa+J2F2en4WnoVn4Vl4Fp6FZ+FZeBa+B+GZZewpDLdv387zzMxMnk9OONOLnvLeySRmjg65BmvP1Hg0G8fG82/a3Ue+wH1/l3c4cyvjcT3LraOTo4x7cjIbs9w4Pj4+zRPCMbNMxeuVpYXodNqn6We82dkYvnsjHvzir8fJ7n4cjw5In7Rr9ZhtNPL5yQl3DsaUnfxrtZidq0fMcSZOnBxGHI7j+IhSzdby+TH1+sK7H4837305mo25aNbnos4xNzcbpWTvDVk+z9NyZSM9FvP02e8Tsv2m14ZMiRvey7b3mvN705vm5b38d5aG8fNOxj8r0+Plsd0fD8Ypx0y2dfXOf/jzX8vzs/D0hL/0137ltP88Vzx2PjzpnjQzA29WId99L+nkaLukLe/mLRMrbMC9WXjQ+/JfFeD0mEmae2+eSdvmqVwhWKZ8Vx4mj+PjaRo8L3GQOyST+Zonp2MkD1xPvqWeJ8iY4/E4783NzcSc7xtm5oxFnJOo12ZiNOyT1qEiwwyRTzNRRybMIStqxK3N1qPGyzX+azTqvINMIG672YpOu4lcKXWxmrU55EazmflZdmtVr9eijfxSzh0cjLI+NfKdmznKMvhOTRlDMsZdXlriTJ61WcRVjSSOKIPPZygbGZOPaXAHmTXhQOJ6b3IUk0CulSb8plD66uxshvRGtuPxUcXvtNa0jY02mRzH+PAwTmapO/VtUC7l7BB5OxwexPbuTjx4+CDu3L0b+/sD5Dov1RuZxskxsn2GeqAnSDkmyNsJaR1NBtHrNeLi2ipHL5YWaZtJxHgwiskBdRgfkudRjKnXYaZHPyDTa8jtBtcex4cHcXQ4op1oc9p1ZvY4dvd248aNd+P+/ftxRKXmFxdieXkplhYWYnFxKXr0wZXLl6JDPQ4ph/nMUc4DdMHhMe04lYXS7Rx94lGj/asj23/aD4W+pMtCn/6uro+yP2zP0v/eP6Tug34/RqNRDAb7sb29Hf29/WwPw9FkAm2Ms12Pj2ZiMBzF5vYO6dbiQx/5wfjRP/ET3I/Y2dujeaEJ6HFC+nRbHMsnHMf8zVVl9NfhBDqFJ6QzCjTt9WfhaQm3bt+dXpVQdWFFfHb5DEQgoJKR5fyTKRGW34VIKomQb58nA68zrmDMNM8IO8/8zfi6SfFbIbUGQ80hmEzMOOWI2Pzk78XOp74gJccxxCtBziEIZuBQwZVS5mgwgFgRXDJzo6m0Q3gCIo8AYjCGcY4nCOtulwyP4nNv/268cfdLp2CsAeH/LwFjj4fTuI8F6/3kJyVU+uy98aZ5ZZvyr8raCKf5eK767ixUvx8/V0Hl562zfn8Gxp7GIBj7/YJ9/KQwMyWo0v38N6WHKrYcXj07TUJ6yesCxiTc91K26cD7p8Razhl3KjNU9gafZLrE9Y50WNLKJ6Us00NFdCSgyuQsj2CFWMoi8lNGJSgzQUDmIYMw4wrcDlXqgKNOqxk15EMjlW89Wo0WcgAAwm9lgCCsiRzxXEce1YkjqHLAmIqXolmWanBZ2oBMzJLnZj07BV0qSDBFtEmv1SKfJnKLB4K4LqDBSIJCgcYR8k1gmfey3Qo4LXWxPUu+KvQJoOI8+K3Cef4+u+Yd25bf4If87SHuTf6nxWYBYbOAkoxLHgIUox3x/Ig2PBQwTQ5jH6AhwNjc2ol1zrv9EWCJ8hwSWbRA/Db1nKEe9fpMrK4uxMryPHWdA9TOxWQwjv2dvTgEjFhVMqX1eE8QhAw+se4CQtEXEWaop+/NoiwG/b3Y2tqIe/fvxfrGRrZFizZcBNSurCwDbhdjbXUt5ru97Lca6RyOAT20ly0BZC9FpM9KHxQg9vhR+rbQqG3m7+q6AmLnr49BT/bbBJAsCOvv7ycQ29/vR58yDzgLxkxHwHswGicg29sfAnShSWjvxRffF6984EPRbncBj6QLfZjtMfU+JB/zOoZGwJTl4L9j+kPkVmNAcXJ8QBtRVgr0zVTxLPyhDrdu3U0CteskEoXcMdcKleRxCZYYygR7dyaZVnDl7yI0jxA8ee2Pisi9Lil7UU4+y0gSeBnpZWrc889/Cqal+V7GNSRDwBhHEPfmL/96jG/dZ0TIKKc/SCKdQ6DOKNjm6jlSPBruJ2PPIvm0iM3w3PdzNDkYMnI+yLznugucTuLTb/9GvHX/qwhJwRijMM4KyGn23zacknsKzCe/8a1YYtqCT3w3bxFKW5+F0/vTm6aQwd+n+ZTz49lW5Thfnsev/Wk/8j9texL/wf/w9fLwWXhqwl/+v310evUHD6dUf4525L+KOlFP5YJTdc+ohS7h+SkYe08CJUa5zLfKmypg76blx5E9+UiDKszzClCLuiClAD3jFIUk/8zMTlQ6Rsx8HciJhU4EM8SpkbbWLZWxaWmRqsvnHAu9bnTbBRTVtJ4Tt8HArg5YUsFlSQFulkRQZ7m9VtlWMrDwj7JSxW182kirGWU8BJg4ykzLGoDCsWKrMUue7QRjWsR8J8tJGU80g/B7bip3sz2oo88TKHGes514lm1GmCAHtQhZFoNny53NkW01vT8924Nm6i9eI3htPNIyH80uSmXKoJyekJmWGnWBaQiQTHdCWY+0yiFTx5ThYHwUB9R3MACA7A5jZ6cfQ+Tz0SHAgKLOd1uAsSXaehZANwJg0jagoRnB3cEhQOmQ9LUKNuKEtgB1Ir+5Jk/7pgJjtdnj2N/bjrt3bsaDh/djNBxGh0H1wsJCdNAZ8wsc8wuxurwcFwBjLWT/aMjgXL0gYEk9RavSSB7WRbrSCua5AmFe+6w6zgefG7S0GTI9+8D2mozz/sHBQfQHg9jb2QGI7XHsp6VsjA6b0E6mPx6P49H6Zuxs79CHERcuXI4PfPBDce3a82mR3NsfZN90uvN0CWkf0U4c6trkM63B0Id5C4Kzjei7brOZg4ZnYOwpDDdulWlKCcIgEyb5SYR0PH1OUPBMwQMRK/aXob1KU7WMzjlHhgT/V4jl1AFMq3ndUcHkYMTIahxHgCJHdkcQqYQ6GY9I+ygFpCPRigVmZRQEV3sE8n/zUcyMeGfYz/dy1AlhnjiSZVRxTPrHo36ZonRExUhB6TzH+xQsThAQ5m/iteZ8TCjyJ77xi3F7421GXfWpZew7B2NVSADz+1D+N7HGVGk96d3HQVf17jffL+cSpnFOb5bIp+8+dq7C+d9eFlANw5PJMzD29IX//f/916ZX3zo8TgNnodBMKqFplCnJnSqls3OezoUiF0g9j4pWy8/H81PZCSg48tFU6XGtvKhkiHSY4EtXCW5lucoTrlHUdWSPAzNkgTJGIONUn1N8bRRxt9NNd4e0RjWaMS8AAxjkdCAJVeDNVLOI5s+fCi+v09JBGRSORBCsaHnLcnBUMlHlmhaLLGdRzg3zbDejzdHt9igPoGwOGaasUm75pmkTN+s0Tde0zMv6mrah1LvUvfQdzynLIfJToFbacvpsWgfTqX6XO/yfZebItDlntfydN6gfin1ynGDr2LIgD2cEH74nAKOsdcDlGPA0Ie85gS71OXEaGDA1Ayjl5RgODwFBTtPtxQGA6ejoAICBTIZCRqP96Pd3kcOTaAIanDY0T2cvWu1OnJDfAf0ptLBcLdqR5gLc7cYGAOzWu29Hf38nao1aTg+3AbfLyyuxvLIci0uLsbS0FMuLS9nGo9EwAZtgLNvXdqBN1CcmWgGv82DMc/YBwbNtb7BPq36vficQUrdxNl0BlhaxETpob496ahlD5+z394kDLdG+qQMpzw5A7dH6On14FJcuXYlX3v/BeOWVD/D7OEGt07QztKsWyVqd8kBXObUKf2R/Uh8tqNK9dFynDjRvtOotyk2/UaDs+mfh6Qlv37xNx0pcdrB3JFoIjn8VkeUDOj/N5BKhsbxVoiWRi8yPAFkCosPxMA4YGYwHfUYDfRiyn2biNKuD4hW4KYSmxJ3EA0G1GA11GenI5AKtWcDULARptp0Hu9FYH0Jks3EIcWsdy3chQstTg5FN/3iwR1qMOhnxgsJyRDUD0zrSOtrd5R2FKoK73owxeXz8a/8w7m/fAow1AGOMjp2mnCqD7zRk82RLlKAiy7bhXP4jlMblVOJZp8Iu5fcp6/hz+k72A/Hth3IjX8pzitfp7RKm7/skL0u6BtP2sL2qfE7zI5y/V5XP62fTlE9fqMBYpTSeFM73/flg31evJW8SrYqrdSrvTSNU8SQ7afFkRmDhFeeK5s+FcsuXqvdVeFybJ1dm4zTpjD4L5Yd38wybTn/zTMHj9cmY3+NUpFpPWvB4r9uO+XmBTyuBmFZ2LV2zyC6PJnJFq5S6VnkkwFDuOeBUeTsNN3ZwKKgyd54l73FfReq19denzHZRMep7Zjg2D17SvcKpzd78fCwsUBbAWJOBnvp/xgky0rCVMu60LVSs2bZ5LQ+Ww+Dd91gGeb+SyznItfwBIDp9x3O+mqFKx2DTeWTmhOwv2lyr2HngcXKMzLHNLTP3zKOAjmK9E5AJNh0Ia9U6SMvWTNSRqY20yuS4uqodmTo9eASg6scuQGp3eyv2d/fRDWPa9Yj0mnk45eo06iz9pPtJs9VOQHXvzs24f+9O7O9sIeMPcgajJ7CmrwVkCcZWl2N1dTUW5xco8wllGsf4oPQxBU/QNwG82J5zToPSBtb5PACrQFnVFh5V+1XtW7W9wTbxmCQoFmiO0grWR++lv9hwlGUY8FvgZHqH/N7Z2Y71jS3asBVXrl2Nl156BTC5Sr61GB7QlrR3C/olyQRuszXypk75ZxtlncyzDBZoLWiumQOO44n68pll7KkMb90AjOWfxCWhCcbOEZ9Cxod5X8EE2AJ0TSCqowMAl46djFpGAKSxVi/n5onDy8SHsJ0CEFzpm5FM59QA4CgZmlEqIKjVbMMgjHKmDqM5RZoMgURwHpx89n77M3H4QP8ARgvkdaSFyxyIb8nqEK/TEwI1gdZMWsOoCaCtBtOekN7x/m4KNP0wZuY7OYf/O1/9B7E1eJij5yZMWgeQ/cHBmO2XGsNfRVdw6dmpivNBQfftAy/li9PrkzLF8ngo/TP9keHsnXK/yqf0o/eo+uk759Osrsu5jKg9noGxpy/8H/7zX6efz2jsfD+fhifdI6Q1hEf0Pr/k3hJMo1JO/mUM05jeM8zMoBjy2ren6Zef+Y6AwlcSPJBwkTU84R6cXgZg8LvKWfmiEtXQ0qjPpRP80dE4rVlam3rz3VjotQFfKCBkidNRHYCYVrD5di/TUo4ZEnA5cHMAyHmORHWSNx8HjqkkLYOIjwI6FVQsEMcxGTN4tCzp7E5iWsaohwNEb2iROwK4VY7+3bS8dWJpaTEd/ZstBoTTNshFBgDIVKQE20MAaN2VlEbz/1Juf5mFyp/45k0o05nAGrS0MxgZV4sUh3HPH4IDQ/XbwKskrbImfWVcPqNaplely5HReT5b55iCkwJaMpmsg4fJmLfPeYF3Lbl14o++dLrTJ8WKWQbVI/pyyEB9NBjGLoNjQZl5a+WjNOiBRvrxDQFTW1tbucBs/cH9HOjXnPZFPvcYsAuq5wG8xSK2HPMLBfy20CECOEFQVpMyOEgXxNoOSWf0v4N/aaGq31kdz34bTttu2jaVJcxQgTGnJj12d/ein/5h5dBS5oyQ9Ou1tGjdrdcEWrp2/bn44Ic+CIi8mBYyp3rVl3NzddrX/rDdGug3ABh0aTsKxkzT6Xkpp9AGtES/tpsdaGQeQNz2+bTkz8JTE954+wb9SbfS8TK3TF4YXfCNsAIIHQ72YjwEbHEWdGmGnUBcEkhOvkPwrkQSaDUQjnMCLZhFtK4vl+bryjFU82uTZwWYaYKeCmn+0ydCOcQ/OZgzDA3zHD1cj/5vfpqBMIKJdCaAqmNGEJqbcxUPf3UY9IQRmg78cwhECiQH5SqcGkx7ojA8oMwIUAHdXLsdO/2t+I2v/AJMsB8t0mq1qIOjI7n4fDgFVI/dnwbLn+jrSeExMFYxT77zxMCDUzBmIN3pT7qolGD68vlYZ6xnjOnzcxFs36IQq2f28fkUqnvlPa+fgbGnL/wf/4vfmF6V8Hgff7uQ1oJp358P5ylb8FAF4ye1ZfzUxFCe1/5frgyzEK78nwF+MA2VtedUcE4zkoYgwamrpH8Ul0BkZg4FjAxwetFVckuLC4CeTnQ7ALC2/liutnORjmUp6Vme4ihNDqTl4FDLWBZRHqA8+qZpWUpLA4qwDDpRgIC2A2SG4EArvnEMtsucbg/E0x8sLWVxBDhsxMrySiwsAgYY9Fk2fcQUIak8+UvZJ1g9oUz8+a8KWmyqGxXbW37LWLVmFbLs2dYAASvDpYO7tGYrv8/Fr8CH0cs7PqMPlJfWn3p4n/8zHaVU6gD/+D0zR7kBLJYsB8f+UUABlnqipGmbWh81CACHHi115Ww+xPEQdCbwRL5nHXjF9hMw6bg+GnIGsEhPTt/du38/3r19KxcIaHk7HI8AYifR67SiA8B1alLA6yyKqyZXL1xggN8gfcpK+gKksTMxgBatXVo781r9o3xHVwn4zoMvrw1VGT0MVR3OA7Hq3kQa4dBHTKvYzvZu7O31Y4AOGqSvmtYrgZTlGQPUdOLXp3kmLl99Lp5/4cVYWl4iLeg2u8Fp9qIvaZ60WFouKW0CTeaMUtKtqyYpI+80AZ/NZps2cpq+Dn9c4Tl1oID20LPwFIWvvvkODEV3O9ph9HEIU0wG+zHY247hzlYcDLbT8dB5faciFHBztWJWrjXrABiET6OdICz9CwwKPg7/uJnASwDW7vSirlVsppb56YB6TLoGGUlCTMaWv8knQVxtNgavfT2OX3sHUlWYRBxC1DOab2HKijnqXOdSb0ZFOvWbCGyfzx1tBcIwoh6T3S1EBulAxOvj9fit1/4BZZ2kU2/x69CxtjDiaZDqM3wL8k7pMmXex+M8DsZ8niPZ6c9vCjw4ze+94Zg8zj86z25n11XZi1AtgWu4vQjS6Z0nvOu5HCWN/+B/+Gqen4WnJzwOxv4gQWVo/9v70tl5Gjk/QJE/KsuBXOa/IhuMI/0IU8q7juDnvOZfKj1eK/6j4/Tt8h3BUlqMeM+tJQRY+o0uzHdjZXUZENaLxTzm4dN6kVVHTlMe5+DJgSCZJq/r72S5vU5FS/qTiS4SxM/7KDkUl9scJChBUfosrScoO9MUqBxo4Uee+IL1MR2nUR2EmrZToYtLC7F2cSUuXrgYHQaA6a/GYf6uOLSc+p8KAEwX9Z2yp5IvWUb+SvMU3rMxk1ez+Yin0vWwnU7BUj7M51qzjrTYGZdw+sQ8iJe/Kb8xlETWP/sn60X9p2lZZ68zJvXUkid4SXBlV5sW78zVTDcTIaZn+9jpWadiHVwDHmxX60AZTP60voIZzraHlsRpEekfAPDoIFflb+9uxzs3bsQXv/CFuH3vXqbfqM/EfLuTdNCjnd2yYhFQvrC4GL35pVgAmAlODpD9tvuUNBMAlXYrfojm6+/HwVg5l/b1eVXeKiRdJbAqbVbShEYSTA7TCiYA298fxj5gzHvG1xKmjjOeU5X9vb1cqfv8iy/F8y+9FL2FxYzrth4tddm0rbTcCca0jGX+cJMzUNJpWZxylOnU5uqosS7gdJ5yCSrrtNVirD/alu9s2mfhaQqf+8zvxWh3Pfa2NtLHazDsx5iRSlq9AERuD6GgacMMWrvKXLuEkCIWZinELqPKORK0jO6cv4zS7CBA2z0GULPRHx3G/si9ZxCASSoz0YAZTEuhk6NECVLG4ZbLz+e7oP5PfzLqdzfiZM4VNjDEwTD3VHEqspQBYUDZXOVUjWQ1Q+dUR/owTHL6tN5dSqB5wkir0VmIt7ffjo995R+nL4lgrNUslrFkxWRIEs4MpuFbgKQKiBm+iQXynWlaGTh/WzBGOM3nXCTbmd8pdKe3z+d1dl2VRaE9vST4XEZ/vHz+fm861aED/zMw9rSF/9P/4zenV986PK5sDFKA9JXXU3rQGnQ+7nlAdgrG5Flu58pDrh2AVT5jpuMeYycAL+PnwhxA2yH8q0VKoIZ2MWaCGJ21FxcW4uLahVhaXswVjwsAMKemzPoYACaI4mXSLuDBEiVPTIvmAM58dTLPOMiE8ZHyzGki5YOeC2UVn/krL3I/LBSdDuz6dVXp+zzbgvfKcy0Ss7GytByXLl+KtQsrsbi8kMBMMKOyTACYVqBqGgtAIKDJ8gkQCyAwXac/sx1tLvLwogyEpoAAOWHwlofpWpwEU76fmEhVXeJnOxjfP9Kr+rHcMS61414FKspd2oN65RQlaXmvWLZmos65ADLLS2Y0nj5xlIK3ShoG72S9qadyNwN5lXr6w3IDaJzuJZ+cIUHO+o4rMvUVy5JbBw6B8M2bt+LdmzfirTffAsjsxyqAS79effAWewLzBWhkBZ3ULm0FzamHrFta8LhXQBTgjDKZnyA/CYVnDvwFYdlu1FPL3fmQ7TOtn2enIe1Pr6u0BWBOteZ0KyBsPC57hxlX2lTnHAxHse+2FsTVl/DKpUvx8ivvixZ60W1CaITMX+CV5ZF+Sd/fh+jJ7F/iaR3UKkaLZrvps9cGiNVrXdq8gY6dB9iN4+a7D+PunQfS7rT0z8JTE/7+/+c/j2Hud+KqF4gDgtDs6ZLaHkSvxcuRRDL0lDBSqMm8EL+DxwP49OBoLvaPIKpoRIf3rqyspClZ8tkZjGJrZy9HpO4BJjOkoybpKmgbMIL7qLgUvQm6V3AhSmO+VY+uIOmzn4rOzj7vCbAog1MQkBqlgDBhDIToLKDRUUMKeAGVgoty5mrLw0G+O1vvWAsSR6iS9+2dm/Fbr/4CIPAEReDqHEcWRfD/zw3fzAIkpiQ9tZDxPIVsyeTbssw5q1pOR1BO2yYF9mOvVQLWdM+X31vez3eneVYjQEMK2cfK4kjb8AyMPX3h//z//K3p1bcOVd8/HpI3CRUd5JQl54zNO1PWzfdVvElXPjPkNJzx+ZvqNd+b416dC4GMFrAJwMg9/9xcuc3gx8HW8tI8smIhtyhYcbPObjd9jHJfKAdUmTfyhvfl8dziAX5WmWlVUaEn+MhcVfxT5QlPGA7g/wOBHCBM7KeYO0bRuTrS6asjXS6OC3hT0jXmBBFHMUaxOt2p1UUgOT/fjcuAMBWq06VzDeQW71CczNPa55Qe9RW0mF6xzqhzS6Okxd8bJXrKoZQPpfB5XZLinqdpG/vTNKlm3kvwJM/zLH39FAy0uCAgZaSVNC63S0peFzBmnZWZmbIPKVqupMz0isys8SJwKdu6Wl3uHl8mKiDIxL02CeszDcpd62o9Bb7WpYBR2sNUuFHFNz+BoNNxgizBiCvrDYInrZx37tyNhw/uxWB3h/4YFsf9lqsoyxSlm9O6YlJdkC4v/KUfYLYJYA+ArJ+YLjFOH5d+KvRbgTHjVf1jME7Rb4V+PE+gRds09R/Pi7VrkNOqe3t7gDG3ryB3nkmTTpPqF6dFzDhaeF968cW4xEBDS56O+gfEa7lgjbJoXXNmycVnCeyhTdOxP51GV+dp/hA05ka4jTb6SiPJIoONuRgcTOL2nftxGzC2vz9SD2ZNn4WnKPyNn/lPklHqELgOkZ1uL1zFApXKoRAFDJpEwTW/R5PZGAK6dg/nYsggdXg0EyOYzhGfDPX8pYvx3MW16HYasbG/H482INZ9mIX0ZhAmkBtxZ2IInbsKyo38wD/JRDJtC8ZxqmIAKV1Z7sbR7l5cfPXz0Rox2iAOnBHHboORTA7oIi1Ht757DOPpizAD46WTZgoomH64H7V2ixcaSdwzABv/dg424re+/D9Rj50clbeeBMb84TtcfifELQucfz1/pUR01D1Nw9/TWE9mGStXYqTA9JzvOOp7r7A+Hwogs8jlTYO/M49pev5/Ps8nXZdpj4iffgbGnrrw0//l70yvSngSfUkfSUfT3yXAkHR6dc/3kop832vfOX3BJ9M0vMdPN5ostAqNwndaJ3wwh2KZgz9z1SHX+mXO95qAmS5HL1a0gM33uM/ovuaeXyrx4zLNl1ND093oySi3seBegjNklmMGgceE+CquVJQqZO67ws9Bh+UfTw4YMLrLOwANQOZ9dz3nhZRpFeizfHVKnWCMNHUEV4T0Op1YQ5leuXI5rly+GO1Ok1jFojQh3VT2KEjLJRCwPQRz2cI2A/KNEmeZvaHT+2kf8NxpQVubnyVyYh5fNOTNZPcEYl7zp6uWNxy0Gn2GMvvQNihyoHqfZyVhHmtxKfW33arpT9s6QantR1TlszI4/eR4RzAm0KkJymgj89ESWtFDBVrS55f+K/UkLm8nwCPRUgbvlUGhv5XnHv6vtcwyF0tWAUhWQRcXXWd2tjcBN4Dq0SDLoGWry6Bf1w1BkW0vDR5kXcq0pMBFQGz/OC1ZLGOGbwZjWZ5pPTx/83EE2Co+YgJ9wdMQsLXXd/sKpymHAHfprUyP9vP+INu1Xm/Eyy+/FNevX8s2EhhKn7PQO5mTtgBSHUveNJODC+9ZTtskp/Wpl/vluVq1XmtGo+20eJujA7A7jjffuRW3bz/gN+BurkkbnaeAZ+GpCH/rv/4vckRalnxrLpUpReYQoOic8wEAbPsQogeACcL2IU55UmacQDyQVbz/0mp86PlLcWFlPq1ed9e349b9rZhAErMIJtOecEghAi5kYszBIC2kn86ZsGM65Ld1O3MUxfEcae7duBEvvvW1mNNnjUxdBXUCsUtofu4omSiZT6JmhOv0Q4O6kHaOFgWRMAURo9ZxVSVMT3wFxsHxKD751V+O+9tvU456+oy5zxhR3xNSjJBhCsDfL1DBSkgZHLWmhAOMpaXBnz7wIlMu4Yx1eN+IMmKV4TkLmSHjVuaHc8H7JZkqrRIUdyW/6a/TvEo4/zNH1rSz+xj9+z//bJ+xpy38lb/xselVCSqrQgH8cSm/2L95z98Zi2CfZ9+jGHhWmACehE+k5/QjInZuHwP/oxnymTzmvTr8xy3iHamCSdvFPYKc4+igQBYXtGS048LFxVhZWYj5btmDy2kwp2N0XdDNQCf6/CwRh3Qp4DE/4xyOnU6bDhCVQZTJeqm30u+IwRgFSpmVVrOpdcEVkk5VukHp2IFlVojq+SJxZ5QHpGf99UWdEQBS23ajjjxbjcsXL8TK2nJa7+oMHgfjg7TmuEVC+VKIQCBxSLaR7Zt7jpkmbZRTYPKrDW5Tk08BC3Op3G1uy5MtTvmFKQVpescHunFQXH4dTkq/maF1R/9HbnpvlaaCy+61PNV1JjGNI1Ysn0LyKEBDRe/0sXU5BLg6hZzuGryTC5pIQsDqlhKWjgSyrIKDUnZiWEaC9bIc1tv8zMc8iszhPm09R17WQR8x62BGWuwEZLlJLukKSFxEYRvllkrE83+ngt0ywjKnDxr9pd9VbjzOXzU9bZvnhr/Idc8m4WH7VlOkHueD76eF0HSrMtvuSXPFCuuCgwH5aQ1LXzH3FdOCKrjib4z+cXsLFx+Y3gr088Lzz8fahbWcZRoS3zxqbgOCnhLYSduWN2mVeplvgthpeRkWULrjaLZ6vNPj2j3I3LalG/t747hx616sP9oE4PHOrK5E9B2J2OLPwlMUfuUX/m4Ktoq4/WyI4OsQlLV1VI/NkaO92dgFDGk+lSiQBxADzIdQc8ffy5cuxg++eCUuLnZic28Qr9/djM2dPkQvNcEIkIX7fR0reHm3CVfIqLkkHfAjuSEjYHzAGe/42YeFbic/nzH6+lfi5VvvUsZkxRSeLlFPQiM+lJvgypHOsY66wzGgq4tkLAJBaXQM01i3+uIS5XFagLd9j0K8dvvT8dq7n45mYzY6bvyKgPW188GcxUMyh9dV8HeW43ywruduPg7GqqBoKeKlhPOscypUq3uPgbEMCPfy+FyiBO8pSKZJZFqmc5a81+99p9SqtIdPMj7t9dM//418+iw8PeE//Ou/O70q4bQ/PUuG0EOhr3M0kD8LGEngwzkHMvCrtMz/Sbs56CERt4aYALr8nTvO530jwOOHw+T1XrcG/y7kCsiLK2tx9epFwBcpzbpYBpp0WpC/kjVlOuEZZO60oMov5QtPjZHgivv65FQKPl0lABXKJIFR2RpgjOwQhCmrlFQWjeeUTwvWcDwClB0ia7w3tbARcQbZViMdgYbTqoLJ+VYnrl+9Ei8990KsLi5EExBGyRLYpfTxs0hTxGMpfdd2tTkKICFdypnPECjWL2Naft8nJJClbN5JwOZVviPw5RpBK6DMkiHf5mg38YOLykdj30GONrjm9/jAaUbAqnKaOo3yM0NlUK3/UcXbykkVvFsh6MPUaPoNSAbhKf8Bs3RCBcy0NFkOQVf2CSnUbB8FJG3uIbDJrUIyJumTbkVj5meuWWf/I8zxjlPNY1EhbSUg89oyufo+t57g3QR6nHPvMdqoOKzTM85+WBffc6oQ4JNO8JS/WOFoP9ItZdC3CjBW1wo2LR/5+PwMNJY+NEj77zloO8nQOkh/Tk3uM7B3Q1fBmKDM/cwSjAEcKWFuXbG9vZNxV9fW4sUXX4zLly9nvofU0/gWYG4WQAWlJS1z5HSkdGo/UD+vzZcqx2ydM3VoAL568+5HBgjbP4rt3VHcubMeD9c3ee8EcNaJ8TGgLvmpavGnPPzcz/1c/IW/8Bfy+n3ve1+8+eabef14ePvtt+Nv/s2/GR/96Efjs5/97PRuxL/yr/wr8aM/+qPxb//b/3a8/PLLee8v/aW/FH/jb/yNvP53/91/N/76X//ref29Dv/j3/p/p1Dtw9D7k25sHsJYx/WYBa0/PB5H3zl8+U7BDHHo/+GaoGOY5crKYvzxl6/GheWVJN71zc145+EOaUFmjGzdIUX/A4OOrPyC6GA0GEti0yFzvqV5n5EHcZqNdnTBV3uMPp67tAYAjFh947W4/uiBZEkexRnzaITA1yrG9YkCGiKf0cdEi9kIppjvpgArgoHnMI7Ctza/nEItgQw5qlju796Ij3/tl4l/kL4IgrH0kUhEVRj1PFm/B1Dx+HGC/yYOMJJhCqiq94uYPhMEBvNJIfat2OgcKFOGIB9P86uEiu9WRwlF4Jz9LufH8/Bnda96/6f/3rOtLZ628DgYk1CyP/2b0sg3h3J/yqoZN9/zN3wtzabPllYcwEFOI+lbgNKQcPzEmNYcB1JLC524uLYUly8u5wf/XfnmdhVuk3N8cojCMB8FiqBJQIdUQHnkDu78SYLp02TS/uZiDMBQXjh9rqJS8fkuKaGAy333BtOSIihLMGbRSSy3qOBQeavYR8izsVYrqmythUhIkrL9Bjkq31aWFuN9L74Qly+s5UemtfohzhLoJTtTT61rAkHFhLfkMdMSoCk/rE0JU77nt3fTKsXvso/itG9Mh+iCh/ydYMAmqvoM2aYso8kdLO/3xyjiXRTyXuw6hTccxP5uP3d6d+pM0HqY/nGlrSpLWLpoZD6Ck1rZKmR5KS5duhCrq8tpvezNt0N/PjftdpW5XzKoI/vTEkn7dexAZxsAJ94TfOYm29aHuuuIUgXzLBkmmXgH5aE1C4BlPamPtwXT/CIq75NOAjNoJrfWIAPTEaA5xVdWFNpe9AE04BRmrmikDQQ6xjVL00irGketDkyaWsfK85JXdWTJuK8OO3/tWYDr1hhuXWE+O7t+3qismBRwOSWp/5d0ppVij+euDF0DiL3w0oucL1AW6pDpyj4FIEvvDkIsl9Yw08rP9hFJejBvg7TU6jRyF4LjYzctXqI9m3Hn7la8/c49yjNEk7k7AXVBJ/oFA3rl+weM/czP/Ez81b/6V6e/Suc8Hv6r/+q/ir/4F//i9NeTg6Dsl3/5l/P6z/7ZPxu/8ivlI77n73+vw//rr//XCLtmbE8ASLDSIdLGqccG479N58g1qyoY6ogsQFTd0RzN8fzli/EnXnk+Xry4FA8giLfubsQuwqEvkSE1arzTRmjlt94gxQHgTkJTmslkBvcP6gC+wD8wTAP034omI8/R4SiuX7kSb63vxo/c+mosbG3wHkQ2gWABcDrfKvzlrmPBGMzixrJkkAya3zXjz83zuBOTne0UnPXFFV6RUGFqBA1X0Z/sx8e++o9jp/8gpynbEH1+DPgcGKuCdPBtwZjVS2ltqM7TGP8swBgM+N4ClOD7lWAp4Xw+5YXH8/Dn+Xte//s/9/3jM/axj30s/s7f+Ts5cHrrrbfy3vLycvzET/xE/ORP/mT81E/9VO7g/aUvfSn+xX/xX8yNGX3+m7/5m/HDP/zDGf/x4GDsx37sxzLutws/+7M/G//Ov/PvTH/9sw1/9Wc/Pr0qPS05FgFf9W2hr7PfU42YqAL61nLiICcVAgpGoMCBbgt9t/QfdWWXDu+tRj19WDrw5EWU+QUGZxdWFzjmeQa/AqrcCkLrk4McB1M68HuWInOakWcgjQQMWoF0cbBAFkmLjsouy5hKE75FkeXeVO4ZSB3S8kNs6b342qjvtYQVsJcrtzmnBY/6aR3Tr8gtGrott8NBkaI866Sv79oygOT61Uvx8osvgrlmASX9XNiT/lWUIEEYfycCBX4rc5RmFq+ytmgpoqV8mG3rlXGtq3UqQAGhx82MxT27w/tcEkewAYggD2Xt3u44tgBb6+s7cX99PT+O7Ye6pbttziOnYXMVH3U1LY7aXNOuy/ao+jqBImWzJubp9J9O7QIwtw6Z73XiwsWVeP6F5+Ly6koszneyPvnpOUqqvFbVn5CfItz93UxDi495VEDK4O8EZzZM/i73jpDXWgz17fM9UgNEzJX+EtAQGsht28b2dCPfdLynD33fuin7lfO50pNfLj4TjI2m4EhasBwCnVIm2rImWLQ9lIvK2dLeVSh9IAj2+VmbueecTvj6pTktWT767SeO3FXfAYH5j4l3GLtbu3EwPMyFBR/8wPvj8tWrWQ/LlHHJVD2VAwrBsgMQCjUaU3b0rEaKshij6AH7yjZ2erPd6ZLGHLR/Ehtb+3Hj1npsbvZpR62JzRhLKPSOYEz9e1az7/PwnQCxpyXcHCzE3YNabCDgtob7sXvUj+0jRxiAmxkEhkKjWSvMA7PPIoxfunwl/uRH3hfPX1yMrf1RfOnGvXi4vZeE0HDfk858+oPUEWI9Rsf6anXm56O3vBJNzs3OQiyvunx9OWZbjDzbLmFfZATQiUOYRt8EHfx1uG1CqFBvMk/qC8gs9w2bLT4lPEzmTEYVaAnEkv99gQMmP4ZZZOwEWRC6Kwsldkf0TUYZq/OXUiiqHMpULO85bHssmJyELsMY3/Kk1aA8LhcCJh+UFL17Gs4DOVNwerY6rIOhEgJPCkV5lSMdkL911KzfWTgfMQv52PHe4Lvvff/pDRsoLq3Sf/pP/+m0TFdAzKAyc4AkL2vhNjj9UIErz/7+VuHu3bu/LxAzuJrquxWqviuHNFOUmIAsFQ3gRTpUjalaHZCoUOUrlYNK41CFhmI0nrQ5N6MtXF8qBkMzYxTEcSx2anHlwkJ88H1X44d/4OX4kR98OT78/mvx/JWlWGiT+mQYJ+P9mDkaxtyJU0sHKOIBAyfSsBzwpTYUrdNOTaqk5XP/9DPNgzgCrpyGpNz6e4219KDM5JYx54OJe4I5/cPB4HEA2HIDUS0X1kMFKw7TmuJ2ODXq2lHByUs6+ZO3QGMRIPLic9fjBz78oZxS1f/U/cnc/FRlnys5Q9DhQZseCyocviJLyEOAIZKq+Fqes5zV1JmdIRfmJ5R8xpEuIWPrxG8Ag4dKdX90GPc3tuPLr78Tv/2JL8Q/+pXfjL//D38p/n//4J/Er/zab8cnP/PleO1rb8fNuyjkrUHs7Vt/enLO7YeWkL+riMd5BqXzUWsuRJ179fZyHrXmYjTaxOnyu7UYR8i/7b1x3H+4G+/cfBC/97mvxD/+xd+IX/hHH41f/dXfjddeez22tgcAImcNXABFPk6xcdiNOY3KOSEp8jcRj4RHkKoEG+kuQshFDchG/wqQsT1sB30B6R9eE1jnVDL9rLVpRB9p6dPaaboOFASyAjQtSYIbV1bOzy+iQ6C9hQUAXAcA7aBaf7Hi+2YXpOzMbhJ0Of2ps385HCB4PkzwtZ9WR88HgCS3p3BnfR31tWBZtgq0yWde5z5p3L906VJ86EMfBNReJO9iJax81AxZbwpRvTccSVvGaVBXLZrQncAK/ea2Uk1AWK3RgV6a0HrEnXsb8cbbt+mTPnrQzc25ry4QfM816E85Vb79IxAcDT8OxP6z/+w/SyGfgIDjn/yTf5JTkU9D2DzoxyZCcxCH0Ve4QQiHnPXtkpiOIIiWCJ1RsHuHvf+la/HjH34h1hhB3ljfjc++eSce7QzTab6bn6OolxVSAK3OonsFtTR7Ra3tSk1GzL2lmGkhNCCyZtuluW2Eh8t0Xe1iHvzudmMXwVuHAWsI1TSRi/hhQgFJfjycA80AOIIQJXQPGVUn0ymTKvx8l/9jlvQPAUpHTpFMwVgyBgy6ung1pzRzZZV5ybEIku80iL1OD9Kt3vzOU/jOQhFuTz7Ohyfdr8r3Ry385b/8l0/dA75XYRE++G6GqtuLPFLxQNMchbYLPxgH9knLhWfGKflt1jrIZRbAoZ28iS7xY2M1QMjc8QjAtI+QH8eFlS4g7Fr84AdejA+/8ly8eH0tFjoAu5NRTA5QYMM9FMwwGgCZblvrGTkCbJzeMq+0XjhdJfADILnn14HHFFBpZdD/SwUsvFE3+aw/GMS+FgrA1og0XJE20qGbax2pdY5O5clzfaCoLPkVmawFzKlS1WMLeeTnz2ZQwHo7Xb20Fj/0kQ/HB195JS6uriBKjmPEwNSlSa2WSt+kVKLFQqj/kX5VZcWkA0VLaRyBCe1MgfXd8pBrHR0KzIqHv87pTnkKyAoAmwCCh2ha/Wxv3X0YX3rta/Grv/Wx+IVf/NX4h7/8a/Hbn/xMfP7VbwDQdmN0CF/7uRuOmPNokYOr3900tAEgmJsCsxYysEM8FTbHLHKYA6lKe0Wmc3gsUPGrKfOIwSbgdi72GQU/RK7fePdefO4LX42PfvS34xd/6TfiE5/6Uty4+ZB+odQAMzf9PqLcB/SR/eMAVatcLhihkdIdxIEr7VFNFeeKV+JOiJcWvGw9p14LyFa2OyjIdDi0bGox0jfLNGxfZZppmLZWUQfsgri0HqFLOugVP8zuzvRltaR9JQib0oGHeXNW/ntYNn3CqnO5LismBWACe33BygrKQdKvAwjj7TNYc8C3tbkZC/Pz8dJLL8Vzzz2XYFDgZvrmZVkqQJY0YhtM86eApT55fwZ12aQ+9HHuFuCMUTcGBydx++4WgPleWsYOAcVH6KykIQ6vJ7QfWZEWXZA5fZ+Hv/bX/tr0qoS/+3f/bvyVv/JXTn3DDP/qv/qvpk/YH5apyG8XBggzPy1kJx4BhnTOZ4wQA3qzmcKjFoccjp4/eO1i/PFXXo6lbjtev78dn3/nXjzYHwHKATqkVXfjVQiu26xFr6OFivchrjp86cpHwV232UDoIwhB84zJy/TkbB1ikjVnGdk1cnQjYS3pnQbBS6yybqKJE0pnXAguhxRmISiT0BnKa/ie1BCQgEeFp4RZlzGnH53dPNiJWZ30iZfbXxBnkRFjk1GG/gG+IvOQqs3zWLAcBImejCu7Vik5taEIskaWlrKV3cAdNcsuvMFzXk3Bdf7dknJhoPNHFUp5iEP9cqVlWt/KUaZTnxzOg7H80Oz0Z8nrDKydP59/52kP+n7+vb/396a/yrSk/Lq+vp5t6tnfug380wi/+7u/m+k+fny3pijPgrwFFUoa8KBKIH1noPdUChBq0QsSuxYpLT2HCcI6zVnACsptluvaSTRnD2PmcBgLrdn48Puei5/44x+OH/3hD8UPfvB98dL1C7E034hWHZAFENOCNsd7CJTcE2ow8Ft9uwmOtBw4tegUo1sAuPJrdOC0GrTozu0o9xlAklynsnZXchVtAWGj2HWF2u5ebG5vo4y2YntvFwBT/HbcJFS/Hvd2cqNN/ZkEelqz3O5G9waBmFOR6R/G9czRJNoM3K5dvgiwfDleuH6VutdIY5DAtNtppbyigRgk6qSuEJMXBbbU13IXYXD6l/xDpLRgc1VWsgoGCgA7QoHONcp3eAOZRxOgZI/i0dZufPG11+Mf/pNfjf/+5/5+/I//+KPxqc+9iuK9H/soYS1Y80sXo9Zyb7N52qmLvAOAcdBD5OceXe2o1wQhCwxyF+D1ejmQ3eaF0IMWikVrFiA3C1hz4DvLIPqY+8bVJ8kpr3Z3McHcITJ6hPi9dfdB/Opv/E783M//g/j4pz4XX/nGO/EAwObWRqZTEzjQh04yuvgqZyh0EYH2bIMCPuxZ24M2Aqh5aP20/8uMBGSTIMkoykbfE9QC2OkvpwKH0JAAKNvc+Pm+PlgF0DiYbzHAF4z5qSR3CNCKVkBZKQev5vV5/vR+BcoM8otx9DN2etLVkR4C/fxEFvGN4+9NQJgAzT053/e+V+LChQuZzpkF7SyPYpEjL46ko1KYBKP6u7mDfleDRWuefvAzRz3atxmbu4N488a9eP3t27HTJ16jy+jJqUktiRClhgfbLfVgocjz+uP7Nijgq6C/yL/5b/6b019PZxiNJjFkqLHnSA5egVWDMRWdDDHSwzpN+iHvDz9/Pf5XP/QSI+BmvPru/fjsjYcxPKlFrd2NBiOSFmBH65LOkjOMnh05jiG6MYw2xwi5jlAfjxVss7HQVoDLqAo4p0BdaYIQpjwuJ9ccPgIVrsQoZimbjCtxuU8ZpeQKQau5n/RlmrSEcUjYCsoH2w9jpOzhd8Ij0j8mvTnK0h/uxqRLaqSpr9nxCEZi5LjSuwSTEA/mcWTL2xyPB+9/c9C6IOO+/WgYn7p5HL/B8Ss3juOj70T8OudP3DmJz9w+iHd4rpJxafcfJJyCsG8KTy7P+VDaIK+m5xK8XY7z903v90/zaQn/8X/8H0+vChDT/0t+1TfM4NnfDpocUH2/BPu0OFRD5yg2QVhuGcCoqAbfyUUQPxThlgYCqCP402nDcdQY7MxORhGAkrmjQaz1mvGB5y/Hj3zk/fEnfuAD8cEXr8e11cVYbMJzrr4DqIVWr2PB0H6M4acJgCgVXcmpWLtQTLnRM0pEQDIz24SLa9ybRc7oq0o8eEjApgVsb7+fG0VvbO9wLhtrDkhb/pE9VcRjgNahm7mmW8UEneSAaCYaujpwODByWlKZ4qbOPtfy1203Y7nXjZeffz5+9I/9YLzywnVkHG0DwpI3eTV93Op1QRVAlXsM8ci3WDlS8+WhvJke/BTh+sUPlatfHBFcJhDSB8opJNpDBao8cgXk2zfvxW/+7qfj7/+DX4pfAIB9/tXX4/46ip8mPQZoOZ04C/DSkrU3cFDqlj2dVNC2XwNl3eutosCXGOC65UEdEHBMOwE+adNUyWpn6QD5mNv6CIRyZqGOwgcE0x/5ObtWp4AqynloA1PumXozy+nua5355egsLMcbb92MT/3e5+I3P/ap+PwXXot37zyIvSHtT7oFZDJ4p9Pt77Rw0qdpCaN06hObSfr0yj40SKcJmAQTiCMPgYWfzeNpgpoRNKXlU2Dub/uhAC3hNbJ/mpYgye0stIz5qT6/WZnfe6zkXJ4FQoKjqR6ZHhOnLBmQez4Yk1efvgD0u2JTC53bZiSYgp79LU26otNvk/7ID/9IvPDCS+SF7qLDcmoVneM7E3QrrwEsTxgs+OknFwQwiIDW3QrD+1rDOrr3dBeyP9xDTIvlYHQSb737IN54525s7A7Rt4LtXvKSba37kHVKHaGRwhaGXunx7+/gFOV5H5F/49/4N6ZXT2/Yheico56Fae3Abm8+llq9ZI4JAsVvPn7gucvxYx94Pi4vzcfNR1vxjdsPo3/AyLIjEyvk3cjOTWAR6o66Yb10rOUYMao5RFgpltNvhbyIihCQyY5y5CUzlpFkccrUojTi3Xn9xRQi+S5Ko9mE/hREiFni7tcBeAhXR38nSFBXeclmBwcoBEbyJ+Qh08/wnqu28kO/jET3Jkg7AKFTNwqABnW/uHgNYnZZsKOtSlAUBj8LaW/gVO6THfU6iRvr/fi1d47iE49acWN3Jnf0Xm1M4nJrHE2U3fr+JF7facYnHnbi198+irfvl9Vn8tFZeFJ+yWfkQb7TbPOYPqPivDFlRiNS5lSCU8Fk8H4xjxPT+x5G9c40Wt6aplGOTPKpDjrin/cP023gWznifz+F0z6kh3MKcqroBGTl0zZ2NkMtBkjcSqu1YGyWwVJt5gCA1Y9u/SiurPbihSur8crzV+KHPvgygOxqzAvA0hcMUMSg5nC4HyeH0DIKTEps6mZAolo19O9ySsstck5Q7PKtS+9n61p0tIQX/6g+ymi3P0DR7MXDza3Y2NqOLQCYq9b86HIfRTgYDZETOv9D27yXnzg7penCR8odfU3zSxo5oKul5cvtavy4tADNrRuUTWsrS/HhD74v/tgPfDCuXloBfJkOYI720K/UNtMCoyLNqSSVqZZ8gc0ULSjRkpE4W1/xiwaasgjBa+Wbfm7HtMNR+rc56BwMJ/Hm2/fidz72mfjlX/vt+G1Azds3BTS0BYPV49lW1LWA1f0KQS+PNmBrZfky9XazUGQjsrfkBRZ2SwtGsfr71Wb9RE4HsDlPHRzoIjnsc2VyHpYa0OOhL7CAERoRYFgngU36hgFkBFfHgKHuPHlfvBhLq1rmutHsLsbO/kG8/c7teO1rr8cXv/zV+OKXvhZvvfMudQCUQ1B+mUDAJ/gEMmU5BIZ5kJ/yKe1CnPPgz3JMmzZDXqeAtc1pY8pY+qQCOtJsAV66phR/R9qettYqapDmBWO5vYXgU/BGvcyzmiKsjklasdRZ0C0AS6DlZ47cxsJnFquK57HHs22wQKcLqH/55dzeSX3iM8tVZC7vZJrlHY+qDtVnk6hclrMDwOr26HdAWJP+dz+xhw934huvvxsP1ndiAs80oYP0EUOfOnNkLRXhpR3tQ80ZUCO/S+7fx0GH3e+3kEQGQcuccwjOJkLE1Szuxl9rd+Llqxfij73yfCwv9eLO3kG8ubETrflutDl0QBWha6LuQ8BDiEzbPXInBqJ+RhB9nR+HECCEOKcvBszSd7SQIxGuEU7QzrQkjFxhll0E9BwE3GT0kX5iEG0ePE8TN8S419+O7dlhTjlqDcs0UoDo+H8QE4GYTi9KKphROSqoaSFgNu/fiUlnJmrupN1qhSuuFpvL1FuTfzEfS+BPDBaT547AhwjGT98cxCc35qN/NBcf7I7iz7w8iX/p5Wb888+14p+73ox/4aVG/Ln3zcSfuX4QH1pAiUUtPrvdjW88cCfpIjTOwhPy9BZlKa0zPVS2HPz3nld89u3CFEOWkJGrG0/I9ykPX/vae7fl+HN/7s9Nr/7ZBRcJVH1THT/zMz8zffrdCUkXdm6eDeWcFl/ozWMW3shBkzwhEJvTIqT/1DiW5pvxIoOvj3zgpfihD78SH375+fQP1QI2ezSMFjzcAMzl91xRllqfjhjQCXTKlhQoAi0TKpeFxegtLOf3aXU2FkiNAWg7e4Cvrd1Y39yJ9e3d2NofoOD7scdZq5gWEGWHjvvKkqxLjlyEmEWRqtg8pxtAVV2uXTXp580EXV5r5bKMfud20c8ZXbwQLzx3NV68fi1WFjv5Tq7u1PqVZ94FpOT0mHJK5Z6FIGqeSDBBGQflKYM2My9WQAdy5uhAVOuUFntB2JBR583bj+Jjn/pM/P3/6R/GP/rFXwHQ3EJeOT3bYlC7EO3eap5tK325Ju73iL4+5KzVvl7vcDj11kxLSoILZG+D9+scc3MN6l7L8if4po9yvzDEYLGc2N8FKFT7gRWgA22oy7O9rS8ykGf1Vjs6DM4785atFw36dChA5Z1Gp8cgezbevf0gPvelV+P3PvfF+NKrXy3O5TsD6iXgsk2yJ1JPlIGuOkNaLG1KD+Y9264E27LQq/2bQHHavoopp/rsl0Otogz0K1/IfOjzrMtZagJMN1fVn8zvOVpvZbv7phnPo8rHQ4BUVk0yCJAW3TID3ebGxkTIcwK1nd0EggIxP3NkfxuvAKNy2Ly5HQfPpNc8yMv8HAz5dQG/a6p/WX5oPYFwl3gR9+5vxutv3oxbtO8QkD5D359oddPKrGGButiCRU9RX3gyXVeyJf8IWMa+H8NRCyABgTpKOtbk20DIrrZj+cJ8vHDtYvzQcxdjeb4Vj/rj+Maj/TiEyReXuowImozQEFYSP8xyeKxlDEI4OQxXwBRghhAajGOXEe7u/hCB1Gc0PI4HW/uxub8HkIJQYdJcESWh8rrMtgmAa3Cuj/3mGOkzEsqNXmGg5DmYYn3nQRyQl74clsB7ZTzALxjKFVUnPX0qpFFHz2lfSsbsP3wYO4OdmGsDvvSXo9zd+kL02ouUpwhfadzRVgqBc8H7+s/5wfNP3kHAjhfjamMv/oXrR/Hjz3diteM0guLfkYvvAnABjJeW2vHj19vxL12fxMXmML6yvxhvPBwhps6A1uNB1eNRnlYxStnK0LHc8YaCtYqpRaQ6+ywFg9F8nu/4i/+Nx2W12uksFCDxNIebN29Or/5ohZyqQCiXFX9SoLzBtf5THPltR3grXOE4GUIP42g1ACoL7bh+9UJ8EBD2gfe/FFcurEa37bY0hZJzmwqn9SseRKF4dhSu5a0L3c/3FnNZ/9LSSvmqR1PH8tm0MLklwNb2XmwAwDY2t2NzExC2s5cArPgCAa7g04r2ku/9HxCmpUNwlKsrOedv63SsJaDQvmfLpv0l9P1UYXGdwIz69lDGL73wfPzAhz8Yz1+7mp9ry6CcAbBUluqG/qxcaE2RL7S25D5RxEuApWyYHhZXn6hi/dECVQa11rmGsmy268jFk7h161783me/AAD7aPzKr/1W3Hu4lVOM9UaPXIlzOAP41NKlPHQLEAaYyivS0lG+TlkoTCpz07Y8WX/7MRlaAKllazblYQN5Y5/kfmfEzS0mPHjuvl3lc0O2W6EVt09wStbtHxq8Z9073VZ+rL0LEHcAPEKe7iGzs5GIo6+v07AOyK3j1u5+vPbVr8fHP/nJ+NwXX6XOD/M9F1LlzAfvKYUqQJZ+dVW/kYb9pUyzJ6SBCiQlILcPqbd1T/8y7uUXGZDzAjP9rQowt69IgXQrcGVaglKBmD5ltoVO8j6y+Up/lr4VTKWPmFPinJ2CrACaTvwZB1pdf7Se6f6JH/lR+OVDKYrdP0yAaXkSbFEG6+09/lFnFySQD+lZ7xlAs+XxQ+cN97IDiM0CpnXdebC+FV/7+pvx8NEm7aeVssF7ymgtmtACraTV1fRtFvvT66LjLBntwPlZeMrCLCOtWr0dhzCX+8iM9NeCKCSWD127FJcW5+M2gvONh+uxpcUqHe5hGgUyIOkI4lMwyexOTeSIEmIcOTfO81zyC1G7c/GQ37lZIaMNTd1kByEFv8f5oVO5Q8vZzug4WoejmD3Q9wyymjK0zC21HR2NEow1XFHEM8VRYWsLVQTTASObE0DkTMtNCo3hc1eMtXOX7QfvvhujNqPIOunyvDnbjKXOCpEkZQSEnOoL5dUSiOfu09uDg/jM3Yidk4X4SG83/tTz9Vidd3UR7xKncuAtpTLI/DAjaS126/HPXZmN5RrgdrAU63vDVCCqvMeDqZQCmG65897jvSEFgBdEPo2RjF+Y1aflrfOVKsG8ZOAq1ZLCs/C0Ba3Px/DHMUBrFqA1J0ABhM24R98YnnK7hgmDnRhHp34SK91GvHBpOX7glRfiw6+8GGtL89HrNKPW0sH6OAYu9ZevkQdjQMLBuAAGYY9+XiczjWgxiGm6pULb/cU6UZ+tR434OtI7lbOxsQn42o6trZ3YRpY4QFMhzs2gWDgfDAFj8DpMgPyw/OIpfwhzoFnyyU8leVAm9zp0RWSNc34zkQgN7+ku4Vkw4bcunbKs12KhC9C8shYvPXc5Ll9Yjo7fXFN5Ui8BTTX4kk9c6ALco248E7CArXIXeAdpPHEnf/co9KCE6SfllJx+VumsLu/Plv2iNrYG8epXXo/f+dgn42Of/HS8c+duHLhDugDsRAd+p3SRtXNO3+qpy+CQDAViueCG/E/8ALurBWpHMddEStTc4Brg6IFoq7k7e8NyArLn6JU54jgFDbhKYDKVm1qIlN012ka/QfBU1PXlJX59lhJx1meu3apF10VUtNk8sqopSCOe8kFw1263YnVtJbrzTp92YnF5CRC+QByBDu0AUdy+dZd6fzW+9OqrcffBA2Q7A2PEyRx5O3PBsID24n/a3s9eKVOVPekq49YZtJHX9ofyi4rQBqUelkQ5Ss0BJC4EkZYKqDIUGWj/FvmVaUhDnJ2qbLaa6eRfRw/4nvt9oa5yn7YBA4aNh4/SR2xCmdVbkxH6bUqTuw4m1reTbl968ZV44cX3JSgdOhMDfTh1SpWg1wLix+g0QaN6cYDuG0Nk6eulNRPw1WpCO9R/ttGKRmchjujQd+8+iq+/9W70rSRxZuYAaTMt6uOmr3Xqbzu7whfaMS3a3GMmF2yoH2lJzt/3YOxP/ak/Nb0q4ed//uenV09vGNfoZIhDAtZHzNGA1s5Li71YYGR3c3cYX/TzRgAQhZ5ELagS5Y8cuUCEqm6tQY4+NJBChznadGPIMXEcsebIYDSOIeBjvLePIPI5DI4AMI7ArcHIbcsFBZOZ6OkU7MgEAp5FOMxCmClBEIjDkZ+i2Odd8uNespvUJyd4EgzCVMeOALV+ORqR4wgN6iozPLz/IB5tb8SMU5XEM+Vu7m4s8KEC/uOc1ykC8lFs7o/ii+udGNbn448v7cQPXikjGj9BYbwSu4TqXEKmkMyoH8sPLo9yFPvmvquWXC7xpFDeKSkVhQHnTe+9N1jOIni+TeDVTIL/qpTPQnXHg7RKZs/CHyA8aTXld3thgArYzVn9pqD+MpA2tC2I0UnfjZhR+ZwXUbYvXbsSH3n/i+nAfv3SWu6e3+L5iQ7xKEv5SZJKSvDCwRCH02/HKkz4ryaIkA/lZ8ZTGm/68Ijfynt4/xHnDQDZNve0NOgALY8UQiw7w8N7KiTTnpJcZU2orCMOyIqlx6O6dvXcXE63Ooj02k/maOVxo1C/7uHO+Qu9Tjz//LV430svxvLSIsof/qYMpuu+Ugan9PyYs7TvM+t6fssc88/yUW7Lr9yyqIKDyjJUa7ZSBgiklI9vvHU7fvN3Ph6/+Vsfi6+/8Vbs9gUkAKFWGzBVVjk61VhzQYP+TKlgqRdp6tun1SRXcQqc0Lc55Zr1dLryzNJTA3Bq0cpNTYmjHLToJe60XQRh1jHv0Ua0jZ+i04KmL510IRDjZ2587UfctYraVn5HmCSgI4EblYaOaHJbwtYCUDQAt67krNPWvXj++vXcyuUh8vfVV78SX/7Sq/HujVuxubGNzEaek4Rtqk0zF2Nww/oL5Cx4rjjksH2ljSqcTq/aJ4SMl/14DKDSCb5YTKWZlIXZb5SQ6wps+6700ev2cgsMV7nqSN/vD/N7l+6e74au6Vg/1vF+DBDScneU1rGtzZ0YoQdfeOHF+PCHPpJ0OOC9svm2gE+aoGz8pRUX+nKVr1tz6DpjfAGsgNCV/O4+0FtYzMUTu8S5cftu3Lz7IHbhH5omWgA0iIS6mnahw/OH6Vmn/D09l02b4adspe/z4ArKKvgJpF/8xV+c/no6g4JL8JUrbQAVdHFc7zXjpbWFuL25H7/z+r3YQpD0d3dzp2o3lfPTHJqyZx3pkEazqeOsH/121NVEELY4ihPtnEzPaErh1ofINTs72tCJ0flvzbsThJfL32Xyh31HTCexcDIFYweM8JVGgkZXafHe9v4mMoGceT9N7wpuGRHCT0FLHv2N9Rjs7cTxfCuOyDcBmfKVEZyjIpno7de/Dvjbi5muJncIOf8cWclcpX0S4Dhdyenu9ji+sLcUhwjOH57fjhdXm9keimYFUwqQ8lqG/M175aYXHkXZXF5sxfOtvdiaW44H+9RjCnTNLl/IF6ujpFwpeCVLnp8Qvh0gsxomJ9A6n3qmz8VUpmSYnZ6f1vAn/+SfnF6V8Eu/9EvTq+/voDJKsKLS8prBSxyPOMbhPmJL8+10P3j/i9cBYW7SeiEuLqOcGtC+U5gzLsIRLsFPDohQvlK4fKYyT36DNhT6+ijBmPDyUeztuCN8sRw8fLgR9+49jEect7f3cnWZ0ypaDnKvKRBbccQu+zBZXsGDtKtyKQsNkguTbwt5lt9JlvzWmtLW50ZgcXo0E2RoHXPfwosX1gBiz8eVK5ei2+smMCnKuYDMVF6pwKxTppxnAVH6X3lodVA22pIURYuH/KvJTGuN1iad9nXF0FH/3qOt+NJrX49f/52Pxe9+6rNx894jBq2CDxFVPeYXl2NxeTWtM2ruBBz8E2QKFKyPCxAE0086GoIpnguoXHWeixW85hCg5TPvcW1buPm21i4/a+QekMplV5M6IGyRloPmxvS7vD0AmFsSdQBkXQ+BnNYzaAERHz0XayGn3DPu5Oggn7mPnMBtcWE+VgBhPUD+ot8jXbtAOshZgI6g/MaNm3Hn1t3YZzAuYHcg7VYOiGvJdNoWRXbbvsKx/OO6knkCjjMAUoBW1Z/uQyZgmnDO/iVJ450P0pTAXx+tXm+ecgKEoCGnJ/N7krkK0u1X3JYFvUPfC9KHgMj1h1s8m8TlK1fiAwCxJfrQ+wKtpBHKr2Hi4GgUo8kIPQfNC8u4p5XTXQbM368q+A3Opl8WaHfRoc3YG4zixs278fpb78b61g760j0459GPqDjYV/qzvt90TOt1GrinVeyPhGXM8NM//dPTqxL+rX/r30onXVdaVsFPr7jr9yuvvDK984c39GDiLgTiKFXHwIWVxXjp8gpEfRJfub8dD3b2i5kVgSLhwTqANoAYhLW2tpJ+Iq6i6sDgKRABY8uAGxlXZpexFYyCpZznRqDkuAcudGNHdx0ejQb5TTgF7757D1GWhiseIa4TmIvYaeU6YaSSUx/76zBRK2YoFwVJbk5w5giIc/oX8N7+gwdx0m1SXgQuwDBXYYFINBG7y/Pe3m68+e5bsXfE6CXG8Wj3NjkJiqZ0nf/57zjubo7ijYO1LOcP9bbj2hLgkCf8JIKCwvcsaXWUcAZ7qlB+O4K+1kbIUdSNQ30FytPTd0/Tejyc3bOa4Xyx+fvbgzJnuaehum+o7ivbziddvVPFfTyNpzF8+MMfnl6V4Mav53n0+zX4wW6VEOwJ6HHfrX2AyySWGGBdu7QSrwDC3v/itbh+cSl30W+iMmYPBzHDUZ85jFmUSKBQZvTHhL5ykAClC84EZa5q9vuPfvvQaRiVrdOPjx5txn0A2IP7gDCu9/fgKECavKw/mEpTIJaO01xXo3kVrgrUo+zzJ/hCeaF0C6hgMCcAQcakEsujABEHf25b4QauDgAFHx0UraBxsduN565fiyuXLmbc3NlcIIgccmoyQR+ySB+iYiUrFjitJbnljiMXgJJgKbe84SzDufWDK0Nd2aiFUP/YOcrhdOWb774bv/7bvxu/9tsfi7dv3kZmEbfViyP39WqheOstZOg49hjcupBBi1Cn12FA3AFcMZDVOJRS5SinYD38LmQegqa0cpVBrwsocisPnmk1K/5iWs8EzV5z5l5aw4ybizYCAOUCrXL42+nJNiBdULUAjcwju7sttwYBMFEW94yrI2MWOvVYAcgvLzDQrke0eHce2d4mnYVuK1aW5rN8+ekrKjLf7cQS4GxpXmtkPfqAsEcP1wHpj+LRxna4KtTpNo/82gJyOx37pQjqfSpPE61xzSnFHf2mRTBpfHooqwRg+fmrKS2VvjaNSp7l20mH0qPX7tq/srIafrJPYJUrJ0E/DjQS6FH9weAA+t7NlZXLK2vxgQ98GBC3XPylSR/lUmiE67SIwR/6RY8BqwnIoGn7woFCfiYLMGh/u7DFLV3uMWB588YtQPxmuOvAMcDODV3r0I2+YmBD0i91fPxQhFeA1MNQprhpl/z1fR7cl+j8JpFudeF3LP2geNVIT/r0yvngJ1jON2p1COK+26HFqKk370qnGQBVK66uLkPszbjJSOER0DwJdQTih+DcN0wHYMvqVhYrMJzfM3Mkya3kFqcMIJ0EaJrN4aTCZAgNxDB8BdEQWaEhOBsimEaMKhUcfhfzIIUx5SIfP0kiuJJBi+AGY0Ho+4NdRmu1GACmtKzliirBmEHlATO73Hm0sWHuMcvITdAyQ13ksF6rA+E/jN3hW3Hz4Rfjk1//5fj0G78Wm3v3UglYF4qSBF1DkT3cH8eNkyspvD7U3Y7LSy3SPR/ov+lfSg2rXQUTysapgtcwEgksIMwWZ0cxrC0hnBUQRKd9jF6AXRXKO08Ce16Xp2fB/rGZMy1+pyO/gXs+y0sjEPLdEjmfFZF19vxpDe4hdv4rGPLpv/wv/8u5T6A7Zhs8a9n2u7EOnr4fgj5Uk4MhQGyc005LvRbAayW/nPG+F6/EC1fXUKqt6KCAG9C2nypKf7LDUV7PAc5UwrokqIRh0wRkCcIOD9Jq4DdotQRtMVDbRFFtbu2lA7erJLd3/W5fmWbRLld8eQrNCcSSrjgKGNKCpyIVpBGbe8oP/by0EAmyOgCsLnLJozc9/KC/38PU8p6WIOL7joebta6trcaVq5djeRkgANOm/+cscmIGBa2/l4qbPHNfKRS4MilLmYrduQGtLx5aM8qhwvWZwELLg4A0gQP37j96FJ/7whfjE5/6vXjjrXdoi704ckqy3UPu0QkAt3qzrCYVxKXTNvUAQSUwcDrLBRc0RQFNylBkZ2UxLNOSWryK5cs6KT+Lg75WS6qX4Ip4KHynDHODW95tkJ4WUbAe14KsmfxmcBc0tQjwWkb2zwO0Ok3jAs5op9osYBBgHkfD3PB3TmCunYfriV9XGPXBaP04OthP4A7BIX/L5rqH0J4r3xVVvU43/cncbqNOvf1u4/qjrXj4YD3PTg+675ZfYNCqVQAxdaIdsh+oWIP2qwsu6BsH2dKI3wxVpuU96uyZF+hbigK9lR39XXHpwEHaLf1bDumtTFPbxwKrC2uXoJXV7GP7g5bnmI0dAJjT7Ls7e7G0tBwf/MAHY2XtQrjNyvDAaUdpYRaecDUxNEa5DwVjx27nRL3Mxxylc/rNzcdb7W6eB9T71v31XH36cGOXclMvtw5pL6QV1X3ldN7304HfyjJWAVHD2T3iSrN5949A+Nt/+2/Hn//zf37661sHAdof9rDM6KUDobUQDqtaySDENx/uxuvru3SoXAFB7e3BMDAcDKWj7UShrMBHiCy74StCsA7TpFMuhLdzCMFD+WJ3ha9OjI6YZKpc/YhwVMC7GaQCXiZytDBitKisbkDQDa1wbm0xBX+kSBrH0UcIyLjtWicO+rtlJC0yghmqj8m6AasMOPZzFvv7MQNgnAz9xqVpnUQXwdhG8hxM9hjB7MV2/36s791BWKoQqANEriAg0bizMwGIXUMAHMUHG4/icteNKrPpvinIFoWNv5NAPADo8ixCrTEfe2OEavJVYa7zwTK/F5yVkCvZiP/NbyCcS2Kn4YxZZeDpzW8RqrhPe/hP/9P/NDd7rYKDo7/wF/4Cynot6+f5X/vX/rUcHH0rq9mTtqsQvD0pPCmuh9+y/W6FEz9bdDBIpbq63ItXXrrOcTWuXV5N68bJBD5AcWot00ZdgJdWL8AFfOOQR4uY+3e5VUVO7wuWtIa5E7rbToycnjnIFZJO96vA3Jm8moYsys5VaPJjobkKlBWQ76Hiha4Fe1poGNy1GTRpYfesb5SO5jPUo1h+lC3FbypXj81ZzgJAnPrRGqS7RK/XjQsXVmN+YT4tbZY58yBusYAhA/itDHJFooehUmwVCKgJnDh4Usovr6F8HVuZpspe36L7Dx7EpwBhv/Oxj8ftO3dTFHV6vZjVB810dM4GfBX/MP3CAFMCDAarxe9Ly5Ygz/oKvIqfWAJV6nR6L+tO2YiX8bkuaUynJam7MxBpHUSWp0+YII533dDWFbPtJgf4QbDVoF2dmhaQCcYYF3KP/joc0L8ArskwNwA2Xi0OGTBvx/r923H33bdj6+G92Nl8GFuP7sfe9iPAyqPYXOe8tcn9jfzqgrIpLZfoFAFVp9kGnPXSv8xZGGlHa9POzm7kfm46yUtrvEdzU0fqbTsBLtPJn7YscpmHBOMlLU15LPuPPjaN0s/lKPRWnmec7E/ACn0rrXpvbfVCPP/cCwzgLhC/fPhby29/v/iT6XN39epzAPxr5KERATqHnsfQeK6wpT5moy+hG91qoROkaxBwe5DcUNcvL0ADda61vD7c3I0bdx7k7vox2wS0N9MiRiT6tS13kB5lRecKOJM2syYl+Kuq0+kBXUi/2R7TeE990M+gCk8CVI66HWHrsOvo+/E4Ws7+o//oP4qPfvSj0zsRP/qjPzq9+sMVnHYbQECrC91YQzjkvjFv3I71jb04cP4aQjhptXILCEGIjoa7LkfX3D6CkCAbTecCrTT7cwdaQFgJuBipIKSHAjiIVvClJHSPMgWxH4hVkOeqJ/LeHrlVxlFodzrZ2c6VmjMQtFMHOjQJzPYZmeXmrQgrn4vEjhkd5u7YMjPpWQbZbsLz3Xv3YmahHScjRqD7bpUBk0P8i90lGF5Gd7SIIlDwIeBVFNZzj7K8vjsbN+svBGO6+FBznTZqxhFEb/2+XfBx2evI6R3FM0DyMUDlSimKEr0GcVAu+0cKfu5VaTsSz0PB442zTAW5put4z9Q951YGJeI0OAYsfwaZ00PAqdCaFqvkMWV0JFmm8d50nt4gn7rr/nk/z28Vzn/O7J92+G5+KFzFeWltIV558Vq8dP1yrC31Ygne7qGFtYq4SMZNTgVd6WeZ4ARFj8IROAgWBE4CKZWO/jQjgJcgTAtAfmoIHtW5uewrJt0VKnQQ5ADNe/lsOvhJyzXnYuVR2cjvggiUFYCgARBDdFAOaVM+MX7FN94DkNUEQ9BwTX7ReuOWMU7tCTgEcs2Yn+9FD9mig7RlOHCVm+URaPLbMpeykA7vJ92fO5L2ydZ6nyAEBAQCJuWa11paVLbp/8rg7itf+1p+veErX/1qvq8FbjKdJtNyk3LRinE/LV/IDv3ZfCZfp1M8bWE822AuVy4KMHXKF7B5LqCsAmGnh2n5LgBMIFZdV75kgrCc2uRo8dytPLSG1WYBWHMTQFJEt60PIYNwaGSB5wvdZtKJa2U9nKp0OlP3kP2dzdgEhLnBr35ly9IU53Q6ORzHeLgfg92dGPX3Yn93O3a3N2LQ30+ZbT+5kGJ1ZRGeXAEoA1ZpBzf03dxcz3293DdMukpphkwy2KYFPhXZxSNI4rxsoh353zvGLTM09iP38oDGE5wJvE03X6FNpUFXKJbZGb8ec/HixXju+nMA+Us5Zbm+vpHTlqZ55crVuHjhArQHgJNnSEPpKr2bpH2RqzGnAxP1ldtVCMLcb8/Njp12rDV6ALiZeLS1Hw8fbaPLiOuOAACx4xOAvtx7CB+RqFua6JPojEnhL/mD1uCQjlKGe09a4shr/7jMe1Tesj0LT1H4937uE/Hg3sP4yGVGBQCuV7/xThwilE9aheE73U40OOYQPl2YVnP1sH+QK0EWeu1YXVyOFRjNT4IMEEJdRmA66jM8T7P2+qN+7iw9gXiO9kbRXFxAMPhR2wmCqZ7f9VpiZHb92sW4vXcQG/vj+GDtIP75G5+PExh1BqKem19MAp/sb8bXbn0pmavmaILyve9Hfizqj3ZzrzD3HTocDeP27l2Yu+zm32CUfe0jfzya9xmtMdLIT5Sc1OLVW78bX3jrExC8oxHgFvdOmvMBUozDGZhCuTA5iJXYiUutUXQRbsoBhYPM+HjwlgL2fHgyO2RMBDrPONwM8uvH16J7uBUf6I6SkWR0wViu7CIkgDrHdFW6KbO8x++Sd0m7BG6YRoqLs+CkrwDsBI73T6b2MM3Hy/vv/a1Xp1dPf3Dw9Au/8As5QKq+oqHV7Cd+4ifiJ3/yJ+OnfuqnErxpIRO8nf/SxuPBwZZK+DuJa/jZn/3Z79r3Kf/WL342Ll9azY8Wo0ejhYLX+qLsTsuXoEDhDq9o8dLiXEbVc8lPbimRU3gwQPp7JcDSP6xYgibwuFDOzUZVav4WsKn0SpCOpEFBVTmjvpAlWjemU37VfcoibZMtoZTJJwYVS0XLqXzgf8+8Rvq+U8CY1jEBSFeXiW6XMhVF5cBM6k/gA3PMJriD1aln5XNkOS1jlb5B3hOIyQta8W04fd/8EHl+P5D3/TTPl7/85fj8F78c23v9qfWizAzk1hZcl3vFFzQ3Z0V+mF9azpF7OQ06zbMKKRLKfxyWSYtgARgC5Kx/iWkPFIXsP98BWOQUVbYTA1WBAjJWCyLVJR0OAenBEMDVjjVo328PtwBuTmkPB3sAFgA0vTUY7CO79VtzteEwNjfWAVc7SS892nhlZSkd9bU8aSX1e5T0SCljWoTKSk8/du0O9TrKu3pRx3nl7QiQXPb06idYzj3qANLOzmjVy131tQRSJ/BgqXH2o/Rw1g62TUo0+5p8FV8OAOy7YiHisVZf8jSuANd3/VO3uQLTdhLsyhsjynPnzu34xCc+Ea++9mocAK6uXrocH/7Qh2L14qXcBB1VBt3CF7TFsbyQA5pD+AP6kG94rk9yuwv/cc7BDX3VBIw5vf3o0Ubcvf8wtvcPaAvag2eH1NNlEvoguqGunSqlVPJYOs4jK1Ta4vFQ3dMil+/zcnn7WXhqwv/2//ubUWOEcm15Pt54uBUPHm1FQzDiFAGE5sqqxYtrKYwXlzqMiNpx0B/E0Uwj5ttzALIuo7pmdFrzENJxNBjZPtrbS8f79vEotjcGsX9w7FfwYtIfAeIg1OWF8Jtxfml/POzHMoy9xIjp7t6QuJP40bn9+OM3X42jrZ38bNFcd4m3j6O/fT9ev/UqZfLbdoVYX/yRH43ONqmPURoIlcNRP27s3s6tMnglhV/jyuXo1RZjuDuMPoJrj2d3du/FXUDbTEsBLkBD+Jz4Xb5B1I92ozdzGAvc7jJyd4RiWo+zgDpHgk/5WW59U6iU1OMMlAKDs1Merx/B6CTyvrlHAEiEthEQ7BU7aQMr044VQ6osuG8a/M5707glGMej5HP+bDB6mtY5UqBPZbxxslzTsn4/gbE/KuF3X72ZgyTpaAblMJeWJvvTvlVlSjjQpNepxLWQqUyDUbu3tXAVJSV9TFQ4xvH+9DqBAspNf1KX7mvh8JkK7+woik/dYJoCkVSE8K10a/r6b0l7Wn8SsgFysmwE4yWhEorFQ072cRmYOCUzB8h02supScFYExCgMtZiYX1zOpO8rLN1dbPmMuWjMha0lDIaKjBmsO2cvvSrIVaA4seAwagLmba3d+PNt96I177ylXiIYu30FgFeDCpH42hPV0jmXlKk7Xu5fQ/Pc7sB8812caqyADKb85sCrxf/NcEY8SzDtN4+9BWvStkLz5Iy8cosQgIR+v0YeXZ8wsBYLySq13GqEpDjFhTLACRBeW4D1O8DOP0s3jjpQOunQGl3Zye2t8qHsN0pfmGhlyCrS5s7myEYcWEE42BkobMMpe/rDObrWukAI64a7SXQamdd9Ndz3zG3o7BOgrG0IkJLgjV1gs7u9qdTnH5POGVSqWn+FTryKHeLzyFXNIxpaoX0CQ3h/5ykhWpat5GDUctqyC0xeJ8mS2CvW8urr345fu3Xfi1B6CsvvRw/8JGP5BcIDuhL99ZjCJH+0/lRegYogjGB6Vy9VQY0lEUfQQFZvdmFHgBcyHO/q3nrzj0Gb7vE7UAXrTRcOGFUB7jChlMwZihld0FO8pzX2d9n5+q+oZLZnpM+eHj29Fl4KsKf/7/+QrywuBDbgpjNbZgKphacwGhHMKmkd2ltOYm5D9FeuXKBEZPm05NoteZiuTUTI0bTK8sXYZ4WzH0QDxFYMmVzAvjZ7MfO8CDGWrKcVhyOo3dpLUciEvhkPMz051qduLe5nwL0T89uxItvfT0mjMpmEbi13oJcE+vrN+LG3beiU+/liF0T7qWP/EA0BxH9nT0InhEe4ObOYAvAxShewcXo+QghUIMpVAryb01mPD4EKL4ex6Ot6M5NoteiPgzDmpRbYpeoJe8c6SoAnkDZytxC+BXrfHP4VixR3VZ53DxaiXFtPp6fvBVtGRohed78dpbGFHxp8vAX96tnFTMakiEt3LlwPg0Pf/rxdEPuT5TvlPSqtP7yf//lPD8LT0949Z2H8NYYZSPg0KICLRGSbjigbM4I9OxjQRFADF73O5K6EQjA0peK+ypOVZZxBU+6HGhdaHVa0VucT8UpvfjJGLcEUCGVfMxRHpK+FSVO3emkTv7czF3VOVCjkLnTnEUhyuNpqSOOVqPK/8VtAbQUWCbjut1AKlXq2EOGeDjVVwEx46SFjHctkwsR9EBQJhWrGb8BSy5UqtrF8magPipqrYN+tFwgRWHCDXBv3rwVX/zyq/HG66/nFz6chtL/J90dSGsMwPBD0WmB4SxgnaMeWlJsOweQOTycgiYRQG2ugRwh/yxHFiDv+0M5VMAboE1k53P52oikmUrZn7SZG5Eaj9YiEmkJq2YE2Qc8oz3qrnqsx9pCJ1wkcWxf0y9jp57pO6esBdYODvcBX9ubG/Hw4YPcjX55aSkuX7409UVzT0qyp519x7xS1tgGWffZnPZz6watYQvoFmdXjGP60pTtpN+vpbRPvTbkakPqZv+6ElPrrtOsytfSPuSVP0rwt00gLTlYKIf0XsnFElcwZr/bLx6NGv0uRKf80rrTvk7z5pcqOHZ2tuMTH/943Lr5bly7dCkuX7mUIMxNW8vZdmUgrY5xAEE6Uk/Db4LWtBhCXw0A5fxSzAHKRuPjeLC+HeuuytwD+Gp1JJ7Tkn7UHfWZVjR6FFrJImf5E0Ta2rbvNJzRaxXnyc+egbGnMPzv/ot/El2Ew5vrD9O3a7bXiRlGQQqvwwePEpR1lntxESYe0b2zMFmPkbejHoVU8/gggFlRBzB1FpbyM0Z37t9HUM3HfG0cOw+2YwDjj+YQVrswPsTXW11Kf682eQm+rl+5HH0Ien27z4hrNv7s7KO48O67UJsjDkbc3V5uY/HWva/F5+/dh+BbMREQSsQdRhgIAr8GkH5YCLnDw2ECvxrCuQNtzpD/Wm8pri5dihaCrjfbgjkP4ks3fy32h4/IswkzFuFdCNj/Czg5H54EyL7TUM37m67hLG3a63AhBq1LcXX/a9Frw5QIFdjMSBnDuFX8iuFSqfBuua9Qem+6FVOWnwV8eat6nic4P4ulJFFPnGN6wzMw9vSFr998QHeinOGrBFqVdIc+yoha8S5ti30KeBGwHAHMyy7ygDCnb3iWSo7nGZlrp61SSS7L6+20drhaT2dmdzJX2U5U8Cip8l0/fWgK0Bq5GIdkLEMONvgh5sgVjkcANcsMgWojSzBGPMGT/OzZWpi2r5qv3xrUz01w0EJeGczXtK27Tu1Ou/kORUSenaQvlmnpLJ5KGb6vAN/5wYvTumU1HnIN0HeAwn3jrbfj85//Qrx786Zcl+/7aZojBk2+39I/iMEoAi0tdA403Vy03e4C6g5yQ1Gxi5jKj477IXGhjNghVS79kzwrH0+vczqN8qaV0MGZ5cyWKHFyCx9vcyctfVMAaxRBwpy+dWCzVlN3E8ABZ1fSHtFPuwAO2/toBADTOgMgckpysD+M23fvxMNHDwDbjVgWTLkqcr4X7iWmn1sB5ocJxpQnrt5rNNq0m/5rbtfRjR5AyoUMbYC7fSkAKxIQeoG+yqaqmmKlOUGU1iwAEg2kVXCeNARj+r9JdxoDss0pc1pu6WfrXVnHJHOSyf5PGZdnQZq50sK2F+l6pFUSIJSWPIijtDVtJkAEwDrFfe/enbh/714Bq9CRe2L6+Ty6LS2kltl83Bx5RjRFaDQXUu/Z6Ln9ScNV+3PxaGuPNvVj8AdpNbT8oxHvCKClRy493I0/SysotH7k5X56pXTfrI+SXs6dDV76a+4/IZRbz8LTEn71c2/Ho+3t2IVBjw8YoUBo7ZWl3CX6aG8/ifeIUYOOtosAln2GBm6uutxrguYZ1UG4TQjHDQ9HUFSDkeRgdxfmgxGgimOEcPooQSIKN0cjfpJD867IXyfebncxtof8huE6IJ4Pjbaj4eIA8pP+arPkMx7GjQ0Y5EhmQqjCIM3JOOZhsucYkTwXjXieeO+nTL3JbvQYrV9FqF6BmRcZCS4yin/l0vVYYKTSZDSq1WD74GH0DxBKKfCczKCUSdhnxG2gmKdE/j8/vDdd8ynHSfQnszFpr0ZntJ5O1rbVNFIeWaap0OHXNJny7lkc752FMwatGLjU7fQ+p8xH7veW/F4SPg0/8a+fbQ3xLDwdYXN3C9CBUqbbHTz44WhBdk5FJnsf5eEeYW5iqfXHkbqOzFpKYWWCisbfWgoKuNFXSAvBhUsXYmGxF62OH6o+UxCp2FDK+pq599jebj933R8OyxRY+vKEViuAFwXRh2vWrTUAY3Wu/ZxRjXMdGmwlUELmJF+miuauypczv1Pho+TbbR3ktYhZH531nZal7siRnArlvspZ5319oQRRbpUjYMmBFe2S8TnS38scwD25kTPyYI4y7O7vx5e/8lp87OMfi3duvJ3t4pYRaclTUcIyllFrnIo5/bRofB3x89NCtFOzNksd56ILYHFLDp34y4727h1mHeay/fLgOldR+kzwQD3mKHNuVUH5si0sPIe4q7AzZRUA8I7WMNs59w9rzqSbxUqvFUuUwynKo8ORKDwV/t72Fv1+QD+cpL/UQwa6N2/cyOk501q9sBoXLl5EPgu0XCCAHKY8WjmTRvjfsiSw5ZnAS+d8P5ekRczFFAoY/YNdPJE0QPnSvYK37RfTsdi5pxr1djGGv3P3+oMhrx9RFupNPaGGbB/LkLRpCew7UtHbzT6ufHHF1vlJKemMdE0gLZSUQd8/z9JJWlh9Jq1A61runClYWFqi/AvkMBt77pknbdEGuUk59T/iSHo0Pum6YrQGuPdodZyenI/90UzcW+/HzTsbsT2gzWoAYQo2Bjm69YmbrGtRtA62SAbS0r4p0PaPyqTMPi/PC8/xxrn76q/T3xzPwNhTGP7uJ16N+w8f2ed0L2TACGB2GXQvpzO6UkBBpTGDYGpI+Iw0+4wgHAX2up3sfP3KFMLuEeaSeJf86gCqc7pY3zGPliwtWDmVIfcQ1zjuI1Sba8YuwlQmXERQv3+4EbM6BR8MEvDJXKP+Tmys34sVmPoa9HuBJObJ6yIC4ANXr8eFWjcBlztJbw63Y4sR3oRhjKP2PqOwvcEwOu0eQIwyMNo5phAb+7diIBijXo7Gz8i9hORrz9Pjf0mY8sg0KLzPfvcBuOPupegMH5TP0SSjnb1TMVhVQpkxf8mA3kvmnMZ7QvB+pTRLqPJXnHBBG8n8ZSVbeW54BsaevrC553YvCHv4WLxgXxYLFzyqRUMgBgjLfZ3gZacM028GgvC9nE7kXvpXQQaNViOWlhbj8qVLsbKymABIa4Ik4nNBB69FfzDIVXFuV7DN4M5rrR9p8XCVZMYX/FSKV0CiEuF3Jof04bkuEN4rXKji8X8VuNYClB7l0UojGDPN9D2jvCpfQZZx8uCdU8vIVEHLLVMC50rFXudCfiNYGJ4d8o4O5kIa6/TZz302fuu3fis/7+N2GU7B2Xa+o4jMxTVcWz6n+Nz2J/2vaP9h+l1txz6A7gBQ6iBWJX6MjKOHsl3KFhWCEM+0CWBwTgBBCVxsoQepn3XyLIBzECkIRmRl/glQ0l+LNARy1pX0mw33EqvHggCp20r3i8l4EAcMcu1fv34w6GutOwSIDeLundtx79697L82dbx0+TKAxP4GQGqFJG3rrZ+UoKpYmeg7gJiA2NWD1ZTx/OJ8+n8JUAU5Ar+JVk3a1oZLyz/X3pd+ylcFnDZ2ccX0oD7SjiCOQiZ9JDDP7rM/bfMCuLP/aa/yRJA3PXwHea/1yb71XrUgRbLIjvNEovantKJM1BJpnfzUlPLVuK6itX8FeNZFupOem/rFUVcH9PqJNbsLUat3AGLHcefhdtx7tIOOcSBQAJcbBOfm43NueFumlD0ky5I3epKOLe1bjup+dT5/v7pXhereMzD2FIb/8h99PBnTEeQMRMVFzGr2R5ArKE5A9I7MoKAcMTgy8GPeEsz8ov4HLoVW0Cle+F8ihUFlEAWSDqxSczErQ/QyFMk5Tamj6MLCIsCIETX0JGOtxjhe7j9KUOdI0ynJI4RIHzC2vrtZgJOgkLRGKBFHO24uWJ9poHDM7zA2Bo8AYxswPKOxQDBO+sTd4/dhTquMj4bxECC2vvcO9XK1DcQtM9AeTzr+6QbZvqQKz/DzJAZa6xevR3v4kFG0goZ24lk+z6NivOo3B0HB4/0MnCpGfDx88z21CCdumwZFSIF0Fq1cPANjT1/YcNUbwMs+lYj0R5IX5S2BlgqlKKOixGRPgYp9r++MCj61Dwlo7ZhHua6tLgPEVLAFuBSlxQXBT8i4mnR9/VFuorsjEBvsp5Iv4At+Z7CmvtDikxYw5Ij5qALlc5NS0QrUSD1B4yHywe0OsrzkJ506ZTWvxaXnh57r5EGdkEWpdEUnx8XCkTTNnwAp/W7MQJBi4Qmu4hTNpK8kStSDloiyKpDyUE6d1z/56U/Fpz/z6SxDu6NzPnUAKHht/ratIKVaQOD2Gk6PpuWNtHVOV7b6qbfhcA/QsxuD4W4cIM+OjkeAEacSlT9OpQqADynmIeWk7ShH2ePrKNz0AFzAIeAqoCs3h+W+QNYBr+fcisJ25Pd82ynGbi7m0NqUq0m1UAEI+/39BFWCIZvFKcm333orp5bn5xfiwtparHA00QOCLT+1pAxxxaB+Ul6XjWcFTrWyYnJxOUG79OK0sfKk+O/RO9BS9iFnacL+oHkAPLSlFjUG5GU7jjpnDs65efiUHsq0nSMLrVKmaZvRwxTeRSB2vekacpozO5rf3CsyMRPiPfp+Ir3xG96QVnKzVoLl9QsyqVugq8IXtPFsI6eqB4BY6VydJm0ZX5/DZrPN8ybt0Y653OTXryxM4v76Ttx9sBU7e0NAXSd9yASDp9POCaaKlS91rjSTesj2qcpdjipUACzjTa+fdBiegbGnMPw3H/2clAxhuuIGWAVzQeEx052PBsSeZn6IpQ7DHUNDDK8ATqB74reJOysBQ9Q1mM3xCxIypyEliTGC2rl2RXiTtOqMBqDc5JOJ+5bBrMuXLwC/5uIAEKVgvV4bxws7DyB2iFb5ekJ5EGQDBNjdzQ1GZwhqynMAUw4Bc47y24xI5l06TDk0wx80d2OmtROtziFlGTFiGaFYhjGerMfO8F5sDW7HZv82rE3O1B26LoScLfLdCnI7DIVQGDtFsnA9mvqvpRXhjKlKufiDafM8/Z3BJDwM03cef7c6V9f8mh7nAvLI52VKSFFGXkT58Z/8/tiV/o9SWN/cihnoKbdNQMBX05LVIQirLAf5J12pkQl0PwqxgaJU2dbSArU0BT8OzFwwU3x9PMY5NbhFfg8fPIw9wEv51mQBYbmAQHCnlccBT6YvDav8OOB9FxoIDlyR57talAQu+mgdTkhLCwSK14GJe4f1FubT8pJ+X9ZHi17SrcqVJFX4VELa9Ya2kXygfENpOyC0pjrnJ9NTPlKI3LEd+ZNPQQmbWxvxyU99Mr786pcyFVcDus2FZfHzRe2u/mp1QIjWoHZ+gHxxcT6n6QRki0sLeW+B8uYKRJEUgGsmbDdXLQ7phxF1EKjt53Tc0USLlVOIgiTakPI6fTuX50m0tJxRrwLaBGECNacvCxgznjLZD367YGGJci5SNjBTysTJhDxp85HtyyE4OxgOAdDr8c477+TmtV0GtVevXEkfsRpyXVBk29rWArGcmiPvucYcoMnPTgnUpt95XFzMvtGqJu1IX/atZ4N0p2wpFlfKT7pOQxfgpXUNcEeXpBWQC+mlsgCmhRO6mgAEpZOkHyNIt5ZHQE07lJz8v8gv6T/BjndOnLr2nvRRwIx6TauwlkKDFsYMtinlSeCEThSMqav2GWQcUg5lpcm2XInfcCuONjSxGDPNbuyPJvFgYzcePAJ4axGbKVucOIuRbWGZfF85S7ZV3pWMtkrfKlQyvDo/CZB5z+MZGHsKw3/721/ifwnDkQtAYLYWc4AinfhnGW45gnG1bQOBJHPNIDDdcd9PF0m6jpBO9P8a+FHhkxTWNUaJDQhDZ/0hArwiHncjbiHADonrx8EV2ksra7G/MyA/COt4Nl6Z7MXF0WYSK0MP/kdYDrZjZzSK2w8fJhiTpg9gogHlyakVyr7g5npw7glCb9g6yE8gaTJuAipbnp3Hb3cZ9VJXKD6LxOFZ512FrjdKSb9bwfycGkHQL12Pxv49wJgjwLNSVG1HKcvt059eFM7NOBwlqnWrIpVnlUAq4eyZIf1d/FNS8UiF7G/fewbGnr6wsbmdtCFNu6prjIKuPqKc1m/pgb/sZehC5SpFeCQIQwnVGUy19TFqqYwZ+AAW9vb20uq1v4eSGfRjv7/HvZ1ceeZ0noM5acn00TeZoDJFS7XgIsEX5RDEpYVuuteUylW5oqJPpatJPpUsaUzTczXeIuCmBzDUlym3U0AOGMk/yVtFV20HYbBuroCU17md5UtgxzO3rFCm6TM0plyMBROY7aFsb925FZ/5/Gfita+8mu8KxA4FjcRrtltpTXOqazanFVXWltHpL614xXNJUKbPlGCsBThr0o5+ksgPcjv15SatWgedIpggT8c5fdgHHAnM3CYE4EObTw76FM0tQ0jVb/XSRsfHrt4blylM8vXbti3SqhPPex3SXlnsxeJ8h/5Edo4BeoCx0XCQ/aWTukDZfrj/4D5A7K3Y3tlKIHX1ymXk8XI64Ou/lpSRaQCqqLNtKyjNzyxBI4IuV9Yuzgs8FwCinbQq2s72a07nQgMpU6agw2qTfVrrnIoUlDltnVRJH5Xn/Ef8nKIUfPLbWRIBGb1KHxA3aQS4Dcizb0q/SwvqMZ5B/2Xa2vIYr9B7PvJM7KI7yuAkb1hfrp19yUVh3Kkseu6B5qa6LkTQgd/9w9w7rJGbubapdwsddRT31gFiHH1A2ewcQK3RIQ+rI2jUlplZkJNMchYqoGpIHuI4tZB5b0rbpZ4lVNcZd/q8Oj8DY09h+Ju/9OkEPUhhBm8Q/piDkfUMI9HgOIYRHVLk/jz8KQjdAiJXfnB0IFYtZpMDGAJh4cfGTyROiGLMyKvPPT8cKwNq0u7C6Ad7ZZ8ZLXHd5nwM94cx10SwweQ/EP3o9jehThgC8BYI7UOE/73B/VgfPmSITD4edd5vHUejS6lqCMK5YYwb49if3SfPfYi+CGc4IMvqCKbJSKah35jgbH4hRzYuo849y5IPK0YuCgqqTuY5I///5cH0zkJhtANvLj8PGLsfDYSN+VbhPPOVtyvl+Vgcjirqe9+hKW2HbxEqZWzSpqlCrZJ+BsaevrDu9jT6h+XqyKMECQlEUDqpgujbis4lE7tbgCOwEIgZdKT2UNHt+x1K95tCYe/t7sRwMAw/7K9jvj5RY/gTrZbppZtAHipOlBz5qmBPABcJuvKZ1jBBWNkKw/ipPMhbS4jTf1okDN6Xd7W6OD2pn6qKM313+MvpHqpUFCYvqNSntC8oSj8z/tK6r92eRyrmIxU8+fiNQYFVA+CpxeOtt9+OL736pbh5+0YCCj9LNNL/64Q47pvVVpnyB8845apjuP5zTqfaxt73z53/zdOz75uW5bad3Q5E61mrW3yxclUo8pEGy3abAFzdL1G3jL3dTdrKz84hR/l9dDigX7VwIZMp04yy4hhgRt4Cm1ZjLnrUZXkREEh5Dw8GAOc95JtgpPRNWUxxlNPKX/zC59JPzOnFCxcvxMrqavhZOsszEcBP+6gAMQBUs6xeddoyN2idguTFpSWueyk7pDPfU0/4niEHfNTfKWn1gK4iWsUEdZZbKZt50EspcYlne+j4bzvmdGq2uTrEPtdoUICUoKY401PAKW2kHEsgNqUF7jvW9BCcyQRpfOBGps/zBGZJs6RJ2ZzdSRBIGva1dXbalhSg/zFgfg5w3mWQv0gFm7GzP4rbD7ZifRvecMM+4HFOXc6hR6erXNN3LcthnoVWPXK1KOdTQDU9quepxyz19HcVz3J7ffreuetnYOwpDP/NL34KhtAnAJrSoRUidefjYMRTY7QT/SEdDA31RxCThME1RNuBWOswrhvDnsAA7lvD/xBWLa1qGc9RBKNf58ZbMJ2jjRkY/RBaVeh0BEjkfeg+GowY3S38Iye70d7fTaCnwDxmhDga9eOtTUZwB+vcgwAbCMrGMYwJc/s5IY7JySD6Y7fRKE6pKoMUJDCZykk/F3KJYwsG8TvNUBeMdeaTobSe+Q253Elb5kyGKcJB4v6nFcC5qRBpyXJB+m7LOLP8Qszt3YWFVTRnjCfDeSNjeo8/BX6xZ5ffVchr/50r75OviyLON4yvYDAbr+3sLMEzMPY0hvuPtmThpHtp3g8XSy+FZqSBs8MgT6f/j7zJb5WRDuYOlgRcWsQOUOrF8Vzl6LSOClrfLq1ZpMzvdPxPnpkCMK/J349HO8VVraiUtgpfaqXLIuQgTCuLpFfKznscTg8tOP2FHFI5GlSYRQmhmalS+qRKx7xsneUB66rCMwJX8BxnjlwJRxmM62pJFfch9XFH/Vt3bscXvvSF+MYb30hwJdA60PLOe/qIlZTIS7nGPVdauqLUb0BqMevOd3Ornqbf1URxa0FzIYB5WObcsZ2yWVynVt2/TKf3JmkLcvxweFOQxrn4mwleBYICm2EMhnuI4r0YjvbTCX90ABju78UAsDxGPmpt87NXfvrIFtCKlPWj/U1L0Gyb+NmeRw8fxuuvfy0ePLgf3W43rly5MvV5AxwiA+03v7ZgO0+7iPZ2k263rqB+yE4tacsryxwrmUbZomEKxqWF9MWyn4oMMx3714UbOuuXaUCnJAXe9iFxiWW8arCgPMrtM6BHwZh+ciRnj6bVTUDvm9JJsZQWwKhP5ETrJ6lJH+5sX0AYh/I/GYD0eTl71T7hKbdKSbhRgH6ZVHfatJQfMM3g3a/NuPp4Fv11PNOM/sFR3H20Hfc36YtjLaBuJG47QpMMitQpWr2qtKFEc+MoaVqy86E8OQv5Dsd5WW7wt++XaVpl+dnzZ2DsKQz/3Ue/mKO7BB7Qs6M3wcuMswWM3uDK3OPLaT9HNM73ux/ZAoy5sNiNQ4DW0Ug/CIgfwtAHAI5IgTejsOZdpzTb0IkCyJ3xh/tjns/EPGAIekXwRYyHh7HUnI0PHzyIWQSMn0FyVHyCoNzpb8ZbG28mEfutTM3aihxHG7kPy3sIcSqOk6GLUM9RIQKiGrmrcLQdJ+jifU3O+RFXgFlrfina88tRB5zlRnzEUcgoyMwhGdb8Smb/s8LZu14xmgsE0+pLMbtzO6cbsg7nGItCnP7O/+VqQlWKZFTa2Dad3npinLxnlGwv707z8b6PrWM+K+88A2NPX7jzcAvQIaABqNCpx7PwgX3On5+AsWvl8TK9pjLwLRUEfyg4pwwFViMGQQNXAHLtgL6ynOm7iJbJd9xewEU48lZ1lP2n4JfkNYGIViOewXNSVTVy10SiApf0UsPCh+pvrVzypRZrLWKrOpI3kUO8k9OtyA+VrPGnZEuo6BjlyUnYU6bFSr1U3m4FkfKAu1pU9gd9omttmYs7d2/HZz/3mXjrbZ3Y+3EAGLMNKuuXe44Jriyn9fCZckRr2ti4AIYJoM6FSy1BDUf6zdpwtK9gMKUH8sx9qgQIWi1H1CfLSpvUWvUC5ni3wUBYUNbsNNI/y41xj2eJe0J7krd9k9PEDFq1mAkZ1laW4sLaaoJDp/e0iCqz/BsOh2ml02I16Pfjjde/Ee/eeCdWAFIXL7pKdiUtYm6Pke1KIykv3I7Db2ZqzcuPkZN2binSacfK2kp+aF8gJm1V+9JNpufc6qOSOZzTT4z0BWKmVUAIjZGPlV92cenHfI9AKsTwmb+Pk54SXNIGAmW7+MCFYLSln+dyBaRl8TvIvum9kpIATMDiDIh5elcFhz7jz+TTIkb/alHTd7ksPrN37DYHCvIPcppD2nT68QBGe7TVj82dYTza3Y/hGBqbde862hGZfmJnQ5Navsw14RiZZX35K9tXlDaownt/8dtXqussezl7pE/blJ+0pHFx9uwZGHv6wt/5zc/FIYSWJlsE6RyjDOXzzAHX9j3y5JiRbW7gxw0FuiPJLgTa5tpxjQ78KWzgYjctnYiuIGgeQ5ymzX3uSTB+DV9/L4XEUns+xs6Q8uroMOJaJ+KFwb2cLtWC5ohZ34n1nbtxc/NmKhFH8Lkai2vLZ3mKkpEIkx7z2pDnx3+npCF3y6wwhLHLap1C8oJIt9NoNDsIVsBZbzFqKAOZoozSFKwKl5Lmdxqq9LM8XlqM8jMmM/Worb0YsfUuYEyTfEn7vJAqYZoGodyp7k9D/uSdrGeJ+94YmVi5mmZOq2Uchc5M/sc/CYDnP/6vPwNjT1u4/UB/y9KfgjCZRCWTg6NUNvCr5ykvS2MFRKHAU7EVJWQKTisRJUkmBzHJL+W51nGtLU5H5TOOyv9Lq5nKOEHZ1BJlyDJBYAmYSFsa1P9GYKLfZ9k6AbmDrFhcXk4g1oIPHTAZN6eb0tKRyWXZJViVmgrXdL0nGEgyV/74R3mtt8pLgJLbeXBPK9nW9lZ87etfjdffeD2VvdtXzDHQ1FInqBIUmUYNuah/lH5RfuonHfq57zTniDrvAXL6gJ78mDiAwc8jWR4t8Moxd+R3RV1LSxgy8oT2F8Dp00cr5aB0pk4faYXJ+AWg1fU3A5R15rXAubcj9eSvWNwQmgiIpaX5tG65WEDZZD+4l5ZfRhC0WPnufC+3sHjNLwi8+Qb1aiYIcwGCoNctO2yt9PWiP9wKxTZzZaSfQtIaZps4Lak/3NqFtfSJU17kog7Bi+/Rrra/HabsSnrjIoGYcpU0qulw+zPPxqfDiJr9Vx3TO5lHQm8ElOm7ubB04Ot+pmpre7dEIw3LYKpQBffsb14GhKmf8qBe1Z/31SkG03JTYNs9LYrygnTOswSO0E4pNa9Bn7q8uEn52zfvx9beMMYn9IubiQPEckABC7mIxpmiBHqn73q/8KPWt/NgKu+fP6xFdZ3xz47zQKw6zv9+BsaewvDzv/HJXJkzgUiPdNxHWNVqzRTicHKcAJYUsGkK5bn7YOlzcQj1duE0vSgcGR5xX2LtcZwQd6JTP4JJ34C5FI6zObXpKFO/siZM2asjIBBFubMxTPNSbRxXRpukIBHKKDNxwOjv1ubb8WD7DkViJEt+flPN0VI1+oXaOSnck8UKZ0GQhoo4q2vTLj+r+7zH+zJxChOEq2mSC1EQiK4aSovZAkKUUSD3FNqpsMgm8/s2ocr7NPAz70xf9PowalG/8HLExo2oI6CnBcxw/m1KnH9VqHwiTvMwTdrI3/n3nnSm12e38hr2Lc/4RxNmG/qa7z4DY09f0DKWAcEME9GRZ/1ZlNyUZ0pnwzruPaYi5XCqJ+OXePKYvlaCNXdp1+rlHdNTVhQHfMCYAA2eSH6cvm+cAsiKfPDQcd7D/HJlpr+RLcoe3sipJgc8S4vLZZ8rQIIUWintJG/kAv9b9OoO1ZRX0+6QIWk42ZdCUF6Vof4/CZ6og+2i4trY3IgvvfrleOfGjXzPrRVst5x+BISplOVzwYclzFIik5wKy13mASOLy4vpayXYUbFbz82t7dh0sUMCtAFATasJbaiMsm0ScDnoA9D5BQL+JpzHRwCoQ61YtImgk7iCse58O6dBm5TLfdacltM65S73AtbrV3W8X7LCBdByjJDd9o3528Y6nr9749144/U3ADD7ceXqlbJSlnK3c2q0lkBywqFFrw6IEKwLorS2OYWpv+/KqltYLCWAc3pbQO6qeRdkCaoSWNlO/OVA2QE0Z1de2r65FxrpJy1SR+myAtmV/C506vX0TLuRBId97cCAtqJ++4NhDAdj2nkQDx+tZ9nnaRN32Nc6RjTqROuCdEkmf5tPGXUWakmrlcRKSB3Hten73LwF7radtJ31MS406DckN3cH8c7t+7FNGVBiUFqN/kVvcQDDNMZmNrNkZ7mtg697XQi0yOgq/+q6OlI2+yzjT+9lm56VuQrVO1V4BsaewvB3f/NzoTEXMZLfcHQX/hqMfgLTz3Kt0Cgm/qNc7pzmWoh13w1dBSo8VmjBbQiWueLkCMGMYE4ZoSzHVlAWn4Nj3jk4mOTO1H4yQn+G49lGHJHuB+oHcWG8D9dQMAhOB87h3ma8/eAbsTPYIC3yntJmBpjFa5kmFQflygOmzG+nIUireyR2Stzp3Olf8kO55x8/YboKlMGACk/upbVMMzijYi1lDcCZU5vuXu333cRE3/HUJZEVDFWwJAdu2rj6Yhytv5XL0g3I4SzTeQYzWNcMWfFS7iqO75QHjpC8Potf1dMHGY+jGnX5M89czKSw8n3B2LN9xp62oO+KfVdGydwQVOVZhVeAiWBIYKUvlwos+Yc4lbLIOPC0lhdXPRpHntBpOi0EHIYyKIHPyCOn8WVONY1p8FvLk4DrgPzcjiaVvTyZfGW86Uo3jilJxkJ3Pq5eu5YgQ59RcFqW3ZP/pZUvAZnltG7FUsBdlKFZS8+krtgiblqyKTtJlHw4C7DWt9bj669/I954803k0SjdK9IHTpWKUHMj1uR/B0dTAFrqb7rkR10dLDZb7VheXo611QvpPyVQ8VNxKn236HDDV/3u3AR3j+ud3a2cYnQaMXeHt81IU5Am+HJ1p9OYtotWM4XSSc26AS64N4Hn9ZfzA9wLS+a7Govzy/mOX1MQ0Opgvre3n3JOy515awH84he/EH3Ksrq6EquUdXXtQjrvm57ATdChBcz9trSGackSYArGBKQrK8uAseIj5opM6zcajADqxUc3wThtllYe2t78ddDXUT+/KqDFzwa0lYkrTdlXXpeBdXbx9L8SXPyQmxPTN9KkltjhiHwZCPT7+uS5yGQY29s7sU+dsw7Iaj91ZR9oebXzKsswBeCndFEAVwIb7tnX0nIJ3Oee9aDn0/LnFK/BOnnPmZmDySx01M8tLMKvxCRdkp50qmyWNrnOwYK06B8P5Tf9BkmGoO7ifwlzGvzN7dOQ73G23B6G89fnZfzpNRfnkvjeBTfvu337VpwMIEgIwEKmw6co2EahmOWe6pcKZcOdHQZuZaA/c2pMp9T+zmZ+KmKLjlfQuFmdn+XxUxISh4QyglAcRQ4AIzd3W/FGf5ZR0TD2J5pWj3KrBztZX6sx6LkGM7fcu4YRSvf6++L6haux2KjH4PA4vvhwP95iZNOJUXy4WYshdbg1RMABYC5023HICGxu434M5xjZ9HrxgV4TRrsce4/uR+NgP55/4WpuAunKnf3NYbz95VfjqH4SqxcvQcj6X7gFhLam4+hNBjGaaeVKkEanlyOiCSOP2kIXZjiIGf3EEDotRkOusNwejmIFBl2sKQSG6Yh6MJlh1DYXC4ziRrv9GMJEPZ0+6YMD0hWoHTBKORwexMVLKzE64j7vOpKQAP/XjZ24vnMfMAVzyiCMErcevhuffP23Ym+0eboxoCOtanRgOeXvGgRP79GdMhtC0/7jujhunvV39rH9zvsKBv0BSr+XZ4b87Vv8J4OZV6NBGwM40w9E6XnM6HN/K4ZbGzHY2Q6/92aevmMyyVCmIRud4wqtWRX9GQRj/TlGp6/8yTj46q9ERyXA/ep9w3m2eg+LZUbe41pZBrH6XAEq/xuq+FV+SdcSNSHbgaDAo3Vod+5rpSBz/Qj/4n/37NuUT1v47Ffe5H/7V+Gfp6nic3CCskEGjVOxcS1tAAYkCe1GPlNBJlCDnnNFHArQGAIRPx0jDzoNOQcN5VYO8hp8oeuCDuvmqWI1/fzGJdfGkb9kkEKFytQ6+RUaVMnKi0uLS3EJgCAY009JhZgAijRMN5U3v0+tKHk9VXbJSaROHlrsVP5p0UN25TcoSd/6H1D3Bw/vxle++mrcvHszaX+IDDpAbtd1qG/rpD6b1qJjP+lGBgIUeU2fVx33ra+DM/fa6jTbqR/0I3LDVHdjN66+bcOBVjFA2O5u8duiPMODQabZ6vJur5vO/6ZTNsq2H6gH1aHHbMicDqYTkDjc12mcozlbjx56o41MaiOzO7PttGQJGEb7A2ThXE6z2XYNdNTG1la8/uYb8c47bwKk2vHc9edjbe1SOuG7T5jfEHXDV9szV0pWU5PUUfkq+Lp06WJaw4yvLLEOfm/UelnGqmeVgdnVXDiV6yau1bRkgjTilU2JBfCCrKIXldnW3qOAs0Ke0lHSYQD8uSmt7O/1Y5d6ap0SiO3s7tP3J4A0V5rOxMsvvxIvvfw+2rQBoNfJHn1BW83Qf4KgI1c7kraWPcvqopRjN9uVrimBND6TnwazjLQrZwEhr2a7tNGPLtIAg8bX396I1776dgxGR/nt5uOZ4rcmGMsKGHixgG3S00xG5rM810CXtea/KmoJ0vNZcLrbI/XStA1tqSp4XbBMiZNnOvM9SX6vwuZ+P9bv3Iy6QkAAZgVgGK/PasG9rMCZYswzHezZitjBCg1/9fe2YofRxcNHDxON56oSSGQ8BIhBlCLyCQzgx1ZHnG/steLNQT36gLAdmH2EAPEL/hLohJETpYIaWnHodN3SKqCoFfM9RoUrF2OBUY8mbYHXr93ZIL2juNqJ+FALUDDXiIf7e3HBVTsIUvfemjx6BOhpRgvhceWFazHL9d79+9HtuJVEGwGA4IVI7735bjzaehiLF9dy5eC+S3QhQIHq7LGrJgFmXkO0s61eTLa3o47QiAaCDWbtdt1d2RWUjKKo52IXhqUJXXnTbTViTP32h0cAQpgWsOIX6VsIsi51tM2QWMFgJknthcursckPzdhu41enjH+mtR0r2+tFACEExrsbce/eG/HpNz8GMY+TSZz2zO/gJZiCyaaHfVYd9pxdWxwpz0KamCV84yk1DER0tJ/ATJ8BrlNx8DijSwhcKEjImGLB1NSnfEqFZ9TrgP4Y7DyKIaPeiQsefA/llSxDAvKfvGmowBhXGc9p4YP2xei8/OMxePUXo42AqJgo5RPhPFudvy51LcH708FeFiuVLAl4/3zbKKB9Lm1XYEzhR8R8NxUddbJf/uLffi2f/7MM/5f/4Wt5rupVnR+vW9bj3O8/eFAI8q4yoXrf9vFeXk//U0h6SXDVVMlrSl905PFsrn3lVdruWBVJPHhoBoGO3oHE6Qd4fswATKOHhuUGF27CeXVtOdZWFqKrz5GO9SfwH+8JI2YV/MTXx0UfqYnggawttd3jQ4vivQNBlT/MN9+1bSw19zINXuCcRTca/HSoBTqVi4lZb8qpEuIvLQ/Kr0N3hSeuYAzFruITiAhMnF5KMCbYIGEtz1pG+siBAwaYghytMNVUV1rSLI4ADGCvNSt5lrrJS/qF2bYpczjrs3T54uW4evlyggTfrwZPPvfI8lcH9fCPlKiPRSIeVUuXCS4cPOvjpNLXn0mwY2vu7m3Hl179Qrzx9jdie5cBHmBFBDFEhjswayLH5mpHyJk6aZjn1N8JeU9pI5cP0KmuhOwgp9soe9veerT9Eoj5JJ9NZYbXlMk2sb12lRXoDLfL0LrivmN2U9m3qpsWL33SVNxaMG1Dp4T19zoZ007EW+4tQE89xHI9JvvUczIbvXYbmQyoApi4yMmsbSfbfH1jPT7xyU9CLofx3HPX44XnX6KNnQI2jjvru9pynKDJ/tUS1mVw3UbW2+f2h2BsfmEhgXhVlxEgTh8z6c8BskFLn+nkNiUwhO0hDdE89Cm05nQm8kX6szzHfiUlwZj062GZHBR45h3pCdoSnKY/njTXH9KPGkAAvCCigUpFZMPrfrBeOX7x4pW4cv25WEC3QgjJU/pD+7UXQW0tgRqgNRc6MBiw3LS1elmgdIjuIlMqBG6w/JSvDAbgZwBZF+Btvz14NI7Pf/ktztup44+ND62bRrKagXdPlB28cZz7SJIsLwvYpOustdfZBtP75TL7/zgRrsnIR1JbFc8SnL9frg1/KKYpNeU+enQ/nc6Lkp0qa6lhytzVoWCYlj1DuY9otJI0QFpdeD4a7IHGd2JzczMBhp9waNKa7pys0KoEkAJtCDHcGrbiZr8RWwiEIU3U594ReR/LqMuXorV2JWYBXpOllZhfXAOMXYwVCH0IU+j83iX9FgS1gjARzN3b2Y1FhNUSAsAPv3aoiiOsywClHsLDvHsQcJs6HsHoMtMhQEsTsgQnhD8Q9MC8w90+BD2OWZdmQ2Tj0SBmjywbjG18hRAjw7kFfQKacTzoMxIkDeqmQHMTVTcTrFE3dE+2se3lCkeoOqcqtR65xNvtLlTqrsCpw4h+KPwgrS/HsbrQjT3a0ufohKiR/g/WRlFDAOn0LyccbN2n7nfj3tatBGDJ5NP+tF/PHxURnp09ioCogv0t+WacabwM9ndyfpnSVFBkHNqzSttDBVA5MqcC9jlM7fRle2Ep6gBY3z9GYJQpTtLlnzkpyOUw0zhfRp/MdFejvnIlDu99HQFLW/ss/39yqMpzFkp5oejp7+wKym68Et+QZ++ZOv9O24JgeUtZFSL5JH78p/7Z+4x9/Ksbp2UwZD3Olff8sz9YsA6Gs/e9o8DLKQLaynP2y3sOnqU1lcP8/cv402u6J39lYvwnHUDAuSs6Ated02fgDQ/Zxn2fVpYW4vLaSly+sBIdp/9RLFqi5pAhkFfyj4I+lRV0qAwTXOSIfHpfJSgwSBqE11NpWEriJuihUJaLAmV6KmKJIP22VHrSJe9V0266BxyMR3HgQBJZqYX6AGClhcRpLfNViWoVcSprdXU1pw7dG0saEihs7+3G+uZGbAMwhtC8/jVOQ1oHC5O8A88KOpJX5GHSdL9BBzPl/kz6Z62srsXly5diASVne6uErasJyUfZRqRbgTFXFvI/skmesgHsX2WMK7XJW0xkF6r1jInS3Wag9/Y7r8eNd9+M/nCX9wSPI56f5G76bkQ6M3OYANq0bM+5OQfR5EG9clU2bekzik7c0r4CQPlH1nWqy5kCwfgYcJsrSaUJEnP6U4DYaLl6W1kEwBD4AoQEGemHSjyd+XN6jj6XXrUwHiDDPTeQN/pFtf30zpE6SOArTRSnfvutDFQLeLAsX/vKa7Gzy0B3ZSVefPFlzmv53FWDfh5IuZQWsE7Z+8z+EGjaF067uqGru/OnrKVR1XlaEk0/UYP0Sv7ZXsQp/YuuQMeU1YfoUe6X6XH7lbbMg+tpf9o+hsIL9td5upemir+fU5QD9JTtMRgoZ+2j8t1MYY006+zUxsZmbG9tpw7T91CrJ9kkbTkIle4sQ7UJsfJc/SLJOe16dOiK3lYCOHVohQu0itYb7RgcnMTe4Bgd5o77W7EP7/iBeagg42ZHTg/ztJlOQ16TXlbaZ14nQeWRcae/rZMfr89BjbfzHc7T6291/KEAY3tDUPP6w/RTslCnylROyXvnKkF80WVe8buAMxuSpqKDNXW7h8tgfz+2tjZyHt4Rkl/hd2+tBGIQwWQKxhwl3D+oxRv9JgBMixgCDyBmnBk7FYB10lmKcbMXVxBu8xA8lB+LjFK6PB+Q3p29vSRgTdA9iGAFxDOCaB71x7EM+Jqnu9t2jHJKoDN3FPONZjrML8w7ygNw0QbWwl2L+wPNyJZhlNa8AcL3JJ0tXbpMnSVIYjfq7TihvAkhZKR6I9owrWmUeW4YhnIJxhzLNRFudcpxQhnc6VqLlXyde6pwLz8DwnsK1fzgKv3gNy1dqTM7Bji2uzHgmRxyBEDrUIr31wFjlMs+OBrtRn9zPW5t34zt/iYjLEAY6VZALEFZ9pl96TvZbXldztm703Nh8oyUt8/un9LC9HcGlZaH76SQpb+TjqhfplOUXZqupR/vA2Jr1MkVmE5npNCBRmjQZCjTpxUz+ZJfXma7zs5fiAagfHz/9ZxuKLHOQlW+LM80POm3DGse1f30R8l/08wIXmccrks0nlXpcLKf/Ono7LsBxj7xtY3pVQnn62So6p7hsWffPpzFtf2tpyyTAAyw5b0CxmwRucWjxCNDfhY5MCWnaTl8qpuBsfkP3oEIkofmZqDr43GcwGfAKAZstbh0YTkurDr1tgSPo+xJc9Z95ByNO9pHcUtfBTChdGjzApUKFMhVhijgopTsV+NKb/q0lFIj1SgjsTlIIJViAQ4FeGWtp++YqnnqntBnkOWO7Pv7uzFyCg25oFJKKxCyqPpAtOesNc8so/JjY2szfa62dndz6k0ZoCw6srGgOacYtTg5leO0nspMq5Npe3hPy4QNKjhTWa5duJgzAzZ3Umc2tgqzgLDq8HcCUuqmtUE5bbmyOyhG7q5PnLIlRXEdcZ+o4XA/3nz9a/HVr3+Zem/RVgIXgBtlTiogzfzYNiApq2PZuCjyhui0Zz532o36SAO2d4IG24C29WsFAqpcVTptL4FV1inLSB4MpltuE6R1lM4TPLhK03qoJyyvFsYEtfR5LmqgPo1aE2A8Txst0i89+LQGENMaqYP5UQIUQWHFK27O6p5eX//G1+LGO2/T/nPxgfe/Py5dusIAAS3CewWMAbqRV7p/+Bmkaoqy0ypgbHlpOXpdZDlxjOv0pxYxAYucU/ank/agQeqjjhN8WS/bynxTflKHBEzSqXSY59LbVZmJkm1mvW1X9/JK/Yq+ErDqsK8+0zIm4HLPtOKob9tDf7w7Gvplh3F+puvtt9+Jvf1+aTcAZTXNmTTDn4sPciqbPNTllmIO/am11cPyHMp36KPc3gIZPwPd0mxx5/7DuH3vUdx7tBWbO/AQZT2h7tq51V8FS9BClMtaFkFCDmbC/aQ66y1xycneU35nWxR9k9f525BcUd7PCwLx/Vlk0zTe9Pw9BmMy6UyaZCf9/eycclhgG+UJYMxrKqYS4z/qVqw8vucIRguHQGx7u6yOMa0OgsQ5/PxoqoQCgUrUdubO4UxsHCzFHmBjWxBGR7t8GVmQZZsB8HR7CzFAaR/ONuKapk463/zmm3Mxhrl3GZlSmOiA5F0u2+bly5RlTGE1fXYQdhLm5GCA4B/H2sJ89Ny9nnIYVhe7qSD8KrzflhxDJHsQr0TnzvkyyGCI0jByTnVCcAjj2glMJaBiJKUf2zFMtLS8BkhESGixYxSS9AST5YpD0nVUMaPggBmULCeU1embJqk3EQQdhKz7wNhekriWMUfEbn/h/P0RefQaM4DQk1iaPYpXZgGREr+CaX89+jvrcXPzXUDcAGGg6XsKwuhLz+/pR/8jlHPF4CVOFc7H+X2vOdJXRaXGwRPog/+TVoyngIGlqb9CKt+hXDV95DpuIOu3MmlbmZx4Nl0FNKo8kqt4Nrd0HZC7nGDMUd7jYcqGGb0KVVnPl5mLcibfVNrQnbRV3i/PMi4/uU1Q5Ze/fDcPbk/z+W5ZxqpQtU+WnbJUx+l9oQpEmPVJxv3Wh9Uowavyy9p6rTVMQVeNTOH8PHukrwfvQznwG7eInU+8TQonR+44Dz1Qpjn6rkEkNznwszVtBk4r8N+Vi8UKtrLUjUUUbQ9Q4gecneTSqixGtt+1WBXlRNnMdyqHLBdsUOqZodBesXRaRsrEkdOT0GgOEEwvQd0U2HHo16rPlPd1tnezUHfNd48tV9Rp2Te+oN2Bp75VWl1aADDzUXkNkA3uZ7W9sx3buzvpCL6+uRk7/b10zHeLBkGYgMxVfnVAWLpwAMj8rVX91DJmG0Df1WEefmT6wtoFBm+L2c4CpLQep8xUhhZLimDHw74pHYLIybRryGH5U36kh5BF8mjulwbvycMHw37cfOet+PpXX4vd3W14rDwXEHeckmu3ElSU1X6CC+Qk8mlOdGcbQ3ZNlLCO+Q5S7ZYECKR/MEKZ65+lrOBNnb0FCf6Wl40vMBH0uXO+1qDyvU4y4XAqT2CmXCwWLeRotoN1V69AM9xzynCeNmo1OqRzkisI+30/3A04Mk8BoADOtoIe3LpCf6zPf/Yz2c/XLl+Ol158ORbQP1q+BVROwzMioV7F/63b7iQA10ImAFsAHPfoH6cabUenMwtw9/uZWgcFLf7BAwIxfrvwQR1jnbU0SVuWx4UgzirwIgf04tn+tNUohnE0EFRWscnhCfplksDKhQlOI/ep8z51HgDIBGPkiC7Up4zBvVuGQG8aTPoAMAfDOvXfuX03BzVXrl3LVa9puXRqXUMJ7eJnovKj6QK6KQBzsKbrjlO4qjZRphKBrmAgshM3b9+Pd2/diwcb4IK9Affd4Bcisf+Im7hDPDHt5JRfVtKe9cS1tHIqg7ynnJbo8yj55bXtq0qAplM0cel/XuePTLf6XXrDy+8xGJuJPRhs79GDFFDFFFmIO2ujoLOgnBQCBgVuxptWOmtBcLSmRWgIqBOIbWxsJODoIGDoIggfJoBQJJZylhmO4sZhjzLMgZLHsU1n57e26NRZgNURzHwAQBotX4qVTi/u0eG1mUY8123ExgDGJt+REvh4FHUEqB9MPTxmBMlZ87mO8j0IuymR0FUKqFF/N7o8W5nvRBtC6G/vMrppRLeFVrCsCBmtXRs7e0mA1usQoeOIyl325wB5kxRcekKQKszj6sAaAkrgV4MhF0Vw1G9AGgIvt3jQN86l2I6yGwpk/wCXDYQu/JSj4haCodHrkiojFuLPUz4hi8J7bXU5BY0kN7/Uiv7wOK7UjuP6CUA0+wsQs3M/drYBY1s3SdMVMtUUZTknwU8Puy2BEmeFcpp0s4+nHUrIOPx/9qwEr6vf56+5yMNfyn+ZVcVVHvnMfPIXDxUiWjx4bnnoI83iDRRbjnhpe/dw08IokxpkUJMxzfaFl9LB9PDBmxn/mwL5G6ryVWV8/LehXNMfdgR9mNPACoPTZyV4efaz1DNDCg5OCKGf+C6AsY99Zf20fJ6r6/Ph7N57n58r9TeFtJBaQYUYlyn2Oft2ToPzrLzP/zwos1n0CXzlY7qRs1NUCLbsN6/hZ5Splq0TlIsfcu5C6wKwC8vzsbbci5WVXu6E3nNvKAZJ7ojeasDDgh0O07NxE+STZvYff0I6y5IOxsSx+5Rd5ajofkr7lNcyO10OAZFWUWAVfVqtBGOU008XlYVFWhT2AWJ74c76WnBUmt0eChjAKM+mRRe+FID5vck9ANfurju/D1D4KEHvcwxIawSQtKFmVbxawlCGOqO7wtqBrMBC2Zr8aYPCfSoe79uHOeWGPFpcWMiVfYKB3DrD+qSitt8KqKw6zu7M1iI9D8ur8suNYInmtUDFvawGKOT0V0Lm3n73nfjqa1+Kh/fvx7wbqyJLbD83NHVvqSVk2srSMoNXyk3OTYGRVzSvg8PaDANIZKFThLlVB7JeGSiYMX3liodlONIlRTlAB/pb604SnSBgvJ8AkUS8MZVjWh2hOa676AXBUF1nc9uPP4FSqwlAAhTNa3VHtggEhwOnlwGCvOug3ywoRNKLG/Q2OTY31+PN198AyDXj/a+8EqvLq2lZcysKnfatjwBcIOrCA6ci9RVzN35BWJt87S8BUgEvWvxo68zM/ih9q4tKfq+S/jx/tlD2Z1r7qHcBY0V3Sauln2kndY9xfUa72edOn9ouAt4EuOgoAZngTADsdijqdcugNc42d+C/B706PamlVxBnGgsuDAGM+sF2gaTfU5UHpDf5QpDpFhe2g/ke0r+2o4u26u4xOVsHBA7jwYONuHd/Pe5z3u+T9jH9N9dCj7oNivWQBqEF2oMn2X9Z35TF2WASsP+KFYxDHpIvcnDP2WgZb/pM+UBRMt3kp2zzcqhJzLW8U66rULTM9zDsM3I7AuVWlbBOCbSsWIYi/J4cMjINyyiGBhwxctxjFOXqSVdKJoGRjihagixmVK0iEAadevuwHTvDWmxA5LsIrp60SCd0IfYWI5qV516OwZUX4905AEprPlZrrdiAqPp0/iIjo69u7Ma9wUHcHCMGENpH471ozozKqBeaXYKQ1hoz0Z0FAAFryq7N7SzncH8HRTCPIliMnd0B789FrxXR6TWI04g5huwS8N5AJQJQhTkcsTYQJnOk7/5ZOoxSKdoBIaFAFIAheL3jrtKNpaWYcRNC36O8Mo7f55IndOLXBC8ppBBGoDQYXR0jxN3ocKbZA/RRXsEkcRa1jKV/Qj3mue52a4A1YJt9o7Mv6dm2g0MEzoQ2yL587CCd86FS0jwqz/yZbafi8n7p3yeF8wr+vcH404M4+t0ILCcHjCppQ9OtAKEkJuAa9/u5uMER2Cwj6flL12Pl+vsAZrTfNJ33BASK05v5MWWzIhjjfKzzv7Me05B9MD3OAvWlMAoE76el4OyVUpXqApb1VX87FeLZo7BMifXdDFXfVtfng3UpfVh+V9ePxzsN3ubIelWgh3p5lqd0mPdwwsLhzQwgi87lBb/1B/hnANBgwNGYc3sWQRh0eDSCJ4/Smrs634ora4vx3JXVuH51Ja5eXooLq/PRhab1HatzdNwjisGMU5Y68Ts4yy1TcgBTaEdnXwcslCB5rfiLlbY/65FyTyUlDUrTSYsqN970udcCrLSCcdZ6rruCysZd5fUDc8WjLgXuDu/HrD2cSlRyO8U1hK61fm3v78bgYJg+rAemyXMPVf4RZ3eI78wDTrqFz1u5KhCehvdt89ybifK4p6B+Qpa91IV0eGZwunJxYamAIJSg9XHAI0GqFHORjsBiek7gQgemsiOTdJCmuzzqSMQGA1stWTXuzyBTuwyGHLjubm4Axt6Njfv3ct/DJmk0afMFQXQPIDi/GMsArR7ApAsI6841ow4aPh4yKKU4C23kKry70lmK+Sb1hFrmkKFzNAQxowVQW2h1kWnzDIgb0A1l4/lkSPvv9nMQu7+1E3ubW7HHwF4rnQN9/qMxnNTSvlMc4FsNADwyvQsw6qAfuo02eVM+8nehgI78OpYLKBIcoWdG+vsx+HePMi2ZLpbQj84V/A8futjsMKeatXa5AEoQbB/kNDd95eFWFp30E+OQLlxJqR60L3m/fNS9OOv7bvWeYMq+8CsoAl/LrgWvTF36nPJCh4IddaR551Yo06OAbfUodELfePhb3So9SzeCWS2NWvJGQ62OPpOP9UMrgEmdk1OTgDC3t7Bttnd2YgiAunzpYjz/3HO5AOL+nbuxs7XF/X7s+Xx/T/ScMiAtzJztC2e9+vumo+X4hAHMKO7ffxh37z2IXfrT1aBz9LuA3VX80qUzWU3K4cfbNVoc8q4+mNZfWVpNh0vfaspyyMqFM6D+vAf5nII0AZfGi9PBox1SNf70uYfPkrt8Po3zPbWMHdBDGw8eQD00rtNZEITStwhhC2w5IUCvKXkqeF+0QuVhWiX0B9CSkQ776+uxQ+emD4W+DzSXBFkBMS1KNvbWZC7eHHZiC2IRUO0zKmuSx1x3MSYwendlLRbXLuVmhl3npHm2dngCM9twrraKuDtSkNIhHLsn9XgOgOI0YydH1fUYIqgcTUusTokMB7sAGZiHBOooiZZMCDPs7vTjmPI7CtC/bcDoaYPRwtGYrnc/Kxj9cNSnncoy5mNNAjCeVrJjRlxu0eCcf7YdYEKn01QCkipE5qizwQjKlTsqF1d0OjXXgikkLreCcISsQ2wdgJXfgnRESVsJEPy8x/L8fOyQf6tdiwvzLiSYiSvH/ejCBEgJuuIkBht34t767djYfwBzC+Sm1gH7iD4rIMjmk0hL3+Zhm1b3qj8Jt3ouIZ8LRSGWe1Wc6Y9kDH/LRv4roxN+y0AqFenIP9O0ngYETCpGaMTVs07R1JudqNNmpjkeD9RIZsA/QAF02rn6wRQKh4/ezTwM5f+zUN3//YK0lTE5e2QdaDcF33vql1xf4ubh/XyeP7h3Ej/2Xdj09eNfXZ9elXBavmk4/zt9F6cVzHOy8vRv+qw6UrD5UlbLPuZMP2X30/5OHdtjeugJnBTEkr1G5focyjHBGcrncMjgRCsCgxt4cYkBjlawSxeXY5XzYq8ZYC2E+SFpHwG85mIe2pf+vXafJURq8o5WEXlJ3xaJN2URBUu+z4JSNOvp9JhnfqfCQvgXvzLBXDmsg3SY25gQT5Al3ekI7lYNfXi87AgvIOJdc5jKN1fMKSP9nI/K3NV9xtXf1u0BDlScpuc7DOxy6rHTjDaga2l1JVYuXIiFpen3Isncdi4H9VC5wuvWsywEKXVw+ldApTXP7x9qpbl88WIs5fQkbYDStU4O2Mq2Cih06md3VZZwz3nYn9n5XPPX1DpFOQ6pizMKWuiV1+v378RrX/4CeuEOsnQCUEZ2QQD5fUSOHvmsLMwjO+lA2mgWGeu2RKM+PEo553m+trgUC51emW2xHtRRvu4gO+cZpCrLXHylv5u2rAlAKb/FiXx0cJb0xnv5we/JQSpv9zSTfBOAWm/e0+JV02WFOmnhE9A0AWA9v5+rbNbtZQpKtPodAC6sb+WALk3Y/soi23AImHjrjTfz4+49BnvXr16LHuAzV0HSx+apBdNpUlfLdgBrXWmWa+9ZTmWcZdSqlXvSJbCwfIIL+6VYxMoeYjO5cOx0SlZQJS0k0CrTuDlgpy08ktireOQh2HO6UUvWhLYXgGkRc0pyf38Ajbq3GHTJq4IwrXWVZU7rmQtPtgFaDjr0KRvwjh+W/8iHPxwvvvhCxtVy5ofvuQSAFuudvoHz1H1RlyHS3t3eSRCrhc22HdDe9+4/iE1AvQMLedE20CqbsyW8JH8rP/IzfamjpEsotKJffk9ZuvC09ZZ8fehvH+Q18cECGabPbGdp29uVjD5/pIXNa9JTlSdAKz+/d8Elw0d0aE7zZEEtVClSiuW8x7UNVC5LY+RzLqiEhOTIVWvTFh27RYcI6nKvFJIq31lT6EFAInbiDgFVd8cLCMNaHNCYbm3g9xd36KS54wPnPKOuYzfCXb+oDwM+nm+5emcuLgBClmk2O22NPJzqfAGC7tH0G4cuFNAfYhBt3tPXZAjh7jEa0r9EsFc7HEFEHYRJI8YidojHVYx9iHa4vRcHCJVmpx4XAALHLUAmTXPAKMlFA0cQ+cQRzCxACQEyR75zjHRdHej+OIK0E5h+sLObcalYdrT1s/6azxMUUUanP+cR1goQ25FiQqwIPkdkpNtwxROA1hWbfj/Ndk4TMsJahl50arWuwrFvIFwUjyP7/piRC6EoUxXpOTBxGnynujft54qSPfznvTyMMw38/ua0Hg/JJvleXnmmjFVQADoCErxDELSPeWSkBJ+j/n62l3TWRFivXH0+li+/mFOYRShRBtokgaUj5Wl+xs9j+leFBIHn8s824d2qHv5/ekCLeWEep3dLSBBgytM45nUaZZpW8sR3OViPx4/ToABTOTx2nG+P88Hb5Yl1LAKzsoLpZutXJzzqAKg6vNmCx9q141Tac0fDOBnvo5zhvdohAKwel1bacfXiQjx3eTWuXVqJi8s9FOUc/QZgmzC44Sw20U1AIOaHm2EaeEVFVkbIWacpzyhX9HfyI8buEJ5qPjvCkto3WXju+oeWgFcENwI3u0bhnsCT32kRE4gdMhAEWO0wUBs4PUnepqNM1OLvnov84P4kdpENmygenfG3d/cTjOmMr0pXUWgBO0aJKPhSzfNuFwC2sLocPc4CM6cnrVNa4hL0lUFI9gn5OnBSEanlVFret/6CwYura+mTVKc8Wr9alM9Bb8tpM+lTIUL/Vgo/D9Iqh2AKQMQ7PeRdh7a2Xxvk2QJY24/9rQfxxte+GHfe/UYcjbaJ52yBQGIU7foRIKoZS916LDLo7TX12Z2NbgM+pf8XWjX6eyFXfPNa0kYTgN4lz4uLC/HitYvx0vXL8dzFlbiwBEClzyGRaPFuDTqYRVZqQW3XkPPcX+S/ZfeRhO9JJoHaYBfQgGwdI3sdBJ849Tka0/DQJJTaq7cpXwGKfvlES/yRFiZkjVPkDt7Suka72lZlZagABkBNX+4CSlxRmGIF+UlTpgWsBQATTAnYbHOBiD5zuUMAv1345hdOHPgfCfTMlzOZIDekRf3zBH2QBmnYL+pHZXoBX05HOnCwv8k6aZ40Jb2UOxQ5aaE6Cl/7rq4eE4BYAWfIf4EVoMopVTey1UqmRUwne326BGSCsJ2dnfQP26VNd6Hlna3t1BXve+mluHbtGmXT309rXWkrdVIXoN2WfqDFefSUFi3B+xc/95n4xldfjTde/2q89dY34sbNNwBjNyjPDvk6zSoo7cfMZJhW83btKFpzh9DJBPo75D56kjZr0y4LtG0HmrbxE8grh5wBohlsyzzTLkVt+tv2tc2M61nd5kG2PDu1mNmmJUKJnwe149kxPzx/jyxj7koc8ejhA9rJvX3ApBQmlVQe00Jz4hfxeeat/PNtrolnh0nYbuC6vbkZ99cfJuDKL9kzmhSkSSh5oGgVPjpX6ie2PtQJnVELTDN0VAmRzALAZpoenZjtLsVKr4VQm40N6HonwQoMQgGaomaE7BKjaFduwM900AkdDdihl+p08DEdrGPm+p7z3Iz+BHgQ1cn+diJ8Tf4t3j2ykqD/IaMLd8nPfWAgiiVGhCeUrS9DMooEBcXhYI8ydmIGohRsdQBi+jo5mE2TLQJploY9hljKqkhG9RDPDOk6ehIEuqpUEOJGsBdX/IYjoJA6OtrodVq0M4KXEWqOkKmL22ZcX2MUxr07O6OcxlFIOsJYGW5FHQbMVSQot+37t+LWo7dRMMMU1k5bJGjxyP4sfZr96MW0H9MB2+spEM84dPhpvPL49N28cXrvLK0Swd8lHcPpM0KJywVVSz8XlZAqlfiO3Hwg87u4I6+pv0BXq6IfIB8jMCEU2qwVrQsvIZAZ7a7fyvoZMieJcxqqvB8/nw/eqe4q5CDnbHvbi07x7lkEQnV5euvcMxL4rnwO6XHLWBVK+76nQPmXZ5X6t2mHDPRD6d9pWrxXLBvQNtc2B4N51B7Xx64M5rmWJ6fFjw9RTAwSUNiX1pbj0oWlWJrvoqxnAQoABBRtNaUJYwEuUJ49BK8DkjrgCl51rzGtzK64LaN46QHegDakU6WRd5zSy5VllJH/uVfVdNr5eYP//Ge9+Wl/SnPKIi1fQx3zGYiqhJ1eFJSltY3IvpOUCR2MkU1avRzo6APmtKXAzHxtGbMStKXzvYcr8hykKWO41qquxWzPRU2AOHeW149HEOY2HFpQpPeqnOUo/ai1R+d4AdgFgNjqyiq/i8xVZju4U7GnAz1tZf3s2jJdWWRK8v20/uir9NtS/thvghMtmvPdJgp8M956/bV4843XGJBuR6c9i4yiHY605h8gd7ReMujtNQE7yH66I7cjoaV6yMGrVy7G2vIiZYKX6UvPfoh7BYC2tNjNfm4ju5R7Tjke6ATuZq7QhLBaIN6bb8fy0nwsAMKUcw4mSvtAD7RRLsKi/PKneubggHsjLWla9gRNyAXkvJYp39GqekhbS1NllTY0yCGV6yifswfqPRuIttt8tB633rmR7bS8sBQX19biyuXLucrS/rBd53sLuWBDv0GtkfoQKroKrRaQlL6N9Keg2HzsEwF2WuD4rdVOkKfcKgvatNLxju/Stw6s+Y9CSdHlXmU187qaRTAPrU7m6QrSgdatviCsWMyIwkE68jX04gDDNHb3dtH9DxOMebjBrm3y3HPPxQ/90B+LCxcvJk1abhdJWF+/qZnTtOS5SP8ou9/8xuvx2qtfjrt3b5OuVi7atEF9BUoAqDrywFW5bdqo225CUw3arRVd6KipXKChpeEZmO4IPWYfG6RVeVE1Ulnt84/8CzbxX+m38zLNy9Q9XCgtypPHQrarLXv2vErjewTGZmIPQbRLh2SFkpo8859CjyOVMRWzUnbUtKbTk1NnxWx/BJjTjPmAtFy5IehoI4gUm0cJspyWhOAcxXDeOZiLh8Nu7CNsBWc7WpQEOxDK8SHvAMTmltfiqNWjE7ug8Hr4Xca398dxdziJBxCd/ieOVtrk30JDVEQ3hIgvwjjLEMTucD8ZzW+W7SIIZynHC5dW42RQpgpzqTiCWeIa826Luo653oYwXcHYhliatMsJgrDZ7eReXi71RvZEfX6hMDXKaFZAKjjMNoPwAAqWRSXmKMJg/XWAXZCBIUQLLOOuorTcrPAQxCYzNamLixsWiaPFL1UgguHKAqNICPnunsv/Z2kT0p/MxCqj1xrvSaTHB3uxfveduLP+ri2ffeMo+/cDY9KmV97znwJDUvW5BOt7+ch3806+nb+rNA35PK89SzVnoTx7773TQAXL1ArpUX8VUCpD2lvhlGWHPuqtdio9Y/q8deEFaI9R8sbdQrfcN1TlMZy/Npz/bRoG72QdCdkWWc7pMy7fkwaXCoXqh0/OPc10fuwn/9l/DuljX3mU5Tp/nA/lp71lhfLyXNxv0Q8ElVqVFPKPyiocS30FYDXpnQe5GN0FIihyFSn6FeXViYuri7GM4lVpO+XFv4yTqyJPUCCOgAFlTfjTBTaeHTSkAoLuzUulaTuqOAToWd4TcmHAIDhSt7h/UvYf8bKY07405CCG3yoozwkmvUU5VXrFSblMM+qQLAhz6tHxCCovlUB+QofyCMLKlCVlFyyam2VzAEZ8AaMbTQvAWozoc3Ua8k8rXm7eSQO4MtytBZSRuQqN9CyLskK5qoLXQpKrEpElriSUbwVYOsXrU3TxwoW4ehFQoMylLWkVgJauGE7TTemVMheHaoEYHWJR849+zWsNdr5HPSlDWnkAxG1k6fbWw/jS5z4FEPsKA+ttyhGxBOiqzWlJOkiQvQBQWugyoFzoUg77BqAEiDXNi2srsbrEwBLQ7cpZ6UFZt7LYi0XoQavFgPpPALKCNAqQC6kEZe12nbQ70E0P0OZiDqcvu+iOg5wudMpLH86UZdaFentwRR/RJ8ruhpaqHu3VIGlBm35SxYep+F4xYEVeG5Qr9rOrQ1Pe2CAG6Obh/Qdx784dynUMPS9QpsVYWV4GNJgnPIBsWlhaAlgyqAZkO2WpvLQ/k4apl/5d+kQ7PS5FGSo5XGRycR/R3UVeOp0u5f0ypW6dTIuzB9fpvM9RgbZqpknA6d5hHsMh7bXXD7/tqf+X5F/xfH4FgYGt7bVDm7rP3X5/P/XS3s5ettGVK5fjIx/+SFy//ly+I01q2LCuLk7QsNCCMASmzmrcfvdGfOW116K/txPPP389Xnz+uXjhhefjOc4XLq3E5asXY5F+dHGP9gdnqRro1GJM8Lud+sv5CSkXPsynldF+0mfMuqkX7XBbsPAebSIoy+6CoDlylsJAvKyrHGU/Se3ww5OCuibffsLz7wkYsxgbm5tx2N9LoVf5F6R1YtqBWkskeevu76RGD+76WQun2Y5gRrexeLS+nnPPWp80Z2q5mkyFXO6zkkLNkeUJoKod94eHscWo5YT7SYSUKHf7b8GEnI+6SwgyBNwcnYbgW6AThS/bCMj18XE8oMMWACeUJJZbEBsC3067tTeIEQR8DeLpjweM3g+jg0IYH/IUINVGqPSc52YEIViE4gBk7hlzEh0qewAIu7e1G3WIwp35HQFq2m/NL8IAZMAoekL+c4wUHHXOMMpvzwCmYCYoN5BF6fs109U/7IDR8SxCqYfwLytPsgkpqe3tnPUFBI9+HtZtpIMrZRoBSN2tmGaJ/QGCBMK8BhjTkrl7cBJu26Gwa0Ogqwe7lIEHENZRfzPu3nozHuzeTeJUKGeeZFqBsTyq/qxo0S7lv7zHkWfveJ33S5Q88l5SfvlN2nnPSBmMXJ5VtFNuledn8cr16bvJGAhLKq2q4WaWVV8ZBZJp5J5ktEtnaRWgCrhduRaT/a0Yb94tdHsuPCk/g78fZ0JjlBJXoVwbzyv7Od+YRsm43Dgtu/c8l3/xo/+b7wIYe3X9XDnKPfs4A2Anp7f845nKWiWS1m9uCGh8MKWEc4c+X05Dlr4z2K6p/D0QfFo8ygat41wV6a7lS4CwS4AwadktYvQxmj3RgtEnnUMGTfAQhwJZHxn5ySmasrkludK/lSNwgnIrZF3s0xO90/T21DCN4oIJ3XoilR9K1GnHagrSkJ8ES0XmIRCDquBvFbDuEmkNA4C5WnI0HqZ8Eiz5hwrlWr+vouTy80fIj+IHxj3SlN7zU3EwYFqUOUuTCwCR+aWF6Mw7DYlcomI5/aRCpj72h0pa0nYQ6IestajYfoKw3DTURUscgjFXIwLJaLtm+uVcXl2jnRfheyWefSFd0kTTqitLVLYeyevcU8YIROUpik08G0P5oeM+/U/d3ELEhUyvfuH34mtf/nwM97ZyW54FrVgN5eKIMuj3N5crXS9dWAEwuWciydI+anz3hPNQio0He7n44vqVNehhnr7WBaUfW4/uxxhd06H8S/OAJsE4hVLutlys0ZpLJe1qRrtegKfvWG6SSrGtd9kDrMgzF1v52SFXTPa6C7mooeOsCvUS7LoC1j3hhoDfdKCXbknD/jukXw6g4UKQ0pnVcPB3BBC7G1voxcnBmPZeos6AQwCZ9FmfdRVtt4AwZHbyBGnaCfZzfqKIvJ1iTwuW9Ex5srwc+jALtgXKszNl+o83KZsybgrCKGf6OXqPfivTlh7FAinY02IlqBqNnGUSeE5y64qd3b0EYllf0pIOXG1bQ39WFuFdgNPWznZs6iemyw1p5MIN9JV+Yh/+yEfSX1dM0Mu6un0HgwrA6IxzVMgWZcTW5sPY2VyPKxdX40f+2A/FD//gD8VLL7wQ165eYkBWvjV6YW0tljVkwPOp4ZAZ+pIea2k9GaGfXKxTo/86xF3J/QV7DOLMw5ms3ChYEyVtp+4rqyZpC5jab5yWrWHou2QEuV+ZhrQgrgtVfK7K5mce1X9uaExS9F3RMWl8UFDYT99NMGZ5ZN503H94P50vU6hQEAVv+RZlUTL8ysKmcDTkNXE5cq4bohsh2DbXN+Lho0eZtsuBOyDaJEjykAA8EoxBOPf6jXinT/4IQr/Kvwendej4FMgQTjRbcQgxbLeXYxXmmodB93lXaex3KeHhuKrVTY7l3aHCxfcRyLXZo5hH6N8eKQAjLgDmNhE07rzvVhMXevW43K2nANcxX4UOhcQs6S25uSSC4NF2P7ZhRL+NtgDTzdObMzDYhHR7Fy/G2G97yX8waqsLyAIMzC+vZscfjSGwHO1oOVuKkx4Cino5qtAJUtO0jOiqQplTp32ZQP8Kx2zWX0VlAuoXlYxpaU28vtSN3X3aEELtIsztkjblWuzvxImUSpmGm3fi1q03YmP/UQp5R2MCMtsqpyxolCKoIUb7E4KtRpil/+3bfJLpe1V+FuItZy8KFXmdv8vDaeAe6Xqnei4TlffKvepcHVXIt6izAscyKnCtl6twtLDax1rGeksX0grZvfRijABi4837ScNPCufzOZ9XAq3p7/zfKhHKPduTcgtaLJVt5O2z10/Tq4Cd7ZexifPdAGMf/8r6WZmqekzPBUSWh/5lCX2W9Sjl9qj6O2/b/95DfHn2dVtUtwBH7/rD5BckeK6fiMaN5YUuCncpVpfmc4SrtQRyIy6KQOGb7zhVU7K3i1ReOa2GUnKFcQpCSlisAh4qMe9YbkEM18flLD/4Z8i6+q7nabC/VELKG2VPlZ7Kyo1MdcIeuEUFStrrnPoSeEFvhxyuZFSRa62XX3PFHYMyFavDRVWnzvxujFq1qW4a+oEJxnqCDAdRPMxtCTi0ZDjlmtOH2c7of+SAfCkI04pebRba4jod8GkoQZZWsXnSXNJC415Z5GV/qmhI5hw/S4c+IX2OdIDmfdvWswUyTjkAP9yvAYL0ITsY7sXrX38tXv3iZ6O/u0maR5QFgE2+WsdyWxKScKGRU6UCwl6nE/v6y+3tpTXj+evXY5EB5/bmRuqDZUCpSll56oKpW+/eyD0Z15aX4tqVywnCpQWnsGgKutGhKP1OWyWtUUZpMP2qoCv9lpzq0irjykbBgasBa3NusttNIDY/v0x9GLCiz1zN7krYtIhBB0lNpJd9TV/4zU8Bs752TsHZTmmJ4tnGA0DG+ma4+tKvubg1xxrAwlkYp4f9dJPbWmgRTRpLoKSlqgApEiI/AEv2b5HBlQ4te6NpxKD+MgoAK7+IwDvlfdOSF6DjBGHVueTh2TzNuwKPTkUejIojvvXWIlZorch8ZVcBblrN9hOIebjgRMuwVigXIbz8/vfFDwCqVi6sZjm6fjYqdZltU74n3Wmrn2bCVe+ubL5y+WJOa774/Av5sXc3La4zeJAmc7aRd6VTrbdt5QPpmZbWLxoq6WgBYL+M/nRaut1upPXVlanSh19BkH/kea2Xgtf80Lx0TdoKliInHHBI62AWj/zjmfKBQ7o/lW8cuXWXd2kb0ynRbC/jfpeD/OkeOMeADktigc4O27Bc+8xVfQnW/M2LCsQcDUAcMtg+aHx9C+JFsImiWzCazySIIgynPho87x/W4sFBK0Z0xjaoXOY4QSj2SVdL0IQ8HL3UanQoZdQKxBAm/anc4rLBoaCp07grAJlOeuMexzZpV34IM4eDeKlBB9E/hwBL9zNx2ww7t8W7bofx3GI7rl9AsKBRjoYQMgTsKLXtMnNeFISNKfeehOCSe94bImgQs7H43LVoao6HKPTvcmn4MUTtqqCOJnLey2W5kzGj2dWYX1xGuKPA5gqAlEHgJdrE0dRM7A4msb43jp3t/WiejFMw97otaioxHuaIdJlRqoLJuXindOiJZEwtb6I4HTQV+Ac6bjIKLf1HPM8mRPnt828V7Nrs328TSprfPs63CqW8Rcj8fqHKJwUc7ei7qbCpr6ugUrFpMdFi2l2M7sJyzOrs+W1r+J2HKn8PBWmWG8H37cpu3Ergfid1/KcS0iSikvGHeZ6VsYgUysM5wTa0kEKLx54zDievPBdhZDv71NG8llsVIqCK0ayDnCZHnRFRu+mU1Hy89NyVeOn5y3HpIoqwq8IkAQBNtf2AbZHTZeYNvatAzFGLQm5yCr+dgsFSiWl5ynW+BC955BQNyqoopXIo1KWFnMIhTvZT/mVL5G8VsdNV+oW5YauLlcreX+O8X20jkd+GVLFxLfjSL4ncshgKcZvQX8XawdW0jNbFD0rndBPxTLN8FmkvFwKUKSXkH/JJeZgO91PwpQWssogtLS7mVJD0Zq850BUE+G3DleUVlNVyuMO7bZPqh+yrqbpKwaSVhnclC3s/73OtlcD75ayvLT18jDI9PuD5ON78xmvx2d/7WGyt32ew3KevAWv6bnUZiDJQnDuuxbiPHERetZ0KbPUYdJ7E3vZuTgHquO5KTBfe7G3vIIyO4tLaWhzTxgcMtu/fuYWO2IyLF5agmctx9SKgUiA4q7/hYTRmdc2Y5GKAxU4tFwQstGuxzKB5bb4VFzhWOvVYpTwryNslFHaPtlsEhF1YWom1Bb/IsgBtumjLjUldNUkfI9fd2DVXXQrm6V9JSt2VDvnQn+VWts9xv2wEfBJXLl6iDXR9qaUf1frDBwDKIX0CCGyrAU4S8LiJq3oNQst+yEHvtB/sZ1VkUmLqQsAZYFJLjPmTPLQEnUEfSSNJ23RQBt+hQNNzObwuhyBMepf2BVnpx0id9XsUfBonwbz5UA6JRZ0tDdpf237uiMNVl8lvlGvp0lq89IFXYmFt2c+K5xYsM+pQ5EC9id4BgLnRstPG/b3d3O5Cur1EW12+dBm91IC/LVcmmIcLBsYH6KgDgWkj/ezWVtfi6tWrcfXylVwgcO3aVe6tAnDR0zMCtBE6eCa3vPnQB16MD77velxeW4h2zW2phtDJIf3iLgryATKGttMJqA0AbOjG4gIFqdwutz8BZhRmepSghMvfMnVeJ7fwJ7/QP9/taUrbzCnK48F+EQB2Xh4KxqkSz2uKa6GlHmmF38ZzRHs4LkuFtYjtQrSabv3eo87puboDAnMjv9wNWQF3MIl3Bp3YPJrJqYGBo1SElwyBRIvGworzezHo/f+J+9Muy5LrTBMzn/36vT7PMWUmMpEYCYBUFVvqrtIHqdcqfeiq1r+Q/pvWKrXUq2tiVReLJEACBAEQCSDnjDl8Hu/1edLzvHaPh2cQbC2tQqaOx4lz7hns2LCH17Zt2zZXBjkfHaMHQg/CdSNVDMd8X6IViE2PXpdVmFVTL3UOAWlC1o/lht7Zdhm4OoNBIQAEmGuZ2TN26KVthcOUq/OT9E6GCu2OwHAY4qrMQ4B7EPgB+zHXzwE59q5mF+bSZEf6mXBvGCIU5MHdCIUhiJxex+FBGR4fLhMAr/SsAX8CibnpKRibtGCUgEgEQIZ2BVCU3aFemcfgi85kUaBZ5zK263gpwB0icBHXe7PtBLXc652Wrb2TcnF0Wtp8ax6BGtB7ibLZeFpebHxB/eqzoSJE+dF+CoD0kmzCNGpOQocZarV504Wu9+uen7e/3zwPWd8SdN2a+/VKpSc3xEmOjfJtNsvebF9Ou/6O9KSeqz8j30KxOUQ0ODxeTo4OS2vuAUqG1j/eLxe0VUOkd9Phh/+qhaCfj+ZbUVg+/4+WAQGIkKkCjnuUp36hbnkzfMJVLwqOOHwdlrGffLTJ/8137+z9k1oO65uM99uhCnOF+1VV3uxRINy2rVQgCVdhWaNEENgIYYf6x9BY05Oj8QlbYV+YqX5DWaKIjkeEozttphXNmqq9zUa2QI+0XazD0iY7NVvrtqnz1GWtY9/lV8qSyu/TSi2D1gEBmikoF6rC8php9FzVpybgCjnTKCtDEzjs6P0oKNJJnEDrhz1r3fmRkJt0hqzTikNelZmCsSi5VJCdxgrG9BHz+/lOhkENGEvHkGTlPR22tcJoabDD59CRFjCtPIIz6Vo/p1iUScdSazk0qKpWsfZ4C5mAdOOeQ7DeDxBrasi6k9/Ipe8HhHnH/HLfATGaJt8xLpxx37SAvXz+tPz4r/687G5vlumpFvLnjA7mWNwq2nY0yeP5iYBmoExOTtP+dHzoALtkzvbWDjJmpCzOL5YxlKG+VjvbOwDLqdJpTcT6uLb2orx68SzDfG89vAeQH45V9eQUUHx8UM5ODskZHWnoyKHuzkSLNAdJT185lSpthRx16G8CeZ37KNxqBREwGllfqT4cXWNohgzVoZcyEoM8bUB8ZhRSBbZnJBL0YdNntQHk+oD1D+AUXHZ398vO5jZAkW9SFq1/k9SJVrFYZ6lf28O2N+hri3wJlgV5WoDMuz5htk/4KzTD180Am+1oRyEBr2mPtCt5bPJa6bkem3P36nvtjMlaNodwXVHACWcGs60TXvi2PNaXmYKkBKsFUO7t7yfaQZe2scPlKg7tmcny1jffK+9965uAsLFMNrPtHSa2/XW6t00E18fdfdLphj5cmN5ln1x1QkK3g+OKBpLZEPLZSW1OsKAA0fGmIQ8YIFe/SjsgjgrFmk0nTsDn0n31Odqfepye7lDvtDn3nChyeQ7/Ugepe+rYVWusYzt8CY3B7wGVJODbtq2CLFXO5kndbZNcybGeZ2iTl75WMKaoO6Eh90H89oIzji5jk/HmaCGqIpXJ+3/8TA9AAMEd/S4cW9/eqQsWuzyGU6UlKBG7wtKjRKMz49rxaHl6NFh6EFVmCCHgLhD4l1TgaGey3MwslsHZxXLRopEmJrN80TiVqmAxT0OatMkayZcZiH65XQAqjv+7w1TkSZ8MAY7Dhc6ktMHaEKY9GJmPPl256dEjhIGcveXi25f8nlSgDo+UlweH5UzTMveH+I7TggWqw7OdMggDnMPk19xXlNnTckbjJKj+GPTvQuhzPKdVz9mhZ92j9JidzGCPxbrO2DsEl9lBADCHc074RuLRuPOeMzFFcFRdguzFqRmG0lrXAyHu7HbL4cFZTNMPkePT9HKzXRyW3RePy6vNJ7EkxCpB2zbHCATaL4KbtvRoGzftXP95r95HZOS82er1ujdbVfa+5Xn97/Vz3stjVcGxNfcUPs15cz10d2er9NhPgLqui0NDN/SwkDmlt79bWguPuHdexgAQKmZN7gl10bznlu9wkI7MaTLjhfzLfne7/SZbzhH8sYzJ10nr9Z40PJpojvX06wBjf/nRRr5vwSxSVLhK6rZEHq1DAIa3+KUSqeBLgeS52aZeuRtBxPkwUkkQJsiiU1ym2+Mo04myRGeghi1AOUU4SrdHUeppG2WJ6SQnpoWKtL3gq6yvKO3DO03d1U6g58lsti/Vaz/v/k6qClc3ylBLXLfcV1HB31XmXIaXoqAAYMcAI2cuOuSohcxljgLYVHSko1XMd1XViBJ2lIPpSo/mjWNkJPJI8GVnKr6sDruoqMYsn6V26Zo6LJll0Dgqc6xvZwlW3qczpqKmXJ5bN/rz+J69yjjuc09e1So1PzODjGkH0LopC21f6zbPNdfJJ02V+zay4NrfChFDYMRv1MY3Pyh/l6LaWHtVfvo3Pykvnj5Dhk3kXTse5qmFrBmjg3xxellOus5GRHa2ppDZ46V7eFRePdevag95r1VvBhasvlZ+e2VxCdmoFaZbXjx7hvy6KO++8zbpDQO+egF8Z6dH5eBguw/+BDpGsUcGUy6BvRMAzgEMF7SdkB2y4fvjZardoTxjlIM2uUYhj0xQG1pVoEIUf5b94T3b/Uq9g6BQ1tiO0lLjq2i7tWhDLWKRLd6jjvSLEqp5fPbFY+qt+nkZKUB5NAn4aAHOMpPS4UraS/kZXy8Uk5RqrLZxvpO4klo/+Y50L33EBwz5JN1VmnUIHFrMeV9n9n/fXmPPuTpMfXp2DhiDvqXngLCTDKmra82L39MwomuIKw0cdY8T1FUfMY+uDhEK5/703Ez55ne+Vd55/90Msed98m2HKjHnyLeT3hy9uqIttHo7O3Z1eanMQZvS9sH+AfVj2CY6QFR1rJPotqxyQL4EpVqAG4uhLihai+X/OuTsZBXzPQxPSKvKJqn8BmDrShMTdUYuoNE8ydtOcLPdfFZfPmdgJqZgOhvSvryBfCFdmjLp3d0HbpRDVb74QOQRciyuGF+vZWyg7HW75fRgt2a4n6kambdmzGdeX5fhRdwcKLzK3XgvznLZ3toO0HCMV+dLhUwj6OyJiP4VNGfn1+X50UTZp5HWYJju8XEZoSchQqbOyw09q5mFlXIKc2n7ug/TTSPsFII9wIkESBuXMWp6ZaYVAGZe5wFDy+wKzn39xCD0U4hynJ7kYJD0MYpawUc5EHYTEvQZPQry4YxGoFm5PD4v96ba5ZCe1NOtvXIGY8/NTAHuIAcaeQABDFXQ+Agyeh/2evULOfU+eZ9vw2zUyT49yCHKOsx3obAQjELRsXcdgC2AAWLTY+K6s8HqEhVnyBbyx1+cjGVq7oWqrEdA15BCkh7hs409fgPiVH58563WQGnD0BLU9QnA+MXnZWPPmYUq1SrU67HWlwQeQc15LBZp27olIKSEyn3L1dCADVSv193MkxrXed+CNBunUWCe+pz5T+P6fG7Xd73n6d1n+8e75xGi2ThyWYEkGGvNLMSqeIgwb80+pDd7ggA9T+gLODICX6uO+cu7bMkB/xSIAhOz1mTv921fygv5TFZowjCyZc69mkD/sfp8P72vxWfsY0NbWKLkorZlk5nko/KuVxT+mXbPrsCxCGk6aEhLiTPgYBHYR0UIZXNNC/dsZzxxwVYWZ8rCTKe4lqtDlXZ0EowTpSltaU2wK1qd72udCDICXtjjVE568nOGc6Q99ia7dzeVlFuSpAy1Sm2Dpqw1/RQyDQntc08n/YCwBnhxdPkhh5TOoZdzlHwc8lUu8FUsY8gnY4S5ayGjZAFn3ovCNA9UVCx6gilBCrydZcuQeVpDvBd/lmTKXj75hw7lDflPRRz3Dd7VKpNhVb4roHJJIT4W3ku9eKTeXFLHsApaZQRtFjh1S3HrRAx51zavu38Os5nvCtT4zbM8lffkeWWJlvdR2vmk2ys//euflk8++gQANIKSv4nSPke2qKgGnZAEADs6PCm728p5l8E5g+d6ZX1ts7wAjO3vHQRszEzNpdO6ublNWQ3oSseab29t8NyzF2V2dqY8eviA/HCRtlWh97qHWbdTmpsKsBlP5/xci+LZCUDsGIB3FmCkQ79hETKp4Yb6u7RUglqA2MAYxUJWUOW2cw282w99gcy02FogjaKvhXEepb6wuBBn8cVZZ3/OxtctMyanZwMwpnU4Bzz06Jhvb25R/q1YvGZn5sry8kpZ0Cmdd7XOWFCtr86SPTT2GXmHMQBzJSCu+v/RFpRN8KFYl/4uqYN0AARm8GAsX1CctBOLL9dDowFjgkqe8T3oOzqDsuoDZpucoc8EonwlfGYQXP4jjYF02LuHvVjEHL0y9pijQDRwGaNOVu+tlrff+0aZmZ1O58HyZMkrvmv8yzHo6KS7X87BC0O8Z1im+blpXkd3AVAPD/azmPrzZ8+j5x1q17eQ18KeAnBDSEXmsBvmSjqwvPrfVUOQVmDqyiFG6Vq5YTm4YRvKhPreyQv6mEljtq/fj6GCtATe6ufKH9W6JraRf6vsq3wSuZPMWUUVN0TW856+sHZgvlYwdgFF7GxtFigHoEGGbMYIR4Ukv5JZMylQq/fSg2W3kA6/HR8dwaBb5YAG1tfLaaoG2Wt6prGOBYjpi3FRDk6HAGOl9CCmHkDImYUu7j0yMV2m5xfLKIQ+3OqUORgBsuUdGp5GdG06Awra09CHqwXzU+dpxEybJ6fDA1elZdBA8np6Q++FGr1GSQzTaFnfslzEgd9hSseEx8jbkIRHmi41NMK3FifbZWO/V57tHvI0G+k7xDgx1SlDOudCuGekhJgBcFFvfmN4vFzRU4yzOXVyPjSSoUyyST3ZoxL6oPwUxgiTECHfUjB6x03TrnV02w4QvL1smWIYBtPPID5sCiSE+R6MxaOlBb+NoHzeaSuWtN5RP/vP6Z1+XvZ6W0kjBE350tNI+1ZCvCVK9hBi/3cDfuo1j+Qjv5trdfeCf5z0f9eHmnv1nXr0pnSVs/795p7Hu+d3t9dALK9k85rPTcwu1B7h0WEZm31Aj+2AHi6AjF76KCDeXrIOpirE16l8eTPJL3/x9eZ3rI/bLTxhck2HpF5u8mWe8h1+J488/yf/4/89977K7Sef6MDPt/kutczuiZmzjSuAND8K9SFo0SJJe1qxXJ6sLrztEALXFP4ONXIcG75BKXXK/eWFsjQ/lRArow5dwlPGEUtcKZ5TIAfc5fsek4PUh4JO+otVNkKPe3y8ApSqmHyLHPb3utUhmdrOFqD6x9S6z5O5JtD2OznEIqDMeT0U6VJg1fleQGanKGAMvlU+qfRqpuusuiZivhNCvKvsiXWMD6pEE3ICZaxzsp0wh0/ibqCiJRlzVv12/HZ/eNI6hVFV6i7VEx8xwRh1Yi1ZHuvL+tHqGjDWB1n6krko9SS0nLUeyVf4lfe8r5Ky6LnWrzo7b7a3baxiUUH5lNcTfJQ8xekcRX4IiPrrv/hx+Ys//0t4SHeK67K5to3SPil7O4fluHcGWDorG6+2y8b6bnn1aqtsALTW17fLs2evAsS2t7WyHBbXHTyig7q5SUdQp3dk2Tkdb4fRXr5Y45kDlPdCabfaaVvz73CaAXPtrDv0NwVIErgIpp2N77I7Ktml+fkyOznVl2PWk+ACnaJrEZJ/eMThMd4jXZfvEWz0jlw/1LhlVUk7BOyKBQ9W75W3Hj0qj956WJYBYg4lqssyxGi7jnh0SSVB4UiG0Axr0QU0niFrfvD975c//Sd/Wt5++52aX3SLQ6H6B1q/0pw6UZ9WAeX5cY/rgizaljbOcDb1b8MJ3gyblBmB7I1jvrSkvggwY88vjtJ2hie1hsXaKwg7ST0Kguv6orxP4yuzpSd9IU8cwiSPgsQEdwVQ9eKnjV6h/CsPVss7776doUmBlB0GZzwLxAS/l9DyATp+69XzcrCzmYCsyo6Dg934Aa6/elE21l7SXjuhewOea5hpt1oZWox8gDsMa3N5ivK/rq4M+lproVS3hQ0l3BRX+q+7JKwMiK5SVHifcslLiwuGGnFCRZ0Ih1LlHGDXTyuySD6QEaxfr5seO5f7Z/5f9R+VnCsCf9P4WsFYjwY9dIiyLxhtQBWmGUvmIjz7GW22PENRaHSd9wxauL2NMiANZ1m0aUj9RRR2onSP+oqJts/oYT05HC9bEGyP3zaJ48llvF16s6tlaGaxLNEjuYbpdC693x6HkOmp0VuzZzk7Zq96oMy2RsvylOumXZcdCNL0x4cUhQg18jx443jyOb2g6USCvrqkl0RPSjPo9BjgjbTN1xAgNMMRNC4JZyq+5tHn3SNA4yl5GCpXfOMIYnbZDssu2HE9y4FBQCKCtIcAUyh3T3T0BQRC8PZKXPRUC44zywRjmvpdw9IZgHqdRKFTnaMgewnNILNhJM7TFihEFaX1b0+3RZoypBGs7Rke06NVWYySloDswWhVigrok83Py4sXT0r39BAGqMBaITbeGk+epPlc51m/dxdw3LZ9/7xusgRVJIWyvX4mZJxyuHmWe/1r9ZH+OyF4T2QML+e/eo9jTa+eK7jubnfvNelYx2NTM+UEwWvAyKHplXJzRg/7/BDQO87uJIw2Ob8u50c9iiAXv95Sdv/6ad/dGhBwew+gEk42617yNJd4RmDB7y89zxbGp17/5F999WDsv3y4FbqkVviubYnggZbMaJQ2vFPz6K1qNdbOpEDV8jVwAw0Crpxy7lCvPUPXaTVQ6+I8Am9qokwgnKFqgJhA7TKgLWn02zPCUlqVZvndAIeE0oD+E2SSc166BWNNnbnbTtZ7s1cwZp6lB3gUfgkg875HfjtsU6WzPFwVv507/TtVUloN9BMzCrlgzOcFZHV9SerBqiIftlW1gPFNK8pOEHnNOf9G4WF9b5zYk8kG8I5WwJpvqgzeFRim49nPk50grSE1PhMdKGRjFo5GyWeIkmvWjfUmMPO3ZBZLNR8VCHQm2nHczzu0r3KhWrFru5p9r8mD4UMLYn2QkHXdDAP5XGNNcaRAq5gd6Q9+8cvyb/7nfxtQZWr7uwflkI7o2ckFcl2lSof5wKGtHoq3Rx3qPgE/XVxl+MmeKBSQ/Zh31l5tlqeAtI2t3bIJIBO8bW7tlE8+/YL3j5DHkwEMApBr5KOLRm/v7qGMRwBKi+HXg/0uin29vHq5FgDp0KeAVDKLk7pArO8MfnlJGW+0qhhIdxAgcFYOugeZNOHKCQ79CebsAN9bvle+8/63yrfff7+sLi/HAidAcOmlDGPahhzrMCN1yK7M1Iq2tLAIkJwt3+L9f/bf/ndJw2FKwbaroDg86AiRscwcjktsM2jstEeduSQQ6Sr/9YsaBRQOoYe0Vum/TPNQf7Qd/1cwdpf+67mbx+hS2lBA7Xey7ik6XOAb9wnpQBqBntxs+5PTi7IHAHMo2fiaFYgBFqF/gxEvrCyXe4/ul3k6XK4Y40xjhzalb8GlnbLnj78oX3z2Udlcf166+7sZWtZfbO3Vy7K9uU6b7QCCe+ilYUDScOri8GAP2h9MXLkEVSdtZcb1xSmUpsGEjiBywdEaR9E0FAi2M2woNUPK6rusW019Vks6dypLRqdq6HBoe3F+Nu1kOlokazgPZBTgT9ljNAdrsenA8Fp4qMoeK0oBU2V+nuELctXXAsYUOxZp15mPOu5DdOmxyuAwcc2kpeZ6/7zZqyAoNIjOqSdx/vcYICbwsBEhGk2wAWPs9gAMErd9Mlo+OwUdQ1BjA8PlkgYZgEHbSytlcGKxTMFYRrc/hLFimKYy9bDa0fLI7wSLJI+nVzaEyx8h0AYuy0fb+7Gu6ZAvklc4nEMwEt01PabJERoaAoBMywhlmh4fIi2+oX8XvWSX0hjj/ZXpyXLC+Qc7+4mer/+CQrgLwyrnnHUj47rC/A3EYcyU3d45BDdWzi4H4itmEEmdMZ3We0ZvSidWe0MGgzWeTjW3VmXiDFbH4a13hyoTvNLhUL4loSlYJR6FVRuwqDJyPbdRBL3fcVxcom4jbVfobGlxG4DYuxuflrW15+X0grYlnxOTM+W7//v/U5m+/61iQNmD/e0w9KgzVdPufovm7h+bzd9VFtTr/wCMeezf8/x2yy3/87xez5M5r8Kl3vN2c/0fnjfbl+5zlElHaIOxzjQ9ta0o3MHOchm8PA0YU5AKxoxVN9yaoH0VWg5ZypCVhjw3rddf+fL2pXz4cBRd/Z0SiOKpd29H8XmPY7/Cbt//Oixjf24E/vCuADtquQpnds8rUOrnlbKonFWh9k4d4haICbD08zQwp/Gj7q0slIW5qRo6hWdg2jzr5JhY0EhHZWZ78hmrPHmw3OnQmRdoT7mSPAk2+pmI/wZ5aeooSqfW6hubCknlyGnqVSBizus7KRvnWqNiCVMxnp4EfGVqP3Imw5XsyiTz44e1fzlUGp8trVrkK3KPfA3Co7oj1PhKdU8EfXm4/6wUUEteh0TrUFNVpNwMeHLVEX125BmBlkNwxlCC8XlOS7dtxU56OkdHBvOnQtEZXktOx3egX61FtqH3/Lp1QTMEmLlZi6lJ0vWYfFFeDvndDIVGXpAXOy9//6tflv/8n/5zWX+1Bi8ZUb4Gmna2m77A1nVdWso8OusVWYiS9nxQx3l1A8dhgNAwsm7AUBLwxPm5Cv0aWXheur3Tsg8I2wfMHR0Bko/4vXeYIc4dgN+LF+sBfeN0xqem58jvQEDD1uZ2osffW10FON0L8BAoGj/rBDB4ifwfHABMDXXI5li+eyRw7HXjB2VHXN88A8jOzDhh4GF5/733yjfefjfgTsXv0KdARuCetRQ3Nsvm5kasaoeAFy1IAtb4HvG861K+++43MoxZF92uk0GOesbPGwgwOzQoLbSX4USeOddCBlAz/9KNPmZj0MUg7SmpGEw4nWPq/tqYdldabOtoUuMjll1dytFhcwFfFjk/1iqmDq5WXlva0R87PfJjfMT4vg76e1rEAIVOatBCJp+4FvLC6nJZfrBa2ug9Y3Tp7+51mYpc8fxhefz4s/Lppx+VtfVnvHcMT2mFa1ZLsA6P0LXHiEj5VN/IOtFC2XLJs7o4jI+jv4wK4D1ktEGDNwByn3/6Me29E70aGqeOXGEmHYzIDoplTpS/ELx1oJVLB3/dc+SYa/SlgG52ZqJM09b6ZcNKvOUQsB0G6ibhUny6gjHVmDwcfUnSblJ6sA03+Xra/GuyjGmCvy7b2xsBMK5TpZCyMvgvFWGvP0I0u8LT7MKaNhqV7XTeHkh7d38fQWVkaNc3c3aLBFQtYgqp7A4PxFdspBycXpZjpWu+M1TG6RF1pul5uPYYDbE61UrP9JkzBO1VkqXnmrMhwhuIbQ5wJMDokk7v5KpM0dBHRwflGT04IZuOoDoIn/I9wdGB+UQw6N+yMKGVTAB2URb5XtYyozF7EI3O/cuzU2WfnuHa+m450kIgxyiQRtqALSOFj8aUfczzLQSIQ7OicFitTNB721nbKFRsrHeWmUrIMhmjgAItgzr8alIVVEkYgzxrXQ7YUwIENvVW/UtgUIipRf1relX421Ydyitjn2mypnep0+IkQGxxyB4wqV4cld1Xn5VXm89J65R0hssf/bN/UdqzK+XTD39dJpGzC3NzpXu4H2UdH7p+28acG7Ks/6fdc87/3qsX87t5J9fu/M47/b1/4fVv/+U6O8TeXL+9f2f7R3/7LPQ72poswxOdsr+1jnA4KYPtpQCK8WuERAScvSKUDDQlPVycufj7aT5N9ZJCLY9N3Gx3v9nkyef8Yv1d3/G3TqK5RloRGjL2G+/7ia8DjP3lx3u3vJot2ZR/+Z+6UBkLAAQ2YAB4SqUORcGbdnAMXzA/NVnuLTmMs1SW5+dCp1cXx3kujvm8O8K5QxcDCjnKW+vOOrKs9VjlBekLxvp7BJzgg4p3l75jrSMftV5TqRyT+9utWgXIPzTuaQVgVjj1D+16XcXlsEgXReyCyIkrhZKKLw28aayppO23rB4/Iu0FiJk/88I5fGK8KR3yfdZrgjBjBTpd3+uZmcZ1k6gWZvOgDHEmHEoCOnNJtAyn9dPXB8bfdlathwxZ0R7mSTFokQVIsXRRRq1pEyhtY4q1J1DefNd7PtcAbSuj/vZ/jv7HNfPgn3kzX951TzgFOybk35ATezvb5V//639dPvztb3NfmePzWvFIgvJZV6TqOakbYFkgav/D8EZ2crhAmtQLoNEYieAv0iB3POvsb5XqNRr+ht2JTIpDHf739g/pKG7G32xzcyfDZVrKtJgddnvxa9L1QIugIYLMi9d6yFp9gLXfOkNveJR7QxPIzGHk/GWWl7K9jdU1gPyd7Iwnev87jx4Awr5RFhYWMxSpxdEyG/D05YsX5fHnn5cv2J8+e1q2trei0xztOT4SbFzHGmoohqUl5AvvbQMUHQqNdZbKMqSQvluxkkF7/pYeLsiL8to21WInbTo8OQkYFNg6ImQHReDkCIfrUV7Qka5+ZH1AxtHdzkasvOjABK/t0dE4AexxzWFFkkh927n23I6H30xZAF87AJ4dQG6PcgnEBimTDvtL91bK9PxsuUYHXA5Az9Sbs4FVuufouE1k62eff1IOusgX5MaoxgRk7Jn5pHw3gMysuYkccdIPFRZ5o85Wr2SJKwEZOqsz6eQT7xth4Lj83d/9rPz0Jz8pW1tbMlM6L64uUWlLGgQsaY+hjtSnNwCqm4FL6k0DBYUUZFHOxNCEVpUF+pPNLUyWefSb8v9Y8HhxwsN2PEkHCQYL0v6kp+wgr3JUIztNR1nkNTPxtYAxM3MIwfd2t8LQ6cWaERlQQeU1dzIUgOY7YXyvXUf5aYrc29tN73OCBpxsGS0XAkVJ1SB4jnFXJ1kF0MH5aFk/hnHgSn2uzgCA41NzZWpphW+OBtDYipMQyrtz7bJ1dF626eUsAB4URjsg/ccQoktczNPjuaal1iHKPXpiMxNj5RRhbL6OYMwoG7J9yH17H6dQaPfoonRowDnSuwDEnQHEJJqzvnCcnuoAqCbKxwCqo33HtWV88D1AUJB5g1A8Or3IUJ+KRFEnUr9GwNxA9JbnRHAFoenQa4Tw4VHjCAFS+W28G4WlDqTWufczsYDvK+wEXtf0+sIQUJtEJrAdpyACQP0kZO5p8mg7aBqHloKRZkYHypzTgRSUZ7tl8/nHZXP3Jc8B3qZmyns/+NPywS9/Xo63X5YhwNoYQNLyycyail9bvPJ/dts9tJGLVfhXiuCsf73ec3t9nqN7pfrb514/29/uXK8K4MvPNcdmu3vdv9HOdLkBpB7QodDKdzk+R53dAMZc6B7mhPaEB5rsbQeti/bitMrK6KYRbaP0yvmXv3F77OetXsjDqZcABKq88g33ueddn/R529rta/EZ+2z/dR6TL2iP3wqt6tOlv4YWGq0rN8UFm6Vgmh56HCnz051Ez54CSLiGqpYDe74DCfKJ8CONOpxJgQVkPMNX+KsWQQutleQ1EKvHOBErTAVffTCWI/flIfNcn61tWpuB/+wAkXLKRFkELRV45Wc6LQZpbhSU4OsIQKYFQr9UFZSdwPAUec9GnrUs2ElSCOc+9VLLoeBXOfIc+fHzw6OAok4bJeFsQgAGQEbQlHY2TXjRLT103onPEfUn6NLaZm89VjF2fZLshTt8JbEHxCkjyYu05J7hR8qmfNNHbCoLXOvrCpixDqmX1KV17HdTZxxtAColQMx0lUkqGdLzut8RBDq8daa1EBn5P/+//t/l048+hm8AYKQpaFT2K7O1rsSKKIi2/WhXrYJaCmkQrglWU1HUEcKUSrPj7m/lj+84uSFLSFHcsTEdrdUNaFae1bJmpHhjKzrsedg9plMLYNjbD0CrPmgHZXFxhXqYyrNeu0A2Do4it4aUvzqGj5bzK+TgGZ17gIcrKEhTDim3+ss0zdG5dvki/bqkDf0FBU07O1vltwDRX/7yF+XJ4ydlb3c/tOTwnMO4WjT1FXv44GFZXFpMBHmZ3YkKB/t7yBkDJ5UqgzkRuGmZlWbt+Ng5EFAKUmKRZBdQaa2fMKBpux16ozIybO7MXsFPovbzfgXTtWNum2qBy6xJ6usk4SucodsHbXbIU+/oKPgjQ8jUR5bcQl8KxhwK1tJ3ToMIthaWlzI06YL1Q9TXJQBHoK3P2Ai6SsGxDwDb3tfijs6anCgLi3PRYxoUhgA9UERxnU/pTfFnvjNBjDqQGhwiV79KNvK9DvzKFuXyq+dPy9/97c/i+6bLjfxq3DFBlHWYHR7LpAZ2+TMym7T4ErSlDM8p38rXoov9sjQwAmjsTE3FGi3tJ+jvMe+QbGaJc808y0O2X+QQ71XO6m9c+5qGKW/K9t5eMUCpzJNeo4xODpMxmKYRrA1AM5+eaibNOl9HvbJ/cAijITxopDF7TjS2PdYqCAEzVLzXTmCoJ92xso9AqOJPlEtFwNjT9FiMSaZgP7q4KVvd89ID9LT45sHxZYGky/0Jeu6anS/Pyg7CZByGFqRdIRNeQHTdMyPRt8jDDe+ekMYJeWrHp+0SgjHY3yXCQMEyQTnmri/KCPk8h3ROyaML9D5anMlwwQfPX5VXR9SL+ZfAAWJDNKaR9gVnF5xMGtfs6LBcd+mlUDEO2SoYbkD3Z4BCY6DYk27TszOejmBV5SHBTyioOJfBoJlyzTnIEKKj3gQQULCxWCbYq1l2AOVJ75q2EM27qCrUCOiT0XmfcsygVecTmI9eUe9l2Xz6SdnpbtN2N/TUJ8vsyqPyyQe/IG/7ZXJsqIxzTYdHFZnj/FF6bB4l6NpTqNfcPHdvFEDlCs74F9KoF/3v9tn6lwu315vN09vnPM+T9Xez3T1vtv5X2a4D5BEDpUcvX+V4OT7PO9DBNSACZeFzCgQ/IBAbApAZl8xheSo6deXmt5t8yBe+WIdnFAo1HwrE2/xQdvmkUX5ely9yWxniI77DUZX1x18DGPuxccZUwNCCAAsxX3264EMX301gzQHo5eYUuqYrdHNWpgFhKwv0juenyvxMOxNvHD4QvEm/N/Rgh3nH2GKmrWXNTRq+tnzSgGUWDSgvqATrwLq5uyscAyK4H4DgKzn3WpUzJmSdCQTcY/VyOF8oGOuKaVcx33TydMrvIb8M3Gp8JR2oT0/hUwT7xYXK6oI8ChzNnv8pl6pw93eWPWLXL+wSSjK0juLcCjRO4DC9+VHqZALF7uQGLQBCT+tH/ytnvtnKAiWHJVVU4wIxyqsS0qKoAtGVocZBgl7Iu4QX52TKpHKqM7ypC9LSd0zH5I7r87XaZZROqhON9AVTJpu9KKD+Nd9yUWUB14CWWp8zT/Ivz2bok6Lr0qAcPkNW/vLnvyj/4X/5t/GVcnkf69fZ89Z1luWxHX0v79Z2s41s/WuvCSK4PgI/2W6XtpPtDI+pqF3MX0uZQ5kCL/WLA0oWXSA3jJweGLSz6nCnPp0jsRrt7QHIdnplY2MPsHENCEYej0zSvlel14N2R6iP8Sn42Ik5vj8YEKOLgiFKnJ06PFZDJ2hRNA5ZjeTeglZOAoZ6x93yxdMvys/+7mfl408+LruAsKPDHuR9U2an5wBwM7TNMOBrrqysrJR791YzK1B9t7+7W/YAYpfIDpe9Okc212FwAdF1wM7TJ88y4/Jw36FO9sN9aLJXBtEBWa4HWujQ6Z8FBA1zzaFynegTXZ60IKrIdhs6bizQq511V6vRcmict/NT/dEueExu0KLqTE06+M4utU7QnfsHvbILuN0ChO3uH5R9dJI6ztUhZgBV86tLpTM3XUYnW+hQeBt+GNOiC83fAMx6yMhXW2vlkGMN+kp7azVGdxkRQKA8N7eQeHPtzICdREeNwnsARC1y+5QbnemM7NOTLvV7Uab4trRuyJKNl8/LrwHCbfSiQ/fybI1V5uxbQBz1EvcG/wxdAq/UCXjSNcxFFUXuIukC8qFLa8NdPep9Z95mxuf0TNasHrFaoZMbdjukgjQBmJcjl+ATu1fpaMg0XPpawJjLH+1vbWSIqwFiKbzn/snMZCg717NxLhjQ9OjQnGZPC+7yPi7eHbOfBISwurWI9c3PO8fj5Tk6cM/rXHOoQ8Y9gWmPR2BOGFYTuun0eP9p7zRDk22IDe6nYhF2CMZReuoLgzADjWsvZ3L4unTo5Z9THqXUND1K4+Rs9HrlgB7XKMJG37OzbreMXQGQaGh1ywUoLg6EJK+ItYzLsx2I8KwcbO0rRsupwg5ldkxeO1OTZYR802XKguo2YZtqWdveKcfDAC3uKaDp+pCXcxTGeQCAAsKZKd7TGd9AeC6JdAXB6ngehYMgGKA34wLD7uo2e1OaeQU/Alp7as6wknLid8J7FzBlRCTvzAHEZkdsJBRO90V58eSTcniyHyFvD356lh4Hbfrk8edlBQEzDlB1+avEfqISbGe3tHvav9/mbLd0cOeaaeXA96oyrb/yv8/191zpv/el99lepykLVUZqnnl9r7/1Tz3kWU7as0sIQ9rnYDdA4Xx0hrq7KePnh6ElnyGR0GJ6PcOjZaw1Aa1V8znatZ9uTTWbnMn2Zj5e56V/rqaTCtRQnFdLGxuXvdO8I0/8ydcQ2uKnn2yRDfLA9yA26AZhI30jWAfhGQgOhUG35vq8tEZvyjy0vrzsdH75BdoahH9gDJ+VN+UlnftNq1/IfKdWFWWLgraM8o506m+Ont/ZBWHN3lxLMtZhf2tALf9y3fNqBavfFXzFCtl/xnN5P87L7PERQ/C7a/UwNlOG3cy3TcVu+yfwJGXzG4aV0SomjWipk//t7Xt9tDVaWiggY4ZVvy5jNJ2iVJytVds5Fgv41nIJxjIs6a6spN4zhAN98Vnqlm+bcXatXw4Fav1KnCuATSYFcI3a4b5R+VvxF9NvjDd5tyolSn+bjnXhMU3E0TzJQQHMzW/y7VGCbPxLN9c2yr//X/5N2dnaBuxNUJeKHzKZtrMeanum80K5IvvZSYK6In/kN+VUXqfebHfrwd9e77ezz3Its/D76boJ4Ox0O3ScsAX89jn+8y55EXw7RHYDb1+WrZ29ckjHemRovEzPLKD4Z8irsya19PUtowDvWIJtP2Sm7aHMnaAdtQQLELroA4HU8xcvyq9+/ffl8eMnvHsR8KwxwWClThJwhqyWsaWlxewGcNU/a3dnpxiBP0P91KvDigJIa9q6+ezTz8ovf/nL8oL0fS4O5IA2hyqv5TnSMUisQGx5dRUwtiBRUhQBhn1xnfLpkEOfrtkscKxDlJX2Q+foQy1xLpQuALXdtU8JRgSQtqWrtOjzpi/4HiBslzIfUHZ9JlvoDZ31F1aW0AfVIkZ1p+7HAUr6J+rAv7a+Xl68ek4Hp5eh/HH0aSUDeIR2dAh9GoCzMDdf5tnn5ucBPdOhZStDy50WuTqbVav1EfQ8UR7efxSgbOwy03lFXWmQ0Br21ttvlwcPH0JDlf4q7fDRSs5JN0t8hZ7CFZzzHHvkAo+Ex6FFHf61MnpRf1et0i5Q7tJdznA9OemFVp0RLf9fCq6lP9qDBHjNtCvdfy1gbM+eJA0mjzS90xTSC+TD/8xPrnniFTNO5SlodAw87B3FWU6Hch16FXQSTz1CiCJ6UOjpBSDgZLQcc+/g7DzWLyPX34CmZxeXwC/j5fgGBqPy7HUbRNKFxZU0rZHrMgpyv6BRaCeIAyRPXqaEuQpdLRx8b2IM8DJwxXvXWSpDv7Gdje1ybBBaGOFSVH4FIUHoHSo+PXvLSjI0e5mB4KZA0S926N0AsMZp0HmEZGdkjF4zvdfpdi07vUsB28npZRmkF3GK8BdYOcPIqfFTEKm9T4fNdEo0yGH8vagzvhbmvER5CBokgtqrrMMDVxAaVRMm9l0ZIQucwmUKLQnQYZf5qakEVtTXTeEgPy2M0+OyyqDeo93Py8unn5aT8yMIUWUCkx7uldXV+2V+5X6C0G6vPydtZ3qO5/7dNub/7P1Ludco0WbzWv8pzm2YXPW/ei97/1o9ybW7W02zf6957h97lt/NtfzPu+355VhDjH3jdjrQ5jnbuMsvez0ytHVCnSr8YcCBWMi0LNK7pJcM795ulaVN/fW33Oo5LJo81Gs+qUDRguOPeh2a6idx9/2vA4z9/PM9ykkJoA+tgUPwAnKIPMItVwruC4TocJmbadMDnS1LCzMIJ5fcIcPcd4al9iHjPl3ZeyQN97utXlV8Uw/KharAbcfmPOCEem4Uc6Ocm2N913pq0qnnzd6AsOrDVI9aAeQVHfEFFQpwLSINCMusSZUX+bUDaDa1cKE2+eMcOheAe26Yi1vLmPcBZLajIGMU8KV7gXHDVOzmV/4y3fgE8W6EOPxsWRM1H/6xoySI8vlaRnlY0FdpRC0p35JQgNkYIEvLt/Isflx22kjTcxe7nhhv33a+tHo1fwFa0FtTVzQQ6SoNrctQX56xA8CDuSY4lb99b+3ly/KXf/EXAIdPA/T0RfPRxDWkfTIy4o7cqQCVDOZlNg+es3+5XZUNtiNp+BgfzZBqdIr3mmcraJUHVYDSUvXNG6Lt6DwM6tuJcgQdjI7SYaJTu71jcFI6rNeD5f6Dt8vqvYfky5iNxmQ8Q5YKYNABFMJ8qDLsSCgDDXWk0zgEHYf67e2t8vz5y/L4yZOAFIf0rHflrkq506azzW8BixaxR289AnCgvKGr/f39BDMVKNnOWlcNajo22ooz/N/+7G/LT3/2s/L5F19EH2lJM2iqzuQdwzqQrzEA3kTHa3Pl3r0HpYOesA0tvzJEy66BcTPqRJsZeiUBTTl3CLQJY6G/lz7PwnPX3nRZPUoOf1wHpO3uHZTN7W2OzpzUP+wUXkD2UR9Ts9NlbmmB40wZ7UwktpggzGFTZaLrL6+vrwHG1uCt09ABGaydB9rKJY9cpN4ZoQ7hZ91H8m87ahnWv292ZjazRaUdO0P6UI4C3u49fKu8/fa7GQaWjBzyT3Bz6vdtgNj3vvd96nuKd+RJqZdj+EbDDvXNuX2GOmInoclncnSlOc/tgMr5WrCPAZJXztrkYwJytChlGCszlN32OTrWl66X740ASjW+QApJN+WGVm24rxSMhYcpzO7eTrk+Oc6HG8HaWMBq4TyaH697XyCgAuulEiVoa7VG2h+i4hSe7IIKCDKoXqsYlb13Ol42jwfKMcLMntwFDTgwPFauAGND7emyMNlOZciIJxDWIQym8KI5ymxrrEwiGHe6e3HAH705J/+V+BwO0BTZQ1g7DCqJTkIYo5Rhpj2K4D4q572TcskuGu9Qxqw9hhQU7DkjUaFAnyJT92mz8ny/W44p1xGELbO0yOdAa4RrI+X8eqgcHXQhbKPoO2Y9gOAYK6eALy1a9vbmO6NlkfrYA6Dp8zUKBem7Y7Rg68+ewaVERtoKXHt0In7rDe6K0nA6cWYnUU82CU+XcfLhOPcAacxRXwohp0VDnxE+C2MusK40Oi8HGx+XV6+e0Hs7i1DV+sUHSm/PeHJHoJZe1vRyOMQ2dqtt3v/h5u8c3rjOFprg2Fy9/ZXn+orBjOWkvv9mOvXcb3is9MV/oU2BV7M170k3Xk08Ho762E3MLpVe9wDw2/NOOblBmCOsO9f06HgowhPhL22nFqm7zBqjXXQ6PqWHdIXQ8bbPV+FY069fq9/PsSmXP9151noQMNT7zV99pnlP8fB1BH398198IfnE6d7ZjoOAr5jj4ZnOxBC9z05ZXZwti4szZX4aITxqnQMQeCY+ZdRPBWB16FvLbIpJ8Shq9nqltlXdK/io+2sF/SULSX/39+v3Xu/Nlrrv/27q1M3zu7HD9AvroTR00vf8iF73Mdf1vxRZ+1d7uaTF3iwOrKaWduwo5jnaXCXlJvC6u1c56D1Tg27MA0pROTgxQacOxaNyUonHIZxzgZT5t6yCtAzPWkYBE3nXYhk54H3ykqCXXLdeh5EtgjADX6rgWyju4YFqKcsSLzKFeeGdlLBpEBuHdEObaagGiPGMR57RDUEdJSD56d/8TfnFz/+OzrQz3q4zlOdQm8OO6oFYFswbecxQD2WwLh3BaGKrqZhtS/fkh+cENU1Tpvw842zMZogy1gzua1FS9slw8qVDXjyEjqAMDsfG+dy09bmDP8+gRa798Id/Ur75/ndI147jUKxOghTLa10rW7XuS7tG69ci7HC7ylnw7gLmWnvWN9Yz4cqYk+Yh1jTyqQ+w7Zg4ZAsL5e133i5Li4tU7VVZX1sHyBkz7TzlsrwBcLSTAP3Zs2fliy8e59g7PArtC8ImAHVTUzNlYX6Ga9Aj5Xcxc9NfXl0p4wCaflNRzrOytb2TuGp+p6H5+D/yDYGnywc6CuC3NWcFILFTgTx/E5B22D1Cr+/HAuji3we6y8Dbw5Rv0gC3K8tx1h9GpyosWuiRCQCQkwn0K3v24kVZ31wjD5epC9tdftDKqARVj0ib0r+dDMOOCHCmZ2YS+HZ+fr4sLixmtw4c6l1evVcePHqr3AeACuIkEy2A+iprlZyenCwPDauxuECnqer98B+0ElqnLkLqvskx/3Ea+vQ3NEBWaGsZWtBmR7Tqi0PrYXe7TAAIp/w2D7Y742kbn7OuE+WBtGSxdEDY5TKIEdqHfr9KMCaCPKdB97c3MyOqMQc246QpVOqiEbo2g78HisEzXZPK3mgPYWjEaUNZCBJUdBJRM/tD4SlgOL4YKE96w+XQabb0Jgw/IYA65XtjEuTYVKxAVuAB4PBQE+fuHgIWgAPD2wt1RqVOf5v7KE/+kIwADc24gDsYRsGn47xEVHtICBB6DWOtURodBoUhp4ZLmdWCN0Z5ycf4+HBp810X2ybx8mDB6cqX5aO1nZhvXW7hBMCnv8swykvT+Q3CIHFoHLoZnwAEHJVL8px1sviGwlN4t0KP4wjGkUmM1iwoc5X/ZqakgXatq1it2C8oe8JaQBT6ImSmlcKM72VmCm2mD4ij4jr8z7RbAaPNEkqCyflxLYgS8HHZf/EhwucFRKxDJXUBgVkOaTz11a+jWJsk6LTzG7t//fM3ty89RwL1mRCN/+oz2fv/3z7bv9J/qLlfn+F/hT8nUF7NV7aaviXL5n13hPTEHGBMAYZC9omja+oYQT5500Xw0eAKLt+l7OFdFTHHIWhKIa/iONWqBh2lcuoH6jvst7/ZmttRhH6tfz/pwsnSYAUU/PaWN/rpfB0O/L/6eKO0oDFnRtJVgbYMgTJIj3+4LADElpfmUAxTZdIZxAAwo+bLU9KrOwTJDm1YP9IlZUzPNMVQBrwuM2f1r1++KisEXK+BWNJQSrJ5bJ51q/X0+v1ap/W6fOHuVuWJfK2FQKV0WjAc2MAAAP/0SURBVE7PayR9p/Q7xf4sVgSFal16SIEu8IpVVLrX6qQy4XxwhE4Y5y7wbM9+GPmgFUxfL4cksyMP7kbQ1wqRIUnyZq/eXnWGJCmTHSuDsmZtyVyD17huPeRteNUYV/Jti3qxfVq8IyAj0aQNe+fdpAFdjo9O8Jv8AjqqPKH+SM3v+1f5giM8b1vFGmD9weu2l8OYkUKkbwfPo53jD3/3YfkZYMzFofW/EcSobMlsyexI28h8Sei2C+exktmWPOtRWWK9+KxlFKw0WwXjgtDa7uZfQDk80L8W2pDvTKsCCMFZhihRfIIw3QiMwQgFBFy4IPr3v//98v3v/aB0OpMBKOoW9dAlyty6UYbq/uGSXZdnJ5HFylr9JgUyzop0mb7NrW3Oe1SVLWNZAcYADn2UpkjbjqkO+w8e3C9LLmxOXWZ5P95zhmTaFloKTZNvhwlfAdRevloLwNTSpk7aPzxIO1mN0t207i3k0QGQCb51/8EjgMdiGUV/SKNS+iF53NzcBChqfROQODmlhmqJdQxZn/Aplp96k6YdnhOYOQGiS5vuojMNxrvbB2EOMcor+svNrSyUxXvLZY7vjgNExqBhQ1m0yZvD8n5XS5p04rJeBmqtw8wu71fXB1UQSNsJ4koaLWjV1Qlc7mp5abHMTgFABWryCMcpfq8sL5d79++XVQDZ7LQTIG5iaMjQIrRD8gnYqj+112PRt1G5bwUak1MGkRWldVuuXqKGOYFKQwO3soR7EVhUqp0l+ebItUn3D6DdgYQU4eNpD9vFWc/Sk8PctUvDRgZifKJt7ER85cOUxwi13t52LUwKAiPIkCk1mbAY/Hb3uoQrYjWYmqbHPXoXXpu0R2Evg4q1xykBB4RBJA6/iYB3zkbL5jHfRFCeeZ/C6sTpepA3kwtlAaLQ+mWvdQdkfwqBD0FMgxBeoXcjY0X52hoOpdCLlLD3j5wObUwciZK0YQ4ZTed9wY8K+Agde865ccqGyP8UwtdllcZJwx4z/FXGQcrT0xNlsdMqJwe98mz7oBxo+uW9ThswBFdfnl6VHg+3hhEi7E4KUOSd2FOhjGMw9Vn3AHGCEIEYOggVNETuzyDodQLWXyOWQ/azMBdKg2cNEJlp4xCw4FWCa5SRs14Cosg7/wd0DaBEXQHg6nIg4FPzq0uazI3r/8bJZa9sPf2gbO+sh2AFYsZkibOi7Rlh6e+QcQSL32yEjCRQiZvq9oZ3+4SfB+9sPudFjxJy817dPJeGuOeruRfK6t/nDdrcdOv9vJH7PlcfUah51afDKjUdjoMw28T0Yjmk55MYY5SpezFYzgfHytxAt/ov8GSGdiiaZfcjmQVnXSjQpF3pUt8IufxLW/O7n5f+drcs9QL/FAD9nyoa0/ft5rmvA4w9fgXPSF8X0j8djyloGvC1ODdVZiZbdJpQjM6Ygn7sOMA0ZJxcUj2xylIGncq1xMRBlt/yky1kIZvyNsUOWIiSpS6hnQq+anmjjBVo/Yff/O3m+V3AVkFXHY58DcL0/ahDNfaktYapoI7YDWHgkGNdS7LfESSfla9J12EUlTLKPeDK3fzBD/poDQnG6JjZYUtAV8GavOYuqbBLc82wn4pYxaY1Ij1vHhCcqFjcSTrXA8Ysp2CI/NmZGidNw/44kSdWnDyTD/BPS5JWmRb32wC8MWrcduAb9SwtYJLuXks9ey1vR39U2ULd+YzvRCYrH/mW/mE/+asfl2dPnvF95WltCwGRFuJY4E2Ea2kjE2ezTgW6dfWCGi7klN02qPGtXGXAWFvVdy9uKWkzZyzSjsi5dNLNZ77BHnmE/CV9QUzqG16VhaxEs3GGnlGuf+fb75c//tEPoqy1htmOmSjFbt2mvtXA19CNE064ph9eXU8REQzt7B90y+7OfnGdygbIaBlLGIV2HQ52iM3guosL84lrZhrGHdNPTMuaQ8oNbWeCBmXZ2FgH4G0F7GnZmjMUDPk0usDBwV7qI9bUgVpG9dvERKc8fOtRmeXZxHHjujJSC++TJ095bz/fsVPhdwWTGYZFF9oW/EuLB4zRjoo2fbIsowF2NwGPXYffaJtLblrXSysr5f7bD0sH0GOMOFeTaHUmuL6cTomAc2NzjTIOlUf3H5R333pYZgGNfDTB2135YBSCGKN5Zjud8t5bb/HMI2QKINbwKwA7gZnguFk7OSMQtjX1pbuOBgxp7jLlsQOoHEI585yF8D3pVz0l6elHbdum3inxFe0YWqY8guI6ClcNJYmrdg0n8I7cohW5WqIHSkt/RO7v77hKwEZxJYJxdKcT6PSl1ie7rp4xkmFgrWRuygzDs8gIXzEYc8oqBAQabno8AV1KEwsfZq2E5x5hya0LmNGKzlABTOjCqG0aQTCQAHdUbJB7gIZgjMZBOb7sjpVT3nN2pdfPJSR6f/pmGH9ryhlDEGaHCrihog+PYfDuIYQzUlYXpsqUwVoBYioGhbf9pnHBBUR1eXXKu6535RIOfv86jpUKaM3UgrJzvq1flLMqjKWklW1iFKZCYV3ZsNTIW4tTZXW+U9bWt8rRAUCrRS8HZbN/dJap6pp697vn5ZoGsyc+MEIjS2TkSWHVnp5K/o7oeQ0BqqzKusDwdXHp2pGxCZjRmZEOS0A0+pdZXxCQvUN130h7ivaA9CAI69I2ML6RORyyxwDRDkGAWjMlJmcqKfCUOq7R6dCovdDr043y6vNfl939bQixtp9i3UZU4GXnP/eYZ/ntkca2mdPWHqWJ/OT6m8ffdy2wKvfqt+pe/zcH/lnX9Wp9R+XoFY+V5uo3m+1L3/GfRyuLhAZHUWDT8+VwZwvmhdkpZ+/0shzdjJW54ZP4jMSnwFdkbto6PX+2WCtkZJhVwKvAOz05Ig/9euh/t279c9q3ZuI1MMnWVCpbeImyZO8/4/HrAGMffvIKQSRtDAWE3YtzPjwKoTsk6b2ry1MEo7MjyV9axesKNAVnbSX7PGkxf8MDTXndrWPlRGiKY8z6FFO+rLv3X+/Ne+7ev5uOFjR3f1fZUa3pCll5xHOVqYrdcDVdALMWAHv8DlNqmT+h569/jZvxwBS0RjZXdpg3CpYmu0BZuysLVOqZWCRY0Z8OBe8mrwrUVQpOAKhDcPbKoR3SEcBpPREkZK1YiNC61Fm4KhaUH1f9pCMF8qvWGYfPHDpOOBHK65JG4+wqGj5JvZuuw56AMWShv2XKpi1q7vr0xZ768xiOY+c7KjTzbl78HbDIXd1J9EP6+1/9qnzwq1+X85OzgA/rP/48yF1Igfqo9W99K9/djU/V7FlaCJ1hQFWPRrf3uv6ax8foA/2d2JvfWYgdOW4wVNtLsCFwSxBe2pJCpFyKnQx3sQtYHNU4B1QZy+o73/5m+fb73yxTk21AKm0J/bpOpct0OUs4dUwijgw4KcV1Du1Q6TbiEJsK/cjJWIfH5JX3+GYN0SE4r9bbWCNtC+SuM1dXl5bK/OxsOTk+KluALddbrp1mQaVBpkdSf5bz2bMnAWTKda1A+kDJE4K1dByoIydxnXA0rILv6bj/9rvvlBnAmGV3d7Rk/+CgfPjhh3G2l860ZlZ/OMvmg9CwepWjVHDJ0REf61N3oTXA9gaAQ54wMoDgcKQ1FkvY6v17ZXphtgyg+6i00p5ql87MNIBjALC5lbUkrde3798v36PO33v0VmnRHifo4Fnq/gff+lZ5l3uLk9PlHvl+595qWZmZReeQFdpZo8MVbbrx4kVmSBrEfAx5os+2/OHMShfKN/aaQXa1YlKwcgXAd4RMHz/vC4C11qZS5AvkrX7VdjAFbdZJQvVAJ+FNeFg6twMZnSAYs36kJ97PbGPou9XqhL8OD4/K81cv0N+n/NYHTv9M1ymdyB4e4nV5oPK9oA/e/yrBmA26u7sN/Z5SsCoM7bWkEO7+ySzuSpbUHb1TKlww0YXpfL4NIKBtg0JV7Il3ooDjmWpOvip7pyPl1REMRuV7P7MXIb4LCPiKilAozQDIrMtdFOkZleA09UuY//SwW274hkuyTMB1xkgyyvKBSzsgjDMlnLzZw5mmMh1+iMLkn8FsewiF04Cz60ylXZ6eLEsQV3uc3ml7nEamMs5VwmeJsu9aZIcQywGga1TlNQ46Hu8kltnM3GxCUWjm1oiQde0og+Pd9p4VKB0A3xlpRQkhDPyuZtdxFR9EofldorIeml5WwBR1rAOt071dMmKAujvrHcc3zF54hiypF6RChNCNljiuO3Eipl2ujVM306O1F3x19KI8++TXZa/XjztFnTi+HvBF3Te7vVJBmL42+rppzXTqs/Th7jsSp0n4X4i7Oc+Jp6gDTrWkRH3cud4cmz2/33wm++vn3Kh5/utfz4PkghPzUoFCfW6IOh6bnCmHe5vUAUzL+/sogO4NvbkR48KhaLhuur6W902XDAcmU94Mmxj/CMF8ofBE0FcQQn7yLfnB7Jhz0iJrudzfkrb11H/W9P0Nauaez0pkN4Cxr95n7PMv1sscgvbe8kKWMOq0RgEB9i7JH/x3jWJwCEch10wRj9BjT5lT0r5Ac+MYCuCyZbEOXgMxfkNzAbTsXvd411esaVPP7/72vs95rbF+NRaxfJb681zLQnxl4EmVvwFdXUxaC80p/Fd9PeAx8uLwolYJhxxBS2Y2YEvLmUOZWgliOVM+odTT/hT0Zsg2JY9qdcvKFt5M58+2q+DMTeWv5VmF4FCSvfWGLz2PrwvfEAzpD2YHMj1v8iffajkYoeLaWsAAAX7RgM36RwnEBBGj8Ymiu2m7UDByxlPQtnQso1nvpJ3cck2uU1kbQy7P8KJWA2n1BtmmfPjisy/K3/3tzwEW3bxnPSiDnP0taHKIzCEuLTyGZhB4eZ6gp4COWHiU8dJ1dusSWULb+dM2rRvH5JlcU06fuV0HlPqJnxf8JVDR8hVndb4vvVl3F31ApU55662H5Yc/+F4x7uPFKfqG8in/VeaWP7Px+JzL6rjKip0r5aT5cehRWaqz+/Zut+wduiweIM21alHK8QNCfwnYjAIw4VEdMjWJrgFkABAMTeFuFHkbQ5BrxzYO5siNF4AOZ0065OvalLPz8+X4DJ0EXS8vL0XZa0E8cvhvdydgbPXevfKn/80/Le+++26tM/NPWQS4Dnd+8skn6XRMdtqxuDb+YlplrU9f0AcvEx64dwhYcsbkxtZOgNgBOlG/5UTQhxem0Vn33npQ5hdnE9usg/5bJG/3H9wrzvB/8uRzAOBvyxEAsAPfLExOlYfcf7A4Xwao51PoYJlr3377bcDXdJmlTAvo2Snq/prynO3tl0vKr8VsnLq5Ju8GMJ/Ucsi1E8p1Cf1kfIJ8UXEBXraZPnyORgAe6AnA6xpgqC/B9DUgM35yWlv5zgD35bm4QqWd2T3CU7oLRbbwlyF6+aEvyxJQF0Dl+fhEp0yMT5STy5Oyvb2ZdmuTT2N32sGaALg6vKpuuDjVCqdFU8s38uqrBGMCo30QsQV/3VtVWLL3C9YITgWVTJ9p0VTkGcykY3uc9mmUxlwYQUclhdGpKBW7oSbWjkbLDswnMDmFIVR646Sbjs5YuxwNDKdCVqfGYina2kMIgO4HSXsKEDYEUdlziYWDBh24OqExtX4oyKvjo7Oq7I1MQHBjJFyHTbSIXdErOwnqNpSETnwqq6xnRaXHjwhh24LO5ybGylEZKq8o2xV7d/sggmx6qq5F2T2pvjUKIJG4pnIBqstsODvvHIA4CxYcGxrJlN7MyoKpbk7OIzxU+vFbSR3qS6awhkwVarRJhBpCwQkFjpNbhxKXAfioqhBe09P2vibgqU4nZl8Zeox2mhquY/one5+Wp599VA7PeiHU9JJtV9uTtDyqwDjht70M8tDs5KcCa5QkbWY7+ttnyGLeqRYsU6ppKU2TTvP7jePdvbl2e7xzXq9z9C+3PKPs9YH+b2/wPQ4jrYkyPDFVuhluV0ndlAMA+N7lWFluXWaVggaM+Y5lCH33aT29H+otJn+UII1RzrsHoWnTq1s9a9Lo/8jvXGs26MktitxTH+/fF6j/8dewNmXv6Ipe/XQW9daSYHwfLQYJUyFQoCYFsxSbTb62baU+LoS/+u0sEMmAn4igfy87/wQDHClSwNfrHWEJCNLc34Cxhuaac3fvNfel8WYY0vPQPN+XNwQAdSjsJOcqM61hWmxixbWeBUbwtE7lCTzKbzsYhuyps9H6IADgFmBFvh0qchgzeXUYU/8wZE2Gz8wrzFbBZa0LqS9l7tedZVdAC8q0bNnLN66bCkI+9zf4N6AXnR6LmL+bIRl9zAxw6VCkw7xGq9d5P2vWDtIx4FzmvLmi7vw8300emr2fp9qIzbHuKjxlRjrEADGVSg8A9ou//bvy2Sef5TGtLQd0KJ0BmOE7FOpBH3hZ1w0wVs5VsMU3mza07WxDfjf03/BSQ/9u+U1uA9AddsqtfjnSvlqaoDDyogxVwerbJDizDd5xZt2336eT3kndSbsXUdRV/umkjxLgX7U+nUIXuqkolw1JoeItA6Nl7+CobO8I3qF98q7DvUfLIr0kQC8gzDBBCwAXh+NUyq6vuI9MOVcP8Xnb3nbT6dsO//bWVnn27HHy64xJY2xZ55Y3IUr4hp3qTmeiXFIuQZ0BY//5//GfB4zNLixE7kh3dii2d7bL8+fPyuPHj/Nbn0QtMoaHEKToK8nTcYUZBrAbGmk/Sxv1eHcXnbkfnXnCc9qIW+THqPoOhXYAj0a9101Gq9wSHTWjG7x49qx89Lvf0JHdLcPU6zT600Dr9xfmygPy16KeXf94eQagqfsMwO/muFfGab9h+QrQfgkdjfHuEPkBYScw+RjvGJtTHerEKA0+tpkegfLAlUYMdiMLaDXLkCZHAxFrta2hmwZidTVorqNEuv7YickYVmgSmSV/QutKqipz4Q7pSj4QpUs38KgzmuPvp/FCQwxtokFld3snMdCAa4DfTkbXHJ1TT0uDgjF1nzz+lYIxneSPd/er4OG/+IvxUbmmMpKnnFNIr5kxHSMtYM8Kok5cYFW/FE24FYjRADna66rA7ORioLw4GoyvmEpegETzlDNjoqBExycNJTGJIAKo8N1ZgIdDKnAphAaggShnJiESiMGewjlA8JKGHKAndEHDGQLi5BoBjNCxkQyUqgVAaxvSkOxWAXqFMBdwdRC+mkJVGDWwJYKLsnb47mxnvJwIUqMEztLLODkhDVC8we4Od4zOTKNKfOSXlOkFAAL9JgLVHqACeg7wGD8y8pMYN+YCqXpGb8zpv1XhSDiVmCJgqRd7+AVh7JBGiEGi5D2bQB+PLKxKWbgaxWc0gkmIy/ht1nmLm1NQ/eAg9b79SXn6+BM6ItWCZi9SYrPX5u5QSR0vt4dYlSS1ke/a7s1mO5PFtK/Ws1jXeI4sV/pg953XG+mYFvdNUUZpnmvSffOc/27Pb69b6Dtb7nnMj/5vvjPa6pQheruHu1vUiT1GepmA4u2zkbI8flWmWtUvpb5W04hyUdlSv/mNEM1ySdSFgs5eeALCpgR+i/+SSk2pyUvKbT14p/mI5aVttKp4w2dtZyde/OhrAGMjg/ob2UGqykoHfgWUZUqcNTKlUI9VA4FWhRmCLWWsCl2+ybVc95qF8wHepTyKCYVfPTbDktAjRwGO8iP0ZD29sTfXPdoO8kiGYji6NdcEUFlPr2+ZEYA5Td2YTgIssyMwUP+blkotM6Aojx06cy1gS1uTT8GftBjLDu8kIKs8MY7cQUl5P5v8FvFXAU0dqqjv67BPzcGD1dqlm4BOzInpxjfTseVZlVFmUFP3PmvnKnHE+F7LzpayQ15ity2oOdJ36KvOErQ3HzDWpymSZLdEdTM/tol/oTfLJaC2I4xsqcvOUUfIBBXcB7/+oPzi578oO8ZCRLm73qLDWlmah3p1FEJeaiYkNGBZfvKY+uWjyQ/1Eb9XZdWdzXu0MGfNbj45Up9RnGyytHukAnVWQSk8xze0aAkElYFvv/VW+cH3/6gsA4y0pFiXgt0rrZtOxOJdAdzlOXQBn55CFzUQbw0dMTU1Cw8aouG87OzrxI5uGHBSRovyANjJl/LfiWdOrDJUg/5os4AlRznsgDv7Th+mzGAlDxoDZgAlWsC0zj55+iTWFQ0EhnGQlpQpU9OTsbYZx0oApy+VQWe1iP33//3/ufyL/8u/KMvLy5ALOoD8Whad/Z8+fVoeP/mivHzpaikDAYiutai10G/rYmO6+tUZfd9I+k5G2HZSghYx+QS9JRQRiArE9Aeb1DEeGp1bnC9LqwZonSsu//Tb3/6mPH32BDo5KwvT0/FHHqGdZqiHBcDlXLtdMqeV6y3qf1iaotxXAPgheHPg9KTcQEujtJcAzAlsWtEEWDfo51Pyo0XQiX5Zs5K2PYLutGpbJsFZOjIwjMYDr9l5kIayWD48IH1Lf+OU2bqk0UN/mekuLfFuRphkOho/MosyJGSN/JtnuaV+hkDrbziO9J0NrZ97Aviyy7/jdI7iRwhNuHao5kUNErbRVwrGZMZLehQKtCo8K9N5Xi0HrwWnirUGrbOndBmB6LRWrWLkNgBMIeh9K6eCMY4IBoO87gJoBCpHENepoEFfKxD4+UirjEyvlqMrgA5UJP7dPT4tm92zCIJxANIlwinOftS3QeZEzcYSEhAM3wC6SJfEy4AmTZD48LDCl2aBIHT6t4kEEWMopqFLfbeuITIaDGF1es6Rd63wicSBGSw7ENj8xCjM5FIZEBP5HeQZ/YgUnIMofmeuCLbQ4GUEITDDdZ0iE0CSb7UQtvrhnUI8etMp5KSWM+RXepbkSYuhAs5ziUfGTJwfHQEgoKz5R52af3stEfiUQUFm71ulMEB5Ou2W9Jme7ARl7+hveHNWeuu/K+trz6kPBBRCrxkfb5SCQlD/hhGAn8oiO3kTCDYOySrYUL1fhZiTR451WBOh7AWVV571UVlGpZs3Qjt5RBrq725vnvPf7Xm9zlGzXf/6/9Y2Mj5Rhth7+/TuBOBsx8fnZe1ooCy1DIkiU395k57TmqF9vkEFqnT1BckkCsp92jvIEHGzSRvWgZvvNOdR9v081/owXXmHMtRKsTT55o++Bp+xsxMBhJ2jOtzjosN2TuxZ2wmw5HWrPJr2Sza5zg411uOAAq25hlCUNimmz0Y5K9Sye44CR7pWUMYDEjBb055390a5Rzj25YayQRniNYGY+YxPKsrQ3XOtBQnuihwyjh+JkUfSVBDbjuRFvenmdaR5Mut9v6n1zN2hzDEn7yC/DOhaZ1TCpaZX3w7QqmUhichDkuM/uVhrlz15PhehrZJUsUj58rIdL7DYrWXs0iEmntdHzCERZ5g51HiKnHNNQWnGjvDoSJvvmg9SyE5q/aaqOWP3o7ZPdvmOez7EnhqnXnSaVnmolDy+evai/Lt/82/L559/npGNg/3D1Kc+r1qDpXBl1lisdLSn5bVem537XOG83+Y5NrRQj76vS4ry36Zp2jXtSR3Ej4sHVbr5BsdY6rmftTx5KUOr/C2vrJT/5p/+0/Lo/r0AGuvY43Fvn/f9PmlCC66EcHmhJYWOE7Q9kjqkbZHPE53JyPYt5Pd+VyCPrEa5az1VRsvnDgPqK2bk90n0SovydwBAgoMTeP+410uelJPWs53WmVkXnx4rG+vr5eWLZ/W75K/6odbhS52+9YdT/8QoMDZcvv3+e+Wf/7P/tvzpn/6Tcv/+Kt8XjF9niNHORrWyPSuv1tYyRGz+9G+yrhw+nQPszbAL0g+6R+XV+mZ5tbFZ1ja3EktMIOZ6yRfUzWinU+6/9ZD9UeKGaRHTIrcqEJuZLmdnx1mD8/NPP4Euz8vKwnx5sLxUVmZnyyz8sDA1We4tLJQJeOa8P8Ro6Ksb2oCKLAO0lyMwY+SNHlOMHMbXjJsStN7d3y+bG+tlg7K8ePqsPH/ypHz2ySfl+bOn5cmTx+XxF59nxqggyDrOjMbJKXhnkHbVJWcUXaRlcTgR/rVYynuCOelAGrM9uBR+1/1AuoycgublC62uGb6UF/iTfzTSxNjBuRNlHJp2VQZdJbSCOlvWYd9hsImyYaI1RB6c6GAf5/yrA2P6BG1vrVOxCJVYYbTA8FUKlYJRMYKzCKhIBAQmhVZhGQ1ZC5doH+gRUFOZT8arYC2zmqiIs4uBsnY8XA6tFJIRdd7oXG6SrckyBnGIQKcT+Xuo7BttmXd91nF+V/OfhDh8xmUcjkTk5G+3e1p2tw4cnyzTMPYw6evc7lCMgVR1cjRPE6MwKLsMMkU6+nMpIEfJs2s7ppkAWwqD+SknE4yWtcPT0lVQwaibx1fl4Ogg+Tk9vSr7EMsJAlS/lFjB+PakTE6ZHWo9B3qN8NtenIFnlZkjOl5RtjGVEKfmSxClH4u37AEomFRCQfjcUzFpfXMJG6OfCwoU9OiHlFV/sWraPY+lz2nIR8ddeij2UmjD617Zff6rOGaqVGINUyEpBFWaPBOnR4/Wn3tf2MZaxjuCM3tkCjiyr0aoQplnJXDbW+fYc4Utt0Mzcogbz1YxLln5oy/YPe9fi9LOtVxJuzZbrtXXfu92N61hgNiwQ937O5StTmM2ivWz/Yuy2BosC6BTqvkfbM2QVTofpKWlQvqPNQABaC/8HCZtvhXQZULsXDEB/8+WI9fD+DybGWl5qr5Th8LL1zJM6Qwul4LSQnitszNKQdqq+TKPKj3vQV82gXn0RcpTeb1uKWN/r++yN0cBTh+wZOe8qafsilYT921+N+k2QMzNawIrrVzyksDQY2bnIXS9p9O3zsl2NPRrOtJijcC8pp10mBZMy9sJTwHQ8ivyV+QYZdV5f2gE2rbDMQ4PjEPP7CN08obh9SGAmZVguTKUbfvzzjDvyDOZFAQPDCgjoCnOaE/yi4yhUuOP2AFcKQdGqSp9UvVrGWGvwAyeJT/n+tdSttlWp7QcgjyHv0nthE6D4H94GCA2MkU+RuF9gWrtILvZAiqdhrW0sLvZSaxDKNQp8su4iVoXVPJ1GPC69A4Oy0//8q/LX/3FX1XHeuSlb2fWJPnQOm+nx86i7ZH4TioxaKPZFWLStZTjfjtE6v+c+9M2ruC1oY3+zjmSLfJVERIe45/L2jicaF6t+9zn3cWl+fLDP/p+efhgJYDWkYvLC4D4+RHPaBUB1CrPQcXXVwAD5GPWl0XUqsAd5nX9S5QaZb0oe4dHpXukbyF6zjKTm8yYBHQpj6cmJsokvD7J77lJ9AzXzpCjZ8eHyGHSVbnzTYctO+gHw+S4HuWrtZeld7if9LRyjiD7VeAUpRzubVPv+4Du4bKyNFe+/e13yrfef4fzxTI7PUm5b2LNOzk9tkKyEoDWsC5tJVjZ2dnl29QrukZ9UetpMOV4tblTHj9/VZ6+2igvAWIbzg7VWjiALgJ0zQP0Vt9+VJYfPihziwsJYjqLjl2cn0PHorNOu+Wj3/yqPPn0oxgkVmZnyts898N33y1//P63ynv37peHhqiYnS+jyPUzZMkgvAfSjjzUBcgZ2HV2p+0Blji7KEe948xUff7sZfn13/+6/PynPyu/++C35fPPPi2PH39RXr56UdbWXpX1jVdl7dVa1vV8/vwFoG0rna17K/cDwo4Bmo4A6f7kOs7ywBmdli513qW+40soffX1kaunuNsZ0m3H4dyMUkkT/BaDaOVUxlU6U86IIZRF8CpywZm0hrq4QJf1TpD56GV1nvQ0QXvbYcuC5F8VGLOHebCNorYQlEzmvO3Fs9fekdxfBZS9l1r5Otb3fbPIaAABDOWucgsQY1ewGhV++3S0HJzSC6SAAkAFnzG92vQWHDC50mHVOCt8c6ntUORowN7Zaa/MT7Ygxsuyt70JUp8sD2Y6EIQRwqsPSPegW453TksPYSGYzIQBKr5OFacMEsmpQ3TOnBwCtLhupj1iezJagfrCwkaHqKZ57Ygy7ACGToHDL/ePyzm/HX48Ji0qAKVwWY5RBhPk1/Uy7f1OILjtLVxSh4LNa4hVwaJwdNjV+nC8e5QyZ/aVyoT3g9G4L9K3J8SlCEaVABcpQ31PPxRnomTMHIHnMJAMoflXAtRhcnZ6OguXjzosS2GGymHZ+eIXmQXUKE2tXemZUmYVooKkUZ5+3L8ISs8VqjyTcvBuBWd11lu1kHi/KjB3hbLWR8tUAR70JKFx3ZPmO/kWm+lnz4989vae2z923my3aZH+SKuNUp1AOO4Cylpcd3mos/LFZq9MjQ+U1elW0v/Sezn39aoMKu1T7faAYEJ9xyIIeoehubznO/xFgfnHBa9b9nq3qqzUHfXlfTfv14cBY//yqwdjDqFYrlgpUGCVN82Z+ahtVX+/3n7ftbtbU28Ww3avIKwCq9CJMqRf4FxDOd1Ns3nf59y8HgsY/FSXe6nWMIFZ4yPm0GScyPUbgd5jFeO+M6QFYQ73qwgba4cVHAuzzGxW5O2GzuR1tTvXBTbWA/ot7RX65fv83y+LtE7ZeE5az5AJz8kvWma0lnhPge1UfoGYHVI7Mzrkh0841/rcMWQC97XYu+5sC3kXH1HAlgGrtXTIrS2DXjt8hqxx0ezUF+/V2rM8npFDjlazHanULXmhaNyiPNRlnJupH4d9SaF89vGn5T//x/+1PH/6DKXTQS4LruRxvm9F5F0PpCdtIGPe3Hzk7vbm79+3mUd3H7YOtcaHx/yO+YY+zbOyDFER5e4Q4B/94HvlBz/4btxfdMhXBjq8rrJtA4gc/q0AifcFYuol9IUpa3mM0z5tYtijHkB377AL7fCMT1ifpGNn08Xe47ANmFbedvjeVMdhqQvkiOthahXrD5nRjsahclRGmnz16mXZWF8rBvu245bi8KdPo473ts39e6vlW998t3zvO++XpYW5fHMcfaluks6tA61iT58+T3wyfb9cN/Lzx4/LxtYW+o+0TpywIg/0ysb2dnny4nn59LMvynOAmEOU+/CFfmPKms50pyytrJb7Dx+Vew/uZSg1cc3IyypAzBEsIxNcnx2X9RdPyiky4v7iYnmbfL61vFy++dZbZWVuLhYvekQ8p7XruPp7QU8JT0GeXYLJmJZGQ9Dn6tXLtfLFk2fld7/7uPziF78uv/zVr8vHn3xWNja24WHkpumlDmvYCI9aBW0Ib2mh1V9xbm6W+m1FdjnEHssum3W6D7A1TIgzW7X4S6NO/tCfzOF161z6Um77nhImM1/77aLhSNqT//1d5YMUw5FNnaZ1Uzlit0O/VDuCtrvWsxHXpjX9rwqM1ZAW+xGOVXFU5g8og3AVSnJTKpM8G1fME1eB12rTduo4t3S6a8CYAtV71VfMGUzX5dXRSDm8qD24LI5Kmue8d0WDjHYAYvZYATNtCN2ei8w3Z8VQcQ7jtUH7xmQ5BB2vzsyUmc5YObCXCUM63Nij19SFII0hNkQvRydOhbcWOyOwayE7BpCN0G3VMXEahjZ43djoYJkB/M1P09sBWDrUN8E1Tb2WWf+N9cPTctU7qQCGfHURqM7KjAkUgIMmSO/KpZTGFZJcmu0YEd+eA+BNNI3QOBNMwbgUPUO0MpDGVEfB4fgI+Tj+mhZ1HcskbWKPz7ZRYDn5wJ6S33D8W4JzVhYVG7+GSXp1DlSM8D0DSg5fbJadx79O78s1vrQ6CqiaIQYBiELSc9s+4FvCYPN3Mtuck3J9RiFOvsmnwsX3eSI7T6QX3dCCW8rhe34jz9b0IvgpaM763zE/brn/j+xv3nczHR34B0cRlK7MoHMut4w/9PGrbnwP35p33b1ahma7m4bH5JUtioJ8GUjWYWbN+KcAMkuYhPOM5ePc5uv/uXn09aQHc1Slz/O+l3Yt5UdfBxiDt+MuYG9WkJH8wnspm3vdmrLWS7UMnudqymodSR/e8Lz+rj5iCCd5zmO/ffNGnq/XTd/d93y2CmJnCFYa0dqlsM1MSNrHZ1WumYwjIENQuyyLAjtyhTIBL5OWUeBb8LuzJuvwQ+OsT3rwp2lqsfVoXbjxBe5Vq4/gxjaX7jz6F14znxxriA8UN+WqfGNzh8oDzlp8d7Lvc0LGAQwASviVxBELOoSPR9lb9kR055oztwy5M0bnU6veHp3JYcDDeKvDOy1ySJ3xHZvFvITZs3EhbWAJzIMPiMO0OKF0lAvc1SIXcIty0mF5FwX+H/7dvy8//+nf+gbfMbBln3ZDnEmZzXPp1dQr797d6pOvtzd/v7lVOqlPvT6vvjfRg9YkbWCnbXBIEHOcsBU/+uPvl2++/y5t6wxCgAAAV8u/KtQJEC1kjiBXmRfXEu5ZXsGC8svhSf3FhtkdfdkHxOwAcM58hvvWueW1jc2TFhY75lpgHD62Y23cyNMTfZqQ37SlslfZ6nCWemFndyezJ/f390KzXrNzoGWvmUz11qOH5Z233ypz01NlCmVOY1BmhztHQ+M6kqujtnZ2y/r6eukCcAy98fT5y/Lhx59kRqsWTIceBWgGb93Y2cmQpIt9O0J0cNTLBBXbdGF+vjwChC0uLMXCI2h0aHeGPK8IcpBjlzxPRZRHq4vlrXtLsZJpyb2/tFC+SV7nebbLN3Tk13esRydeOhJYaoAQ3Fyhx3s9weFRlpP69W9+W37xq78vv/z7D8onnz0uL9e34n/obNX25FSC8wq8Jugsj4+10bGTAO65rD+Z2avj4/AeupP6f/DgQUau4pdOuQwm73Dt3sFeYq65eLruNGNasqnDbWjbtnByg8sBOqHCURzBbsJeSGOUz/pW9jcYR/53U540slF5onXdNAyzFR46R+Zc0f7qUtMGO3wlYEz0t0Oli3wFAFHO7DJ/9RtT1ctIKhCYlIbIEKXECpCwN6r/kTMcMsWUAluwADIK2/gOHF8Ml72TsXLIO7vsJwoNng0IoHHGnKEBgo9A4D+d9JxdeUFvXkbJlHyOTpGdpvEUQx2ElzOQ1iEIl8hoAeQMCpshPQhqfHqyDAt4IGbYKVYxp3ZbsROTE6VNF6tD3kW9CtQO4MmyaH6+P9eh56q5e7j06J1qHbNndenySsg8l5jQbjwBmFMiGSwUri1Z3gghO0q9ORnAntYlxGQ1Gp7Csp1SN5qczYfv2rhR2LxvLy2CkPMoAtK4hjjs3flhiURmqACKd7TUwOBxaEVxORtEVdjuTGUopCPAPXtVNp78Jgo5yN+dtuZf2vouEIsi9Zg2Vzn5u54317L1j/6u1q+qvKLMoB2vh/j7DMC/pN1853a7c5qN3w3oz3PsHr/0zp3t7j2/N4zwGRpvZ13KUY7kAsFxUT5bA5xRn+8tt0M7bs27vtdsnsms0r3nDlsH8NK+8scZvWR9IbLxQFVYfqVJtaZrkknWIpCeCrOpWy+7fR2WMYWYvFitY+bV85oDLvn/6/LfOomTaY6e25b5zZ4/25Y/rSkBYu4BYfW8AWiVBmp7v5YhKD1pD3pWbvjbPGnZljbvztrzmsDL2ZICsVgHOAqy+HzoynaxB+suD1nHBn09QnH47AVKVACmP6N+ZYEXvNcMvZlOOlsqdstA3hoQVstlfUi/8C1pqIz0UdICbY0g4BTz8CwdRsoUKzy8b8UaP8khFZWBTvr6I2XmH2n7vABTnxRjEur3s4nyG5+YLJMzs+IpNuov9Ug+yJdtcdtu/pGWeZD+AsS0EEmLylWuanV3mMbOo5amH//lX5X/9B/+Y/x7BRQqINMzyUoXFZxEsJs+AqrS9ustZe5vFUi93mzLN/dmu3stlmdzyPvKbsFq9fuCBpzpC8R+//33YhWbaBsKokte6UBTta4QMSEQo66Vd5ZVOeqx0hC0wW9DtAhyjeNoh+wcObuzf5gJWBb1hvvXod868iCFq9xnpjoJqTSGLNYSp4sLsJF2sBTIekD1DKDKkSDbb3t7J7vftr4FDraV0ecfGHdraYk0JyOfzb/O+xOtkYBI5bv173JUGxsb6OC9jCa4CsvR0Wn57PGT8vnnj2M8yDXy0qPtNAK4Gs2JHXr1ArvR8w3i+s677wJk7sVB306f7jPTM5OZWPJgdalMclx/+gU647T80fvfLG+vLJR7SzNlDr035TOAsVnePUPPHe/vl+PDQ2iIbwH4tD7J59bZIXX57NlzQNfntwDsw08+TSiNLjTvMLCcYQdJx/iMLkDLns/NLQAYFwFb04BTXY6cwKJypH7a7fLtb32rvPPO2/HlVH5YR3bIekeHHPUBH4R+O7H0afnVSKF7jNSm7rajo/FG0pX2JTR5OzzMeXSLD7M7DE815Vp2m9nf0CNcFR1pHcqHAsAaYFgr/FcExrRYOc3WqacRomSqEabm1Ly7VRYCHJEhQZbMZDgMY7GMDJB1GOEWhPWP6b0CIBS03bNWOYFXnK3hMGUdj6UyYYoAA5DxZLsD6OqUYwDT7gnPXTiDkGdgtliQ7HX4B3Pas7A3IIMbRG9zix4E9W2vpgOHxtEeND46pdUOhQAByjAjbWfQVOfNNJ5AzB4tzyj4aOsI7Db5sfek9Upn4R4NboT8Q3oD+5SnxjU5Ly7U7XqWHXoA19SbvgX23Jx1M0o6l6Tn0lA3KBHjGom828PmHQAlAVBPztrQiTjDqtxPT5gyU4vJs4JyiPw6NGk9y8gRndT/Bb0cnSr1eTunTmsslvMsPFsnGfDs8dOy8fh3acXEOOIbAlyJuQFi2WngWMuo07sCtBIqN/lkjtm8V8GFNyRg04i/GflPetSzeVcAKvylCR9vLG+WrL5/55h06x690N/y22P9ebv5uxHwPjBKz0u/sYAxgBkvInwuyhdrO7TjTfn26hTlafJdN8/Nby2fWy2LeU+ytKMxebJGHu3mqgo19/xP2Zr81sdVNPWeYJui0qbc638vfMW7Pv91WMZczLjmx71RwDV/bvXUvNX8ud195m491Tqp10KntnF/93dzz9/NUVnSpJVeZx+MuUkPdwGYckKFpnLTSmawygQTVSEgiB2aVOYIpARYKr4AMTooQ/CckbQNh+DyMz4T52yAj/5jiazPdxN9X0suu4JWa5qdsWboPiVMoypnzJMxsFyZgI4MtxLPimftbMmD7qk9+FQ61AIm8FLhapFqfGl0KHd5HUGogTldyNlFoDc3t8va+jYKHkW1tAoga1MHvEBadmKsOeUVFyKX/OMWm3f8ZafXzpnWMHJDHQ4JOJBV0qrfffL4cfnX/49/Hadkh+4kVNevbYYp0zq8X9PmxLL3//q37lBH3e7+9lyObp673S1G/16z+79DopYt1gsybufeEQatYAKxH/3ou2VqeiK6ojVuJxeeO+qWMejJUERwIooIeQrgpfASUmR0LB18MzNRAWIpK8Crhy7ZBVicnqF8rUs6toIxxWxde3K0zM5OlcXZ6dKJrBZIH+a7WeGlX7/NEkkaHXaMUL+xnvUepfNmSSwtUvP9YTZHXVqACi1iuvE4CUt5r/uDVhxBxmG3LlnkjEiVvvpYy93O3kE6//oQZghd3iGfzvC+kf5I23UsXetxYWmxrD68VxYWF2NlMpSGQ5OLK0tlaWm+rCwv0IG4LGsvn5bt9ZflrdWV8v1vvVc2nn9RNp59ERebRdIZoU0uer1ygw7R7cUArJfoe3f1afewV16+eFl+/cFvyi9++avy8aeflw1oynyeUy7XTbYz7OQ1fTEdZRoaE8DRISG/Lil1/969srg4H6ODtOYoleDWNT/f++a72Tudji0MfaLr+GsDFl3n8uHDB2UZwOiQ/yV503Kp4cPlqhbnBXkLZW5mCrq/ih5UFyVmHX/KIFceUKdUi1jlI4Ggq01kUh0dGvlZWeDm87ap4EsZcAIgE4sEr3wVYKzHR3q7OyG2CFEFKITqhVsUydYI1Qgmrpkpe/wGeRWUKEwdo70LxnKkQs8AXYdn46UHw5wB3JytpONlLG3UiECjTa9Ewh2nC+FYsENqClUd6RTdYhJ7tzr1HkMcjqtHKJOZo4vrCO+TQ83Q51Qn5YjZ+qIMAqpc2mgQYhgk7xKYMyVnJobLwiSEA3G7u9alyuKUtBQQRwgr/Tf2T68AeQYqLOWIBt7tuc4ZAGpirEzynsLaceiAOuro+vyotIdgGv7OyOtFiABhT14HIRyVzaXX+IZtbvn9klY7wVWC5Ekk/M7sD3avC+x01Deqccz1pOeMlivA4RVEeaH14NhggLQR4ENF1RqfrM683U/K3qsvUq70+vlwHPZheq8FVHm05rgegdzfPPev2fKbnxGtvFdv9a8J/rhmGhnOZQ/Y45uKdYdFbEe3+m3ffzNtc9E/T97q/fy+80yzcyV//Ah9OtRjmBGHE4cRyNKzIUBe7R6W3d5p+fa9qTDTm1tNq79Rt7VOLKOyXgbtW04Q7gpq4xlZB8msObDR+mVzo3X4z+vc7YOxW4DDQUD6w3/5f8vvr3JzCMWtlq///Ttlja+Q+eeaPNtsPuLez3Lu390rGPO8tnNkhy/cedb7pm0a9TeAhzp0E3gJwhqrmN+Wn+VvrVrNgt8H3RrQNWtNIj/0PzVLdlh0SDa6vuf2xbWiW+866QvCBGkCP+VUwpSg7AVhAV+AN4GYsf/Mk+Ux+1qYzJeWJ4dJzgEEAhwJ12FKLV36LNVeOHKMtBBpoWV9xByqFKjFZ4l0XcXBYTTLn2dTH3YWS3n2/GV58fwVhRkpb7/7fpmZX6SilLMOoTjC0AdE0iK7YCxtyPfNq5v05bU4vweE1Qjkdv787TDYn/37/1B+/rO/jcKRhg19o4yIrGevW22rZqtf9ntf3mpHqj7XgK3Xb3HeZIytaXOPr6/XkRM3ZZGz3xwGcsmbR289KD/80fdQuis8z9ev4DF0gTPnHHnJaAl16wSmG11krFtph3pyRvcFoElo7GLiygEXGT+jA6Zf8yFyWwuT61xqU1TumjfbROvVAmDETrOy9vyYDi40B2EmD1nrmHec5ddud7LYtkNzxgJzUfA2AM3ZjQ67LQIq5mZni5MCzG/AF7rJyWR8NcpegK6FMn5OgDJXibHdySr6jtxBD4706FaTWerwUUI+ATQyI5L8zs7zPUCf0fQXAChTABJHaRyyn5rh/uJcmZ7tlJnZSfLdKh99+EF5/viTcm9prnz/O+9Dz+flw1/9vBzvbpV5w29AG93tnYDcIfKqVVWaVv/sARZfvHxVPv/scfndh78rn332OWBxH96g40Qe6+oWLUCik/GsW3QOvObEF/ep6U6Zm6+Lo3telze6CmCbaI8n/Mc733g7gW8Fk9KEdCIfyp9z8/NZj9RnjSG39upVfMb0wXQRcsFYZ3Ka9FqhDRcC12Km030wAPI38koeh9xjFZdSqFfzpxyX3pTa7pZb3ghP8YzvxoIKzWgdU0Y0XPMH3TT9qbCjWMnWm8zlZibcFJoKKQtigZyW7VsBDTBDw7wRNtyv4IwGuxrN4tpnCEuZxuVHtHhNQFzToORRCJkqCCG6RJI50LIUB33AjWtm6idmT84FxZ1htIty/fizZ5l94nIuLRp0BERt+keCGisUgdPbOyxnJxdlBITbub9SxqbaBUorF11QNQQ33yqlM3RVxhDnzihJgEiZnDQ2YJb1o9OyzbPHomKU+v3p0fJoaqQ8oqfzcG6m3FuYy/TmU8rOJ0uH7xxTdkGiYMylK45OzuMrd0bD0vYIFGoqwwoIJOsLcHWNwHH2lT3sc5TQAMLHHrjMcA0wPQMwn+3vlhMEwOnWVjlaXy/H9KpP9g/LMfk7OqRMCAaFrPW+s7EGYx2U6bYAbr8CJIfbSFMhFNCV9uq3eZru97X+6+21UPXo/7W968Yv2ixEzsH0nRY+5lASexZGR1mpZM6ok1OYRMupz7vdFdr1C2zcev3N37/d3qHd64yZ6pPn5nta5+wNTwOeD491+q717taAIzfPX38LYCIdktd0pThcmSa/nSDQWVghwyhN8m8RVJqX59C7SVf2qEfTk0MAZanvqjm5xgO00dexpTh8r/JtrZPX5Xxd/n+41XrwudDL7S6Yb/YR9jp0UZ8T0EgHNYV6FMgK3KS9+p7AS1nSWMXc7UxVR+W+wz571uHj3glywCWOpJcACNJwaMbgmgKyCyre9REFbYk7iJxQFtkDdvFwAy676K9DnPqT0RzJh1VQaeBOPaQcljwpZDhMZ2V3hxlt8Pgl8duQNR2Us+EGNKA4UUQl5qocdjYmoRUXQtb6corSffH8Rel1e3lnzyn/8O9+76jce/iwzC0s8mnAG+m4W0fmQACmH5J5rzK25tk9AJayZjiGo76kVrpD624eP/no4/J3P/8F9Y0cFsAgTxpZX+ugnr/e8oWcNXRydzf97N7v7//Yluff2KSDxt9HHeFoh0E3Hz16WL71rfcBM3O8B80gGBFV8ftVwc5QZ6PkVWCbwKCUvXbmLHrVP1qWhocdsh7n+jAypspedyeC3dxIp3b2KYLtqjJGyerz7NCW0d8Pdncz+9FJUQIywa1trQuIlkaNEXvG8drT7WGkuNj1O4/eLm+/9XZ569FbZRFA3VZGkKa6wHxPIPecvDWMLLkWCCOHtOoZ0PTqzIlZ1C11ox7VmmpZtOJ6zLC8oxhadpGhLUDZ/PJ8WVgB9AGsZuamAF+Andmpcm91udx7sAJAmynLy7PkbZ76PS6//e0vytPHH1HoM55ZALy06KRtIbOOkYutMu0Igp0ieM7Oxgk0KVXoD/ns2Yvyk7/5Wfn53/6yfPr552Vjc6cOnUJb+nELxLQsjTp7VIu3eW0Nlfb0eBmbpLPSHuGcuphp5ffVADrq+qQMjtN5maQz1KZDRfsP877LlVkR0rUW7wDOmZm4EBk2ZA/dt77+KmEwXIkgtCtL0s7W5wk8tYVe9L46ID7s6mABlJgAGaCFm5qFpvhtRwC+vHF27qUzos+ji13P1HOBue/okz5JHl2JwQgMMYb8oS1jspTOb1qLGitABC6FtKD1WhWy3tRcqcaRmP3dAqnaA7OH4kUrUWbX+iODaD630fZPx8v+Gdd5zt7JWaBXKZMwzThEZBThcQhYYetY+DnvaP1yiuzlIb0U0jkn/b0D10I7KXv0chyXNhDf3sY2lXleRnhXE/YYoMfKuoa5rugFTVHhYzYKzOV6g4sQ7OrCTJmcGIlwMtr1g/mpsjrVCoDqke4NPRMdFV/td7PEEq0CGLssJ4cAJpVE77DMQKiXoygX6KE9ArHIUjD3DI1FDSbycQQl5/bMj2E8nfsdOrRn1uJ9mTt+KX4T8MWTt8SYHp/XKPcFebhC2VwYLE8rGPvZEfmgx3ep4KcM+tdNGbqhfV3uzwyUlambsthG0M8dlb0Xn8QJM8Mz9hIUQl8CZTYnx367uuV3f2+2u7/r0Xf9ywX+ycKCmlxI2n7Dod8MmSK8VKRZj5QySkfJQ5/ObtMmf0mLn81193/wnPl9YxsYGaX3S3vo5AlN+T39UQ4OeuXzzcPy/grCC/As8dfi1rR+/1aBhEeFtwuIZ/06+MEZSGcILRKoj3JQceaXAoLn/Z08WxRvpFwc8vxN+eG//OqXQzo4pLcbZGgZ+nnNJr/6u1ai9dBYye7u8n4FYFqP6u5vZ0M1FqXX9+t5855H29Hn3Bs/sbtATMuYezNjUmddHfWz5A4y4JR7CXWhwiVFvyEft5yZKBCDh7JQdR+sxUfVslK/dszitE9R0M3kiTzaW5cPkqcKHt2T3X5dNB0Jlb0KW19DLSjO3rPtBAWuEGLP2wjdWlpVoucAMTtEdqhGB4bilOxkJIGZLgSGK5BftYQ8e/68PH+5XjqAtR/+6J/EsnAusKepQpd8W3qRouQTkrQ2/ZU/Go9/AsMaazCdB15WXmg1cvhm/dVa+U//8T+VTz7+pLYRe21j07fMlZ/y22O/LnKJvdbG663hN2/HV+vO5r1bWcLuuRmveWbjfj2TpwRkI7TVGd+6KQvzc+U733m/PHiwih6gTWn3czq+CVNBvbbHAN7j7TrJifZ2CBZijgzJrHnqIAtgI18MZzGiDEaGa7U5piO+f9gth/Cq9agsli5sfwP0Oqw11W4Bui/K4f52OaTTmxmbtj3ZNUalMkT/Jx3ku6SzvgGQ4duzAOj79x+V+YWlMjE5GT81Z29az76vJVULqZ11QU6aTSseZbpET1mOGj9Oq7SVRMeVNMYm2hlyf6kFCDmmJWycPKpvJybGy+TUVGKc2RmZzj4Z8Jc4d+g1gdnc7CSdmV55+vlH5ekXH6Mfbso7D+6Vtx/eK/PTU6VLOUfR5cYQsy0FhYJIRYUWub3dg/KrX39Q/v6D35a1zc34qQnCTmgTadFQT65sMKG1kDwIqIzRJ0+2Oq40MJZZp+POegVkyV+u/2h5bgau08665ggyHYbUF2/CCW/QtDMYDTliAPOsxoCccGWDp08eA8h2Ur+diUn4brTWIb+dMbwLCHMdT/ljEr5ysoCAVoLWEpqOnCCXmhaLxPeaRlY2yddawrVaWh/utlV8M3lGuaN1zGZMRIQ/NBgTNLkEkjMmJDgZyI9GGVLACAQIJYxK5oxRJEVLzFaWPkfGG6kWsLpX3yBBTu31GF9v63Ss7FF4LpdjmMeWcU2okenJLEfQQhC5JIUldamiMBZMamW4XJKWNCtC7jBeTK4puOxlHBzQeL2APv3CZmhcw0uIZh0yuCJdBfIoPZvW8TnEMlSmQdyPjLXScbbEDcCJPMHIKyB4LVUS3RH57wEgtwB/5vf8BhABYbg+pPGNLiHu9NIgApcyOomFBJDJt3SQjFC1rigv/F9GFCI8r/+KszAdqoz85zsUi6MNb+8aYMzJNXm4Qild9g4Q8ignZ7TAECJ+Bb4C11mb0yMXZWHspMwP75eZwY0ycbVWxs/Wy9D5K4DsWuluPC0HWzUytLMeG+uYgMyYNbWtEczUfbObHbf0Nr0GHVQhXe80R8447wt00m8u1/uvnw/g4txyhc4QUAokacVNpRfTcP95c1DTrGm5m0Y2K8kbHOrTX94GaXNBmDN+EwAWkCBDd7uH5dP1bnlrDkA+3allu03T79TTu5tMbX79vjTulx3m0oKhxfKMtlEpyNBNPfhXs6iKTCJkip+VvGtbc81nfvSvvnowtn+AcMr3qmDpZy6HAEaQSgPC7lrPmuPdPe3Yb6cKvF7//n2793xOYafy9Vy5oBVMQOa5R0GZQ5OxjqGITwAuGZrk3OFJQW3AO3/yjwGm9fcSfAWI8V6ibJsXaDs+l7SHBOKSJ1rPjJ/osKVDk/qrqCCaMgjKbkO8sGfiDHtqhW+7C8a0VMP2sfY6RCkIM2CrzvuOEhjjS7BlJ8kOqiBsSsuIwydWO+kYN+pXv/77soXiOEEB/uBHf1yWVu8VQ9EYFf76mjyoHPw+dWg5fDU0A81ZF/6QHj2aNwGKFjxdRrQQ+G3lxE9+/BP2H1M/NeyCgMzymZYy0QryG1FY2WraSZ8Mk3ryXamjbvFh9Zp583e/rfPXnPf3Zrv7m5ZkV084HHyeoaZHD++Xd9/9RpzNlVMOQUkPWsTGAdDxqUVmCDR5PXkRdLsMn6FQMjmDenJo2vYeHLTTBNi7Goi/2CFg7IhjrTF5eiCLQLvckU77zrY/OtwvBwCU7oHxq865xleo44wAATTmAC2GZ9o96CrQyvzicllavl9mZ+fzTeW9oUn0m9JnS0tbfIsot/lWGqQeEAZ20tWF9ZcWdt1g0B0A+8mpGWi0lQ7IBiBIi+7M3HSZIp/6oUn3WhIFKtad63Quzs6WRYcsATRz020A5mQ5OtgpX3z823LMcWJ0IGtLvnN/Fdk3UybhA3WJMSjHoAtpVivY6PB46XWPyouXa4Cw35XffPRxWdvezmiVFsdBymbHxtUtdA8QPHXMl4uMI1M9nwIkTk626DA5EkJ7UA+Vz13A3CFZ6Jy60HfTYVWB5vzCXIZgNbrs7+2VHb5pGB4jA6yvrWWFiCPk9/bWRuTn/NwCAHSWZAagFV0aXEu1V3rgAKWE8mF6ahZd30r7kQlrn7xT47RdX9xll0clzegDecqjbQavKNs9F/yRQPhPsC0h/cHB2DFA4mB3uxIMGRK9y6yxSjRHrnloLDXkKbu9Pi07IkkrO+CLzKfiyXQsZLxzfDFatk/1wQK0UFAXA7cWbmikcYinPaHTvmEtBjNM0eseADZOq8CkQUe4Z14EdlaMY+Y28BCo+3JsnO8ByLb3IK7zLFt0eEaPOj0EiHYcBgVgXcHIpzCKJuZxhN7YGMTE+7Okrf+IzLl34rBUKXNt44sMlN9u7JfN3kk5uqogcBaQJ2g9PwHQ2aAKYo4GnHTR70N6xXoRkUWIit6qglOAxW9HmNUPWssk+nHqST87Hct1PHWvQS7PI0zPILyLADB60iglTfXOzDKmyw0CHIhZ2jeHpX32vAz3PivXBx+Vi4PPy/n+y3Le3SznvR3S2Cmnhwh80tDSqX9GjRFGT4B8V8Vj1dLmXLNR0979rQqO0Gu2nPevpZCvD2xel4jrM6SaYwPm6oYQ5FzhrnVJ3w3b1DryEXuR/QSye5DOmi3phPj4z71/rdmbLb5B9KINxGnvzaE0LWP2tj9dPyorkyNlda5jU9fnk5R5qGVvvmOK5t/nrL8GzJieeRekXRxr6UBpJA/WpS/VvORazWboxPY324rfBvR8LWBsf7efdzMD3fXz50/zcWspSR3WDNfy3ClHf6+yoR7dGzDTPOt5szX3m2c8uikTBF0KZc+VE557TQuZbhNx1tcCze86G7LKkxHAhgpAvxhBl4pY0BYFC9hy1lb8wFACVrilqUscjWTYx7X4AsZ4X4VZQTSPQo+Jv0c7KwvlE69XGUZvmd3U7HwqI/UF0yomELJe9cVSMbYQ/vao7SzFn4n3jZyudUzw5BCsjt8fffwpiuO0vPv+t8q3v/M9yoJyvKQMyKgBlF6lRWiEtoEy8w35JAXKf16t5wFj5C/AkGccIr2hs7qxtl7+45/9WXn69Fnq3zTSTjwuoIuSYmvu/b4tT7xxy+/m26aVA3XYP97+7l/zmdvf/X1QhzsqyWXkBOgu/v3+e++hkGd9PNddHFqaUM5OjIxHZg5JpwCW246+FjF2F8HOuqK0p2EchgQN1iN1qr9Y186zAJXn7PBr0dWQYOgEI9CPj9LRPj3O0OQxctel9YAP0Wu2u9Yb13K002IcK0M1zC8sl9n5BYDEdIbotG4pE7wnDVYAr08ctELeVerZuKZLwzkyPPG5zgUp+klCZzzibMPp2bkALsNCOEHA2cFGzReANbuz/gVjhtgQgBuVfrrTKbOTk2Wyha5D7q89f5LO4tTEWFkCnH37nbfKMqBtjIwd7x2Wo/2D+Dk76WOyMxlQ+OLZi/JqbaP89Kd/W34LEIsPmJY7ZJ6jAgHw6hD4q85i1gpGXgKo5rPu5dz8bGY66pbiChKxxkqnpKNBRVqTr09sE9pxEhB3794q5Z6h7i/i4yoGcLh/e3O77AJIszwau/m8t/qgLAOEtcq59vPxkWFvzvINO1st6mIMoG07W9fSxzi/tYSq1+0E2NnRZUa5LBAVr8RCBt1UGVZpOfqbo3pLFpEvva8++IODscNet5xScD8g/8tClWEgZirRzObjZNQKyfTQPlPpB6GlLCCNSq0M0j9SOHeF0e7peDmA+Oy9KADOw0wUlDSMbK5DpD3nE4hTi5Q9IgGExBj0HOHqkKL3ztJrmAAwtanMORpncm6+nF3Rs6YRhy8Hy/H+YdaM7DouDwF0DB5LA10MjpQeZXIMfhzGHqCLa3C/NoR1DYECq2IJ00n/CoLbA3TFYkbFLE2OZZhSq12i4PP8uYtgwtz2ahT+bQUJ4OJMcAHhDobpariQcb4tOKNG6XFdZUkkrWrOWtFqc3WpD8FpAsPaAzja2SkXKiMUjcEEJbqYT+mxjZ1vl9Hep2Wsy37+oozeHCC0zss4eW6chl193wkJWgadsaSgVsEIwpqhl8YSFWVJGSMs++3NaX77nFsV1lKHP/znb5/pv+cLXMsx5821mk5z3lxXxWgu1snWgIHSjZ8KWMv9/tOmfycPt8n0ty+nXbcI3FbnFoxllQfazP3DVwdZHuqtxUkS7H+LPWnn5ZqmxbtN1bJHKdY8xKJI3gegTZc4OaNH3aQTJdrPpwDXvxpkUEVrip6/rt8ffg2zKff2t/m/lqa2Y7LY3wUTuZRNcPa6LPWdSg+VThpg5X73993nmu3uM173t99TyTZDk5fIDvcGjLnr4yUQ09plJ0U1Jg2ouB2emZycklB4zxnWPnNOe+iDpHKoQEwlIXDz3JlaRs02sra+J6ZDhiisKdtW5I22qrRH0rZ07llr1ocgjDJz3aCZBpR0+nyGLHg0gpnrAgb5LBYGaE4lLCATnPm+Kwno3/rJJ5+h1E8AD2Pl//Df/fPQqHGwHMLXuu+ixNXnTaBMHthjwVR+mM8+HZnHgHplMrQtfx/sQYu8JCj7q7/8y/LXf/3XkcMWzGEan89vy0ae3EL73Evb9Y/ufCHffXPjbj3eeTZ/zXsmYx79zTdieeevoQ+NDMBVE4qz+/vvvVtWV5dTbwbszOw38qTMb1EXYwPINOSnlZE1MPv0kqyZNuV2iEHl2k6MtnH0V50tqWuIw5PKfPWNesbZcS5T5LCYwWSVq8pcgZixtATcBmRVxgngtdwowx0613K1sLJaZ2kblJfrWuQslH5qxtG6la+W1WowJZpJgJx2zBAlZUCun5E/6TgjKuRtGrAkjbcAVge9w/IUelEfCjAmuKZzu8DC4T+XbRLka8iYEYRNuHTTYDnt7QeIOSNUx/xF9vcePSzzDqNCxWfdo7IPwGnxvbnp2dJGnx4DWDfXd8qTJ8/Lz/7278qT5y8pmzKOjgtgS1ktgLdttdh5dMjWjpHO94tLS+XefRccXyqzWfvSUTPrQb1TAY4zEg3polFA2ojhhTp1Uo7tMQmw1WKoj15WoeE9datDjUukr2VycWm5zC8ulTEwg5nQ/9eZp8qEEerDUDcB5dST3xboaq2cJP2A5NCghp3KW6FJThylyYQgyik/Z6KZBEY+BWoBZRxjLaNFMwnuDw3G9mDey5NeFZgQjQLHzFBz/PYa/5MBG0J/sWaoRkGnJcMhylg3FAz8BYAFjFEYzp0JuX4yXHr0AFys1+G5rgLYipBh6MWgkYEnQ4CYgTj5+46+VScQjZYsBaVhLAwaZxA2BYoN3RJkjBjBf7RML86UqwGXWzouN+MT5JoeB8L8EGLfPzgpAwCpKRp9HME1NTtVBhHWgygDGW+CnoMTAi75vky3o8M+oNBqd1mMd+dpWMq/tt9LOI5h8t4hP2NUkxGK9R855b4xczo2OPWgydn4KQpKhUdL4uK6JmdXf1NY2lvrIaBlTIcUsuYXxKlFLJYwmDConbzf0FscPnpVJk4+L52zx2VyaAeQekGvUcFBPcBYAV0cYx5nj0WA3/HPkHioR3tqUTrkO8CL82aLoKRMVXgqZ/iR6/VeA7zgglz34JP16bqFdqiLXOG/qjju3M8H+und1Jg8ArIqkCB23m982eo3+1/wneTLc/Z+3j1G+PfT90ThbOBXnalVeDqYJjAv7f/pqz06FRfl26vTJsgL/bKw1W+xeYkyZPMCp9K2wx7UUO4NUueZGMA75/RCdeg2vbxfNTQ7R+7Hp4FMDmgRuK2bWo6vA4xpGWu2Cr7IU8rnLtgwO7Z9cpat/v5yO3h+F1jdvX93u/u8ys899UHJlQ0qUvdL+EIhqFLSYuTu9e5RjaRtL7wOP+pf0opidCjD9emMRq5DvzMdpYtaEr5gnkI/ffpPp6Tyhdb0ulEH8KVDXMqWunQT9UAK/ETe8Qj3nWAzRpsrA9rQ6LjpkL4dHp+Rn3TEH0dBK6hN3WVwfNZ1DQVjlk16c4b3+sZ6+fyLzxNh/Zjr3/vBD8uDt98tY4byOaOzAHjQ30l5oNInSQuUPQCL/DWhagzuqrXXzrFDKwMuYExdObPbsr16+aL8+3//78rzZ88Bo8hM3tJapHKy6f3dDE1n9/yNPQfv9tuz2fNK6LvuPpcWCN3zDpUj8CO3/K5gJbKjfpUdXief5uvdb7xTvvHuO8j2CUDReTk+7kYZj9NW7RHqEd2g5LRJnNClTrnkvtZTrUlomdCHHS7DIk1Sl3bWdRA8QwcZv82wCwbvNpSHBoZ5Ou8LC4ZWGKNDfEXHvxsgpoN+2pBvSz+uVziGHLHM6r8pgEtneo4OPuBiDJ3gPgoAIh2tYg51Sx+6uQjIMixPnZNY1Ye2E3LfTrquKAlDhIxygpegwyX+5hcWy8QUNDXRzlqTz9deZSJagp3HIgwdsk8DXLTCTtHBmOlMlSn04jQArbe/UzbWn1NXlwCtTuKHPVhcKCszs+WmB9DtUb8aNEhzYXaujN0Mlt72QVl/sVV++7vPym8//Lxs7fXi/zw5t5jQGU6eke9H4QNHs+yEDtvBIW2HbycBY0uA6RX22bmZ+Me5ZJ+0qoXRjmjWO9Z9iHw6O7KihZtMijsiX8MjALuJSYDPDZ00eGlwNJ0nLY+TM9Pxq5wDiLUoq50Wn9Nv/Ai+uSbtAfT5MPoWKQ8OkOxoQ3g+X+G39ChI03KWEQ10v22RDhR1IR1J19KZmzhHf7LQO89Jdy6VJO6QJX34DwrGXI5of287a02pBJ0pFEGGsKH2uVaFlxkyc/pLNb9F5So3mV8iU7g3FrF6vMj52cVg2TkfzfCcMy+om3LGfgHwQfWGmIU951wTqMXBFsK20h2etBJFtM68lKEydktenV566QxKZ1+QzhBCTEK+QOHZu3QoQgafhHjiAEj+ruhRtABec60RemQwlgKAdHWxj3cv6SjM7RGcXVyXHvs46SncNHmOAqROdnaTR1H4dHuyHJMnZ+zoeyWCFsA420JwYctqvbPnRZNmzbOsPwnTO+mBh1KnEnt6SSghQZjxZyLEFdCA2MGT3TJ+9GFZuHlaZsYO6QldQdj20Ov0eXseKjxnLHpN4FUX9xZ8qZjqkcvJn78FMra5vTfbM0DHa5afjV85r/fqO5zmeq75RxsKMqqIlS7cve+RdG5/13RMLyDAa0mbl6A521eHe4WsgtVvxV8n7/Z38+w7yR2bafvVHH2GpMxEtgGYbgIgC2VR/y70Gobi9+ON/QD07z6Yyfum3Wx3z2+3/iVeTx4UuKQUwBffFGglwSFpN7cvpZc6c/ZX5Y86PNO/7ynnX4tlbE8H/rpVEJaTL9VX3c3TG/Xe372uQPbYPHP3WdN1f/N56TIAjrQFWgaObIYjbW+HAAVcJ3REnD3peZfOiL1ve6OCGBIrbQUzPXv9VOSzo+OTOAJHiFqn/Kt5UDnTQhx9zqFpBa+WEb9nkEdprgLl2gbmTetXrtu6AGsFMVA7nTWVs/5iWtXs3CgnlYeWy9GBSElkjoLaYU45SOsZP0nrOhMS1tbXsvDz02cvUECn5RvvvV++/8M/pkwz5FXwIshVDulfY4LWo/VrjshbX8YqNf0ZixhlNx8BY/5m14FbP5s/+7M/K7/54IMAO/1yHK4xzdrhqW30/3XzmVo5eb7Z663axrcb9We6sb7x0zwni57bLvzVfCKHkacqZGcevvPOW2Vubi4gOLokow4FIDuUMCEGKwXS1DahLA2NCUKlIQG7nWADXM9MTtFGNaDzCbKzCY7qaIbF12o1Y0yu+YVYThwSMwSCkyoMnWEd25bSgmXRuqoVSgdzrVJTgLghANAN6VwjcwfROXYk9RGznqIHqV+yCO/XOrIuMqwqPQse+ab6QAucqzTkmrKJ3dhcM/POklyJrvz408+yFJITVYyxpaVQy9IsAGWa8moRm0UHzQK6Wsj+Lny+JXi7Ok34ijlA3STAaI68O0vyYGennB+dUaetgFYrZWdzr6y92CyPH78oXzx5Du+dAwbnS4u67ADW9GuW18KPtLcuIFqhE4meevHocOnC/CxHwCl1Zxu6ZzSCDo08Vn00x+hUjcbZf4r0M8xIR8VYe06w2Mtali/K1vZ2eH1qagb5KpjV51vnf9K9rEswrfPMq41tZLmdNkAdtNBFhkgPhsUQ24ygUwSvxiq0DK7c4/CluqfBLI5wuRqN/R4n1dhWVZ/S8VZ292lY/gnNQ5zSlw37hwVjNPjB7lYYRKdUh+1cD02zXiQJH/dPpksvzN4/osaM2qsx6Jpj6lUI1r0BZFrLnG1yBBDbPQU80Sj2ygwMJ8OKkkWupiXYERTYYEZWHlWIeU1gQYM59GBPBVbO7nRiIyg7hFGuTlK5ckMW8kS4jepLxpOaqL3VganADRn/nl6cK8tzk2W5DVGMVStSZ2woDW0sMa1zThYYHxngN8KLfG90LwOiRNLO2uzwTg9FYIBZIyY7y9N6apFne9j20jKLizQVLCMQ4yigRcuIdSTocojStBMEkO8ZNd/ZkSc67cOgcebk+tDxqzJz+VlZaO2XyXEthH3ARVnjR6HCY9c8LVDIzu/4v3hOBURJCB44yhgBYiohK4f8Ccq8lmFLalJB3wjd3BcY5Zx3xMJe44pqh2JBlxCPUkca8pm8W9sk1z27vZ4f9Zx7SYc6cUqzwzN1+EEGrvlt3vPvNjG/k9/99Nkr7Xkis9Dj0WeMNjNoX+Lf8Cd4f7F1ULa65+W7K+0oWF5Lftxu89ffmu96NP2AV97xedtZ0729tJur83J66HIolXObIckKxqBlJYntT7/BuvSi3xXQ/fB/+OrjjO3S4Wq2hk9TbsrmsZ4rbMifNNHfmrr3WtpDumK/+7t5Rr53a+65N0DM3fsCMYdcGkHoUSEfHzHBFUIzscSUM6QpbfmMQlzhrF+K17o916YUuDkrS6f9askwH24OecfZP2iAcpkXFQj5yYK/md2FoAZc1TdsL2mNU3kc+SW4kY/Mp0pbpeJvhyfrxKUaA9BQErWzdZN7CnYVr2k5pKYsdIaXCz6/cM3B7hFAYLJ88/3vlKV7D8oY53bmYHcJglQsB0wmvSRztlUtR84pFxdCl4kPyDXlkjLcvAtuH3/+efmf/p//E6DsJHnlrSgay+jmW29ulvPNzSvSsBlp2rmpY7e7v/3f5M1Zcmp25Mecm2dkyp02mV9cLN/93ncz/OQbTrbRmd+VDbRAKuOUzYLf1CPlsr6bsgu4/Wp7cjrDV1OGDwFgCIwcdTEK/P7hEWCMjhL8p64R0LtU0PT0NO2Eckfm7u/tAsSOU4fN5CaVsB0trbH6FU/N0XGfmS0XtgnKvT09CzCh821OkMN2dJVkGVI3j2y2DQlFZ2bUAzrRGpbJFexn0jpgUbBsUdQ5GhFGoMnF5ZUsjfTBb35b9g+68QXrTLTjoz3Pt6c7LmA+nECydvDH+c55t1s+/c0H5aS7V6YnRuMjdm9xvswCQC5Pj8v22jqA7IJ0OujXsXJ40Cs7WsTWtstvP/6s/O6jT8sB+RkYAbhTthtwgNEMDKo+o3M9QHSM7+kYH0OHsyc5xjqsDxv1hDagDcUEZ7Q9PKM+pC60ELaoSwO5OlwYIDY6EXCsVVEAfX5+WY6g1/X1zbIJAHXd1IXl5bQrlVk2t3fLq3VXKdivQGx9q+whB7KKAnXglwSwp32jjw79RmVwkfg2siOjGJED8Kg0RXvLm9Jj3E64L+Cy/ZqVRaRfIyp4nrbkt/Koofk/KBhziuoxaDmkpDCCsBo/MRVFnBI5V5jaw2xQv0DMAshAQf1ksNkrEPOavd6bsnfRKltnNabUiQRnApTFKbouaaBQTJwSGkaz8eT4SBwSpW+ZU7+vM4S1TGnYCoPy2QsYGlRYkvEspK2jHkIdwKjJ0WECTZuXVPzeCQKTa4XzG97Xcfv9penycJpnAABTIHX9wnQo1Lyt5U0fH3tVCrFjhBgVUiaHAXcHR+W051RsmBDiMXxGxvphwn3SoJLKNPlE5IRIuRkGc+jVnoI9a51/va+QuKZOh/jWKQL6pOs6dfbIqT/SHrpAaB8/LYtDL8piG6E6WsGmQx8KqZjEOY8VjD0+YYA9gZfoXauYYCY754KAEJ15l5jYYw31t3+hr3rv9e6l3KDdq8KqveqqbJtnag++PudW5W1zn13BxHb7TP+6R/NTX6CJEDjWdfVN1NJQ6U96ceOtesJ293sNk0ShSF7sgrHqqImwpF2jIqCRl5u75dnOcfnWIoJsYixCvWbldXrN1lyTYf2Gv7LkjsTpe+RvOJ2XgXLW209gx+SS9wLGOFq0KA6L6HfC19YNv0nmR//DV28Z26XDlYpht46ymxkvZasn5qlpy1qG18DKvQFWzXnzjMf6vkLt9f3m3OvKhLsWMY8C7/iI0aOtSx4ZI+wiPKNAlbeUQ/rJ6EvjjMjjk6NYmrR82b6u5FGHJd37+ea7FQhyTT6hzeILwv2moxKgTD1w4DnzTZ4tB3Qk33rus55nuILvaUzTEi3oGgtg0C8MmckzCVHjOySoUlc0CT4PDg/KsxcvysuXLzh3ptdomV9aLe+9/+0yPbdQrrSGQUMO5TkioNW9Upq0o7y1vcJQkdPpENqJ47eyzjI5rKdzs/nd2dosP/2bvym/+fUHed4OmcA04RN8lvfl4btb+Ob3bZL5G882W9P2zbnWJJ+sz7N7DKCs7yv1qjFSvhksSytL5Z133on1yXpSX0AYxdJPoA+U97W8yk7rlyP1oLVTWa0+sc46UzMJtCrA1SXhmvp06SMDvLresstNQRABYlqXtMJpYRKIdff3E8E9NECerD+tIjqnC/4NMupMyYmpqTICAFI+Demgb7gcre3kUb2lr5ryGKqyMpPv1Azt5yiI7j2GItIH2KHJgDM63Y5+xGLJt+18HwHW7IwYd84Aqzs7e+jH0TIDINHJfhzam+LbOhBNjI6XFYDlPOXqAU4++eDvy/H+blkAhM1Ptsr8FAAJPThCfg64j+ItswBXKdPZkmuvNsuTp69iDXuxvh09Wyjb4HiHIwBegwLfvKRyjP/VmgLoUi8xpHBvmjqRL538ZvytsdFh2sbgvWIC2sYOFe2lDLC+nQXqMKyT9eLfRf05EcoF8Se00qEvFI5Qaii9BRibpu5dTUV3ni1AmC7ag8pb9vHOVJmcXywzi0sJlLy4ulqmqY8b+ZN3obayv9+lw3ZZxvmmekD/MvMC5aad+C+8FQBGu6v7bbeKX9QnVXYrg7QAKhvsmFW/MmTGHxKM7fcO6dEfROkFfFFx6WFyVCirGKsw1V/M8BVkDHrTGda1whz2safG5VoozhswlpmB4Jjtk5GAnYsLQAkP6g9G0WkIZ2mgxAQzVNTcrNGPx5R9VFx1huVOkPkxDKXwzNpuNODlgHFChiPMz4+7gErS5HoX5G/vJAEiRfm8Iwg64zvH0IYWGJ0WNesqEM5dp4iyHdDKu116KAP0THjnhHT3SOtcuYxAaQH8Jm4uy8HGXjGS89XIYJlCMTj2riDzmZ7AjHow6v8MDJR6ClhS8I9kaMwZO8bMUShZV0f0yvSTcUqusZTs1V5APKMXvdI5e1pWxjfKdOsi1jCFkwpAH7kIe/JflzXSAtHfVSj+loE4Kqh9rlq9aFPJkPMorvwiv/3fVWhW4XkrQD36z2fyfH7kXp4l/SqEK12kB5FNgsi/+m6e49z6aa6xN+du1qPpuYyRukcgLmNYDq/neeixed6jkMJ/NV3++mX1l+k4KUPa0r/R542AvUUP69ONbnl7bqwsTLdDu3fzwA//3W5cyTU5MzHjotTrcKuPG4RRYX9lTzdLJNV6983khDyYhjGffEHhZP7855DW1xGB/03LWDYz5wbt3t3C9zlaDxVcebTMDcByb2imOTbP3r3f3HMTgGkVk2c9F4T5W2f9Lj3cXg8+5rfDiQpNFa7KV/+wOAWjRHXWd+kZFZb5v4ZfHZaIBVhl6Pek+z7tQwyWJOd2ROo0e63x9VkJR9qqiph3eDqKHzpxiFIAoULVV8mZfLR85JKcpMzUR0kHaliSDoTDT7px8C5lVrFbvpcvX5ZPPvm0bG3t8Pu6TM5qEfpRefvdb1L1w5RFmhqn7IIL8oUci28TaTRgLLREUQR7FilDk5bb0nFMJxm5glAuH334u/Ln//l/TVm0uqQTYRlJWx8r20bOMUEps6ZuQv9wv733e7amzZstMoBjwFj/HrntP+elCnx9ToC8uLJaHj64n9/O0HdYV7llfQsyredQIuWrIzKkY/uyqz+0P+nwvbJ6v8yijF1/MkuVUadGrt8/PASQ9ag/5HdrvCwtLZaVlWWAQztD4js7W+UYmtOK6bf4DDQB7QKItf7Mun4idDcDIBiDBgcABeOd6TIMIHNSmAYE28tCRb5ZDvJpeoLKyHL0Qx3xOE5sSIP+OhwaKxn6wFUQdGdRBgnKYoni3YODbllb38gQnrNDDcFh8OA5wNQkcq0DEJuig+nSRYebm2X96ZOyt7FWZida5RH16mLfy3PTdPK7ZW9zq+xsbJVxAMzF2VVZf7lVnjx+WV6t8d76TnnxCiDGdUMBFdK9ofwCzkvaS+vfIOU0nuehQ70AZoeXE+PM1QoAYRMtl4By4kIdPZMHDIzuAv22eazRAat0igFxOuO32LVY1YXc9cmrw5DO1rz34GF5/3vfLffeegtQNVkBobxH59p2nhIgLy2X5QcPyvy9+7HYjQOcWwC8ttZR/cppY+O0IQyow6us56mLU1bkYHeETkd/gaQyWR2sZc7hbn1LdZXQKOKInPwSw4B8Y53QxoIx+fIPCsZ6R72s3q4wq75Yrwke6soxMxpgditZwGXlauHJECVCsbFIeGzAmEpLMObC4Os9CIZnJSzDPdC8xaCvDhkOg4r1mTBAn0N2CkpFxa5mY9KcGHVYQOEOQIKwnWmZsWjyvkPPZ+/U4cPrctrbK7uOI58A/gBmDjWOwpgtGnoSRL/gEhIgYmdnDhgl3cZA6A1CDBbUHq6mV7JeRmGsA4hzH4C0RQ/lEmJwSQt7E0d7KoyT+HsdXFIuGNjxaGqnTAQMDdOI9DBIX+dPLU8KyGuujUCo5xCzSsdgoee947IP2ncowTXJruglUTFl/GK3LN18VlYmdmBAOinpgVefFZdHkijirM9RH7EGnCUuEnmvfitVGcQq1t+boUiFYwOE7irLeqz3717rX83vaknLaTbPVd4RRuy2C4f6ft6tf1Eo+efLjYD+ckI+MkBd8X+dKcPT9ph9rI7fv/HOnS1grQFt/uYxV1vI89C1PWbL7FCHi95+tHZYpkdKeTg/CT3R6MkfeVAqQsPJK3sKJK3292SfdFTm9XnUwiA0SxtZDye9fdobYQzT1gR83Jd8n/+vzaPWilpXttcPvgYwtrO7yf/kgTxVXrUl6nktk3fzSMrR1HUDqO7uDdDK4/0yut195y4g89olCqYBYr7jNeWEVjCHKF0WRn8xZ0tLAXHipR61wC+vrpRllKiBJF0WSTCmoBeo2d5NrzWz2DzC5xWcwS8ojqz64K4gpp1ise6XWboN7dJeAV7yqu0HDSSeFRUSHzDqS7k0QqcqDtpc0zrgpCKt1c68k099d2dzuxzs19UupJHf/e7D8vzFy1hoLq+HyjvvfTdxxSZRrPoz6eagX4vDiLUzXBWE7wu67CCaP69Vqqngi49F6VdfJMAbMm93e7v8zV//pHzw97+OJSIy2fcihighv60Xad4qMDXb4n9z43bTts3ebF/63eSP3+nQU0/V59hr8InP+gxlGRk3av1qWVpYQl6RN+rGTnAmGfGGMszOp/xhulpLlBu6frj8joBFnl5cuVdW7z8sLUCSnXo7xWMo+r39SieNFUNn/aXFhawX6QjK9uZGOdzfpd7OyQ/yE6VrXQgGBHjGD1tYWipTMyj3dhs91cmSelfkyXWIHUFSrqRyeLMOESvnoW++qa50+DpO+sgbAdiFFjF2I+4LxjJDHtDoKIz8mMDGpCPItN+2s7tfjtA/Y+iR2amZMme+pmfLFHmZApiMUNaXj5+U3/7yl2V7bS36bQoAMgdQmgYkSb+nvL9POt29Q/SMxoCrsgEA+/jTJ+Xxk+eAvpNygs4RXGrpc+akyxI6VDo0akR8/a5dfmmy8jPllfOlfdvFJQvtxIzDZ9IjXB2ZaEfa+/KdwdzdaifPHfqjfFWeAMI0zvC7A5gSiL337e+Ut959t8xBGwIqffIEZS6e79qtupw4XDrO8y14yIlaRi6AsAMctYr5DhnmefQI/NQ7pQ0AlFq/6uo6tBNHaVT+EHiZP4P62rk+pZ3ERjavI3fSjG4JoWXaKpPgoM0/GBiT+A4g2AEIxkxaMVHYnFvlOpOaWSvboUidJ90yrMg1wZjXq3B/Dciqv0a1jh2cj5ddCEBhbLBTa90ZdK2RKqy7EOYpQuJiyAm3zvShkigkqUaw2VNySM7NOEPx64KwHa13fPrw5LL4yyUnSBImvS5dhNoxQGn36BRQdRGr3PjgDb2KdsyqxlyZGhumdwFj8Q2XcJim0Q3g6CwVa2bjsBeHQJ0Rx4auE1E/SzHx7TOAlT7ADqWd6Eei4OA5gar14vIonkua0/YIAGAKS03MOtbqI3NyuFeOYRKnEzu91x7UAHnu3ByW+fJFWZo4JJ0qkBrn4QxL0kYKrAxJQhBeq6ALwuDbiZHEsRK6v2nJ7ApGCei1orVtG0F6e63KvhylxDfv141j//T2en730yBdTjiyexWhERDHXwU09Rlfy1t53f/6F6hcTdgymQykgEuZTINnpLMGBDTf91u+n09L2fzUGVaBaar2dhUEMtUANPSbF3u0x3V5f2XGVOpfPy03DxGwqYwqRLxTdSKKkvYYUIvwrSh00r/hW+cnh+XqpFfz00+z2QZ00kbwqLKGR/0A/9i/Dgf+nZ2NFMWt1l3/R0pVt5Q/ea713NDQ79u/XFf1vGkT78vbd59phicVehleRDbomK/1K0CMDo7nDkFJGyollegyCvvR248S48nZlTt7O+XQAMgqUepYK6UATH8grS1+10Cu+oIZG0qfFsMYuECxcksekJbMlnkTmOXcdjTv7PKMgV0VvVqwXWTbayMI41imaWeDZA4DzKQKh9Eg7Mgg/dHsZfcOu1lQeWtjO2EsXLbN4ZL5xdXy3T/6k1hz8kXq2gkm+ujW4XJzQIZUFP7mV4guVzlqCYQnco9vxhn8HGBK3enYrFXsb3/6U5Q4igRei9zlXWV7BTSmw7HfVs3WtFPTZs3Of3W/s3ndtvZoW9/dfNKUYfl8Qn2g/6T5tUOoZBf0OulBK5WjIZZL0OLsvgrGlBdN2ipq6cWyayEpgBaEL+3tzLrlew+hDZfRI1Xekc9dF3Ftbb0cHu6nzXUsf3BvlbaBP9FZOwAxV22x3vyE5dDgoNVG/7PVh4/Kw7ffib+SoETFPkAbgfLr0GR0JXuOZJH8ZWkm5ZQgGRljezS+YcbLFIRdo4su2QVlkfk8E6d48utRgCnIsxwaGHoaAmhrF/temltICIqpicnSBpCMopuff/G4/PTHPylPP/08ljfrbHFhMUOraXsA7hn6cRRQNdmeLVvb+xmWfPZyvbx4tQUfkQ+qcgBwOaY1CRDjbEmBzgS/J6en6zJEyGFnDM/NzpRJzpVh0rvR8B1ydRH1MerWiWgCMYG+hh2tTgJ/WjJWY61R7nJZZjRSh8p3h2eNrTa3uFQWqfM233UynhPk9Bd3ZMPArYYraUKIxPWEdmkByEYBi1rZDPQtmK4zW0di8KkAqx0rpkPWWzs7sZg6aqZMEk8oKwSCWnTjgw7NKUf8rbT2t4YOad7OvIYQh9Rt+j8YGJP5d10c3IRDlVxUiVhYfisUq2DV/FhnF8lgOuLxdkyRWsBMx4ymFxbGAYiRJvVc9k9HAEdar3Tmh0AQLOcSWxrEijb9EQiiBaPZgPVbZseGkkBlbCtA5/6M93LT4U/9QlrDA6V71C3HPGt4h8nRoTIBcbSH7Vk6i83ewGmGP/QNGOb3Ynu8rMxBbOP0vI4QYjSI7reHDkuaT8q4fXxZDmEYlxd6e65dFloAx619GMTFbOkNU97jcwiR4zj5m4JwnABh29lIMobAowVBUlGArh714dBHKceGEqFXlNAVEIQWMf0hpoaOyvz15wCxXmmNUxcol7rUioALwqa8oxCwdVaHJAX/KCTbiTbKMCTfbUBLxr9pT8/v7m4e7wrSu/d8x/b0WLcvvxsaufO7OToc0DzXfFdF0gCl5r0obesp3/c535bw+79hdHstIyhQe7/OOvKu5W+2+o1aznzHBP2W56ZvakMwPPUnQw0K9nk+n752RiWgifZ5f6UulZRM+M989/OebLn1790CytSNStS0620FgVaAqysYHCVQX7tNoZ5TP5nCzlETeZQU178WMNa3jNX9db7qdue3ZaEc5ssy3t3vXvO82f3dbM1vhXAEGnV1CU9pFTtXAUUO0DmD5/T7OkRAOpSUCPo847Pynz5jU1PT5d333isPHz2KlX1jc73sHeyGZxKOwg4dbaBVLJM0+J7T552+3qwwEWXAMfk2b8itTHnv84ZZj1WZNBwmi3M/7yd0Bfngqcp33KvDk5Qxig75dlr5VpAhiJA6PLo0je9sb22Xzz77IotJn587u7tdvvGN98u3v/ujKJczFHMdBhkJ4KjWSuqfOkunxaMwg/PI2DRT/R0LuG3FY4JBW8Bl437y47/im5+mHCpFATDFrjRO6nBW0pEKvnRkz4O/Z2/a+e52F2y/vkd9ciofRxeQZ4F3+J2r1fqo3UcwNlru3VspsyjejLrQpukMs5uppGjjqHzTavAdv10i74y0p+bmyv133gGQLcaSoW5R4QqQ9LV68exZ9MW91ZVyb9l1IscBRcdld3uTfQsQcZw8ORvQjr9WQ0MnLN9/WFYfPCoz8wsJ2xBL5UgfkEkT7oKwlB/aMHvQ7LUTSQAjQ+TNIN5ZEqtvDXNo8qynsz47HfpYiANO0KnkWz0n+NIKJRiyrBvQjrW1ML9Y7q8+SCiOyXYFYnYKnj95Xv7iP/9F+fC3HwbgOcNyG12+s7tHtUn/htkYA5CepCOwf3BUPv30Sfnk8ydlbWOn9E6v+FYHADbN0SWedMx31ujrMkbPqFMok7yQWfuWmfbWMnatNRPemaKeajy9i3REBIGCYDtDtp0yz9UfBGIX51fhbYGYJG4sPa1nzhY1lEcslNatnR7azE6W+FYeqRP9nCWLHOG9AcqofJdGGplhnVXcQhoc3S2TE3YSo4282jFzRrZAbHdvLzMw9f31mbqmLXVD3uVNh5CNYegwsbgks/OlG5Wv9fKHAmM6yPb2dmOCl+ZlgFufMXYvOmwos5kJp+DyI+PvmmEzi1Km6+8ynccaKfsagEQv5mIs/ld+ywoz/sc1DeHXhkDfYzMLIPC5jONKIFqxHAbQYV8JoxB007RoOicSOsj8mJ6neXdpijbgyiFOfS70L3MB7umR69Ie1CKGEFRYAA6dsThMxY5cnpX7c52yMtMGcJ2kJ62Fz0i/lyiIIxjmxe5B2dnfL10af+j6onQQ/m0a4Hj3uOxD/Mfkx0Vf9Q+7ps4Ec8YHEqCNWXekp3nZemrDYJqsjSasj4srzh8fHsVvITOxzq4AkdcAsSeAvkMEEkJdBUG6WsScnFAtZCoG9vjT2Zuris9d4FWHIrnOLnDwukVP23LSWGvcKuDIWX777N3ty79fC9wqfGu6ze9sClz++f1c61/3OwF1/UvcTd78UV9RSJseN9EIvnUXDI7R65G5ZXzvudU81LI35wr6AOAkGpZEWSNU7E3x51Ehk6Gtm4vyfPOgHJzclG8t0itEsLhV5exXaprZODTXc49/GdZki69Y/5sKhigorp8d7kH/F7WcbLnPDUHY9VXtYanVeTzf+TrA2Nb2ev/Mje8np/X75s1jU5/p9XPubpnuKt7muudunrulTGz+FgBp1fKZDEUiO6pVDKXFb62TWsWOoP847aukzuk0IU8Ea2k9ev7zKNp3vvEOvfNZFM12efnqZYYOHPlSLiF18icItzPSgLKGPs2Tssghk7qf0XimzitkO+XjqNJQcVfwSNvC225jPGRoBdefdKk2O0akjBDTkqPVQavHReSgtdCUT140PuDa2kZZX98CJJ2S9li5f/+t8sMf/u/K4up9cxBFpM+MoMW1NaVft1i9cs6R/Fag5B3rWBmLLOM7NYA0dUF25ZHHnz8uP/3J35QunQHzoXO4zdJMblDJ+y/0aHJvbE0bv7k3291rDQ007e7moz5t6ua5eS7+edRthnZoK4GkMzxXl5cy9CaotM7rDMrh5FmrRKydKHkS4Rr5J1FnrRvuaOXBgzhta/2Of7P0wD2tkeuvoHXacYX07y0tlQ766hSZW0NY7MWHK5Y68wV4933DKD1woe93vxmgx81Y3wRhw9CHSj8APrxQaT4WUXZXUXHB6QFnEEae06nQOZ/OR4Ylj05iEFD+63bh8KQKX+gQyxD7EEDMJQFdyaXHe84CdALBKrSyRDlnp2fja4VUK2sv18pf/sVflY9/9xE6YbTMTM5EP57xzgF68SXlf/L0ZUJVfPb4efno4y/Kx58+BoRtZ0gS2Ee5AFD9eGwCIOtCOan/pe2WTj5H6W+QtEctO+cBYNSBvpK6zmQ5MO5ZPrGAljwbf2x4PDrdToFAyvzZ2SB5AKgzR7WAG9+zOvXrYmA7i261bo3qgwaNyOz62mr11SIXQIsskdgynM/9TPaBB72eGdS2jXnnqDwQi0hHC4vzZXFlOfLEupUffMeZm4L86ZmpCiDJl/VgOllmC9yhJTdlIdEEBSZdqiF8/wfZ9GGIs6ESCQLL8CQVa0FlqMpM/JY5rEwJmBzIYHB7JcRk+fUW5mT3eH1NReZ2+kqOFAeoKODGpwFiEMMVQur6BmFIg81PGijRnooC0iWOAGAQ7wFCW9DkuQJM4evqRCLbHXo6e5ubZYJKmp0YBKHDkMdn5fl2r3R7Z2F0w0HMT0I0LZQxjOzU3Z0D0wQEzRrpeKxM8u3V5fkyB0CDk0qPNHsApr3tw/L52mH5yccvy+ddhC6Es8i3bwBop9RR6kwhTF6GYbAZGk1LGHidXis9Acqg4+DK6mqGXw8AeRddCAolpO/A6ck5Zb4pCzfPy9zoDkqBXjaMby/cPTN7qHPNpHHUl0lIR4EWwOWe8zRbiIND/S+7DcDO0fshUt6JD0oatl77x7ZKA2/e9926eZbXk+7r52z/Sgv1t7dMJ3KMb1fQxm0ZXJRus3qLXYY1ey4BBSeV1tRMBjd0sDTJ5jvpeft8/fkPNoFXPsK7rrGXOuD7hkWZmbAHVoNC1jrxOejZd/pbgCR17q3UgWyS3/b26qxX3wut0+Y2gutgjurvdlvuJm12/0E7+Q4Cxl5e/7GveWu+ar7qVvNYjw04/n3779uatnZvlLSb/Ns463tufeY56jygjOuCNe+52YuNzyi7Tvs6CZueK4Ts7u/GiqZVrLa71gyDeJ4H2PkNXRwEfUZwz+zM3hF7nRjg7jWHhpzlZQ5tUukhR/KcoVMUZvfwsPSMO4VSJMOhUY9aoHXWN9imlor5WWflGdPrpOzs7MSn1J60w66bG1vl6ZOn5dXLV/DqCD3rybK0uFLefvsblNvy61MqgKhWQjWU1jQ7VDKAoAUIcqeFbDPpmfxKg16h3ux4edzb2Su//c1vE0JDmWBdWMfWXwWZFqHKgPz4Pdvddmx26zrn/WcaOsg9vts8V+/xX86jPW6/7dEULKsF8JqxIQVf2upU+nY6lWmvvxVmQylSFort0RAGWo4WV+8B1JdjSbpGHt44ewIlfnjcKy9evgy4+eY3v1UeAtiMrm/HtQv97G5tlsO9HWS14zJ8hfxo9XC24ur9e2WV552NZ2wtHdhB9/FBMoSS4DAgDGFj22ntiaUEeqSyy6CyQGClg37vOIBMa5/Wovj3uVNftkml1Utol3uU1BmK0XecJ3YewMbhwYcPH5VHDx9mJOrSRZj5tjG4/vrHf1NePHtZRscmyuzMQvTo8JDrQAImJqbKwOhEOT67KS9e7QHADsvB0XnZo0NwTh0OGlgVYNchff2sjsAA6qi0kTo9eQUTsLsSzCDXhrmPiipj7HQ5OUcX0XLjpDWIDNvb2iufffJ52drYoawDpUMeJvUDB5DZjjrna6jQOd46tP2tc0NjGOtNmXpJW6gfBcbWtQ70DrUn6Dl5kLSkdWddGuhW8CYwTkwx6lFQ2yfDHAV/AjNpQTBtoOiRPsCbmKYDwHEa0L1470H0yw48v769VS4HoGma+ejMuHToHvECH3d5pjjuI5v8QPcQPU7e/mCWsTjM6rwvw7ALxFRQFJsMVKYRAcp0sYxRKaJdrzk+bA+3YUZ3n/MZkapWtO7FSNmCKJxBecq1OkwJsuRZTajDrboWljWtqfgIpXxwCkja2o7gtjIUbCFcex40pA2laXgUBrskrxKUwszp7lrdBHOTYwo1vkXvxJ7A2Q3lgsjGeaelQoaR9C1zhoioG4hDkUfKCch7BHBooNdDiGwH4X9zflLmIZzd7YOyBcgb6Uwk+v6gQ6qwj1axYYW1AIx60b8kZlaBFAW7iEXuqkxNTieSs+Psuwpux61hXH28lof3yuLgc4gMguc9hyWrRUwfFQEZxE991CFJgRi1xh7l5ZE6uWuRisCkjhrAk+tszXmOtxd8rgr3eqmfTn97/W79Tt14pv9Gc5ZfCIsk2U/D/bWgrsKZj9U9wtDrFUx+eVNpcA16QgKXsQ5gDKa7pC2kyfRoTZ8nm6P/eZav8U1LZBtoEfO3vS2VfD5Kulpl1o5uyirY25g8qoC7ea1b/zf5a6559EyBHMEyKuwmvzyawLIqEKPCZ1Zl3W7fZbcKBJ86W9tT8NaP/tXXbRkzT7Zn/webbZOysVun9bdtU/fbe3fOm61Ryt5rLGLNdcGRVqmEa2EXnBkHSGHbow1shzqLGOFJGqpx22kcUDuF0NQZvwvPGLF+D4V6kck7r0FCKrX/vcZXNX4rzc51hyvNl0Mu6diQpkAodETbCoIoVRTnsTPfELIqWtdEHEYumJ7t6+SZ0SHkH23sxIKpzmRiP2nlMV3f0xp1uLdfngHE1shzF4CGBiz3H75dvve9HwAwZ+PLIg84wyzuN+TRXdqu9Eld2j78yqbM4kcd5pO22ZBngwI4bhx1e+Xp4yflVz//uwyN2gmJVcP2Y4+PS+qr324c+xXH7pf/8U1rCBWQ+lFWmW/T9BtNu+e50IXy2V/m0uvmlbYir3Ze7Ri3AWEOay3MTZfVxfkEqJX9h3nSoa6kYaORT2W9OsDJHPHpoqM7MTUJcLof2qh+gYZHGMokkK10oHtpl3srS2VSgXp5VrY3XpVXz54CWDczEpGgnaYrdZCu4RO+8f63yixgWT/VhG+gPIknSJGlS7dahxVQuYi4sQXVDwimcmNsLfJg8Odz+V+L2MlxhhDjyK81DH2TWGLQWWid8mk1sgx+UwChTnII+8Fbb5VZw1kABKXFyc5UOhd//l/+onz00SfoiDqMpj9UrHbqCehJp/cW5ReoTc8ulDYdhxt0lVagUXhqvFWft9wO+xkqRpCjPBPUuzn0LX3FR5w9FlY6wg5RapxpOgGxZPJd6yQrnVBXdrQM9eKwqbv3rD7BmD55gib11j3aUCuVhgdpRatn5DPpOqRpHUFpyRcNRbo8BS0K7ExHvzDzr15Ihw+ZYr5IKbpP2su3oa34nEELukU5/NnMhncLICZ/gi1n1yoPjE9mx0qZMdmfuHBI50w5oRyw/U/AG37nDwbGDgAE14CfCsRgVK1gVEbDxI3fh72HCwhMYtSkqFBw+E1hJzM2e9PLjU8IwrV7NsZu/K46TFkZGWVqZYwNl9Ob4XLm7DIUk0ExezxrSIpzELFAhYzFKXJkyF4pWeMb+hpIxAqYcS5KEJ3JscweGQvCtu0QuDD9bGe8LLX4Foxn7/kcRm0hFGbpSY3SUCJ/lYWLyNoA9moVDLuHJ+XJxn6sMYjLgCrB5NnBbnwCTukRdFW6EIfAzDHpcVC/rSqRSmz2mJ3N5DNa9PZ298op9b3z8nkfjNGY3FuauCorg0/L1NgZhA3RjOifwq7gF9xRRnvkGZYkc9VXRCa2jfgW7Shdccrub6+YhzvX7uzxMYFQ67M2Sf/5HOozzda84xarVv9384TnIWrSrL/zP0c/nku37zTyP+/kQV+qF73mlmc94Zb0JE04DOS6aGNTU5yrJBHqfDPKijrR7yqN1n83ysF7/ha8IugygQCGHKA+66dr8NGn+xdlepj6n66xxvJpju55v783Wz03fYV5FQ4GqnVTENhRUcipvM97ztSq/OHWpGO++Tx84i9B4kD54dcAxra39RkzD81et6aMtm+zxyKYawpf7/tc3TNUw/XmPbdGKVcfLc33daJEdjojmeJ/ob+YSqjyokDMRbIdjnHIwt65chcCJ93akzbgpkp/f5+OkGEIIqtUkioX6IPvK7vEtbRGlGwCu8JH8RWRh/ht71Yn/viCQQ91BMCOTC2nfGenxg6ndGFqsUxTVsNB2FYeXdaG3MF/nPMXcKdvDm3qcmg6aNtb3t3cARyp/HcBEnQQO9Plu3/0o/I2Ct+AoYncjkLRcVm4Yl7CIHzHSR4ZjfA6abrpQynPSjg3gIsB6vT8uMc5ihJ5ube7U37+s5+VZ599EZ8kqBxFQr4EkrxvrEfJMMvy8B1BWRqTY23H+i0hqeXzq/XIPRUg37NN3W1x+dIkTLvCLa8mh7meIR54QJmtZYXeCZ3Uq9JB5q/MTZXVpbkyP6v/EzISQOFMdeuUF2kP6hXAK/ji08mnHR79mgw8uryyEosKDRJlKRDWgrn26mU5Qr4at1I/sU4LeYzOOthaL9svXiQQqr54oWfetfMPw5bxqZmyeO9+efSN98rE9JyIuwyRTy0k14MOb5kHQX3zh45Qw1wD6i4BYufoKfZr/afZda85g071VTaO2TEdeofwpCuHETNMSbtZNuk08eqgIZW8AdgFmMZMSznbnXJ2Uv2VdqCpv/nrn5UXL9fSlmOUT9njsKYuEloJnUVqaA+XFRoeBXhwPWGkUocAU2UgNCG9xUptHaStbGPpjEdgpiFVNe+htAFhaEHPTQdApiUwk3AyqnZB+16jd4doR33IzsvGy5eJl9nmWzL0zcV1rMnyj3rQ4eQVgNjy6r0A0OpsrzFEyyftYt3wHUPJuB7pkFY48iw9OEEK5qdNeI9yWhGx/kqBBn6+EWugV3lseBRahgAHBo07B+gEnF6SlpNoQlu8o++ekRHEMmdndVF6Q6IY2UDga/QGecaFycVCWtatO/3alSunALI/CBhT7h0KxiDYCsbIOKWoR5lOwYbQ4LcKUOuTAlezogJWU2+QqBXCsdkDyNipz9I9HyvHEKUzYWiTckG6/lmh45NO0+2URafhTmhtk9l5hkauS3dYaVQqQMzZGlnyiO86BCGuO4EgXO7i4uiwDNIDmUYILAK8VmY6ZXIUgqJhkHUIB/4D5VrRmh5PKMu0kYkX6NXSoG0a2ICpCiAB2ujQdTnonZSX+nRRCEMt9OiN21sZgUl7J5zz7AyNqdnyhLxkzUGuObPSOpDpfca60x+t026XLvk+3NmGWF9k2vv58VmZaQ+VleGXZWZkuwIx6iCR9Tm38ZtArrUeBGWUSwViG8mEClKPfIvT/K4tx7nPebHZvOfz8JVbo1C5kd859z57FCv3m+3NZ5vNa/V63Wpe3rjWP6+v13PTjwC4k16jeGQwmoG2dhjK3w7fDCIo5yPoDUsh4A1wQKgmb0mn5tutqR/+IVjpPITmaGOY0GdVFAZhfLl3gSK4KquTKC3STCoe+7tbk+bdMvmgPy1DZvDxPcW0QsWelzx0eugkDQR1/7UmzQyXkp30+DjROvPD//GrD23xD8FY3Zt8VYVcz62/CsI8r+Ar9W29KiO43mzNuUeBmBYnzy8RqnZ0ruFDO211SBHwAP+dnNQgry6UXWdQCsSiGiIodcR2BpnTzLXe7xmLDzmiPBKIOZzht7QMxC8FRaCvhx1H8yj/OAyib6sAzI6RgExw11iS6x/5hl8DsmgTf2eYWnKhPpwVnee5rsOyvmMqTjuCdgiaSTXy1YS+RdCj1rHdvZ3y/OmTgMhzBN+jd94tP/yTf5rwAEZwdxxEmlRWpPb6PHmbJ54Jj7DXDq+qw/0SAIbA4bcO1S5Qr5O4PlK//PkvAIFbVbCT97yfAmldslz5QP8bKj5/1+81G1/l/35mbrf6WwBjxeSX+eIkNGPFsWUCAtfTgedarCc8PYz8VW4ZXHl5YbasAKgm263MnNQPtgVICBjhT58inc/VRzd+j/zJUyrtNiBrfnEhR9tZg8AE7WtIDEGv8cL0X9J/ahJ5Kwzd2VwvLx9/Qb2sxYKTsgoqec4hT8GYQOztd98vcxyHoTdX1NAqZifAOs9LtIFDrNaPwHjo5rxawy4BYOfoI3SoC3Lb4ThDzl+wC0wEXqf6iUETmcCCPtEnUloXLNtBMG6m4S0MAK4P6uLySmYVtgEA6jn5oLt/WH5B+z59/pz6BvhMVP9X6T+O8tBeDdtSrf8CHP3ArD+HxK1PjRNuyp/wc/g9l7yY+teqleDB6nCBl7yJ3pSP6yS444xUOXzoCE/3YL8cwJu9w4MyPdl2fCkjPuo/l2mSvuVtacUOmHRo7DbDV+iGIJ2aZ4O7atWTZirW8NuAPSc22gC8Z+y4LBdm20i8ZD70rdyFBMUk1r3fFKg6W9P0h+K75uorA5E/1r2Az9mU+n5JNxp5agw6gb5+Y04sHM4zTnCUzl05ILNf2d20mB3TZn8YMEamDw8OKCWAQ+L2L8xVjxZE5G5dNI3iFmsPFZY1p2w00nHz2Ow6L59cDpWDs6FyGKd6KpeETnn0jKRR9YnvNUYlWamOF59L8PQ6zuNATyEhJllfQKKYTjA5ehai65PdA4iFRuN6FxS+tb1Vujv75XivWy5gNgH09eUAYPCy7B2elO7eHu9fldnORJmdbAGCOmVmegKCQFEDgJzG7hCqKwLcX5xFQF/BRKeJ2t8lb+DiDFnY6oKm4RvDZZyWDpccRx9Mt+IKAX4DY7TKNo1kjLJ2QKWEfZ7hx+2trbK9sVl6B12E1ki53zous+VZHPYbS5gCKpYwj/wWiPAv16yrhomiBPlePVdM2oLUbYSkeUqL5pq7F6OEuN9sSSPH0Hs9Yatgh++x5Z3+/np7fe127wvPqNQ8Wp9v3osi509d594o/7vPyYyxUPXzWGlRq6mme5gdJlHQ6TA7Mipj8m6+yRYyNN/1nWx8YxA6UoBFAAnGOLrAspl4uU/PlpdXO0299svS35NEkxbb7TXz7PO8HNBHW3Ez36jxxoZiuTjv3R2q7CsyN163g5JZldDqj/6vX5dl7Mvbm2Vr9rRV/ygYq+ceve5e31HhN++oIKslvdJNBDg7nBuaVC5oeTbWoABLQRc3CQRj/DtUBLxnXcbiQW/a9Lt0tnxumPaWHwR1KsqRURQ5skjB2+m4mLBRvA1fUYGXik4riecVJMK3AeP9LXTmF6VYRXVTB+TVcnFLa034XYDoDdpMJaHck79yDbqT77OyBmVXpm6sr2dGnwuBzy4slW995/sZprRnb+BrZ7pZn3frr/l+3aAsylj3al0NMBCY8e3kiacEIirqTz/8uHz6yafp4GXok/oU9CY95af1bxmTPmlzDJ/m192t1kPd6n3pnBc50RrZXOW3tHF7z0MtQ+PjGtDCGy5rNzfVLqtateZnM0ypL+0Iz2d2HkA4Vjzrw/T6x0ue0e2khh2okfDHBV/QkDTW6KFDAIEWKIHYtE7ldPSvTs/L3tZGWXdocgu6FwhkeJuN9IVVDnW1pmfL/XfeK4++8W4Zbk9SROiDtJOPps6p/7oDYrSKIfsHkUcBYQCUy1NXUSF9vpFJWtI0gMXfATKnrp/M8+oBaDwTTcirDuEZDiVpLZeJlUdZXYjcYVMBhwaEdWjp048/je+hoEagIF8KwLKkE/yiNVEwJjDzt7vt7Z5OVOjf52gji0ZCug7In35Dv3Hp+tLhQa7l6A64DB9bLo4aQrKfHMO/x4lOcOb5kXs3OsyRKyeo7exsh+4cThbIkAnosiRciEtXiTlcdtGFwA0f4iiCPtS1nmwy8YD1osyuHbSMqClnwpPKAoGjvpFaxM7K0VEv5Yksp6kFXtc39Tu2QcpK+gk9Qx4PDvYCxKZnprMyg0O4+pS1kBtZ8YDvaNU/7ulqUPndIWhliUdne1Od//Vb1omkMCqTWAUsQPYqHKogrp9SkCoQIqTrBQpRmdAtwuLuLvq8FuAJpkqWLjKQ6gQE14IBnVYqU+ycXJX17mnZZN84oKd8dl0mpqgEKv7IgHeAFteqOj90OKMAgCoqtpK73Dum8sdIa2x2sQzMTJUegOiLFy/Kbz99Wj578qysPX9ZdkHtJwCF48uzTKE3VMboMMxoA0OkrQ49M61ps65f1Uq5jmKavSidkyOAWCnT4yPlHtBvChAwDlEuwxDjIO4vyOPa0UEUq46MLQULVbZC47Y6gLJuF4ak7ri/T6/1CFBo/CGdt+fapcwMbJTxkauYYRNIUqEvsbnz2xrMkKRtQduEmW73vgB0r63S316LzN+73b5/953Xm5cDcv5/2Pwazf57tze/JX34WyFRZ4NCCpxXoWFPCeZBgg/1wZbP2ltzqSH9JCYmp8PUsSz1aU16TLr5ggWoh9Atey3U63LL0PqquAzWxc1YgLgO083WPPfm3tzLJ3hewdqU2+t+L8mQ72GURYBanq3vNpu/M3sJhVMtZF/95jd/3/7m9vue+fLef7C/vW7PKju0btgB8bqb7gqZ/Zd6QIBSXoViA6pigeBZAZB7I4tM4whAa8iL5pnmWxX4OaSvb8pYYonpw5WFxBH8ArFmD2BDcbnVoVMkPXmwGKaV69BXo5j4yi2f8cEIcd/hCt9VJlYlqXVAJ159R0xXAa8iO0X5duFxQyUM0pv/xrvvs78XRWmcpChPeZsyNHtTd+6eyxN+3qP0kxmI5NNdmSqY8eisTR33f/fhR5mib6FSl32ar+VTvvuTtuFITeYZnryz97f6sTzrq3XnP+STC0Rr2XB3OCn5tj48ZxeABSRy7mQmKi5DVwuzU4kEv4R8duk5l40bAgi4RI/LybmEk+0RwMxuoW+QA/ZAdSvQwqPCti2HqU+zGEd/yijw1Tpj/ErXHnZNY4dFu7u75eXjxwFkdtyUn2lbvmkHyKj3BuReWl4tCw6XtQAL1JOKuooV6bDWTeQH9T2o0eLKWJDGdNPypUXsuNyglLWMuTpNlj1yBxg0kegFPRozBI7KgwQIpkzSkqNA+kfZkZ2bny8PHzyChjtl31n86A5lwwe/+nX54rPHoZvaSXEJwckcbZu4w7THqR/p3HQdVpc+BgJeO9OGr6iWHn3g5D+HUkO/fEPrjtZcAZc+k1mxAXp29KCSh3K17rZzDAWUQ2unLjS2uTHG9qnznc3N2lnRAkUd2zm4QpcOD4yUifEJ7nntlHcF5GABeHOI3ckJZ8caWzTZ0OYZphZgytPwM+CoPU1nC2DnkkzjlNeh5DoyYsux204AOt1ajsEMhnmxbAGKAuTwpmuVHpY18rmxsUVH8Bo9TYfNkBrkb4RvTS0ulTnowkkck3QApucXEmLDxdpdqkr+EZjaoVKU8Pn/+q3O6KHwMZlXNq+bycuF/JMxGmFJWWMps2G4Fq1D47hV5r5zRJhewPlZW46EzhHCmp2p3/SU2ijBGQhkAcAyOwESRZC6AKpJjvCf1w1PcU5lHlGZN1Tw+V4XQLOTtSFvRgEvPOOwwwjpK+QvRyHQ1Qflm+++Vd55sFrurcyVR/fny/z8TBnQoRElrv+QyyRcjLTKweVg6Z1fJ4DgDT2pa9DeCADM3pxx0XYgWMHqyBnC9uy4TMBEy5TBhcCNpj+DYHkbhD862iouSOuEAIc7ZiGkcYTIPRhmnvpytQCHZA4R3IcAyDO+JRBYGKE3N7AfASRhB3zBoAlRQUVxCgNpglU5VGH9GozRBty3paoPGFv/nq3pc29umaLcPNvfalr1imnqOEBLRxAZgsM039xqG9e9ae/mKX/7fZNya9JutubdMBAP1dd5BrqgCStzweDN8GNmjfXvnaP09B9sTQrWDRUCw1+QBtohi3C7mbB5y2dIlw+4CLsKtGay/5y5pI5nJkYh6tFMa46U72/msymbW1OO2+umm2v8hkb4v57HCgTF0ziCMa08ggs0RPbEFbPsfCtltF3VkP9/3O6Wze01PbzOl+f1/utn3txtLzeH1QQwPu91z7WGNSBNQabTbIYmEWbRdXmTKtKqorXEeqOubsGDT/gd+QTlMz6uZammLZAygKadHJ1sFb4uvqwj9/7uXtkHpCiUBUqJ6cfzbqSWY6yx7FqSTM8eevyk+GRomT/bSctCAwDtMKiIaidC0hkgbcAY5aI4yAMXMD9Px/Le/YdlYXElNOtX03nob03d1R8NfcAf0LsrNDSuCfqkRRHyvj6qgh392Yyu/vzZs/Li+XOUGeCAcuiTJy0rqwVNAlnrzmv5ltdua7zWfXb5Ped93u9vDgmbIZ8JWPYiaTh6METaI9ymtdJ5dahOHh2HtxYBXw9XlsqD5cUyp88n5RoCoMQVxEYXtNBOgxdX6AQtN/ozUXDqVWfr9tRULGIOYTkUbRtdAYiUkeqk3Z2tcrCzw3cNIE7NUCdn3cNyvE+bb74qh3vbmeVuXhILEvCVWerIXqO6Gxbj3qO3coywpSFdcqfOwoOPOUYW0glHW8K+Z6VcaA07AlB02XvkvwfYoMx9532DoLvrX+2wXqLvu1NWgV7a3upUxpMXh+THkBNTM7NZcslI9xmGgwY31jfKj//yx4B8vkt9q/zv3buXCSMCG/WlIykTWg4Bq1qkdPWJLzWgbFyfMu5L0/o2GQB3a2uzbG9vlwNArMBE3cR/NDJ6Ji0r4JJU+B7trp9yncFPupyHHr0mfVGnTiCRDgRCjmA5Ye7YIUv07cOVe9DHQPniw8/Kj//LX5Wnnz3JfXXkpbL7EnlwAe+dAFhPDVwMVmD33KHdM46hM+qj0q0/qUPqxuHIM8qkJVIr3slRj/beS+iSU84pNHms4DXBWsmn9GNdGEqnrmt7k6HgDriAiiqGljG8SHturrRmZgISDYTbpm0WVlcSo+wAAOuaoTuG1KK6jvl+lXr/lZvmXp31KpNyIf/xhXCbBKMosq0sSL+hqHAJKr8ozN2t+e3RXuHl9UiiaJ9x2aZ2mQoLkO9olr2+KDOtwTLbHimzHFcmSnk4NVRmR6kkwJpTUR3nB6oDdC5o/MvSGkAIQURjCFaBUdteSveoDIOEB6lkgdrhKUSi8+/kVLk/P1u+tTBbHpCWwd6OERuuYRnwKVgEiB2DyA2Id3zodOQrFPMNhOu0eFA0lR1lDTjb/f8w959Lti3JnScWqbXOI64qiapCKwCN7p6eIc2Gxo9DNmeM4hmGRj4FH4FGPgGHZkPyE4XRxozkmM00utHohqxCFapuXS2OTi32zp2av9/f18rc59StBlAFXHTsjFyxYoV09/Dw8FA0sgkJnnzXgM0sTG8VhvkeyH4w7wgB4Y6O4BB7QQNdRILYIs9N6jJBZ+S5aEd7+5HeHyzdtNXbZxAwzIyGmanIELy2hLNaqC/Dt/cWboKumHWvMYr/uHkdJV9pXusAMPfvbybmt/reG92hizG/cZNU+Db+vacLG4O2j/8a+Yy5x+nKzi7pwbQUcmSCjgTFbRYhZ5hOQPsbO9Cxjq43MsG+ODJxS2kZpOXlOdzQiji/F3TL9uXQrRmvd77HhbkLW9+iRcFveo6R1pyjV/PNp3vDu0LZ1BTs/ivK/LdhqOkvWGEYOI5Z3y2/9nVc+63qYn21fbg+jH7pNIGBtse5bgUVhTC3mnv4sbspfU8YeEymQcGJHZRrxZxasSuUGWfNi7dlgPtp2pnlsiAKWFl7Rts/ZZTvaN93R8I1APJIi5q6SHkpozVPmaWt/uc79aopEjonw5FHdmN29XDxtdMgTtM4/ZSdzXR+/ZouNSBi8gqGf+zRBiD4u7/x/fb47feah2l6TlbOO6KTUFi3/KE54khNumXsZdV6FQ8ogU9egD/5hF8Qwo5NYfOzTz5N5yU9CytnDYSXmhDrVdpGssMdSsNt3fmIFYe99Xv9NBFF8PeX8QLfE4bPllFHdpkyGLFcbpKa4t0d6w831to3Hj9qjzZKG7aI3yQ8HMkkWjG1YwpjN2qFiKdga3nNL+fEwQfFdTQWPC1RaTY8GPisnSB0nSBQ9Ms/Zq0LOPEexv0Xz9vx7k6EM3fcC0utfMMrpyYnZjIV6L2YOadsfoG+iupIf9JVcpPuFEyw4kmtGBagt6uLYayL9ZEmIoQqHJdGzO9qwtxBqVZMQY74wPt+raV1dfmPax7n6+Ly7QdZ/yUd52R+hBUvef+TP/qTnBm2HKFhJVpgDyx1MKAWLJolcF006+a2uUxdev2fB7YKp1dqgTzv7vnzTB16+LhltCT2NS6LSa1JQ3zGIpjctQVoX5tNJFrDKbiQn0KZC/gVflwjNj8zmxsHzsTDzm472Nlvz73s/KXuXQQl2uXRaTtDoLlB8Do9PEGARiCXLdMXXw0RXE9ovye0M9qaV0g5K5ILx7XyjvMhaRxG6HNJ09kp/Sr4Fu+Haq+kC2jMZUXLc93ZgOCxNLcIqghoHjS85U7eBYQOaM1uxE2H7vL2AFg3FyEmtFmEXAXluYWVPA3nobr7Ryfto08+y9WMfyNrxk5HMKk0YpgbhGGDlTX0kmhOt6YCzpmKPHc7OU8P+4k6M42V0tmZFNPtmS+dJsLWySXSJoB0PdgVBB31IUIK6IzqeXlpsS3MevI0BE0c83JniUQlEUyCoezEGozasVOBCF5qlGxUMtsXSPgH3usIYk/OYH7Uh8xhhDRWAHY99JySsyD3EoFtivhLywtta4lRA4hdYJSmkKSa/IJ4rg97uLYcpvmT504/MrIh3Ij6X0CERwhjp4zipqi7V7ecUdJZiGhrZUmeljrkwELgdkVa8zCJId/ddv7y+bP25Weft8Pd/bY0N93eWzluK9fPaVxqAlzIioVI3NqtsAcoIpgVbmQo8kLwgsMRsu92KoDqNZPGjl8/Zx58xj+f870YQpn+PX6d1Q0fShoVWUadEvRBYhJOpp5A/X+yT5j+TUM8HzI1/Pv87sPgps7+7uojQBOrwhi2piaAMSMZ1w6MYDTuierT6gUEuxFN+KoJQtseOaG21k4qHXn3SS3NwdUsgvNZW0MwgwzuTAQRAFHTFX4ADv66cqd0+WfHqcpceBmHssIADHt5ehCGYbkKVqQkf7NYKRvp01Z+93/1v823v00jIzbXceuvYF716oWvoN533cF9mXzrbG8SrotXwlgJYneWd/085NIdyx5l4XoxjyJwkFPTkyREGmrEnFL05HPbXnY6Ee/GETFtkJC8wxPgK3Aa0u35DtbvY/mXv8IP/AZ6kb+odXZtUqZ8aGuFE+nbeggFjXgBh7QwR/bWq6ZmSjug1kJNg1OUauPOwK/LJexE3TH9wccfty+fPKNDXG//yf/wf9TefucbkCCdlHWcKEEsaxhJV6uJMBQcVFnih7W+8sJaNA4MyNu2qVbCwd1Pfvij9md/9sMIZqW9m4nGMVmFHqXcLsHORFMbaz27/LogCl75FHcFEy+KM722CBBEyFFT6EDZswAVxpbnXTy/3B4gXGwhDKwsKCQhPDYG0vDxaco/TRqlTWHATl0UwhcXV9ri6mqbAu8eE3RNe52Sz8/XUQhq+MSTcBDvaiDtpF1ztry00BaA5ZVaKPoyO+IDOubz4WmERDV3ERYos0K+GhDvGd52N9+732hzCGUTCHzyhqxNsj36o6z2cx4OrQCG1MjT6UkP6XbR/ghcIHxHs0TfgV8W6tPHeQi5/WV2TeK2j5Sa3MXoLMoMg7+pmbnspl1aWsmp8+ZvXfV/8eJV+9GP/rz99Gc/b/vQkwOJeQRG24VcSGHMNZLZ6NLRsv2EawVdLymM9g/22+6rnaylVguWK/goo4N8tWn9Epi0bHDhbklRLZ1lx6lox4praUBlgTgwH6ehgRRhS1gV9zK1zJYBN+GhYGdeMhKVNy4h8LBmF/8rX7i70iU5Hp2R228QXC/ox4fHp5l63t3bCTyXgI0aPxBS+AfPp4fiGKESgcyDfE/ga6+ePWk7z55l56pCl7tPhYV5eP+0BFDT4GrL6l5tYedab6eTPRZDALgz1WN2TmnTniNnHNtVBl/weOPUPZo38CYEsWlw9jchjB2Tofcs1u4igEZBivmWBK+k7jML+rQUwN0rqiRdAwJ80jiLId5bGSFCLoLLLAIZowWQlLlxiMSG7YnGOW1YqR7iPL9BaKPJnl2br0dVKJi42E8mDTGPEKTIz9PubwHmBQSg5umURgn42i2Cy+0sQINQruRUbpfGfcvoYgBtHAC0PYS1K6TwBwhOv/mNGoU41z0rxyGfWfOkbG+vr4aJ/eT5TntOQxioCgUGuRD8jBEvjQ2KZBQwX9uFIdkRgNihwofYaxqTiw2XqKPrJU6Bm6rqF0++RCB7EYb9eH26PZ540uYmR50ABhPtCCVrxWR0Nhb87eTGBRgJJu8i0Nexb3f27lvFxRF/n3eCCKYPf+f22VlNxbl3kxzPjlao8338PkZnEvYulfykC8Mm/7t43XfC9iNzHpVaktW/ytvHtcP1XJzZ5WUaK8K3DJ4G0ptEky5Dm/7Dh/RlgG6pVhjr0yyme9X2RjD/67O2gTBm2CpPWU39xyCkm57x7r+bB2GsFzb++OZ6L9JxavWSgcRYKilbFzPxnGb9x//L/02+/W2aEsZ+0fT17AUqme49DPDzF3eVvach/Xo66I3vvbCkDT9wQIXbZRGnjIzVVqlloh+OgKYwZpvLFCXtx2kbd00OaPd1GbhC1TWDQdJI2mrXsDwVViJQWb4qAH8llGnsRPp1ZZn+BP85ssK2Rpur8tKmiWNN8xdLevIfymwbqovAoTvSclAgw7cDChapwykDA0f9L+gAf/b+z9sRg79vf/t77Z/8R/9xW1xeo6yUC1i6Y0z+akYhwypm8vQleXfkXPWwo1MosJPETV4T1FvtmGt0/uV/99+3Lz//wtSSlsJYBsiGxSiWkWrcGpuDeZfpMu8MrVTyT939YvkKx2oN7LRczwOvBG4OHhWu1IYpmK0szLWttdX2cGO9ba+ttSX48eykgtc5lo6MDs8r96ZskwhhHneQ66RI14HV3NISAji8V/jSVmfTmSK4gCfPqorgR8dpf+O0n4KAmpgFBBgv5R7SgSuIjU5P6NjPIgi4wYHWlT7Lga1XGd1Sdjqe9s63v9M2Hz+m30AockE836yodVbo9EozehOEFOjvckgeCBG41YSpdQEY+NXT4x0uzi4Q0BEI6cAVRLzgPsc5qe2hriJVoUANy9x8XWK9hLC+gjDovaTSBoGy+/bPfvjD9uc//glxEWLp7K3FGYIJyUaoWUQQK42YGjY1ZLWTUgXFzs5ue/r0WXv65Gl7tfMymjGn8fo1fdGq4q5zMrXUWdoif3cPg9bQQL9OOWdb6ofb/lU/NbQODIpeih5yFqbfDMOX3BZDftZLlCt4ZwOACg2EMvGYqVTi2T+e46eW1J3yHtOy8/IFeDzPeXS5HgtmoSAmnvdfvsI+b4evXrT9Z0/b7pMv2qunT9rey5f0CV6q7oHRS8AZXgK8HBjb9hXqFNCkJenK1nGuJhMe0/MVl6vcDzqq/3SKU57h8RZOI29sbEbTbbri+29EGPMgxVsqXEwYK8DJXI6gnwcjiiTPsVEydP2UuwOlilJfloQos+hHoVYqCwSzHmuyHSP5qu7LTfSGl9NMgwQIcYQUtXdykZP1BYwNyOkLL+POoYg2BwjldgbkupV3yQ4145UsPNvcXGsbD7fao3febhvbW21lezPTG3MIYccj142cIeWO2vHpYV3eOslIa24xC+tVf3tEhwhaWHSBKI3y8ra9t+XN/xftw08+b5dnwAZh8YZGpOo9J31TD89u9lBYO4RZ3PsQ2a7woT6nNKA9GPGpI1WJHAQfI9R59orbzpWsv7k6aqs3z+hwaCDUJ40E4qhjLGgoEHSIOsRQDcGWI2rybv07c98R2qg6Z2dk0OJVnIJRgigQ+cGAfqu46Xg6d5i1bjP6iu9h4H38Chzf3hguX30aNPla9i6N7lnfq07alDFJ5aXzJ278urpnmFZ5zy6uRqPp2gw71Whz5S6k6TRbYGT0SrTVHai1g60ysrMiXehsf8j75ahtztXuM6uuqZzu04gPTgXH/lmfujqmHSVGOl0Tuoa2zz3fyGC9uYsLDKp/bb/7v/h6hTHzTl2lrbF3tUf6ZUTIU3hl+pBvKThWYaI0Sq+no+15gM+4ac8RxmgfnpLt+T0nMEynnOzgbe/2gE5RKSh7fEwOigQ+7lbOydukq3BoOr2gVVow2hf+CiA5/oD4CnGWXW1BpqW6Yy1Ke2CHqFag6kYyxbcU6rr0TNeO3o/ULNOBaqvnERBc1+o0jPffOpDz/knX7dgpuo5H4QJgtGcvXmRN0n/6n/6P24OHj1uOUMBmW75dFWUu2pJKhV+idXCs95QlPLU6hhCJAw9gZQepJuwv/vzH7Y/+8A/bEH5p3exwFHotufW0ecqfzcNEfTdfv9uO+F8m9KzlL3CpUHa8mmguaSc2v/AmnnbGCiWujV1fXmxb6yttm4HsukIVAaMRw04p0CCIuX8RZGJ5T1oMgBSkyMPdtC7M9ogJj5bI9UN887R2hWj5TN//SFN2+pkhoSxqVUYnp23gUUGDYU7A97DvWae0rQ/tXHzl+Bk6f0bhuVT64XvfyLqgW/AI8PheAz1honB+feWdw9DF9QjeMIwmzGnJmoL02U9JUi61Og4uoGU3q3jfqBsEcrireJO+1YRNzeKEllZW2uLKeqz+Hv6qUKUg/4d/+Mftww8/Sltx84dn2MlfbDdqk6GK0LdwqVmqBv4HbXd3L2sHtQf77i4dgXsEBWrkQD/HJdEGrF+OcjFP8Qld2B4U1qQ7yUCalx9nWpwYuuW9mTLXr6MF3+2zFXiNrwKltMeTJfgAW+nGs0xN3A0KUv6zJ0+ypvPxAw/lXWhrtJVl+mWnNl8hhHnagNcEmr5tyzRv1KApjCGs7iGI7SB8vfzyi/bi88/b3vPnxK0pa6dQVRSJS3mHMFA7try00mY96Z93lUseHD06VQt3EC137Y6mmFQsR4VAM/3ATVrNsTZu2qOcSwyulqAhB4+uP/u1hTGb2xGVh8ozKs1ojdL0DVcGLCOzXYZx0vCsnGrhnEWCO0wRxJZ2rISxAILn6GqqHUDHR6M64C4LM0n7yt0wEKC7Y9zR6MLHq4sBEu15LvtWUrXxO297jFAj07QhSjQzjL4W52fb2moJUu8+2IjKdpIGcH08aMNzGDcjlLkBaQKki4uzNknZnQqsC04dRcwhUApY1yCBbPyn+D50pAZZPVidZ0R+2U4OTnPGkJqTc3jIBITgHPw8cHFHxcHxadtzxwaQXHQxL2WWaS8BywXn8ymnh1neQHQ7CGKvnj1n5Hac89TeXthrC7dHGWXXfZPVULRhdrSwWtwtHqphSPA84g6OhKbu4qHl0/8zoJaG2zP3YDze9e4zHv6PX3UQMuz69vqzdxsn78a9S7uM7v5bvmNoE8CQxg/+e2GlT6uEsbEEiOMpzHHxkPasYB+nwlJO0ptZWIqiytsjApO0JOF1by1C4mDdMu60AIDlz3LEm+Rv28EZ+fKyNjns4NXHJQMB3JvO/+7ZmwIa5Sgap1WErhwJ39ARjY73YdR01H41bmciEPgDRv/4f/51CGN7/Ld+1r9wUe+97YWvYoL6WUa+JL6mD3cfx7Awczs0wmpeE8bCF+ikHMjQcana94wxO5uct0TlpYtMH9tpwBtcI+Sl4BcMitKh4G95TEeT8wi1tJF+HVCmHWlPjny1JYjVuUuGTzvCymB7ISP0x9O03Y0pv9Ptd+sjA16cmQ/PUBPh1IZM2kGT2gTzlPZMc2MdBg2zHlC3Z89etm9/+7vtd//pP6ewalyAF50wGC9lGnHG4apgXnRX7VvjNFkGtsDIYwcc2NmxJm9o5uTgsP3Bv/799tmnn3c8QF42nTV4PX7SnvmRW/LEEVKNo7KpR+fWJB54M6Zuje3QqUL5lPXuNUMeqrrGwHaNPmENPryCULYMfDyXkUDkekXH7nQfAhJJeS4a8hl1tIMFN+BHZqc2wrsmH3iq/vZ2u6ADd8rQqTl3matxGg5P6UDpbCmTeFAQc6nMBf3EpdYdt3bGlJ1P1EEavCyhA1i7LMbT+6+g75Wtzbb59ntt2oNIGaR57JKwSt0Jbzx3R0426nBTZ4nlPDH6SoUvBcCc70Z+Hi2iYOGCdDVgakrcJOIxCyolwAr040azZQQvb+egXl72TWfuGrVzwrt28uWrl+1nP3u/ffLppwheI+hsnjRMU/p3Q4tt4jpryi6cbuzo3d2Qn332afv4o08yHemMkZXJwAbhSGu9ZIcKNQpSiBdF49RZvNgaDKPNEhisAq/P2M4duiIhqDhCmOvWEtd0tNKwtAMM7Wul67R54JM2ifVaM3c6bmyutwdb21F4ODV5hAD58sXzHNz7/PmzOocT+DrV69pAzzI7QuDcf/WqvXr6rO0+V7nxoh3vw1udsib/zDBhlTWUaZBMCq+Uf2FxOe1bwbk/nuPo6LAdHuxlmYFAs217MoPnuqmBzO0D1E7ZwbrbdkurzdBCOiHxS9rpry2MmZiFEXjVedmAtX6VwYJsgCdxqhlTK2TVlhm5ZEEdJavpA5muBNy5VZFDhMfnU+0Q4WhIWE+ZHvHNBa0KWjI314s5YgkxQKBKqvZKjopztgmN6+hgt50fnyAEMtqgMWbnJwzBk2+XEaAE4PEJEu7ucYjSOWbv0JqF48y7o1EhDILPeSp0Aq5Nc5zhvOYywFbF7chuGqLJbe/U4Z2ttTa8uGk/f/aqPUcoGzLKcfePR1rMgECPjttkVDI9C1OAUQwgmCWAtjk305aB4SLPjaW5tjFXalvPR9p58qwdvHgZxvpobbY9nH7R5idIj3pEG0YZShhTEhf21QgyEuncEngahD+efSMYNwZLWN3YCn8fLn7imdgyRCP0jVCbBLTJqxpgz6TyXWPH0qWon/TRu/kfd/L1Pd+wNlJeK0hXH/yjwaI8WuMmn2gAu/imRxr1XuWuLBxJwlIYpVyeuU7QUY3UaadGOPJLUJ/8SXOTMLNppyqhh1jTzO+mndK3nEMZqzcHwQEfzaQz925LGWOZzGcsnM6sOaG6VttLrrOTkk5BYSwd2FiyOqteOm7b7/wXX6cw1tuqw/j7nSYsMfDral2Cc9FPhSm8GW9cGKvOrAZqcdOu5A9OKbq7cAjz9egHly145pj05AhTfiPM5Dluv3fDzsXVeYQyko2VvzjAUDizM4qGAF4i48zUtcxUpq/ggK0wWgc4MGqYqv7Sj1PY1sfvCwgVxpVcXA+mhsOyu/Xe0b1wySiZCJ4K7s9OS34ldKSzHAtAdT7/4knb3Tts/+Q/+uft8VvvUmYVQrfUg7ZiHC1GWFkO6a/XkvrU2Oqcecj5SaHtWmgtx3Pkrwbo048+bv/29/+gDejIhJ1w9lDNaMT4ZYmH6ZOP5e8S9g/rr/KpZ1n/+eyF3gygOzyGJ+kJH3Qh+yLw2l5did1cWc6yjawjIwHXheUQVMLmTC6AoFCkIFY5CzrKSAm999FZvCH4nl9eaetbW7QbBzJOIZdgryZtcpoywC89dDfTVrQrr9/JDlLoCqmlwpG8PPMK2hE/rqPyANSllZU2ywBuSAe7sv2wbTx61G7suElrhHAlj5CebihvhLFL+hIFyVvqSz3KD+FIAYynxzbkNPoL8EE/cUWf4WJ910BeuFNQQYyOW82WVxCpFVND6pS1VxU5Q+PUtTM/3kX5wx/+WfvxT35KnavvdQdl4lAnBxRO3+tW2LItKajY53kGmXdVevyLbcF2GJiBLAcWoWnLQv2i5QH2klnghMPZFwWz8Gzi+Iw8wDP+ROgHZn24KRA5DZ82rjQU7VrXl5mufpZD+nb9lYMsb0xQwLLM7777bvvut78T7Zm7H59++STasqN9BKNTF/cPc4jv0cFB1rp5R+yRO0CxJ/rv7mQdrlcMzlO2tWjXFmmrtBFw79Rk8gYmWtugdOd0toe8ei6aG0HcyHB8uE8bcmobeiGg/GAdQXHZy+vBhYonNWMOtD0f0OsM7T9c+yr9evPOry+MgdjjkyMaiURDUcUET9uKD6/RkHHJANVWKYyJJNXyjtRUAyqM5b4oEN0LYxKhqvHTq+k2oPAZdUCgLmxXVbpIa11wAT0EqqTs6NPxg1j0fC7P6snlnAhSK8tUVA5EvKW11ba65CiVTpWRsKOs0auTdvLyMFeQXNF4Ds+HOeX+BCZ2TOM5dKqSRuvCu8uJpTbD6PW3v/dW0skOGejF6zkkIE+D3oQpP1yZb0MX4h6ctc9heq8A+iuI4Xx0BfHMtHmQvED4BeK949SmDAUG6ShczdqQ7x70qFaedlrHWbx41Q5e7mSdxbfWb9rS7XNnWWmormdRACubET+FKQvhh/jv0JJ3n+JLYnvTFB7vvxXDLxP/JFK4Tlh/CT8Wt3s3p/KrsPfmPk5v7uLeuSlBXzzcvVBUQcbjl/s+rjRYESvfOLvvvvu9f2ckxAjz6vwMQec88DOMJtOVhrOuqS/whLFFGAtjGU9rsg3A7RmYXb5WGKMBjoG2L1+fp0Z6x2PMr/JTqLADsxu0LLmzknY29D5FRu8JxNc+XtKVYVKU3/oXf/uHviqMjeetCY11theoUq7YsO7YqnIPO98LSIaXyScANotstTBKOw8h4YJy14ipEVNz5NEudlo56NJFscKNdBWws1OMcqjVHl061ULHYlmAkcKFbTYClgMtNVUKAQuOutUU2Pk56u87FDoS4ro0oLTOnRAOfVjubJQxEOX0nCWnRmT+IzoDy+jg6copK8rq5qNL/K7cbW1YRvcX0J6doIul9xih7+wets8+fwoz325/7+/9FrzKhdnShGfBAzNBST1SNpxqeClG6qQglnUq1pM6eyYVzJV3NRk3ObrBQ669omawf9L+3b/+t+2Hf/Yj+C0wJmGqEFgJFzgzqZMZiU9OyF81wkMhGz/CTpO3mwDkg0YubGqKPkMTwo4YCmJTbne7ZshC+R6sLmWX+uONtba1vNzW52fgiYQB79MILm6UmoL/TgK/SWA3kenJ+3zEpQLTDU+nJV0H7IGeSFttfWMjh/fal5wOjtrZaNCm56ExMiZ4rIKF64fsVBXI1FQRAThTZ/6uyNsNH14NtLKyhiC2Dq0stxGw2j05bW9985ttmm9ex+eatZuQOSUT3sS7oS9RCFOjl1P1z0f0L+RxyTdp4MyF+8AdAex86DSldK8AiLB0qVsopqQIKS6tcU0YgwPKsLS+3da2HzDYIBD1dhPav/2jP2pPvnweXA5J293984srxFe4cLpM7eoEdHiTPnkawczyDE6hVdqT9L26spr+RA20eKtBJfBW4AqtCz/bNDBEmJIUpbVQBM87Hk1TjkBm9K4NQbl5ZioTt8qLTFUnvulXO7Ivk1bE7xSduYKKy4Y8sqPnK48ePGgPt7dzqsD7P/2LCGF7O6+wO+1k96Advdpt5ydDBHgEYegJ4aNd0ybPncUD5zP4AdE2x0BpkUIuAY8VhNB1+vTN1eW2DU2ukOcKcsrm4lKboN3ukearFzs1lU06CnQD2uvBq1fRtA0Pj9s1MFfJ5Bq6RWhxESE6sJEsIiPJH2nL1FPFkdckXVJGB42/tjBmQmcnXlvAi4CiYmFUZOoILheIUtEsxkcaV+3qiFNtlhoqRx2ObmS4vTCWM24gKHdPHp9P56wuNQKZxrSTIm0v9qZWbYGRrPnZOr3mJLsuaQSuRcg0EizIsszRYDZc0+XIl9GEZVqC0FQtnjzdS2dsaOswsmIQLeODtgJVORpWAe2IW4b4Wz94t/2DbzxS+VwjYXjE4BhBc1Bz/rbJ7eXFdkyD+PjVQXu1hyR+dJiRyAHfncp0OtKLwg+Ax8kpTJm6yAhtWwOKcUJdjxHiToiTBqdw+OplO947aGvLs+295cM2d70PLFUhO1qnwQF7F0HWFAmETb2r4RRh37ljZetl8j72yx9+Niaf/OtClulC3T3DgBLG8Dr9V099c74QxoZ0b7o0urTHn7173BhXEnsznLjt3/NMxnHc+ZXH2Hu+Gc938AA92FBcN5bGTnkN2gtgvbEaCuTuaCs67+pTBaNhjdoQYX3+cp+RVnmPm5S3c1cG9Sac47ZDw5puVORkmDV/GcE7lXqcLfem7Lc+vkanmqZ/9D/9Lzufvz3zpjD277PpjDv7pr/PPg3fBVjtXqxzfGwvujM4w7q2sj9tX82Ymnanc9Siy2sCN2wWctPO1XypESNEeEFpwOBHCmAMxjzI0vVbuQoJfzt2eUyHhsAcsohNOWlBanrFfWiIQGl/4Efh0dFzjhSgfHbuau30DxOmcgpl1kFNiGtXHEXnXt7UVSETXnQyaC+e77ZDGPv3v/+bOVvsVpqbpCMl37Ra4dbBz45MwME5U0aZSDRjWPOt5R6WAR6ikEUaauYAdPv8k8/av/q932tHh0eBv2WQn5mFnaEOeVI84Id3uMNta8zuwtCrYSxFghma9LrwfrdMKRJc9GrUZgngQv1tBrUPEcZWEIbnyX/aPkA+H3ue9ZdIRDXrQnxhLy2Yu4K0U4bibpJB9bUwws/1dGoQHX27nlch25K5lkuEZuYgQgkCDzw1a7egJZ+u99GfTJKPP2lke+tB20AQUDsmT372aidToo/efScbBBws3YKInsbqRhk6VwSySaz1dl2YRylkXaEDCIQxd/5JCyWgQxfUVXp2wb1rxkA6eBDngTbpz7WFpVWEzI22tLae/s+7WL949rz92Y9+1D7++JPsys1UPXgWPcIs94pSLftUaVm8uI47l5cDTfFnPsLUPli60dhHRjPVf4fOXbgf1hOaNn2wgSM8TCPeAbU2QpfvelOD0I5xtSBUwdxpytKU1Xf7LVGVsMAzGy54n1/0Boylto/w49o212/tIwy9QgBzM5vt1nykt6kbFTLKBiprsNTDtYFebeVCf5U5C+ByA8FzY3W1bSJoP9rabG8/eogQBj0SbmVpkX52OU+vJ5MGnZmLRttBIWVwuZDr0w7gh4cIw2reRrR/8RplUOgY3ILfEsSon/RHGdSgimu1fS6x0P7awpjHNShtBhUAL+psf8EIQAEQIj63zMN8PLE36yosEIzSQpUwJhNEAHM05zsNw5Hw4HymDW0kAMI21mBKdlSqJj2odYnGssyIVpWn2ixHzca34nKHEYR9TsN2e6kNTrXorIQAc5LB3zAKOT5CiKKxnDFi8/6zmdnFdongdVVVAPFTbR2CdpfmcGah/eY319u7mytRsUuULrIUWSPSdEG+U6fffLjWriGwHz3daTunCHqqKGk4JJE7LEfYE+wxhORuIu/atLGool9TokbAeoCwpvQuE59GWNyl0Tkv/tbGdNuefkG8swhfEcTydCqlRhXpNIIVgMBDBl0Np5g4Bc9XTf8ej4QVf7aBCmvI8iM++PWj32MMbwvTaVhwmLC8EzLf01F238uA8/h177q7b/UU0fdp3fl3bk29msMb4UxTZ76XX3wTtkziGsCeg7xy7RB1UEORTsQqjtXpXnAwH/Do9LJTIAa0qCFMGhRtYTi10ubPEZQnoYnKJZZC+r/L3PLc23jnf5nAJgzKJ/gkPwoRYexieEyc+/patlqbU+a3/sXf/t2U48JY6GHsOV4v/Xrbv49/1/ZxEh8Y9cKXNoIZ7StuBIoSxmjjapRo5znOImFJxLSx6aTtNBC4ZOZXdIQSYt9R1hqwWowf3oSVDBTasrMSm4EhiZI1psMbGMrgBnwE76EFNRYO9mqnuGeTWR5HvskLGnHKJ1OghJOPZOE83+cZMcvD3KGXnW0KhnTs83ML5DGXowo8W2zFTtcBIWmRY/2EGzZwA2bpQPmVFk9/S2fhrYd81LVWfsOX+un2GJ8/+cM/an/xk58GzumI+alh1VQdxU+XlyuE1Fbkh9cdPfMk3zSl5FtP4eC6IpHjNBAMHZ571Vbmpqrj295uWyt0sMDJzcdqw1yrdYuAbRmdmlRgtBMvuGOBW6aipxkmK4TN0C6EC7x5pPCCQOa5bE+evcgtAu+8+15OmLcDFMb9FJILqD1vyg5TQVh3BDGs8DKMuPL6pI3tzVxV43or6c6zup69fJWNAo/efbvNLJIWYRVWFP7lljfXlJ2hOj0xoDNdtaIeY6HQh3UGhn7JgXtOkuddja/TgG5EcZpS8Fpuz5JT+eDyCDV0c4vUh8Hg3MIy9H/TvnjytP3ZD3/UPvn0s6w5M42izVKKhAx4Om1pmtKvuKbV8AO2lFu6kYakA+GsW/o1nCY4pwzpIkSwCQlu/IIb6SMWmpEO6F+rr0lMySN9Qeg1toJJaqVxrjRMz8GCMDQjebA0Jy15yv2HH30UmM0jHHlOn1o9p//Cs0kvu2Wpj9E92mpeuYB62M6W6Utdi72yvNTefvxWexfrmq4HG+AXP4VCBysKWS672n31qj378kn74rPP2x749hBoz2y7QY5wduLC8/+gp2jB6LezphB7RX/uRpCTk8M2QC7y3s0cHg3tREPuwItyu8TCaWAFM9dR/o1MU57RgNxNYF1oKYUUfzJH3DI9AeL6CTVjIzo8dwwpAUcCB9Djwlg/Mo6KHTo+vaARQLiGm4EpZREihZ+fh4jUigFgGaoahFFHyBc3IHXORZVuRwWZSKjt2DlehLE5j4uYjfT66vlR2985aecA85Kyz3gKO4ByIb+NcqQ6XYYCAgYITHMQ9MLaQvvGg+X2LS8H9+T/1RUk6Ln2YHMZwqK8w4v2YGWhffet7fbqaNB+/4Mn7dk+iAQmjuRmqPOmWrrlhbZMo3pvfbV9w7usKOvq4lo0ausQkqralRDXdDQAZwf77eVnT8I43ttobe3mOTC8KWGMMGk8wFytWHamBA/SZXUa/CuiFze+BnuY+lQeaW022N7Th26f4jMeSVuCT9jyjH/CJkj37P6N+5fThl3li4n/fRjbeu8et/cR6psePqWb3s9fwvlIGM19GoGLVlgEHhjqq0DmYYsZwYWYu/SwvTGfrEeCsUuHWQvDZzsio7iledBo2KMjaEWGbKTOjqVl+n2ZC36VtqbyBI/pHMu4HsUO/up8kKucIriYLwFsK8RIfNvRb//nX980pTYwtDyYcb83v3+Vv8/xeP5SD2x4AG0lbqwChYzMRckuVHZXmG09gzmw1t9DWYO/WVhRpeX0oJ2O8EoeKar5Vj7yG3dK54BM+Ux6G0NQxq5cltUpHDvou3JjswZGilHggW/I4zKVQ1tU+IuG2vYJw80J5HSsXsPl5oLaUYlQiLW91S4rd1S6K3ulvfXWu5mmnEU4m5hwvZm0ZnnEfcEtJVV4wFTHBRwMA19QG2Yw+YWdQK9xyJo30nK33L/6vX+Vw15dC2tDUPOTtXWmkcS7+tuxC+O0Wb/RDrAKd2ai5tsBRHgN6fAazZ+ComtvpeQ5yra+OMdA0g5wBf6HIAY8PTcMCQS+SxmcmoSGcz4V8bSKA8JeIYIGB2xdrD+jpJJzvtxdr5bKzVJudDo4OkIYe9aO6RAXlpbaNkKfh5cqdPUdvx1jtKrg253UtRaK5EkLokhfIj/26Ic5BtYqBdzJt7d/2HZ299sBnez240e5G9Hd+WqiomVSfXeDgICllyZdhT8FBrVu5ENemaokX6+xUxBzrVieV0CPfsjlORZDfHusjUJY8I97fmE1a8XUzBOl7e4dtD/5sx+2n73/QdYeGdH62ee6hlJ+UBoyn9IHHT7vCmAK3fKttAmeoXHr4Tfh1D1tIxmACH/Lxb8ITXz3aTvLmi/TD474gwYi/Es1ycN3adN2xNOw5oFNn6Vf3h2oiGPzIh/SdrCjxjAHJAMblxRYENdpZe03b2qgyDLrMh1oZbDjBp70jV7Mvdi2Njbad7/znfbtb3yjbaytBg+u8XKtmfe/Pv3i8/bF55+3p19+0Z4/fdp2X75sp9BQbj5QE39k2JPcBT04PIIPn2bTxxlpKP94yb5TzwpoaoLFf9YF8q6Q7LIFD4/28vOj40MGk0OqWIKz2l0HW7+6MEZ+QsIG4NkeAhood8gFCQDcpw1cYpVZ2QDcIeKdbwouMgoJpRfEfLpeIU8Ar4bLC8LVbuWwVwp/TqtZWEXQWppPY7xC8HJBI0JrjR5oRBKjOx897JXWlgNZb4YIaYRxV4kjnEsajmzMxfhrW8ttdXOpnV1P5NR99+5k95SERPyFRvmpw1tvr7f/wT96p729utAOT67ai/1he7yx3NaQwFWDPt5axa61B+tLbWNhrn3ybKf9+OMvs4PHHSirjKK2kcQ3F5eR0JdTd88/ghpzBplC5pmNEQIcUdcBCD4Goa5pOHr6vO292I3G7N3Vs7Z4tUeDcIdGjbijHbNhkI8ELpGWAQbiBHIV5jYmOQ/k3+FKRBqk8BUb0hbFxk308iOsbk11SoSp6Hdxe3f/TGq+j39PWn7pwnT+mvu4VYYuUKw0chc+fxVW0/v3tisWxsZfoz2ffIyvj7L1HmEMWNcVRJTQsG8aQUe5vDA8TDIw6MqDW7o9bYtt8mLQ5m7OSIty2N4op/kX9zMZBQHTM0G/d6ZLK3nAUJI+3mHKtqGr83ZxvEe8wsud0OyTtPT+7f/i6xXGxq3mq/zHbW/G3+++8+v5QJ5USHcWoSvwdMKYo2P5ju/Z6EMaCscKYU5LycAFb7RpdPAupQjUSS/HBmSgpxbMHVGkhxCtURPg9GVGq6YHzPsOym/jwpglz60WRjQzTHUquiy//KtG7bY7w6m5tsNwBC+/8OkIPvHAt1oQtX1Om29uP2LACS2pGSE2lE8KRZMeJq0Q2mdsU7EDE5wOYqtMxrCDBwamCY9ZmHWX6Ww6hH/7b/5N+9M/+WNgSedBPGlSwdEDctP5uiHCBRckntpKqtZbIsO61tbO1MyueDDkTVkMqobAUrsUw+cysPQA17e319vWylxbsdM0QfoDCkeHNYpGTOFLWCk4In4gwAl3Btp2VGlvwIin07Zekee9vyd0dAcng7Z/eNiePXvevLnkxDVQ1OsUwWyTTvjdd94mNW9jWQjteHi2QrqCsMKYwrQbLqxPOnD7ETr9qbmZHNJ9cjpsr17tkv4LhL3jLBt45xvvtRXqpGAIhYpxeIhlV6BS+DoHBQgLPK8uhwykRlEKuBbLq3puGfjbJzpjZJ8kWD1LrLAG3MGBGjEHfzkvDZrwSiw3D1wA8M+/fNp++Oc/bj99/+cIooXDokronj4kR7NYP2EKbfXnFRpE/LqJQXq+sw5mDActRnAHDrbB9CfSJmWxPdgvJgx9rnxd+rZNhGbsf0w/eRCGFx7dd2iBDxHCSKcEM+BFeft24zPCGNZBkuGcRZM2PebD9iOeFG5Kg5aeJBroZfpUy+MmgGXajVc7ra+ttO98+1vtB7/xPYSx9UxLv3rxrH38wYfts08/Reh60vZ3dnICv4cge3D82spq29rciPC26v2SCOMem7G6uJT3JXe0Uq4FYQKcPa9MYYyGW8deQU/RktFX1tS08tEgbW6A9VDnITSatZzyB+odTT51+/U0YyTkIvXLs0EAKUXcMdZYgAvyRJiqOdeLOU25srKcUYiSrQivdRrFhGWgJYzJfG/a8eVkO4NIBxDtOcKL0zbuCLl14T5pz88s5GBUWZBHX7hgX6Tb2AYecQES3ZXi+Hh2GaKemWjXE6RN3gsAeh3Bbnl+qq3OQRCkNyK8As6khw0C9AmY5QjCfvjWWvvd77/b3oOhUNT2px/utWcvD9sW8RcZ8YVpEe8a4XBrxUMEp9rLw9P2yYvDdm4rVUgkjAv1XoGUZyDoCMQNTo9oTBdtCDHUrqGbtggs55AEZ8iHLjkLDne+fNKOGZmtLU61d5ZP2vTlAXCoNWI2HJlINRw7DOJ0QlZG78GFjQLi9ZNNXg9N/+jfMYTuXBVOPOrHo8IhVPhMDn73cRfnPq2KW+7IIXGXzTc/JExfRtIUuN33mAS/f+/D3btL0Lrzj83nzrwePqknrEzDTo6yUTgZVq3vUVVfcaosFb4c9c9pQ6dK+rVDZQlP4zy9ptO4OmsLN8Nifl1ar5lkWvnyL14JcheOONJe957pCsrnNniFsdwDZ6ZG7cKIG5ne1zFN6Z10BcP7uo0/tXdCS2f7b/3zTT+Nrl4Q09baUdtqCWKl3meUCQ9RM+Z2d8PYcQkjOxTX75RWsdOmETcaNtI2zQh38JjEw1dcGz5HTmCjVaAkMnsSTviUl/o48i9+Js3VehdpKJokf7Y5KiGVWS2tnV6EMKy7MBWGct0L+SiMReNADPO5oJN2Z9z80io8ZYn44Bz+nuMs6PxCL5iiGGNVHhQn7TwwU5hKmfhoXUnA8iiMeQSQyzXsiH7vv/+X7ckXX4Y+7fTsEJwic7Bs3acVAslI6z8H+xqTDWSoa4qe1HFTEOHhehonwVwXNkeYBQrnfZKPtzbaNnxxmTIsKihYC8sKLmyFEcJIK4IYCbuMRS1nDtWmAyzhBGERtA3pD46HZ23v5AQh7KQdHB61fXjj3u5eNJxyK4VdtWE+H2xtte31jQy23FmnwKpmymlLhYMcsUTdxXOECuFHuZ3NOHYgfHTS9hD21IrZx7hT8+HjtxCO6Mdsl8A5WhzqJg3ceMp+hGLyuUH4ot3mLDE6ZgcDCmM5woJ62MddOaDQAmTf1YLVtLRCN33BghdQm9ccbeCmPX+5095HoPjxX/w0t8QoOIY2+KsBBBigTOIugqxCLPWp+mHtE+Tl+GWwIQFhpJ/QukklbMFBmEjf9i0lOEn3FS7tx3RMN3GKHstdfn4zhYKrKYVsoAH7K+MSwbzxrj6symfZPCYiAyis7da1mNFC266lbWy0zMDAuq8uLWXpkkfEfP+7322ba+vt5fPn7fmTL9vTL75oX3z6Wc4Es/2triy1Rw+32+MHD9rm5nrbQAhb8x5TYO2uTtuMig1nqdRiW361d0sLrj2nLQNnBThlDo9nmQNv2chIHx98K+jjdipT3LthJ9PUEchrilXh0XTN61cXxgLRBvG7E2VIgnZMIqi3gN+KUNgQNgWrax0uIn0CyQBXppb2LuPAKtVLlApl3ku5fz7ZTiBaGcUVhO5RGp5Y7462xYXFNg+TU+r2ugkPTrORuqhxNPLKJIACws8QsM4AzgVpPt5cbL/x1kZ2SqQSINA0d06GOSR2jkZxPhq0g9FxkK2Qc0sjePfhantrbaEdK+lSvqUFpHGEu9XVpbZBoxzCRPdOR20fuwpivLz8Be6/+PI5DVnV5BGEQz0UXHnOk/YydV+l/MswHE/Zd1uto3K32KrGDwMGHpdI388/exLh8sEyo8zZ3TZ9PQgCayRRDSWEja3FkFU9aD8MJ2rkPPHjp0rdb/gEX31D1PRxe1z2fnk3runzTFy/2cBMTHfnZ4TX4mONYablBdZ56k6anZFWKnSZxOev/Mvcp/l6OOnNjkF6qjDGsTNNiDCn+Bq2i1osAH/KJR3wj7ziVWn2ATGmrPDnAYuOVjNNOW7A50A1Abidvzmy0MnHtFOqJGXpyl3l11HP+zKRT9IuDxn+NMKfp3mfHZYwJr56Y7yCz+3XspvyTWHsTTjpLiZu/cs9HuZNd290lUBcdeu1SwoYCmNuw+/XjGWQBaNTSMg6PmCUuwjtTMmPPqyEMBLNNVQ8zavvjNQCqUXPrmqFJJk5DDdCEW1cHlT8qdqFaSpMKaylbuTZa6ANU1OqpR2ySlqKEmHMrfIe8pojMcjXkbwRzcct+id0qIMhg1o6Yu83XMzp6vOk56YeYUdlus62Ol2sNGK9oO9yVxvOAJdyS4vCTXiWpoM4wPDw4LB9/OFH7ec//3lOaWfsYYmTZjZCkKT8wQ5YGOQb9QSwBkzbAXwdDDo88pfzGw0HbU7A4xnb5qywzeVFBLH19nANAZMyTCGoyAejKaI8DjZttf6RDPxrItpNzwZzwXhOtEeYUABzucrx4KwdHA/aHgLS4fFpOzwZZNOEU7H9eYsem/Roe6u99+7bmfKkYu0BHe0tgqhna4m1kIQCS/qbThCjzVknj0By+c3RcNBeHR4g8B0j9AxydZ3HW2zRea9vbeaqrWiKxKlKAPDtejEX709OXFEn1x9i1YhBr3bATlFGGLNPUxijTDfZOelxE9AbpVNL7zrBLMFBEPVIC2/+kBa+ePK8/flP/qJ9+MknwII+gL5DCCqcWPbUzScwy9Q29KJQ09Nw7xafPrXpgzs6l/57egqOg2fiScyWTnKwv9EBEO/ooUsrQjpWXObd0hk0z7L8kW75m1bKLO7xcCCQqUaAaZ72aw7CTo7AAdZ6RlYA3+JZWcIw7lxU67y+utL+3g9+0L75jffaqxcv25//8Ift2ZdftJ2dl7nr0gX73/rmN6Ix+973vhsNWB3MWgM40w9f6dp+r+iwzA7a3BjkIbkReqn34iI8xPLa7xLfZuaSBJUkWUIEzujFs9QpWthL8Q4fB3debg+DCw0a99deM+Y8qPOvrwtjQUEQ6eJV/WQ83gXmuprVlZUwip4IiokonBXzjT/vnr5/MIRpKYjhZxYS6urGag4IXJgTIIX4UwA9JP3sGiL/m4mZNrq4paGSJ6MURwu3IOwMoj/B/wI2MARQJ3Seat+OGKmovnY3k4tBL8h/HyHzZHDabgCcJ+ZfwyCOLyEgOuO3KYMbCBZg6Euk+/zgpD3dPQ5T9ULvdZD22cuDtjO8bPM0snUIbRYhbdOdGhubacQLS8vZHSqz9g6sVRiw55Z5F+X+YNgOrQ/C5ZGLCT9/kkb97vpEW5942bzs3BG3UnsRTKdilrjJq28IkFH8hV3fECR9BYQ0AsPyy1++/3KrwdW9EztPwY07eeoHhfZh873cmri/4pslAbz51PvffdNN2uPmPp7PcktrlsPX+zR4h8jv37t4eZJhF1+X+cdAf9XJVeemNUCefLPJ1VUrTh3K8KruOPjS2gBaMsLMxUGVpzPmaRkN15dFRhS49Ra/GLJSqOjjm4/b0O1oR4e7MPazpPOaSfkQxv5nfzfTlJrxZ297hj7up+3NuHt87ahGAUfNlgzSXdIljLl43wv0a4AWYYz0++ksO1Tfc1xO9+vQnLyKTpyOmm4eMaNfBn7mofYdXtZ3bGqulmivLqtYpH16Wnlvei1BDRyrQ6fE+RbtSH508qCwH1E7lWc483PR9qkdPAPAHFxLdAeYy6vr0YpF80qj1bpcQ8Gsh1VBR7e0je3oJ/RKWRTE0lmaF/zWkOlQ4GtqCTzY8wRB5oy8LYeahzP4lrSc63GgPZIgPelVeFbeTo2ajzzGjrNgqvhwkw7HjUhIF3DWKwaUc+3h+mp7hCD2iOfaIsKuB4RdIXQCY9dtkTH4srMv3iRPlKcqiDpLYcnP4J3ydg/HPjpF+Do6bfsMTg/h1Z7d6JlzpuW6r2U6RnfJLYDX1ZWF9vjhNu/wfAaxbgpYQuB2Z5znT9nfeNaY2gppLnRKWVz75plWx8R5dXDQXu7t185d6E8hzfJ5AvzK+loEeKcDPThYrazoqeNEnKJUe60wLHzVhGj5pkX4urYPAumZolQIvnGjFnijneeQZ5Ds1Kz3TTr482iTfYQRtWHv//wD4HACD5oVAWkjoTPwlJ2uvESbxTdx3wtg2r4tFu76tthRVNxJErTft137EwWPTMuLL6zrD1WChAxMh/fQRdLE33ikG62YbgKYht/9ZntIf+W7bYl3p0ltl9KuQpmKBduLwvYJ+FaZk0X6hLE1ra44jbhcmjFw+e7bb7fvf+978IbzTMF/jsDqdKFa1rXllfbeO2+3f/j3f7N9//vfyyY7d2XKS0bO2DnrAI0oZ8BVwB807ezYvMsfwDH97Cx9+oyDNuhrapay42e7UtttHg7sFqF7p8M9m9RrER2kKMYq+PfW9ZRnJ8NsFnB68xIh300uv7YwdgKgcm4NwBMzIqakXhtxLeAX2e5WdBGeQs4a0mvtWpHJFPMNQ8Ntw7DRS8QXEOhwNBlBrtZ9QBAAZG4ZadhTiKmsI8V0VhDuNW7ouqYmZHgA1/urXIdx7gJJRgvXk3PtvM0jkLU2uqbhEWaIAOb1F+52vLiinDYgfgurS20aJjK1uthOqc/BzVybA/kPEAS/BYNZ5ZsktzcYtdNz6kH5HO08hhFswBj+5KMn7c8+fpZdNMLmdmGZ0BL1TVug7mc0qINcsXTTho6QKLfn9kjMuQoJZC2SqIfUPf/yyxD3O+u3bam9ijrUs6wUxCRatWIScWm/asQiwdpwzNTRCm0lTz5FSEvT8wVDlApv/PhgcNw30GL2YfyGofH4afx73PyJ//LEku7dN726fEisc9tQ/Z7Pd+E0d36x/L//lAYNRssfkzx8dpakE/8u35S3ylF+HY3ib3lKJLNYwqd8UkBMyphQAJK4DghyN6DTz8JDm99NG8BkXcs4c74Ls7EZlqlSvG7Gy3Nn60No2nLk1fQRNCzb2eEOI7w6a8x3R76WTLcd0m//51/Poa9vllvTu7+K+fe2D9ebcXcvjPWmn57U2hk6hXanGXPAhB8JkB/4gCHaicsoFcYUeIwnTxGMWejfWYHsQ2N+WeQv3yGO2jEFkmWEMAeNvSAms7esSZOwth87kGhWKKd8zHSjxZN/YK/ohFMfbK3dqjVqrhNyka9FUNPiFNS8O+Wwi/NL0YJEqyEd8jSJKi94hicq6lU9aNN2gLRxwZgyOM3O93onD8pnOeUP5wxMP/zgw/azn/28piOhMU9nP0U4kcqLV8MboNsIBymjVE0VSCdvMoqU3LyslwtxPdBUIeO8zVImF+g/8vywzdXsmPRMyAkElGsGES62trN07U/OoGRQM0t959QIrixlgKrwd06l3Wm+f1waMGcXfEaLCA2cA0PXVPXaE7UQaijsZDfg16712QR/25vrbcTA9sWzp1lMvUbf4TKXwB+chPz4pxCmUHw8ZBB8cozgc0jex+0EIdW2qPZLfLgpYGXVa2zAGR2zuzRD2+GxgkT8w+8ZLCtsArhocXLA6yUdvXyevsgZIAWxWrBvIcRhtXk1YJ6y772FE/Rragd3dvfaH//xn7Sf//zDaMS8BcAyO0AJqShsSxK2N2ASzboFkndYydSzrPgs3ls0HOGJMLbbWOL4TT8Jr/oEca8wJX2Yj0/bN7ajwQhZ0Ec0xsRJmvHr+ybcpJ9pcAQqhSrPNMs0HeVXGDNfYWY7tC+zvXtp/pA6iwPzUfupBszjsVRifOPdd9p3vvWtaLk+/vDD9uM//xGgv0Q4X0g918DZt77xjawdVGA6PUHQ3nmVU/MVxEYOEMCVy4wUtlSazJHuAv38onZ5MWfWLawtt1l3ZcJj5DNqySyn9Zf2FO69z9J6O/0urBRgcw0a4TyBX4vInHbj4Mj1Zc4aqi3+tYQxGVzupXT0BcDBwBjzFfAAmULYeB29yABksJ7foTBWa8WKsRQzvBfGLKwLFY/OGoIK0iON19PtJTKvnlAN6zSmGq5rRo1UHaDeZlHnFcRNPRsDEIgaCZXwNl71GiL0/BwB7XCXhjGAecCIhzTyo4M2TdwZBLA5Rj5TK6ttnoa7trnZNpxbBhHvbSy1rTkETAhrZoLRJOVaohM4ZqS3v3fUDg5PUs5vPFwnzkJ7/+lu+9GnT2s0T4Fc3yBznDgjTxkaROlCQ88QOh7IwGGuMAo1eTIsbw9wfL/34mU7ePYS6XuyfWP9ps3d0tGTQu6jhIBC7MC6RiEdY7CR4BAfaRQ2IvHid/Ek0YsZHmlsFEf8Fe7wxJZXhev9TS/vpJBn52+6+t69d1a/dBydefN7CRyVh6bilOnDdG/jwe78CVHP18JiDD7+/pXh7r+niN2rnxMmQNG7fprAS+bsIYw8pfuCsaM4b4goPUGEsdStTJf0a2V6vSz3JkWRoRK/woBb6IKGkWnKS4T0XgA0T8uefhj7dZ3A37fzO3ro6uL7uDCmHf/eu3sz7i4klJ804zljCj8RyhycMeir3ZR06LQz14QJJzViCjVZvN9pCxzclZBVAlk/0NPIPBX8DJeOhPgKXL0WzOMQvEbGaUWRkYNmyddBoZ0nEYPPkEf4FX6+4GlH7LRKhLEIZaUxSy0tE+VOhwLzTplnGUXP07EvLkUoUTNSB3ROk3dyARbmJ/wK5iaW9DAKZiEz6wc8yJA/On4FDWBox6iw4tDlgA79z3/05+2LL75IWqurG0QEVggFTvEJxzpWwdyIQZVgscmzjlsx144/R/NI3uZJZ2L+3kKyCZ98++GDts1zjQGpa8duEMJcypKF+vB9w6oFi5CL4Os9ou5QViCzTeWauNNBe8VgdXf/MFowd0eeqkUkL9h8tTnCuth+Xo0YfFSN2LZC4IMtBML1trgwmzU6nsZeJ6afBbYLDoqpT9UVoZ6n+D1ACPPQ3QMP2HY2RK0V/Yx4EjbCTPpYW1tHGKNThta0xVM7PgodqBXLNUrBP88IYwhhCGNaNWBZO6YgJh2qgaQPC66FO9LVDHThFKQC8SHl+Yuf/qz95Kc/BRYn0MhMlA4iyP5MWHjAuchSOA1ssKVZFYEm7dPy+VJlLUve9ekuXtVDvwo7MUHPmXc1XuVf4W07RV/pd/hOjpUu7z57YSxXKOkfv14Y68pKGUoY6wRBrHB1cKR8cXhwAI68aaYENNd7bYCDdayHv7oZTg3nBz97v716aT9p2ghA4M3F+J4d5kHprtXa39uNIObBzKbnVWmeZ+oxJmuE3Xyw3ba2t9raFulvrLVVtbrra219a60t4l5kcCG9KYwvr67y9PouzyNbhn/QlsGZbc41omplFRyzaUftGe/ZJAGOhZlrzrIrOQ3t19SMyWaOIXQvsU5DBahBlCgR8GRYo62S/lxcaR/uWR8SKJIJ9CTxyihpGDISClXM5BaGO42g09opAOMDtAbRdelmLQZpL95JoyRsB0YFj87Os/5LBrLuReLkq/Cj8OeZH/Nz021rfaE9ZgTl+T8u5PfG/eHUXDudnG/nEzPtBgHJ0ThJtO9trbT/5Lvv5Goi1ewvEaam55Yj/HkUxTZIcMenO3sGg1HbXJpH4FxoHz7fz6GvR0BkjtHU6ByBbG8fqWiqkXK7AUmWeYa6HQ1OM5ecIx+oy6IMG7jY8R6+fNUOdvZgNtPtvdXLNnu1i8Rdo8FoxGIVymqknMYE1IVJGoyg4RlfG5EuK4apPkQm0DcyG4OsW6wZr8NpH/7u6b/SIonTchvOl97UaKqPr+0Fsz6sr7hIA6JUYkwHdP89cUybctz739saVZa7/55nrD+SNlwX5j5eamyEZJliCwxDdmHyvUsjcfIdmMKYpx0QOGoFuI5oEw5m6HrCa96nh6/CdGKC085Zj5jKA2NZ0g54dn4l5FV8jw6YQfizAzw/2m9Xo9Oko/ZCkxLG4+u5DsmDF3sY9VYjrfSj697fOvXf+6fmK/26p0bBqRfGSrBiMIaQo2Bkh6yGXf/kKT4UbuAFk/AFeZGMXI2V9+BqM31HBrYPF+daxv7wV+MqGCwgzLmcQbjXuYgurfAk8zOYNwIF+afzSFuq8kYb1WMVD8tr3h7iGOEPP+kvgyXyNG6dLeTUhncM2kAoy7RXKbkTHIGMMigISrNqpKS5ags9XIniM22rJT1N6oixjJbJwYAdk2GuqMdnH3/Sfvb+zyLQmh8tHV68EkHsFD5+Dl9T8KCGgV3aDLCQ38pE7FRTV3k1tGiryhoZ6upBmg/o9N5+SGe2ttoWCO/hsl4BdIUgBEMXFCmbgugy+aphml/wQm/yROhxGtAF6TvQ10sExx0Esf1DT893mlCYknvqpBDrFKEC7WwWbC8heKkJ2aLD3F5ba2sMoBX+FMTsHBXWrJO4PDg4TN2sj7TkQN37lbXeZSzu0pcogNHGc1QKeDP8OnWzg3c6ql8rdjc9Rxin7kpQhW4dMKgdJf0bBDDPqMp5l1pnapRLEcQ8dZ+igSfoErwokEmDUpVHdfz4Jz9pP/6Ln+T4CrXyKhiER3bhQb/SpWEVQChFYHxHp8DLZ+8n3cQtBPJNIlLIqm9l/CaurHNn80741NWBfeeGNiLsk4xtXQoJLAyfZ8VXQ5S8tQS2DSZrQU3+CmKZppRucFsSlzWdIIi6Ftw40o3rtdSGrbs799Gj5OeZYJ9+/HHb360BsNeSra6stgcIVQpunkZgWz4dnETTZiS1Xtr51aXcyrOFEPbg7bfag7cetdXtzbbIYGKJb/PQlPm6LMWBXj8t7XpT1zW6DGuRMApbakkXENTy5F1tmZsMg6fYwo90ouxiugpjVDnKJ+vya5m+c/0qI0ALwVraI0Tuu7+/zECqEfYuoFhPqMiZIow0JiG8i8PjNoBxnDnKoENSWwZ9IxDdZAfkxtJK2wIZKzRYD2hTb+YunrmbS0aDBcTb6cU2vJ1pLwc37cPdi/bs+KoNaQwWTeYyfXPe1pAjpxCQPnr6ov3pp8/aHz7dbR+dtHZ2Pd2GI/Km0315ctF2zq6RoDfa7/zmd9pv/+C9trnuTijKMufVSLNtXSYBgcy2CwgY4NPyRgiLjoyuYVRzNxft2yD+OxDPCkNJNyNkxElnNCVzh2HI9KEBiFIh1sbyy2BY+AicCS/DdMRSnuX/VSbhO1sdaPdhzPTffpnptZyvxzX8fdq97cv51zFvplHp/NVMH9LyVRnL564+CkwKN9g+TG/s4tLNEaf/Vp1wfJOWTMZMvCLEO1LT4q1jl46P+7hl7axLs8V7wtz7KWjcmwrvs+pdvjF4Jw405fPrMG/CPvWHWfZ+VdavNm/G/aUGhnV3rAO48ekyBJp82rp1jYAujdOm0nTpCKOZAC9Z6kAy/RSQaTkad1rftkk/ixAD44e51lQTI2c6OLX3jsY9+NELk08Hx3TYCmLey2GKCoeuB5KXiTuHeZSP+DfSz6072cqdQSPWhmhMSoUAT1nUAsDEa+qr4JXRtMIFtDPFQFBUkgLlLgEuvRa26ljwVtifmfW7nVsJowoQJIyfmhzrimB5cRt+4/2DOy9ednlNtsvRIAPZt996G764ntkEEiBOCXc5Fdw6kI9HGdjpyoPksWrmb4QJPHmRTmYL4Wd7dbk93thsWy4jIS2vhplA6JhhcDuHkLGK/8baRnuw9RCBZrttEHZufgkhEqEIpL5C+PrSM59evMol6Qe7++3y7MpZUHJzOsj1ZKttLhsclrI+bJF6e2isV9k8QkjyWiX9bj2H7uQ0J/u7s90dbssK3tTpeG+vPfn0k7YLLA73wfGxaxClKc/0mgMhs9TX3XkIfW7yUFsJDnuNx5LTU+BhZtp2ibDlmYLwZc99VKFgOM9yU8JSAFMQg2joxygoBDxBfeeoy/zMIgNq1+jNgy+1bwimCOgz5CntvHj5sv3pn/1p++nPP4igqHIgigqEfclKt9OU0rZllc7Mluyph21QhNaUes6+ogy5DSHaOKmWdyyxbEbU2ZZCS1M4wyIi4ktfRH6GiUBlXJLN2jSeHnES9y20Ad2UsFVCWmg0gxALRDjK5kYSz/6kMHiRD59yF6RxyNP1X+6A9daC0+PDzA6p1XJKcjlaqEWErM2afj4btOdPv2wvnz9rQwSthXkX8C8zGFhvG8tLbRL43AIfhcPkg0C+uLbUljdX2/LGalvkuf7wYXv43jfa429+q22+83ab3V5vk2t1dNYt7dMjtc6B2+j8qp0NRm10OoImGRQiGI+QLVzH5vEVWV7Zte25RfKhPWiX1pfb+tZ6W9uoc0mtwyp1sKxzMxNtcU4NHvGorzj41Y0IxQbSSaqe/o8ZY7yGcuTWf5VWigSSDEZ3pWEUEaWWSO0O4ggWNoh7SoTz1TvFzgDE4fC8HTjFR5hpKMNvW1T62w+32tryfOaHd1/ttxdPX7ZjRkQXCGxe4L17fNG+3L9so8nFtry+CcC2AZINmYYElXlRrY1GImDo1r48GeVwwcOLq7aBcKXQ5Fq5I0Zax+QxgmkfOtVJFdz2KpN/CLJdv7AAsJ0Kfczzu5trNGIqc3nRXu2+pBNF4HLtBI1c7eES8bcWPIB0mDVjlwwHs6uJP4oG8dMRKAhEGAjgOmPD8Z2CA7e7Q1XTqHxWw9Rtg4kw4TcRgX8JUmX7dN7sNPuO9HVb8f2bW4aQ55ez68lRrprJJOfHrqzG+QWDl/69wHFv6j0xxr0xJbjcCym9AGBXHB8ixfKjJN3USoJ0cSlTYEL6HXPqHhS34NSnqdHdv2aK3dFvPAxZmkThab8pcyxa1g+PwFlnwSzGuNju7e6p0R2wdibvCcA/KuUoWriG8XX278r09flKvGJ+mf9f1aRuWMEhyrJgXjr1I/7RGEVwA9481V4WxguACjN2Bo7ixU0Ay1M6jwar69BcuO+o2Q1J3tWnFj9LBfgmnrM5gDyc/nNrvXFFoX697TUNOWZDgciekTCJQ0dqedW8KUTqp1bGZ5UxXSbp2galtR5ufT1Mu+jnLj/ehUeEcawaQMtlXoEC6Xg3psTiGVxPvvwyuzdN0jpQ3Ez1at555x0EpK3AwLW24UkINSmPgKecrveiRghjk22WcngPr7eQeIaTi6ffevQw2gDh5pIS12DZmS3aOT563Dbp+LYePqoNTAyIXU5il+wOyS+fPmsfffRJ++zTL9urnb2sY7sc2UEhuMwygJ4t7YMaBaef1PipqbIMLpa2E/c4A6+ysb6efXlN/mc8PVqgv+1gbW21PX78KHX+4MMP2+eff57dwWpOFDoVvBQ8bV+2tWiAcCJ7ZaoNMQF+oZBaMxLyv+zmjyRTNOj6I62YE4umpc10HDCdpz4LakEV8jJIwG8OoQy6cZ3Y0tJi2z88aH/2wx+2n/70Z+3w8DAJiW/P4fSIqJ43mb4lzMJ6vve0MW4TLm2laCpxCKu55/fVbmxp9umxuntLkDtrxL4dGdMnaWcqe6w91kCiyqCgkilVbOg2fQJ9NoKZfWV2I1rUjoYVclwn5uBImnLXokt6Hj1+0NbXV9rB4V57iiB2cFC7yxVyNhHGFdRcL6hgFwUOZYsQpoYLIdoDYDeg103CbXnkiTdBbG+1xdUVygjeoRlno87UkoKDA2hj79VO23+12w4ZHBzvH+CPAI9Vnjg+OGjHuo+OcwOH7Ufe4VIjCcfBX47JgEajiUc28CgsZ+dc8+15qJ6k4BmAv/aaMU+pVXLOKLVHBqUI04DBOE0pwm2gThFKNN73VNOUpqFKVyZbjV6pP4yOxn92NdV2Rt7YjlTKu8IQYy0kVhiF6sAFt/zOwnwQkhiFDRCyVGW72F+GbWPxZGYvE/Ui18mFBXhK7bDsb36XoubgMBPuXLxipDdRDPr08KTtvdhhdHzMiIS4i4vtIXlOgngZ2NtrC2170fUNZ20Zwcy54VMv/4XG1hdgGjCzn73Yb88Z2d3SUD0TzLurvLJpiTI+WGLkRc3NK1dKyTQxqzCpC8ro4tFzF7tCjHswUk8LXl+abY8Wz9rE5WFGXznkFSLvpyqjLpf4hX3gXw2DB89iBvr7syHg7NwaGpzv3as4rLDV2O4asn6d7TyIOdkeff+ftMX3/kEbuesLZnlyuE97Rah1CJdghu/i3Bnimriu0A1uYCM9/EJQTPx93jEi6axorTxkCN033PHvvhmuNzIHGUe+yZQCHF+BgYykiyN936WDkV1ZxmwYgZlO0Tk4LS4TTbkZ3Yj/awT8iZNnwL3iae5d927rUcxSi28YY5IiT+Box536iGd38tG5Do/bxYkT312ZSOMOHpTz65imPIABaXrYvGmrTmW+yl93b8bdBcOqi7CO5lghgLargOBygwHCkueMiRsiR4hxyq+fsrEDcA2Xp3XLUyLAQIJmnY0ttvXAVGEFeJNOpkGvaGvkUYvxxbtCAKPXOTUWClC2I5g1cSxzv1ZTE3oRfVX0hDE9y15rgmgHxLejz5QiNK8Q5fEGaqEWPaTSa27UZtnuLGSXlqan8YLVPTz73lFn+Cd1lodGk2Hd5Mtdwf7w3/679tOf/MS38GTLpmDgVJpU7XSlWiCFEte4Wj+1bdbR+jtppn7PjUNZnIwY5e5Ezw97G+FGgWwW+CvkeUewuFjD78Fbb7UHj99mwLuO30KbBKauwzqF3+3Qsb3a2W878GevGNqls3PnohpKVQ1qjhRS5mYQXOCnwj+71uzYqLflqcM9l9pDtQ8Mpj1WQo2f65hdxO1Ud9b3OB1LmaQV/rWnz5+1jz/9NOeHefTRDUCMRodvOV6BujuN5LSUQpjnWblWWIHOtWhZxE0Ym67wmSTcDfwXaoWOvJJPYax4rJsVtK7pd/G+qHEHZe4wxIKyTD9m9yp5vNrZaX/0J3/SPvr440DdzUIeu2O8rFcNT7W8CjaltSwNVPfUD3dPJz0/e/O9hPveX14k9RU9lZ9PwimU+s3wXTppy34XNlrqXv6GNe3S6ObdNqpQIh115ZIm1Vh5JIVw9Jw3UgncL4Gf61IPDvYT3400a2srCFEbEaxUsDgl6dO6uNRgaXEpa7fceGP7Mw2fnlO3gPATfEE3LsRXGFtz/Zfr/tQmU37XeHoo68GuS4J22+DosA0Qtk4PjtoZ/p607wYYNWIX8KFeM3aOTOMxFVkTPzzLFVta1yiKX5c72DbDx7DKNtGIy2OAdWiMd6opKf16ppBXiCAHMjCLMuWnwV+e1HErQ5WpuBbs3uiuNHppW4L04DrQmMV2NrCTo0HbPThtu8ejdoTAc+4utnM6QyVbKm9DFVFLK0ttFqnZnRKXCEvHe0dtsLcLU7kOs3Ad1tUpI4/93TYN4K+PTtscwN5E8Hm4Nt/mGL1ewTSUhK3EDx6uIERdtd2TM5jCXHvASGt+YaUtIxh+48FGewRjkODOETYHx8N2AmIvQOQcxLYFU9kG+WrWomKH+c3QwBZvJtsWguIGhCTzuwKp5wi53g5/dnwIEmv0aoeQjkR49SDjqVcg2ql24uafyL3DBg3KcP1rcObPJ9bGpcUZIyH3puLZPeImTBneDEu4+dWNtvmd32offfAX7Xr/SdtcnG1bDx4hgMOQDKbA1eG4Oqd6NY9bp3rIQE2TaXXZp2y96cv4puVfwvXvxQhqNNabu7C9m28RxDpTroJZdcJ6VjjT6QcJekt/0lQfXYhktyqdpeu6qgzG01317Y1ph/47OGgM36dfmpb6RmwTT56Qcdx+slP22p++PnfGd4sR9f/XY8bL8FVun9p7urr3/+sa4SKcYjshq+BR6acDgqFFiwHsy686pLzTUeAlmjpYEx/AKjxf3zjN5JobcEl6fYdRu5TpZIkvE1VDpjUuGRcNgeMupdfKwoc0xYTFLe/ycmrTtzO+6o42yFQmwpg7wWvNZ9Fu6tlZjWmPw+/OnbStVPlFYOw6PWklwgtuR+0e8DocjLLWpqfFHk7yFwemHnj5gx/8Znvw4EHWJ3n0hRVxgbECiYNHpLWcI+ap+o/W19pbD7ba2spy0vC+wIFTl3QwD995p/3gt367/f1/8s/ae6S58e57bX5rq7W5xXZJXU8uLtsXL161v/jwo/bhp58jgBxkmtQ1cwtzdKwLa21pbrnNT3okxhT518Gb0TkrbAJ1tQlrKwyK19Zy1qOH2t7QCecMM4Qhj/1RcBMlOXYA/np+MWoffPB++/LJl/QVo3bMwOaA/sDrb3Zf2Qkf5yyoWXC2RFkcHHvk0Ap2FR6/pHBO7qVNrz5GOGbga0bSmzRkvgoZPS0gfDmId9PAhQcW03mLX4UP1yu6FkqcfPLJp+3f/eEfR0voxoJ+Q4qkEB7T0QeZBt/JWxt8d26/9eXq3G9a/UNBvst3bVA8qRj+lhqLlzbXU2FLWxZWU4YXZ16VIcN/bGe2RWlZAaN7VxuWtugztjSEPb3bZtxVO78ArsGpR054p6NtcBXhSfi4cWIJ+Ht91/OnzxC0vdeRNIirv+vQ1a65HtJlBc4Uzc1BMwsK1eY31VagkTWs2lMHRQqAI2j2eH8v9z6/+PLz9vyLL9qrJ0/b3rOX7dhDfumHLxHCrmk756eDrEEc0p/HIiucHkPznnzgWXT7h509aEcIclnvdoogNziJcHbXjwNHFSe1aYE2C6xrsPNrmL5Rgy9f4qepzqgYhsYO2HBx5/+4+UWfGKJb6IzCIJLZPBmdWHCJhvcrEOLc9uIsQtfceVuZPWuLE2dt9hrAIVB5UJ8jJBelugDv8soLu89B8EJbQdJ2nvoEgF4iWI1owKfDkzYCyJcHx20dgvrdv/ed9q1vPcoBrI8QMJaRrvcQ+DwHxsXz+whN8NSo5Acw2dNzt96Tt2cI8U3t28X+fls8HbW5k1Gbp9iLk65LQACEsStVuwvEA2mHStTEP7UcEJONYAEmpAYsc9EQs0AJVMdgK/wCW/HQP3uYBoY6aES6tfnwy0011L6xljGOOVOSSi/CFd9tidRpfnEVwtxp+08+bZOjQRsyonFKwXathiLFgoE4cs8L5XmNUZCfTCyqfhtw75+y/CKJ3tGWaVkU66yVzrq6lyYMltJ9603l/qYpX9NN+M7ntfy7NPKNf32YGItvuJSZB+7q7A1Ytg/fx0n9ujgCtY+XuhE+zLAP6y8B8pd0Zcg+428Y4edcyt+R6cvxprkrH89fFubfZwIz4dfbHoK4NaYZjW9g6R/MLcKUglSvHUhQDPQHk1bw9zBOr63JAussFVAQoBPBkTRJz3bQwzobkGifpumOKTVH9a3W8Uh7oTjahkJh3T9ZU2uWJbsj1YZcOEKmHLTt7KRE8HAxvb1ZsG5ZqVpfX82bcOv9NTkEmwjuujNYtOPp7Kouaro+/uijtkeHY2eoFuiKsELCaUSb8CV1OIX/XAKXZfjiW295iXLd56imy3U7t+dnWes6S0yP7Xn30YP2zceP26bh1OAj2EwDv7fefaf9o9/5x+3v/c7vtG/+5m+29bfeblPLK66YhvmtNFJpH37xtP3wZx+09z/6rD1/5e7F2rk4OeVVO2qcnJKi8511gxUwdBE98FMgnIKpuKZ2GlpfW5pr2xsrWaM7R50vKeOZl+nb8cH3hZN3TNrpC3N589Nnz9qXT79sZ4Rx16wC6DRx7ZQP9+BhL18wYN9tw8MDOt+TNkndXEPsurjVJa/FQSBDaJAvK6Co3ZHunIm5gA5G0NMlAr6CV6a9zwbgoI4zuTtUlzh13IE7QOdCWy9fvmpffvllc9r0+YuXpEHa1NuNYZfAXcGuNGHwCC1plMYUepDRCheL4j/MmzTz5vudib/0JEWUUFbCWW8JwhdZi/auP4nVVLwYeVD6KtuOtPj6gChlxm17UPhSQPbdvmF+3nYy2Y4RYBRibKMrK0vQYe1SNL/9vVcIzjtk57o8d1VOB39+N64DWtdzuhZ0xeNNoGW1mB5D4RTlwqI7l5EFKJ/t4sgDfXd22u7zF+3V06ftAByMDk8QvM7a+fExssApdtAuT2kbrvF2HeLZOXQxbCPPI0W+uKCfv1RbplZMrf2A/g//AWE8G+0EecJp5hOEfoVMhfCRpySAcwqcNgZx1kC/oPirGxEWDUf33ndC47bW63QhCHuHPE0fsTNBvjbgF+GMCijlDQC8BAHKludY39eWptrm3E2bvhEog7ZzeNqeHJ615whXL06G2VXpAa7zCyB0ZTUMRnX5wvpmLhGfAOGqtQ9GhEUwUu05RCA7uRq1PYFKA3r4cLutvrvd3nm01Ua8vzoetnOKn2kKGpQqXP33yNNvz3YP287eYUahdcLudQSs/cFRO7wASVfnpMu7qky+uV7AM3U8YHYPKfrV0VEbqKqnrhM0ekdZLpyV0AMqhCBhEqdw9Rl3D7N6GqIfycQnkfmOR5y/1PRpi8c4Cc9PQUcVO/CMu7MGGp0eQlwQH8Tr3W3en+aZcoRQtkoK1RCpBnjrmUj8wgw643vn1NF/6ooec0dHnfG9T8f8LJOdJ38p/501Ff5M5p7ofbu3r5WlM+mUTZtEnM5KnQmbEXGEAJkNHa1x/UTqWeiaNDX689bZCtMZy37ntHxafTrruyavvV987srax/P1TnD8WzZ93j3cNW/i5U3j968K0/uPf3sND/hLx73xm/VMGPzv6kyQaA7TEWgNd5+OgmppYqUEpw0UomrqoGgd6yQT/k6T2XlewShragFiIj87FkfjTonq1lju0Bvx0/m4hAI7H4FisaYmGXyFLu2Mw/6gEYSOWQQN1w1JQz3eraps+U3Y9vDxeeef/52mhLeCDeXUAgf5hstIPv3ok4ze5VfHdDLWyzytm7tFfSqIuknBkfwig89vf+c7WVPjWivXXGkVSB5ubLS3trfatkf/kP61HRGDSadbHiF4/cb3f9B+8A//YXvrm99ss0vL7Yq63yBsnsO3PDvxw8+/bD/0mIaff9h2D48iGE5PuZN0EYELWGGnJ3lHMHPR/5wDX9LI0Qh2wuDPNWvOaKjh8CYVNWZexD04PohQFUFMHPK0zg7Gvebu8y+ftCdPngeGdYAvfQP1czo6fEqhcnjaBvDgYzrpo5fPeb6iYz5EKDtvM4SfnSIuHb9CocdX2Ic4LexBtqMzL4we5jgNdwIqoHrYrEkrECpQKoTNyAgpgwPxI2Dw+WeftR//+Cftgw8+yu5RD4O1z0QUCs/JZDO4Fd/iuniOdK+PbaCePY28aXpaKvq4p63YECTxFOioiwRaAhnp4u0C/eqPtQ44/KZfham2WWmF7jorbzRO8Um+49Y/T+gmx09g+dQJaFOB4R7wVliRjt0BqyZX2vIKo1cIyipXFhCwPDnAo51cf+VSJ6cl1X5teCA8QthSBC+nkz3aCsEPt3VXM+khsi4Zcs3X4d4+z/1oui7os2+gE88cpXNuN2cIXwhmVwpiCMXZDXvhAKVszt7D6jbdWIVnrFp0dwEPENIGyBYeJu+h8q6D69fCuaZRDZ+0EOEe2PxKRhRoRJAADi/xvXvGkEkIRKT52sUqsurMePgxYzzpzV1KnrtyBQFOwLxuGS0YxwbhLhlJ1jViXhzrKGgVBE6TvKMjtzGPEGyAYJsHec4PyxhyZs3+frvmuUpenmR8TdxZRqpLYbYwD/L94ule++Dnn7fBi4P25adP28efP4saVOHr6PwaQU/REEYFQtSsub5LjdwZ390uLZO7QNg7ooEfgcTPQfouDfsAhniIFH2MAKkAdoDkfAhxeLGtZ6ooXd9AdI6YHHn1664cUF8DCyGpTWPKlw7uvuuov7IJU2iOdiqOrlMAacJZm8Zvwx/rnMwjeLCTMx2SseHYUKKJmcbSoM5PKfP+8/YP/unvtpuNR9T1tr1iFDOnMCkSLYhFqALV864OuvXuHK8Zw+BPXgZMXbChqTHT+/e2GE6fdueXkBii6h1mMWbLt9LqYRK4CDNhYJrWuQuX8GagVcDkJ8hgRYQtek9IYey3clYaVbC7evRPTTkTWkeMLjHnr/fv07gz8X7D72syv1CWX9P8Alw6mHVv1FL3PRx62wvN4/Dkw/13GV7w3dNIlVtNQ2iad+PK3F3u4Llm4l9/D4JVk5KRNeHrbLH7/JMOT7VibjLK7kN+Tk9mlxnI12/GdWHRKst8CYPwUcJ8p8WTUt9Id7w+r5WbvF5/L5sOEPi49mnn5U579vR5RuoKiT2tG6dou+pnB6kQeslg0bbjQudHjx5m95odn1f7LNDWH25v5ggLZwY8ssHOxINa3/vGN9v3f/CD9va777U5hCRvKbminp6k78Xnr3YO2x/8uz9t//YP/xjecEQedpB1ttoUgpfCqXATXgosQkI4BUrgxpPMs0YWOz8/05bBg+u33Hlnw3OK9ByeKo9Lpw8c6oL9OpPL0+ufv9jJQHeO8riDlqDRSDiVq4ZKoc51YdOu90KQOkMA2H/+pB3tvGiDg7022N+N1uzkaL9dnA3gz6MIsNrcK4wgP6GABs/3oG8PwnUt7xzWniqLwxl0DzxUdne3PUU4/PzTTxEyXkWb4oY0Ny64joyCW4Hq/8AY3Ru4lkbEd+HcOpZ9040j9FBPTe//WtuAq0DIfOQZf4Ux+zTFQLwN0j0TT1rh0XPLXmCbJA2f9Y7lm23EaThhm+OjAl9oQXo1T8I5rejRE2q48KW90X9iFdL6zRYKy+f25aengbECmMeoeHiqwlquHPKdcApdNRhxsFPaYfugedJyOlh6d5H93s5e4H/sejD62gsGFDfA/Nb2ruZ4JP7oBxG+bOY3tF3XmnssSewVgy9AVf0n7YhvWrXTDi4M6zpzZ4XKOntm26rBn+s0e4HN9qN1rapw+5VMj6jqdjrkjCFfA8iDRJ9l+J6X18PdGz8mpfwVzmo+VQneaco5gK3AZaM8OFabdNFOzifb2c10G16B0KvbNpCozy7b6ciT911QetEOT0EoQJ4EmHOktQBib5HABwhDswDcwwNvXdwJk5gGgJM0tiFSc67ewD59udtGJ2dtAQFke36C0Q+N5uysnZDHAOB6arI7HxXEnOsXiRLoPJWYJ8/LwUmbpPFeISUrfJ3SIB1FTUIEbr+WCbhbqUYqNR2wIChAlFCRyMAXX9xULhHgOWbuXnEEDQoEgrGzYdCkYWPpI0ucvZWJaQqHZdOAKZuh7T/uLT5d+kEVjsPPf9YWR/ttfW6ijXaftVW1A50QmXBJk7h3zi5ynN3zF0z5U4oqyy8Jdsdg+gfvFdZn56Ye5cAmra4Tixs71hIqr+qwY6lH3ukw1TiUdo8wKZfdRbmD9HSq0LzEq1/3n+A88dNbqaz7punziZHbGXjMVOjkcGfSrlLv8s178vy7McLjq0yPmx6m/z7T1+k1my99vD4tw2J5+kV8RFM1jsQxU5Azf/EmrPtOraZM6iJlBQCYOO8KLbYV8xcvrllREPNQWDVjGWTRaVg6v5u305ApnXFIqdbvlPCVxeCkGS0ZTwU214u5XGGWgZ/njRlX/P0yEFlW8+rhGHpJYN1FnwpWdT5YtWe10z9///0IZFKpmwbUFAm7GsnbOVS7D2w7oF7TITvt8+DBdi5Sfuvxwxwl4LocTzN3obTHcFgnF8a//da77bvf/X57F0FscXk1fMrF6G6wOjo6bf/m9/+g/Tf/r/93+4N//W8YbJ7AeJxG9ggJ6oDNSfwKrdEaATOs3bMD0Sz8Br6gODw/uyLn65oqz4UTDqPzYRuqESPjXsuSM6Eon8cenZ5dtP2DY3gzHR7wrvO8EAIQymzb8kaP68iJ7qTtERgrC94VjBs40FvD+w/b0f6rtvv8y7b34lncJ0e71G+vnR4fICwcMSg9ahenalhcZ3TKEzfvgxP6kP2d9urF8/bsiy8igH368Sftk48/bl98/gV90AC6qrVhCmQ5DR6c2pydhpbfuwpawQwgYO9poKcHanE/0Oj8NP3zTRN6I+2kbkbyLumvy63LMZqx0IX9gxIhztKI8V033hHGKPMU/d8E1jClRIC+EYikf48EKaHXw5Qns2Y6QhKCmNP+Tvd7NZGlNc5bbz1GGFsDbwjE+3vQwES0XQoa5rmZAAD/9ElEQVRgEeDAkxpNUImfC/jnEcgcbFTetmM3qmhtH077ulPaDXmek3i4d9jOgPv5cNTOnXoceUQFdnTRLpATvCbMs+BysDzP80vaEwLaOdbL2hW2LnpLncft+ZhbmUBrm3Cw4wBP+aDaH8K5gz7y0oLdX8MA9EDPf7oxIlgzTgS6e41AovBv7Gv38AvEYZjELeZSix4FTGmaFE4mlFovYDwwunR+VoOwStXHCDmlBnTdFRUEyUC7TQxPW6OxTIy6Q2rJwgWg8zOTbYnR4KKjmZmpdgFir0DyGcg8p1FOwYAmRCiE8+DBcntndamt5lyQ22jGXCcgg3NrrSOxi3M3EzjP77kzjAwcndmGqNsKhOi5PjZ4DyqUuXlzvGeOeOu7Z6OsMxJ1IeP8klucYdIUNIKUsICgrm8RGqmzLPS+w3I07/+ALW1Hh3XMOiIFEr7mPX58Vpiy/zJtCjjesBO7e5pY8sL2Ye++aZJXPc4Odlo73W9L3lIAXFMighY+K37KmvfyC71Ugbu6lKEk+V8pv25ey3/cjOXzpsn0lP6U35FOXyeNz/FyGL+31td0E5c/BVEPXXT9TVWhhAA/W3oZpjuv7FiTZCXo/zJ9Nti+nD0ey106sIJUfdMYUncugiZMaTWMV+Hrm7X62zc9bHp3//wF2uhMH/6rvv1lpo9RdS1YkJA++SutFlYhWbrugtwZ3tM2AI3R8+zcOZ/JNV10Fr7LIH36niuREDoUwlZXV9vy0vKYIFZrgnQL/9Qrf5YBQSAd0BwdkAdS23k4HenUSmnMfKr9carMQWAdhYIQ9FcAzzgMgSjVs9L3sFcIk0bkGccM+lwvdkSHFt4EHxUW8qac2K7ASXJa1zzd0LNqgRjWJRQt63beeedxe88DMbc2gIHnqDEknLJDdGH1WttY34zbwe7IXeF0YGp4Pvno0/b//W/+P+3/9l/9X9qP//RHbZa6q60TAQpcC8BlcWEJ+AAjO2zKqIBXB4A68FFILj4SLkQbtsN1R5077Fzc7bSyU339bnThT+MkrPs9XRd3k5P7vd8SCYzO2R31hiQPcOIAK/cgAgM1WLM4yKIt0jesLM7BlxEWaPPetzlP0qvw5Pk5uDn9ihox1yhd3diRD9vVcNBuGMRfM0inI2gTV2pcGIC7685jD46P2pD+Sc2YJwuoEbF+HtehQO/UVaa/5E/YCF+UTfzEdH2ownxwxy8UYN85KR0WffB2Z2wz+v2C7b7HYf8Q64SoQlYnaHU2i/cTlCe492gPBTCFuEnoKH4IHBPwH+9YFMCGSWPCzynj3JFKOHcVu3FtBUE964p5V/A/A3YKXe549IgKw7ie6wg/29gs+HCTg4KbQl2EO2DmkpBoTuHHTmcqoHvwanZJgls3ywyB9bFKFegkd08Pz5uXtasEvFaOgEZ039IAHSRF7uTpEqfh+UVu2lGQ155Tl7LKG/hdOAvGO2nUs75FSMMvViEM/1zLaHgEL+8/VU7IbSIRzH4NzdgvN3doDiFo+imAEsjwyL/77xqR/qYxVPAZF50oT68VOgbZXvjt8Rf8gyAuo0nyiAobrQC5RCgawRxsiDk9m0bhtN8tBJ/rOfBzt5DpXUAUVwhEEyDzFuZ5CVMwP9WrmxurzTsqZ9fWc1L0/uiqPTmBGbu2Ycb1CvNRiVpO754z/xCYDR9h8RZCUyDKqGDegxFX21vbGzkhWlW+F4U7onEhn0xU7Z9qU6cVTgfeIsDIEUZl81G6v+gvDOYvnYwZj8PuF+DYwfwNY3r5dR/7Rvq6KTZIdfJNxtF5x1be42WojoG2E3jo1tgx/LpmnFZ682aZdf1iHXrzun/CxlV1EBZEjo8m6XSvfT7RLKbTkxkqAIALh+yECwhkUna6ELOQKLjYsf1i2XtjmHGrMVtLVPG7smEUwK6gE01fnmgMgqDy+zpNn9+b+X5VOf4my/bXS0m4ds4uZrRiYKi0Y04r31vLqSZmCeFLIUytmB2l05IKYf1F4hpHurqzgD+ZkCrt3gX5Cm7ygDutjwJCoRO3nQZCCPzAabTx8kktf1VTNGMM60Hd7EE7WrNcX37+RU4nd6TvQnz9DFftkwFTtAbEs1yBU9GqSdWVbGfUY7K5A237wWamLqVBR/eujfME/Y3NrTZLx+omJi8bdxemC9B//1/9fvs//u//D+3/+l//1210MmxbqxttwQX6dHLuVFycQxCbX6BzLsFUGKlJEfbunFSzyGvKYtnsIBQE7XDViq0giFl+jzuxg3UgrhZJXio8s+wCuJyBMzdTubTkynqC7xwhgVVAFR7GsQweLurUmZsDXBPGmBuB0c0YhFU4xX8JAc11SZ51tebAHJgIl2UH1JRvEaFgnniubfNQ1BJWoA8G+64vc+G59cv0JTSiIGr7drG3C72HrrUVr9RbrZ70ZPUJUobypszChzTu10jeu6XXO7/OGqeP17tju2TNhC88zEyeU7RwZ/TvvvlUZs+0JE1BjdhkZwF8CWaEtP5JIoJbqDRx5h2AkLfLexREvZroYG8/7cU1Yg6CvLLo+fPnlFeN2GK+2YdqQyPALpb3vr6+O4jyUHdvqHEq0PVax1lEf5SnsoBHyqgRBh0KF7F1LqdcW75rX+6aw+s7zZYnNGjxKqsw9potIWxEuro9hstpyRzHFYGsrAf3qsDxXl3dhpGnm5e5/8omyBTYnSlc3aNXDxtvj9Oo7okjpvQyfkXyxaKEHGIEjaMVtyfnwEWQEdUt36ycI4iRAtXZsA0vRrnGYp9GeXxm5RjlgGSFKaf+VCmavov5JpDY3PUz71lgNCIv/pzwQDgIxGuJ4Fw5tfcWhJ0iwZ6fjPC7ajOIzvM0VtWpkzcXWWR4wmjsDCDmbDQXFk5PtC2vUSBva+UhtSMwfk4dLwhzMjrNQn6J7+zouF2cHrdrRgSuPXAqVR2HF8quMiqYp96Xwo803KwgUYqw0Y2aGBg4cA0D7QHWG3ECUlQj17RVQvF73bzWIMVDZ3RXg/WNBsZT1GTqjfJUp9MZnL4btLzFmm8QtB/vktVtXDGs6juBX0vP/KocycyvicM/P8ekOnfmtZe/3NjYuqTG65wS5x03lZXGNJbfWhTXUcDGh2dKREOvckLTMgIYgoCyM5ti5O3J5D1cqg5SLWm6E6V8k37CkHHPIO9MZRIcp2DxqKQy+vTXha8vBuN9LImv2xQM78ul6XH7VzV9/B4ePF6jvb6yqX9X2WQBmCJH0NETOP53JumYrrynBC7TL22UQhYZYBWgFtwijxC2vLjUlmDqarjUyntVkAvhneaw89fPIyocPKlNy1ldwYsaBdsMtuNlKXJVAt5R/FBtXk52h08Yptdyhjr+PTAzTG+teKretfHAq2MGToW6hOKDDz7Ibi7P16odhW5GuA0fcV1Lkulp0ri8K89N4fakerUYS/PzbQ2YbHti/vpWhFQvMre0DB0zOyG/PT315oIzBMAn7b/9//237f/8f/qv2s9/9j5CGJ3rgjeh1A5xO8m5ydloNFzbOwcecnE0MMl0ZI+vbmB9O5GeEsHMdUFzuRPS86bUfji4dg2QuxWFSdbrmQZ9RS9Yu3tVbYQJkkPKXd+pI9+ngIezFh4x4Poj+wynKz2/bGHBzt0jMcDVvO2csDO2c2dDajoN1pzBl+W3v5K/qTaYhN9Pimtxq7BO/+AOQWk6B50Skey7env7Q60hitbV/oT6uDbJNUcJiL1rG+aVet7bmm4vt2EU1Hpb9P6mpawUWDj4rsY2/C+/MuJLLJSQXjZu+ZJ14RmtmU/KGaubkE5v0l2mftKR9VWQIrms77Jc7mYWZ66TPh2ctrcev9U2EcZ2d3YQTo8Rtmvji3BTI7aEkOUUZV9ny229s7QAXMTilhbUODlD5lpCTyo4O6PdQguZufIIrI4uPH7psn/irwCn/xnxnYm6Baa35HVDXtZM600gV0DJAYjWcCpKFNquOuEta8UAU85KBGZZTxZ/wKcGjuf1lTzBdIhDYOH2N2qKbiTYYhbjxm+F2Arj780w48Yw0TrxU8I0piOyWRsvQJ9dmOd9HiJaaJNzy22B0dbawnRbW1bF7AjrCkYw1VaXvMPSHU7TbWXG027ncgDsHCO+9ZXFNgdkpkajNk2jngIJN+fn7VZkKPCBGE+K9gLo50N3PSKMhVnJkEcl4RL/+qouEz5254RqUOJ6BMfcJILVrVvMzyNwuU3bOq0vL7T3ttfaMg1fAl6wQVFP65WzpLQSgvACSAU756MR9KbmeelgHDh3T8KWLfh9lQncTewNo1d96zwwErsN/69qEtWy6v6KPMaN5dU4KtX07ykHjbdL7W/EWBY1Af1djl9lkjv/bMyGz8gtX14vSbQpwgVPO3Q7+GJa4AlPFyWr846SggaosW4u8Kww8fpKUy2CAOYv3C2DeM3XTrizEcSvOuA7YwP3ZvyvyRSt3Nve9HjUlL/4VVtR9FkV6G0ftsL459VG7h+jOdRsU6ZfYFR95XswAh87kBKwXAqgLXwoXAkj49CEAku1DL54KT9dA+nPZirROFm/xTeFMU9GV1vjLkOnv/YOynpf4uHxIQKZx+YwGEO4cK2JUzV26rJpEEDhrqGHvn6Uk59TTgy0S1ZEEPBAVKfbnMovLYxCCh0kdZPu3oRtTSERN1Y3Ae/8be90Dbi9GULeosZ259VODg21Y5dP2syqoxSA8hkXtrs+TAGR5IDZ7C08FTqahnctI6KswVsXgdUC/GamOT3knYCP2sr6gza9tNJu4GVO3RwhhH3x5Fn7oz/+k/b/+L//P9u//O/+ZRZEb6+tkwoQQcBwKsqpLYa8yWfG63OEO71TNCuBlR0Xwi2/mwmfdKA3arzgpQhKK6ur7eGDt9rjR4+p7ySC5iHC2AE48FwwYQmeTYc6Rdgj94BKWsBfAU0t8hQ0Fu018eYRjOgq2iLPOQKBEr5TLgUIhIGF5bk2v4JwtrqYq3Sm6V9mGNQ7PZmF+6Thjkkvhb+07Fj9PKvMQf21U49no/QHWSOEYHbl1CZxvUYJcgAb3pl5gkAwgubp7PFxSvkaQdSrgwrv0Bh4rbWI1kY/3dI8PMu6pu497RWeY8cGlMLY727KiPZOgcwMpIxr07FA1V4VuLyWqBM9COO6JjU4ZWsnKd8imJVbmDq7M8W7WkGv+bFM0nhoFLfaZc3a6hpC0iCDnNoBOZ+DUw/3DgIvzw9zsX6mtJ1xMBHTEk/AKYoa/MqtMEopL8/b0Ntrzgf0w5W257rVxezCg7oBtwto0bul3fjnmrAzBLGBm+86YeySfDzt4EI8izPePY1Qlck59VK5Yr9vGI+I6TVdDnS8RxdxBVpQw1zCmcLWJfn4rlBWbQ9LOOWLc3ERqPyKxg4BVhDEWc1CPO6OeHDGanyKdMPLADTdp4S9e3ZuHNhaNOfcbaYkKbknF58DGIGT3QgIOEhFbXGmtVVGMuAEAmNES6O/hZnMIqA5wpV+s90Z5nHLi0R9g+B0eXDSbk5HEbpOL2/asfPAHspIOeYoJzm1w6vzdnR00p692GtTAN77pKZg5BdWNPWfQgIftb3Dk3Y0ICzE5nEWZ5dn5HfWDrCXNIY1Fx/O0BFgb6YYvRJf1bkjTe8ko1TtCmLw0vBjBDvnkp2+dOSWhbdwzdElHfTUAuWSCQsimWmHA7mq5QnkgDV1UACJYCBoebxpBLejI79WR2rjlxlBtBJ/vnXmjQQqvM/8rzLkBdvh0bTKS1LTXe/kkG9JM2ErfzsXewfDgGIjdv6ESUJl8j01/cuN8Se79RDjafQm9bUgMGunGVNnmZfFwvQx8vQT33uBrD/s1Y+ZppwDjzIm/FM+6i2jLO2M4UyF+vDod9VBHLGQcfrzG2gxWk3CFzxNQ1oUr3zz0zX0S9ircxo3g4SrIbR9FoD9nZjAEBvBp3Onvv9eY93eDFPv1raiSwvirZ6xvR9GYT558vPpr08hQot4MBvorqYly05NlECWHXcwe9uQi2g9WdsR9enxMaPzk2he3ArvmVFqxVzXU1clXdhXxSRfrNWx4zf/3k/8WdY+X7UCTqU43ZZO0PDGq6RiSsjS6v5lcEylyKjah6e+++46KM88ev/999uLly/gtY7QSyNmedyxmON0Ls7xs2NTXMKEv9JxEm4K0NotL8GX5FfCToHSE/SX6EDXtrba6sYGtD4bPvdiZ6e9//MP2h/8wb9rP/vp++lIXWMnJjwSw47UIygWZhGAzV8BmvQKXlaBsnVw0NPfDS/XCGTOg1lEB6mbm1vZJLC1tR3Nnye0XzIIlhdaFzV/aiizeJzwTlvJ5yvdwkm0Z9CE2hqnDN045fSkAnU0OAg/dvKuUZpGOptbnG7zi5SbQf3MHOWmLAq/NHLSE9fQIg3x5hp6AM6hW3FOY75xkxj83H5HVYjrps4pd05rpx8hkfSFXn3kfaj9Dt3wY6zFFhaW+802FbrX8q230pd93/jUZeovLZFOaDN8rWjG1IVN4gUu9aQlxVqMng8aP2vJjGN6FpG6aqWg/j5L2ykEQH2BUegJwcyceHq2lzSgwKRwLr/cefkqa8fUimWn46tXEazUopm9U5ROS5fWzkGEuBG39MEObMCx09VOY0oDnnbgDTs571M4Yz3pQI2XLLV2PNImIiCpgbRy9rDigtowGKF2wBD5gafTkbXWSyGNQRjyhoKXGwPPqV8EMOqmAJZn504Y4yFviOu4Ce/6MQ+Ed71ZH8Zpy7+lNWP3Js1KwgziJTLRIojL9Az1l5mQI8Fd+GkrUJrNfCzWc2M8F8wG6QhJu7u/lwvEr5zKg7CAeTulg3Kn5f7osu0SZ1/AnF2E6Y7OVE+CJE/hpuG4/VQGuUpDfEiD3IRIHBlOk+/C1HVbItyc0j5lGtiWptzV6VTHVS08XFtDIITRgmAR4nVGVwhySwRdX1huN/Or7YJ6OGqUwb/aP0IABMGwvgEj9hs1djBpEa2EbcMTdhKd+QhPBcWriaVqBoDHOkYYw2HYfh1ZrPDDlABUbz419w07UE7jCsHfo+cund707yX0jZkw1hK2etO73kyjNwY3mhmOawMM2pU04cZNlffelAp7LJzFyHOsHF26yYP3pD9Wprs0eXVt3iQdkAJA1edNU2lUOY3Pe0fT9Q7Dnp5jNOwJ0J1R2oYvMZC8s57X5hREtjRracAy4rFSd/8tA4yRJOwkM9KGvm8juIHrC3CuNsz6MaR3xP4finkTV3+56eApnvqoefYvfDcI/4I/4BG82tmkwykcV6fUxeGhvuCu4/KHMJBLtKN2E3fayUxV2CYP7y4IH9RgD1o3TZl93w59t5CUIs9+t+2bpverwZK51EGv/Tq08L+uTuOmhP3OksZXpo01f76SpmvSnC1wravXvZ22D3/+87a3u5ukIwwYmnKonTFO1rrhzgXzPB3U2q4VVOwcPYbAacPMQNDZRbDB7eBjag6+tzDfBgh0H336afv9P/iD9sd/+qft5cuXKYPTSV7/I+yXXeS/uIRANgcfp+Mkzd7O0+Ep7NUl0YW/qmvX2QtnjMLFOsKfZ595l6A42d3bayfUM7hXVUJ6lq+WDBR+1PooHLmMRDikNeHfL/r2SAQ7d6cop5FAp2duEQSEJ0KYp7bPUi7alRrMSYQ0hS95/eWVC/dt1PJBcVhWwUOhMkyZdq1G0COWroCt7TzKANcsqw6hHLMeCoz1PCo7ZaPWTk/ozLpYN3+EHaeA197Dd8oY3hjSWc/vhICuvCs8Yq1HziYjQAli1q0X3AjnO1Zj3KQTP1Pv3Pmm26f1sRyKNFr4UuoPr5LO6M/oEAMbl/cs00d6DdLzp08igD18sB3h6+XzF5lBcsesd41ms9uiByfTXoGvQmpOrce/1opZCtuWAtYVMkFd8m/bde2ii+Q9NDcL5Dt+68Yb+9bsZqRctTlQQb7S4UHp5ecluCkkufje/jyaMOOCX6ch/a74bRyFam2+GY/vWjVnasYicCnYYeNPWWodmWUhDm5r86sbMEG+eQYXGjqxCMjWJmgqRuTThsODdyorEnkVsfemEJlREt6ySf3szxBYUxk1W0ChwuLvllrdtzDYWxq7HZQnwB88f96OaLCjwUnb/eJJO97ZrxPvQY4IcdroVAbMu6p2O9WN+Zm2vTTfViEAOEi73VxpCxtLbWUdYlncbEsrK21/eNH2TkfkqFqbhgoTyNQjTGdz3XOIptoQpA0p1hUd8+ziWptb2WrDudX2bGK+Hc2utFvCeiM8rZ18vScOBgnSlKIHEElgaQOGuKg0YYAvwp4Na3h+3U5vVoDSbBq1jN6OXAk/kn2BpgzfxIOw14xDujfVmPLvzqSzk7lIoABfbaRCRO2YwS3yzEcrnzdT6lwXaFd5QhgiXlyaaPc/uxplBrxr9a3SlTFKSWm6q/xJK4RGKjxK+1AM5DX6yTeeXb01ftc6RXQ7RTzydmSXwP714fjNLK7AwBVoCAzMSyCDWXX5yGgcFCRNS2+Hri/52aHZuTvguDpjlItfwqWvJx5P5ICyMPwpmH2uTMFOMgKfhPFDvjwJilCVgQsNVXjLHAJi3l1/MuHaFcJNL9BhLGOXSGvOdEXIfximh+tf3Ygn/vsPY/x+PUv5awumEazGcC86eXvtW77zC8oiFvgOrqAt4QkrgcnCGGlzMsML2pWDNLVfEcJoj2aq0NSPvhW0s4wgafcCWglnfedlhjmok/iBAf4BBcmJ09LWKIjZgdQo3RG9tspq+KLfcZuPsWXwJaTanaI/NeqmK4/d2XnVXr54Tp7AkGLVVVvKB3Qm1E06cnG1WiTvz/MgS93Wwd2Mnt3l0xoJz5TZ2QWs3HYIbxqS3wn86ZROb4BVMJpGKPTYCwVbD7pdcZMCQpjpXzMYlq9HM0XZ5WbumOzvnIw2B5LvcZeOlwGxbvPffvigPXj8qC0sL7V9z2U8OS4cUm53OudE93n4LXaSePI8rZpBYaXWRvqJsGCdsMKu1jMBR9rlHO1yds60Gk/KSHucwW+atqrwImtQs3QVLRgwIwfXEMsraweifROwppN3DXHOigRGV8DYM9nkj/ZdNxTclurUuRepDztNmTM24RnSMM97WPhez/peNBKk5kHdtCbq1C807k/cEzSCZ8HWNkU9YGt920qaSb/L986v8pEee5t341n20IZP6ZAn+esvf8pdnNRXWMwQxwkWN9A5ZesuSNeYvUAQOz0+at/99jcjYH304QfhobYvjddYqUHO+WERvqAVNZjiKmW3braNErad1lXb6/ICrUKQbUuByWUI0kA/jeg6rpwNRplLOwWeSEM5Q95gnF6As1kGrPIN+1dqGQtjz2YQrO7YULbfDSuOtPIcLd+Thrzcp6Qgr7B9WsaC369lQg8SvI7O9AQjpYSZ8NOI8Apvw/D7X26i/aDAPmOAjoh3RHcVJipjnQKoNEwYhFcOXJ8z0sPDKw2Gz563iUukbRCHCNTW5mfbytYadr2tby21pY3Vtry93hZWFtoKhPAILC+SlYzgu2+ttW+9vYE/ZZWJWR5bqJR9gxBHY3MBv03LxjINh1ucdyS5CLOi3NcuJpRZXrWFy1F7fDVsSyOl9gsQT5mpA5WIQDl3cwF2aJBkklGiZE62jkRlNp7VIrKU6AfX9LwzSyDUnAu6HXSIZST+hLtwEn4B4H0Yzd337hn43oWvkD0ek6bJpjx8sBX2FlBkOlPru/H4Jd3gzvTiXcYgWHzv85WhysS04NeOqS9DPSts32llJ0zKW9/7sJoqwf37m0ayq3oVGmU65Q8TXlpN/jI0tzl3WStnxvruyLUal9WFsZgQLzISF3pmXQO4jJAF88j1IIysc5FuOpzOhuGVvRc6LFeVp46p4B0mlLTobExLeE/SQYQYIliav0EprzD5OzI9Ht60fz1j3akH//u4NKuyfCr4UGfBILwMn3DCIaH9F1gqJBm+PhuumKAj4IyMaXfyC6cenMJwt6FPBYkIYpjKr/Bi2uKp1445Ks9F2ggTtaHD/Io2JCFHutKMU9GW03LUHZSEpxwKZ3ZaV2oQQmCycAtr2B5+tm7aREY8VU8CYstYKvmOaYzOz0gPnjc8zYXgLxDGso5GGNgG02aE23RoK8cS8O46riy2Jp056pUDNamXxwi4mWFxYTEdpHQ4gj8dj87a893d9qnXxwwGbW51pT1+6622tf2QtN04AO2TRxaEW0/4skKCC6/VmNX04BT5deXnf876SjvgTZru8B1/+LAHd25sbqbdnNHhPnn2tB0en7QROByCPy/SziCK7/IihRoyCbR62oiWz3bGS9aTEfZ+WrK0XwpecwyKFMZk8xHGFMRIetJ1ZoR18X3xDWAK3pxRcYpS4EYLRF9z7RSw/YU8gTKWYIYw5jthpDvpRO3XsVNzh0dZMC5mEWUQIEkXepAGpL1QUJ4FM03RZlpAcFw0eu+vn22kr7e2dopSFwWyhBHm5FER7+JHMOvyLD+sTwCqFbKuuYsA6Dv/agf5TdL3hgTd7iC1EUzQv4lvaWt5Yb6dnZ60w/299nALnBL/yWeftxNg4EGvuRFBwQsazDliZK72Mge88q5WrOeVPjUKWU5PupSg1nzRntOO07VEY2Xbr7VcCmj2m0IbeOPOgvvMVvAkTHY42iQpm7SUmsk/CI9X0ZVAMX9g2PtpjVPhDP9VtltxR3oOJupZa0qrNr+iEUEhfLP2xeKAFFkIeaRwYarYnqDsfPpprp7pxJ8IkludrZLQhXlasuGVl11gucC/lfmptgTWlZJp/yD3COCP2szcXFvdWGtrD9bb5qONtrQGM9lYaWvbG211ayOXyXqY39LcdNtcnW/ffGejPdhebpsgeZkWNru00G696Httob2zvdLmKNfLfYSnkxNKQ4OSGdBSX41u2v7wvB0Nz9oQwe+E0fThYNSeHw7b6Ui1LFK1I26Zo2W/vWqrdNBrNNrJqxEp8R2UpHHABJbsbIVbNHZdIxamlKlIHJDAlBxJ2VGcXtCpTK51BFKjvxpZFzw7DAQ3glPkBB/d9whxhM871BM3vxjBLj74+V3SUpsVfxp0EN09gh8fcZdQkfw0+uVdR+Wb9OxXJHRaSbQHoXjLliaOoxJQmLsrY777LxklTcvUr4XpbR+u2JbulD7wq2IHGPlmJxu3cSnHhLtp55baFY06o1iZp+WL7WCrepY0psGFi7CnEezTCWRdBYx8cSVMiciphnkXzMyv8uVrlSDvvBG3F1zvDXUU33QE3nKgUCesb6Ehal1wreQSL7D5Gk3h5BetJrTT2Z5p9qb3781XxX9txD6WRrQaCqJaOxPDdMTmKNdUfUtc3mTy9wIbYUBhCWEKQFo1HPXMlMUFbtqsdOmIlhRIX6FLQaGeJeD5dK1KTd2Vpkx/aJL8M1InXa30m7KTlgKKuxxzCj7lsg2G/s2P8vcwuLnriLXj/uV3/w0L/atVl4/YWQlaO7Wf/uQv2uHBYXagwRwUEyP4CRs74BSUfNVQ5JBV6rVIfTzbyaMWPGJicXEBAWuzrW+s58xDj+g5Phu2naP99nxvF764144Hp+Exmw8ftG9+5zvtwePHbREBbmlxKUInRQz8PWvN9uYiagWx/gyx4Ce4FM+UCRN8x1Ybzy7K+flovuxwXYry6eefk/eADuwqPNFbQJT7nCJyOkiBTC0e4138SQP4mGcEEvIRXrXzUAFMrZyDb9s1Aooy3bRaMYQA/Oxf1GZnIT3h9CuNHUAMPqQZOn74RT/lq/Dle6aBoS+12yoH3GDjO6khQM6baDs5HbYBQgSlvuukw8sIJezEV9F/2cCHjz3963dn5EPEjFbNuNhs6KDOVFW2kfiWvXZSGopnwlf7jA/+wQnv+lmGCLDGN4z5UgbzSg8FfdoTydj9TtLRZJnGFYMEp2YXweEyNHXuzQXno7aNILa+ttpeIFjv7e5kTWFOQADPHug6P1eCV9VH/NSuyWhRLTf52BbSllW8IMy6dKlmvhS4RA/tzHbPS84F1I2Hgx8FMt39wFoenEX6pOdyJWsTK5r9jtunxrzH4T7uvjN6CSd5AxUomrbd25a1lt9mCN5xWJeuCfxNGUqQDvPehJnw02SUKdqodCrwWlBK5hBKT76ZjEhYoALudFEZ4LQgYyCHD+1s5KWdF21iyMgIgIr0a0ZtEozzyY7E1tbX28qjh21mfa1NLiFkba61eQSzKXdt0GEe7Jy0U+wQAeqCxjG3xSjvnbW29XC5DWiBf/Ji0D4/uGh7VxO5zujV0Vnuvzw4GYA4JfZarK2kf3R4nGkORzjHg4M2dUkY6jGYmG/XUwvtgvSOCXtEGV0EfEMDnFGVG+Qj2V8yuqLsMmOh5chVXZhuGY1rIZwqEJGn5zftbHIVgWy6CKpDZrbQBtESWcfIBS3mHguC956YarRvw+a980tY40qJxtI7nypehcrb3bPc9S7u7vLA9iPfEKR+Jql/3nXTmCso/+qbzuoIZR6GlQnIVCo9v7kIVCYpY0m+lLk6QuCB4ARI6OiwMjdGPVlnBTP0kD8XGd/ylIEqPM2urgPf2aydkem6RsQRQDRbszQo3hWQXLSsBswtzxQi5U2+4HZ2fgWmWzusqhHa0DtYYnvTO3sYVf0In3qX370Qh9WNcfu7wpjRpYOY+hQznsfflbHsvRl3/1VMhRfPwqOjld7gxKujg7LpzBPmHr74dEytgyOf/Zb2YcdpW+E94lviwhChgSuFb771Qpdrn7J2B7e4KTosWhSvdgyZvqPTiV9y1NT/Hue9UKYQNg+Pye5b+GCQiL2LZ3jLRvh+ur+vU7lp0/DIO0EMa0TDe86ZAhQR28sXL9oXCCtuQvAy7H5tk7Rjx+U0pYvn1Vp56TEB2gJlW0OAWltk8OpaHQaHChyekL6yvtoWV1YQdG7b8XDYdr3Pj8Gpu80UxLKRijTmif/o8Vvt4aPHEcQsW0ovjIGPmgcXLhddgyN5jnDrcCQEy21nzpNv1luYC2M1mSfU6cmTJ+3Fzqt0YC4TUDspm3L2QAGMCOGTTld6QXTtFixhxHTViMnvytrJi2vx3Alf4SkKS5OkYfpa/OABXsAeK41IZUokYqXDW3/ESdBGoeQz6dKAd/Ecv0+03Lowv9TctXd4TL+hgEZdrkmv552a+l9Ger/z1/3aV7Iw02TsaNf+VZ4qlXeCF3HuLfU0jS6dpNR908/2o2/CCU+tPnwrt8EVksyjyws//WWbCltqxdSQKaiqoZ2gXO4+9WBX8aEwtuvF3INhjhGJYoVy1zQk7cs2R9nJMuH7sgdAwFZYe3iqcoAHDY88rgI/UEF7UANuMNs6T/4pYNkv9Gu/Mi0p3sgjSVL2hCWPWPz7dWB+Czb4+yrTt9PXjGXFyit6twkE5p3t/eyfpCHh/iubFMEEJbb4VOLjpoikGpZVFnlmXEjvCnVXGd5N1YbOm8QQ6ZrEzwDk4dllOxxetf3jUTs+OgeRnvislAthwFDUXB2BmFMk4pM2304QhE4QXGZnF9ra5mabgtEcD13fcNYGCHGn8KmTqdm2S+M6Ja/T68n2ycFl+/B4qn14dNv2FdJofDdYO9+5pZW26qncCHOqU7OoE2Y3f3vRbi6cftSeBfGqHecRwDYdbTXyuq6zxCTYM4gVLIc5WVFH2zWFgRDprkrqkrNNCHw1GXKhUVSHIMM+P79uJzeLNF4EA4BTZ5lIODz5hajECX7peAJScRAgB8q9yTfDi8Du+x1x0TBkcuPGb+M2Jmi3lL5XoxGv3deEE+c4fCucY3z2ydugTSPPvPc0k5c0GKlVwbT37+OHQcggZbAZ6XZkTbAIZzRSF8xnPYMdnWmZJiNEpw69OmV+YzvfkNDCcM0rwqOcIOF9J6+kTR1hnpmm5NXi2DlOI/BfDA6rrl19jdrDozemmSQtg3F5K+2jmeRDaD/hKIMduOGc+lCLkvS6b7ykPsIkZf0PwFiWcdubN/0Lf/e2OudewBIUvhtOK0IEjZ2LT1l1AC8AYfrgV8IXlomN0RFLSOhAvCQO6ZiG+em2wWSKqQujEZbRnkw6Qr/XgNkGfbdDjcAG3VnOilTPEtoclat1u0y6HkTpQa8iK9N3cILAITGKRu6FMYtchfeMJTsTTfwCC+HSwQtCVQtjQq5P+vSTT+EPZ5niOUJwUgCTNg2bJM3b9HhRuePmJA9hVZjLsQi0Acsi33ADkrxsQHo7B/vYg3Z0Co8jH8AtN5eNIZCppb7JYvTtra324OHDtrK60ebmFpKVC5XVXs0tLvAEj1rgk0NNFWbtiPUCJxF+eReLliEDLf5clL2zt9s++OijHFmQGzCw8mWx6gBNbbWCmHZhabEtLC623FconzZbntGK0b6NnsXgwMkwrnczzWk1MvPwYt5zrVI0YQrfZcNjLLsoFIywDPlvLQRX+wIPzpQX8AHWkpPvlxfw7ZEbJRBcEcQW4BX2Q7sHRznDKvcjix7SFK6avp1oxIl9YQajyZ+nNl8lC75pie2RStVm9Ac2oZJxSyySDR0BP2nddCpXn0VX5qNgBEbCa+RJHr8kSqJxM3/j+k5+Wo8NsW/0u3TnBd39xiJvx8mdk6sr7cWzZ7kU/GpUA4I56M/1ZNnVCtwte9Eo9bDe8nd7T+CpNjtrPIFnDm7POjE34ylsqd8orZf9q9puT+HPGV/01dJtWeUG2gYJKgSrQb0DApZW9wu/mO67xtabFty9332z8CLe/gRr0jZqabrnDfyBy7Lh5cLSNH5VYwJmXOSiSa7l7ExPTH1BjZPRmu+9SZAK0AWLSyTLg8+Jc3GmJgPhyA4VP/tLBbssyhZ0ME01UNeQyxCBzB0qqiZX1lYZhXg+v2fR3LZ1zxyjsXqp+MwSDHXRhZ+LbW55tQ0mlts+Qs7hUIGH0abnEFGAyTnCLS3DTDwxf6adw7zcpurt/B7K6kGE/T1pIVrKor/XS0zelhAmca6QryOxKcpzzejzBjtBObz8W0EspwaDvOzACBN3xDuZkWup9iFGjIcdHp9Pt4vJjQiqCqMSnwuCszDRJ+82hv4ZEPNPuN7hJEZ3NVy9/Rb33ZevNuNpVDgZh/7du+nwDI2MGV9f95IQg8y8GTdMYswmoddM539nzJuYBpWwsWHwWJmnTDVMX0btGhCZfYjLuHRUc8ttcXULxnBKSjSgPu+kjekq1TMkTdzgw3SEr4HnFlcRxg4qfBff+mjH65OyazUGtYPu3g0rHQWecuYYmbqMZUg48UPdUv5yJyOefRp/l+Z12ro3v8Q7xnKXlQmP0WdXP20/NSk+y6+rdmcTB6v/uEmHkfh2ZMK2BGpA3sFYYSXdIMywYF5TkSWARTggvslXh6uw4pqWEsYiKIsfEjQZ21+mOfU3E1JVU+SF2Ll/sGO51ZESLm/Eo52WtXsodwmHpufTchZcfPZwsl5Z5IzwoDbs1csX7QEC0Ttvv0W+k+FRLtIvDV7VxSMGXBu3vMjAkgGmOxoVRnMdj1p7+I4LovePDtsXT79sH336Cc8nbe/wIPzXm0joYuCz5+Gz2VhFfO0kaW1sbbcHDx60dQbAC8sr8Li53G4SzRXwdB3sDXxbK0L6pSkl5BQOU7+0RWBD/U8GJ21vf689oRN3p1xORBc+pFXYkw9SDjs98pgGJlnQH6EZ3iofgG+r7azpR62CWwliho81PILRJNay2s4jNOrukdUbce4gV407eI9GHnyJN6e7fM/hovRHdeWNg2bxtUg5ZqJhPBkMKcMsQqraxIJDdodSr9A52URTGLcUI4y6987GV7JycBn4YdP5Cz+eoZuiHQ2fX6O/9HHYDCz6NPv88ffJlxzS2wsTphFNI6nknD3CJ47pUxb7XPmsfZj+roNz6nv7wVY7Hp60z774DCGVgS9dmoftepG4Vo1YrsSK8KswbFskz7605EuSmY7MlCSCVu1GpA/kmZ2PCmvAPRtzwIu04lpRIdJP92vsFS2XdKYlVOCVw72xqaRu4Ho7SWzcau88V83ZlJyz1lvi5rw1vsdSVPnJvRXeblwpG3gCJ1GtNtABgij8FQ0I578NfBzRcVmHvPEEUfqpYbE4jjYlXM2d1qUPjOn4DV5UgMpnECWyIdZazEyVyNKpoyzWJIKL6g03c3Pe5ttlW7g9bwvXx21ratQ2566RuD3rphYFTsBEr6YZlVzPZO0V7SQjKpmR041nR3ttYnQEwFxQCSLml9v1wmqbXFjGZ4bUp9vl7SRItlyWYbZdTsy1rc01RoXrObnbG+XBPvWDEBWyVh60q6WHbW4DBjm/Qs2U8BkN2JhB6iVC27lC2CWMEGle9e48acACsshWJicDk1nIsDxg9uQMgXFqCxJwHRnJQYBZh0V4hTNHlfWUmXVwAs5FgPzvAR3g95Yweun2dcz0oTXj7hg9TDxP/mlDyP037F0sy9I5MdJHnp1fCVP3/l9t7hNIOP7CjMb8dedTksE/5fHldZIXDgurm9mufzE8TrjxvAM3LfhKXEeSMigZF4zdjO0sZdpz4Pby7LTyrehliH/f2ZY1vaRpwC5wnEauymAoC247AjHnESwmbi2LSVY4GWmSGCv337Xp4da7rctXmYK1TL+eGnnleHy/xVLdCNpyOj5lPZ9B+u9YIdJ3ND4rXwU5Uec/2gf4clR8mZEygzuZLEHtZLzTzp2T8oq7wQ8dq4KY5RHmhjOC5ey1Ik7/5RmBTQ1s4dk0PExWIUC+VwJHld91ZLoNZweeOvvr2ue47QdYoZ3x9otbnmqC7qB8iTC2ggC0tbmVNV92xB4XAPlQRgR6BQZ4hX1NrdFxwbSDvdoZrubFPIbno/Zy51X7+NNP2yeffxbBzMXzCjvmbHlNLyeX2zsCbwXGEljhYQwyFcbcAbm2uZG24vmQCk9RzpmG9QpH8mcNXqcDjWnK/1ycfXJ6igA4BGc3mV3wKAODuv6sOtrbnEm1Tn7zi4tpo8LfTj1CNXnrVnDN5gs1XnkySAbvnvc4E2FsnrjudC8hLAOA4E04Fy+FIfPkYR2wdwMn/MVzPzj2qYDgZ8+1c0eugpiHBx8derYYnbO0Qbi0dcpnnr3WNeVO/vc0XqZ7jsErTjuM3FqA7aBatkL1Oy0VrzRpJ77LQ8g/9ImtxO4ehOhMV00FvtLS4UZYwUk5tZO0F4+EuQKu9PXUK4NLcL+8stz2D/fbp59+nAGEdOI6xW3oxNtxTC+7lsGn5bgTxihEtbMSsBwQOeWrAEbyWL/Tr1Hl0oLZDwp/LLQZDRhwLmG5rN/jjr+DnWpTPRoDZ+qWiln5AEIKvbehYurV2/tvuisNeVAlpUCmKXxU/Eo6giyyTH3/FY0ZSSxSpYkXkerG4LQQ9378IATlP+fVLWgVS2OBEytx/OfTOOCiLc5MtIVFGMaSF+tCpFKAFeAnI/KMr2Uv1l6Yz6Xba0vTbWuN9+WFEJZz2E4fepDq3uGAEdZhGx4ftsnT47bcztvt2WG7PthtE7zPMlpbcPEm+csALcc8jcVFhfq5hbnOKIGxIUi5i8lF2857r6+ttO+8t93ee7wO4S2GGX7zO2+1xccP2xAh8OL6vJ1fnbVtKrWxsFQH4AGBIfkMVP2DRM9W6afJXCchMQmSdMi9Rgd4epDd4GalXUy6nqMjro4Ie3dGaVhexU4RHuW/h7tJFd4KT4IevJCHgnL8ujD805X3cndhcYeoFbDlsp2xsUqglTYF6Ewl1aXzhhHfpiDMx4359DajrzcDaMgv3/iZvkH6sAmfhP2ruH0SHu63uPWQDooR/ghBSvrEPzZlT4ErLLQUhgnNyVAVtBNeTa8MBDq5Pjsu+PVxNV0Z7srS+Wn7MISucB1tp5g+6LA1N9eXOZ9OUykYz3rep3mX9t+xuatTX/87MwaTGMtbuNL4TQs1FXPsOGPVMV1GPbFV+4ozXutM995/1YswRfPltoO0g68pawUCw9mJiD+nILP+ilRl0t7C4fpCvmbNl/cpKsQ4UMo5RQhhapQUxnIgLLYXSKxDBDzDw/tcRC+/slOvKU/Hx9SFMqTNdmUpLZidaQcH/NPGOiuE0qY6f7VfnlzuXX4ea3HBu8x9e3M900Q1aqes0jf1dnH00kJW37ZzhBsHgbaVXBdHxzq6OEP4OmjPEOxevHrZDg+P2+hsRD/vgmwEsCE8k84wWhGsOzLVvl2ew82oo+WVXymQLS4vtZW1tbaygYCEoHSFFJiF0pSbkLxTB/Cba99ApNhMWxCr+sm/wEMtgL/KjswFrFpHz53MullwdutU48pKW3/7cXvw7jttaX2tXQMDZ1EsSzq7aFe76Ul5vEIa42af9iHTrguz80dIkwQqTrX3EsCxllVciivZGs8JMhGP0kjoxu+gL2yvExQ8ZLjWinkbwmQ7HXpND/igQNY/mxHMSzqUl0zUtLh9nbSWdX6mTrZUIyxC/OUdeKUEvDhFOZUDroUk/ay4IP2qB2l1z34HJFVM3OyGJG76dOJqnSIEAaRRtKZxLXOuP+Ip9SY+VrhK49LRurAHAKPRWa6usr9fZYCwv7uX+1Ktzw30oybM88VsF97X6cX54iKVssxVuPSLWe8Yq4bR/hfaYVBRG3KgJeCtUEbEwg+u+2L7Lh0ZrrPUwbZjOWvzRFpV+AfRAyP+VTl4ihv5UISrpIi1mL17zCYMDqMbKJrKuClPlST+MQSU3m3PBvmVjRmr/u3d/f8wSEvDu26feefPiumltVoV496E8frsvniL/iwF93oFIZ7GCQIm6f8yighznqHRTeY6haWF2eYF3FeTc+349Krt7J5C6ErZMzBVGM3IKcObtgTBbtoQAcL56QiGVsCYdkfG1WQ7v/HKC8oBwpYIN3tz2a5hZsPTQTsZeDbPqDUY2Q3PBcqoetXrG+YXVtvi6nrbeme7PUIo87qlFRr4CkQ6R52XVJVT5lPSO3AnQqjtus1L2uSXDkCioxwSvus5nL7MKAmmE20M6dgJHJ7PtMuZh9QPYupGY2HkITLcVECmUUTHk7r6HpRgfBSedEuE+c93qdhGWIEqeGFl3NnjOYRrKPyCP2xN0fRB9fOtEuzz/EVTOfXmPi1LVaamgO7jF32V0an1cwWxERBea1r43H/jSbufdRcP+BqdHgWnFarMeP4+I3wZmfq6rs81YxKJu6YcUfvp8uwEf3BJmAhWY6bSq0Z9B2PK1tcunZH5JF5eujTAHR3mFTiPgGIRu7Q04jcMwwJ8DSYCgTh5wxbtwtpw3xvqGUstQhOWswSSqoj+JXyUpROgLj0MCt9h+/jR4WqnGBhFc0CH1dU5wj/5OKWlQOF1Olc3tRkjTczyyQhNNj0HFvjZrrylY462q1bMTlBEXHjm2EChQx40F0Fs3hPo5xYpyXSuWDk+Ps7B0x4grQAWYYwBn2u4LE5ohjxqJx/0Qsxc4cRPEPWLgzPwob79coMIifAHr9hRc94LZpoIX52gJ91Ek0F8L5n+9NNPA1KFqVsKfusMwTwZ3Q6oz35rVydteb617bWFtrGy0CbtwaDB7FoDToidbXTFgHWAILb7vL3YfZUzsABqm76BCZ4jyFwBr2uElyt4Hvx0Fr4zS2cob5uxzpRRa9lEt2uhlpaXc2jrxsZ2W6GtuXN5RN7nxL11ig4BhV4Z4WmqefOJZze5QeoGHnxDXt4sMXFx3RbB+wK48KDjyZmFdu0RQpPzDHRxr622ze//Rtv63vfaEsLYlTv34Lu3Cpiz4GAOYXp+EgFAfHoEgzs73VjB+xx1mXWGhHAea9Fbd1VCS7ZVeecleMhlGdKTbU9hyW1Wt+CXsooid/UpIOTqNW9LUSl5hhAO4UnT7kxVE3t0eACeEIIVRnh3nVoOrDVdaR47fUtfwS+0BA5ioRnf3Tg2abuXh5BxpspylAR9it/wV6DyDLXs0sePWpCXbQP4+Q089TcRpJmAkwkGGLnSCGpQqMsF6YR189y8bYXyzYIjNamUNuu8PBIlghzhFNIcwHhw8MIs7Yo2+mh7O5fFP/n4s3Z+dNbmoKUF+ucl8DfnWZyBI/Cyv4pQGtDSJkiLenklkRvuvInHi9+zRoyyVnvByoOhJRUC8gvbl+sye95B0QALQNO/s5Pgw2NnwnOVbqcJ3+UpPrTyFNlQhClgFw0ldbW92hp7m/bb+RlBdwB6Z/kuWoNavplob3mvEssXfmVDohiZgdVM5xKX6QuIIhpt/PVLOe6z7KVNU8oTe2/0lwhkrtU4r2iQHh6Y7cH8SQxqzrzEdW1pLif7LnhWFIje2ztse/sHBECAAemSlFqGVQhvm44NqaydnF220dGABgMBg/SpK5ivDeTsrM2eHrcZRi5zFyftYrDfTmk8l/h7m7+HAy663ovinl1PtH0YlGvW7IQbguEAHrd/PGxPn7xqP37/i/YFo4Gz41fthA5/b3jSnpP2mVOSEJFEvAZBy7wckc/KDRwV4ZbdqqJPMyKvrCsgX90S7SkdwnByq51PLGX9RI34HXny3c4HQjWPMHjgx2sI1pFBqdAN03esFScU1VvRVhSU7xWuwga/Hb78H7QCGz5VvBSyvgdQMX7t7eumTytfJZTOmI/m3qfK25v7MljGKmdoKWRGWfnsyDPhIMZ0fxJlRl0TbX59s00D8+Hhq/qG35vGuDZHR9hpeITJdRnQZaa7YGBz88vtajSgo0QAMI4/wkZIik/VpdoJxvIEZpSFZ84hw09vY/cmeRNPrZhb5g2QdPj1wcanMb4OkzqlrF39OvdX2b+OMbwj67vRe2ezkB7YlwBWNt9ob8ZxgGY7EQ8KKQqp0YYQxu/SQEjK8mD9hYRMW02I6zWAv+EVKD1CwTPH7KK8esXDJ+cRGNTKm7733XnSt2Ej5Nn2EMZ8mmwvrOY8LctBeVKmlKfK1Jdt3PRkH+23z5TZFIt2IqSZJ+1XoTOZEcZ4rqlygbs8QK392ZlXOA3I/xYBZAqB8STCxxqDw/XVJasOPCf4Rt3mGArCW4x3PDxrRyenbcBTnlvSLHQuz+Xdezs9OX8atxf+u+zLtl7XG3WWQoXX5F2B1+MKvNdygwHqO237waO2Zrtzqoq6ZKcbaaWmabjAxoEP8QBlrXFDwJEOtja2mheGe1uCp6tPIjVtv/V2+8Fv/Xb73m/+/fbo7XfbwvJam3WNL3m6ueACuhCW7ox0ze4c1nVy8whq0Y5lfRLlpENxSjLaKPJSM2VdxFMsRStsWM2uXcoysPLj0IBaGwf0WPEUmFFG+bD9nXX2ZHhhrHY2V/WZMOlJE6F1n+BGRYc/Ieqg414rozBVZer9+vcynRsbdJDeXR1MMTRY1niSG0GSVnabCg88InD53lnbiLtO00ala3moZTEefZjrEvXPQcLQkpd+q0V+8fxFe/rlk8BgEZxYKDViS7jngY3ulN+idk/hbN9U7do1jGOWdFRYZM1g2oR46BQQ9oGxussGT50t3pki2JPgujc9jFIGPvU2MLJUuIlecAt9qL3U/qI72s3YGjRm4DgW5g7+Cd/Zrhx/bUOZYkwwJfz3GIHQV1IjQDT6/TLTA2YGaEgyWTdFPA/lW1pAGl+ebCsrM+3Rg5X2cHWeEZON4JjR7FG7HB7TQM7b5upcW1+i0U1ctHmGdVoFrqOR0wmXjGad22YUce2J0liEG0/whxO3C0eXakoc7TKycWTkPPcSIxiZwfDac3fIkwZ1PBjBxM5p9J2AQlm97PTFwVE7HA4Ycl60BeruCHxrbbO9tfmgPYYZPfBcM+o2soOep3OfdS8MTMNGAGGrwnanTy5EpQF40bnaP9fKSXjeRL8/mm8XM+8yanDaRMZWIwUJstbGFEH26lk7Lk2IUst7/PhT3S6PR/rLex+mRmQd3rCOfmRAAOU+PvXLZ/146019GTe+3fv4vbe9FkiBxbR648BF2xOwIC5b6YzTkUn4WkKTFFcNK2XHVAPAEsYdrAubD9uIjvXiaDf0GYH0TWs8fjlTjNfaUs9IlmfSBb5T8ytteILwzyguCz5To85YVjK8F5i6Z+e+t9KPMNDt5yorEIaEzkjbDth0+W4QK5F0qxn3dfw6jOUfh7um9xu3f11jfbPgWgZtByAOSaeEsWL4+hUAeguEMjLWaVjiu+anGxWPl0UchyrEoxYYqxG2nZRgLXMnIeDqImSPd3DHnbizU1BT5JERnvZdQhHtjUz8Jo+wnOZlm7Oc8grXJfWQGC/LLzVjaBSnhdd63g96pTA7eNjV9WX78OOP2vOXz7N8wekvj7IwFxdNv/3247a5ud5WlhcRNAeUfRShRCFzAX6iRsZpnxP42MnpWTsduAEKnscY1TU47gYUvqZXsMNlWah/NLX+pVj4d0+LLHzkRb67QcnzwhYXl3PH5AMEsnUEq5n5BfgU+QBywZ4pvrQBB8/wQ9weq1HHGJy3rQfb7d333muPH7/dvvfd32j/6B/8g/Yf/7N/3v7x7/7z9ta730bge9CWVzfaOnzWTRNqRNxNrbDoDENNhykczmf62MXiEfKlOQbUoTPC5GgFwtvmpaesEbUjDU0KA2ACjqPNlfAoI2NR4AM9yQP5HmWDwgvxFRxqU8hsOz4dtIPjukFAP8MFjpgIXaQvnPMHbUbg6mjGB5/LXQ8xUmH9qdm1DLh7m3IkUqVTPLT8BHXy0yIAal27xb98T32pg9pmw8bmXbTKL0W4Oo+ZWAcfwtYpR4W+U4TOD97/eRsOThkErKXsLunxPDuxnPV7wDVwjwXGCP8qAXJt3AV0iPUsMacnnZLsBbEMTICbeFCwje2++y39HvZOCNOSZ//UhMd2tqBetvcb9xeuBUPesZZZqyD1pttn0hb2Xfiel5nGV1lT/7XMjR2SGZhZ5xdCTAZlwjTuq48FGBIfceKbnra+WNhitnkBUQhBDL/WYR5bi7M5tHV9ASEL4eXhwlR7RNypY0/0PWx7B6ft8GQYhjrvaJbRkaO6XNapoEI2V6sr7WxpCW+QTiNSkBjdUodJF2zONo/VHBBuaH0gGOPdnF9RRy8fxwbxl20E4m/IGx6c3T0p64xIYyQ2OEPou2kPGXG+vbzSVhfX2+3SJgLkZlubX4VBwwDJQ1W9ayhWYBrrMH2JX7hMAi9Hb9H0QdhuFc6WbGrj6dizhIVO0yEcDS/b6dSjdjG5FmHQrbw1p16MMLb3R9C8O4MlowlxFajzDFbyK+L1m0jIvztzj1UMccOYTecuLRmL7vt4ptllwFdgxLNPJzkmCfOUbgLKfNHo1mW4+tY3Bp9FKz5No19ImtApS8HTAkVgicWfp5+n6RhmFlba0asv2hWdWIWtfMdN1kxoYNama0fvNKVlCzBhyFeT8+3kYIec1eTel6924ljHzqZslZ6YJjDhKE+ytdX0rYi3aGzAOuVyvc+dVs0gqYthSEfJmLLIJL8OY700YWp/if3rGMP3OO1t0uHbuF/Btr7ZfqXjIBRTTI+2jQ1DNzJ+gU9gLYyrw0la/BQqZOQybjsepysVwtSKpaMkiSsauutDXY9lmqZvR5TOiLSn6FRm6NwVOOy8NXZOCmNqu/86kLDGVTfS72zBEoqhPFlQTj3UjtGic5/mT9//KULUKWWBH1KH1bWV9hZC2KPHj9pv/MZ322/+4Aft7bcetsHpQdvffQVfVVCkI2SAZ/qn8Kz9g2PSGrThkEGpF9E7RQjP8LBSIaUVVh4061IIBZK0mR7+3ZNPNjmetIbwH9oH/MjF/k7jSdPLq6tta+tB29zabovwyBl44gRtitYTIeXS+pN0LaKfiYbL0+rl699CCPud3/nH7T/+5/9J+2f/9J+1H/z9f9CWluGxKTOlnIK/MrAcHA+i4VSbFzySRuBHmq7NjSAGLCP8dzTTa6bSqeqnoKaQAQ7VjLozVms6FrDulgVGdv7YXB0nGHiosckF0wrG5rm4RFudbPtHx+kz1P71dSy4FT3d8UcTAedF76HUavq4yo9w2LwbwzriEWtocYL1Jz7EVdGRiSRiJ2iBW56lYdczMfL01eZjWJPzmebENxfXSz+G6+nUIGq61IoNEDg//uDDbBBR+LIQnmOXkwGIE6EPv2jWyEgBWPibtXD0bDatuyT7dl7LbfiO5TVuYdYrHfrZnr481revcweOqh95Fi8ReghOb9iasyx3hHIt4f8q1rTfNHc47L715brDB0Yw/0qmzy4A1QiVX2bM8K4wZEqB1XSNS/y/zKgRms1UZVXSu64UZFxMOrqaaC/Pb9sXpwglPNUKnY0QlJxiQLDy8tUhjV+ivPTQrrkVhB+ELtzIJghdCCYQygxFWIGmLEpOUCadeco8Nxy0ieEZDIIRNmHnJq7b7O158s89VZ7zRYN1YaZEsnc8bJ88edU+f7nfTglzYT1pcNcwvRsyub65oGHCjGBQAwhoZm6xPVzbaG6lhhzbJYRxSSFqUXEhx63BNq5eW6CVIak1c/R7DBM9OJ9qw9lvAI+ZjBi8TL2/UD0LHrG1yNFRYj1d7KgWrIj8nnjHCbi3r39//Zv2zuTdVl/+hi83j9BHF1aUU6eeOPPjWeb+vWzPIOQAvZ/OCp+04ypTufRpYWx40+A+cbDATT/fvTP04uy8DfdeAGvCEVz7pom2rPtgGnYmTqHIlVzbk6lgp6cPX/K9UqLWgUHK27eRMZNy8y/w6yoQN0H7OqoFcvdZDuwcDZJ53+ArfB4YAxcj/jrMXbnH3L/s/a9j+jjWv6+jxlr5ntFnV3/dwvqOpu9os2KoFVMjYQdbpmBqWtp0yHaupGV+pqemZGlpIRt/7GRMM+3p8rydXZzl3C3PLrp0PRdtuRYTO30205YWV9ramgvmvQS8jrLwXDGf1GYcWX8pbMz3NWtng/VHtaK9cOu9l1a7q/DZi6ftyfMv038sryy1re2t9vDRg/ad73ynvfvOO+3Ro4ftLQSxd999u61Qv8sLaImhZQaVCJhubjpB0Dk8qcHsKcLY1TkwqkU0gXdpi6AxhVb4qtjxVHYXeetWgBiv451AgYHVpMOM5R2URbhZAV5OWT56/Hbb2N5uc8CrXy9Gk4q1e3fdmbvpPfLndDiKwLu2tpZF4dGWpvNU4CIcsL8ZjNrTL562Z9hz3DneAvwSKLxEGlIb1tsIWdBJ3hloib8IZuTpsRMed+Ga0AhlXZycjE89XL8cS9m8H9SpSisoH6yNHOCOd4/4mF9ebYeng/b0xXN4NX0a9HkBfpMf7tCmcONfNFEBqgY36dlf9iYsjHetEQ2f9g+ePCqktyUelenbpT49j/FF+ScCGYiM1g+/lCEWfwW2TmsGoMJD9VPod72hgwPLaFy1YtLK0d5B23n5KrBZXlqKEsHoi51iQbcYcdbFzQSkyBup8J5zIdWCIYTZvtK+XQonPUAbWmNYk7q5BX/Sozu7q2MUCr5334RNYCXgxm1BI7aHZ8Lpk2f/jRJGIANPPLUk8JW2/z5ue/8+/leFM/avZHoyca7dxtpXvDcFijJ1P5sYr0pauXTUHTCAGxF474jvHiDFlBW+LakNX83UEMI/AWEvQNTT0Xk0TDmbhFHoQs4DWzbV5h1h7nRTY+QBqZdgZbB/0EY7L9rl+TDrHbxZ37U4p4RVdXwyPG/TSClvkf3KrIvyaYzXwzZ3dtSmzlTxI/CdnrXB6KINzq+jgTqHIe4fHLZnz3fay729NNoGEx4B+CPKeTAaEmaYtQPXEOst5XywvAnBTLYnTiuQ3wCGL+OVoFXVCj6FqL7xTBFXJrSwvNhWVlfScZAAxDqigY/aye16O5vapMNwJKrwRdlkELGOGCBqGQRP59P74y3MkyqYFHnaoIt4tYWfzlgOwiVAcKbt8KXFLZZtXEmnCxeNF78ep3lLXsbEGJ4yhvPGr9LOJ8rWC3RFGsa9t6GnCjpGM5g+bQ0R7w70w8pgZJTZZj673E4RxNyEkWmIuzIm4n2aMBcXj1dDgt7Bb6YsqZ3XVzGsCI2NTg8T0wL0DDVlDXBfN4EX/oGXzz5ImCkpmHeXnzSc9WJdySLwgoyqC34BA21F99doejyIo949br/Kv4fpL7Oa/tkLXf2zBiPdVFK3PkVsOWDJjjvpHLq3AxSImQISX8RPJ9ODx3IE7nZw8heFJ+mBtk5noWCr4OAShHOEsDMEFo9RcDrwCkHMhddq36Vt20iOUKA8tYmDEmG9BcT1Mrbl0HBnsq6M/Hu/8XrHn3zrvSxehLVu4t+O/YrvRQOmZZk++/wz6nwRXrywONdW1pepB4Lo7ERbXl2kPhPwhRHpjNo834FY24Huj4732vHpEXxvrx0cHUSzFp6j9hx6dvYNyEN/VcYIIJTCheMTfJSG3UHnL83LggFX3X2dNME97xlQAy/RIA/y6XESaxubbfvho/b4rbfbg0eP2xydtxoypycVJryXVRvt2OCkHR8fhee6WWI0HLazk5N2A35kZBenw/blJ5+0Tz/8KJoZB852/NKBOFEQEx4OqBS4tblLM0IFFlrI1KRtj2eEJC1xdVsP60OtaJO2SwUxnggP7jD1uBVpyo0gte6QfGfm2iKCmHV4sbvbjuk7FGcVStWKye8Shzwj9FK2UlQAS8p+p8U1PDkL2tANZdAKpfAY/yyb333g7m2O0fGbvCNuIeyzbN1OYJsSTl37Cr7Aa4SvakNZM0ZXHmETnhReiodtKO0Ie4HA7KGu7vBdQwi1rXlsijuRiZ5Zn2jHyFOhrqd7B7XusowQdgFtA1O1sr6nDyNc1mhKF6mTghntIDSGzU8A4SZt+ehdG+2tcJMfCGOtfsZJAsIz0WMMKx76AWDifoUt/vJXsz0/kneN87bY/x2my/uvbSy0gBmeHKWCsZHyfrHAmjCijglplKqj2rVhagHGOAPXLaGfgZDDs9aGEL6jI7c0S+amK2txhLuwuowEvpATfiVOAT8zB/IRYvgXZF7CeG4P9sGQ3SfCjossZSoA6OQC0fv8oq3CjN9ZW2wz87WzKtvWIZAzRsWno0tGkQh4NMLrWfJCqNqAuc1DnI6s5sjb6YGllRUa91wY9gmjTtd2eT6Oax6eDY9pB+cwx8s2oPOeI/8FGybPJRjfPMTpjhWZIgUDScUMauoDwqT+MjyfpmfDcrpicno+QujUxUGbmUC4oP4SJlCKW2RFDZ1UeA1h4uhMQvMecu5xVl71PYE7/87ofvNdpmK4ahZ8NwXTCdPmW9x8Le+7f6ql/Z4wfOvT7tPPM+4338tUOOmmS5J3/UoNL11W+HTIwG9mcZUR72I73fmSFEtLq/GzC/RThviUccp6xrOLEMrmV72vry4V91w6r+S4mUcQfvkBpbezrJg+U5bOHdv9UtCEE1K0CQpm25Fx9+WdmluksU7kVP/B7ouuYpiuYPfpYeg84UvtH/2L/3W+/W2ag4OD5K25q9dXvI/7a77KT9O/2w4zBSf8AxfxKT+QzGXEVNNF0jjCkGnTDibkKK75SdoyNzoSnwLmyg6TNByMyJiTcsdbpEOzqo5HvsW3CHSuP3EQo1ZZ7YbvJQwVr4J+EMgzlZmrXLopa8qXQy7JxY5nMXc0whyIoyBTzBiaIF9tb/r3+Gk7eKQCMcUTK24N2Pr1roPhSfv9f/N7bW/3Fd89/ZxyYeVxXu1FgdoAIWtwKt+5assM5ra2NpvrXz2OQ63Y7t5+22MQ6d1+4kDt0AyD11ovY5HIk8oJK5+KwKmPT+qUDst6YiyjAkVwQXit9fA9bfFOoiDd7plOERx4NtjS6mrut/TAVuPK28xfYfTm1g0aairdyEJc2QnvLvAfnp62V0++aJ+8/3778Kd/0Q4ZcLsLfx4BNReCy1dnFb6mSJv6Uf+sV8J61dHMvG4ELvDqpg6FJDVAXoFmOT3fykwtazQ1CgjAS16SmRKFMf2Btyh0jdMAwdBBXzSl1OmU8O9/8mnuMR7dlNbKnf9qA0O38PgsmKe8EVQKcoUH3sO7KEt4tz/dsRU2PCxkbxy/KxhjRRyFspw2i8KfAxHjGkY84s+/KL988tHvNZ1o2uBdv84Czqy9M26mGIGLgugIAWwfgfMSnpgjYPjmlLBhcwG4AyrCmldIxjJ0NA+agZ+Cl20PYYx2no17wBX2JqhtSjy79k90W7V+giZtiAQz+NYIjzzH3fUs+pQ/W4Byj9sIT/0T2/vxSP19r3R8L/+yfjNOn9Z9eN2WtNK6D6u/9lcWxpIuRjienJwGKWJPVV5lVhXQ9E8bktYC2cAcjWYBZAi4GGT/vLMKUQD7cASQcWfXDsB2alFAumX4Ng3K3W0zbUhgr9+YnIBBKqVD9Go0ZibNx90ul22KdIcimvKqMoVtIRC1trow15YRxK4B1NnZKIcc7sGwTgjrheDmn9E5HfnMYm0PX4J6ZeRe1CtTl1EPIcizAXakIDZqg1ywe9gOz4dthTJsKSASbhYmvyADoHw3UPctZZkVS7xPqu5F2Aux4JfrHIjrURuOKm2sjgzvYAcepmZXiU/wq31gLgwK7iGG4Aac0CLLXX6SLa78D0X0DZ+fpN2Buz4lPW3vrue9u76SRLnjX7SQ5tEHIN9YTe+2dRvIDHkfTz/Pot7UNcn4D6/KkH+WMWkZjj8Zf/duWErRpW98Rn5L6214fNCuz05hCpWuEStti6BfhddMK9jbQczMtoW1bZj3CrhmoHC8g5AOjTplffBxmI8msUwoD2hXzqG7Hq+ZLhiMXsHb9oMfbk9sN9rwYKddnBxW2XlPvYQTTSkjYgOlXhNfuzAmbnvzpl/g3vlpxt296f189jzD6llR6U8hLG4ejpTdTWXdxZeHS/Y7KO0kDe/TNV92uibttwvCKYwJqx504tf2WhcQ18jUvP2Ztkzegyuzlgxbg0WLQqdu5wIteGSDU2DGdTBh+dxFtjDLoGx5JYJa+gUy7KdDtUVrVTbd/XtMvhex3H1TGCK+9bP9KogpYOr35MvP2r/51/+Kjv+EDs96tHbBwA9GZwbt8JDBGbzxu7/xnfaDH/xG1o+tra9lYb/rtoTfzs4u4Y4ijLmmyyxd7G766YjJU6FHTUo0KACx1vdQJ37VUetWvKgOXEfVS7os2iQIH0lLoOg2cGezNIN4LsFYpXzrnpG24OELwoBO/mzAd8IIHwket1Osu3u7befl87bz/Gn78tOP25PPPmkn+7ttEpwpjNlPeJr77AxCGbzWdXLOMHjel1pQYZMrkHDXVUoKY/JkAGnliWs9PMxXIUBenQvl6WMclNdsASXCr65dU4iotXEXIwRzwk8jcE1BE1++fNU++vyLdgKcrxjoK4TZ5ssKT/MF5pRZuAZ2/HegL/8Tzr6XcCYscIsLxCsH2sK0p+GcGxbYG16rEC2bFYeGsy2Iu0o36fAewRUrngvXfE86trH61gtfMzwtj1ov8/CeyUME+xFCqFoypyalBTVhKi5sN3Wg6xiNkLd1s5wOrLKBxqf9He0VMNP+HIiprZaP2tf5TvvkqVaxpiSlir6fCdXkmYQ74zfhU/n6rPZYAlG5hX9wQJ36d019t80J80o2OMg3/+sueAe21K/CGW88Tn3X9H7989fSjGlsoqeMSiZVe5LquDCmGa9MjXDu1ewyQgGjutd3mVNvIohhHf0pLR+NYDKqgQ1HpSUo8XlFfsdnCExDRxsT2ZLt9M8tTEZtlpq3yVuZ5HlzbJsdFxCNC/M9msDzWeYUpmiUEzTITEdATKf4WxpP3VePtsC3BQQxM1VdKqHeeBHvyYD0pRg65sGgXV9c0gjPs63cUfwQQczTrD0x+AGM+63lTeq90E4uz1I216ypGl+COUzMLbUlrFeHUDWIjd7WKTEa84j62dDtrAMzYKAgpuauOmR8IKqZxXUiXrbpqwEEX1o/O29hHlwYFgLOPL84EdgkGDI2U//xnSrilLiIq3f3P08Tw/bCXhFcb3knn0TPe+VfowM9qwHXS7LKCLQ0E+Rr+fTrvvfpamxg4/6JTOA+jPlUffClDPrdvYMiQpgC8JxPAx+d0FHBrfuRp+n3HWOlzx/vuj2PbBKGOjVFJ7z+sE3PLzAyPmvDo512eDGDYHzeZofPiyl28Xvbp1kleN0IH+vhz11t4le6c62KdKE243T3abscnlqYxDc16yf9kMB9Xvj9w//Jf2myf6tGLUpvfrGO937a3oz7venfG+nTV2lTxp+pC+laBsxTbbG8wDAOSDzry05SPxmysEznilDST6t4H92FgzDTIb3kT1H5dBdGm9KTRqaEw2MqzdAn3xXY0gHRcSvIuLEmHbftESMuouWHrhYXFtvayko6HvOSVwR3XV37pzDr7Z3B7cg+P6PhZVs3oZSX/M4QthT07NB+9MM/bX/+oz+jPrcIMggv8AxJUOHJWwQePnjYvvHNb7RvfvO9uiHEw7G1y0sR6s7ghafeN3kGLQ8H8BmEHgjQnYXCcn6e+s473Yo3PNWPlCI/j7RwLZP5ZfqKr+locFjF2PiJW74Txg7NbjO8BT+twk9gglVTpaCr1tGDtldXltvq6jJgsX+hXAx+byeAM2nYl7iJ6dJjPI4P28XgBFnP21Ym2yJW3dMUQpsDbrVi7kyfAW85bR9+ntP3oy1DQHBQjOAVrSrtUFhHQy4dkpv3IKpHsJZqxsS12i+YNJayuF5MIYtA0qZChd2CWh0vBb9B+Pro8y/bEwSyc4WnWdf91rrT2nkHfUH/OfMrfgUreaxlKhoSRJTA7xaN0lTYgK6DtUIWsC008PTdapQ/VUxahjeu/WiELsIavn/36XuEOARoaU0c99+cehQGHlyuEHdGn3l0cJS7Jp2qzIGuwHWWNuAtD/Pgtc7bI7JlonyQT2BrwW0D0YgBN8AnSLGhlLRDwZz1YeTFK34VVwVJBDISSVsivP8JFuO7Lz6FXXUZ1r8CFM+p8MI8dCyMbGs8e3/D29Tv+rL4+U2/8negVNO4lYZpK9NXmPI3bMXn2YfLk/R/XWFM41oDT3Y25z4jks83K9FbgaS6OS4AJyNzhJU5d4i4Z0y9IFZuifq6HV3AhC71B2lA1gWQI9xquC7OaCj8ZmaR3BGdlNCPjt2xMqTByHBOosrO6MtpRzrRK4Qzl80H6HOMlCD4WfI8cwREudVSuVlA9iOxzdLI0wCV3BlpT7hwG8Y1Q5rTxqCjoHBErGkOF/faEYxI74LybywttK2t7Xa5qLraQyKv2vKcxOqi4SUY+DKjBzp8448GxEfIgilc02AldE+gvoLAp5x3h7Bz5QR1CqzsBICFo4XJqSUEh+XWLhHGbgcpu1TjQ6wA1HIDCnzTWH3nfxpwphNBoKAqHBpYVwLxzffXn8FTvcSWgMG7Nu9Yc4A2EtLvnUnYLo28Gwl3L8RrKg+9LSt5kI7FqfQSIDadVxdGwaQ30XIlXcNQExiEnQ5tIGpz09J0j8rDDHka17S8xgopDoatZuwBQtw8wsBpGxzstIPzmXZzftqWbo5ShmKW1pkkCjAdXPWxJCk1pt7jyujXTkmGQwcy5+0R7mYbtMHLp/Sxrs+wWJbJZ5UvuZiMIOfDP/rP/vaFsd3d3a4uFqGelkdbzK2v6/338Wfv7k3/3uO8GGGt28oWdZ62+8IvVh4Az3Bn45UDOX4ybOGgsNIzS9uicbNGMvzEkW0gVuEts3Fpn3bsatAuRqNMgyVd0xP39GBOuXgfpYKCC5Jdf+SazKTBU4HQNXtqBFaXltsSwrudpRq11DnoqroLJ9vtmyYwJE87mfrhV18oL0NCYUv51WYtLy+3/d2d9vu/9y/bq5fPo5lf8MBrMvIonK3NjVzanbIieOivYH8GT9zf38/ZTzs7Owh2o6Srhk/aC3+Dz0pn/uzE5+BTar5y2DYFCn2H4IQkfHxavFu3KqvPEryoM8F8ilM7vdz5h0kY4sSfp/VMp8R7XfaPgEBn7k0ma+srWfu2gtsO8QIh0svQHair9XJ2YY60p91gRVrzpOGVcgsIXx4HlIu+FQwQ7rKYH3i4PtB8nJrMJeHmOSaI2cjcBa2AJr15bljo2wqJO/B9iYCWmQm+38if4eniVZo1PIkAT+AHb/f8tg8++bQdnTGohqdP0r4Vwoiads7/wFi+IT4sguCsAQPveRNuvhtWPgDs/Aln/gWmWtMUD5afJ9GJ3wtiJYDhTF5pa4Yhhn4RuvLd9MudvIisJsydqaUVpU8EVvqNBoN2oEZsyCAhigVvqaCtKFin3Riu4pgXqCJ1aIy0gV5g5qa50kLTjwHeCLWEUwjLWjGbGuWzVdg+wg9sR1ornm+9KVfaWlwdfASOT+GmpcKpo+XiKVzz7Nw8CtbBAe8Ao/fr4V3vptfF72zRe4W7D3+f7l14C9F9+7WFMRMZMKpyAWUxQguhvwRW33sLBiBYD8UsQPIapqZq/01hrH+GiQL444uJdjy6bmdg5QjEDCB+yd1OLocXOpqat+FN5dBGF5jO5dRlNQxqtJzjprMDlVeu8VFFjL+j3VnSWad8Mu0z4rmDTe3aDQQ4mp3n6ToBmTMl1v+WkTYjAMu1wOhqlvxzYCvpifBc+t2Nml1Qu7W+RAe+1gYzsznn5+r0rK3xfY7RUS4Pnl2kvgh9V6ft9pKyUx7XxZ0Tf3iCQKm2jtHsBMwlV+1I2Iy4Ll14TpncNakSzc4mHc7MMg1gtd0iIExNntEQU32RkcYfQ4swH19lvHnpPBJEd/0L8YPBuHsTfGLEk+lqX8M15Yk/5a24Fa7iactI+Gmc3bcQJybhOr+Kg+nCmaZJ2KDil/cuDG6JvH/vfDuj/zSNWy3GZfDlSObOjOWVfOMiC9yziyvkI/OeB5db0VpdnJ20k/2dtnsx226Hu211+jzliWXYJ30InrtyJ0Vfenhi+WPAR9pOUUA/fqYhRxjj2+gYJueRGT3iwJUMqdLTj6dgMCn8vg5hzE78q0xghu2ZU297M+7WvPmt5x22G212EMoDHP3yjAYBgEZwcsrSAQn+0qf8Q8ErIJURAhPT40t9zwhauFV+flPjUFoJfYQq8CRMBDUN/tJSzsiic1HTJL+ap81aXi8qNqxXAFGAdGDetacwZnhxFm02yRnPOOFx+DuAMk/pwNx6fmf+mcbTWA6tJUvbxt2VyTPCPvnoo/YH//r34ANnEf5cB+ZUnBt8tre3sm5NuKhxGCGEHR7st51Xr9rx0VFguGq4B9vtrbfccfkIYQcaJ335Zzo7wqgp9GgdhRsKDT9RS2MHLtlRepjLRDQnhTvhbdB0XOm8xJsdevmBzVSttHyFA5ElvmvK2DZZOBFepq/gtLa+3ta2NtrK2mqbReiMBsu2C6wcrHuTSu7ZJE01MAumxfd0eBQgGjfX+FGX3EXJe01LEg6Y2Z5V/+UqOuIbz/QjmFFPd0bKJ50ypBLBa9aMwYejJUJysI+QVt0B6E0vuZ5nQg3jUnu+f9A+/uKLdkWdrhnUtSmF3wAs9GUZzUnW1QtE0djgm118hrUk+BnGdV1S9104aSbhxUs9awcmYXArzJXWrYsDLZlmpiFDVuCNcHfaOdMXL4bhg3kqiNnPCV/XaXv6vrNAB3sH0bCq0PDk/bQXnr0glvpgU0eeUrTVydFQlKO0Yfb1CmT6AUPenaasARltmEiAPe3NcNGaiYeuTZhmb+SFvfVjvummTiWICS+8unL1QrD4iBtrcP1878suLUfAlZaN36VT33xq+7D1XuHu3aGr+JlO7y776wtj2AEIuWGU6hRLTVNaGK1fLYBkhuFVIg5DEogYhZYaWdYIo2c64wKZjHh0eduOLkCGGMDOwxQcAbno0UW3VAv6rpGQ6vrZeRob+ftFYcUF+Y6Ohgg2owsZBmUlLxJv67g9CWgf5n5uuQDS9cxiO2dEM7m8VnWhkXr2zbkHPtowyXMWP+fDFfKyYNcNBAhNK1mE6m0As9ndOTUz385dNyB8Dg/bCuW+WV5vB9fT7eQGeEGA8zfnbQFE35KeOztdFH42gCkKL8oNR4yQ6F1s05fnlB/YOJKgTJ6fBhUDXAkaWPI+PbcKH5jPFU7TkwgJIF/qJIc0LKNYL9/Fi+94dBSMDYXYqItg4peHVFVOKSwaKAKYlh+C89i8BoeJz78QX2VUf31Yjf587wnZxpc4wOzO8J5RdB+3Mzrvkk05uu+9Z5efzBTemQGB2g6Zx+tlIML4O0aXjXIWOvDKrRlPjUYY83DFi8FRO9x91V6dQW/nOwjY0GpiGLFLJ2XokqTyRfeUkUeyS9nslBgtQ8u+5mwjOnPbxHD/Rbs4PTByhe0T7I3Roac8sV+XZqw3wk9beCv3uC0W2tFA9+wHDb4X8+poAzhUZyw8SM8QtPUarN3A5A3jIIS2QRs5v4LvdL/sAgQMdp7hQ5Sn6MRmYXw1aCYI/Zg1qfsuDqI9u7qMxklBHXYQXpHOBLvgKF9BDPzMdus91YJ4KKVTVd4KYjXnaOMry6u5Fs31P/qZifUybl4wU/jbOfZa6dTTf10Ew0eTalzD6AfNZIkH7x4fcM4A+Cc/+fP2s/8/c3/WJNmy5fdhnnNkRM5Zw6k687lDD+hugGiAAkFRZpQeSIqQnvSmd5k+hr6BPoeMT5JgMpORoCCQaBANsG9f3Hk4Q52aq3KOMSMn/X5/3zsyqm7dbkB97gE802P79u3D8uVrLV8+/+zHSWBjCzkD7raQPXfv3ovSMaGz5giDuw8Pjw9zar14dj3WJ599XD799JPyHkqYd+ju7G6WnZ2t0vH+3xUbYZWLUU7v395Yz1rWReUo8dOYAynOKg6C8wonwZB3WN6XlR8LKqMqcSgGiUgAjLRhHUXxIp4NnsqYGyPSQQpiwIHfSXBB+UkHpbu9U/Yo39bebulu9spatxN8ObJih1QFwikxO8kqk8p578j0bMcVFFjXhy2twvvOMqAwOMvgov0F8s4IVWgM2Mi+rm1zshO5i2xVEctp+naExzRGDt24hJF3lWtpVMXCA2oVx9NL2h/gviKfn3z+VTkeTMpKt+dFQ9Ck9I1cka6UQ9CgT/NNjsGPcGBDHEIBSrBRwsQ18OnWWvjgnwA+vcYpi/FBt5SniKClTL0aL+mAq6pspNhYFC/sTCnDM7s7/U7+dl6ddrTGvIVhOBiWs6OTzNysoGB2wa+bIhxJdVQsmxGEwQxIl/8UQCq/go9tp0BrBkEucORkfWB0xz+tHuHqn23U9Q04I7Jx+I91Ot8OmymmrkybdIMuEJG2IGcwkkKTt7ZdN30ro/TETZlre2Z80sNZ3T5xNGlVxZdXo/kNaBItaWgJIxL145nBAsMlHdM1f2IlHdOs/n7+GxsbzBRWyVZT1jtGAG2AaiNUw+YJgK2yVXunIMLCvG2T1k3pLl9HG8+IG/5WZt355Llf9oyuyiaK1gqKklOYw8OzcvjisLx+/LIMR9Ny4c7IK89t6pSu1zQgdLxjax14hsT1iAlUlrIIQd2gKC1tbNRrlCACh0EF/5pGXHAkYs/J0Vgq+xT2sOy1dXu9st71PjbXPCAsvCZnbYPeV7cMzi9hRhS83a0wr+fS5JLeixG9KQ+UdOGnaxPACQhdvEAAoJxlbQotTRaDOlwOzm4QCqs7d8rK/p2y5kJit6y7ngJAc9TG2bD0y34Zrn6/nE62aLzqAYSOKHgGmWsaVFJnT+DJCf4yBswwOwJDq54HF7S9EXFhudt6zbse8WtsiA50hRCx/CeI1Vld1VjHEnD8+QKhZvTP8DCaNgq5iSaNW1rSSCO3kfHHJg44NJ49/NAQCbpV3gZXxrERqLDMHrMyaZKuX3wijdrdelVhQvwpfFHeBwhlr8dZRpnOegYjCz+PmlJjklSTdnLUNkZ5ArIsm/k5VWK215c0pl48Hjzk6yzajD8MiJWf/kM3Faf1aUP8tgLXmlRj1cYTpj3SIhilTrN+C36bjWqlzhTYyAMaYI95yKL9C2gY2va7jYo9euWPsqaOYFzQsXLKa5q1ok5/iWUFskqYB7Z2svYF/hNWs5dPCHdBeHfQKbMrD9jQEQ+4VAA0gtYqHBlBE0yM9B3B/5bM46fyimEIXOlX/rOz6k5HNzHQ0GPdRPHs2bPQt0qF6SuTVh0NIx93cL9GaX72/Dk0OqaD2i3b+3tl78H9srm7gzKynoXsXRStDazrsvb2N8vDh3fLx588LA+8V3erS6O6UAZnx2XsrSY0hy7RcCTK3YlZ2K8SAGLALOWmHPwpnzL1qwKMO4hriuf3jEL4h7fl0/i8zMiSljrDhD5o5FXGLJPH9jhjsEJZ7rz3sHz6ne+X7//BH2J/vzz44MOc5eUSBHGncm58FbzcYpIpyrpjMqNijoYhW7MGl3CtTZ3Mu4XV8hHOToImB7siT+p3VCdgikwGdsuh22Uoym3hOTih09bv14NsIxRNa86Sl0/hjQKWZy1/fcdNPr5X5an1xwJT/IEzlrAZycGd7z4lK/GZMITHja6c2R9H9RaBN+fFEa6OFBHHekodKT/ryG5G46w0+Mx14ifQoE+/u47SAYn1dXiGzkvKlfRU6iyjoSpNy2OqHqSU99R92pvaDkVJE1fkk9FxaEy3eK7hq+JrPVs/thUzM//uk3et4QAltrrr+2yNV2N9j4innEa9jaOe0oTDo4avuK/xWr/GnbDGNTxP3Q2pNSDN3PmurVD/zUyG4Bu3CNeKqNZU5NcvVpIQSMQGkQHTswqEhr5NSVOZAaZaBjkg6ZISOcVIESFsL9i+yQn9G7ytU2FeIDo5HZXjk0E5Ox2GKdccJSOciFnHvb21BuOul86GF5Uul4kKCnm5TmxJQUClT/GXea4Gp+Xy5Khcelcl7yQRJqsKqMwsU8PoEKPavWXKYnT6IR6n4Vq6NbDsWoYtes2r793PJcRI8zIgj2OyW77i3YWojaJjL8kRLroiuSLJqQJ10FWFqsKP9G9Q7qbbu2WVnqLTEmv0EjtY1z1AqWV8Piqv++BhYa+crv1hORjvl/75IgLNnpsLX1HCGsXMHklVzGjIbMxkCBSzenq/DYEMIXNQjw0TCOeblp9ZfVmLlZ0jDHBVfyx/bZzUuVSRCE29w0kRLvYWDStntvETgF+9tK2hvmqiNe0842foysC5ncBhMegkhw5akU2K87Cbd3W3zMI365qXrKOxceDPxvFiOirDqQvJJ9S2o6VNvlijJXXzITHz8NOtqcxuQNdjQOICEnxJXypoLky+mHjYa8MfjZl3h4N5bevm37eZ53tN6m0eXsy7/OZNcCUOccv7VRmzfy/WnLZq16LUKRFliumpGInkjHLRaVFpkp6tfxvYhDOIaeMwjjizwyHNhF4J4+hHrnYhz1ZOqSDYwEZxQ9FJp4kPybdJuz1tP/VB+OTLd//axqPSbS27MPgaL0zFSf023xGp6cQ38tIjKVTGjo7cgLKS6cXOeq/0NjfoCLow3INTgY1y9Da2Ubg2ytIanUM6go6vnA5H5fnBq/Lo6ePy5eNH5dHjr8qjr79EcXtc+oMTsHBV7u5tlc8+fb/s76LgQNuj4UkZTwbgxzVkTiFb/ouy5nosIHN9bdvQAzZkLc07klHpvrW0VdA4+AJnwb840YgLw1oXmPCBdaFsxa7kiAjbGdsP6cGrlbbL/v575aOPvlP+8E/+pPy9//jvle/9/vfLBsrmgps4hA1FzKMsVtdRwjoqZrg7a6mrum7MNWKVhjJtrRvYoujbemKEy7bDTqPwedBzTgGwfnhmtsf6VWb7bMrh+jSFyKuDQxTiCVhdLCPXlvFNBaVOT1ZeCD6Sm6bBCQ9pR+Mv2Io4ETfx41kt7sDc+kXi1jjUQU3HNJXbUQcJU/nL+0Xz5FcbcWWdAKM794lAuVD0Gx40/mgyLq8PX2fzRM62y/Qv/IJym9FDyuasQ+IIFzAFZpKd1bHEUP/NIq9ZchCcVlmWNocPlYaqX+ULy1FtgH/LmJfeLX6SP3BkxF28A1t1VxoUb63NqBZ+UUoh1tlIF88oVuI2adbnrdtyVhv8+82/uTDV1rqed7fWevkbG3utdZDUv3BiAHjDNK/tYkXx6DNKRwNwvBrTFqJ5QZm5KZsrN2WdQqwQUqa2J2CO1FK55P0FST0/GpfTIzcUXOeAw7WdzbJMT8pFqVOE0OI1wtReysFxmQ765RjCmhJXpedyZS2jJ5SoXC51gA0kIthvVJbU2nF7daVTsTKTZbp27h+mnt4oAG0oaJYRmKenp9mlVJmXnhpKRQchMECQj4F3cLOMYlTK9oLnEsEgKyhS4A0wSBamJ+3FddemUEmOjvEtQ8gbvbK8tV3K5nYEh729zvZW2XKx7hbKXrdjhVCGRRqkaTkdTMrZ4m4Zdn+vHJzfLSeTlTJGETtHKEy0NjCNYuamA3esOloWhQwcqmBml4tCBzjTUyF1UF2ZRfTjntkwCY6mjmUu62hWnyFuvyfQzFRhUsnRNAyaEEkvKee9ZcKZ5U+BCGBkRgBtIpJAA4Ojern+iXLIZI6SgM6E0Pis6dXnzDiETIJ1NFa6NZKNc03r0ob5kg7C+bisCi+48n7Pekm6bhNMSknbBj9uvrVG/yjXwkp43Vp7f1MaRqfDoMI2dPM0Xi17/iw/T3KuH/89mhnPvmVa/xkdNKbivVqN3+SZCGyCKQCrMYzvVaA6ZZJjCmxUneLFX14xkNNIWb+DvV0rJldVetCoXKnYaB1t8j0jHNSRdZHmyc4WWDVOaIjvWnlL4MLbxDNAVRzq2h8+zPJNozKz+ZT0apl55r2W/122NbpMwzxUxh4/fpxdrSoUKmQpP3A5+u0ImVcMebr9J9/5Tnn/w4/KlgoKuLoGb1fQ1+D8HGXsSfn80Zfl8Yun5fD0NbJtWrZ31svHH79X/vTv/lH5X//n/7D8J//w75Y//Xt/jN9DGtyFMhqdlAGK2cLiNcpL5WWnsTJlJryNDc+IS8sMZK4DElfyXRq1xtrw10ZOurD+q6X0Ka+Nr7h2VqAevKyS7H2adMMXHDFDQVtaKXt39ssHH39c7ty7m/Vh3rrhQv2l5vBbpyaXnH5Flno4bw74dYQMfOTasTTQhOVZp0bxw7Z419iAWjbfVfKj7DtSqcIPHdXRcmVRXQZDYpH3Ryf9cg3cKyjM7qrMRh3+qgJmYSvv3sqkipe4fQoEZh4/fkt4LS9VAZEC/K11kZEv8Dc/nSnlGkbKtg01vv51ipIyGy+2KmO2TbmKTxmFv+skR17S7vEpyB3XE6rsSvausYuyTdy0VaQnNCH62Iq7Omtxy2/Shwe4WuKqgPEdOGU1qz+33STsmzxh0uY7b+RzRYa26ggV9qrwtE+t+JeuahqtVUl1xJcqqk+n1/MNKEkv6eMRedK437YVBiwAtratq1Ypi/LVuMWRf2TzNzcC4KLyv87cFqRm63t6pQKCv0/Q76d8m7cS1MZy3T2jwqIAMBkJzlGdc6J5VYbb3btbG2Xr4V0UlN2yieLilIOL/JeXYaKzQZm+OClDWlHvmnSkY5Ee48L6Zrmh93WzvVfWUGxW1+lNdruZNhMqR4nObWSJcwPDTiQKQb9wumIKcV+XDQDzDDPvOTxHYHqWTO6SpNLdUPD5k+fl4Oi0rG/3UKroqQLB/uJV6a90yxFwTBD4Z8NBuSKbNXq4OacFwbDURVFzHcrd3bLU65WF3laZSliA4DqIrTt3cp2IAndjZ7t4AO4iSqHk7eLe/mBQzha2y3jrD8vh9QflaNwrAxqsCQIkI2UIFJUwpwEyUqZbnKII5BR/ymTvJAsnSdP39FSsqjxxSKh51bM+44bZUlHUYbV+rXX6TtP4t9/T+CUtXpq0iZ1fSaWOgFnS+i1hdDZBqLZYFUqFa11IXYPMG4PrO8/s1jzsSHitSeOjwzq2frHDCfiZDMoajY+jeCpkWb+i8NCCx2pxX/hOA2MYcH2lZu/0s0O+bb5RpBcy6nY+OAXw2qhrWl7Qyi9haJKoyw6AS9j+AzZtnc5oozHz77Xnq7CmUDFV6bm0sbOBSBrUCnVp79v1Qe4ezHSD0g6TtZTQrgqzccRVGlK4FIlR320QU6/13YZYpca1XfaYzeNNGG/hTAejelDHIt+1P3UEJ/DdRsu3t8PXBqmOnNU0b9OuFg1f6gu6aplbfOgejQYoY4/K2dlZRJA7xw+Pjsvro6Py6uAg05Ie37C1s0tHjg4m+sG5smVCxwzlYAjdjsHn0I4Y6S7RoG7v75QPPnpQvvv9T8sf/cnvld//vU/Lhx/dLX/rb32v/O2/7VTgp+Xewz0Ul6syHJ8g3/pAOEUOXyOPpT4LAazAD0Z1onxRvqYaqZ2UzXKIXUdMVACCr/BwAsWAgeDMsCpwrfU9Oanv0IH0uCBSiXxXQf366WPs12UwGTpUV1bojC93qGeVLeq0XoSNGkLeaKz4O43YKl/wr/WOVb5DFHGrKAq3ptJNVQzqFT2142o5o/iDT5Uzl3uoIConj06oG5SxnJMFn3t9nsqySoLKj0pRmmPwMN+At+9RaOJ2Ktj3qkTM/MUj1rRWkEGGiSIkrDxtBeqi/Po9eNf6jTRjmzjujNRt/eQ7754h5kiXo83D0bBOTUJvylGn5B1l8tiQdpNHRpxom2TFekuDHUV5suUB8YlYo+5q2wL+rGfCtcpZ2gugiPwNTTSEESJpTZXOtyYZgpMqo9u6qiOePls/63H+O26r+21LuLpY3/Ra2/g3z1u36bVPcD+XV1XubsO3fq2/T3lcy+vf3FhZDrm2uAnOG6tn4x2mE60OAQNGSmKjLqNlWFhf/LSa1l3tUuku2wNtE5cZL8r4+rJMqbwRjd14fJnri7p7m2W9t0kvEOEIcVxNxmU06GPH5Wx0XsYoMIu7e+ViHXWo0wljTWAaL9Je6m2XK3c3+jc8LVcINugoyp5MZ09h4dzFm/W8tLrjgwpwzRBC1BODodSytb1R7mxv5i64rc4a4HpAqIexkhCEvHF1Xh4sTMpoZb08vlxC+bmI1rBIT291dZ1emwfiElZYveMOZazTWSfttez4LChZcE96dmFo8L+2tVm6KGTr21tlrYfyBhwC6REAg2G/DK9WynT798rJ2vfKwWS39Mf2pB0Nc+1Mq5ipiOnniNntSFkdLVMREw+UWWHUlB0oEbpV0MbdWPPOmjGIE8kQq794q41OQt0aPzRGXKee543pJU3JFloKcbeEL2WTZpOP/ullUWMKRdeweZF7FpOG0hoYkhKmTbuBgeKkbBH/wu83g5muAgT8X6GI98fTcjMdBtQoXwodla8oZlj5THmUjHwHByr1pK3QzS4u0/Y73o4y52Bf6PVyNIpATbpGtxzaBi/J00jWQQPrt2FuefLd9reZt+t8/r11p7Fu6rT61QZZf02bhw2KDcLMIj8U30j9CP4oZDaQEiz4bhXqahsh7UgI6fhsp2Gynoi0zNt8L0mj5g8PwCfxgzdIMX/CkQ4XcdPpU7aRSe31WjdNuawfwaMMNj6Oolf6JJ9G8bCIFQcVJ7c4VXCL14qXk5OTHE8RP75DZkljglwa0RkdjJANNPqd3kY6yd4e4b2I7tAV8inhtct836Tjaad1585e2dyl44oCs4icHZ/3y/HJAQ3wMR0O5GCZ0MldKxubHu+BvJqekd8psHpe4oRyS31VYRYndVS4wpv2QTyLF0uRbzZINPh8w5l44jPtAYgQD/jiIz5UeLzweyE7WZWT8tgSbYLriM3v8Oh1+cUvf1qev3xGGnyD19ORRgHL6JjrwzICRi7mSd6Al/YBAoBE6ntDZZFZ0kjbVkkzETihI2nTpQpVTllfimT5Ogoo4eVr70g+PLbjf14XpxPuykywwixuQifmR3EzihNb8RY8hheoTsJY3Tir5cVGX/CrEieUKmwqV6SlNS0ie4BvLGWJQiZ8WuBQ4TBs0jducOz04kKW8KxCR9Kmi/X7x6dl7GABbZU0n1ExFTF4xuU/9SgLlU1Sh2YBC6CUTZSbtEPv8jN4UBFzqt82xnaltiXyRK31KntrfRhH30oTuKSVpJ8Maj58b43+wS1IAQWNW9v6z1mVR6zTreKzfbb4rXHejGf4+lSG3L63YStct/BobmGqtjXte743fn8jYwNnI/Jm9lWQNvh7w7j4dh7gSwReBSivbxjDJSxY7XiODAgK4PQ0JJR1expUjMzVRVDkTjYq2gp1p+YChHPy6qCMzoblisp3LYX5Lp5PyjW9qQsavAlK2rkMgtIzRBk6c6E/StjC2QlMJtFMyvRskDPKVlD+1lGktgDJHopXjkSgLq2W0bU3AJD2EnCgCNrCugupC3F6O8CHH3xYNrZ6pEleKI5niyhiZT2VuUkvc/Hmoiw7Igfc2dqrkLCR4NmTUMDBudSKctlBOK1RkiUaBpUC8ed0bN2cgOK20c0tAV7nIVo9lNCezemY8nQ/KsPNPyqvrj4qr8cb9JgXypjvWcwcxewaJcx1Vk5T0v9VIcO6fiwWyTMbLUs9AxMWFIb4a72Ch7zrrsI11s+NqfHq860voYWqdCVIY0zDtGBOC0Ug63k2ChVOrtYGuZTVCErpS0G0qmA1McP82xqCyiaZ5jQPk6fsjobauxuNpqWjQKMOIUmJQikI7C3damtCKW9NsFrCqjAbTiXStYdOYbjz73wg7TlCYhnNVFuj627xqalefq/v34aZz3/evMtv3rTx5sO17ta/5Xm959+1GhuO9NobJcht9J5vRIjwKxVEPOgT3nf6qCpVbc/bvAhJfIWpckslLIoZDZV0k2l54kX5sq5tcLGtUmjjMIOJdOqZSo6+17oUylvB2pQNmyalKWOUDp+mlzSbhsfAbxli5FcaE67nz59nGYTyzZPkvQmgrgtD5kDjKmReSD1G3rmb+/0PPiqffvqd8tGnn2bK8u6D98vO3Xtl//6Dsr61XW4ouyNlB6fH5dGzuo7s6cun5emLJ+XR06/Kcf8IRWy9fPDJe+XT739cvvd7H5X3379LA7xEJ++YTvAZuEEhQ9FxPZnHCwkvr6mnjABRVkdKLKi4iUIArlQk+J8Zy1rrvHHzh/Qi2hVy0LC1Q6zCsL6MUkin5cmXX5bPf/GzcnzokStX9F9RFFAqVzqrsU5XKgczKkYdkRB4qnWXc8WwWROKRTuLYnYdQYa9QXa79AB/SoFI57sdKsDKlLY0RaXp9kwxO/SeReiMy+HxWTnwIFTC2plVIZO/+UneycHy83zT3jbMNCFz4SodmHkbNm698fd7/IDHOBXH4r/BNd/1N0wUOGDIURWhf+OIW9MznGfmWY9XZeyhwGf9cjH2uFqkKoFVjHOUBXE9TsR2bg1FxilNkk4mrQxsFTE7DNK8bbDtm1cbph2x00qE8Ad/hrFI8kTtaOjWB3+RnVDVpKMCXbjeryrP4JU8haFVCLW1vM0zbsPV760CVZ+Gr+9RhClPtfoZvg3b1lA1rf+tm+ec/yxfPzTm1lXDfSOHvproEAXhBuVGEKFLPEWYQsvKaQDlXyRKiBGUIFYcG9y5/OxGUZhiZkKrFVYwsqMOw8vFckq3zhkemyraw/Ty7GHUHGuFO/hgWv2js0wxrvY65RIYVaxMzx5iTttHmbkg7tLmVqGbWCb2HqjYy9NXZXx8gN4zzpZwFb49F+haKZ1eLvx2NGsVIbh55y78vYpSRKqUyXzdFSSBOyrmOoIjBKSnd6t0rZL78GxSjp22Ai87KFOb15MyQcEaXJ9TvmnpAz9ZUelLZQMiV6B5IK09k1XSXiGfaORQbJ4w1QKNwg2ZZnhYXOOWQMVvKBvbDq3frHTL8sb9crN2D2jWwIWjXsJ/2+CkDqyLJCazyKimZqWBB/98ihNsdpNIwPoZDGKIgoLJe1jc+vZDHIGt0ksCNPVOXhFyjSVsYMDc+uOH9d2GMmFwy7n6o4nS67ouYxRQGwTvRVMw1ZEl8yW9Jk777jNwYQ1LlRugrKx2yxJW/HR629DqWpmOzsrx65flx18flvvrV+X+joejkI64AAcgIeUPz+KMYNKPUDK1iS/SoGQnXGI66FlP5Z6OTkr/5WN6/1C4UfJT46ah4q/GsDGoioH5AXH542/hBH7PGUueGJ/zgin00Nj6Xv1ac+v/djjTgVbBu+npLZ6q8G1NFZ7NT0OLkjWCHZ5xvVSOuJAOUhmghfoAQ6nbkEfq23SAmXTywFa6s9Gv9JHIWEdfBEE/00083Cp/GbkgjV4XGdDtRTnMSAffa2ysbuC01lyL4yniMeRVQ/jAv7pi2mZJY54qIubrGrnj46Pyg7/4QUaA3MG2tr5eO50pi4XxDDI6ZShhW1s7ZWdvL7smlYHOJNgBqAonHS3klzd4eG2bO4LP+qexziJ4KPIUOePREQ8ePiifufbsgw/Ke+/dL/fv3y0725vFOzC9ku38fIQicpFGyyMkrEehz0gj1s56i4+s21FeAWsaJhEk2NKvI1d883s9R4zGHR4Rp9l0Ex5WCVgoHXSai8mgvHr6pDz7+osy6h+W9VU6tcC7jgLmrj43buVcsVXqxbjgSX4DYeSBn3hTEbFDpKw0jPlSgbXxh16Ul8h1bySoynop/ZN+OR+dl8spygQypp0yvXANLh3YFdqHC9SWXz16Ul4cnWY244IGCYkNPB4wDl4oh5tFpIaKl4bmyVZqifiQlnhTgleZWt2Gz/egjm8Nrago5Z20nECC9GMNWxVj4mtNg7QcwVKxytqphFugvqwbw1k/njk3LoM+bSh04qDAOvhzdDI30tgZoCwqZd6nbDphJuHRiVsWladcG57rjcCr7qltcPhqjjdx1JkWaDR8qGLWlE4mxFV5t8IfRICwOkJlx8p6FJfiwbLjLw4JU991W77GL27Twa1f5I9w1/R1R0HT8tK2a63SJjzz7/Pu1EXyqfES14Lq31rz52lSge+bUMY0Lv6+GI8awEnaHCA/mSs9ECFsjGHqNmCX/RMK5SWEaYXgL8I1KgW6W4WsCsybcjJFWUKYTKxUarQSGExAtmrn7qARI1PgmaJ8Lbo4n2f/DPhW16N4eVZRTsmH2fhHunbK1VqvbPPtBgEzePm8nKP4mO8mStgdlDnXFFwsrpUrBGB20ADz6iY9UqK7VmwJ2OtC7mlOf9702hGA6uEekN94MiwrF+PyeoAiBiwbl+OyiIBcRYFYuJ6Wl9NJOUWoTcBfB4HhaJikaLkQdfRChxn1U7DkUFkrW7ygiLlAND06yuSxGC7WvTFMQ6TiKPiDpsV3lFAI/XrFNWj3S+k9pPe4g9DwZHGnXxEwKB8tE5Aiv7olMuAyb+FL/YJ/8A51Be8hZMLlV1KIHw7TAAYFjkxY/UzdPxFXlTC5NA0fzroYXnowNd2JwDfDJ1bSb409z9WtveBrRE9fJdph9HbDhXnMp1OlBc95q7/CExz43bPFPDHbkZH1zR2E+GqUsVcvXpR/8+Wr8tn+Urmz1RWQylU8kgvvgbyh/9iWF3i6rsenxpGZpWXqDACGr5+W85OjxCU0IBB+ZiizeI6pz5peSvWtKWOatkytu31KG7ffLMWbpg0rLbxp9K/fjCcu5sPIi216UVL8bijChJ7hHXfMJgQ/oXfyqr1vraFFeRXwSRr6SErykbRO9oLXwp/1LwbDHaFKXJ9uHLBx072zvQW/d5JgwhCjLUlrQ8KNSTmkr6bBSYNkKOIKuM22RnhojpowtfP15Mnj8oMf/iCXf7t7stvtho5UJlS63E25tb1dNjY30/BPJh5xcViOjw7he5UKebDymafve32cdzy6CF1elz67jrYh40z/zr175f6D93KOmXDbWDvt6MjINn49z/mipVcJduqp3d2qfFTmOEpmY+3ZZU4p2mm1nMGndJKWkydh625GLE8VpLrrjXBY0zHfjumsLJQrZPvhy2fl1fMn8OIpMCNn1123Z33RrtCY5NwyeD9niql8Jf06EmY+/FS38rHJ17yCe+rAxpykaCs8ysNlI9DSxXU5O+6Xqafve7wc9KYy5tQ1xQcXHrK2Wo76o/Lls+dlYCcc5bjeOyPdrKOI0UaRR6WsKsNCN8GL6AEXPNNYY1VAMwJEyIxwhe6IL+qIW8PX+I6COcKVtkGcEi5nw2Ht0Lcjlek84xc+oF6DY3CTK4zAmUB5on6/j+I5Hke5885V75jUeg2Sipz5ZeRTeE2MNKXeVpmtipijYM2Is20PAbyVJiNg0iJlU9RKkxmJJp7RndL1GQzh4De0kwf51AZCN/nbDvnJ8ou3hqakgzzjB8ZtBuLv9xomI18JI05UyGpacYPNWg/VP/xvvIT9zXeft1ZIKx7aZ5tPhV9wb5+1JfgGjHPkIjcYaxLPjhCQvwimoxX6uUJYibYJLpgybxjTeG2Y5qlJehRgdcltwcSREPncJc461eeI1QqIVxFxh6BrngzgCfiLF+c0bv3soNm5tw9hQRDjQU67t+fmUL3D/Xe2e6S9WPrHr2AyegKE34bB9zxEFiiz75Fel+QS5c/uhiNtpwg6j8BQqNFbE2yFlMPqElQUIXoYpy9ell8c0Js7uyx9YBpdTnMkx9riZXmFojZwLdqNgo4yEcfKWQZ/ruk6HZ4h8KZVYIgAYAsRwhgeBCsBexRHmG0dxXK9B/d0CUYPccMbADZLb0sBjfAhYafCpvRoh/R6Tk+B7Xy1DDoflIu7f1qWHv4vy9rD/6ys3vvTsrzzHZTXh2Wpe6esbOyj6OyXa5g28/w2cOnhV6aqEFP4MJECX2FF7V7T+CnrbShduI6fPUmtwkyhlqFO3j0AN4qYBeKZ0QqZjjxsmqKYSCYylRIAG6bCuaCwuP9hWehulOHpEcFusrbBBqQyZRPPZywQGx/r+hKlSTut6mhEpiPBf8oCXHXHFH4KXupiMPQO0kmuY9FUmq+2NfM0rGmVC2k9VzPxakPrQa9WzBUN5AQlsiKP8ho2MZp4xCG4IAa2lFsLXCSUMN+GqQrCbX7z7rfN7bcap76/GVdrY1/XB9WpRa3+4rAVdEYNnsUdfypLuZTYRsIRoXWPl6CHDE4yAkSduQXfu0MdPYuMakybr2t90sBBE1GAsBWWapMn4Vs4ap7mgcxRfsBj6ZUbJinfGiCe5WO1VbcN1NwINPWscQRPI+ytMTw/hL0pg/6wPHn8pBwcvA5uvE9Sf5d9eMH2Bh3J7Z3dsop7BB09ff6sfP7Fl+WpSgENaz2jTKVuKYv7t92sBK+srXvdkIeobtORXc8as0Xki0psH6UndjQswwmdW+h+ARm8surhqkuk0UNh2y/buxvB3wi5Ohj0UWC8j3ea6fyckA9+625TGm8b8UZpixLUYM6/YLBFAGHjBWbilCfp6E7OzsrrF0/KIYrYzWRYeh3XLdWpMu8YVvb2UEqTdpsHcmAxCtkqbZUjKACrJWHlQEbHkKs5A66JZ4c3uzgXtM7cuKSGtgM5JR6zzolKjRxEpul2enJ0flFevHqVNXwefaRiYmfL4x9qttJt25BXmqr0LW3hlrZj+YZVvmn0EzctHYq3jDQmrtjzm0UyHk/eY5tvPlslLWssTdf8acdydp9yDABVrN0xaedfmlFJqwcfo9yClw449PBXrW2VbaEzQlqRBIWHu1tFrLVVEdPC38p1gosb5Zhhw2vKPL5VRS3FjmnhT1liAd28gUe0hE8a47capsFLYxOX8s77VUs4cdjaxLt1t3UzC8uz+t2mMR+mhWvezofXXUeAq/8s3Dc1MkZbhSY9oPJBRJOx2E7mAEmufqn+DbLaC8I1iNwwaBbeUjnxs6JIYyYUsaY5vFxGmSFt3B74agVekLwq0jnpLGWrLQWGgFQaTg5QlGCY3ffvIUSWyuTkNHEWV7tZ2OkIV29XIbZWRignF2en5Xo8LFf0Gnvkofo1WVhFwemGWBdUihAyDsa7mH9l6uJShIHD46S/iWBb76ynIRjRa1qljAMa2M8fPS+Ho2m57A9AGHFoiU371fAYxeyibDQ9jh7Kg9Nqspu6uQvqPSBWBrP3mLvm/IZHRsOcXkRoZJGreEPAjtXkieei9ZwijiAQv5JsWwd1K7q4BX8ImSm4ml4tl8lNp0yXt8rixoOysvNRWd/7pHTvflJ6+5+Ue59+j3RPyujI7e1Cl4qK8hR+kJlUXBrrCED8sFHSrG6d1HF0rMZUXqoe/srOUbjFN/hwGjunsqM45agPe8DWcaNIrW3vlK0PvpspgePnjxCWY3rLzbZrhI1pGdc4EqkCV4TWbGu+liVWmhXZhJV51za2UHqpT+q8s7Ebv4vhSfn8yUt6vwfl739njwaBHn/Fxm81tSEmTBhc3AED+MhZdW7OwOccxX746mkYKlA1+DScHuJPvFlnNUDrLwctlD/+r3/3I2OvaGjE0bxtTfhOvM38qjJVzW+G17TvCrOKI93xybMNrlxQDuhvuhm5FA+4FfbKh2yoSTiVOfyMp5/4ISF5QGXAxsAOoGGiePsnHk29UaaFJw0d7pSL+LVsjs54wrv3QK6UXRQbFUKgrQJWlwnxNE2kFGyAb8pWM7G2alkb/BiBZ5ypbMP43TLUpQhnw3750U9+VL746ovEcfTaUTEVMddGdVRAUEZy6PPRcY6+6KMYiTPLLH7sPKgkeMdmiontIPc2HOEnjGdIueHHBfI2xmfIQ6cy3QxxQbre66vc0318clheoxgOUfSSkJDTuaq7WV2v51l85OcMBem60xAMBhYVSHmM0LIDgg0cU0b5OcoK35Vd7SJ1FYHlJfJFLp8cvSrHr56XyeAMhYCOb0fZZh3dZHrSc69MP7tjXS/m+l0UMacoPdbCgYOsHbOusHU9Ge/CIR3xJ34dTfN4I0fGjKMC5ojY0eujnBV5jb93UNYT96ty5g76s8m0fP3sVTb3LDrjQuHcQekUrjsPc60QmVWastwqp9IV+SqeeM4UNuBIP5FwoKK+A19GowyLpeg8xSPx+CoNGc7jkJRwOUnfdwI7VWc6KqPygktyMnIZS/tA+Z2WHEI31rmKWA8cdrF1SpKOj7jFbcc/Ck4LF2lL5/a/63IAaJinilWmJXmv05TyMjwp/YtyrH4EdSAyz9ZfmgqPUE75q27Qoow8UwbrzfLEBhD/Y33XVpmEWxs4K6x5tv7grba4t2WRj62H+g6ezXf2rP4+23e/tXIiU+2NuyppwuN7a2v8lNDvZPCNKWMmnAvDQbqYs1ASQgCQangGohgRQMVJ+GKe9wgMKjkjIfpbUY31vfVTiRmjeZ1NqxB1NCjTjaR/rbYPUampe3TANcyUeWqEwOb+Tultd8s5wmgsI+lPT9n01nqbZYXGXAHSp6G56J+Wcxhd+Bdh9AuY+pJK9z7DhYlTjfT2oGiH5ZfonYL1skKvNMP7G71yd3MVhWaxjEaTMOmH252M1v3i+etySe9SAZXT1W1kFTg8vOV+A6G6SB5eWO69mI6c2Mi4sF5BHgUtAgThwzcXDVsOe11XvLuObAGGHyMQHAZWQezC/F3CSQASr+heMT5lyrSAOFNxw18FKb0XBLHrrQbjq3I6KeUEezpZLsPr9bL//mdlYfh56b94Rb3VWjbROp3Ia9wkVr/k17Rb0yoNaWoaxaQyFm7gi4IVpQvbPuMvUWuJSpgoVcngpnTvPCh7n/xhmP7Fo19m2sJLk107YlzBlDlkFM2McfALI8lpgSefa7IGyFZpepG9DdJBsb+YQCs7hqRROC0/+fJZOT4dlb/32S5CQTW4mgiPxl0Brsa0zMccEI/BVegega3gtwHsv3xapmcnlS8cNTQMz4TNKGMgNZMG39oGdnD5J//o21HGWlNx+WYZ23ef0qewRQ6kNw6t4cYnNoKoebd+2t6icasQbcJHm65xxJlDrfInSKL8NPzwjY2YmanA1J2/NlCkRXDPf3OEQxU4qFNpIFxGprCVSEkbfjU/4bCxUljjhE6qIreyTGMOTMoXodl0vZjrTXkjJ/4ILJyEsT7MS2ow9TQ+1GFGkeW5xLFptYGyHE7tERBTlTCTIEV4WNn4+Onj8uf/+l+VA5SgKF/IizXpfLObtV3evWj2XgZ+QofyFDpyZEM+V3Gc0BF0p6XpqowlXUe4eigva46uK0vrjQQXdP76g0EZogBeXpxDreDoCjkkrgkzRikaDM8S3nsy7927Wz58+H55yHMf5XR/a6vsIgvXrE+aWJcLWLa6KcVpMVCk/LGjpUYVlFFW2MKR7Lozb4mGXyxdlY7rP67GZdg/KsevX5Qr5GgHmWz6dRkC8k8lgU5nZKRy1U4rnbOcyk+GS0sqZvCZ9YpMtGKvBUpZC55peaAt6gC/5IpmMKG+Lq9sOMHVAoru4LycvD4ul+eO2i7kAODsDITOFzrdgsgsT18dluP+OTKY2l1RMVyL/F2hLF6htwwdLCMvVWpro0+NgJ8oYbgDEjTk1GOdBtRKgzfNGZvEB1oHIqSsJTc18C1rwlS85BvxmTjIL8qpnKsi1idhqIWsWyMN/cWda42dmhzS/tk2uj7MdWEd6sljK0ynHR2LogFOqzJT8ZVOhxDZR4KPFFu2v7n5JMoXVUjZtfU7T8PL31ibQ1mbf9yk57s8A5wEo+6Al7xz9RZASz+Z8eB7Ky+ibPqNJPPEX3zWZ8VBFCHgDo4sh3iPf/Mt9XJbB5kCBia/yY+6LS9BEq+uRWvTnLNNmNboThra6pX3CAkKa7rfiEmhLDXpaigfefCTvKqAbI2AaKPV6qYw0aAh6gwNtwDP2VZAa3urF2WdvGSGbN2G6extOTaxSW/seliVIE/mz8WxCB233E5G51k3lvUREF6Et4qK54nhNzpEERsc0+OZZAvwBkyOmCiLExphhQ7CYZfeZw/FadmhavynlOtKoQB8qwiwBfwHg1HpHx6hNEooCEdH0kinh8C7GCHEIHavK1lyjccdpwq6MBCCwZ6kC2oBy5sEXIPm6ftwRqZWF1E6I7Ah1y3XR0AJPXqCOfgRQO2lOzKkcJBhHJ3bWO8Gn2v0fFc8qduzyO7sl83YO2XHxbjv3S3dna0IZ5W+awS4CzZlzMFpvxwdDxAw/bK8cae8OuuWaenBLAgucJypPOLUYeXG8heGo8zqW+ppQYTvIhQwlzz/h4ZAxPiprVsJo3XP17lWpnTHkzuqzH8J4bf72Z+Uvc/+NgKkX5784kco0sfZaeUuH5kBACu9EXdmTMdn4OW7TASdOPIWRVArI4ND/R1Fi7KYJByJtSd8mQN1dzbp7fJdPITeG6Pr9s2sKm407foD4aDlyWiGxh2UWSumFDIsnyOshQ9bFdZ4Epp3/oJ/6uEaWrse29D9+zczOmjKq2nx3/rN16v27bpuFbR8Cw5ubVXYbBBqw5OeP3723NdRMtxyX7fdKxf4bjx43WmU4Aul12cIVGoFpLzCNyqPUSAbcSXUwX0Do+lpPPCTVBEfnfTya8iqKEYu4aUvuabMNT8TrWUjtZQrnQp9SZ9QGalrbUb+mm/y2NNnT8vB0QHuynPt1Jrfs1MNmozyRtnjj/VgUztzr48Oy+ExtAVQ7rBcgNfdQKICVztmK6WHfLj/4P3y4Ycfl52dvZTNO1hVOPpnjpYMkFtugjoPb+zdvVM++85n5bvf/U756KOPygcfvl8++/Tj8ge/993yJ3/0B+Xv/MnfKv/R3/mj8rf/+A/KH/3B98v3Pvuk3LnjYdU0zih4jgSpdLW4bTtMvtcpSdoDMLWOcDsf98vp6UE5eP0c+XkMpi6BDzogDcsd2kg6+MnHdG5UwlwjRsIVz7EIIPysA8tvJ8qyRPm17irGU7d2SlUinNb0JoCOsvXc402kGetVNZO6sR75fkM4ZzjO6IQ7VQkgpL1K9jzDs9KWMh1Zjtsaz2iY7RBuKcFwVQEAH74LDd+N7ghZ6FGrfBJnvEThMl5jQ/NY8ekzaVDxZpNn3pFkKN0uFclCd/wcUfUeU2mvQ927DrJuSjFf4SR9cNWOOmZqXnwChzM0tQ2AzLXgMmexgatcs+eACfi0XZas2x2pld9q+PCJsJFhbOrTzC28737ztaERQtdp2kbZBCfVWv81LuBWPPlO/KpEYk1bHJFe3nWL82TFN1JPPN3YqnBh8Z8pX024FATb4le3ZWnLRIgadi7vCn81cSetb8iYkD18K6L+zLKqjbKuAFtfBDKaLUgwhMi3wmyoZCiNAGosgCZA4+4tqWxQEY7wQBAmSa2TDv68KHxzVyPeF5MxwscF2L0cqno1mWZt0rLrPPBf295DqCGwIELXAzlN6CaA3ro9LooyHUNopLS9kSuHHIE6QVkbAauKoHe8bS8h0CaUEiK7QoE5OKnHZawsIlDOh+X46CzK2oI7UoBqvdcrnY3tsry5g8J2XU7syTrs3x9E2dimt71LyFVw5JTBiPxc9zKhjFLulkJY1ACXvXUJXjK5hvnthUiEXqK+Tk9MBl6GqRZRzK4oZ2d7p6zvaHdLbx+F7O7dsnVnt+ze38uBsU61WhchJtKVoDxpvkvPe//O/XLWHyF0uiLZpWBRtqg0qBy304Hxp57IXwJX8GaaEHcOU6zUHqvSY49Uck06FomCtWmmXg2L0Q00oRXxvnH3YXnwh/9p2Xn/98vJqxflq5/+RblEmVlHuCo0Q1Xh8sokaQx5tozcpikiLWuM3tj20lmNX9LzwwrLNQhVoF6c0yih++xtoki3NNiYJplaljZtTNzmbVoZrkFwIsSzrgR6OqehtccfCQGuZnyg4G/KEbDkL9JKUvyEL8RrDf6tGMsyX7a/yrR4eFf4wG5B3mFa7/l4bfgq1KzLaq0DOyWuHfM8Pkd+bOgVpiajddQ9nULSq40AtATPi08VtKxfFE5aiypIlSlGJAjh6rSm6wW9aukyeTolptJU06/WHAOn+fKj2zTzfUYp1l8bhvIknPHNtypiGRUFDu3Z6Wl58uRJyr27u5vLwtexKlNZ60Ti3pJhIn67C18/fP/9sru/V3obm2WbTti9994rH3k5+MP30lAeHh1lcf/B4UkZ0bFYWlgpu1v75eHDj8onn3xaPtV++lm5f/+9srW5HQVte3sXWbBBubtlw3SRI05x5kgDYLYcLonY3uqV/b3t8uD+nfLBg/vlg4f3ygcfPCgPP3hI+B6NOQ2oo1eB/Tp0PKtTUQS+vZjcUXZaiTL24OqjEzodyCJk1EbPS6lVNuEh5EiVN6RJnahgqVx6rVW7Y9k1Y/KUuHKYyYO1o7jqV6sjtq75JD0kiEdV4ANN9VD07eovoqz0o4y6c3c8nWYJCSI8U3D98aQcnpxGXl+RdmSeiePOJgH4WdlMEakm2zy+KdMIY/ntUNTRG558rJ2QhjZqMrxHWmL5A1HxE3dYad3NAYmDjRgxPd18i9JnHN/5qBLuPZKCMfLSb8/aRIkEyvh35CeeuY6KsLnbU3wCZ9pk8rZ8YgkUxA31wk6OSlfadWCgKmHY0Dbh/An88i6RGtPSQPiisb4La1uGWVmbMvAgnHi5xYP4Ce50N3n4FG7leHBMXYjj2bvheb5hjTf3bv4ZLSMHOwla/Yw7b7NBoimTZr4srXven588v7FpSs0YheGCnpOFEJoWKUBBZtXGtN99V/BcuYJbfQotHaK1KK5/imDEtgJJtz1A43jr/eBise6ovHBbi8LougwJN8HCkVEiFmCaaxSmqdOG/WEZI3gconaNkQR0OaURHA1gOBpU4Lnqn0Rh8i43R7G8vHtlo1e2oJ8xjHjCu5sEdkjfefYuTOoUXceKXqAnZQ8ApWhzu5uNBaeno7JO+fcRHi9P+6Vvi4mgoEBhgilCxl2b01E/i/l3tu4UV351wdH0CuYeD2sPEeIRvns0/juk5S5R8XchXJZXXPIPGkIkncXrrEkT0Uvr64TBifKahawKBZ725ro0Wr2NdfAu8ZGEAsERMhp3XmsjDz7++I//mMaumxsONpdfl8nLz8mftInntSgyR0u06dUYl+8tscXqZ6FrkuRXhVPe9Z4PG1v9rHejyeqd3l65893/qNz77O8gWNfKs1//CPtvyuL1eRqhTjYokK+WzG5hILqC1r/GL/6NmXdTitm7ebtmzCMnzqejbFu/oSE+OzksP39yVu5srJSP73QjgGbGuO9I22e211v/Vhc0tNrxlgf6B8N+OXv+NT1VD+wkrPinDH6rFWMC/JNPm5V5ZggfoyA0/N/+3/+f8/67NC9fvkxZ/iqrEXet+21/Tes3/619auacMa2igov/RjEPPvCD8E3WZip4we1Tpcnz4OpIU83X4CrnyhLxJl01kfmvYWqDhcCVpgkDhFESkh/BlVE7W9u5F9K4rq1pv2c01TT8jV9Vrmpx4BOsbstXcdQ2zObue41To9uwXZbnL56VH/3oR+mUuQ7SYy3c4ehOQXnuiviOQAu9cdxNubeP4tTbKPsoZB++/0F5D6VqnU7VEHn36vWrLLRX/t2AH/HhNLg4cof2IvjaQNHbQ07e3dsr9/b2y/4uyphnmmWjRDfTpI6grCw4deWUYT2JvQcfBm/A4UaXc5dmXJyDZRpnABzTkQFoGve6C1TUu3hcZcS1SO35cc6beIaiV++c0FEZ989I1w6z05LUM0qxmzV6G114ajWjgN476cYr+cwpyYwS4gbAxq8ZKVNTqRUbk3rwD4IgZBA58a4zZLFHlyzBiNPRpLx4+qKcHKNwjeiM2XY46kNgbyw5GY7Kq+Pjck4hPfzbdVJpz7TAa3uhArpM2vabIqOwtpdalYUobPxFOcBP8ARzZvEBdTx9t33lyY/tQ/UzLb/7TeVhMTg1TkbNkNe+O3Pi+i+Vq/PJuJygRDor42iYo8vZLWk9YJ1VEs+z0TDSlcYqn2kbWcQzQyK2xeE32+lqVc7EsAg3jhCmg6uf5cSG8HVbgEZ2pz0Bd3rVNsawtcziNDicRa3p5FvjjjWN+IPTxi1+0z4YP+Grfw3n99vwNU9s83er6Omuac0/tRply3ye7bO1mribp9j4xoyVq8JQBUzNMO7YGqYFAkeAyOGoDRiGVXiqEMwDOW8rEkrZWr7MNJ2S0d4AoiujTH0YAfYr6xADXJG5/CuEhSNGN4PzEO0uvbM1hJU7YG5gqi16WCsLl2UKwys4TMuFrKcwW6GXt3MJI42n5aLbLVsIpfs8t0HsNvkqfJYRpmcXg3JIT+mys1E2dzaItkJvAyFEHgPKpAB47717kqBbjnIY7YVCCqVKobKGd4/ep6rU5dUURh41SuZ1enqOmO0hdPY3Orbc5Rol0zslRzCQYRxZcb1ex3Qoz7o9GOJ48OsVT4/rW0RwIh3KNe9Rf2U2R+nWe8H5KsJ3Y3ebMu7mNO4ewt6e//69/fLBJx8C9ohiUIIlr2eXyVSOzd56bhnSigYIKkk3QfKt+mOgUHue7mBrFWyNdaubmG2E2rihiLrzbAnhsPvRH5SP/uP/qtz97p+WIYLv8x/8s/L0lz/MZezdNZRf8CTB1yQaWNo0AxPvebEZ55OEZHhsdVd7TX0qOoQsjOW/yrAChrp0bWGuYkGZdSeXIojUkm5Lp5qUB3eEEuVQfYgiVj/XRmMNscz7dOghr5OMFmfInPoQlihlCFAIl3eCqjSj/OYb7ryn8becwvAfpmnrI3Xy1vvbdv77vImQpa4UhrV3buNVR8U8M8nRFte0uPV+Y93dlXVnZV1sLJppFOA1N2J4DEZ4RjkhMYSGK61kqkF/bKaufGIvHb0cT+LnCJwjU5JUK4RjiJvOY/ts3GlgkrrlcpRMa/mSOXSioNZCI6n/2ug5He7U4OtXVXlyjYyNYpRAwntI82kfRZ6OotcivT44KEcnJ2WCLHL0fxdezlljvW6ZoBg9e/G8/PTnPy8vXr6C3pxdqLJ2NJyU50+el0dffF2efv20TJBd63RiN1BE7u3dLft7d8rWhmeLqYj1ys7OPsrePdLeL7sobLs7W8C0TsMN3V67Kxx6vzqn8zYskzEdTmTd5HxURt5WAdKkazAT3k6Zg0PkFXXqIb6ud72hQz48PS0HwDz1vECV1gZ/2a15M0UuIJvJ0w09ObaCjjCJU53AEYWL8qmMpCNKNxv+cvQ+G7eojnazWEZaYDA7iK6luPKyYxSxFUfF6IQSAfjh+5DGda7eGyJ7VS4vSOiUTurr00E5HZ3niilHxjL9KV1QZ7VOVfMqrWTaDPAE8Q1L+XyGxvNnI107o3K5UPm06Us62IzWGFc/cEoJ3vBfRQF0rVoW6QODT3lGcSE9S1cqZI5uum7ZM/O6nfWqrIHTOiqGQoYVbpKNUUraoXEjiSNgF9BqpnYpf9aJ2T40bYSQVfrXVB1B8rdk87eSSAuG8yF+tLotm2vFqM5Y0NOEqXGq0tPGwd2E0xpXPITPgFd8xh0LLQY+02vx27hNV4tvi/OsfRTHPKvb8KZ5a03X/Jw6VlSnTi0peddnfW/9ZlYgvinjkKYNg1i+FaZivCktpvpRWN1YBaqE0TaiCjyRoDDCEb8WMbcW4qJiNugl9ahAF0R6nc/UIWwY9g7K1yrCyNEjj32YwjRjeiyeNbb5/nvZ+j08OktaPXRB14QNDj3ocBzlQa3+Bubd29oq912Aid90e7PsK3QQCidnJ+VrhMrV3mYZgu3XF+MydIZgY7csE8YFpVfkL5tvdB0md+v5atmmNjcRTqs3F5QXuIF5lbj29HaI5/Tb6eiwDCZn5QTBOby+QPg5d79WdmCQjU63vOpfloPhDd8Wy7Hlstz0NG/oMYvBLsqTB/LRCgS/VxCMGxzSK8MqSMYu0IV57CmqnI1IQxJSOXDaw4Mk11E4OxseKLlUvvPdT1OvS9nSTl2trEc5iTIFp9U1LvONDw2M9USdprZx3xrdtR41bZyWLvxNHeOy0fOA1d2Hn5YP//5/UT75+/9bYLpTnv3yL8sv/+X/uxw9+QKCp8xexQGcxsk6NtNK/tXWlGu6QZI2YBiudWv58Z84hlFAC1FgkqtJV8X5ikZGGllaBk/UXZt+whKmLYvGMiRpcOHOtwgf8JNpFToiNv9X59De2QFCiwYaGMILiaSt8Ac0NQolAnBlgTJlhovTqOgX+y2a+XJq2jrVzOOh9W/92vpun61tTfvud43xq7BtrLjjWRUy3Hyva8bsxdubh/+RKa4bzFUtdKjSAIG+KGURflXxkn6dCsMbC70AhtTnN2nJXczKDw83dVG7O8zcEJQGCms481cmaVIO4aZRSvl02xqRx21D0JSRRgwHb4Gkugmj7LuG99sGRwXyydPHdFRRPqBDR8Ust4vhzdt6l2ZdrO8OSA+p9sokT+nXeGzBhEZXxaMuC0BWI1cc2XJhuh0LT1k/en1QTg6PUVCRiyhiq35DAdFvcHKKTLssXqFjeRxFOe8Pyuj0LEtBtI6CuWvSkbfh4Bg4zmLbkTHPNZuoRCFtVMiy/IPkZut5rGdgy3qxLAWYoCwgZ4mTzUiOuiGfsiOx4+5RNyEg04xEGk4LqgTV5RMuWuEbSMwAAd9cPmFGdTqzjsKlcxnc2+asgFOVLeS9WtYCCtzymr2m+DkS5szH0EX74CyL0lHeJi41GYzLIQrxwAEA/JXlKx3aQ/KhuKl/6cJZlPADZU/DzTOvggYclQaBMfRCg82HNNpNGMCtuOJHUZBG3biG42OmJUkzikK+Y0yHxyJtoyNjBAl9TaYe6HoaerYD01MBI426/swlMHZ0DC/OKtwZZeKdGhRrWNw4nJVSJlalzDZAPDpCqEImEGCZcskOWkndzkA6O7zMrEHfMpY3vMD3WP2Az3JYd8EJukBwElh9Bw847KxFXpgAcbXh0XcYybHysjngti6S25um/V7NbVq37Zh12uDrLdt+ny9v+w0IvzkjAurIWAuU2GqzmEfC7RNyjhKgUbjasLvgL0O7+FnsIJ90InixCj63Oe+ter7YchnDvJpNAnZwq8i8HrtQH6KgdzV1ZySCrHN3LwvVT5+8KNPjoxxRIWMdng5L/2xcVElkUheAerr0GvBeXUzKdOEiQ+oXR8flib00eqrrkPfZ8Vk5RalbdHgfO72ESQcILXpHyxDctqNMu5sh5LPhCMKgTCg5C+tdKg5RAax31zfKna2dckE5Tl0fBgHbi/NapVw/TgWnoaGBGUO80+sVCLzQw3QLOsJheF5unOcnDwkP1CMQ65lKrj2wisW2O5SWXDyKgFPipNdGPkPeJ+BGDGZYn7qw1+juLM/F6W50yve//2mEvIwooS+ghLjWKetuUtfUZDQCLESlaev6lgDfbfw+HyfrdWyQuptl7zt/VD79h/+ofPq/+Edl4+4n9JC/Lj/5s/9H+fVf/JMy7R+kjhyZcgF9RjMaGsuf7/4n/WRUrTypIJQ0IwgNVG2CUQ69fMYB02ukO8NcO90C3UxsmMDX6kpiYQ1Xw7auGUqIq+Kb7fP27vO+Fnw7SjM8fFmmw34TuE1F0ybgozJsnggXRxbqFKb1C+zSrcrZt2ACR/Oct7/NzNf/27SQ+hKvSug3zJvhqrnNq05xNzJB2RCZQAMIgeaaFujYKXjvhu264xClrI6QVQGdRs50TJX8rWaxV0vRwETDYkN1aecFO41CJl/VNTUK+xq6xnsDD5bLFinFqO7208wQJvSHcc3a1RV8CP1fQl8CZiNiR9UjKh49ehRlag2FRNhUzHKPJt93NrfKnf07ZW9vr/SQL/K+FzofvH6d6Sd3R5qWo2kPHz4s3/nOd8rHH39Ydnd3shY0nQ5kpUqpZ3VtdDql62J1OqdPvvyq/OgHPyhff/llGaDcnXtMBfJvhCJ2RtrH5PH6+dNy+PplOQVOd+LZYZF3QtvIjb479EaTyMD+cIy84bv1JPzWWTPq4qiaSoDrMceDfqy8poJgnaps2Fhqs/CeOnDR/DVpuIlrkfpeIM3FVcqEctFOSeZWEmyYnrK2ddSOtEZoWlVRFjyn0ns+kUGr3RzyfKliBrzHlPf5i1cZ/XE6zrDXMGEfef/6CFygkBn0irA5rkZ5at4kLm5h/eycT4OPn2jXJTS3pKHCXpV2laq20yDIhpdeo2Rp41/j6+/ylAyaE8d30wBCiQtZ5CYHFba6BGg0GmL70NEkSq7T0fKKI2jmKxyirN7VWPMJr7Z/FCajv1hU5zzJJdORNFNRtHPsEu6kpp/xYyuu9dddTa0Xy5I33e+wwhVFDHdVnOQh/OKueDJUxW1SrU9+MvrKh9u0xFHznrCNnfs+//5X2YRtn/n77fESpn2fc1tn35jJDg4aHSsrhsKHwEPsIq0FoKlYgylEYXyFjsymkpJLs1VcHFqu6CJek2QQWpmyt0z1L6FYELcbKixlSK0fQ2CTjLAB0wVPGtD1Xp1umyIQRvTUFntr9HS8i7EgYFUAvPdyCWUO5ecCxQyhcjqhl4l7A8G/1h+Xk7NBuUB5WlxdLyuuQzkZlC5xvFa8nJPm6XHZVumCKT1awnKPT4bl+NlrBOoJCs5a2UPx2iW9HoJ117RWNsry1RK9b+GlF9/pqoKhzKGsOXJGuCWYf4xg9B7NG5UwgPa+yKqowYAqRuDrAgSMXWNBr1X8IRFgvBsaIQQVcF5PXEN3XtbAk6N17thUYNKlTZ2puKjoZQeS7+Dywf17ZXNjM0qrQturSJbWepn2yCJj67GGTn2qoFW3v7fG9/bZWo3V6hCtAjHTfnc/KO//8X9Wvv+/+j+Uz/7Bf116ex+WV88flR//f//v5cf//X9TXn35s7IC87mAt+f9c5TDNCIYkmClMY20V10Y/RW8GrI2+4BApCp7gIkGKT21gOM7FoFrQxWYwZcjIy7kdq2IjaG4TEnMKAlVp9Jg1ovEo947Cd3jtpHwcE0zmp4dZhevHZi0FUrZpGla/OJfi6PP7Z8mvGQDRboRMthvw8z4uAI2e/67mLfpYd5d7ZvfNFXw3uatjWIFvaqEiSPrwNEBR8g8/HMD5WSju15yPQ604ghLXQdGfNIW8lRbaMWGCORT99lxqaXu7SCSWfHgWEfIXFfTzaiS8qqO7GrTQJB2YBfgOfhNlrf8OfLjyEfWhfkZulK5ShrU4RQelv4GKDyX0NuzZ0+yRklFzJFrzwpzasn0e3Tstra2yr27d8v7D9+HX98rWxsblQb57hEF7jQO3ZK+Sur9e3dzrdEu8TYpRweZ7bE52/D07mavdGiA7WPIl4OTEzpBL/KcOuqGQnZ2elRGdHAvwIWyw/J4uLdKZNb6etwI5VWOO5U3puMydFkF8kxUZmTKUUVwZXgPswbRUQIcEZt4bEb/GJkH3KYPLNU2DbidzEXXf60hMzooYmuukUEua536x1+FDOvIloqbMjAjYdKJ6YAbao1nldO2K1nfRD6ZZQHONeTeyvZudtx7Vtnz1wfl9eGx5EH+pJOpy+tycopiisy/QX47rWl75rmPUcjgZ+lEukIKoyyhfKLAtdOpsG/KHcWL0t2uA4MWhAsYVVDzjbLXjoRxTLd2KFT3Eo640rfTjdp6flgN7zl4lt8lFl4RNx7Rlk0ntB8lS228vcARZA+w9jDfNSLltgXlPW6yAV6QAhzZuQuu6v3E1DuVSnPEU2VMt9+qUpYjKhCAhue/ylOFYMNvWkoT/IeneUv7Tp42Q65HjmwThkxT8iQKQQjPO9+qvfWTSsLburHiTzzn3DrLY5rGzfeqxAaH5k8iylHfo6jrh83xIiSiYqq3zwyAYPOOnX+abluv89Y8DTPvbmHB+c0ZE1MxCMP4q7CJEcVV+MwLV/2rhqxCAQGTgj0Je58SvI0zUFYkYVslLEiCGVaWr8rO8k2OuTDuhN8pvUsvAF+gsbQnKTOv9Xplc3ezVgiEd+eDB8n9akgMwnV2tkoPZW0dxKYXPL7I4tEuAqO7tlFO6SE9Ja0bT7iG0b2L7QRBPe30ogS5acD58kWEzgiBfYowmfTpebw4LqdHJyHU0cQ1bihhnlsGjB6/IGE5mGGFZks+nOGOJO84y+JPwjhn74Wqp+eTcjo4zUL/c6jxHOGgAHW6RCXqZoGeLFAHDhjPO75USAlgpUSoyxAypXm5sFdmlckzlSLzGJ76USkONWHu3r1Dj3aS3mA9PBDUI4RWaBRML/U5V6fWU63v3zRt3ftsrYS/vLlXdj79w/Lx3//flE/+wX9Z7nz/75Yb6v7pr35YfvBP/5vy0//h/1kOHv8MpXqSY0UyhUK5FHJhbPJMvi0YPH0PDWLiJi8VtvRQFXKxll3qa+I3pipkWuJRd64TMylFY2jKKRQkTa53cUgl2TTl9l/6bIww5AgCcAcQ5AON00iokHm58ujoZUbbolQ51Sq914iBjQhxz8OnIan4K+HitHzU0bdhVBrm67B9/3c1vy1Om+5vmlpPbX0miPhUauNnVYA++NybOmyQXH/kcRedTMHIK2IxaRu3yaJitr6EFnRSpjTOWGWOglh6UT71kCcqY5niIqw2ODCB0JceeWtM4+ZhnWZE2ck6Gq3s4rTjRvyUgfI43ZjT8uFlr6N5gTKUq4FoHOXRBRrqGtYriZBJnum1tV3u7u5lkf2dvf1c66Z1BG88GJWjg0Nk0THPoyzHEL4ecmBnc6Ps72yX9+7ulw8f3iv39raReyitlGENGetSjQd37pRdFRPoWgVsMhgih0YZtXJKyylhGxN5wUbG0bBnz56VZ69ellNHxVDEPO5hMEYugz93oMsHHpnhyKPtgjuULy8d0R+i8KoojAkjb4onZFes7Qn1oyJEnipIyglHx9QqbuCfrAmDHtxw43pkaWMJeZV1hcQTZ6EB08JGv4CXVYZHKLkTOsXytlegrdJZ9pqj5d5meXV4VJ4+e5HZiDEyPmvLSKk/GFBHroOjI+/9pNBZjhWBNmpHARmNexU8ZdSWcgcO27JY2wGtvG+jDA1DHbG8O91IKPBKEU1PeveJNT2tcll/v7eKWFWkbCOpSxWsDqoghR0M+2U0HJB2KRsb3bK9vYmuqRyl9eDRcYQSPNbrp1RclPfKLfnN9tRlGtZFbVtzDSJWWm3XjNU1ZLQn0LSKrn/yqW20pZN/XZ5UFTCt5GytxNH41ac4qhvEKl+rePlsFSF5MCOmuKsCV99NR5Mcm3S0y+A7o+PgO1Y4/Db3rsIcP8PjJ17bjnQukw8whLGeGyv9zT8zw0aYt22bb+t+wy8Qf2NGpWJV1MPsjpoooJBAIKYKwHyJoW55b4UuiHTkAKTJNFa0TCqRhvGsI8P4m0qqlSLx7K+pjKGVEybTWxKBzKXAI22SLF2IyNEx87OHPD4b5HokGXP17k5ZQbgK6wShcQ0SVzfo3cBYnrr/iq7SKWlf0cPuUqaRI2bTm9JX8QGBA+IswLTL23tlQi/1NfAeLnXKhIbc3aVTKtZ1C0dD3PSiLKN+F+Q3dYSOBuJi06nMOiXpugp7F6tr3azrEJ5LyqoipwA45zkSeQpvBIMMYWfDtRKu43BxvPdUXqIoeFitCoQ9zwh8T9ne3S8LCGkPi1y6diK0jiSolKYxgwlD7OKbp1MZg+Eo+Ld9ceTM03+WaeBs+nO+TJ7KtCpU23qvo1XVqtWkcbPOFYyb22XjwSdl//f+Xnn/T/7Tcue7f6csdrfK0atn5Vf/+p+Uv/zv/m/lJ//8H5ejJ5/T6z4PXWU9HMqszJaRq9SvxEH6PKQz/iu9hEZwt8Z8sZqE0WSej4d/zTfDVQPNNi5Kl9FX0xXfucAbDHnfnkPkKbzWjgWJy7QxpBVmoy7M0zxUlNPJABeTs6NyjoLdAJy4ig87KMmc8BbNeIKljdDSbUMuDchSeNmwX3lj/rdkKkz//+X3rnhtevPf3pm+qIrYqniQn2yY5OU0UMiMNLw2Qri19vxzMjuKiQ0UMYPXyJMmC91JMP6mSy7xqgHEr2mq4PR6XjNWRzqNZlhhdVrzncY0+M85ZipfTd3Vxq3yhUZ/pxgvVbhId3Njoxwevi6PH3+dQ1ZdyK+S5iGrd+7swZt7xTskcy8mxobEacotYNTKsx6J4XTl82dPy9dfPSqPHz3C/bw8f/q0vHr5KmuGbMzv39svH3/oyNqdjCjaGXVK7c7uLv4flLv7e2mcEcxYeEC4gcUrj9zx6HKQrKdrpsAOjo7KyVk/MvWccp2DminWJSgW19EUWojiDkg7h5b3fOqB3F7BMwGpdkZtD5B7yidwXRXSZvoPHlpa6WCJKz/Z4eGbvLVEPXtsg2nbmbWhyxQ18SPrKFs6oKlbaQ74kJ1eiq1CBtOWLvhbRgE1TeXxr774ohydnMK/yukbUHBV+mfDcnxMB5nCASkpIXvlXWhS+ggNklYUJvJ1ZyMQRnFSwrYKSabc/Yu/dFeVMg9zrQopIEmPEGam6PKuPlDxU+m94ihhA0lNoyovi2lPJ7QtuasZv83NHvTjpgsUSDuBCJKqY6A08p51eR64qyJGmuLJ9jX0qsLVKGA5skJFmvbFOs1oWei7pevKP/O8Lb/EJmXdlZ9bf73zyHuipPxVCfUpjup7Ha2qMkCrv/Ih6WDaNLPmOd+xhlUu26Y2VhiqFc+Gxd+wWN1R2kwzSCXNOVuXNpkO4ZPebfrvsqbTpplyxJ+4gfgbNB6OJ3ASekW97QVVTaHaam2Nb5bPiguAMhNPtVIX42sEVOP3akWQlSHxLZbNleuyQxh3VNpDS4MGAdehXQQotqtidk2vEphcS9F/8bLc0LsRTqciMnXZnxRPWCn2hlZ65WR8kalFd+ptoqw5RdA/OSnHIwQRys4iCt/lZFrW9u+UpfsPysXGVhnR4/PKpCUE0BSmdv1TByQML66IN87w9w5MugEcFwgtR/GOEUlnIWCvI6JngYB2Ya1lcdhXhvXS8LUlt26vlkusNL2MIgbJ52iPlFJlk96kZbxc7ZSLLuWgZ2jPzikET93vdFH6UDQ9pd+6WIWJwGJZpKFa7JKnC4ODX4gJNKr47NBz8rqPLG4l7BTlFBGas9uW1jZL7857ZffDz8rOB98pvfsfkf4+iuFqmYJzbx3IkL/KMQrqUm+7rO29hxL2adl6+J2yuvteUX84ePG4fP6X/7z8+J/94/Kz/+Efl69/8uelf/AMeewuyeWyiRLWRcDmXk3JwSqWFiQMkYFLRve9+jfvuFshEEYzKMISmfLXmpCREeCQdhrDI03qVCatCgK0s6aQh8oIK7W3wqY1YU7gNpGapzTOO8EuEfzjg1fUWz3CJZpuA2sCxKaEeWaUTDpO/pRHQWBZsdZh1rrNwv9uTfJUsGFbGLT/LqbFlc+38Tbv1z5n+aScdZRgJijhf5Vled8OQI3jyIKCboGePvwThcxzk1znV+nbBihoTmgcoQ38mnQz+mGa+GXxPPk4ZZ+NSk3+kUNNGHk4eTdp6paE6jpE4fI7/AoxaC1IbhGhYXOtmMrM1PVdpBe+5fvz589Rml4WrxyycUsDT3m8IHx7ewv6W4ny8/r1q9If9nO+mqPZ9+7dkerK4cvX5ez4JAvxpR9KxfM6679evXgemaZ82CCeVp4bn52Us5Ojcj0dlY21lUxfuknKNWQqYOK+Pf0+RyeIK/4c6Tqhk3tMZ9dO2/WCiow3lUC3hgNvOQ0f3DhS7DEUuSwfo7y3HK7Lyyhb0zi5DMFRHRVq1+1WxQMlCxx4BI+dG6c8PcLC6UllZN2l7OJ5pxdRxvxuOGRYGj7qIw2fPCkJ0DasNSflZ2mDI/8uI6CcKnYqrY8fP80Cfg/BXV5Zj/vYKdu+100pX2py0oOKn/JbUaWak5PxCdCOMFnvyjHj1PVPynnqBhzXMNJ6DWegtr0TZmVQpbvq3yoht6fiO3qLHzYKoBkhM0bA6SYNp9vcMemoqKOauTuaGlHBMcukbTzgV7EIT2BVMjPdiOjLDkkKq5VdfGZaEut7lqo0nVPf5QP54w0rP5BhW07AwkgZ8gyZKHNjK3xVQRVOYazlDg54z1StbsOJo6TrezXVzZvJJy/jiSN53DgV78FdIglTk5fvKMX17MkAGWNSeW9s6ozAVUFrc363Me9at4075hbeb8y4g2lhuTn81dxAuqMigk+VVKtf81l/y6OPDCBwrmtwPZdHO8wWQSZsrQgJxt4FvxDbTdlZuyg98l2m8pdgFs+7keVdf+C6nzH+Vygzbt8+e3FoPaMY9MoVCtf09VEZoJxNx67PQCBMRuXYu89evqAClsvgvU/LUXevvD46K8+P+sB0GcXPEab1Dz+B6Tvl9NWrMnl9UG4QbNeHxwVJhxJyUfqXpYwRsMvXlANYzhE2bsN2apPmpPAll4MvoNQtNUTcQyi4tVvBK0M5JZeGB+GV4XiAX0FpcwfRJULGReAehFjoUYZo8LsgmAruEpzjGoicFYOw2gAviKhcc+GxHlOv90DYTNc3S2dnJwLNvBQKcGm5e2eXxqeLgocyRy9JxUM9WyG71tsoXk3y+vmzcohQP/UcoPEo25pV8c4RcB5S6xSrV1a5y8Y6HQxPaSCelKe//kl59OM/L1/98M/K1z/983Lw+Bfl/PSgLIIrp4c3UWo3UQ69YsqeWiu8NM0jdBTy0vruBwL5zEiRvXA/gtvW+goV4fhN0k96PhtbhaINtOtZ8IDRvKkhUxwIbNfa2BDpH9kjI7ZAytw0JCoEGgXa8qpTWyjT1Ff/1bPckdowSvJW0Jpz/pJfvqTc5By3pp4w7sfqF7hJp4b53ZsZ/zbGdwXs2/7BnbA139sw7wrbhmutJiiw8Lw7qiTeVWpUANLYiF9kg5uGcto6vOBTYaic8cqkNRQvR3Rc+7K+6uL0ZejLxlfhV8MADrxPJ8YOlm6s1SJOqca8XKLMOOW5ubUJD1DndOKUz8InnMLoFHgikqBHZvhep7v1szyOQxPaRJdovOAxdzuHFC0mP9ZrwpPewavX5fNf/TojYplipVzS8xo8sQEcTskMkFsvXr8oh6eHuM/AQUFJ2yh393bSiVmkfJsoM588eFg+fu9+uYcCtw7My45sDFF+aKRvUIBWLDTPwcFROUOxm/Rfl0vSmyLLFunoXcnbdFpXIcweNN8BFtfLqpS5G/ME+fj06avy6OlhOTqDvic35Wx8yfMiO+pspKRpYXeTkMpYuzj8yunJyZBO35hy23Fsd8M2dQdOVlGk3C3riFOOWJAHXPtDed1lrIKUq4+wIEuhV661uJ1ZuATHjmdTxWErVBfqiA46ovPyHFkIvOMR7RRt15IzHXRmrQfEdvn8F5+Xly+OyvRyqXgVnxddDC6uyxnKqdN0TqOtNeut3MnekQbxXySym7QAL436DXVxQ50vLCJP0vDXp22Ya/Syrgj5HrrE2LmQtlQ0lDNReeOuSpYKVFoSw1EugUUSZfmKMl5/b5M5OzwsExTkRdquLdqTPcrWhWekgWX4ao1Oh21OBlFMIQRJC3pN6lcrwO3RUOAQme75aSrYUcBAZnbRV90JC7TYHF1kp91mn/eM9Gukddqo0H1d7g9i4BPeaSF4ehcm7Ru8AYvCZyrllFfc8LSeczclbkHUiiljO0PjDlYRrQ6RHaH4zRQ1ovH4DeuyG6eCraM6JazyZx2ZJjILmG5cFuDa9KQJ7WHVPXI4cMoKEE25tbqTuJn+Fls3YRHWcgF3pquDpG/QSCzLML+04fBva94Wvq1J46Xlu8Tg2ThVy18qk/NJhKt+QJywWpEdSzhHjvY6N2WTIMaRwb1yh6+EXcx0ZR9kDfvDcvL8ZWTl6r172XXjlmnPr3GY3d4TiUFhEAzCpbPSLSsffExFLJbhs6fl7IsvILbr0tvagjCWEAwoVafH5eiLL8vZs2cIrX7xHrdjlLkzKsTDYQ9Q/g5QkmRIqfd0MIZ46OmhyPTSC6sVuQI12/PcAN5VhRXEm94NAskDbEcqFVYcRnaRSRc73XKNcEKVK1cIgkWUJncTXUjwk3HpXLq4VuKy8lMbgWPFDCGGKWlcovjdIMRcR5d1Bvit8c0lBK5pe4jwdgjbHoNV4FoCifb62vUR2+mtuqX97Pg1CtnTcvDsSU7DPwMvHrchlzqcP70Y02vulxH+YxqN8dlhOR8eo0SOYACEAYl6Ge3m+lrZQgHzsEnPSXNnlz2nyssy9W/SUaZE8Wtpwwquo1d8w3onYRKwxa0J/EYab5tkh6mKnEqdggN/GMct4SqW9BzAEbRunnyVHqU/YTB9mcvdsxV4cA99uWhfJWFyclCG4CvCWZprjEpKW46UJWCSngKPcumnIoajKYNpE9Yw/xbl+qZMpioa+7aS9fa7Zh4u3bPyYdrn28ZwbRpx44dsVJ63PwZrjPXCr3Wg7IiFh1xrElliJxGahT8yXcnTEbIcd8HHVIHoJtmsCxOmJu8oe+YPMXmosMfLZNQM/0RoTCuP3i6N7/NlbJ0pkdlI301et886Avba3ZDHx1mg79SkZXHTiLsi7bCORqNMBzqyNp16fpr1kaYpU5z37t4pD+6jgN3ZbzoOC1mcf4Fi5c7H8ZlrUIfpHBQ6oo7W2oHbcCQKxSI7yeFjNwE4NSWaVASyDosG3EZ4hEx7TYf21auDcno2zDSki7bd8DMcTyJvO+Cs52Gx8Lanurtjr663RP6hQORicsqdBefyibIv+FRhU6ZXpbu2AQp38I9/ref5OkcJ4ilPRfKZBlb8KwuyTEIcXUCDyAX/aHdTtkF/hC56UdZRVHZ296Ad2gNgf/HVV+VXv/hFpo/NY3x+Xp49f1EODsE7cmYVuVXPOFNprLSWqTTpL/nX9ko4bXgzAiMNIIelteyWbISV+LX9nI1OkZ40mjV5fJx9100aebfNk4bxl7ZqPEcPvUHgPGsOo8yTlgf2uqElo2VkCdTId5Q2vmkdeXT00s0Oyi7J2xHa7B6lXbRuL7WUGy9ozZEyFbOK34yehYYBTArHrc1b82zxYaejjiLpp7xsv9W2L0oYTy0oCE8SY+4JThubAYQ8xT+lgkaqLgCdUi4RY/7J9x02I5dN3uKzPsnTfMUt74E17+23+qy2xq1+1VrFiqm37Qx24RPvwkweiRsMfcOmY6NDhrVC9KFAAiNnvmGaRgXrk6YoyogIUtgoYHIeFoxRkSzB3doWmWrROysoDCLfdwqJvlAWbSxIdzA6L4PDkyg+nXv7Xo1Yrt2ZCIwyb29nJyNDq9t30L7Xy+qlQ+PdsjY6LV2nyw6e03tYLtvdTRiZxoY0Jy9flsGTp2WEQPNUbAl2PLnMwbNHKJFDBJvrKVQIvcnf886OJlOUpYVyZ3OjMsHaWtkEMUsoTpn6AnYPXkUcU2FLmepzbZkjS/ZEHLFKr9aeJRTqjh8Xsa51exmWdxFpphFQMg0PsAjXugblDI8+cDnPP6Rxn5COnFDvVaxTJ/ZAQjEQhmtRdrc2kn96bzB3BKPEKfGsbpQ1Gjb96unMKE+NTS9OokwdqbDgRx16ia/1qu2u2bB1siBf4e/2asNYn3VKR1qRqGV06aQyfx0u190yO8HysdraAdCT2BYRi298apqgWU9M+57nnNW39VOXco2YMHjPnIuJc75ThKTlM0/zAUb+VFCscxVpotRv0r/KN64pyvnQi46zLibZ52n8GMrQMm1gJwFH+QRKljKcZc8ZPS18TbzG9Ts3yXfOtn7vMr/NXzMr81tmPm1tFJSmfIlBoY0rnoO8mWn9rRcbsCqMndLykFYPsszp4tCtV+o4/eVoV0aepRuUY4Vi1t9QCeYtPaZxII0NGjMVMgnwikZKuLQEFDRzDxTN61umgX+uzLdlrIqYJrJPXqa8Bwf1Hko3DBjXA5j39ryOqJs1TgeHB2VEQ+va0jXKtrxEB5NG89yRdmDe3dktn338cfngwQPKSRnQPBx9cTF5D6Vub7NX9lHsetDyojSNXeO7CpvqjMd5eF6iZQwvi1vgsypcyN4/G5RXB0fl4PisDM8Js0qHELl2NnDH+pSyOJJVpxZzVRVuuUQFJEdVAEc0OhQyG19386kkpzGLzEGeEC/rr/QXTurTDTEqbS6JqbZe2eOVRaYbZY70rCdlSTAOzPJhplQpxzVKmUcAqWx41pq7H93Jvr21k7s7bZTPR+Pyi5/8tDz9+nE6AtaRCrB3fJ6dnoXXMy2K7MoaNWmFtKOMIYvnpxP5b+hDBziormr58T1h8fGpgmA75qyG5ZmFtSDA4UJ0y2xedj5t4F0TqbJrS+puW+8T9Zy8ne2tcse7iLe3k5nlEH9u7hC3ulfBoRtdVPrFexbnU/+esaciOp1eFQ9kd3p2ShvnOWvtXZNRcls2iLWNxENYsebX8mXlzQYvlKsqLz4rn8mv9X0+fLW27eoB9VltVSThYemifQ8NiB9pBLoxnRn+3rTir1Xa23zzDGwVlgqT6c+/38apHYbq17qFpYX7N20Lf4WzhsUCzzdubGwpTSqhtdGY597fafD2OIsVhEvVahczteVYdN0KXQsyq9CZXSo7a/Rcl0uUi3WHEQnrFUADGtIQBiXVrwxH5fLlQVmAuFx7sEpPaBElq3iQKQSZygaZCxDatND73H1Qpvc+KmsPHkZJ8uR8e7Nequrxhd4H5/D5EkJ+tdvJHPw1ypnD62trKHrA4xoCEi4jwLBh7TrMDiO5zsVT82UYp2EcrVPQup6s3dkooTgd4yjXFQx+TRwJxf6v5+d4vUkngqdkKHnFUT7S9MyzhWt6nDT6i8B64/lAo34OfxyfA7eaAnhVGK7AcKoKVwhAlTVSDnMKyxSNTwJfsw4ot4pZ1k2sIsR7Tqku1yF6rIevepm6O0Z7vPtU0aoWt37QxgZW5au9ZkOCrMpHFRTz1GGjpEBNC6DbkcuGht5taUYcLiatxMevNbP05+zMhGHrd35q/KSh8iNOXDdXBV16tdBphKT0SCjj1VEN6YyeAD1vD89UcfDO1tyNR72OD1+WydlxaLmmbw5vmnnYTNMRuZy6T34x+UaYBlNVMSNMbgP49ow4am3Ll2/b1syX6V3fW9OG07bKTsVrxW1ravxbGTAvxPNMY1j9asNtg+Ni8U6Usl5GYF38TgOuogJqg2LShcSjEJMDfGj+djDhM0fFyEcrMBWuplwGat+berF0bRlb2H3Vry2f5dJPODVJi5jyoSNj/TPXJDkqt44itp+zxDRnNLSHxydl0HfB+xV8iKID3XnsRSyKhGW6e2evPHzvXrm3v0t5V8vW+kp5/95e+cPvflb+6HvfK5+8d79sIO+csrxGRqCdoGmd83SaTaWh4iNKBjTv2tvRcJpRsBNnG06JtwA/b+0V72p9/gpFZThGhiI/NjZLZ71LcaSN2lB6qj6/wAaP0Vm8cZ4QfhKl9QYFO+J104X1lXXEaQsc7antgDv2VcBUxFzn5bdW8VZ2O5oiHbSKtWXI0gKHc3jWcpktMk+FAvyp5HlRuootkdPJOTw4LC+ePs/6YLSTMjjtg+9+rVMVdmRXdk0SN7BKd6RrfumM8iIcKvZAgL91y5PotTGWTnGLY9Ks1vgN3hs/icd0nWp3l7BKX1XWajlN2yUkLkXxbYgidnJ0jDJ9kQ0dXofl6Kr406R9I11HUaXZKGbwhTjVqGTm+CRPFqBzf0Eb4GDDhUoY+LsdHVMJk45n5N/Qby1vnpYneLi14qMdIaz82lrKkzK1to0z7/fX24rbRnkDgCjJfsPd4r19F8CMevGs8ZvnnGy5/fbu93daZfasXLfWLPk8sxUXfiNOsP8NGxURz3uRiDQRPDhDUlL5zDSNHqY+qzBbXa1bn1WWJvT83J3hQkqnLI1jN4XPiWMhfPb4dB9aEokTkjq/ct2SCcug5KNEkYBOBnVKd5Ne3BaWyvdaosv+Wbmmp3kzQrjQA7hEUPcfflwON3bLpUJoMiYsDIcAmMCUGTEy341ergyx1zaYjsrL1y/KVKFGdp775YjYRCWC92UadS8qtzeCZKrUi3ByfZuKp2tePNYCiGF0GUb4S1mn3I6ETUhkFGZAOSBezkVzSFkljaDLCDWnY8BC6YBHRwCjyMBcK+NBWRKXExQzBOASwn71elIWnEYVvyp04M6FxJrrxVWUv5UyRml1+tC7OyVaF+1KNNeL+KGAJmN8rAcJPItXEaiZcqA87Vbp2oOxrsjGcokgYGsbJRX11ty6qmkVeXFYmV208EfeteE0QZUw/HjXz3BaaaN1x/pHvHakRb/WJBnCGycg+oqNIgDOsiA4wsf1AzQKri2wMNJiUsYp/lFWTUwlKb0r65t47p4cHjwjb1RpomWxeOCoudW0TIm4vAta6Bs/HNU2ZUwcv+vkKT9Iy9+Wmceb5g0cz9n2W2tad8r6V5i349bHbTqtqQqZDbVKEjTaKGCt0qQ1L1Eo/Tky5jpId5Hl/LHuWhSynEFm3Tl17LlXaahslOAXsvVS7PAtRl6FCsA5+VAPtT6ErtKo9PebRs/GSriY0Fngp97w88gUT9vXqIi5KF9jp8hF+RvIGhvHIy/45vsRDa6jYyoNmUaUCKRt+HlMp/Mc6zICR9Tv7W6X9/a2s2bswzv75bP375VP7t0t93nvgpxrz/RCIXMd0Qo0ZrkcobNjLa8gQmiQSzlBCXv05Hn56usXWUd7gmJ21J+U18jVQ76NL1C0Vnu5w9VRMnlGhck7ND1E2mlOca2U8oR9j8qQbPGKgkZ1IT/Im45pHSmvilaOfzC9xrqL0vsoHdGSC9rR42r5gWetJWW0yy9UwOzQ5gR8nHVk7KKcT6qSsbYmTWyTP+mBy4OXr8tPf/ijcvzqdbmis3wMzg8PDjJKZFkcQeqso7iRtrUpTWRaDVzWs76Qd9JHY2uDqxKGJY7lV/mHYnnX7bO6600N2PkyENmp3dAqT6/ycubF/Jx6zIgYcI+84/bklCJcpW3a3kHBRNG6tM0gvQ6yXEUhHQHSdWSv19uIYmvZVPJV5rMEATxqPV3fTRhZpB99Fn+eZGeTmmYsMxaUSXykrU0bDb61INyya60g3/PE1oX54oWyaxsciLPaZuhfFVBxZxrBYWOzWF9cJZ3qjk0eQlTd4j9tbJNG+17r5jdtK58ozczdmvn3WTieb7rfna62Dadsm5eNgPXNGxfYSrBWpASgyQhCA4SmBWQemNaoeBhfjV2icRTKQqjZm0QtVFXEfNpY2QPa79yUDooAX/CvQjlXazR53NxcZMTLLdHL9BYcrbgZnZdrBMmNZ2n1B9hhueksl/H9BxmxuvPki7L9/OtyDcFfffBhGZZpmbjwkPyc2uxs75Qr+NeD9AYOC5Ofa7lc65WTkGECF0k6AsZveY1C5IidAkawsm6AQjllmpOrYQQVMegURlvKSf8OQXvAYTpoxHUIeQHJuAbB24B4rIcMk8t2aWBcOJ7djsTzgluntWz0HaixwpfPUSzH9PDOURrhqrp4lB/C2Av0nJU+vd2zS49kaHua9GdRzlxUKYGq6tnzhaVrPRLXuvZ4i0WnIPffowCdMqC7XM8HqnXemnfVva/xb/9wz9NMa9pv/zbmXXlIl2A+eIkiqDTJtzfDtjlbR94FasNuGAWS07L28CPU/I6tQ+jiDPgijBAmNErSvhtE+tCR63KiiDV5zZfFZ9xNxsZTwRIH0jJBa5j6Gb9GBbSRsRX7nXDzb5pZmRvcte/zdt5/3vw2QTTvNsx8uKTDX5tm61/5v+JHOrV+lBF24mxUfc/3GcYqnbucwWlKj3DouYbMkd3OSkZlPFDYs/4ceSCX4pEAyqGd3d0oJ7VupB2UH5L19dbWOJq2DLYJbf5tmaqptG211rCWQ7eDUpfllZuCJue57Dsn69NgOjXpHZV+O/JCamSFU0UeCOu0lUdcOEpPyxlFzANavVx7FUDv7m6WO3RA93qUl/clGt4llM4FZME1HbIb6DvaFuW1UWxHq+16XaGsjJCTZ/1RefHyuLw8OMn1P6f983KCffT0dfn80fMyPr8pm7t3y9q6F+uriK1lKca6RwWhPFl3KhM2sCq5F1Nkr/LHETGULxfl25Bat+IkIzggKPxqPQpTY+1kBzqVbxUBeVkFAnyERqQV3l224TVWKirGyBIKw1/SroDf87H3FXtszgb1C6+iHp0enZavvviy/PoXvyyHL19lN6pXRanwCVem9iwHdBRl3zaIGq0jq61VjgIh9SpbBpeh1UoPhtE/ygf+WbeEf/Wr31TKsmmFcqi81TWOrYJCnpTRttZNcwqlkeuWB4Pktb25WXZ3tqHr9ZydqZIvnOYVWUVaPeS35006xSqFTgnjbQ0q/E49KuldGK+i5fdQMbAZ3/amyk+sAo1w8mDKF+WnPmUAn4DZ+Fd3vkdR0993eaHaKEmUsb7rVmlq8dQoUETSmoXljW38bmVCtbM0YquceONdmuBpuOgN+Ldxs4miSSP5NfBqha8+5/3q07RrXb1pQwOiURrnmTTFa1P3vwOzkGHP3AVmFVoZtSrfELqG07R+gqXb4xm8P1Jid/jXeXoXqWbLMsKmRVSt4AaBvHdXr8t2x54XjM17mIXCy/DX9Hiv8FOULyCAOy7EdwTDaTiEhkrLMr261c5mKQ8+KJ1rFLEvflrWD16XxTt3S++DD8rS2bHHM2dx7J27+wjI9bKq8BKRIH9zfbNsbe0IVIb61+xhoziNri7KhCIO6YUdw/wSumuIhEXl5QQG6AMjhc+IWxoAymSr7WjPBUL2EgHklmvL6QYDe8EuVD2nXPZ+7UHZ+DuVuQQDXiPgLPs6uMgiQXBheEcFZc5FGM/1eNk+jKDy+AqVqTAAAsApz9E1gg8cnQL3yYie5I2LoJ3uIbcFrwrpkWvTAFMW8bx552H5/f/0f1fWPvij0rn3aVnZ2M/luQ5vp7YJW2u9Nb5pZYD6Xo8C4IVEM4JFnNZY7/FPvngYVn/C6Qok/MukUaIUKuZZE69h89P6VRzXe9J4Nd85YxaUDKHuJg/oxRRIL1PpNNzmF2VXvKenXllKJl6Bhj2A0p716NWzMh5CP03yLQ0HXOHEJmszFN6Eqa+++K4mHnz4AWGV+sxUKLh1vXEC/fs1oYU525rf5ta8/U3b1te80V88tQrZm8bw4l46amRCrO5WSIvzKiijkCEHcqTDutPoVSlbJUC21iszxDf5ufB/x7VE1CcA4H9JLuQlrMkb82aR2mquhnCzAHxoyxi5lLLQOAJT1rXR6RsOBzno1TWzKpbi4hL55xmEHnGhUmZyt2svHeXbLJ2lNXhX+XBdjl8dlhdPnpTh4SEy67xsQLseq5M1p8oa/C4GZ+WcDmQhH5vjG2SCd0uq0LjQ/dhDYo/PymB4jhJ2VL76+lk5Ph1Bd+ulP7kuXz07KI+wh6fj0h8j59DnXHO7c/d+2UIpc6NSZjSQWyA/5bCRrUd4eKMHHVpwa0MoJvMdOO1Uto2jftk9jPJQzxZT0VYRqm1BlG6e7UL0dFxFtXwCbpV1znTgCx8CI8rKyBFD3Mr9Lnjr9baIu4riU0r/+LT86ue/LD//8U9yJtvBq4MyEecTL153LXGH8khHFTbbGNubKAnCT9b1OiIsgGhVrqhe3KJBWpyjVr/x9F2FTAXOctQdk460Sa81vuXR6rQT4bpeD3LNtOTxURn2B3Qmlso+yvudvV1wguwB11rztS1V8XIN4tbuTtnwaBSUSneETpBvtgfKrSzKwD2FDmZTkZTJdjn8hw1FpxDgwkIAq4Dq19K3xiD1h3eeFXf1Oavf+FV/m71YkguuYqtbxfMNS0Bx1CpotpnaumYQWpg9b2np1goTZgZThSf5kXYbz3T1v03v1hpWen7zW+NOOr9pTW+WJta6npWzAekbN26VdXG5dZDt3VE9agX9NtPiR+Elg7neIJo9xOLOnBt6fy4EtVCaFoEiwJEBt1u/v35VNuiiyBg5BwdrFzYjU/QGr6Hupa0uvTiUEYTMAkR7s7+Vhm5pc6csffZhhnVXj448hbAs379bdj/5oKyM+hnluvPh++W9Dz8EkUtlenKcoeLcpYkgcli9K0G4XgvBNgLGPtTZRxiMRxPSu8wW+SGCwOnAHuG9vmlILUSQhDKgaQSPFUP9lGsX9NvjoGxeelzXKdkDQTEApVf0Vi/BTfCMNHFa9Ep8nF/lHB8qoiz7hAmRHGVCfO/BdL2ZQkChMUHx9CgOBRhkCUNdl86Ca+1kShdzOn1JeGBwGnJ9TWLq5Nwy66A2LAADXJ/+yT+gtzwuX/30L8rC8KDcv3MnZzPZA1U+zhg1VVjdvsreKjWhFeoivVyFQCIRnOTbuFRnbI1XnyaXJDU4xJ9l0czybIzkky8wnULVBFw/Et8mWB4Nnamsecl87hbVEs7Fr9aFRua1559cAyeKWK5igf5RxIcHL2gUn0dIz7Ocyq9ZRAgkL6yPVnrrjoZo2NsyEDwCBN/0+A1fpyhvy/jvy7yN63e9t2b+m892d6am5W1NwjRhZ5bOQj3LKEEStgrZKmirsFfQ1YY9J5KDoxwE69obeMwdht5f6e5dr4PpuahfHiNbR6ntutn4biMXut0N6ttt/uQNnFYRzvpeQZh1CFoTpcAweeNXIm7fUo5a/46Z140f+ZKF+45+OWJkY29n1FPt7aRZPkfqPHjWXZW727vlAzqPe8C4AClMHBE76ZejF6/L2cFxGR6foJi9gv6OyhVy4no4Rj4BP7LsGp68GNORA24PeM3l3yh8583SkMlomlPnn3tW2XBS+kM6lZe1U/n81Wl59PSgvDzq0yFcogFfKX20sUOUNdeOLSO3O+u9ygfgPx1rlE3hr+VANKl8ohhYd3aGlDfKfRVQ+sbgBTlOPHf4ZaG8dUMcL+B2o5e77FWotKvkkzVkyr7gF1yD03qnKLJH+UYeKrhuejjn6Rq4jc1t5L0HbPfK8GxYfvWLX5e//Nd/UX7545+XV5T91GugCOu6Y9uhdnN2q0w4Pe79yE5LqghJOxm5skGPVT5UaxyVrTTM1LOjZ1HaLDcw618VMNst6jnWkS83JtARNwz1ZEciV1ihbKlsnp2epM68f3Vn212rbpSguNSzzw60bWNvm+PSEteQbe/sIJ9oDzxmZzSkfoe5p5gS5jiiMW2W37zSyvXHngOXw13l0dB8VZ4lcnFiRrhwzBtz1/LbyNrIuvCqTxUXrQqNtmnLgbVa4hlWvM3CzFlxDcJj5/yVy77fPpv4IK+1wb/P1EWFqRozVa9sYfvrbJUvb9taTmnkTdsqbbOF/r5TD/JHC8E3brKrZW09C80zyhE5xA+Vdyu+KmFrW7eYSOOHUPbcMZnQ3uLY0TEIxKtk0iMSiRYwSAbZWBdT9lYuyl7nOld6LDpFCfGQWObDxffi+kqZnp6Vm2evyxVEeu3N/6/7pezRS/j974XaL549KRcHh5kuXbv3kJ7HuIyPj8v2Bw/L5r336hUYpLG2uJb1YK4/cGoQFYLKheEp3gmoHV3elFG2hl+EkS89r4Q0HQmTgZe6Xp2xWrZW6XED+wXwdSn/7sp62aRx36U3vrq1FWLMbkTykKudXk1FkrfTC+3oT8ZtKCsaFMoB3ze7SdfzwyKbXHhPuk4JqPTYM78Ej5cylAF4T92AqO7NZVm9QHiLV0UtsK8u18ZDfF8tKBARpBBeRpaIt4xQsxf8+U9/gJD3jKKjMpkMEcIolObndFrqmKcNaaxkQZ5a4ZcD5w3lEqSEmTf6C63PJAXdGFDf9j15VRMckVdLX7xGOCdf/xu6TArEbRX+1lxNUbDBi6NfppvGASGQxgOciiUbAG0aCepQmM/PTkr/1WME45R4FaYIsRhfakNUcSCMPmuY6BrgWlDFr3Alqk/8lYL25q2vG+j2N3D0LZvURfNs3fNm3u+v+96a1s+nrtswecOK+aqIVQGoIHQE+VYw1t6oDVwVzp5ZVac9XPhcp8gcaXB0zLPt1u3w8d3df3u79aR7+cnGTZP6CxzKNh7gfR52KVj/md/cN+NEUdDVeDsCF16k4Ts76xcvBT9GiTKfS+SGRxN4IGp27yG0HRFTSdzo9sr+zm55eP8+8HfL9fSqjE6QTR5WTbwtwriZZ3B0WE48O2zQL5eOCrnb8eS0jE/tYAIE+Zu3G4cG41F5+uJFefTV43JAOt672O9P4OMrOmw35cXrk/LVk+fliA7XzVKnLKxsQIZr2FXk3kLWlH31+Gk5ODrNrjvX/66rcMEnuX0DovbaHDBn1YmNjIYp03JOHPVBpVH2YLHWq+/ISzvcjo7Jb/Kh1rqWAlxDJR4zvabCgPJgR5kPGYU7AZ7T49McTCvby4s+2zVn/dNh+emPf1b+/F/8y/Kzf/OzTE8uECCXsQOf66+6HugtHSmLVcBwRwEjfl37ZSPvH25sSiBtwL1KJ8f/cOSbZ1XmnkroTKXL9gtyJH1kC2Eym0EY2zkX7TsVqc1aXPDgbl6vtaqXt09Cszs72xn1chr2AgVUZdQz2eQL+cB2VEVsAyVeeXI2HNBxHpSByj5KeKYpbSuJN4EWzrUqYzy9wi+dJaWRMwJYDyy23fCIHv3pTknN1BlBsGTbWJWQaiufNu+4syks5fRJWOUn+MkIYXDUTPeKD8rQlqW1ptdaTft829QwVQmMJZ3qNtMapsoPnvjzIX4+5tP8be63jd9qem/ad/m3I2UNGN+8EUx3ptjw+eI7tIahMlOBvlVhpm3NDEHEy9Zo1xwgVNTG7SGmtwQz3q6l0dYKVxmTUO91r7KTzwNOPf3dodYYavsKZryk50hiZWE0KcsvULref78sf/f36VUOy/Trp2UZZWmpS6P74L0yAMbzp0/DiCpQh4++LKfPXiq/ygiC9GRrG02kWVlLJS7mAu7p4Dw7F70fUsFjo+05O+swhNhYAz4ZMcxCI0CI4KG3tEpPvVeW7+yWlTvb2bHj1OP6Go0GZcv2bXCy6oGB3sRvl5b8ZYoJSphKgw1Op+s0McSrsgDcNwo6GqEFmDbz4E3Df4NCYePgGgCvtCArGK8ynQpbDqfDc82BNYpndU5kWLqua+sePOnaNwUOKKD3eT5EOAxP6N2j7NozA4bsDCWe9dUqQoljYpq4sX4gpXhLA761T/8IE3eTnyZp8qzKVDyaZ3X7PfSEyUibik/Swc+wTZq667M+Gt8alzr1Hj59l0QETwUymIFxXceoQK9RXc/i7kmhuRz3y9mLx+VyNKiDIilem3I1NTtCR5ESdnzSuFcYMu0pl0Ir2uivYRjCqHjjdLel5a9p/fs1qZumjC3eNTM8Y+bd86YN36aRcP7rrh/e+N6ato4j2OCRqpC1eVdhrnLdKmX2Rn33zwZAhcyF/Rs0ZFlHBp924LGtrc1y7/57GYGSjmu+JnmbdwXs1iRX0n6XmcWPu8pAlQeNHS3h91yop8gbjyaoRwvU860SFr40ZZUTb+nY2dkpD+gc7mzt0ojVaThvBXF9453t3fLx+x+Uh/fulz13CUKXKl6XNNJTR4ZoyJ1+k5RMO+eUwa/j8wmK1HF58vR5OaQDKn27cPvV66PyBQral4+eZOG+246WVnsoTx3khZ1naXAFEl9CoZuUr7427ONydOLOYTrJKDPu0HaERVmnUklxMkKlQpTzreg0ZuTZkY50OMVJi0vS181/ZII2soQyAbfLLHIUEp1u16M5wjd2fSZlU8lRcTlrlDHTdrpTOTMBv69eHpQ/++f/vPzT/88/LT/9Nz8uR69fl+lwMmscTcMZGc8UC40Jl51h3QAU2uOZURYsyWKqLJPx5WrNm3Rqx6Chx8ZavCgo1G9mSpA7hjWO352VMG3PffN+yaGXtSNznY50yjI7OpHVxs9xICq4TX67u7vlAe3Z1vY2OD/P8Rwn/bMyRPm+sCPQtAFVIXPmxvag2ii4oddqqwLGU6Us5dQ0TwBMGbFtWdsy1Pf6jFW05Xv7rN+1FSfip+Iocedsfb/l4/rENPzVGsO1ptUt/q1sE+cNo+e/pTWNeXjnreWxTU4dW05pCdvS2+/EuD0ZypCaZzjyGYufDoVB2paZoVGxMDIaYXJ+DkTojhGH6qcQn6MS7my8RV6t8BAvhdymbXxvFaWLeDKO68FcWO1aChUOhVLWa4z6KFx3ys1Hn8C4NLZHr3NExfJWtyzv7UZILE4GZWUbBaq7Vk6+/rqcn5yFYRbPvTakNrI3CMGMNMH1I9xj0vdIDhfg2l5eA9uNuxHBh3XlsLTHXyCOsrvFIy2sFIf1aRHK9U4PwbNIWjc5+DZ3h22sVyLd7JUOvc0deqXr4HYThu74XTjsmKBsLKLoZXMCZcpIDuGXs37DQ2Lr3H96qcQV9SpNU/HBm9VybZ1RxnP8PdsLyQPclQkl0yooYPY1BABlyqga9eXi9MNnj8qn3/09Qi+X8WIX5r6mR3qCIkelkGaCihOfwiAAcqWOOTqo324VDOu59TMoPqn3mZmL29LFvGn9El+FTIVnpvQ0kZs4hmlHG1vj8Rb2st1Wr+Btz7QThiqcgJU6XO10QcViuTwfl/7rp+X87Cj1lrTNDy0+U7GmPQOxyZdws1OZ8ZJxA7c5UrdO3YZjCWddu3Ywi2Sd4yBUGqv/wEzwPYfHt91vf2/N7FtTN63y8q6wGnGkcBZf4vu2/sGL7lbQRNjQkRHNDsIQtk5ZrmZ0oQcPbnZ7ZQt+2UXJubt3h45YB/q18SSCfG4no0m/hU/zLtjq1KWOvGIsA8SfeH5rnqSnTOrTQKqILa8slG5vvXQ3u+nERQEQaNKxIddvb3+vPHzwAJGxjjyZ0jGc2COC80q5i6L26QcflE8/+rDcv3snBygrc7K+FPrv0WGwnNJkXQog7lCKVjxrqofc3cS9UYaTSxSr5+WrJy/Ky8PTnKOIkCSaB2pLczYka9AkCqNWnoTXyaKcDYbl9eFxOT7u0/f14nOBpyPZ3SgrnQ2HlwmPTFJJJPzVzVLS9OkGAKdjVSw0kn36neDYBe0Irdh6I0aYI09HjFTKPJrh3N2SLkcBJ3ZKu57vSKfaHZ+ePXl01C+/+vUX5Z/9j/9j+bM/+5/Kl198CZzjtCPhbcqTziy0kV2WoYHaCVMJk94ywgMNqdRbl9kBGYsbWqkjPM0oj/HFF4XJ+rBY8/LZ+PExl9zjRqzXjgRu/hPWLYwj2kF3TXpGWg/a3EfB8ggL15kp0UPTKGgeOaRSts13R8QcTXWG6fDwsJyeeRhsHQ3zhgRHK21bvZIv8lx6xVbqxEqf8I6dvtY/o/OAVBfiOyJGmfGLzBKWd9jKn7dP8dx+S0cKKwnJpxntJ1zlWWyyrplbB7hqHRjf9FrLl6TJt7zjDkwmlee837ttHa27TaO6/SYZGP/W1inVW1v9a9zgoUknegrls5zV0oakzPqT3/8FQ5l+J0YAhjRKYZym8NVYqOYdwIPVxsyCxJPKBViNgsqLTl3I70Ja68uhdQVg23BGxilcbsiPuEfIplMI1it6bASvDB9BimBCINuDLg/fL96CcTXpR+np7G7n5v/p8QBGIBUIwQXYDoOfk/YSwgKxlzxXECwOU8vsIR4YwOFrR8tUbTZ7CFKY3/sJHVqX2RyO9cR9Fwl7FcolSqInVsu8OVQS5eY8ahGZp8FHCNNLR/xlcX/Z2CqbKHYd8zUve0a9ToSZzOnBr+sOQwOvl6Pbg74gqQsEkOgRBwsO31MnIZ4IMu9cq8Q3BU8dBLX3Ya72tssWgnM67SMc5YSbsg7i18GPQmJl4bQcPfkiC0htqNT2Pb5BAfHBJx+n13v4/DG9ctdYOZ1QTSX4+rR3GmbLM54Jgw+2+tfw1VrP1S0F1G/GtypDAySo17xJPJ6VAZMq4fIBW/NJOvHy2ebRJGQwshMfTrNM6JH2HnwPZR5F63KUtKKIrdvALIPOaem/eFIGKGMgutI+roRLevySnvwRxTDAVCMjyxPWTXBjDIdhkwd0IjvgVhnzJPHAtkr6Snjcf/Jf/p+M9Ds1Li6fx9dfJ9i0rXn7vTXxg3aDoJS/1m+ljdrIzWgluPMFdxDDP7bWbGsSuDodGkkYuapasJdGy45VkqQOcDV1RF2iCOzt7JXtre1EzyJwwgqVwr/mRblJgwiJm9xMJ+nFO24572qhyqRKo1pkgMsWfOIvbFdX0/LjH/2wvHr1nE4OnSn+1jfXM8qtPPESbhU5FTEXad/dv5ODXYWm760Xo2HulSzTSQ6Wfs9F3MCXcVsUsRsaYndL3lCWFeUKsLmj0NG38fg8ioujYHBrbld78vQARexVefbihI4h6XS26NC59KEqUTnpXhqm2hzNyig6QtMRGe+EdGrx6nqxnJ2NyuuD0zJCOdrc2S/b+/cpl9evdZFbXrFTFTtH4L3D0hPdHQXy3ELXOKmgKD+UtSocskB2GiK3bq49k9FF+sCOvDkfTzOyLz+6VGA5V/Mt5Z7cIZ3TwfiinAwuy0l/Ul68Oiw/+OFPyp//q78oR3QYN5CtKqaeU6jctDPuMhJnFGw4s2AcOaeMlwaEyzVdKlrSkqSQ9Ul+E+9+j7sJazhqy+lKF95Le/lmPCrDm0iyzhm/Fd5zIwq4dEmK9HlF/TsaNslIe21fdje3yjrtg/nZpih76rpe2iZw5qySU5e2n4PBoBydnmQjSL3gu7G2z1Ib9EBXoz5tR0OB/smXyhep3265j1B7pXFotyoqlYeigNhu62f5gF/+joIivsQRzyhRhKtKifRTObMyGdGTLTnw3iptppd2qwFH6ASiykb9xWnFYeoFG2XId+OST+DQHZiqbesv3/BvFbzIK/lcuJp3AsWdjLEqjFVpbK1lq4pl/Ak/+04myjFxqNXdfvudKmMC7iJAh8aDbN5nBQRgHhXAxlT/+t42thKGU0JOdflpQK/A9VMu/owS5uiNjEnAqpRV92pBeYLGno4cxlaIofyQBiiG+XHz3c0BLo73CiGvwdjcfy+VMnr+CoGlykXa7jYi30l3M9NCNxCz59ysIVQWdjZBruRzhVDcpLHeKBcINUc+FhGg9uzsJa4gFKCT0pWoInw19OQgQrrkUZC8/9FeGxxZpsDkaNbGRh1luRgOytXJKT3QFXrsKHc2DNs9BBh5U9HLjqgRzt7gSqebYy2u6JVa8VkfBvPdIKAVUNkODR4Ewl1hrilZJhlhURCO8d9S+SMve6+e3nx17cLOaQi9i8BYNTwCbrmMS//VF+Xs+BjB5yJEYIE5JjQI56eHZel8VLqrdXi9En+t02oqFvK0GG/TQfOUkd42t3Tis/pFDMz8hc8Grrrj71OuxlHDxekLsN3GeyPOLCwOYMzlwQhnG73Nh98v18ODcnOOYASvq12nbDyh/6KMXj9HGfuaBuKcBCojEz0/Ml4EB3HimQ9z+WrlFf4cuYuv9awfUjvvhL1B+84BuPgtdRR2Ne4ffwvKmJdXt3hphVoLv6Z9n7fz/hrrR/NmGJ/VL99AThQX/hwRSQw+WV9efP9m3Ll4zdMsbv3ykALi1qbeFbS8+IdH+E0hamO8iSLmqIgNlrIl4YxLItIrTVDSNOkmhQpj8+vIvnVnA1dHj2u5ZyNjmeapYW2wXCf2l3/5g3J6eprlDMPxIJtwHD33Tlzh7doAo2TlMvA7d+m8rZSzE5Qlz0mkIR4ewYs0tPcIs008zxX0qI7r0TgHu9qxzJEYPKWvMbI550pJYwvL5eRsUB4/fl5+9avH2T05GLpu1Kl317cqz7DIipkiJtrgb0fuREwm5Rp8OkvhgbRHh6fl+YuX5fnLl1EGHK2/c+9+ef/jD8v99x6UvTt3yhbKY2YxyCOHyyKjVD5Ae5Q7M9ItZ4g9cev0mfViHhcIe3Hk3Yku6PdWkm5vq45U46eiOaHM3pLy4sVh+fGPf1J+8uOf4X5FZ5qeDUbF1JEkd2ZaT5kmjSKm0lUVsUwvUr4o8tg0+PipWEVRRNCncefdpxRSG/pqVcQyugcN5Lt+4pBwTpeDUfKyGUD+Ik/19yijMXXnpe4jFDGVCm9j2KCNcXrd+HW03TXLHitFGVRewZvTqxKmu3CPz06pz0FI7xL8Ts7rzn4DSIXGz5QktGD523Y1o52xJMS/pvICHEAZ4o2tbvGickVZgLP6yWM1ieCq+RbFivcckMrTuHg177rbsBXPTpnXNOdtzbO6q9LnWjyna5WzeOaZMKQVRZF3w9d4Kk01rfrt1u33W9v4GTfladLAVsVtLg3SUyHM+ywcaTTftXjeWnFKuN+tMoZ1uNo1CmR5W6imYoCkwuGv//kuIehb3yUS41gp1y4ihOHU7D2RWuZQkVHrb4lHSqsKmUPE1+UQ7eKEHpG7aiJASf+SRtKdOU7TyYgOX+9s79BzG5ezl6/gdNdejMv560NTK5Pte+UCmFZQMrxgvPPw/UK3BAWH3uTJcVlDQG4//KCM+8MskL2GkFadwkMYrNFzAciygayyr2vJMiSJEHWtmDtUJg6lq4DJWC5OXevlDLEtNxjQ4104Os2ol1OUF0PKORiXBXrHA3qduaMSIvVyWnF1SW9zBSG8PB6VNZTHRZQ7G4Oly/P0Lu0ppFdpaIQ2fA89LJQrBJACziHyvU4vTON1MQ/u75QTGFeF1t6SU6OdJXFrD/GqTI4/L4cIWee8M0wOEdorIJPg20W3VaESOo11TD2QV+uX2rb+ie+3NGKtv0/TaeJUt341bBNCj+qqH2/d7RPbwlG9ySMO06uM1Brf9b91V2NZVnubWY/Se++zcnmG0j4dRhGz3qSbEUro2bMvodNz4pIGOCOHWlTLlSzb8iTZGi6Wf3FglgpEmYdALpZdWlmEl6pCEGGpIsb3RUfFVqqf+Xzbypi2FTra1sx/b/3n3a15M67P6p93y97UV2rBcI0gVdjmQ2v9nCBzebRP04V/E7S+3YbRRFDiD81nIl4ah7/WUMjCKVSDeUbwE66FxbB4JS1TU2xZD4mQh4qYT5Wx2uBr0sBhKwgEjFlACXpcfv6LX2TjgGusbBjtWHm4qKG60Nne/j4dv50oDMZ3kfro9Ay+XSo9R1HIy4X7D3f3yibyxJ2TCxcXuSz6cjKikViG7VVg4Gnox+ttXO/Fazmksf/qqyfl8y8el5evTsiRNFFIs2t6abWg8xSPB2qPCMpRB+KAvFWiEBr41vpEJCOfHZNbyIjM6Wm/9PuDcnh0VJ4+e15eHSBbQeb23k7ZR7Hcp1yugdvc2iqbyMwcsCseSctryM4BcAoAHrdwznMy5aly5RoxT4i/WsgB1VmAjp0k3HUZjekcjVwjdVq+/vopSubn5Ze//HV59NWjKL2OyjgjocyyFsW9nf2M9POUH1WwHAHzmREoSpXpQ2yrdGUBOmF4rYqD4XDnO+8+q1u5iKJH+tmBqdwkXhrvYK/ulnREzHZtiPJ1Rrsz7PdT18rk7S3PENtCEUfmEyaDDOZLPBUw1xSr2Aq7dKMCllsZHBGzojGuC3NaUv6SZM0rOyV5Uf5q85dnKB7T0mpr6nvoX6QkZJWlrRJVv2ODD3FVv2vTNqh0qXT6HVvjqtCJ6zqamBEtp64bOHzWtqK1pt2kiTujYeZt9j7yXR6ufvW9+rVwaVsYZt/eaQmHfffzTRh8/ob1e2NbJZAP+fY7VcZiyMQ5bhUAIGiArQ3H7SFx/tRn3L7E3horTIFmD8ArKUxHotO4Db2OijXE0xCTl2Jf0mg96V8ifKYZRcsiWHsgGRp3OJMGdnOzvEQgjVCmltYRKjDp5BVKGXGX9/ZpCOkZPn8GEDSKD94vXRQ3NwUMXz4rN2cIOHp32Qpur08ke6Dk3XtllbiW0aM2Vq4vKoOvwjD0XDyjSybwzBvP3NdKDDsI4QWE5qrrr4bTcnlK75hGfsq3TmejLCBcVhxNI02nF4AW90rp0p2iP1LOEVwOAS86pbGIcuXBrJTthrAK8BUY2Hs2czgr+UvsSATyV/Z5EvVa2e9uZJflQmepfP+z98qZQu5sWKaks8F3pyo79BjX1m7K9OTL8vLpkyhjEuCMEQiTXgduibU11k2IHj+ct8YwbbDZh5Yebs0b9NHEsRFsw/ls7fy7ScYnYVt/GQGrIcDt97jqS/XFkIC00tvJNvLu3Y/LRf8Awev9dDSW0N/49ABF7BGN3pAyQudNTOt5lk6TbxptX/OLiT+4kjmBpW7115t0EE5ZT2Zgv/EhM/Gy1Bo8hKIGS8V8G8qY05SaFrctvuafb9t5/9a8/W5d5LX1sk5wR0g3YX1KPyoBCeJPAvFd3DXumb8PX1p3/vRQsdUHdxxYeVelAjhW3IlIg2Yd1BEbp91qeGNrratQTU06z9p4VXP7VDY1LxqjNNHsQFquCfz+y1/+qhwdHebqGoMrJ1TEsnuPzpu3AHiQpw31BR3M8bBPx2BYtrvd8tnHH5X7O7tlC2XiztZGrjjy/t0pCpAdxLODg4yK2dBfQVuOiKmkuMHJ0a9Hj5+Xn/7iV1kf1kfuOCre7W1nWtKpxgssEiMKlNZRdEfH0njZqIof5bk4hE+E2cZdBayPMiaeUhbkhqe5HyIrH6F8umbrtSfbI8NzxyY2OxjtXIojlEenyXIZNTJbHkTXyiiYGwUGw3EUruH4spyNJrkX8+ikn4Npnz5/WX5GmX74w5+Un/zkF+XnP6d8KmEnp8C3WpUwYHedmLMkdToPzJPvOjytkaQi1/LE6hdrg9u8U3+gIfVZzxXzXaVLWnXKUbnoN+sdP0rkmjDldKbTlJN8y9IPZYxDY7Rd7qJVCfMwV5UuN5ZsbXrck6N3wtRYErdtcfmOI6rBHeVQYbadUulyoX/dpHEZ2lLR96gLm2XbAuvKq798nyfVahp+0gWMrdHpe540JnETsFVKaiDDVJmvXztymGRwEzTWOG16wSu24pW0glkxbTwtfs0zfqSrv+nne9LjU5MPv3mahN818W/Cmnx9r9b3d9nk0dhZOrH+1e+tO2Xkr9IwrjYOdZ73OT95w+fvVBmTHETmaDopHjIqI7UIEuIA1xh8KxU0fgovBVuMflgJ1+FrCUptX8XBYVh7BvpHEIZp6Ym6pob3hcWr8myA8HHhKcm47kJEmZcLVh0KH6+sl8kqAkxiJvzFy5c5k8dDFIXrGsFhY7uy1Svb9+7mwMDRr35Vbo6OS+f+/bKy0S2Xx0dZHCvRpwHduVP6iyultwYBDj2rpl4r1HFdGYzvLhVPhpYJrAzXtXkIJf3OsnB2lmH1s8HY7g6wT8signkFxupcXZbl/V7pI3iWYJ5Ncco3C7zgSBmCOig7Pw+ul9YRMODGNTdrCEPP53EI+4YeZUeljfQvwauwyEgdeuL39rbKOYrbOTh8eP9OuRgh+PuTMiXevb31HHtRe3Xgs/91efb1V6J2JhxqNUO0qTox6FfrvWGWxlaG9dtcuPqa+vF4gupRGV1T45pOk1b82p/2e3VrZm4EeagJ7jCugso4fpbMkkRsFTwyi8psu47BBsZGYWlto1xcnpfu/ocUfoIkwxJnMjgpp8++LNPBafJMvk3eCrgZHDzFTZpsnm+EU1hIm80gim2PozUClmDCBrCUvNx4irDx14RTPGII822tGWtNK3Tb8rVlf9v+dd80tU511Hcrxj/9Wi+CJJzHGOR9Lp35tOZNduiZtn9WNibp+jRtyhC8+6Qhc6edfGJmhsoUivRgVCpT+WLkpGci2JqevxlLq+588914OI3ThG284nZa6ax/Vv7Nj34c2baJMmXnUhjc0eksgNNSyq2qhI14wv/ksk6nzBGwe7u7yAcI53xSdoi3jPy4Qsm6oCPssJfLEzQqN+PxtAzhaXdFHx71Mx35+ZePy6E3kTgCseTZYHQwFlScHAnDz0X6KFju0L5SnQAWR8Scimzv2bVw4sgRGpWxETL04PCIvMZREFQuXSyuOuC0qP4nyLqvUcp+8atfl19//nn59a9/XT7/4qvy8uWrjKadDSblpD/K7MH5xPMmL1HuxuWYTurhyVk5xr6iDI9fHJYnz15GqfziEUoeaXz++aPy6NHT8hT/o+PTjKA5RdqeVVk7i81aMGGW14CvnkWncllpT9JQeapKFu0QNudV6SZORr2oiyhgPKNM4K+MlIJa/8optonGrbt8IzMNrxuHEs/1iXWR/gAFGsV4hU7wxno2sXlLhIvza3hlbR1lc23Y2tp6ymZbde4yG+jB9kia0h1r28h3qcE6cL2Y7/Y6nJEKzcboAHr5hrK38nam8Fim8I1sc+tfFTHfiU8YvJpv1T3jU96zAz7f5aSK53Sz5JUZBOKN79RR7AyO6k5ePqXRPKtfDVPD8pPEfY8c8Ls8HXcN87Zt487btG3GEaa4zbum34bxPX/Gb+Dwe90JjMVU7n/LGBbh/s5v34wx6YVyeDYoE9cQgUBK4X9TGAm+FnpmBDqmMnZSSIH4hMd0PIRJj3Ioor2oPYSQC18nZ6cw7Lh46asL6lUuJtPzLPr/82cX5fMDmNr1ERfnEDIA2LtEqbK3t/7gg7K8dz+Ed/n0y3IKA3toqochni9DMPZCIPL1h/dywXgfhj8HsKW9/bJyZ7Nc2XPJ9STjnPWzur9fFj74COZZK9s01jf0/GSm9+7dyRC2lWVDKzOMEIxOew1TC5fAfll6MiOCzLOyZFq3HC/1Nsvq+Lzs9TplirA+OxuWTWBfXd9EQLrzEWUKob2G8uVw9Bh8O8XhlUVXo34OxO3IzIS5Pp9m7QFsW8a4z5oemAJoD+Xru598UIaU363g/8Wf/gGK6bQ8O+uXKfDcX70u+xeuQykodQjIz//78i/+yf8Lhp+mx+4aFtc6ZIgZIWHPc37IVlPrXBrw3XqWUSuBa2ygJPqIsBBxkJN4YT7oSNqY0U0Sq26ZwI+zb5jkR1rSkARlPuaRtPG3bTWOUY2ngMi35p0XoqK0Xt6U7u6djCLe/d5/UiYnj8v08FE576OIPVcRO5vlPZ+/o1zV36QaODDmYcnaUTIQlYbfEVlxQr8iYdRJjRs47WygiFyOULBR9BccpiTBJMnP//H/+q90/U7NX/zFX+RpGet0hPVZy9z6vF6utAAA//RJREFUte72W2tav9bdWk3dIW3Fii7wFaXHeiHNGqF5Jz6V5DP01dh5OIyv0pQGBpupeRoe75104Xd2x8L9WSND+DRQxkMmqXS4AN3+2wV1EeQKk2GTphUheTgNVz/XaeIKtyZhbeAatxtlLIf3T9qIOsp/ASyWx8X6X3zxeflv/7v/Fvl1Ue7d3SMs5YGP9u/up1x9aMuRbNPwwE8Pq10GKWuLF2UDJec+nb/z09NygZLyYHun3LiQfeDF39AJ+Y+RjaPpKFN9LtYfYlVmnj57VV4fnGSUyTWRHpzqTkmvdFAxUyZKgBU3KGLiFZgzUssnYasjWamhWV1ckq+7353FyA74KDt1itT6WXL9I0Ik/IxCcalM8WxD0vMctQ06plmYbiZgUQXJpRGETifb6TZlnsrGOfzlYbQecZGDSakfn4FHWWEKKJ6SVj3ws8LgusMoXc2fqpP85lRu6ig517DKs+ROJVtS2TTKWZOHCpY7Z0OrfLThBmPEJQD4z7oxI0snC1dljTAqUfpZRqcqpVGPJfE+5olHTtB+rawulR4y352Qpikc4sejUEzffw9Yr8o6+AVob2iw7XPU1c5+znVLUJUvFbJah9K+y0+Ua6ZDgvETaKnZP72l9MpXNZBu4a64SQDexYQhLXcNW+V1ldltnNZE9inXeEYh1ZPko8zwrMquOkJND40/nc4Kx1x+PKpfY0nPbFTqNMryCnMN58c2bL406SQAplWuRFjCYOsXnI2Nn7aBJ1gxbL7Vh2GSF38VhmoMG9luhWASrYn7O56mbKDgce4J9ICSXiaZi2KFiyhLwRqABF6ESDj6td/1i5v47p6xwpzzr4sV1yLwVAhwzAqbRg7r+it0sZyE7zC06U1RynJOk73glbW6RuzksExevS6LYxSbFQTQCviEumXO5Xt3gWipjB89z12U04fvlwsUHc9oWaZ3t0IvlO4IxEEvfG83ZxZtAOv49Qvgvcr04yJCS0bICcoIGgnf6Ykc3Erqlyh1SBd6cCiXMJPM6Y5IT+ImlxDv8vZmGaBUukjXO9UWVmk0RmcQxnJZQ0nzwD/TU+i7pXnVYy6EEcXVtR+ZwqTMN6swL4pZzh+DqFx75w6tBx99nLVubjpwPv+zh+4oWy2Hl66DWy5bNBxbMgqwqFsvDF6V549+jQDwCI7VykAyBGlqQXXqdL6Ow8gzYpyv+0qs1RjRb+G2+kyI2/A2ohL6bZxqZunNnvmtjOcLtjLh7XeTFyS+xDfPJpx5O01iA+PmDfHT23+IQnRahq+/ytTkxcDzlNrYpml8XUk0iStY9GxpO0piAtX3ChF0LnHzEsGQ0pmGo0HEhB7TzhgEQW16INTAofe//V99O2vGNLUMta7b91rnKXhM+16Vo6acc+HnrQpIg74YMeV7vmFnRvxQ8TVOpbO389XUV/POL27jwVM8rYoEaOP4tFGFN9q1QpqZ4NQaj3COZFR4yDdp3ybTmpTVJ3+OSuu2kbbxS6PEvxtebhavy2gyKr/+/Nfl+cvnhHaEXKXI0TkPd13Lhdru0N7Z2Cj7m1vlLsrWHXjb9WHXxF0Bhh34+4wO6vDwuPSW4UNk2znKkCfyT1w3hbLlAvbRZFoODk9z2ffPfvlFeX14UiYX6p905Do9YEIuOAq2tCrEyFsVUyzKkBiglay4RibVEcNax1qVsKz1wrhOzNEdceeoWF0MLp4qzboOUt6NnAYZxnXq0NkKZzUcCRsiUwcjD7yd4p6WgZZ2ZIj888gNjxEaqbxcqFikDwP2xK2wIYeBPXUKkCpMme5Fg80TPs5ZZip5hrVeKYMKkkpW6pmy+Z7F+8an4usIGf6EdbdjdTtyVuPp72YM40lnecc/uypJsJ2alARUBHNFEd8ttDvj7dC7WN9jOm4X6XuRPfRA+BXkvel7PqWn8itzc6UU+V/Se0jbQTqOgkU5dWkO7cytndvwJv3gx6MagaoObMuX8pVV5jMUkHfbhjwpS8uHfhfXsaQ13w5k1E/aaeJllAlSyK5THGZdp4OxBIiiG1vTSuDkYf5tfjWPClOTl3lIkwasHxLG7yGNJl5rk7HPBL1Nt31vn/Px2jJlrSS2zTfT9YZr3MbR3zCzNISleVb+wbbpJrffsXFazOMZFDTvMhLGbzO1QuaR4uLajdJDMHmi8AkKmYs7vStQpSw9SgofhlBgwCm73YXyvZ2lsofi1iENh2ZVkFy06Ny8xzGMnz/OYvkb4izs75Ry905ZuHvXVbPlkkbPHZcXL45KgTEuPvggDGrlrkHMS41gWV7plBunLbd3S4fe3ujlUwTJpNxQ9imM4wnVS/Q+xYULUceNArdCI7pOQ78OeuxdqZpFciG4PVHiCuGoUrYNc14gJD3cMVdmCIsnc9MT2lThQmhPBihFpH1nZ7P0OjAtwn4dJcrh6THhXNSKqpkjLPrkf0PaG/v3yr333y/vf/px2dul3AsIY8riNvRresjnaJ+Di0V6nzQelKNDul6JFGGCYuIlu+1hqre21musf437XcZ61bRCwrUhbdD65TaMpk1nzmtm2nxaOzPvCvyWSRtPOYTDjB36vr52RExlzF68zOYURp0Kng4H5fTJ5yhiJ4SHqWbQvmnMOvDzD1SzsgQ+bRMtr9S/RqY2bH2StlOXU+DyOAsaWnvi0lyNi5v6lHa+DfMGXjG+W6YW5+33t9//OjMf3vRa+06jEMWKg9Y64Q8FRZl1VFFpQ3PDb80fLyV+RqVnaUc5UCjSyFm38LWjFB79kAYY/DtCDlFAH04ttQ0sQpZ0HbnOqAi2Xq+Cmzx9hqCQDeZDkoSuo2O63HW76FpSZONwPCyPnz1Gbi2kAab5LFeOntDxuXSUAx7vIM/2t7bK+3fulM8evF++894H5aP9u+VObxNFzBs7OmUPubjrKfHIAu+ZdMRjgqalAjM+vyqD8VV59Phl+cnPf1V+8fmjcnw2zI5zFbFud6usraKMZc1pPd0+p96jHDmDEYWFQtRGhyfFAA34gz8N+LExFS9Os7mZyREay24ZPSQVicsfHeIb5C885syASpQdVHuaS4tryO11Gq86TboYxdDbSdxIgay7RpmlU3qFTLr2Hs5Vyrq+WVbXe438r1ciaZ06tU69f9h1alFutbYBhuV7Oo/IMBtLR5psM6pCVusrSkGelJN6tL7lxvoub+KOn1Vt3UuStFcURwVczGizSJ92KG7ycmRT5aoqduDgclpG/UF2S57TOfdEfo8H2qLtcQQ0mwfIxE55Dna1bYNuLdMa5XH3oiOOzoiMwLmbM7yiz7WBlzzdbapS5mY1N21cQRcXtAM+r+lkt/yj8XQBKi31ppdKWFWqqptfLAXEtjwUZSQddJUTlY/qJ2nIB7EJI834DSuOSSU8hH9wys/t1UZV0am2jlRW2+ZBnCafKHg0lLHkFYUnfk1egdE8axqZWsYukFelZ0olrD6FMW7j1+fMDd6zNrKxxk2l8z3TkHErS6SSFku3ViOeLUN78HBND53DtJswv1PjgKo7k4C2DuU20DlUqrDStAK7feYTbopZ3xvi0KwgNLxPbHd7i8brupyhkDmc7hRdDuUMAVXr8LiV+fHWIhaMwnSmSnJhRKfsri7oeSIgMvwuYjc75XJ/t0x298vVOgiDiBdeuPsHIbe1AVwIFRrkBQTqyuAsEC6ilIy++93S/+gTGGapDOmlDs7OyjI9WU+9P7cxV2mBcQYoTDnFGqaxUA5hd+npWDkKesvkdmawhdBZJY4MhwIFY15R1l3g6aK8Xd9MyzG9KJUDp0HGKJOLV2NjBQf2stbAd4e4Y3uYMOrSKuW7npbzwSmK22nZ2uqg2HbL/p39CDXvzezL1DQQnnvjgYzWCWoJ6cLEKkpQ5gpwLy8Cb2en9GgQNPbGyI7wvPhTq+5NA+Ir81MHEi+m1rluexCSZNOAVyJI3fvu8w1DZjlUk29+r+k0xhZ3zpoUAdokm7CmR3kaaRQKizdxVHqpC3uSjjLKLCu9jdCUOyW146MX5fy0UcQaGC1f3CSTi6aBL1mRZBYH578JZ5j6NjNOgZnHfFnllysa09tpL9MwflMe3r265dvh5mrexvcbuJ8zrf9v+/5NGNOW9uSb2tMHNp9tniDQ9X8iKzWeumrrXDnhNJs70GiskRUqFKISaqyyhKA5xNPwiivS9zviONZwPusfcciqtY5UZ0SBiB4lY2Oz4s5YaGo8GWWq8uzsuLx6/RJlA55fNnnPALRxo+MIndmwryO3utCgC/Q3cStNt1AyHuzslbsb22UBObaDfNlz8b+HmqIMnZycZfTIw5uPTgfl57/8svzgRz8tnz96mt2Ia+tbZWNT/t1CSfEiNkrimjElNkqMyljbgDmiZWckU3IiRHyIA37qbkCn/fCnjOcoj5dTOprwjnLLKUlIOnhwarKOirWWREjJkWenhIkOVZMvipnK2AJKGDnAfyhqwEhvFr6EN4HtinqzM3kDHiT/cIe8A57q6JHnlKmA1aOQ4gZ/2ZBlI9jwaiAgXp02tKzWaa1L19plvZ02jKdsFWLr1jJJQxJFbddaha1VzuRRWh3aa8Pxh7848V5JcTjsn5XTo6Oc1ehxI9Lf1gYK9tZm6Qoz76vIohWsz1hnRKgPaVeQVMRcY3wODWidus36MGUXATJKpmymDJHRPB2IyPoxaTNGPFjipkzgwEN8ayF8byydez7NTK1TrXgzzFt+0o504Xtw23wXR8Q3R/FW+ScUGGVFm9FNeFKFpdKh37SE5VkteAaeTAOTuG7TnzdpApJvUwZhgj6SBxGkaa3w+l473Y1/A0ule8tiZkBPeq59rDcX2AmUb3li38wdf3wMHxj4C80Dr7CYZiUo3DX47944/x9Jg1FI3tr63prWf2aa762fBdC10qvrn/ZQyIbDAcrDqCzY27Fn2DBaRWytxDW0h093lhBYayg+q2WDXtQlCo13bl0g8GSoXHmDwnJ9elYWnj0ta8+elOWJfhdlAUZRUXMjggJ6GWHTffoYwXdRyuZeGfzeH5fn9z4sXRjDLeQTBMna9m4OYC1OG650y4heyGAwzvC7PRaVEeQyhYHgEBIOSXvq9sWYXq0KBH7XKGCpJIhgQjmX6TnBteV0Ss/zrF8y3khZBiDFjcqwJkiyZ2yPfLEM6RUPTkflcjQqm2uL9LiWc86QvW17LD16VnhlDcMR5T4+Pi4XlNfDB+25DVXgwKFxt7M+CYGpBMCEeToIDZQxcRJdI3X1Zp3V32rwbfx5EqEKhmqraRgGmx2FjgiZcBrYGnfeVnMbJ2Y+w8YQujpkCt/fiI8xP4WETLoC3gloz9JSLlGXrs1TWb66PC+DV09RZr0qRoEDPZLOLfyVKVUGTDMZNqbmG2jzppBIL07YE8J3PYEl8QlF43Q9wU3EhVVEvQeF0ohJFDaKKTN4SRq8f9umxeEbuMTM+7/97beZhJsLO6vP32IMP08/jl7OBGKTTn1iFdDBd003afNSz0RyNGUN24ngTa4qd9g0FPilU6c8MW6TpCFNxobb9OQH497CnbfqDBxSlTCipKCgOAI7ptNzcPCK7C7oSCJXOjZA7hRH0XAsCQLwqpvNbjcbbq7hx2dffFke/fIX5Qre7qGcrEJIg+PTMjrtl9HZsDx5/CSHmIqPwXBUfvn5l+XP/+IH2S152h+X1e5mWUcBcxew53DZ4FU0wc/gI+uzUHA85sG1SiowGVlCbnpBvopE2zBG6eFdqxLiZeOjwSB4cgRIkmzPUXQkUPJOIyrttrTvsAOYAd3wO/x0TSCa52ueruETvpVVr6jaKCsoZIvUk5YXZL4XhjuV5zIMdxO62UHbC+yOHNWT6JdTnpy/lTVXdbSstY782eBmZJT8ssZNxTnPWv+ZrqQO6tSa7YqNNGWxPeDdeDW8+HEEHbfhsKbvmY+ShqNUXl6eRfqDOoJoBTgq6pSj4TIlmbSaelirtGlewin9uW7OmRd3g+bAXt7dzKYy1ipk4REDa1LJPuCPuCqthqax+lXaxTZ+cWNafqr1Zf3V8tdng4vm/c1vjTKT97l4wSM4Iy2nafkke8a0adTpvGpVgAQn/AtT6ta7ptnCVJ/vskmPJz+xM7/Eqd9yDpnf8A8M7ftc2HYhvgpVZM28zPFPf54ZPSZ+pSPpocEB/mKyxadpmb6mLf/v2FxDWACDQqZGHuADtKYCNV/Z86Z9r98pZPyshJXSQQlYR/na3NgoZygSnkGWoWoIVwGa+WcRAiM4h7uzvlC+v7NcdukhXag00Q3L7kaRSK/U4WKPwLi8GJfrixHxgdN1OTDlRY8eGk/vBVMhW378rCw7YgbzXDz4uLzo7pa16TmCkZ7h/vtlYe9uWep6LtiILuxOGdODOz07SU/YMqyCeTdPr1m59twQFruUY+zuToS0QsMRNnvjLjpeubgqG/RmnY4aOB1JL3IAHN5VObygB02qlzIq3z3+wuM+6nEglOHiGkG/VN7bREiheJ6fHiDUh2UZAekCJHtr51RGDoIk/wsUzTXKrkJx7oYEcLDVWQWXEpXaEYZ8cj0Pikq3t0Gd1KnQ9AL47DN5GxyPWnttPVYj4VqZUSJ4+inf9Xuj3qsJsfP+hl/c0IVPbZOe8fOlCVtHS1Qkm/D81ixUWnmXVqhLadSvls3wizZY3qJAI+W9n/2Xj8vRk1+A03FZXt8grFRc83iDdoXD9wYWPJpnhd9RMkcHw+RE5w0YeGqrBso/4cB/NgDQmVhcxSo48mcM/AkWnBhfpvoWzDz+Nb63ZZ//9na4b9IoBE1/XhmLAmyeTb41/2prDWgUpEpx+BqZ4OhPu4bIRtlRIXdkO9pgHUlXjlZ4SXNdRA6dECo6sfUHEVt0lTbFbNaHaalUT1lX+Yqlg+QIkqNj03Noh7zXkIljOkUvXz4PcOnxSw8qLXSQlBW5YQM+dpoS1aZc0el8/MXn5SkKmQc5j05OUMROyvDsrLx68aK8fvWaDtgQOy6Pn71ACfth+Z9/+KPy5dNn5XQ4pkPhURmuV11AgfHy614a/Yx62WioeIAHF4mrBNTjJlxf5UgTnd2ZYqN8UmkAd5TFK6XE1dS1t1gVtpwCb+MDLyGB08Fr0I5stX1V+bvh6egGbt7FqX/StTJFRCw4Lcm7y1Gc2myr2PokGdJD8VtTIRQOFNll1+XegDNEK7i0o+kIU46TIP26YN7OZqN8Ya2POp2oYlaf4iXf81ShqgqEylkUJb5VRYunZQGg6q7lU2lTSTX8GjJUnAAeCuu4nPWps8Ep5boCdpVcp4fpnJs2sMrnrcwSH3I9ZFXlEvJAxcvr9oa0L26UUKFr75J0E9hlBhrq6FhriA7CGhzz1K1VDik65BQNr8Ftngqn2RffgUUa5dkqGLVdqDiM8kE5Q0e626ffGny3z+gEDV5bpcq0WyMMbe5RYeChW3iqNXwbt8JLWPwqXD6x5Nema5tjzNZEnhq3+R7lj0Tm37NbvbEpe2sJZ3q1/TJwxW0lbr5T2Q7gBGfAU0fk5LUat/rXNGOT4+/YSE4Sq0crXCkIA3k1CkwZ6682hm8rQARSCJ8IFg/c3Nr2GovrcoJC5q6fNRrPTFc2hZwJGRDz2fZC2e+BEARKz14SaTqML/E6NehaDiVrr4twXkcBwb9srJflnS0qhcrf6JUynpRlGGjlwd3S+ei75cSDV/tHEaBXuw8QAMQ7eV2uEYoLm9vlcn2rjPtn5RJB6lo1tx0vEd+7Im8I63ESDuVeUqlXNL494O0gsEZwiEqSi3S7JL6OgJC53KiwQKsNuVHpq8C1VK49ABCcLMOUHdJSQHmWGj4IYHrWXtUDY3/97FWGshfVo1Dh1m9cAGzP1bNvbkp3DSKBbZ1Gye5UlLougm0TyaYwMA0rLDxBGKlxvbebxswpNhuwKBrWa/tnFP7aan+jkSahtqlslbLqX59199pc+MaE6Fvj55k1vya8bh/YynAybctIlSHCDODVqQu/ZZGrAm8JodzdhAbcyABTUQf9p1+UwbOvc/H3og0M8QQ9DE1ayRcrZHPQpSwybTxxXKNI5xBSqkdlro3n98ALnm+mOOgwq4hJV8FTymM+BKQstToiYpO/PPBtmDdw35hWIdK0+A+82PZb668xjbctAaq1AWqCznrtZil9UEd4gAWVr8uZpYWKnferFgEOjjyFPvQpPMT2CjLXRblLOkLSukiergd0GshGuRkx4aPTjahStSFfkPOABYVNpcw1ZfPriXJsAW7XGa0sYXmiR8em8+VoOnJF7jx4/SobIjLaoSEuWRa4vHTguV7PdbDig44m3xboDK6S35byg3ScJj87fF3Gg7MyHg5CH0t0IJ68PCh/6dlav/6qvDzql+mVMq+XZRKQbqVZ0Y08slF0Cm8RhX9hzR3ajsTUETAPGV1GkXDUbmml0qKdPI9Z8G5LUqFjSWMnPkivPxikvsJnFMf7U5eg4Q4hcoAnCFIhEUcVTw2+tKBANNTpJxtRcG+GqX9oKVNkblwC5kXxoUVZBVdLhSd+HTqLvSXk9/J16VGeDnmtkccaaYCBTC2ap7beAUnZyaPCZn7ATVifKuEZ9QPgVmlT6azT2LWulfUq1Sp8znJYlhUUwFV626trxBFvlMlO7hXy9GIwLNMh9YE8cXevB3F7rZH3i3Zdy2aZoS+XgKyhNHdUnlFKHSFfRp57fJGnAFzQTuTAXmjQHbLuLK3TjuQFjdUdpVARRK1s18pDShCfhov8wPoe+SgJQmutrfdN4sdPRnooZ6YOwY3KTvAELuQFLUUP/eZIIHCQESxyCK5I3+SjlINzOxaue9NqXJfo+j6ppsoJ4ps2eVS2Nw3DuTO10orvtSPdWPwcffWAbJ8kFis9qRBmFJS8U39k0S6ZEoKUwXKaPza7hymn5+lJlDfUi0prcOFTw1Mlq8WHOkY7/akVX763th7/UvHd2lZmhmfi+h2bBvT0lNydg4RMxdmT8pvTPbNG6TcMYUR4k0h9Gl4GpWJ7W/Tw6vqxfr9fvC6JUpeO00owStsIV2SthEG/v7NUHqwvZ52W90OKDntcSmMVkmV8FMmesL9IT3B9f6eshyJQnhBAN/v7ZeP3Py1r739Yhlv3yxglS8Ze3biXhZeLI6ewaAR29soCsN3AhIsXtKzA7GicJ/8vdzp5wrVpBLw2aoSAtie6hQC4vLgpZ16tBBM7lLtJ4+DIn6cwE7EMcEtMCvEOhHdBVbo48wzK6vM+BQcjGHfKd1KBMZfKs4NROR07mQlhkbW9qMfPD8vZqG6D7lLWLWeTKarXDXu69QnC1em6ayjHteN1SzsBCK8wkYm6G7vpZTuiEGWMAqV+iGONppZxS3ezOvabfrahlR7fMIZriV53G2/eT7e2oZ4Qh0qO6bXh05jH5a/WzIhhGWC0Beo00zSEUxFLutCom0RWoFfjX4wH5fjZo9J/9ZK0AZgyOvXidGbySyFJL+5bWDXte5SvNmwDn6foe7+kfumBJQKfp/if46+wgH8VLLWsVBp14dVeZpcIiSRTN45v0bTlfFd5W+Wr/dbWm6b1a59vmzfCapt05u1vM/NxWxM5g79C0xEgo0cxh/9aYcpP8JsGgAYnu+3sxPE9SSIXbCi0vktVumFCfknfIFgbaNsBWTsNUPM0U+M5FWWjYKdqSsfpV7/8VQ5vXqMztbm1mQNfNzc3y/bGZp6uH+oSvgs86zTcypfvfPpx+eiD97MmVHnn+rDJmA4eYbxb8stHj8pPf/bz8hQlT7peXnW0F1BVcngXF/KIo/zCpRKi8uW1S5bXMqk0rfPuQaNdj1agY1qnAJ0S9M5H+CYNc9PoEG+IHJwiw7zdRH7McgbKHPxiAkNTBxmtoPVUKXR0MY2jeEzdGvvNuk59NVY8ZnoQW/FLGVCY6vShst7lHyhE+EWZQs47iteO9jl96jRgnUIkcZS8OipJmuJIm3TxIzNhzCxLrLDXvNMI037on0Xh+Kl8OAqUXZL42QG4nFJPrg07OS7D/mmmEr2Y3jtGhanuru+A616mgc1T5d8RMm12qJuycgfly/Vfl6TRrv+q90tW205NKh+UwwkDLmMJWzsjDU4bq2nd0kZ9VrdtcztiW/GNX8MzdZTq1gAmP5XOW8uvP4E/+NRaHmzkWdKRx8hX/PlN2og/FKG/YXmfjXRh06GmnkwicDbhE6ehmwqz9eKT+iR8qyi1dgZPU8bkk/DVXWGRvlu3YXnOpcFPvs/HJVHwXOtAxZdaiQXAlElLwJlbK/q+BVMrxCs7lmHwMBjWugzzQbCzEZB8umXCysKt+01jfKePvHTWe+S2UciOjo5yTsuKTAdxr6CQZVdUI1jVTh+sL5S/tb9Wduhdug1cBl6HcV0ptAQcjpBNJsMQeXeLRpmM7IFc3X1QFvbulA8e3C17998v0933yvHZSVn3fCmYanN0VC6ffFGu+yfluocitrmbQ/uuxsO6CYC0Pf8sTIL1WAwF4sLEKa/V0h9PwpwXKANHuBcUbMAS4bThgYky9kUZU3FeCmuPVgIe31zQOyIdiQqhOoGBB/SEL8CN6z3oOJUxjbs7qyL0CCdOEBvldFi3u9tjzFUZMCykERxMR6NyRQ9OpY1OHsRyVTYRtNn4AD4cDbA3s9LbzlUttd6sPyyCoypl9S/KQquEtOHwC0Ni9Ev41lq/llNCbfzacO1zZnlvCb9+rnGIDJH7Hi+MH2UA8YaWA55tYj152tEq8bG43sutBYsrlO4KBfngeTn66hdldPicJGxcSEgBOB2irPWScKVdYTKPalrYkmfc9Xv1avzBYUBCSMDFOEhrCiwecLVEPaziQ+chvd0WD+KRd8Goyp0J1Pdvy7R5aubdmgh87Nv+rWn9f9v3FM7ftwp0G/7fMV3e3/Rr01d4Qwd50xCmCSdJzoS14WyAEl7hj/UPdxSD2BpfkNvyZzlGbMWFwlthHSHMvwL7lIb5q0dfVuHeyCdHWrqrnbKxto5sWoPfOlmYr0Kmuq4yppxzCvPVwWvSGJQpeTic5qL8n6Pc/eQnVRFzHa35Oc2YQ0GVg+SbBhWYVAr4Cfl5F2IPJcv03bW3iIKyjFa55HRfB9m2sZE0VCSzJpe0LMgafiqRKpdndIbt1DnNKSblR5GShhMbzxv4rtkk4AiQ8kNlI7hNiloDIrS8XB2bReNp5K1L8GmzdkOnFrmXjol/REmeM7epUE74yhGLJeS7jXhGAYEv06xa3E6/+i24AZYoP4Fb1rTuqxKSxlzckXL8fFr/5mSdJlzNQ5Jw7W1dnzsu58jSSzr35uO9v+vkax2rGGZ0Dj+t0765l7IZqZfuNNKRCphrwTy+YrYgX1qjwNJY25nUikdN+x77xnv9/rYJ/imHT8sjDJapVYKk0UpD1Bl/NUzzfMNWHKYMhsVtli1cGv2Ux4TyrdrEkf6w5BUe1DZpVJtgjeXdOhCG5ql/ktIPmFtF6a2IscHJ3HsL5wzQeNeXWf5tPlEGTZvvWsM1YWyPknZjNTXufDnetLWmvyVjkVxceQ1AEkQFuCl8YyrJGJavTjPAfL9pKrGJfKlq0R5Pb6vsbG+XdXoYx4dH5RyC9UoTd11m+LmpWOewHcb8ZKuU7+zRG1lZi6DrkJTnkZm/Sp7D42sIpaUpCgkMdeMo18ZO+WRnu9wjn4KAPKJH2n39uOyMT8v++aisDY7KKoJiCcVwZfce9bOc9SFwJd3lRWedinsdz2mEJ65xQzm6QlPqdFfLtUobzGvPywWsCkvXdNm7zHD5nc0yuazrAiTOHmW2NzUCT3hl2kOi855Kp2B4iSLqGjjTyM5V0qu9LMoK7pw+8KoTFZIJZRydX5bxZWWGGxQzt9XbaI0vVKStEwSBDE8CxlKRNu/lzkbZBP+GsFbTg8PK8Fp/fPDl1i8+uuuzmhouthEsEmm+mMYbYW+NRWtHWQG+Ie4qMP3GS80NvOXcpMUVwqmMOtCkaOcVOnA0bJUGyXhXo2E5efqonHz9eZmicAuVAqFCgFKNgu1NCtXoW7+8bYCAX76FjoWxUTp5jTIqDeN7DR04SpY2SPxmzoP8GiZ3aiiAWk5bT/zaht48/Ptt+PldmPm8WrdPbVVGqm39WtN+b/3nv9d6izOmFVLat4Vxa+bTmM93Zhv/jO6Kc97nG4hZYqbRPPmJd8KA/xq+haFGkb5ciJ8GEt7VTmlszYsv1kasnR/5TeMaHhtTR46W15bLk2dP6CRNaoNBoq4HkjtXrpFX8OESuoidxb3eRtmjg7AMvdioH7x+XV6/elXOSctJIO+NfPbydfmX//p/Lv/mJz8rr4/c4eup7K51rA2bZ5dlQfsKstKRXxp7p9cQeeH1jMBTPhVBNwtsbKJ4rbp2DuannI7ceUSF64FcAO/ZjG566G1sIYfWc66Y65ZU1sRTGlGemoo/y2jpnIpqLfJVP8P7xKZfIu7FoaOOAtgoZVkzFMWssSC3VdJa2gjPx5JCrfDwk4LAqS7rUVlIkLgzigV+sqaJetDWC7+xgTuiO+72rDBldEbhANQdpCpf+jsKp6K3RJ7KTqeNB6endGqR+sDiukOndp2WdEpyg/rZBHddOsx+y7QZwNb1arWjoELvGjDvkvTpgeaVrqHpyPWgeKaQhQ+kwMYdGsckXBP2rzIzPKbs1QZX2IoP66nWkfiofNFYYM+aOsuQcC0OK323z1v3rZVGrSiVleTxG9Y41hlAYglKvPoeN7Yd0fT7rfWDdV5xoBU/rTuF0Y0ztvEHysA5e2/cNTy2BYb3lGkuHzvPb5azPv9aS/LfqukiXDzqIYQzj5TG6GfDGoGGEFjESsiGz/cQGA7jNe82bKudHgrZRtnf2wmyjk6OE8gF/u36MRkuShmEb+/vezuL5cHWUtlp1kc4ynbN944KGjAu0/t08amIvpmOy87StKx7MfPqejk8PCidl4/KBgJiHRg3L8YQKMoOStrCOooTCtdwPC6LKJTu+hmsb5eb7lbOG/M+ytFkUs6pvCsIqM/7+ekotTianMOwK2V3o5tROtcmeZK+hx96VxmFiUC9j/KjUuvoiNckeTaX7OtOHfHnbi1PcB4QB7bNNGoOhCXPMEhGBRbif00PejIckr1niakNlJzQ7Xk+rls7O5+Cu2V62lfl5cG49Cf0RhUIbkVHkF/f0JvfQEHFzBpA6wX4FRo4U6+puFmFazF+M0BjDJewmKSFlZg1GRVqzHwcDZhQ3vqhfiNO8sVm1YIjYU4zEy45UGeZcoQDXKC/giK2CG26QeK8f1yOH/+qDF89RqlEhQZHUZpIU0gyvUojKh1VKMzPz34nwZRv3vBeZU0UqTDuFU9wm3PNpjSGDl+qnDkasWL8Cr9lCrw4ri8hdOLUNLQGsyyVP+bx822Yt+tAEzga276/y/w2f01b35pgYv5dHFPweb/WzOfd0o4WMo0i5P2HTtqoqKiMw/AmCG6hD/001jPG5M2jHsvQ5lUbt6pAU4XQj1P1jlZPpxM6XvU4B6vFkWY5rE5ZynN0cFz4Q311N3qZXnz0NfJjcwN/R55pgCN7lsvGWresEXsLxei93f1yh86dl3935EGXYpydBUDl2pgO1C9+9UX5F//yX5d/9YMfllcHp1nv6MGtrh3zKqU1FSeVDeLUIzqu43Z9kvDlTDJgv6GxVx64XKG3LjyU0RtEbi6CLhUEF65n5yLWI226pD9CxvTpmDrS2EHBWLIskbkuvhev1pcyB2VuYY0GG3gWV0nfqTz9bMDBEbCI2kyNgcS6rgyZmrbAjUbgD3lquwDicatsVYXLuoni67oqmU3DO7VFGiqGfMMCPnlWt3noBjXAiwJBgb16yBHB3CICQJY5neGUXfciyifKrMtX7BBTThffa13k7+zHGIW5f3xchihi7n4VGgcJMjqJQmu8jY5tzAq4rtOmjsBl9yZ5CpfAK6NUwHK3pIoYtGbnMYqYtC2t12ISFrd1idW032z3QrO4Ew4EqyxEC5cX/gqrkuvTLmhGAck3G1TwlY7lC9uS2AbuTOPiyLuyjGfFY8VnRii1uKsSUtvdnAnnoIkV01rhbmw2AqySNnWUARXyUAG20luFXJjqFXZ4x5qHwLZlSpJJr7rzEpt8CNx2viRE/So8yAhsCNQ8gd/F+e06Op8Rxgmru8ZtiHlmUzd/xTsxv12jYHIhv9pp/iUabDXVr9Xqqy9AN5/mTXCvg/SyHgfsdzd2ctbY/v5eemln/UEquWNjC8HnxGW4Mbs9qPh1en7f30PodVHGYJSLDA+vFQ8GdHrxhkbSNRCeaL+EsFq7OgeBKHr0PCevX2Q0zSuGVnd2G0JFiQFQT9X3RP8lhNgSAgRXmSBgz1FwxjS+nvl1SSXmhOQLetQjR85chloyQnVnd6NsI4CFs9MB5h2Uu5MRxLeKkOyFsZcdYSQte1ETFQtqsoeS6Hlj7gkTwwsokCoXYsorkxzatvHP8DG4WMBmFAiFyqFvHJTBEbFxDjRdpmHxVOejk2HqrT+5Kc9OxuVg4JUy1E+UCVJfpJe3sYsgWW6ERFXAzDnPvOPQNia1C/585i/f86EaiXn2xPLM5/Y7pqWblrnCjFIW/oHNRgD8eBJ3GIzgjtrlyIxrmChHVtQt/sa9mo6igB1//euc2VZTIBzpa0FBzQt6cyTTxnCWN6aWw/c5tprBRhoyLan6h1S1XSEdsMQzsCq1b5MLPYnEhOcZnOMXZTDv1d8p4/ZMs2/DiN8WJ5r2Gbw3dt68y68183HaNN9l583b4d82KmBtmFYhU3ESPYhX6MHGoNarQtSR5uDdCsboTWxcLcw1r1nDFnelB79JWungENxOSs6mstFqGi5rXYXLy6eTLxFfv35VDo8Oo9TY0fF6JkdUribTHALdpeOwiUzYRblZAfazw8MyQgnzXsoJssgDnF8fHJVf/Pqr8mf/078uX3z9LFcC3ZDWirsk6RytOuri6AsKn/B5DE+rHGT0h3xUGlXQlHWXKFXKj1Xgy9INGr9N5IwKgiM9rleNYgnOXGNmoygevEdS+eGImbixjCK04retQ/KDwI0LBvLMyAkhdScemCI5vop3cYdwiUUBa96rn4jGgpdY8axsw6/Ftx3P5NOURUXJNWQqWu66VJlyB3uUBGzdLVkbfb/HbRzalbip3ChMpNXhew8Z7OL7xMffjp1nwo0HgzI4OclTfDv62KU9UeFy9EulLjv4VVoa3GtNW4VZGksHgnbH9cVuoIrSTxmVo1HEKL+20jVWfwoO1VPyxpCeZubHe+ojTp54ZzZBGPCLZMKd+pE2rB/wF0v4Su+trfReOxm3fglDQr6bUw1T06k5V5POjGEpbxQw8KKCJl/iwZPwpiNbgiStwJl2lDwt9WinVD+Bz8wPVjyRffxbBa3SX7V45BlebtwVeOrQz/gRi1e+A4/ruquSVq149jsR814LjA3MdvqbtPKO2zSNM/fMSDhhq63xtKTy7RuFUoCDGGSg1kBeljEFjTDFaeE18W9MlK8mnH+hIuLa6Ha3dnJz/S4Kkveiea2QU0+eSZZRMa2MAFNo9zuL5dPt5dJbceG8Z25BATC204FeiptzUGw1geZmMignB0/L2eNf1+MtYLDVja2ygCJiulekcek0YVkuFyhiq5MhzLRYjrpb5RzGmgCrysBiZ7VcA6vrxa5U9KiGKwSnUymr5NftbkYZ29hCUXjvvey4XKOxdT2Zi82X97fKBQLBoyzcpSGcjpYpgDJFCbOvIcDWZXIbaqCfqhQCg7tEFvnuFlupHRoIjtNRQvFyE8B46B2fKFwwiAqCl5I7baDAWUH7Gg9IR8l/fkFkeq40HOvuPFxeT71FaIgxYHHhvyKyvoND8tL6Hj/cqe/4UY/AI0lErDbEXOf0gUUO1SNR6lPG1yTtJKgQoHwweS2jOx5NBEYRNuOAz1WnJLEuenZ6aHJyVI5Qwk692mg8CF4CjFmHoaUxrbRHeRC81kUNmMAY6VlFwFyqaelYOq0KrN+rX9ITfBlSwZOigDu/C6tppadH+g7vGF8xzFNlDkkc0q9Kmg7st2SSX2NSnr8i75SFcr/LzMdt3X+VlX98zpuWFuZNG15j3rrrtAk0H1pSxiRgtaQbHmiJCD+niGZ5hQ5q3WdEgDqxEc8oADzoGh/XIFlVobImXUcVarVeJZ600UepevHieTmfuEHHjTM07P8/7v5zSfokS+/ETqpQGREpX1lVXaq7R2AGuwQB7FJ84w1Q7JK8hFVc3gJvhrb4RjMaaba2MAy4AIglBosd1bq6uqpeLVJnho7M5PN7jntEvFlVgwG5XdPdHunp+rj78ePHj4u/O/1a5ZprMsb50t1OO/a2t9V/r32f4PTyyqvXbIfSF7jA+ee/+iL+8ic/j5Nz+WtysdXsaYKlPigexKH9vnhhb4fznJ3od7dTsFAZWPVHI4D4OISKa0ESAUBwMfnS/INHj+KHn34Sh+KlXMcwk7DmFSzVCTi8IzlQud6+eq2JxbU/0GJiR72hS2G5rHgJZ7Ibf0KF7cZL4qb6sSKWmtUYaDtXZehdVXCwgGWdgzx2yu68FmH4qV1sJ4yVHcbLYqJpQ2n4h7cmV7V4q1fBVL98cSGFVwQrPgYgP0VTWlUVvj4axtXFWVxICOMSV86GcSZsT0Jwv92JLu2LAKZEbGXWK1K8AwSN0Tfo69JsC8+F/wlXEKktWM3NVS74QV4y6gmvNCbnmnO1DHqHjJd0j3I/MAGmWtCwNQIoNKGxEEGZ+kpXgYw4NlXRXDGqmrDabomHhS5+tLDb1PbM993JjOwKTIEqtVeaioClIilcbV40SOdHJ83taTJKMwUa1RWawZ94Usm3MdEOKOGpGE/ADbHRjiMNPISpKns4kbS/sJTT0B2PgmZ8p60CGFqqcJIcv4rdsMBfJSBgEIyV8O9a8fUIn5QnERbPoiAeyqtqZQXT1x0RTbtUtZo046rjNDqxvbMfu72+Z52nJ6fw2Whv9xYCmQlQZUCYgol+0ruJj7fXois/7nuG4V8DT70Q4WasRlsfnsXNq+cxeqrBmsPyYjxbYpjbfVbFOFMhd1NMT4LbpfJrimkC4rx3EOdikhOxioZmq9utZjTEJDfVUa+V35TOJCGOW6Wb8tt9dD8GYiS7O7K/9zA2O2LI6pBXUCcMu9+N3m7fW5ZcaQGj48oLtn+nLFOpbuDQb+DJzTkJGl1d3QRL3cHV8u4UMA3e2cq5jcl0zU+niKwlqGhWLNhTUeV0fuP37hjM5reb3pq5URkQXKFonlJpq/5erYGszFySMaDvKmKRKWWp2vEcN+Mv00LWSyFlteHzSRXmiRB4M9ZZHdRApBFS8Uo5FAcakPQUvDLAdvam6A/czUeDuHz1VZx99YsYHb8RwLnQonRZwq8pcEj95hLMcXAu0MVxr840We5qZmG5Fd1fTiJE4Ud0t42salqfCXOeq3QPTqTpJ9QB4QtclQ7vWRjpYBwqBVvq34WqX3FVXd21rqtq1a/aa9y7ehXmt+kUdpNuUJVuanrKclezHayekoOO2hbtlxuETwRaa/3lqqYsK6oK1gxcHoTKAIDd8IR7b8WoHXg3kG08hACVyoM+g5u/7NPkK7/EvY6jN2/ixfPnZr6Eb7ebsafJV1sTA69qiyexfeWPicZDdcy5n8aZsh3IiovyffHmKP71n/15vD0+jf7eYWz3dkR+rDA0NQG98XU9bU02dnYlkHU509k17+GuL1bg1lUtVvMpay0jghP0fz2ZahKqiepOPz5+/734UPpwZ9fChIVK97YbrzS9ffUqBioTwgXbnkK4tPiw3Ak3V4FSM9ByNUXm661c+dmeZOw+6TIpPfG3lNOm2sWmNBPOTaVLP+pCuLTiI0QQx1pwfHUCQpnoguMia6obV5xQTfiC/qkvqZ0ogwpQaYMxIu9Roz1zRc2raiogAprxoPRcEs49ccPLcz9nxIdjtLG3mtvt2BH+exLGOBPGyliujrGaBi1SZ+ED7gEspWNc4UOsyVyCmGCjEbbo2/A+T3JLP4CuLYhB45jEI1zxfI2FdFWOT5iFE/gHvBLaLRqaVZmwv+NfNXQu3Pp6CbcRughTgolwjnD8jqY9ZPpXcPpNWkGGAT9b3xBdiCh8NECZ+JoKa/qb2tB9T3WTyTUnHtscV/QI/SiNQDqtCymYrKoR1ytnNJvLjVapFY4yPahNUxhE03PlTzz89TNrMLz089BSdPUHkAUvpcOkBRhnSWt39Ze2YFc1/tKA+s4VHa7Z7prt5XMTSTzW8uVgLAgAe0ZE/TlcFavEhl5RJjQlawh2W8zjQDM6ln4HQ465r4s5IaC13SF8DkAaQuRCvg/31uKwJ+KQuyJ4rtxuaPDrcawNL/wO5uhqQE4iNHU6xRUtRI+ZjwTAtjpdo92KrmZW6EFnL95wt48IoNnpRYs78kdnsa1Z6lqzHVMxzs2de7G5fz+2dw/i/e99FC0JapwP60vo+uDwgZ8+mU7nMaKxe+3oHB7EUALmdKBZarMRc8orQmOGy+F6ZhjMrgZixmPVk21a6s5XnBx69ft5dC7V3ec4GOQVLhHES7IjxeMtM4iVp5AE3Nd/cKRpmwGnJabSR2RVxcUA1vjyT0La5pZmgO0eGBNv0X95e+DULw/zY5eSHe32k6ptic4BljZMTfvjrnG9/G0rQwFLxpzxU0+V0LguQVCStYLyYD5JzJSUnpWwrUZLbcB1FRLWBPZGwtTg7dM4+erncf7yaczGA/u745T8sgxL5XJRCxWCh9F5602jsMv0bj0oq2hX2qxqrlRlZcuZqOPJ2x2fmSGoJEvkWMuyhZlQFpz+0lMOBlDPJEV0gGEAUTLFkR8e6O9AUcc6KKzWu+qqqv2b/O6qZdw7dpur+TjoG9UyzrsaRduZ+ZvRCm/yrsK9hTBHWwWOfZnWDeGls0qbKNwZBObhaxZAlEeaEhjUH8mRp8XwZyXszevXcX525jNE3K7fl6DUFV/qqL/yGPi9/b3oaaLHA+EITHyFzjUWDLys+v7857+MP/03/0NcjSYSvOZ+OUMzJ5+b5S1Ztt2bzW1NyJiMrcf+/n7sSyjbF0/kgD5l4GJnXulgKlGoVKZoTmGT0TDOjk7i5M1xrCnOw8N78cmHH8bh/q4neAgh8L3pZBinx0exrb7XE3/jjsSGJkQIQ6xMiTsqHloCiMqdghZ9Ax4Er5IpOwMwK1B1pSoFoxQOvTKlvCywgWM1CYN8Cno54HtFTO3ocLkR0MThil35qd8xzqxLM22h3er5J3EPdzf8mRQx+PvcVtEsHPiRbjQ8k/hq7NlYgrHGA58Nu7yQDCsBVgGMAXkODKGcD58khEpXMwUxadmpA30XBR1yVxh6KsHRh/OVD6RJP/OKmOKkUOb1cVMn4U4vXCXfS5o1Sdew2k+Fh0rzKLMLxjfheME+ZK+6+sGnEB55u5U+lCuJ0HYKqFUIWtUi94Vd0aTIE96YOvtO6qwNE0n4mjTtr3bI9KIRafie61NoxGMBJm5lsFxpkhb8pDHiLHHs+LamO2GQTullJ9ATXcGCT9gu/3pxK6kqXlOgk1Z610I4NW4VRo1I53JhUoaSvpb9GzWF+u7VbTQ1S+P5IkpYiQO1sKtw2CHE6l5VVA2vd32LUkO0NFPs7YoJiRFx/xi3FCNodbp9b1v6yyC58+X7ZvRba/F39iPe725GT2Xz1Q8lbwSvK81Y2M5CSEEwm58cxXzGxqMYkIQ/Zg/bHDBsaSakGdhsvRFjCShjVYcDm31J/ZujS83UJKjtHcTlSLO07X4077/nVbFNpWt2e4IvhnzvXmyIST/a60VbRHF6ciEhshkH772nDroZFyeXXpm7VcfmKaemOqo/eYbZQDh0djHjmbhLbrAiT07d79iiZPZnzOmP2aMfA2bmJ4YzmbAyJIKSVIAwZvYlpn6l9H0NEAhyg/HEW6Mss6+LWXNeY7OhmWB3T7GFNxgJhKn8bPr3rqoDmsNK3LsqOy2atqZeKpgE2FsxfM578RQKb9bxhaS6a2oEPZivOoDP/3W2o8F2j8oOs70eXcXV6+fx9sufx/GTz/0awTpCpX53lfN0OTOsMjK82MadgW/RT5YxVcZXBxXp8BAvW7+cUcsDoApfaLmTM3xdkS8/YNkuOGoD5yIcZF2zLOZh0lmub4H3a1QuQ1G1v3xTOVbjoXCv6m9TGV4cUhU0efxN67u64mHiLirzTTjW6b3Is5bL7tWfvRPfPlhcVhUoTsJKkzxJyxUSbN+xesMzOMdv31roYeXe93uJP9CXuILi8eOH/gipubWuAZ0+pkFYghP01ml3vLX5Z3/xl/H02Ys4vP9QE7teHJ9KKNDkjA9R6K/QPRdfs3IylsBGOXZ6PcHdk0B14AtbuZEevuSVPMqsOnkrUG3IxyRj8cyTt8dxciSBTP3p/sFBPL7/IDoq85qEBc5HvX753Dfus+rG1ps6iOuiIcjw4DdeIZH2T3ipqxu2s+WEXU2SAxuDEmGZxoIWq30WroRPjXTcSZbuouWueXGRNXax2hK31MmmtNpMudB0VtlW0uQtDZ58Pxh92nFYqZGf6oRQhicvKFxK+Do9OfG9YTxnhT9ftvuQfmlP4leh3IKl8IMbHHlyITzX7cZVbT/xU/Mal0DdW37QkeMQJo1i4LeiDpikkcZcVVVoqPW1nwxsxl1JvxQMKLNoGq0ym1XJbm1BRZp6yXT4qpZ/wquwUhN3ITgtNOVRAaSVpeCSD+WFLpYaf4GwdnixOx0mmCowrAk37LQncqgf7lqmjAhuKAvx8V+slqnSuCu+gJEwi1/RNZy2sPBWVAbzL02nXUn/ji5hKtHfhlrzl0FcPcEMgAJXxmdlgqUSdCRZCFoJTqWw4kmFUBVGvVyTbcHOTt8XwrKnz5IyAkdLDIwLPWGiMCNvm6oD9htr8ce7EYctlqeZM3Ioc8z+nXp3UwA18Csr7uPaVIfgVnZmK3wZuTYbRUuCwexmPSZiFlMJVxPVjRWonetZtMRQEVJ6730Q54LHea+pBIqRhBkepOZU1kBwuevn/r1DMVIRierQZnYrv8P7hyLKphj5SVxLoOKW/fnlWdxKwGNVbCgmwfYqa1aNVsPbpkat8iGcH+ej2FZD0ATpzHbcyZn1acbMwVWfZ9BMd45QBmsXA+BQ//nVWNXfjNFgGucDCZvCMcxQnEH4mYigJWRu74npkC/SwbLJRGrpxkN54qyBPv/HD393Cg1glEuIvpVgisDF16g8CCyC8UcHnJNzQ6CAo3rWvOhYvGO3xR1zCI+Kj7qZTmJ0/DpOnn0Wpy++iOnFqeqmcpoDkB/lSyir9JR+4EllpANTVsqmPK/5IhIsCUerinZgS1HEAZBcZqfIKludreEvKI5PHkYJecmS+dhqpu3SCBa05hmxTAudEvbgZVayswL3XauKq7s4qCrx965y+e/4VzfgKsxiWOFnrR9M8m+uoKNCV6SDN8iXYZlGMZ3hBiTBi3IItyCXhma7X/5emaSa0IK0+Yf6YoOPbNR3PIPn+gW10gYDCm01n/lsKKtImtX4Tdiri3MLZny1zflZtjBZ2emJHz6+f1+C2FoMri486I7FW2h3hKtf/PKX8c/+xb+I4XAY9w4fumjwLc7I8kUj21rdnV6M1R+HEpL84olgHIlnjCfiQZ1W7Ozt+MUS4PnxbOW/pb6VzwCx0sGWHKJPaNJ3Gl98/nk8/+qrmEsI3BXf3FE6Dq7zGDjPL1X8cLifLb3sIdQdRBmlC61WsODnri5E5nmy6u8dJ+MF7lRXrJh6EN/hxJN2PDVNrpKpfwk/nhgS10xPWriuq1/17FmFx9o55SSfXK3LdJm/2Iz+pT1XxsgfIWwswYtzYefCC1+18lQVdWYVc6/P495dbzmThkm+v7CERiSksIIEb6Kf+AtJmRxRmSpfNBM7MAYd0t4I0txDyfYjOzQW0uSPGOYVdNzSi9UyxUGRPm2p4KVLQQmBCkFL7aQZYX5QARfHLX9r/FgJQ0uwx4/4QphIQ2GJM9zwsqVAlqYFPwIVp9pT8KrxShmK6d0B6AZYhkcPpw1VU/qf60O/AqT+yQPT9bQ7lVCQFUe771I+lUcWeDT//dW0ipZaEakD+akM+UU1Ac6IHA3f4Awj/W2Xxl51rae1YFEv7CYchQNyER+/u5o4MpXiu1euoDTXTviZARHjtyvCTKZ2raoFYu6oRJ7qqU7R7R2Y+fQ1Mzw/P1t89cMZMu6JqpfBIqDwqfVeey3+7s5NPGptRF9wbpjVSijgyySg+hNwIRzM8fk2THB0/DxuJiOfMxsIzk1/N/rtbTHoVuyJSXckqG3dTKP/4L1YV53P56xc8eBtUwz0RsLZTbwdzVhEiXuaud5IKLucTOPZ0Xn0W9vx6Q9+4FnvxYi36uaxpYibg0GsXYmpK95ITHgkYeNaQpOJW+W9Vb2YVaoXx60GjE3VdV2Ml07IrJgzApybukZSELWwLMtXVHzVwqohzwPBGMXNLaAdnVxK0JNb+V1NbmJ4K9YIscMUxPhjti5hjLdCt4UvBjlYHoSIHUK3NKK2Trv37vETzlUQtRWrXRIlpVn1YgVMCJapfJQ/OhV0QFcRbPVAU4UIn9cWaE8LYbSr2gYWNdegMTp66TNhp0+/jOn5uWbQcxWldCLSS1VaQt8VFKoiroJVZpXA2zWsO1IP4UX+Lg/cEj4iYQn4eXu+4LEioNHDfd1lJz4sFH/EXtnkCcNMRiOqX5RD8cWBzVQos7zXroVHhD7hv6pvK/f/2GoVV1VVhouqA0Utj/EiXf2rH4JC9Vu1V34AdK8sCL+0FAMxpvkoOFD9oW+08V008aqG18lQX2MVXv3XK4zQE6upOSyzBYzcTNMRR9imEsrjWoO+Jl4yfe5I8TZuNYiU/WSV2m2KYOG3q27Har+ZhCvulCJ/5aV+uX6tsJtRTMfnEmCexdnpqQZpTah411U84kb9el/95qMHD6LHwMCLHYI50ODPnYRMRp68fB3/9X/zT+NXXz6VcHft+6sQTthSZBWt3+vIxYrKTHWVMCH+tcUxBuH14uIyTiUADlWXzsFu7JLP3r6qkJuUfpdT/YdB1jSpvG81GI74YOn4bbx+/ixOXr6M2cVVbCvu/d2DuDw5i4vTMwmTvAyiMjQR5JROfA5BSOyEbil0lsYyfVQhJ9uVrTq2L+E73s51HNq7tl8KWLlFJjRo4ASvXMJddUvadyaSVnA31vJppI118cl1zrcxqYSHudtqEi3eKRpoSMhpKx/eB17jC1MJzTx9dy2+ir3X5mJW4Udxh5cXuR3JV5IaQ241BvBo+46E2X3xm13xGz+7pLK04fcNtS1XZai8nDWjXJXG6e/MmSaKO1X+vI4yrVpxpqJfvh3VsOCPqaZKw5UWviBcbaMWFq2qnwhGCmLCuX7mC+Lp3l6DhhRuLZj0U3pmxSvn93yeDtzzSL7bgO3YhrdTvaVecA5nqs9V5VUj8Cj5A1NaWbiN3c6UQ0hmVWlVMLNWAMIRj/JvQmvqf5QTQSzHYMESXOJWXuKxTBq60T9VQO0hOBz78W6OyiwA1sCvYbS0awrfkF9+zKVxBaKk8CTh+iDpWxPGlvg0Y41MxhziCzbpkCFcTtJR3xWNStxTdvEDea3q3A2h3GqPFfu3af3/7pWKZeVPg5tiRjBREZa1/B0OkUFNKuLy68lk6u8y+YxPOLoEWRmeBI7t3cPY3dnz8xNsWfI+ZIMl5W5XZl0hk1bnY+Vlv30bf9Bbi4dilj0JNlt0AglxXI7oh8TFLDckcDF7GT3/Mm6uzmDLMdJMqaMG596yHcHiOo2HYmoHTKmlrhV2MrmNK8qshmeF7a069/H5qZ9D2tnuxli4eHtyrBnxJF6dXkT/YC9+8PB+TGa3cclNzsqD8x4TlZdrPOiA08HQN/WviemPZ+O4mKnLMqirW09VV2bI1B3WNlXedUYBc6ITzEcTMUYNjmJCrPZcT8TEVHYf0tePthhfIlCqU6oOPLPERwb8mHXyWT6CyXarF73+vnAuFqdZPit6bKeuCdfr+MnE36b0Wg1XG92oHu5sKne9mwhuIvDSamdRN03rNqfFRdyUsdFuR5OtSAmr0BJCpu/nGVzE8LUGvqe/jNOXX8bkQky0CGGuvzvtN6vVDle1akpxrFEw16ngVVzmdRmUk1LKD+aiamQa5SVmwgoNQfXWcOqQglzWzauDhIsTu87UlPYSbNcfgQ5f4SCZsCKTN3Frwb4DVXFSVbWv9s2/TtU4q+ZqWox034lbdPVD1bKgYeCY3spR+2R4zsLd7sae8KX0CGAKdJy7qMs2y/ytTIPq4YLp9rVbdM/gKs0ZTd609TaH+sL19TSmo4uYDC/VL/gyeSj+suYzYG9evSCxL/9ksGN1BWHjvUcP4/7hoYUrHv2mB7Bd1mg1vSX53/zjP4lzCUOTseJrQOOM1ngwikf378d7j9+L/b1dl+PJ069iKh6Q22rhLTZ2A87F93gqif7SFp/Zu3cvdvb21HfYvudDJdUH3ELXEiDZFvUbi+pPlJut1ZPjo1yNkh4Ph8ImW61bEsRYPRJ+6KwIP9ApZC1T3dnjqP2MfciegTzdCFsegJVA0VK7LUlTBnDZ0VwvgXDg7U1M5ZfbmojVCAp0O2DTX5HR1d9VJ/w5N4a/V6konISyG+GeNuWjBr6aRyjkq1NWzMeXV/6y9OLiNE6Ojlx3zobBQ7iTclt8i2MbXP2x3Wrk+WHKrvzyTBX5qIYFp9BjfbLIq17FXPhJG/9FV+XVGZWf3o4mhEkDpgUV07aw6HQZg/9V0R+g/7oSBf+2oCN/82//FA+tZF6dAuekcVrwSVsqnrVwJ3/sPmRP/taURelJ5/T0u1VNmEwlz7YlLf6YogEyt1abKgLCdQrnwNO4TIu6o0rLTOqRr+NQJtVFJv2dOoMLC8CAhLYoI+HKj7J6QcW0iQCrliv1wKT8WWnyU3bC7Te1DeHGh+LSTpUPpTuLS2wXG3jStR1XtcOJksbfjiJzltjdih5QSmVXKyxlZAix7yBioZZ+RoQ00WzHT7q13Y/tvUMxrAM33IU6FQJEk3t4OEOmQdz3kKlDcUiTFbL77Zt4vLMWXXW6LeXNHBKGO5fQwSPdMRvF+PzEKy8qvZxDCUrj2NVs7ADBRpL4nmZIDzw7lbBCZxMDGEtI6IrRQUrnx6/j6u1LL/nz9c65BLUvNQPmsD1Mut3vx0y42Razmw7HcfnmTUyvLmOmmfL8UELPbtf3lfEAMe9TrnOWS/EoB0yd5fDrVkdMAQl/IyYwmclUAp+YmaiU51GYMSBgMlsdXk4kxLAtm+XlIks+sx+oPAiadFQ+2eZiXGrgZSDBlBQXN4K7AYNq77pJcnXDDUEzZEPIviBY+xUT9bWmXXqAboiFmRCHk3m8mxUw3/GmPP0lkOJzEevo7DguXn0Zp88+i4uXz2MyuHQZ3fnpOEWt5Pw1taDDohbu4ldDZsIT/jynBCqgC8q6xh5KyYC4HvwLfVspDGZYAeEvrNjfs2eYqvyq9h1iMj1DVCLsKIPATjziSP8mqFrub9M1zqpZVbqr39fTVHsKVKmNCFBjE4bnlGaUTLRgxFZOmvwhHSR6Vy1o05wU+CXZIi6uohGQEZSFd1bkOCDuL+3EJ0bqp9xbx+oIwharRWw9nh4fqz83osP1NvAB0eYDCWGP7t+zcHCldLzGAD2xanF5Pog//e//Tfzoxz/VONGIdruriVVXk8v96GoyxhLKdCS6vxpYiN/r9dX3x/FWwhO3+zfVRzgnOhYvuLgSDxF/2Gion0p4++DjD+PgwX06VozGXA594xVxViKpOzTJytBYkz0ExCvxO/rS8OpccW7jHhdsy42giiBINUEf3YxWqKslqXAn3a+axFkIUAzOSoxOPqGx0XFX0gk2blqUj5EYzK3l57vAFAF8O47+5SF5+h/9g7IiwCU8a8FhVwQTQSqvsNhSHS/jlfgHK4NXl6fmp/CYjoRjvkplRZAXWjjXx9fsXU0yOU/HXWI8PE45kl6puXiELAi8VRCDbuvW41LjXvoZe8W9ikkU+LEAC0KkyGuVx1Q++226pr3rbzLHQDs8BRniWquNUgijkZUmDafN+LK7cUQ/Mt/VKhta7cSev7+ClD/d09uFooUsB0DlqVbJFkq7PK0zn4xXNULV0sx4BRVKWspL+QW3xnFawqRxm8aIX+tjOLiLWRT8xWHFm2zsLnBSU/alHXzb7xt0AhIN/1+kAPi3o+hM+SA1z3FQYAq1rNBSJzkmArLoct8Nk8pOm/aaFsW9O0i8LOXzQC8rT5yT2JBwgUTMW4w+61SVCKa7wdtnElLm6zGRsMEe/y3xEXz47FhwiAATYCtT09hoUR5lORdx3Vee3Oh8djX0FzZslUwvz4MLZq8vjmPw/LkvW1zv78dNZycGRy9ibXblw/ZI73SuwXgcbTHvYwlir5+8MLNs93reSoSZz8YSDrdbZjItDwqqg8rcYHAQcd/wpSGdR8x4PhTDFcOnA7BJs95pSTDLwYul/svLka9ggNiB11Rn4UtTlm/Z3nm03xeeIt4OJxI41+PR7VDll/AmTwicmeBochWvTp67k5rJKV7OcEqHcFvRWkn8tpV2WhCo4yoty9nKmy1H3tj0Ob+m2kw0A/OlvTgLNpGAOzh9G4OTtzE8exMTztuovplP0kSlD4xKE9+mvik8/aA04Udtfrsl5vv+H8bFVz/hpt5kEHRG+AaDENELHNetmCp0QYHsqqvLpnTpQ7itVqzCsCrM15R4045ZAqd2fDNfxfGWnTz/J/+b/5Skv1b19OnTYvvrletdcIBatX+zIj7xSlrqCq6LJjUaDIhsjQf0SiIPXESiPfLqmi3hTTNrwolaoCzLYgipPBgUd80XIUL/TZekVXiWBT9FEw2yIoRwwsH2y9OjePnkSbx98yrm6rtb6kMtrrxQOV69fhO/+MUvlP46BRDBRqD5+P33PcCfHx/FLVtmgs5Ka9ysx89//ln8m//+z8QLwk8PbbGFz4AizaHwV69ea9I0o2Tqq43oSRjjnBl3LCJU+cC96ItVNgQuVmn9zqQmNHt7Euhkp468dQkQPuQBB3y0wySASRnnlhiIvXOwdhMvXr3wh0O8YzkcXJX+JUFG4a4b/UA+eKMhb5s5HpoX+HySTNJiJ0+4A3HNK+zWgG0/+kniW9zXaYADX/HlqXIryIKwBTHykJtzWtlOykOejie0esVHbp+lRYBR/Xa6PFO0HWMJtTw1xdmwIRO5+cwTVdqQ+vak++18sYVrLhC8vMMDjakf0nbOR5pCQY8aNWRKECtm9YOOFm60GtlbjyUe1McvJxcrSnW0m0pXJT/3GekqOFW3V4aL/yJcOEVQ1V/xK+HgzrrGX9qX4cIlEpQKQHjqkn+Rm8wLbVaNe+mnzmKdX9SqPrQvcBkziFciepcE036ZdxXGapkcQN74Oc1KesNjx4U4iQd5EF1aboVbl/TgkcC7cMnTOC55ugxy15XLLF+GY3I2+2uC37f9XE7V/W9XGKPQYjyqDF8ZgQfcRspCVTc11h/h/okcQbiUmjFNEfIyLeSadvwI2xTD83Kt7BMOdI9GZpIM9CDYzBeuZyUiEYidxnU0Zb+abca1GNVU8eYSaNhiHCM0KQ3PCPJW5Zpmu5xJk4jir3L6yg/mcSTG1lVH56uqWSne6PlXcfP2WB1CY/m9h74/qHX+VsIQb8Hdxujiykz1RjOt6WTus2Fn55exyZeBNDxCiPLXPNeEsCFhkqciOGPCV5acb9lkK1B5rbH9KKHpWjieI/SKQLYl1HC9Bg+gC4IPGvsppLyz0Sti3RazPoQxzeIVpyvc8Wn8q4tBdISH91RT7kIiQT1Uf3szi9cnL81QfA5FaTib4GcvxLAgUj/PIgFLgRaGfeeb4vpRd/kjONvUAMJFmut8par8WKD3geghl2CKWZ4dxUhC2Pj8KKZsCfGxBWQBDeSf7e48MpM2oBEZ36CWcb6u7M+fDdHsejM6j38/rr76kSZ5ogNx7BonIy1hVbj2poAVkBSudCaN2lnsnpzIi8fDEc49KlB+x5JSnJLECqbw9/7Xf/vC2LK+f71ejYtKxmVf+8EPUlHPrHcJ9sBVVYWxij9oir6Nhk8QlPkQ17GKXkEgA4IMzkx5MCSR6ZtA7NLKt676IoD5JQbs+KiP/eLHP4qf/NWfx+tnT+JIAtlEwsp2p+2vJs9Oj/2uJLTc0aD+wXuP4u/83u/56TPodz4aejvtWv2d57JOT8/iX/6//1W8fnMUfU3YJqKDqfjOaDTOrS3xk67Sch9WvmGoCaLKA95Y7YaXtTXhQvDyFT4SzGZTnoWaW2i7d/9evPf+43jw8IHYV9tn1Ibca6b6MFDTR32RrRBGHogFr1+/9FYrQldb/M7vMWqyyKoTfAnhzUIbPAkt3GOydWe3EGVBQDDp0ikYya5c/ZGEcmEMgNThS/RdJl6O5zS4ScMqWG47ylCR+VgKf8GRk7ahvdjNAN/ddsfCKnmzOIPw5Jv4OcYi/HCOlrckz09PNfF96/ckeYGg3dz0ahiT6a7qyxeoPBfFJb1+eN110QCtPFV0qEttkVuSUMlceOKslw/hF5rylrDpSHbiYZfGpMzYCbOmbqZKBWGklazMY51GCKh9YFWDK+NLOFp1Y/c5PCEr3QJLuNzY2U7MuPTJjF9Xw96Fo7ai7Ypbf2kiBNPODivhTo8dfyNKFpWddqL8JS67HESyUMWYIUC5Baj4DDGELcLlCUAHYgV4wrFwBG2oXeUpTCkO8RY6DSb73mYtafCkjuAXlduvaGClvQpci/Yo8BZpBae+h224Dk9dy1jzS51+f8vCWCoY5xAmwmqGcUvNsvxUOJGkv0LsJVg2IcXxaCXoGBTap+ilSpjqOBJAhCNRspgX228SyHyuwojbSOKmM3ilQWlk7/hM31pczddjRh4IPHwRqTCiWHBQGTkrcjOc+CAmn5ff3xaTVT4TyTgbmjW7C4mI+AhgOBz43cnNg/3Yf/ShGMF5bIgRrnMwfyKBQzNkPn1v9Hu+SwhhCwIcaUbK1gugbmY3MZFww1kHDorOVC6+ykHxjBHnxgi7HuZj53AqtkyZlGzv9MSRGn4WBOaJMAz2QgMBdVqThNluJ6OhzoDlq6WD/cN4PhhFr7kWj6+H0RDTZ9UMyZXD6uujSZwdS4gcrUdrbSduJo2YjdQhxmLYIzHDeTs+PPwo9jsHYoZNCeJilqpPEi8Cm4i+9C+fvwG+Bgm2ZycXJzE+O5ageubBayZhlTMcRqvKmYnsUEVEJ6wsyV7pKRV+xfoNypOBCmJFGYbBqrNd38Z8XQz50Q9i9PKnsXk7M52KdWZkqZpvpUkXT23BxAOVxaTTY3k3Ptp2xV/jIXe1a94tJg004mJTUsflV2B9F8LYV199VWxZlmqu6rvqrv9q3KUWkorCXSroOmJPJpz++OAmjD6LJg1+MEH6NIJYwkn4mKnJp9qBVJQ6Rm4RozNvghcpcas/E66WFBTxH/ql7KyOTa/O42d/IUHs+ZPczmebXxOIw709g2f7UE0YezvdePTwfnz4WILQwV5MRNtjad4r5JqYy4tLdc1m/Oxnn8V/96d/qgGhEeeXAw3iKrn6CAIS/Io3EFm9gpfMxTu9+kP/UV35YIlVr7YEwfOLC0/c9ncPLSRccCZNgsh9CWGPHj2MnfuH0d/bUZxRni1Tf2ZVm0lqbpsLDcLvVP3t2dMnPj/FV4R8PXhPadnW45wZuxvgSZGNq+VgnHg2DvWPoRFhCW/vWskfHLINmBSQcVnpsgAmOwJCXhfBQJdt4SFWbSYvx6NMTqMEbmHFaTGxww+34vNeLy8R9IUbys0KF+f3Xj17Fq+eP9eklSeMOK6iCWtbQpgEMJ4zym1JCZ6EISRQJtGrV5eUD+XNmjFkpDA2Ex44fF8FMnDpVTJp0638cgWMGuNnIBR0YSZfSQ9TPVbV1fHtlocQaQEBkx84o1x39Gr/gEaqcIs/aS0UC1dylriZLwi2EEQYcardwtWKW3aGYsqY/vBy8qP9kq+jE760xgzfri9ayPwUR/GoQ0YEZtWUgXQy0QaWdtCWfum/KKPgcdDfsGSHYhxH4H2OF4v85UmOVhV+CloJG2HQcYvhsJI3ZrqzPPZ3GTIvp5d2Bmj9q2EAW8RR4/9GCGMQBgM+QgplRFFPqqHirvzS30jAlZHs7wO3OISZRXhVcttVvLaa224oSTM+pM4WZL5XuSGds0yWrnMGTLJb3xNGDqOZBAc1KgIXx9shVIiY7cEJF8JyTkOdj0/H9/s7cS7455rxrt1yLmtTAhxfxkScbO/FWlcM897j2Gp34/KLX8WmhAyeP9kYSTBVWbh3rLu/H1cSkGbzcWzTcKrktbgRnX00n6i8YhINCG7N2xUM3Jw5GYn5eoYiQuPm7msJeFxex838OUPV7FXMqNeVkHTLmZGJl/xn5C08bQhmu5Uz3HXOxai+kPODw4M41iCw19uK+3zIUA61sv3L3WYxHcTgYujVQ5idsKowdQyVg/N4j+4/jvvNnoS4/EJ1eH2qunABJV+KasYvgXQ2YHA6jdH5ifVYg9xkxIHakVfGKtfKZta/QgcLVdww49q5FkpJkxpW9EpwoZRUq1aQIqWmFd1oRrvZis37H8fkxU/8tZ077Iqq+aYm2/wBk65fqmB3hU3cFDwUh86t+H67EqGSpQLgEE50GWnNtE4m/fe+g23KJ0+e3KnfsvyrbtTdsKpW3ZjU18v1hTHbv+CrqmSweBiTdoOPevYGYcSrYXVytcjjr9NAKso8hD4vP2etn0yyxMTTZRJfICUt5KsToEkJXoPT43jy+S/jUsLK/f1dH67nQDj97fzkRDCu476Er4cSYB4eHqo/rMVQ9H1xchQNwWmpzAMJQ1eDsep0G//6z/4svnzyzF9+j+lP4imqkLcQeZ+Ss6/0SxGQ77lC+Opxn9jBgQQTCYPiESenp76gmA88rvkKW7yjJQHt5OxUgsLMX5pzCTWrZgeUV4LjcDiOKR8BqQyswoEVePTZ6UmcqKxMkrrbLdetK1isMoF7+iar/1wDAT/AjwtTEVhY1ea/OAosU34s9Moud36pJxqQXqyIyeT8lle+5GBSyGpYfdKJcOAQxw93q81TWE5YeX/klnkT5eAMLmH9Xtd8jkkeE9hrTXq//OWv/JYkbYmbA/19zqQ2JXipQPAxnkjK88R8AaoyqS4o+Jp7dmbtVS9vN6pswkSuiK1oD9xS0CskBf0utMLwxb+qFASKf0lruladvGIk0wKMTNMrftLZn9LOuFb9Flru3KZElzAhNO01rkwLWWjsBY78+Oo+86YM6Uca+8nNAkmuhuGntiLsnfKrlvLHj3B/9VjyAZcWlqiP/IiYghupC39QPIcXu2ErAjwky1HSeqFG46PzhJbIjHJnXPxIVxXwwHPmW5TzMgj9K+6FmWXwNih5Eokw/aPPvdua2Z4un4GRPAV41G+EMIZiG2s0ljAjYpaLqrjAFNmMUP/sls6Bj0pnuIPT6YZ0sBUhWVWIbxFZ8LfYQlQng7FMxax48w1GznI+RGdhTJ3KyITfrV1HT9M4RLHzm7y2AYBGtxjQbDQTgxyJ2clXjdDaP4jbZieOuGxWghRCGk9AwYS4tLS7cxDr7Xbsi6GdS3iZPvsy1iQQzg7EpLc049KMriEYvFc5lKA0ePUmtptrcSiGeQEzFnO5kVDU7u5Eq0V5VRz5MXP280Viphww5ZZ4zk+tyQ4O2AJh25CnW5rbnehvCwcq75AtV/3GwgP1pa90t4UjEQsL7jCXTXGbBzs73iphe/PwZhrbI83KJUTxFSqrjrfj85hJ8Busi/G3W+aYMAO+Vm0L5we9vgauXJrnnN7zV8/i8vQipleTGF6MYqSByA+nz8UEN7oSclXm65HxjKKM2ep/jaoEYGIobb9Io9TufCt+NcgqHQki8zQ9Qgac3VJ5SH3d6MTG/gcxefYTz8YXMUsnhrlWerXCKJry017QluOoE5PetL2SzufFJooIw5NGZZUSUKme0+TXpmsSxv4Tx/t1qm9aGauqumtd3mU8y7jYCXsXT5kGzNgtKze1u55y5qAibzUGg5mZtzwqDML5oINVseqf7ZGwl7r6ocivKMFlIMmgxKed9C13MMUFJvHUJ3xeTAIN9+xxtc3g5DhO375WHxvH/k4vdjTwt5oNCyQTvngWsMP9PW958fUeW5xcldAW/exud2MgAenl85cq3mYMJAQhjA3Vl7gce0e8gM/vWdW6urrwKgvFdH2l9w/2Y0d981r9kpW1umrG5aTcJ8bX1PQl8IHw1d7WRGiiSZPqs6cJFl9V8lXy/uE9fyAwV76XmlyyhcNlpvBIbtvHbLc0iVNc6oAEwpmpvd0drxzNNbFl9RBhOLe7wCH4Eu8UPYMDeXtFTK0pnUKZ2KZXmHA7XOVEWMBkBcpMSW2QzZO4Z2ZEK3nLk3TKh25Cfyc/hEK2h9me3O3tWDjjLBjvbPIVJR8m8KXkudqNdLQL58C4uJVtTYTlRoOtTAl24qusFnoF3+VJoqQNfOZLuEaABp8phElDpyrwQhCj3MSVJk3qTA8VwhMx39HKoGry4l8VwqBxTPexolPoyb6AP5qdp2rH31rlMn7dRjWsatLXuApb2IEpPOPnNPTPDKswcnWLSXzJRxr+RgNRPgYWDDlcQ8oKTv0lo+xUWmRqq4U8WTK+PDBu1fPsQbkEW2Wp/Nz5y35r+YoylbVWwgmTrnhKYS3x58K5jErrvLFjISltnPHyQzLZXTgoj2xlgo+SxrCxC5C/cC9lq3ohEFJO3IQTT/bfGGHM23zqbGzPbViSrUhWlWtdUFSiIMNO/0qU4lcZukMNI8NK6CIeb0muS+iJ+dTL7JyzAFEmLmmvjMEDzIgpjwSUDT404GtCCRoqM9ddcCh+LObor2vWt2JG2dWhea7Ez2QEX2Gqjlut2G2os0uA6mowh1H1RJxPXx5LoBnF2f69OGvv+noMZmAUnYdi2cabiFFfi/k8eu+hV9bOmT1L0Gsc3vfVG7PLsQ/f3ophc1cNX0RSc7YcfO+LGOWUNPir/Fu9Tmxvb3u7cSbqnYzyjEm+86gZaKfjmSHlYDGIbVvy3+lppi/Ix1fDeNC+if5o6PbgC0cI8nYutyo7fvAoGo/fi8aDh7F1/3FsPnoUW/cexLVm7kPhaKjyXArSi1Nw31JxObOyFaNJS/jfjY8e/XF8cPAHsdf7QJ1TQtqUVYBsC1ibid9NDNHLLK1b2xZPWg23O2hGWoa/o4pfNYhjO/+kxR0Y2MgwO7AYbms/1rv34vrFz8XshGmSKF3VVUBAwWQpAxplIUt+NU013SdVTPLA80YC6S2NrTYyKMHMKmdHxs1qAFXL2n03K2OrwpgZS1G1vtVEmQHKvapX/atKOIQv2yntSzeDB0mgAAtjJT0mfZbJFIIH9treFe67miG/qoo5KfIjekGoSqCxg/hy0F4yWd0SgSsK57o0yZEwxnYk94nNhpdx8uqV+MEkDnb7wVuEHKDn7kDOJLHqwzM53CM4n4qmLzUJUR9mRQy+9/LpM7+l25ZQdSlh6s9/9CNNgrhEWvmrXzMBmqtvUSW23qAGVgF3+n0V7zqOECwkbPCB0kj9ktXpDz543xMhdd7Y29nzitrR0Vtfd7PVasTF4NL95PA+58b6gn8Tvf5O7Ozue/V9LFiT8VhCzKkvPaVvI7ggYNIh4X0+H9vt+mZ/+AX+kDCrUT73qjS0HWF5vkrtpTYjDi0BPFF6cRchgUGL1RLCVH/i+71I9TULzMoDf1+ZgRCjtkDo4mgH8cAPZ8E418bW5FPR7IUEX3YrWpsNf9l6JkGVs248FcXVFKyy7Wuy2FM9KA+T4naTPLmLi7NzKpf7nshBecNmaZr8UlKmimXBS3SEIFbPinGcxfGLCW1Cw8Dxf6qjH2FZYQVUjSK8aMJN92g7041QkoJrEUq+QRNv4VZy4tJXoPs8/8XYR7jiYaphHLfYl0JYjVc18Yum3RBYBZc47psWQCjnSnnRTksYWnbhtlRqJQ6JElPgloLXMAtqlN9J5Ed+JU+PRdCaJjbysJ9qmWYpB7CgMRVwkQY/x9fvxqyj+snALPZFnmlJmLLWx8QFTTojOt6Kpq4FhPOsq2q/McIYyGbmd6nZou/MosAqKCqrl5VSqUXMMkvFCCVtVlzamKDCNYyQdBM/gzM2/1iB6mjWtK2ZKV/mwcBY+fGXWOrcDc1sISxnZThials38aA5t9A0jbaRySHWpoTI46vLuJRQx5NJ15cnsTWfRKjjc7C2vaWOKeL4fK0XM/H0nZtJ/Oz8Ml5cSuBq9SXQcD5sEk0x6C3NgAcIi9v9aAjGOoxQwlzs3It2Z8c37482W7F28EiC2HnMTk9jQwxW88SYX43yYlPqKU67KSbA4f3ri6H9XOfOluN4GV3Chs9kTVlZ02xQDK3b76r+ef/QfMwWImfkxPyFB96ouzi9lOB5G/euJ2DFM2FWC/QvNmbjGDx7Htevn8eamPg6n8IPruK+mF5fwkVXTIcPANrqtLdK3xbT8x1FwGi14+CDj2ND9R6oHMPdvbg5+CCmvQcx6z6MaWM35httCZzIm3ztCiPOGTJCCrNjqMENLTpRd7Q92w+1sBS/jG8rnV5p4ImkuRV3xe4YamNw4zQaiKf994Q7QT/+SoKuym96S2W6lE4z3T6DyF/hN3kmkT+FmRmSl0ue4aKP68mNzyrCL/zVF0kMS27/w9Q/lBOyMvbrF8a+/PJLl2NVV3XXz4znjh/qm9y1KiiHgY8Shf5LP4R5MZChMk0OIghh2VfhD6BG/5TWDNbIWdWlEaxWM1Uq00DiuoDIwR58e9Cfqb+w5SWak9+1BK/ZeOgznWuaeA0vztVuIw/wjx4+8GoVV+UgLJArQzkTtLn6+dnRcVydnyrNhc8ssWrTU7ruwWG8Pj6Kv5AwNlEZuIqCu8EYFFnB97EAyinFZAuBZyiewWoZl8kizPBE0e7uTvS6mvwMBz4f6+MLEtIQwM6uJPRt57UXJ5RZgh5PK3F3IY/pc+UPaWcT1enqypfMUj6EKSadPpphRGuIVNob9UW6AAIxAhHboXX1mzbIla6cZOZWpbT6GnbK6zi256Wk5rkM0vIHrtOrL2BPd1hYQvDqdHjjU4Kg6kJ83/2m9rkUXr8SrZ6dnsUH73EX277vS+N6EeIgRCIwswqGAMZ5MLZ7KQ/1bDRYBaNMlAyyqAIVzZ/CEzskFsYUgRZBYPBZMcVDGOMcL2XxVjoxFNdwilkVNvJYVRZWsFBhlaP2Gejd8asfwoT88rZ8xiqEkBRw6A85fmU69yFMwfTX7rLrT5r+VcPhdZmW8OR98pdbgIo780wN7CyPP9QSw3I6lwOzlLvwOfdJ/aXgluH2IF4CUpziT5BU9vlSX2mvAEqzUJFlVLDLkWkok8umMVm+Ml3JEifTAl4FcJgFQdIV+MTLvGuemcciHC1VWxCRBO69aFEik28pE3kaJqXBtN1OwwLmb5AwlgimYLy/ZnKjwtTJofwjHA8VXj9XvNTJFUrDIZj2dqwkAlRFVkWqmbmEwK1WJ1qdbZ8luJXmji62MddgbuqwmV8OgGTUtFAmoU0CxWS9I8LdElMcxlDpJjcS1MQ4YERsYayJoXFWq3UzjavxPD6biYjGV7ExGcSXA+UnltTqdKMVYwtxLTHLC85THTwIlUjxxrGuDt3UbPssGoJ/GwfKf9zZjavbpoTIYXDVBmdKphuNuL0awqVVJs0KGNTFMLnQdUMcg0Pzmxq4NptijGJkqrhm0tOYclaLrS6VGcbf2W6KXvjqdC5GLyFOndF4VDk+vHcYJ2fMkmfxeF31Y/VNv5s5K28zrxbwmT9bwL65XH6bwvO+hLitcw1cEu42EaQ4T3fyJtoizL2WBhy1bbfdjB/eE+O8VH1Uj9b0Oi7efh6vnvyFBpQrXyi73n8QsfeBpMJP43b3g5i19/wG6IQtWT5woJ3EFHz3Ew2m9qKd4X2VAabhFhVjzK7OeOt9frgtHkrnjquqWxDDQ4pBb9R7TwLuQILzkRkYq2XAXNAZnQ07DKjCNOnKj/zAi+kdPyexQfnUXYUbwRMjX5dA7I5OQUtE18XuZOhmYBRYf3/vf/ubcYC/+ht/K+67/qgML/26MOz0pxFwg38GYMKpvyu/UEwEmhLiedILZHHWCRwyKGSbAFvKkjCwixvYd/Sij4NXmWrWdCN8SbMixqF9BDQ+aEHwutZEidv610TnklN82HtPQhhXSPC1FrAQ4hBYEGz4ao97wa45q6qycaE0qzZcYfPBhx/G9t5efCnhDGFsqrT79x/Sjd1f+zu96PW2JXxqIqPycE6U866c+WL7sa98uxKijEPh4vWrV14pY0Wch7y9SgvvGI/iQkLYQH17T/mxsnOiiWGXN32lWSHr9Lqxf3AQvf52PH/5LF69fhndTtPnrlgVVEfwah8T2CvVibNp8Ew+HthRGdgiRDhkwPWRD3gqtKr2Q5BLYS7PorqhpOE5bmfaQmF0I77cvBHeOQi/KRyAB7Z/u+KZfeWzw2oWgqV+w3I1xdHr175/7Z7K/+DePW/bHr99oyIL5wLa3mr4K1cutWUSiZC4zZ1spXz0aZdT5YBi6GfwcwSsfLEB4Ur+io4JB0HAgtciiHFj/gy+6/iEZl+1sAjAFYV/VdkXcvB2vuI7rLZA+BYgpGvfwTRfEn593Q/CjVLVwV9/zq9+yQouMRGyLBDTp7zSSH8kjfqS3cBF+E1hyd2FIgDApnBCeTw5pVzpTwa1jLLZv/Zngt+J43QIQgSg4HOkJY08S543fFQjGNkKGUb5VBHDQaCzUlp+mAk04efZM9op6+S0yoP6kl4WxydffzAle65UlXav5cfhqFhSmS8vnVaOK9MrbgiC1KloyuQtZsKKnfKqNNa/QcJYKs5sccs8A70r7splBamAkY3bYQSXEMcrSrRtl8NLWIlXyb7GxaTT05G2GpodsUQtJsM2AtuWnmmAKJULGB5U3bGAy8H+mQ/WX940Q/NlH/6EIfGkhM9raUB1owvKhgSFkWZrzauL6Fwd+7LX03Y3tuYb0ZhcxO6Lz6N5PYmJyvFi97EaVDPc2dgzwqYYHDfVTyX4jafj2NlSnRrbcaY8mmsp7GyISY5uxfwEP8aaqYppUeaNEdeGSKjUYOUvFue3YvjdaIqxQ5zDK75KzPNmMNY9MTA6McySx8J5PHxDQgFCFds2Dx4c+uHwkcK/t6by8eGAaiggGnAQLsWEVG/e0OPrTZhNg5n6gwcSFCVw6gcRMwBcja6EXRG8cMh1IfvMYFs7EmAFV3E6YrIX57+KwdkX0ZxdRGP4JuL0q7g5ehJx/jzmV+dikMJv71FsHH4Ss/4HMRBeN2dXZibKSTgw+m1a09n85RwlWY8Hn/6d6Dz+xFu/XGzp+4rUjj40L9CeyVE9MVkAMNsd7X4caxcSJOeXgkfHS8qqdLZgONJVuINpJp7SL8NNTct0xGecm2ogguFo9m9ic8KMQ3oLeCBRBTQ+VTTS/P3/+D/LOL9GhTBW67aqVuuAMuOTwo29DjrVH7UKZ8m48CvtZtyQRqboikE5B2cNfsIhs/tmo61+yowcXKmvrm0JK5wHFSyEcuXnbitf3/9jPGpgFNIQoiROyIkW3Bl+idPMXq1jwQMh7NrxEcoQvNYl0FwPr4T3UWw5Hh+/qG9xnYQmFyqgaRq48znHICYx5hUNznPJn2tsWJFhcKTfsZLFmS2OOHzx5Vfx5ZOnPh+z3Vd/EB1sqg/Cx2/X5pprqO5c+SLk7Ozuxt7hvpjnWlypPFeDgbc0OcDPAIVAyfaan/uzUCmepLCm+kdTk0hxBtPSRMLa5WDCPM4TtraEuw0JX61uM96ec4msaH0TQUUTH/WxDSGVluS6HCZh5MdqIX2HLz7ZNmT1iS83LYTciKfDHxQfu9+nVJnz3UbG1xQU6J8bhAk2XWtdE8fu4V7sie8cPn7oc7MHh4dxsCO/3q63R7viEx1NqLkn7OTtkSbB1wrf8Tajt1dvVUbxVm7L5yJvrqfgTBg44CtNzKQz4Uj9HlELIVFRTLe+b402piMqjiglrlVGhAUEMLYiucwVQYzVMbom/R1hrHZd01M1zYOEE/ulaaHVbuVZ/G/wU1wLXCqXeYIK5aMn+Mn0FRVKkwIVbs62ZZgM8TPwmbsaWyovz0gxpji93MDEDq5JA7AiLxRd+iBa4ck/GauFMwhAfghF+LsvQ3D4K51XmlH2Jw9WstQHhXMEJXp1BZ5CVxG+0P7UVm7aRGnzXjBgUF8IYznZIqzCw43dojTgFd9nbvXnfXHK6TqIfjXm8SSTy25NuP5MCNizLtSLcpjlSlczq6X6y8JiEunokxxck4+S3vmRn8srOzjDbtwp3W+aMEaleF9qKgYHXsCOC2zyBDGJgfw5gnz1U6vUQXPJ3BXH9iQmFFCqgk4cXkyibGzCfHryUweTQDCbigmbACA4EEdDy76S+/Y6Apk663pLjd4JXutmK4KlbIglxJBg5tyQfS4GviGGzNNFLNOLa0lwGET/+FlsXonZKe7ZzmGMJWh1xNw7N5NobfdiW/FYnRpcCysIaBzw1yA0VTk1BTSzmEmIY7a9PrzMA7K7vdhS+Zm5rTcliGkmyBMh65pV7tzf9cHfZrsZYxiw4vUloEHUHMb1xwyq57XcrARB2twcziyPmS9nKN5qRv9RjKM5kRgKHuH2GnQSpzc+aEz8mRh1Q4Lizv5+3F6OVRq1h/xhWoPJQDgVFoWoje1WPPrw+7E1EpNTnRAG5+oMT45/6stkvYKpTuwBWMyEs3itm2FsDd/G5tmzuD156lWAtYd/GBMNxOsS3Ni64EBolk9trPaznfYT/IOPfxj7f/gfxpMnX4l5szW7FVdczNug0zjWUhWPkWBP+x/HxumvoqN292wHuI5NB5cdBqA2oPkNw0mTVlE0m+MQiIwnWgAO9IJAwPUZG5wVwx9JgkYEHqbggFenlQIiV5kgjP3D/+N/np6/RvXFF1/YrP3L/aIWRqq6V3VVd/3ejeseL4U98ZS1k5ab81oeGDXgIQaQxnfUSaBIOMngWKWWQ12uxNePFWzg0k/AcbZWIpVWAcHQG/Ht5g87eLZWg6FZHaMvI2SJRrm/TzMQ8R7lItrnq2AP3IrDRARBhbNXbFVxLpXD9Y0tCQTb+UW3BTGkHymuoVBB/cLFm7cn8cWzpxrM19T/O9FWfK9qCW3QJisYvCXY3mpq8rQfTQl/E5WHew5RrHyxNQntkKalidiN+I8/OpB7t9+P+/fvRb/fi9Oz83j15oiqqY7rcXx6ogmYBJdeO1rthvoEl14PRNe38fDBPdV5aqGSL9Gp04ZGeV74ALFcps0OgYVQtRn9CT7jR8SFdPgoZffgj3ChwnkQVHIPkIpDe1FI+m5LAuHBw3vx6R/8IH74R38Y73/wvu9HO+DIQ2fbOECYY/LbF4668uNLSvJnN4Cri8ZjTc6E0y22NUUvXE3BShiauNwdlgJMGewhTZCEAU3I9LaivLDj4y8mpfFHEGPyCa6hzNQZT8RkZfrmB1xpBnbCgJdm4gGT8MqnjBtMaeOqhCFbeLWr0D28mskIQncdqxgPqQtxyY4JDXVE4EqhSlkAs2jSEDHzcPYLXQU92tmwHZcAxS2RbOIu2lUhHmH2w74K2H+Ga1g47IFbJtip0SWa1+1PYADL/MJxEcwyImUAh6wm1vKkAFgA2V3KI2emyzHdsEo6tzM8x17AS7N42F71qlq64DcqM/Dli7lILzdld1vbnuZvnDAGFpC4+VqQQ+hGCIUW0TuwtM4q4+YPVYWxqugMqwgj9SKyVOI+EQXMZMSyqrO2trvOymdCpAkgHsvX/jpFHobkdBGdjXnsbSKUcLGgGKMYsN+BhAFsSRASYz4fi3mxHKROAYPmLFd7ehXN8+PYlCDjw4bqxae792Jrvu6PBcZiWlw6eKAgzkkNNejywPdmp6eyRHQlNE0nQzEcDRIwJtk3JfBs7O/FWnsr1gaj2Nzvx7pmj2Llsbm3o/SaCWr23tlu+1zI2cmpB/nH7z9UnDUxz05wdxoCz0DlYGDhq8uuGONwNIu9nV7cu9eVMDaPx/Nx9MTw3PmYHZePIFh5YjvGA5IGmx3NZrvdHQljXCopJaQxk7wYSXBkhqWy7bz/fuxt78falQY47hDT7HYYo/jq7S88qOVMb9meNAq4Z1CDyTDTbc/PY3byLGb7H8VgXQPe8EgDluKpIy+SWQmO4j/8/b8Xn3/+eVw9/ywas6vo7uz7Kg1WS71tLgVdoGhxuunFbStm7XvRPv8immofCMv1lzINkRFJ1L5sNZobkhK3bDBN/JmxydtM3OHYlZ4tSgYqprJOr0ESCKgKv9Iqaa/Z0tRAC37+/v/+1y+M/epXv3IZat9B13JVP0xU9bvrvmtPtYxrLWwthDJFw0o+IIqZL/2wKSGDy0l9VYv8jErg6IdgwpNetI2PHAimjw4ojgc2t0YKZ+54Czd2aYDJzld+SihhZeoVJYQtjfaxNhulqbjwiauLEwlAEwkgDPyaBEh481u2EtYmKgcH2RFOttvbsd3lXVxNsFQOPtKBGcFb5sqKy5q5euLZ85fe7kKYaWnShOCwK+GJKyUQKg52uSZDApX644MHDyxccXb1XGk5LwX9QhN8AcnK4Y4mUT1NihotcHEbZ2dncXxy4ifSWMWfqb9RVT4GODk7jrdvX0vIk6ArIazZ3PA9ZP/e3/27yvOB0KG+OeJogyZ7gsWPSQgCkAVBCaY8OYfg5ctVVa5OpxntNtupCHk8YyamJl7IBNEis1chNOzCnxTOF6SPP3w/vvfJxzbb4mmbguOrMFRQVhYnk5H6y9SrPhwx4czXtoRXjrpcXl4YNjghX1YrO622BVhWw9j1qEJYHjWo/V2wEMDpr3JUAUvYSbv8qH9uQSYfQ1BWkMIx+CU1iTgWCis0yMAOHIdXBX2X/Ks9hZfsT9mW2dcoq4Uv2a3Vxg6nT9Rw4bEKUF45U5xMm/2GOPJweSocwuCJ1c0Qm+VQXwEW4biVBk1bVbvd0ozB1W0YxUQgchwp3Cic9ipwFOB86uS25pswEMZY5cZN+bK9vDBieOSV+eXkG9gJI+tCZfQnM8+HkZ89SmQZKwo48OMMWIn3b9GATXtdAcvyowms9XGs6l/Ub54wprItVsfUqbmRmvJS5KwQlooY/BiU+KUizmJgWPxqbMgfcYP08Np3usNCOb6YO2enuPgQ5sSBW2KbsKR9BQbMxPlgcIDyJvobU828mjHabPtC1m0xX/KdTmZxpdkmXRBGwm3ZbGkwu7LkLuYd42meEeDaBBWx2doMbvnZX5tFt7kVF5IJtzT4tMRUeiy/i4k2N8XQb6YxmlzHRksDEwk1GEjyiQ0JYlsS/rbuHfoy2k0JXv2HD2J+ce5bubtizkwq2NbY6h/E4W7PdeTUFZ9pb63fBHIR31MSxlNE01suTGzG731vP351No9Ha+PYGV4aabyEf1s+G+dG/rGYNbd6I1DsStDqaNC8HggHyoQtoomE7aFmrWYAGmjuf/rDaFyJsY34UlRCmpj4yfwsnrz93PBF2mackIGRnpjHIj8BlRUBp63BY3b+Jia9xxLIurE2PI0WS4XLhO5o8P7tw4fx9MkXcf7meez12rHV6sWFBiIzs4yakd3ZYdKzONm6LwFT7TJ767ZjzCZs2bFW0tL5YASmY3kSF74Ns69pPO0isuIgKwh//ihAcVPogqbFvg0/6Zsy8YEBj7pz/Qk4JPS7EMbqyljtC+5r0ot+53KWuhWzhld3Ve/aE1baV3X6eaZPLTHV9xDEmhy4LoMLDDqzyLyYRDHpQTBiyxqV58kqTNmdwIiWfwphrIQZEKtI+DMoS4ir25X2x0QYk4DGTjIrZFfqVwgg3HqPAMDqpVfxBANBhnLeuyeBSTwl6XgtLq6u4kgCEWeReGuVJ78Y9M8vLuPy6jKmEjhYEYcmupo8HWgyxReZfM24t9v3F9EIGqxgMVjCq1gNYsUKQhMmPBizldeREKgS+RA/AtNEQkx/l/Nhc+FqrolZ33XnwP92t6P8L+LV6+eu7/37hzFQWe/dO4iHjx/FwcGhL45GEEYQpZ9zLtarTxKmwAMTKG9JCiZzi7YErFYHoUwTQb7mZPtSwhptg7DWEH9pb0sI2+nH7t6et2wfPHoQ++JfW33uWFPzqPy3mqjNxLOmKufw8jJGl+cx1cSP82JM7LYlcFKnM7UH7n6/b3wjkHtVjBUW0RoCTV1RggTAHe2V11SkoMXPwpc0JvSDmV9IZtsSl/SGIXexur8agvxQ/E+qIwyfVKbFFW1BRGb2L/qZ+J40NO6PC6Rddky0SHtRF7tJV9ILJGOC+w5u2f1Bgswq7GQ+mcbCSoln4Qu+IvdqvFq2RdwV+6qf3TXfYl9qVVV1q+EUNPMxQrJ8RLIf7cV1NQhjuAlHGFPFzTPwy3i4wS1xgOl8pYHjYd9xMyzjylPWqrKl5KW8axvWOi3L/tdrALqsXgAofiXPhbuYq/o3TxgriiXksWb7LP2rnIvCo4zABQaX/quq+i3SuENIy1nY8TKO/6da9YO5b7X4smjHHYFPvJkREccdQ8zVAwGNJT8LZCLe3voodrfYZtqOvS0xBjFuz3jFQHm7csgZLHX8nhjRTBTCrJU7cVRIdRQJCGKkrY3raElg2746i92G+H6zF5ezzXiwuy1Z6yYat3N/9Xk2mkWDe8xUhg0JT3wFxQqaiZknPQ76MVcY96A1dg9jp7PlB7W3xAz9xIkquoFA1+5JiKFeXGi75lvvOdcxnsguprazs+1419fMum7ivf2d+OxoGDsSBA+HZ1492Nrhi9SpD/Svi9Fynw9v5MGg9j/+OJpcADNkFpz45ekm3y0nx/bD+3Fw73HcHF8EjxOvAWe7FV+efB5vT585vlik43qZWe5sztKOxr9MgMuvQ9yLlzFo7Me48yiuL95Gt0EHg3YEg3/C02w2jvvf+yjOJSS2d/bi/Pg45ioT512I7XwQAQQb4flifBOn259E6/JJ7Dc4JShIQqL7NPkvFOWRJxm5eKVzC7fi4cWTtGlFOWyGkKa0Gr1EIlIKFHx/WFCYugcEEdRcDY0fPEiJPJD8w//Df+E4v06FMFaZkxnpHfVtjAu1an5dA0s4Z4Il91IZc7SCEsIYWXlC4GGrXp1DCpyAK+hXib1iwjUODPR8Fc3AYjDCvc9PIekWuAhhVRCT9CAtfw+wrIphlXjE6pX6KK9mpIA20wSHx8DHylN1luADfTRbDQ36ov3ZVAO44goXuaW8ltcuSHjhfBgrV3wFyZd+lxIkfO5rf0+ANiQMjVyP+/cf+BLXHQQmTeS4t6wpgYUVNt6M5doGth3pa6II0xrCB5orLgYS5g4O9r0VyVEBVlGHEtRGk6Emg7Po9buuP+e7WCEnT1YOR6OrePn6RexqAsaEeKCJEUcOWGVj+4+4O4f7cU/l25VA2JaARd1ZCbzhS1MLKXzkoLLJn8uc82tL8XMJrxZmFYcm4ab7Hh8eqJ4IjH7/UXZflSG93WE7V+2uOs9VlvNXr+Pt06fx+snTePviRbyS+Vz0ePzmVZyqzqfC67r4LAf9uf2eD7HYFiY/BBrYAudeNbyrPCqAFG4LW5rUQEd8NW7KwE92JqarAhmbG5jyNuXIWlSmg0wFEqJQuOIVf0gO74yDLVWl9dpvVu3QrYZ0u31AX2X2NiNhgi/v9CeO/FK4lOn4CpM/Qq/HKMdXP8OEh5JYyv0NfyVAcM/VMfpS5ucyyA/6QLts4k/KxnFJiz/oXAo6VALgadofu3SeCcNf/4pOYSr1omwLP4QaFj7ynFkKZ8J7Zqh4dMAUwshgkXYRjqlAtOPliprjVv+icXNGD1g5VuBf4NQK3NHwI9sX8cgbv8SV59qUAUU+NtJEGfcK/40VxlxYNTCP20r2cIGpCJ3AdXbl/VfqhydM3GT/bmVlr5qeYFN/3vJKCG5cbO4omO5hmYZDd62OZoFictcqDzNAoVtZJsH6cD+EK4S6gytoe20WBzw0vtGMm/WOwptKkwz+SgxtW4IQe+DXSkO+MC1mbzCSawljm5q93g4uoilG1hbzG7R2Y7reiP1NcRMOv0pIHbDtqXhcMslFhZ1NlVlwZ2K4Ql1saSbdFaOcXg7ihrMR+wcuF2WG2FhAY+tjbYOnPrZiQ7NYGPNMAwxwOWMykb4+Oo1Gt+3Vu9s1Mbq169jZ7voNztvBKN4fnce6Bi9WiRCkmMWvM8MXnIEGrLkyO/zo49hEeOB8mXDLz5+fjy5U/9s4+PT7oblyrF+q7rSPfK+F39dnR2pWniw5iG5zP5qbnRjNrjxWcp4KGjdtCEa2YFEK4MqM9eHbGG7uxbQnQe/yjfCewTQvOJhJ8FoTLnc0YF2cvI1rlZcbvQEp0KmgAVrvdhZvbzUwqiz7wy8FPw8+kzdZm66KWtCblGkJgNCG2p/oJi8pooALYnJO7Ppa6WB0+hHHJoMDyUinODzmjjAGvVvIEFzjXOn+wX/8618Z42oL0zq0W+pZ6/pt9m9S4OXr4YkY/D0Igx3Fc1z9PEAoX593lK4rTyhWYHJ17MYCBCtEfGG4qcGIxgYatOKmwK54uTKWwhhuf8giPwQwb09SHk+UOCcm2r2RQMaVnnw5zKsQMkkHTC4I5aqF/MpRAgijtSAzGRuzWqV+SluyasUqzunpabx++8Z0+NEnH3ulGnRcXVx6UHzv8SOvED04OHSdSO9jE0ymFI7gx8A2leA3loDFF41sHUJmh/cO49PvfxqPHz/06iBbdlPuPVTZ2tyev9OL+48eeNuULVS+mHYc8TfyRoilb5HXlQQcn8VU2Y81WWGisq9ysarFhagHEtoODg/UbzY1YRXfQCAzzvhKkZ4jfMo9Vz4TruCQEIpwpeE1toQ4rpfIp4YkOCvTvN6CM6vA47LZ43j25Vfxxc9/EZ//5Kc2X3zxNN48ex5HL1/F1bkmcGorvqZm92F7bzcOHtz3LsNA+dHWFkoEG1M1W9CdaUuTQlOB21121RsTX/l4MJWYWQQwfApNyp90zsBmgSnTgz3hJcz0m+SQ/jI85qxo3FVV92IFDDzKhM4sTCKwEEfAwDBtRViu6KNxpz/pHZc42GXi1j95pB8J7FSbOh9rRQEeweRvmkDwUVxr+dVySVvgEBBMYPEvwzNN8UzT8fCubv5SCMJtQavkgeaYiQaqRR4Uqq5apdClNNiBIafhOM/MkjZ0e5W8lmE1zxW7lDky8F2OhI/9mzT1wyxA0o52OuIkLJTxZFjFDztlkfqNFcZQEBE3ycMEhaZSCZVflIxGgMEfhiSf8lMj4cSHyCtmohjGWZBgnSEZ5+vxK6NHGm+082tLluARmNzByFHlRCDjYlWWkJ1eJmcb+hJZehokZxIi+LoLpkqH4TD8WHLVBsxbwh0Mgi+PGARgfAwEEFWPWb30xXpbpbmJ9mygGd/MX3HNYJCTERKVSnGruEovBjYdDsVQcybe1kA0PuXDAJb/e9HeZMBajyGH1FXetc2mysMD4JsSBKYqA0Ij9b4RfOWjet1QHtWBQW0+kyk75edQ8OnJWXw0PffXnF4BEJMlLV+EccXF2dlp3Kr8hx9+GBsD7ivTjNnovdUAMrEwttlpx+Enn8TmhQSxqXCqssO8hSkNXGz1Pox++3G8//D34373gRjueQwmmgHrV+k+W0//AV7aj6brMCscSCDb2I7JzvckkL2MrsdmOlDSANd6zAfnsaUBlzaotICwl5AT5OlkGuf9P4jNq2fxYIOvQgXICtokTsZFVdjCpOqjAhaadKGkPFBbyJLJn4QtjZlWpPPHHwhgmBosctaeh9ItRKgNNiQ0slILjGTWa/H3/6Nf/9eUrIzV+q1q1F03tFZV9atqNV7al3HSFAKKAm1qbdFeXuzKaheCWYZJKKUPCgdMlBDCXr586RWBfT4aAa5/mPAN/Vca0ylDK3byUt/joL5jIu0TNxvB25Kch2SlnutTphLEZpMrC28paEyLAKI/wWGri4yBDc3zzNGb16997QIaYYxtQgQlVsTee+89D/SsYJ2dHMdYfRj+h6DC9QxcHntxemyex9knJoYc2GcA4shDCg6a0KlPcx6NevPuJE8jsW3KdiLXWFzwpbXwdF9hnO969eZ1XF1dqg7XvjLj4YMH8ejBPfOPM9+4P7UQxjNEF6dn4nsz9fnjGFwNve3JdiOrdLzfyGpWv9tRWnY2JPxI0/pVi5P4bBcXrHLRLQQ/G0lAG440KZoEt/fbrXIONIHkq8hnXz2JJ7/6Mp5+8VW8fPI0zl4fxVD87Ea8iUl6W/yr3+tHZ2c3GmzZ7vTj/vvvxb33HvuJvfMLTRTVhj6sr3ZHGKNJaX9rrCYMUYLcHrTVj4iCOMaWMbF8l5h00oriWOtnUpJLJmC8qiITxzvhRVWa9yqV3CkwqVyY0il8pdu60DXCF2OLBS2l80qU7QnLQlgNV56k05+1bwSgfI6T/Yy4FmyIV3gH2vVQhNQuoO2EWdjBE38pC2SOlPCcAD+VtfrD+2o/TZh3NNiiQpnxoi0yX/JTWkxaDnsVfNAuT2oLZtJuP8MSHMFA08vzg4mMU+uU7URc8k1z4aYg+st8sgwsnuTW4zJftP4pqiOnG3M9t1TtjQKujczb7kySbqnfaGEMwoIA8t4xmGb15z/Vz8pmnVyrUlHQX3wxVpR97ZkBGQ8LBGfDmsZYIpp4qPXYarai0+Ws1YYYEwxY3VXlAqa3CFhhUlgSutJKd9bG0dtQ3M1tCTccIJUAJv+RGlnNmVtTWxLexEh5TuNWzJ4lfRhuS8QMcSGAbY7OvH0nCSVml1exrkEHHG1pUJ5dXXm2yRNHlPZWgllbTI+FoIkGEe7n4h4dVsMYVMaDS28BaP4v5ilBUoM7dTTOZfqLMA1I12ttAZiY4TbbjZjebGgAmktA2vBt/C+PzuPT+UU0NABZwNAgxJuXlpbF7E/OjuJmUzNpDTabQ/AFmyMv1V9C0PnlmS+53H/0XqydsEqlEgl3zDamKgP3A2Hf1yz+oN+NzTHw1+L46pU6ENsgajfazKXPdkhbUXIjkG6O38YgWjHsvR/XV0fR8eemCMfCLj2V9iL6SuoCUSBYfZjHq8bjuNnajvuDL/zJPHhyPa2IB4x0K1vr2qeTRhwk/ItBsLplIUt0LZR47HdS+c9FA6q7b/1nhi7NyhfKTFR0QTn5wMFXp8BMOa+nPvL3/3ff3QF+l6VUqg44xv+KNpNe8V+1r+pv8k+EYKamnRHEOCfFvVpuO8WzQCo7h/jn6gPPnj2N09MTCzh8ZUgfW0AxtzeWS9sLf+CX8ot+vQXpeMUkniZfajD9cQVMvqFK/2GViq97iYdg4y1DlccDLD8YsvJDgGFVC5hcacGD4QyWnNukLqx+7UogowxMsC54T3I8ct4QB49d8xEPh+8fPXwYXQk8XCjL1RN8NcYhdSaDbc6F8eWlJo3wIpQnkRJc28IXgt9wOvbZz8cSVi7FQ05OTlROTdwkTO3t7noS+Prlc9/JxWp3R2nn4r+jS97XlSAoPnJ+eh4/+8lP4vnT5574dcRrWCGbjDSp0SSV6314YJttVN6MpOxsFXL/Wp+zYqo79E1dp2PxMuGHlUO2bi/OL+JS+lz6+PjUq2ID2VnVC/FJvkAHH9tN8bKtlsqtCTIfW3HmrNuPQ9Xr3gcfRFdCJYIUHydxlYimWKqb8AGPcvssaZYGhIbmCNHCuZ80kgDux73dBVnFRxiTXdER2kjKfWOY9F/Dkha1WPNLwWBFKVMokZ+FL/+gl6QZhCb7Cz+c68oPC/BH2Mq+lkKbJh9On/682YmgsCFtWMqnTs6AmXeHyV9CUvqrKAhI0o6D0Ax8haHymADlLf1Q4dhrOe0nd1W4LcxgL3C82iM/whD2LLjd1cpn8cWiyqn/yctkNy8VLMqJHeFGgVlO6o4pLaJUOlcIINKZL2lzG5O80rQwZbu08qplRhW2UCwKI560t0hpJ5ehpK15FA2cFOYqXAAlbo0rdFEVdzaLyvRK8ZssjKFYLh+LgfHJ+EK5gphUvliL3crB9pU/jYW9KgKXbpBil72LvzqV7XQwKcdZTSPC4GtLbqqeS7Dx4f4S11uNdCIEMzUkRAMRNGMe+5vD6Ippzjd6EnIkAEng4ovK2TwfCWbbi5VAN6LS8wAvF6Ka4YpxbbJlOdeAoJkjjMavBIi5sXJ4C2PTQMQKV1d+sgoej3PXu27WfXCWPGZjtkvmXjm7pYwqdz4zIkFLTGcy5hJLZKl53KiuTS6ZVDgDzxyiFKNqN9bj4X4vjs5H8Xh2EZ3SPuCJOovDWhi7mkhIFKPsHR56ZcxfEZbBb6L6nI8u494nH8VOpx/BCwEaqEAlz1QhDK5NNWO/L2Ht8f1YG048IIxvxvHq7ImY4cx5waxKK77TTijctAy3hjcnpzFa68Ro5/sxvLqM5s1IAwNx6OC0sZo8Uy1oQiw4JkLm67W9mPY/iJ3jH8VhRwElfk1BbzIMwyMgmQxMGWU/H7gXs1edqnBVgFjBKFGksC94VN2IY6YE05RGAKvXNrB1wGH/Un0JY9/typjbuqjqtxqGuRpWVXWvauqDyWQmdcLGD1gM6B1NIDoSOmDmCKmr+XMdC08C/fSnP5Ww8TD2JeB40HIc5VF/QjCawSWxTVtgCp8M1orjUZjy0HdYmddALYJWvxAvuqHP04fUD1pt9Xn6+K37q69e4e4u9SUGR1Y0ESTob1y9QNmJQzoEJOpEuXuUVXVGCOMWf1baWA3j+ADX5HBZLFuDu7sS2vRD0Lz34GFsqG+V8UP40oBFWaAV1Y0LYa+uBj6bhkCxobwO1Zcef/Ce8PNevPe99+OTTz4WzF1/BWotoZG+0Rdv66usk8HIk0VEzg1JFwiTLcFBoPxKdPD65QvzZjCMwAkvFMeJ7baEx46ETcHgdROu8qAu4JOJHme58iwd261tlxk+iQCD0EP4ZCLBV32FM3bgmjbb7vRid2dX8Pqx1Wj7y+91CXusvvfuPYj7H34YuxJYN/u94P3hCwnlfqQdvqp8EY5z1YKjGvBGCcD0J5n5riQ9Xi0tfNVD+hawFFYP7CeloIrAJV2awHZTU/FwPLWFaRgtT3CFWQ/cp5CzXPlarIih6fPyAxysAJ0CGf5ZCrlkZ1KNECc44BI6qOllKrr7jKwuCxYLGkontLus+Hu8VDx4Ta6okSb9MSl8ClLkjDCFX7rxd7jTlDzxkr0KJqt6kSfpVI6Eg8ZeyiZTFv1pgl/troTClBkf+uFeClmOkm1SYOPt/IhjN3Zp4pY8SQROnbjArIgRF3A7erWsNqy0y2kbZclftmeO+1mXhFntvjOu+leFXX+/8cIYReYW6xGrY3RIKlL8zSz5lcq5AfBfMSEY13vpsVBGCH+OkAqmZagiPmamBCHIENF28pRFrC0aYiKdXt+CFwdUfeGpOEl2DDFlMR+0ZzdmNmvR4+vDxsxCUXNrO2YJVMKO4kngmakRO6UDkStL/VyHcaPBl47W4uD+fOKOQkdgi4RzGYhUMAZfokh5xFAbEpj8TJMEm8m6ZqkSSNoS1sYKo34u21ZTnVuCWxMIKYyxCiAvn9fgrNum6onia6d1tgdkb7U1y5VwN5jdxs7wLHZmI+OOOkK412LWMIvhVLNl+fT292NrKAFCjC+35sQEha8LhT/8wQ+iPRLex4qJMKZwb3OKqzUFa/ej9+JGM/ObicLFEI8Gr+LV6RPVIbd8PWuUdqEFerU9sWd75V1ErcmxB7px9/243Nzx6tvtbKgZd26f0vrM2idi3gMJTxfrvXjbehTzxn7snP00HrQUX3kCz5mRh+0o1V9tYRtMTRhVNT0AsNrlLx99QJ+BU+0rmsAkPXRFZMMiAuV2x8Va4ggvPismu5mt6uNzrc5LMZT+u1gZ+6ZtSlQ1k/mmXg27Gw+16odwhappQa9S2YSmc2DfFs64NoIVw9xS5CMa0nM+6C/+4s/9peDv//7vGQYTjsQfitj6gS63XdEecDUEC3/rSAIyoQEEZoQwVsAkFag1NaAjjMk+Fd3yFas/9FDe9B4GQ0wzaUCL1rmnkBUgLt1ECJmKjwGXPpmDba6AdCQ8zCWAnBy9jXMJEFy9cO9gX/XtKH8JJGyTWji4jk63K/D53M4NfV3l4OwXq4WtdscCK3jyl5YthD/u+tqK3f2D+PDjj+P9730QB/cO473Hj/214mMJLz3FJV++CEXwaor2xB1iUwPLvf1DCVZd0e8sRlcIixe+z+v9h48sMFLmX3728xicnwuOBEwmbsJFW3XM82fidewoKG6HLyp5xxYhU3im/03F2xCIuCaDic/VaBQj+ADNpLKw6seVFP3ejgRHcALPbfiKn/Z2LzZFF20JqQcfPI6DR+9F53BP/KPh+xSH52dxqvJxYfWG8hJlCS58Uy0ut7+ahO6gP7WReWqSnHFNW6UAph+kIf9VTbo0RFeawdoPBYwCx/2AtsYUbUjMEF5VEuzQjHh5CvQZJ3VZGVP7up9DY/aXWcYSYCHkJA3xRXFJi0la2Zm8yUh+obi1LAikuQIFLyn+hqmik86wMz+vXpFWfgvhhSo6stxKn2nlJtz50yeBVeNnmlXlcGt4N/ljVncGJlxXwCZucGo/R17aHRcPBrRS5kXemMJl1p06Jc81H6a+0vq31MpkweP5k66r6nfVAnekq+Uo2nlbF/VOmEHbjyi/8cIYCqJk3YXVIbpSLTzVWTSK/yf6vMVgLzoXcaiyQ/BcKBDCrMcDYVEJIZVQ7Dior5nWIlAxupaYw3Z/F3oR4+RciRi2OjGNhMDDNoEFM9VDrS9GdxOHm+M42GQrkktit334l04qcSj6inNbOlNfQttEzJZ6NLYULubOc0uUjdueuU2Zu66u5R9iOO2OBC8JhiyNdcT0WBmDGZKeLU+wdStm6nMnlamJONnOMTEpHliBwfNRAo+b8xiwAp1mTQMR12uw9N2ifir7xuA87o0v4F5OL3AezGAkrMoNp6No93rRnAoybVNwzhdvEzGwhxzuv5gIthKyolbwxscArYcHPhM3P7oQfrlkYxZPjn8ep5evUggFTzLpYG6X0j6UY0HoOIqdc339tZFv8h+L6w67H8aw9SAuohVns/W4vNXgsr4bV9sfxoUEttlmN9aHp3Fv+CQOWoJIIxd4hqx/bHMuKKgwgYwifwSoqWbZfLwgnBrFDk+NcGk6LQAQaBE0DBBDaRZupTXjFO7ZlsST+mYfwPm3I4yhVs0Fc7oTvmqv5qo/OKgzaOwMknLZj9WjDvdraUBHUWXicSDdzFV4Y0Xsl59/Hj/44fd95xZf4+HvgYUGEVDjmzYC50rLbf7ehpQ/ghirtsRjkmPuoDAO6XOAf+1WkxT5X2viMZawQBlYDYMikv8nXVu5/Gp3hA0J/z4DKdimf9GQYnrwp+ysXPG1JFtqz589lcBzKQFoP+4/emQecCIhicHX52dVKrYnuYNsJLiIF4LqazGaEpDanOOSne3KfQko9w7v++vERrMtfPRjb2/fq2tohByOAXBOEkGX7dSjt2+9Lbmt+I1N8YgNVrPUBhAfbaEfzzbx1SN1ZhLK5diccWObcsKLGsIp27YI0Kz8Meij6aeUixUrC46UU23EihQ8a8CqnHAxkObuNXYHOO/Gm5k8Yt5s93z29VplmgnvDR405+qL9z+IR9//NA5l8mTchuBbgBC+r46P4+L1m9iEP0qYlLfZFKuGrL7R1p5My4RX+VwYbSP7Kq+Cf6LlsdC125mGFU8W64yLmbTswV6mV8IUE3tdvbIQpfAUnhQHOyZhtoM3aWjY/tWdcInvjy3ghQrPvpf54We706hocnvVVPFyO5D41AN7aiV7100daWjqqfhEcH1L/qtx0Q4v/tjdG2SCr3qwfoHLlTBnJPjsAqV/psdkBTO/Tkx4S5iraYnvKAlbYdS9ltVa9eBHPij+u22LVveHHEwf9N0MJ63qRi8HBulWYa5qhVX+hbaH46dpVeNKVzw4rtRvvDAGSigqAsVQzIcZKoWH2KhtrQix0iYlS7WXWPqXtlVV06ZKWHTEbAC0GrioJYxUGV7d6iQSalrdnbwpGwbFNoYYMAMqjIgO45Uo1YPOBEPmioqDxjj6LTpUO7bWWxKsxBzUoL55W/GaIrKp3Dye26ChYb0qF18irWmA4G3JliiIrdw1wetK2OAwPUvsnBnbLIOVhTUxH55l0VTd9xJxeJ/ZPfnxjhydX4U2NdKZbjV74utKDzIiRma1mmCbIfLIuPqzGH4/Jlen8eDqTAOXKkudFR9Gyk3o5C22p5mxmDsSNWgsPYqvuOaNNQ0Yj2L9cpwEr7S+cw3cS+hoPjiI2cll+MZzlWc4OY9fvf6RBqZyqzaMCLy4LdxKqUoe+Lit0tcmh/dbStePq9i8einYo7hZZ6tDg3ejT4zYmp5F+/Jp7E1exv11CZMSllc7DiqhOgdnh1PFF20Kd7L4PJjPhskTnJLWWn/wDpliF2b86Vn9YXSCSiPL7VmttfyFk8zHOcrE4T+r72KbkueQzIhdzjQpD2b1Q6363dU13aqGXrxVDrpES5zToa4tDfys9nBJKnyAM1KsZAmzpi8ELASWv/qrv1S8dvzgBz/wA92sJnNw28Ky8aXyZMnkRgibidxn+SVwcmCF54qJBTELXhLEFGeLvOg/EhR4dJ/VVVay6YM+GK7k5MGAM1PZbhjAZJ8qvVfwNOgOJMANpxPfsM/KEBebwgs4zM/h+OH5RZy+eettTA7SM/lhte/1mze+k+97H3/s1fi3J2fqOzfR3z2ILfpVs+U7ubo7u4LZ8rlW97dG27S4pknHxnoj+p3d6HWJ07YwxICzKb7l1TsJJxDRxZkmPaKpTqMjXqF6qE7Ec7gidFoqt+rNHV+Ds3N/HSkE+YA/Z5fYZuVKDb7K9C38UpTB27bKC6YBtXP1xO7ers/L7ezv+i6xg/sPYufgMLq74qMcjWhrAqtybjY7scExBvT2bmzuHURHgurBDz6Nh3/wwziQINZ7//3Y4tmolvgaqzLKL4Tvk6fP4vTZi9iUILum8iDErPJ1lClJ9WR7ku6EHZW9uvRbWXEzsRfJWdsNXSDEkU6xvbqmQFbXoE1vE8ofUSJN+rDKwIRK4T56gKlAv0wgO3zYTxiRXnnLyP7BapYiWugiLjAUz0KS0hMHHur+B3PGGxjideSDUIUQ5sKAB6IAC13gLIQrxWMyLgdRZSeN0FDovOZh+lKuXmVzWpny80SDMCdGoEqcOF+XDf/ENyb55BeU0Ad2ZYhbZt2JyHvGMh/Su5VIJ6d3ImySLMuFBkaWi/RkJFXb0la3YHEpvsz8CY+GAV3nqiM1pT0sGMtugddxSVnchMsFbwK6sjVY8rZQ5/IqP7ldNunMW+FCrOv0m69u41Kda3B6rMqq+KoUVaBRIEAj2jU3rrN6RoBs+rN0DVbuqpImG4IOJSTSulbKBxj6wfDvIooBwwy4oJAZHim50uHy6FWcS494u26u5mZQUOeBscHsfTv4jO0OzZrF6MYatI9mrXg+b8aJ5CVmhwhVPDY7FBNpamBndg6jGAsGB+bHymwuIWJHzHswFUPsNGJPzNpfWileQwS63e7mcr2vQ9Dgo19THW97uy0BRMxReGHbgFUHFlvoJzwODhOZisPwFRYD/lDMf7u1Ed31G78sMBtIkBGufv/7n8TVky/i33/1mVfm+PISLG5KKIUsb65HSnspn7VoTgVcZcutyus4vTgJse344ad/GLdvz2NdgwercG4ylX+j24l1zaRnCgsGBpX1zfkX8aef/WPhcaoBZzNaEpJY4kdlO5VWolkZYAWMDoI3cKsiVuaDS8yUKzyIJFAwVzoNnZBgz5IUGUZsepIin2rnP/GQqbJTrksYZiCXB4IY8Wx4iDdueUIGRb65TUJ41qMqd1zKVOrkPKpdpm1wn2IH/n/yf/1LfH+t6k/+5E9cNnTiJfGOedcfYQNVw6q9mqv2LQn5FrbUP/iqkOhsb3EJqM9abSWsa7bRFcbgxcoXK0t//ud/7q8UP/r4o/j4o4+VjofumcRIonV/Bkf5g7bcWBK2ELgMVXlCk2qMNNXvuBOLvnxzPVFfUnz1n4nonncZWS3r9rqiVwllauMtFchbXorHvV/wJ1aYxpdXXvVa5449laelfkcZWDmCnnhL8Ujl5vJS+ABfFO7s9f2o/liCG5fCwru2d3fjwQffi4vhJF68PZbgxVuNjzUZ24w+X0wKR0xeBsOx+u8k6Vn9mDNeIkYJi7nVx0o+lymzrTniotbxNJ4/eRoj5f/iy6/iRMLg0YtXMT29FP0zoQJ/olvBAJ9r6rtzTebAG4fzWxJ+5kyQJYI2muoza+Ixt7y52fTj3T2ecmvlhbNtCdTNbVbghQHhijZCMGxIc2H1rQbb4WQmPYmJJo3chcaM5PpmS1XYEj/SoNjpRoetSuGH9yq3NRk0T6EDqQ1p0/U1tZ0E26NffRafiy4unr+IDdEIhy3YHoQv0RbQLHmww6BEFhbwo4+6n0GaSTpuM1vskMuMA53RBEHesjGeQLiYygPyJ6oowtrJLPgojsLhFR7g5Y0QztDsAV3pkx9QLpVZ7kyCv8ysgvxUDwtF5CGhV7ROHK71qEKeBTHx7RTasp8q1LBtF2ALYgBEEY8w+6leouncXRJ6Sxr381IIxyvx9U/lJR8wknFRKVAlFsGbhSbZrB0HD8pEgVNbOFMewN2gXmDQSEjML+CVPKxqWWQFrvNxsGKWtKlKSRRISVMpPFMqgPzAC/hEC6baPSETQz/qK2X+LeU4mZngCr6stQxZEFpX9CWr6bXAquq3YpsyFWdDtmICA60Dtituy516QXAZvkAGCDWyv0kt09MHq1nTg/NKRt+mPADVOJrhs6ze6fXE/MRMxLCZYV+zLC543rKUP2c5vLwsJsp1Ed3NWRxI9xrcobQtMA3PaiDETRE3HfdWsOm8PP0zZaakXFkxG2vmhxDmNxX140w3Z+y406ynfGAuMM25ysDWAx2eMxFUlBu82QYSxxXDbrqcMAMEMSiVz+sRpnxImUFJcEdidgwyu2KkHLI/GByJEajuYoi++FWMGuK/Vd3XOO8nwW5tHTjCpOJwFmfK1o/wsNfsx/Vw5IEiGwJAYkq81TfiK7ZcbaP5Xp49iZenn4v/qnzGGzOYbDzqjc2uAqa2IW7731HZZpSNdpBg51lQzoqQ5aoyjBVll/1W8oTQlIatM1Zl6HXZmR0KCapNxcTYbkaQUJ28aqbgKohleUEdaTKdPSqMYqKKjzX+wPsH39EBflSWdaU8xf3X6Rqvmu/aEwcIY9TFN7VLCIM+2epnQgTjAzcIYigEj1cvX8WTJ09ip9+Pjz76yAfSc3tSOCE+gwZKMD1jFRzaPQ+Fi1e4oeWHu4Tj5uJStimJR3Z8uDId8Saj6Fn0xwF8zoEBg+1KaHsyn/rJHvKeOG7Sr6+HkOCUW4aN/KBEtO++QBmUI3S30+ewe9uP7J+enIoQ1mLv3v1oS7AZCM7z12/iVAJap7+j/NYl3PRj9/BhrEvgoX/NJTQJO66zim69KX+2IlmRmUuQ5TJaBkuE2Mvzcx/GP5IQNmWye3EZX/3yV7ElWubaCj4UYSsT3IFF1i3ocz4iIHjwHHgXX2Py9iHhu6ojX2rDb6fiDVPOSs45H5bnXVkZ4Z44hFZWpRioBcx3E26xLbmzE/29/di5tx/79x/F3sOHsfvgYew/fhT3Png/9j98P/qP7kdjtxu3zY2YiS9tiO+t88yT8p8LP6+++FX87M/+LF4/exItNV5O4OGBbDcLL6oPK9JMwLwyrSJAHdDdquknmmQSwd0bnc6Fhna9JclPdWF1yHwdniI68YF8hdtNPJle6Zad1f3cjpSbtPKzlluGcJNxySOFK+ohu+CmW5GAJRNhzILDIkxlw2QlDhiyp3/GW0yaiql/C7vTVT8ZrqfCoFTCvLtDXhVe0fX6C/KRh3HiLxMNoMC0Ig7CVWoLXfRT2fmozH5e4SywWRUzXNyJb0NZMW3XH/hbujGzTAog5rsaeMYNcUqdSFPySf/kNaswMzn/oAdhxVa4CkbSSgmWwkFjYEJNgoNlobCrbun47VCiMR9KFX9xj8iKUznYIEyUaqYG8YSDKKtioIzQYla0eOXLTLqgRj2WtGw1ca9YnRkYy0XVxoFAUO6EslNOmGGzuxP33v843vv+H2oW+55nPggqXMrKSg+H9mFaHWZ76O1u9DuN+Kh9GX/QPY8/3rmNj3udOBRz6ojpcji329AAJcbKsykd2ZmdshXDsj8zJFadxPron67zRIPR5Xig8mh2jKfqyAoZN23DZ/LeKpVX8ThjASHDGFgh4CwazI2Z7vr1JOYDzoTwxZXsMhmIBhcDC20T1XdTghwrVrwVpymnZtHCIQKJOxKdX/mARmlkum67G/d37im+HHRuyuA2kWIlUIi8cQdSEpk3GkDOh0dmpMzaKR26tqfZp6zuCOSDX3EvwspPlbJmHIZibHpQLkEuhcogVdu5KuwZEz/ZcfgfaEMQA4DCVvOj7hLE+ChI6DCT9x1iCroL34WvFSgqO/ydeFbELdbvSHmg+mt0VXftq+7VetR60Xe8PQltCl/QFdc/wPi9rVhgwCAxWT3jKgQEMaBxpxb9iXM47hPSMHlwRNY1vc8DqZ3c5zGlmWBA82hvt3uigimaJD70KPpgokIZOQvlr+0cV9lI0KL8lAm/qhl8WUXiC0UEudlIgg2rYuo73CeI0HUl4QE7Qk5LExAf5ha9d3f6sXdwqCpsxFxw6grSVHAvlW6qcm0ihKm+0BKrYT5iwbDMpalM9hjUNMFgwJEoIuFjIgF2GIPhVQwGFzEcD33FTL79uhEvXr40Lru9bZdreMkKOOKd6gjuVVduzUcAgycigEnss6DGIf+9nf1oN9keJU5TQlpXvKkjISzi5OQ8vuTeMOk3b9/4GTaEI+5k47UELqz1qwUIE+Jn1HVdekP1bu72ovPgIJoPD2LjgO3KRly31mPeVL2aKjH7xCrHbDSIV0++iC9/8fM4P3rrrUn4HTsM4IuPHmYSSKeamCI4s+VNhaEF0nscoUGxyY/VTl9xIW26QaveyUukaF+1FW1ftYUr+XscUMQqXFWdgtfSTA0+BQ9+h8YBz7AmfTWlwQ80YjohOrxBpadccrsBaShr0pU84OfFrHbogjAED/Ktggl+WSDVz2WBjnJ8y/h39bvhAqTkCGfytyCiOBY3iEtfgSbzqIwkadtZxBCTlClqq4IYfdiwXRHj2oKvdC2HzeKufhWP9vPYUwWt1JQnV97uaqWzLnAWbuWr0ieFZPtXO/lQJtNE8TefEe0kz8m0Vi7jEk9LvfHbtDKWimVzlpXZDgNHwlLSHlodBZ0BQoCRhJU42WAgpyrcC0Ucx0uSsb2EC1dWHqBX0lQJHAXcRXyZ7lyy83+z0fZsj4P+dIJrMWwOvbJiRm5eJeOQv5gnAwnXFbQkeHQ2xrG7OY3dBndltSKaYk6bDXdi3x2jDGC4CHXXgkvna6lRWYrnZmtWaPg6E8YPUwE+ZQKHlJEtnDmrYIoPq1YlFMb2ytj3fYGqNZiVGNq1mP+1mKcHH/BPOs6naUa6t9eL7uVRNIaDmJ2f+uD9pgZFry4pXs58lLEGDPMHhB6VrSWmvSnwDCSoxJ+0cSdCZquK1rCQtBaj2UX88sVfqDgjz8gZcJl5kqziviq7DG7ZRphVp0cxVsLfVZkvKsOS6aV9JS7RJHSyygV+KL3jSMPk3NHUXsxQa7LbuWiRcQAv2q4o0iVP0L9Ey9fUCgkXtSzLd7EytvpQOGrVRMNcqnvVvhqvmtWOQkBKQSy/gvRB9I4GY7UztITpR6Xp41KXEhYY2E+OTnxQ/eGDR36HkLNnibvMH6tYYv7gEZwOgo7VL6BDzn15FUx5219+XhFDUNCADU9x95L/WDSOm5v92Wqcqq+w8sUzR+oVcSWBotHmbjMmOnP1sdyuHFye+/6wV69eOg0CIG89Xl5e2qQ/9np9n9Hk9NKW6t/q9nyRKWfMNiR0tfq7cS5YV+Op+oImc5q8EQeewrDAoXef01Ingw55BYDVOSZN6+InGxuUUEIJE8JZCoIz2dkmHVxcxOe/+GVcnp3Hw8N7cc0FrOKxEBuvdPhrb+UipIhHCa9qNro19+1RR+4Z80dB4gmOL17VkBDGs1Uw4fF4JmFrENzQz4c7nIXjrBztzTlaeASHy+GxCDP0Cfck+bECSGa+v1D8BsmPevhcksdplUv1GB69iecSwn72r/91HH35ZWyJf2wrvV8koT3gP9Ac1YAmVDfGBzT++FkVC/4ebFGFTCu5Ypp2gSe36ZM6yK3iOxy7z3cphv1VFuqWQhUmaRTP7hKPtLIjkMLngZM8JP1ytUYZUiGvktEvUlchnn7i82TmORmW6RJOZkIlEraJFTtaeWQYsBMHdhPPEYAj2AhMuGWnzfBb9GfykukVT/0tlONIM/5IM3b5/jCV188dFZjAshAnkwZ22YErtSogLdprUTYM4tLO6WXPUg7DsM5y2ASeC4lGYZbwhaKGy3yt/y2KGJlHlp+2xo0AuCi3FFvQVZD7rRPGqCQHQUdiFhrpi08qNYNNmG5ig4oLCUauPPCjYR0rVW1kpym2GoHmdidQHMdT56VToehEjkt0+eEPBMdVGO1PoIndJldh9CSUHURvZ8/ntGBEHITlbh8GifwEnXuHNABx5YQYG8dkOhvz2JNQ9qBxHTttvszUDHmLix15QoROJ8HKW5kIYsxi89P0mQrC/j2MgrKPphOvpLE9ooJqAJHpOskpk8FF//JTfDFz7vnh3MwaM0sxfwQrZplgFJCuq2a1+71u7E40SL14GbdifHxyvtHWjF0IudEgx2W2DFjeklEa8kTA8qy9DooQq6z1bJ24dkw1k95gxsQsSulenz+NL17+WLhny2cpkALOcFcVzuLnchKHFq3RVuITTmf5uno3Tl0dzY6aYaymsfonKUFVynZ2LHk5mrcI0HgqvnRedYFAofgKc2ckEBOwiVzDXpYAhTBRrAtVylFw+g++gxv4eQ4p8fF1vOG3qmq8ar+rcuaYlaqrSlznwAq4r2VpcshdtKFsvEIGvQBG5uuXr+Lpk6eG+73vfS8e3L/vPgSdgSjlrHTiAc4DLw3vnH9RcmNc/MNbk9ZEwGSigQDGBEY0K+0+pXa6ueZy0qFXPVjB4hA/B9bBOxMD31Wl+FsqtycgmpTw4c1ocBVXZ6cq8tzxeaibN1uPj4+8BciZxI7qy0rYloQNJjjrEu5Ui2h2u9HZO1Bf3vA25dvzy7gYjUOyfGxxjUWvZz7BBzOuJyKMwrD53jB/QCCh8kZ9WX1xLAGNrwhZieIKEF4r4Jzay+cv4stffhF7O7vRaTR9fQUPakPyfNzAahhbk3kFA3TO8QbetGz7GAP+CGJcyMoD7nxwwXNGo+Eozs8uldfEQhvPs/FYtz94UDm4p5Gzbbz2wdY+ZZlJ2KR/MFkBCayy0fZZsdJv1PHhwRu00WAUZ+I9X/7kJ/Hkxz+J8+fPY0N4baktm9Ic10DGoMkxqkKYw8MH9gVb/1PJD5qiL6IrDedYsHTbz/7CiTX0hgZHGYZAlV9Cgrv0y+6NHbbH2JTjCukRrJ1GpseOAs88xI2R5ZOX07JVXA/fVxgEwm9ylUsmaaRzhQs4MvVnRfzqxpQyHuyXcQ1bMPNLTAF2GiKpb5GXYcoscIw3/4BTCqA4Prft9OADWIxD0C3pFC6T3pnCSfpleVOASfi1/GjlUxrN5cRvocBVxiNKclLgZLwUjAjPcn9dv+tvCNRV/gblctr4Rr0KI92ZX/ZRGqTUE5vhy1Rgqc5vlzoTExmfnmiCAPOpCKOdqahthVDklqACoYIUVx5d4ldFF0c52p2wqryNZQSTjwgHN/5qFQiSgSLhq+EUp6LWDaC4LACxQpWDrJjl6CrOjl/FpWZ0w8vTXKWSoNlgVclnuDjjwHkL7hli1svzKZrxikFdXTfjdN6Ks6mYPcx1ytI7gxCH/MWopaeyjOnAyq2pcg80wLCF1m+2o8t9QE1WxsAfZzg0AKicMFYGgZzn5+y0pboNYJYCBX5bGizqcy8wuY8e3YtPx8ex/ZO/ipvhRayJIa/3dpRStVR5SDO/vGLxSIPGple8QMamBlrsHILe6nScHzMmuuT1xbnKqoGwtyeOK1xI/cWTfx6/ePKv/OUn70c2JKnS38DvKg2gVsna/uBcpjtQVcTRX017tyt8DcaKcpi0UGow3sIx/EyTDIyhkci47ZtanhbG5Adu2AJBYffKIwp4pFspl9mbrfhlPDMymwpQHf/Tf/Qju3+d6p/+03+6wAdlXi0j9uqHZhCtdvyrqmE1Xa07/pz5YoWLw+GcFaOvIRhxlqzCe/3yZXz22S990/7BwWH88Ac/iMPDA+OHFTaVQLQBgnOFGNhsdRKBk0qsfmnkV3fh/inhEkFN8FkNY8LBeUqeVkIoa2j8EIAYD69idCUhRQMJ57rGbPFJqEIQ4+tEti3HEn64voEBdX41Vr9bi/O3r+Pi+K2ElS2vSvEsEULbTMIVglRTQtU9CZL7h4cu6/n5WVxIgJupLt3d/bjR5Oz5m7cWxtaaLa8Q8TRbf3fPAhxX2LCdCw7hLx6Q1b9YgWJixQsmwwECkYSvMQ+baxAEE+IrYwkyMJQf/dlfxZuvnsc+q2+vX8eWcCKRKW4lKK0LPVxnQT3pc1512RJP0cSwrfZRphY0uttdn6NjkjkhXwmNCGNzlYUzdU2l2drQpFPl2+LcJG0p3EoEdr9viAdsiHcwIWtKON3c5jqLtnjDtut9ozhsW6LXGsKl+MNA8Lmh/+2zZ9bzy4voq336KuPs4kptnPwHdSN/qK32HVn0r9BuknNR6YBf3RSSheZQgMJOX+Q/9krvFrSII7pLOxNO7CXcW6nZF1IDb+l2XEhWfrXMRLJgJiupUzrWH4Id8WDAAMKbuIXmTQPkC3xA2Z1wYRn6SyU/8k6rSlzcq9pbn4Yji9yoRF2BLz8E5kVcKQu41LWkYexw/FK+hb3CY6yp7VDKinJ6ejNeBd/KyWGOL13LiU5FZtJI6yALl/PPMgIJPJgKXAYs7yriQRfoBVzifkPkZb5LVYaBDFN9ckvUNcA3S3gn2W+tMIZgw+fst6MBdXSjuZqYrmRKovV+kopcExX+slY/TBiClQIqyhXLDWZCMgxZnC47WVWEm7DKrG1VAT81duDJLobJwKJE8pOwJSZ5efYmLiSUDc5OvIXAHjoMl4OuQPSXWkozF3PxuRVWsISEwc1WDK634vSmFVcTVuv5OujajIotCw03rhsizkx1H0uoYiXqwd5u3N/t+ktNhi4YrWoiRqsZsArbUDrq5NsoVAAe4aXjgXi2I/wxAphSXvcPd+OPW7fR/fN/LSHqQsyykZ+iG/dIK6rjaGgh9BZhC3zIztbsDV9+iXE3fJFl7SwaPK/yvbytnX1lw2PGV/Evf/r/jKPLJxoYmH2LeWtgIHZtw0ybym1dVG1n2/1TOD95YV9Nt6oq3IUpP8eXG0Gc5nad8FOAyYOVF89Ikz7wc34SzKyU1luU2EEPafQDPjQFXSA4VIaThUw75ch6YAJDNE7ahX/Ef/ZffffC2Kqq9cBEM+BWdxWkKCt+uKuq8RG++Hqy2+XuvYb8Ejd8eczKGStlmL/42c/jmQZftjM/+eSTeHT/gcNQnhQVfECznPNJ3LH1LoFO2qxYExy2t7gXiz7BqjD0zMoaj3nTDxEyoDMezh9KEON6C7bkWAmaz6c+B8YFrdDyaDKOyc3MZedDkNnVMFrqQyP16fOTNz6OQL1r/eFhMGlWQ/jKksuVB8rn6PQ4zi8HPg+23uz4S2munEU/eO/9OJTgxiQJQY6LUmkJtgY5c5aCBoBVX9WFFWlW4Thb55v4Fcb5VAbrMULheBpHL17Hm+ev4lTm8OIypudX0RSIJisXCFoaYTmnyiPoDfW7rYZyVBBCGRMjtpO7KjttgRB2cXbmR8f5eIFy+Rwfq/EIt5H4417Fuq1WV6ZYNaE2OBG8+FiJCRtv83Lv4lxlv4ZmFMZTRAiWnDvzVjGr+Mq7KXrh0uwG7an2oZlR9BW2hKi/O+WKoj2gsbuKXQVP6GWv9Ek02i5hLPutTcLl7UP6CsWdYa6e2lllL3Y0KvtE9SO+tPFS+If8LIwpPMsOHOIRKM1WpQKx8p+tUsNyGixO4H7A4F/LWhV2rxAVe9ZNkBTfcKXJl7O7hMFvkLichj/HQeBU3ZwmcWucGlbC89NRTqP8FQXcki61wgyMQhBd8WW6zxrastwLvFCSElh5JfhWJOWjgAJHvoZBXK/GUU7HSzjgpOaxqpJfLEMSVi1z4iX9vkWJBymC4atVjJusI7h7N0+ywf1bK4yhRmLKZ8fHmtlO3fBGlxuN0CSYFMay06McByRVs1TfHa9gwp1Ipgz3ZYQtUi6FsQJLbuwQmhvJsQsQqVXUVisHVPFna6uuknl/TsZcs+rx+WmcvXkphnbk8x5kxb1BjXbXzBfFalkKZpgSzASHhZaRBvmL61YMr5txMb+V4HUdQzFrrqWArIE1FnPlgkUgfXi471uxuYxisaqnOHypycqYhlH9lxCn8l4rwNUXXJgoy+br4nd4djqN+Hv3+tH7V/8srsX42WbZ6PQUmIMDdzndckZOZc6vQbNTw4jY+rnRzN0HkcW43YFZ3RtcqU630ezuejXtzcWz+Oc/+r+rrmMJY5ti/E3PsEFcxTNtUdtmFfer7awY+jmV/HBn+Dcp0qzCqzDcZjQZ6Z0nfS9FI5+5EH6qIk0yMTsgANVZ8TahwYSHqvnUlbF8Q6/GKeUjfS0DVvk7VI5att80YYxBGHNVKFvVFa+EcXXFzs6uhbEUxER7bBkqK09eVFtMvp788osvRVc38f5773mLkpUh5y9dcbhoLwgXTNL3JOizBS8pRYKVBmsEBAktKYzhl8Iwq17XclMmvoJkRexSfbMjGu1ucyv+NCZc8SBhDiGQel4OBzERL+r3exZCphcDCQeicU0YT09exng48uWqPOTNeRlKw7ma8XQel4rDyjb3iY0Fg2teGtu9GEw0odLg9+D9j8WjNmJfgtju3kHwOgbbouMpq10jlUdijDuoqEIGZeYDBrb9fDBe9aINwKtv8FcdOcN28uYoXnz5RPWYxRc/+UV8+dlnsYfwxLUsEgLhnp2tZrTUbxGitvgIZUNcQfS73e/4PrfmFs+vzVymweWVhNYrrwyytYkAx5UavFTA8QI6jldwVG8um6YLc+6TlmMFjX4Ez5mobafScCUmkwit/phHcJE3WZmH/+XkhS6n/BTOxdhrare58IJw7T4i/syqu00hJ3sNFJEKOrNZ9FIpvuASkTgWlOTMAVmestdVLxI6jiz0CLa2bXd8BSqteRsmcWkn4SMFBMLQVC/hZb8SJuSJMGahlbI7THHFwIFD4b6pX6EzL0zVfeEH3EwLbzGIRViaC3jFJK17lMLV+Omn8qMRoCljTWOo8HwDxo+8ZSqeElNaw3OoTMYC75iobqQxbIXR22sLKRuXRYhweJ3XoqBj+6GzNoJDAqqqvMjP8cGjBHzlhyINsgETgRz5qsKeeK78Y6EMb4kfTFTlN6vKz27xUzwUdUvIWV8redq/5PNbd2ZsqVIo4K1EDpwjOEAsNApEZgXCITCICC8QAyIKgvK/VLGYcNJK2xVFmtKAaNtLeoLIAzN9rE2k6WFVGyTjlZ8cMCT4kBtX4RBLQ7PW7v5hdPf2JXB0TGwTMWoeJuYqCYBwEB+mmodlOUOm2ap0ayuiv3kdu41x7LVkNteiL2bIw+QcDG755nwNjghL6s2ulTLmCZMOTx2pMJBVQ3Xk2ghmeD6HBv5URlYAvCyuzgaz574iGD4dal8w+mdvzAhZWVgXA6cD0TEtLLDqINPMy79CwDBM+fuCWNU/CV6tIEF7TWVi25bO+/TtL+LZ0S9Vhg0PkJxfoVip3LhCDZ1k0YJW0DlMeNV/YSM91bG9ACOB7AvQUoRTB4rslTDp7IyK5YikkZ8bk7xWU6ur4ydb4qGsMCLQyo//hq80i06Jn+zJpCo9Zzx3XsOXGzu+ODPpd3pmDIW5Wt/qXtWo7BNLOwyMgRSNP32AC1tzezIP7ZupS7OylWlv41QCxLPnzzVZOfcbhQhjpHEfAn+KV/EIThJf6QQErNfrI8DWROWGy0BZXcLOaq+FMbYQRX9K4HM+SoWgwS3zbOP7vKeEj5kmEUyK6gcxE86QIcC18gkyX8GjzHlCaTS4CA7Uc/CfbUzKxsoON86fS3h5e3Ik81KC2Dy2up1o7+xFU8IYb9g2t3eiJ56Au7sjvsB5LPULXsLgfUb4E/LkzTX9FeFXAx8okBCHcMNHQT0/JbQrobXrfslEkGeWuNKCVXPOvz3/6isLjLjbTIwEo6l+yVfbHc7vlRUt2mlnV2XpU44NbxWeqz24ioNtWD5m4I4xrruoXxa2xZxabfEE4Y/JGnzI1/YonMJS3BS4oQXKT7tgqJ3gEdJMUPy+pMrN80Zbmhi2VfeO6sy1OrQh72TyRTf3vSEY+1Z9tXsKcggE5CaYtok++Q9hrKili7KVfqq00Bh9nvrgib/D5M4weFLyTEzGJH9gZH/Boc8rvWFIp11h0BjuVThyQ7BKljhyUQiXAUxVRcGO54kOfNhCWylXycswMqLNFLAAVvpjCU87zqUfdcD01RSko5xFGCOOIGS9CDNcg7AJfonHL1d/U2ijQvXsmS8Cdp3Ih+olgLQnoFoO3xRQ7BWu1QpfcXpytjCW8QBYTfCKf/VDU86khaoKLMqEy2VDg4MlnJq+qupeatXTtKM4jpZp0ZUfKVIxShoxrnfL8lummB0eiUGHZqX5ZV0i2ApEmlGqIT2y0RjZeNleJb6CEg2wXfmTlng2HNEsPFG3VKRNE+YuOAuYQKkwU9W4+FV/WJDdlkvSziDl2aH9r/210+jiNC5PXsXl2bG/DJpr0IAR86k7q2b5VQr5axY5Z5UMGMz4sa8Fk9yJONLothEjzDl2MQr95mzZrGu23G5FUwyTMys8ZC1MqbMIB6oXs8OxgFioABdiiH5wnEFS4TDcD/ba8clXP4ubVy9VhrlvzfYtyqqLuKwGunwkHMWZEDNXMW2fGRMcPlrweTJaQPi8mQx9We16NJXPLP7lT//reHr0i+hqoG41OX8CwzM41Ru4OCh1wTntYTuacmcbJO6XHbgqux2kfxUugwFuvLA7Ah2VfCxm2Ye0d4XABXymcZTFeMj2XaPsMBfwIX8FO34VTKrKsmJSP8UnYikDqoajvJIm9bexMoa9lgX7KrOqbsLd/RSHwQN/6BymxcQCAYxVFgQr33mneoJTzm5BT+CGg+8vXzyPl69e+9D3e4/fiw8//NB3dy1mp6s4kRXa4moCYPEVJOssrIqtS7Mq5nvwRJu8KAFdQ4+s5E7lh8DAYXVamzNXPDjdlyC0s7sT0xHXPlyYjtudjidI5wP5zSa+Wb633Y3p+WVsqI7ryuP46EWcqf+22x3Vf8v1urgcxIUEGa6fuRbvok+3VP/uwZ4nM5vNbdG+cLkp/22eXNuP/t6BhJmmBUdWh8DneDKKkQQ6cMzqFYM3B/T9IQP4VV/NK0LyQt2LizOV5dSPaHPR61TlePP0WfzyRz+2UNNR+Zoqd2NNwpcEnQ6rW+qrrKIrKDo9ytPy9Rgn4r2cfXOfUBrO023Dl1QwJkzewtXEjkkbg+lc+GTiSDzOqCJFcsZPnckrXdA5tMHZWBR8cK7wvFpCQGleBZneWWEmneKAQ44I3K6pDWVer4m/wCDg/U4Hb8dUf3N/UhD0ien/7yr7FNrFhckAXWnbxGUaLWEIPwUek9NcGaN/0AcApX+khR8QD3okToVH31i4M10qlRUhyH1mmSaXh9LNh0zwVAsj4JQQpQfflKIKZfh5O1HK5Sj1zvxrfoQBn/pm2UiHQJuCEOkzrrscfqRVXAupKJXTQcRzp0en9Eh6C9uyq1oqHTyU8VXlUdnrqpGbzNpQlH+2X07ms46V56UQBkhqi4fBS5MGH/gTcfDM8li4Qimig+4oUEB/Ml+jDIqTq2rYM8Fdc1UxLrpKaaSF/IUr6pglR+Gf6rdeGEONxAzOjo+8XUll+bmB0G54ETKVtts2K/qTia16lJBs9ESLhbGaFq1QiND9We7sbMlEoA0TLBDkX1HrPCqaF4Ys2Iu/G01232Oj1kqhDO1ICruJ6XjgG8CvTt/E8OwkBlcXGk9meQi4tR1NDQq8QcdXKu4OSuN7xwQXIYuCG75A5mWHCGNi0GJUvNPI00o+T7KRX3LxHI0ZpOJj+JSYqJRy0vGSQWad97ab8emLz2L20x/HhsrCZbfZWcWEZbnVIOVVB/BDJ1fCdQ0+CI2OCHPmzIsGCz5euLnmklzNstsHcTZ6E3/y5/+3GE7PosfZlGaujpXuJAV+QCBtVHwKXu8qZZ+m/y/juNVMCMDCR20o03b9gwWYUZT0CyW3mdE35OdOCu9CCPPdY3iqqmKe0KHx4vZNZUFNaaANymP8OVGCfzeLLCfFWZq38V98Rwf4UZTVA0NRuKuf624/ZuzURW1/ywDJSg3nm1jByRUdaM7vJe7segUXouLnldrrievGbfEvXz6PN29e+QB8p9OLTz/9vu8WIz+YtAAWIYVLWkG8UC+3maj6KNuR9SJXVqs4wH8zHeV2JWEWyDQ5EJ1Cexw6pzVoew7v8xA2h9S73Y7clzEdnplGtrt95bHpy1hHSstBfLblxoq/qbbnOtjXb57HqYQ5Vt0ury5VHvU5+oP66s69+9E7OFQ/5jb6ps9cMgghnHGOEtit9rYFslanr3gNT8i4IoenmNhOvbo6t1DLYX5GuSHnwTSp2lTchuBwVQZHJHj3EiGMx71fP3sWR89fxPGzF36/8fLNW688HfCs0PQmWqy6C3UIV9utpmA3xV/EM1SHsfozwthQ/AhBi69BuVIHIWRb8XwZrNwIY6xmwyMYcIV9tdeK4ABfER5yxRl+BX+F76lJ4GFSdSsJ+QxBh4Hulq8tlYavuYXFmFgQyw6CuRjU05CZHmYT9oTDrSilr7wNlTRFL4Smq2ACieVKVKXvVVqvApTkMvNHaBIYeBOWq4Co0m/snzBt58tr4humyiE/VvhgdAh7uJfhUGZ1ZxnhQ4AybqWNPZl8aVvTujAlnbFi/xR0EqagulAJzwlFBMYKEwMnwEG7ZBqA1BU3t5nKmucXgYbQxXZg5rPEpdIoHJ1TitI2NhNmuhVPfcDHiPCXKjVz38NOMQkCriC7joZv5gsdUVbBKgzc9cSq+tSyYCZtuKZ2M4nD7ToWP6e7o1iMAe6qkohMTsVFPVI579IGKLKjjsD9nRDGUGdXAzG/fFAX3KVJJSEsOo+pvhBYKjem4xQPqSpB8yVceuCSSu+iRAJqWGZgND4dh3RJeMpHzQ9DqI3hPAqaydNKDZ0q40AnxOEH0zFzwi1t5iRTfMqzSd7Um2rmO7o6i6EY6+DiKEbexsyLGxvcWI5wxixcDDoFIthgZuuzMzA+lxmmRgA5U25m0m0/OryJsKSyz8SgXV9wYTyiSaN/Cqe+HKjvv3oRw//uX8eGBg6NEPJXPA02qOvhQAKZBkENCtQJPKxLcGRw9BNKMDgYDlxYnZ+DqPP5SPXYjRcnn8d/+1f/D2U3i64GhWZzXQPVVpkc8q8YLo+d36oW7ZDYsN2JZC1BC7UkgSokZSqq7GoXRVhVFT4R8HYbVkEMZZQk/liJgSEQ6HjSFVa6VzKRWsAuKt0qE5ymuP9P34EwxnNIlHNV17KbIRYGlwq7RAr6nRDKoXdolHNWZsxrWxLE9uPw8J7ojpvrc3AGJ17pFu65noEvDJ89+yqO3r5x2gcPP4hHjx5Hzx9+LPuaP24RDVkYU5m82gjNr0PzKRB6ZUx9IDR5411StsSVUIIAVyoonP6sdKz4ejLDeSjRLxc293pdr+xwmH82OneuXQlJt+tbcXYhHqTOxLkurnhAGFufcmHyPI74aloCE1dJjETvfBDDV9Df+/SH8dEPfi+uN5u+zHWDA+tb0JmEWE1KLAqq/ybhsG3PRwrrPsfJxwRtDeAIulyRsakJCluBXF3BHWIbit/t7nhLE743V90vz87i7evXcfTyhVfDnn3+qzh5+SpuBhJKVa51lavf7AguX0+qnwkHu/1+HPAAt9qDC2OPT4/jUoIYAgLCVkv48LEJDcB+Q1d+TbYjSa+2TsGEydu1y0C7Q9u0EzIR59mgYZwswaQwxrAOHcBdkgeyyq/iqHmEdbWLeZn84bWz0llrl8G12ls8DltV3xJfmiAmCTmp4g96TTomtNK1aV0mwqdpnlCZxCVNCl4Im7lKZGFMOGNM8HaczMU9mLJXATDdYoFcU4FT/9x/FM5F13XL0T/gOr9Ujlfi088og8Pslp1gtQ9u8ki40ipH8VIchLWMWyI5P69KOZIKBW4cG6PEXRHOvJomusy737KMBaDsKZh57FDkBS5rJeS32m6+ewtHzQfax4+88PaAlQr+4BVD2WkHl0eJyAt7jqsKlB8XzTomfyS4zXZ0uxfYVZGvkxW+Vsv3zcox01qULzqn3HfVnbygbcrEOPsNsX8b1a0P1fL5szEv7Z/tGc7P/qsahDuOIxWFXSiqceyjxkA7Goikw4HXROpSgMNIWEkvhZhXlQlnqV0GOpriZdzasdJ0x4ahyayPx7Ly1Wj3Yufw/Xj46d+JD//oP4yP//g/iMc//MPo7h1q8L+Oy+OjePv0y3j71edx9vqZV9T4dJ8VpSarS52ii50Hhm0XU+W2/vn4Kmaa+W9IIOpL+DnobsZhd0vmhsyIe5K37vUi7qP767G3vR7Ne3u+7NW3gUvwUgWFSnUWocRbJmKgvmUfQRM39Zfp55PATSLbwhm43tySMKjBm87H+RIhRBEKrmp02WtbVdzfVQ5TbJIbhF0oOdQAtFW27bsKJp8aivCQoPQVTgLLtlopQ1WyI2zVW9HdzsDiR/3RWWsiL/TX4Eg5r2Ku5keSKoh9l6qWsZbzbnlR7/qJ2cid27DJctjagpl3uz1vTTZ9ZhESYSDOFbTcSrnxxagnJ0cSMCQ4qe79/k7s7e3nuSxF8aAuCwMzyuOGGjW3oxQBWLJZy+nVbpbkiG/8ZVraC1jgFGEu8ay+IGGKL5PruRzq4TvFFGZmLwje4mSSgym9rrA8L6X6Ct71dOLLXyvPaGhS8vh7H1o3en1PUrZ396Ij3ertR7vPmbF+tHs70dnZ82H+DU2OhLUYX88ksOb2PqtUHODnmSM+dji/OLfAenl5HpPJUHjm8xzwgFCZ946NR4M4PzuNNxLKTo+PY3hxJfl0Fh31t21N4vyCgerPitje3l7s7e6KbzS8ovf69as4Ozm14NXb3va2KB8rEL+t9iANgiivjaQgJj5G++cM021goVh1QHD23XIWrNQG4htL2qLItJP0wk/CnOJOlZ4b9SV2W1xLkS3bYdWs6l03/Qcyyn5kIUltaj6rOsBrfQ62avuvaKVJoQshKwWttGd4DUv4OUbIW1pumQhWFkbId2HKn/CVdI5rv4x/Vy/jOpMCJxcdLMxJyyPt+Dnu0l7jEsfwnF521dlHKEpclUJ/0m7FUqYCM9Mt4y3xnHlhptb/4nZ5pd7hD+llVeuUOvFX06AWNizSGZZlAGKF69VU0wx+SQMOKQDgCNWPeFVVd6aVayVvVE2zqsl7oY2T0g4Ld2qfvTO81HUFkF5BVmDod0CteXmcQ6rXQkTtzGlWDXOWWTr3QqOKgWKwfcdDyj6OW2FlAwmkmDcNZyeR9Kd87ADBNf4qvCSDSnA0RtpL45Ufnbd2PHQyBmmYHLNOhyumwjYlSPX2HsS97/1+fO+P/mF8+O//z2X+/bj/4Q+ivbMb3PZ/9uZFvP7yl/HqVz+Po6dfxeXJsYStoRigBg3ly6pEg6+evA3IW5XlazYNInwdNRryODKHmiUkbYj5wnCl2QbZ5IJa/HY0ez7c92DnQc1oKnVXQg8eglefY2JGD2O2BpkiSwQWBklmV9zCjDDWYqVuowjaBZ7xWmFb1bACx+2NHVyXdmGwXCShcFWnynbAVmAAT27PcFUW2mGh5E9c5+iypB1/C28iisyLTmgjw/TLjk4ecisOMoEDrb+uVumo6qrk8v+/Jvn/6OrbyvNNbhR488oGB68LLikyqyl8ech5Ju67A2fQBbiHtsHRVMLE5eVZnPMWquiGCcO2BBO+SmSrE0D0Ghoj82O1WmVw+yE8A0taZq4cFLvLiUAo5EOr6ge++02CFG4GHddFtOmzlxIejGLlgzBG2XgJxL1Z8bwNK7eFjNlUEyJgK63LJ6U0o8EgRiOuYxjGlurx4Uefqn/uxFTpt7rdaO0dRKPb14SmF2sKn2t2PYsNn9fkKIEqsqgn56hYsZ6ob3OzPe/O8u7j5cVZXEgg44ODCddxSCibDq8kCA7j9OhNvHz5LN6+eRlXisN1HdPh2McHNlR1zhO1JfBtg2NN0BDC9sU/EJq++uqLeCq+weWtbVbexYNYOeOQfkPCW1PCGathbM9iWkCTP1tUi/MzCFvGNTiqOlcy9VebQqbqqfi0a+JW4bSm8AkP0X+fPZurXXlWzJosMpuFRtlOwxVFn6UNV3kr5PiO234piLEyeFcruts0hTHBsh38MUmvMDKvVMtSuSwKI5x40BkO3AKQGh4oGrWqMEqFKqSaT/KsrI8ztD+8KvlVCgbEIS7uNIlbnyUiTRUYMk2ashSdeeBf40IrNe5S+MjyO64q6fCatoavKLcXXvJfwsp4uOEVFnaxC66MRNGKu8J/R7gCriNmvgLq8DwChIamFA+39ILGMP1Ld9JTabMC+xs19TIRCQ/Cpy+zlR3hC6G26ixHmtaypxt8iZZ+e7+m/LriIONcRMJXh1TTlQRRaCk3HKZCq72GLUzQsrCjYAiY/MvUGY5OocqqmKtpsaZzxa+YIgXZ1RBQlBX5lFCnW5YD813CllZjV4HNnUGmZ2FiIpwb45mU7b170b/3fuzcexTd/Xuace8q/qYPLY+uzuPq9Ej6OK7OjjQ75sHggWbwY89UoZWEx4wvywGB+sZsMWcGLwYqOCi8A6L1rG86j+nLN/bjfiCQRz3JkzM59ALKTPwNzrfRIZi9Ky+0Z2VKy3YN9bpVW9I9np1pIJhdmcnzLh4wUMKEO5Pt4CXBFI17GVaiSWV9SlCJtwqHdqVplsyhalSJ5f8MLtiqRlkYVSQYAahzGKb+kccyrv6rzRPuqq4Fxb6i5F3LaJM87CpKfv/Bf/SfF8evT/3bnkNaDaOQWWbarA4MGxrEc9WFlTHOl7gyjgvtsUW5HjMJFxfnEsTOTmMwuDL99Xu9eHD/QXRYKRI86rxQokdThdrPwje0pmJ47kmDeDDnjCLnxhC65j5zRDpfv2L6ZJ2FbSrRnmmcFaU8FtDkK0kJIghACIkz0TTxED6UXYynfL137YtPmSzxteUaK6PqL+PxVZxfXMTJxWWM57fx6MOP4/4HH0qgEOOWANTZPYy1Nte7NHyWkonIVPGgLg7qzyQweXgGr6oKK0qses3VX9n6xT0YcJ/YqV/0oJ95yxUBV+VkpezV6xdx8vZtTC4HMZNgePrqTVydnEZLWOPN2676HB8oHEhA3NfEilUvzoSdCeZ4PLDwu7vb99eg8Fo+DGAlfZsVMVbZlb7JqhpabYogZh6STauiXFvY9sqiNOcoVcwMoznUF9xMHgVV/lvxDP28CqkAPhjip9ZyPCdVgzs6bf4NOjv5UoO+Be+QkXwu+3je55W0mytj6r9Kk3x2qfOrRdkdL01gAtZ+2PEjzBo+Ukz52y78mWfj53Ecu8qDW2H+YjIBGjYwHV+RTPcFJvEp64JXyY9KYtZtRnYVEpa04gMTvRrXwhLpCZcdLkVacItJfH8AwFmogi/DID12Kcflp/Ik7ESy+bit+NkzdbXavpqfyoBvgQvMjFdUFVSl8F6WIbXt1DW5gVSBvQCSbm9dk9a4kaO4sYh6HIewuoJFHTIScDMeOvMmCnghDH5W81vRwKiwqiak+P3OnBlLxQxyLY7FwG981428CuFkhaF27CArkb1QBIN4oQP/aq7GSWEJf1zLuGytOI18mSlVtQpj9ZCfUni2rW7id+eqgjG5cdAFHjAqHAYjVK6q5GoD2dU4aEv0K+6Mb8Nu30auQY7LKqeTYUzEwDkPMx/xWLEYu5ilbyIXHGacrIJ5RU4MFgaytclXXjnzpdNB9N6KkIZJdYY3Mf4ffuK37XhPzwPctQam4aXgyk5cpaEjbLb7Pth/Pb5kT9IH9/3osaq3rjx88PRKZbyZxL/84k/ijQQyvqb0mTGfg6BS0ooPtsDRqrrrTpxUe5oGUByEm6mSztre9k+LHTJkqbDlrvlkNLW1Bk+G9GT62WYoyIcB3rGVRild1yWoUg7/X2Rv5bYv8J2/4jKTW/AbKdL/n/+rnxTXr0/9k3/yTxZ1zjpSh6TzVXc18Utaxc7t6w0LYoeHh14VQxGnnmUEBIMRh9LfvH4ZZycnvgaisdWM+/fuxeNH7ytO3swPUow3a3AtrJYVFFbBKY2oT3b6z0x6mqtfnF2SEMMkQZKMJiESpLArLYjnGgeEGVbj6BeDy8vYkyDSltBxdckFqiNvA7ZUl53tbsxGEnjGQ/UZtlH7Eki2fE/X9VACmYS+84vj+PLJ0ziSQNbZ248f/PG/F9uHD+IGAaa/G63+ns933qofQBc8P8bN+dSNFucCVc5gsfKEJMIFrmw33k5GnkBNphMJrZpYXZwljSmdeq0Ew46FwzNNtgYqHxeknr89juvBOJ5//mVcHZ/GXns7djvd6EgQ7Le7sa/yXyvu0dHbuFBdmZx0u3zcQ1vRPjfGA0ceNkTUpGtJSGV7TwimCbIPyYrQRduwjcsXqjM+zBEP8kooxxncZGolac6loli5oA1jja3YIoypDPQpfzQERoRnVtygKVIVcoMa0lKUw/yfOGlCNpUWCcKbOFVYAgq8DL5G2TPuchxZtS81GSD8Z7iFK8pY3JjAtbvkU7WLp6wsDAqFZOvoToE7eZJrRnTgLWAWP8NRHGl8q5vKIqyZ91DfojIYNxb7mCcj7LlJnDH+UsoLR9Yj8/VQKD+iQaE1Mv6ME9k3M91SUbZS53RaV+FLlmIux8RUCERq2VVQRbl/GI7yTGB2G6bhqoyKY9wJgFeo8FUkyp2CaLqx1LJlvVZUeksBr8RxBPCidLYy2Uy/Cn9Vkcy8Cn/sBMtJGcD575gwloq7ek7FZNZnIxMXiHG9SwOtCmML5IOfYq+ququvG08/mpYwGEW6jVP9Ww7mJgDCZQdMAWXlFAxOQGKWUwiElgAiJrTswbYEFJvVokHf8QVkCmIeuKVq05LadpyGlYdpi1M6By62aTxz1aCFEMWMnq2EGbNvDUisEBDOKgLvW8IwXS/XUfUWM2leadD45QsNRBK8GFgQwGDKCHoawIwfpeVG7Y1G24PhjQYUcXL5K77C/XAwwhZqKKFRTPxPn/zzeHb8mb/qajbzIk7jr1Qii7GCZKm7blQKslnvqjxwSOGV1nfTVTySCKsxWNJ48i27/R0uXGAqwMK9uxkQ+dU2wod/CCA1z5V87qiEm3kDpcZLc5mGcv2X/+jXL4ytfk25wEOx0761vNWeUQhfj0ajGb1uL/YP9yXc7Hi1pQpqEEq2KWeDJnF6ehRv37yOs9MzwzjYz8fAdyS4gLvEJfhVXuAChs0gXvyNH8IRwORn2hVti9A9GeJOKu6ryrdXWfHljnvBEm2yssPdW2xPTkWfY01eDiRA0i+vBldeieK5oY6Eo76EGVaQhoqz3tiM3s6OaepmNI+phJ6GBqfB+Cp+9tnncXx5Fe998mk8+vj7cctlzqpL/979aPX6mnwIF8IRl5/ykgb5o4CFYMDBeO4UBFcz3nAcDSVIjnyM4EKC2LGEp7evX/nR7/FgYFrpNDvGN8Lkyfmphc6jl69Vtkm01jcllI28KvZw/zAOdiQQCvZYdblCABZ86Hdza11CM0+QNYXja+FGcHkdRGVBQOTaC94EpVxeKQbt0j4zKe1tIUld4HI2561M2uLGL4j4WTXakopKGnCTSVtY5lSYHJwNExdRn2Iai6l/sovanKcSYpN5V2U/tdDmAVM/RaON8a+82iBwVyEJeKIB7Pq/iOswaVR1oxB2vAKPMAbMor0SVMJdPNGi81AYqpbJCJNXHQqWghYwyTvLQv+Wh8b8Eu4/+RM1YxfYWV6PaeSh+Bkn09gG3IVfCmJOr7GRfLDjn5HAU6kTflIJL+EKm+RofxtKk4JoClXJp8iJRPinNgxrAyvhWDLdUpEPbVbKVeNJqRcbFn6LazsKfMrBdCz5AGUmXq1D0W63TKN/SkIaWVXXuoWJ/ztpqioVyLAlbjDBCbqqxFfiwuF2p2cN+50UxlBXYlbnJ29jiw4AlYNiI0FIM+KSeEBMIk92Gq8SjvxsWhdsVVXiEbNKyRAqTIbGrPbqXxsAldtm0pQLQ7CUMSEOB95q/Kpqfgv7Kky07DCuGoa6a6+mf2KQ2C3wCQBjFkyLTsnskzoTT4AVmHnYLcXMdpsZvQYZw7KvlDr99elpnP/jfxG3Z+eum7c8YcQMdmLydI4tzaIR1BC6YN7zoQaVDTG+rS0LZNwvpkDx40lcj8Zqs7X4//zq/xVPj34WHV+oydmUzRyAS73u4gv1TX538UGcGg+/1TSLuNKuv9yr6eQwnlD2pu1Y9SSMdl0EYBbD7Wub3auqwq7KbrJRW9ld/r0TT+2W7ZTO//If/Tgtv0ZV7xmruqrKrKtwlbTPKsi1r1dgdXW70/VbknyV6EtAlZzzVrk1TBoWqkZxdXURR8cSxCQUjEUD3M/1wfvfi8ODe6qq2j62RKe53eje484kZChv2sB9AeQgeEnY4lA9wlhepcIdfMpT5SKMrxJz+33mM0GbjRxcJxJYOFfGKhRp93f7Fi74UtErZvLf5uC9BDJWl6/kz31M/X0OvG9p8iHh42oioaURl+NB/Ozzz2M4u473JIjtSqici9abvZ3oHRxEW8IYo7FXgdiSRMvOhwRbmw2vOoFPhAQamwP3TG4QxpgonRynIPb5z38ez5585dv1OxL2NtfYQpVAhcAgOjp+eyTMqXsJdvN2I/qa3CCIdTm3N57G5cV5nB4d+XHwTqcVTbURzx6xHcdHFuqyKo8EQ7YiJYzlObFNwdMgLpjgB9Mf8RRhzAKZ3DPh8JovVqmjeIIvnqW94KFqPovi8CVq6PN8al859D/mRFFD13M4leqS/uiHQp99loogYgKeePw4W+xzbKa1JQ3bzdZgAQyufR6MtMVd6buGr9q9qkVcaYcpoVepcAuuLSUudspEjROOyu/4woBMCwSUTfVKIYizXQisiZtMU2Fk3VBgAf7qv5IP2rClUcSFxzNhxMsTRgcpDhaVlfbj6z4A+X/Jj3KV7aaMDwAnTvy5TAaqP6dfmplpuu2nenkbGXCGh7ES9x0FDkgiepELEXmhXAYDMRSOG9ZtZ8BdI1wyFENIKMsCpKllFk7tlJ0QEvEHXkoa+0l5MUde1Z0yhFPJv5RBYdkO4DHjoZZW8iN8CQeBkPCE8DumqGiXAbvTcxvkDFoVtvaJA5mrfqRAJ4KMUPtJFQNVw6padVfhy5CUdjVsadqQouGXcFaVSID+4LgJoxLWMv6qu9pXtWd7IlIfQl0w8aJlZ9uRFQk0B3F92FZ236i/Wb8myk+4+SKM2S9uGDBPnHiLUnkjPLHl5MP/ZXbc2r8XjQf7ZrL0tUrUPoxJHkoPkijnQsle2wH//KpN3c4dRiRKuY1YtP6VuOlxRwF3Ffa3qIorFLBMI8Ve9d9UZbpMi6LOFbZyudPWf3O4qCqIocBnJq91pFOX8EXYr19V/ICz2rcw68CLov7QDGHYTYNijO32ts+JseVI+ybONHCrvRGivDJ7zdeCHNw/j8HwwtthHPTv9nq+YwsBnxXbdTFtvvwDtsvkgVxlIc8imHnQ8TAPPTG4Y8rt8tFXcnKBsEZcMMogjPBAnXwHFv6Kh5u8+PBAnoq/FltrCIYqh2ibA+0c4EewcxnkhyBxLkGNFbEt8aP773/obcm1Rju2Wh1Ed9VxLOHzKiY8a8Qbi1MJj7M8LgA/AC5lonwqrA/cUzfKgMxyPVVe15zmkaSkcl+dXsT525MYnl7F2Zu38exXX8WLz5/ExevjaAln65PraCr+B4f345P3P4iDfj+mEiRfv3oZg8sL3xPW67HyRf/e9PYk722yFYnmhn3zA/EKrrWgb3t8FDLhghO1zbToieoyVV3sh31+az1jgqay+iyY8M/XkTMJyfNb6ZAQK0hQ0rWIXkXNsU44KC0svaLwVzhjuIUBadrXvFPtBb8z3zMvXfLTd7QYzKpwZrD6MeGjDdBJS8mfORP4jhZcf5mpfJZ5JN2kxq6y04kLM3M++FE/maRVljkwI5jJzH/yo61tS7WKgexDJNVPhTNclYUxAHgVBmaVc8jD+HI5yBdc1XguUKbFz1p+8G5hIAMURQCctZxEdxKbSQdLne1D21gQUXsQl8hZjiyzvexd3Atd/fLqlCyK8K3yrKv/YTLR4zk9rnMhgvNB6M5sSh0Ye7L8lIX6Jw6W+ZbM5JJSHJ+hc1rZ5eU62E0d0OQlE7c0jwhyQMCTbkWrGpX5yR/Hahi4F14p2e+cct1V6Z3edtw0+PwdBlyJN6tMh2ZZ2UROGMEw8+quysBSOayYxcPa+JT2qpgbEgLPzlThoVmuz7Q0CIEUwaSaGnB0dxpYsXLmmIMLquazyF/KRArxrbhNrfanPBCviFJ+eeg/BTIzJxExg4gPnLLPb2GpfK1ZBCcLbRoMYcoIU8TBj9laCnUljvSW/Laajeh8+FjxRJi1nJSF6pYObwKEoIvigGleJaB6eBoDaWKUziCmvah8JVnBBvoSE1KKD5NCO4+V9lxo+TtsReFvPBb315TCq0qmUGIuYC3deQA2YaJqfjDb1El34Mb+xMFe4xd7daMW8cp/BWYcfgv4Nfy7Ue+Ur9hruS2UaYD16ofsCDEUrdPZ1iDPc0cazDdVYP1VploHTFZxOCDPFhnnoNja6my3fbkrV1mQCDpEuR1KW6TwRP5qffBcJlv6pyiUT24L+CmMuccoDKEfwc6CVmlb12GO4JblJx1CX213yowCLJOVdSF/U/2MsvgLLcHGZCVoOB7G+eVl3G42JIh9EPcePY6d/YPo7+5FjyePmm3nzUsblIOtf95chaX7zUyEQfk7PxDm0U158OVnGU0Gl0Pr4dUwxlejmI45E1q+gpb/unDT0CA1G4w5wxF7nX58/Ph78f6Dh9He2Iq3r17Fy+fPfIaULUgEr10JjHwswaP8vI7AW7DWagPueWPL0pMy1R+8UAd/Uaryg7MpK4fCIR8e8NUnV3DwMghyJNoXSlMV4RA+hzDGb66+wbbk9ZpgyY6Inv1ZpqoLnX+jkn/yuOQxnGf1YE37SJu+Kp2JzyB41bBFuPzz8D2a8Dw7toxT0iiMOldtnp9/dkMeC2HBaTJdLZthebVRsEq8zKfEEyDnL7/k4cqnmNaU4Y7WP4hRxjJd4uFdGN9kJ0PXBT/jRmmKUOc4uImXFGhFj6r9HkU8Y4DyOG6qRZSSXhEXbqfBlHa0Yr+r0gfCT2Au/0pcl8Wgqr88rJfuGjdVtafpqLYtFTCXbZcanCQuFMg/VW4FBS4EbpFzllZ2u6UZwsQSBJfEwBAeTMzSWcA6sv1uKt99o1k4rDcR981a/5b2/x9UJYJvUtV/AVuS+Wo2no2rpWr+dZ96tSzVXfOBGGsHcVgROjIvxdF/ZoFoMxT3U82c6Sh3tOGJGbAKxr1ACFcWworOgXJLecLMBAPBq6xGoBDekplkuLei3vsgNnd7FGWhIEjioGBKAihaLLixp8otZsI2BIIc4VnfjAsjrgrUGD/4Kcz6b6iYlHpi+u+gKp6/SeG/EJZVjGRKX1e5PUlYCScNSPkWuN+kSP5tA5Lp4N8B1v8/yjRTaYf2KpoBDWWcSBBjq83tJ8Xgs7fHI+A9xS34LMXNds5K8fA9N+zz5SECyqZob6dHOr4EXpfAMnfcjYYEMjVk3X7kUmM2tADq82CCj2guNig7botIysAc0QIWW5a8YIHAx6qcGa4GfVbmfNcZuFYdyJNVImjfgiarU2qEHNRz0oGft+am3O6vouk3nUx9uet6ux0PPvw4Hn/0aTRVl66EMa602JQgxlNmrL6NrgZxdXYWl+cnMRtd+TzYHC1hDjuXJt+MRjKHMUXIEn6G5+dKc+Jb9W8kuF6ensbJ67cKH8U6VecqEZW3qUnStoTBg04vDiUM/0//6I/iD77/SVydn8WXv/w83r58KV4ZsdNVeWRaINy8leDcir78WqyYCxkIiU1NytoSyvw0kvopghRC13gyiYHKOVadEcTmCGDCuV/6oF1ra4Artwo04NbKcNk9QYEmELxkzGUnLnbH1T8EYKUsqYiMXVNY6EztlbQk2qQtV2jTmjCZ5msyq668Lv1l4qf0uBFmqCc8Er60WCmBXG0qdwgFtye+ypulM4V55ZUvv5WGh9UNyzCBpfII6d4tgOfKtOBE2Q0P4V5+ajveZRRgl935K5zypHCHX8kXbTxQ17TblD/pna64ZZNW2b0FWtNj0ocJTTsrT0qsOiZcTK/uyFzgFS23xwAQQflXVO3fy7qRM4r2Izf+pQ/h78AtsFEp8KufFV3d0KD9oR/FY0HDZSYRfLfAdpiCKv+0N7CxSNu/hNl0ZPDBSldZ8SKex3BolPxKnuozKoV/SbGoBAiFVnu2DzAKPsCYABBKqX+nVU+McKu97Qbzsj+mmAQMEyR4dSyjJoJLoxYP6fR/x29Feel5xS/taLemdc7MM042nRQEoA7rxiS8UAg+NGa6UNmwhiDY+LtzrShgWEBbaJEP/wBbIKaiLKxAoWsHyZwgeJLUtGZS1sz6WYpXZ7M935yjkzAmucPLjk7mthYNHiT+3nug1qrW0VddkIFU5q0wtQUWln7tRxhp1Fa0Rd6anO7EfdamlhtV0f9OO0izvWHhJb2ssKMpWu2UqNW0pHlX+FuFoLzlzCYFuNlP1kv1zxq8CyPT48hOmB2xBK7WY2m1cmfHz3nZI82iarkW5VsJ+3WqxYAk7TIq/9pvwACrnGjoAYbOea/9/b3o9toaRBSXVRDObVliYCuQr+bkJ+FrNLyUQHIe48EompvN2Ns9iF5fggtfJwJdMMkrG4DVK76AlAAkWO6LEqJ84ars/qpSglrmx3kxiwAWPDZKuLEs08KYstjYUHmmI8GZqQ6cbeIQ/9yrQdcStmYz8uDiV+UPCoQLhAi24NbFsGeDmfS1BKh5vHp9HDzm1Lv/MJoSwG4lDHGX2Mb2TkRzO27ZclX/oX8hTA0vzyRgncX58ZGvnpmOBjGVEDaS3+Xb19KvYnD8Os7fvIqLVzxh9CIuj17F+PxtnMrv2eefx5tnzyS0jWO32Ym2aLMvge+wux1N4erT9x7G/+p/+T+LXnMrXj59EucnRzGZXKk/R3Tkt9ftxv29vdjtd6LVVj9u3EoIvYmO8NLRmNxSfVsacLm+gkFpKgYw4GyuBMlzCdBXrMaxKifhcibpaja/8V1s4Mq4U3we755az63ZoiTMK5tqDvTtXK2kznMNXkCyqUq0BMqlWYlkqK2aGPQNwhxb6cThFp51ZUOR5ZYf5FuEGfrfgocpjZ90khBlQYxwaW9Lyc88Su3Nx0VoC2dCHjfc8wA622QiIIArLfmpbMLbjWj+Vnahze41uVVAlyOwYzq+0iHQSHBeE717sC55krd5iqL68XP6nHRSruyqpyAZI9Q++ZIBL3T1J46ASrOyKZO6Mqlehz+7gMpbk2651ZPV1gghbMEJByqTw0tZ0XIIvgonpSJZV8EOvMLrzMeEA3YGWPF0eRWRNqVEbMODc48jGmTqyqIFPAmuFiCBQ72FBDR2jxngyWWQv5GgeIJKb0ffqM5ekHE5sgxZFnAmeMSRNk8u+EYIvVE9xRXEO5hw8Z5sjnlMEpj2QRumC/EMXkq44V3UdRHwJqYgFw2KF1p5Z26puZtOtfSZy6zB76pSY6n+0RUzvxXz40FZUE+L0ZCEY2YD52Ai3FhX/1Vd1V03bfjtKgmmrgbc1WqRv7EyMWIpaZMQVwEgvKjxnRf1UV2lFJMQ66pqWrRnSwu7OgJaMMzE8BPRpU57ZV6uQ6nfQgs2h/C73//Ub+xRYncwOguMrMRB+SsrldFXWCgObVBXlrzaB+UrDZsV0/nY+ZL+3wVn/y5qtV1W9Tcp/Bc0IzeCQBXMV9Ms3XfgUA+pGs6vqmWaor4h+dfifIeq5r2qaRdvU9GGtHFpJ85XcY0FK1usLEGjHIoHV2pyp4UOZAmukmBVbCqhDDi8WXl4eN/CnIKtAZpCqxxkYZ1tAHVDPtCc4eNWNN+OL3j6B9HJYNRXHPKVnTSci2RQINyr1TIR5HDn5aWC5vgS1mYzb2N69c/x0IIpvSEmDlvl8D9nptoSwHb29sWoRbsasHv73K6/E1sS7raEGzSCHl9KziREvXnxMn71y8/ii89+EV9JuHr+1Rfx+sUz+T+PV8+exAu5Xz35Mt48fxbHL1/I73n89C9/FD/7y7+Mty9e+CtKSbfRbmz544KGKnewuxN/5/d+L3746ccSdKbxsx//KJ4++VXMxqPYbrfi8N5B7CoO11WwJbzFxzGs5CAsC495eH/T28t8ZaoW92riiAfKWQ0bj91m1NePeoMj4WKpic/5MIQzuR1HGqFCpgdmtYFXMFTeXMlIXQdh22XCj9JV+VHxK7xh8SOu0ia/ws3gLj+07DUsdfKoGhfTQgBuwXcZVvRCSCimV7aqXdpCitIJgM1aThZZEobCqITNpa5lWNXEh4uL8hbxLBzqz6a0BUTiVxzIW4kX+Ey/TFPdjmQ4ckvIkMNtkHETjttEQRVftf62O54iSK3aUXav2Cvc4mGD+niVSU7qgR3hEhEFgc8fauBfdM2DvKmbt1HLeAJugZtcANiMd0K2V7OybtYut9pGWhVxGgTG2m7GR1Hma4xBsA0VMs/HpQaWUiYM5cNKGWYtY8JFoEy4lLna69jpeFLkI6ZCrV3K311VKtxSZ+nv7YY4oJlnUkIyZJg15A7zthRWlK3SMB7jX9oN5MSpEpGgkPT2WqjamOSR9/4AIgcJSA7GJEO6NDLw0U6Ln7O0rsph0hAtjek8pGFGi9j2I47spVAOkRttt/0LNMcT4TssiST1knCrHyS4quhAnP1wJ12kk1ZY6/792HqgQQgcyMczKuVBJ0P48mFktYGiu0MkfuRQfLWM4XD7PoPoXD4zzaaTEascLmvVaTBrLNX7mvomf+evvMwASvrsEgBSh8GjqGznpQKe4ymOY1EJ/BUvZ6nAl3bdUeB3CQcKcDZ2yEXyCgMDpnCXMaCLe1UtYJY434V6p62LrqoyHhRCCucPd3Z2otvlTUdm+5meePRFBmNIAxqazqYxHA68PQkM7uval/DSbLSUhsGvbI9TT7YllT4ZJmYKRL6odSEcpaBU+2EuQpiNuv2JxxeUuDnSwJSXZ49SrckueEqTQiTZCV4RJICbcAhIWGCB2T1lGQ5Ggn3r81Y85I8AwnnKDeGBgYRkxOV6CN5ZbfLqhdzX01mcHx3H86dP4ukXX8SXn/0yPv/5zyScfRaf/+zn8Ysf/Sg++ytpCVQIYD/+sz+PZ198Gc9+9WWcvHwdHZX1wf5B7HS2/bUzOwMfffB+/NEf/n5cXpzEP/tv/yROT9/6q2QO6e8f7MbB4V50uu1Yb6yrjJuxydeRRcBA+Gqo3C3Baba42oKvXae+A80CKbhQfXP7VoKW/CyAzaueq++mhufRP+rWJRRNXwEXtQ9gNyJF/5WuVunsXV34jmgCuoA/5EQy3Zg17hLOip+9nWNR8FV5L/pejb/U1S9XfVKnWxpBz3kqmgYW73hgByZ56kedqWsKee9qVC0rKsuosKpLPPcBojlYbrQFspJ/iWetMGCg78KxPYEYWGIi7avxV+2r2rGLiVr1t1q13kmzcBunqZYtsZKwqNU0xnXFvfGNBlaGe4wp9lX9Ltx01xW8jJOw8F+likW6JNJF3GpfRs7w9M96LfNeqgU/L5qVe/QSE7/LSsja1kDQ4rkklhrZlgAR/CpSjNGlO4U2/N5FJNFqHDslOqc7zW9ThLnTCJ6a3tt9i308uVdhpoIxJMuqijLVeO/GzVIu/O8UIwkCeOjMy7ddk8qEcqeOVqTJ4EpQd7X+eVASwKUfSu6t7e3Y/uh7mpzIX1519pKzGYQTClnKQxBL0dKm9zLQ8Xm9B0wNvNzGDgz/yMfp/93VAkdfU2RcdYL/trjv+tNGtR1XVInzDcnfUQRXeAudQUu1LNbXVE3zXao6y1vVOQisCGKiVQaIbdFBp9Oxfy1nDlgS5BGeLJCz/cfXkxe+NoLzV81G2+m41kEpVH+1u9rfMKQtBDh96RPcdK90bGd75Ut2zqxxzx2rXDnpyr4nVm63hbapwpWebXjKM+FrRjUnDDonElleC2EKrwIZUpgHfZhuKRPxMHmPdCKBkge7qctgOBJdq88XYQaBz30Z+lZSxmyEnq5wxcPnnabiqeyXZ6fx/MlX8eUvJIj95MfxCwlfn/3ox/HFz34WX/38F/FE/i++/DKOnr+IyeVVbArYhvLjOpjr8Sg+ePgw/hf/8B/Eo8NDCXM/j5/99EfC2TQ6ba6jWI9urxn9ne1otCV8bQk37FDJ5GoP7jPzQX2OeViIzvbiofPBYBDjCfeFIUhnW6JoC1bFqHMe2i/uqllmUFxWOhDC8uxRur0yIr8MS3cOukv9zsQQP+E+B+UUvPKLxoxruiRcOuNnOgtoxY6fnAuYNKU1NFLgyPY30yQsAhgrbfJ0PmQAbP0z/7f7WzS8z/zP6cABOBWs4r4bv5YRDb7wAz56UX7cJcy62Bfha7nl7Hxpw2qXrnEXdmlUtVe9hLWEoxAi2l3j4UZXNzgjHvhbquRnqam/YBSTtK5nTQs9QLQVP/K3Sd4riqSr5XhHl/yVxTIiusBb1fr3jpsy1jG5mlUt65C6qhpv1V82jSCr+1a/y0p4RPW3xdx7ed2FZ8YWyoQcha0iCG1kZzIrxynttGgM+S0P3DuaFXb8SKWYiisrHBdVIjJkGYYDiYd/xvUqHb4SHJ1XCTdj0c9h/p/K+dtH2jDxdaZYiqJOmKziKbY0Y40fO6YOCgMT1/JDZ71SZ27ooqAa+ihxFRlGW1XFDWr7g+/53UwYrHq1/fxul+PYuVDrnJFghrKoYZaHPEaToRj7LP3lQVrjjnoXfP7blBn9O3niyLygBWvyAz/UmQCWn6VXs6htTbmMhwKTspJHhZUBWedVVcu7aLOSfrUezppwvKQxa2j6g4OC55Le5fmOVM17VXvwE0OmbHMJIfhx2ShblAhVKBiRlQqba4iaDSoN8U9OTuLi4syXqbIStbu7G9udnuDQUwQX4curLrlydRdfYGjRhpgKhsUyLsZMbQqxF42dcOL5IwMJD7jzguOpYVOuqrDjx6F+eEZdEZLD4YShEfW8YiY65iC4nyxCICNfTUqgEe4Gs2AnGpsJHngyDOGGwZrrY3hsuy/B7GY8jVfPnnlL8vzt27iQvuI82clpjLl/7ZSXRiToSfjqqIwP9/figfDWbWzGe/cO4/c++TC2W1vx1eefxc9+/JfCxTwePtiPx48P470PHlgQW99MQZizLZtN4VomH1twyev2dttbk6qK8DJx+1xeSWAec+ktz0FJC18IaQhgac5jMp+5fnlYn3M7yVfqGSfwQF/863S2ag64tYUTV/gVvigNT/THSghlTAqgw0KLfBwBLdlPbq7e8QPmqh8X2VqIII3TCpYmDxyk33Q6BLp08wW5vzQvmoH6a5o/yqM0ykzxSUtZsAu+0q1tNbI8yreWf1W7PHf85Om6W9ktf2l/5CTYVbBdhPO3KNMKHP0Zr/hLicLVDtIi/MyHcaPkJbe3CnFbKw+1HRqKr6bjyVjVys35wDpXVR1FnBd2DOnqToU9+5r+is6+lee7armIi19JX8qZ/u9mnH6pqkCabS4T3CoceqzpsDEZSME/aU3/jJ8qxC/qUMv2DXo1XjVR1Z+8TafQh8tyt+S/44puvcvliq2WhZC6vSHsuRXeRWi6bVlh5LiTkQt50ogPtCjR7ion51fgYJqQcbvZS2PZnnChHgfLNxsRk8aVzSZCmRqTKEU5OmaxAA/Wr+HFeWV+S5UEgWkHCawgSmvSpFdRuJY+VeBgS4DEXGFQiawqbE0NDo2D/YSKhwmvELl+ZjwQOPFFjfjnygarD7SLAuQ/nlx6m5KykkXtFKjVPL9J1fpb405vN2UOEHJYg7OFQ1qKBim4RylKsUi7IOg8l2Av/tF+haRQmHfxX8vzbWo17Jui1fTvxPPvb0+5PDIZkOcSQGAwbDNub3fd5rhreUFnCmZJz9wpxm32nDsiDlt23W7ft/W7h7kBSr9wPqI3/7LN3EyKQit4UUJxWA3LRl728yqk0UBeFZtJVJDf/7e8c1uO4zbCMCTSJJdnUpREU7ItO1blKlXJ+79CqnKRF3B8UOJDTJoil7s8OPm//0fPDleyc3AlvhCWzcGh0Wg0GkAPBoOxTgqXTw7lY+YaKdSOK9w4KD4rsl3eAowpdH9tLStGPLZzmvxZDVK6Jl7ewJpOZ14ZYyVpLrw6fyvfllR5khVXn7gvwxD5MWFjyPIZI84bu5vNvVKmjO2h4AFyms389YB1cba/MWkT9Z2V67u2K9m9/PhFe/H8pH3/zdftz3/6Y/v7t39ru9ub7fHjw/by5Sft05e/sbHlw0iR5cMfNSS+57iNjVXvG9vg00eqN2MBq3xX4p83JjluBF5vZHBhaLICBs/IhHEANpFdjXO0s1fF+hiAmIgvwJV/3KdtUHRHOOMGw0FNXjFqCmpFbAzg03KDsQZdQOMQVyZCHhWzl8zGm8qk2Iyz4FGuNJB0qYRIBMB7C6B8GA3M30z4qJHHKsrAIIMYiVRNft+IO07aJUgeAXEdhjFSfstEV69eIRfSC19xkrDSXQGnG09hy50yCXcILXDRANoAf/JxNT21CZAo5RlBubFfAZfjuH4t3oZ8Pc7t08HbD/oWBPOqzObfwA9eEpd8Q0PYuDce/5g/ehn4AUlVweQZjCtmT+UFoF3OvEsm5qPXnSEE2rVCJwxDwuLLEwh1g26u5Q+86UoWBZRn6OnviPuHDy09PDiUpbDpDf1IeFgBQrDqTGoChRlV0hD+V7hMtG5+8HkEIhiatGiRPgr7FxdcGll3JTSoMnogAoGyKSNF9TwJx+EJWN8ApwccgqB90jUae9TCC75IR01Ry/BOWMOFfhm8CIdK6L3NqVQpke52+2A8YtTuoSaT7Y/4jqBKghfFwR53zR44HIcisloWRv3WJKmi57tM0b+YnylOk5SVFuV1ra3I5UoGyzB2jtPPLYKsLfT7ONQ3A1ZPVxG+G5MX0LziHF5p40qcrpZ7xwko/wjKjf3lStZ0bJINJurkwVVe6j3Q7ThcFJPAr+CqLeCJx1qsiGGMscqAfuCIh2X2FFlfxO+1Jnc2gWOQQCOHjG56rxWPUOKg3RWZuqsR2GPhvuUGkUHhK/1IBdjKVpyMAylU5CQaTOhMujSYN+GLDwwfVkuQPatklIMR5n1mZFM+Jml4Y2XOdRE9dJBVEjb5U4eaWFgNusJI2txqExmivG14ccV3JK/b7HLqPXE8ip3LsMH49JEQChM3lYE15eBXlcERMeuSAas5rD7NZdRxICz73tZVDrAhvZyIrz0ZY490k3m0t9dOnhy1k6OjdnN12V59/hcbZCuSwQv1w9//4Xft8dNHKuu1yp6pGnlEzONIDnadTDZsAOLHEObA1vOLy3Z6+kM7f81qWAwuzg7jIFfejizZcnFfcNv0Pi5gsvQKmQCVRo6lK7jkjyt/pWdiS7u57SSTrCbkXMOsMiUN55tU6DsUOrTTorQFbVzS1d4aZwrcroLQVXhVfhtlXMF5oHJ15Y2/AYLnibwbYKirxz1oCDCyYjgpzWNd5GB+SFd86ZBhSOvxKjf+Dj3dfvE14JeTv08Fvjqtg/3KZxzaLmi5uqzwCRT+mP5Phkf+PEIWEO71GfNvmTitpwtcNnih1AFZyaeLcawTrOhF59AZg+hkJuvIYxo9D37XV1Gpt8qGB6f1+rv8Pg73uJQT8DghWOjqwsgbg/UOUksu5Y2BOsUfLt4ZF+msa4DbOzxsK+sT38VqRPVI4oG8z4L+KQzUHUJAE8ndte6qNZjdcUhjWinfaWRRPo2Es59406TsCD3UKUXF9qvLFR2V4BgGMga2avSxYwAFJ+oUf2GB7lpC682scUqQyrijxBhL2Bz2/EAMu1IaU7WDp4QpQyDZ8Rr724rb+e2nbfVwX6jUTxHQcqfiKhq65u4Nv9I1sHD1oySNbLTPxfQHuAA1ndiEetkd/l2XnM7d6x43rp8jBWCwBiNWRpg9P3zbzy+RP8fGv+LR1Jdwfq5u/0md/1+uZMg+sSdPntioIq6MzAzA0m0ZG6U/s/mVH31dzS5dp6yK7cgQ2ZR+aqDzyClZp3vo2vuFDbreZ5ygFuKqOB+WKkPBq16eicxWb9eUi17RcuyN8mROPvHHFyUIw3OMooc2KMnHI1KMyDqLj8lV3HgyXF1TPsXztiDGFx+9X53IoJHhssqeK+n4XPFTGWTsuwJYcWKlyatMos0mfxFWWSu5UZRRuCF5YJTeYQjJAOLcM0yPNeFMxNfGisoR6hONZx89P2lb6xzi+tf25WeftWvJdGd7UzefO+3x42zSv5hetG+/+8btwOeOMMB2d9irttW21F4YY4wK1/Pbdnlx1S7OL9rlpXidYbwiZ9pQ7SIufPwE2xQkJ+zeTFRZGaRpuE1VjfyJqLwxmXGk4A03ivILR+LDE7ogRth7QziAcZb2g6NxGvJWCy2MAnC4qtwFnkTsVS+l+bHkSjfyeExJeTHQvDLm9H7FAHO+Su90bJQJejwFmBelub6Mdw6jO1wD+LMqtogbQPTij76Zb3DNfMBjp3A4jyxvITKGqkyXJ5BfzRGnoLuUPBnfMgpWOnThlXLIp4hAd+N2KzyuBvwC8+i8gp7ubkhYjv6auY2xAai5TunWr07PQJj6Ih+BwkYTDT/+N201gCKJd31Vn8rP3FI8umzydr+d0gDw5GEYCR+jPKIEW6mPXI296IsPQ9e1wHV33vsyG2iNrva7PG5WKP2ddBqI1Ok4CVu3gN7ngRGEiIeBvfs94Hc3pGngdLqEf52dco0AAAi+SURBVCc6NBZnHdXd+cLE6hOEoO7mGZxQHvIX2AkNXDX7EG8lJf+AFIeyhCxpanj/Kg2lVjSN3eMgDi7xCSVvoNPqPEdXglhGX+EWQWg7zqnUNm+eLTvQ1/YP2vaHH1jRXJ/byI5UDsl0R1AE1BhEmMSYhJEXZdxKrvPrqxATJO8vdzzOMohidZCqz+BgTGIZl1n+t/HxRv6RG2Q4dj0D0UkS1R6HqzxvzWsO3ga/rvMjtp0dvz3J4ATfDE7wxqRNNTz5KI79RVMZB5eXrzX5z9w/JpOJjbmacMZ7hhBMrTyj3dH8uEFvKcCiip9oJgaMKMqXBrpPgZY7WOhLzwSra+/5KA7KBvdWukodqBP50d+anPkqBf3DEy95NCjn2IYffdbWBcbWzY0KfygjaKdtbkxgSvrEY1nqPfUnkC4uL9sUI01GGXut/MKL+gBnGWHgPXpy3J4//6AdPDr0Shmy4OaHc9zW31tvB7u77Uh9bFeGFI8zv371qr364gvzyyeknp0ct5P3jy23z7/6sp2dn7XVdY15XT57e7ttf2+/TdY2ZbyssgDdZtN5OzuTgTydideMJzi3n/oDh0CzeogcqcuNjERWO+/rqCQvudekEwNOP+Tewe3Xr8tQ+fosGIqESR1NdDjoDoZKB76IUHqWsNpMMsPvdhMJ/DWJLvgEKEtAMTx6fCgZcMyHz5IK5AypxOMHz/iwSKWihBnb5PXKoMCxEFc723AYAbjlL2PM/C4BcRhfXlUSLa8+gVt+4gGYUdhziJw4dRvVqn7aKzOfby4FuMSaGYdJ59aFfGM/Bkxdc0MtZOMEUurCUZ7LJz/gvix5Mi9I7/JCC3OQOGdeM+CnJugPK2IjuvjNM/xTVfHQeS5neXQgb2j1q2BwIkCYegOVT//SJ8XLWF9qXADwk1YQ2vfLKH/JwHKg3pYBOMprzHfOUfkHbaJBb2vvoN1JmGgDiiHpuC/Z72bBf1+tnJtBXIMSSVEIiXKExmqY+yQ9lHQHKAOtU2Mo5GTls2Xvnkw46iDdVn/TP/gw3UWOdBI6GZOM8IkKUm9wgp0O8QP/RrznoizQScdYdKP7dONIW7hBseT3hl3RWHYo8dbLF+3BliYjehwTDgYZSuucKoTbauSFH7mablYq2OQ8u72SPBhsgm74pc50xIGuQz2WYZABasHgIX4VUZ1qcN3P/xr4ika5yDnOfiWRHBT+CYzS/XLjPGOXdsKRvgz/ewdfy1DxGGEcZcEgRRgZZICCb4Zxwhhmt14dytuT7DHLHqwdGRcbMlx4ZMjREPQL3zCobtUmPjhSV+usyrWOC7zaJcMgKqw4pWNA8Dht0E3RwnC44ZR9yZFJHAce/PKNVa+MKQ88eAJfWW2319figPRVb+DnZgHdzCSG/mOI5TNAr2Vcfvv9d5qgVmRMPW3bO9t+S5ItEtm/lL5+KzrXNxySyon1PPajX6g88cCes62d3Xb87Fk7efa8PRadvd19y4bPQmG08vblvgzfo4ND8/fq1Vft9PtTP3Z8dHjgk/KRO63D49HTs1PLYf9g3zxtiqetyZZXA3lsO30t4/CcQ3fP/eiUx5RZ1cwKmA9xlUzY2+a3JW8UZsWOtlLYfURl0UZ8U9JtpDA9m8dKNFMeK2fKhK9areLqw4K7jDKx9UkOQ85Gudpa4ZoYB5AhUpPi8iTJXrECG84dp8D6K2YyvhRUWAxziCdvtRukhTa6FD/E8cIG+FSIf6ptqiqX/8gB3a2xwRXXv+o3P+XMGzj9Gl4VFlTe9Im4GGExBijD+MQTrrQhvcKagXrcEI9Aij/nW+CQXn6XvQSDMx3w9af8yHqgMTh4zy+MqjjhkDeQuICwfE0EP7jE0QfhmTEirmcinh/XKhsWDR3nPsvCg4deR+tf9rL5CzRcFZeVU1Zp0Ulwq24lt5TlErgWUEh392UWXqo+76zbYW+H7gx9IKwGiggoV/1TW0VgdKQSnsOspjFQiYYnCzWWOxvguAi8/HFqECZSDdwZqAQy10lnsMqAlUaLaulOnEZUOsv2oZmmw1Gu950RR17ygA8ZpyssD4Nd3IL/csbRlTt+0xhw33SVrTCUw0AYSTAgv81Njo/b5NmxkFQfKS1XctDRyZwVQdUDZJWvKrkjUOe7u2tNcvPIAYUHb8H+f+9EjzslOCnnMXZEm3rhLDP/gj8uvuT5BpDWYdktx1N7t4IjUz9oVCdGHs4zom03JvIrO/jikRGTPCtbVMerFeK/M68otZ/89B02gXuv2LwbOZy15f1KnMO1YkOl9pUZlF/KbuDIEymG4tQaXJngFWcDzjdVxKWPsinf33wUFX/GSx4eC85nM+mVjEDpvUZSG1Lsh+KtXkZkSsVYgxdVzI8JmZyd/5pDTmfCU9soArhjQF7faDOVe3YxbeeXs7Z38Kh9+MnHbYc3Q7d3vA8LHjD4JhubquuOZLXnb1TuHRy1g8dPvBJ2JMPr6dNjG2Hvn5y0XY1PPmaCb0NurHmVDcDYYgC/OP/Bn1HiQNcNyXFzIpzNDR/kykZ8n3SvuqwJn1Ux9rptbmvcUxraxP61i9fn7UzG2unpWTuTnyM+5uwLQ6aSfU7DlxykjJywP79W+yAkx8dZZorEOMuZbwIbX5Kj+3wwaQv0mrFgAIXRFa9ISJ4cwrvq4zYCQhEwqWNQEa58Pa+ayYZc0aKhXBZHkEj3VtKfQidjXQCulUY7ijYHsyqDkJRfkInZKiIc8OQXDuB7aOOLRgf0CX2AHo3jMlxjOeKGUPrysqu4oc87dN/djxOi//TDCKBslal/oaFrDM880vVJ+9JxvyWq+KwoLozTGBwBr85VWH5wbdQ6jlXvzsLIwYPpdFrgL2gs4gE/dgQ6Tj2OVeAesGfX86PL6/HCR84pk/9KVFtS99SbcCWiBY6034YbweSSznYN5hEpK3Bq1OHRqMqIIYaESVfZHTzsOCt0iQv9At+oyeegnI3Goe4C/A+4aYXuw/ZP5+xxCevEQh4AAAAASUVORK5CYII=" style="height:185px; width:426px" onclick="Ext.DMS.util.showImage(this);"></p> <p style="margin-left:0cm; margin-right:0cm">Hovedparten af operationerne udgøres af SMILE.</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <h2 style="margin-left:0cm; margin-right:0cm"><span style="color:#2f5496">Forundersøgelse</span></h2> <h3 style="margin-left:0cm; margin-right:0cm">Før konsultation</h3> <ul> <li>Fremsøg dagens lister i SP (Tidsplan &gt; Afs.: (søgefelt) -&gt; ”ØGA44RK”)</li> <li>Forundersøgelser: smartphrase: ”økrkambfus; Læs henvisning</li> <li>Kontroller: smartphrase: økrk1d, økrk1u, økrk1m; læs operationsnotat om der var komplikationer (”Oprforløb: 1” = ukompliceret), dertil evt. notat fra tidligere kontrol</li> </ul> <h3 style="margin-left:0cm; margin-right:0cm">Under konsultation</h3> <ul> <li><strong><em>Spørg som det første pt., om de har pauseret bløde kontaktlinser i 48 timer forud for undersøgelsen og evt. hårde kontaktlinser 1 uge før – hvis ikke, da aflys og ny tid!</em></strong></li> <li>Anamnese:</li> </ul> <ul> <li>Refraktion: Stabil indenfor minimum 2 år?</li> <li>Kontaktlinsebrug: intolerance? Kræves for egnethed til refraktiv kirurgi i off. Regi.</li> <li>Tørre øjne? Hvor hyppigt dryppes der?</li> <li>Erhverv: Kampsport? Militær? Alle former for fysisk vold/slag mod ansigt øger risiko for flap displacering/-læsion.</li> <li>Endt amning/graviditet &gt; 6 mdr</li> </ul> <ul> <li>Obj:&nbsp;</li> </ul> <ul> <li>Punktat tørhedskeratopati ved fluoresceinfarvning</li> <li>Katarakt? Overvej CLE</li> </ul> <h3 style="margin-left:0cm; margin-right:0cm">Refclient</h3> <ul> <li>Ref-client skal være gemt med alle data</li> <li>Hvis indtastning foretages af uddannelsessøgende læge, skal refraktion, corneatykkelse og k-mål konfirmeres af optiker</li> </ul> <h3 style="margin-left:0cm; margin-right:0cm">Information</h3> <ul> <li><strong>Alle</strong></li> </ul> <ul> <li>Kan gå i bruser næste morgen med lukkede øjne</li> <li>Undgå hav- og karbad i 4 uger</li> </ul> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <ul> <li><strong>SMILE </strong></li> </ul> <ul> <li>Forudsigelighed:&nbsp; <ul style="list-style-type:circle"> <li>Knap 80% når samme syn efter opr uden brille/cl, som før med bedste brille,</li> <li>98% af øjne ser 6/12 eller bedre)</li> <li>83% ligger inden for +-0,5D og 95% indenfor +-1D</li> <li>Bygningsfejl over 1 cyl reduceres i gennemsnit med 80%</li> </ul> </li> </ul> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <ul> <li>Forløb: <ul style="list-style-type:circle"> <li>Tåget syn første døgn</li> <li>Efter 1 måned kan brillestyrke bestemmes</li> <li>Efter 1 uge status og afslutning</li> </ul> </li> </ul> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <ul> <li>Risici: <ul style="list-style-type:circle"> <li>1-2 % taber 2 eller flere linier ved operation, men ingen falder dog under 0.3</li> <li>1/4 klager over glare efter 1 md, men kun 5% efter 1 år)</li> <li>Tørre øjne er en hyppig klage, som dog aftager med tiden, men få personer har selv efter et år forsat behov for at dryppe øjnene med kunstig tårevæske</li> <li>Infektion under 1% kan medføre nedsat synsstyrke</li> </ul> </li> </ul> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <ul> <li><strong>LASIK/Circle</strong></li> </ul> <ul> <li>2-5% risiko for at miste 2 linjer</li> <li>Risiko for nattegener</li> <li>85% sandsynlighed for visus 1,0 binokulært uden korrektion</li> <li>Relasik først muligt 6 mdr postoperativt</li> <li>Hovedparten oplever midlertidigt tørre øjne i op til 6 måneder, 5% vedvarende (typisk dem med gener præoperativt), tørre øjne skyldes: nerver bliver beskadigede</li> <li>0,5 promille får en keratitis</li> <li>Ved stor pupil: Større risiko for blændingsgener om natten</li> <li>Sov med hårdt skjold 1 uge</li> </ul> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <ul> <li><strong>PRK</strong></li> </ul> <ul> <li>2-3 uger med ringe visus, ca. 1 uge med smerter, bandagelinse fjernes efter 1 uge</li> </ul> <h2 style="margin-left:0cm; margin-right:0cm"><span style="color:#2f5496">Undersøgelsesprogram ved forundersøgelse</span></h2> <h3 style="margin-left:0cm; margin-right:0cm">Alle patienter</h3> <ul> <li>Pentacam</li> <li>IOLMaster</li> <li>Visus/refraktion: visus mec, cc, cycloplegisk reaktion primært v. hypermetrope &lt; 30 år</li> <li>Spaltelampe (inkl. funduskopi, efter dilatation)</li> </ul> <h3 style="margin-left:0cm; margin-right:0cm">Hvis PRK/LASIK (hypermetropi) eller CIRCLE overvejes</h3> <p style="margin-left:0cm; margin-right:0cm">+ Atlas</p> <h2 style="margin-left:0cm; margin-right:0cm"><span style="color:#2f5496">Refraktionering (se særskilt instruks):</span></h2> <ol> <li>Tag udgangspunkt i habituel korrektion</li> <li>Giv +0,5 sf eller -0,5 sf. Herefter +/- 0,25 sf indtil bedste visus opnås</li> <li>Find den bedste akse med kryds cylinder</li> <li>Find den bedste cylindriske styrke med kryds cylinderen</li> <li>Til sidst afbalancerer man ved at give +1,5 sf for begge øjne</li> <li><strong>OBS</strong>: refraktionering foretaget af uddannelsessøgende læge skal konfirmeres af optiker</li> </ol> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm">Ved tvivl ved FUS. Få emailadresse og mobilnummer og konferér med senior læge</p> <h2 style="margin-left:0cm; margin-right:0cm"><span style="color:#2f5496">Eksklusionskriterier</span></h2> <h3 style="margin-left:0cm; margin-right:0cm">Generelle:</h3> <ul> <li>Alder &lt; 21 år</li> <li>Alder &gt; 50 for myope og SMILE</li> <li>Ustabil refraktion indenfor seneste 2 år</li> <li>Velfungerende kontaktlinser</li> <li>Hypermetrope med &gt; +1,50 med lille ACD og under 55 år</li> <li>Oxford score &gt; 1</li> </ul> <h3 style="margin-left:18pt; margin-right:0cm">&nbsp;</h3> <h3 style="margin-left:0cm; margin-right:0cm">Corneal refraktiv kirurgi (SMILE/LASIK/PRK):</h3> <ul> <li>Belin Ambrosio Score</li> <li>Total: rød</li> <li>Back: gul</li> <li>Steepening</li> <li>Inferior ≥ 1,5 D</li> <li>Superior ≥ 2,0 D</li> </ul> <h3 style="margin-left:0cm; margin-right:0cm">&nbsp;</h3> <h3 style="margin-left:0cm; margin-right:0cm">LASIK og ICL</h3> <ul> <li>Kontaktsport</li> </ul> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <h2 style="margin-left:0cm; margin-right:0cm"><span style="color:#2f5496">Generelt flowchart for refraktivt team</span></h2> <ul> <li> <h3><strong>Hypermetropi</strong></h3> <ul style="list-style-type:circle"> <li>&gt; 50 år: RLE monofokal (torisk IOL såfremt corneaastigm. ≥ 1,50 D)</li> <li>&lt; 50 år <ul style="list-style-type:square"> <li>Op til + 1,5 D: Lasik</li> <li>&gt; + 1,5 D: ICL (ACD ≥&nbsp; 3,0 mm), alternativt multifokal RLE (&lt; 40 år)</li> </ul> </li> </ul> </li> </ul> <p style="margin-left:36pt; margin-right:0cm">&nbsp;</p> <ul> <li><strong>Myopi</strong> <ul style="list-style-type:circle"> <li>&gt; 55 år: RLE monofokal (torisk IOL såfremt corneaastigm. ≥ 1,50D)</li> <li>&lt; 50 år <ul style="list-style-type:square"> <li>Op til -12,5 SEQ D (op til -10 D sf og 5 D cyl): SMILE</li> <li>&gt; - 10 D: ICL (Intern ACD ≥ 3,0 mm)</li> </ul> </li> <li>≥ 50 år – 55 år: Individuel vurdering – helst afvente behandling og fortsætte med CL/briller</li> </ul> </li> </ul> <p style="margin-left:36pt; margin-right:0cm">&nbsp;</p> <ul> <li><strong>Astigmatismer</strong> <ul style="list-style-type:circle"> <li>SMILE/LASIK/PRK: op til 5.00 D (Bygningsfejl over 1 cyl reduceres i gennemsnit med 80%)</li> </ul> </li> </ul> <h2 style="margin-left:0cm; margin-right:0cm"><span style="color:#2f5496">Kontrolprogram</span></h2> <h3 style="margin-left:0cm; margin-right:0cm">SMILE</h3> <ul> <li><strong>1 uge:</strong> Pentacam, Visus/refraktion, spaltelampe</li> </ul> <h3 style="margin-left:0cm; margin-right:0cm">LASIK/Circle</h3> <ul> <li><strong>1 dag:</strong> spaltelampe</li> <li><strong>1 uge:</strong> Pentacam, visus/refraktion, spaltelampe</li> </ul> <h3 style="margin-left:0cm; margin-right:0cm">PTK/PRK</h3> <ul> <li><strong>1 uge: </strong>spaltelampe</li> <li><strong>1 md:</strong> Pentacam, visus/refraktion, spaltelampe, tryk</li> </ul> <h3 style="margin-left:0cm; margin-right:0cm">ICL</h3> <ul> <li><strong>1 dag:</strong> visus/refraktion, spaltelampe, IOP</li> <li><strong>3 uger:</strong> Casia, visus/refraktion, spaltelampe, IOP. Afsluttes til eøl for kontrolforløb; 6 mdr, 1 år, 2 år, 3 år, 4 år, 5 år.​​​​​​</li> </ul> <h3>Ved spaltelampekontrol kontrollér følgende:</h3> <ul> <li>Flap in situ?</li> <li>Interface inflammation?</li> <li>Flap folder?</li> <li>Infektion?</li> <li>Debris i flap interface?</li> <li>Epithelindvækst?</li> <li>Vaulting af ICL</li> </ul> <h2 style="margin-left:0cm; margin-right:0cm"><span style="color:#2f5496">Postoperativ medicin: </span></h2> <h3 style="margin-left:0cm; margin-right:0cm">SMILE/LASIK/CIRCLE/RELASIK, flapløft</h3> <ul> <li>Tobradex x 4 i 1 uge</li> <li>Ukonserverede lubrikerende dråber x 4 – gerne i 2 mdr</li> </ul> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <h3 style="margin-left:0cm; margin-right:0cm">PRK/PTK</h3> <ul> <li>Tobradex x 4 i 4 uger</li> <li>Voltabak x 3 i 3 dage</li> <li>Ukonserverede lubrikerende dråber x 4 – gerne i 2 mdr</li> </ul> <h2 style="margin-left:0cm; margin-right:0cm"><span style="color:#2f5496">Behandling af komplikationer</span></h2> <h3 style="margin-left:0cm; margin-right:0cm">Postoperativ keratit</h3> <p style="margin-left:0cm; margin-right:0cm">Der skal skelnes mellem tidlige (indenfor dage) og sene (indenfor uger) keratitter.</p> <p style="margin-left:0cm; margin-right:0cm">De tidlige skyldes oftest gram positive bakterier og de sene som oftest atypiske mykobakterier og svamp.</p> <ol> <li>Overvej flapløft, hvor der samtidig podes til eswap og skylles med Cefuroxim opløsning (samme koncentration som anvendes til kataraktkirurgi). Påfør på dyrkningsseddel: ”obs atypisk mykobakterie”.</li> <li>Hvis der ikke foretages flapløft podes forsigtigt fra cornea. Hvis dette fravælges podes fra konjunktiva. Begge podninger med Eswap mhp dyrkning for svampe og bakterier. Påfør på dyrkningsseddel: ”obs atypisk mykobakterie”.</li> <li>Seponer steroid</li> <li>Antibakteriel behandling: <ol style="list-style-type:lower-alpha"> <li>Tidlige infektioner: Ciloxan og kloramfenikol</li> <li>Sene infektioner: Konf. mikrobiolog</li> <li>Ved obs svamp: Natacyn fra Alcon</li> </ol> </li> </ol> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <h3 style="margin-left:0cm; margin-right:0cm">Interface inflammation</h3> <ol> <li>Rp Maxidex x 8 i 1 uge, herefter x 4 i 1 uge</li> <li>Giv tid til kontrol efter 2 uger, hvor der skal måles tryk</li> </ol> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <h3 style="margin-left:0cm; margin-right:0cm">Makrostriae:</h3> <ul> <li>Skal behandles hurtigst muligt</li> <li>CGE99 Anden operation for vævsforandringer i hornhinde</li> <li>Epithelet over folddannelserne - ca. 5 mm i diameter – fjernes</li> <li>Flappen hydreres med alm. fysiologisk saltvand eller skyllevæske.</li> <li>Folddannelserne udglattes ved at trække 90 grader på deres retning i hver sin ende med tørre spyd</li> <li>CL påsættes og Tobradex x 4 i 1 uge, herefter fjernes CL og der fortsættes med dråber x 2 i 1 uge.</li> </ul> <h3 style="margin-left:0cm; margin-right:0cm">Mikrostriae:</h3> <ul> <li>Foretag wet PTK: vand på cornea, indstil laser på 20 um dybde i 8 mm diameter</li> </ul> <h3 style="margin-left:0cm; margin-right:0cm">Lenticule rester ved SMILE</h3> <ul> <li>Sprøjt ikke væske ind i interfacet, da det vil sløre oversigten</li> <li>Udtag lenticule rester med 25 G VR pincet</li> <li>Udvid pupillen og anvend retroillumination. Herved fremstår resterne meget tydeligt i operationsmikroskop</li> </ul> <h3 style="margin-left:0cm; margin-right:0cm">Intraoperative suction loss (Ref: Titiyal et al: “Current concepts in refractive surgery”)</h3> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> ###TABEL_1### <h1 style="margin-left:0cm; margin-right:0cm"><span style="color:#2f5496"><img src="data:image/png;base64,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" style="height:285px; width:188px" onclick="Ext.DMS.util.showImage(this);"></span></h1> <h2 style="margin-left:0cm; margin-right:0cm"><span style="color:#2f5496">Diverse info</span></h2> <h3 style="margin-left:0cm; margin-right:0cm">PTK:</h3> <ul> <li>8 mm zone i 65 um dybde inducerer 1 D hyperopi</li> </ul> <h3 style="margin-left:0cm; margin-right:0cm">SMILE</h3> <ul> <li>Ved lenticule dissektion: Når man tydeligt kan se lenticulens kant, så er man i posterior plane (meniscus sign)</li> </ul> <h3 style="margin-left:0cm; margin-right:0cm">CLE</h3> <ul> <li> <h3>Anterior optic capture -&gt; 1,5 D højere styrke for linsen -&gt; myopinisering</h3> </li> </ul> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578972527Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699578972527Ansvar"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Ansvar og organisering</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm">Afdelingsledelsen, Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger.<br> Afsnitsledende overlæge, afdelingssygeplejersker og ledende lægesekretærer, er ansvarlig for at instruksen udarbejdes, revideres og implementeres.<br> Den enkelte medarbejder i Afdeling for Øjensygdomme, er ansvarlig for at kende og følge instruksen</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578972527Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699578972527Referencer"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Referencer, lovgivning og faglig evidens samt links hertil</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578972527Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699578972527Bilag"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Bilag</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578972527Top">Tilbage til top</a></p>

Rigshospitalet_¥jensygdomme (HOC)_Refraktiv kirurgi Generel instruks_TABEL_1.

Inkomplet posteriort lenticule cut Redock og gentag hele proceduren umiddelbart efter Inkomplet lenticule side-cut Redock og start fra lenticule side-cut. Mindsk lenticule diameter med 0.3 mm Inkomplet cap cut (ant. lenticule) Redock og gentag fra cap cut Inkomplet incision Redock og gentag kun cap side-cut. Mindsk cap diameter med 0.3 mm

<table border="1" cellspacing="0" class="MsoTableGrid" style="border-collapse:collapse; border:solid windowtext 1.0pt"> <tbody> <tr> <td style="vertical-align:top; width:176.95pt"> <p style="margin-left:0cm; margin-right:0cm">Inkomplet posteriort lenticule cut</p> </td> <td style="vertical-align:top; width:290.6pt"> <p style="margin-left:0cm; margin-right:0cm">Redock og gentag hele proceduren umiddelbart efter</p> </td> </tr> <tr> <td style="vertical-align:top; width:176.95pt"> <p style="margin-left:0cm; margin-right:0cm">Inkomplet lenticule side-cut</p> </td> <td style="vertical-align:top; width:290.6pt"> <p style="margin-left:0cm; margin-right:0cm">Redock og start fra lenticule side-cut.</p> <p style="margin-left:0cm; margin-right:0cm">Mindsk lenticule diameter med 0.3 mm</p> </td> </tr> <tr> <td style="vertical-align:top; width:176.95pt"> <p style="margin-left:0cm; margin-right:0cm">Inkomplet cap cut (ant. lenticule)</p> </td> <td style="vertical-align:top; width:290.6pt"> <p style="margin-left:0cm; margin-right:0cm">Redock og gentag fra cap cut</p> </td> </tr> <tr> <td style="vertical-align:top; width:176.95pt"> <p style="margin-left:0cm; margin-right:0cm">Inkomplet incision</p> </td> <td style="vertical-align:top; width:290.6pt"> <p style="margin-left:0cm; margin-right:0cm">Redock og gentag kun cap side-cut.</p> <p style="margin-left:0cm; margin-right:0cm">Mindsk cap diameter med 0.3 mm</p> </td> </tr> </tbody> </table>

Rigshospitalet_¥jensygdomme (HOC)_Refraktiv kirurgisk team visitering unders¢gelse og.

Refraktiv kirurgisk team, visitering, undersøgelse og journalføring ved optiker Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Bilag Målgrupper og anvendelsesområde Instruksen beskriver delegering af visitering, praktisk udørelse af undersøgelser og journalføring til optikere i refraktiv team, Afdeling for Øjensygdomme, Rigshospitalet. Instruksen angiver: - definition af delegeret opgave, uddannelse og oplæring, tilsyn og kvalitetsmonitorering, dokumentation i personalesagen samt praktisk udførelse af den delegerede opgave - ansvar og opgavefordeling Dette Jvf. Delegation af forbeholdt sundhedsfaglig virksomhed, vejledning fra Region Hovedstaden Gældende for optikere og ansvarlig overlæge i refraktiv kirurgisk team i Afdeling for Øjensygdomme, Rigshospitalet. Definitioner Afdelingen: Afdeling for Øjensygdomme, Rigshospitalet Fremgangsmåde For delegeringen Opgave der delegeres: - Visitering, praktisk udførelse og journalføring vedrørende - Forundersøgelse - Operationsindiktion / treatmentplan - Postoperative kontroller - Afslutning / epikrise Kompetencer og kvalifikationer, som personen, opgaven delegeres til have: - Autoriseret optometrist Uddannelse og oplæring - Teoretisk uddannelse og praktisk oplæring: Introduktion i refraktiv kirurgisk team i Øjenklinikken, ved erfaren optiker/øjenlæge i de første 3 måneder fra ansættelsen. Ved at følge erfaren optiker/øjenlæge i perioden diskuteres problemstiller vedrørende forundersøgelse og kontrol. Det sikres gennem samtale og ved læsning af de førte journaler at optikeren har erhvervet tilstrækkelig teoretisk grundlag for og praktisk kunnen til at kunne udføre opgaverne selvstændigt under supervision af erfaren optiker/teamets seniorlæger. Efter 3 måneder er optikeren instrueret i at alle problem patienter (dvs patienter med unormale øjenstrukturer, unormal synstyrke, usikker refraktion, usikker operationsindikation, operations komplikationer og uventet forløb) skal forelægges en af teamets seniorlæger, som i journalnotat tager stilling til problemet. De Øjenlægelige seniorlæger kontrollerer journalens indhold og kvalitet før hver operation og i forbindelse med kompliceret forløb før afslutning. Øjendråber og administration af øjendråber, undervisning af ikke-sundhedsfagligt personale, Afdeling for Øjensygdomme, Rigshospitalet, ved medicinansvarlig afdelingslæge og sygeplejerske - Dokumentation for opnået teoretisk viden og praktiske færdigheder ved: Findes i det journalmateriale den enkelte optiker har ført og som kontrolleres som ovenfor nævnt. Ved 3 måneders samtalen dokumenteres at optikeren har opnået færdigheder som beskrevet under teoretisk uddannelse og praktisk oplæring. Tilsyn og kvalitetsmonitorering - Tilsyn og kvalitetsmonitorering Journalgennemgang sker løbende ved seniorlæge i refraktiv kirurgisk team Løbende opfølgning ved problemer MUS, medarbejderudviklingssamtale, ved teamansvarlig overlæge for refraktiv kirurgisk team. Dokumentation i personalesagen - Af stillingsbeskrivelsen skal delegeret opgave fremgå: Visitering, praktisk udførelse og journalføring vedrørende forundersøgelse, operationsindikation/treatment, postoperative kontroller og afslutning/epikrise i refraktiv kirurgisk team i Afdeling af Øjensygdomme, Rigshospitalet. - Eksamensbevis / dokumentation for teoretisk uddannelse og praktisk oplæring: Optometrist eksamens bevis Øjendråber og administration af øjendråber, undervisning af ikke-sundhedsfagligt personale, Afdeling for Øjensygdomme, Rigshospitalet. 3 måneders samtale - Dokumentation for at der er udført tilsyn og kvalitetsmonitorering Dokumenteres ved den årlige medarbejderudviklingssamtale (MUS) - Dokumenteres af: Teamansvarlig overlæge for refraktiv kirurgisk team Afdelingsygeplejerske for refraktiv kirurgisk team, er ansvarlig for at dokumentation kommer i personalesagen Praktisk udførelse af den delegerede opgave - Patientkategori, herunder diagnoser og patienter, som er omfattet: Patienter der er henvist med Patienter med brydningsfejl, uden anden øjensygdom. Langsynethed (hypermetropi H52,0) Nærsynethed (myopi H52,1) Bygningsfejl (astigmatisme H52,2) Forskellig brydning på de 2 øjne (anisometropi H52,3) Gammelmandssyn (presbyopi H52,4) - Delegeringen er ikke gældende for: Refraktive patienter med andre øjensygdomme Refraktive patienter med somatiske / psykiske sygdomme - En læge inddrages i følgende situationer: Ved refraktioner - Større end minus 10 dioptri i sfærisk ekvivalent - Større end plus 4 dioptri i sfærisk ekvivalent - Bygningsfejl større end 4 dioptri - Anisometropi større end 3 dioptri - Amblyopi Patienter som ikke opfylder de refraktive kriterier for offentligt betalt behandling som er: - Myopi større end 6 dioptrier på begge øjne (målt som brillestyrkens sfæriske ækvivalent). - Hypermetropi større end 6 dioptrier på begge øjne (målt som brillestyrkens sfæriske ækvivalent). - En forskel i brydningsstyrke (anisometropi) på de to øjne på mere end 3 dioptrier (målt som brillestyrkens sfæriske ækvivalent). - Astimatisme på ét eller begge øjne på mere end 3 dioptrier (brillestyrke). - Andre refraktionsanomalier, hvor anvendelse af briller eller kontaktlinser ikke er en mulig foranstaltning på grund af medicinske eller fysiske forhold. - Andre refraktionsanomalier, der medfører at erhvervsevnen i patientens eksisterende erhverv er truet pga afhængighed af briller eller kontaktlinser. - Uregelmæsiing astigmatisme (uregelmæssige brydningsfejl) som ikke kan korrigeres med briller eller kontaktlinser. Ved abnorm hornhindetopografi (pentacam undersøgelse) Ved øjensygdom Ved somatisk / psykisk sygdom - Praktisk udførelse: Jvf. Øjenklinikkens instrukser: Refraktiv kirurgi team, refraktiv forundersøgelse Corneal laser operation, Refraktiv kirurgi Øjenklinikken, præ- og postoperativ ordination af øjendråber og anden medicin samt vejledende Refraktiv kirurgi team, postoperative komplikationer - behandling Refraktiv kirurgi team, postoperativ kontrol og behandling - Andre instrukser der skal efterleves: Jvf. Region Hovedstadens dokumenter SP-Sundhedsplatform: Lægelig vurdering og journalføring Journalføring - vurdering og indhold Ansvar og organisering Er beskrevet i Delegation af forbeholdt sundhedsfaglig virksomhed, vejledning fra Region Hovedstaden Referencer, lovgivning og faglig evidens samt links hertil Fra Region Hovedstaden: Delegation af forbeholdt sundhedsfaglig virksomhed, vejledning Lægelig vurdering og journalføring, dokument SP-Sundhedsplatform Journalføring - vurdering og indhold, dokument SP-Sundhedsplatform Fra Afdeling for Øjensygdomme, Rigshospitalet Refraktiv kirurgi team, refraktiv forundersøgelse, instruks Refraktiv kirurgi team, corneal laser operation, instruks Øjenklinikken, præ- og postoperativ ordination af øjendråber og anden medicin samt vejledende, instruks Refraktiv kirurgi team, postoperative komplikationer - behandling, instruks Refraktiv kirurgi team, postoperativ kontrol og behandling, instruks Bilag

<h1><div id="Afsnit#1699579072122">Refraktiv kirurgisk team, visitering, undersøgelse og journalføring ved optiker</div></h1><div id="BodyWeb#1699579072122"><p><a name="1699579072122Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579072122Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579072122Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579072122Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579072122Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579072122Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579072122Bilag">Bilag</a><br> &nbsp;</h3> <h2>&nbsp;</h2> <div class="collapsible-item" expandedstart="1"><a name="1699579072122Maalgrupper"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Målgrupper og anvendelsesområde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>Instruksen beskriver delegering af visitering, praktisk udørelse af undersøgelser og journalføring til optikere i refraktiv team, Afdeling for Øjensygdomme, Rigshospitalet.</p> <p>Instruksen angiver:</p> <ul> <li>definition af delegeret opgave, uddannelse og oplæring, tilsyn og kvalitetsmonitorering, dokumentation i personalesagen samt praktisk udførelse af den delegerede opgave&nbsp;</li> <li>ansvar og opgavefordeling</li> </ul> <p>Dette Jvf. <a href="###FOLDER###" target="_blank">Delegation af forbeholdt sundhedsfaglig virksomhed</a>, vejledning fra Region Hovedstaden</p> <p>Gældende for optikere og ansvarlig overlæge i refraktiv kirurgisk team i Afdeling for Øjensygdomme, Rigshospitalet.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579072122Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579072122Definitioner"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Definitioner</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>Afdelingen: Afdeling for Øjensygdomme, Rigshospitalet</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579072122Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579072122Fremgangsmaade"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Fremgangsmåde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p><strong>For delegeringen</strong></p> <p>Opgave der delegeres:</p> <ul> <li>Visitering, praktisk udførelse og journalføring vedrørende</li> <li>Forundersøgelse</li> <li>Operationsindiktion / treatmentplan</li> <li>Postoperative kontroller</li> <li>Afslutning / epikrise</li> </ul> <p>Kompetencer og kvalifikationer, som personen, opgaven delegeres til have:</p> <ul> <li>Autoriseret optometrist</li> </ul> <p><strong>Uddannelse og oplæring</strong></p> <ul> <li>Teoretisk uddannelse og praktisk oplæring:</li> </ul> <p style="margin-left:80px">Introduktion i refraktiv kirurgisk team i Øjenklinikken, ved erfaren optiker/øjenlæge i de første 3 måneder fra ansættelsen.</p> <p style="margin-left:80px">Ved at følge erfaren optiker/øjenlæge i perioden diskuteres problemstiller vedrørende forundersøgelse og kontrol. Det sikres gennem samtale og ved læsning af de førte journaler at optikeren har erhvervet tilstrækkelig teoretisk grundlag for og praktisk kunnen til at kunne udføre opgaverne selvstændigt under supervision af erfaren optiker/teamets seniorlæger.</p> <p style="margin-left:80px">Efter 3 måneder er optikeren instrueret i at alle problem patienter (dvs patienter med unormale øjenstrukturer, unormal synstyrke, usikker refraktion, usikker operationsindikation, operations komplikationer og uventet forløb) skal forelægges en af teamets seniorlæger, som i journalnotat tager stilling til problemet. De Øjenlægelige seniorlæger kontrollerer journalens indhold og kvalitet før hver operation og i forbindelse med kompliceret forløb før afslutning.</p> <p style="margin-left:80px">Øjendråber og administration af øjendråber, undervisning af ikke-sundhedsfagligt personale, Afdeling for Øjensygdomme, Rigshospitalet, ved medicinansvarlig afdelingslæge og sygeplejerske</p> <ul> <li>Dokumentation for opnået teoretisk viden og praktiske færdigheder ved:</li> </ul> <p style="margin-left:80px">Findes i det journalmateriale den enkelte optiker har ført og som kontrolleres som ovenfor nævnt.</p> <p style="margin-left:80px">Ved 3 måneders samtalen dokumenteres at optikeren har opnået færdigheder som beskrevet under teoretisk uddannelse og praktisk oplæring.<br> &nbsp;</p> <p><strong>Tilsyn og kvalitetsmonitorering</strong></p> <ul> <li>Tilsyn og kvalitetsmonitorering</li> </ul> <p style="margin-left:80px">Journalgennemgang sker løbende ved seniorlæge i refraktiv kirurgisk team<br> Løbende opfølgning ved problemer</p> <p style="margin-left:80px">MUS, medarbejderudviklingssamtale, ved teamansvarlig overlæge for refraktiv kirurgisk team.<br> &nbsp;</p> <p><strong>Dokumentation i personalesagen</strong></p> <ul> <li>Af stillingsbeskrivelsen skal delegeret opgave fremgå:&nbsp;</li> </ul> <p style="margin-left:80px">Visitering, praktisk udførelse og journalføring vedrørende forundersøgelse, operationsindikation/treatment, postoperative kontroller og afslutning/epikrise i refraktiv kirurgisk team i Afdeling af Øjensygdomme, Rigshospitalet.</p> <ul> <li>Eksamensbevis / dokumentation for teoretisk uddannelse og praktisk oplæring:</li> </ul> <p style="margin-left:80px">Optometrist eksamens bevis<br> Øjendråber og administration af øjendråber, undervisning af ikke-sundhedsfagligt personale, Afdeling for Øjensygdomme, Rigshospitalet.<br> 3 måneders samtale</p> <ul> <li>Dokumentation for at der er udført tilsyn og kvalitetsmonitorering</li> </ul> <p style="margin-left:80px">Dokumenteres ved den årlige medarbejderudviklingssamtale (MUS)</p> <ul> <li>Dokumenteres af:</li> </ul> <p style="margin-left:80px">Teamansvarlig overlæge for refraktiv kirurgisk team<br> &nbsp;Afdelingsygeplejerske for refraktiv kirurgisk team, er ansvarlig for at dokumentation kommer i personalesagen<br> &nbsp;</p> <p><strong>Praktisk udførelse af den delegerede opgave</strong></p> <ul> <li>Patientkategori, herunder diagnoser og patienter, som er omfattet:</li> </ul> <p style="margin-left:80px">Patienter der er henvist med</p> <p style="margin-left:120px">Patienter med brydningsfejl, uden anden øjensygdom.<br> Langsynethed (hypermetropi H52,0)<br> Nærsynethed (myopi H52,1)<br> Bygningsfejl (astigmatisme H52,2)<br> Forskellig brydning på de 2 øjne (anisometropi H52,3)<br> Gammelmandssyn (presbyopi H52,4)</p> <ul> <li>Delegeringen er ikke gældende for:</li> </ul> <p style="margin-left:80px">Refraktive patienter med andre øjensygdomme<br> Refraktive patienter med somatiske / psykiske sygdomme&nbsp;</p> <ul> <li>En læge inddrages i følgende situationer:</li> </ul> <p style="margin-left:80px">Ved refraktioner</p> <ul> <li style="margin-left: 80px;">Større end minus 10 dioptri i sfærisk ekvivalent</li> <li style="margin-left: 80px;">Større end plus 4 dioptri i sfærisk ekvivalent</li> <li style="margin-left: 80px;">Bygningsfejl større end 4 dioptri</li> <li style="margin-left: 80px;">Anisometropi større end 3 dioptri</li> <li style="margin-left: 80px;">Amblyopi</li> </ul> <p style="margin-left:80px">Patienter som ikke opfylder de refraktive kriterier for offentligt betalt behandling&nbsp; som er:</p> <ul style="margin-left:80px"> <li>Myopi større end 6 dioptrier på begge øjne (målt som brillestyrkens sfæriske ækvivalent).</li> <li>Hypermetropi større end 6 dioptrier på begge øjne (målt som brillestyrkens sfæriske ækvivalent).</li> <li>En forskel i brydningsstyrke (anisometropi) på de to øjne på mere end 3 dioptrier (målt som brillestyrkens sfæriske ækvivalent).</li> <li>Astimatisme på ét eller begge øjne på mere end 3 dioptrier (brillestyrke).</li> <li>Andre refraktionsanomalier, hvor anvendelse af briller eller kontaktlinser ikke er en mulig foranstaltning på grund af medicinske eller fysiske forhold.</li> <li>Andre refraktionsanomalier, der medfører at erhvervsevnen i patientens eksisterende erhverv er truet pga afhængighed af briller eller kontaktlinser.</li> <li>Uregelmæsiing astigmatisme (uregelmæssige brydningsfejl) som ikke kan korrigeres&nbsp; med briller eller kontaktlinser.</li> </ul> <p style="margin-left:80px">Ved abnorm hornhindetopografi (pentacam undersøgelse)</p> <p style="margin-left:80px">Ved øjensygdom</p> <p style="margin-left:80px">Ved somatisk / psykisk sygdom&nbsp;&nbsp;</p> <ul> <li>Praktisk udførelse:</li> </ul> <p style="margin-left:80px">Jvf. Øjenklinikkens instrukser:</p> <p style="margin-left:120px"><a href="###FOLDER###" target="_blank">Refraktiv kirurgi team, refraktiv forundersøgelse</a></p> <p style="margin-left:120px"><a href="###FOLDER###" target="_blank">Corneal laser operation, Refraktiv kirurgi</a></p> <p style="margin-left:120px"><a href="###FOLDER###" target="_blank">Øjenklinikken, præ- og postoperativ ordination af øjendråber og anden medicin samt vejledende </a></p> <p style="margin-left:120px"><a href="###FOLDER###" target="_blank">Refraktiv kirurgi team, postoperative komplikationer - behandling</a></p> <p style="margin-left:120px"><a href="###FOLDER###" target="_blank"><u><span style="color:#0066cc">Refraktiv kirurgi team, postoperativ kontrol og behandling</span></u></a><br> &nbsp;</p> <ul> <li>Andre instrukser der skal efterleves:</li> </ul> <p style="margin-left:80px">Jvf. Region Hovedstadens dokumenter SP-Sundhedsplatform:</p> <p style="margin-left:120px"><a href="###FOLDER###" target="_blank">Lægelig vurdering og journalføring</a></p> <p style="margin-left:120px"><a href="###FOLDER###" target="_blank">Journalføring - vurdering og indhold</a></p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579072122Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579072122Ansvar"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Ansvar og organisering</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>Er beskrevet i <a href="###FOLDER###" target="_blank"><u><span style="color:#0066cc">Delegation af forbeholdt sundhedsfaglig virksomhed</span></u></a>, vejledning fra Region Hovedstaden</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579072122Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579072122Referencer"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Referencer, lovgivning og faglig evidens samt links hertil</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>Fra Region Hovedstaden:</p> <p style="margin-left:40px"><a href="###FOLDER###" target="_blank">Delegation af forbeholdt sundhedsfaglig virksomhed</a>, vejledning</p> <p style="margin-left:40px"><a href="###FOLDER###" target="_blank"><u><span style="color:#0066cc">Lægelig vurdering og journalføring</span></u></a>, dokument SP-Sundhedsplatform</p> <p style="margin-left:40px"><a href="###FOLDER###" target="_blank"><u><span style="color:#0066cc">Journalføring - vurdering og indhold</span></u></a>, dokument SP-Sundhedsplatform</p> <p>Fra Afdeling for Øjensygdomme, Rigshospitalet</p> <p style="margin-left:40px"><a href="###FOLDER###" target="_blank"><u><span style="color:#0066cc">Refraktiv kirurgi team, refraktiv forundersøgelse,</span></u></a> instruks</p> <p style="margin-left:40px"><a href="###FOLDER###" target="_blank"><u><span style="color:#0066cc">Refraktiv kirurgi team, corneal laser operation,</span></u></a> instruks</p> <p style="margin-left:40px"><a href="###FOLDER###" target="_blank"><u><span style="color:#0066cc">Øjenklinikken, præ- og postoperativ ordination af øjendråber og anden medicin samt vejledende, </span></u></a>instruks<a href="###FOLDER###" target="_blank"><u><span style="color:#0066cc">&nbsp;</span></u></a></p> <p style="margin-left:40px"><a href="###FOLDER###" target="_blank"><u><span style="color:#0066cc">Refraktiv kirurgi team, postoperative komplikationer - behandling,</span></u></a> instruks</p> <p style="margin-left:40px"><a href="###FOLDER###" target="_blank"><u><span style="color:#0066cc">Refraktiv kirurgi team, postoperativ kontrol og behandling</span></u></a>, instruks</p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579072122Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579072122Bilag"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Bilag</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579072122Top">Tilbage til top</a></p>

Rigshospitalet_¥jensygdomme (HOC)_Region Hovedstadens ¢jenvagtordning.

Region Hovedstadens øjenvagtordning Formål Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Formål At informere aktørerne i Region Hovedstadens øjenvagtordning, så patienter med akut opstået øjensygdom tilbydes den rigtige sundhedsfaglige ydelse. Målgrupper og anvendelsesområde - Skadestuer/akutmodtagelser på hospitaler i Region H og Region Sjælland - Praktiserende øjenlæger på Sjælland - Vagtlægeordningen / 1813 - Praktiserende læger i Region H - Øjenafdelinger på hospitaler i Region Sjælland - Ambulancetjenester - Hospitalsdirektioner i Region H Definitioner Fremgangsmåde Generelt I henhold til Region Hovedstadens Hospitals – og Psykiatriplan 2020 er regionens vagtberedskab for patienter med akut øjensygdom henlagt til Afdeling for Øjensygdomme, Rigshospitalet-Glostrup. For den regionale vagtordning gælder følgende retningslinjer. Patienter med akut opstået øjensygdom kan fra skadestuelæge, ambulatorielæge, praktiserende øjenlæge, praktiserende læge, vagtlæge eller læge på afdelinger, hvor patienten er indlagt, henvises til/konfereres med Afdeling for Øjensygdomme, Rigshospitalet-Glostrup, vagthavende øjenlæge, telefon ###TELEFON###. Region Hovedstadens Centrale Visitationer (CVI) er ikke involveret i de akutte henvisninger. Eventuel transport af patienten rekvireres af Afdeling for Øjensygdomme. Afdeling for Øjensygdomme, Rigshospitalet-Glostrup kan kontaktes på følgende telefonnumre: - Vagthavende øjenlæge Rigshospitalet-Glostrup, tlf. ###TELEFON### - Vagthavende sygeplejerske, tlf. ###TELEFON### - Rigshospitalet-Glostrup (omstillingen), tlf. ###TELEFON### - Sengeafsnit / klinik for Akutte Øjensygdomme, Rigshospitalet-Glostrup, tlf. ###TELEFON### Særligt for indlagte patienter Regionshospitaler uden egen øjenfunktion Herlev og Gentofte Hospital; Bispebjerg og Frederiksberg Hospital; Hvidovre og Amager Hospital; Bornholms Hospital Patienter, som har behov for akut øjentilsyn og som ikke kan flyttes til Rigshospitalet-Glostrup, serviceres af vagtholdet fra Rigshospitalet-Glostrup. Afgørelse om flytbarhed træffes af stamafdelingen og vagthavende læger i Afdeling for Øjensygdomme. Regionshospitaler med egen øjenfunktion Nordsjællands Hospital (Hillerød) og Rigshospitalet-Blegdamsvej Nordsjællands Hospital (Hillerød) Patienter fra skadestuen og indlagte patienter på hospitalet ses akut i tidsrummet mandag – torsdag kl. 8–14 og fredag kl. 8 -12. Vagthavende øjenlæge tlf. ###TELEFON### eller akutnummer tlf. ###TELEFON###. Udenfor førnævnte tidsrum henvises alle andre akutte patienter til Rigshospitalet-Glostrup. Rigshospitalet-Blegdamsvej Afdeling for Øjensygdomme modtager akutte patienter fra andre afdelinger på hospitalet i dagtiden mandag – torsdag kl. 8-14 og fredag kl. 8-12. Vagthavende øjenlæge tlf. ###TELEFON###. Uden for dagtiden henvises patienter fra Nordsjællands Hospital og Rigshospitalet-Blegdamsvej til Rigshospitalet-Glostrup. Akut operation af øjenpatienter på Rigshospitalet-Blegdamsvej Ved operation af patienter, som har brug for akut kirurgi uden for dagtiden og som ikke kan flyttes til Rigshospitalet-Glostrup, gælder, at afgørelse om flytbarhed træffes af stamafdelingen (klinikken), Afdeling for Øjensygdommes overlægebagvagt og HOC anæstesi- og operationsklinikkens bagvagt tlf. ###TELEFON###. Ved operation stiles der efter, at operationen foregår på øjenoperationsgangen 6013, der åbnes af og anæstesimæssigt bemandes af HOC-personale. HOC stiller ligeledes med en ikke-steril gulvsygeplejerske. Rigshospitalet-Glostrups øjenvagthold (læge og operationssygeplejerske) udfører det operative indgreb. En akut operationskasse med instrumenter til små-kirurgi samt rød rygsæk og håndspaltelampe til brug ved tilsyn findes på afsnit 7066, klinik 666 og vedligeholdes af Afdeling for Øjensygdommes ambulatorium, Rigshospitalet-Blegdamsvej. Øjenkirurgiske instrumenter og tekniske hjælpemidler, som f. eks operationsmikroskop, findes på operationsafsnit 6013 og kendes af vagtholdet fra Rigshospitalet-Glostrup. Rigshospitalets Traumecenter - Traumecenteret serviceres i dagtiden mandag til torsdag kl. 8.00-15.00 og fredag kl 8.00-14.30 (ved vagthavende på øjenfunktion Rigshospitalet-Blegdamsvej, telefon ###TELEFON###. Udenfor dette tidsrum tilkaldes øjenlægevagten fra Rigshospitalet-Glostrup. - Mindre operative indgreb på patienter, der ligger i Traumecenteret, kan udenfor dagtiden udføres på Traumecentrets operationsstue af vagtholdet fra Rigshospitalet-Glostrup. Kontaktinformation ved tvivlsspørgsmål Afdeling for Øjensygdomme, Rigshospitalet-Glostrup, - Ledende overlæge, telefon ###TELEFON### - Ledende oversygeplejerske, telefon 38634 702 - Teamleder i vagten, overlæge, telefon ###TELEFON### (kirurgisk retina sekretær) Ansvar og organisering Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, har ansvar for, at der foreligger en vejledning om retningslinier for den regionale øjenvagtordning i Region Hovedstaden. Aktørerne nævnt i vejledningen er ansvarlige for at kende og følge vejledningens retningslinier. Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag

<h1><div id="Afsnit#1699579145745">Region Hovedstadens øjenvagtordning</div></h1><div id="BodyWeb#1699579145745"><p><a name="1699579145745Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579145745Formaal">Formål</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579145745Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579145745Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579145745Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579145745Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579145745Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579145745Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579145745Bilag">Bilag</a><br> &nbsp;</h3> <p><a name="1699579145745Formaal"></a></p> <h2>Formål</h2> <p>At informere aktørerne i Region Hovedstadens øjenvagtordning, så patienter med akut opstået øjensygdom tilbydes den rigtige sundhedsfaglige ydelse.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579145745Top">Tilbage til top</a></p> <h2><a name="1699579145745Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <ul> <li>Skadestuer/akutmodtagelser på hospitaler i Region H og Region Sjælland</li> <li>Praktiserende øjenlæger på Sjælland</li> <li>Vagtlægeordningen / 1813</li> <li>Praktiserende læger i Region H</li> <li>Øjenafdelinger på hospitaler i Region Sjælland</li> <li>Ambulancetjenester</li> <li>Hospitalsdirektioner i Region H<br> &nbsp;</li> </ul> <p>&nbsp;<a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579145745Top">Tilbage til top</a></p> <h2><a name="1699579145745Definitioner"></a></h2> <h2>Definitioner</h2> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579145745Top">Tilbage til top</a></p> <h2>&nbsp;</h2> <h2><a name="1699579145745Definitioner"></a></h2> <h2>Fremgangsmåde</h2> <h3><strong>Generelt</strong></h3> <p>I henhold til Region Hovedstadens Hospitals – og Psykiatriplan 2020 er regionens vagtberedskab for patienter med akut øjensygdom&nbsp;henlagt til Afdeling for Øjensygdomme,&nbsp;Rigshospitalet-Glostrup.</p> <p>For den regionale vagtordning gælder følgende retningslinjer.</p> <p>Patienter med akut opstået øjensygdom kan fra skadestuelæge, ambulatorielæge, praktiserende øjenlæge, praktiserende læge, vagtlæge eller læge på afdelinger, hvor patienten er indlagt, henvises til/konfereres med Afdeling for Øjensygdomme, Rigshospitalet-Glostrup, vagthavende øjenlæge, telefon ###TELEFON###.</p> <p>Region Hovedstadens Centrale Visitationer (CVI) er ikke involveret i de akutte henvisninger.</p> <p>Eventuel transport af patienten rekvireres af Afdeling for Øjensygdomme.</p> <p>&nbsp;</p> <p>Afdeling for Øjensygdomme, Rigshospitalet-Glostrup kan kontaktes på følgende telefonnumre:</p> <ul> <li>Vagthavende øjenlæge Rigshospitalet-Glostrup, tlf. ###TELEFON###</li> <li>Vagthavende sygeplejerske, tlf.&nbsp;###TELEFON###</li> <li>Rigshospitalet-Glostrup&nbsp;(omstillingen), tlf.&nbsp;###TELEFON###</li> <li>Sengeafsnit / klinik for Akutte Øjensygdomme, Rigshospitalet-Glostrup, tlf. ###TELEFON###</li> </ul> <h3><strong>Særligt for indlagte patienter</strong><br> &nbsp;</h3> <p><strong>Regionshospitaler uden egen øjenfunktion</strong><br> <span style="color:#000000"><a href="https://www.herlevhospital.dk/" target="_blank">Herlev</a> og <a href="https://www.gentoftehospital.dk/" target="_blank">Gentofte Hospital</a>; <a href="https://www.bispebjerghospital.dk/" target="_blank">Bispebjerg</a> og <a href="https://www.frederiksberghospital.dk/" target="_blank">Frederiksberg Hospital</a>; <a href="https://www.hvidovrehospital.dk/" target="_blank">Hvidovre</a> og <a href="https://www.amagerhospital.dk/" target="_blank">Amager Hospital</a>;&nbsp;<a href="https://www.bornholmshospital.dk/" target="_blank">Bornholms Hospital </a></span></p> <p>Patienter, som har behov for akut øjentilsyn og som ikke kan flyttes til Rigshospitalet-Glostrup,&nbsp;serviceres af vagtholdet fra Rigshospitalet-Glostrup. Afgørelse om flytbarhed træffes af stamafdelingen og vagthavende læger i Afdeling for Øjensygdomme.</p> <p>&nbsp;</p> <p><strong>Regionshospitaler med egen øjenfunktion</strong><br> Nordsjællands Hospital&nbsp;(Hillerød) og Rigshospitalet-Blegdamsvej</p> <p><em>Nordsjællands Hospital (Hillerød)</em><br> Patienter fra skadestuen og indlagte patienter på hospitalet ses akut i tidsrummet&nbsp;mandag – torsdag kl. 8–14 og fredag kl. 8 -12. Vagthavende øjenlæge tlf. ###TELEFON### eller akutnummer tlf. ###TELEFON###. Udenfor førnævnte tidsrum henvises alle andre akutte patienter til Rigshospitalet-Glostrup.&nbsp;</p> <p><em>Rigshospitalet-Blegdamsvej</em><br> Afdeling for Øjensygdomme modtager akutte patienter fra andre afdelinger på hospitalet i dagtiden mandag – torsdag kl. 8-14 og fredag kl. 8-12. Vagthavende øjenlæge tlf. ###TELEFON###.</p> <p>Uden for dagtiden henvises patienter fra&nbsp;Nordsjællands Hospital&nbsp;og Rigshospitalet-Blegdamsvej til Rigshospitalet-Glostrup.</p> <p>&nbsp;</p> <p><strong>Akut operation af øjenpatienter på Rigshospitalet-Blegdamsvej &nbsp;</strong><br> Ved operation af patienter, som har brug for akut kirurgi uden for dagtiden og som ikke kan flyttes til Rigshospitalet-Glostrup, gælder, at afgørelse om flytbarhed træffes af stamafdelingen (klinikken), Afdeling for Øjensygdommes overlægebagvagt og HOC anæstesi- og operationsklinikkens bagvagt tlf. ###TELEFON###.</p> <p>Ved operation stiles der efter, at operationen foregår på øjenoperationsgangen 6013,&nbsp;der åbnes af og anæstesimæssigt bemandes af HOC-personale. HOC stiller ligeledes med en ikke-steril gulvsygeplejerske. Rigshospitalet-Glostrups øjenvagthold&nbsp;(læge og operationssygeplejerske) udfører det operative indgreb.</p> <p>En akut operationskasse med instrumenter til små-kirurgi samt rød rygsæk og håndspaltelampe til brug ved tilsyn findes på afsnit 7066, klinik 666 og vedligeholdes af Afdeling for Øjensygdommes ambulatorium, Rigshospitalet-Blegdamsvej. Øjenkirurgiske instrumenter og tekniske hjælpemidler, som f. eks operationsmikroskop, findes på operationsafsnit 6013 og kendes af vagtholdet fra Rigshospitalet-Glostrup.</p> <p>&nbsp;</p> <p><strong>Rigshospitalets Traumecenter</strong></p> <ul> <li>Traumecenteret serviceres&nbsp;i dagtiden mandag til torsdag kl. 8.00-15.00 og fredag kl 8.00-14.30&nbsp;(ved vagthavende på øjenfunktion Rigshospitalet-Blegdamsvej,&nbsp;telefon ###TELEFON###. Udenfor dette tidsrum tilkaldes øjenlægevagten&nbsp;fra Rigshospitalet-Glostrup.</li> <li>Mindre operative indgreb på patienter, der ligger i Traumecenteret, kan udenfor dagtiden udføres på Traumecentrets operationsstue af vagtholdet fra Rigshospitalet-Glostrup.<br> &nbsp;</li> </ul> <p><strong>Kontaktinformation ved tvivlsspørgsmål </strong></p> <p style="margin-left:40px">Afdeling for Øjensygdomme, Rigshospitalet-Glostrup,</p> <ul style="margin-left:80px"> <li>Ledende overlæge, telefon ###TELEFON###</li> <li>Ledende oversygeplejerske, telefon 38634 702</li> <li>Teamleder i vagten, overlæge, telefon ###TELEFON### (kirurgisk retina sekretær)&nbsp;</li> </ul> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579145745Top">Tilbage til top</a></p> <h2><a name="1699579145745Ansvar"></a><br> Ansvar og organisering</h2> <p>Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet,&nbsp;har ansvar for, at der foreligger en vejledning om retningslinier for den regionale øjenvagtordning i Region Hovedstaden.</p> <p>Aktørerne nævnt i vejledningen er ansvarlige for at kende og følge vejledningens retningslinier. &nbsp;&nbsp;</p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579145745Top">Tilbage til top</a></p> <h2><a name="1699579145745Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579145745Top">Tilbage til top</a></p> <h2><a name="1699579145745Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579145745Top">Tilbage til top</a></p> <h2><a name="1699579145745Bilag"></a><br> Bilag</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579145745Top">Tilbage til top</a></p>

Rigshospitalet_¥jensygdomme (HOC)_Screening af AMD ved sygeplejersker og.

Screening af AMD ved sygeplejersker og optikere Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Målgrupper Instruksen beskriver delegering af funktionen med "screening af patienter i behandlingsforløb for våd AMD, aldersrelateret maculadegeneration" til sygeplejersker og optometrister i Afdeling for Øjensygdomme, Rigshospitalet. Instruksen angiver definition af den delegerede opgave, herunder: - Uddannelse, oplæring og praktisk udførelse af den delegerede opgave - Tilsyn og kvalitetsmonitorering - Dokumentation i personalesagen - Ansvar og opgavefordeling Dette Jvf. Region Hovedstadens dokument, Delegation af forbeholdt sundhedsfaglig virksomhed. I dokumentet er en lokal tilføjelse gældende for Afdeling for Øjensygdomme Gældende for sygeplejersker, optometrister og læger i medicinsk retina, Afdeling for Øjensygdomme, Rigshospitalet. Definitioner AMD: Aldersrelateret maculadegeneration OCT: Optical Coherence Tomography BOB: Bedre oftalmologi for brugere SP: Sundhedsplatformen Fremgangsmåde Opgave der skal delegeres Selvstændig screening af patienter i behandlingsforløb for våd AMD, aldersrelateret maculadegeneration Uddannelse og oplæring Grundlæggende kompetencer og kvalifikationer: - Autoriseret sygeplejerske eller optometrist - Minimum ét års ansættelse i medicinsk retina, med selvstændige kontrolforløb i AMD over en periode på minimum tre måneder. - Oftalmologisk basisviden svarende til "Oftalmologisk eksamen for ikke-lægeligt personale ved Øjenafdelingen" Eksamen: Mundtlig eksamen, afholdes af overlæge med et censor-team bestående af ledende overlæge og oversygeplejerske. Der testes i: - Basalt kendskab til AMD (Lærebog "Praktisk oftalmologi") - Retningslinjer for injektion / kontrol / afslutning jvf. Region Hovedstadens dokument Aldersrelateret maculadegeneration (eksudativ/våd AMD), udredning, behandling og kontrol (voksne) - Beskrivelse og tolkning af fundusfoto og OCT ud fra caseeksempler - "Situationer, der kræver inddragelse af læge" - se under praktisk udførelse af den delegerede opgave Praktisk oplæring: - Efter afsluttet teoretisk eksamen, opøves erfaring som selvscreener i AMD med selvstændig varetagelse af screeningsopgaver og ordination af behandling. - Screening under supervision af speciallæge ved behov og som kompetenceudviklingsredskab i funktionen som selvscreener og efter gældende retiningslinjer. Praktisk udførelse af den delegerede opgave Selvscreenerens opgaver og ansvarsområder: - Undersøgelse der omfatter - Anamneseoptagelse - Visusmåling inkl. refraktionering - Fotografering (OCT + fundusfoto) - Evaluering af OCT og fundusfoto - Ordination af anti-VEGF-behandling eller kontrol i henhold til gældende dokument fra Region Hovedstaden, Aldersrelateret maculadegeneration (eksudativ/våd AMD), udredning, behandling og kontrol (voksne) - Registrering af screeningsresultat i BOB - Lave best ord. til injektion/kontrol i SP - Information af patient og evt. pårørende - Inddragelse af screeningslægen i henhold til retningslinjer angivet nedenfor Lægens opgaver og ansvarsområder: - Løbende supervision af selvscreeneren i klinikken - Lægen skal stå til rådighed jvf. nedenstående retningslinjer - Lægen er ansvarlig for, at resultat af klinisk/angiografisk undersøgelse på dagen registreres sufficient i BOB Situationer, der kræver inddragelse af screeningslægen, efter at opgaven er delegeret til selvscreeneren: - Tvivl om billedlæsning og behandlingsindikation - Manglende behandlingsrespons trods gentagne injektioner uden pause (>3 injektioner/4 ugers interval) - Visusfald på 2 linjer eller mere uden samtidigt ødem eller blødning - Ordination og beskrivelse af fluorescein-angiografi - Behandlingsskift (lucentis/eylea/andet) - Behandlingsstart (andet øje) - Afslutning af patient - Mistanke om oculær co-morbiditet (blepharit, trykforhøjelse osv) - Anden diagnose end AMD Tilsyn og kvalitetsmonitorering Minimum hver 6. måned: - Møde med overlæge og selvscreenere med: - Casebaseret undervisning med udvlagte cases fra klinikken - Undervisning i billeddiagnostik med specifikt fokus - Afstemning af instrukser/vejledninger Desuden løbende evaluering af den enkelte selvscreeners ordinationsmønster, ved hjælp af udtræk fra database (BOB) ved teamledelsen. Dokumentation i personalesagen Af stillingsbeskrivelsen skal delegeret opgave fremgå: - Screening af patienter i behandlingsforløb for våd AMD, aldersrelateret maculadegeneration Certifikationsbevis for gennemgået praktisk oplæring og eksamen: - Dokumentation ved eksaminerende læge og teamledelse Tilsyn og kvalitetsmonitorering: - Dokumentation én gang årligt ved MUS - dog skal planlagte tilsyn for den enkelte selvscreener løbende dokumenteres og være tilgængelig (se ovenfor) Ansvar og organisering Er beskrevet i Region Hovedstadens dokument, Delegation af forbeholdt sundhedsfaglig virksomhed. I dokumentet er en lokal tilføjelse gældende for Afdeling for Øjensygdomme Referencer, lovgivning og faglig evidens samt links hertil Region Hovedstaden Delegation af forbeholdt sundhedsfaglig virksomhed - dokument SP Sundhedsplatform. I dokumentet er en lokal tilføjelse gældende for Afdeling for Øjensygdomme Aldersrelateret maculadegeneration (eksudativ/våd AMD), udredning, behandling og kontrol (voksne) - dokument SP Sudhedsplatform Akkrediteringsstandarder Bilag Kursusbevis for uddannelse af sygeplejersker og optometrister til selvscreener.docx

<h1><div id="Afsnit#1699579187491">Screening af AMD ved sygeplejersker og optikere</div></h1><div id="BodyWeb#1699579187491"><p><a name="1699579187491Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579187491Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579187491Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579187491Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579187491Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579187491Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579187491Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579187491Bilag">Bilag</a><br> &nbsp;</h3> <h2><a name="1699579187491Maalgrupper"></a><br> Målgrupper&nbsp;</h2> <p>Instruksen beskriver delegering af&nbsp;funktionen med "screening&nbsp;af patienter i behandlingsforløb&nbsp;for våd AMD, aldersrelateret maculadegeneration"&nbsp;til sygeplejersker og optometrister&nbsp;i&nbsp;Afdeling for Øjensygdomme, Rigshospitalet.&nbsp;</p> <p>Instruksen angiver definition af den delegerede&nbsp;opgave,&nbsp;herunder:</p> <ul> <li>Uddannelse, oplæring og praktisk udførelse af den delegerede opgave</li> <li>Tilsyn og kvalitetsmonitorering&nbsp;</li> <li>Dokumentation i personalesagen&nbsp;</li> <li>Ansvar og opgavefordeling</li> </ul> <p>&nbsp;</p> <p>Dette Jvf.&nbsp;Region Hovedstadens dokument, <a href="###FOLDER###" target="_blank">Delegation af forbeholdt sundhedsfaglig virksomhed</a>. I dokumentet er en lokal tilføjelse gældende for Afdeling for Øjensygdomme</p> <p>Gældende for sygeplejersker, optometrister&nbsp;og&nbsp;læger i medicinsk retina, Afdeling for Øjensygdomme, Rigshospitalet.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579187491Top">Tilbage til top</a></p> <h2><a name="1699579187491Definitioner"></a></h2> <h2>Definitioner</h2> <p>AMD: Aldersrelateret maculadegeneration</p> <p>OCT:&nbsp; <span style="background-color:#ffffff; color:#000000">Optical Coherence Tomography</span></p> <p><span style="background-color:#ffffff; color:#000000">BOB: Bedre oftalmologi for brugere</span></p> <p><span style="background-color:#ffffff; color:#000000">SP: Sundhedsplatformen</span></p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579187491Top">Tilbage til top</a></p> <h2><a name="1699579187491Fremgangsmaade"></a><br> Fremgangsmåde</h2> <h3>Opgave der skal delegeres</h3> <p style="margin-left:80px">Selvstændig screening af patienter i behandlingsforløb for våd AMD, aldersrelateret maculadegeneration</p> <p style="margin-left:80px">&nbsp;</p> <h3>Uddannelse og oplæring</h3> <p>Grundlæggende kompetencer og kvalifikationer:</p> <ul> <li>Autoriseret sygeplejerske eller optometrist</li> <li>Minimum ét&nbsp;års ansættelse i medicinsk retina, med&nbsp;selvstændige kontrolforløb&nbsp;i AMD over en periode på minimum&nbsp;tre måneder.</li> <li>Oftalmologisk basisviden svarende&nbsp;til "Oftalmologisk eksamen for ikke-lægeligt personale ved Øjenafdelingen"</li> </ul> <p>&nbsp;</p> <p><strong>Eksamen:</strong></p> <p>Mundtlig eksamen, afholdes af overlæge med et censor-team bestående af ledende overlæge og oversygeplejerske.</p> <p>Der testes i:</p> <ul> <li>Basalt kendskab til AMD (Lærebog "Praktisk oftalmologi")</li> <li>Retningslinjer for injektion / kontrol / afslutning jvf. Region Hovedstadens dokument <a href="###FOLDER###" target="_blank">Aldersrelateret maculadegeneration (eksudativ/våd AMD), udredning, behandling og kontrol (voksne)</a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li> <li>Beskrivelse og tolkning af fundusfoto og OCT ud fra caseeksempler</li> <li>"Situationer, der kræver inddragelse af læge" - se under praktisk udførelse af den delegerede opgave</li> </ul> <p>&nbsp;</p> <p><strong>Praktisk oplæring:</strong></p> <ul> <li>Efter afsluttet teoretisk eksamen, opøves erfaring som selvscreener&nbsp;i AMD&nbsp;med selvstændig varetagelse af screeningsopgaver og ordination af behandling.</li> <li>Screening under supervision af speciallæge ved behov og som kompetenceudviklingsredskab i funktionen som selvscreener og&nbsp;efter gældende retiningslinjer.</li> </ul> <p>&nbsp;</p> <ul style="margin-left:80px"> </ul> <h3><strong>Praktisk udførelse af den delegerede opgave</strong></h3> <p>Selvscreenerens opgaver og ansvarsområder:</p> <ul style="margin-left:80px"> <li>Undersøgelse der omfatter <ul> <li>Anamneseoptagelse</li> <li>Visusmåling inkl. refraktionering</li> <li>Fotografering (OCT + fundusfoto)</li> <li>Evaluering af OCT og fundusfoto</li> <li>Ordination af anti-VEGF-behandling eller kontrol i henhold til gældende&nbsp;dokument fra Region Hovedstaden, <a href="###FOLDER###" target="_blank"><u><span style="color:#0066cc">Aldersrelateret maculadegeneration (eksudativ/våd AMD), udredning, behandling og kontrol (voksne)</span></u></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li> </ul> </li> <li>Registrering af screeningsresultat i BOB</li> <li>Lave best ord. til injektion/kontrol i SP</li> <li>Information af patient og evt. pårørende</li> <li>Inddragelse af screeningslægen i henhold til retningslinjer angivet nedenfor</li> </ul> <p>Lægens opgaver og ansvarsområder:</p> <ul style="margin-left:80px"> <li>Løbende supervision af selvscreeneren&nbsp;i klinikken</li> <li>Lægen skal stå til rådighed&nbsp;jvf. nedenstående retningslinjer</li> <li>Lægen er ansvarlig for, at resultat af klinisk/angiografisk undersøgelse på dagen registreres sufficient i BOB&nbsp;</li> </ul> <p>&nbsp;Situationer, der kræver inddragelse af screeningslægen, efter at opgaven er delegeret til selvscreeneren:</p> <ul style="margin-left:80px"> <li>Tvivl om billedlæsning og behandlingsindikation</li> <li>Manglende behandlingsrespons trods gentagne injektioner uden pause (&gt;3 injektioner/4 ugers interval)</li> <li>Visusfald på 2 linjer eller mere uden samtidigt ødem eller blødning</li> <li>Ordination og beskrivelse af fluorescein-angiografi</li> <li>Behandlingsskift (lucentis/eylea/andet)</li> <li>Behandlingsstart (andet øje)</li> <li>Afslutning af patient</li> <li>Mistanke om oculær co-morbiditet (blepharit, trykforhøjelse osv)</li> <li>Anden diagnose end AMD</li> </ul> <h3>&nbsp;</h3> <h3>Tilsyn og kvalitetsmonitorering</h3> <p>&nbsp;</p> <p>Minimum hver 6. måned:</p> <ul style="margin-left:80px"> <li>Møde med overlæge og selvscreenere med: <ul> <li>Casebaseret undervisning med udvlagte cases fra klinikken</li> <li>Undervisning i billeddiagnostik med specifikt fokus</li> <li>Afstemning af instrukser/vejledninger</li> </ul> </li> </ul> <p>Desuden løbende evaluering af den enkelte selvscreeners ordinationsmønster, ved hjælp af udtræk fra database (BOB) ved teamledelsen.</p> <p>&nbsp;</p> <h3><strong>Dokumentation i personalesagen</strong></h3> <p>Af stillingsbeskrivelsen skal&nbsp;delegeret opgave fremgå:</p> <ul> <li>Screening af patienter i behandlingsforløb for våd AMD, aldersrelateret maculadegeneration</li> </ul> <p>Certifikationsbevis for gennemgået praktisk oplæring og eksamen:</p> <ul style="margin-left:80px"> <li>Dokumentation ved eksaminerende&nbsp;læge og teamledelse&nbsp;</li> </ul> <p>Tilsyn og kvalitetsmonitorering:&nbsp;</p> <ul> <li>Dokumentation én gang årligt ved MUS -&nbsp;dog skal&nbsp;planlagte tilsyn for den enkelte selvscreener&nbsp;løbende dokumenteres og være tilgængelig (se ovenfor)</li> </ul> <p>&nbsp;</p> <p>&nbsp;<a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579187491Top">Tilbage til top</a></p> <h2><a name="1699579187491Ansvar"></a><br> Ansvar og organisering</h2> <p>Er beskrevet i&nbsp;Region Hovedstadens dokument, <a href="###FOLDER###" target="_blank"><u><span style="color:#0066cc">Delegation af forbeholdt sundhedsfaglig virksomhed</span></u></a>. I dokumentet er en lokal tilføjelse gældende for Afdeling for Øjensygdomme</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579187491Top">Tilbage til top</a></p> <h2><a name="1699579187491Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p>Region Hovedstaden</p> <p><a href="###FOLDER###" target="_blank"><u><span style="color:#0066cc">Delegation af forbeholdt sundhedsfaglig virksomhed</span></u></a>&nbsp;- dokument SP Sundhedsplatform. I dokumentet er en lokal tilføjelse gældende for Afdeling for Øjensygdomme</p> <p><a href="###FOLDER###" target="_blank"><u><span style="color:#0066cc">Aldersrelateret maculadegeneration (eksudativ/våd AMD), udredning, behandling og kontrol (voksne)</span></u></a>&nbsp;- dokument SP Sudhedsplatform</p> <p>&nbsp;</p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579187491Top">Tilbage til top</a></p> <h2><a name="1699579187491Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579187491Top">Tilbage til top</a></p> <h2><a name="1699579187491Bilag"></a><br> Bilag</h2> <p><img src="/icons/vwicn005.gif" onclick="Ext.DMS.util.showImage(this);"><a href="###FOLDER###" target="_blank">Kursusbevis for uddannelse af sygeplejersker og optometrister til selvscreener.docx</a></p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579187491Top">Tilbage til top</a></p>

Rigshospitalet_¥jensygdomme (HOC)_Serietryk Glaukom team.

Serietryk, Glaukom team Målgrupper og anvendelsesområde Angiver retningslinjer for hvordan glaukom-patienter skal have målt serietryk når dette er indiceret Gældende for læger i Øjenklinikken, Rigshospitalet. Definitioner Fremgangsmåde Øjets tryk varierer procentuelt med patientens individuelle trykniveau. Døgnsvingninger på > 10mm Hg på samme øje og konstant højre-venstreforskel på > 5 mmHg bør give anledning til yderligere overvejelser. Gentagne trykmålinger indenfor samme døgn kan anvendes både i den diagnostiske og i kontrolfasen hos patienter med glaukom, men bør anvendes med omtanke. Det kan bruges til differentiering mellem primært åbentvinklet glaukom (POAG) og intraokulær hypertension (IOH) hos patienter med normale papiller og synsfelter samt tryk i området 22-30 mm Hg samt differentiering mellem POAG og normaltryksglaukom (NTG) hos patienter med typiske glaukomskader på synsnerve og synsfelt. Det kan kræve mange målinger at afsløre en højtrykskomponent. Der er indikation for at måle døgnkurve/serietryk hos følgende: 1) Patienter under mistanke for normaltrykglaukom og man vil sikre sig at trykket ikke bliver højere i løbet af dagen 2) Patienter hvor man vil fastlægge på hvilket tidspunkt på dagen patientens tryk er højst 3) Patienter hvor pt-ens synsfelts-defekter progredierer på trods at tilfredsstillende IOP-målinger til de vanlige kontroller Ved behandlingsskift er enkelttryksmåling sædvanligvis tilstrækkelig, evt. vejledt af et tidligere serietryk, således at store formiddagsvariationer ikke slører vurderingen. Det samme gælder patienter efter ALT- og diodelaserbehandling samt filtrerende operation, hvor variationsbredden i døgntrykprofilen oftest er lav. Aftenmålinger kan i sjældne tilfælde afsløre en højtryksfase hos en ellers velkontrolleret patient; de foretages på en akut vagt efter aftale med vagthavende og Ø 34. Normalt foretages serietryk-målingerne kl. 08:30 (09:00 torsdage), 11:00 og 13:30 i glaukom-teamets regi ved samme spaltelampe med Goldmanns applanationstonometer. Det noteres i journalen som flg: Serietryk 08:30/09:00: mmHg 11:00: mmHg 13:30: mmHg Ansvar og organisering Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger. Afsnitsledelsen er ansvarlige for at instruksen udarbejdes, revideres og implementeres. Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen. Referencer, lovgivning og faglig evidens samt links hertil Bilag

<h1><div id="Afsnit#1699579158892">Serietryk, Glaukom team</div></h1><div id="BodyWeb#1699579158892"><p>&nbsp;</p> <div class="collapsible-item" expandedstart="1"><a name="1699579158892Maalgrupper"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Målgrupper og anvendelsesområde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm">Angiver retningslinjer for hvordan glaukom-patienter skal have målt serietryk når dette er indiceret</p> <p style="margin-left:0cm; margin-right:0cm">Gældende for læger i Øjenklinikken, Rigshospitalet.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579158892Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579158892Definitioner"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Definitioner</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579158892Fremgangsmaade"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Fremgangsmåde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm">Øjets tryk varierer procentuelt med patientens individuelle trykniveau. Døgnsvingninger på &nbsp;&gt; 10mm&nbsp; Hg på samme øje og konstant højre-venstreforskel på &gt;&nbsp;5 mmHg bør give anledning til yderligere overvejelser.&nbsp; Gentagne trykmålinger indenfor samme døgn kan anvendes både i den diagnostiske og i kontrolfasen hos patienter med glaukom, men bør anvendes med omtanke. Det kan bruges til differentiering mellem primært åbentvinklet glaukom (POAG) og intraokulær hypertension (IOH) hos patienter med normale papiller og synsfelter samt tryk i området 22-30 mm Hg samt differentiering mellem POAG og normaltryksglaukom (NTG) hos patienter med typiske glaukomskader på synsnerve og synsfelt. Det kan kræve mange målinger at afsløre en højtrykskomponent.</p> <p style="margin-left:0cm; margin-right:0cm">Der er indikation for at&nbsp;måle døgnkurve/serietryk hos følgende:</p> <p style="margin-left:40px; margin-right:0cm">1) Patienter&nbsp;under mistanke&nbsp;for normaltrykglaukom og man vil sikre sig at trykket ikke bliver højere i løbet af dagen<br> 2) Patienter hvor man vil fastlægge på&nbsp;hvilket tidspunkt på dagen&nbsp;patientens tryk er højst<br> 3) Patienter hvor pt-ens synsfelts-defekter progredierer på trods at tilfredsstillende IOP-målinger til de vanlige kontroller</p> <p style="margin-left:0cm; margin-right:0cm">Ved behandlingsskift er enkelttryksmåling sædvanligvis tilstrækkelig, evt. vejledt af et tidligere serietryk, således at store formiddagsvariationer ikke slører vurderingen. Det samme gælder patienter efter ALT- og diodelaserbehandling samt filtrerende operation, hvor variationsbredden i døgntrykprofilen oftest er lav. Aftenmålinger kan i sjældne tilfælde afsløre en højtryksfase hos en ellers velkontrolleret patient; de foretages på en akut vagt efter aftale med vagthavende og Ø 34.&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm">Normalt foretages serietryk-målingerne kl. 08:30 (09:00 torsdage), 11:00 og 13:30 i glaukom-teamets regi ved samme spaltelampe med Goldmanns applanationstonometer.</p> <p style="margin-left:0cm; margin-right:0cm">Det noteres i journalen som flg:</p> <p style="margin-left:40px; margin-right:0cm">Serietryk</p> <p style="margin-left:40px; margin-right:0cm">08:30/09:00:&nbsp;&nbsp;&nbsp;&nbsp;mmHg<br> 11:00:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mmHg<br> 13:30:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mmHg</p> <p>&nbsp;</p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579158892Ansvar"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Ansvar og organisering</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger.<br> Afsnitsledelsen er ansvarlige for at instruksen udarbejdes, revideres og implementeres.<br> Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579158892Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579158892Referencer"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Referencer, lovgivning og faglig evidens samt links hertil</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579158892Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579158892Bilag"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Bilag</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579158892Top">Tilbage til top</a></p>

Rigshospitalet_¥jensygdomme (HOC)_Serumdråber bestilling og udlevering. Cornea team.

Serumdråber, bestilling og udlevering. Cornea team Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Bilag Målgrupper og anvendelsesområde Beskriver proceduren ved bestilling og udlevering af serumdråber til patienter i cornea team, Afdeling for Øjensygdomme Rigshospitalet. Gældende for læger og sygeplejersker i teamet. Definitioner Fremgangsmåde Behandling af patienter med serumdråber skal være konfereret med speciallæge i cornea team. Hvis blodtype ikke er registreret, skal der bestilles blodtype. Hvis blodtype foreligger, bestilles serumdråber samme dag som patienten er til ambulant klinisk besøg, hos Blodbanken på Rigshospitalet Blegdamsvej (Tlf: ###TELEFON###) Serumdråber leveres på frost i pakker med 14 flasker til 28 dages brug (1 flaske må bruges i 2 dage) Pakken skal sendes med transport til Ø44, Afdeling for Øjensygdomme. Bestilles serumdråberne før kl. 8, kan transport foregå med standardtransport mellem Blegdamsvej og Glostrup. Bestilles serumdråberne efter kl. 8, skal de sendes med taxa. Dvs patienten skal typisk vente i afdelingen indtil dråber kommer, ca. kl. 11 -12, alternativt gå hjem og møde senere på dagen (spørg blodbanken om forventet leveringstidspunkt). Patienten kan endvidere, efter aftale, afhente serumdråberne på Rigshospitalet Blegdamsvej samme dag. Skulle patienten mod forventning blive forhindret den pågældende dag, skal serumdråberne opbevares i fryseren på Ø34 indtil afhentning. Læge/sygeplejerske udtager transfusionssedlen, og sikrer at det leverede produkt er kompatibelt med patienten, dvs. at dråberne er af samme blodtype som patienten. NB. Rhesustype har ingen betydning Transfusionssedlen underskrives af to kontrollanter - sygeplejersken sender sedlen retur til blodbanken. Dato for næste bestilling/kontrol skrives i SP på Serumdråbe.-listen. Antal serumdråbe-portioner samt afhentningssted noteres på bemærknings-linien. Sygeplejersken sørger for at serumdråberne bliver bestilt den pågældende dag. Patienten skal opbevare flaskerne i fryser (husholdningsfryser er godkendt) og udtage én flaske hver anden dag idet holdbarheden er 2 dage. Der dryppes efter afltale. Imellem drypning bør flasken opbevares på køl, såfremt muligt. Ansvar og organisering Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger. Afsnitsledelsen er ansvarlig for at instruksen udarbejdes, revideres og implementeres. Den enkelte medarbejder i Afdeling for Øjensygdomme, er ansvarlig for at kende og følge instruksen Referencer, lovgivning og faglig evidens samt links hertil Bilag

<h1><div id="Afsnit#1699579143096">Serumdråber, bestilling og udlevering. Cornea team</div></h1><div id="BodyWeb#1699579143096"><p>&nbsp;</p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579143096Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579143096Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579143096Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579143096Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579143096Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579143096Bilag">Bilag</a><br> &nbsp;</h3> <div class="collapsible-item" expandedstart="1"><a name="1699579143096Maalgrupper"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Målgrupper og anvendelsesområde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm">Beskriver proceduren ved bestilling og udlevering af serumdråber til patienter i cornea team, Afdeling for Øjensygdomme Rigshospitalet.&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm">Gældende for læger og sygeplejersker i teamet.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579143096Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579143096Definitioner"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Definitioner</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579143096Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579143096Fremgangsmaade"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Fremgangsmåde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm">Behandling af patienter med serumdråber skal være konfereret med speciallæge i cornea team.</p> <p style="margin-left:0cm; margin-right:0cm">Hvis&nbsp;blodtype ikke er&nbsp;registreret,&nbsp;skal der bestilles blodtype.</p> <p style="margin-left:0cm; margin-right:0cm">Hvis blodtype foreligger, bestilles serumdråber samme dag som patienten er til ambulant klinisk besøg, hos Blodbanken på Rigshospitalet Blegdamsvej (Tlf: ###TELEFON###)</p> <p style="margin-left:0cm; margin-right:0cm">Serumdråber leveres på frost i pakker med 14 flasker til 28 dages brug (1 flaske må bruges i 2 dage)</p> <p style="margin-left:0cm; margin-right:0cm">Pakken skal sendes med transport til Ø44, Afdeling for Øjensygdomme.<br> Bestilles&nbsp;serumdråberne&nbsp;før kl. 8, kan transport foregå med standardtransport mellem Blegdamsvej og Glostrup.<br> Bestilles serumdråberne efter kl. 8, skal de sendes&nbsp;med taxa.</p> <p style="margin-left:0cm; margin-right:0cm">Dvs patienten&nbsp;skal typisk vente i afdelingen indtil dråber kommer, ca.&nbsp;kl. 11 -12,&nbsp;alternativt gå hjem og møde senere på dagen (spørg blodbanken om forventet leveringstidspunkt).<br> Patienten kan endvidere, efter aftale, afhente serumdråberne på Rigshospitalet Blegdamsvej samme dag.<br> Skulle patienten mod forventning blive forhindret den pågældende dag, skal serumdråberne opbevares i fryseren på Ø34 indtil afhentning.</p> <p style="margin-left:0cm; margin-right:0cm">Læge/sygeplejerske udtager transfusionssedlen, og sikrer at det leverede produkt er kompatibelt med patienten, dvs. at dråberne er af samme blodtype som patienten.<br> NB. Rhesustype har ingen betydning</p> <p style="margin-left:0cm; margin-right:0cm">Transfusionssedlen underskrives af to kontrollanter - sygeplejersken sender sedlen retur til blodbanken.</p> <p style="margin-left:0cm; margin-right:0cm">Dato for næste bestilling/kontrol skrives i SP på Serumdråbe.-listen. Antal serumdråbe-portioner samt afhentningssted noteres på bemærknings-linien. Sygeplejersken sørger for at serumdråberne bliver bestilt den pågældende dag.</p> <p style="margin-left:0cm; margin-right:0cm">Patienten skal opbevare flaskerne i fryser (husholdningsfryser er godkendt) og udtage én flaske hver anden dag idet holdbarheden er 2 dage. Der dryppes efter afltale.</p> <p style="margin-left:0cm; margin-right:0cm">Imellem drypning bør flasken opbevares på køl, såfremt muligt.&nbsp; &nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579143096Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579143096Ansvar"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Ansvar og organisering</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm">Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger.<br> Afsnitsledelsen&nbsp;er ansvarlig for at instruksen udarbejdes, revideres og implementeres.<br> Den enkelte medarbejder i Afdeling for Øjensygdomme, er ansvarlig for at kende og følge instruksen</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579143096Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579143096Referencer"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Referencer, lovgivning og faglig evidens samt links hertil</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579143096Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579143096Bilag"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Bilag</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579143096Top">Tilbage til top</a></p>

Rigshospitalet_¥jensygdomme (HOC)_Skele team Botulinum Toxin A (Xeomin.

Skele team, Botulinum Toxin A (Xeomin / Botox) injektion i øjenmuskel - fremstilling, håndtering og bortskaffelse Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Målgrupper og anvendelsesområde Angiver retningslinjer for fremstilling, håndtering og bortskaffelse af Botulinum Toxin A (Botox/Xeomin) i forbindelse med injektion i øjenmusklen. Gældende for læger og operationssygeplejersker, Afdeling for Øjensygdomme, Rigshospitalet. Definitioner Xeomin er et Botulinum Toksin A, som anvendes til kemisk parese af muskler. Fremgangsmåde Bivirkninger - Meget almindelige: Smerter, lokal svækkelse - Almindelige: Ptose, tørre øjne, overfladisk keratitis, øjenmuskellammelse, øjenirritation, lysfølsomhed (fotofobi), tåreflåd, synkebesvær, muskelsvækkelse, rygsmerter, influenza lignende symptomer, utilpashed, svimmelhed, sløvhed, rhinitis, øvre luftvejsinfektion, kvalme, mundtørhed, hudsår, stivhed, øget muskeltonus (hypertoni). - Ikke almindelige: Dyspnøe, Myrekryb (paræstesi), hovedpine, conjunctivitis, mundtørhed, hududslæt, ansigtslammelse, svækkelse af ansigtsmuskel, keratitis, ektropion, diplopi (dobbeltsyn), entropion, synsforstyrrelser, uskarpt syn, svimmelhed, dermatitis, træthed, taleforstyrrelser (dysfoni), svækkelse (asteni), Muskelsmerter (myalgi) tremor, øjensmerter, diarré, dysfagi synkebesvær, mundtørhed, opkastning, colitis, hududslæt, erythem, kløe, øget svedtendens, skeletsmerter, betændelse og smerte ved injektionssted. Kontraindikationer - Allergi over for botulinum type A-toksin. - Generaliserede forstyrrelser af muskelaktivetet (ex. Amyotrofisk lateralsklerose, Myasthenia Gravis, Lambert-Eatons syndrom). - Infektion ved injektionsstedet. - Blødningsforstyrrelser uanset art. - Antikoagulationsbehandling. - Hvis musklen er stærkt svækket eller størrelsen er nedsat. - Perifer neuromuskulær dysfunktion. - Har eller har haft synkebesvær. Komplikationer - Infektion i eller omkring øjet - Perforation af øjet - Abrasio af cornea Fremstilling til procedure på operationsgang VB3 Mikroskop: Indstilles med hvidt lys Lejring: Hovedkrans og evt. skumstøtter Ingen armlæn til kirurgen Instrumenter: Lindgren kirurgiske pincet Kolibri kirurgisk pincet Engangsartikler: Bordafdækning Vatpinde Gaze swaps Steril øjenlågsholder (Custom Eyes KIT, Glostrup Hospital Lucentis Kit, REF 590518.) Optrækskanyle uden filter (Grå kanyle 27G 20mm) Grå kanyle 27G 20mm / Gul kanyle 30 G 13mm 1 ml sprøjte med luer-lock Optomed øjenforbinding med tape Sterile handsker Mundbind Afrensning: Povidonejod 50 mg/ml (Povodine-iodine 5%) Lokalanæstesi: Oxybuprocain 0,4 % øjendråber Kokaindråber 4% Medicin: Xeomin 100 LD50 enheder Nacl 9 mg/ml til blanding i Xeomin Natriumhypochlorit 1% (til inaktivering af Xeomin). Optrækkes med 5 ml sprøjte og optrækskanyle uden filter Blanding af medicin Tjek om indlægsseddel om det stemmer overens med hætteglas. Foretages i stinkskab i urent skyllerum VB 327 (VB3) med handsker (blå) og maske. Alle kanyler, sprøjter og hætteglas skal efterfølgende inaktiveres med Natriumhypochlorit 1%, hentes i medicin rum på Ø VB3 Xeomin, blandes med Natriumchlorid 9 mg/ml (0,9%) Eksempler på dosis blandinger med Xeomin, 100IE pr. hætteglas: - 2,0 ml Nacl 9% blandes i Xeomin hætteglas, det giver 5,0 IE pr. 0,1 ml - 4,0 ml Nacl 9% blandes i Xeomin hætteglas, det giver 2,5 IE pr. 0,1 ml Præoperativt Desinficering af øje: - Øjet dryppes med dråber Oxybuprocain 0,4 % x 2 - (Vha ekstra vatpinde og iodine fjernes make-up og andre synlige urenheder fjernes, hvis ikke pt, som forventet allerede har gjort dette.) - Øjet dryppes med dråbe Povidone-iodine 5 % x 1. Afvent minimum 30 sekunder før injektion. Ved allergi overfor Povidone-iodine dryppes med Klorhexidin Medic i vandig opløsning 0,05% Procedure ved intramuskulær injektion Udføres under aseptiske forhold, hvilket omfatter: - Kirurgisk håndvask - Operationshat - Sterile handsker - Mundbind - Steril øjenlågsholder Efter desinficering af øjet og indsættelse af steril øjenlågsholder kan kirurgen dyppe Kokaindråber 4% på injektionsstedet med en vatpind. Limbus gribes med kolibri og muskelbugen gribes med Lindgren pincet. Medicinen injiceres nu i midt i muskelbugen og der ventes 30 sekunder, før kanylen fjernes igen. Ved intramuskulær injektion i UA: Der kan bedøves på maske imens procedure foregår Postoperativ patient medicinering Ingen Inaktivering af Xeomin / Botox Undersøg om Xeomin skal gemmes (kan anvendes i 1 uge efter blanding) Inaktivering skal foretages i urent stinkskab på VB 327 (VB3) med handsker (blå) og maske. Træk Natriumhypochlorit op med 5 ml sprøjte og optrækskanyle (uden filter) og injiceres ned i hætteglasset. Husk dato på Natriumhypochlorit flasken, da den kan holde sig 1 mdr. efter anbrud. Affald Tag en gul plastiksæk til skraldespanden på operationsstuen. Alt engangsmateriale, og den benyttede kanyleboks skal i denne sæk efter dagens injektioner. Sækken skal lukkes med "drill luk" og ned i gul papirpose (Klinisk Risikoaffald), som clipses og lægges i Ø VB3 affaldsrum. Uheld, spild og affald Spild i forbindelse med patientbehandling tørres op og kasseres som klinisk risikoaffald (brug handsker). Alle brugte hætteglas, sprøjter, spild, etc. og det resterende Xeomin skal inaktiveres ved brug af Natriumhypochlorit 1% i min. 5 minutter, hvis det ikke skal gemmes. Træk Natriumhypochlorit op i sprøjter, kanyler. Det SKAL foregår i urent stinkskab på VB3! Ansvar og organisering Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger. Afsnitsledende overlæger, afdelingssygeplejersker, ledende lægesekretærer (klyngeledelser) og funktionsledere på udefunktioner, er ansvarlige for at instruksen udarbejdes, revideres og implementeres. Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen. Referencer, lovgivning og faglig evidens samt links hertil Moorfields Eye Hospital, London, UK ved Prof. John P. Lee Akkrediteringsstandarder Bilag Rigshospitalet: Botulinum toxin A+ B - Anvendelse, håndtering og bortskaffelse. Instruks

<h1><div id="Afsnit#1699579052134">Skele team, Botulinum Toxin A (Xeomin / Botox) injektion i øjenmuskel - fremstilling, håndtering og bortskaffelse</div></h1><div id="BodyWeb#1699579052134"><p>&nbsp;</p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579052134Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579052134Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579052134Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579052134Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579052134Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579052134Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579052134Bilag">Bilag</a><br> &nbsp;</h3> <h2><a name="1699579052134Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p>Angiver retningslinjer for fremstilling, håndtering og bortskaffelse af Botulinum Toxin A (Botox/Xeomin) i forbindelse med injektion i øjenmusklen.</p> <p>Gældende for læger og operationssygeplejersker, Afdeling for Øjensygdomme, Rigshospitalet.</p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579052134Top">Tilbage til top</a></p> <h2><a name="1699579052134Definitioner"></a><br> Definitioner</h2> <p>Xeomin&nbsp;er et Botulinum Toksin A, som anvendes til kemisk parese af muskler.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579052134Top">Tilbage til top</a></p> <h2><a name="1699579052134Fremgangsmaade"></a><br> Fremgangsmåde</h2> <h3><strong>Bivirkninger</strong></h3> <ul style="margin-left:40px"> <li><strong>Meget almindelige:</strong> Smerter, lokal svækkelse</li> <li><strong>Almindelige:</strong> Ptose, tørre øjne, overfladisk&nbsp;keratitis, øjenmuskellammelse, øjenirritation, lysfølsomhed (fotofobi), tåreflåd, synkebesvær, muskelsvækkelse, rygsmerter, influenza lignende symptomer, utilpashed, svimmelhed, sløvhed, rhinitis, øvre luftvejsinfektion, kvalme, mundtørhed, hudsår, stivhed, øget muskeltonus (hypertoni).</li> <li><strong>Ikke almindelige:</strong> Dyspnøe, Myrekryb (paræstesi), hovedpine, conjunctivitis, mundtørhed, hududslæt, ansigtslammelse, svækkelse af ansigtsmuskel, keratitis, ektropion, diplopi (dobbeltsyn), entropion, synsforstyrrelser, uskarpt syn, svimmelhed, dermatitis, træthed, taleforstyrrelser (dysfoni), svækkelse (asteni), Muskelsmerter (myalgi) tremor, øjensmerter, diarré, dysfagi synkebesvær, mundtørhed, opkastning, colitis, hududslæt, erythem, kløe, øget svedtendens, skeletsmerter, betændelse og smerte ved injektionssted.</li> </ul> <h3><strong>Kontraindikationer</strong></h3> <ul style="margin-left:40px"> <li>Allergi over for botulinum type A-toksin.</li> <li>Generaliserede forstyrrelser af muskelaktivetet (ex. Amyotrofisk lateralsklerose, Myasthenia Gravis, Lambert-Eatons syndrom).</li> <li>Infektion ved injektionsstedet.</li> <li>Blødningsforstyrrelser uanset art.</li> <li>Antikoagulationsbehandling.</li> <li>Hvis musklen er stærkt svækket eller størrelsen er nedsat.</li> <li>Perifer neuromuskulær dysfunktion.</li> <li>Har eller har haft synkebesvær.</li> </ul> <h3>Komplikationer</h3> <ul style="margin-left:40px"> <li>Infektion i eller omkring øjet</li> <li>Perforation af øjet</li> <li>Abrasio af cornea</li> </ul> <h3><strong>Fremstilling til procedure på operationsgang VB3</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3> <p style="margin-left:40px"><strong>Mikroskop:</strong></p> <p style="margin-left:80px">Indstilles med hvidt lys</p> <p style="margin-left:40px"><strong>Lejring:&nbsp;</strong></p> <p style="margin-left:80px">Hovedkrans og evt. skumstøtter<br> Ingen armlæn til kirurgen</p> <p style="margin-left:40px"><strong>Instrumenter:&nbsp;</strong></p> <p style="margin-left:80px">Lindgren kirurgiske pincet<br> Kolibri kirurgisk pincet&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p> <p style="margin-left:40px"><strong>Engangsartikler:</strong></p> <p style="margin-left:80px">Bordafdækning<br> Vatpinde<br> Gaze swaps<br> Steril øjenlågsholder (Custom Eyes KIT, Glostrup Hospital Lucentis Kit, REF 590518.)<br> Optrækskanyle uden filter (Grå kanyle 27G 20mm)<br> Grå kanyle 27G 20mm / Gul kanyle 30 G 13mm<br> 1 ml sprøjte med luer-lock<br> Optomed øjenforbinding med tape<br> Sterile handsker<br> Mundbind</p> <p style="margin-left:40px"><strong>Afrensning:</strong></p> <p style="margin-left:80px">Povidonejod 50 mg/ml (Povodine-iodine 5%)&nbsp;</p> <p style="margin-left:40px"><strong>Lokalanæstesi:&nbsp;&nbsp;&nbsp;&nbsp;</strong></p> <p style="margin-left:80px">Oxybuprocain 0,4 % øjendråber<br> Kokaindråber 4%</p> <p style="margin-left:40px"><strong>Medicin:&nbsp;&nbsp;</strong></p> <p style="margin-left:80px">Xeomin&nbsp;100 LD50 enheder<br> Nacl 9 mg/ml til blanding i Xeomin&nbsp;<br> Natriumhypochlorit 1% (til inaktivering af Xeomin). Optrækkes med&nbsp;5 ml sprøjte og optrækskanyle uden filter&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p> <h3>&nbsp;<strong>Blanding af medicin</strong></h3> <p style="margin-left:40px">Tjek om indlægsseddel om det stemmer overens med hætteglas.<br> <br> Foretages i stinkskab i urent skyllerum VB 327 (VB3) med handsker (blå) og maske.</p> <p style="margin-left:40px"><strong>Alle kanyler, sprøjter og hætteglas skal efterfølgende inaktiveres med Natriumhypochlorit 1%, hentes i medicin rum på Ø VB3</strong></p> <p style="margin-left:40px">Xeomin, blandes med Natriumchlorid 9 mg/ml (0,9%)</p> <p style="margin-left:40px">Eksempler på dosis blandinger med Xeomin, 100IE pr. hætteglas:</p> <ul style="margin-left:40px"> <li>2,0 ml Nacl 9%&nbsp;blandes i Xeomin hætteglas, det giver <strong>5,0 IE pr. 0,1 ml</strong></li> <li>4,0 ml Nacl 9%&nbsp;blandes i Xeomin hætteglas, det giver <strong>2,5 IE pr. 0,1 ml</strong></li> </ul> <h3>Præoperativt</h3> <p style="margin-left:40px">Desinficering af øje:</p> <ol> <li style="margin-left: 40px;">Øjet dryppes med dråber Oxybuprocain 0,4 % x 2&nbsp;</li> <li style="margin-left: 40px;">(Vha ekstra vatpinde og iodine fjernes make-up og andre synlige urenheder fjernes, hvis ikke pt, som forventet allerede har gjort dette.)</li> <li style="margin-left: 40px;">Øjet dryppes med dråbe Povidone-iodine 5 % x 1.<br> Afvent minimum 30 sekunder før injektion.<br> Ved allergi overfor Povidone-iodine dryppes med Klorhexidin Medic i vandig opløsning 0,05%</li> </ol> <h3>Procedure ved intramuskulær injektion</h3> <p style="margin-left:40px">Udføres under aseptiske forhold, hvilket omfatter:</p> <ul> <li style="margin-left: 40px;">Kirurgisk håndvask</li> <li style="margin-left: 40px;">Operationshat</li> <li style="margin-left: 40px;">Sterile handsker</li> <li style="margin-left: 40px;">Mundbind</li> <li style="margin-left: 40px;">Steril øjenlågsholder</li> </ul> <p style="margin-left:40px">Efter desinficering af øjet og indsættelse af steril øjenlågsholder kan kirurgen dyppe Kokaindråber 4% på injektionsstedet med en vatpind.<br> Limbus gribes med kolibri og muskelbugen gribes med Lindgren pincet.<br> Medicinen injiceres nu i midt i muskelbugen og der ventes 30 sekunder, før kanylen fjernes igen.</p> <p style="margin-left:40px">Ved intramuskulær injektion i UA:</p> <p style="margin-left:80px">Der kan bedøves på maske imens procedure foregår</p> <h3><strong>Postoperativ&nbsp;patient&nbsp;medicinering</strong></h3> <p style="margin-left:40px">Ingen</p> <h3><strong>Inaktivering af Xeomin / Botox </strong></h3> <p style="margin-left:40px">Undersøg om Xeomin skal gemmes (kan anvendes i 1 uge efter blanding)<br> Inaktivering skal foretages i urent stinkskab på VB 327 (VB3) med handsker (blå) og maske.<br> Træk Natriumhypochlorit op med 5 ml sprøjte og optrækskanyle (uden filter) og injiceres ned i hætteglasset.<br> Husk dato på Natriumhypochlorit flasken, da den kan holde sig 1 mdr. efter anbrud.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p> <h3><strong>Affald&nbsp;</strong></h3> <p style="margin-left:40px">Tag en gul plastiksæk&nbsp;til skraldespanden på operationsstuen.<br> <strong>Alt </strong>engangsmateriale, og den benyttede kanyleboks skal i denne sæk&nbsp;efter dagens injektioner. Sækken&nbsp;skal&nbsp;lukkes med "drill luk" og ned i gul papirpose (Klinisk Risikoaffald),&nbsp;som clipses og lægges i Ø VB3 affaldsrum.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p> <h3 style="margin-left:-34pt"><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Uheld, spild og&nbsp;affald</strong></h3> <p style="margin-left:40px">Spild i forbindelse med patientbehandling tørres op og kasseres som klinisk risikoaffald (brug handsker).<br> Alle brugte hætteglas, sprøjter, spild, etc. og det resterende Xeomin skal inaktiveres ved brug af Natriumhypochlorit 1% i min. 5 minutter, hvis det ikke skal gemmes. Træk Natriumhypochlorit op i sprøjter, kanyler. <strong>Det <u>SKAL</u> foregår i urent stinkskab på VB3!</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p> <p style="margin-left:40px">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579052134Top">Tilbage til top</a></p> <h2><a name="1699579052134Ansvar"></a><br> Ansvar og organisering</h2> <p>Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger.<br> <br> Afsnitsledende overlæger, afdelingssygeplejersker, ledende lægesekretærer (klyngeledelser) og funktionsledere på udefunktioner, er ansvarlige for at instruksen udarbejdes, revideres og implementeres.<br> <br> Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen.</p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579052134Top">Tilbage til top</a></p> <h2><a name="1699579052134Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p>&nbsp;Moorfields Eye Hospital, London, UK ved Prof. John P. Lee</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579052134Top">Tilbage til top</a></p> <h2><a name="1699579052134Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579052134Top">Tilbage til top</a></p> <h2><a name="1699579052134Bilag"></a><br> Bilag</h2> <p>Rigshospitalet:</p> <p style="margin-left:40px"><a href="###FOLDER###" target="_blank">Botulinum toxin A+ B - Anvendelse, håndtering og bortskaffelse</a>. Instruks&nbsp;</p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579052134Top">Tilbage til top</a></p>

Rigshospitalet_¥jensygdomme (HOC)_Skele team forl¢b ved operation af.

Skele team, forløb ved operation af børn og voksne Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Målgrupper og anvendelsesområde Beskriver forløb for skelepatienter i skele teamet i Afdeling for Øjensygdomme, Rigshospitalet. Omfatter børn og voksne, der opereres i uiversel- eller lokal anæstesi, med eller uden justerbar sutur. Gældende for personalet i skele teamet i Afdeling for Øjensygdomme, RIgshospitalet. Definitioner Ø20 - Øjenklinikkens ambulatorie, team strabismus VB3 - Øjenklinikkens operationsafsnit (universel anæstesi) Y23 - Dagkirurgisk operationsafsnit Ø36 - Øjenklinikkens operationsafsnit (lokal anæstesi) UA - universel anæstesi LA - lokal anæstesi RBA - retrobulbær anæstesi Fremgangsmåde Forundersøgelse: Patienten møder til forundersøgelse på afsnit Ø36 til - Almen undersøgelse - Ordinere postopertiv medicin jv. instruksen Præ-funktion, præ- og postoperativ ordination af øjendråber og anden medicin i Øjenklinikken, fra Afdeling for Øjensygdomme. Recept på ordineret medicin lægges på apotekernes server og skal afhentes inden operationen. - Narkosetilsyn hvis ustabil ASA på 3 eller derover, eller hvis patienten specifikt ønsker samtale med en anæstesilæge - Samtale og information om forløbet - EMLA udleveres til børn - Der aftales mødetidspunkt for operationsdagen, 1 time før planlagt operationstid Præoperativt: Det videre forløb præoperativt afhænger af om operationen skal foregå i LA eller UA. Patienter der skal opereres i LA: - Patienten møder i venteværelset på VB3. - Patienten skal gerne have indtaget føde og drukket væske inden operationen, for at undgå peroperativ ildebefindende. - Patienten tilbydes, efter lægelig ordination, tabl. Triazolam 0.125 mg ½ time før operationen. Pt. der skal opereres i UA: - Patienten møder som aftalt på Y23. Børnene møder med EMLA plaster på begge håndrygge. - Patienten skal faste og tørste, jvf. Faste i forbindelse med anæstesi, fra Region Hovedstaden og Sjælland. - Patienten følges af VB3 personale fra Y23 til VB3. Peroperativt: Patienter der opereres i LA: - Efter operationen dryppes øjet med 1 dråbe Spersadex og 1 dråbe Oxybuprocaine (voksne) - Der dækkes til med blød klap Patienter der opereres i dråbe/subtenonal anæstesi: - Klargøres med ocgtt Oxybuprokain - Anticeptisk præparering, jvf. instruksen Præoperativ desinfektion af øje og øjenomgivelser, fra Afdeling for Øjensygdomme - Øjet bedøves ved at applicere en vatpind fugtet i øjendråber Kokain 4% på det sted hvor conjunctiva skal åbnes efter anvisning af kirurg (NB! Kokain beskadiger corneaepithel, undgå at berøre cornea) Patienter der opereres i RBA: - Klargøres med ocgtt oxybuprokain, samt ocgtt Alphagan - Anticeptisk præparering, jvf. instruksen Præoperativ desinfektion af øje og øjenomgivelser, fra Afdeling for Øjensygdomme Patienter der opereres i UA: - Anticeptisk præparering, jvf. Øjenklinikkens instruks Præoperativ desinfektion af øje og øjenomgivelser - Efter operationen dryppes øjet med ocgtt Spersadex og ocgtt Oxybuprocaine (voksne og børn). - Der dækkes til med blød klap. Patienter til postoperativ korrektion af justerbar sutur: - Klargøres som ovenfor anført afhængig af anæstesitype. Postoperativt: Patienter der opereres i LA: - Patienten følges af sygeplejersken til venteværelset foran VB3. - Sygeplejersken tager imod patienterne. - Patienten går hjem når patienten er velbefindende. - Klappen må fjernes efter 4 timer. Patienter der opereres i UA: - Pt. køres af portør til Y23. - Sygeplejersken tager imod patienterne. - Kirurgen vil om muligt tale med patient/forældre efter operationen. - Patienterne går hjem efter gældende retningslinier. - Klappen fjernes ½ time efter operationen. 1. postoperative kontrol: Patient med og uden justerbar sutur: - Møder i ambulatoriet Ø20 efter aftale. - Patienten ses af ortoptist og kirurg. Patient med justerbar sutur, som skal justeres: - Patienten møder dagen efter operationen i ambulatoriet, afsnit Ø20, efter aftale. - Patienten ses af ortoptist og kirurg. - Patienten venter i café området. - Kirurgen sender patienten til aftalt operationsafsnit, Ø46 eller VB3, når der er meldt klar fra operationsafsnittet. Forberedelse til justering / knytning ved kirurg - 30 minutter før aftalt tid følges patienten til Ø46 eller VB3. - Tilbydes lægeordineret præmedicin (se journalforside) tabl. Triazolam 0.125mg. - 15 minutter præ.operativt, lægge Xylokaingel x1 i fornix inferior i operationsøjet - Kirurg tilkaldes når patienten ligger på lejet og er klargjort som beskrevet i afsnittet "Peroperativ" Efter justerings-operationen - Patienten kan tage hjem straks efter. - Sikre at patienten har fået ambulant kontroltid i skeleteamet. - Patienten skal beholde klap for det nyopererede øje i 4 timer postoperativt. Ansvar og organisering Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger. Afsnitsledende overlæge, afdelingssygeplejerske og ledende lægesekretærer, er ansvarlig for at instruksen udarbejdes, revideres og implementeres. Den enkelte medarbejder i Afdeling for Øjensygdomme, er ansvarlig for at kende og følge instruksen Referencer, lovgivning og faglig evidens samt links hertil Fra Region Hovedstaden Faste i forbindelse med anæstesi, SP-sundhedsplatform Fra Afdeling for Øjensygdomme, Rigshospitalet Præ-funktion, præ- og postoperativ ordination af øjendråber og anden medicin i Øjenklinikken, instruks Præoperativ desinfektion af øje og øjenomgivelser, instruks Akkrediteringsstandarder Bilag

<h1><div id="Afsnit#1699578987967">Skele team, forløb ved operation af børn og voksne</div></h1><div id="BodyWeb#1699578987967"><p><a name="1699578987967Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578987967Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578987967Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578987967Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578987967Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578987967Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578987967Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578987967Bilag">Bilag</a><br> &nbsp;</h3> <h2><a name="1699578987967Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p>Beskriver forløb for skelepatienter i&nbsp;skele teamet i Afdeling for Øjensygdomme,&nbsp;Rigshospitalet.<br> Omfatter børn og voksne, der opereres i uiversel- eller lokal anæstesi, med eller uden justerbar sutur.</p> <p>Gældende for personalet i skele teamet i Afdeling for Øjensygdomme, RIgshospitalet.&nbsp;&nbsp;&nbsp;</p> <p><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578987967Top">Tilbage til top</a></p> <h2><a name="1699578987967Definitioner"></a><br> Definitioner</h2> <p>Ø20 - Øjenklinikkens&nbsp;ambulatorie, team strabismus<br> VB3&nbsp;- Øjenklinikkens&nbsp;operationsafsnit (universel anæstesi)<br> Y23 - Dagkirurgisk operationsafsnit<br> Ø36 - Øjenklinikkens&nbsp;operationsafsnit (lokal anæstesi)</p> <p>UA - universel anæstesi<br> LA - lokal anæstesi<br> RBA - retrobulbær anæstesi</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578987967Top">Tilbage til top</a></p> <h2><a name="1699578987967Fremgangsmaade"></a><br> Fremgangsmåde</h2> <h3><strong>Forundersøgelse: </strong></h3> <p style="margin-left:40px">Patienten&nbsp;møder til forundersøgelse på afsnit Ø36&nbsp;til</p> <ul style="margin-left:80px"> <li>Almen undersøgelse</li> <li>Ordinere&nbsp;postopertiv medicin jv. instruksen&nbsp;<a href="###FOLDER###" target="_blank">Præ-funktion, præ- og postoperativ ordination af øjendråber og anden medicin i Øjenklinikken</a>, fra Afdeling for Øjensygdomme.<br> Recept på ordineret medicin lægges på apotekernes server og skal afhentes inden operationen.</li> <li>Narkosetilsyn hvis ustabil ASA på 3 eller derover, eller hvis patienten specifikt ønsker samtale med en anæstesilæge</li> <li>Samtale og information om forløbet</li> <li>EMLA udleveres til børn</li> <li>Der aftales mødetidspunkt for operationsdagen, 1 time før planlagt operationstid</li> </ul> <h3><strong>Præoperativt: </strong></h3> <p style="margin-left:40px">Det videre forløb præoperativt afhænger af om operationen skal foregå i LA eller UA.</p> <p style="margin-left:40px"><strong><em>Patienter&nbsp;der skal opereres i LA:</em></strong></p> <ul style="margin-left:80px"> <li>Patienten&nbsp;møder&nbsp;i venteværelset på VB3.</li> <li>Patienten&nbsp;skal gerne have indtaget føde og drukket væske inden operationen, for at undgå peroperativ ildebefindende.</li> <li>Patienten&nbsp;tilbydes, efter lægelig ordination,&nbsp;tabl. Triazolam 0.125 mg ½ time før operationen.</li> </ul> <p style="margin-left:40px"><strong><em>Pt. der skal opereres i UA: </em></strong></p> <ul style="margin-left:80px"> <li>Patienten møder som aftalt på Y23.<br> Børnene møder med EMLA plaster på begge håndrygge.</li> <li>Patienten&nbsp;skal faste og tørste, jvf. <a href="###FOLDER###" target="_blank">Faste i forbindelse med anæstesi</a>,&nbsp;fra Region Hovedstaden og Sjælland.</li> <li>Patienten&nbsp;følges af VB3 personale fra&nbsp;Y23 til VB3.</li> </ul> <h3><strong>Peroperativt:</strong></h3> <p style="margin-left:40px"><em><strong>Patienter&nbsp;der opereres i LA: </strong></em></p> <ul style="margin-left:80px"> <li>Efter operationen dryppes øjet med 1 dråbe&nbsp;Spersadex og 1 dråbe Oxybuprocaine&nbsp;(voksne)</li> <li>Der dækkes til med blød klap<br> &nbsp;</li> </ul> <p style="margin-left:40px"><strong>Patienter&nbsp;der opereres i dråbe/subtenonal anæstesi:</strong></p> <ul style="margin-left:80px"> <li>Klargøres med&nbsp;ocgtt Oxybuprokain&nbsp;</li> <li>Anticeptisk præparering,&nbsp;jvf.&nbsp;instruksen <a href="###FOLDER###" target="_blank">Præoperativ desinfektion af øje og øjenomgivelser</a>,&nbsp;fra Afdeling for Øjensygdomme</li> <li>Øjet bedøves ved at applicere en vatpind fugtet i øjendråber Kokain 4% på det sted hvor conjunctiva skal åbnes efter anvisning af kirurg (NB! Kokain beskadiger corneaepithel, undgå at berøre cornea)</li> </ul> <p style="margin-left:40px"><strong>Patienter&nbsp;der opereres i RBA:</strong></p> <ul style="margin-left:80px"> <li>Klargøres med ocgtt oxybuprokain, samt ocgtt Alphagan</li> <li>Anticeptisk præparering, jvf.&nbsp;instruksen <a href="###FOLDER###" target="_blank">Præoperativ desinfektion af øje og øjenomgivelser</a>, fra Afdeling for Øjensygdomme</li> </ul> <p style="margin-left:40px"><em><strong>Patienter&nbsp;der opereres i UA:</strong> </em></p> <ul style="margin-left:80px"> <li>Anticeptisk præparering, jvf. Øjenklinikkens&nbsp;instruks <a href="###FOLDER###" target="_blank">Præoperativ desinfektion af øje og øjenomgivelser</a></li> <li>Efter operationen dryppes øjet med&nbsp;ocgtt Spersadex&nbsp;og ocgtt Oxybuprocaine (voksne og børn).</li> <li>Der&nbsp;dækkes til med blød klap.&nbsp;<br> &nbsp;</li> </ul> <p style="margin-left:40px"><strong>Patienter&nbsp;til postoperativ korrektion af&nbsp;justerbar sutur<em>:</em> </strong></p> <ul style="margin-left:80px"> <li>Klargøres som ovenfor anført afhængig af anæstesitype.</li> </ul> <h3><strong>Postoperativt: </strong></h3> <p style="margin-left:40px"><em><strong>Patienter&nbsp;der opereres i LA: </strong></em></p> <ul style="margin-left:80px"> <li>Patienten&nbsp;følges af sygeplejersken&nbsp;til&nbsp;venteværelset foran VB3.&nbsp;</li> <li>Sygeplejersken tager imod patienterne.</li> <li>Patienten går hjem når patienten er velbefindende.</li> <li>Klappen må fjernes efter 4 timer.</li> </ul> <p style="margin-left:40px"><em><strong>Patienter&nbsp;der opereres i UA:</strong></em></p> <ul style="margin-left:80px"> <li>Pt. køres af portør til Y23.</li> <li>Sygeplejersken tager imod patienterne.</li> <li>Kirurgen vil om muligt tale med patient/forældre efter operationen.</li> <li>Patienterne går hjem efter gældende retningslinier.</li> <li>Klappen fjernes ½ time efter operationen.</li> </ul> <h3><strong>1. postoperative kontrol:</strong></h3> <p style="margin-left:40px"><strong><em>Patient med og uden justerbar sutur:</em></strong></p> <ul style="margin-left:80px"> <li>Møder i ambulatoriet Ø20&nbsp;efter aftale.</li> <li>Patienten ses af ortoptist og kirurg.</li> </ul> <p style="margin-left:40px"><strong><em>Patient med justerbar sutur, som skal justeres:</em></strong></p> <ul style="margin-left:80px"> <li>Patienten møder dagen efter operationen i ambulatoriet, afsnit Ø20, efter aftale.</li> <li>Patienten ses af ortoptist og kirurg.</li> <li>Patienten venter i café området.</li> <li>Kirurgen sender patienten til aftalt operationsafsnit, Ø46 eller VB3, når der er meldt klar fra operationsafsnittet.</li> </ul> <p style="margin-left:40px">Forberedelse til justering / knytning ved kirurg</p> <ul style="margin-left:80px"> <li>30 minutter før aftalt tid&nbsp;følges patienten til Ø46 eller VB3.</li> <li>Tilbydes lægeordineret præmedicin (se&nbsp;journalforside)&nbsp;tabl. Triazolam 0.125mg.</li> <li>15 minutter præ.operativt, lægge Xylokaingel x1 i fornix inferior i operationsøjet</li> <li>Kirurg tilkaldes når patienten&nbsp;ligger på lejet og er klargjort som beskrevet i afsnittet "Peroperativ"</li> </ul> <p style="margin-left:40px">Efter justerings-operationen</p> <ul style="margin-left:80px"> <li>Patienten kan tage hjem straks efter.</li> <li>Sikre at patienten&nbsp;har fået ambulant kontroltid i skeleteamet.</li> <li>Patienten&nbsp;skal beholde klap for det nyopererede øje i 4 timer postoperativt.</li> </ul> <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578987967Top">Tilbage til top</a></p> <h2><a name="1699578987967Ansvar"></a><br> Ansvar og organisering</h2> <p style="margin-left:0cm; margin-right:0cm">Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger.<br> Afsnitsledende overlæge, afdelingssygeplejerske og ledende lægesekretærer, er ansvarlig for at instruksen udarbejdes, revideres og implementeres.<br> Den enkelte medarbejder i Afdeling for Øjensygdomme, er ansvarlig for at kende og følge instruksen</p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578987967Top">Tilbage til top</a></p> <h2><a name="1699578987967Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p>Fra Region Hovedstaden</p> <p style="margin-left:80px"><a href="###FOLDER###" target="_blank"><u><span style="color:#0066cc">Faste i forbindelse med anæstesi</span></u></a>, SP-sundhedsplatform</p> <p>&nbsp;</p> <p>Fra Afdeling for Øjensygdomme, Rigshospitalet</p> <p style="margin-left:80px"><a href="###FOLDER###" target="_blank">Præ-funktion, præ- og postoperativ ordination af øjendråber og anden medicin i Øjenklinikken</a>, instruks</p> <p style="margin-left:80px"><a href="###FOLDER###" target="_blank">Præoperativ desinfektion af øje og øjenomgivelser</a>, instruks</p> <p style="margin-left:80px">&nbsp;</p> <p style="margin-left:80px">&nbsp;</p> <p style="margin-left:80px">&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578987967Top">Tilbage til top</a></p> <h2><a name="1699578987967Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578987967Top">Tilbage til top</a></p> <h2><a name="1699578987967Bilag"></a><br> Bilag</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578987967Top">Tilbage til top</a></p>

Rigshospitalet_¥jensygdomme (HOC)_Skele team konkominant og inkomitant esotropi.

Skele team, konkominant og inkomitant esotropi - akut opstået hos børn (under 15 år) Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Målgrupper og anvendelsesområde Angiver retningslinjer for udredning og behandling af akut opstået comitant og inkomitant esotropi hos børn under 15 år. Gældende for læger og ortoptister i Afdeling for Øjensygdommer, Rigshospitalet. Definitioner Akut opstået esotropi opdeles i konkomitant og inkomitant esotropi: - Akut opstået konkomitant esotropi (acute acquired concomitant esotropia /AACE) er karakteriseret ved pludselig opstået fejlstilling af øjenakserne i indadskelen med samme skelevinkel i alle blikretninger. Dette betyder skelevinkelen er konstant uanset blikretning. Denne type esotropi adskiller sig ved sin pludselige debut og senere debutalder (fra 2 års alder og op) fra de almindelige typer af børneindadskelen, som infantil esotropi og akkommodativ esotropi. - Inkomitant esotropi er karakteriseret ved en skelevinkel som er større eller øget i én eller flere blikretninger. Her varerier skelevinklen afhængig af blikretning. Dette kan tyde på parese eller restriktiv skelen, for eksempel abducensparese, blow-out fraktur eller Duane syndrom. Fremgangsmåde Baggrund: NB: Differentier mellem inkomitant og komitant skelen. Inkomitant akut opstået esotropi kan skyldes neurooftalmologisk patologi, og bør henvises til akut undersøgelse og udredning ved pædiater. Komitant akut opstået esotropi skyldes sjældent en neurooftalmologisk lidelse, og derfor anbefales følgende fremgangsmåde: Ved initiale konsultation: Der foretages neurooftalmologisk vurdering inkl. cycloplegisk refraktionering. I dagtid kan ortoptist/børneoftalmolog/neurooftalmolog evt. være behjælpelig med supplerende vurdering. Udskriv brillerecept baseret på cykloplegisk refraktionering i overensstemmelse med instruksen Børne team, børnebriller - recept, fra Afdeling for Øjensygdomme Undersøgelsesplan: - Visus måling - Neurooftalmologiske tegn og symptomer (pupilinvolvering, kranienervedysfunktion, ataksi etc. & symptomer som hovedpine, kvalme/opkast/ændret personlighed etc) - Motilitet (inkomitans af skelen og evt. nystagmus) - Oftalmoskopi (papilstase/-atrofi) - Tilstedeværelsen af følgende risikofaktorer kan tyde på subklinisk parese og intrakraniel sygdom: - >40% større esodeviation på afstand end nær; - Recidiv af AACE - Nystagmus eller papilødem - Neurologiske symptomer. - (Alder > 6 år) Overvej udredning med MR scanning af cerebrum. Lumbalpunktur er indiceret ved mistanke om infektiøs genese (evt Borreliainfektion, spørg til flåtbid). Ved patologiske neurologiske tegn inkomitant esotropi Barnet henvises/overflyttes akut til pædiatrisk regi, til videre udredning inkl. akut MR af cerebrum. Efter kl. 22 foregår akut MR-scanning på Rigshospitalet. Aftale træffes (helst bagvagt til bagvagt) med - vagthavende pædiater afd. 5054. - Før kl 21 på tlf.: ###TELEFON### (pædiatrisk bagvagt), - Fra kl. 21 på tlf: ###TELEFON### (pædiatrisk mellemvagt). Uden patologiske neurologiske tegn - Efter ovenstående undersøgelse og brilleordination viderehenvises barnet subakut (inden for 14 dage) til pædiatrisk gennemgang og evt. MR scanning på lokal børneafdeling. Aftale træffes med vagthavende pædiater på lokalsygehus ud fra patientens bopæl. Kontrol ved ortoptist på Rigshospitalet-Glostrup aftales. - Ved fortsat uafklaret patient, udelukkende set af forvagt: Barnet skal ses dagen efter af bagvagt evt. sammen med børneoftalmolog (evt ortoptist tilsyn) mhp afklaring om der er indikation for: Akut henvisning til RH pædiatrisk afd/subakut henvisning til lokal børneafd/eller blot Opfølgende kontrol ved ortoptist som skitseret nedenfor. Ved ingen mistanke om neurologisk årsag Efter ovenstående undersøgelse og brille ordination gives opfølgende kontrol som skitseret nedenfor. Opfølgende kontrol I: Det er lægens ansvar at planlægge opfølgende kontrol ved ortoptist + skelekirurg ved Rigshospitalet-Glostrup <2 uger efter initiale undersøgelse. Lav AKUT VISI til skeleteam. II: Ved opfølgende kontrol planlægges videre forløb med enten afventen af spontanforløb (hvis brilleordination), fremskyndet injektion med botulinum toxin A eller skelekirurgi for at redde samsyn. Der er evidens for, at hurtig behandling (< 2 mdr) øger chancen for genetablering af parallelle akser og samsyn. Ansvar og organisering Afdelingsledelsen, Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger. Afsnitsledende overlæge, afdelingssygeplejersker og ledende lægesekretærer, er ansvarlig for at instruksen udarbejdes, revideres og implementeres. Den enkelte medarbejder i Afdeling for Øjensygdomme, er ansvarlig for at kende og følge instruksen Referencer, lovgivning og faglig evidens samt links hertil Afdeling for Øjensygdomme, Rigshospitalet-Glostrup Børne team, børnebriller - recept, instruks Akkrediteringsstandarder Bilag

<h1><div id="Afsnit#1699579049869">Skele team, konkominant og inkomitant esotropi - akut opstået hos børn (under 15 år)</div></h1><div id="BodyWeb#1699579049869"><p><a name="1699579049869Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579049869Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579049869Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579049869Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579049869Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579049869Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579049869Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579049869Bilag">Bilag</a><br> &nbsp;</h3> <h2>Målgrupper og anvendelsesområde</h2> <p>Angiver retningslinjer for udredning og behandling&nbsp;af akut opstået comitant og inkomitant esotropi hos børn under 15 år.</p> <p>Gældende for læger og ortoptister i Afdeling for Øjensygdommer,&nbsp;Rigshospitalet.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579049869Top">Tilbage til top</a></p> <h2><a name="1699579049869Definitioner"></a><br> Definitioner</h2> <p>Akut opstået esotropi opdeles i konkomitant og inkomitant esotropi: &nbsp;</p> <ul> <li><strong>Akut opstået konkomitant esotropi</strong> (acute acquired concomitant esotropia /AACE) er karakteriseret ved pludselig opstået fejlstilling af øjenakserne i&nbsp;indadskelen med samme skelevinkel i alle blikretninger. Dette betyder skelevinkelen er konstant uanset blikretning. Denne type esotropi adskiller sig ved sin pludselige debut og senere debutalder (fra 2 års alder og op) fra de almindelige typer af børneindadskelen, som infantil esotropi og akkommodativ esotropi.</li> <li><strong>Inkomitant esotropi</strong> er karakteriseret ved en skelevinkel som er større eller øget i én eller flere blikretninger. Her varerier skelevinklen afhængig af blikretning. Dette kan tyde på parese eller restriktiv skelen, for eksempel abducensparese, blow-out fraktur eller Duane syndrom.</li> </ul> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579049869Top">Tilbage til top</a></p> <h2><a name="1699579049869Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p><strong>Baggrund:</strong></p> <p style="margin-left:40px">NB:&nbsp;Differentier mellem <strong>inkomitant og komitant</strong> skelen.</p> <p style="margin-left:40px"><strong>Inkomitant akut opstået</strong>&nbsp;esotropi&nbsp;kan skyldes neurooftalmologisk patologi, og bør henvises til akut undersøgelse og udredning ved pædiater.</p> <p style="margin-left:40px"><strong>Komitant</strong> akut opstået esotropi skyldes sjældent en neurooftalmologisk lidelse, og derfor anbefales følgende fremgangsmåde:</p> <p><strong>Ved initiale konsultation:</strong></p> <p style="margin-left:40px">Der foretages neurooftalmologisk vurdering inkl. cycloplegisk refraktionering.</p> <p style="margin-left:40px">I dagtid kan ortoptist/børneoftalmolog/neurooftalmolog evt. være behjælpelig med supplerende vurdering.</p> <p style="margin-left:40px"><em>Udskriv brillerecept baseret på cykloplegisk refraktionering</em><br> i overensstemmelse med instruksen <a href="###FOLDER###" target="_blank">Børne team, børnebriller - recept,</a> fra Afdeling for Øjensygdomme</p> <p style="margin-left:40px">Undersøgelsesplan:</p> <ol> <li style="margin-left: 40px;">Visus måling</li> <li style="margin-left: 40px;">Neurooftalmologiske tegn og symptomer (pupilinvolvering, kranienervedysfunktion, ataksi etc. &amp; symptomer som hovedpine, kvalme/opkast/ændret personlighed etc)</li> <li style="margin-left: 40px;">Motilitet (inkomitans af skelen og evt. nystagmus)</li> <li style="margin-left: 40px;">Oftalmoskopi (papilstase/-atrofi)</li> <li style="margin-left: 40px;">Tilstedeværelsen af følgende risikofaktorer kan tyde på subklinisk parese og intrakraniel sygdom: <ol> <li style="margin-left: 40px;">&gt;40% større esodeviation på afstand end nær;</li> <li style="margin-left: 40px;">Recidiv af AACE</li> <li style="margin-left: 40px;">Nystagmus eller papilødem</li> <li style="margin-left: 40px;">Neurologiske symptomer.</li> <li style="margin-left: 40px;">(Alder &gt; 6 år)</li> </ol> </li> </ol> <p style="margin-left:40px">Overvej udredning med MR scanning af cerebrum. Lumbalpunktur er&nbsp;indiceret ved mistanke om infektiøs genese (evt Borreliainfektion, spørg til flåtbid).</p> <p><strong>Ved patologiske neurologiske tegn inkomitant esotropi</strong></p> <p style="margin-left:40px">Barnet henvises/overflyttes akut til pædiatrisk regi, til videre udredning inkl. akut MR af cerebrum.<br> Efter kl. 22 foregår akut MR-scanning på Rigshospitalet.<br> Aftale træffes (helst bagvagt til bagvagt) med</p> <ul> <li style="margin-left: 40px;">vagthavende pædiater afd. 5054. <ul> <li style="margin-left: 40px;">Før kl 21 på tlf.: ###TELEFON### (pædiatrisk bagvagt),</li> <li style="margin-left: 40px;">Fra kl. 21 på tlf: ###TELEFON### (pædiatrisk mellemvagt).&nbsp;</li> </ul> </li> </ul> <p><strong>Uden patologiske neurologiske tegn</strong></p> <ul> <li style="margin-left: 40px;">Efter ovenstående undersøgelse og brilleordination viderehenvises barnet subakut (inden for 14 dage) til pædiatrisk gennemgang og evt. MR scanning på lokal børneafdeling.<br> Aftale træffes med vagthavende pædiater på lokalsygehus ud fra patientens bopæl.<br> Kontrol ved ortoptist på Rigshospitalet-Glostrup aftales.</li> <li style="margin-left: 40px;">Ved fortsat uafklaret patient, udelukkende set af forvagt:<br> Barnet skal ses dagen efter af bagvagt evt. sammen med børneoftalmolog (evt ortoptist tilsyn) mhp afklaring om der er indikation for:<br> Akut henvisning til RH pædiatrisk afd/subakut henvisning til lokal børneafd/eller blot Opfølgende kontrol ved ortoptist som skitseret nedenfor.&nbsp;</li> </ul> <p><strong>Ved ingen mistanke om neurologisk årsag</strong></p> <p style="margin-left:40px">Efter ovenstående undersøgelse og brille ordination gives opfølgende kontrol som skitseret nedenfor.</p> <p>&nbsp;<br> <strong>Opfølgende kontrol</strong></p> <p style="margin-left:40px">I:&nbsp;Det er lægens ansvar at planlægge opfølgende kontrol ved ortoptist + skelekirurg ved Rigshospitalet-Glostrup&nbsp;&lt;2 uger efter initiale undersøgelse.<br> <br> Lav AKUT VISI til skeleteam.<br> <br> II: Ved opfølgende kontrol planlægges videre forløb med enten afventen af spontanforløb (hvis brilleordination), fremskyndet injektion med botulinum toxin A eller skelekirurgi for at redde samsyn. Der er evidens for, at hurtig behandling (&lt; 2 mdr) øger chancen for genetablering af parallelle akser og samsyn.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p> <p style="margin-left:80px">&nbsp;&nbsp;</p> <p>&nbsp;<a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579049869Top">Tilbage til top</a></p> <h2><a name="1699579049869Ansvar"></a><br> Ansvar og organisering</h2> <p>Afdelingsledelsen, Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger.<br> Afsnitsledende overlæge, afdelingssygeplejersker og ledende lægesekretærer, er ansvarlig for at instruksen udarbejdes, revideres og implementeres.<br> Den enkelte medarbejder i Afdeling for Øjensygdomme, er ansvarlig for at kende og følge instruksen</p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579049869Top">Tilbage til top</a></p> <h2><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p>Afdeling for Øjensygdomme, Rigshospitalet-Glostrup</p> <p style="margin-left:40px"><a href="###FOLDER###" target="_blank"><u><span style="color:#0066cc">Børne team, børnebriller - recept,</span></u></a> instruks</p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579049869Top">Tilbage til top</a></p> <h2><a name="1699579049869Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579049869Top">Tilbage til top</a></p> <h2><a name="1699579049869Bilag"></a><br> Bilag</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579049869Top">Tilbage til top</a></p>

Rigshospitalet_¥jensygdomme (HOC)_Stuegangsfunktion på Afdeling for ¥jensygdommes sengeafsnit.

Stuegangsfunktion på Afdeling for Øjensygdommes sengeafsnit Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Bilag Målgrupper og anvendelsesområde Beskriver afvikling af stuegang for indlagte og indkaldte patienter i Afdeling for Øjensygdommes sengeafsnit, Rigshospitalet-Glostrup. Dette for at sikre et optimalt patientforløb via et interfropessionelt samarbejde. Gældende for personalet i Afdeling for Øjensygdommes sengeafsnit. Definitioner Stuegangen: Det interprofessionelle samarbejde mellem læge og sygeplejerske hvor: - der følges op på planlagt udredning/behandlingsplan - ændringer i patientens tilstand varetages - udskrivning planlægges - journaloptagelse på indkaldte patienter foretages Patientkategorier: - Indlagte patienter, som fysisk er til stede i afsnittet - Indlagte patienter, som er hjemme på orlov og kommer til stuegang efter aftalt mødetidspunkt - Indkaldte patienter, som møder til journaloptagelse i løbet af dagen Fremgangsmåde Stuegangslægen har plads i stuegangsklinikken. Lægen og de 2-3 sygeplejersker, som har ansvaret for stuegangspatienter og indkaldte patienter, aftaler indbyrdes hvordan dagens patienter prioriteres i forhold til: - Akutte problemstillinger - Børn - Tolkebistand - Udskrivelse, lang rejse / modtages af hjemmeplejen - Journaloptagelse og anæstesi-tilsyn - Fortsat indlæggelse - Infektioner - Isolation Rækkefølgen ændres ved behov i forhold til konferencebeslutnnger. Sygeplejerskerne varetager patienterne ud fra principperne om kontaktsygepleje. Stuegangen begynder klokken 8.30. På torsdage først klokken 9.00. Indkaldte patienter: Sygeplejersken, som er ansvarlig for modtagelse af indkaldte patienter, aftaler med lægen om den første indkaldte patient er modtaget sygeplejefagligt, eller om patienten starter hos lægen. Efterfølgende modtager sygeplejersken patienterne sygeplejefagligt. Journaloptagelse: Lægen varetager journaloptagelsen og stuegangen i forhold Lægelig vurdering og journalføring, dokument fra Region Hovedstaden Journaloptagelsen skrives ind i SP. Senest klokken 13.30 skal journaloptagelse på indkaldte patienter, som skal i universel anæstesi, være skrevet og klar til tilsyn af anæstesilæge. Aftenrunder: Den vagthavende læge kommer i sengeafdsnittet, Ø34 med - henblik på: - Varetagelse af skutte lægelige opgaver - Signatur af blodprøvesvar og stillingtagen til eventuelt tiltag I weekender: Stuegang for indlagte patienter (incl. de, som kommer til stuegang fra orlov), foregår mellem kl. 8.00 - 10.00 hos bagvagten. Ansvar og opgavefordeling: Læger er ansvarlige for: - Lægelig journalføring - At sikre nytilkomne blodprøvesvar og undersøgelsesresultater gennemses - Billeddiagnostiske undersøgelser bestilles i SP - Udfylde rekvisitions sedler - Cave udfyldes i særskilt allergi/intolerance-notat i SP - Medicinordination i SP - Recepter - skal lægges på apoternes server - Frigivelse/afstemning af FMK Sygeplejersker er ansvarlige for: - Sygeplejefaglig dokumentation i SP - Udføre EWS og evt. måle blodsukker - Udføre ordinationer, så patienten er klar til at blive tilset af kirurgen - Relevante plejemæssige observationer tages op til stuegang - Bestille ordinerede blodprøver og undersøgelser - Medicindispensering/administraion i følge ordination - Opdatering af patientoversigt/patienttavle - Information og udlevering af skriftligt materiale til patienten - Skrive patienten på orlov i GS, hvis denne overnatter hjemme Sygeplejesekretær er ansvarlig for: - Dokumentation for kontaktpersonordningen i SP - Sende tilsyn/henvisninger til andre afdelinger/hospitaler via SP Ansvar og organisering Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger. Afsnitsledende overlæger, afdelingssygeplejersker og ledende lægesekretærer, er ansvarlige for at instruksen udarbejdes, revideres og implementeres. Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen. Referencer, lovgivning og faglig evidens samt links hertil Region Hovedstaden Lægelig vurdering og journalføring, dokument SP Sundhedsplatform, fra Region Hovedstaden Bilag

<h1><div id="Afsnit#1699579016585">Stuegangsfunktion på Afdeling for Øjensygdommes sengeafsnit</div></h1><div id="BodyWeb#1699579016585"><p><a name="1699579016585Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579016585Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579016585Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579016585Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579016585Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579016585Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579016585Bilag">Bilag</a><br> &nbsp;</h3> <h2>&nbsp;</h2> <div class="collapsible-item" expandedstart="1"><a name="1699579016585Maalgrupper"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Målgrupper og anvendelsesområde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm">Beskriver afvikling af stuegang for indlagte og indkaldte patienter i Afdeling for Øjensygdommes&nbsp;sengeafsnit, Rigshospitalet-Glostrup.&nbsp;<br> Dette for at sikre et optimalt patientforløb via et interfropessionelt samarbejde.</p> <p style="margin-left:0cm; margin-right:0cm">Gældende for personalet i Afdeling for Øjensygdommes sengeafsnit.&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579016585Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579016585Definitioner"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Definitioner</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm"><strong>Stuegangen:</strong></p> <p style="margin-left:0cm; margin-right:0cm">Det interprofessionelle samarbejde mellem læge og sygeplejerske hvor:</p> <ul> <li>der følges op på planlagt udredning/behandlingsplan</li> <li>ændringer i patientens tilstand varetages</li> <li>udskrivning planlægges</li> <li>journaloptagelse på indkaldte patienter foretages</li> </ul> <p style="margin-left:0cm; margin-right:0cm"><strong>Patientkategorier:</strong></p> <ul> <li>Indlagte patienter, som fysisk er til stede i afsnittet</li> <li>Indlagte patienter, som er hjemme på orlov og kommer til stuegang efter aftalt mødetidspunkt</li> <li>Indkaldte patienter, som møder til journaloptagelse i løbet af dagen</li> </ul> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579016585Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579016585Fremgangsmaade"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Fremgangsmåde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm">Stuegangslægen har plads i stuegangsklinikken.&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm">Lægen og de 2-3 sygeplejersker, som har ansvaret for stuegangspatienter og indkaldte patienter, aftaler indbyrdes hvordan dagens patienter prioriteres i forhold til:</p> <ul> <li>Akutte problemstillinger</li> <li>Børn</li> <li>Tolkebistand</li> <li>Udskrivelse, lang rejse / modtages af hjemmeplejen</li> <li>Journaloptagelse og anæstesi-tilsyn</li> <li>Fortsat indlæggelse</li> <li>Infektioner</li> <li>Isolation</li> </ul> <p style="margin-left:0cm; margin-right:0cm">Rækkefølgen ændres ved behov i forhold til konferencebeslutnnger.<br> Sygeplejerskerne varetager patienterne ud fra principperne om kontaktsygepleje.<br> Stuegangen begynder klokken 8.30. På torsdage først klokken 9.00.</p> <p style="margin-left:0cm; margin-right:0cm"><strong>Indkaldte patienter:</strong></p> <p style="margin-left:0cm; margin-right:0cm">Sygeplejersken, som er ansvarlig for modtagelse af indkaldte patienter, aftaler med lægen om den første indkaldte patient er modtaget sygeplejefagligt, eller om patienten starter hos lægen.</p> <p style="margin-left:0cm; margin-right:0cm">Efterfølgende modtager sygeplejersken patienterne sygeplejefagligt.&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong>Journaloptagelse:</strong></p> <p style="margin-left:0cm; margin-right:0cm">Lægen varetager journaloptagelsen og stuegangen i forhold&nbsp;<a href="###FOLDER###" target="_blank"><span style="color:blue">Lægelig vurdering og journalføring</span></a>,&nbsp;dokument fra&nbsp;Region Hovedstaden</p> <p style="margin-left:0cm; margin-right:0cm">Journaloptagelsen skrives ind i SP.</p> <p style="margin-left:0cm; margin-right:0cm">Senest klokken 13.30 skal journaloptagelse på indkaldte patienter, som skal i universel anæstesi, være skrevet og klar til tilsyn af anæstesilæge.</p> <p style="margin-left:0cm; margin-right:0cm"><strong>Aftenrunder:</strong></p> <p style="margin-left:0cm; margin-right:0cm">Den vagthavende læge kommer i sengeafdsnittet,&nbsp;Ø34 med - henblik på:</p> <ul> <li>Varetagelse af skutte lægelige opgaver</li> <li>Signatur af blodprøvesvar og stillingtagen til eventuelt tiltag</li> </ul> <p style="margin-left:0cm; margin-right:0cm"><strong>I weekender:</strong></p> <p style="margin-left:0cm; margin-right:0cm">Stuegang for indlagte patienter (incl. de, som kommer til stuegang fra orlov), foregår mellem kl. 8.00 - 10.00 hos bagvagten.</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong>Ansvar og opgavefordeling:</strong></p> <p style="margin-left:0cm; margin-right:0cm">Læger er ansvarlige for:</p> <ul> <li>Lægelig journalføring</li> <li>At sikre nytilkomne blodprøvesvar og undersøgelsesresultater gennemses</li> <li>Billeddiagnostiske undersøgelser bestilles i SP</li> <li>Udfylde rekvisitions sedler</li> <li>Cave udfyldes&nbsp;i særskilt allergi/intolerance-notat i SP</li> <li>Medicinordination i SP</li> <li>Recepter - skal lægges på apoternes server&nbsp;</li> <li>Frigivelse/afstemning af FMK</li> </ul> <p style="margin-left:0cm; margin-right:0cm">Sygeplejersker er ansvarlige for:</p> <ul> <li>Sygeplejefaglig dokumentation i SP</li> <li>Udføre EWS og evt. måle blodsukker</li> <li>Udføre ordinationer, så patienten er klar til at blive tilset af kirurgen</li> <li>Relevante plejemæssige observationer tages op til stuegang</li> <li>Bestille ordinerede blodprøver og undersøgelser</li> <li>Medicindispensering/administraion i følge ordination</li> <li>Opdatering af patientoversigt/patienttavle</li> <li>Information og udlevering af skriftligt materiale til patienten</li> <li>Skrive patienten på orlov i GS, hvis denne overnatter hjemme</li> </ul> <p style="margin-left:0cm; margin-right:0cm">Sygeplejesekretær er ansvarlig for:</p> <ul> <li>Dokumentation for kontaktpersonordningen i SP</li> <li>Sende&nbsp;tilsyn/henvisninger til andre afdelinger/hospitaler via SP</li> </ul> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579016585Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579016585Ansvar"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Ansvar og organisering</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm">Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger.<br> Afsnitsledende overlæger, afdelingssygeplejersker og ledende lægesekretærer, er ansvarlige for at instruksen udarbejdes, revideres og implementeres.<br> Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579016585Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579016585Referencer"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Referencer, lovgivning og faglig evidens samt links hertil</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm">Region Hovedstaden</p> <p style="margin-left:40px; margin-right:0cm"><a href="###FOLDER###" target="_blank"><span style="color:#0066cc">Lægelig vurdering og journalføring</span></a>,&nbsp;dokument SP Sundhedsplatform, fra&nbsp;Region Hovedstaden</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579016585Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579016585Bilag"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Bilag</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579016585Top">Tilbage til top</a></p>

Rigshospitalet_¥jensygdomme (HOC)_Suturfjernelse Externa tårevejs team.

Suturfjernelse, Externa / tårevejs team, Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Bilag Målgrupper og anvendelsesområde Definitioner Ingen Fremgangsmåde Et operationssår heler under normale omstændigheder uden komplikationer. Suturerne kan fjernes uden desinfektion, og umiddelbart efter suturfjernelse er suturkanalerne helt lukket og ikke indgangsport for bakterier. Patienten behøver derfor ikke plaster, hvis cicatricen er tør. Tidspunkt for suturfjernelse afhænger af sårets lokalisation. Operationsdagen tæller som 1.dag: I ansigtet: 5-7 dage. I hud: 7-10 dage. Transplantat: 7-12 dage. Pentagon: 10-14 dage. Generelt forlænges den tid suturerne sidder med 2 dage, hvis patienten Har diabetes mellitus. Er opereret i samme cicatrice inden for 5 år. Har fået binyrebarkhormon i mere end 3 uger. Generelt kan suturforlængelsen forlænges op til en uge af logistiske årsager. Men suturer kan ikke fjernes tidligere. Suturfjernelse Remedier: Alm.suturfjernelsessæt (steril anatomisk pincet) Rene medicinske engangshandsker Evt. plaster Udførelse: - Håndhygiejne udføres inden proceduren. Se regional vejledning: Håndhygiejne for sundhedspersonale - Patient informeres om procedure og tilbydes pause under proceduren, hvis det vurderes nødvendigt. - Patienten lejres hensigtsmæssigt. Afdækning ikke mere end nødvendigt. Suturfjernelse betragtes som en ren procedure. - Emballage omkring pincet/vanna saks fjernes, så den er let tilgængelig. - Handsker tages på - forbinding fjernes - handsker tages af og håndhygiejne gentages, inden rene handsker tages på. - Suturene fjernes ved , at man med pincetten griber fat i suturens knude og forsigtig løfter op i suturen, så man med saksen kan klippe den over tættest ved huden. Det skal undgås, at den del af suturen, der ligger over huden, trækkes igennem vævet. Herved nedsættes risikoen for infektion. - Suturen trækkes ud og proceduren gentages indtil alle sutur er fjernet . Fortløbende suturer fjernes sting for sting , under hensynstagen til at mindst muligt af suturen som har ligget på overfladen trækkes ned under huden. - Cicatricen kontrolleres for evt.defekter i ophelingen - det sikres at alle tråde er fjernet. - Operationssåret dækkes af absorberende plaster ved behov. - Patienten informeres om ikke at vaske området de næste 24 timer eller hvis der er sivning. Ansvar og organisering Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger. Afsnitsledende overlæger, afdelingssygeplejersker og ledende lægesekretærer, er ansvarlige for at instruksen udarbejdes, revideres og implementeres. Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen. Referencer, lovgivning og faglig evidens samt links hertil Håndhygiejne for sundhedspersonale, vejledning fra Komitéen for infektionsforebyggelse og hygiejne, Region Hovedstaden Bilag

<h1><div id="Afsnit#1699579076495">Suturfjernelse, Externa / tårevejs team,</div></h1><div id="BodyWeb#1699579076495"><p>&nbsp;</p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579076495Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579076495Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579076495Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579076495Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579076495Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579076495Bilag">Bilag</a><br> &nbsp;</h3> <div class="collapsible-item" expandedstart="1"><a name="1699579076495Maalgrupper"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Målgrupper og anvendelsesområde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579076495Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579076495Definitioner"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Definitioner</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>Ingen</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579076495Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579076495Fremgangsmaade"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Fremgangsmåde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>Et operationssår heler under normale omstændigheder uden komplikationer. Suturerne kan fjernes uden desinfektion, og umiddelbart efter suturfjernelse er suturkanalerne helt lukket og ikke indgangsport for bakterier. Patienten behøver derfor ikke plaster, hvis cicatricen er tør.</p> <p>Tidspunkt for suturfjernelse afhænger af sårets lokalisation.</p> <p style="margin-left:40px">Operationsdagen tæller som 1.dag:</p> <p style="margin-left:80px">I ansigtet: 5-7 dage.<br> I hud: 7-10 dage.<br> Transplantat: 7-12 dage.<br> Pentagon: 10-14 dage.</p> <p>&nbsp;Generelt forlænges den tid suturerne sidder med 2 dage, hvis patienten</p> <p style="margin-left:40px">&nbsp;Har diabetes mellitus.<br> &nbsp;Er opereret i samme cicatrice inden for 5 år.<br> &nbsp;Har fået binyrebarkhormon i mere end 3 uger.</p> <p style="margin-left:40px">Generelt kan suturforlængelsen forlænges op til en uge af logistiske årsager. Men suturer kan ikke fjernes tidligere.</p> <p><strong>Suturfjernelse</strong></p> <p style="margin-left:40px">Remedier:</p> <p style="margin-left:80px">Alm.suturfjernelsessæt (steril anatomisk pincet)<br> Rene medicinske engangshandsker<br> Evt. plaster</p> <p style="margin-left:40px">Udførelse:</p> <ol> <li>Håndhygiejne udføres inden proceduren. Se regional vejledning: <a href="http://vip.regionh.dk/VIP/Admin/GUI.nsf/Desktop.html?open&amp;openlink=http://vip.regionh.dk/VIP/Slutbruger/Portal.nsf/Main.html?open&amp;unid=X7D4F2E2222BA9A46C12578AA002C7928&amp;level=150241&amp;dbpath=/VIP/Redaktoer/RH.nsf/&amp;windowwidth=1100&amp;windowheight=600&amp;windowtitle=S%F8g " target="_blank">Håndhygiejne for sundhedspersonale</a></li> <li>Patient informeres om procedure og tilbydes pause under proceduren, hvis det vurderes nødvendigt.</li> <li>Patienten lejres hensigtsmæssigt. Afdækning ikke mere end nødvendigt.<br> Suturfjernelse betragtes som en ren procedure.</li> <li>Emballage omkring pincet/vanna saks fjernes, så den er let tilgængelig.</li> <li>Handsker tages på - forbinding fjernes - handsker tages af og håndhygiejne gentages, inden rene handsker tages på.</li> <li>Suturene fjernes ved , at man med pincetten griber fat i suturens knude og forsigtig løfter op i suturen, så man med saksen kan klippe den over tættest ved huden. Det skal undgås, at den del af suturen, der ligger over huden, trækkes igennem vævet. Herved nedsættes risikoen for infektion.</li> <li>Suturen trækkes ud og proceduren gentages indtil alle sutur er fjernet . Fortløbende suturer fjernes sting for sting , under hensynstagen til at mindst muligt af suturen som har ligget på overfladen trækkes ned under huden.</li> <li>Cicatricen kontrolleres for evt.defekter i ophelingen - det sikres at alle tråde er fjernet.</li> <li>Operationssåret dækkes af absorberende plaster ved behov.</li> <li>Patienten informeres om ikke at vaske området de næste 24 timer eller hvis der er sivning.</li> </ol> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579076495Ansvar"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Ansvar og organisering</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p><br> Afdelingsledelsen i Afdeling for Øjensygdomme,&nbsp;Rigshospitalet, er ansvarlig for at instruksen foreligger.<br> Afsnitsledende overlæger, afdelingssygeplejersker og ledende lægesekretærer, er ansvarlige for at instruksen udarbejdes, revideres og implementeres.<br> Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579076495Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579076495Referencer"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Referencer, lovgivning og faglig evidens samt links hertil</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p><a href="http://vip.regionh.dk/VIP/Admin/GUI.nsf/Desktop.html?open&amp;openlink=http://vip.regionh.dk/VIP/Slutbruger/Portal.nsf/Main.html?open&amp;unid=X7D4F2E2222BA9A46C12578AA002C7928&amp;level=150241&amp;dbpath=/VIP/Redaktoer/RH.nsf/&amp;windowwidth=1100&amp;windowheight=600&amp;windowtitle=S%F8g " target="_blank">Håndhygiejne for sundhedspersonale</a>, vejledning fra Komitéen for infektionsforebyggelse og hygiejne, Region Hovedstaden</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579076495Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579076495Bilag"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Bilag</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579076495Top">Tilbage til top</a></p>

Rigshospitalet_¥jensygdomme (HOC)_Svagsynede tilbud til patienterne.

Svagsynede, tilbud til patienterne Målgrupper og anvendelsesområde Oversigt over relevante tilbud til patienter der har fået skadet synsfunktionen. Gældende for klinisk personale i Afdeling for Øjensygdomme, Rigshospitalet. Definitioner Fremgangsmåde Har en patient fået skadet synsfunktionen, er det vigtigt, at patienten er informeret om hjælpemuligheder. Den fagperson der er ansvarlig for patienten, har ansvar for, at patienten er informeret om de tilbud, der er relevante for den enkelte patient. Man er svagsynet, når synet er mindre end 0,3 på bedste øje med bedste korrektion eller når synsfeltet på bedste øje er mindre en 20 gr. og ved hemianopsi. I hver region findes en Synsrådgivning eller en lignende instans, der har den overordnede rådgivningsforpligtigelse for regionens borgere. Tilbuddet er organiseret forskelligt fra region til region og nogle kommuner har selv hjemtaget opgaven Patientens hjemme kommune vil kunne oplyse, hvor patienten skal henvende sig for at få hjælp. På Foreningen af Svagsynsspecialister, findes en oversigt, under "Information" i menuen. Eller på Øjenforeningens hjemmeside. Uden-regions patienter der følges i Afdeling for Øjensygdomme, Rigshospitalet, skal informeres om, at de kan få hjælp og vejledning hos hjemregionens Synsrådgivning/Kommunikationscenter (se ovenstående liste) Uden-regions patienter, der udskrives til anden øjenafdeling, skal informeres om, at de her vil få hjælp og vejledning, hvis det er relevant. Hvis patienten i forbindelse med udskrivning er i målgruppen til hjælp, informeres der om tilknytning til kommunikationscenter eller kommune. Svagsynsoptikere fremstiller og forhandler special optik. Patienten kan henvende sig direkte til optikeren uden recept, men optikeren skal have udtalelse om visus og eventuelt øjenlidelse med henblik på, at patienten kan få dækning af udgift. Svagsynsoptikeren er behjælpelig med ansøgning om økonomisk tilskud via serviceloven. Oversigt over svagsynsoptikere findes på Foreningen af Svagsynsspecialister, under "Find optiker" i menuen. Institut for Blinde og Svagsynede (IBOS), yder rådgivning og vejledning af unge bl.a. med hensyn til studie, voksne bl.a. med hensyn til fastholdelse i erhverv og forældre til børn med synshandicap. Ligeledes rådgivning i sociale forhold ved synsnedsættelse samt akuttjeneste ved pludselig opstået invaliderende synstab, bl.a. til pårørende/plejepersonale. Dansk Blindesamfund er blinde og svagsynedes egen forening i Danmark. Optager kun medlemmer med synsnedsættelse fra 6/60 eller synsfelt på under 10 grader. Fuldt medlemskab kan opnås ved visus 6/60 eller derunder eller synsfelt på uder 10 grader. Man kan desuden blive aktivitetsmedlem hvis visus er 0, Relevante web-adresser: Foreningen af Svagsynsspecialister, http://svagsynsforeningen.dk Socialstyrelsens information om synshandicap, http://socialstyrelsen.dk/handicap/synshandicap Kennedy Centret, Nationalt forsknings- og rådgivningscenter for genetisk, synshandicap og mental retardering, http://www.kennedy.dk/ Instituttet for Blinde og Svagsynede, http://www.ibos.dk/ Synscenter Refsnæs (Region Sjælland), http://www.synref.dk/ Dansk Blindesamfund, http://www.dkblind.dk/ DH, Danske Handicaporganisationer – For retten til lige behandling, http://www.handicap.dk/ Nationalbibliotek for mennesker med læsevanskeligheder, http://www.nota.nu Danmarks optikerforening, http://www.optikerforeningen.dk Patientforsikringen - Erstatning til patient der er kommet til skade, http://www.patientforsikringen.dk/ Den Uvildige Konsulentordning på Handicapområdet, http://www.dukh.dk Synsregister, https://www.rigshospitalet.dk/afdelinger-og-klinikker/hovedorto/oejensygdomme/for-fagfolk/synsregisteret/Sider/default.aspx Øjenforeningen, https://ojenforeningen.dk. Synslinjen, https://synslinjen.dk. Ansvar og organisering Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger. Afsnitsledelsen er ansvarlige for at instruksen udarbejdes, revideres og implementeres. Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen. Referencer, lovgivning og faglig evidens samt links hertil Bilag

<h1><div id="Afsnit#1699579112228">Svagsynede, tilbud til patienterne</div></h1><div id="BodyWeb#1699579112228"><p>&nbsp;</p> <div class="collapsible-item" expandedstart="1"><a name="1699579112228Maalgrupper"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Målgrupper og anvendelsesområde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm">Oversigt over relevante tilbud til patienter der har fået skadet synsfunktionen.</p> <p style="margin-left:0cm; margin-right:0cm">Gældende for klinisk personale i Afdeling for Øjensygdomme, Rigshospitalet.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579112228Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item"><a name="1699579112228Definitioner"></a> <div class="collapsible-item-title"> <h2>Definitioner</h2> </div> <div class="collapsible-item-body" style="display: none;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579112228Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579112228Fremgangsmaade"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Fremgangsmåde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm">Har en patient fået skadet synsfunktionen, er det vigtigt, at patienten er informeret om hjælpemuligheder. Den fagperson&nbsp;der er&nbsp;ansvarlig for patienten, har ansvar for, at patienten er informeret om de tilbud, der er relevante for den enkelte patient.<br> Man er svagsynet, når synet er mindre end 0,3 på bedste øje med bedste korrektion eller når synsfeltet på bedste øje er mindre en 20 gr. og ved hemianopsi.</p> <p style="margin-left:0cm; margin-right:0cm">I hver region findes en Synsrådgivning&nbsp;eller en lignende instans, der har den overordnede rådgivningsforpligtigelse for regionens borgere. Tilbuddet er organiseret forskelligt fra region til region og nogle kommuner har selv hjemtaget opgaven</p> <p style="margin-left:0cm; margin-right:0cm">Patientens hjemme kommune vil kunne oplyse, hvor patienten skal henvende sig for at få hjælp.<br> På <a href="http://svagsynsforeningen.dk" target="_blank"><span style="color:blue">Foreningen af Svagsynsspecialister</span></a>,&nbsp;findes en oversigt, under "Information" i menuen. Eller på <a href="https://ojenforeningen.dk/ojenlaeger/synsraadgivning-svagsynede" target="_blank"><span style="color:blue">Øjenforeningens hjemmeside</span></a>.</p> <p style="margin-left:0cm; margin-right:0cm">Uden-regions patienter der følges i Afdeling for Øjensygdomme, Rigshospitalet, skal informeres om, at de kan få hjælp og vejledning hos hjemregionens Synsrådgivning/Kommunikationscenter&nbsp;(se ovenstående liste)<br> Uden-regions patienter, der udskrives til anden øjenafdeling, skal informeres om, at de her vil få hjælp og vejledning, hvis det er relevant. Hvis patienten i forbindelse med udskrivning er i målgruppen til hjælp, informeres der om tilknytning til kommunikationscenter eller kommune.<br> &nbsp;<br> Svagsynsoptikere fremstiller og forhandler special optik. Patienten kan henvende sig direkte til optikeren uden recept, men optikeren skal have udtalelse om visus og eventuelt øjenlidelse med henblik på, at patienten kan få dækning af udgift. Svagsynsoptikeren er behjælpelig med ansøgning om økonomisk tilskud via <a href="https://www.rigshospitalet.dk/afdelinger-og-klinikker/hovedorto/oejenklinikken/optik/Sider/medicinsk-optisk-defineret-varig-oejenlidelse.aspx" target="_blank"><span style="color:blue">serviceloven</span></a>.</p> <p style="margin-left:0cm; margin-right:0cm">Oversigt over svagsynsoptikere findes på <a href="http://svagsynsforeningen.dk" target="_blank"><span style="color:blue">Foreningen af Svagsynsspecialister</span></a>, under "Find optiker" i menuen.</p> <p style="margin-left:0cm; margin-right:0cm"><a href="http://www.ibos.dk/" target="_blank"><span style="color:blue">Institut for Blinde og Svagsynede</span></a> (IBOS), yder rådgivning og vejledning af unge bl.a. med hensyn til studie, voksne bl.a. med hensyn til fastholdelse i erhverv og forældre til børn med synshandicap. Ligeledes rådgivning i sociale forhold ved synsnedsættelse samt akuttjeneste ved pludselig opstået invaliderende synstab, bl.a. til pårørende/plejepersonale.</p> <p style="margin-left:0cm; margin-right:0cm"><br> <a href="https://blind.dk/" target="_blank"><span style="color:blue">Dansk Blindesamfund</span></a> er blinde og svagsynedes egen forening i Danmark. Optager kun medlemmer med synsnedsættelse fra 6/60 eller synsfelt på under 10 grader. Fuldt medlemskab kan opnås ved visus 6/60 eller derunder eller synsfelt på uder 10 grader. Man kan desuden blive aktivitetsmedlem hvis visus er 0,</p> <p style="margin-left:0cm; margin-right:0cm"><br> Relevante web-adresser:</p> <p style="margin-left:0cm; margin-right:0cm">Foreningen af Svagsynsspecialister,&nbsp;<a href="http://svagsynsforeningen.dk"><span style="color:blue">http://svagsynsforeningen.dk</span></a></p> <p style="margin-left:0cm; margin-right:0cm">Socialstyrelsens information om synshandicap,&nbsp;<a href="http://socialstyrelsen.dk/handicap/synshandicap"><span style="color:blue">http://socialstyrelsen.dk/handicap/synshandicap</span></a>&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm">Kennedy Centret, Nationalt forsknings- og rådgivningscenter for genetisk, synshandicap og mental retardering,&nbsp;<a href="http://www.kennedy.dk/"><span style="color:blue">http://www.kennedy.dk/</span></a></p> <p style="margin-left:0cm; margin-right:0cm">Instituttet for Blinde og Svagsynede, <a href="http://www.ibos.dk/"><span style="color:#0066cc">http://www.ibos.dk/</span></a></p> <p style="margin-left:0cm; margin-right:0cm">Synscenter Refsnæs (Region Sjælland), <a href="http://www.synref.dk/"><span style="color:#0066cc">http://www.synref.dk/</span></a></p> <p style="margin-left:0cm; margin-right:0cm">Dansk Blindesamfund, <a href="http://www.dkblind.dk/"><span style="color:#0066cc">http://www.dkblind.dk/</span></a></p> <p style="margin-left:0cm; margin-right:0cm">DH, Danske Handicaporganisationer – For retten til lige behandling, <a href="http://www.handicap.dk/"><span style="color:#0066cc">http://www.handicap.dk/</span></a></p> <p style="margin-left:0cm; margin-right:0cm">Nationalbibliotek for mennesker med læsevanskeligheder, <a href="http://www.nota.nu"><span style="color:#0066cc">http://www.nota.nu</span></a>&nbsp;&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm">Danmarks optikerforening, <a href="http://www.optikerforeningen.dk"><span style="color:#0066cc">http://www.optikerforeningen.dk</span></a></p> <p style="margin-left:0cm; margin-right:0cm">Patientforsikringen - Erstatning til patient der er kommet til skade, <a href="http://www.patientforsikringen.dk/"><span style="color:#0066cc">http://www.patientforsikringen.dk/</span></a></p> <p style="margin-left:0cm; margin-right:0cm">Den Uvildige Konsulentordning på Handicapområdet, <a href="http://www.dukh.dk"><span style="color:#0066cc">http://www.dukh.dk</span></a></p> <p style="margin-left:0cm; margin-right:0cm">Synsregister, <a href="https://www.rigshospitalet.dk/afdelinger-og-klinikker/hovedorto/oejenklinikken/for-fagfolk/synsregisteret/Sider/default.aspx"><span style="color:blue">https://www.rigshospitalet.dk/afdelinger-og-klinikker/hovedorto/oejensygdomme/for-fagfolk/synsregisteret/Sider/default.aspx</span></a></p> <p style="margin-left:0cm; margin-right:0cm">Øjenforeningen, <span style="color:black"><a href="https://ojenforeningen.dk/" target="_blank"><span style="color:blue">https://ojenforeningen.dk.</span></a> </span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Synslinjen, <a href="https://synslinjen.dk/"><span style="color:blue">https://synslinjen.dk</span></a>. </span></p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579112228Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579112228Ansvar"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Ansvar og organisering</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm">Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger.<br> Afsnitsledelsen er ansvarlige for at instruksen udarbejdes, revideres og implementeres.<br> Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579112228Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579112228Referencer"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Referencer, lovgivning og faglig evidens samt links hertil</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579112228Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579112228Bilag"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Bilag</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579112228Top">Tilbage til top</a></p>

Rigshospitalet_¥jensygdomme (HOC)_Svampeendoftalmitis tilsyn og behandling.

Svampeendoftalmitis, tilsyn og behandling Målgrupper og anvendelsesområde Beskriver tilsyn og behandling af patienter med mistænkt endogen okulær svampeinfektion indlagt på anden afdeling end Afdeling for Øjensygdomme, Rigshospitalet Gældende for læger, sygeplejersker/SOSU og sekretærer med tilknytning til akut-team i Afdeling for Øjensygdomme, Rigshospitalet. Definitioner Endogen okulær svampeinfektion kan opstå ved hæmatogen spredning til øjet fra et extraokulært fokus, typisk hos alment syge patienter, der har gennemgået: - Større abdominal kirurgi, organtransplantation - Langvarig parenteral ernæring, CVK - Immunosuppression, HIV/AIDS - Diabetes, cancer - Langvarig antibiotikabehandling - I.v. stofmisbrug Infektion med gærsvamp er hyppigst (især Candida), skimmelsvamp sjældnere (især Aspergillus). Infektionen viser sig typisk som en chorioretinitis, eventuelt med spredning til corpus vitreum (endoftilmitis), men hele øjet kan være afficeret. Generelle retningslinier for visitation: Patienter med svampesepsis, der har øjensymptomer eller er sederet ses af bagvagt og visiteres efter nedenstående retningslinie. Vagthavende øjenlæge skal sikre sig at asymptomatiske patienter der ikke tilbydes øjenlægetilsyn er i relevant systemisk behandling. Det skal understreges overfor stamafdelingen at pt skal selvmonitorere synet, hvert øje for sig, og kontakte øjenlæge mhp. kontrol efter udskrivelse fra afdelingen. Fremgangsmåde Patienter, der ikke kan transporteres til Rigshospitalet-Glostrup/Blegdamsvej: - Tilsyn ved bagvagt samme eller næste dag på stamafdelingen (På Blegdamsvej og Hillerød går den tilstedeværende vagtansvarlige læge tilsyn i dagtid 8-14.30) - Hvis mistanke om okulær svampeinfektion med chorioretinitis, men uden makulainvolvering, uden vitritis: Kun systemisk behandling efter aftale med mikrobiolog/stamafdeling. - Hvis mistanke om okulær svampeinfektion med makulainvolvering eller med vitritis (endoftalmitis): Intravitrial behandling ved bagvagt eller kirurgisk bagvagt (efter aftale med sidstnævnte) med mindre patienten er terminal. - Opfølgning efter 3 dage. Hvis ingen bedring, kan behandlingen gentages Patienter, der kan transporteres til Rigshospitalet-Glostrup/Blegdamsvej: - Tilsyn ved bagvagt/forvagt samme eller næste dag på ØGA34 på RH-Glostrup eller på RH-Blegdamsvej - Hvis mistanke om okulær svampeinfektion med chorioretinitis, men uden makulainvolvering, uden vitritis: Kun systemisk behandling efter aftale med mikrobiolog - Hvis mistanke om okulær svampeinfektion med makulainvolvering eller med vitritis (endoftalmitis): Eventuelt vitrektomi (ved vitritis). Intravitrial behandling ved kirurgisk bagvagt. - Opfølgning efter 3 dage. Hvis ingen bedring, kan behandlingen gentages Systemisk behandling: Fluconazol eller voriconazol p.o eller i.v. afhængig af infiltraternes lokalisation (hvis kun chorioretinale infiltrater udenfor makula og uden corpusinvolvering kan peroral behandling forsøges, ellers paranteral-behandling i 10-14 dage), svampetype og resistensbestemmelse (konf. med mikrobiolog) Behandling i mindst 4-6 uger. Intravitrial behandling: Amphotericin B eller voriconazol iht instruks. (Amphotericin B: 5 mikrogram/0,1ml, Voriconazol 100 mikrogram/0,1 ml) Se også Afdeling for Øjensygdommes generelle instruks vedrørende endoftalmit: Kirurgisk retina team, endoftalmit vejledning ved Ansvar og organisering Afdelingsledelsen, Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger. Afsnitsledelsen er ansvarlig for at instruksen udarbejdes, revideres og implementeres. Den enkelte medarbejder i Afdeling for Øjensygdomme, er ansvarlig for at kende og følge instruksen Referencer, lovgivning og faglig evidens samt links hertil Bilag

<h1><div id="Afsnit#1699579218304">Svampeendoftalmitis, tilsyn og behandling</div></h1><div id="BodyWeb#1699579218304"><p>&nbsp;</p> <div class="collapsible-item" expandedstart="1"><a name="1699579218304Maalgrupper"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Målgrupper og anvendelsesområde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p><span style="color:#000000">Beskriver tilsyn og behandling af patienter med mistænkt endogen okulær svampeinfektion&nbsp;indlagt på anden afdeling end </span>Afdeling for Øjensygdomme, Rigshospitalet</p> <p><span style="color:#000000">Gældende for læger, sygeplejersker/SOSU og sekretærer med tilknytning til akut-team&nbsp;i </span>Afdeling for Øjensygdomme, Rigshospitalet.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579218304Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579218304Definitioner"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Definitioner</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p><span style="color:#000000">Endogen okulær svampeinfektion kan opstå ved hæmatogen spredning til øjet fra et extraokulært fokus, typisk hos alment syge patienter, der har gennemgået:</span></p> <ul> <li><span style="color:#000000">Større abdominal kirurgi, organtransplantation</span></li> <li><span style="color:#000000">Langvarig parenteral ernæring, CVK</span></li> <li><span style="color:#000000">Immunosuppression, HIV/AIDS</span></li> <li><span style="color:#000000">Diabetes, cancer</span></li> <li><span style="color:#000000">Langvarig antibiotikabehandling</span></li> <li><span style="color:#000000">I.v. stofmisbrug</span></li> </ul> <p><span style="color:#000000">Infektion med gærsvamp er hyppigst (især Candida), skimmelsvamp sjældnere (især Aspergillus).</span></p> <p><span style="color:#000000">Infektionen viser sig typisk som en chorioretinitis, eventuelt med spredning til corpus vitreum (endoftilmitis), men hele øjet kan være afficeret.</span></p> <p><strong><span style="color:black">Generelle retningslinier for visitation:</span></strong></p> <p style="margin-left:40px"><span style="color:black">Patienter med svampesepsis, der har øjensymptomer eller er sederet ses af bagvagt og visiteres efter nedenstående retningslinie. Vagthavende øjenlæge skal sikre sig at asymptomatiske patienter der ikke tilbydes øjenlægetilsyn er i relevant systemisk behandling. Det skal understreges overfor stamafdelingen at pt skal selvmonitorere synet, hvert øje for sig, og kontakte øjenlæge mhp. kontrol efter udskrivelse fra afdelingen. </span></p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579218304Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579218304Fremgangsmaade"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Fremgangsmåde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p><span style="color:#000000">Patienter, der ikke kan transporteres til Rigshospitalet-Glostrup/Blegdamsvej:</span></p> <ul> <li>Tilsyn&nbsp;ved <span style="color:black">bagvagt</span> samme eller næste dag på stamafdelingen (På Blegdamsvej <span style="color:null"><span style="background-color:white">og Hillerød går den tilstedeværende vagtansvarlige læge</span></span>&nbsp;tilsyn i dagtid 8-14.30)</li> <li>Hvis mistanke om okulær svampeinfektion&nbsp;med chorioretinitis, <strong>men uden <span style="color:black">makulainvolvering,</span> uden vitritis</strong>: Kun systemisk behandling efter aftale med mikrobiolog/stamafdeling.</li> <li>Hvis mistanke om okulær svampeinfektion&nbsp;<strong>med <span style="color:black">makulainvolvering</span> eller med vitritis (endoftalmitis)</strong>: Intravitrial behandling ved <span style="color:black">bagvagt</span> eller kirurgisk bagvagt (efter aftale med sidstnævnte) med mindre patienten er terminal.</li> <li>Opfølgning efter 3 dage. Hvis ingen bedring, kan behandlingen gentages</li> </ul> <p><span style="color:#000000">Patienter, der&nbsp;kan transporteres til Rigshospitalet-Glostrup/Blegdamsvej:</span></p> <ul> <li>Tilsyn ved <span style="color:black">bagvagt/forvagt</span> samme eller næste dag på ØGA34&nbsp;på RH-Glostrup&nbsp;eller på RH-Blegdamsvej</li> </ul> <ul> <li>Hvis mistanke om okulær svampeinfektion med chorioretinitis, <strong>men uden <span style="color:black">makulainvolvering,</span> uden vitritis</strong>: Kun systemisk behandling efter aftale med mikrobiolog</li> <li>Hvis mistanke om okulær svampeinfektion <strong>med <span style="color:black">makulainvolvering</span> eller med vitritis (endoftalmitis)</strong>: Eventuelt vitrektomi (ved vitritis). Intravitrial behandling ved&nbsp;kirurgisk bagvagt.</li> <li>Opfølgning efter 3 dage. Hvis ingen bedring, kan behandlingen gentages<span style="color:#000000">&nbsp;</span></li> </ul> <p><span style="color:#000000">Systemisk behandling:</span></p> <p style="margin-left:40px"><span style="color:#000000"><span style="color:#000000">Fluconazol eller voriconazol p.o eller i.v. afhængig af infiltraternes lokalisation (hvis kun chorioretinale infiltrater udenfor </span><span style="color:black">makula</span><span style="color:#000000"> og uden corpusinvolvering kan peroral behandling forsøges, ellers paranteral-behandling i 10-14 dage), svampetype og resistensbestemmelse&nbsp;(konf. med mikrobiolog)</span></span></p> <p><span style="color:black">Behandling</span><span style="color:#000000"> i mindst 4-6 uger.</span></p> <p><span style="color:#000000">Intravitrial behandling: </span></p> <p style="margin-left:40px"><span style="color:#000000">Amphotericin B eller voriconazol iht instruks. (Amphotericin B: 5 mikrogram/0,1ml, Voriconazol 100 mikrogram/0,1 ml)</span></p> <p><span style="color:black">Se også Afdeling for Øjensygdommes generelle&nbsp;instruks vedrørende endoftalmit: </span><br> <a href="###FOLDER###" target="_blank"><u>Kirurgisk retina team, endoftalmit vejledning ved</u></a></p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579218304Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579218304Ansvar"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Ansvar og organisering</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>Afdelingsledelsen, Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger.<br> Afsnitsledelsen&nbsp;er ansvarlig for at instruksen udarbejdes, revideres og implementeres.<br> Den enkelte medarbejder i Afdeling for Øjensygdomme, er ansvarlig for at kende og følge instruksen</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579218304Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579218304Referencer"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Referencer, lovgivning og faglig evidens samt links hertil</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579218304Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579218304Bilag"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Bilag</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579218304Top">Tilbage til top</a></p>

Rigshospitalet_¥jensygdomme (HOC)_Synsunderst¢ttende hjælpemidler.

Synsunderstøttende hjælpemidler Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Bilag Målgrupper og anvendelsesområde Angiver retningslinjer for henvisning af patienter til synsunderstøttende hjælpemidler. Læger, sygeplejersker, optometrist og social- og sundhedsassistenter, som ønsker at henvise patienter til synsunderstøttende hjælpemidler, fra Afdeling for Øjensygdomme, Rigshospitalet. Definitioner Synsunderstøttende hjælpemidler kan være forstørrende optik, specialbelysning, medicinske filterglas, læseTV og andet. ØB1 - Afdeling for Øjensygdommes ambulatorium på 1. sal. Fremgangsmåde Patienter som har et varigt synshandicap med synsstyrke 0,3 (6/18) eller derunder på bedst seende øje kan henvises til synsunderstøttende hjælpemidler. Der henvises som udgangspunkt, når patienten er færdigbehandlet. Hvis det er patienter med længerevarende forløb og/eller kronisk sygdom, henvises der, når synet skønnes stabilt eller uden udsigt til fremgang. Patienter kan desuden henvises såfremt læsesynet er så påvirket, at patienten har vanskeligt ved at klare daglige gøremål. Dette skal i så fald noteres i journalen på henvisningstidspunktet. AMD-patienter henvises tidligst efter de første 3 injektioner. Patienten henvises til synscentral/kommunikationscenter i henhold til bopælskommune. I mappen "Henvisning til synshjælpemidler", som findes på ØB1 i AMD kube (rum 110), findes skemaet Henvendelse vedrørende synshjælpemidler.docx skemaet Samtykkeerklæring vedrørende synshjælpemidler.docx samt oversigt over synscentraler i Danmark (se Øjenforeningens pjece Svagsynshjælp, side 26-33) Vigtigt Skemaerne udfyldes af læge, sygeplejerske, optometrist eller social- og sundhedsassistent - Sæt kryds eller skriv hvilken synscentral, der skal modtage henvendelsen. - Udfyld skemaerne - skemaet Henvendelse vedrørende synshjælpemidler.docx - skemaet Samtykkeerklæring vedrørende synshjælpemidler.docx - Husk patientunderskrift på samtykkeerklæringen. - I journalen skrives hvilken synscentral, der er henvist til, og at patienten har afgivet skriftligt samtykke. - Noter i journalen at synet er stabilt, eller at der ikke forventes fremgang i synsstyrke. - Aflever skemaer til sekretær til videre forsendelse. Sekretær scanner skemaerne in i Mediemaneger i Sundhedsplatformen og sender skemaerne elektronisk til synscentralen. Har patienten brug for kontrol af brillekorrektion henvises til svagsynsoptiker, da ikke alle kommuner afdækker behovet for brillekorrektion. Er patienten stadig erhvervsaktiv kan henvises til IBOS, Institut for Blinde og Svagsynede. Ansvar og organisering Afdelingsledelsen, Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger. Afsnitsledende overlæge, afdelingssygeplejersker og ledende lægesekretærer, er ansvarlig for at instruksen udarbejdes, revideres og implementeres. Den enkelte medarbejder i Afdeling for Øjensygdomme, er ansvarlig for at kende og følge instruksen Referencer, lovgivning og faglig evidens samt links hertil Se mappe "Henvisning til synshjælpemidler" i Amd-kube, ØB1, Rigshospitalet-Glostrup. Bilag - skemaet Henvendelse vedrørende synshjælpemidler.docx - skemaet Samtykkeerklæring vedrørende synshjælpemidler.docx

<h1><div id="Afsnit#1699579136535">Synsunderstøttende hjælpemidler</div></h1><div id="BodyWeb#1699579136535"><p><a name="1699579136535Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579136535Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579136535Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579136535Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579136535Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579136535Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579136535Bilag">Bilag</a><br> &nbsp;</h3> <h2>&nbsp;</h2> <div class="collapsible-item" expandedstart="1"><a name="1699579136535Maalgrupper"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Målgrupper og anvendelsesområde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>Angiver retningslinjer for henvisning af patienter til synsunderstøttende hjælpemidler.&nbsp;<br> Læger, sygeplejersker, optometrist og social- og sundhedsassistenter, som ønsker at henvise patienter til synsunderstøttende hjælpemidler, fra Afdeling for Øjensygdomme, Rigshospitalet.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579136535Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579136535Definitioner"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Definitioner</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>Synsunderstøttende hjælpemidler kan være forstørrende optik, specialbelysning, medicinske filterglas, læseTV og andet.<br> ØB1 - Afdeling for Øjensygdommes ambulatorium på 1. sal.&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579136535Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579136535Fremgangsmaade"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Fremgangsmåde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>Patienter som har et varigt synshandicap med synsstyrke 0,3 (6/18) eller derunder på bedst seende øje kan henvises til synsunderstøttende hjælpemidler. Der henvises som udgangspunkt, når patienten er færdigbehandlet. Hvis det er patienter med længerevarende forløb og/eller kronisk sygdom, henvises der, når synet skønnes stabilt eller uden udsigt til fremgang.<br> Patienter kan desuden henvises såfremt læsesynet er så påvirket, at patienten har vanskeligt ved at klare daglige gøremål. Dette skal i så fald noteres i journalen på henvisningstidspunktet.<br> AMD-patienter henvises tidligst efter de første 3 injektioner.</p> <p>Patienten henvises til synscentral/kommunikationscenter i henhold til bopælskommune.&nbsp;<br> I mappen "Henvisning til synshjælpemidler", som findes på ØB1 i AMD kube (rum 110), findes</p> <p style="margin-left:40px">skemaet&nbsp;<img src="/icons/vwicn005.gif" onclick="Ext.DMS.util.showImage(this);"><a href="###FOLDER###" target="_blank">Henvendelse vedrørende synshjælpemidler.docx</a>&nbsp;&nbsp;<br> skemaet&nbsp;<img src="/icons/vwicn005.gif" onclick="Ext.DMS.util.showImage(this);"><a href="###FOLDER###" target="_blank">Samtykkeerklæring vedrørende synshjælpemidler.docx</a>&nbsp;&nbsp;<br> samt oversigt over synscentraler i Danmark (se Øjenforeningens pjece Svagsynshjælp, side 26-33)<br> Vigtigt</p> <p>Skemaerne udfyldes af læge, sygeplejerske, optometrist eller social- og sundhedsassistent</p> <ol> <li>Sæt kryds eller skriv hvilken synscentral, der skal modtage henvendelsen.</li> <li>Udfyld skemaerne <ol> <li>skemaet&nbsp;<img src="/icons/vwicn005.gif" onclick="Ext.DMS.util.showImage(this);"><a href="###FOLDER###" target="_blank">Henvendelse vedrørende synshjælpemidler.docx</a>&nbsp;</li> <li>skemaet&nbsp;<img src="/icons/vwicn005.gif" onclick="Ext.DMS.util.showImage(this);"><a href="###FOLDER###" target="_blank">Samtykkeerklæring vedrørende synshjælpemidler.docx</a>&nbsp;&nbsp;</li> </ol> </li> <li>Husk patientunderskrift på samtykkeerklæringen.</li> <li>I journalen skrives hvilken synscentral, der er henvist til, og at patienten har afgivet skriftligt samtykke.</li> <li>Noter i journalen at synet er stabilt, eller at der ikke forventes fremgang i synsstyrke.</li> <li>Aflever skemaer til sekretær til videre forsendelse.&nbsp;</li> </ol> <p>Sekretær scanner skemaerne in i Mediemaneger i Sundhedsplatformen og sender skemaerne elektronisk til synscentralen.</p> <p>Har patienten brug for kontrol af brillekorrektion henvises til svagsynsoptiker, da ikke alle kommuner afdækker behovet for brillekorrektion.</p> <p>Er patienten stadig erhvervsaktiv kan henvises til <a href="http://www.ibos.dk/" target="_blank">IBOS</a>, Institut for Blinde og Svagsynede.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579136535Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579136535Ansvar"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Ansvar og organisering</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>Afdelingsledelsen, Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger.<br> Afsnitsledende overlæge, afdelingssygeplejersker og ledende lægesekretærer, er ansvarlig for at instruksen udarbejdes, revideres og implementeres.<br> Den enkelte medarbejder i Afdeling for Øjensygdomme, er ansvarlig for at kende og følge instruksen<br> &nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579136535Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579136535Referencer"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Referencer, lovgivning og faglig evidens samt links hertil</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>Se mappe "Henvisning til synshjælpemidler" i Amd-kube, ØB1, Rigshospitalet-Glostrup.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579136535Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579136535Bilag"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Bilag</h2> </div> <div class="collapsible-item-body" style="display: block;"> <ol> <li>skemaet&nbsp;<img src="/icons/vwicn005.gif" onclick="Ext.DMS.util.showImage(this);"><a href="###FOLDER###" target="_blank">Henvendelse vedrørende synshjælpemidler.docx</a>&nbsp;</li> <li>skemaet&nbsp;<img src="/icons/vwicn005.gif" onclick="Ext.DMS.util.showImage(this);"><a href="###FOLDER###" target="_blank">Samtykkeerklæring vedrørende synshjælpemidler.docx</a>&nbsp;&nbsp;</li> </ol> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579136535Top">Tilbage til top</a></p>

Rigshospitalet_¥jensygdomme (HOC)_Toxoplasmose induceret chorioretinitis behandling heraf.

Toxoplasmose induceret chorioretinitis, behandling heraf Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Bilag Målgrupper og anvendelsesområde Angiver retningslinjer for behandling af toxoplasmose induceret chorioretinitis i Afdeling for Øjensygdomme, Rigshospitalet Gældende for læger og sygeplejersker i Afdeling for Øjensygdomme, Rigshospitalet Definitioner Fremgangsmåde Behandlingsindikation er svær at afgrænse men generelt: - Læsion der involverer eller truer macula og/eller det papillomaculære bundt - Læsion der truer eller involverer nervus opticus - Vitritis og synsaffektion Behandlingskontrol: Kontrol af Hb, trombocytter og differentialtælling ved indledning af behandling samt en gang om ugen under behandlingen. Behandlingsstrategi hos ikke immunsupprimerede voksne: Behandles i 4 uger eller mere - Tbl. Daraprim (pyrimethamine): 1. dag: 100mg (4 tab á 25 mg) Efterfølgende dage: 50 mg dagligt - Tbl. Sulfadiazin: 1. dag: 2 gram som støddosis Efterfølgende dage: 1gram x 4 - Tbl. Isovorin (folininsyre): 15 mg hver anden dag - Tbl. Prednison: 1-2 mg/kg legemsvægt dagligt Starter 1 døgn efter ovenstående behandling er indledt og seponeres inden ovenstående behandling er afsluttet. 1+2+3: udleveres fra ambulatoriet Ved CAVE Daraprim eller Sulfadiazin kan bruges: Tbl. Dalacin (clindamycin) 300 mg 4 x dagligt i 3 uger eller Tbl. Rovamycin (spiramycin) 3 MIE (lg) 2 x dagligt Begge udleveres fra ambulatoriet. Behandlingsstrategi ved immunsupprimerede voksne patienter inklusiv AIDS: AIDS patienter henvises til epidemisk afd. , RH eller KKHH, og behandlingen er livslang - Tbl. Daraprim: Dag 1-3: 50-150 mg/dag Efterfølgende 3 uger: 25-75 mg/dag Efter 3 uger: 50 mg/uge - Tbl. Sulfadiazin: Gennem 3 uger: 2-4 g fordelt på 4 doser/dag Efter 3 uger: 1000 mg/uge Nyfødte og præpupertetsbørn med oculær toxoplasmose: Behandles i pædiatisk regi. Ved klinisk, serologisk eller parasitologisk verificering: - Tbl. Daraprim: Dag 1: 2 mg/kg Efterfølgende dage: 1 mg/kg - Tbl. Sulfadiazin: 50-100 mg/kg/dag - Injektionsvæske Rescuvolin: 3 mg 2 x om ugen p.o. eller i.m. - Tbl. Prednison: 1-2 mg/kg/dag Starter 1 døgn efter ovenstående behandling er indledt og seponeres inden ovenstående behandling er afsluttet. l + 2 + 3 + eventuelt 4 skal gives 3-4 gange det første leveår. Disse 4 præparater skal efter 3 ugers behandling erstattes med tbl. Spiramycin af 4-6 ugers varighed. Normalt ingen behandling efter 1 års alderen. Ved mistanke om congenit toxoplasmose infektion, men uvished om moders smittetidspunkt: - Tbl. Spiramycin: 50-100 mg/kg/dag fordelt på 2 doser Oculær chorioretinitis under graviditet: Konfereres i afdelingen samt med gynækologisk afd. Behandlingsindikationen er multifaktoriel. Kraftig titerstigning taler for behandling. Anbefales: - Tbl. Daraprim: 1. dag: 25 mg x 2 Efterfølgende dage: 25 mg dagligt - Tbl. Sulfadiazin: 1. dag: 2 gram som støddosis Efterfølgende dage: 750 mg fordelt på 4 doser - Injektionsvæske Rescuvolin: 3 mg per uge - Tbl. Prednison: 1-2 mg/kg legemsvægt dagligt Starter 1 døgn efter ovenstående behandling er indledt og seponeres inden ovenstående behandling er afsluttet. Fortolkning af de enkelte analysemetoder Blodprøven undersøges med en eller flere af følgende metoder: ELISA (Enzymatisk immunbindings metode) for IgG og IgM: Benyttes til alle prøver. Positivt resultat for IgG og/eller IgM tyder meget stærkt på tilstedeværelse af specifikt IgG og/eller IgM antistof. Ved toxoplasmose giver metoden sædvanligvis positivt IgM og IgG resultat fra henholdsvis ca. l og 2-3 uger efter smitte. IgM vedbliver med at være positiv i cirka 8 (5-12 måneder) IgG er positiv resten af livet. ELISA for IgA: Positivt resultat tyder på nylig infektion, og bliver negativt tidligere end IgM. Positiv IgA kan findes hos nyfødt barn med negativ IgM og er diagnostisk for medfødt toxoplasmose. IFA (lmmunfluorescens antistof metode): Positivt resultat for IgG og/eller IgM tyder meget stærkt på tilstedeværelse af specifikt IgG og/eller IgM antistof. Ved toxoplasmose er IgM positiv fra cirka 2 uger efter sygdomsdebut og IgG resten af livet. DT (Sabin-Feldmans's dye test): Positivt resultat regnes diagnostisk for tilstedeværelse af specifikt antistof men viser ikke antistoffets Ig klasse/klasser. Resultatet er positivt efter 2 uger, stiger i efterfølgende cirka 8 uger og er positivt i resten af livet. CFT (komplementbindingstest): Positivt resultat fremkommer nogle uger efter de andre analyser, titeren kan stige gennem flere måneder og findes derefter negativt efter 1-2 år. DA (direkte agglutinationstest): Specielt interessant ved AIDS, da titerstigning hyppigere påvises ved DA end andre metoder. ISAGA IgM (lmmuno-Sorbent-Agglutination IgM) Er den mest følsomme metode. Værdifuldt til undersøgelse af nyfødt barn med medfødt toxoplasmose. Resultatet er positivt i 18-24 måneder efter akut infektion. Sammenfattende vurdering af analysemetoderne Akut infektion: Serokonversion (skift fra negativt til positivt resultat) og IgG titerstigning med mindst to fortyndingstrin mellem to prøver udtaget med tre ugers interval er tegn på smitte inden for to måneder før prøvetagning. Stigende CFT titer er tegn på nylig infektion. IgM (akut respons) kan være påviselig i 2-12 måneder. Tidligere infektion: IgG er tilstede livsvarigt efter toxoplasmose. Svagt positiv IgG titer (DT< 250) kombineret med negativ IgM tyder på tidligere infektion og hos immunkompetente på immunitet. Reaktivering: Toxoplasmose betinget chorioretinit og symptomer hos immundefekt patient skyldes primær reaktivering af infektion erhvervet tidligere i livet og følges kun yderst sjældent af IgM respons eller IgG titerstigning. Pharmacopia minor Daraprim: Et antimalaria middel som virker synergistisk med sulfadiazin. Plasma T 1/2 efter peroral dosering er 4 døgn. Er en folinsyre antagonist som kan give trombocytopeni og leucopeni. Virker ved at hæmme omdannelsen af folinsyre til folininsyre. Er teratogent og må således ikke bruges i første trimester. Bivirkning: træthed, hovedpine, kvalme, opkastning, feber, øget tarmluftdannelse. Sulfadiazin: Inhiberer folinsyre metabolismen i visse bakterier og protozoer og virker synergistisk med Daraprim medførende en bacteriostatisk virkning. Kan udkrystalliseres renalt medførende nyresten. Det er derfor nødvendigt med væskeindtagelse på 3 l/døgn. Må ikke bruges i første trimester. Rescuvolin/Isovorin: Antidot mod folinsyreantagonister. Mindsker risikoen for knoglemarvsdepression. Clindamycin: Opkoncentreres i choroidea. Ansvar og organisering Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger. Afsnitsledende overlæge, afdelingssygeplejerske og ledende lægesekretærer, er ansvarlig for at instruksen udarbejdes, revideres og implementeres. Den enkelte medarbejder i Afdeling for Øjensygdomme, er ansvarlig for at kende og følge instruksen Referencer, lovgivning og faglig evidens samt links hertil Bilag

<h1><div id="Afsnit#1699579150137">Toxoplasmose induceret chorioretinitis, behandling heraf</div></h1><div id="BodyWeb#1699579150137"><p><a name="1699579150137Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579150137Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579150137Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579150137Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579150137Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579150137Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579150137Bilag">Bilag</a><br> &nbsp;</h3> <h2>&nbsp;</h2> <div class="collapsible-item" expandedstart="1"><a name="1699579150137Maalgrupper"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Målgrupper og anvendelsesområde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>Angiver retningslinjer for behandling af toxoplasmose induceret chorioretinitis i Afdeling for Øjensygdomme, Rigshospitalet</p> <p>Gældende for læger og sygeplejersker i Afdeling for Øjensygdomme, Rigshospitalet</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579150137Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579150137Definitioner"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Definitioner</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579150137Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579150137Fremgangsmaade"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Fremgangsmåde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><strong>Behandlingsindikation er svær at afgrænse men generelt:</strong></p> <ol> <li>Læsion der involverer eller truer macula og/eller det papillomaculære bundt</li> <li>Læsion der truer eller involverer nervus opticus</li> <li>Vitritis og synsaffektion</li> </ol> <p><strong>Behandlingskontrol:</strong></p> <p style="margin-left:40px">Kontrol af Hb, trombocytter og differentialtælling ved indledning af behandling samt en gang om ugen under behandlingen.</p> <p><strong>Behandlingsstrategi hos ikke immunsupprimerede voksne:</strong></p> <p style="margin-left:40px">Behandles i 4 uger eller mere</p> <ol style="margin-left:80px"> <li><strong>Tbl. Daraprim (pyrimethamine):</strong><br> 1. dag: 100mg (4 tab á 25 mg)<br> Efterfølgende dage: 50 mg dagligt<br> &nbsp;</li> <li><strong>Tbl.&nbsp;Sulfadiazin:</strong><br> 1. dag: 2 gram som støddosis<br> Efterfølgende dage: 1gram x 4<br> &nbsp;</li> <li><strong>Tbl. Isovorin (folininsyre):</strong><br> 15 mg hver anden dag<br> &nbsp;</li> <li><strong>Tbl. Prednison:</strong><br> 1-2 mg/kg legemsvægt dagligt<br> Starter 1 døgn efter ovenstående behandling er indledt og seponeres inden ovenstående behandling er afsluttet.</li> </ol> <p style="margin-left:120px">1+2+3: udleveres fra ambulatoriet<br> <br> Ved<strong> CAVE </strong>Daraprim eller Sulfadiazin kan bruges:</p> <p style="margin-left:160px">Tbl. Dalacin (clindamycin) 300 mg 4 x dagligt i 3 uger eller<br> Tbl. Rovamycin (spiramycin) 3 MIE (lg) 2 x dagligt<br> Begge udleveres fra ambulatoriet.</p> <p><strong>Behandlingsstrategi ved immunsupprimerede voksne patienter inklusiv AIDS:</strong></p> <p style="margin-left:40px">AIDS patienter henvises til epidemisk afd. , RH eller KKHH, og behandlingen er livslang</p> <ol style="margin-left:40px"> <li style="margin-left: 40px;"><strong>Tbl.&nbsp;Daraprim:</strong><br> Dag 1-3:&nbsp;50-150 mg/dag<br> Efterfølgende 3 uger: 25-75 mg/dag<br> Efter 3 uger: 50 mg/uge<br> &nbsp;</li> <li style="margin-left: 40px;"><strong>Tbl. Sulfadiazin:</strong><br> Gennem 3 uger: 2-4 g fordelt på 4 doser/dag<br> Efter 3 uger: 1000 mg/uge</li> </ol> <p><strong>Nyfødte og præpupertetsbørn med oculær toxoplasmose:</strong></p> <p style="margin-left:40px">Behandles i pædiatisk regi.</p> <p style="margin-left:80px">Ved klinisk, serologisk eller parasitologisk verificering:</p> <ol> <li style="margin-left: 80px;"><strong>Tbl. Daraprim:</strong><br> Dag 1: 2 mg/kg<br> Efterfølgende dage: 1 mg/kg<br> &nbsp;</li> <li style="margin-left: 80px;"><strong>Tbl. Sulfadiazin: </strong><br> 50-100 mg/kg/dag<br> &nbsp;</li> <li style="margin-left: 80px;"><strong>Injektionsvæske Rescuvolin: </strong><br> 3 mg 2 x om ugen p.o. eller i.m.<br> &nbsp;</li> <li style="margin-left: 80px;"><strong>Tbl. Prednison: </strong><br> 1-2 mg/kg/dag<br> Starter 1 døgn efter ovenstående behandling er indledt og seponeres inden ovenstående behandling er afsluttet.</li> </ol> <p style="margin-left:120px">l + 2 + 3 + eventuelt 4 skal gives 3-4 gange det første leveår.<br> Disse 4 præparater skal efter 3 ugers behandling erstattes med&nbsp;tbl. Spiramycin af 4-6 ugers varighed.<br> Normalt ingen behandling efter 1 års alderen.</p> <p style="margin-left:80px">Ved mistanke om congenit toxoplasmose infektion, men uvished om moders smittetidspunkt:</p> <ol> <li style="margin-left: 80px;"><strong>Tbl. Spiramycin:</strong><br> 50-100 mg/kg/dag fordelt på 2 doser</li> </ol> <p><strong>Oculær chorioretinitis under graviditet:</strong></p> <p style="margin-left:40px">Konfereres i afdelingen samt med gynækologisk afd.<br> Behandlingsindikationen er multifaktoriel. Kraftig titerstigning taler for behandling.</p> <p style="margin-left:80px">Anbefales:</p> <ol> <li style="margin-left: 80px;"><strong>Tbl. Daraprim:</strong><br> 1. dag: 25 mg x 2<br> Efterfølgende dage: 25 mg dagligt<br> &nbsp;</li> <li style="margin-left: 80px;"><strong>Tbl. Sulfadiazin:</strong><br> 1. dag: 2 gram som støddosis<br> Efterfølgende dage: 750 mg fordelt på 4 doser<br> &nbsp;</li> <li style="margin-left: 80px;"><strong>Injektionsvæske Rescuvolin:</strong><br> 3 mg per uge<br> &nbsp;</li> <li style="margin-left: 80px;"><strong>Tbl. Prednison:</strong><br> 1-2 mg/kg legemsvægt dagligt<br> Starter 1 døgn efter ovenstående behandling er indledt og seponeres inden ovenstående behandling er afsluttet.</li> </ol> <p><strong>Fortolkning af de enkelte analysemetoder</strong></p> <p style="margin-left:40px">Blodprøven undersøges med en eller flere af følgende metoder:</p> <p style="margin-left:80px"><strong>ELISA (Enzymatisk immunbindings metode) for IgG og IgM:</strong><br> Benyttes til alle prøver.<br> Positivt resultat for IgG og/eller IgM tyder meget stærkt på tilstedeværelse af specifikt IgG og/eller IgM antistof.<br> Ved toxoplasmose giver metoden sædvanligvis positivt IgM og IgG resultat fra henholdsvis ca. l og 2-3 uger efter smitte.<br> IgM vedbliver med at være positiv i cirka 8 (5-12 måneder) IgG er positiv resten af livet.<br> <br> <strong>ELISA for IgA:</strong><br> Positivt resultat tyder på nylig infektion, og bliver negativt tidligere end IgM.<br> Positiv IgA kan findes hos nyfødt barn med negativ IgM og er diagnostisk for medfødt toxoplasmose.<br> <br> <strong>IFA (lmmunfluorescens antistof metode):</strong><br> Positivt resultat for IgG og/eller IgM tyder meget stærkt på tilstedeværelse af specifikt IgG og/eller IgM antistof.<br> Ved toxoplasmose er IgM positiv fra cirka 2 uger efter sygdomsdebut og IgG resten af livet.</p> <p style="margin-left:80px"><strong>DT (Sabin-Feldmans's dye test):</strong><br> Positivt resultat regnes diagnostisk for tilstedeværelse af specifikt antistof men viser ikke antistoffets Ig klasse/klasser.<br> Resultatet er positivt efter 2 uger, stiger i efterfølgende cirka 8 uger og er positivt i resten af livet.<br> <br> <strong>CFT (komplementbindingstest):</strong><br> Positivt resultat fremkommer nogle uger efter de andre analyser, titeren kan stige gennem flere måneder og findes derefter negativt efter 1-2 år.<br> <br> <strong>DA (direkte agglutinationstest):</strong><br> Specielt interessant ved AIDS, da titerstigning hyppigere påvises ved DA end andre metoder.<br> <br> <strong>ISAGA IgM (lmmuno-Sorbent-Agglutination IgM)</strong><br> Er den mest følsomme metode. Værdifuldt til undersøgelse af nyfødt barn med medfødt toxoplasmose.<br> Resultatet er positivt i 18-24 måneder efter akut infektion.</p> <p><strong>Sammenfattende vurdering af analysemetoderne</strong></p> <p style="margin-left:40px">Akut infektion:</p> <p style="margin-left:80px">Serokonversion (skift fra negativt til positivt resultat) og IgG titerstigning med mindst to fortyndingstrin mellem to prøver udtaget med tre ugers interval er tegn på smitte inden for to måneder før prøvetagning.<br> Stigende CFT titer er tegn på nylig infektion.<br> IgM (akut respons) kan være påviselig i 2-12 måneder.</p> <p style="margin-left:40px">Tidligere infektion:</p> <p style="margin-left:80px">IgG er tilstede livsvarigt efter toxoplasmose.<br> Svagt positiv IgG titer (DT&lt; 250) kombineret med negativ IgM tyder på tidligere infektion og hos immunkompetente på immunitet.</p> <p style="margin-left:40px">Reaktivering:</p> <p style="margin-left:80px">Toxoplasmose betinget chorioretinit og symptomer hos immundefekt patient skyldes primær reaktivering af infektion erhvervet tidligere i livet og følges kun yderst sjældent af IgM respons eller IgG titerstigning.</p> <p style="margin-left:80px">Pharmacopia minor<br> <br> Daraprim:<br> Et antimalaria middel som virker synergistisk med sulfadiazin. Plasma T 1/2 efter peroral dosering er 4 døgn. Er en folinsyre antagonist som kan give trombocytopeni og leucopeni. Virker ved at hæmme omdannelsen af folinsyre til folininsyre. Er teratogent og må således ikke bruges i første trimester.<br> Bivirkning: træthed, hovedpine, kvalme, opkastning, feber, øget tarmluftdannelse.<br> <br> Sulfadiazin:<br> Inhiberer folinsyre metabolismen i visse bakterier og protozoer og virker synergistisk med Daraprim medførende en bacteriostatisk virkning. Kan udkrystalliseres renalt medførende nyresten. Det er derfor nødvendigt med væskeindtagelse på 3 l/døgn.<br> Må ikke bruges i første trimester.<br> <br> Rescuvolin/Isovorin:<br> Antidot mod folinsyreantagonister. Mindsker risikoen for knoglemarvsdepression.<br> <br> Clindamycin:<br> Opkoncentreres i choroidea.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579150137Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579150137Ansvar"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Ansvar og organisering</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger.<br> Afsnitsledende overlæge, afdelingssygeplejerske og ledende lægesekretærer, er ansvarlig for at instruksen udarbejdes, revideres og implementeres.<br> Den enkelte medarbejder i Afdeling for Øjensygdomme, er ansvarlig for at kende og følge instruksen</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579150137Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579150137Referencer"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Referencer, lovgivning og faglig evidens samt links hertil</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579150137Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579150137Bilag"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Bilag</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579150137Top">Tilbage til top</a></p>

Rigshospitalet_¥jensygdomme (HOC)_Trabekulektomi kontrol og behandling efter. Glaukom.

Trabekulektomi, kontrol og behandling efter. Glaukom team Målgrupper og anvendelsesområde Angiver retningslinier for ambulatoriet kontrol for patienter der har fået foretaget trabekulektomi. Gældende for læger, optikere og sygeplejersker i Afdeling for Øjensygdomme, Rigshospitalet. Definitioner Fremgangsmåde Der stiles mod et trykniveau på 6-10 mmHg. Den mest almindelige operationskomplikation er tilgroning af cikatricen fra skleralsiden, hvilket sker hyppigere hos patienter under 60 år, eller hvor der tidligere er foretaget operationer på bulbus eller konjunktiva. Der er peroperativt mitomycin, 0,2 mg/ml peroperativt under conjunctiva. Post-operative kontroller - dag 1 - uge 1, uge 2, uge 3, uge 4, uge 6 og uge 10, mere hyppigt ved behov. Behandling ved ukomplicerede forløb Postoperative øjendråber - Monopex x 6 og kloramfenikol - 1. uges kontrol: Sep. Kloramfenikol - 2. uges kontrol: Dim. occgt. Monopex 1 dr x 4 i 4 uger, - Efter 6 uger dim. monopex med 1 dråbe om ugen Ved kontrollerne de første 6 uger noteres følgende: Filtrationspude: - Størrelse og udbredelse. Ekstern filtration? Ved ekstern filtration pålægges bandagelinse - hvis der er fortsat siven efter 7 - 14 dage skal conjunctivaldefekten lukkes,Ved ekstern filtration skal der gives kloramfenikol øjendråber x 4 - Forreste kammer: Afsmalnet eller dybt? Hyfæma? Ved hyfæma skal gives Monopex x 6 og cyclogyl x x 1 samt ordineres roligt regime - Tryk (IOP): - Ved hypotoni (IOP < 5) og ingen choroidalløsning eller afsmalnet forreste kammer: Monopex x 3, cyclogyl x 1 - Ved hypotoni (IOP < 5) og afsmalnet forreste kammer og/eller choroidal amotio: Monopex x 3, cyclogyl x 1, bandagelinse (KTCG00) og tæt kontrol - Ved for højt tryk (IOP > 10) forsøges forsigtig bulbusmassage med glasstav eller vatpind langs lappen eller med fingrene (massage nedefra eller ved lappen). 1-2 af de corneale U-suturer (KTCG10) fjernes med mantoux-kanyle og sutur-pincet. Ved fortsat manglende effekt kan 1-2 hjørnesuturer fjernes med laser-suturlyse med Argon laser (KTCG20). De første 6 uger efter operationen skal det tilstræbes at IOP er under 10 mmHg på det opererede øje når patienten går hjem. Husk: Den altdominerende risiko ved filtrerende kirurgi er trykstigning som følge af tilgroning af lappen. Energisk indsats indenfor de første 3-4 uger kan formindske tidlige failures. I denne periode skal ethvert tryk på > 9 mm udløse handling - eller journalført argumentation, hvis man vælger at observere tilstanden på uændret behandling. Ansvar og organisering Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger. Afsnitsledelsen er ansvarlige for at instruksen udarbejdes, revideres og implementeres. Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen. Referencer, lovgivning og faglig evidens samt links hertil Bilag

<h1><div id="Afsnit#1699579152336">Trabekulektomi, kontrol og behandling efter. Glaukom team</div></h1><div id="BodyWeb#1699579152336"><p>&nbsp;</p> <div class="collapsible-item" expandedstart="1"><a name="1699579152336Maalgrupper"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Målgrupper og anvendelsesområde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm">Angiver retningslinier for ambulatoriet kontrol for patienter der har fået foretaget trabekulektomi.</p> <p style="margin-left:0cm; margin-right:0cm">Gældende for læger, optikere&nbsp;og sygeplejersker i Afdeling for Øjensygdomme, Rigshospitalet.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579152336Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579152336Definitioner"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Definitioner</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579152336Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579152336Fremgangsmaade"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Fremgangsmåde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm">Der stiles mod et trykniveau på 6-10 mmHg. Den mest almindelige operationskomplikation er tilgroning af cikatricen fra skleralsiden, hvilket sker hyppigere hos patienter under 60 år, eller hvor der tidligere er foretaget operationer på bulbus eller konjunktiva. Der er peroperativt mitomycin, 0,2 mg/ml peroperativt under conjunctiva.</p> <p style="margin-left:0cm; margin-right:0cm">Post-operative kontroller</p> <ul> <li>dag 1</li> <li>uge 1, uge 2, uge 3, uge 4, uge 6 og uge 10,<br> mere hyppigt&nbsp;ved behov.</li> </ul> <p style="margin-left:0cm; margin-right:0cm">Behandling ved ukomplicerede forløb</p> <p style="margin-left:0cm; margin-right:0cm">Postoperative øjendråber</p> <ul> <li>&nbsp;Monopex x 6 og kloramfenikol</li> <li>1. uges kontrol: Sep. Kloramfenikol</li> <li>2. uges kontrol: Dim. occgt. Monopex 1 dr x 4 i 4 uger,</li> <li>Efter 6 uger dim. monopex med 1 dråbe om ugen</li> </ul> <p style="margin-left:0cm; margin-right:0cm">Ved kontrollerne de første 6 uger noteres følgende:</p> <p style="margin-left:0cm; margin-right:0cm">Filtrationspude:</p> <ul> <li>Størrelse og udbredelse. Ekstern filtration?<br> Ved ekstern filtration pålægges bandagelinse - hvis der er fortsat siven efter 7 - 14 dage skal conjunctivaldefekten lukkes,Ved ekstern filtration skal der gives kloramfenikol øjendråber x 4</li> <li>Forreste kammer: Afsmalnet eller dybt? Hyfæma?<br> Ved hyfæma skal gives Monopex&nbsp;x 6 og cyclogyl x x 1 samt ordineres roligt regime</li> <li>Tryk (IOP): <ul style="list-style-type:circle"> <li>Ved hypotoni (IOP &lt; 5) og ingen choroidalløsning eller afsmalnet forreste kammer:<br> Monopex&nbsp;x 3, cyclogyl x 1</li> <li>Ved hypotoni (IOP &lt; 5) og afsmalnet forreste kammer og/eller choroidal amotio:<br> Monopex&nbsp;x 3, cyclogyl x 1, bandagelinse (KTCG00)&nbsp;og tæt kontrol</li> <li>Ved for højt tryk (IOP &gt; 10) forsøges forsigtig bulbusmassage med glasstav eller vatpind langs lappen eller med fingrene (massage nedefra eller ved lappen). 1-2 af de corneale U-suturer (KTCG10) fjernes med mantoux-kanyle og sutur-pincet. Ved fortsat manglende effekt kan 1-2 hjørnesuturer fjernes med laser-suturlyse med Argon laser (KTCG20). De første 6 uger efter operationen skal det tilstræbes at IOP er under 10 mmHg på det opererede øje når patienten går hjem.</li> </ul> </li> </ul> <p style="margin-left:0cm; margin-right:0cm"><br> <strong>Husk:</strong></p> <p style="margin-left:0cm; margin-right:0cm">Den altdominerende risiko ved filtrerende kirurgi er trykstigning som følge af tilgroning af lappen.<br> Energisk indsats indenfor de første 3-4 uger kan formindske tidlige failures. I denne periode skal ethvert tryk på &gt; 9&nbsp;mm udløse handling - eller journalført argumentation, hvis man vælger at observere tilstanden på uændret behandling.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579152336Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579152336Ansvar"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Ansvar og organisering</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger.<br> Afsnitsledelsen er ansvarlige for at instruksen udarbejdes, revideres og implementeres.<br> Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579152336Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579152336Referencer"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Referencer, lovgivning og faglig evidens samt links hertil</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579152336Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579152336Bilag"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Bilag</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579152336Top">Tilbage til top</a></p>

Rigshospitalet_¥jensygdomme (HOC)_Trabekulektomi præoperativ forberedelse postoperativ information. Glaukom.

Trabekulektomi, præoperativ forberedelse postoperativ information. Glaukom team Målgrupper og anvendelsesområde Angiver retningslinjer for patienter der skal indlægges til trabekulektomi i Afdeling for Øjensygdomme, Rigshospitalet. Gældende for læger og sygeplejersker i glaukom team og sengeafdelingen i Afdeling for Øjensygdomme, Rigshospitalet. Definitioner Fremgangsmåde Præoperativt Der ordineres operationstype og præmedicin. Patient skal fortsætte med tryksænkende behandling til og med operationsdagen. Hvis patient skal i universel anæstesi, skal behandling med Glaupax seponeres fra klokken 24 aftenen før. Kvinder yngre end 50 år skal spørges til, om de kan være gravide og der skal lave graviditetstest. Hvis der er mistanke om et præoperativt højt tryk-niveau på øjet, skal operatøren kontaktes og ordinere supplerende behandling Postoperativt Al antiglaumatøs behandling til det opererede øje skal betragtes som seponeret efter operationen. Diamox skal også seponeres, med mindre situationen for naboøjet er meget kritisk. Patient må læse og se TV. Der skal dryppes med: - Monopex 1 dr x 6 i 2 uger, - herefter 2 dr x 4 i 4 uger – herefter nedtrapning efter aftale - Kloramfenikol, 5 mg/ml 1 dr x 4 i 1 uge pågældende øje postoperativt Udskrivning Afhænger af det individuelle forløb. Sædvanligvis går patienten hjem samme dag eller dagen efter operationen. Kontrolundersøgelse i ambulatoriet planlægges dagen efter operationen Intet vand i øjet de første 2 dage. Ingen svømmehalsbesøg de første 3 uger. Stillesidende arbejde kan normalt påbegyndes en uge efter operationen. Spadsereture er tilladt efter udskrivelsen, de voldsomste sportslige udfoldelser bør vente 3-4 uger. Moderat alkoholindtagelse er tilladt. Ansvar og organisering Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger. Afsnitsledelsen er ansvarlige for at instruksen udarbejdes, revideres og implementeres. Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen. Referencer, lovgivning og faglig evidens samt links hertil Bilag

<h1><div id="Afsnit#1699579183101">Trabekulektomi, præoperativ forberedelse postoperativ information. Glaukom team</div></h1><div id="BodyWeb#1699579183101"><p>&nbsp;</p> <div class="collapsible-item" expandedstart="1"><a name="1699579183101Maalgrupper"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Målgrupper og anvendelsesområde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Angiver retningslinjer for patienter der skal indlægges til trabekulektomi i Afdeling for Øjensygdomme, Rigshospitalet. </span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Gældende for læger og sygeplejersker i glaukom team og sengeafdelingen i Afdeling for Øjensygdomme, Rigshospitalet. </span></p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579183101Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item"><a name="1699579183101Definitioner"></a> <div class="collapsible-item-title"> <h2>Definitioner</h2> </div> <div class="collapsible-item-body" style="display: none;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579183101Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579183101Fremgangsmaade"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Fremgangsmåde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <h3 style="margin-left:0cm; margin-right:0cm"><strong>Præoperativt</strong></h3> <p style="margin-left:40px; margin-right:0cm">Der ordineres&nbsp;operationstype og præmedicin. Patient skal fortsætte med tryksænkende behandling til og med operationsdagen. Hvis patient skal i universel anæstesi, skal behandling med Glaupax seponeres fra klokken 24 aftenen før. Kvinder yngre end 50 år skal spørges til, om de kan være gravide og der skal lave graviditetstest.&nbsp; Hvis der er mistanke om et præoperativt højt tryk-niveau på øjet, skal operatøren kontaktes og ordinere supplerende behandling</p> <h3 style="margin-left:0cm; margin-right:0cm"><strong>Postoperativt</strong></h3> <p style="margin-left:40px; margin-right:0cm"><strong><em>Al antiglaumatøs behandling til det opererede øje skal betragtes som seponeret efter operationen.</em></strong></p> <p style="margin-left:40px; margin-right:0cm">Diamox skal også seponeres, med mindre situationen for naboøjet er meget kritisk.<br> Patient må&nbsp;læse og se TV.</p> <p style="margin-left:40px; margin-right:0cm">Der skal dryppes med:</p> <ul> <li style="margin-left: 40px;">Monopex 1 dr x 6 i 2 uger,</li> <li style="margin-left: 40px;">herefter 2 dr x 4 i 4 uger – herefter nedtrapning efter aftale</li> <li style="margin-left: 40px;">Kloramfenikol, 5 mg/ml 1 dr x 4 i 1 uge</li> </ul> <p style="margin-left:40px; margin-right:0cm">pågældende øje postoperativt</p> <h3 style="margin-left:0cm; margin-right:0cm"><strong>Udskrivning</strong></h3> <p style="margin-left:40px; margin-right:0cm">Afhænger af det individuelle forløb. Sædvanligvis går patienten hjem samme dag eller dagen efter operationen. Kontrolundersøgelse i ambulatoriet planlægges dagen efter operationen</p> <p style="margin-left:40px; margin-right:0cm">Intet vand i øjet de første 2 dage.<br> Ingen svømmehalsbesøg de første 3 uger.<br> Stillesidende arbejde kan normalt påbegyndes en uge efter operationen.<br> Spadsereture er tilladt efter udskrivelsen, de voldsomste sportslige udfoldelser bør vente 3-4 uger.<br> Moderat alkoholindtagelse er tilladt.</p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579183101Ansvar"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Ansvar og organisering</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm">Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger.<br> Afsnitsledelsen er ansvarlige for at instruksen udarbejdes, revideres og implementeres.<br> Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen.&nbsp;</p> </div> </div> <div class="collapsible-item"><a name="1699579183101Referencer"></a> <div class="collapsible-item-title"> <h2>Referencer, lovgivning og faglig evidens samt links hertil</h2> </div> <div class="collapsible-item-body" style="display: none;"> <p>&nbsp;</p> <p>&nbsp;</p> </div> </div> <div class="collapsible-item"><a name="1699579183101Bilag"></a> <div class="collapsible-item-title"> <h2>Bilag</h2> </div> <div class="collapsible-item-body" style="display: none;"> <p>&nbsp;</p> <p>&nbsp;</p>

Rigshospitalet_¥jensygdomme (HOC)_Triesence Alcon. Ikke markedsf¢rte lægemiddel.

Triesence, Alcon. Ikke markedsførte lægemiddel Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Bilag Målgrupper og anvendelsesområde Vejledning til brug af ikke markedsførte lægemidler (tilladelsespræparater) Gældende for Afdeling for Øjensygdomme Rigshospitalet Definitioner Fremgangsmåde ###TABEL_1### Ansvar og organisering Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger. Afsnitsledende overlæger, afdelingssygeplejersker og ledende lægesekretærer, er ansvarlige for at instruksen udarbejdes, revideres og implementeres. Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen. Referencer, lovgivning og faglig evidens samt links hertil Bilag

<h1><div id="Afsnit#1699579085376">Triesence, Alcon. Ikke markedsførte lægemiddel</div></h1><div id="BodyWeb#1699579085376"><p><a name="1699579085376Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579085376Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579085376Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579085376Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579085376Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579085376Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579085376Bilag">Bilag</a><br> &nbsp;</h3> <h2><a name="1699579085376Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p>Vejledning til brug af ikke markedsførte lægemidler (tilladelsespræparater)</p> <p>Gældende for Afdeling for Øjensygdomme Rigshospitalet</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579085376Top">Tilbage til top</a></p> <h2><a name="1699579085376Definitioner"></a><br> Definitioner</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579085376Top">Tilbage til top</a></p> <h2><a name="1699579085376Fremgangsmaade"></a><br> Fremgangsmåde</h2> ###TABEL_1### <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579085376Top">Tilbage til top</a></p> <h2><a name="1699579085376Ansvar"></a><br> Ansvar og organisering</h2> <p>Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger.<br> Afsnitsledende overlæger, afdelingssygeplejersker og ledende lægesekretærer, er ansvarlige for at instruksen udarbejdes, revideres og implementeres.<br> Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579085376Top">Tilbage til top</a></p> <h2><a name="1699579085376Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579085376Top">Tilbage til top</a></p> <h2><a name="1699579085376Bilag"></a><br> Bilag</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579085376Top">Tilbage til top</a></p>

Rigshospitalet_¥jensygdomme (HOC)_Triesence Alcon. Ikke markedsf¢rte lægemiddel_TABEL_1.

Handelsnavn Triesence ”Alcon” injektionsvæske, 40 mg/ml Indholdsstof Triamcinolonacetonid Firma Alcon Danmark A/S Dispenseringsform Ampul 1 ml, indeholdende 40 mg triamcinolon Indikation Kronisk uveitis og hjælpestof i forbindelse med vitrektomi Dosering Ved kronisk uveitis injektion 40 mg subtenonalt eller 2 mg intravitrealt Som hjælpestof i forbindelse med vitrektomi 10-40 mg intravitrealt Virkning Syntetisk glukokortikoid med protraheret virkning. Graviditet Bør ikke anvendes, utilstrækkelige data Amning Bør ikke anvendes, utilstrækkelige data Kontraindikationer Okulær infektion, glaukom Bivirkninger Okulær trykforhøjelse, fremskyndet kataraktudvikling, nedsætter det lokale immunforsvar Kilde Alcon produktinformation

<table border="1" cellpadding="1" cellspacing="1" style="width:500px"> <tbody> <tr> <td>Handelsnavn</td> <td>Triesence ”Alcon” injektionsvæske, 40 mg/ml</td> </tr> <tr> <td>Indholdsstof</td> <td>Triamcinolonacetonid</td> </tr> <tr> <td>Firma</td> <td>Alcon Danmark A/S</td> </tr> <tr> <td>Dispenseringsform</td> <td>Ampul 1 ml, indeholdende 40 mg triamcinolon</td> </tr> <tr> <td>Indikation</td> <td>Kronisk uveitis og hjælpestof i forbindelse med vitrektomi</td> </tr> <tr> <td>Dosering</td> <td> <p>Ved kronisk uveitis injektion 40 mg subtenonalt eller 2 mg intravitrealt</p> <p>Som hjælpestof i forbindelse med vitrektomi 10-40 mg intravitrealt</p> </td> </tr> <tr> <td>Virkning</td> <td>Syntetisk glukokortikoid med protraheret virkning.</td> </tr> <tr> <td>Graviditet</td> <td>Bør ikke anvendes, utilstrækkelige data</td> </tr> <tr> <td>Amning</td> <td>Bør ikke anvendes, utilstrækkelige data</td> </tr> <tr> <td>Kontraindikationer</td> <td>Okulær infektion, glaukom</td> </tr> <tr> <td>Bivirkninger</td> <td>Okulær trykforhøjelse, fremskyndet kataraktudvikling, nedsætter det lokale immunforsvar</td> </tr> <tr> <td>Kilde</td> <td>Alcon produktinformation</td> </tr> </tbody> </table>

Rigshospitalet_¥jensygdomme (HOC)_Trykkontrol efter Ozurdex- eller Kenaloginjektion.

Trykkontrol efter Ozurdex- eller Kenaloginjektion Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Bilag Målgrupper og anvendelsesområde Angiver retningslinje for trykkontrol 2-3 uger efter Ozurdex - eller kenaloginjektion. Gældende for alt klinisk personale i Medicinsk retina i Afdeling for Øjensygdomme, Rigshospitalet. Definitioner Fremgangsmåde Ved trykkontrol ses patienten udelukkende af sygeplejerske, SOSU-assistent eller optiker. - Øjentrykket måles med iCare - Visus måles på autorefraktor på aktuelle øje - Der laves udilateret OCT med fundusfoto på aktuelle øje - Hvis tilstrækkelig kvalitet af billeder ikke kan opnåes gives dilaterende øjendråber, Tropicamide 1%. - Hvis trykket er under 23 mmHg sendes patienten hjem. Notat skrives i SP af Sygeplejerske, SOSU-assistent eller optiker. - Hvis trykket er over 23 mmHg og/eller hvis der er tale om en forværring i forhold til tidligere målt tryk eller hvis der er stor forskel i forhold til det ubehandlede øje, konfereres med en læge. - Sørg for at patienten har en tid til lægekontrol ca. 2 mdr. efter injektionen. Ansvar og organisering Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger. Afsnitsledelsen er ansvarlig for at instruksen udarbejdes, revideres og implementeres. Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen. Referencer, lovgivning og faglig evidens samt links hertil Bilag

<h1><div id="Afsnit#1699578914600">Trykkontrol efter Ozurdex- eller Kenaloginjektion</div></h1><div id="BodyWeb#1699578914600"><p><a name="1699578914600Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578914600Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578914600Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578914600Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578914600Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578914600Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578914600Bilag">Bilag</a><br> &nbsp;</h3> <h2>&nbsp;</h2> <div class="collapsible-item" expandedstart="1"><a name="1699578914600Maalgrupper"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Målgrupper og anvendelsesområde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0px; margin-right:0px; text-align:start"><span style="background-color:#ffffff; color:#222222">Angiver retningslinje&nbsp;for trykkontrol 2-3 uger efter Ozurdex - eller kenaloginjektion.</span><br> &nbsp;</p> <p style="margin-left:0px; margin-right:0px; text-align:start"><span style="background-color:#ffffff; color:#222222">Gældende for alt klinisk personale&nbsp;i Medicinsk retina&nbsp;i Afdeling for Øjensygdomme, Rigshospitalet.</span><br> <span style="background-color:#ffffff; color:#222222">&nbsp;</span></p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578914600Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item"><a name="1699578914600Definitioner"></a> <div class="collapsible-item-title"> <h2>Definitioner</h2> </div> <div class="collapsible-item-body" style="display: none;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578914600Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699578914600Fremgangsmaade"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Fremgangsmåde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm">Ved trykkontrol ses patienten udelukkende af sygeplejerske, SOSU-assistent eller optiker.</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <ul> <li style="text-align: start;">Øjentrykket måles med iCare</li> <li style="text-align: start;">Visus måles på autorefraktor på aktuelle øje</li> <li style="text-align: start;">Der laves udilateret OCT med fundusfoto på aktuelle øje</li> <li style="text-align: start;">Hvis tilstrækkelig kvalitet af billeder ikke kan opnåes gives dilaterende øjendråber, Tropicamide 1%.</li> <li style="text-align: start;">Hvis trykket er under 23 mmHg sendes patienten hjem. Notat skrives i SP af Sygeplejerske, SOSU-assistent eller optiker.</li> <li style="text-align: start;">Hvis trykket er over 23 mmHg og/eller hvis der er tale om en forværring i forhold til tidligere målt tryk eller hvis der er stor forskel i forhold til det ubehandlede øje, konfereres med en læge.</li> <li style="text-align: start;">Sørg for at patienten har en tid til lægekontrol ca. 2 mdr. efter injektionen.</li> </ul> <h3 style="margin-left:0cm; margin-right:0cm">&nbsp;</h3> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578914600Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699578914600Ansvar"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Ansvar og organisering</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0px; margin-right:0px; text-align:start"><span style="background-color:#ffffff; color:#222222">Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger.</span><br> <span style="background-color:#ffffff; color:#222222">Afsnitsledelsen er ansvarlig for at instruksen udarbejdes, revideres og implementeres.</span></p> <p style="margin-left:0px; margin-right:0px; text-align:start"><br> <span style="background-color:#ffffff; color:#222222">Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen.</span></p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578914600Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699578914600Referencer"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Referencer, lovgivning og faglig evidens samt links hertil</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578914600Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699578914600Bilag"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Bilag</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578914600Top">Tilbage til top</a></p>

Rigshospitalet_¥jensygdomme (HOC)_Trykmåling med Icare.

Trykmåling med Icare Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Bilag Målgrupper og anvendelsesområde Angiver retningslinjer for måling af øjets tryk. Gældende for klinisk personale i Afdeling for Øjensygdomme, Rigshospitalet. Definitioner Fremgangsmåde Øjets normale tryk - Opfattes som normalt, når målingen er mellem 8 – 23 mmHg Ved tryk udenfor normalområdet - Måling af tryk applanatorisk ved læge - Lægen ordinerer videre kontrol og behandling - Hvis patienten, ikke har behov for behandling, kontrolleres trykket igen ved næste ambulante kontrol eller ved egen øjenlæge Måling af tryk med Icare - Tryk måles af sygeplejerske/optiker med en håndholdt ”icare” - Tryk måles inden dilatation - Icare tændes ved tryk på nederste knap= Enter, under displayet. Efter 2 sekunder står der ”load” på displayet - Tag en probe i æsken, tag toppen af etuiet, proben ”hældes” i hullet, tryk på Enter så proben fæstnes (den vibrerer) - Patienten instrueres i at holde hovedet i neutral stilling og kigge lige frem - Afstandsholderen hviler mod patientens pande, proben holdes ca. 5 mm fra cornea - Tryk på Enter 6 gange, icare siger bip for hvert tryk og et lidt længere bip den sidste gang - Når trykket er målt skal proben fjernes: Tryk på Enter så der står 00 i displayet, tryk 2 gange i højre side af den øverste knap til der står "End" i displayet - Tryk og hold Enter til proben kommer ud, proben kasseres, icare slukker herefter Ansvar og organisering Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger. Afsnitsledelsen er ansvarlig for at instruksen udarbejdes, revideres og implementeres. Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen. Referencer, lovgivning og faglig evidens samt links hertil Bilag

<h1><div id="Afsnit#1699578994531">Trykmåling med Icare</div></h1><div id="BodyWeb#1699578994531"><p><a name="1699578994531Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578994531Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578994531Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578994531Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578994531Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578994531Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578994531Bilag">Bilag</a><br> &nbsp;</h3> <h2>&nbsp;</h2> <div class="collapsible-item" expandedstart="1"><a name="1699578994531Maalgrupper"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Målgrupper og anvendelsesområde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>Angiver retningslinjer for måling af øjets tryk.<br> Gældende for klinisk personale&nbsp;i Afdeling for Øjensygdomme, Rigshospitalet.<br> &nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578994531Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699578994531Definitioner"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Definitioner</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578994531Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699578994531Fremgangsmaade"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Fremgangsmåde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p><strong>Øjets normale tryk</strong></p> <ul> <li>Opfattes som normalt, når målingen er mellem 8 – 23 mmHg</li> </ul> <p><strong>Ved tryk udenfor normalområdet</strong></p> <ul> <li>Måling af tryk&nbsp;applanatorisk&nbsp;ved læge</li> <li>Lægen ordinerer videre kontrol og behandling</li> <li>Hvis patienten, ikke har&nbsp;behov for behandling, kontrolleres trykket igen ved næste ambulante kontrol eller ved egen øjenlæge</li> </ul> <p><strong>Måling af tryk med Icare</strong></p> <ul> <li>Tryk måles af sygeplejerske/optiker med en håndholdt ”icare”</li> <li>Tryk&nbsp;måles inden dilatation</li> <li>Icare tændes ved tryk på nederste knap= Enter, under displayet. Efter 2 sekunder står der ”load” på displayet</li> <li>Tag en probe i æsken, tag toppen af etuiet, proben ”hældes” i hullet, tryk på Enter så proben fæstnes (den vibrerer)</li> <li>Patienten instrueres i at holde hovedet i neutral stilling og kigge lige frem</li> <li>Afstandsholderen hviler mod patientens pande, proben holdes ca. 5 mm fra cornea</li> <li>Tryk på Enter 6 gange, icare siger bip for hvert tryk og et lidt længere bip den sidste gang</li> <li>Når trykket er målt skal proben fjernes: Tryk på Enter så der står 00 i displayet, tryk 2 gange i højre side af den øverste knap til der står "End" i displayet</li> <li>Tryk og hold Enter til proben kommer ud, proben kasseres, icare slukker herefter</li> </ul> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578994531Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699578994531Ansvar"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Ansvar og organisering</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger.</p> <p><br> Afsnitsledelsen&nbsp;er ansvarlig&nbsp;for at instruksen udarbejdes, revideres og implementeres.</p> <p><br> Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578994531Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699578994531Referencer"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Referencer, lovgivning og faglig evidens samt links hertil</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578994531Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699578994531Bilag"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Bilag</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578994531Top">Tilbage til top</a></p>

Rigshospitalet_¥jensygdomme (HOC)_Tumor team choroidal nævus.

Tumor team, choroidal nævus Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Bilag Målgrupper og anvendelsesområde Angiver retningslinjer for symptomer, fund og opfølgning af choriodalt nævus. Gældende for læger i Afdeling for Øjensygdomme, Rigshospitalet. Definitioner Fremgangsmåde Alle nyhenviste skal have foretaget: 1. OCT wide-field EDI gennem nævus 2. Farve-ægte foto, gerne Clarus 3. OPTOS farve og autofluorescens Risikofaktorer for udvikling til malanom: A) tykkelse >1mm B) serøs afløsning C) symptomer D) orangefarvet pigment E) lav indre ekkotæthed ved ultralyd F) diameter > 5 mm Det meget suspekte nævus: Nævus, som er tykkere end 1mm (A) skal som udgangspunkt følges i Tumor Team. Hvis tykkelse overstiger 2 mm må melanom mistænkes. Det let suspekte nævus: Nævus, som er tyndere end 1 mm (A) og opfylder mindst to af de øvrige kriterier (B-F) skal som udgangspunkt kontrolleres efter 12 og 24 måneder. Hvis nævus er stationært, kan pt som udgangspunkt afsluttes til fortsat kontrol hos egen øjenlæge, der vil kunne genhenvise, hvis der er mistanke om vækst. Det non-suspekte nævus: Nævus, som er tyndere end 1 mm og opfylder højst ét af kriterium B-F og skal som udgangspunkt afsluttes til fortsat kontrol hos egen øjenlæge. Det juxtapapillære nævus: Nævus med kontakt til papil udgør i nedenstående reference ikke en selvstændig risikofaktor for transformation til melanom. Denne type nævi skal alligevel vurderes særskilt, da eventuel vækst rundt om papil kan udgøre en hindring for bulbusbevarende behandling med Ru-plaque. Ansvar og organisering Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger. Afsnitsledelsen er ansvarlige for at instruksen udarbejdes, revideres og implementeres. Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen. Referencer, lovgivning og faglig evidens samt links hertil Shields CL, Dalvin LA, Ancona-Lezama D, Yu MD, Di Nicola M, Williams BK Jr, Lucio-Alvarez JA, Ang SM, Maloney S, Welch RJ, Shields JA. CHOROIDAL NEVUS IMAGING FEATURES IN 3,806 CASES AND RISK FACTORS FOR TRANSFORMATION INTO MELANOMA IN 2,355 CASES: The 2020 Taylor R. Smith and Victor T. Curtin Lecture. Retina. 2019 Oct;39(10):1840-1851. doi: 10.1097/IAE.0000000000002440. PubMed PMID: 30608349. https://www.ncbi.nlm.nih.gov/pubmed/30608349 Bilag

<h1><div id="Afsnit#1699579167682">Tumor team, choroidal nævus</div></h1><div id="BodyWeb#1699579167682"><p><a name="1699579167682Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579167682Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579167682Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579167682Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579167682Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579167682Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579167682Bilag">Bilag</a><br> &nbsp;</h3> <h2>&nbsp;</h2> <div class="collapsible-item" expandedstart="1"><a name="1699579167682Maalgrupper"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Målgrupper og anvendelsesområde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>Angiver retningslinjer for symptomer, fund og opfølgning af choriodalt nævus.<br> Gældende for læger i Afdeling for Øjensygdomme, Rigshospitalet.&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579167682Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579167682Definitioner"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Definitioner</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579167682Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579167682Fremgangsmaade"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Fremgangsmåde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm">Alle nyhenviste skal have foretaget:</p> <p style="margin-left:30.0pt; margin-right:0cm">1. OCT wide-field EDI&nbsp;gennem nævus<br> 2. Farve-ægte foto, gerne Clarus&nbsp;<br> 3. OPTOS farve og autofluorescens</p> <p style="margin-left:0cm; margin-right:0cm">Risikofaktorer for udvikling til malanom:</p> <p style="margin-left:30.0pt; margin-right:0cm">A) tykkelse &gt;1mm<br> B) serøs afløsning<br> C) symptomer<br> D) orangefarvet pigment<br> E) lav indre ekkotæthed ved ultralyd<br> F) diameter &gt; 5 mm</p> <p style="margin-left:0cm; margin-right:0cm">Det meget suspekte nævus:</p> <p style="margin-left:30.0pt; margin-right:0cm">Nævus, som er tykkere end 1mm (A) skal som udgangspunkt følges i Tumor Team. Hvis tykkelse overstiger 2 mm må melanom mistænkes.</p> <p style="margin-left:0cm; margin-right:0cm">Det let suspekte nævus:</p> <p style="margin-left:30.0pt; margin-right:0cm">Nævus, som er tyndere end 1 mm (A) og opfylder mindst to af de øvrige kriterier (B-F) skal som udgangspunkt kontrolleres efter 12 og 24 måneder. Hvis nævus er stationært, kan pt som udgangspunkt afsluttes til fortsat kontrol hos egen øjenlæge, der vil kunne genhenvise, hvis der er mistanke om vækst.</p> <p style="margin-left:0cm; margin-right:0cm">Det non-suspekte nævus:</p> <p style="margin-left:30.0pt; margin-right:0cm">Nævus, som er tyndere end 1 mm og opfylder højst ét af kriterium B-F og skal som udgangspunkt afsluttes til fortsat kontrol hos egen øjenlæge.</p> <p style="margin-left:0cm; margin-right:0cm">Det juxtapapillære nævus:</p> <p style="margin-left:30.0pt; margin-right:0cm">Nævus med kontakt til papil udgør i nedenstående reference ikke en selvstændig risikofaktor for transformation til melanom. Denne type nævi skal alligevel vurderes særskilt, da eventuel vækst rundt om papil kan udgøre en hindring for bulbusbevarende behandling med Ru-plaque.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579167682Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579167682Ansvar"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Ansvar og organisering</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm">Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger.<br> Afsnitsledelsen er ansvarlige for at instruksen udarbejdes, revideres og implementeres.<br> Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579167682Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579167682Referencer"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Referencer, lovgivning og faglig evidens samt links hertil</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Shields CL, Dalvin LA, Ancona-Lezama D, Yu MD, Di Nicola M, Williams BK Jr, Lucio-Alvarez JA, Ang SM, Maloney S, Welch RJ, Shields JA. </span><span style="color:black">CHOROIDAL NEVUS IMAGING FEATURES IN 3,806 CASES AND RISK FACTORS FOR TRANSFORMATION INTO MELANOMA IN 2,355 CASES: The 2020 Taylor R. Smith and Victor T. Curtin Lecture. Retina. 2019 Oct;39(10):1840-1851. doi: 10.1097/IAE.0000000000002440. PubMed PMID: 30608349.&nbsp;</span></p> <p style="margin-left:0cm; margin-right:0cm"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30608349" style="color:blue; text-decoration:underline">https://www.ncbi.nlm.nih.gov/pubmed/30608349</a></p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579167682Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579167682Bilag"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Bilag</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579167682Top">Tilbage til top</a></p>

Rigshospitalet_¥jensygdomme (HOC)_Udadreagerende og truende patienter på ¥34.

Udadreagerende og truende patienter på Ø34 Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Bilag Målgrupper og anvendelsesområde Målgruppen for denne instruks er alt personale på Ø34. Instruksen beskriver hvilke muligheder vi som personale har for at imødegå og håndterer situationer hvor en patient eller dennes pårørende skaber utryghed via trusler eller udadreagerende adfærd. Instruksen er delt i op to del, som beskriver handlemuligheder i hhv. de situationer hvor der er potentiale for en utryg adfærd og de akut opstået situation. Definitioner Udadreagerende adfærd: Trusler: Fremgangsmåde Situationer med potentiale for trusler eller udadreagerende adfærd hos patienter Fokus i situationer hvor der modtages en patient, både ambulant og til indlæggelse, er på sikkerhed for både patienter og personale. Patienten Når en patient optræder truende eller udadreagerende er det ofte med baggrund i nedsat mental kapacitet fx pga. stress, alder eller sygdom. Det kan medføre, at patienten oplever situationen væsentlig anderledes end personalet, f.eks. pga.: - Sanseindtryk og forståelse kan være anderledelse - Der kan være nedsat opmærksomhedsevne - Evnen til at planlægge og strukturere kan være nedsat - Evnen til at forbinde årsag og virkning kan være nedsat - Der kan være langsom og rigid tænkning - Der kan være dårlig impulskontrol og affektregulering - Der kan være nedsat sociale kompetencer og empati - Der kan være stor stressfølsomhed Det er vigtigt at huske på, at når en patient er opkørt på den ene eller anden måde, så er patienten ikke i en læringssituation. Det betyder, at det ikke kan forventes, at patienten fuldt ud forstår konsekvenserne af sine handlinger. Personales samarbejde og koordinering Hvis et personale på Ø34 vurderer en patient til at kunne skabe utryghed på afdelingen, så er det vigtigt, at dette meldes ud, som minimum skal ansvarshavende sygeplejerske og vagthavende øjenlæge koordinere planen fremadrettet. Det er vigtigt, at følgende konfereres og handles på: - Hvilke konkrete handlinger fra patientens side kan true trygheden? - Kan den øjenfaglige behandling udskydes til patienten er mere rolig? - Hvilke tiltag skal udføres for at bibeholde trygheden, fx: - altid to personale i patients nærhed? - skal patienten skærmes på en stue? - skal patienten indlægges på anden afdeling? - ved indlæggelser: skal der kaldes ekstra ind til aften/ nattevagten: - Det akutte fastvagtportørkorps på Glostrup kan kontaktes på nummer 3-4934 - Plejepersonale fra Ø34 – faste og vikarer - Skal vagthavende øjenlæge til nød blive fysisk på Ø34 natten over I den akut opstået situation Baggrunden for den akut opstået situation er Instruksen Rigshospitalets procedure ved vold og trusler (https://intranet.regionh.dk/rh/personale/arbejdsmilj%C3%B8-og-trivsel/vold-og-trusler/Documents/instruks-trusler-vold_2020.pdf) Tilkald hjælp – Glostrup - Ring til portørerne på Glostrup på 39002 - Ring til politiet på tlf. 112, hvis I oplever: - Grænseoverskridende adfærd som varer ved, fx verbale skældsord, nedsættende eller krænkende ytringer rettet mod enkelte personer eller en gruppe af personer - Støjende adfærd, fx højtråbende, generende adfærd for patienter/pårørende/ansatte - At en medarbejder føler sig utryg - At personer udviser mistænkelig adfærd - Overgreb, fx slag, spark og bid, hvor nogen lider fysisk overlast - Risiko for brug af fysisk vold - At der bliver fremsat trusler om anvendelse af øjeblikkelig vold - At de implicerede nægter at imødekomme ordrer fra personalet, fx om at forlade området - Igangværende hærværk, tyveri eller indbrudsforsøg - Våbenbesiddelse Oplys om afsnit, evt. stuenummer, årsag og antal implicerede Begræns og beskyt - Bring den truede eller voldsramte medarbejder til et sikkert sted - Hvis medarbejderen har lidt fysisk overlast, skal han eller hun følges til Akutklinikken (Glostrup) til behandling - Medarbejderens behandling skal dokumenteres i Sundhedsplatformen som enhver anden patient Gode råd hvis en patient eller pårørende er truende - Optræd roligt og med tydeligt kropssprog - Lyt og vær opmærksom - Vær aktiv – tag initiativ - Forklar tydeligt, hvad der skal ske, hvad der er muligt og ikke er muligt - Brug et enkelt sprog. Vær konkret - Vær ikke dominerende eller underkastende - Find og hold en passende afstand - Overvej, hvordan du kan hjælpe patienten eller den pårørende til at genvinde sin selvkontrol - Giv dig god tid, spil ikke Tarzan - Kontakt eventuelt Krisepsykologisk Klinik for rådgivning af patienter og pårørende i krise Procedure efter episoden Beslutninger om den truende eller voldelige patient Den ansvarlige leder eller ansvarshavende skal træffe beslutning om, hvad der skal ske med den voldelige eller truende person. Skal patienten fx isoleres eller visiteres til et andet hospital? Patienter må kun afvises eller visiteres til andre hospitaler, hvis en lægefaglig vurdering viser, at der ikke er behov for akut behandling. Hvis patienten forsat skal være indlagt, skal der sammen med politiet lægges en plan for sikkerheden under indlæggelsen. Det vil ofte betyde, at politiet skal opholde sig i nærheden. Orientering videre i systemet Vær opmærksom på at orientere øvrigt personale om patientens adfærd til både kliniske og tværgående afdelinger. Dokumentér episoderne Episoder skal dokumenteres i Sundhedsplatformen, hvis patientens voldelige adfærd kan have forbindelse til patientens sygdomsforløb eller have betydning for behandling, pleje og medicineringen af patienten eller føre til afbrydelse af undersøgelse eller behandling. Eksempel på formulering: N.N. har på grund af xxx (utilsigtet medicinpåvirkning/sygdomsudløst abnorm adfærd eller lignende) været til fare for sig selv eller andre, hvilket man ikke kan udelukke igen vil kunne ske, hvorfor der selvsagt må være øget opmærksomhed på dette fremover. Tag hånd om den truede eller voldsramte medarbejder Den følelsesmæssige reaktion efter en episode med en voldelig eller truende patient eller pårørende skal kun sjældent håndteres af en psykolog. De fleste gange er der tale om en ganske naturlig reaktion, der først og fremmest kræver omsorg og støtte fra lederen og kollegerne. Psykisk førstehjælp - Lad ikke den voldsramte være alene - Skab ro og tryghed. Vis at du er der, men giv plads til den voldsramte - Lad den voldsramte fortælle, hvad der er sket (igen og igen) – lyt! - Undgå at bagatellisere den voldsramtes oplevelse - Undgå at kritisere den voldsramtes handlinger - Hjælp eventuelt med at kontakte familie og pårørende - Følg eventuelt den voldsramte hjem - Sørg for, at den voldsramte ikke er alene det første døgn Defusing Som en del af den psykiske førstehjælp kan det være nødvendigt at gennemføre en defusing med dem, der har været involveret i den traumatiske hændelse. Defusing giver de involverede medarbejdere mulighed for at dele tanker, oplevelser og indtryk så de kan danne sig et fælles overblik over den traumatiserende episode og at sikre, at de ansatte ikke forlader arbejdspladsen med en række uafklarede oplevelser. Roller og opgaver Lederen eller den ansvarlige sundhedspersons opgaver - Beslutte om medarbejderen skal sendes hjem, om der skal tilkaldes vikar og træffe andre ledelsesmæssige beslutninger - Holde samtale med den berørte medarbejder dagen efter episoden blandt andet for at drøfte, om der er behov for psykologbistand - Overveje om der er behov for psykologisk debriefing ved Afdeling for Krisepsykologi eller centrets egne psykologer - Sikre en god og tryg tilbagevenden til arbejdet for medarbejderen efter en eventuel sygemelding - Anmelde episoden til politiet Kollegaens opgaver - Underrette ledelsen, hvis medarbejderen ikke selv har gjort det. Hvis den daglige leder ikke kan underrettes, orienteres afdelingens ansvarshavende medarbejder, som er ansvarlig for at træffe de ledelsesmæssige beslutninger, der ikke kan vente - Udvise kollegial omsorg og støtte og eventuelt yde psykisk førstehjælp - Underrette ledelsen. I mange situationer kan det være en kollega, der gør dette - Eventuelt henvende sig til Krisepsykologisk Enhed eller centrets psykologer for psykologbistand - Overveje om episoden skal politianmeldes - Udfyld skema til Intern registrering af vold og trusler Tag hånd om hele arbejdspladsen Lederens opgaver - Mødes med alle medarbejdere i afdelingen om episoden og tage hånd om eventuelle psykologiske reaktioner - Vurdere om episoden giver anledning til forebyggende foranstaltninger, sikkerhedsmæssige tiltag, personalemæssige justeringer eller lignende Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil https://intranet.regionh.dk/rh/personale/arbejdsmilj%C3%B8-og-trivsel/vold-og-trusler/Documents/instruks-trusler-vold_2020.pd Bilag Tilkald hjælp - GUL.docx

<h1><div id="Afsnit#1699578888092">Udadreagerende og truende patienter på Ø34</div></h1><div id="BodyWeb#1699578888092"><p><a name="1699578888092Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578888092Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578888092Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578888092Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578888092Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578888092Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578888092Bilag">Bilag</a><br> &nbsp;</h3> <h2>&nbsp;</h2> <div class="collapsible-item" expandedstart="1"><a name="1699578888092Maalgrupper"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Målgrupper og anvendelsesområde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>Målgruppen for denne instruks er alt personale på Ø34.</p> <p>Instruksen beskriver hvilke muligheder vi som personale har for at imødegå og håndterer situationer hvor en patient eller dennes pårørende skaber utryghed via trusler eller udadreagerende adfærd.</p> <p>Instruksen er delt i op to del, som beskriver handlemuligheder i hhv. de situationer hvor der er potentiale for en utryg adfærd og de akut opstået situation.<br> &nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578888092Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699578888092Definitioner"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Definitioner</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>Udadreagerende adfærd:&nbsp;</p> <p>Trusler:&nbsp;</p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578888092Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699578888092Fremgangsmaade"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Fremgangsmåde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <h1 style="margin-left:0cm; margin-right:0cm"><span style="color:#2f5496"><a name="1699578888092_Toc121987615"><span style="color:#2f5496">Situationer med potentiale for trusler eller udadreagerende adfærd hos </span>patienter</a></span></h1> <p style="margin-left:0cm; margin-right:0cm">Fokus i situationer hvor der modtages en patient, både ambulant og til indlæggelse, er på sikkerhed for både patienter og personale.</p> <h3 style="margin-left:0cm; margin-right:0cm"><span style="color:#1f3763"><a name="1699578888092_Toc121987616">Patienten</a></span></h3> <p style="margin-left:0cm; margin-right:0cm">Når en patient optræder truende eller udadreagerende er det ofte med baggrund i nedsat mental kapacitet fx pga. stress, alder eller sygdom.</p> <p style="margin-left:0cm; margin-right:0cm">Det kan medføre, at patienten oplever situationen væsentlig anderledes end personalet, f.eks. pga.:</p> <ul> <li>Sanseindtryk og forståelse kan være anderledelse</li> <li>Der kan være nedsat opmærksomhedsevne</li> <li>Evnen til at planlægge og strukturere kan være nedsat</li> <li>Evnen til at forbinde årsag og virkning kan være nedsat</li> <li>Der kan være langsom og rigid tænkning</li> <li>Der kan være dårlig impulskontrol og affektregulering</li> <li>Der kan være nedsat sociale kompetencer og empati</li> <li>Der kan være stor stressfølsomhed</li> </ul> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm">Det er vigtigt at huske på, at når en patient er opkørt på den ene eller anden måde, så er patienten ikke i en læringssituation. Det betyder, at det ikke kan forventes, at patienten fuldt ud forstår konsekvenserne af sine handlinger.</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <h3 style="margin-left:0cm; margin-right:0cm"><span style="color:#1f3763"><a name="1699578888092_Toc121987617">Personales samarbejde og koordinering</a></span></h3> <p style="margin-left:0cm; margin-right:0cm">Hvis et personale på Ø34 vurderer en patient til at kunne skabe utryghed på afdelingen, så er det vigtigt, at dette meldes ud<strong>, <span style="background-color:yellow">som minimum skal ansvarshavende sygeplejerske og vagthavende øjenlæge koordinere planen fremadrettet</span></strong><span style="background-color:yellow">.</span><br> Det er vigtigt, at følgende konfereres og handles på:</p> <ul> <li>Hvilke konkrete handlinger fra patientens side kan true trygheden?</li> <li>Kan den øjenfaglige behandling udskydes til patienten er mere rolig?</li> <li>Hvilke tiltag skal udføres for at bibeholde trygheden, fx: <ul style="list-style-type:circle"> <li>altid to personale i patients nærhed?</li> <li>skal patienten skærmes på en stue?</li> <li>skal patienten indlægges på anden afdeling?</li> <li>ved indlæggelser: skal der kaldes ekstra ind til aften/ nattevagten: <ul style="list-style-type:square"> <li>Det akutte fastvagtportørkorps på Glostrup kan kontaktes på nummer 3-4934</li> <li>Plejepersonale fra Ø34 – faste og vikarer</li> <li>Skal vagthavende øjenlæge til nød blive fysisk på Ø34 natten over</li> </ul> </li> </ul> </li> </ul> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <h1 style="margin-left:0cm; margin-right:0cm"><span style="color:#2f5496"><a name="1699578888092_Toc121987618">I den akut opstået situation</a></span></h1> <p style="margin-left:0cm; margin-right:0cm">Baggrunden for den akut opstået situation er Instruksen Rigshospitalets procedure ved vold og trusler (<a href="https://intranet.regionh.dk/rh/personale/arbejdsmilj%C3%B8-og-trivsel/vold-og-trusler/Documents/instruks-trusler-vold_2020.pdf" style="color:#0563c1; text-decoration:underline">https://intranet.regionh.dk/rh/personale/arbejdsmilj%C3%B8-og-trivsel/vold-og-trusler/Documents/instruks-trusler-vold_2020.pdf</a>)</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <h3 style="margin-left:0cm; margin-right:0cm"><span style="color:#1f3763"><a name="1699578888092_Toc121987619">Tilkald hjælp – Glostrup</a></span></h3> <ul> <li>Ring til portørerne på Glostrup på <strong>39002</strong></li> <li>Ring til politiet på tlf. 112, hvis I oplever: <ul style="list-style-type:circle"> <li>Grænseoverskridende adfærd som varer ved, fx verbale skældsord, nedsættende eller krænkende ytringer rettet mod enkelte personer eller en gruppe af personer</li> <li>Støjende adfærd, fx højtråbende, generende adfærd for patienter/pårørende/ansatte</li> <li>At en medarbejder føler sig utryg</li> <li>At personer udviser mistænkelig adfærd</li> <li>Overgreb, fx slag, spark og bid, hvor nogen lider fysisk overlast</li> <li>Risiko for brug af fysisk vold</li> <li>At der bliver fremsat trusler om anvendelse af øjeblikkelig vold</li> <li>At de implicerede nægter at imødekomme ordrer fra personalet, fx om at forlade området</li> <li>Igangværende hærværk, tyveri eller indbrudsforsøg</li> <li>Våbenbesiddelse</li> </ul> </li> </ul> <p style="margin-left:0cm; margin-right:0cm">Oplys om afsnit, evt. stuenummer, årsag og antal implicerede</p> <p style="margin-left:0cm; margin-right:0cm"><a name="1699578888092_Toc121987620"><span style="color:#1f3763">Begræns og beskyt</span></a></p> <ul> <li>Bring den truede eller voldsramte medarbejder til et sikkert sted</li> <li>Hvis medarbejderen har lidt fysisk overlast, skal han eller hun følges til Akutklinikken (Glostrup) til behandling</li> <li>Medarbejderens behandling skal dokumenteres i Sundhedsplatformen som enhver anden patient</li> </ul> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <h3 style="margin-left:0cm; margin-right:0cm"><span style="color:#1f3763"><a name="1699578888092_Toc121987621">Gode råd hvis en patient eller pårørende er truende</a></span></h3> <ol> <li>Optræd roligt og med tydeligt kropssprog</li> <li>Lyt og vær opmærksom</li> <li>Vær aktiv – tag initiativ</li> <li>Forklar tydeligt, hvad der skal ske, hvad der er muligt og ikke er muligt</li> <li>Brug et enkelt sprog. Vær konkret</li> <li>Vær ikke dominerende eller underkastende</li> <li>Find og hold en passende afstand</li> <li>Overvej, hvordan du kan hjælpe patienten eller den pårørende til at genvinde sin selvkontrol</li> <li>Giv dig god tid, spil ikke Tarzan</li> <li>Kontakt eventuelt Krisepsykologisk Klinik for rådgivning af patienter og pårørende i krise</li> </ol> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <h3 style="margin-left:0cm; margin-right:0cm"><span style="color:#1f3763"><a name="1699578888092_Toc121987622">Procedure efter episoden</a></span></h3> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#2f5496"><em>Beslutninger om den truende eller voldelige patient</em></span><strong> </strong><br> Den ansvarlige leder eller ansvarshavende skal træffe beslutning om, hvad der skal ske med den voldelige eller truende person. Skal patienten fx isoleres eller visiteres til et andet hospital? Patienter må kun afvises eller visiteres til andre hospitaler, hvis en lægefaglig vurdering viser, at der ikke er behov for akut behandling. Hvis patienten forsat skal være indlagt, skal der sammen med politiet lægges en plan for sikkerheden under indlæggelsen. Det vil ofte betyde, at politiet skal opholde sig i nærheden.</p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#2f5496"><em>Orientering videre i systemet</em></span><br> Vær opmærksom på at orientere øvrigt personale om patientens adfærd til både kliniske og tværgående afdelinger.</p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#2f5496"><em>Dokumentér episoderne</em></span><br> Episoder skal dokumenteres i Sundhedsplatformen, hvis patientens voldelige adfærd kan have forbindelse til patientens sygdomsforløb eller have betydning for behandling, pleje og medicineringen af patienten eller føre til afbrydelse af undersøgelse eller behandling.</p> <p style="margin-left:0cm; margin-right:0cm"><strong>Eksempel på formulering:</strong> <em>N.N. har på grund af xxx (utilsigtet medicinpåvirkning/sygdomsudløst abnorm adfærd eller lignende) været til fare for sig selv eller andre, hvilket man ikke kan udelukke igen vil kunne ske, hvorfor der selvsagt må være øget opmærksomhed på dette fremover.</em></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#2f5496"><em>Tag hånd om den truede eller voldsramte medarbejder</em></span><br> Den følelsesmæssige reaktion efter en episode med en voldelig eller truende patient eller pårørende skal kun sjældent håndteres af en psykolog. De fleste gange er der tale om en ganske naturlig reaktion, der først og fremmest kræver omsorg og støtte fra lederen og kollegerne.</p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#2f5496"><em>Psykisk førstehjælp</em></span></p> <ul> <li>Lad ikke den voldsramte være alene</li> <li>Skab ro og tryghed. Vis at du er der, men giv plads til den voldsramte</li> <li>Lad den voldsramte fortælle, hvad der er sket (igen og igen) – lyt!</li> <li>Undgå at bagatellisere den voldsramtes oplevelse</li> <li>Undgå at kritisere den voldsramtes handlinger</li> <li>Hjælp eventuelt med at kontakte familie og pårørende</li> <li>Følg eventuelt den voldsramte hjem</li> <li>Sørg for, at den voldsramte ikke er alene det første døgn</li> </ul> <h4 style="margin-left:0cm; margin-right:0cm"><span style="color:#2f5496"><em>Defusing</em></span></h4> <p style="margin-left:0cm; margin-right:0cm">&nbsp;Som en del af den psykiske førstehjælp kan det være nødvendigt at gennemføre en defusing med dem, der har været involveret i den traumatiske hændelse. Defusing giver de involverede medarbejdere mulighed for at dele tanker, oplevelser og indtryk så de kan danne sig et fælles overblik over den traumatiserende episode og at sikre, at de ansatte ikke forlader arbejdspladsen med en række uafklarede oplevelser.</p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#2f5496"><em>Roller og opgaver</em></span><br> <strong>Lederen eller den ansvarlige sundhedspersons opgaver </strong></p> <ul> <li>Beslutte om medarbejderen skal sendes hjem, om der skal tilkaldes vikar og træffe andre ledelsesmæssige beslutninger</li> <li>Holde samtale med den berørte medarbejder dagen efter episoden blandt andet for at drøfte, om der er behov for psykologbistand</li> <li>Overveje om der er behov for psykologisk debriefing ved Afdeling for Krisepsykologi eller centrets egne psykologer</li> <li>Sikre en god og tryg tilbagevenden til arbejdet for medarbejderen efter en eventuel sygemelding</li> <li>Anmelde episoden til politiet</li> </ul> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong>Kollegaens opgaver</strong></p> <ul> <li>Underrette ledelsen, hvis medarbejderen ikke selv har gjort det. Hvis den daglige leder ikke kan underrettes, orienteres afdelingens ansvarshavende medarbejder, som er ansvarlig for at træffe de ledelsesmæssige beslutninger, der ikke kan vente</li> <li>Udvise kollegial omsorg og støtte og eventuelt yde psykisk førstehjælp</li> <li>Underrette ledelsen. I mange situationer kan det være en kollega, der gør dette</li> <li>Eventuelt henvende sig til Krisepsykologisk Enhed eller centrets psykologer for psykologbistand</li> <li>Overveje om episoden skal politianmeldes</li> <li>Udfyld skema til Intern registrering af vold og trusler</li> </ul> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#2f5496"><em>Tag hånd om hele arbejdspladsen</em></span><br> &nbsp;<strong>Lederens opgaver</strong></p> <ul> <li>Mødes med alle medarbejdere i afdelingen om episoden og tage hånd om eventuelle psykologiske reaktioner</li> <li>Vurdere om episoden giver anledning til forebyggende foranstaltninger, sikkerhedsmæssige tiltag, personalemæssige justeringer eller lignende</li> </ul> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578888092Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699578888092Ansvar"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Ansvar og organisering</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578888092Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699578888092Referencer"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Referencer, lovgivning og faglig evidens samt links hertil</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>https://intranet.regionh.dk/rh/personale/arbejdsmilj%C3%B8-og-trivsel/vold-og-trusler/Documents/instruks-trusler-vold_2020.pd</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578888092Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699578888092Bilag"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Bilag</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p><img src="/icons/vwicn005.gif" onclick="Ext.DMS.util.showImage(this);"><a href="###FOLDER###" target="_blank">Tilkald hjælp - GUL.docx</a></p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578888092Top">Tilbage til top</a></p>

Rigshospitalet_¥jensygdomme (HOC)_Uveitis ambulant kontrol.

Uveitis, ambulant kontrol Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Bilag Målgrupper og anvendelsesområde Angiver retningslinier for ambulant forløb for patienter med uveitis i medicinsk retina team, Afdeling for Øjensygdomme Rigshospitalet. Gældende for sygeplejersker, social- og sundhedsassistenter og optikere i medicinsk retina team, Afdeling for Øjensygdomme Rigshospitalet. Definitioner O.U.: begge øjne OCT: Optical Coherence Tomography IOP: intraocular pressure MR: medicinsk retina Fremgangsmåde Kontrol af nyhenviste patienter Sygeplejersken skal gøre følgende: - Hente journal i SP. - Identificere patient med navn og CPR-nummer - Lave retinomax og brillemåling - Måle IOP med I-care - Måle visus o.u. - Spørge til allergier - Dilatere o.u. med en dr. Mydriacyl 1% (samt en dr. Metaoxedrin 10% hvis der skal laves FLU angiografi) - Udføre OCT o.u. - Evt. klargøre patient til fluoresceinangiografi - Evt. blodprøvebestilling efter aftale med læge - Give patient tid til næste konsultation Efterfølgende kontroller Sygeplejersken skal gøre følgende: - Identificere patient med navn og CPR-nummer - Måle IOP med I-care - Spørge til allergier - Dilatere o.u. med en dr. Mydriacyl 1% (samt en dr. Metaoxedrin 10% hvis der skal laves FLU angiografi) - Måle visus o.u. - Udføre OCT o.u. - Evt. blodprøvebestiling - Evt. klargøring til fluoresceinangiografi efter ordination fra læge - Give patient tid til næste konsultation Ansvar og organisering Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger. Afsnitsledende overlæger, afdelingssygeplejersker og ledende lægesekretærer, er ansvarlige for at instruksen udarbejdes, revideres og implementeres. Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen. Referencer, lovgivning og faglig evidens samt links hertil Bilag

<h1><div id="Afsnit#1699578992340">Uveitis, ambulant kontrol</div></h1><div id="BodyWeb#1699578992340"><p><a name="1699578992340Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578992340Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578992340Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578992340Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578992340Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578992340Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578992340Bilag">Bilag</a><br> &nbsp;</h3> <h2>&nbsp;</h2> <div class="collapsible-item" expandedstart="1"><a name="1699578992340Maalgrupper"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Målgrupper og anvendelsesområde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>Angiver retningslinier for ambulant forløb for patienter med uveitis i medicinsk retina team, Afdeling for Øjensygdomme Rigshospitalet.<br> Gældende for sygeplejersker, social- og sundhedsassistenter og optikere i medicinsk retina team, Afdeling for Øjensygdomme Rigshospitalet.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578992340Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699578992340Definitioner"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Definitioner</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>O.U.: begge øjne<br> OCT: Optical Coherence Tomography<br> IOP: intraocular pressure<br> MR: medicinsk retina<br> &nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578992340Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699578992340Fremgangsmaade"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Fremgangsmåde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p><strong>Kontrol af nyhenviste patienter</strong></p> <p>Sygeplejersken skal gøre følgende:</p> <ol style="margin-left:40px"> <li>Hente journal i SP.&nbsp;</li> <li>Identificere patient med navn og CPR-nummer</li> <li>Lave retinomax og brillemåling</li> <li>Måle IOP med I-care</li> <li>Måle visus o.u.</li> <li>Spørge til allergier</li> <li>Dilatere o.u. med en&nbsp;dr. Mydriacyl 1% (samt&nbsp;en&nbsp;dr. Metaoxedrin 10% hvis der skal laves FLU angiografi)</li> <li>Udføre OCT o.u.</li> <li>Evt. klargøre patient til fluoresceinangiografi</li> <li>Evt. blodprøvebestilling efter aftale med læge</li> <li>Give patient tid til næste konsultation</li> </ol> <p><strong>Efterfølgende kontroller</strong></p> <p>Sygeplejersken skal gøre følgende:</p> <ol style="margin-left:40px"> <li>Identificere patient med navn og CPR-nummer</li> <li>Måle IOP med I-care</li> <li>Spørge til allergier</li> <li>Dilatere o.u. med en&nbsp;dr. Mydriacyl 1% (samt&nbsp;en&nbsp;dr. Metaoxedrin 10% hvis der skal laves FLU angiografi)</li> <li>Måle visus o.u.</li> <li>Udføre OCT o.u.</li> <li>Evt. blodprøvebestiling</li> <li>Evt. klargøring til fluoresceinangiografi efter ordination fra læge</li> <li>Give patient tid til næste konsultation</li> </ol> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578992340Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699578992340Ansvar"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Ansvar og organisering</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger.<br> Afsnitsledende overlæger, afdelingssygeplejersker og ledende lægesekretærer, er ansvarlige for at instruksen udarbejdes, revideres og implementeres.<br> Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578992340Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699578992340Referencer"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Referencer, lovgivning og faglig evidens samt links hertil</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578992340Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699578992340Bilag"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Bilag</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578992340Top">Tilbage til top</a></p>

Rigshospitalet_¥jensygdomme (HOC)_Vancomycin ¢jendråber - blandingsinstruks.

Vancomycin, øjendråber - blandingsinstruks Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Bilag Målgrupper og anvendelsesområde Beskriver proceduren ved blanding af Vancomycin øjendråber i Afdeling for Øjensygdomme, Rigshospitalet. Definitioner Fremgangsmåde Fremstilling 1 hætteglas Vancomycin, 500 mg tørstof til infusionvæske Natriumklorid, isotonisk 10 ml 10 ml sprøjte 5 ml sprøjte 2 lyserøde kanyler 18G Spritswabs Steril øjendråbeflaske Etikette Fremgangsmåde 500 mg Vancomycin opløses i 10 ml isotonisk saltvand. Hætteglasset omrystes grundigt indtil opløsningen er klar. Opløsningen er nu 50 mg/ml. Træk 5 ml op af opløsningen og fyld dråbeflasken. Udfyld medicinetikette. Holdbarhed 1 uge som øjendråber. Forholdsregler Bland dråberne i ventilationsskab. Ved risiko for kontakt brug engangshandsker af latex, nitril eller neopren. Handskerne skal straks skiftes ved beskadigelse samt kasseres efter brug. Uheld, spild og affald Vancomycinflaske mærkes med dato og opbevares ved stuetemperatur i ventilationsskabet i 24 timer. Spild i forbindelse med patientbehandling, tørres normalt blot op og kasseres (brug handsker). Hvis der spildes medicin på huden, afvaskes der med vand og sæbe. Kanyle og andre skarpe genstande bortskaffes i hertil egnet kanylebøtte. Ansvar og organisering Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger. Afsnitsledende overlæger, afdelingssygeplejersker, ledende lægesekretærer (klyngeledelser) og funktionsledere på udefunktioner, er ansvarlige for at instruksen udarbejdes, revideres og implementeres. Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen. Referencer, lovgivning og faglig evidens samt links hertil Bilag

<h1><div id="Afsnit#1699579207319">Vancomycin, øjendråber - blandingsinstruks</div></h1><div id="BodyWeb#1699579207319"><p><a name="1699579207319Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579207319Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579207319Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579207319Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579207319Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579207319Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579207319Bilag">Bilag</a><br> &nbsp;</h3> <h2><a name="1699579207319Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p>Beskriver proceduren ved blanding af Vancomycin øjendråber i Afdeling for Øjensygdomme, Rigshospitalet.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579207319Top">Tilbage til top</a></p> <h2><a name="1699579207319Definitioner"></a><br> Definitioner</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579207319Top">Tilbage til top</a></p> <h2><a name="1699579207319Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p><strong>Fremstilling</strong></p> <p style="margin-left:40px">1 hætteglas Vancomycin, 500 mg tørstof til infusionvæske<br> Natriumklorid, isotonisk 10 ml<br> 10 ml sprøjte<br> 5 ml sprøjte<br> 2 lyserøde kanyler 18G<br> Spritswabs<br> Steril øjendråbeflaske<br> Etikette<br> &nbsp;</p> <p><strong>Fremgangsmåde</strong></p> <p style="margin-left:40px">500 mg Vancomycin opløses i 10 ml isotonisk saltvand.<br> Hætteglasset omrystes grundigt indtil opløsningen er klar. Opløsningen er nu 50 mg/ml.<br> Træk 5 ml op af opløsningen og fyld dråbeflasken.<br> Udfyld medicinetikette.</p> <p style="margin-left:40px">Holdbarhed 1 uge som øjendråber.<br> &nbsp;</p> <p><strong>Forholdsregler</strong></p> <p style="margin-left:40px">Bland dråberne i ventilationsskab.</p> <p style="margin-left:40px">Ved risiko for kontakt brug engangshandsker af latex, nitril eller neopren.<br> Handskerne skal straks skiftes ved beskadigelse samt kasseres efter brug.<br> &nbsp;</p> <p><strong>Uheld, spild og affald</strong></p> <p style="margin-left:40px">Vancomycinflaske mærkes med dato og opbevares ved stuetemperatur i ventilationsskabet i 24 timer.</p> <p style="margin-left:40px">Spild i forbindelse med patientbehandling, tørres normalt blot op og kasseres (brug handsker).</p> <p style="margin-left:40px">Hvis der spildes medicin på huden, afvaskes der med vand og sæbe.</p> <p style="margin-left:40px">Kanyle og andre skarpe genstande bortskaffes i hertil egnet kanylebøtte.</p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579207319Top">Tilbage til top</a></p> <h2><a name="1699579207319Ansvar"></a><br> Ansvar og organisering</h2> <p><br> Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger.</p> <p>Afsnitsledende overlæger, afdelingssygeplejersker, ledende lægesekretærer (klyngeledelser) og funktionsledere på udefunktioner, er ansvarlige for at instruksen udarbejdes, revideres og implementeres.</p> <p>Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579207319Top">Tilbage til top</a></p> <h2><a name="1699579207319Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579207319Top">Tilbage til top</a></p> <h2><a name="1699579207319Bilag"></a><br> Bilag</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579207319Top">Tilbage til top</a></p>

Rigshospitalet_¥jensygdomme (HOC)_Visitation af vagtpatienter i Afdeling for.

Visitation af vagtpatienter i Afdeling for Øjensygdomme Målgrupper og anvendelsesområde Angiver retningslinjer for visitation af akutte patienter til Afdeling for Øjensygdomme, Rigshospitalet-Glostrup Gældende for læger, sygeplejersker og lægesekretærer i Afdeling for Øjensygdomme. Definitioner Fremgangsmåde Visitation af vagtpatienter - Patienter, som meldes fra vagtlæger og skadestuelæger med ønske om akut vurdering, ses som hovedregel i vagten - Behandling af akut konjunktivitis (dog ikke nyfødte), abrasio corneae, fjernelse af mindre og overfladiske fremmedlegemer m.m., som kan klares af henvisende læge, hvor vurdering ved øjenlæge kan vente nogle dage, kan følges op hos en praktiserende øjenlæge afhængig af det enkelte tilfælde - Patienter, som meldes fra øjenlæger modtages som hovedregel altid. Men ved tvivl om akut indikation f.eks. hvis der er tale om AMD eller veneokklusion konfereres med bagvagten Patienter, som skal ses akut efter kl. 18 fordi det er relevant at igangsætte tidlig behandling (listen over tilstande er ikke udtømmende): - Akut glaukom/vinkellukning - Bulbuspenetration og perforation - Traumer med mistænkt retrobulbær hæmoragi eller bulbusruptur - Ætseskader (efter skylning til neutral pH på skadestuen) - Keratitis med truende perforation - Postseptal cellulitis - Endophthalmitis (Endogen endophthalmitis med viral eller bakteriel årsag samt postoperativ/posttraumatisk endophthalmitis) - Akut retinal nekrose Diagnoser som skal ses i Afdeling for Øjensygdomme, fordi de måske skal henvises til anden relevant afdeling samme aften: - Nyopstået oculomotoriusparese - Nyopstået diplopi - Embolisk betinget retinal arterieokklusion (opstået for under 1 måned siden) Alle tilfælde, hvor ovenstående diagnoser ikke kan udelukkes Alle nyopererede patienter, børn generelt og patienter med akut synstab skal visiteres med ekstra omhu Patienter, som kan gives tid på akutteamets vagtliste næste dag, såfremt de ikke kan ses inden kl. 18: Hvis der kun er symptomer på conjunktivitis uden noget sikkert cornealt infiltrat, mindre corneal abrasio, corneal glødeskal uden mistanke om penetration, bygkorn, sorte fluer eller lysglimt (uden gardinfornemmelse eller tidligere amotio) kan man bede patienten om at søge praktiserende øjenlæge næste dag, hvis næste dag er en hverdag: I flere tilfælde kan den initiale behandling påbegyndes efter undersøgelse af henvisende læge (f.eks. skadelæge i akutmodtagelsen). Eksempler kan være behandling af keratitis (helst forudgået af podning), iritis, øjenlågstraumer, præseptal cellulitis og arteritis temporalis. Kontrollen i akutteam gives til næste dag. Visitering skal altid baseres på et lægefagligt skøn i det konkrete tilfælde. Nedenstående liste er ikke nogen endegyldig liste men tiltænkt som en vejledende oversigt over diagnoser som i normale tilfælde kan visiteres til næste dag. - Traume af øjenlåg - Blow out fraktur (hvis visus og motilitet er i orden) - Hyphæma - Dacryocystit - Dacryoadenit - Præseptal cellulitis - Diplopi hvor akutte forhold er udelukket ved CT-C angio eller med varighed > 3 dage - Opticusneuritis - Arteritis temporalis (hvis relevant behandling kan opstartes akut af henvisende afd. efter blodprøvetagning for SR og CRP) - Iritis, uveitis - Toxoplasmose - Corpussammenfald - Retinal rift - Corpusblødning - Amotio retinae - Keratitis uden truende perforation - Glødeskal - Abrasio corneae (hvis de skal ses i Afdeling for Øjensygdomme) Hvis adenovirus mistænkes skal patienten helst ikke komme til Afdeling for Øjensygdomme med mindre der er tvivl om diagnosen. Opfølgende kontrol kan evt ske som en aftalt telefonkonsultation med patienten. Visitation til opfølgende besøg Vagtpatienter skal efter 1. besøg i vagten: - Afsluttes til kontrol hos praktiserende øjenlæge, eller - Kontrolleres i et af afdelingens teams primært Rigshospitalet - Glostrup eller Rigshospitalet - Blegdamsvej men Hillerød vil også kunne medinddrages, hvor dette skønnes hensigtsmæssigt, eller - Kontrolleres i vagten men kun hvis 2. besøg allerede er nødvendigt næste hverdag efter 1. besøg (eller før) - Når patienten skal have kontrol i et team bestilles en best/ord på ambulant opfølgning i et team - Når patienten skal ses subakut anføres ’akutvisi’, team, ønsket tidsramme og patientens telefonnummer - Alle teams og matrikler er ansvarlige for gennemgang af ’akut visi’-patienter Akutte patienter med behov for fluoresceinangiografi I dagtiden, mellem kl. 8.00 og 14.30: - Vagthavende læge konfererer med bagvagten eller speciallæge fra medicinsk retina mhp. indikation for fluoresceinangiografi. - Angiografien aftales med akut-foto-holdet på ØB1 (tlf 3-4061). - Bagvagten konfererer fluoresceinangiografi og evt. behandlingsindikation med speciallæge i medicinsk retina. - Er der indikation for anti-VEGF-injektion, oprettes forløb i BOB ved vagthavende. Hos alle patienter, der skal i anti-VEGF-behandling, skal der foreligge fotodokumentation som minimum OCT forud for behandling (AMD, retinale veneokklusioner og diabetisk makulaødem). Uden for dagtiden, weekend - og helligdage: - Findes der ved vagthavende læge indikation for akut fluoresceinangiografi mhp. diagnostik og udredning, bookes patienten førstkommende hverdag på bagvagtslisten mhp. dette Akutte patienter med behov for kirurgisk intervention: - Patienten konfereres med kirurgisk overlægevagt (vagtlag 2) efter at være undersøgt af bagvagt. Det er som hovedregel bagvagten, der kontakter kirurgisk overlægevagt mhp. videre plan for patienten - Før kl. 22 forberedes operation på Rigshospitalet - Glostrup - Efter kl. 22 kan operation udføres på Rigshospitalet - Blegdamsvej Dokumentation af telefonopkald til afdelingen for Øjensygdomme Telefonopkald til afdelingen for Øjensygdommes akkutteam skal dokumenteres i patientjournalen efter følgende retningslinjer: Følgende situationer skal lede til journalføring af telefonopkaldet: - Direkte kontakt til borgere, der ikke har et forløb i afdelingen, sundhedspersonale fra plejehjem, hjemmesygeplejersker, værger, forældre m.fl - Patienter, der aktuelt har et åbent forløb i afdelingen og derved er tilknyttet et team eller tidligere er set i vagten og afvente tid i team Følgende situationer skal ikke umiddelbart lede til journalføring af telefonopkaldet: - Lægefagligt råd til anden hospitalsafdeling eller praktiserende læge - Telefonopkald 1813 Dokumentation i journalen ved telefonisk kontakt ( som ikke leder til besøg) skal skrives som følgende: - Kort anamnese - Hvilke tiltag der er igangsat - Hvad der skal lede til ny kontakt til sundhedspersonale - Ønsket opfølgning Fremgangsmåde: - Hvis patienten ikke skulle have fysisk fremmøde, men blot ringer med spørgsmål sv.t. en konsultation, visiteres til at skulle ses af privatprakiserende øjenlæge næstkommende hverdag eller anden visitation, laves en telefonkonsultation i SP ( se nedenfor) - Telefonkonsultationen registreres på en telefonkonsultationsseddel som påføres navn og cpr. nummer samt anamnese, behandling og ønsket opfølgning. Denne seddel lægges i dueslag med angivelsen " Telefonkonsultation" som dagen efter journalføres af akutvagtens sekretær Ansvar og organisering Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger. Afsnitsledelsen er ansvarlige for at instruksen udarbejdes, revideres og implementeres. Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen. Referencer, lovgivning og faglig evidens samt links hertil Bilag

<h1><div id="Afsnit#1699578970288">Visitation af vagtpatienter i Afdeling for Øjensygdomme</div></h1><div id="BodyWeb#1699578970288"><p>&nbsp;</p> <div class="collapsible-item" expandedstart="1"><a name="1699578970288Maalgrupper"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Målgrupper og anvendelsesområde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm">Angiver retningslinjer for visitation af akutte patienter til Afdeling for Øjensygdomme, Rigshospitalet-Glostrup<br> Gældende for læger, sygeplejersker og lægesekretærer i Afdeling for Øjensygdomme.</p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699578970288Definitioner"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Definitioner</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578970288Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699578970288Fremgangsmaade"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Fremgangsmåde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm"><strong>Visitation af vagtpatienter</strong></p> <ul> <li>Patienter, som meldes fra vagtlæger og skadestuelæger med ønske om akut vurdering, ses som hovedregel i vagten</li> <li>Behandling af akut konjunktivitis (dog ikke nyfødte), abrasio corneae, fjernelse af mindre og overfladiske fremmedlegemer m.m., som kan klares af henvisende læge, hvor vurdering ved øjenlæge kan vente nogle dage, kan følges op hos en praktiserende øjenlæge afhængig af det enkelte tilfælde</li> <li>Patienter, som meldes fra øjenlæger modtages som hovedregel altid. Men ved tvivl om akut indikation f.eks. hvis der er tale om AMD eller veneokklusion konfereres med bagvagten</li> </ul> <p style="margin-left:0cm; margin-right:0cm"><strong>Patienter, som skal ses akut efter kl. 18&nbsp;fordi det er relevant at igangsætte tidlig behandling (listen over tilstande er ikke udtømmende):</strong></p> <ul> <li>Akut glaukom/vinkellukning</li> <li>Bulbuspenetration og perforation</li> <li>Traumer med mistænkt retrobulbær hæmoragi eller bulbusruptur</li> <li>Ætseskader (efter skylning til neutral pH på skadestuen)</li> <li>Keratitis med truende perforation</li> <li>Postseptal cellulitis</li> <li>Endophthalmitis (Endogen endophthalmitis med viral eller bakteriel årsag samt postoperativ/posttraumatisk endophthalmitis)</li> <li>Akut retinal nekrose</li> </ul> <p style="margin-left:0cm; margin-right:0cm">Diagnoser som skal ses i Afdeling for Øjensygdomme, fordi de måske skal henvises til anden relevant afdeling samme aften:</p> <ul> <li>Nyopstået oculomotoriusparese</li> <li>Nyopstået diplopi</li> <li>Embolisk betinget retinal arterieokklusion (opstået for under 1 måned siden)</li> </ul> <p style="margin-left:0cm; margin-right:0cm">Alle tilfælde, hvor ovenstående diagnoser ikke kan udelukkes<br> Alle nyopererede patienter, børn generelt og patienter med akut synstab skal visiteres med ekstra omhu</p> <p style="margin-left:0cm; margin-right:0cm"><strong>Patienter, som kan gives tid på akutteamets vagtliste næste dag, såfremt de ikke kan ses inden kl. 18:</strong></p> <p style="margin-left:0cm; margin-right:0cm"><strong>Hvis der kun er symptomer på conjunktivitis uden noget sikkert cornealt infiltrat, mindre corneal abrasio, corneal glødeskal uden mistanke om penetration, bygkorn, sorte fluer eller lysglimt (uden gardinfornemmelse eller tidligere amotio) kan man bede patienten om at søge praktiserende øjenlæge næste dag, hvis næste dag er en hverdag:</strong></p> <p style="margin-left:0cm; margin-right:0cm"><br> I flere tilfælde kan den initiale behandling påbegyndes efter undersøgelse af henvisende læge (f.eks. skadelæge i akutmodtagelsen).</p> <p style="margin-left:0cm; margin-right:0cm">Eksempler kan være behandling af keratitis (helst forudgået af podning), iritis, øjenlågstraumer, præseptal cellulitis og arteritis temporalis.<br> Kontrollen i akutteam gives til næste dag.<br> Visitering skal altid baseres på et lægefagligt skøn i det konkrete tilfælde.</p> <p style="margin-left:0cm; margin-right:0cm">Nedenstående liste er ikke nogen endegyldig liste men tiltænkt som en vejledende oversigt over diagnoser som i normale tilfælde kan visiteres til næste dag.</p> <ul> <li>Traume af øjenlåg</li> <li>Blow out fraktur (hvis visus og motilitet er i orden)</li> <li>Hyphæma</li> <li>Dacryocystit</li> <li>Dacryoadenit</li> <li>Præseptal cellulitis</li> <li>Diplopi hvor akutte forhold er udelukket ved CT-C angio eller med varighed &gt; 3 dage</li> <li>Opticusneuritis</li> <li>Arteritis temporalis (hvis relevant behandling kan opstartes akut af henvisende afd. efter blodprøvetagning for SR og CRP)</li> <li>Iritis, uveitis</li> <li>Toxoplasmose</li> <li>Corpussammenfald</li> <li>Retinal rift</li> <li>Corpusblødning</li> <li>Amotio retinae</li> <li>Keratitis uden truende perforation</li> <li>Glødeskal</li> <li>Abrasio corneae (hvis de skal ses i Afdeling for Øjensygdomme)</li> </ul> <p style="margin-left:0cm; margin-right:0cm">Hvis adenovirus mistænkes skal patienten helst ikke komme til Afdeling for Øjensygdomme med mindre der er tvivl om diagnosen. Opfølgende kontrol kan evt ske som en aftalt&nbsp;telefonkonsultation med patienten.&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong>Visitation til opfølgende besøg</strong></p> <p style="margin-left:0cm; margin-right:0cm">Vagtpatienter skal efter 1. besøg i vagten:</p> <ul> <li>Afsluttes til kontrol hos praktiserende øjenlæge, eller</li> <li>Kontrolleres i et af afdelingens teams primært Rigshospitalet - Glostrup eller&nbsp; Rigshospitalet - Blegdamsvej men Hillerød vil også kunne medinddrages, hvor dette skønnes hensigtsmæssigt, eller</li> <li>Kontrolleres i vagten men kun hvis 2. besøg allerede er nødvendigt næste hverdag efter 1. besøg (eller før)</li> <li>Når patienten skal have kontrol i et team bestilles en best/ord på ambulant opfølgning i et team</li> <li>Når patienten skal ses subakut anføres ’akutvisi’, team, ønsket tidsramme og patientens telefonnummer</li> <li>Alle teams og matrikler er ansvarlige for gennemgang af ’akut visi’-patienter</li> </ul> <p style="margin-left:0cm; margin-right:0cm"><strong>Akutte patienter med behov for fluoresceinangiografi</strong></p> <p style="margin-left:0cm; margin-right:0cm"><br> I dagtiden, mellem kl. 8.00 og 14.30:</p> <ul> <li>Vagthavende læge konfererer med bagvagten eller speciallæge fra medicinsk retina mhp. indikation for fluoresceinangiografi.</li> <li>Angiografien aftales med akut-foto-holdet på ØB1 (tlf 3-4061).</li> <li>Bagvagten konfererer fluoresceinangiografi og evt. behandlingsindikation med speciallæge i medicinsk retina.</li> <li>Er der indikation for anti-VEGF-injektion, oprettes forløb i BOB ved vagthavende. Hos alle patienter, der skal i anti-VEGF-behandling, skal der foreligge fotodokumentation som minimum OCT forud for behandling (AMD, retinale veneokklusioner og diabetisk makulaødem).</li> </ul> <p style="margin-left:0cm; margin-right:0cm">Uden for dagtiden, weekend - og helligdage:</p> <ul> <li>Findes der ved vagthavende læge indikation for akut fluoresceinangiografi mhp. diagnostik og udredning, bookes patienten førstkommende hverdag på bagvagtslisten mhp. dette</li> </ul> <p style="margin-left:0cm; margin-right:0cm"><strong>Akutte patienter med behov for kirurgisk intervention:</strong></p> <ul> <li>Patienten konfereres med kirurgisk overlægevagt (vagtlag 2) efter at være undersøgt af bagvagt. Det er som hovedregel bagvagten, der kontakter kirurgisk overlægevagt mhp. videre plan for patienten</li> <li>Før kl. 22 forberedes operation på Rigshospitalet - Glostrup</li> <li>Efter kl. 22 kan operation udføres på Rigshospitalet - Blegdamsvej</li> </ul> <p style="margin-left:0cm; margin-right:0cm"><strong>Dokumentation&nbsp;af telefonopkald til afdelingen for Øjensygdomme</strong></p> <p style="margin-left:0cm; margin-right:0cm">Telefonopkald til afdelingen for Øjensygdommes akkutteam skal dokumenteres i patientjournalen efter følgende retningslinjer:</p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Følgende situationer skal lede til journalføring af telefonopkaldet:</span></strong></p> <ul> <li>Direkte kontakt til borgere, der ikke har et forløb i afdelingen, sundhedspersonale fra plejehjem, hjemmesygeplejersker, værger, forældre m.fl</li> <li>Patienter, der aktuelt har et åbent forløb i afdelingen og derved er tilknyttet et team eller tidligere er set i vagten og afvente tid i team</li> </ul> <p style="margin-left:0cm; margin-right:0cm"><strong>Følgende situationer skal ikke umiddelbart lede til journalføring af telefonopkaldet:</strong></p> <ul> <li>Lægefagligt råd til anden hospitalsafdeling eller praktiserende læge</li> <li>Telefonopkald 1813</li> </ul> <p style="margin-left:0cm; margin-right:0cm"><strong>Dokumentation i journalen ved telefonisk kontakt ( som ikke leder til besøg) skal skrives som følgende:</strong></p> <ul> <li>Kort anamnese</li> <li>Hvilke tiltag der er igangsat</li> <li>Hvad der skal lede til ny kontakt til sundhedspersonale</li> <li>Ønsket opfølgning</li> </ul> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong>Fremgangsmåde:</strong></p> <ul> <li>&nbsp;</li> <li>Hvis patienten ikke skulle have fysisk fremmøde, men blot ringer med spørgsmål sv.t. en konsultation, visiteres til at skulle ses af privatprakiserende øjenlæge næstkommende hverdag eller anden visitation, laves en telefonkonsultation i SP ( se nedenfor)</li> <li>Telefonkonsultationen registreres på en telefonkonsultationsseddel som påføres navn og cpr. nummer samt anamnese, behandling og ønsket opfølgning. Denne seddel lægges i dueslag med angivelsen " Telefonkonsultation" som dagen efter journalføres af akutvagtens sekretær</li> </ul> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699578970288Ansvar"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Ansvar og organisering</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm">Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger.<br> Afsnitsledelsen er ansvarlige for at instruksen udarbejdes, revideres og implementeres.<br> Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen.</p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699578970288Referencer"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Referencer, lovgivning og faglig evidens samt links hertil</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699578970288Bilag"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Bilag</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p>

Rigshospitalet_¥jensygdomme (HOC)_Visus bestemmelse Afdeling for ¥jensygdomme Rigshospitalet.

Visus bestemmelse, Afdeling for Øjensygdomme, Rigshospitalet Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Målgrupper og anvendelsesområde Angiver retningslinjer for visus bestemmelse i Afdeling for Øjensygdomme, Rigshospitalet. Instruksen er gældende for læger, optikere, sygeplejersker og social- og sundhedsassistenter. Der er særlige retningslinjer hvis der indgår forksningsprotokoller. Definitioner Visus (Synsstyrke) Udtrykker nethindens centrale funktion når et fjernt objekt (f.eks et bogstav) afbildes skarpt i den gule plet (macula lutea). Ved lang- og nærsynethed dannes det skarpe billede henholdsvis bagved og foran nethinden. Visus bestemmelsen skal derfor foretages med bedst mulig brille. Det er vigtigt at understrege at visus og refraktion er to principielt forskellige ting. Man kan godt have normal refraktion, men betydelig nedsat visus f.eks ved sygdomme i macula. Refraktion kan bestemmes objektivt (se instruksen om Refraktions bestemmelse, Afdeling for Øjensygdomme, Rigshospitalet, hvorimod visus bestemmelse kræver patientens subjektive medvirken. Visus måles som den mindste synsvinkel hvorunder et symbol (bogstav, tal, billede m.v) kan identificeres. Jo mindre vinkel jo bedre visus (fig 1) Afstand til tavlen En given symbolstørrelse skal ses i en given afstand for korrekt at udtrykke synsvinklen. De elektroniske synstavler kan under menupunktet distance indstilles til afstanden mellem tavle og patient. Ved spejltavle adderes afstanden mellem tavle og spejl og spejl og patient På de faste tavler er den korrekte afstand mellem patient og tavle angivet. Skala For meningsfyldt at kunne tale om tabte eller vundne linjer eller bogstaver på synstavlen skal symbolstørrelsen fra en linje til den næste ændres med en logaritmisk faktor i praksis med ca. 25 %. De elektroniske synstavler kan under menupunktet ”scale” indstilles til log. Andre traditionelle tavler kan godt anvendes og hvis man skeler til tabellen nævnt under notation kan den omtrentlige korrekte værdi angives. Notation Den traditionelle Snellen notation udtrykker forholdet mellem hvad patienten kan se på 6 m’s afstand og hvilken afstand en normal kan se den samme synbolstørrelse (fig 2). Normal linjen er 6/6=1,00. Kan patienten se 6/12=0,50 betyder det, at det patienten skal have ind på 6 m´s afstand kan den normale se allerede på 12 m’s afstand og tilsvarende for 6/60=0,10 kan den normale se symbolet allerede på 60 m´s afstand. Tabellen viser sammenhængen mellem de forskellige måder at udtrykke synsstyrken på. De grønne kolonner anvendes almindeligvis. Den blå række angiver normal værdien. Rækkerne over angiver en synsstyrke bedre end normalt og rækkerne under angiver en synsstyrke dårligere end normalt. De gule linjer angiver en halvering eller fordobling af synsvinklen. Ved en synsvinkel på 1 enhed (5 bueminutter) er log = 0, decimalværdi = 1,00, Snellen 6/6 og patienten kan læse 85 EDTRS bogstaver. Tilsvarende ved en synsvinkel på 4 enheder er log = 0.6, decimal = 0,25, Snellen = 6/24 og patienten kan læse 55 EDTRS bogstaver. Ved synsstyrker mindre end 6/60 kan man også graduere til 5/60, 4/60, 3/60, 2/60, 1/60 ved at flytte en løs traditionel tavle tættere på patienten. Er tavlen < end 1 m fra patienten gradueres synsstyrken som Fingertælling (FT), Håndbevægelser (HB), Lyssans + projektion (L+P), Lyssans (L) og minus lyssans (-L). Fremgangsmåde Praktisk udførelse Afhængig af den kliniske situation bestemmes synsstyrken på hvert øje for sig uden og med bedste brille. For at kontrollere om synsstyrken er optimal bestemt anføres synsstyrken evt. med stenopæisk hul (SH). Som bedste brille anvendes enten patientens egen brille eller hvis den er irrelevant autorefraktor værdi. - Man starter med de største symboler som det forventes at patienten kan se. - Derefter læses et symbol i linjen op eller ned afhængig af om symbolet kan ses. - Når linjen nås hvor et symbol ikke kan ses går man en linje op og beder patienten læse hele linjen. - Kan mere end halvdelen af linjens symboler læses går man en linje længere ned. - Den mindste linje hvor mindst halvdelen af symbolerne kan læses angiver synstyrken Eksempel: VOD: 0,25 (6/24) sc, 0,50 (6/12) ec = -1,5sfæ -0,75cyl i 90 grader, ingen bedring med SH VOS: 0,10 (6/60) sc, 0,25 (6/24) cc = -1,5sfæ, bedring til 0,32 (6/19) med SH. Visus bin: 0,25 (6/24) sc, 0,50 (6/12) cc (sc = uden brille, ec = egen brille, cc = med bestemt brille (autorefraktor), bin= begge øjne samtidig). ETDRS (early treatment diabetic retinopathy study). Denne tavle er særlig velegnet til at måle patienter med betydelig nedsat visus og bruges i AMD klinikken. Tavlen har 5 bogstaver i hver linie og anvendes i 4 M’s afstand. EDTRS tavlen har kun 14 linjer svarende til 70 bogstaver. Den øverste linje svarer til 0,1=6/60 =35 bogstaver. For at graduere synstyrker under 0,1=6/60=35 bogstaver flyttes tavlen ind i 1 m hvorefter de første 30 bogstaver kan bestemmes (tabel 2) EDTRS tavlen findes også i de elektroniske tavler og anvendes her med patienten i 4 m’s afstand. Ved de store bogstaver kan der kun ses et af gangen, men man skal i hver linje præsenterer 5 symboler. Antal læste bogstaver står på tavlen (fig 3). Ansvar og organisering Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger. Afsnitsledende overlæger, afdelingssygeplejersker og ledende lægesekretærer, er ansvarlige for at instruksen udarbejdes, revideres og implementeres. Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen. Referencer, lovgivning og faglig evidens samt links hertil Refraktions bestemmelse, Afdeling for Øjensygdomme, Rigshospitalet - instruks fra Afdeling for Øjensygdomme, Rigshospitalet Akkrediteringsstandarder Bilag

<h1><div id="Afsnit#1699578903591">Visus bestemmelse, Afdeling for Øjensygdomme, Rigshospitalet</div></h1><div id="BodyWeb#1699578903591"><p><a name="1699578903591Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578903591Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578903591Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578903591Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578903591Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578903591Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578903591Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578903591Bilag">Bilag</a><br> &nbsp;</h3> <h2><a name="1699578903591Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p>Angiver retningslinjer for visus bestemmelse i Afdeling for Øjensygdomme, Rigshospitalet.</p> <p>Instruksen er gældende for læger, optikere, sygeplejersker og social- og sundhedsassistenter.</p> <p>Der er særlige retningslinjer hvis der indgår forksningsprotokoller.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578903591Top">Tilbage til top</a></p> <h2><a name="1699578903591Definitioner"></a><br> Definitioner</h2> <p><strong>Visus (Synsstyrke)</strong></p> <p style="margin-left:40px">Udtrykker nethindens centrale funktion når et fjernt objekt (f.eks et bogstav) afbildes skarpt i den gule plet (macula lutea). Ved lang- og nærsynethed dannes det skarpe billede henholdsvis bagved og foran nethinden. Visus bestemmelsen skal derfor foretages med bedst mulig brille.</p> <p style="margin-left:40px">Det er vigtigt at understrege at visus og refraktion er to principielt forskellige ting. Man kan godt have normal refraktion, men betydelig nedsat visus f.eks ved sygdomme i macula. Refraktion kan bestemmes objektivt (se instruksen om <a href="###FOLDER###" target="_blank">Refraktions bestemmelse, Afdeling for Øjensygdomme, Rigshospitalet</a>,&nbsp;hvorimod visus bestemmelse kræver patientens subjektive medvirken.</p> <p style="margin-left:40px">Visus måles som den mindste synsvinkel hvorunder et symbol (bogstav, tal, billede m.v) kan identificeres. Jo mindre vinkel jo bedre visus (fig 1)</p> <p style="margin-left:40px"><img alt="" src="/VIP/Redaktoer/1301G3.nsf/vLookupUpload/ATTACH-RHAP-A5WJRR/$FILE/Visus, fig. 1.jpg" style="height:257px; width:292px" onclick="Ext.DMS.util.showImage(this);"></p> <p><strong>Afstand til tavlen</strong></p> <p style="margin-left:40px">En given symbolstørrelse skal ses i en given afstand for korrekt at udtrykke synsvinklen.</p> <p style="margin-left:40px">De elektroniske synstavler kan under menupunktet distance indstilles til afstanden mellem tavle og patient.&nbsp; Ved spejltavle adderes afstanden mellem tavle og spejl og spejl og patient</p> <p style="margin-left:40px">På de faste tavler er den korrekte afstand mellem patient og tavle angivet.</p> <p><strong>Skala</strong></p> <p style="margin-left:40px">For meningsfyldt at kunne tale om tabte eller vundne linjer eller bogstaver på synstavlen skal symbolstørrelsen fra en linje til den næste ændres med en logaritmisk faktor i praksis med ca. 25 %.</p> <p style="margin-left:40px">De elektroniske synstavler kan under menupunktet ”scale” indstilles til log.</p> <p style="margin-left:40px">Andre traditionelle tavler kan godt anvendes og hvis man skeler til tabellen nævnt under notation kan den omtrentlige korrekte værdi angives.</p> <p><strong>Notation</strong></p> <p style="margin-left:40px">Den traditionelle Snellen notation udtrykker forholdet mellem hvad patienten kan se på 6 m’s afstand og hvilken afstand en normal kan se den samme synbolstørrelse (fig 2).</p> <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; <img alt="" src="/VIP/Redaktoer/1301G3.nsf/vLookupUpload/ATTACH-RHAP-A5WJYT/$FILE/Visus, fig. 2.jpg" style="height:313px; width:302px" onclick="Ext.DMS.util.showImage(this);"></p> <p>&nbsp;&nbsp;&nbsp;&nbsp; <strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p> <p style="margin-left:40px">Normal linjen er 6/6=1,00. Kan patienten se 6/12=0,50 betyder det, at det patienten skal have ind på 6 m´s afstand kan den normale se allerede på 12 m’s afstand og tilsvarende for 6/60=0,10 kan den normale se symbolet allerede på 60 m´s afstand.</p> <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <img alt="" src="/VIP/Redaktoer/1301G3.nsf/vLookupUpload/ATTACH-RHAP-A5YGDR/$FILE/Visus, tabel 1.jpg" style="height:537px; width:456px" onclick="Ext.DMS.util.showImage(this);"></p> <p>&nbsp;</p> <p style="margin-left:40px">Tabellen viser sammenhængen mellem de forskellige måder at udtrykke synsstyrken på. De grønne kolonner anvendes almindeligvis. Den blå række angiver normal værdien.&nbsp; Rækkerne over angiver en synsstyrke bedre end normalt og rækkerne under angiver en synsstyrke dårligere end normalt.&nbsp; De gule linjer angiver en halvering eller fordobling af synsvinklen.</p> <p style="margin-left:40px">Ved en synsvinkel på 1 enhed (5 bueminutter) er log = 0, decimalværdi = 1,00, Snellen 6/6 og patienten kan læse 85 EDTRS bogstaver. Tilsvarende ved en synsvinkel på 4 enheder er log = 0.6, decimal = 0,25, Snellen = 6/24 og patienten kan læse 55 EDTRS bogstaver.</p> <p style="margin-left:40px">Ved synsstyrker mindre end 6/60 kan man også graduere til 5/60, 4/60, 3/60, 2/60, 1/60 ved at flytte en løs traditionel tavle tættere på patienten. Er tavlen &lt; end 1 m fra patienten&nbsp; gradueres synsstyrken som Fingertælling (FT), Håndbevægelser (HB), Lyssans + projektion (L+P), Lyssans (L) og minus lyssans (-L).</p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578903591Top">Tilbage til top</a></p> <h2><a name="1699578903591Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p><strong>Praktisk udførelse</strong></p> <p style="margin-left:40px">Afhængig af den kliniske situation bestemmes synsstyrken på hvert øje for sig uden og med bedste brille. For at kontrollere om synsstyrken er optimal bestemt anføres synsstyrken evt. med stenopæisk hul (SH).</p> <p style="margin-left:40px">&nbsp;</p> <p style="margin-left:40px">Som bedste brille anvendes enten patientens egen brille eller hvis den er irrelevant autorefraktor værdi.</p> <ul> <li>Man starter med de største symboler som det forventes at patienten kan se.</li> <li>Derefter læses et symbol i linjen op eller ned afhængig af om symbolet kan ses.</li> <li>Når linjen nås hvor et symbol ikke kan ses går man en linje op og beder patienten læse hele linjen.</li> <li>Kan mere end halvdelen af linjens symboler læses går man en linje længere ned.</li> <li>Den mindste linje hvor mindst halvdelen af symbolerne kan læses angiver synstyrken</li> </ul> <p style="margin-left:40px">Eksempel:</p> <p style="margin-left:80px">VOD: 0,25 (6/24) sc, 0,50 (6/12) ec&nbsp; = -1,5sfæ &nbsp;-0,75cyl i 90 grader, ingen bedring med SH<br> VOS: 0,10 (6/60) sc, 0,25 (6/24) cc = -1,5sfæ, bedring til 0,32 (6/19) med SH.<br> Visus bin: 0,25 (6/24) sc, 0,50 (6/12) cc</p> <p style="margin-left:80px">(sc = uden brille, ec = egen brille, cc = med bestemt brille (autorefraktor), bin= begge øjne samtidig).</p> <p>&nbsp;</p> <p><strong>ETDRS (</strong>early treatment diabetic retinopathy study).</p> <p style="margin-left:40px">Denne tavle er særlig velegnet til at måle patienter med betydelig nedsat visus og bruges i AMD klinikken. Tavlen har 5 bogstaver i hver linie og anvendes i 4 M’s afstand.</p> <p style="margin-left:40px">EDTRS tavlen har kun 14 linjer svarende til 70 bogstaver. Den øverste linje svarer til 0,1=6/60 =35 bogstaver. For at graduere synstyrker under 0,1=6/60=35 bogstaver flyttes tavlen ind i 1 m hvorefter de første 30 bogstaver kan bestemmes (tabel 2)</p> <p style="margin-left:40px">&nbsp;&nbsp;&nbsp; <img alt="" src="/VIP/Redaktoer/1301G3.nsf/vLookupUpload/ATTACH-RHAP-A5YGD7/$FILE/Visus, tabel 2.jpg" style="height:244px; width:445px" onclick="Ext.DMS.util.showImage(this);"></p> <p style="margin-left:40px">EDTRS tavlen findes også i de elektroniske tavler og anvendes her med patienten i 4 m’s afstand. Ved de store bogstaver kan der kun ses et af gangen, men man skal i hver linje præsenterer 5 symboler. Antal læste bogstaver står på tavlen (fig 3).<br> &nbsp;</p> <p style="margin-left:40px"><img alt="" src="/VIP/Redaktoer/1301G3.nsf/vLookupUpload/ATTACH-RHAP-A5WK3T/$FILE/Visus, fig. 3.jpg" style="height:482px; width:707px" onclick="Ext.DMS.util.showImage(this);"></p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578903591Top">Tilbage til top</a></p> <h2><a name="1699578903591Ansvar"></a><br> Ansvar og organisering</h2> <p style="margin-left:0cm; margin-right:0cm">Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger.<br> Afsnitsledende overlæger, afdelingssygeplejersker og ledende lægesekretærer, er ansvarlige for at instruksen udarbejdes, revideres og implementeres.<br> Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen.</p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578903591Top">Tilbage til top</a></p> <h2><a name="1699578903591Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p><a href="###FOLDER###" target="_blank">Refraktions bestemmelse, Afdeling for Øjensygdomme, Rigshospitalet</a>&nbsp;- instruks fra Afdeling for Øjensygdomme, Rigshospitalet</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578903591Top">Tilbage til top</a></p> <h2><a name="1699578903591Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578903591Top">Tilbage til top</a></p> <h2><a name="1699578903591Bilag"></a><br> Bilag</h2> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578903591Top">Tilbage til top</a></p>

Rigshospitalet_¥jensygdomme (HOC)_YAG - laser membranectomi. Katarakt team.

YAG - laser membranectomi. Katarakt team Målgrupper og anvendelsesområde Angiver retningslinjer for forløb ved YAG-laser membranektomi. Gældende for personalet i Grå Stær Teamet, Afdeling for Øjensygdomme, Rigshospitalet. Definitioner Fremgangsmåde Patienten på gangen: - Læs henvisning og før den til sidepanel - Opret notat via oftalmologi faneblad – vælg AOP-notat og herunder YAG-notat - Overfør henvisende øjenlæges visus eller fra internt øjennotat (gælder < 3 mdr) - Diagnose: Tilføj ”efterstær” DH264 og gør denne primær (udfyldt rombe) - MiBa: Tjek for evt. MRSA - Dilatér henviste øje/øjne med Tropicamid 1% (spørg forinden til allergier - obs. anvend ikke Diamox ved allergi for sulfonamider) Patienten på klinikken: - Konfirmér CPR med patient - Oftalmologi fanebladet - Objektiv Øjenus - Ved manglende visus, måles det jf. instruks - Tension er ikke relevant at måle - - - Spaltelampe: afkryds som hovedregel ”bagkammer IOL” og notér graden af efterstær - IOL disloceret? I så fald konf. med senior kirurg - Multifokal IOL? I så fald konf. med senior kirurg - Kapsulophimosis? I så fald konf. med senior kirurg - Grad af efterstær: er det relevant at fjerne. - Risikoprofil - Irit-patienter: skal såfremt muligt være i rolig fase i 3 mdr - Information inden behandling: - Informeres om kontrol hos eøl såfremt nedsat visus opstår (CME) efter nogle uger med klart visus - Postoperativ medicin: - Alle glaukompatienter: - T. Diamox 250 mg som engangsdosis (obs. cave sulfonomider) - - Tidligere irit-patienter: - Ocgt maxidex x 6 i 1 uge – kontakt egen øjenlæge ved gener - - Retineret viskoelastikum bag IOL (ses som væske der siver bagud ved laserbeh.) - Ocgt maxidex x 6 i 1 uge – kontakt egen øjenlæge ved gener - Øvrige patienter: - Hverken tryksænkende eller anti-inflammatorisk medicin Ansvar og organisering Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger. Afsnitsledende overlæger, afdelingssygeplejersker og ledende lægesekretærer, er ansvarlige for at instruksen udarbejdes, revideres og implementeres. Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen. Referencer, lovgivning og faglig evidens samt links hertil Fra Afdeling for Øjensygdomme, Rigshospitalet Visus bestemmelse, Afdeling for Øjensygdomme, Rigshospitalet, instruks på VIP Bilag

<h1><div id="Afsnit#1699579047644">YAG - laser membranectomi. Katarakt team</div></h1><div id="BodyWeb#1699579047644"><p>&nbsp;</p> <div class="collapsible-item" expandedstart="1"><a name="1699579047644Maalgrupper"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Målgrupper og anvendelsesområde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm">Angiver retningslinjer for forløb ved YAG-laser membranektomi.</p> <p style="margin-left:0cm; margin-right:0cm">Gældende for personalet i Grå Stær Teamet, Afdeling for Øjensygdomme, Rigshospitalet.</p> <p>&nbsp;</p> </div> </div> <div class="collapsible-item"><a name="1699579047644Definitioner"></a> <div class="collapsible-item-title"> <h2>Definitioner</h2> </div> <div class="collapsible-item-body" style="display: none;"> <p>&nbsp;</p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579047644Fremgangsmaade"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Fremgangsmåde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm"><u>Patienten på gangen:</u></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <ol> <li>Læs <strong>henvisning</strong> og før den til sidepanel</li> </ol> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <ol start="2"> <li>Opret <strong>notat</strong> via oftalmologi faneblad – vælg AOP-notat og herunder YAG-notat <ol style="list-style-type:lower-alpha"> <li>Overfør henvisende øjenlæges visus eller fra internt øjennotat (gælder &lt; 3 mdr)</li> </ol> </li> </ol> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <ol start="3"> <li><strong>Diagnose:</strong> Tilføj ”efterstær” DH264 og gør denne primær (udfyldt rombe)</li> </ol> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <ol start="4"> <li><strong>MiBa: </strong>Tjek for evt. MRSA</li> </ol> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <ol start="5"> <li><strong>Dilatér</strong> henviste øje/øjne med Tropicamid 1% (spørg forinden til allergier - obs. anvend ikke Diamox ved allergi for sulfonamider)</li> </ol> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><u>Patienten på klinikken:</u></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <ol start="6"> <li>Konfirmér <strong>CPR</strong> med patient</li> </ol> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <ol start="7"> <li><strong>Oftalmologi fanebladet</strong> <ol style="list-style-type:lower-alpha"> <li><strong>Objektiv Øjenus</strong> <ol style="list-style-type:lower-roman"> <li>Ved manglende visus, måles det jf. instruks</li> <li>Tension er ikke relevant at måle</li> </ol> </li> </ol> </li> </ol> <ol> <li style="list-style-type:none"> <ol> <li style="list-style-type:none"> <ol style="list-style-type:lower-roman"> <li>Spaltelampe: afkryds som hovedregel ”bagkammer IOL” og notér graden af efterstær <ol> <li>IOL disloceret? I så fald konf. med senior kirurg</li> <li>Multifokal IOL? I så fald konf. med senior kirurg</li> <li>Kapsulophimosis? I så fald konf. med senior kirurg</li> <li>Grad af efterstær: er det relevant at fjerne.</li> </ol> </li> </ol> </li> </ol> </li> </ol> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <ol start="2"> <li><strong>Risikoprofil</strong> <ol style="list-style-type:lower-alpha"> <li>Irit-patienter: skal såfremt muligt være i rolig fase i 3 mdr</li> </ol> </li> </ol> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <ol start="8"> <li><strong>Information inden behandling: </strong> <ol start="2" style="list-style-type:lower-alpha"> <li>Informeres om kontrol hos eøl såfremt nedsat visus opstår (CME) efter nogle uger med klart visus</li> </ol> </li> </ol> <p style="margin-left:36pt; margin-right:0cm">&nbsp;</p> <ol start="9"> <li><strong>Postoperativ medicin:</strong></li> </ol> <ol style="list-style-type:lower-alpha"> <li>Alle glaukompatienter: <ul> <li style="list-style-type:none"> <ul style="list-style-type:disc"> <li>T. Diamox 250 mg som engangsdosis (obs. cave sulfonomider)</li> </ul> </li> </ul> </li> </ol> <p style="margin-left:36pt; margin-right:0cm">&nbsp;</p> <ol> <li style="list-style-type:none"> <ol start="2" style="list-style-type:lower-alpha"> <li>Tidligere irit-patienter: <ul style="list-style-type:disc"> <li>Ocgt maxidex x 6 i 1 uge – kontakt egen øjenlæge ved gener</li> </ul> </li> </ol> </li> </ol> <p style="margin-left:36pt; margin-right:0cm">&nbsp;</p> <ol> <li style="list-style-type:none"> <ol start="3" style="list-style-type:lower-alpha"> <li>Retineret viskoelastikum bag IOL (ses som væske der siver bagud ved laserbeh.) <ul style="list-style-type:disc"> <li>Ocgt maxidex x 6 i 1 uge – kontakt egen øjenlæge ved gener</li> </ul> </li> </ol> </li> </ol> <p style="margin-left:36pt; margin-right:0cm">&nbsp;</p> <ol start="2" style="list-style-type:lower-alpha"> <li>Øvrige patienter: <ul> <li style="list-style-type:none"> <ul style="list-style-type:disc"> <li>Hverken tryksænkende eller anti-inflammatorisk medicin</li> </ul> </li> </ul> </li> </ol> <p>&nbsp;</p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579047644Ansvar"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Ansvar og organisering</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm">Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger.<br> Afsnitsledende overlæger, afdelingssygeplejersker og ledende lægesekretærer, er ansvarlige for at instruksen udarbejdes, revideres og implementeres.<br> Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen.</p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579047644Referencer"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Referencer, lovgivning og faglig evidens samt links hertil</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm">Fra Afdeling for Øjensygdomme, Rigshospitalet</p> <p style="margin-left:40px; margin-right:0cm"><a href="###FOLDER###" style="color:blue; text-decoration:underline" target="_blank">Visus bestemmelse, Afdeling for Øjensygdomme, Rigshospitalet</a>, instruks på VIP</p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579047644Bilag"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Bilag</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p>

Rigshospitalet_¥jensygdomme (HOC)_YAG iridotomi. Glaukom team.

YAG iridotomi. Glaukom team Målgrupper og anvendelsesområde Beskriver forløbet ved YAG laser iridotomi i Øjenklinikken. Gældende for glaukom team i HovedOrtoCentret-Øjenklinikken, Rigshospitalet-Glostrup. Definitioner Fremgangsmåde Procedurekode - CHC05 Præoperativt - 30 minutter inden - 1 dråbe Pilokarpin 2 % eller 4 % (pupilkontraherende) - 1 dråbe Maxidex - 1 dråbe Iopidine (reducerer risiko for blødning og post-laser trykstigning) Analgesi - Dråbeanæstesi med 0,4% oxybuprokain Om behandlingen - Iridotomi udføres sjældent i den akutte fase, men kan overvejes ved pupilblok hos yngre patient med klare medier. - Der anvendes en Abraham eller Wise iridotomilinse - Laser indstillinger justeres efter irisfarve. Brune irides kræver mere energi. - Startenergi 1-6 mJ. - Spotstørrelse 50 µm - Spots pr. burst 1-3. - Iridotomi skal være 0,2 – 0,5 mm stor og udføres i iris periferien, sædvanligvis opadtil, hvor øjenlåg dækker. - Prøv at undgå at behandle et iriskar. Såfremt der opstår blødning fra et iriskar: lad være at afbryde behandlingen! Såfremt der er behov for yderligere skud vil man ofte kunne nå at afsætte disse inden det bløder for meget. Hold kontaktglasset på og pres let for at komprimere til blødningen aftager. Efterbehandling - Timedryp med Maxidex det første døgn, herefter x 4 i 7 dage. - Eventuel tablet 250 mg Diamox ved fremskredent glaukom for at undgå tryktoppe. - NB! Husk at seponere pilokarpin efter iridotomien, idet der ellers kan opstå bagre synekkier til lens. Kontrol i ambulatoriet - Kontrol gonioskopi + trykmåling 1 uge senere. Smartphrase: - ØKGLAUYAGIRIDOTOMI Ansvar og organisering Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger. Afsnitsledelsen er ansvarlige for at instruksen udarbejdes, revideres og implementeres. Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen. Referencer, lovgivning og faglig evidens samt links hertil Bilag

<h1><div id="Afsnit#1699579021067">YAG iridotomi. Glaukom team</div></h1><div id="BodyWeb#1699579021067"><p>&nbsp;</p> <div class="collapsible-item" expandedstart="1"><a name="1699579021067Maalgrupper"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Målgrupper og anvendelsesområde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm">Beskriver forløbet ved YAG laser iridotomi i Øjenklinikken.</p> <p style="margin-left:0cm; margin-right:0cm">Gældende for&nbsp;glaukom team i HovedOrtoCentret-Øjenklinikken, Rigshospitalet-Glostrup.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579021067Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item"><a name="1699579021067Definitioner"></a> <div class="collapsible-item-title"> <h2>Definitioner</h2> </div> <div class="collapsible-item-body" style="display: none;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579021067Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579021067Fremgangsmaade"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Fremgangsmåde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm"><strong>Procedurekode</strong></p> <ul> <li>CHC05</li> </ul> <p style="margin-left:0cm; margin-right:0cm"><strong>Præoperativt - 30 minutter inden</strong></p> <ul> <li>1 dråbe Pilokarpin 2 % eller 4 % (pupilkontraherende)</li> <li>1 dråbe Maxidex</li> <li>1 dråbe Iopidine (reducerer risiko for blødning og post-laser trykstigning)</li> </ul> <p style="margin-left:0cm; margin-right:0cm"><strong>Analgesi</strong></p> <ul> <li>Dråbeanæstesi med 0,4% oxybuprokain</li> </ul> <p style="margin-left:0cm; margin-right:0cm"><strong>Om behandlingen</strong></p> <ul> <li><em>Iridotomi udføres sjældent i den akutte fase, men kan overvejes ved pupilblok hos yngre patient med klare medier. </em></li> <li>Der anvendes en Abraham eller Wise iridotomilinse</li> <li>Laser indstillinger justeres efter irisfarve. Brune irides kræver mere energi. <ul style="list-style-type:circle"> <li>Startenergi 1-6 mJ.</li> <li>Spotstørrelse 50 µm</li> <li>Spots pr. burst 1-3.</li> </ul> </li> <li>Iridotomi skal være 0,2 – 0,5 mm stor og udføres i iris periferien, sædvanligvis opadtil, <em>hvor øjenlåg dækker.</em></li> <li><em>Prøv at undgå at behandle et iriskar. Såfremt der opstår blødning fra et iriskar: lad være at afbryde behandlingen! Såfremt der er behov for yderligere skud vil man ofte kunne nå at afsætte disse inden det bløder for meget. Hold kontaktglasset på og pres let for at komprimere til blødningen aftager.</em></li> </ul> <p style="margin-left:0cm; margin-right:0cm"><strong>Efterbehandling</strong></p> <ul> <li>Timedryp med Maxidex det første døgn, herefter x 4 i 7 dage.</li> <li>Eventuel tablet 250 mg Diamox ved fremskredent glaukom for at undgå tryktoppe.</li> <li><strong>NB! </strong>Husk at seponere pilokarpin efter iridotomien, idet der ellers kan opstå bagre synekkier til lens.</li> </ul> <p style="margin-left:0cm; margin-right:0cm"><strong>Kontrol i ambulatoriet</strong></p> <ul> <li>Kontrol gonioskopi + trykmåling 1 uge senere.</li> </ul> <p style="margin-left:0cm; margin-right:0cm"><strong>Smartphrase:</strong></p> <ul> <li>ØKGLAUYAGIRIDOTOMI</li> </ul> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579021067Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579021067Ansvar"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Ansvar og organisering</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm">Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger.</p> <p style="margin-left:0cm; margin-right:0cm">Afsnitsledelsen er ansvarlige for at instruksen udarbejdes, revideres og implementeres.</p> <p style="margin-left:0cm; margin-right:0cm">Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579021067Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item"><a name="1699579021067Referencer"></a> <div class="collapsible-item-title"> <h2>Referencer, lovgivning og faglig evidens samt links hertil</h2> </div> <div class="collapsible-item-body" style="display: none;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579021067Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item"><a name="1699579021067Bilag"></a> <div class="collapsible-item-title"> <h2>Bilag</h2> </div> <div class="collapsible-item-body" style="display: none;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579021067Top">Tilbage til top</a></p>

Rigshospitalet_¥jensygdomme (HOC)_Ætsningsskader og kemiske ¢jenlæsioner Akut team.

Ætsningsskader og kemiske øjenlæsioner, Akut team Målgrupper og anvendelsesområde Angiver retningslinjer for behandling af ætsningsskader og kemiske øjenlæsioner. I akut fasen, herunder telefonisk rådgivning til patienter og pårørende. Behandling i skadestuen samt retningslinjer for overflytning til og behandling i Klinik for akutte Øjensygdomme, Afdeling for Øjensygdomme, Rigshospitalet Glostrup. I post akut fasen, herunder tilpasning af behandling i forhold til skadens grad (1 - 5), basale betragtninger, klinisk forløb og vurdering, ophelingsforløb og pharmakopia minor. Formål: At angive retningslinjer for undersøgelse og behandling af ætsningsskader og kemiske øjenlæsioner. - Akut fasen - Post – akut behandling i Øjenafdelingen - Basale betragtninger - Klinisk forløb og vurdering - Ophelingsforløb - Pharmakopia minor Definitioner Skade forårsaget af syre eller base. Evt. termisk skadekomponent. Kemiske stoffer: Baser (ammoniak (NH3), kaustisk soda (NaOH), læsket kalk penetrerer generelt meget hurtigt væv og kan udrette størst skade. Ætsning efter fyrværkeriskader skyldes ofte kombination af termisk skade og magnesiumhydroxyd (Mg(OH2). Ætsning med Flussyre (HF) er at betragte som svær baseætsning. Svovlsyre (H2SO4) findes i batterier og kan give svære skader efter batteri-eksplosioner (lokal varmeudvikling). OBS alle ætsningsskader > grad 2 skal konfereres med en bagvagt (Ammoniak skader SKAL kontrolleres på øjenafdeling) Fremgangsmåde 1. AKUT – FASEN Patienten/pårørende ringer og anmoder om råd Information: - Øjet skal skylles med rigelige mængder vand. Selv urent vand kan i ekstreme nødstilfælde benyttes. - Nærmeste åbne skadestue skal opsøges akut, og der skal skylles undervejs (ambulance, privatbil). - Skylningen bør oftest fortsætte i op til flere timer. Ved ankomst til skadestuen - Patienten skal behandles straks ved ankomst. - Kontakt til vagthavende øjenlæge med henblik på videre visitation. - Telefon til vagthavende øjenlæge, Afdeling for Øjensygdomme, Rigshospitalet Glostrup. - Hverdage, klokken 8.00 – 15.00, tlf. ###TELEFON### - Udenfor dette tidsrum, tlf. ###TELEFON### Klinik for Akutte Øjensygdomme, spørg efter vagthavende øjenlæge - Vigtigst er skylning med rigelige mængder neutralopløsning (oftest isotonisk saltvand). - Skyl mindst 1 time, dog oftest flere timer indtil neutral pH (se nedenfor). - Fjernelse af fremmedlegemer i lokalbedøvelse (Oxybuprocain 0,8 %) med vatpind. - Vending af øjenlåg - Anvend lokalbedøvelse (Oxybuprocain) og evt. øjenlågs-spekulum. - Kontrol af pH med lakmuspapir: Ved neutralt pH målt 20 minutter efter endt skylning kan patienten overføres til øjenafdelingen, Rigshospitalet Glostrup, efter aftale med vagthavende øjenlæge. - Når en patient med behov for øjenskylning er i akutklinikken på Rigshospitalet Glostrup efter lukketid kl. 22, skal Klinikken for Akutte Øjensygdomme kontaktes. Er der tid og ressourcer i øjenlægevagten overtages skylning af øjet indtil pH neutral. Det vil være en individuel vurdering på dagen. Konkret aftale om hvordan overtagelsen af patienten skal forløbe, må ske på dagen mellem øjenlæge-bagvagt og læge i akutklinikken. Overførsel til Øjenafdelingen, Rigshospitalet Glostrup - Patienten kan overføres til øjenafdelingen efter aftale med vagthavende øjenlæge, når pH er neutral Ved ankomst til Øjenafdelingen, Rigshospitalet Glostrup - Sikre at der fortsat skylles, hvis pH ikke er neutral (7). Hvis patienten først ses af sygeplejerske, skal denne fortsætte skylning med isotonisk saltvand. - Fjernelse af fremmedlegemer i lokalbedøvelse med vatpind. - Vending af øjenlåg, anvend evt. øjenlågs spekulum - Kontroller pH med lakmuspapir. Ved neutralt pH målt 20 minutter efter sidste skylning kan skylning seponeres. - Vurder skadens omfang i henhold til modificeret Roper-Hall klassifikation Roper-Hall klassifikation ###TABEL_1### * Ved epithelskade i konjunktiva svarende til limbus klassificeres dette som limbal iskæmi. NB! Vær opmærksom på intraokulær reaktion (IOR). Ved IOR bør patienten rykkes et trin op i graduering og behandlingsniveau. 2. POST – AKUT BEHANDLING I ØJENAFDELINGEN VED ÆTSNING Nedenstående post-akutte behandling efter initial skylning tilpasses efter skadens grad og karakter, og kan kun til en hvis grad standardiseres. Behandlingen kan være vanskelig og langvarig, og kræver medvirken af erfaren kollega. Ved tvivlsspørgsmål konfereres med overlæge. Behandlingen tilpasses efter skadens grad (Roper-Hall klassifikation): Mild ætseskade (uden for klassifikation) Konjunktiva bevaret. Ingen corneal epithel skade. Cornea klar. Ingen limbal iskæmi eller IOR. - Behandling - Lokalt antibiotikum/kortikosteroid + evt. blinkhindrende klap. Fx: Spersadex x 4 eller Hydrokortison med Terramycin-Polymyxin B x 3 dgl. i 7 dage - Lubrikerende uden konservering - Kontrol ved egen øjenlæge kun ved manglende bedring eller forværring Grad 1: Cornea epithel skade, cornea klar. Ingen limbal iskæmi. Ingen IOR. - Behandling - Lokalt antibiotikum + klap. - Lokalt kortikosteroid (eventuel): Fx: ocgtt Spersadex x 4-6 dagligt eller occ Hydrocortison-Terramycin-Polymyxin B x 4 - Ved smerter overvej dilaterende - Lubrikerende uden konservering x 4 - 12 Kontrol i øjenafdelingen dagen efter Grad 2 – 4: Skyet/ødematøs/uklar cornea med epitheldefekt, limbal iskæmi. Eventuel IOR - Behandling i akutfasen (0-7 dage) - Lokal - Ocgtt. Monopex, x 6 – 24 - Ocgtt. Oftaquix eller Moxifloxacin x 4 - Ocgtt. Natrium ascorbat 10%, x 6 – 16 - Lubrikerende uden konservering, x 6 – 12 - Ocgtt. Atropin 1%, x 2 - Ocgtt Optimol 5mg/ml x 2 (Ved højt intraokulært tryk) - Systemisk - Tabl Vibradox® (doxycyklin), 100mg x 2 - Alment - Eventuelt dagligt debridement af nekrotisk væv - Brydning af konjunktivale adhesioner med glasstav x 2 dagligt - Blinkhindrende klap - Behandling i tidlig reparationsfase (7-21 dage) - Akut behandling fortsætter samt - Nedtrapning af kortikosteroider (10-14 dage post-traumatisk) NB! Nu risiko for hensmeltning af cornea ved brug af kortikosteroider - Eventuel brug af CL (husk antibiotisk dråbeprofylakse) - Evt. kirurgi, se nedenfor - Behandling i sen reparationsfase (dag 22 til adskillige måneder.) - Modificering af ovenstående medicinske behandling - Kirurgi: Amnionvæv, konjunktival oversyning, limbal autograft, keratoplastik. - Ved manglende re-epithelialisering efter 14 dage bør kirurgi overvejes/initieres da yderligere epithelialisering ikke kan forventes. 3. BASALE BETRAGTNINGER Forløbet afhænger af hurtig behandling, ekspositionsvarighed, koncentration af kemisk stof og dennes pH. Alkali (baser) er værst, idet de penetrerer hurtigt, forsæber cellemembraner, denaturerer kollagen og emboliserer kar. Syrer er almindeligvis mindre skadende, idet hydrogen ioner præcipiterer proteiner og danner barriere mod penetration. Det corneale epithel kan således blive uklart, medens underliggende stroma kan forblive intakt og klart. 4. KLINISK FORLØB OG VURDERING Bemærk tilstedeværelse af lukkedefekter, trichiasis, symblepharon, epitheldefekter både af cornea og konjunktiva (særligt ved limbus), corneas klarhed, inflammation, intraokulær trykstigning, IOR og lens. 5. OPHELINGSFORLØBET - Øjeblikkelig - Relateres til udstrækningen af okulær overfladeinvolvering, penetrationsdybde, relativ toksicitet og koncentration af skademidlet. - Akut (0-7 dage) - Re-epithelialisering, cornea klarhed, intraokulært tryk, IOR og linse klarhed. - Tidlig reparationsfase (7-21 dage) - Svarende til den akutte fase + forandringer i cornea klarhed og tykkelse. - Sen reparationsfase (22 dage til flere måneder) - Epithelial gendannelse skal være fuldendt (kan ikke forventes at ske herefter) Hvor manglende epithelialisering ses kommer fibrovaskulær pannus eller steril corneal ulceration 6. PHARMAKOPIA MINOR Medicinsk behandling individualiseres under følgende principper: Inflammation dæmpes med - Dagligt debridement - lokal kortikosteroid Agtpågivenhed ved Grad 3/4 efter 1-2 uger hvor steroid kan lede til ulceration Ulceration kan hæmmes med - Salve Terramycin-Polymyxin B x 4; - Tablet Vibradox® (doxycyklin) 100 mg x 2 - Lubrikerende øjendråber, ukonserverede, ved kompromitteret tårefilm. Ved Grad 3/4 kan overvejes subakut amnionhindeplastik, konjunktival oversyning, Tenon-plastik. Mydriatika - Dråber skopolamin, cyclogyl eller atropin x 1. (helst ukonserveret). Lindrer cililære spasmer, hindrer iridolentale synekkier, nedsætter angiveligt inflammation ved karpåvirkning. Kunstige tårer uden konserveringsmiddel - Øjendråber x 6 dagligt + PN Danner beskyttende hinde over det konjunktivale og corneale epithel. Fremmer re-epithelialisering og transdifferentiering. Vitamin C (ascorbinsyre) - Vitamin C øjendråber: Natrium ascorbat 10% x 6-16 dagligt initialt, herefter dim afhængigt af sværhedsgrad. (Opløses fra hætteglas med natrium ascorbat injektionsvæske i fysiologisk saltvand, så opløsningen bliver svarende til 10% Natrium ascorbat). Seponeres ved epithel opheling eller konjunktival oversyning Vitamin C er co-faktor i mange enzymatiske reaktioner blandt andet i dannelse af kollagen. Beskytter mod skade fremkaldt af frie radikaler. Støtter reparation og minimerer ulceration. Seponeres ved epithel opheling. Tetracyklin - Tablet vibradox® (doxycyklin) 100 mg x 2 dagligt Nedsætter kollagenase-aktiviteten specielt ved alkali-æstninger. Effekt er uafhængig af antimikrobielle egenskaber. Virker angiveligt ved chelation af zink ioner (nødvendig ved enzymatiske reaktioner) medførende nedsat kollagenase aktivitet. Inhiberer desuden PMN leukocytaktivitet. Støtter reparation og minimerer ulceration. Seponeres ved epithel opheling eller konjunktival oversyning Lokalt antibiotikum - Øjensalve kloramfenikol (uden konserveringsmiddel) x 3, bakteriostatisk virkende. - Dråber oftaquix/vigamox x 4 Okulært antihypertensiva - Øjendråber optimol 0,5 % ukonserveret x 2 eller - Øjendråber betoptic S 0,25 % ukonserveret x 2. Steroider - Kortikosteroider uden konserveringsmiddel x 4-24 dagligt initialt (Monopex). Ansvar og organisering Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger. Afsnitsledende overlæger, afdelingssygeplejersker og ledende lægesekretærer, er ansvarlige for at instruksen udarbejdes, revideres og implementeres. Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen. Referencer, lovgivning og faglig evidens samt links hertil Bilag

<h1><div id="Afsnit#1699579034456">Ætsningsskader og kemiske øjenlæsioner, Akut team</div></h1><div id="BodyWeb#1699579034456"><p>&nbsp;</p> <div class="collapsible-item" expandedstart="1"><a name="1699579034456Maalgrupper"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Målgrupper og anvendelsesområde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm">Angiver retningslinjer for behandling af ætsningsskader og kemiske øjenlæsioner.</p> <p style="margin-left:0cm; margin-right:0cm">I akut fasen, herunder&nbsp;telefonisk rådgivning til patienter og pårørende.&nbsp;<br> Behandling i skadestuen samt retningslinjer for overflytning til og behandling i Klinik for akutte Øjensygdomme, Afdeling for Øjensygdomme, Rigshospitalet Glostrup.</p> <p style="margin-left:0cm; margin-right:0cm">I post akut fasen, herunder tilpasning af behandling i forhold til skadens grad (1 - 5), basale betragtninger, klinisk forløb og vurdering, ophelingsforløb og pharmakopia minor.</p> <p style="margin-left:0cm; margin-right:0cm"><strong>Formål:</strong><br> At angive retningslinjer for undersøgelse og behandling af ætsningsskader og kemiske øjenlæsioner.</p> <ol> <li>Akut fasen</li> <li>Post – akut behandling i Øjenafdelingen</li> <li>Basale betragtninger</li> <li>Klinisk forløb og vurdering</li> <li>Ophelingsforløb</li> <li>Pharmakopia minor</li> </ol> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579034456Definitioner"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Definitioner</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Skade forårsaget af syre eller base. Evt. termisk skadekomponent.</span></p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Kemiske stoffer:</span></strong><br> <span style="color:black">Baser (ammoniak (NH₃), kaustisk soda (NaOH), læsket kalk penetrerer generelt meget hurtigt væv og kan udrette størst skade. </span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Ætsning efter fyrværkeriskader skyldes ofte kombination af termisk skade og magnesiumhydroxyd (Mg(OH₂). </span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Ætsning med Flussyre (HF) er at betragte som svær baseætsning. </span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Svovlsyre (H₂SO₄) findes i batterier og kan give svære skader efter batteri-eksplosioner (lokal varmeudvikling).</span></p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">OBS alle ætsningsskader &gt; grad 2 skal konfereres med en bagvagt </span></strong></p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">(Ammoniak skader SKAL kontrolleres</span></strong><strong><span style="color:black">&nbsp;på øjenafdeling)</span></strong>​​​​</p> <p>&nbsp;</p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579034456Fremgangsmaade"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Fremgangsmåde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <h3 style="margin-left:0cm; margin-right:0cm"><strong><strong><span style="color:black">1. AKUT – FASEN</span></strong></strong></h3> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Patienten/pårørende ringer og anmoder om råd</span></strong></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Information:</span></p> <ul> <li>Øjet skal skylles med rigelige mængder vand. Selv urent vand kan i ekstreme nødstilfælde benyttes.</li> <li>Nærmeste åbne skadestue skal opsøges akut, og der skal skylles undervejs (ambulance, privatbil).</li> <li>Skylningen bør oftest fortsætte i op til flere timer.</li> </ul> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Ved ankomst til skadestuen</span></strong></p> <ul> <li>Patienten skal behandles <u>straks</u> ved ankomst.</li> <li>Kontakt til vagthavende øjenlæge med henblik på videre visitation. <ul style="list-style-type:circle"> <li>Telefon til vagthavende øjenlæge, Afdeling for Øjensygdomme, Rigshospitalet Glostrup.&nbsp;</li> <li>Hverdage, klokken 8.00 – 15.00<span style="color:black">, tlf. ###TELEFON###</span><br> &nbsp;</li> <li>Udenfor dette tidsrum, tlf. ###TELEFON###&nbsp;<br> Klinik for Akutte Øjensygdomme, spørg efter vagthavende øjenlæge<br> &nbsp;</li> </ul> </li> <li><span style="color:black">Vigtigst er <u>skylning</u> med rigelige mængder neutralopløsning (oftest <strong>isotonisk</strong> saltvand).</span></li> <li><span style="color:black">Skyl mindst 1 time, dog <u>oftest flere timer indtil neutral pH </u>(se nedenfor).</span></li> </ul> <ul> <li>Fjernelse af fremmedlegemer i lokalbedøvelse (Oxybuprocain 0,8&nbsp;%) med vatpind.</li> <li>Vending af øjenlåg <ul style="list-style-type:circle"> <li>Anvend lokalbedøvelse (Oxybuprocain) og evt. øjenlågs-spekulum.</li> </ul> </li> <li>Kontrol af pH med lakmuspapir: Ved neutralt pH målt 20 minutter efter endt skylning kan patienten overføres til øjenafdelingen, Rigshospitalet Glostrup, efter aftale med vagthavende øjenlæge.</li> <li><span style="background-color:yellow"><span style="color:#222222">Når en patient med behov for øjenskylning er i akutklinikken på Rigshospitalet Glostrup efter lukketid kl. 22, skal Klinikken for Akutte Øjensygdomme kontaktes. Er der tid og ressourcer i øjenlægevagten overtages skylning af øjet indtil pH neutral. Det vil være en individuel vurdering på dagen. Konkret aftale om hvordan overtagelsen af patienten skal forløbe, må ske på dagen mellem øjenlæge-bagvagt og læge i akutklinikken.</span></span></li> </ul> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Overførsel til Øjenafdelingen, Rigshospitalet Glostrup</span></strong></p> <ul> <li>Patienten kan overføres til øjenafdelingen efter aftale med vagthavende øjenlæge, når pH er neutral</li> </ul> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Ved ankomst til Øjenafdelingen, Rigshospitalet Glostrup</span></strong></p> <ul> <li>Sikre at der <u>fortsat skylles, hvis pH ikke er neutral (7)</u>. Hvis patienten først ses af sygeplejerske, skal denne fortsætte skylning med isotonisk saltvand.&nbsp;</li> <li>Fjernelse af fremmedlegemer i lokalbedøvelse med vatpind.</li> <li>Vending af øjenlåg, anvend evt. øjenlågs spekulum</li> <li>Kontroller pH med lakmuspapir. Ved neutralt pH målt 20 minutter efter sidste skylning kan skylning seponeres.</li> <li>Vurder skadens omfang i henhold til modificeret Roper-Hall klassifikation</li> </ul> <p><strong><span style="color:#000000">Roper-Hall&nbsp;klassifikation</span></strong></p> ###TABEL_1### <p><strong><span style="color:white">&nbsp;</span></strong></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">* Ved epithelskade i konjunktiva svarende til limbus klassificeres dette som limbal iskæmi.</span></p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">NB! Vær opmærksom på intraokulær reaktion (IOR). Ved IOR bør patienten rykkes et trin op i graduering og behandlingsniveau.</span></strong></p> <p style="margin-left:0cm; margin-right:0cm"><strong>&nbsp;</strong></p> <h3 style="margin-left:0cm; margin-right:0cm"><strong><strong><span style="color:black">2. POST – AKUT BEHANDLING I ØJENAFDELINGEN VED ÆTSNING</span></strong></strong></h3> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Nedenstående post-akutte behandling efter initial skylning <em>tilpasses efter skadens grad og karakter</em>, og kan kun til en hvis grad standardiseres.<br> Behandlingen kan være vanskelig og langvarig, og kræver medvirken af erfaren kollega. Ved tvivlsspørgsmål konfereres med overlæge.</span></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Behandlingen tilpasses efter skadens grad (Roper-Hall klassifikation):&nbsp;</span></strong><br> &nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong><u>Mild ætseskade (uden for klassifikation)</u></strong></p> <p style="margin-left:0cm; margin-right:0cm"><strong>Konjunktiva bevaret. Ingen corneal epithel skade. Cornea klar. Ingen limbal iskæmi eller IOR.</strong></p> <ul> <li>Behandling <ul style="list-style-type:circle"> <li>Lokalt antibiotikum/kortikosteroid + evt. blinkhindrende klap.<br> <em>Fx: Spersadex x 4 eller Hydrokortison med Terramycin-Polymyxin B x 3 dgl. i 7 dage</em></li> <li>Lubrikerende uden konservering</li> </ul> </li> <li>Kontrol ved egen øjenlæge kun ved manglende bedring eller forværring<br> &nbsp;</li> </ul> <p style="margin-left:0cm; margin-right:0cm"><strong><u><span style="color:black">Grad 1:</span></u></strong></p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Cornea epithel skade, cornea klar. Ingen limbal iskæmi. Ingen IOR.</span></strong></p> <ul> <li>Behandling <ul style="list-style-type:circle"> <li>Lokalt antibiotikum + klap.</li> <li>Lokalt kortikosteroid (eventuel):</li> </ul> </li> </ul> <p style="margin-left:36pt; margin-right:0cm"><em>Fx: ocgtt Spersadex x 4-6 dagligt eller</em></p> <p style="margin-left:36pt; margin-right:0cm"><em>occ Hydrocortison-Terramycin-Polymyxin B x 4</em></p> <p style="margin-left:36pt; margin-right:0cm">&nbsp;</p> <ul> <li style="list-style-type:none"> <ul style="list-style-type:circle"> <li>Ved smerter overvej dilaterende</li> <li>Lubrikerende uden konservering x 4 - 12</li> </ul> </li> </ul> <p style="margin-left:0cm; margin-right:0cm">Kontrol i øjenafdelingen dagen efter<br> &nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong><u><span style="color:black">Grad 2 – 4:</span></u></strong></p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Skyet/ødematøs/uklar cornea med epitheldefekt, limbal iskæmi. Eventuel IOR</span></strong></p> <ul> <li>Behandling i <em>akutfasen (0-7 dage)</em> <ul style="list-style-type:circle"> <li>Lokal <ul style="list-style-type:square"> <li>Ocgtt. Monopex, x 6 – 24</li> <li>Ocgtt. Oftaquix eller Moxifloxacin x 4</li> <li>Ocgtt. Natrium ascorbat 10%, x 6 – 16</li> <li>Lubrikerende uden konservering, x 6 – 12&nbsp;&nbsp;</li> <li>Ocgtt. Atropin 1%, x 2</li> <li>Ocgtt Optimol 5mg/ml x 2 (Ved højt intraokulært tryk)</li> <li>&nbsp;</li> </ul> </li> <li>Systemisk <ul style="list-style-type:square"> <li>Tabl Vibradox® (doxycyklin), 100mg x 2</li> </ul> </li> <li>Alment <ul style="list-style-type:square"> <li>Eventuelt dagligt debridement af nekrotisk væv</li> <li>Brydning af konjunktivale adhesioner med glasstav x 2 dagligt</li> <li>Blinkhindrende klap<br> &nbsp;</li> </ul> </li> </ul> </li> <li>Behandling i <em>tidlig reparationsfase (7-21 dage)</em> <ul style="list-style-type:circle"> <li>Akut behandling fortsætter samt <ul style="list-style-type:square"> <li>Nedtrapning af kortikosteroider&nbsp; (10-14 dage post-traumatisk)<br> <strong>NB! </strong>Nu risiko for hensmeltning af cornea ved brug af kortikosteroider</li> </ul> </li> <li>Eventuel brug af CL (husk antibiotisk dråbeprofylakse)</li> <li>Evt. kirurgi, se nedenfor</li> </ul> </li> </ul> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <ul> <li>Behandling i <em>sen reparationsfase (dag 22 til adskillige måneder.)</em> <ul style="list-style-type:circle"> <li>Modificering af ovenstående medicinske behandling</li> <li>Kirurgi: Amnionvæv, konjunktival oversyning, limbal autograft, keratoplastik.<br> &nbsp;</li> </ul> </li> <li><strong>Ved manglende re-epithelialisering efter 14 dage bør kirurgi overvejes/initieres da yderligere epithelialisering ikke kan forventes.</strong><br> &nbsp;</li> </ul> <h3 style="margin-left:0cm; margin-right:0cm"><strong><strong><span style="color:black">3. BASALE BETRAGTNINGER</span></strong></strong></h3> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Forløbet afhænger af hurtig behandling, ekspositionsvarighed, koncentration af kemisk stof og dennes pH.</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Alkali (baser) er værst, idet de penetrerer hurtigt, forsæber cellemembraner, denaturerer kollagen og emboliserer kar.</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Syrer er almindeligvis mindre skadende, idet hydrogen ioner præcipiterer proteiner og danner barriere mod penetration. Det corneale epithel kan således blive uklart, medens underliggende stroma kan forblive intakt og klart.<br> &nbsp;</span></p> <h3 style="margin-left:0cm; margin-right:0cm"><strong><strong><span style="color:black">4. KLINISK FORLØB OG VURDERING</span></strong></strong></h3> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Bemærk tilstedeværelse af lukkedefekter, trichiasis, symblepharon, epitheldefekter både af cornea og konjunktiva (særligt ved limbus), corneas klarhed, inflammation, intraokulær trykstigning, IOR og lens.<br> &nbsp;</span></p> <h3 style="margin-left:0cm; margin-right:0cm"><strong><strong><span style="color:black">5. OPHELINGSFORLØBET</span></strong></strong></h3> <ul> <li><strong>&nbsp;</strong>Øjeblikkelig <ul style="list-style-type:circle"> <li>Relateres til udstrækningen af okulær overfladeinvolvering, <span style="color:black">penetrationsdybde, relativ toksicitet og koncentration af skademidlet.&nbsp;</span></li> </ul> </li> <li><em>Akut (0-7 dage)</em> <ul style="list-style-type:circle"> <li>Re-epithelialisering, cornea klarhed, intraokulært tryk, IOR og linse klarhed.</li> </ul> </li> <li>Tidlig reparationsfase <em>(7-21 dage)</em> <ul style="list-style-type:circle"> <li>&nbsp;Svarende til den akutte fase + forandringer i cornea klarhed og tykkelse.</li> </ul> </li> <li>Sen reparationsfase <em>(22 dage til flere måneder)</em> <ul style="list-style-type:circle"> <li>Epithelial gendannelse skal være fuldendt (kan ikke forventes at ske herefter)<br> Hvor manglende epithelialisering ses kommer fibrovaskulær pannus eller steril corneal ulceration</li> </ul> </li> </ul> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">6. PHARMAKOPIA MINOR</span></strong></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Medicinsk behandling individualiseres under følgende principper:</span></p> <p style="margin-left:0cm; margin-right:0cm"><strong>Inflammation</strong> dæmpes med</p> <ul> <li style="list-style-type:none"> <ul style="list-style-type:circle"> <li>Dagligt debridement</li> <li>lokal kortikosteroid<br> Agtpågivenhed ved Grad 3/4 efter 1-2 uger hvor steroid kan lede til ulceration</li> </ul> </li> </ul> <p style="margin-left:0cm; margin-right:0cm"><strong>Ulceration</strong> kan hæmmes med</p> <ul> <li style="list-style-type:none"> <ul style="list-style-type:circle"> <li>Salve Terramycin-Polymyxin B x 4;</li> <li>Tablet Vibradox® (doxycyklin) 100 mg x 2</li> <li>Lubrikerende øjendråber, ukonserverede, ved kompromitteret tårefilm.&nbsp;</li> </ul> </li> </ul> <p style="margin-left:40px; margin-right:0cm">Ved Grad 3/4 kan overvejes subakut amnionhindeplastik, konjunktival oversyning, Tenon-plastik.</p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Mydriatika</span></strong></p> <ul> <li style="list-style-type:none"> <ul style="list-style-type:circle"> <li>Dråber skopolamin, cyclogyl eller atropin x 1. (helst ukonserveret).&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li> </ul> </li> </ul> <p style="margin-left:40px">Lindrer cililære spasmer, hindrer iridolentale synekkier, nedsætter angiveligt inflammation ved karpåvirkning.</p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Kunstige tårer uden konserveringsmiddel</span></strong></p> <ul> <li style="list-style-type:none"> <ul style="list-style-type:circle"> <li>Øjendråber x 6 dagligt + PN</li> </ul> </li> </ul> <p style="margin-left:40px; margin-right:0cm">Danner beskyttende hinde over det konjunktivale og corneale epithel. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p> <p style="margin-left:40px; margin-right:0cm">Fremmer re-epithelialisering og transdifferentiering.</p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Vitamin C (ascorbinsyre)</span></strong></p> <ul> <li>Vitamin C øjendråber: Natrium ascorbat 10% x 6-16 dagligt initialt, herefter dim afhængigt af sværhedsgrad.<br> (Opløses fra hætteglas med natrium ascorbat injektionsvæske i fysiologisk saltvand, så opløsningen bliver svarende til 10% Natrium ascorbat).<br> Seponeres ved epithel opheling eller konjunktival oversyning<br> Vitamin C er co-faktor i mange enzymatiske reaktioner blandt andet i dannelse af kollagen. Beskytter mod skade fremkaldt af frie radikaler.<br> Støtter reparation og minimerer ulceration. Seponeres ved epithel opheling.</li> </ul> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Tetracyklin</span></strong></p> <ul> <li>Tablet&nbsp;vibradox® (doxycyklin) 100 mg x 2 dagligt<br> Nedsætter kollagenase-aktiviteten specielt ved alkali-æstninger.<br> Effekt er uafhængig af antimikrobielle egenskaber.<br> Virker angiveligt ved chelation af zink ioner (nødvendig ved enzymatiske reaktioner) medførende nedsat kollagenase aktivitet.<br> Inhiberer desuden PMN leukocytaktivitet. Støtter reparation og minimerer ulceration.&nbsp;<br> Seponeres ved epithel opheling eller konjunktival oversyning</li> </ul> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Lokalt antibiotikum</span></strong></p> <ul> <li>Øjensalve kloramfenikol (uden konserveringsmiddel) x 3, bakteriostatisk virkende.</li> <li>Dråber oftaquix/vigamox x 4</li> </ul> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Okulært antihypertensiva</span></strong></p> <ul> <li>Øjendråber optimol 0,5 % ukonserveret x 2<br> <strong>eller&nbsp;</strong></li> <li>Øjendråber betoptic S 0,25 % ukonserveret x 2.</li> </ul> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Steroider</span></strong></p> <ul> <li>Kortikosteroider uden konserveringsmiddel x 4-24 dagligt initialt (Monopex).</li> </ul> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579034456Ansvar"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Ansvar og organisering</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger.<br> Afsnitsledende overlæger, afdelingssygeplejersker og ledende lægesekretærer, er ansvarlige for at instruksen udarbejdes, revideres og implementeres.<br> Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579034456Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579034456Referencer"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Referencer, lovgivning og faglig evidens samt links hertil</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579034456Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579034456Bilag"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Bilag</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579034456Top">Tilbage til top</a></p>

Rigshospitalet_¥jensygdomme (HOC)_Ætsningsskader og kemiske ¢jenlæsioner Akut team_TABEL_1.

Grad 1 Grad 2 Grad 3 Grad 4 Cornea epithel Defekt Defekt Total defekt Total defekt Cornea stroma Klart Stromal haze iris kan ses Stromal haze Iris ses ej Opaque Iris og pupil ses ej Konjunktiva/ limbus Bevaret/ingen < 1/3 limbal iskæmi 1/3 - ½ limbal iskæmi > ½ limbal iskæmi Prognose God God Tvivlsom Dårlig Heling Få dage Uger Protraheret heling med fibrovaskulær pannus Risiko forsteril corneal ulceration

<table cellspacing="0" class="Table" style="border-collapse:collapse; border:none; width:708px"> <tbody> <tr> <td style="background-color:white; width:98.75pt"> <p style="margin-left:0cm; margin-right:0cm"><strong>&nbsp;</strong></p> </td> <td style="background-color:white; width:76.55pt"> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Grad 1</span></strong></p> </td> <td style="background-color:white; width:106.3pt"> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Grad 2</span></strong></p> </td> <td style="background-color:white; width:106.3pt"> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Grad 3</span></strong></p> </td> <td style="background-color:white; width:134.7pt"> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Grad 4</span></strong></p> </td> </tr> <tr> <td style="background-color:white; width:98.75pt"> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Cornea epithel</span></strong></p> </td> <td style="background-color:white; width:76.55pt"> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Defekt</span></p> </td> <td style="background-color:white; width:106.3pt"> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Defekt</span></p> </td> <td style="background-color:white; width:106.3pt"> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Total defekt</span></p> </td> <td style="background-color:white; width:134.7pt"> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Total defekt</span></p> </td> </tr> <tr> <td style="background-color:white; width:98.75pt"> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Cornea stroma</span></strong></p> </td> <td style="background-color:white; width:76.55pt"> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Klart</span></p> </td> <td style="background-color:white; width:106.3pt"> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Stromal haze iris kan ses</span></p> </td> <td style="background-color:white; width:106.3pt"> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Stromal haze&nbsp; </span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Iris ses ej</span></p> </td> <td style="background-color:white; width:134.7pt"> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Opaque&nbsp; &nbsp;</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Iris og pupil ses ej</span></p> </td> </tr> <tr> <td style="background-color:white; width:98.75pt"> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Konjunktiva/&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; l</span><span style="color:black">imbus</span></strong></p> </td> <td style="background-color:white; width:76.55pt"> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Bevaret/ingen</span></p> </td> <td style="background-color:white; width:106.3pt"> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">&lt; 1/3 limbal iskæmi</span></p> </td> <td style="background-color:white; width:106.3pt"> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">1/3 - ½ limbal iskæmi</span></p> </td> <td style="background-color:white; width:134.7pt"> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">&gt; ½ limbal iskæmi</span></p> </td> </tr> <tr> <td style="background-color:white; width:98.75pt"> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Prognose</span></strong></p> </td> <td style="background-color:white; width:76.55pt"> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">God</span></p> </td> <td style="background-color:white; width:106.3pt"> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">God</span></p> </td> <td style="background-color:white; width:106.3pt"> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Tvivlsom</span></p> </td> <td style="background-color:white; width:134.7pt"> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Dårlig</span></p> </td> </tr> <tr> <td style="background-color:white; width:98.75pt"> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Heling</span></strong></p> </td> <td style="background-color:white; width:76.55pt"> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Få dage</span></p> </td> <td style="background-color:white; width:106.3pt"> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Uger</span></p> </td> <td style="background-color:white; width:106.3pt"> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Protraheret heling med fibrovaskulær pannus </span></p> </td> <td style="background-color:white; width:134.7pt"> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Risiko forsteril corneal&nbsp; ulceration</span></p> </td> </tr> </tbody> </table>

Rigshospitalet_¥jensygdomme (HOC)_¥jendråber og ¢jendrypning Afdeling for ¥jensygdomme.

Øjendråber og øjendrypning, Afdeling for Øjensygdomme, Rigshospitalet Målgrupper og anvendelsesområde Angiver retningslinjer for arbejdsgange ved ordination og administration af øjendråber, samt retningslinjer for øjendrypning til sikring af optimal behandling. Gældende for personale, som varetager øjendrypning i Afdeling for Øjensygdomme, Rigshospitalet. Definitioner Fremgangsmåde Ordination: Ambulante patienter, medicin ordineres af læge i FMK, Fælles Medicinkort Indlagte patienter, medicin ordineres af læge i MDA i SP Håndtering af øjendråber: Opbevaring af øjendråber: Før ibrugtagning opbevares øjendråber i køleskab eller ved stuetemperatur som anført på flasken med øjendråber. Efter ibrugtagning opbevares øjendråber ved stuetemperatur, dråberne tåler generelt ikke temperatursvingninger. Når flaske med øjendråber anbrydes: Skriv anbrudsdato på flasken Fjern evt. løse dele fra flaskens hals, før patientes dryppes Holdbarhed af øjendråber efter anbrud: Konserverede øjendråber = 1 måned Ukonserverede øjendråber = 1 uge Engangsdosis øjendråber = 24 timer Brug af flaske med øjendråber til én eller flere patienter: Samme flaske bruges til flere patienter. Hvis flaskens spids kontamineres, skal flasken kasseres. Patienter med infektion eller mistanke om infektion skal have personlige øjendråber. Udførelse af øjendrypning: Rekvisitter: Gazetamponer og øjendråber Udførelse: Sprit hænder Patienten sættes godt tilrette. Informer om øjendrypningen, om præparatet og evt. bivirkninger. Husk at informere om svie. Bed patienten bøje nakken lidt bagover og kigge opad. Træk ned i nederste øjenlåg og placer en øjendråbe i nederste øjenlågsfold. Bed herefter patienten holde øjet lukket nogle få sekunder. Øjet må ikke knibes sammen, da øjendråberne så presses ud. Undgå at dråbeflasken berører øjet eller øjenomgivelserne, pga. faren for beskadigelse af øjet og kontaminering af flaskens indhold. Dryp aldrig direkte på hornhinden, det er meget ubehageligt for patienten. Der er kun plads til ca. 1/5 dråbe i øjet, så den overskydende væske vil løbe ud igen. Tør den overskydende dråbe væk så irritation af øjenomgivelserne undgås. Rækkefølge: Ved drypning med mere end én slags øjendråber holdes en pause på 1-2 minutter imellem drypningerne. Dryp først med tynde øjendråber, derefter med mere tyktflydende øjendråber. Ved behandling med flere øjendråber, holdes en pause mellem drypningerne på 1-2 minutter. HUSK - Nogle øjendråber kræver en pause på 10 minutter både før og efter drypningen, for eksempel Trusopt. - Nogle øjenpræparater er antagonister. Ansvar og organisering Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger. Afsnitsledende overlæger, afdelingssygeplejersker og ledende lægesekretærer, er ansvarlige for at instruksen udarbejdes, revideres og implementeres. Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen. Referencer, lovgivning og faglig evidens samt links hertil Bilag

<h1><div id="Afsnit#1699579132160">Øjendråber og øjendrypning, Afdeling for Øjensygdomme, Rigshospitalet</div></h1><div id="BodyWeb#1699579132160"><p>&nbsp;</p> <div class="collapsible-item" expandedstart="1"><a name="1699579132160Maalgrupper"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Målgrupper og anvendelsesområde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm">Angiver retningslinjer for arbejdsgange ved ordination og administration af øjendråber, samt retningslinjer for øjendrypning til&nbsp;sikring af optimal behandling.</p> <p style="margin-left:0cm; margin-right:0cm">Gældende for&nbsp;personale, som varetager øjendrypning i Afdeling for Øjensygdomme, Rigshospitalet.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579132160Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579132160Definitioner"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Definitioner</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579132160Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579132160Fremgangsmaade"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Fremgangsmåde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm"><strong>Ordination:</strong></p> <p style="margin-left:40px; margin-right:0cm">Ambulante patienter, medicin ordineres af læge i FMK, Fælles Medicinkort<br> Indlagte patienter, medicin ordineres af læge i MDA i SP</p> <p style="margin-left:0cm; margin-right:0cm"><strong>Håndtering af øjendråber:</strong></p> <p style="margin-left:40px; margin-right:0cm">Opbevaring af øjendråber:</p> <p style="margin-left:80px; margin-right:0cm">Før ibrugtagning opbevares øjendråber i køleskab eller ved stuetemperatur som anført på flasken med øjendråber.<br> Efter ibrugtagning opbevares øjendråber&nbsp;ved stuetemperatur, dråberne tåler generelt ikke temperatursvingninger.</p> <p style="margin-left:80px; margin-right:0cm">Når flaske med øjendråber anbrydes:</p> <p style="margin-left:80px; margin-right:0cm">Skriv anbrudsdato på flasken<br> Fjern evt. løse dele fra flaskens hals, før patientes dryppes</p> <p style="margin-left:80px; margin-right:0cm">Holdbarhed af øjendråber efter anbrud:</p> <p style="margin-left:80px; margin-right:0cm">Konserverede øjendråber = 1 måned<br> Ukonserverede øjendråber = 1 uge<br> Engangsdosis øjendråber = 24 timer</p> <p style="margin-left:80px; margin-right:0cm">Brug af flaske&nbsp;med øjendråber til én eller flere patienter:</p> <p style="margin-left:80px; margin-right:0cm">Samme flaske bruges til flere patienter. Hvis flaskens spids kontamineres, skal flasken kasseres.<br> Patienter med infektion eller mistanke om infektion skal have personlige øjendråber.</p> <p style="margin-left:0cm; margin-right:0cm"><strong>Udførelse af øjendrypning:</strong></p> <p style="margin-left:40px; margin-right:0cm">Rekvisitter:</p> <p style="margin-left:80px; margin-right:0cm">Gazetamponer og øjendråber</p> <p style="margin-left:40px; margin-right:0cm">Udførelse:</p> <p style="margin-left:80px; margin-right:0cm">Sprit&nbsp;hænder<br> Patienten sættes godt tilrette.<br> Informer&nbsp;om øjendrypningen, om præparatet og&nbsp;evt. bivirkninger. Husk at informere om svie.<br> Bed patienten bøje nakken lidt bagover og kigge opad.<br> Træk ned i nederste&nbsp;øjenlåg og placer en øjendråbe i nederste øjenlågsfold.<br> Bed herefter patienten holde øjet lukket nogle få sekunder. Øjet må ikke knibes sammen, da øjendråberne så presses ud.<br> Undgå at dråbeflasken berører øjet eller øjenomgivelserne, pga. faren for beskadigelse af øjet og kontaminering af flaskens indhold.<br> Dryp aldrig direkte på hornhinden, det er meget ubehageligt for patienten.<br> Der er kun plads til ca. 1/5 dråbe i øjet, så den overskydende væske vil løbe ud igen. Tør den overskydende dråbe væk så irritation af øjenomgivelserne undgås.</p> <p style="margin-left:40px; margin-right:0cm">Rækkefølge:</p> <p style="margin-left:80px; margin-right:0cm">Ved drypning med mere end én slags øjendråber holdes en pause på 1-2 minutter imellem drypningerne.<br> Dryp først med tynde øjendråber, derefter med mere tyktflydende øjendråber.<br> Ved behandling med flere øjendråber, holdes en pause mellem drypningerne på 1-2 minutter.</p> <p style="margin-left:0cm; margin-right:0cm"><strong>HUSK</strong></p> <ul> <li>Nogle øjendråber kræver en pause på 10 minutter både før og efter drypningen, for eksempel Trusopt.</li> <li>Nogle øjenpræparater er antagonister.</li> </ul> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579132160Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579132160Ansvar"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Ansvar og organisering</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm">Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger.<br> Afsnitsledende overlæger, afdelingssygeplejersker og ledende lægesekretærer, er ansvarlige for at instruksen udarbejdes, revideres og implementeres.<br> Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579132160Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579132160Referencer"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Referencer, lovgivning og faglig evidens samt links hertil</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579132160Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579132160Bilag"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Bilag</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579132160Top">Tilbage til top</a></p>

Rigshospitalet_¥jensygdomme (HOC)_¥jenpodning håndtering af.

Øjenpodning, håndtering af Målgrupper og anvendelsesområde Målgruppe: Alt klinisk personale i Afdeling for Øjensygdomme, der håndterer øjenpodninger Anvendelseområde: Beskriver arbejdsgang for håndtering af øjenpodninger Definitioner Fremgangsmåde - Lægen laver best/ord på podeprøver i SP (eller skriver en bestillingsseddel til sygeplejersken). - Sygeplejerske udskriver PTB. - Lægen eller sygeplejersken finder podeglas, medicinske engangshandsker og “blå” prøvepose frem. - Lægen sikrer sig patientens identitet. Etiketter m. navn, CPR og navn på podninger påsættes de rette podeglas. PTB blanket foldes sammen og lægges i blå prøvepose. - Læge og sygeplejerske udfører hånddesinfektion og handsker påtages. - Sygeplejersken åbner indpakning med podeglas og skruer låget af glasset. Hold låget med den ene hånd og glasset med den anden - Efter lægen har udført podningen, lægges podepinden i røret, som sygeplejersken rækker frem. Der anvendes sikker kommunikation, for at sikre det er de rette podeglas. - Sygeplejersken skruer låget på og åbner posen med ren hånd. Røret lægges direkte i den blå prøvepose med uren hånd. - Handsker aftages og afsluttes med hånddesinfektion. - Prøveposen lægges direkte i køleskabet i skyllerummet. Ansvar og organisering Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger. Afsnitsledelsen er ansvarlige for at instruksen udarbejdes, revideres og implementeres. Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen. Referencer, lovgivning og faglig evidens samt links hertil Bilag

<h1><div id="Afsnit#1699578963721">Øjenpodning, håndtering af</div></h1><div id="BodyWeb#1699578963721"><p>&nbsp;</p> <div class="collapsible-item" expandedstart="1"><a name="1699578963721Maalgrupper"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Målgrupper og anvendelsesområde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>Målgruppe: Alt klinisk personale i Afdeling for Øjensygdomme, der håndterer øjenpodninger</p> <p>Anvendelseområde: Beskriver arbejdsgang for håndtering af øjenpodninger</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578963721Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item"><a name="1699578963721Definitioner"></a> <div class="collapsible-item-title"> <h2>Definitioner</h2> </div> <div class="collapsible-item-body" style="display: none;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578963721Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699578963721Fremgangsmaade"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Fremgangsmåde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <ol> <li>Lægen laver best/ord på&nbsp;podeprøver i SP (eller skriver en bestillingsseddel til sygeplejersken).</li> </ol> <p><img alt="" src="/VIP/Redaktoer/1301G3.nsf/vLookupUpload/ATTACH-RHAP-CQZCV6/$FILE/seddel.jpg" style="height:150px; width:200px" onclick="Ext.DMS.util.showImage(this);"></p> <ol start="2"> <li>Sygeplejerske udskriver PTB.</li> <li>Lægen eller sygeplejersken finder podeglas, medicinske engangshandsker og “blå” prøvepose frem.</li> <li>Lægen sikrer sig patientens identitet. Etiketter m. navn, CPR og navn på podninger påsættes de rette podeglas. PTB blanket foldes sammen og lægges i blå prøvepose.</li> </ol> <p><img alt="" src="/VIP/Redaktoer/1301G3.nsf/vLookupUpload/ATTACH-RHAP-CQZCXS/$FILE/ren pose.jpg" style="height:267px; width:200px" onclick="Ext.DMS.util.showImage(this);"></p> <ol start="5"> <li>Læge og sygeplejerske udfører hånddesinfektion og handsker påtages.</li> <li>Sygeplejersken åbner indpakning med podeglas og skruer låget af glasset. Hold&nbsp;låget med den ene hånd og glasset med den anden</li> </ol> <p><img alt="" src="/VIP/Redaktoer/1301G3.nsf/vLookupUpload/ATTACH-RHAP-CQZCRN/$FILE/Pode.jpg" style="height:100px; width:200px" onclick="Ext.DMS.util.showImage(this);"></p> <ol start="7"> <li>Efter lægen har udført podningen, lægges podepinden i røret, som sygeplejersken rækker frem. Der anvendes&nbsp;sikker kommunikation,&nbsp;for at sikre det er de rette podeglas.</li> <li>Sygeplejersken skruer låget på og åbner posen med ren&nbsp;hånd. Røret lægges direkte i den blå prøvepose med uren&nbsp;hånd.</li> </ol> <p><img alt="" src="/VIP/Redaktoer/1301G3.nsf/vLookupUpload/ATTACH-RHAP-CQZCUB/$FILE/glas i pose.jpg" style="height:267px; width:200px" onclick="Ext.DMS.util.showImage(this);"></p> <ol start="9"> <li>Handsker aftages og afsluttes med hånddesinfektion.</li> <li>Prøveposen lægges direkte i køleskabet i skyllerummet.</li> </ol> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578963721Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699578963721Ansvar"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Ansvar og organisering</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p><span style="background-color:#ffffff; color:#222222">Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger.</span><br> <span style="background-color:#ffffff; color:#222222">Afsnitsledelsen&nbsp;er ansvarlige for at instruksen udarbejdes, revideres og implementeres.</span><br> <span style="background-color:#ffffff; color:#222222">Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen.</span></p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578963721Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item"><a name="1699578963721Referencer"></a> <div class="collapsible-item-title"> <h2>Referencer, lovgivning og faglig evidens samt links hertil</h2> </div> <div class="collapsible-item-body" style="display: none;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578963721Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item"><a name="1699578963721Bilag"></a> <div class="collapsible-item-title"> <h2>Bilag</h2> </div> <div class="collapsible-item-body" style="display: none;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699578963721Top">Tilbage til top</a></p>

Rigshospitalet_¥jensygdomme (HOC)_¥jentraume observation af patient.

Øjentraume, observation af patient Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Bilag Målgrupper og anvendelsesområde Instruksen er gældende for vagtsygeplejersker i akut-teamet i Afdeling for Øjensygdomme, Rigshospitalet. Relevant hvis: - Patienten har været udsat for slag mod øjet. - Patienten skal observeres og have foretaget øjenundersøgelse med henblik på diagnostik og behandling. Formål: - At observere patienter, der har været udsat for slag mod øjet, korrekt. - At forberede patienter, der har været udsat for slag mod øjet, til øjenundersøgelse. - At eksisterende øjenskade behandles optimalt, og skadens omfang minimeres. Definitioner Fremgangsmåde Alle patienter obs. penetrerende øjentraume (hul på øjet) SKAL have hårdt skjold på UDEN blød klap under. Observation af patientens almentilstand - farver - respiration - BT og puls - bevidsthedsniveau - ved svækket almentilstand lægges patienten på leje / i seng og vagthavende læge tilkaldes straks for at tilse patienten Smertebehandling - Lokal eller systemisk behandling, efter ordination fra vagthavende øjenlæge Observation af øjet - pupil +/- lysfølsom - pupildifferens - hyphæma - læsion af øje eller øjenomgivelser - fremmedlegeme i øjet Visusmåling Evt. dilatation af begge øjne som forberedelse til undersøgelse i spaltelampe efter ordination fra vagthavende øjenlæge Undersøgelse / behandling Følgende undersøgelser og behandlinger anvendes ofte hos patienter med øjentraumer: - røntgen af orbita ved mistanke om fraktur (blow out) - tbl. Paracetamol ved smerter - occgt. Skopolamin ved ciliære smerter - oculentum Kloramfenikol som forebyggelse mod infektion - ved abrasio (rift på hornhinden) anlægges blinkhindrende forbinding som smertelindring og for at give ro i øjet. Se Afdeling for Øjensygdommes instruks, Blinkhindrende forbinding, anlæggelse af - hvis der er mistanke om penetrerende øjentraume, må blinkhindrende forbinding ikke anlægges Ansvar og organisering Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger. Afsnitsledende overlæger, afdelingssygeplejersker og ledende lægesekretærer, er ansvarlige for at instruksen udarbejdes, revideres og implementeres. Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen. Referencer, lovgivning og faglig evidens samt links hertil Bilag

<h1><div id="Afsnit#1699579007747">Øjentraume, observation af patient</div></h1><div id="BodyWeb#1699579007747"><p><a name="1699579007747Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579007747Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579007747Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579007747Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579007747Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579007747Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579007747Bilag">Bilag</a><br> &nbsp;</h3> <h2><a name="1699579007747Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p>Instruksen er gældende for vagtsygeplejersker i akut-teamet i Afdeling for Øjensygdomme, Rigshospitalet.&nbsp;</p> <p>Relevant hvis:&nbsp;</p> <ul> <li>Patienten har været udsat for slag mod øjet.</li> <li>Patienten skal observeres og have foretaget øjenundersøgelse med henblik på diagnostik og behandling.</li> </ul> <p>Formål:</p> <ul> <li>At observere patienter, der har været udsat for slag mod øjet, korrekt.</li> <li>At forberede patienter, der har været udsat for slag mod øjet, til øjenundersøgelse.</li> <li>At eksisterende øjenskade behandles optimalt, og skadens omfang minimeres.</li> </ul> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579007747Top">Tilbage til top</a></p> <h2><a name="1699579007747Definitioner"></a><br> Definitioner</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579007747Top">Tilbage til top</a></p> <h2><a name="1699579007747Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p><strong>Alle patienter obs. penetrerende øjentraume (hul på øjet)<br> SKAL&nbsp;have hårdt skjold på UDEN blød klap under.</strong></p> <p>Observation af patientens almentilstand</p> <ul> <li>farver</li> <li>respiration</li> <li>BT og puls</li> <li>bevidsthedsniveau</li> <li>ved svækket almentilstand lægges patienten på leje / i seng og vagthavende læge tilkaldes straks for at tilse patienten</li> </ul> <p>Smertebehandling</p> <ul> <li>Lokal eller systemisk behandling, efter ordination fra vagthavende øjenlæge</li> </ul> <p>Observation af øjet</p> <ul> <li>pupil +/- lysfølsom</li> <li>pupildifferens</li> <li>hyphæma</li> <li>læsion af øje eller øjenomgivelser</li> <li>fremmedlegeme i øjet</li> </ul> <p>Visusmåling</p> <p>Evt. dilatation af begge øjne som forberedelse til undersøgelse i spaltelampe efter ordination fra vagthavende øjenlæge</p> <p>Undersøgelse / behandling</p> <p style="margin-left:40px">Følgende undersøgelser og behandlinger anvendes ofte hos patienter med øjentraumer:</p> <ul style="margin-left:40px"> <li>røntgen af orbita ved mistanke om fraktur (blow out)</li> <li>tbl. Paracetamol ved smerter</li> <li>occgt. Skopolamin ved ciliære smerter</li> <li>oculentum Kloramfenikol som forebyggelse mod infektion</li> <li>ved abrasio (rift på hornhinden) anlægges blinkhindrende forbinding som smertelindring og for at give ro i øjet.<br> Se Afdeling for Øjensygdommes instruks, <a href="###FOLDER###" target="_blank">Blinkhindrende forbinding, anlæggelse af</a></li> <li>hvis der er mistanke om penetrerende øjentraume, må blinkhindrende forbinding ikke anlægges</li> </ul> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579007747Top">Tilbage til top</a></p> <h2><a name="1699579007747Ansvar"></a><br> Ansvar og organisering</h2> <p style="margin-left:0cm; margin-right:0cm">Afdelingsledelsen i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at instruksen foreligger.<br> <br> Afsnitsledende overlæger, afdelingssygeplejersker og ledende lægesekretærer, er ansvarlige for at instruksen udarbejdes, revideres og implementeres.<br> Den enkelte medarbejder i Afdeling for Øjensygdomme, Rigshospitalet, er ansvarlig for at kende og følge instruksen.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579007747Top">Tilbage til top</a></p> <h2><a name="1699579007747Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579007747Top">Tilbage til top</a></p> <h2><a name="1699579007747Bilag"></a><br> Bilag</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579007747Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Adenotomi.

Adenotomi Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Målgrupper og anvendelsesområde Klinisk personale Definitioner Fremgangsmåde Indikation Obstruktion af rhinopharynx ytrende sig ved snorken, lukket snøvlen, søvnapnoe, mundrespiration. Recidiverende øvre luftvejsinfektioner Kronisk tubaocclusion Recidiverende akut otitis media Sekretorisk otitis media Cave: angiofibrom hos drenge Indlæggelsesdagen Journaloptagelse, recept på smertestillende udleveres Anæstesitilsyn Samtale med sygeplejerske fra sengeafdelingen Information om efterforløbet Evt. tympanometri Evt. høreprøve Præoperativ patientinformation Komplikationer (blødning), risiko for extraction af rokketænder under indgrebet, operationen foregår i universel anæstesi, smertebehandling postoperativt. Cave: ikke adenotomi ved submucøs ganespalte Operation Patienten lejres med bagoverbøjet hoved og munden holdes åben med mundspærre. Det adenoide væv skrabes af rhinopharynx´s bagvæv med adenotom. Primære postoperative komplikationer Blødning (i sjældne tilfælde) Behandling Is hos voksne Reoperation med fjernelse af rest AV I sjældne tilfælde bagre tamponade Postoperativ observation Temperatur, puls, respiration, bevidsthedsniveau, observation af blødning fra svælget. Kost Kost efter evne. Ingen restriktioner. Analgetika Smertestillende behandling i henhold til relevant smertepakke i EPM Ansvar og organisering Gældende for alt klinisk personale på afdeling E Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag

<h1><div id="Afsnit#1699579355978">Adenotomi</div></h1><div id="BodyWeb#1699579355978"><p><a name="1699579355978Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579355978Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579355978Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579355978Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579355978Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579355978Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579355978Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579355978Bilag">Bilag</a><br> &nbsp;</h3> <h2><a name="1699579355978Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p>Klinisk personale&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579355978Top">Tilbage til top</a></p> <h2><a name="1699579355978Definitioner"></a><br> Definitioner</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579355978Top">Tilbage til top</a></p> <h2><a name="1699579355978Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p><strong>Indikation</strong><br> Obstruktion af rhinopharynx ytrende sig ved snorken, lukket snøvlen, søvnapnoe, mundrespiration.<br> Recidiverende øvre luftvejsinfektioner<br> Kronisk tubaocclusion<br> Recidiverende akut otitis media<br> Sekretorisk otitis media<br> <br> Cave: angiofibrom hos drenge<br> <br> <strong>Indlæggelsesdagen</strong><br> Journaloptagelse, recept på smertestillende udleveres<br> Anæstesitilsyn<br> Samtale med sygeplejerske &nbsp;fra sengeafdelingen<br> Information om efterforløbet<br> Evt. tympanometri<br> Evt. høreprøve<br> <br> <strong>Præoperativ patientinformation</strong><br> Komplikationer (blødning), risiko for extraction af rokketænder under indgrebet, operationen foregår i universel anæstesi, smertebehandling postoperativt.</p> <p>Cave: ikke adenotomi ved submucøs ganespalte<br> <br> <strong>Operation</strong><br> Patienten lejres med bagoverbøjet hoved og munden holdes åben med mundspærre. Det adenoide væv skrabes af rhinopharynx´s bagvæv med adenotom.<br> <br> <strong>Primære postoperative komplikationer</strong><br> <br> Blødning (i sjældne tilfælde)<br> <br> <strong>Behandling</strong><br> Is hos voksne<br> Reoperation med fjernelse af rest AV</p> <p>I sjældne tilfælde bagre tamponade<br> <br> <strong>Postoperativ observation</strong><br> Temperatur, puls, respiration, bevidsthedsniveau, observation af blødning fra svælget.<br> <br> <strong>Kost</strong><br> &nbsp;Kost efter evne. Ingen restriktioner.<br> <br> <strong>Analgetika</strong><br> Smertestillende behandling i henhold til relevant smertepakke i EPM</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579355978Top">Tilbage til top</a></p> <h2><a name="1699579355978Ansvar"></a><br> Ansvar og organisering</h2> <p>Gældende for alt klinisk personale på afdeling E</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579355978Top">Tilbage til top</a></p> <h2><a name="1699579355978Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579355978Top">Tilbage til top</a></p> <h2><a name="1699579355978Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579355978Top">Tilbage til top</a></p> <h2><a name="1699579355978Bilag"></a><br> Bilag</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579355978Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Afpr¢vning og ombytning af h¢reapparat.

Afprøvning og ombytning af høreapparat Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Målgrupper og anvendelsesområde Voksne der får HA på Aud. Afd. GeH (fx voksne med CI på modsatte øre) Definitioner Fremgangsmåde Afprøvning og ombytning af høreapparat For de voksne der får udleveret HA på Aud. Afd. GeH (fx. voksne med CI på modsatte øre) gælder det, at 6 uger efter nyudlevering ved Hørepædagogisk afsnit, bliver klienten indkaldt til efterkontrol. Kl. orienteres om, at ved behov for yderligere justering skal kl. henvende sig til Hørepædagogisk afsnit igen. Drejer det sig om betjening af HA henvises til det lokale kommunikationscenter fra første dag. Hvis de udleverede HA ikke er i stand til at afhjælpe klientens problemer, og det samtidig vurderes, at et skifte kan lette vanskelighederne, er der mulighed for ombytning inden for en tremåneders periode. Klager, der fremføres mere end 3 måneder efter tildelingen, kan kun medføre ombytning af HA, hvis der foreligger væsentlige ændringer af klientens situation, der er relevante og dokumenterede (for eksempel progression i høretabet eller svækkelse af fingermobilitet). I disse tilfælde sender det lokale kommunikationscenter et oplæg til Hørepædagogisk afsnit indeholdende 1. Navn og CPR 2. Beskrivelse af klager 3. Eventuelle forslag til ændret apparatvalg. Klienten tildeles herefter hurtigst muligt tid til Ørepropteknikken og/eller Hørepæd. Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag

<h1><div id="Afsnit#1699579398422">Afprøvning og ombytning af høreapparat</div></h1><div id="BodyWeb#1699579398422"><p><a name="1699579398422Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579398422Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579398422Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579398422Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579398422Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579398422Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579398422Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579398422Bilag">Bilag</a><br> &nbsp;</h3> <h2><a name="1699579398422Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p>Voksne der får HA på Aud. Afd. GeH (fx voksne med CI på modsatte øre)</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579398422Top">Tilbage til top</a></p> <h2><a name="1699579398422Definitioner"></a><br> Definitioner</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579398422Top">Tilbage til top</a></p> <h2><a name="1699579398422Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p><strong><span style="color:#000000">Afprøvning og ombytning af høreapparat</span></strong></p> <p>For de voksne der får udleveret HA på Aud. Afd. GeH (fx. voksne med CI på modsatte øre) gælder det, at 6 uger efter <em>nyudlevering </em>ved Hørepædagogisk afsnit, bliver klienten indkaldt til efterkontrol. Kl. orienteres om, at ved behov for yderligere justering skal kl. henvende sig til Hørepædagogisk afsnit igen.<br> <br> Drejer det sig om betjening af HA henvises til det lokale kommunikationscenter fra første dag.<br> <br> Hvis de udleverede HA ikke er i stand til at afhjælpe klientens problemer, og det samtidig vurderes, at et skifte kan lette vanskelighederne, er der mulighed for ombytning inden for en tremåneders periode.<br> <br> Klager, der fremføres mere end 3 måneder efter tildelingen, kan kun medføre ombytning af HA, hvis der foreligger væsentlige ændringer af klientens situation, der er relevante og dokumenterede (for eksempel progression i høretabet eller svækkelse af fingermobilitet).</p> <p>I disse tilfælde sender det lokale&nbsp;kommunikationscenter et oplæg til Hørepædagogisk afsnit indeholdende</p> <p>1. Navn og CPR</p> <p>2. Beskrivelse af klager</p> <p>3. Eventuelle forslag til ændret apparatvalg. Klienten tildeles herefter hurtigst muligt tid til Ørepropteknikken og/eller Hørepæd.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579398422Top">Tilbage til top</a></p> <h2><a name="1699579398422Ansvar"></a><br> Ansvar og organisering</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579398422Top">Tilbage til top</a></p> <h2><a name="1699579398422Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579398422Top">Tilbage til top</a></p> <h2><a name="1699579398422Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579398422Top">Tilbage til top</a></p> <h2><a name="1699579398422Bilag"></a><br> Bilag</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579398422Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Akut mastoiditis Behandling af.

Akut mastoiditis, Behandling af Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Målgrupper og anvendelsesområde Læger og sygeplejersker Definitioner Bakteriel infektion af mastoidet, involverende både mucosa og knoglevæv. Akut mastoiditis optræder typisk 1 - 2 uger efter akut suppurativ otitis media, men kan præsentere sig som første symptom. OBS!: Tilstanden skal betragtes som en potentiel livstruende infektiøs sygdom. Ørekirurg skal orienteres. Fremgangsmåde Kliniske fund: - Febrilia - Mastoidal rødme - Hævelse - Ømhed - Evt. displacering af øret. - Fluktuerende hævelse ved periosteal abces (retroaurikulært, zygomastisk, Bezolds abces under sternocleiden) - Ofte påvirket almen tilstand, patienten kan dog være relativt upåvirket - Ofte fortykket rød frembulende trommehinde, evt. med flåd. Der kan ses normal trommehinde. Evt. nedsynkning af bagerste øregang. Komplikationer: - Subperiostal abces - Epidural abces - Temporallaps / cerebellar abces - Meningitis - Sinus trombophlebitis - Paresis n. facialis - Labyrintitis Undersøgelser og behandling: Kontakt ørekirurg Objektiv undersøgelse: inkl. otoneurologisk undersøgelse, otomikroskopi og undersøgelse for øvrige komplikationer (nakke-rygstivhed, sensorium, temperatur, almen tilstand) Lab: Leu, CRP, Hgb Ved akut otitis media - Tubulation og prøvepunktur retroaurikolært (i G.A.). Husk podning! - Ved retroaurikulær hævelse og normal trommehinde kan ultralyd anvendes til afklaring af absces-dannelse Ved periosteal abces: - Akut cortikal mastoidektomi samt tubulation Efter podning: - Iv. behandling med Cefuroxim eller i henhold til podesvar - Iv. antibiotilkabehandling 24 - 48 timer. Ved manglende bedring i tilstanden, vurdering ved ørekirurg af indikation for mastoidektomi. Ved god effekt, skift til peroral behandling vejledt af podesvar. Ved mistanke om komplikationer, CT-scanning af kraniet med tætte snit over mastoidet. Meningitis: - Hvis patienten har tegn på meningitis kontaktes bagvagten på infektionsmedicinsk eller pædiatrisk afdeling. - Patienten indlægges på infektionsmedicinsk / pædiatrisk afdeling, og meningitten behandles efter stamafdelingens instruks - mens bagvagten på øre-næse-halskirurgisk klinik har ansvaret forden otologiske behandling. Det vil sige som det mindste tilser patienten dagligt og vurderer behov for evt. mastoidektomi. Intrakraniel komplikation: - I tilfælde af intrakraniel komplikation kontaktes neurokirurgisk bagvagt, og behandlingen planlægges efter aftale med denne, idet der ofte tillige skal øreopereres. Efterbehandling: Følges i Øre-næse-halskirurgisk ambulatorium som andre øreopererede. Husk audiogram. Kan sædvanligvis afsluttes efter 3 - 6 mdr. Se evt Tidsskema øreoperede.doc Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag

<h1><div id="Afsnit#1699579258173">Akut mastoiditis, Behandling af</div></h1><div id="BodyWeb#1699579258173"><p> <a name="1699579258173Top"></a></p> <h3> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579258173Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579258173Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579258173Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579258173Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579258173Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579258173Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579258173Bilag">Bilag</a><br> &nbsp;</h3> <h2> <a name="1699579258173Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p> Læger og sygeplejersker&nbsp;</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579258173Top">Tilbage til top</a></p> <h2> <a name="1699579258173Definitioner"></a><br> Definitioner</h2> <p> Bakteriel infektion af mastoidet, involverende både mucosa og knoglevæv.</p> <p> Akut mastoiditis optræder typisk 1 - 2 uger efter akut suppurativ otitis media, men kan præsentere sig som første symptom.</p> <p> <strong><u>OBS!:</u></strong></p> <p> <strong>Tilstanden skal betragtes som en potentiel livstruende infektiøs sygdom.</strong></p> <p> <strong>Ørekirurg skal orienteres. </strong></p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579258173Top">Tilbage til top</a></p> <h2> <a name="1699579258173Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p> <strong>Kliniske fund:</strong></p> <p> &nbsp;</p> <ul> <li> Febrilia</li> <li> Mastoidal rødme</li> <li> Hævelse</li> <li> Ømhed</li> <li> Evt. displacering af øret.</li> <li> Fluktuerende hævelse ved periosteal abces (retroaurikulært, zygomastisk, Bezolds abces under sternocleiden)</li> <li> Ofte påvirket almen tilstand, patienten kan dog være relativt upåvirket</li> <li> Ofte fortykket rød frembulende trommehinde, evt. med flåd. Der kan ses normal trommehinde. Evt. nedsynkning af bagerste øregang.</li> </ul> <p> <b>Komplikationer:</b><a name="16995792581731421582485814Komplikationer:"></a></p> <ul type="disc"> <li> Subperiostal abces</li> <li> Epidural abces</li> <li> Temporallaps / cerebellar abces</li> <li> Meningitis</li> <li> Sinus trombophlebitis</li> <li> Paresis n. facialis</li> <li> Labyrintitis</li> </ul> <p> <b>Undersøgelser og behandling:</b><a name="16995792581731421582485814Undersøgelser og behandling:"></a></p> <p> <b>Kontakt ørekirurg</b></p> <p> &nbsp;<b><u>Objektiv undersøgelse:</u></b> inkl. otoneurologisk undersøgelse, otomikroskopi og undersøgelse for øvrige komplikationer (nakke-rygstivhed, sensorium, temperatur, almen tilstand)</p> <p> <b><u>Lab:</u></b> Leu, CRP, Hgb</p> <p> &nbsp;</p> <p> <b><u>Ved akut otitis media</u></b></p> <ul> <li> &nbsp;Tubulation og prøvepunktur retroaurikolært (i G.A.). <b>Husk podning!</b></li> <li> Ved retroaurikulær hævelse og normal trommehinde kan ultralyd anvendes til afklaring af absces-dannelse</li> </ul> <p> <b><u>Ved periosteal abces: </u></b></p> <ul type="disc"> <li> Akut cortikal mastoidektomi samt tubulation</li> </ul> <p> <b><u>Efter podning:</u></b></p> <ul type="disc"> <li> Iv. behandling med Cefuroxim eller i henhold til podesvar</li> <li> Iv. antibiotilkabehandling 24 - 48 timer. <b><u>Ved manglende bedring</u></b> i tilstanden, vurdering ved ørekirurg af indikation for mastoidektomi. <b><u>Ved god effekt</u></b>, skift til peroral behandling vejledt af podesvar. <b><u>Ved mistanke om komplikationer</u></b>, CT-scanning af kraniet med tætte snit over mastoidet.</li> </ul> <p> <b><u>Meningitis:</u></b></p> <ul type="disc"> <li> Hvis patienten har tegn på meningitis kontaktes bagvagten på infektionsmedicinsk eller pædiatrisk afdeling.</li> <li> Patienten indlægges på infektionsmedicinsk / pædiatrisk afdeling, og meningitten behandles efter stamafdelingens instruks - mens bagvagten på øre-næse-halskirurgisk klinik har ansvaret forden otologiske behandling. Det vil sige som det mindste tilser patienten dagligt og vurderer behov for evt. mastoidektomi.</li> </ul> <p> <b><u>Intrakraniel komplikation:</u></b></p> <ul type="disc"> <li> I tilfælde af intrakraniel komplikation kontaktes neurokirurgisk bagvagt, og behandlingen planlægges efter aftale med denne, idet der ofte tillige skal øreopereres.</li> </ul> <p> <b>Efterbehandling:</b><a name="16995792581731421582485814Efterbehandling:"></a></p> <p> Følges i Øre-næse-halskirurgisk ambulatorium som andre øreopererede.</p> <p> Husk audiogram.</p> <p> Kan sædvanligvis afsluttes efter 3 - 6 mdr.</p> <p> &nbsp;Se evt <img src="http://vip.regionh.dk/icons/vwicn005.gif" onclick="Ext.DMS.util.showImage(this);"><a href="http://vip.regionh.dk/VIP/Redaktoer/130126.nsf/vLookupUpload/ATTACH-RHAP-9S3GC2/$FILE/Tidsskema%20øreoperede.doc" target="_blank">Tidsskema øreoperede.doc</a></p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579258173Top">Tilbage til top</a></p> <p> &nbsp;</p> <h2> <a name="1699579258173Ansvar"></a><br> Ansvar og organisering</h2> <p> &nbsp;</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579258173Top">Tilbage til top</a></p> <h2> <a name="1699579258173Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p> &nbsp;</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579258173Top">Tilbage til top</a></p> <h2> <a name="1699579258173Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p> &nbsp;</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579258173Top">Tilbage til top</a></p> <h2> <a name="1699579258173Bilag"></a><br> Bilag</h2> <p> &nbsp;</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579258173Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Akut otitis Behandling af.

Akut otitis, Behandling af Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Målgrupper og anvendelsesområde Læger og sygeplejersker Definitioner Akut purulent otitis: Infektion af slimhinden i mellemøret. Slimhinden i mastoidet kan være medinddraget. Fremgangsmåde Årsag: Infektionen stammer sædvanligvis fra infektioner i rhinopharynx. De bakterielle otitter skyldes ofte pneumokokker, haemophilus influenzae, streptokokker og branhamella catarrhalis. Symptomer: - Hørenedsættelse - Klapfornemmelse - Feber - Smerter - Medtaget almentilstand - Evt. øreflåd Hos mindre børn: - Mavesmerter - Opkastning - Diare Symptomerne kan findes i alle grader. Behandling: - V-penicillin (hos småbørn pivampicillin, amoxicillin, eller amoxicillin + clavulansyre) - Næsedråber - Analgetika, Paracetamol I tilfælde af terapisvigt, og når otitten optræder sammen med komplicerende lidelse - som for eksempel feberkramper og nedsat immunforsvar - er paracentese i GA indiceret for at få fastlagt bakterietype og resistensmønster. Komplikationer: Mastoiditis, facialis parese, labyrint fistel, meningitis eller intracerebral abces opstået i forbindelse med akut otitis vil evt. indicere kirurgisk sanering. Komplikationer skal altid konfereres med ørekirurg eller overlæge. Efterbehandling: Patienten anbefales kontrol hos egen ørelæge 8 - 14 dage efter ukompliceret akut otit. Relevante links: Akut mastoiditis, Behandling af Kronisk otitis media, Behandling af Perifer facialisparese, Årsager, undersøgelse og behandling af Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag

<h1><div id="Afsnit#1699579269146">Akut otitis, Behandling af</div></h1><div id="BodyWeb#1699579269146"><h3> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579269146Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579269146Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579269146Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579269146Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579269146Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579269146Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579269146Bilag">Bilag</a><br> &nbsp;</h3> <h2> <a name="1699579269146Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p> Læger og sygeplejersker&nbsp;</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579269146Top">Tilbage til top</a></p> <h2> <a name="1699579269146Definitioner"></a><br> Definitioner</h2> <p> <strong><u>Akut purulent otitis: </u></strong></p> <p> Infektion af slimhinden i mellemøret.</p> <p> Slimhinden i mastoidet kan være medinddraget.</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579269146Top">Tilbage til top</a></p> <h2> <a name="1699579269146Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p> <strong>Årsag:</strong></p> <p> Infektionen stammer sædvanligvis fra infektioner i rhinopharynx.</p> <p> De bakterielle otitter skyldes ofte pneumokokker, haemophilus influenzae, streptokokker og branhamella catarrhalis.</p> <p> <strong>Symptomer:</strong></p> <ul> <li> Hørenedsættelse</li> <li> Klapfornemmelse</li> <li> Feber</li> <li> Smerter</li> <li> Medtaget almentilstand</li> <li> Evt. øreflåd</li> </ul> <p> <strong><u>Hos mindre børn:</u></strong></p> <ul> <li> Mavesmerter</li> <li> Opkastning</li> <li> Diare</li> </ul> <p> Symptomerne kan findes i alle grader.&nbsp;</p> <p> <strong>Behandling:</strong></p> <ul> <li> <a href="http://www.lk-online.dk/" target="_blank">V-penicillin</a> (hos småbørn pivampicillin, amoxicillin, eller amoxicillin + clavulansyre)</li> <li> Næsedråber</li> <li> Analgetika, Paracetamol</li> </ul> <p> <strong><u>I tilfælde af terapisvigt, og når otitten optræder sammen med komplicerende lidelse</u></strong> - som for eksempel feberkramper og nedsat immunforsvar - er <a href="###FOLDER###">paracentese</a> i GA indiceret for at få fastlagt bakterietype og resistensmønster.</p> <p> &nbsp;</p> <p> <strong>Komplikationer:</strong></p> <p> Mastoiditis, <a href="http://vip.regionh.dk/C1256FF200498DB6/C8335D4F4E560DFF802569370052512E/A972C54DC7908D59C1256F64003815FF?OpenDocument">facialis parese</a>, labyrint fistel, meningitis eller intracerebral abces opstået i forbindelse med akut otitis vil evt. indicere kirurgisk sanering.</p> <p> <strong>Komplikationer skal altid konfereres med ørekirurg eller overlæge.</strong></p> <p> &nbsp;</p> <p> <strong><strong>Efterbehandling:</strong></strong></p> <p> Patienten anbefales kontrol hos egen ørelæge 8 - 14 dage efter ukompliceret akut otit.</p> <p> <strong>Relevante links:&nbsp;</strong><strong>&nbsp;</strong></p> <p> <strong><a href="###FOLDER###" target="_blank">Akut mastoiditis, Behandling af</a></strong></p> <p> <strong>&nbsp;</strong></p> <p> <strong><a href="###FOLDER###" target="_blank">Kronisk otitis media, Behandling af</a></strong></p> <p> <strong>&nbsp;</strong></p> <p> <strong><a href="###FOLDER###" target="_blank">Perifer facialisparese, Årsager, undersøgelse og behandling af</a></strong></p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579269146Top">Tilbage til top</a></p> <h2> <a name="1699579269146Ansvar"></a><br> Ansvar og organisering</h2> <p> &nbsp;</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579269146Top">Tilbage til top</a></p> <h2> <a name="1699579269146Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p> &nbsp;</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579269146Top">Tilbage til top</a></p> <h2> <a name="1699579269146Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p> &nbsp;</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579269146Top">Tilbage til top</a></p> <h2> <a name="1699579269146Bilag"></a><br> Bilag</h2> <p> &nbsp;</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579269146Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Anlæggelse og sikring af korrekt placering.

Anlæggelse og sikring af korrekt placering af nasogastrisk ernæringssonde i Øre-næse-halskirurgisk og audiologisk Klinik Formål Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Formål Mindske risiko for utilsigtede hændelser ved anvendelse af perorale fødesonder. Denne vejledning henvender sig til sundhedspersonale og præciserer den omhu og samvittighedsfuldhed, sundhedspersonale bør udvise ved anvendelse af perorale fødesonder. Målgrupper og anvendelsesområde Læger og sygeplejersker i Øre-næse-halskirurgisk og Audiologisk Klinik Definitioner Ved fødesonde forstås enhver sonde, som gennem svælget er anbragt i ventriklen, duodenum eller jejunum, igennem hvilken der indgives væske, føde og/eller medicin. Fremgangsmåde Anlæggelse af fødesonder må kun foretages efter lægeordination for den pågældende patient. Ordination af behandling med fødesonde, kontrolprocedurer i forbindelse med anlæggelsen, den efterfølgende kontrol og længdemærke for den anlagte sonde skal journalføres. Patientens informerede samtykke til indgrebet skal ligeledes dokumenteres. Journalføring: For Rigshospitalet gælder: Dokumenteres i Opus Notat under ’Procedure’. Dette gælder for både læger og sygeplejersker. For Gentofte gælder: Læger dokumenterer i Opus Notat og sygeplejersker på plejeplan (gælder kun for GeH) eller i KISO under 'Ernæring' Kompetence til anlæggelse: Nasogastrisk fødesonde må kun anlægges af sundhedspersonale med den fornødne kompetence i henhold til den vejledning, som følger sonden. For sygeplejersker gælder at kompetencen skal være dokumenteret i klinikkens kompetencevurderingsprogram for sygeplejersker. Desuden må sygeplejersker kun selvstændigt anlægge sonde på patienter med tidligere ukompliceret anlæggelse af nasogastrisk sonde. Sygeplejersker må ikke selvstændigt anlægge sonde på patienter der er nyopererede i næse og svælg eller patienter der tidligere har haft problematiske sondeanlæggelser. Kontrolprocedurer: Sondens placering skal altid kontrolleres af lægen eller sygeplejersken efter anlæggelse ved hjælp af fiberlaryngoskop for lægers vedkommende, eller ved auskulerering over epigastriet efter indgift af luft i sonden. For sonder anlagt peroperativt skal placeringen kontrolleres ved røntgen, dog undtaget ved laryngectomier. Første flydende indgift er altid 2-5 ml. sterilt NaCl. Ved kontinuerlig indgift, bør placeringen kontrolleres 3 gange i døgnet og altid ved mistanke om displacering. Ved bolusindgift skal sondens beliggenhed kontrolleres af plejepersonalet inden hver indgift. Kontrollen skal da foregå ved auskultation og/eller aspiration. Kontrollen dokumenteres på plejeplan eller i KISO under 'Ernæring'.. I tvivlstilfælde skal lægen tilkaldes og tage stilling til en evt. røntgenkontrol inden indgift. Kontrol kan foregå på forskellige måder. Sundhedsstyrelsen skal gøre opmærksom på, at ingen af de i dag anvendte kliniske kontrol procedurer alene sikrer korrekt placering af en peroral fødesonde. Røntgenundersøgelse med indgivelse af kontrast, såfremt fødesonden ikke er røntgenfast, må anses for at være den sikreste kontrolprocedure. Sondeindgift skal altid foregå med eleveret hovedgærde, mindst 30 grader. Ansvar og organisering Det er afdelingsledelsens ansvar at sørge for at det personale som sondenedlæggelsen uddelegeres til, har de rette kompetencer. Referencer, lovgivning og faglig evidens samt links hertil Sundhedsstyrelsens vejledning: https://www.retsinformation.dk/Forms/R0710.aspx?id=113718 Regional vejledning: Sondeernæring og anlæggelse og kontrol af sonde (voksne, alder 16 år eller ældre)

<h1><div id="Afsnit#1699579342787">Anlæggelse og sikring af korrekt placering af nasogastrisk ernæringssonde i Øre-næse-halskirurgisk og audiologisk Klinik</div></h1><div id="BodyWeb#1699579342787"><p> <a name="1699579342787Top"></a></p> <h3> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579342787Formaal">Formål</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579342787Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579342787Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579342787Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579342787Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579342787Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> &nbsp;</h3> <p> <a name="1699579342787Formaal"></a></p> <h2> Formål</h2> <p> Mindske risiko for utilsigtede hændelser ved anvendelse af perorale fødesonder. Denne vejledning henvender sig til sundhedspersonale og præciserer den omhu og samvittighedsfuldhed, sundhedspersonale bør udvise ved anvendelse af perorale fødesonder.</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579342787Top">Tilbage til top</a></p> <h2> <a name="1699579342787Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p> Læger og sygeplejersker i Øre-næse-halskirurgisk og Audiologisk Klinik</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579342787Top">Tilbage til top</a></p> <h2> <a name="1699579342787Definitioner"></a><br> Definitioner</h2> <p> Ved fødesonde forstås enhver sonde, som gennem svælget er anbragt i ventriklen, duodenum eller jejunum, igennem hvilken der indgives væske, føde og/eller medicin.</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579342787Top">Tilbage til top</a></p> <h2> <a name="1699579342787Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p> Anlæggelse af fødesonder må kun foretages efter lægeordination for den pågældende patient. Ordination af behandling med fødesonde, kontrolprocedurer i forbindelse med anlæggelsen, den efterfølgende kontrol og længdemærke for den anlagte sonde skal journalføres. Patientens informerede samtykke til indgrebet skal ligeledes dokumenteres.</p> <p> <strong>Journalføring:</strong></p> <p> <u>For Rigshospitalet gælder</u>:</p> <p> Dokumenteres i Opus Notat under ’Procedure’. Dette gælder for både læger og sygeplejersker.</p> <p> <u>For Gentofte gælder:</u></p> <p> Læger dokumenterer i Opus Notat og sygeplejersker på plejeplan (gælder kun for GeH) eller i KISO under 'Ernæring'</p> <p> <strong>Kompetence til anlæggelse</strong>:</p> <p> Nasogastrisk fødesonde må kun anlægges af sundhedspersonale med den fornødne kompetence i henhold til den vejledning, som følger sonden. For sygeplejersker gælder at kompetencen skal være dokumenteret i klinikkens kompetencevurderingsprogram for sygeplejersker. Desuden må sygeplejersker kun selvstændigt anlægge sonde på patienter med tidligere ukompliceret anlæggelse af nasogastrisk sonde. Sygeplejersker må <u>ikke</u> selvstændigt anlægge sonde på patienter der er nyopererede i næse og svælg eller patienter der tidligere har haft problematiske sondeanlæggelser.</p> <p> <strong>Kontrolprocedurer:</strong><br> Sondens placering skal altid kontrolleres af lægen eller sygeplejersken efter anlæggelse ved hjælp af fiberlaryngoskop for lægers vedkommende, eller ved auskulerering over epigastriet efter indgift af luft i sonden. For sonder anlagt peroperativt skal placeringen kontrolleres ved røntgen, dog undtaget ved laryngectomier. Første flydende indgift er altid 2-5 ml. sterilt NaCl.<br> Ved kontinuerlig indgift, bør placeringen kontrolleres 3 gange i døgnet og altid ved mistanke om displacering. Ved bolusindgift skal sondens beliggenhed kontrolleres af plejepersonalet inden hver indgift. Kontrollen skal da foregå ved auskultation og/eller aspiration. Kontrollen dokumenteres på plejeplan&nbsp;eller i KISO under 'Ernæring'.. I tvivlstilfælde skal lægen tilkaldes og tage stilling til en evt. røntgenkontrol inden indgift.<br> <br> Kontrol kan foregå på forskellige måder. Sundhedsstyrelsen skal gøre opmærksom på, at ingen af de i dag anvendte kliniske kontrol procedurer alene sikrer korrekt placering af en peroral fødesonde. Røntgenundersøgelse med indgivelse af kontrast, såfremt fødesonden ikke er røntgenfast, må anses for at være den sikreste kontrolprocedure.<br> <br> Sondeindgift skal altid foregå med eleveret hovedgærde, mindst 30 grader.</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579342787Top">Tilbage til top</a></p> <h2> <a name="1699579342787Ansvar"></a><br> Ansvar og organisering</h2> <p> <span style="font-family: 'Verdana','sans-serif'; color: #222222; font-size: 9pt">Det er afdelingsledelsens ansvar at sørge for at det personale som sondenedlæggelsen uddelegeres til, har de rette kompetencer.<o:p></o:p></span></p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579342787Top">Tilbage til top</a></p> <h2> <a name="1699579342787Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p> Sundhedsstyrelsens vejledning: <a href="https://www.retsinformation.dk/Forms/R0710.aspx?id=113718" target="_blank">https://www.retsinformation.dk/Forms/R0710.aspx?id=113718</a></p> <p> Regional vejledning: <a href="###FOLDER###" target="_blank">Sondeernæring og anlæggelse og kontrol af sonde (voksne, alder 16 år eller ældre)</a></p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579342787Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Audiologisk unders¢gelse standard.

Audiologisk undersøgelse, standard Formål Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Formål Opfyldelse af kvalitetsstandard F5. Målgrupper og anvendelsesområde Klinisk personale Aud. afd. GeH og BBH Definitioner Fremgangsmåde Audiologisk undersøgelse, standard Ved en standard audiologisk undersøgelse forstås: 1. En klinisk journaloptagelse med hovedvægen på det oto-audiologiske og socialmedicinske område, sidstnævnte specielt mhp. afdækning af lyttemæssige situationer, hvor patienten er ukompenseret. 2. En objektiv øre-, næse- og halsundersøgelse og en grov objektiv vurdering af patientens kommunikations- og funktionsniveau, samt vurdering af patientens fingermotoriske funktion og syn mhp. valg af høreapparattype. 3. Audiologiske tests under standardiserede målebetingelser. a. Toneaudiometri bestående af tærskelbestemmelse for luftledning på frekvenserne 250, 500, 1000, 2000, 4000 og 8000 Hz. og tærskelbestemmelse for benledning på frekvenserne 250, 500, 1000, 2000 og 4000 Hz. b. Tympanometri. c. Stapediusrefleksmålinger ved 500, 1000, 2000 og 4000 Hz. Kontralateral måling. d. SRT. e. Diskriminationsundersøgelse (DS) i ro med hovedtelefon på hvert øre (måleniveau anføres). Måleomstændighederne skal svare til ISO-normerne 389, 8253 og 7566. Testinstrumenterne skal teknisk kalibreres mindst hvert ½ år. Der skal dagligt lyttekalibreres. Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag

<h1><div id="Afsnit#1699579349345">Audiologisk undersøgelse, standard</div></h1><div id="BodyWeb#1699579349345"><p><a name="1699579349345Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579349345Formaal">Formål</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579349345Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579349345Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579349345Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579349345Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579349345Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579349345Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579349345Bilag">Bilag</a><br> &nbsp;</h3> <p><a name="1699579349345Formaal"></a></p> <h2>Formål</h2> <p>Opfyldelse af kvalitetsstandard F5.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579349345Top">Tilbage til top</a></p> <h2><a name="1699579349345Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p>Klinisk personale Aud. afd. GeH og BBH</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579349345Top">Tilbage til top</a></p> <h2><a name="1699579349345Definitioner"></a><br> Definitioner</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579349345Top">Tilbage til top</a></p> <h2><a name="1699579349345Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p><strong>Audiologisk undersøgelse, standard</strong></p> <p>Ved en standard audiologisk undersøgelse forstås:</p> <p>1. En klinisk journaloptagelse med hovedvægen på det oto-audiologiske og socialmedicinske område, sidstnævnte specielt mhp. afdækning af lyttemæssige situationer, hvor patienten er ukompenseret.</p> <p>2. En objektiv øre-, næse- og halsundersøgelse og en grov objektiv vurdering af patientens kommunikations- og funktionsniveau, samt vurdering af patientens fingermotoriske funktion og syn mhp. valg af høreapparattype.</p> <p>3. Audiologiske tests under standardiserede målebetingelser.</p> <p>a. Toneaudiometri bestående af tærskelbestemmelse for luftledning på frekvenserne 250, 500, 1000, 2000, 4000 og 8000 Hz. og tærskelbestemmelse for benledning på frekvenserne 250, 500, 1000, 2000 og 4000 Hz.</p> <p>b. Tympanometri.</p> <p>c. Stapediusrefleksmålinger ved 500, 1000, 2000 og 4000 Hz. Kontralateral måling.</p> <p>d. SRT.</p> <p>e. Diskriminationsundersøgelse (DS) i ro med hovedtelefon på hvert øre (måleniveau anføres).</p> <p>Måleomstændighederne skal svare til ISO-normerne 389, 8253 og 7566. Testinstrumenterne skal teknisk kalibreres mindst hvert ½ år. Der skal dagligt lyttekalibreres.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579349345Top">Tilbage til top</a></p> <h2><a name="1699579349345Ansvar"></a><br> Ansvar og organisering</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579349345Top">Tilbage til top</a></p> <h2><a name="1699579349345Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579349345Top">Tilbage til top</a></p> <h2><a name="1699579349345Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579349345Top">Tilbage til top</a></p> <h2><a name="1699579349345Bilag"></a><br> Bilag</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579349345Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Aures alatae.

Aures alatae Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Målgrupper og anvendelsesområde Læge og sygeplejersker Definitioner Kosmetiske gener i form af udstående ører. Fremgangsmåde Indikation Kosmetiske gener, fremført af patienten selv, i form af udstående ører. Patienten bør være 8 år eller derover. Patienten opereres normalt i dagkirurgisk regi i universel anæstesi (under 12-14 år) eller lokal anæstesi. Dette aftales mellem patienten og lægen. Forundersøgelse Patienten indkaldes til almindeligt ambulant forundersøgelse, hvor indikationen stilles og journalen udfærdiges. Patienten informeres om operationen, klinisk foto tages. Vær opmærksom på evt. keloiddannelse. Anæstesiform aftales. Præoperativ patientinformation - Operationen afsluttes med anlæggelse af konvolutforbinding, som skal sidde i 7-10 dage, uden på konvolutforbindingen sættes almindelig hovedforbinding, som patienten selv fjerner dagen efter indgrebet. - Moderate smerter postoperativt. Der kan forventes gradvis aftagende smerter i 3 – 4 dage. I denne periode vil der oftest være behov for både paracetamol og NSAID. Smertepakke ordineres. - Fuldstændig symmetri af ørerne kan ikke garanteres. - Komplikationer i form af blødning/infektion er sjældent. - Der udleveres patientinformation. Operation Som standard anvendes Steenstrøm´s eller Nordzell´s metoder eller etablerede varianter heraf. Der sutureres med enten nylon eller vicryl rapid i hud. Suturmateriale bestemmes af kirurgen. Der lægges modulerende stritøreforbinding Primære postoperative komplikationer og behandling Konvolutforbindingen må ikke sidde for stramt eller skride. I så fald må den lægges om. Hvis forbindingen er gennemsivet af blod, skal forbindingen tages af, blødningen standses med sutur eller lign. og der lægges ny forbinding. Postoperativ observation Almindelig. Kost Efter evne. Udskrivelse Der skal være en voksen person i hjemmet hos patienten. Ambulant kontrol Ved problemer med forbindingen skal patienten kontakte afdelingen eller ambulatoriet. På 7.- 10. dagen fjernes konvolutforbindingen og der fjernes suturer afhængig af operatørens valg af suturmateriale og instruktioner i operationsbeskrivelsen. Der skal benyttes nathue i yderligere 2 uger. Patienten må vaske hår efter suturfjernelsen. Rekreation Afhængig af alder og erhverv. Dog må det sikres, at forbindingen ikke bliver våd og at patienten undgår slag på ørerne. Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag

<h1><div id="Afsnit#1699579409413">Aures alatae</div></h1><div id="BodyWeb#1699579409413"><p><a name="1699579409413Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579409413Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579409413Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579409413Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579409413Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579409413Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579409413Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579409413Bilag">Bilag</a><br> &nbsp;</h3> <h2><a name="1699579409413Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p>Læge og sygeplejersker&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579409413Top">Tilbage til top</a></p> <h2><a name="1699579409413Definitioner"></a><br> Definitioner</h2> <p>Kosmetiske gener&nbsp;i form af udstående ører.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579409413Top">Tilbage til top</a></p> <h2><a name="1699579409413Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p><strong>Indikation</strong><br> Kosmetiske gener, fremført af patienten selv, i form af udstående ører. Patienten bør være&nbsp;8 år eller derover. Patienten opereres normalt i dagkirurgisk regi i universel anæstesi (under 12-14 år) eller&nbsp;lokal anæstesi. Dette aftales mellem patienten og lægen.</p> <p><strong>Forundersøgelse</strong><br> Patienten indkaldes til almindeligt ambulant forundersøgelse, hvor indikationen stilles og journalen udfærdiges. Patienten informeres om operationen, klinisk foto tages. Vær opmærksom på evt. keloiddannelse. Anæstesiform aftales.</p> <p><br> <strong>Præoperativ patientinformation</strong><br> <strong><strong>- </strong></strong>Operationen afsluttes med anlæggelse af konvolutforbinding, som skal sidde i&nbsp;7-10 dage,&nbsp;uden på konvolutforbindingen sættes almindelig hovedforbinding, som patienten selv fjerner dagen efter indgrebet.<br> - Moderate smerter postoperativt. Der kan forventes gradvis aftagende smerter i 3 – 4 dage. I denne periode vil der oftest være behov for både paracetamol og NSAID. Smertepakke ordineres.<br> - Fuldstændig symmetri af ørerne kan ikke garanteres.<br> - Komplikationer i form af blødning/infektion er sjældent.<br> - Der udleveres patientinformation.</p> <p><strong>Operation</strong><br> Som standard anvendes Steenstrøm´s eller Nordzell´s metoder eller etablerede varianter heraf. Der sutureres med enten nylon eller vicryl rapid i hud. Suturmateriale bestemmes af kirurgen.<br> Der lægges modulerende stritøreforbinding<br> <br> <strong>Primære postoperative komplikationer og behandling</strong><br> Konvolutforbindingen må ikke sidde for stramt eller skride. I så fald må den lægges om. Hvis forbindingen er gennemsivet af blod, skal forbindingen tages af, blødningen standses med sutur eller lign. og der lægges ny forbinding.<br> <br> <strong>Postoperativ observation</strong><br> Almindelig.<br> <br> <strong>Kost</strong><br> Efter evne.<br> <br> <strong>Udskrivelse</strong><br> Der skal være en voksen person i hjemmet hos patienten.</p> <p><strong>Ambulant kontrol</strong><br> Ved problemer med forbindingen skal patienten&nbsp;kontakte afdelingen eller ambulatoriet.<br> På&nbsp;7.- 10. dagen fjernes konvolutforbindingen og der fjernes suturer afhængig af operatørens valg af suturmateriale og instruktioner i operationsbeskrivelsen. Der skal benyttes nathue i yderligere 2 uger. Patienten må vaske hår efter suturfjernelsen.</p> <p><strong>Rekreation</strong><br> Afhængig af alder og erhverv. Dog må det sikres, at forbindingen ikke bliver våd&nbsp;og at patienten undgår slag på ørerne.<br> &nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579409413Top">Tilbage til top</a></p> <h2><a name="1699579409413Ansvar"></a><br> Ansvar og organisering</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579409413Top">Tilbage til top</a></p> <h2><a name="1699579409413Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579409413Top">Tilbage til top</a></p> <h2><a name="1699579409413Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579409413Top">Tilbage til top</a></p> <h2><a name="1699579409413Bilag"></a><br> Bilag</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579409413Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_BAHS.

BAHS Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Bilag Målgrupper og anvendelsesområde Denne instruks gælder for audiologopæder og teknikere, som tilpasser og udleverer BAHS, hvor der er implanteret en titaniumabutment, og bør også følges ved tilpasning og udlevering af BAHS, når der anvendes BC-bøjle eller softband. Definitioner BAHS = Bone Anchored Hearing Systems Fremgangsmåde BAHS Apparater og tilbehør findes på Hørepædagogisk afsnits lager. Skruetrækkere, teststav, prøvesøjle og demonstrations sæt findes på lageret. Før operation afprøves BAHS altid på softband, efterfulgt af follow up hos audiologopæd eller tekniker. Nyudlevering Klienten indkaldes til udlevering af BAHS 4-6 uger efter titaniumfixturen er implanteret. Al instruktion foretages før afprøvning af BAHS apparatet. Demonstration af BAHS før evt. implantering af titaniumabutment Apparatet præsenteres og brochurer udleveres. Teststaven (gennemsigtig stav tilhæftet abutment) med passende BAHS placeres fast mod mastoidet. Klienten kan låne BAHS apparatet og prøve det med et Softband eller BC-bøjle. Klienten orienteres om, at klienten kan forvente en noget bedre lyd med titaniumabutment. Demonstration af BAHS efter implantering af titaniumabutment Tilpasseren instruerer klienten i apparatets funktioner, batteriskift og tilslutning af eksternt udstyr. - FM udstyr er et teknisk hjælpemiddel, som klienten skal ansøge sin kommune om. Tilpasseren udleverer apparatet og stregkoden registreres i Auditbase. Der skrives i SP hvad der er gjort og hvorfor. Modifikationer på abutment Ved behov for modifikationer på abutment såsom stramning eller skift til en længere type henvises patienten til ambulatoriet. Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Bilag

<h1><div id="Afsnit#1699579444561">BAHS</div></h1><div id="BodyWeb#1699579444561"><p><a name="1699579444561Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579444561Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579444561Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579444561Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579444561Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579444561Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579444561Bilag">Bilag</a><br> &nbsp;</h3> <h2><a name="1699579444561Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p>Denne instruks gælder for audiologopæder og teknikere, som tilpasser og udleverer BAHS, hvor der er implanteret en titaniumabutment, og bør også følges ved tilpasning og udlevering af BAHS, når der anvendes BC-bøjle eller softband.<br> &nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579444561Top">Tilbage til top</a></p> <h2><a name="1699579444561Definitioner"></a><br> Definitioner</h2> <p>BAHS = Bone Anchored Hearing Systems<br> &nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579444561Top">Tilbage til top</a></p> <h2><a name="1699579444561Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p><strong>BAHS</strong></p> <p>Apparater og tilbehør findes på Hørepædagogisk afsnits lager.<br> <br> Skruetrækkere, teststav, prøvesøjle og demonstrations sæt findes på lageret.</p> <p>Før operation afprøves BAHS altid på softband, efterfulgt af follow up hos audiologopæd eller tekniker.<br> <br> <strong><u>Nyudlevering</u></strong><br> Klienten indkaldes til udlevering af BAHS 4-6 uger efter titaniumfixturen er implanteret.<br> <br> Al instruktion foretages før afprøvning af BAHS apparatet.<br> <br> <strong><u>Demonstration af BAHS før evt. implantering af titaniumabutment</u></strong><br> Apparatet præsenteres og brochurer udleveres. Teststaven (gennemsigtig stav tilhæftet abutment) med passende BAHS placeres fast mod mastoidet. Klienten kan låne BAHS apparatet og prøve det med et Softband eller BC-bøjle. Klienten orienteres om, at klienten kan forvente en noget bedre lyd med titaniumabutment.<br> <br> <strong><u>Demonstration af BAHS efter implantering af titaniumabutment</u></strong><br> Tilpasseren instruerer klienten i apparatets funktioner, batteriskift og tilslutning af eksternt udstyr.<br> - FM udstyr er et teknisk hjælpemiddel, som klienten skal ansøge sin kommune om.</p> <p>&nbsp;<br> Tilpasseren udleverer apparatet og stregkoden registreres i Auditbase. Der skrives i SP hvad der er gjort og hvorfor.</p> <p><br> <strong>Modifikationer på abutment</strong><br> Ved behov for modifikationer på abutment såsom stramning eller skift til en længere type henvises patienten til ambulatoriet.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579444561Top">Tilbage til top</a></p> <h2><a name="1699579444561Ansvar"></a><br> Ansvar og organisering</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579444561Top">Tilbage til top</a></p> <h2><a name="1699579444561Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579444561Top">Tilbage til top</a></p> <h2><a name="1699579444561Bilag"></a><br> Bilag</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579444561Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Bestilling af Arterie Temporalis biopsi i.

Bestilling af Arterie Temporalis biopsi i Afdeling for Øre-Næse-Halskirurgi og Audiologi Formål Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Formål Beskrive de administrative arbejdsgange, der er omkring bestilling og udførelse af Arterie Temporalis biopsi i Afdeling for Øre-Næse-Halskirurgi og Audiologi Målgrupper og anvendelsesområde Afdelinger der henviser patienter til at få foretaget Arterie Temporalis biopsi på Afdeling for Øre-Næse-Halskirurgi og Audiologi. Definitioner Arterie Temporalis-biopsi: indgreb, hvor der tages en biopsi af en blodåre i tindingen. (Arterie Temporalis). EOK er Afdeling for Øre-Næse-Halskirurgi og Audiologis operationsklargørings enhed på Gentofte Hospital. Fremgangsmåde Ved bestilling af biopsi på Gentofte Hospital Fax med ønske om Arterie Temporalis biopsi sendes til Øre-næse-halskirurgisk afsnit Fax nummer der skal benyttes er: ###TELEFON### Det er vigtigt at henvisningen indeholder - Indikation for at der skal foretages biopsi - hvilken side biopsien ønskes taget fra - fuld patient label - telefonnummer på patienten - om patienten er i et indlagt eller ambulant forløb Vi tilstræber at kunne effektuere en henvisning indenfor 5 hverdage. Er der særlige forhold, der indikerer at det skal ske hurtigere, skal det aftales på telefon ###TELEFON###. Vi gør opmærksom på at afdelingen har lukket mellem jul og nytår, samt 2 uger om sommeren. Er der akut indikation for en Arterie Temporalis biopsi i de perioder henvises til Rigshospitalet. Det forventes at henvisende afdeling har udleveret relevante patient vejledninger (Arterie Temporalis-biopsi, fra Medicinsk afdeling C, Gentofte Hospital Velkommen til operationsafdelingen) Ved bestilling af biopsi på Rigshospitalet: Vagthavende på Afdeling for Øre-Næse-Halskirurgi og Audiologi kontaktes på telefon ###TELEFON###. Ansvar og organisering - Referencer, lovgivning og faglig evidens samt links hertil - Akkrediteringsstandarder - Bilag

<h1><div id="Afsnit#1699579426962">Bestilling af Arterie Temporalis biopsi i Afdeling for Øre-Næse-Halskirurgi og Audiologi</div></h1><div id="BodyWeb#1699579426962"><p><a name="1699579426962Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579426962Formaal">Formål</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579426962Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579426962Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579426962Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579426962Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579426962Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579426962Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579426962Bilag">Bilag</a><br> &nbsp;</h3> <p><a name="1699579426962Formaal"></a></p> <h2>Formål</h2> <p>Beskrive de administrative arbejdsgange, der er omkring bestilling og udførelse af Arterie Temporalis biopsi i Afdeling for Øre-Næse-Halskirurgi og Audiologi</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579426962Top">Tilbage til top</a></p> <h2><a name="1699579426962Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p>Afdelinger der henviser patienter til at få foretaget Arterie Temporalis biopsi på Afdeling for Øre-Næse-Halskirurgi og Audiologi.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579426962Top">Tilbage til top</a></p> <h2><a name="1699579426962Definitioner"></a><br> Definitioner</h2> <p><strong>Arterie Temporalis-biopsi: </strong>indgreb, hvor der tages en biopsi af en blodåre i tindingen. (Arterie Temporalis).</p> <p><strong>EOK</strong> er Afdeling for Øre-Næse-Halskirurgi og Audiologis operationsklargørings enhed på Gentofte Hospital.</p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579426962Top">Tilbage til top</a></p> <h2><a name="1699579426962Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p><strong><u>Ved bestilling af biopsi på Gentofte Hospital</u></strong></p> <p>Fax med ønske om Arterie Temporalis biopsi sendes til Øre-næse-halskirurgisk afsnit</p> <p>&nbsp;</p> <p>Fax nummer der skal benyttes er: ###TELEFON###</p> <p>&nbsp;</p> <p>Det er vigtigt at henvisningen indeholder</p> <ul> <li>Indikation for at der skal foretages biopsi</li> <li>hvilken side biopsien ønskes taget fra</li> <li>fuld patient label</li> <li>telefonnummer på patienten</li> <li>om patienten er i et indlagt eller ambulant forløb</li> </ul> <p style="margin-left:36pt">&nbsp;</p> <p>Vi tilstræber at kunne effektuere en henvisning indenfor 5 hverdage. Er der særlige forhold, der indikerer at det skal ske hurtigere, skal det aftales på telefon ###TELEFON###.</p> <p>&nbsp;</p> <p>Vi gør opmærksom på at afdelingen har lukket mellem jul og nytår, samt 2 uger om sommeren.&nbsp;&nbsp;</p> <p>Er der akut indikation for en Arterie Temporalis biopsi i de perioder henvises til Rigshospitalet.</p> <p>&nbsp;</p> <p>Det forventes at henvisende afdeling har udleveret relevante patient vejledninger</p> <p>(Arterie Temporalis-biopsi, fra Medicinsk afdeling C, Gentofte Hospital</p> <p>Velkommen til operationsafdelingen)</p> <p>&nbsp;</p> <p><strong><u>Ved bestilling af biopsi på Rigshospitalet:</u></strong></p> <p>Vagthavende på Afdeling for Øre-Næse-Halskirurgi og Audiologi kontaktes på telefon ###TELEFON###.&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579426962Top">Tilbage til top</a></p> <h2><a name="1699579426962Ansvar"></a><br> Ansvar og organisering</h2> <p>&nbsp;-</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579426962Top">Tilbage til top</a></p> <h2><a name="1699579426962Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p>&nbsp;-</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579426962Top">Tilbage til top</a></p> <h2><a name="1699579426962Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p>&nbsp;-</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579426962Top">Tilbage til top</a></p> <h2><a name="1699579426962Bilag"></a><br> Bilag</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579426962Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Bestilling af h¢reapparater til b¢rn.

Bestilling af høreapparater til børn Formål Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Formål Målgrupper og anvendelsesområde Personale på Hørepædagogisk afsnit der bestiller høreapparater til børn Definitioner Fremgangsmåde Hvis barnet ikke har ny tid Hvis apparatet bestilles af tilpasseren, lægges besked til sekretæren om, hvad der er bestilt hvornår og af hvem og til hvilket barn (navn og Cpr.) Hvis apparatet bestilles af sekretæren, skal tilpasseren lægge besked om, hvad der skal bestilles, til hvilken klient (navn, Cpr. og kommunekode) samt, hvem apparatet skal lægges til. Når apparatet er modtaget lægger sekretæren det i tilpasserens bakke. Tilpasseren indstiller apparatet og sender det til barnet. Der skrives i Auditbase, hvad der er gjort og hvorfor. Stregkoden sættes på ydelsesskemaet, der returneres til sekretariatet m.h.p. registrering. Hvis barnet har ny tid Hvis apparatet bestilles af tilpasseren, lægges besked til sekretæren om, hvad der er bestilt, til hvilken dato, af hvem og til hvilket barn (navn og Cpr.) Hvis apparatet bestilles af sekretæren, skal tilpasseren lægge besked om, hvad der skal bestilles, til hvilken dato og til hvilket barn (navn, Cpr. og kommunekode). Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag

<h1><div id="Afsnit#1699579400598">Bestilling af høreapparater til børn</div></h1><div id="BodyWeb#1699579400598"><p> <a name="1699579400598Top"></a></p> <h3> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579400598Formaal">Formål</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579400598Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579400598Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579400598Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579400598Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579400598Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579400598Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579400598Bilag">Bilag</a><br> &nbsp;</h3> <p> <a name="1699579400598Formaal"></a></p> <h2> Formål</h2> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579400598Top">Tilbage til top</a></p> <h2> <a name="1699579400598Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p> Personale på Hørepædagogisk afsnit der bestiller høreapparater til børn</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579400598Top">Tilbage til top</a></p> <h2> <a name="1699579400598Definitioner"></a><br> Definitioner</h2> <p> &nbsp;</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579400598Top">Tilbage til top</a></p> <h2> <a name="1699579400598Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p> <strong>Hvis barnet <u>ikke</u> har ny tid</strong><br> Hvis apparatet bestilles af tilpasseren, lægges besked til sekretæren om, hvad der er bestilt hvornår og af hvem og til hvilket barn (navn og Cpr.)<br> Hvis apparatet bestilles af sekretæren, skal tilpasseren lægge besked om, hvad der skal bestilles, til hvilken klient (navn, Cpr. og kommunekode) samt, hvem apparatet skal lægges til.<br> Når apparatet er modtaget lægger sekretæren det i tilpasserens bakke.<br> Tilpasseren indstiller apparatet og sender det til barnet.<br> Der skrives i Auditbase, hvad der er gjort og hvorfor. Stregkoden sættes på ydelsesskemaet, der returneres til sekretariatet m.h.p. registrering.<br> <br> <strong>Hvis barnet har ny tid</strong><br> Hvis apparatet bestilles af tilpasseren, lægges besked til sekretæren om, hvad der er bestilt, til hvilken dato, af hvem og til hvilket barn (navn og Cpr.)<br> Hvis apparatet bestilles af sekretæren, skal tilpasseren lægge besked om, hvad der skal bestilles, til hvilken dato og til hvilket barn (navn, Cpr. og kommunekode).</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579400598Top">Tilbage til top</a></p> <h2> <a name="1699579400598Ansvar"></a><br> Ansvar og organisering</h2> <p> &nbsp;</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579400598Top">Tilbage til top</a></p> <h2> <a name="1699579400598Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p> &nbsp;</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579400598Top">Tilbage til top</a></p> <h2> <a name="1699579400598Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p> &nbsp;</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579400598Top">Tilbage til top</a></p> <h2> <a name="1699579400598Bilag"></a><br> Bilag</h2> <p> &nbsp;</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579400598Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Blad 5.

Blad 5 Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Målgrupper og anvendelsesområde Audiologisk afd, GeH Definitioner Fremgangsmåde Blad 5 Oprettelse af journal på lægeligt afsnit Klienten oprettes af sekretær i Auditbase. Audiologiassistent Indtaster audiogrammet i Auditbase og noterer særlig information om nødvendigt. Tilpasser Blad 5 indtastes i Auditbase vha. hotkey. Udfylder sammen med klienten de forskellige punkter. Hvis der er særlige forhold, noteres disse under ’Kommentarer’. Apparattype og serienummer noteres, eller stregkoden påklæbes ydelsesskemaet. For programmerbare apparater gemmes indstillingen i det pågældende firmas software. For ikke-programmerbare apparater noteres indstillingen. Alle oplysninger vedr. apparatet og størrelse på evt. vent, slange osv. noteres. Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag

<h1><div id="Afsnit#1699579374050">Blad 5</div></h1><div id="BodyWeb#1699579374050"><p><a name="1699579374050Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579374050Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579374050Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579374050Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579374050Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579374050Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579374050Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579374050Bilag">Bilag</a><br> &nbsp;</h3> <h2><a name="1699579374050Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p>&nbsp;Audiologisk afd, GeH</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579374050Top">Tilbage til top</a></p> <h2><a name="1699579374050Definitioner"></a><br> Definitioner</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579374050Top">Tilbage til top</a></p> <h2><a name="1699579374050Fremgangsmaade"></a><br> Fremgangsmåde</h2> <h3><strong>Blad 5</strong></h3> <p>&nbsp;</p> <p><u>Oprettelse af journal på lægeligt afsnit</u><br> <br> Klienten oprettes af sekretær i Auditbase.</p> <p><br> <u>Audiologiassistent</u><br> <br> Indtaster audiogrammet i Auditbase og noterer særlig information om nødvendigt.</p> <p><br> <u>Tilpasser</u></p> <p><br> Blad 5 indtastes i Auditbase vha. hotkey.<br> <br> Udfylder sammen med klienten de forskellige punkter. Hvis der er særlige forhold, noteres disse under ’Kommentarer’.<br> <br> Apparattype og serienummer noteres, eller stregkoden påklæbes ydelsesskemaet.<br> <br> For programmerbare apparater gemmes indstillingen i det pågældende firmas software.<br> <br> For ikke-programmerbare apparater noteres indstillingen.<br> <br> Alle oplysninger vedr. apparatet og størrelse på evt. vent, slange osv. noteres.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579374050Top">Tilbage til top</a></p> <h2><a name="1699579374050Ansvar"></a><br> Ansvar og organisering</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579374050Top">Tilbage til top</a></p> <h2><a name="1699579374050Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579374050Top">Tilbage til top</a></p> <h2><a name="1699579374050Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579374050Top">Tilbage til top</a></p> <h2><a name="1699579374050Bilag"></a><br> Bilag</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579374050Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Bortkomne i-¢ret apparat inden for garanti.

Bortkomne i-øret apparat inden for garanti Formål Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Formål Beskrivelse af forretningsgang ved bortkommet i-øret apparat indenfor garanti Målgrupper og anvendelsesområde Personale på Hørepædagogisk afs., GeH Definitioner Fremgangsmåde For klienter, der måtte være tilknyttet aud. afd. GeH vedr. HA-udlevering (fx. voksne og børn med CI på modsatte øre) og som opfylder kriterierne: I) I-øret apparatet/-erne er bortkommet/-ne, og II) apparat/-erne er indenfor garanti, gælder følgende: Klienten gives besked (fra enten Hørepædagogisk Afsnit eller det lokale kommunikationscenter) om at møde op i Ørepropteknikken (opgang 3B eller 3C) en tirsdag eller onsdag mellem 9 og 13, hvor de vil få taget aftryk af det øre, hvor de har mistet app. Et apparat svarende til det de har mistet, sendes hjem til klienten med samme indstilling som det tabte. Kommunikationscentret anmodes i ventetiden om akut hjælp med reserveapparat (evt. med sut). Såfremt klientens hørelse eller situation er væsentligt ændret siden sidste apparat-tildeling, anmodes Kommunikationscentret om akut afhjælpning af klientens hørevanskeligheder med reserveapparat, og der foretages følgende: a) Hvis der er I) markante ændringer i klientens situation, men II) høretabet er stationært i forhold til det tab, der blev påvist ved sidste nyudlevering, kan klienten – uden forudgående undersøgelse på lægeligt afsnit – indkaldes til Hørepædagogisk Afsnit, kontaktes telefonisk eller Kommunikationscentret sender oplysninger fra deres sidste møde med klienten. Der tages stilling til den optimale høreapparat-behandling, og klienten tildeles evt. tid til Ørepropteknikken m.h.p. ny/-e skal/-ler (evt. øreprop/-per) – og tid til Hørepædagogisk Afsnit m.h.p. tilpasning. Ved tildeling af nyt/-e apparat/-er tages hensyn til klientens præferencer. Personen slettes fra den ordinære venteliste og registreres som nyudlevering. b) Hvis høretabet er væsentligt ændret i forhold til det tab, der blev påvist ved sidste nyudlevering, indkaldes klienten til genkontrol på det lægelige afsnit. Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag

<h1><div id="Afsnit#1699579376237">Bortkomne i-øret apparat inden for garanti</div></h1><div id="BodyWeb#1699579376237"><p><a name="1699579376237Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579376237Formaal">Formål</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579376237Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579376237Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579376237Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579376237Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579376237Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579376237Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579376237Bilag">Bilag</a><br> &nbsp;</h3> <p><a name="1699579376237Formaal"></a></p> <h2>Formål</h2> <p>Beskrivelse af forretningsgang ved bortkommet i-øret apparat indenfor&nbsp;garanti</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579376237Top">Tilbage til top</a></p> <h2><a name="1699579376237Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p>Personale på Hørepædagogisk afs., GeH</p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579376237Top">Tilbage til top</a></p> <h2><a name="1699579376237Definitioner"></a><br> Definitioner</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579376237Top">Tilbage til top</a></p> <h2><a name="1699579376237Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p>For klienter, der måtte være tilknyttet aud. afd. GeH vedr. HA-udlevering (fx. voksne og børn med CI på modsatte øre)&nbsp;og som opfylder kriterierne:</p> <p>I) I-øret apparatet/-erne er bortkommet/-ne, og II) apparat/-erne er indenfor garanti, gælder følgende:<br> <br> Klienten gives besked (fra enten Hørepædagogisk Afsnit eller det lokale kommunikationscenter) om at møde op i Ørepropteknikken (opgang 3B eller 3C) en tirsdag eller onsdag mellem 9 og 13, hvor de vil få taget aftryk af det øre, hvor de har mistet app.<br> Et apparat svarende til det de har mistet, sendes hjem til klienten med samme indstilling som det tabte.<br> <br> Kommunikationscentret&nbsp;anmodes i ventetiden om akut hjælp med reserveapparat (evt. med sut).<br> <br> Såfremt klientens hørelse eller situation er væsentligt ændret siden sidste apparat-tildeling, anmodes Kommunikationscentret om akut afhjælpning af klientens hørevanskeligheder med reserveapparat, og der foretages følgende:</p> <p>a) Hvis der er I) markante ændringer i klientens situation, men II) høretabet er stationært i forhold til det tab, der blev påvist ved sidste nyudlevering, kan klienten – uden forudgående undersøgelse på lægeligt afsnit – indkaldes til Hørepædagogisk Afsnit, kontaktes telefonisk eller Kommunikationscentret sender oplysninger fra deres sidste møde med klienten. Der tages stilling til den optimale høreapparat-behandling, og klienten tildeles evt. tid til Ørepropteknikken m.h.p. ny/-e skal/-ler (evt. øreprop/-per) – og tid til Hørepædagogisk Afsnit m.h.p. tilpasning. Ved tildeling af nyt/-e apparat/-er tages hensyn til klientens præferencer. Personen slettes fra den ordinære venteliste og registreres som <em>nyudlevering.</em></p> <p>b) Hvis høretabet er væsentligt ændret i forhold til det tab, der blev påvist ved sidste nyudlevering, indkaldes klienten til genkontrol på det lægelige afsnit.<br> <br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579376237Top">Tilbage til top</a></p> <h2><a name="1699579376237Ansvar"></a><br> Ansvar og organisering</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579376237Top">Tilbage til top</a></p> <h2><a name="1699579376237Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579376237Top">Tilbage til top</a></p> <h2><a name="1699579376237Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579376237Top">Tilbage til top</a></p> <h2><a name="1699579376237Bilag"></a><br> Bilag</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579376237Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_BPPV.

BPPV Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Målgrupper og anvendelsesområde Læger og sygeplejersker Definitioner BPPV (Benign paroxysmal positional vertigo) Fremgangsmåde Epidemiologi og ætiologi: - kønsforskel ved idiopatisk BPPV, ♀: ♂ = 2:1 - Incidens: 11-64/100.000 pr. år og gennemsnitligt er pt. 57,2 år - Klart hyppigste perifere vestibulære sygdom - Børn rammes yderst sjældent og man kan se bort fra idiopatisk BPPV på børn < 15 år. Primær (idiopatisk) BPPV: - Hyppigst form for BPPV. Mænd ofte ældre end kvinder Sekundær BPPV: - Traumatisk BPPV (sværere at behandle end idiopatisk BPPV) - Høj alder disponere (9% af ældre befolkning (> 70 år) har ikke-diagnosticeret BPPV - Labyrintitis (samsidigt BPPV) - Ototoksisk medicinering - Mb. Menière (samsidigt BPPV) - Akut el. kronisk uni- eller bilateral perifer vestibulær neurolabyrinthitis. 20 % af alle med neuronitis vestibularis får BPPV samsidigt senere i livet - Pludselig sensorineural HNS (sudden deffness) Patogenese, symptomer og objektiv fremtræden: Otoliter (ørekrystaller) kan afstødes fra macula i utriculus. Disse el. akkumulation af frit flydende basofile nedrydningsprodukter fra henfaldne otolitter er fundet i buegangene under operation (histologisk verificeret). Krystallerne kan blive adhærente til cupula i kanalerne eller sedimentere i buegangene ved hovedbevægelser skabende en hydrodynamisk træk/tryk på cupula grundet tyngdekrafts påvirkning jvn. teorien om hhv. cupulolithiasis (CUP) og canalolithiasis (CAN). Affektion af posterior buegang er hyppigst. Ved CAN sker der en uhensigtsmæssig endolymfe strømning, idet ”krystallerne” bevæges af tyngdekraften, ved hoved bevægelser, der følgende skaber endolymfeforskydninger og giver cupulapåvirkning. Dette giver den samme provokation af cupula, som hvis man undergik en konstant rotation af hovedet i posteriore buegangsplan. Når debris når den laveste placering i buegang stopper endolymfestrømningerne, hvorfor der ses en kortvarig nystagmus (<30 sek.), der giver hyperakut vertigo (paroxysmal). Der er kort latens (3-10 sek.) før symptomer opstår. Symptomerne er trætbareberoende på at endolymfestrømning opløser debris og at hver provokerende hovedmanøvre gør at debris spredes til andre dele af det vestibulære apparat – skabende en mindre hydrodynamisk påvirkning på cupula. Efter positiv Dix-Hallpike test til oprejst stilling skifter nystagmussen retning. Nystagmus har et cresendo/decresendoforløb, hvor den førstnævnte er kraftigst. Nystagmus kraft er relateret til størrelse af cupuladisplaceringen. Posterior BPPV: Klart hyppigst afficerede buegang (90 %) Klinisk: Vertigo når pt. bevæger hovedet i posteriore buegangsplan. Nystagmus som er torsionel og vertikal med stor frekvens og lille amplitude og er geotrofisk (slår i gulv). Dette ses bedst uden fixation (brug frenzels brille eller videooculoskop). Canalolithiasis: Udredning/Behandling: Dix-Hallpike test & Epley’s manøvre Dix-Hallpike test (se nedenstående billede 1-3): - Fortæl pt. at denne bliver svimmel (svært nervøse patienter giv tbl. diazepam 5 mg) - Test først side der anamnestisk ikke er afficeret - Undgå visuel fiksering (brug BB, frenzel eller bedst VOG) - Patient sidder på briks med hovedet drejet 45 grader til ene side (den side der undersøges) - Patient hoved holdes mens denne lægges hurtigt lige bagover til horisontal stilling således at hovedet mobiliseres under det horisontale plan ved 15-20 graders ekstension i nakken. - Undersøger noterer evt. vertigo og nystagmus - Patient mobiliseres til siddende stilling uden hoveddrejning - Manøvren gentages med hovedet drejet 45 grader mod den anden side. Epley’s manøvre: - Patient ligger på den side som er testet positiv ved Dix-hallpikes test (billede 3). - Patient underkastes liggende rotation fra afficeret side mod raske side, beskrivende en rotationsgrad på ca. 225 grader, således patienten kommer til at ligge på modsat sidige skulder med næsen pegende ned i madrassen (billede 4-7). - Pt’s hoved skal være under det horisontale plan under rotationen for at undgå at debris mobiliseres mod cupula (hyppigste årsag til manglende effekt af manøvren) - Hvis der kommer nystagmus af samme retning undervejs i proceduren er det er godt tegn på at debris er på vej ind i utriculus (ampullofugal strømning), hvorimod en ampullopetal endolymfestrømning vil give modsatrettet nystagmus ift. initielle nystagmus (manøvren gentages!) - Hold patienten når denne kommer op og sidde, idet der ofte ses vertigo, da der ligger debris på macula i utriculus (billede 8-10) Kontraindikationer: Svær carotis stenose eller svær cervical sygdom Cupulolithiasis: &nb sp; Se billede 1-3 på nedenstående skitse. Efterbehandling ved posterior BPPV: - Hvis der kommer nye BPPV anfald efter initiale behandling skal patient opstarte træning med Brandt-Daroff øvelsesprogram 4 gang dagligt (hver gang med 4-5 gentagelser) i 2 uger (billede a-c, ovenstående skitse). - 15 % får tilbagefald pr. år. 50 % vil få nye anfald inden for 40 mdr. Øvelsesprogrammet medgives altidefter vellykket ambulant behandlingsforløb. Horisontal BPPV: 3-9 % af BPPV anfald, oftest > 50 årige patienter Afdeling: Pt. bliver meget svimmel når de drejer sig i liggende stilling. Symp. værst, når man ligger på afficerede side og har lille latens (op til 8 sek.). Symptomer mere udtalte end for posterior BPPV. Nystagmus er ren horisontal, med stor frekvens og lille amplitude (VMG meget god!). Canalolithiasis: &nb sp; Geotrofisk (slår i gulvet) horisontal nystagmus ved sideleje på begge sider (billede 2-5), lille latens før nystagmus. Vertigo værst ved sideleje med syg side nedad jvn. Eward’s lov om ampullopetal endolymfestrømning. Cupulolithiasis: Apogeotrofisk (slår i loftet) nystagmus i begge sidelejer, vedvarende symp. Ingen latens før nystagmus. Mest vertigo når man ligger på ikke-afficerede side, idet man har ampullopetal endolymfestrømninng. Udredning/Behandling: Canalolithiasis: Pt. ligger på afficerede side efter at have gennemgået lateral buegangstest (billede 6). Patienten underkastes 360 graders rotation som i billede 7-10, hvorefter pt. kommer op og sidde (billede 11). Cupulolithiasis: Først head-shake test indtil nystagmus er som ved canalolithiasis. Herefter behandles tilstanden som vist i billede 6-11. Anterior BPPV: Mindst afficerede buegang (<2 %) Afdeling: Dix-Hallpike manøvre: Ageotrofisk torsionel nystagmus med nedad slående vertikal nystagmus. Der er stor frekvens og lille amplitude. Får man denne nystagmus med samtidig vertigo ved Dix-hallpike højresidigt er det udtryk for canalolithiasis af ve. anteriore semicirculare kanal. Behandling: Omvendt Epley manøvre, henvis til vestibulært interesseret læge. Forløb: 90 % af patienter bliver spontant bedre inden for 6-12 uger. Vanligvis kommer der relaps af deres symptomer senere i livet. Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag

<h1><div id="Afsnit#1699579378464">BPPV</div></h1><div id="BodyWeb#1699579378464"><p><a name="1699579378464Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579378464Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579378464Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579378464Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579378464Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579378464Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579378464Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579378464Bilag">Bilag</a><br> &nbsp;</h3> <h2><a name="1699579378464Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p>&nbsp;Læger og sygeplejersker</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579378464Top">Tilbage til top</a></p> <h2><a name="1699579378464Definitioner"></a><br> Definitioner</h2> <p><strong><span style="color:#000000">BPPV (Benign paroxysmal positional vertigo) </span></strong></p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579378464Top">Tilbage til top</a></p> <h2><a name="1699579378464Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p><strong>Epidemiologi og ætiologi: </strong></p> <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kønsforskel ved idiopatisk BPPV, ♀: ♂ = 2:1</p> <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Incidens: 11-64/100.000 pr. år og gennemsnitligt er pt. 57,2 år</p> <p>-&nbsp;&nbsp;&nbsp;&nbsp; Klart hyppigste perifere vestibulære sygdom</p> <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Børn rammes yderst sjældent og man kan se bort fra idiopatisk BPPV på børn &lt; 15 år.</p> <p>&nbsp;</p> <p><u>Primær (idiopatisk) BPPV: </u></p> <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hyppigst form for BPPV. Mænd ofte ældre end kvinder</p> <p><u>Sekundær BPPV: </u></p> <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Traumatisk BPPV (sværere at behandle end idiopatisk BPPV)</p> <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Høj alder disponere (9% af ældre befolkning (&gt; 70 år) har ikke-diagnosticeret BPPV</p> <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Labyrintitis (samsidigt BPPV)</p> <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ototoksisk medicinering&nbsp;</p> <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mb. Menière (samsidigt BPPV)</p> <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Akut el. kronisk uni- eller bilateral perifer vestibulær neurolabyrinthitis. 20 % af alle med neuronitis vestibularis får BPPV samsidigt senere i livet</p> <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pludselig sensorineural HNS (sudden deffness)</p> <p><strong>Patogenese, symptomer og objektiv fremtræden: </strong></p> <p>Otoliter (ørekrystaller) kan afstødes fra macula i utriculus. Disse el. akkumulation af frit flydende basofile nedrydningsprodukter fra henfaldne otolitter er fundet i buegangene under operation (histologisk verificeret). Krystallerne kan blive adhærente til cupula i kanalerne eller sedimentere i buegangene ved hovedbevægelser skabende en hydrodynamisk træk/tryk på cupula grundet tyngdekrafts påvirkning jvn. teorien om hhv. cupulolithiasis (CUP) og canalolithiasis (CAN). Affektion af posterior buegang er hyppigst.</p> <p>Ved CAN sker der en uhensigtsmæssig endolymfe strømning, idet ”krystallerne” bevæges af tyngdekraften, ved hoved bevægelser, der følgende skaber endolymfeforskydninger og giver cupulapåvirkning. Dette giver den samme provokation af cupula, som hvis man undergik en konstant rotation af hovedet i posteriore buegangsplan. Når debris når den laveste placering i buegang stopper endolymfestrømningerne, hvorfor der ses en <u>kortvarig nystagmus </u>(&lt;30 sek.), der giver <u>hyperakut vertigo</u> (paroxysmal). Der er kort <u>latens</u> (3-10 sek.) før symptomer opstår. Symptomerne er <u>trætbare</u>beroende på at endolymfestrømning opløser debris og at hver provokerende hovedmanøvre gør at debris spredes til andre dele af det vestibulære apparat – skabende en mindre hydrodynamisk påvirkning på cupula. Efter positiv Dix-Hallpike test til oprejst stilling <u>skifter nystagmussen retning</u>. Nystagmus har et <u>cresendo/decresendo</u>forløb, hvor den førstnævnte er kraftigst. Nystagmus kraft er relateret til størrelse af cupuladisplaceringen.</p> <p><strong>Posterior BPPV: </strong></p> <p>Klart hyppigst afficerede buegang (90 %)<br> <br> Klinisk:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vertigo når pt. bevæger hovedet i posteriore buegangsplan. Nystagmus som er torsionel og vertikal med stor frekvens og lille amplitude og er geotrofisk (slår i gulv). Dette ses bedst uden fixation (brug frenzels brille eller videooculoskop).<br> <br> <u>Canalolithiasis</u>: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br> Udredning/Behandling: Dix-Hallpike test &amp; Epley’s manøvre<br> <br> Dix-Hallpike test (se nedenstående billede 1-3):</p> <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fortæl pt. at denne bliver svimmel (svært nervøse patienter giv tbl. diazepam 5 mg)</p> <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Test først side der anamnestisk ikke er afficeret</p> <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Undgå visuel fiksering (brug BB, frenzel eller bedst VOG)</p> <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient sidder på briks med hovedet drejet 45 grader til ene side (den side der undersøges)</p> <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient hoved holdes mens denne lægges hurtigt lige bagover til horisontal stilling således at hovedet mobiliseres under det horisontale plan ved 15-20 graders ekstension i nakken.</p> <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Undersøger noterer evt. vertigo og nystagmus</p> <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient mobiliseres til siddende stilling uden hoveddrejning</p> <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Manøvren gentages med hovedet drejet 45 grader mod den anden side.</p> <p>&nbsp;</p> <p>Epley’s manøvre:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p> <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient ligger på den side som er testet positiv ved Dix-hallpikes test (billede 3).</p> <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient underkastes liggende rotation fra afficeret side mod raske side, beskrivende en rotationsgrad på ca. 225 grader, således patienten kommer til at ligge på modsat sidige skulder med næsen pegende ned i madrassen (billede 4-7).</p> <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pt’s hoved skal være under det horisontale plan under rotationen for at undgå at debris mobiliseres mod cupula (hyppigste årsag til manglende effekt af manøvren)</p> <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hvis der kommer nystagmus af samme retning undervejs i proceduren er det er godt tegn på at debris er på vej ind i utriculus (ampullofugal strømning), hvorimod en ampullopetal endolymfestrømning vil give modsatrettet nystagmus ift. initielle nystagmus (manøvren gentages!)</p> <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hold patienten når denne kommer op og sidde, idet der ofte ses vertigo, da der ligger debris på macula i utriculus (billede 8-10)</p> <p>&nbsp;</p> <p><img src="http://vip.regionh.dk/VIP/Redaktoer/130126.nsf/vLookupUpload/SYSA8MKUA7120/$file/Webdoc_image001.gif" onclick="Ext.DMS.util.showImage(this);"></p> <p>&nbsp;</p> <p>Kontraindikationer: Svær carotis stenose eller svær cervical sygdom<br> <br> <u>Cupulolithiasis</u>:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&amp;nb sp;&nbsp;<br> <br> Se billede 1-3 på nedenstående skitse.</p> <p>&nbsp;</p> <p><img src="http://vip.regionh.dk/VIP/Redaktoer/130126.nsf/vLookupUpload/SYSA8MKUA9121/$file/Webdoc_image002.gif" onclick="Ext.DMS.util.showImage(this);"></p> <p>&nbsp;</p> <p><u>Efterbehandling ved posterior BPPV</u>:<br> &nbsp;</p> <ul> <li>Hvis der kommer nye BPPV anfald efter initiale behandling skal patient opstarte træning med Brandt-Daroff øvelsesprogram 4 gang dagligt (hver gang med 4-5 gentagelser) i 2 uger (billede a-c, ovenstående skitse).</li> <li>15 % får tilbagefald pr. år. 50 % vil få nye anfald inden for 40 mdr. Øvelsesprogrammet medgives <u>altid</u>efter vellykket ambulant behandlingsforløb.</li> </ul> <p><strong>Horisontal BPPV:</strong></p> <p>3-9 % af BPPV anfald, oftest &gt; 50 årige patienter<br> <br> Afdeling: Pt. bliver meget svimmel når de drejer sig i liggende stilling. Symp. værst, når man ligger på afficerede side og har lille latens (op til 8 sek.). Symptomer mere udtalte end for posterior BPPV.&nbsp;&nbsp;Nystagmus er ren horisontal, med stor frekvens og lille amplitude (VMG meget god!).</p> <p>&nbsp;</p> <p><img src="http://vip.regionh.dk/VIP/Redaktoer/130126.nsf/vLookupUpload/SYSA8MKUAB122/$file/Webdoc_image003.gif" onclick="Ext.DMS.util.showImage(this);"></p> <p>&nbsp;</p> <p><u>Canalolithiasis</u>:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&amp;nb sp;&nbsp; Geotrofisk (slår i gulvet) horisontal nystagmus ved sideleje på begge sider (billede 2-5), lille latens før nystagmus. Vertigo værst ved sideleje med syg side nedad jvn. Eward’s lov om ampullopetal endolymfestrømning.<br> <br> <u>Cupulolithiasis</u>: Apogeotrofisk (slår i loftet) nystagmus i begge sidelejer, vedvarende symp. Ingen latens før nystagmus. Mest vertigo når man ligger på ikke-afficerede side, idet man har ampullopetal endolymfestrømninng.<br> <br> <u>Udredning/Behandling</u>:<br> Canalolithiasis: Pt. ligger på afficerede side efter at have gennemgået lateral buegangstest (billede 6). Patienten underkastes 360 graders rotation som i billede 7-10, hvorefter pt. kommer op og sidde (billede 11).<br> <br> Cupulolithiasis: Først head-shake test indtil nystagmus er som ved canalolithiasis. Herefter behandles tilstanden som vist i billede 6-11.</p> <p><strong>Anterior BPPV:</strong></p> <p>Mindst afficerede buegang (&lt;2 %)<br> <br> Afdeling: Dix-Hallpike manøvre: Ageotrofisk torsionel nystagmus med nedad slående vertikal nystagmus. Der er stor frekvens og lille amplitude. Får man denne nystagmus med samtidig vertigo ved Dix-hallpike højresidigt er det udtryk for canalolithiasis af ve. anteriore semicirculare kanal.<br> <br> Behandling: Omvendt Epley manøvre, henvis til vestibulært interesseret læge.</p> <p><strong>Forløb: </strong></p> <p>90 % af patienter bliver spontant bedre inden for 6-12 uger. Vanligvis kommer der relaps af deres symptomer senere i livet.</p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579378464Top">Tilbage til top</a></p> <h2><a name="1699579378464Ansvar"></a><br> Ansvar og organisering</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579378464Top">Tilbage til top</a></p> <h2><a name="1699579378464Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579378464Top">Tilbage til top</a></p> <h2><a name="1699579378464Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579378464Top">Tilbage til top</a></p> <h2><a name="1699579378464Bilag"></a><br> Bilag</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579378464Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Bufret Lidokain.

Bufret Lidokain Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Bilag Målgrupper og anvendelsesområde Formål: at reducere smerte ved anlæggelse af lokalanæstesi. Kan anvendes alle steder hvor der overvejes lokalanæstesi, både til biopsier og andre mindre indgreb på ansigt og hals. Målgruppe: Klinisk personale i Øre-næse-halskirurgisk og Audiologisk Afdeling. Både i ambulatoriet og på operationsgangen. Definitioner Fremgangsmåde Baggrund: Lokalanæstesi er i sig selv svagt basisk og virker som sådan optimalt, da transporten over nociceptorernes cellemembran optimeres af denne anioniserede tilstand. Kommercielt fremstillede lokalanalgetika har lavere pH for blandt andet at øge holdbarhed. Bufring til højere pH med natriumbikarbonat nedsætter smerteopfattelsen samt øger effekten af lokalanæstesi. I afdelingen bruges typisk lidokain med adrenalin 10mg/5 mikrog/mL (1%) henholdsvis 20 mg/5 mikrog/mL (2 %), der har pH 4,24 henholdsvis 3,93. Lidokain uden adrenalin har pH 6,09 henholdsvis 6,00. Optimale forhold for indgift af lokalanæstesi: -Opløsning tempereret til stuetemperatur/ kropstemperatur -Bufring med natriumbikarbonat til fysiologisk pH -Brug så lille nål som muligt, altid skarpest muligt -Stik med nålen vinkelret på huden -Indgift subdermalt, ikke intradermalt -Langsom indgift, altid avancere nålen langsommere end den givne dosis ”blow before you go” -Evt. nyt indstik hvor der allerede er lagt lokalanæstesi -Overvej distraktion, også taktil distraktion Forsigtighed: Må ikke bruges til patienter med allergi overfor et eller flere af indholdsstofferne. Til børn: maximal injektion af lidokain er 7 mg/kg, (eks vægt 30 kg: max injektion ca. 20 mL 10 mg/5 mikrog/mL (1%) lidokain) Lidokain med adrenalin bufret med natriumbikarbonat skal bruges samme dag. Resten kasseres. Denne vejledning vedrørende bufring gælder kun for lidokain med adrenalin 1%, da det er denne koncentration studierne underbygger. Vejledning: Lidokain med adrenalin 1%, (10 mg/5 mikrog/mL) 10 mL Natriumbikarbonat 84 mg/ml (8,4%) (1mmol/mL) 1 mL Der trækkes i samme 10 mL sprøjte først 1 mL natriumbikarbonat op og derefter i samme sprøjte 10 mL lidokain-adrenalin. Vendes forsigtigt et par gange og er klar til brug. Samme gælder for 20 mL sprøjter: 2 mL natriumbikarbonat til 20 mL lidokain-adrenalin. 5 mL sprøjter: 0,5 mL natriumbikarbonat til 5 mL lidokain-adrenalin. Kan evt. blandes i en steril kop Ansvar og organisering Forfattere: afdelingslæge ###NAVN###, overlæge ###NAVN###, februar 2023 Forefindes på ØNH operationsgang 7023 i medicinrum, indkøbes ved anæstesiens indkøber. Forefindes i medicinrum i ØNH-ambulatoriet på 5. sal (7056), indkøbes ved ambulatoriets indkøbsansvarlige. Referencer, lovgivning og faglig evidens samt links hertil Buffered lidocaine and bupivacaine mixture – the ideal local anesthetic solution? Plast Surg (Oakv). 2015 Summer, 23(2):87-90. Corliss et al How acidic is the lidocaine we are injecting, and how much bicarbonate should we add? Can J Plast Surg. 2012 Summer; 20(2): 71–73. Frank et al Minimizing the Pain of Local Anesthesia Injection. Plast Reconstr Surg. 2013 Sep;132(3):675-84. Strazar et al Bilag

<h1><div id="Afsnit#1699579262586">Bufret Lidokain</div></h1><div id="BodyWeb#1699579262586"><p><a name="1699579262586Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579262586Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579262586Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579262586Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579262586Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579262586Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579262586Bilag">Bilag</a><br> &nbsp;</h3> <h2>&nbsp;</h2> <div class="collapsible-item" expandedstart="1"><a name="1699579262586Maalgrupper"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Målgrupper og anvendelsesområde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong>Formål</strong>:</p> <p style="margin-left:0cm; margin-right:0cm">at reducere smerte ved anlæggelse af lokalanæstesi. Kan anvendes alle steder hvor der overvejes lokalanæstesi, både til biopsier og andre mindre indgreb på ansigt og hals.</p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:#222222">Målgruppe</span></strong><span style="color:#222222">: </span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#222222">Klinisk personale i Øre-næse-halskirurgisk og Audiologisk Afdeling. Både i ambulatoriet og på operationsgangen.</span></p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579262586Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579262586Definitioner"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Definitioner</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579262586Fremgangsmaade"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Fremgangsmåde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm"><strong>Baggrund</strong>:</p> <p style="margin-left:0cm; margin-right:0cm">Lokalanæstesi er i sig selv svagt basisk og virker som sådan optimalt, da transporten over nociceptorernes cellemembran optimeres af denne anioniserede tilstand. Kommercielt fremstillede lokalanalgetika har lavere pH for blandt andet at øge holdbarhed.</p> <p style="margin-left:0cm; margin-right:0cm">Bufring til højere pH med natriumbikarbonat nedsætter smerteopfattelsen samt øger effekten af lokalanæstesi.</p> <p style="margin-left:0cm; margin-right:0cm">I afdelingen bruges typisk lidokain med adrenalin 10mg/5 mikrog/mL (1%) henholdsvis 20 mg/5 mikrog/mL (2 %), der har pH 4,24 henholdsvis 3,93. Lidokain uden adrenalin har pH 6,09 henholdsvis 6,00.</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong>Optimale forhold for indgift af lokalanæstesi:</strong></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm">-Opløsning tempereret til stuetemperatur/ kropstemperatur</p> <p style="margin-left:0cm; margin-right:0cm">-Bufring med natriumbikarbonat til fysiologisk pH</p> <p style="margin-left:0cm; margin-right:0cm">-Brug så lille nål som muligt, altid skarpest muligt</p> <p style="margin-left:0cm; margin-right:0cm">-Stik med nålen vinkelret på huden</p> <p style="margin-left:0cm; margin-right:0cm">-Indgift subdermalt, ikke intradermalt</p> <p style="margin-left:0cm; margin-right:0cm">-Langsom indgift, altid avancere nålen langsommere end den givne dosis</p> <p style="margin-left:0cm; margin-right:0cm">”blow before you go”</p> <p style="margin-left:0cm; margin-right:0cm">-Evt. nyt indstik hvor der allerede er lagt lokalanæstesi</p> <p style="margin-left:0cm; margin-right:0cm">-Overvej distraktion, også taktil distraktion</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong>Forsigtighed</strong>:</p> <p style="margin-left:0cm; margin-right:0cm">Må ikke bruges til patienter med allergi overfor et eller flere af indholdsstofferne.</p> <p style="margin-left:0cm; margin-right:0cm">Til børn: maximal injektion af lidokain er 7 mg/kg, (eks vægt 30 kg: max injektion ca. 20 mL 10 mg/5 mikrog/mL (1%) lidokain)</p> <p style="margin-left:0cm; margin-right:0cm">Lidokain med adrenalin bufret med natriumbikarbonat skal bruges samme dag. Resten kasseres.</p> <p style="margin-left:0cm; margin-right:0cm">Denne vejledning vedrørende bufring gælder kun for lidokain med adrenalin 1%, da det er denne koncentration studierne underbygger.</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong>Vejledning</strong>:</p> <p style="margin-left:0cm; margin-right:0cm">Lidokain med adrenalin 1%, (10 mg/5 mikrog/mL) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 10 mL</p> <p style="margin-left:0cm; margin-right:0cm">Natriumbikarbonat 84 mg/ml (8,4%) (1mmol/mL) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 mL</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm">Der trækkes i samme 10 mL sprøjte først 1 mL natriumbikarbonat op og derefter i samme sprøjte 10 mL lidokain-adrenalin. Vendes forsigtigt et par gange og er klar til brug.</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm">Samme gælder for</p> <p style="margin-left:0cm; margin-right:0cm">20 mL sprøjter: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2 mL natriumbikarbonat til 20 mL lidokain-adrenalin.</p> <p style="margin-left:0cm; margin-right:0cm">5 mL sprøjter: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0,5 mL natriumbikarbonat til 5 mL lidokain-adrenalin.</p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#222222">Kan evt. blandes i en steril kop</span></p> <p style="margin-left:0cm; margin-right:0cm"><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579262586Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579262586Ansvar"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Ansvar og organisering</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm">Forfattere: afdelingslæge ###NAVN###, overlæge ###NAVN###, februar 2023</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm">Forefindes på ØNH operationsgang 7023 i medicinrum, indkøbes ved anæstesiens indkøber.</p> <p style="margin-left:0cm; margin-right:0cm">Forefindes i medicinrum i ØNH-ambulatoriet på 5. sal (7056), indkøbes ved ambulatoriets indkøbsansvarlige.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579262586Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579262586Referencer"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Referencer, lovgivning og faglig evidens samt links hertil</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm">Buffered lidocaine and bupivacaine mixture – the ideal local anesthetic solution? Plast Surg (Oakv). 2015 Summer, 23(2):87-90. Corliss et al</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm">How acidic is the lidocaine we are injecting, and how much bicarbonate should we add? Can J Plast Surg. 2012 Summer; 20(2): 71–73. Frank et al<br> &nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><span style="background-color:white"><span style="color:#333333">Minimizing the Pain of Local Anesthesia Injection. </span><span style="color:black"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23985640" title="Plastic and reconstructive surgery."><span style="color:black">Plast Reconstr Surg.</span></a></span><span style="color:black"> 2013 Sep;132(3):675-84</span><span style="color:#333333">. Strazar et al</span></span></p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579262586Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579262586Bilag"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Bilag</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579262586Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Chylos lækage efter operation på hals.

Chylos lækage efter operation på hals Målgrupper og anvendelsesområde Klinisk personale på øre-næse-halskirurgiske afdelinger i Region Hovedstaden Definitioner Chylos lækage er et iatrogent læk på ductus thoracicus eller ductus lymfaticus med siven af chylos til omgivelserne. Klinisk ses chylos som en mælkehvid væske, som består aflymfe med indhold af protein, fedt (triglycerider), lymfocytter og elektrolytter. Baggrund: Incidensen for venstresidig og højresidig chylos lækage efter halsdissektion er henholdsvis 1,5-6% og 3-5% (1-5). En meget sjælden manifestation er chylothorax, hvor der er chylos lækage til pleurahulen. Chylos lækage og chylothorax er potentielt livstruende tilstande og kan føre til alvorlige metaboliske, immunologiske og ernæringsmæssige komplikationer (6). Patienter med konstateret chylos lækage har oftest langvarige hospitalsindlæggelser. Anatomi og funktion: På halsen løber ductus thoracicus op på venstre side, hvor den danner en opad konveks bue og ender i vena brachiocephalica sinistra i vinklen mellem vena subclavia sinistra og vena jugularis interna. Transport af langkædet fedt (LCT), fedtopløselige vitaminer samt lymfocytter fra tarmen til det systemiske kredsløb sker via lymfekarret ductus thoracicus. Fremgangsmåde Diagnosticering af chylos lækage: Peroperativt: Efter faste ses der sjældent en egentlig ductus, af og til antydning af flere mindre lymfekar. Lækage identificeres sjældent ved synlig perforation af ductus men en mælkehvid væske eller diffus siven af fedtperler dybt i operationsfeltet skal rette mistanke mod chylos. Hvis patienten er langvarigt fastende eller underernæret, vil chylos væsken kunne fremstå mere klar. Ved tvivl kan der foretages Trendelenburg lejring, Valsalva manøvre eller højtryks ventilation mhp. diagnosticering. Postoperativt: Der skal rettes mistanke til chylos lækage, når der i drænet eller ved nålepunktur af væskeansamling på hals findes en uigennemsigtig mælkehvid væske. Oftest opstår chylos 1-2 dage postoperativt, efter indtag af fedt enteralt (første måltid efter operationen). Ved konstatering af chylos ordineres røntgen af thorax (for at udelukke chylothorax) og væsken skal sendes til klinisk biokemisk afdeling mhp. undersøgelse for proteinindhold, celletælling, dyrkning og resistensbestemmelse samt lipidanalyse (for triglycerid og kolesterol), se vejledning senere. Ved konstateret postoperativ chylothorax henvises til VIPs: ”Chylothorax, instruks” / ”Thoraxintensiv – Chylothorax, diagnosticering og behandling”. Ved chylothorax hos børn henvises til VIP: ”Chylothorax, Diætbehandling til børn med postoperativt Chylothorax”. Rekvirering af analyse for triglycerid på Klinisk Biokemisk Afdeling KB3011, Rigshospitalet: Væske opsamles i spidsglas. Der skal rekvireres en diverse analyse (DIVANA). Denne rekvireres i SP med kode EPC00148, klinisk information skal besvares, f.eks. drænvæske obs. chylos, analyse for triglyceridkoncentration ønskes. Diagnostisk kriterie for chylos væske: Triglyceridkoncentration over 1,24 mmol/l ~ 110mg/dl (7). NB! Referenceniveau angives ikke ved analysesvar. Operativ behandling af chylos lækage Formålet er en operativ lukning af lymfekarret. Ofte er der tale om et tilløb fra cervicale lymfekar eller en sidegren til ductus thoracicus, som er overskåret. Der skal ikke anvendes diatermi inklusiv Ligasure grundet risiko for yderligere lædering af lymfekarret. 1. Generelt anbefales anvendelse af clips suppleret med underbinding ved ligering eller gennemstikning med Nylon/Vicryl sutur 3-0. Fibrinklæber kan overvejes. 2. Dækning af området med m. sternocleidomastoideus kan overvejes ved re-operation eftermislykket konservativ behandling. 3. Ved fortsat usikkerhed omkring optimalt ophør af siven, kan man peroperativt lægge long-line og give aflastende behandling ved ernæring parenteralt som nedenfor beskrevet. Postoperativ behandling af chylos lækage Der skelnes mellem konservativ eller kirurgisk behandling. Konservativ behandling: Princippet er drænage og diætmodifikation mhp. at minimere produktion af lymfevæske (chylos) i kroppen. Generelt: - - Opstart forebyggende antibiotika med Cefuroxim 1,5g x3dagl gr. risiko for immundef - Dræn til monitering af chylos produktion under indlæggelse. Dræn sættes uden vacuum på dræn. Drænet kan seponeres ved drænproduktion <30ml uanset væsketype. - Afhængig at output i drænet opstartes enten: - Total parenteral ernæring (PE) + ”noget at tygge på” (fedtfrit supplement til PE) - Fedtfattig kost 15g fedt i døgnet - Ved sondeernæring eller reduceret mulighed for pr os indtag, Ultra fruit protein drik (0 gram fedt) enten pr. oralt eller pr. sonde. - Ved tvivlstilfælde eller ved særlige udfordringer kan en diætist kontaktes. - Blodprøver: Væsketal monitoreres dagligt. Blodprøve: ”Parenteral ernæring” (Triglycerid, Fosfat, Karbamid, ALAT, Basisk fosfatase, Bilirubin, Syre-base) bestilles x3 ugentligt og Albumin bestilles x 1 ugentligt. - Daglig vejning mhp væske- og ernærings balance. - Daglig monitorering og måling af drænproduktion. 1. Ved drænproduktion 30-100 ml, opstart total parenteral ernæring (TPN) med supplement per os ”noget at tygge på” + det anbefalede at drikke (se bilag 1) i minimum 3 dage. Se i øvrigt VIP instruks ”Parenteral ernæring for voksne - procedurer og forholdsregler”. 2. Ved drænproduktion ≤30ml, skiftes fra TPN til fedtfattig diæt 15 gram fedt i døgnet i minimum 7 dage. Hvis patienten skal have sonde ernæring udregnes ernæringsbehov og patienten får en kombination af Ultra fruit P-drik (0 gram fedt) og almindelig P-drik svarende til det daglig tilladelige fedtindtag , f.eks 1 almindelig P-drik og 4 ultra fruit daglig. Se i øvrigt Rigshospitalets kosthåndbog (bestilles ved at ringe til centralkøkken eller tale med måltidsværter). (se bilag 2). 3. Dræn output>100ml/døgn og især ved high-flow chylos bør snarlig operation overvejes for at undgå langvarig indlæggelse samt alvorlige komplikationer. 4. Medicinsk behandling med subcutan administration af somatostatinanalogen Octreotid hæmmer tarmmotiliteten og flere processer i gastrointestinalkanalen medførende et reduceret flow i ductus thoracicus. De fleste studier har anvendt en kombination af TPN og Octreotid s.c. eller i.v. 0,1mg x3 dagligt indtil 2 døgn efter ophør af chylos. Der er kun mindre case-series og enkelte case-reports rapporteret, men generelt mangelfuld evidens på dette område (8-9). 5. Coilingbehandling kan overvejes: visualisering af lymfekar med lymfangiografi og efterfølgende kanylering og coiling, konferer med Røntgenafdelingen. 6. Ved operation kan overvejes ICG, for lettere at kunne visualisere ductus thoraticus Sygepleje til patient der behandles konservativt for Chylos. Observationer: - Der dokumenteres i vurderingsskemaet løbende eller minimum X1 i hver vagt. - EWS efter algoritme medmindre andet er ordineret, specielt fokus på respiration (Chylothorax) og blodtryk, væskebalance dokumenteres. - Forbinding tilses og skiftes ved behov, output kan skønnes eller forbinding kan vejes. - Registrer chylos mængde og beskriv hvordan det ser ud (farve / udseende). Der tilstræbes 0-balance. - CVK tilses og der udøves daglig sygepleje og dokumentation i henhold til VIP: ”Centralevenekatetre (CVK) inkl. akutte dialysekatetre ikke tunnelerede til børn og voksne - anlæggelse,observation, pleje og seponering” - Dræn observeres, aflæses og skiftes ved behov. 1.døgn post operativt kl 8 og kl.20. Derefter x1 døgnet kl 8. - Blodprøver efter ordination - Ernærings udregning i samarbejde med læge - Bestilling af fedtfri kost i køkkenet (noget at tygge på, bytteliste mm.), se bilag 1 - Daglig vægt Information: Patienten informeres om behandlingsplan inden den iværksættes. Læge og sygeplejerske går fælles stuegang hvor plan for de næste 24 timer gennemgås for patienten. Derefter daglig fælles opfølgning og justering til stuegang. Patienten informeres om at give besked til sygeplejersken hvis tilstanden forandre sig, informeres om at være opmærksom på vejrtrækning (store ansamlinger af Chylos) og svimmelhed (stort væske deficit) Personlig pleje: Patienten kan tage bad hvis dræn/ forbinding tildækkes Personlig hygiejne som normalt, tilbydes hjælp til dette. Hyppigt tøjskifte og soignering. Psykisk: Da tilstanden ofte tager flere dage optil uger, er det vigtigt at patienten daglig får mulighed for at tale om sin tilstand og sine tanker og de ubehagelige følger der kan være forbundet hermed. Det kan være en fordel at patienten får lov til at bevæge sig lidt ud af afdelingen (forhal, have, fælledparken mm). Opfordres til besøg og støtte fra familie. Udskrivning: Patienten udskrives når chylos output er stoppet. Ofte med fedt reduceret diæt 15 gram fedt i døgnet i 7 dage (ved sonde kombination af fedtfri P-drik og almindelig P-drik = ca. 15 gram fedt daglig). Ambulant opfølgning derefter. Under udskrivningssamtalen kan bilag 2. benyttes til information og gennemgang om diæten efter udskrivelsen. Eventuelt kan bilag 2 kopieres og udleveres til patienten forudgået af en sygeplejerske gennemgang af dette. Diætist kan kontaktes ved specielle udfordringer omkring diæten. Udskrivningssamtalen indeholder: - Gennemgang af diæt, hvilken og hvor længe. - Symptomer som patienten skal være opmærksom på hjemme. - Sår pleje og tegn på infektion. - Evt. monitorering af egen vægt. - Ambulante tider og plan. Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Evidensniveau: Der foreligger ingen retningslinjer eller konsensus omkring behandling af chylos lækage. Evidensniveau er 2b/3b samt 4, generelt case-reports, reviews og retrospektive observationsstudier. 1. Santaolalla F, Anta JA, Zabala A, Del Rey Sanchez A, et al. Management of chylous fistula as a complication of neck dissection: A 10-year retrospective review. Eur J Cancer Care (Engl) 2010;19:510–5 2. Campisi CC, Boccardo F, Piazza C, Campisi C. Evolution of chylous fistula management after neck dissection. Curr Opin Otolaryngol Head Neck Surg 2013;21:150–6. 3. Ahn D, Sohn JH, Jeong JY. Chyle Fistula After Neck Dissection: An 8-Year, Single-Center, Prospective Study of Incidence, Clinical Features, and Treatment. Ann Surg Oncol 2015;22:1000–6. 4. Dhiwakar M, Nambi GI, Ramanikanth T V. Drain removal and aspiration to treat low output chylous fistula. Eur Arch Oto-Rhino-Laryngology 2014;271:561–5. 5. Nussenbaum B, Liu JH, Sinard RJ. Systematic management of chyle fistula: the Southwestern experience and review of the literature. Otolaryngol Head Neck Surg 2000;122:31–8. 6. Prabhu V, Passant C. Left-sided neck dissection and chylothorax: a rare complication and its management. J Laryngol Otol 2012;126:648–50. 7. Mikkel Hvass et al. Chylothorax. Ugeskr Læger 2017;179:V05170429 8. Swanson MS, Hudson RL, Bhandari N, Sinha UK, et al. Use of Octreotide for the Management of Chyle Fistula Following Neck Dissection. JAMA Otolaryngol Head Neck Surg 2015;141:723–7.4. 6. Roh J-L, Kim DH, Park C Il. Prospective identification of chyle leakage in patients undergoing lateral neck dissection for metastatic thyroid cancer. Ann Surg Oncol 2008;15:424–9. 9. Sarah Nielsen. Kandidatspeciale: Systematic literature review of treatment options for chylous fistula after neck surgery. 14.07.2014.

<h1><div id="Afsnit#1699579326846">Chylos lækage efter operation på hals</div></h1><div id="BodyWeb#1699579326846"><p><a name="1699579326846Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579326846Maalgrupper">Målgrupper og anvendelsesområde</a></h3> <h3>Klinisk personale på øre-næse-halskirurgiske afdelinger i Region Hovedstaden</h3> <h3><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579326846Definitioner">Definitioner</a></h3> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Chylos lækage er et iatrogent læk på ductus thoracicus eller ductus lymfaticus med siven af chylos til omgivelserne. Klinisk ses chylos som en mælkehvid væske, som består aflymfe med indhold af protein, fedt (triglycerider), lymfocytter og elektrolytter.</span></p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Baggrund:</span></strong><span style="color:black"> Incidensen for venstresidig og højresidig chylos lækage efter</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">halsdissektion er henholdsvis 1,5-6% og 3-5% (1-5). En meget sjælden</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">manifestation er chylothorax, hvor der er chylos lækage til pleurahulen.</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Chylos lækage og chylothorax er potentielt livstruende tilstande og kan føre til</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">alvorlige metaboliske, immunologiske og ernæringsmæssige komplikationer</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">(6). Patienter med konstateret chylos lækage har oftest langvarige</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">hospitalsindlæggelser.</span></p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Anatomi og funktion</span></strong><span style="color:black">: På halsen løber ductus thoracicus op på venstre side,</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">hvor den danner en opad konveks bue og ender i vena brachiocephalica</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">sinistra i vinklen mellem vena subclavia sinistra og vena jugularis interna.</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Transport af langkædet fedt (LCT), fedtopløselige vitaminer samt lymfocytter</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">fra tarmen til det systemiske kredsløb sker via lymfekarret ductus thoracicus.</span></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <h3><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579326846Fremgangsmaade">Fremgangsmåde</a></h3> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Diagnosticering af chylos lækage:</span></strong></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Peroperativt:</span></strong><span style="color:black"> Efter faste ses der sj</span><span style="color:black">æ</span><span style="color:black">ldent en egentlig ductus, af og til antydning af flere mindre lymfekar. L</span><span style="color:black">æ</span><span style="color:black">kage identificeres sj</span><span style="color:black">æ</span><span style="color:black">ldent ved synlig perforation af ductus men en m</span><span style="color:black">æ</span><span style="color:black">lkehvid v</span><span style="color:black">æ</span><span style="color:black">ske eller diffus siven af fedtperler dybt i operationsfeltet skal rette mistanke mod chylos.</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Hvis patienten er langvarigt fastende eller underern</span><span style="color:black">æ</span><span style="color:black">ret, vil chylos v</span><span style="color:black">æ</span><span style="color:black">sken kunne fremst</span><span style="color:black">å</span><span style="color:black"> mere klar. Ved tvivl kan der foretages Trendelenburg lejring, Valsalva man</span><span style="color:black">ø</span><span style="color:black">vre eller h</span><span style="color:black">ø</span><span style="color:black">jtryks ventilation mhp. diagnosticering.</span></p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Postoperativt</span></strong><span style="color:black">: Der skal rettes mistanke til chylos l</span><span style="color:black">æ</span><span style="color:black">kage, n</span><span style="color:black">å</span><span style="color:black">r der i dr</span><span style="color:black">æ</span><span style="color:black">net eller ved n</span><span style="color:black">å</span><span style="color:black">lepunktur af v</span><span style="color:black">æ</span><span style="color:black">skeansamling p</span><span style="color:black">å</span><span style="color:black"> hals findes en uigennemsigtig m</span><span style="color:black">æ</span><span style="color:black">lkehvid v</span><span style="color:black">æ</span><span style="color:black">ske. </span>Oftest opstår chylos 1-2 dage postoperativt, efter indtag af fedt enteralt (første måltid efter operationen). <span style="color:black">Ved konstatering af chylos ordineres r</span><span style="color:black">ø</span><span style="color:black">ntgen af thorax (for at udelukke chylothorax) og v</span><span style="color:black">æ</span><span style="color:black">sken skal sendes til klinisk biokemisk afdeling mhp. unders</span><span style="color:black">ø</span><span style="color:black">gelse for proteinindhold, cellet</span><span style="color:black">æ</span><span style="color:black">lling, dyrkning og resistensbestemmelse samt lipidanalyse (for triglycerid og kolesterol), se vejledning senere.</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Ved konstateret postoperativ chylothorax henvises til VIPs: ”</span><em><span style="color:black">Chylothorax, instruks</span></em><span style="color:black">”</span><span style="color:black"> /</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">”</span><em><span style="color:black">Thoraxintensiv – Chylothorax, diagnosticering og behandling</span></em><span style="color:black">”</span><span style="color:black">. Ved chylothorax hos b</span><span style="color:black">ø</span><span style="color:black">rn henvises til VIP: ”</span><em><span style="color:black">Chylothorax, Diætbehandling til børn med postoperativt Chylothorax</span></em><span style="color:black">”</span><span style="color:black">.</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Rekvirering af analyse for triglycerid p</span><span style="color:black">å</span><span style="color:black"> Klinisk Biokemisk Afdeling KB3011, Rigshospitalet:</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">V</span><span style="color:black">æ</span><span style="color:black">ske opsamles i spidsglas. Der skal rekvireres en diverse analyse (DIVANA). Denne rekvireres i SP med kode EPC00148, klinisk information skal besvares, f.eks. dr</span><span style="color:black">æ</span><span style="color:black">nv</span><span style="color:black">æ</span><span style="color:black">ske obs. chylos, analyse for triglyceridkoncentration </span><span style="color:black">ø</span><span style="color:black">nskes.</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Diagnostisk kriterie for chylos v</span><span style="color:black">æ</span><span style="color:black">ske: Triglyceridkoncentration over 1,24 mmol/l ~ 110mg/dl (7).</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">NB! Referenceniveau angives ikke ved analysesvar.</span></p> <p><strong>Operativ behandling af chylos lækage</strong></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Form</span><span style="color:black">å</span><span style="color:black">let er en operativ lukning af lymfekarret. Ofte er der tale om et till</span><span style="color:black">ø</span><span style="color:black">b fra cervicale lymfekar eller en sidegren til ductus thoracicus, som er oversk</span><span style="color:black">å</span><span style="color:black">ret. Der skal ikke anvendes diatermi inklusiv Ligasure grundet risiko for yderligere l</span><span style="color:black">æ</span><span style="color:black">dering af lymfekarret.</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">1. Generelt anbefales anvendelse af clips suppleret med underbinding ved ligering eller</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">gennemstikning med Nylon/Vicryl sutur 3-0. Fibrinkl</span><span style="color:black">æ</span><span style="color:black">ber kan overvejes.</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">2. D</span><span style="color:black">æ</span><span style="color:black">kning af omr</span><span style="color:black">å</span><span style="color:black">det med m. sternocleidomastoideus kan overvejes ved re-operation eftermislykket konservativ behandling.</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">3. Ved fortsat usikkerhed omkring optimalt oph</span><span style="color:black">ø</span><span style="color:black">r af siven, kan man peroperativt l</span><span style="color:black">æ</span><span style="color:black">gge long-line og give aflastende behandling ved ern</span><span style="color:black">æ</span><span style="color:black">ring parenteralt som nedenfor beskrevet.</span></p> <p>&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong>Postoperativ behandling af chylos lækage </strong></p> <p style="margin-left:0cm; margin-right:0cm">Der skelnes mellem konservativ eller kirurgisk behandling.</p> <p style="margin-left:0cm; margin-right:0cm"><strong>Konservativ behandling:</strong></p> <p style="margin-left:0cm; margin-right:0cm">Princippet er drænage og diætmodifikation mhp. at minimere produktion af lymfevæske (chylos) i kroppen.</p> <p style="margin-left:0cm; margin-right:0cm"><strong>Generelt</strong>:</p> <ol> <li style="list-style-type:none"> <ol> <li>Opstart forebyggende antibiotika med Cefuroxim 1,5g x3dagl gr. risiko for immundef</li> <li>Dræn til monitering af chylos produktion under indlæggelse. Dræn sættes <strong>uden</strong> vacuum på dræn. Drænet kan seponeres ved drænproduktion &lt;30ml uanset væsketype.</li> <li> <p style="margin-left:0cm; margin-right:0cm">Afhængig at output i drænet opstartes enten:</p> <p style="margin-left:0cm; margin-right:0cm">- Total parenteral ernæring (PE) + ”noget at tygge på” (fedtfrit supplement til PE)</p> <p style="margin-left:0cm; margin-right:0cm">- Fedtfattig kost 15g fedt i døgnet</p> <p style="margin-left:0cm; margin-right:0cm">- Ved sondeernæring eller reduceret mulighed for pr os indtag, Ultra fruit protein drik (0 gram fedt) enten pr. oralt eller pr. sonde<span style="color:red">.</span></p> </li> <li>Ved tvivlstilfælde eller ved særlige udfordringer kan en diætist kontaktes.</li> <li>Blodprøver: <span style="color:black">Væsketal monitoreres dagligt. Blodprøve: ”Parenteral ernæring” (Triglycerid, Fosfat, Karbamid, ALAT, Basisk fosfatase, Bilirubin, Syre-base) bestilles x3 ugentligt og Albumin bestilles x 1 ugentligt. &nbsp;</span></li> <li>Daglig vejning mhp væske-<span style="color:black"> og ernærings balance.</span></li> <li><span style="color:#000000">Daglig monitorering og måling af drænproduktion.</span></li> </ol> </li> </ol> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p><img alt="" src="/VIP/Redaktoer/130126.nsf/vLookupUpload/ATTACH-RHAP-CCQDQG/$FILE/Udklip.PNG" style="height:250px; width:664px" onclick="Ext.DMS.util.showImage(this);"></p> <p><img alt="" src="/VIP/Redaktoer/130126.nsf/vLookupUpload/ATTACH-RHAP-CCQDRQ/$FILE/Udklip.PNG" style="height:682px; width:721px" onclick="Ext.DMS.util.showImage(this);"></p> <p>&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">1. </span>Ved drænproduktion 30-100 ml, opstart total parenteral ernæring (TPN) med supplement per os ”noget at tygge på” + det anbefalede at drikke (se bilag 1) i minimum 3 dage. <span style="color:black">Se i </span><span style="color:black">ø</span><span style="color:black">vrigt VIP instruks ”</span><em><span style="color:black">Parenteral ernæring for voksne - procedurer og</span></em> <em><span style="color:black">forholdsregler</span></em><span style="color:black">”</span><span style="color:black">.</span></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">2. Ved dr</span><span style="color:black">æ</span><span style="color:black">nproduktion ≤30ml, skiftes fra TPN til fedtfattig </span>diæt <strong>15 gram fedt i </strong>døgnet i minimum 7 dage. Hvis patienten skal have sonde ernæring udregnes ernæringsbehov og patienten får en kombination af Ultra fruit P-drik (0 gram fedt) og almindelig P-drik svarende til det daglig tilladelige fedtindtag , <em>f.eks 1 almindelig P-drik og 4 ultra fruit daglig.</em></p> <p style="margin-left:0cm; margin-right:0cm">Se i øvrigt Rigshospitalets kosthåndbog (bestilles ved at ringe til centralkøkken eller tale med måltidsværter). (se bilag 2)<s>.</s></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">3. Dr</span><span style="color:black">æ</span><span style="color:black">n output&gt;100ml/d</span><span style="color:black">ø</span><span style="color:black">gn og is</span><span style="color:black">æ</span><span style="color:black">r ved high-flow chylos b</span><span style="color:black">ø</span><span style="color:black">r snarlig operation overvejes for at undg</span><span style="color:black">å</span><span style="color:black"> langvarig indl</span><span style="color:black">æ</span><span style="color:black">ggelse samt alvorlige komplikationer.</span></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">4. Medicinsk behandling med subcutan administration af somatostatinanalogen Octreotid h</span><span style="color:black">æ</span><span style="color:black">mmer tarmmotiliteten og flere processer i gastrointestinalkanalen medf</span><span style="color:black">ø</span><span style="color:black">rende et reduceret flow i ductus thoracicus. De fleste studier har anvendt en kombination af TPN og </span>Octreotid s.c. <span style="color:black">eller i.v. 0,1mg x3 dagligt indtil 2 d</span><span style="color:black">ø</span><span style="color:black">gn efter oph</span><span style="color:black">ø</span><span style="color:black">r af chylos. Der er kun mindre case-series og enkelte case-reports rapporteret, men generelt mangelfuld evidens p</span><span style="color:black">å</span><span style="color:black"> dette omr</span><span style="color:black">å</span><span style="color:black">de (8-9).</span></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">5. Coilingbehandling kan overvejes: visualisering af lymfekar med lymfangiografi og</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">efterf</span><span style="color:black">ø</span><span style="color:black">lgende kanylering og coiling, konferer med R</span><span style="color:black">ø</span><span style="color:black">ntgenafdelingen.</span></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm">6. Ved operation kan overvejes ICG, for lettere at kunne visualisere ductus thoraticus</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Sygepleje til patient der behandles konservativt for Chylos.</span></strong></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Observationer:</span></strong></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <ul> <li><span style="color:black">Der dokumenteres i vurderingsskemaet løbende eller minimum X1 i hver vagt.</span></li> <li><span style="color:black">EWS efter algoritme medmindre andet er ordineret, specielt fokus p</span><span style="color:black">å</span><span style="color:black"> respiration (Chylothorax) og blodtryk, </span><span style="color:black">væskebalance</span><span style="color:black"> dokumenteres.</span></li> <li><span style="color:black">Forbinding tilses og skiftes ved behov, output kan sk</span><span style="color:black">ø</span><span style="color:black">nnes eller forbinding kan vejes.</span></li> <li><span style="color:black">Registrer chylos m</span><span style="color:black">æ</span><span style="color:black">ngde og beskriv hvordan det ser ud (farve / udseende). Der tilstr</span><span style="color:black">æ</span><span style="color:black">bes 0-balance.</span></li> <li><span style="color:black">CVK tilses og der ud</span><span style="color:black">ø</span><span style="color:black">ves daglig sygepleje og dokumentation i henhold til VIP: </span><em><span style="color:black">”</span></em><em><span style="color:#0000ef">Centralevenekatetre (CVK) inkl. akutte dialysekatetre ikke tunnelerede til børn og voksne - anlæggelse,observation, pleje og seponering</span></em><em><span style="color:black">”</span></em></li> <li><span style="color:black">Dr</span><span style="color:black">æ</span><span style="color:black">n observeres, afl</span><span style="color:black">æ</span><span style="color:black">ses og skiftes ved behov<strong>. </strong>1.d</span><span style="color:black">ø</span><span style="color:black">gn post operativt kl 8 og kl.20. Derefter x1 d</span><span style="color:black">ø</span><span style="color:black">gnet kl 8.</span></li> <li><span style="color:black">Blodpr</span><span style="color:black">ø</span><span style="color:black">ver efter ordination</span></li> <li><span style="color:black">Ern</span><span style="color:black">æ</span><span style="color:black">rings udregning i samarbejde med l</span><span style="color:black">æ</span><span style="color:black">ge</span></li> <li><span style="color:black">Bestilling af fedtfri kost i k</span><span style="color:black">ø</span><span style="color:black">kkenet (noget at tygge p</span><span style="color:black">å</span><span style="color:black">, bytteliste mm.), se bilag 1</span></li> <li><span style="color:black">Daglig v</span><span style="color:black">æ</span><span style="color:black">gt</span></li> </ul> <p>&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Information:</span></strong></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Patienten informeres om behandlingsplan inden den iv</span><span style="color:black">æ</span><span style="color:black">rks</span><span style="color:black">æ</span><span style="color:black">ttes. L</span><span style="color:black">æ</span><span style="color:black">ge og sygeplejerske g</span><span style="color:black">å</span><span style="color:black">r f</span><span style="color:black">æ</span><span style="color:black">lles stuegang hvor plan for de n</span><span style="color:black">æ</span><span style="color:black">ste 24 timer gennemg</span><span style="color:black">å</span><span style="color:black">s for patienten.</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Derefter daglig f</span><span style="color:black">æ</span><span style="color:black">lles opf</span><span style="color:black">ø</span><span style="color:black">lgning og justering til stuegang.</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Patienten informeres om at give besked til sygeplejersken hvis tilstanden forandre sig, informeres om at v</span><span style="color:black">æ</span><span style="color:black">re opm</span><span style="color:black">æ</span><span style="color:black">rksom p</span><span style="color:black">å</span><span style="color:black"> vejrtr</span><span style="color:black">æ</span><span style="color:black">kning (store ansamlinger af Chylos) og svimmelhed (stort v</span><span style="color:black">æ</span><span style="color:black">ske deficit)</span></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Personlig pleje:</span></strong></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Patienten kan tage bad hvis dr</span><span style="color:black">æ</span><span style="color:black">n/ forbinding tild</span><span style="color:black">æ</span><span style="color:black">kkes</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Personlig hygiejne som normalt, tilbydes hj</span><span style="color:black">æ</span><span style="color:black">lp til dette.</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Hyppigt t</span><span style="color:black">ø</span><span style="color:black">jskifte og soignering.</span></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Psykisk</span></strong><span style="color:black">: </span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Da tilstanden ofte tager flere dage optil uger, er det vigtigt at patienten daglig f</span><span style="color:black">å</span><span style="color:black">r mulighed for at tale om sin tilstand og sine tanker og de ubehagelige f</span><span style="color:black">ø</span><span style="color:black">lger der kan v</span><span style="color:black">æ</span><span style="color:black">re forbundet hermed. </span></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Det kan v</span><span style="color:black">æ</span><span style="color:black">re en fordel at patienten f</span><span style="color:black">å</span><span style="color:black">r lov til at bev</span><span style="color:black">æ</span><span style="color:black">ge sig lidt ud af afdelingen (forhal, have, f</span><span style="color:black">æ</span><span style="color:black">lledparken mm).</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Opfordres til bes</span><span style="color:black">ø</span><span style="color:black">g og st</span><span style="color:black">ø</span><span style="color:black">tte fra familie.</span></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black"><img alt="" src="/VIP/Redaktoer/130126.nsf/vLookupUpload/ATTACH-RHAP-CCQDVN/$FILE/Udklip.PNG" style="height:185px; width:663px" onclick="Ext.DMS.util.showImage(this);"></span></p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Udskrivning:</span></strong></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Patienten udskrives når chylos output er stoppet. Ofte med fedt reduceret diæt 15 gram fedt i døgnet i 7 dage (ved sonde kombination af fedtfri P-drik og almindelig P-drik = ca. 15 gram fedt daglig). Ambulant opfølgning derefter.</span></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Under udskrivningssamtalen kan bilag 2. benyttes til information og gennemgang om diæten efter udskrivelsen.</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Eventuelt kan bilag 2 kopieres og udleveres til patienten forudgået af en sygeplejerske gennemgang af dette.</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Diætist kan kontaktes ved specielle udfordringer omkring diæten.</span></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Udskrivningssamtalen indeholder:</span></p> <ul> <li><span style="color:black">Gennemgang af diæt, hvilken og hvor længe.</span></li> <li><span style="color:black">Symptomer som patienten skal være opmærksom på hjemme.</span></li> <li><span style="color:black">Sår pleje og tegn på infektion.</span></li> <li><span style="color:black">Evt. monitorering af egen vægt.</span></li> <li><span style="color:black">Ambulante tider og plan.</span></li> </ul> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:#0000ef">Ansvar og organisering</span></strong></p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:#0000ef">Referencer, lovgivning og faglig evidens samt links hertil</span></strong></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Ansvar og organisering</span></strong></p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Referencer, lovgivning og faglig evidens samt links hertil</span></strong></p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Evidensniveau</span></strong><span style="color:black">: Der foreligger ingen retningslinjer eller konsensus omkring behandling af chylos</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">l</span><span style="color:black">æ</span><span style="color:black">kage. Evidensniveau er 2b/3b samt 4, generelt case-reports, reviews og retrospektive</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">observationsstudier</span><strong><span style="color:black">.</span></strong></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">1. Santaolalla F, Anta JA, Zabala A, Del Rey Sanchez A, et al. Management of chylous fistula as a</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">complication of neck dissection: A 10-year retrospective review. Eur J Cancer Care (Engl)</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">2010;19:510–5</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">2. Campisi CC, Boccardo F, Piazza C, Campisi C. Evolution of chylous fistula management after</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">neck dissection. Curr Opin Otolaryngol Head Neck Surg 2013;21:150–6.</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">3. Ahn D, Sohn JH, Jeong JY. Chyle Fistula After Neck Dissection: An 8-Year, Single-Center,</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Prospective Study of Incidence, Clinical Features, and Treatment. Ann Surg Oncol</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">2015;22:1000–6.</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">4. Dhiwakar M, Nambi GI, Ramanikanth T V. Drain removal and aspiration to treat low output</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">chylous fistula. Eur Arch Oto-Rhino-Laryngology 2014;271:561–5.</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">5. Nussenbaum B, Liu JH, Sinard RJ. Systematic management of chyle fistula: the Southwestern</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">experience and review of the literature. Otolaryngol Head Neck Surg 2000;122:31–8.</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">6. Prabhu V, Passant C. Left-sided neck dissection and chylothorax: a rare complication and its</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">management. J Laryngol Otol 2012;126:648–50.</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">7. Mikkel Hvass et al. Chylothorax</span><strong><span style="color:black">. </span></strong><span style="color:black">Ugeskr L</span><span style="color:black">æ</span><span style="color:black">ger 2017;179:V05170429</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">8. Swanson MS, Hudson RL, Bhandari N, Sinha UK, et al. </span><span style="color:black">Use of Octreotide for the Management</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">of Chyle Fistula Following Neck Dissection. JAMA Otolaryngol Head Neck Surg</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">2015;141:723–7.4. 6. Roh J-L, Kim DH, Park C Il. Prospective identification of chyle leakage</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">in patients undergoing lateral neck dissection for metastatic thyroid cancer. Ann Surg Oncol</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">2008;15:424–9.</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">9. Sarah Nielsen. Kandidatspeciale: Systematic literature review of treatment options for chylous</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">fistula after neck surgery. 14.07.2014.</span></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black"><img alt="" src="/VIP/Redaktoer/130126.nsf/vLookupUpload/ATTACH-RHAP-CCQDYE/$FILE/Udklip.PNG" style="height:686px; width:692px" onclick="Ext.DMS.util.showImage(this);"></span></p> <p><img alt="" src="/VIP/Redaktoer/130126.nsf/vLookupUpload/ATTACH-RHAP-CCQDZC/$FILE/Udklip.PNG" style="height:630px; width:604px" onclick="Ext.DMS.util.showImage(this);"></p> <p><img alt="" src="/VIP/Redaktoer/130126.nsf/vLookupUpload/ATTACH-RHAP-CCQE27/$FILE/Udklip.PNG" style="height:184px; width:633px" onclick="Ext.DMS.util.showImage(this);"></p> <p>&nbsp;</p> <p><img alt="" src="/VIP/Redaktoer/130126.nsf/vLookupUpload/ATTACH-RHAP-CCQE33/$FILE/Udklip.PNG" style="height:236px; width:729px" onclick="Ext.DMS.util.showImage(this);"></p> <p><img alt="" src="/VIP/Redaktoer/130126.nsf/vLookupUpload/ATTACH-RHAP-CCQE52/$FILE/Udklip.PNG" style="height:519px; width:599px" onclick="Ext.DMS.util.showImage(this);"></p> <p>&nbsp;</p> <p>&nbsp;</p> <p><img alt="" src="/VIP/Redaktoer/130126.nsf/vLookupUpload/ATTACH-RHAP-CCQE64/$FILE/Udklip.PNG" style="height:847px; width:599px" onclick="Ext.DMS.util.showImage(this);"></p> <p>&nbsp;</p> <p><img alt="" src="/VIP/Redaktoer/130126.nsf/vLookupUpload/ATTACH-RHAP-CCQE6R/$FILE/Udklip.PNG" style="height:761px; width:572px" onclick="Ext.DMS.util.showImage(this);"></p> <p><img alt="" src="/VIP/Redaktoer/130126.nsf/vLookupUpload/ATTACH-RHAP-CCQEAF/$FILE/Udklip.PNG" style="height:762px; width:606px" onclick="Ext.DMS.util.showImage(this);"></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Cochlear Implant (CI).

Cochlear Implant (CI) Formål Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Formål At bibringe patienter, specielt børn, med medfødt eller erhvervet døvhed anvendelig hørelse ved hjælp af indsættelse af en elektrode i høresneglen. Målgrupper og anvendelsesområde Læger i Øre-næse-halskirurgisk og Audiologisk Klinik Fremgangsmåde Det ideelle tidspunkt for implantationen er omkring 1 års alderen pga. hjernens plasticitet. Derudover tilbydes postlingual døve CI, hvor døvheden er opstået enten pga. progredierende høretab eller ototoksisk påvirkning (meningit/traumer). Indikationer Patienterne udredes via Audiologisk Klinik og her udpeges kandidater til CI. Det drejer sig specielt om børn med medfødt døvhed. Det ideelle tidspunkt for implantationen er omkring 1 års alderen pga. hjernens plasticitet. Derudover tilbydes såvel børn som voksne postlingual døve CI, hvor døvheden er opstået enten pga. progredierende høretab eller ototoksisk påvirkning/meningit/traumer. Ud over de rent audiologiske test udføres rutinemæssigt præoperativ MR-skanning m.h.p. afklaring af indre øre forhold, således om der foreligger en agenesi af hørenerven. Information til patienten Patienten/forældrene skal informeres om lille risiko for læsion af corda tympani. Yderst lille risiko for fascialisparese (varig lammelse ikke set på afdelingen). Svimmelhed og kvalme kan forekomme ofte hos voksne, sjældnere hos børn. Der er endvidere en lille risiko for meningitis, hvorfor alle anbefales forebyggende vaccination forud for operationen. Operationen Indgrebet foretages i generel anæstesi med anvendelse af nervemonitor. Der udføres mastoidektomi samt posterior tympanotomi, hvorefter der via en cochleostomi placeres en elektrode i cochlea. Magneten placeres i en fordybning i kraniekassen over og bag øret. Incisionen retroaurikulært lukkes i to lag, yderst med resorberbar tråd der ikke skal fjernes. Endelig anlægges komprimerende øre-forbinding. Postoperativt Voksne patienter behandles med intravenøs cefuroxim 1,5 gr. peroperativt og yderligere 2 gange på operationsdagen og sidste gang den følgende morgen. Hos børn samme doserings interval, men dosis efter vægt (100 mg/kg/døgn fordelt på 3 doser). Som smertedækkende medicin gives hos voksne; Ibuprofen 400 mg x 3 og Paracetamol 1g x3. Hos børn Diclofenac supp og Paracetamol supp efter vægt. Alle patienter får fjernet forbinding dagen efter operationen, og udskrives samme dag. Der medgives tid til ambulant infektionskontrol ca. 10 dage senere. Får endvidere ved hjemsendelsen program for opstart i audiologisk regi, hvilket sædvanligvis er 3-6 uger postoperativt. Ansvar og organisering Klinikledelsen Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag

<h1><div id="Afsnit#1699579344973">Cochlear Implant (CI)</div></h1><div id="BodyWeb#1699579344973"><p><a name="1699579344973Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579344973Formaal">Formål</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579344973Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579344973Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579344973Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579344973Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579344973Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579344973Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579344973Bilag">Bilag</a><br> &nbsp;</h3> <p><a name="1699579344973Formaal"></a></p> <h2>Formål</h2> <p><span style="color:#000000">At bibringe patienter, specielt børn, med medfødt eller erhvervet døvhed anvendelig hørelse ved hjælp af indsættelse af en elektrode i høresneglen.</span></p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579344973Top">Tilbage til top</a></p> <h2><a name="1699579344973Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p>Læger i Øre-næse-halskirurgisk og Audiologisk Klinik</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579344973Top">Tilbage til top</a></p> <p>&nbsp;</p> <h2><a name="1699579344973Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p style="margin-left:4.15pt; margin-right:0cm"><span style="color:#000000">Det ideelle tidspunkt for implantationen er omkring 1 års alderen pga. hjernens plasticitet. Derudover tilbydes postlingual døve CI, hvor døvheden er opstået enten pga. progredierende høretab eller ototoksisk påvirkning (meningit/traumer).</span></p> <p>&nbsp;</p> <p style="margin-left:4.15pt"><span style="color:#000000"><strong>Indikationer </strong></span></p> <p style="margin-left:4.15pt">Patienterne udredes via Audiologisk Klinik&nbsp;og her udpeges kandidater til CI. Det drejer sig specielt om børn med medfødt døvhed. Det ideelle tidspunkt for implantationen er omkring 1 års alderen pga. hjernens plasticitet. Derudover tilbydes såvel børn som voksne postlingual døve CI, hvor døvheden er opstået enten pga. progredierende høretab eller ototoksisk påvirkning/meningit/traumer. Ud over de rent audiologiske test udføres rutinemæssigt præoperativ MR-skanning m.h.p. afklaring af indre øre forhold, således om der foreligger en agenesi af hørenerven.</p> <p style="margin-left:4.15pt; margin-right:0cm"><span style="color:#000000"><strong><u>Information til patienten </u></strong></span></p> <p style="margin-left:4.15pt; margin-right:0cm">Patienten/forældrene skal informeres om lille risiko for læsion af corda tympani. Yderst lille risiko for fascialisparese (varig lammelse ikke set på afdelingen). Svimmelhed og kvalme kan forekomme ofte hos voksne, sjældnere hos børn. Der er endvidere en lille risiko for meningitis, hvorfor alle anbefales forebyggende vaccination forud for operationen.</p> <p style="margin-left:4.15pt; margin-right:0cm"><strong><u>Operationen </u></strong></p> <p style="margin-left:4.15pt">Indgrebet foretages i generel anæstesi med anvendelse af nervemonitor. Der udføres mastoidektomi samt posterior tympanotomi, hvorefter der via en cochleostomi placeres en elektrode i cochlea. Magneten placeres i en fordybning i kraniekassen over og bag øret. Incisionen retroaurikulært lukkes i to lag, yderst med resorberbar tråd der ikke skal fjernes. Endelig anlægges komprimerende øre-forbinding.</p> <p style="margin-left:4.15pt; margin-right:0cm"><br> &nbsp;<strong><u>Postoperativt </u></strong></p> <p style="margin-left:4.15pt">Voksne patienter behandles med intravenøs&nbsp;cefuroxim 1,5 gr. peroperativt og yderligere 2 gange på operationsdagen og sidste gang den følgende morgen. Hos børn samme doserings interval, men dosis efter vægt (100 mg/kg/døgn fordelt på 3 doser). Som smertedækkende medicin gives hos voksne; Ibuprofen 400 mg x 3 og Paracetamol 1g x3. Hos børn Diclofenac supp og Paracetamol supp efter vægt. Alle patienter får fjernet forbinding dagen efter operationen, og udskrives samme dag. Der medgives tid til ambulant infektionskontrol ca. 10 dage senere. Får endvidere ved hjemsendelsen program for opstart i audiologisk regi, hvilket sædvanligvis er 3-6 uger postoperativt.</p> <p style="margin-left:4.15pt; margin-right:0cm">&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579344973Top">Tilbage til top</a></p> <p>&nbsp;</p> <h2><a name="1699579344973Ansvar"></a><br> Ansvar og organisering</h2> <p>&nbsp;Klinikledelsen</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579344973Top">Tilbage til top</a></p> <h2><a name="1699579344973Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579344973Top">Tilbage til top</a></p> <h2><a name="1699579344973Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579344973Top">Tilbage til top</a></p> <h2><a name="1699579344973Bilag"></a><br> Bilag</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579344973Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_DAHANCA registrering.

DAHANCA registrering Formål Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Formål Dahanca kodning af hoved-hals kræft patienter i ØNH regi. Målgrupper og anvendelsesområde Lægefagligt personale i Øre-næse-halskirurgisk og Audiologisk Klinik Definitioner DAHANCA er en klinisk database for hoved-hals kræft patienter. Da der er tale om en klinisk database har sygehus ejerne pligt til at sørge for indrapportering. Der bliver hvert år lavet en årsrapport på baggrund af de data og offentliggjort i RKKI. Fremgangsmåde Nydiagnosticerede hoved-hals cancer patienter skal registreres i DAHANCA databasen. Dette gøres elektronisk på www.dahanca.oncology.dk. Databasen er sikret med log-on og password. Log-on kan bestilles på hjemmesiden,- hvorefter der skal tages telefonisk kontakt til IT-ansvarlig i DAHANCA der giver et password. Der skal således registreres i DAHANCA ved: - Behandlingsbeslutning (MDT1) ”On-study” skema - 2 mdr efter behandling (MDT status) ”Primær behandling” skema - Ved alle opfølgningsbesøg ”Follow-up” skema - Desuden ved recidiv ”recidiv” skema - Ved Mors,- ”mors” skema. Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag

<h1><div id="Afsnit#1699579437998">DAHANCA registrering</div></h1><div id="BodyWeb#1699579437998"><p> <a name="1699579437998Top"></a></p> <h3> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579437998Formaal">Formål</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579437998Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579437998Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579437998Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579437998Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579437998Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579437998Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579437998Bilag">Bilag</a><br> &nbsp;</h3> <p> <a name="1699579437998Formaal"></a></p> <h2> Formål</h2> <p> Dahanca kodning af hoved-hals kræft patienter i ØNH regi.</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579437998Top">Tilbage til top</a></p> <h2> <a name="1699579437998Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p> &nbsp;Lægefagligt personale i Øre-næse-halskirurgisk og Audiologisk Klinik</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579437998Top">Tilbage til top</a></p> <h2> <a name="1699579437998Definitioner"></a><br> Definitioner</h2> <p> <span style="color: #222222"><font size="3"><font face="Times New Roman">DAHANCA er en klinisk database for hoved-hals kræft patienter. Da der er tale om en klinisk database har sygehus ejerne pligt til at sørge for indrapportering. Der bliver hvert år lavet en årsrapport på baggrund af de data og offentliggjort i RKKI. &nbsp;<o:p></o:p></font></font></span></p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579437998Top">Tilbage til top</a></p> <h2> <a name="1699579437998Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p> Nydiagnosticerede hoved-hals cancer patienter skal registreres i DAHANCA databasen. Dette gøres elektronisk på <a href="http://www.dahanca.oncology.dk/">www.dahanca.oncology.dk</a><u>.</u> Databasen er sikret med log-on og password. Log-on kan bestilles på hjemmesiden,- hvorefter der skal tages telefonisk kontakt til IT-ansvarlig i DAHANCA der giver et password.</p> <p> Der skal således registreres i DAHANCA ved:</p> <ol> <li> Behandlingsbeslutning (MDT1) ”On-study” skema</li> <li> 2 mdr efter behandling (MDT status) ”Primær behandling” skema</li> <li> Ved alle opfølgningsbesøg ”Follow-up” skema</li> <li> Desuden ved recidiv ”recidiv” skema</li> <li> Ved Mors,- ”mors” skema.</li> </ol> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579437998Top">Tilbage til top</a></p> <h2> <a name="1699579437998Ansvar"></a><br> Ansvar og organisering</h2> <p> &nbsp;</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579437998Top">Tilbage til top</a></p> <h2> <a name="1699579437998Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p> &nbsp;</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579437998Top">Tilbage til top</a></p> <h2> <a name="1699579437998Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p> &nbsp;</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579437998Top">Tilbage til top</a></p> <h2> <a name="1699579437998Bilag"></a><br> Bilag</h2> <p> &nbsp;</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579437998Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Defekte eller bortkomne i-¢ret apparat uden.

Defekte eller bortkomne i-øret apparat uden for garanti Formål Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Formål Afklaring af forretningsgang ved defekt eller bortkommet i-øret apparat udenfor garanti Målgrupper og anvendelsesområde Personale på Hørepædaogisk afsnit, GeH. Definitioner Fremgangsmåde For klienter, som er tilknyttet Hørepædagogisk afsnit mht høreapparat-udlevering (fx. klienter med CI på modsatte øre) og som opfylder kriterierne: I) I-øret apparatet/-erne er bortkommet/-ne eller defekt/-e, og II) apparat/-erne er udenfor garanti, gælder følgende: Klienten opfordres til at få foretaget høreprøve hos egen otolog. Audiogrammet indsendes til Hørepædagogisk Afsnit. Samtidig anmodes det lokale kommunikationscenter om akut hjælp med reserveapparat (evt. med sut). a) Hvis I) høretabet er stationært i forhold til det tab, der blev påvist ved sidste nyudlevering, og II) der ikke er sket relevante ændringer i personens øvrige situation, kan klienten – uden forudgående undersøgelse på lægeligt afsnit – tildeles tid til Ørepropteknikken m.h.p. ny/-e skal/-ler (evt. øreprop/-per ) – og tid på Hørepædagogisk Afsnit m.h.p. tilpasning. Ved tildeling af nyt/-e apparat/-er vil der i videst muligt omfang tages hensyn til klientens præferencer. Personen slettes fra den ordinære venteliste og registreres som nyudlevering. b) Hvis I) høretabet er stationært i forhold til det tab, der blev påvist ved sidste nyudlevering, men II) der er sket relevante ændringer af personens øvrige situation, kan klienten – uden forudgående undersøgelse på lægeligt afsnit – indkaldes til Hørepædagogisk Afsnit, kontaktes telefonisk eller Kommunikationscentret sender oplysninger fra deres sidste møde med klienten. Der tages stilling til den optimale høreapparat-behandling, og klienten tildeles tid til Ørepropteknikken m.h.p. ny/-e skal/-ler (evt. øreprop/-per) – og tid til Hørepædagogisk Afsnit m.h.p. tilpasning. Ved tildeling af nyt/-e apparat/-er vil der i videst muligt omfang tages hensyn til klientens præferencer. Personen slettes fra den ordinære venteliste og registreres som nyudlevering. c) Hvis høretabet er væsentligt ændret i forhold til det tab, der blev påvist ved sidste nyudlevering, indkaldes klienten til genkontrol på det lægelige afsnit. Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag

<h1><div id="Afsnit#1699579380642">Defekte eller bortkomne i-øret apparat uden for garanti</div></h1><div id="BodyWeb#1699579380642"><p><a name="1699579380642Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579380642Formaal">Formål</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579380642Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579380642Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579380642Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579380642Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579380642Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579380642Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579380642Bilag">Bilag</a><br> &nbsp;</h3> <p><a name="1699579380642Formaal"></a></p> <h2>Formål</h2> <p>Afklaring af&nbsp;forretningsgang ved defekt eller bortkommet i-øret apparat udenfor garanti</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579380642Top">Tilbage til top</a></p> <h2><a name="1699579380642Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p>Personale på Hørepædaogisk afsnit, GeH.&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579380642Top">Tilbage til top</a></p> <h2><a name="1699579380642Definitioner"></a><br> Definitioner</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579380642Top">Tilbage til top</a></p> <h2><a name="1699579380642Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p>For klienter, som er tilknyttet Hørepædagogisk afsnit mht høreapparat-udlevering (fx. klienter med CI på modsatte øre) og som opfylder kriterierne: I) I-øret apparatet/-erne er bortkommet/-ne eller defekt/-e, og II) apparat/-erne er udenfor garanti, gælder følgende:</p> <p>Klienten opfordres til at få foretaget høreprøve hos egen otolog. Audiogrammet indsendes til Hørepædagogisk Afsnit. Samtidig anmodes&nbsp;det lokale kommunikationscenter&nbsp;om akut hjælp med reserveapparat (evt. med sut).</p> <p>a) Hvis I) høretabet er stationært i forhold til det tab, der blev påvist ved sidste nyudlevering, og II) der ikke er sket relevante ændringer i personens øvrige situation, kan klienten – uden forudgående undersøgelse på lægeligt afsnit – tildeles tid til Ørepropteknikken m.h.p. ny/-e skal/-ler (evt. øreprop/-per ) – og tid på Hørepædagogisk Afsnit m.h.p. tilpasning. Ved tildeling af nyt/-e apparat/-er vil der i videst muligt omfang tages hensyn til klientens præferencer. Personen slettes fra den ordinære venteliste og registreres som <em>nyudlevering</em>.</p> <p>b) Hvis I) høretabet er stationært i forhold til det tab, der blev påvist ved sidste nyudlevering, men II) der er sket relevante ændringer af personens øvrige situation, kan klienten – uden forudgående undersøgelse på lægeligt afsnit – indkaldes til Hørepædagogisk Afsnit, kontaktes telefonisk eller Kommunikationscentret sender oplysninger fra deres sidste møde med klienten. Der tages stilling til den optimale høreapparat-behandling, og klienten tildeles tid til Ørepropteknikken m.h.p. ny/-e skal/-ler (evt. øreprop/-per) – og tid til Hørepædagogisk Afsnit m.h.p. tilpasning. Ved tildeling af nyt/-e apparat/-er vil der i videst muligt omfang tages hensyn til klientens præferencer. Personen slettes fra den ordinære venteliste og registreres som <em>nyudlevering.</em></p> <p>c) Hvis høretabet er væsentligt ændret i forhold til det tab, der blev påvist ved sidste nyudlevering, indkaldes klienten til genkontrol på det lægelige afsnit.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579380642Top">Tilbage til top</a></p> <h2><a name="1699579380642Ansvar"></a><br> Ansvar og organisering</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579380642Top">Tilbage til top</a></p> <h2><a name="1699579380642Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579380642Top">Tilbage til top</a></p> <h2><a name="1699579380642Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579380642Top">Tilbage til top</a></p> <h2><a name="1699579380642Bilag"></a><br> Bilag</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579380642Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Delegeret rammeordination af udvalgt håndk¢bsmedicin for.

Delegeret rammeordination af udvalgt håndkøbsmedicin for sygeplejersker i akut team, afsnit 7046/56 i Afdeling for Øre-Næse-Halskirurgi og Audiologi, Rigshospitalet Formål Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Bilag Formål At sikre patienten en hurtig og kvalificeret medicinsk behandling, når der ikke er en læge til stede. Sygeplejersken kan ordinere udvalgt smertestillende håndkøbsmedicin jf. denne vejledning og derved iværksætte smertestillende behandling i de tilfælde, hvor der endnu ikke ligger en lægelig ordination. Målgrupper og anvendelsesområde Sygeplejersker med daglig funktion i det ambulante akut-team i Afdeling for Øre-Næse-Halskirurgi og Audiologi, Rigshospitalet. Patientgruppen omfatter patienter, der tilses i akut-ambulatoriet i Afdeling for Øre-Næse-Halskirurgi og Audiologi, Rigshospitalet og som har behov for hurtig iværksættelse af smertestillende behandling i tilfælde, hvor der endnu ikke forelægger en lægelig ordination. Definitioner Rammeordination er defineret ved håndtering/udførelse/behandling af visse sygdomme/tilstande, hvor proceduren overdrages til andre fx plejepersonale for en defineret patientgruppe. Rammeordination til en defineret patientgruppe kan uddelegeres til sygeplejersker af den ansvarlige cheflæge via en detaljeret instruks (Vejledning om autoriserede sundhedspersoners benyttelse af medhjælp (delegation af forbeholdt sundhedsfaglig virksomhed) Rammeordination 2.2, Retsinformation) Sygeplejersken skal ud fra den detaljerede instruks vurdere og iværksætte behandling ud fra et forudbestemt sortiment uden forudgående lægelig ordination. Engangsordination betyder, at sygeplejersken har mulighed for at ordinere præparatet én gang i hver vagt. Opstår der behov for at give lægemidlet mere end én gang, skal lægen kontaktes. Sygeplejersken er jf. Bekendtgørelse af lov om sygeplejersker, § 5, stk. 1 forpligtet til at udvise omhu og samvittighedsfuldhed. Dette betyder i denne situation, at sygeplejersken påtager sig at give patienten den rette medicin på korrekt indikation i den konkrete situation. Fremgangsmåde - Sygeplejersken skal sammen med den kliniske sygeplejespecialist gennemgå denne VIP-instruks samt modtage introduktion og undervisning i den delegerede rammeordination. - Sygeplejersken er bekendt med medicininformationen som anført i pro.medicin.dk for hvert enkelt præparat i rammedelegationen. - Når VIP-instruksen er gennemgået med klinisk sygeplejespecialist, godkendes sygeplejersken til den delegerede rammeordination. Godkendelsen udfyldes af den kliniske sygeplejespecialist og oversygeplejersken og tilføjes den ansattes personalesag af oversygeplejersken. - Gennemgang af denne VIP-instruks og undervisning i den delegerede rammeordination skal gentages årligt for at vedligeholde godkendelsen af den delegerede rammeordination. Anvendelse af rammeordinationen - Når sygeplejersken er godkendt til delegeret rammeordination jf. denne instruks, kan sygeplejersken placere en Best./ord af ordinationstypen ”delegeret: Uden kontrasignering”, når der er indikation for det pågældende lægemiddel. Den ordinerende kliniker er den afdelingens cheflæge. - Sygeplejersken skal dokumentere hele medicineringsprocessen i MDA. Sygeplejersken skal inden anvendelse af delegeret rammeordination; - Indhente patientens samtykke - Overholde den anførte mængde, dosis samt indikation og kontraindikationer. - Cave: evt. allergi. Sygeplejersken må administrere nedenstående præparater som éngangsordination i situationer, hvor der endnu ikke foreligger en lægeordination. Den delegerede rammeordination må foretages x 1 i hver dagvagt i akut-ambulatoriets åbningstid, hvorefter præparatet skal ordineres af en læge. Rammeordination for håndkøbslægemidler: ###TABEL_1### Specifik oversigt over præparater: Analgetika ###TABEL_2### Analgetika (fortsat) ###TABEL_3### Kilde: Medicin.dk (Lægemiddelkataloget) Ansvar og organisering Afdelingsledelsen er ansvarlig for at instruksen er gældende og godkendt. Afdelingens cheflæge er overordnet ansvarlig for uddelegering af rammeordination. Den kliniske sygeplejespecialist er praktisk ansvarlig for, at sygeplejersken introduceres til instruksen samt modtager undervisning. Når sygeplejersken, der er godkendt til delegeret rammeordination, påtager sig at initiere behandling, er denne selv ansvarlig for at udføre ordinationen jf. denne instruks samt dokumentere hele medicineringsprocessen i MDA i Sundhedsplatformen. Sygeplejersken har selv ansvar for at frabede sig at initiere behandling, hvis denne ikke ser sig i stand til at udføre ordinationen forsvarligt. Sygeplejersken er forpligtet til at udvise omhu og samvittighedsfuldhed i sit virke i henhold til Bekendtgørelse af lov om sygeplejersker § 5, stk. 1 (Retsinformation, Sygeplejerskeloven). Referencer, lovgivning og faglig evidens samt links hertil - Bekendtgørelse af lov om autorisation af sundhedspersoner og om sundhedsfaglig virksomhed (Autorisationsloven) LBK nr. 731 af 08/07/2019 - Bekendtgørelse nr. 1219 af 11. december 2009 om autoriserede sundhedspersoners benyttelse af medhjælp (delegation af forbeholdt sundhedsfaglig virksomhed) med eventuelle senere ændringer - Vejledning nr. 115 af 11. december 2009 om autoriserede sundhedspersoners benyttelse af medhjælp - VIP vejledning; Lægemiddelordination, Region Hovedstaden - VIP vejledning: Journalføring – vurdering og indhold, Region Hovedstaden - VIP vejledning: Delegation af forbeholdt sundhedsfaglig virksomhed, Region Hovedstaden Bilag

<h1><div id="Afsnit#1699579273563">Delegeret rammeordination af udvalgt håndkøbsmedicin for sygeplejersker i akut team, afsnit 7046/56 i Afdeling for Øre-Næse-Halskirurgi og Audiologi, Rigshospitalet</div></h1><div id="BodyWeb#1699579273563"><p><a name="1699579273563Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579273563Formaal">Formål</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579273563Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579273563Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579273563Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579273563Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579273563Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579273563Bilag">Bilag</a><br> &nbsp;</h3> <div class="collapsible-item" expandedstart="1"><a name="1699579273563Formaal"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Formål</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm">At sikre patienten en hurtig og kvalificeret medicinsk behandling, når der ikke er en læge til stede. Sygeplejersken kan ordinere udvalgt smertestillende håndkøbsmedicin jf. denne vejledning og derved iværksætte smertestillende behandling i de tilfælde, hvor der endnu ikke ligger en lægelig ordination.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579273563Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579273563Maalgrupper"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Målgrupper og anvendelsesområde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm">Sygeplejersker med daglig funktion i det ambulante akut-team i Afdeling for Øre-Næse-Halskirurgi og Audiologi, Rigshospitalet.</p> <p style="margin-left:0cm; margin-right:0cm">Patientgruppen omfatter patienter, der tilses i akut-ambulatoriet i Afdeling for Øre-Næse-Halskirurgi og Audiologi, Rigshospitalet og som har behov for hurtig iværksættelse af smertestillende behandling i tilfælde, hvor der endnu ikke forelægger en lægelig ordination.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579273563Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579273563Definitioner"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Definitioner</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm; text-align:justify">Rammeordination er defineret ved håndtering/udførelse/behandling af visse sygdomme/tilstande, hvor proceduren overdrages til andre fx plejepersonale for en defineret patientgruppe.</p> <p>Rammeordination til en defineret patientgruppe kan uddelegeres til sygeplejersker af den ansvarlige cheflæge via en detaljeret instruks&nbsp;<a href="https://www.retsinformation.dk/eli/mt/2009/115" style="color:blue; text-decoration:underline">(Vejledning om autoriserede sundhedspersoners benyttelse af medhjælp (delegation af forbeholdt sundhedsfaglig virksomhed) Rammeordination 2.2, Retsinformation)</a></p> <p style="margin-left:0cm; margin-right:0cm; text-align:justify">Sygeplejersken skal ud fra den detaljerede instruks vurdere og iværksætte behandling ud fra et forudbestemt sortiment uden forudgående lægelig ordination.</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm; text-align:justify">Engangsordination betyder, at sygeplejersken har mulighed for at ordinere præparatet én gang i hver vagt. Opstår der behov for at give lægemidlet mere end én gang, skal lægen kontaktes.</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm">Sygeplejersken er jf. Bekendtgørelse af lov om sygeplejersker, § 5, stk. 1 forpligtet til at udvise omhu og samvittighedsfuldhed. Dette betyder i denne situation, at sygeplejersken påtager sig at give patienten den rette medicin på korrekt indikation i den konkrete situation.&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579273563Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579273563Fremgangsmaade"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Fremgangsmåde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <ul> <li>Sygeplejersken skal sammen med den kliniske sygeplejespecialist gennemgå denne VIP-instruks samt modtage introduktion og undervisning i den delegerede rammeordination.</li> </ul> <ul> <li>Sygeplejersken er bekendt med medicininformationen som anført i pro.medicin.dk for hvert enkelt præparat i rammedelegationen.</li> </ul> <ul> <li>Når VIP-instruksen er gennemgået med klinisk sygeplejespecialist, godkendes sygeplejersken til den delegerede rammeordination. Godkendelsen udfyldes af den kliniske sygeplejespecialist og oversygeplejersken og tilføjes den ansattes personalesag af oversygeplejersken.</li> </ul> <ul> <li>Gennemgang af denne VIP-instruks og undervisning i den delegerede rammeordination skal gentages årligt for at vedligeholde godkendelsen af den delegerede rammeordination.</li> </ul> <p style="margin-left:0cm; margin-right:0cm"><u>Anvendelse af rammeordinationen</u></p> <ul> <li>Når sygeplejersken er godkendt til delegeret rammeordination jf. denne instruks, kan sygeplejersken placere en Best./ord af ordinationstypen ”<em>delegeret: Uden kontrasignering”</em>, når der er indikation for det pågældende lægemiddel. Den ordinerende kliniker er den afdelingens cheflæge.</li> <li>Sygeplejersken skal dokumentere hele medicineringsprocessen i MDA.</li> </ul> <p style="margin-left:0cm; margin-right:0cm"><u>Sygeplejersken skal inden anvendelse af delegeret rammeordination;</u></p> <ul> <li>Indhente patientens samtykke</li> <li>Overholde den anførte mængde, dosis samt indikation og kontraindikationer.</li> <li>Cave: evt. allergi.</li> </ul> <p style="margin-left:0cm; margin-right:0cm">Sygeplejersken må administrere nedenstående præparater som éngangsordination i situationer, hvor der endnu ikke foreligger en lægeordination. Den delegerede rammeordination må foretages x 1 i hver dagvagt i akut-ambulatoriets åbningstid, hvorefter præparatet skal ordineres af en læge.</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong>Rammeordination for håndkøbslægemidler:</strong></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> ###TABEL_1### <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm">Specifik oversigt over præparater:<br> <br> <strong>Analgetika</strong></p> ###TABEL_2### <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong>Analgetika (fortsat)</strong></p> ###TABEL_3### <p style="margin-left:0cm; margin-right:0cm"><br> Kilde: Medicin.dk (Lægemiddelkataloget)</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579273563Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579273563Ansvar"></a> <div class="collapsible-item-title"> <h2>Ansvar og organisering</h2> </div> <p style="margin-left:0cm; margin-right:0cm"><a name="1699579273563_Hlk108520333">Afdelingsledelsen er ansvarlig for at instruksen er gældende og godkendt. </a></p> <p style="margin-left:0cm; margin-right:0cm"><a name="1699579273563_Hlk108519986"></a></p> <p style="margin-left:0cm; margin-right:0cm">Afdelingens cheflæge er overordnet ansvarlig for uddelegering af rammeordination. Den kliniske sygeplejespecialist er praktisk ansvarlig for, at sygeplejersken introduceres til instruksen samt modtager undervisning.</p> <p style="margin-left:0cm; margin-right:0cm; text-align:justify">Når sygeplejersken, der er godkendt til delegeret rammeordination, påtager sig at initiere behandling, er denne selv ansvarlig for at udføre ordinationen jf. denne instruks samt dokumentere hele medicineringsprocessen i MDA i Sundhedsplatformen.</p> <p style="margin-left:0cm; margin-right:0cm; text-align:justify">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm; text-align:justify">Sygeplejersken har selv ansvar for at frabede sig at initiere behandling, hvis denne ikke ser sig i stand til at udføre ordinationen forsvarligt.</p> <p style="margin-left:0cm; margin-right:0cm; text-align:justify">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm; text-align:justify">Sygeplejersken er forpligtet til at udvise omhu og samvittighedsfuldhed i sit virke i henhold til Bekendtgørelse af lov om sygeplejersker § 5, stk. 1 (Retsinformation, Sygeplejerskeloven).</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579273563Top">Tilbage til top</a></p> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579273563Referencer"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Referencer, lovgivning og faglig evidens samt links hertil</h2> </div> <div class="collapsible-item-body" style="display: block;"> <ul> <li><span style="background-color:white"><span style="color:black"><a href="https://www.retsinformation.dk/eli/lta/2019/731" style="color:blue; text-decoration:underline" target="_blank"><span style="background-color:white">Bekendtgørelse af lov om autorisation af sundhedspersoner og om sundhedsfaglig virksomhed (Autorisationsloven) LBK nr. 731 af 08/07/2019</span></a></span></span></li> <li> <p style="margin-left:0cm; margin-right:0cm"><span style="background-color:white"><span style="color:black"><a href="https://www.retsinformation.dk/eli/lta/2009/1219" style="color:blue; text-decoration:underline" target="_blank"><span style="background-color:white">Bekendtgørelse nr. 1219 af 11. december 2009 om autoriserede sundhedspersoners benyttelse af medhjælp (delegation af forbeholdt sundhedsfaglig virksomhed) med eventuelle senere ændringer</span></a></span></span></p> </li> <li> <p style="margin-left:0cm; margin-right:0cm"><span style="background-color:white"><span style="color:black"><a href="https://www.retsinformation.dk/eli/mt/2009/115" style="color:blue; text-decoration:underline" target="_blank"><span style="background-color:white">Vejledning nr. 115 af 11. december 2009 om autoriserede sundhedspersoners benyttelse af medhjælp</span></a></span></span></p> </li> <li> <p style="margin-left:0cm; margin-right:0cm"><span style="background-color:white">&nbsp;</span><span style="background-color:white"><span style="color:black"><a href="https://vip.regionh.dk/VIP/Admin/GUI.nsf/Desktop.html?open&amp;openlink=https://vip.regionh.dk/VIP/Slutbruger/Portal.nsf/Main.html?open&amp;unid=XDCFC8C0A263E4AB3C12578AA002C8412&amp;level=130126&amp;dbpath=/VIP/Redaktoer/RH.nsf/&amp;windowwidth=1100&amp;windowheight=600&amp;windowtitle=S%F8g" style="color:blue; text-decoration:underline">VIP vejledning; Lægemiddelordination, Region Hovedstaden</a></span></span></p> </li> <li><span style="background-color:white"><span style="color:black"><a href="https://vip.regionh.dk/VIP/Admin/GUI.nsf/Desktop.html?open&amp;openlink=https://vip.regionh.dk/VIP/Slutbruger/Portal.nsf/Main.html?open&amp;unid=XBA8EB3CBC54494FDC1257F650036AC89&amp;level=130126&amp;dbpath=/VIP/Redaktoer/RH.nsf/&amp;windowwidth=1100&amp;windowheight=600&amp;windowtitle=S%F8g" style="color:blue; text-decoration:underline">VIP vejledning: Journalføring – vurdering og indhold, Region Hovedstaden</a></span></span></li> <li><span style="background-color:white"><span style="color:black"><a href="https://vip.regionh.dk/VIP/Admin/GUI.nsf/Desktop.html?open&amp;openlink=https://vip.regionh.dk/VIP/Slutbruger/Portal.nsf/Main.html?open&amp;unid=X9A5DA86A3563E95AC1257C760032ACAD&amp;level=130126&amp;dbpath=/VIP/Redaktoer/RH.nsf/&amp;windowwidth=1100&amp;windowheight=600&amp;windowtitle=S%F8g" style="color:blue; text-decoration:underline">VIP vejledning: Delegation af forbeholdt sundhedsfaglig virksomhed, Region Hovedstaden</a></span></span></li> </ul> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579273563Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579273563Bilag"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Bilag</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579273563Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Delegeret rammeordination af udvalgt håndk¢bsmedicin for_TABEL_1.

Hovedgruppe Generisk navn Dosis Analgetika Paracetamol Tablet á 500 mg, 2 tabl. Max x 1 Ibuprofen Tablet á 200 mg. Max x 1

<table border="1" cellspacing="0" class="MsoTableGrid" style="border-collapse:collapse; border:solid windowtext 1.0pt"> <tbody> <tr> <td style="vertical-align:top; width:160.45pt"> <p style="margin-left:0cm; margin-right:0cm"><strong>Hovedgruppe</strong></p> </td> <td style="vertical-align:top; width:160.45pt"> <p style="margin-left:0cm; margin-right:0cm"><strong>Generisk navn</strong></p> </td> <td style="vertical-align:top; width:160.5pt"> <p style="margin-left:0cm; margin-right:0cm"><strong>Dosis</strong></p> </td> </tr> <tr> <td rowspan="2" style="vertical-align:top; width:160.45pt"> <p style="margin-left:0cm; margin-right:0cm"><strong>Analgetika</strong></p> </td> <td style="vertical-align:top; width:160.45pt"> <p style="margin-left:0cm; margin-right:0cm">Paracetamol</p> </td> <td style="vertical-align:top; width:160.5pt"> <p style="margin-left:0cm; margin-right:0cm">Tablet á 500 mg, 2 tabl. Max x 1</p> </td> </tr> <tr> <td style="height:24.3pt; vertical-align:top; width:160.45pt"> <p style="margin-left:0cm; margin-right:0cm">Ibuprofen<br> <br> &nbsp;</p> </td> <td style="height:24.3pt; vertical-align:top; width:160.5pt"> <p style="margin-left:0cm; margin-right:0cm">Tablet á 200 mg.</p> <p style="margin-left:0cm; margin-right:0cm">Max x 1</p> </td> </tr> </tbody> </table>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Delegeret rammeordination af udvalgt håndk¢bsmedicin for_TABEL_2.

Pinex, Paracetamol, Pamol, Panodil Paracetamol tablet á 500 mg, suppositorie á 1000 mg Indikation: Svage smerter, der relateres til patientens aktuelle sygdom Dosering: Voksne: 0,5 – 1 g x 4 Hvis patienten allerede har fået paracetamol, skal man være opmærksom på, at den samlede døgndosis for voksne ikke må overstige 4 g i døgnet. Bivirkninger: Stort set bivirkningsfrit i normale doser på 0,5 – 1 g, 3 – 4 gange dagligt. Sjældent (0,01 – 0,1%) Utilpashed, hypotension og forhøjede levertransanimaser. Meget sjældent (<0,01%) Allergiske reaktioner og trombocytopeni Interaktioner: Paracetamol kan øge udskillelsen af lomotrigin og kan ved regelmæssig indtagelse i mere end 5 dage, øge effekten af warfarin. Kontraindikationer: Alvorlig lever – eller nyreinsufficiens

<table class="Table" style="border:undefined; width:100.0%"> <tbody> <tr> <td style="vertical-align:top; width:100.0%"> <p style="margin-left:0cm; margin-right:0cm"><strong>Pinex, Paracetamol, Pamol, Panodil</strong><br> <br> Paracetamol tablet á 500 mg, suppositorie á 1000 mg</p> </td> </tr> <tr> <td style="vertical-align:top; width:100.0%"> <p style="margin-left:0cm; margin-right:0cm"><u>Indikation:</u><br> <br> Svage smerter, der relateres til patientens aktuelle sygdom</p> </td> </tr> <tr> <td style="vertical-align:top; width:100.0%"> <p style="margin-left:0cm; margin-right:0cm"><u>Dosering:</u><br> <br> Voksne: 0,5 – 1 g x 4<br> <br> Hvis patienten allerede har fået paracetamol, skal man være opmærksom på, at den samlede døgndosis for voksne ikke må overstige 4 g i døgnet.</p> </td> </tr> <tr> <td style="vertical-align:top; width:100.0%"> <p style="margin-left:0cm; margin-right:0cm"><u>Bivirkninger:</u><br> <br> Stort set bivirkningsfrit i normale doser på 0,5 – 1 g, 3 – 4 gange dagligt.<br> <br> Sjældent (0,01 – 0,1%)</p> <p style="margin-left:0cm; margin-right:0cm">Utilpashed, hypotension og forhøjede levertransanimaser.</p> <p style="margin-left:0cm; margin-right:0cm">Meget sjældent (&lt;0,01%)</p> <p style="margin-left:0cm; margin-right:0cm">Allergiske reaktioner og trombocytopeni</p> </td> </tr> <tr> <td style="vertical-align:top; width:100.0%"> <p style="margin-left:0cm; margin-right:0cm"><u>Interaktioner:</u><br> <br> Paracetamol kan øge udskillelsen af lomotrigin og kan ved regelmæssig indtagelse i mere end 5 dage, øge effekten af warfarin.</p> </td> </tr> <tr> <td style="vertical-align:top; width:100.0%"> <p style="margin-left:0cm; margin-right:0cm"><u>Kontraindikationer:</u><br> Alvorlig lever – eller nyreinsufficiens</p> </td> </tr> </tbody> </table>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Delegeret rammeordination af udvalgt håndk¢bsmedicin for_TABEL_3.

Tbl. Ibumetin Ibuprofen tablet á 200 mg Indikation: Svage smerter relateret til patientens aktuelle sygdom, hvor tbl. Panodil ikke er nok Dosering: Tabl. Á 200 mg. 1 – 2 tbl. X 3 Bivirkninger: Almindelige (1 – 10%) Pyrosis, dyspepsi, kvalme, opkastning, abdominalsmerter, diarré, obstipation Perifere ødemer Hududslæt, hudkløe. Hovedpine, svimmelhed Tinnitus Ikke almindelige (0,1 – 1%) Gastro-intestinal blødning, gastro-intestinal perforation, gastro-duodenale ulcera, forhøjede levertransaminaser Hypertension, astma søvnløshed, nervøsitet Hudkløe Forsigtighedsregler: Forsigtighed tilrådes ved hæmoragisk diatese, da NSAID hæmmer trombocytternes aggregationsevne. Forsigtighed ved samtidig antikoagulationsbehandling. Kontraindikationer: Frisk gastro-intestinal blødning, sværere hjerte – og leverinsufficiens, svær hypertension, svær nyreinsufficiens og svær trombocytopeni. Astma bronchiale eller andre allergiske symptomer udløst af salicylsyre eller andre NSAID.

<table class="Table" style="border:undefined; width:100.0%"> <tbody> <tr> <td style="vertical-align:top; width:100.0%"> <p style="margin-left:0cm; margin-right:0cm"><strong>Tbl. Ibumetin</strong><br> <br> Ibuprofen tablet á 200 mg</p> </td> </tr> <tr> <td style="vertical-align:top; width:100.0%"> <p style="margin-left:0cm; margin-right:0cm"><u>Indikation:</u><br> <br> Svage smerter relateret til patientens aktuelle sygdom, hvor tbl. Panodil ikke er nok</p> </td> </tr> <tr> <td style="vertical-align:top; width:100.0%"> <p style="margin-left:0cm; margin-right:0cm"><u>Dosering:</u><br> <br> Tabl. Á 200 mg. 1 – 2 tbl. X 3</p> </td> </tr> <tr> <td style="vertical-align:top; width:100.0%"> <p style="margin-left:0cm; margin-right:0cm"><u>Bivirkninger:</u><br> <br> Almindelige (1 – 10%)</p> <p style="margin-left:0cm; margin-right:0cm">Pyrosis, dyspepsi, kvalme, opkastning, abdominalsmerter, diarré, obstipation<br> Perifere ødemer<br> Hududslæt, hudkløe.<br> Hovedpine, svimmelhed<br> Tinnitus</p> <p style="margin-left:0cm; margin-right:0cm">Ikke almindelige (0,1 – 1%)</p> <p style="margin-left:0cm; margin-right:0cm">Gastro-intestinal blødning, gastro-intestinal perforation, gastro-duodenale ulcera, forhøjede levertransaminaser<br> Hypertension, astma<br> søvnløshed, nervøsitet<br> Hudkløe</p> </td> </tr> <tr> <td style="vertical-align:top; width:100.0%"> <p style="margin-left:0cm; margin-right:0cm"><u>Forsigtighedsregler:</u><br> <br> Forsigtighed tilrådes ved hæmoragisk diatese, da NSAID hæmmer trombocytternes aggregationsevne. Forsigtighed ved samtidig antikoagulationsbehandling.</p> </td> </tr> <tr> <td style="vertical-align:top; width:100.0%"> <p style="margin-left:0cm; margin-right:0cm"><u>Kontraindikationer:</u><br> <br> Frisk gastro-intestinal blødning, sværere hjerte – og leverinsufficiens, svær hypertension, svær nyreinsufficiens og svær trombocytopeni. Astma bronchiale eller andre allergiske symptomer udløst af salicylsyre eller andre NSAID.</p> </td> </tr> </tbody> </table>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Efterjusteringer af h¢reapparat.

Efterjusteringer af høreapparat Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Målgrupper og anvendelsesområde Personale på Hørepædagogisk afs., GeH Definitioner HA = høreapparat Fremgangsmåde Ønsker klienten justering af HA, aftales i videst muligt omfang tid hos tilpasseren, der udleverede HA (kontaktperson). Besøget registreres under kontrol/justering og der noteres på cont’en i Auditbase. Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag

<h1><div id="Afsnit#1699579382838">Efterjusteringer af høreapparat</div></h1><div id="BodyWeb#1699579382838"><p><a name="1699579382838Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579382838Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579382838Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579382838Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579382838Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579382838Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579382838Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579382838Bilag">Bilag</a><br> &nbsp;</h3> <h2><a name="1699579382838Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p>Personale på Hørepædagogisk afs., GeH&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579382838Top">Tilbage til top</a></p> <h2><a name="1699579382838Definitioner"></a><br> Definitioner</h2> <p>HA = høreapparat</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579382838Top">Tilbage til top</a></p> <h2><a name="1699579382838Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p>Ønsker klienten justering af HA, aftales i videst muligt omfang tid hos tilpasseren, der udleverede HA (kontaktperson).<br> Besøget registreres under kontrol/justering og der noteres på cont’en i Auditbase.</p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579382838Top">Tilbage til top</a></p> <h2><a name="1699579382838Ansvar"></a><br> Ansvar og organisering</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579382838Top">Tilbage til top</a></p> <h2><a name="1699579382838Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579382838Top">Tilbage til top</a></p> <h2><a name="1699579382838Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579382838Top">Tilbage til top</a></p> <h2><a name="1699579382838Bilag"></a><br> Bilag</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579382838Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_EKG på nydiagnosticerede b¢rn med kongenit.

EKG på nydiagnosticerede børn med kongenit svær hørenedsættelse eller døvhed Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Målgrupper og anvendelsesområde Instruks for personale ved aud. afd. vedrørende EKG på alle børn nydiagnosticeret med kongenit svær hørenedsættelse eller døvhed med det formål at identificere børn med Jervell og Lange-Nielsen syndrom. Definitioner Jervell og Lange-Nielsen syndrom er en meget sjælden autosomal recessivt nedarvet sygdom manifesterende sig med kongenit svær hørenedsættelse eller døvhed og EKG forandringer med forlænget QT-interval. Sygdommen medfører ofte ventrikulære takyarytmier med deraf følgende risiko for pludselig død. Mutationer i to ionkanalgener KCNQ1 og KCNE1 af betydning for regulation af kaliumtransporten i indre øre og hjertet, vides at kunne forårsage syndromet. Fysisk anstrengelse eller stress kan trigge anfald, men også anæstesi og lydstimulation med høreapparat eller CI er rapporteret at kunne udløse arytmi. Kardiologisk kan sygdommen behandles med betablokkere eller ICD. Fremgangsmåde Alle børn med kongenit svær hørenedsættelse eller døvhed (dvs. estimeret PTA0.5,1,2,4 kHz ≥ 70 dB HL på bedst hørende øre) skal snarest efter audiologisk identifikation henvises til EKG. Begge forældre skal også have foretaget EKG. Bedømmelse af EKG skal gerne foreligge inden HA-behandling påbegyndes, dog uden at HA-behandlingen af den grund forsinkes, og skal foreligge inden barnet anæsteseres til f.eks. ecoch, billeddiagnostik eller CI-operation. Barn og forældre henvises til EKG-tagning i klinisk-biokemisk afdeling på vanlig vis via ICE. EKG’er skannes og sendes som pdf-fil til Lektor ###NAVN### kardiologisk afd. P, Ambulatoriet PA 611, som bedømmer EKG og sender beskrivelse retur til audiologisk afdeling. Hvis EKG er suspekt, skal barnet henvises til kardiologisk afd. P med henblik på videre udredning. Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag

<h1><div id="Afsnit#1699579385038">EKG på nydiagnosticerede børn med kongenit svær hørenedsættelse eller døvhed</div></h1><div id="BodyWeb#1699579385038"><p><a name="1699579385038Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579385038Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579385038Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579385038Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579385038Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579385038Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579385038Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579385038Bilag">Bilag</a><br> &nbsp;</h3> <h2><a name="1699579385038Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p>Instruks for personale ved aud. afd. vedrørende EKG på alle børn nydiagnosticeret med kongenit svær hørenedsættelse eller døvhed med det formål at identificere børn med Jervell og Lange-Nielsen syndrom.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579385038Top">Tilbage til top</a></p> <h2><a name="1699579385038Definitioner"></a><br> Definitioner</h2> <p>Jervell og Lange-Nielsen syndrom er en meget sjælden autosomal recessivt nedarvet sygdom manifesterende sig med kongenit svær hørenedsættelse eller døvhed og EKG forandringer med forlænget QT-interval. Sygdommen medfører ofte ventrikulære takyarytmier med deraf følgende risiko for pludselig død. Mutationer i to ionkanalgener <em>KCNQ1 </em>og <em>KCNE1</em> af betydning for regulation af kaliumtransporten i indre øre og hjertet, vides at kunne forårsage syndromet. Fysisk anstrengelse eller stress kan trigge anfald, men også anæstesi og lydstimulation med høreapparat eller CI er rapporteret at kunne udløse arytmi. Kardiologisk kan sygdommen behandles med betablokkere eller ICD.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579385038Top">Tilbage til top</a></p> <h2><a name="1699579385038Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p>&nbsp;</p> <p>Alle børn med kongenit svær hørenedsættelse eller døvhed (dvs. estimeret PTA_{0.5,1,2,4 kHz}≥ 70 dB HL på bedst hørende øre) skal snarest efter audiologisk identifikation henvises til EKG. Begge forældre skal også have foretaget EKG.<br> Bedømmelse af EKG skal gerne foreligge inden HA-behandling påbegyndes, dog uden at HA-behandlingen af den grund forsinkes, og skal foreligge inden barnet anæsteseres til f.eks. ecoch, billeddiagnostik eller CI-operation.<br> <br> Barn og forældre henvises til EKG-tagning i klinisk-biokemisk afdeling på vanlig vis via ICE. EKG’er skannes og sendes som pdf-fil til<br> <br> Lektor ###NAVN###<br> kardiologisk afd. P, Ambulatoriet PA 611,<br> <br> som bedømmer EKG og sender beskrivelse retur til audiologisk afdeling. Hvis EKG er suspekt, skal barnet henvises til kardiologisk afd. P med henblik på videre udredning.</p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579385038Top">Tilbage til top</a></p> <h2><a name="1699579385038Ansvar"></a><br> Ansvar og organisering</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579385038Top">Tilbage til top</a></p> <h2><a name="1699579385038Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579385038Top">Tilbage til top</a></p> <h2><a name="1699579385038Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579385038Top">Tilbage til top</a></p> <h2><a name="1699579385038Bilag"></a><br> Bilag</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579385038Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Elektrokemoterapi til patienter med hoved-halskræft.

Elektrokemoterapi til patienter med hoved-halskræft Formål Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Bilag Formål Vejledning til visitation af patienter til elektrokemoterapi, udførsel af behandlingen samt opfølgning postoperativt. Målgrupper og anvendelsesområde Alle personalegrupper, der er involveret i behandling med elektrokemoterapi på Afdeling for Øre-Næse-Halskirurgi og Audiologi på Rigshospitalet, samt personale fra onkologiske klinikker i Region Hovedstaden og Region Sjælland der behandler patienter med kræft i hoved-hals området. Anvendelsesområde: Patienter med kræft i hoved-hals. Behandling med elektrokemoterapi i general anæstesi samt postoperativ opfølgning. Afgrænsning Vejledning omfatter ikke behandling med elektrokemoterapi til kræft i huden. Hér henvises til vejledningen ”Behandling af maligne tumorer med elektrokemoterapi” fra Herlev og Gentofte Hospital > Onkologisk Afdeling. Definitioner Ved elektrokemoterapi forstås anvendelse af elektriske pulse til at øge optag af kemoterapi i kræftsvulster. Fremgangsmåde 1.Visitation: 1.1 Ved visitation skal følgende oplysninger stå i notat: - Henvisende sygehus og afdeling. - Henvisningsdiagnose, dato for sygdomsdebut. - Histologisk verifikation af malign diagnose. - Resumé af tidligere behandlinger. - Henvisningsårsag (henvisende afdelings ønske om behandling/rådgivning) samt patientens problemstilling. - Patientens almentilstand som beskrevet fra henvisende afdeling. - Undersøgelsesresultater fra henvisende afdeling. 1.2 Visitationen skal foretages af læger med behandlingsansvar for elektrokemoterapi: Overlæge ###NAVN### eller afdelingslæge ###NAVN###. Patienten bookes til ambulant vurdering inden stillingtagen til behandling. 2. Vurdering af patient til elektrokemoterapi: Patienten ses ambulant i Øre-Næse-Hals Ambulatorium på Rigshospitalet. 1. Vurdering af om patienten er egnet til at modtage elektrokemoterapi eller alternative muligheder (eks. kirurgi, strålebehandling eller anden antineoplastisk behandling). Tumor skal således vurderes at kunne behandles rent teknisk, og patienten skal vurderes om behandlingen tåles alment. 2. Relative kontraindikationer for elektrokemoterapi: a. AK-behandling som ikke kan pauseres b. Nedsat lungefunktion i forhold til intravenøs bleomycin c. Trismus, der vanskeliggør adgang til mundhulen med elektroderne. 3. Journaloptagelse, inkl. gennemgang af de gener tumor medfører aktuelt 4. Måling af tumor (es) med klinisk foto og/eller på skanning. 5. Information til patient om forventet effekt og bivirkninger. 6. Patientens vægt og højde noteres. 2.1 Forundersøgelser 1. Der skal foreligge en MR-, CT- eller PET/CT-skanning af hoved-hals området (max. 2 mdr. gamle). 2. Der bestilles EKG og røntgen af thorax. 3. Der bestilles blodprøver. 4. Der laves en case-bestilling i SP til behandling i general anæstesi. 5. Der bestilles anæstesitilsyn og klargøring ved sygeplejerske. Hvis patienten har lungesymptomer (åndenød, hoste o. lign.), eller kendt nedsat lungefunktion, bør man overveje at udføre lungefunktionsundersøgelse (DLCO) inden planlagt behandling med intravenøs bleomycin. 2.2 Blodprøver Følgende blodprøver skal tages: Hæmoglobin, Trombocytter, Leukocytter, INR, APTT, Kreatinin, eGFR. Blodprøver må være op til en uge gamle, såfremt patienten ikke er i anden antineoplastisk behandling. Hvis patienten er i anden antineoplastisk behandling da maksimalt en dag gamle. Ved afvigelser fra referenceværdi i blodprøver: Kreatinin > 150 μM skal der foretages Crom-EDTA for at sikre at patienten har sufficient nyrefunktion (da bleomycin udskilles gennem nyrerne). 3. Generelt for elektrokemoterapi i fuld anæstesi med intravenøs bleomycin. 3.1 Ordination af kemoterapi Bleomycin kan ordineres op til 10 dage før behandling, såfremt patienten ikke er i anden antineoplastisk behandling. Dog skal ordinationen sendes til serviceproduktionen på Rigshospitalet senest inden kl. 14 dagen før behandling. Der ordineres bleomycin 15.000 IE pr. m2 legemsoverflade. Der benyttes følgende skema til ordination: link til pdf (Bleomycin rekvirering) Kreatinin-clearance foretages hvis creatinin er over 150 mikromol/l. Ved nedsat nyrefunktion reduceres dosis af bleomycin: - Falder kreatinin-clearance til 1 ml/s (60 ml/min), bør bleomycin dosis reduceres til 70 %. - Falder kreatinin-clearance til 0,8 ml/s (45 ml/min), bør bleomycin dosis reduceres til 60 %. - Ved alvorlig nedsat nyrefunktion (kreatinin-clearance under 0,8 ml/s) kan behandlingen ikke tilbydes. Hos ældre bør totaldosen reduceres til følgende: Under 60 år: Maximale totaldosis 400 000 IE. 60-69 år: Maksimal totaldosis 300 000 IE. 70-79 år: Maksimal totaldosis 200 000 IE. 80 år og derover: Maksimal totaldosis 100 000 IE. (kilde: Lægemiddelstyrelsens produktresumé for Bleomycin ”Baxter”) 3.2 SOP for opsætning og anvendelse af pulsgenerator (Cliniporator). Der benyttes Cliniporator model EPS02 fra IGEA. - Tænd for apparatur på bagsiden - Afvent auto-test - Indtast ”username”og ”password” - Vælg modaliteten ”ECT” - Indtast patientdata - Vælg ”Electrode selection” for af tilpasse til den ønskede elektrode - Placér elektrodens tag-bag på højre side af Cliniporatoren indtil systemet har genkendt elektroden - Tryk på ”energy” for at oplade kapacitatoren og afvent grønt lys - Tryk ”Arm” og herefter ”Pulse” for at levere pulsene 3.3 Behandlingsprocedure Patienten bedøves efter vanlig procedure. Tubeplacering afgøres sammen med kirurgen, for at give så god plads til behandling af tumorområdet som muligt. - Patienten lægges på leje. - Der skal så vidt muligt undgås at anvende klistrende afdækning og plastre pga. risiko for hudreaktion fra bleomycin. 2. Mens patienten bliver bedøvet, klargøres Cliniporator og kemoterapi a. Sørg for I.V. adgang b. Dobbeltløbet slange bruges. Luk for alt. Sæt saltvand på slange og skyl igennem med saltvand, således, at der er saltvand i slangerne. c. Kemoterapi sættes på anden hane. Forsat lukket for denne. d. Slut systemet til I.V. adgang 3. Sørg for at anæstesien får FiO2 < 30 %. Når FiO2 < 30 % med acceptabel saturation kan behandlingen begynde. 4. Åbn for kemoterapi, luk for saltvand. Noter tidspunkt. 5. Når kemoterapi er løbet ind, lukkes for denne, og der åbnes for saltvand. Noter tidspunkt. 6. Saltvand lukkes. 7. 8 minutter efter, at kemoterapi er løbet ind, gives første puls: a. Noter tidspunkt. b. Anæstesien gøres opmærksom på, at nu gives 1. puls, så de kan se, hvordan patienten reagerer 8. Der kan behandles i 28 min herefter. 9. Stop behandlingen og fortæl anæstesien, at behandlingen er slut. Noter tidspunkt. 10. Vask og forbind patienten. 11. Patienten køres på opvågningsafsnit. 3.4 Perioperativ medicinering Med mindre kontraindiceret grundet allergi indgives følgende under operationen: - 16 mg dexamethason som engangsdosis – for at mindske ødem i slimhinden efter behandling. - 1500 mg cefuroxim og 500 mg metronidazol for at undgå infektion i det behandlede område. - Pt. relaxeres af anæstesien mens der indgives bleomycin, således der er fuld effekt af relaxeringen ved påbegyndelse af elektroporationen, som forårsager muskelkontraktioner. 3.5 Opvågningen og postoperativ indlæggelse. Patienten køres efter operation til opvågning i ØNH opvågningsregi. 1. Slimhindeødem: der skal efter behandling og i det første postoperative døgn være opmærksomhed på risiko for slimhindeødem i mundhule, svælg og strube. Bliver slimhindeødemet behandlingskrævende, kan der ordineres solumedrol IV samt adrenalin inhalationer. Er dette ikke tilstrækkeligt, må pt vurderes for behov for intubering og indlæggelse i intensiv regi, indtil slimhindeødemet aftager. 2. Nasal ilt: grundet indgift af bleomycin bør pt. ikke få mere end 2 liter ilt på næsekateter for at mindske risikoen for udvikling af lungefibrose. I en akut iltkrævende situation må dette krav tilsidesættes. 3. Værnemidler: patienter behandlet med systemisk bleomycin kræver ikke isolation eller åndedrætsværnemidler. Vævsvæsker skal håndteres med handsker. 4. Antibiotika: efter endt opvågning indlægges patienten på øre-næse-hals sengeafdeling. Som udgangspunkt anbefales 3 dages indlæggelse med IV antibiotika, men dette forløb kan afkortes såfremt forløbet har været ukompliceret. Udskrives patienten inden, anbefales peroral antibiotika for at undgå infektion i det behandlede område. 4. Ambulant kontrol af patienter efter elektrokemoterapi Som udgangspunkt ses patienterne ambulant efter 2 uger, 1 og 2 måneder. Ved behov kan der foretages yderligere kontroller. Behandlingseffekten måles ud fra bioptering fra det behandlede område samt ud fra skanninger (CT, MR eller PET/CT), der dog tidligst skal ligge fra 2 måneder postoperativt. Ansvar og organisering Afdelingsledelsen Referencer, lovgivning og faglig evidens samt links hertil Plaschke CC. et al. European Research on Electrochemotherapy in Head and Neck Cancer (EURECA) project: Results from the treatment of mucosal cancers. Eur J Cancer. 2017 Dec;87:172-181. doi:10.1016/j.ejca.2017.10.008. Gehl J. et al. Updated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases. Acta Oncol. 2018 Jul;57(7):874-882. doi: 10.1080/0284186X.2018.1454602 Udarbejdet af ###NAVN### Plaschke, afd.læge Godkendt af ###NAVN###, overlæge. Bilag

<h1><div id="Afsnit#1699579338323">Elektrokemoterapi til patienter med hoved-halskræft</div></h1><div id="BodyWeb#1699579338323"><p><a name="1699579338323Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579338323Formaal">Formål</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579338323Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579338323Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579338323Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579338323Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579338323Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579338323Bilag">Bilag</a><br> &nbsp;</h3> <p><a name="1699579338323Formaal"></a></p> <h2>Formål</h2> <p>Vejledning til visitation af patienter til elektrokemoterapi, udførsel af behandlingen samt opfølgning postoperativt.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579338323Top">Tilbage til top</a></p> <h2><a name="1699579338323Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p>Alle personalegrupper, der er involveret i behandling med elektrokemoterapi på Afdeling for Øre-Næse-Halskirurgi og Audiologi på Rigshospitalet, samt personale fra onkologiske klinikker i Region Hovedstaden og Region Sjælland der behandler patienter med kræft i hoved-hals området.</p> <p>&nbsp;</p> <p>Anvendelsesområde:</p> <p>Patienter med kræft i hoved-hals.</p> <p>Behandling med elektrokemoterapi i general anæstesi samt postoperativ opfølgning.</p> <p>&nbsp;</p> <p><strong>Afgrænsning</strong></p> <p>Vejledning omfatter <em>ikke</em> behandling med elektrokemoterapi til kræft i huden. Hér henvises til vejledningen ”Behandling af maligne tumorer med elektrokemoterapi” fra Herlev og Gentofte Hospital &gt; Onkologisk Afdeling.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579338323Top">Tilbage til top</a></p> <h2><a name="1699579338323Definitioner"></a><br> Definitioner</h2> <p>Ved elektrokemoterapi forstås anvendelse af elektriske pulse til at øge optag af kemoterapi i kræftsvulster.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579338323Top">Tilbage til top</a></p> <h2><a name="1699579338323Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p><strong>1.Visitation:</strong></p> <p><strong>1.1 Ved visitation skal følgende oplysninger stå i notat:</strong></p> <ul> <li> <p>Henvisende sygehus og afdeling.</p> </li> <li> <p>Henvisningsdiagnose, dato for sygdomsdebut.</p> </li> <li> <p>Histologisk verifikation af malign diagnose.</p> </li> <li> <p>Resumé af tidligere behandlinger.</p> </li> <li> <p>Henvisningsårsag (henvisende afdelings ønske om behandling/rådgivning) samt patientens</p> <p>problemstilling.</p> </li> <li> <p>Patientens almentilstand som beskrevet fra henvisende afdeling.</p> </li> <li> <p>Undersøgelsesresultater fra henvisende afdeling.</p> </li> </ul> <p>&nbsp;</p> <p><strong>1.2 Visitationen skal foretages af læger med behandlingsansvar for elektrokemoterapi: </strong></p> <p>Overlæge ###NAVN### eller afdelingslæge ###NAVN###.</p> <p>Patienten bookes til ambulant vurdering inden stillingtagen til behandling.</p> <p>&nbsp;</p> <p><strong>2. Vurdering af patient til elektrokemoterapi:</strong></p> <p>Patienten ses ambulant i Øre-Næse-Hals Ambulatorium på Rigshospitalet.</p> <p>1. Vurdering af om patienten er egnet til at modtage elektrokemoterapi eller alternative muligheder (eks. kirurgi, strålebehandling eller anden antineoplastisk behandling). Tumor skal således vurderes at kunne behandles rent teknisk, og patienten skal vurderes om behandlingen tåles alment.</p> <p>2. Relative kontraindikationer for elektrokemoterapi:</p> <p style="margin-left:65.2pt">a. AK-behandling som ikke kan pauseres</p> <p style="margin-left:65.2pt">b. Nedsat lungefunktion i forhold til intravenøs bleomycin</p> <p style="margin-left:65.2pt">c. Trismus, der vanskeliggør adgang til mundhulen med elektroderne.</p> <p>3. Journaloptagelse, inkl. gennemgang af de gener tumor medfører aktuelt</p> <p>4. Måling af tumor (es) med klinisk foto og/eller på skanning.</p> <p>5. Information til patient om forventet effekt og bivirkninger.</p> <p>6. Patientens vægt og højde noteres.</p> <p>&nbsp;</p> <p><strong>2.1 Forundersøgelser</strong></p> <p>1. Der skal foreligge en MR-, CT- eller PET/CT-skanning af hoved-hals området (max. 2 mdr. gamle).</p> <p>2. Der bestilles EKG og røntgen af thorax.</p> <p>3. Der bestilles blodprøver.</p> <p>4. Der laves en case-bestilling i SP til behandling i general anæstesi.</p> <p>5. Der bestilles anæstesitilsyn og klargøring ved sygeplejerske.</p> <p>&nbsp;</p> <p>Hvis patienten har lungesymptomer (åndenød, hoste o. lign.), eller kendt nedsat lungefunktion,</p> <p>bør man overveje at udføre lungefunktionsundersøgelse (DLCO) inden planlagt behandling med intravenøs bleomycin.</p> <p>&nbsp;</p> <p><strong>2.2 Blodprøver</strong></p> <p>Følgende blodprøver skal tages:</p> <p>Hæmoglobin, Trombocytter, Leukocytter, INR, APTT, Kreatinin, eGFR.</p> <p>&nbsp;</p> <p>Blodprøver må være op til en uge gamle, såfremt patienten ikke er i anden antineoplastisk behandling. Hvis patienten er i anden antineoplastisk behandling da maksimalt en dag gamle.</p> <p>Ved afvigelser fra referenceværdi i blodprøver:</p> <p>Kreatinin &gt; 150 μM skal der foretages Crom-EDTA for at sikre at patienten har sufficient nyrefunktion (da bleomycin udskilles gennem nyrerne).</p> <p>&nbsp;</p> <p><strong>3. Generelt for elektrokemoterapi i fuld anæstesi med intravenøs bleomycin. </strong></p> <p><strong>3.1 Ordination af kemoterapi</strong></p> <p>Bleomycin kan ordineres op til 10 dage før behandling, såfremt patienten ikke er i anden</p> <p>antineoplastisk behandling. Dog skal ordinationen sendes til serviceproduktionen på Rigshospitalet senest inden kl. 14 dagen før behandling.</p> <p>Der ordineres bleomycin 15.000 IE pr. m2 legemsoverflade.</p> <p>&nbsp;</p> <p>Der benyttes følgende skema til ordination: link til pdf (Bleomycin rekvirering)</p> <p>&nbsp;</p> <p>Kreatinin-clearance foretages hvis creatinin er over 150 mikromol/l. Ved nedsat nyrefunktion</p> <p>reduceres dosis af bleomycin:</p> <ul> <li> <p>Falder kreatinin-clearance til 1 ml/s (60 ml/min), bør bleomycin dosis reduceres til 70 %.</p> </li> <li> <p>Falder kreatinin-clearance til 0,8 ml/s (45 ml/min), bør bleomycin dosis reduceres til 60 %.</p> </li> <li> <p>Ved alvorlig nedsat nyrefunktion (kreatinin-clearance under 0,8 ml/s) kan behandlingen ikke tilbydes.</p> <p>&nbsp;</p> </li> </ul> <p>Hos ældre bør totaldosen reduceres til følgende:</p> <p style="margin-left:65.2pt">Under 60 år: Maximale totaldosis 400 000 IE.</p> <p style="margin-left:65.2pt">60-69 år: Maksimal totaldosis 300 000 IE.</p> <p style="margin-left:65.2pt">70-79 år: Maksimal totaldosis 200 000 IE.</p> <p style="margin-left:65.2pt">80 år og derover: Maksimal totaldosis 100 000 IE.</p> <p>&nbsp;(kilde: Lægemiddelstyrelsens produktresumé for Bleomycin ”Baxter”)</p> <p>&nbsp;</p> <p><strong>3.2 SOP for opsætning og anvendelse af pulsgenerator (Cliniporator). </strong></p> <p>Der benyttes Cliniporator model EPS02 fra IGEA.</p> <ol> <li> <p>Tænd for apparatur på bagsiden</p> </li> <li> <p>Afvent auto-test</p> </li> <li> <p>Indtast ”username”og ”password”</p> </li> <li> <p>Vælg modaliteten ”ECT”</p> </li> <li> <p>Indtast patientdata</p> </li> <li> <p>Vælg ”Electrode selection” for af tilpasse til den ønskede elektrode</p> </li> <li> <p>Placér elektrodens tag-bag på højre side af Cliniporatoren indtil systemet har genkendt elektroden</p> </li> <li> <p>Tryk på ”energy” for at oplade kapacitatoren og afvent grønt lys</p> </li> <li> <p>Tryk ”Arm” og herefter ”Pulse” for at levere pulsene</p> </li> </ol> <p>&nbsp;</p> <p><strong>3.3 Behandlingsprocedure</strong></p> <p>Patienten bedøves efter vanlig procedure. Tubeplacering afgøres sammen med kirurgen, for at give så god plads til behandling af tumorområdet som muligt.</p> <p>&nbsp;</p> <ol> <li> <p>Patienten lægges på leje.</p> </li> <li> <p>Der skal så vidt muligt undgås at anvende klistrende afdækning og plastre pga. risiko for hudreaktion fra bleomycin.</p> </li> </ol> <p>2. Mens patienten bliver bedøvet, klargøres Cliniporator og kemoterapi</p> <p>a. Sørg for I.V. adgang</p> <p>b. Dobbeltløbet slange bruges. Luk for alt. Sæt saltvand på slange og skyl igennem med saltvand, således, at der er saltvand i slangerne.</p> <p>c. Kemoterapi sættes på anden hane. Forsat lukket for denne.</p> <p>d. Slut systemet til I.V. adgang</p> <p>3. Sørg for at anæstesien får FiO2 &lt; 30 %.</p> <p>Når FiO2 &lt; 30 % med acceptabel saturation kan behandlingen begynde.</p> <p>4. Åbn for kemoterapi, luk for saltvand. Noter tidspunkt.</p> <p>5. Når kemoterapi er løbet ind, lukkes for denne, og der åbnes for saltvand. Noter tidspunkt.</p> <p>6. Saltvand lukkes.</p> <p>7. 8 minutter efter, at kemoterapi er løbet ind, gives første puls:</p> <p>a. Noter tidspunkt.</p> <p>b. Anæstesien gøres opmærksom på, at nu gives 1. puls, så de kan se, hvordan patienten reagerer</p> <p>8. Der kan behandles i 28 min herefter.</p> <p>9. Stop behandlingen og fortæl anæstesien, at behandlingen er slut. Noter tidspunkt.</p> <p>10. Vask og forbind patienten.</p> <p>11. Patienten køres på opvågningsafsnit.</p> <p>&nbsp;</p> <p><strong>3.4 Perioperativ medicinering</strong></p> <p>Med mindre kontraindiceret grundet allergi indgives følgende under operationen:</p> <p>&nbsp;</p> <ul> <li> <p>16 mg dexamethason som engangsdosis – for at mindske ødem i slimhinden efter behandling.</p> </li> <li> <p>1500 mg cefuroxim og 500 mg metronidazol for at undgå infektion i det behandlede område.</p> </li> <li> <p>Pt. relaxeres af anæstesien mens der indgives bleomycin, således der er fuld effekt af relaxeringen ved påbegyndelse af elektroporationen, som forårsager muskelkontraktioner.</p> </li> </ul> <p>&nbsp;</p> <p><strong>3.5 Opvågningen og postoperativ indlæggelse. </strong></p> <p>Patienten køres efter operation til opvågning i ØNH opvågningsregi.</p> <p>&nbsp;</p> <p>1. Slimhindeødem: der skal efter behandling og i det første postoperative døgn være opmærksomhed på risiko for slimhindeødem i mundhule, svælg og strube. Bliver slimhindeødemet behandlingskrævende, kan der ordineres solumedrol IV samt adrenalin inhalationer. Er dette ikke tilstrækkeligt, må pt vurderes for behov for intubering og indlæggelse i intensiv regi, indtil slimhindeødemet aftager.</p> <p>&nbsp;</p> <p>2. Nasal ilt: grundet indgift af bleomycin bør pt. ikke få mere end 2 liter ilt på næsekateter for at mindske risikoen for udvikling af lungefibrose. I en akut iltkrævende situation må dette krav tilsidesættes.</p> <p>&nbsp;</p> <p>3. Værnemidler: patienter behandlet med systemisk bleomycin kræver ikke isolation eller åndedrætsværnemidler. Vævsvæsker skal håndteres med handsker.</p> <p>&nbsp;</p> <p>4. Antibiotika: efter endt opvågning indlægges patienten på øre-næse-hals sengeafdeling. Som udgangspunkt anbefales 3 dages indlæggelse med IV antibiotika, men dette forløb kan afkortes såfremt forløbet har været ukompliceret. Udskrives patienten inden, anbefales peroral antibiotika for at undgå infektion i det behandlede område.</p> <p>&nbsp;</p> <p>&nbsp;</p> <p><strong>4. Ambulant kontrol af patienter efter elektrokemoterapi</strong></p> <p>Som udgangspunkt ses patienterne ambulant efter 2 uger, 1 og 2 måneder. Ved behov kan der foretages yderligere kontroller.</p> <p>Behandlingseffekten måles ud fra bioptering fra det behandlede område samt ud fra skanninger (CT, MR eller PET/CT), der dog tidligst skal ligge fra 2 måneder postoperativt.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579338323Top">Tilbage til top</a></p> <h2><a name="1699579338323Ansvar"></a><br> Ansvar og organisering</h2> <p>Afdelingsledelsen</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579338323Top">Tilbage til top</a></p> <h2><a name="1699579338323Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p>Plaschke CC. et al. European Research on Electrochemotherapy in Head and Neck Cancer (EURECA) project: Results from the treatment of mucosal cancers. Eur J Cancer. 2017 Dec;87:172-181. doi:10.1016/j.ejca.2017.10.008.</p> <p>&nbsp;</p> <p>Gehl J. et al. Updated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases. Acta Oncol. 2018 Jul;57(7):874-882. doi: 10.1080/0284186X.2018.1454602</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>Udarbejdet af ###NAVN### Plaschke, afd.læge</p> <p>Godkendt af ###NAVN###, overlæge.</p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579338323Top">Tilbage til top</a></p> <h2><a name="1699579338323Bilag"></a><br> Bilag</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579338323Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Epiglottitis acuta.

Epiglottitis acuta Formål At angive retningslinjer for håndtering og behandling af patienter med epiglottitis acuta. Baggrund Epiglottitis acuta er en meget alvorlig infektion primært lokaliseret til epiglottitis. Ætiologien er en bakteriel infektion oftest forårsaget af H. influenzae type B, pneumokokker, streptokokker og stafylococcus aureus. Median alderen er 50 år, og kan ses i alle aldersklasser. Forekomsten er aftaget hos børn efter indførelse af HIB-vaccination. Tilstanden er hyppigere hos mænd end kvinder. Hypertension og diabetes er risikofaktorer for epiglottitis Infektionen medfører ødem i epiglottis, der kan give truende luftvejsobstruktion. Mortaliteten er ca. 1 % af alle tilfælde af epiglottitis. Målgrupper og anvendelsesområde Lægefagligt personale i Afdeling for Øre-Næse-Halskirurgi og Audiologi og Intensivt afsnit 4131 Fremgangsmåde Diagnosekriterier -Akut udvikling over timer med temperaturforhøjelse, stærke synkesmerter - evt. med savlen og påvirket almentilstand -Palpationsømhed sv.t. larynxskelettet -Pt. sidder oftest foroverbøjet -Stridor tilkommer under progression af tilstanden -Ved fiberskopi ses oftest kuglerund, højrød epiglottis. Ved voksne ses ofte også hævelse af plica aryepiglottica og aryregionen. Børn har oftest kun hævelse af epiglottis. Visitation og præhospital håndtering Henvisende læge skal UDTRYKKELIGT ved kontakt til alarmcentralen rekvirere akutlægebilen og patienten modtages i traumecentret i henhold til instruks for visitation af patienter med mistanke om obstruktion af øvre luftvej, se PH:S Info . Anæstesihold tilkaldes. Behandling - Foretages i nødtracheotomiberedskab. Pt. anbringes i siddende stilling med hovedet let foroverbøjet. - Der foretages fiberskopi af ØNH-læge mhp. vurdering af pladsforhold. Omkring 20 % af patienterne har behov for intubation. I nødstilfælde kan tungen trækkes frem indtil evt. intubation kan foretages. - Ved mislykket intubation foretages nødtracheotomi. - Patienter skal altid indlægges til observation og behandling på 4131. Hvis der ikke er plads på 4131 kan patienten indlægges på Opvågningsafsnittet (i 4131- regi). Bagvagt 4131 aftaler dette med bagvagt AN/OP – anæstesien. Evt. intrahospital transport foregår med lægeledsagelse. Alle patienter observeres minimum første døgn på intensivt afsnit. - Der gives umiddelbart 1,5 g zinacef i.v. x 3 (Børn 100mg/kg i.v. fordelt på tre doser) Overvej Solu-medrol indgift 80 mg i.v. (Børn 2 mg/kg i.v.) - Alle patienter får taget infektionstal og væsketal, venyler og evt. podning. - Hvis tilstanden ikke bedres i løbet af de første to dage, skal absces på epiglottis mistænkes. Der skal laves CT halsen og direkte laryngoskopi med biopsi mhp udtømmelse af abscessen. Såfremt der ikke vurderes at være behov for akut intubation skal patienten overvåges på intensiv afsnit og have foretaget ny fiberskopisk vurdering ved mindste forværring. Patienten bør optimalt fiberskoperes ved vagtskifte for at afgående og tiltrædende vagthavende læge ved selvsyn vurderer pladsforholdene. Patienten kan ved markant forbedring af pladsforholdene efter passende intensiv observation overflyttes til stamafdeling mhp fortsat antibiotisk behandling Såfremt patienten er intuberet kan patienten som regel ekstuberes efter 1-2 døgn, afhængigt af pladsforholdene vurderet ved fiberskopi. Ekstubation bør foretages i dagtiden. Kost: Efter ekstubation, må patienten indtage tynde væsker per os. Herefter stigende til kost efter evne. Differentialdiagnoser Pseudocroup Peritonsillær og parapharyngeal abscess Laryngit Fremmedlegeme Ansvar og organisering Afdelingsledelser i Afdeling for Øre-Næse-Halskirurgi og Audiologi og Intensiv Klinik

<h1><div id="Afsnit#1699579324660">Epiglottitis acuta</div></h1><div id="BodyWeb#1699579324660"><p><strong>Formål</strong></p> <p>At angive retningslinjer for håndtering og behandling af patienter med epiglottitis acuta.</p> <p><strong>Baggrund</strong></p> <p>Epiglottitis acuta er en meget alvorlig infektion primært lokaliseret til epiglottitis. Ætiologien er en bakteriel infektion oftest forårsaget af H. influenzae type B, pneumokokker, streptokokker og stafylococcus aureus.</p> <p>Median alderen er 50 år, og kan ses i alle aldersklasser. Forekomsten er aftaget hos børn efter indførelse af HIB-vaccination. Tilstanden er hyppigere hos mænd end kvinder. Hypertension og diabetes er risikofaktorer for epiglottitis</p> <p>Infektionen medfører ødem i epiglottis, der kan give truende luftvejsobstruktion. Mortaliteten er ca. 1&nbsp;% af alle tilfælde af epiglottitis.</p> <p><a href="http://vip.regionh.dk/VIP/Redaktoer/130126.nsf/Main.html?Open#Top">Tilbage til top</a></p> <p><strong>Målgrupper og anvendelsesområde</strong></p> <p>Lægefagligt personale i Afdeling for Øre-Næse-Halskirurgi og Audiologi og Intensivt afsnit 4131</p> <p><a href="http://vip.regionh.dk/VIP/Redaktoer/130126.nsf/Main.html?Open#Top">Tilbage til top</a></p> <p><strong>Fremgangsmåde</strong></p> <h4>Diagnosekriterier</h4> <h4>·Akut udvikling over timer med temperaturforhøjelse, stærke synkesmerter - evt. med savlen og påvirket almentilstand</h4> <h4><strong>·Palpationsømhed sv.t. larynxskelettet</strong></h4> <h4><strong>·Pt. sidder oftest foroverbøjet</strong></h4> <h4><strong>·Stridor tilkommer under progression af tilstanden</strong></h4> <h4><strong>·Ved fiberskopi ses oftest kuglerund, højrød epiglottis. Ved voksne ses ofte også hævelse af plica aryepiglottica og aryregionen. Børn har oftest kun hævelse af epiglottis.</strong></h4> <h4><strong>Visitation og præhospital håndtering</strong></h4> <h4>Henvisende læge skal UDTRYKKELIGT ved kontakt til alarmcentralen rekvirere akutlægebilen og patienten modtages i traumecentret i henhold til instruks for visitation af patienter med mistanke om obstruktion af øvre luftvej, <a href="https://www.phsinfo.dk/oakVisitation/HSinfo.nsf/4ac4c919976a2a46c1256f32004a9509/e8e2f0c56a026be4c1256fdb003cc270!OpenDocument" target="_blank">se PH:S Info</a> . Anæstesihold tilkaldes.</h4> <h4>Behandling</h4> <ul> <li>Foretages i nødtracheotomiberedskab. Pt. anbringes i siddende stilling med hovedet let foroverbøjet.</li> <li>Der foretages fiberskopi af ØNH-læge mhp. vurdering af pladsforhold. Omkring 20&nbsp;% af patienterne har behov for intubation. &nbsp;I nødstilfælde kan tungen trækkes frem indtil evt. intubation kan foretages.</li> <li>Ved mislykket intubation foretages nødtracheotomi.</li> <li>Patienter skal altid indlægges til observation og behandling på 4131. Hvis der ikke er plads på 4131 kan patienten indlægges på Opvågningsafsnittet (i 4131- regi). Bagvagt 4131 aftaler dette med bagvagt AN/OP – anæstesien. Evt. intrahospital transport foregår med lægeledsagelse. Alle patienter observeres minimum første døgn på intensivt afsnit.</li> <li>Der gives umiddelbart 1,5 g zinacef i.v. x 3 (Børn 100mg/kg i.v. fordelt på tre doser)<br> Overvej Solu-medrol indgift&nbsp; 80 mg i.v. (Børn 2 mg/kg i.v.)</li> <li>Alle patienter får taget infektionstal og væsketal, venyler og evt. podning.</li> <li>Hvis tilstanden ikke bedres i løbet af de første to dage, skal absces på epiglottis mistænkes. Der skal laves CT halsen og direkte laryngoskopi med biopsi mhp udtømmelse af abscessen.</li> </ul> <p>Såfremt der ikke vurderes at være behov for akut intubation skal patienten overvåges på intensiv afsnit og have foretaget ny fiberskopisk vurdering ved mindste forværring.</p> <p>Patienten bør optimalt fiberskoperes ved vagtskifte for at afgående og tiltrædende vagthavende læge ved selvsyn vurderer pladsforholdene. Patienten kan ved markant forbedring af pladsforholdene efter passende intensiv observation overflyttes til stamafdeling mhp fortsat antibiotisk behandling</p> <p>Såfremt patienten er intuberet kan patienten som regel ekstuberes efter 1-2 døgn, afhængigt af pladsforholdene vurderet ved fiberskopi. &nbsp;Ekstubation bør foretages i dagtiden.</p> <p>Kost: Efter ekstubation, må patienten indtage tynde væsker per os. Herefter stigende til kost efter evne.</p> <p><strong>Differentialdiagnoser</strong></p> <p>Pseudocroup<br> Peritonsillær og parapharyngeal abscess<br> Laryngit<br> Fremmedlegeme</p> <p><a href="http://vip.regionh.dk/VIP/Redaktoer/130126.nsf/Main.html?Open#Top">Tilbage til top</a></p> <h4>Ansvar og organisering</h4> <h4>Afdelingsledelser i Afdeling for Øre-Næse-Halskirurgi og Audiologi og Intensiv Klinik</h4> <p><a href="http://vip.regionh.dk/VIP/Redaktoer/130126.nsf/Main.html?Open#Top">Tilbage til top</a></p> <p>&nbsp;</p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Epistaxis Behandling og pleje af patienter.

Epistaxis, Behandling og pleje af patienter med Epistaxis, Behandling og pleje af patienter med Målgrupper og anvendelsesområde Klinisk personale i Afdeling for Øre-Næse-Halskirurgi og Audiologi Fremgangsmåde Baggrund Næseblødning (epistaxis) opstår ved bristning af et blodkar i næseslimhinden. Der skelnes mellem 2 former: Forreste og bagerste næseblødning Forreste næseblødning/epistaxis anterior Det blødende kar lokaliseres fortil på septum nasi. Dette er den hyppigste form, som kan fremkaldes ved mindre skadelige påvirkninger (traumer), næsepilleri, anstrengelser eller ved forkølelse. Den standser ofte spontant og ses sjældent i hospitalsregi. Bagerste næseblødning/epistaxis posterior Opstår ved bristning af et blodkar opad og bagtil i næsekaviteten. Den kan forårsages af blødningstendens (hæmorrhagisk diatese), forhøjet blodtryk, åreforkalkning, blodsygdomme eller svulster. Opstår hyppigst hos ældre mennesker og er vanskeligere at behandle end den første form. Ved bagerste blødning hos børn skal medicinsk blødning mistænkes (koagulationsforstyrrelse). Modtagelse af patient i ambulatoriet Patienten modtages af sygeplejersken. - Fuld EWS måles og kontrolleres herefter efter algoritme. - Vagthavende læge informeres umiddelbart, hvis patienten er påvirket respiratorisk eller cirkulatorisk. - Patienten sættes til rette i stol eller på leje med eleveret hovedgærde. - Patienten får ispiller/knust is som holdes i mundhulen Patienter som bløder er ofte nervøse og bange. Derfor må sygeplejersken berolige patienten og informere om det videre forløb. Procedure / behandling Ætsning Lægen lægger lokalanæstesi på vat, da det letter inspektionen af næsen. Hvis et overfladisk anteriort kar kan lokaliseres uden blødning, kan man forsøge behandling med ætsning eller elkoagulation. Behandling er aldrig dobbeltsidig grundet risiko for septumnekrose. Tamponader Rhino Rapid (geltamponer er den foretrukne behandling ved pågående større blødning) Det er en oppustelig geletampon, der virker hæmostatisk, komprimerende og antiseptisk. Ved iblødsætning med sterilt vand dannes en blød gele på overfladen af tampon, der mindsker ubehag ved anlæggelse og fjernelse. - Rhino Rapid findes i 5,5 cm, 7,5 cm og 9 cm størrelse. - Rhino Rapid på 9 cm har dobbeltballon og kan anvendes til vanskelige bagerste næseblødninger. - Rhino Rapid er forbundet med en lille cuff, der efter placering af tamponen blæses op med luft. Cuffen fikseres på kinden med plaster og kan ligge op til 24 timer. - Luften fjernes inden seponering. Bagerste nasal tamponade - Foley-kateter føres ned i rhinopharynx, hvor ballonen fyldes med vand, ca. 5 – 10 ml. og trækkes op som en prop i choana. - Næsecaviteten fyldes nu med meche i baner under fortsat blidt træk i kateteret, som til sidst fikseres med klemskrue. - Da der hele tiden skal være træk på kateteret, er det meget vigtigt, at der polstres med skumgummi (f.eks. vaskeklude) foran klemskruen for at undgå ala-nekrose. - Meche anlæggelse: 2 cm meche, blødgjort med HT-salve lagt i baner langs bunden af næsen og op langs septum. Enden fikseres med plaster på kinden. Anden behandling - Behandling med Cyklocapron 1g 4-6 gange daglig i max 5 døgn kan være gavnlig ved sivblødning og smårecidiver. - Blokade af a.sphenopalatina (adstringerende injektion, fx ½% lidokain/noradrenalin lagt i canalis palatinus major, 1 cm medialt for 7´eren , med 1 cm af spidsen af en grå nål bøjet 130º) Øvrige behandlingsmuligheder: Såfremt ovenstående behandlingsmuligheder er utilstrækkelige, kan undersøgelse i UA med invasiv hæmostase (f.x clipsning af a. sphenopalatina) anvendes. Indlæggelse - Ved indlæggelse i sengeafsnittet vurderer lægen, om der skal tages blodprøver. Der tages ligeledes stilling til ordination af smertestillende, beroligende (diazepam), laksantia samt hyppigheden for måling af vitale værdier. - Ved hæmostase kan patienten mobiliseres ved roligt regime. - Kost: Gerne kølig fuldkost. - Der tages dagligt stilling til, hvorvidt der er behov for supplerende blodprøver og evt. blodtransfusion. Udskrivelse Patienten bør have været oppegående minimum 2 timer inden udskrivelse eller hjemsendelse uden tamponade. Patienten informeres om forsigtighed, når der pudses næse. Informeres om saltvandsskylninger ved gener fra skorper. Ambulant kontrol Ved udskrivelse efter indlæggelse, hjemsendes patienten uden tamponade og der vil derfor ikke være behov for kontrol. Hjemsendes patienten fra ambulatoriet med tamponade, gives ny tid til kontrol eller fjernelse af denne. Ansvar og organisering Afdelingsledelsen i Afdeling for Øre-Næse-Halskirurgi og Audiologi Referencer, lovgivning og faglig evidens samt links hertil Referencer: Regional Vejledning: Epistaxis/næseblod Dansk selskab for Otolaryngologi (DSOHH) korte nationale retningslinjer ’epistaxis’ Langkilde P og Bloch Jensen T: Sygepleje til patienter med øre-næse-halslidelser i Sygeplejebogen 4.4, Gads Forlag 2014) Therese Ovesen, og Christian von Buchwald, redaktører: Lærebog i Øre-næse-halssygdomme og hoved-hals kirurgi. 1. udgave. Munksgaard Danmark, 2011

<h1><div id="Afsnit#1699579329036">Epistaxis, Behandling og pleje af patienter med</div></h1><div id="BodyWeb#1699579329036"><p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:#222222">Epistaxis, Behandling og pleje af patienter med</span></strong></p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:#222222">Målgrupper og anvendelsesområde</span></strong></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#222222">Klinisk personale i Afdeling for Øre-Næse-Halskirurgi og Audiologi</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#222222">&nbsp;<u>Tilbage til top</u></span></p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:#222222">Fremgangsmåde</span></strong></p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:#222222">Baggrund</span></strong></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#222222">Næseblødning (epistaxis) opstår ved bristning af et blodkar i næseslimhinden. Der skelnes mellem 2 former: Forreste og bagerste næseblødning</span></p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:#222222">Forreste næseblødning/epistaxis anterior</span></strong></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#222222">Det blødende kar lokaliseres fortil på septum nasi. Dette er den hyppigste form, som kan fremkaldes ved mindre skadelige påvirkninger (traumer), næsepilleri, anstrengelser eller ved forkølelse.</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#222222">Den standser ofte spontant og ses sjældent i hospitalsregi.</span></p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:#222222">Bagerste næseblødning/</span></strong><strong>epistaxis posterior</strong></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#222222">Opstår ved bristning af et blodkar opad og bagtil i næsekaviteten. Den kan forårsages af blødningstendens (hæmorrhagisk diatese), forhøjet blodtryk, åreforkalkning, blodsygdomme eller svulster.</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#222222">Opstår hyppigst hos ældre mennesker og er vanskeligere at behandle end den første form.</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#222222">Ved bagerste blødning hos børn skal medicinsk blødning mistænkes (koagulationsforstyrrelse).</span></p> <p style="margin-left:0cm; margin-right:0cm"><strong>Modtagelse af patient i ambulatoriet</strong></p> <p style="margin-left:0cm; margin-right:0cm">Patienten modtages af sygeplejersken.</p> <ul> <li>Fuld EWS måles og kontrolleres herefter efter algoritme.</li> <li>Vagthavende læge informeres umiddelbart, <span style="color:#222222">hvis patienten er påvirket respiratorisk eller cirkulatorisk.</span></li> <li><span style="color:#222222">Patienten sættes til rette i stol eller på leje med eleveret hovedgærde.</span></li> <li><span style="color:#222222">Patienten får ispiller/knust is som holdes i mundhulen</span></li> </ul> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#222222">Patienter som bløder er ofte nervøse og bange. Derfor må sygeplejersken berolige patienten og informere om det videre forløb. </span></p> <p style="margin-left:0cm; margin-right:0cm"><strong><u><span style="color:#222222">Procedure / behandling</span></u></strong></p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:#222222">Ætsning</span></strong></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#222222">Lægen lægger lokalanæstesi på vat, da det letter inspektionen af næsen.</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#222222">Hvis et overfladisk anteriort kar kan lokaliseres uden blødning, kan man forsøge behandling med ætsning eller elkoagulation. Behandling er aldrig dobbeltsidig grundet risiko for septumnekrose.&nbsp;</span></p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:#222222">Tamponader</span></strong></p> <p style="margin-left:0cm; margin-right:0cm">Rhino Rapid (geltamponer er den foretrukne behandling ved pågående større blødning)</p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#222222">Det er en oppustelig geletampon, der virker hæmostatisk, komprimerende og antiseptisk. Ved iblødsætning med sterilt vand dannes en blød gele på overfladen af tampon, der mindsker ubehag ved anlæggelse og fjernelse. </span></p> <ul> <li><span style="color:#222222">Rhino Rapid </span>findes i 5,5 <span style="color:#222222">cm, 7,5 cm og 9 cm størrelse. </span></li> </ul> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <ul> <li><span style="color:#222222">Rhino Rapid på 9 cm har dobbeltballon og kan anvendes til vanskelige bagerste næseblødninger. </span></li> </ul> <p style="margin-left:36pt; margin-right:0cm">&nbsp;</p> <ul> <li><span style="color:#222222">Rhino Rapid er forbundet med en lille cuff, der efter placering af tamponen blæses op med luft. Cuffen fikseres på kinden med plaster og kan ligge op til 24 timer. </span></li> </ul> <p style="margin-left:36pt; margin-right:0cm">&nbsp;</p> <ul> <li><span style="color:#222222">Luften fjernes inden seponering.</span></li> </ul> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:#222222">Bagerste nasal tamponade</span></strong></p> <ul> <li><span style="color:#222222">Foley-kateter føres ned i rhinopharynx, hvor ballonen fyldes med vand, ca. 5 – 10 ml. og trækkes op som en prop i choana. </span></li> <li><span style="color:#222222">Næsecaviteten fyldes nu med meche i baner under fortsat blidt træk i kateteret, som til sidst fikseres med klemskrue. </span></li> </ul> <p style="margin-left:36pt; margin-right:0cm">&nbsp;</p> <ul> <li><span style="color:#222222">Da der hele tiden skal være træk på kateteret, er det meget vigtigt, at der polstres med skumgummi (f.eks. vaskeklude) foran klemskruen for at undgå ala-nekrose.</span></li> </ul> <p style="margin-left:36pt; margin-right:0cm">&nbsp;</p> <ul> <li>Meche anlæggelse: 2 cm meche, blødgjort med HT-salve lagt i baner langs bunden af næsen og op langs septum. Enden fikseres med plaster på kinden.</li> </ul> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:#222222">Anden behandling</span></strong></p> <ul> <li><span style="color:#222222">Behandling med Cyklocapron 1g 4-6 gange daglig i max 5 døgn kan være gavnlig ved sivblødning og smårecidiver.&nbsp;</span></li> <li><span style="color:#222222">Blokade af a.sphenopalatina (adstringerende injektion, fx ½% lidokain/noradrenalin lagt i canalis palatinus major, 1 cm medialt for 7´eren , med 1 cm af spidsen af en grå nål bøjet 130º)</span></li> </ul> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:#222222">Øvrige behandlingsmuligheder:</span></strong></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#222222">Såfremt ovenstående behandlingsmuligheder er utilstrækkelige, kan undersøgelse i UA med invasiv hæmostase (f.x clipsning af a. sphenopalatina) anvendes.</span></p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:#222222">Indlæggelse</span></strong></p> <ul> <li><span style="color:#222222">Ved indlæggelse i sengeafsnittet vurderer lægen, om der skal tages blodprøver. Der tages ligeledes stilling til ordination af smertestillende, beroligende (diazepam), laksantia samt hyppigheden for måling af&nbsp;vitale værdier.</span></li> <li>Ved hæmostase kan patienten mobiliseres ved roligt regime.</li> <li><span style="color:#222222">Kost: Gerne kølig fuldkost.</span></li> <li><span style="color:#222222">Der tages dagligt stilling til, hvorvidt der er behov for supplerende blodprøver og evt. blodtransfusion.</span></li> </ul> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:#222222">Udskrivelse</span></strong></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#222222">Patienten bør have været oppegående minimum 2 timer inden udskrivelse eller hjemsendelse uden tamponade.</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#222222">Patienten informeres om forsigtighed, når der pudses næse. Informeres om saltvandsskylninger ved gener fra skorper.</span></p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:#222222">Ambulant kontrol</span></strong></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#222222">Ved udskrivelse efter indlæggelse, hjemsendes patienten uden tamponade og der vil derfor ikke være behov for kontrol.</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#222222">Hjemsendes patienten fra ambulatoriet med tamponade, gives ny tid til kontrol eller fjernelse af denne.</span></p> <p style="margin-left:0cm; margin-right:0cm"><a href="http://vip.regionh.dk/VIP/Redaktoer/130126.nsf/Main.html?Open#Top" style="color:blue; text-decoration:underline">Tilbage til top</a></p> <p style="margin-left:0cm; margin-right:0cm"><br> <span style="color:#222222"><strong>Ansvar og organisering</strong></span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#222222">&nbsp;Afdelingsledelsen i Afdeling for Øre-Næse-Halskirurgi og Audiologi</span></p> <p style="margin-left:0cm; margin-right:0cm"><a href="http://vip.regionh.dk/VIP/Redaktoer/130126.nsf/Main.html?Open#Top" style="color:blue; text-decoration:underline">Tilbage til top</a></p> <p style="margin-left:0cm; margin-right:0cm"><br> <span style="color:#222222"><strong>Referencer, lovgivning og faglig evidens samt links hertil</strong></span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#222222">Referencer:</span></p> <p style="margin-left:0cm; margin-right:0cm"><a href="https://vip.regionh.dk/VIP/Admin/GUI.nsf/Desktop.html?open&amp;openlink=https://vip.regionh.dk/VIP/Slutbruger/Portal.nsf/Main.html?open&amp;unid=XCEFBF27DBB06BC31C1257FB800345ABD&amp;level=130126&amp;dbpath=/VIP/Redaktoer/RH.nsf/&amp;windowwidth=1100&amp;windowheight=600&amp;windowtitle=S%F8g" style="color:blue; text-decoration:underline">Regional Vejledning: Epistaxis/næseblod</a></p> <p style="margin-left:0cm; margin-right:0cm"><a href="https://dsohh.dk/wp-content/uploads/2022/05/DSOHH-KKR-epistaxis.pdf" style="color:blue; text-decoration:underline">Dansk selskab for Otolaryngologi (DSOHH) korte nationale retningslinjer ’epistaxis’</a></p> <p style="margin-left:0cm; margin-right:0cm"><span style="background-color:white"><span style="color:#222222">Langkilde P og Bloch Jensen T: Sygepleje til patienter med øre-næse-halslidelser i Sygeplejebogen 4.4,&nbsp;Gads Forlag 2014)</span></span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#222222">Therese Ovesen, og Christian von Buchwald, redaktører: Lærebog i Øre-næse-halssygdomme og hoved-hals kirurgi. 1. udgave. Munksgaard Danmark, 2011</span></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p>&nbsp;</p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Mononucleosis.

Mononucleosis Formål Fremgangsmåde Formål Opfyldelse af kvalitetsstandard F5 Målgrupper og anvendelsesområde Klinisk personale, Afdeling for Øre-Næse-Halskirurgi og Audiologi. Definitioner Fremgangsmåde Indikation for indlæggelse Indlæggelse ved medtaget almentilstand, truende luftvejsobstruktion eller manglende evne til at indtage mad og drikke trods relevant smertebehandling. Ætiologi Sygdommen er forårsaget af virusinfektion med Epstein-Barr virus Symptomer og fund Halssmerter, feber, forstørrede lymfeknuder ofteuniverselt. Klinisk findes hypertrofiske tonsiller og adenoide vegetationer med tykke grå-hvide belægninger. Der finders universel lymfeknudesvulst og hepatosplenomegali. Blodprøver ved indlæggelse: Hb, tr,L + D - EBV-DNA (analysetid 3-timer), EBV(VCA) IgM og IgG - Levertal (ASAT, bas.phos., bilirubin, koag.fakt.) - væsketal (Na, K, crea, CRP,) Biokemisk ses monocytose og lymfocytose (virocytter) i differentialtællingen af de hvide blodlegemer. Samtidig er der typisk forhøjede levertal. Differentialdiagnoser: Tonsillitis acuta, peritonsillær absces, lymfom, CMV infektion, HIV infektion, Behandling Observeres m.h.p. respiration og almen tilstand. Eleveret hovedgærde. Observeres for evt. dobbeltsidig peritonsillær absces specielt hos børn. Ved truende luftvejsobstruktion afgør tilkaldt læge om der skal foretages akut tonsillektomia a chaud. Ved mindste mistanke om lymfom må der ikke gives steroid, idet stadieinddelingen af lymfom vanskeliggøres. Ved svær luftvejsobstruktion foretages tonsillektomi à chaud. Altid tracheostomiberedskab. Ved mistanke om bakteriel superinfektion samtidig med EBVinfektion gives penicillin og metronidazol . Metronidazol har i to randomiserede undersøgelser vist at afkorte indlæggelsestiden ved svær mononucleosis (1;2). Patienter, som har fået ampicillinpræparater, har ofte udviklet rødt, plettet, kløende exanthem. Ved dårlig ernæring skal der bestilles diætist. Udskrivelse Patienten udskrives, så snart almen tilstanden tillader det. Udskrivelse er ikke afhængig af faldende levertal, idet disse vil være forhøjede i op til 30 dage. Ved udskrivelse tilrådes forsigtighed ved voldsom sportsudøvelse (f.eks. kampsport) i 6 uger af hensyn til risikoen for miltruptur. Der er ikke videnskabeligt belæg for alkoholabstinens. Telefonisk blodprøvesvar og hermed diagnosen til pt. skal gives af en læge. Ambulant kontrol Tilrådes hos egen læge efter ca. 1 uge. Ansvar og organisering Afdelingsledelsen. Referencer, lovgivning og faglig evidens samt links hertil Relevant faglig evidens på området - Lennon P. et al. Effekt of metronidazol vs standard care on length of stay of patients admitted with severe infectius mononucleosis: a randomized controlled study. Clin Mikrobiol Infectition 2013: 1-3 - Hedstrom SA. Treatment of anginose infectios mononucleosis with metronidazol. A controlled clinical and laboratory study. Scand J Infect Dis 1980;12: 265-269 - Obel et al., Ugeskrift for læger 2001 (34) 3335 - 7 Akkrediteringsstandarder Bilag

<h1><div id="Afsnit#1699579280137">Mononucleosis</div></h1><div id="BodyWeb#1699579280137"><p><a name="1699579280137Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579280137Formaal">Formål</a></h3> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579280137Fremgangsmaade">Fremgangsmåde</a><br> &nbsp;</p> <p>&nbsp;</p> <p><a name="1699579280137Formaal"></a></p> <h2>Formål</h2> <p>&nbsp;Opfyldelse af kvalitetsstandard F5</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579280137Top">Tilbage til top</a></p> <h2><a name="1699579280137Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p>&nbsp;Klinisk personale, Afdeling for Øre-Næse-Halskirurgi og Audiologi.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579280137Top">Tilbage til top</a></p> <h2><a name="1699579280137Definitioner"></a><br> Definitioner</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579280137Top">Tilbage til top</a></p> <h2><a name="1699579280137Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p>&nbsp;</p> <p style="margin-left:4.15pt"><strong>Indikation for indlæggelse</strong></p> <p style="margin-left:4.15pt">Indlæggelse ved medtaget almentilstand, truende luftvejsobstruktion eller manglende evne til at indtage mad og drikke trods relevant smertebehandling.</p> <p style="margin-left:4.15pt"><strong>Ætiologi</strong></p> <p style="margin-left:4.15pt">Sygdommen er forårsaget af virusinfektion med Epstein-Barr virus</p> <p style="margin-left:4.15pt"><strong>Symptomer og fund</strong></p> <p style="margin-left:4.15pt">&nbsp;Halssmerter, feber, forstørrede lymfeknuder ofteuniverselt. &nbsp;Klinisk findes hypertrofiske tonsiller og adenoide vegetationer med tykke grå-hvide belægninger. Der finders universel lymfeknudesvulst og hepatosplenomegali.</p> <p><br> &nbsp;</p> <p style="margin-left:4.15pt">&nbsp;</p> <p><strong>Blodprøver ved indlæggelse:</strong></p> <p style="margin-left:4.15pt"><strong>Hb, tr,</strong>L + D</p> <p>- EBV-DNA (analysetid 3-timer), EBV(VCA) IgM og IgG</p> <p>- Levertal (ASAT, bas.phos., bilirubin, koag.fakt.)</p> <p>- væsketal (Na, K, crea, CRP,)</p> <p>&nbsp;</p> <p style="margin-left:4.15pt">Biokemisk ses monocytose og lymfocytose (virocytter) i differentialtællingen af de hvide blodlegemer. Samtidig er der typisk forhøjede levertal.</p> <p><br> &nbsp;</p> <p>&nbsp;</p> <p style="margin-left:4.15pt"><strong>Differentialdiagnoser:</strong></p> <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tonsillitis acuta, peritonsillær absces, lymfom, CMV infektion, HIV infektion,</p> <p>&nbsp;</p> <p style="margin-left:4.15pt"><strong>Behandling </strong></p> <p style="margin-left:4.15pt">Observeres m.h.p. respiration og almen tilstand. Eleveret hovedgærde. Observeres for evt. dobbeltsidig peritonsillær absces specielt hos børn. Ved truende luftvejsobstruktion afgør tilkaldt læge om der skal foretages akut tonsillektomia a chaud. Ved mindste mistanke om lymfom må der ikke gives steroid, idet stadieinddelingen af lymfom vanskeliggøres.</p> <p style="margin-left:4.15pt">Ved svær luftvejsobstruktion foretages tonsillektomi à chaud. Altid tracheostomiberedskab. Ved mistanke om bakteriel superinfektion samtidig med EBVinfektion gives penicillin og metronidazol . Metronidazol har i to randomiserede undersøgelser vist at afkorte indlæggelsestiden ved svær mononucleosis (1;2). Patienter, som har fået ampicillinpræparater, har ofte udviklet rødt, plettet, kløende exanthem.</p> <p style="margin-left:4.15pt">Ved dårlig ernæring skal der bestilles diætist.</p> <p><br> &nbsp;</p> <p>&nbsp;</p> <p style="margin-left:4.15pt"><strong>Udskrivelse </strong></p> <p style="margin-left:4.15pt">Patienten udskrives, så snart almen tilstanden tillader det. Udskrivelse er ikke afhængig af faldende levertal, idet disse vil være forhøjede i op til 30 dage. Ved udskrivelse tilrådes forsigtighed ved voldsom sportsudøvelse (f.eks. kampsport) i 6 uger af hensyn til risikoen for miltruptur. Der er ikke videnskabeligt belæg for alkoholabstinens.</p> <p>&nbsp;Telefonisk blodprøvesvar og hermed diagnosen til pt. skal gives af en læge.</p> <p><br> &nbsp;</p> <p>&nbsp;</p> <p><strong>Ambulant kontrol </strong></p> <p>Tilrådes hos egen læge efter ca. 1 uge.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579280137Top">Tilbage til top</a></p> <h2><a name="1699579280137Ansvar"></a><br> Ansvar og organisering</h2> <p>Afdelingsledelsen.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579280137Top">Tilbage til top</a></p> <h2><a name="1699579280137Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p>&nbsp;</p> <p><strong>Relevant faglig evidens på området </strong></p> <ol> <li>Lennon P. et al. Effekt of metronidazol vs standard care on length of stay of patients admitted with severe infectius mononucleosis: a randomized controlled study. Clin Mikrobiol Infectition 2013: 1-3</li> <li> <p>Hedstrom SA. Treatment of anginose infectios mononucleosis with metronidazol. A controlled clinical and laboratory study. Scand J Infect Dis 1980;12: 265-269</p> </li> <li> <p><span style="color:#000000">Obel et al., Ugeskrift for læger 2001 (34) 3335 - 7 </span></p> </li> </ol> <p>&nbsp;</p> <p>&nbsp;<a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579280137Top">Tilbage til top</a></p> <h2><a name="1699579280137Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579280137Top">Tilbage til top</a></p> <h2><a name="1699579280137Bilag"></a><br> Bilag</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579280137Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Fast vagt i Afdeling for ¥re-næse-halskirurgi.

Fast vagt i Afdeling for Øre-næse-halskirurgi og Audiologi Formål Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Bilag Formål At sikre patientsikkerhed og optimal behandling til patienter der har behov for opsyn/fast vagt. At afklare/beskrive retningslinjer i klinikken for anvendelse og bestilling af vagter. At sikre hensigtsmæssig og ensartet arbejdsgang vedr. vurdering af bemanding, bestilling og prioritering af vagt behov. Målgrupper og anvendelsesområde Læge og sygeplejefagligt personale i Afdeling for Øre, Næse og Halskirurgi og Audiologi på Rigshospitalet. Definitioner At være vagt/fast vagt betyder, at man er tildelt en del af plejen hos en patient, der har brug for øget tilsyn i forhold til deres sygdomsbillede. Ud fra patientens sygdomsbillede besluttes hvilken form for vagttype, der vil være til gavn for patienten. Herunder findes eksempler på vagttyper: - Vagt ved akut kritisk sygdom Uafbrudt observation og pleje af patienten Kan omfatte alle døgnets 24 timer eller dele af døgnet - Opmærksomhedsvagt Kontinuerligt opsyn og tilstedeværelse af personale Kan i nogle tilfælde dækkes af hyppige tilsyn fra plejepersonale Observation og afledning af uhensigtsmæssig adfærd og patientpleje. - Vagt til suicidal truet/psykiatrisk patient indlagt uden tvang Uafbrudt observation og pleje af patienten hele døgnet - Vagt til dobbelt indlagt psykiatrisk patient med henblik på tvangsbehandling på somatisk afdeling Uafbrudt observation og pleje af patienten hele døgnet Hvem der er kvalificeret (hvilken faggruppe/vagtbureau) til at varetage vagten, aftales ud fra sygdomsbillede, behandlingsplan og bemandingssituation. Beslutningen tages mellem stuegangsgående/vagthavende læge og afdelingssygeplejersken/ansvarshavende sygeplejerske. Alle eksterne vagter arbejder under primærsygeplejerskens ansvar. Fremgangsmåde Ordination: En vagt ordineres af stuegang/vagthavende læge i samarbejde med afdelingssygeplejersken eller ansvarshavende sygeplejerske. Lægen skriver ordination, indikation og behandlingsplan i et notat i SP. Behandlingsplanen skal indeholde: - Indikation - Tidspunkt for revurdering af indikationen - Observationshyppighed (eksempler: tilsyn, EWS, halsomfang, indgift/udgift) Seponering af fastvagt skal også fremgå af patientjournalen og ske i et samarbejde mellem stuegangsgående/vagthavende læge og afdelingssygeplejersken/ansvarshavende sygeplejerske. Indikation: Generel indikation: Patienter der ikke kan lades uden opsyn, enten på grund af deres sygdomsbillede eller fordi de er ude afstand til at huske eller følge anvisninger fra personale og derfor er til skade for dem selv. Husk at afklare om patientens behov kan afhjælpes ved andre tiltag, inden der bestilles vagter (f.eks. faldplejeplaner, medicinpåvirkning, smerter m.m.). - Ved akut kritisk sygdom (eksempler på indikation): - Uafklaret sygdomsbillede (påvirket ABCDE + EWS) - Re-blødninger - Patienten kan ikke sikre frie luftveje/suge - eller kalde på hjælp i situationen - Sepsis - Stor blødningsrisiko - med angstproblematik - Delirium - Efter længerevarende ITA indlæggelse med multiple problematikker - Opmærksomhedsvagt (eksempler på indikation): - Konfusion/delirium/demens - Risiko for at patienten forvolder skade på sig selv - seponering af KAD, PVK, Sonde, Dræn - Angst - krisereaktioner - Adfærd, der er til gene for andre patienter - Vagt ved Suicidal truet/psykiatrisk patient indlagt uden tvang. - Vagt ved dobbelt-indlagt psykiatrisk patient med henblik på tvangsbehandling. Se den regionale VIP "Tvangsbehandling af patienter på somatisk afdeling – dobbeltindlæggelse og brug af fast vagt" https://vip.regionh.dk/VIP/Redaktoer/RH.nsf/XB9C311EFDA212EFFC12579C7003D7028?OpenDocument&ref=internalVIP Obs! der er ingen lokalaftaler mellem RH og de psykiatriske centre i Region Hovedstaden eller Region Sjælland - Ledsager fra patientens bosted - Se under bestilling og afbestilling Bestilling og afbestilling Hvem skal dække vagten og i hvilken rækkefølge skal de prioriteres: - Eget personale, herunder timelønnet (Se på bemanding og muligheder internt) - FADL's vagtbureau (kontaktes på ###TELEFON### hele døgnet. Ved ønske om vagthold kontaktes sygeplejerske på ###TELEFON### i dagtid på hverdage. Afbestilling skal se telefonisk senest 4 timer før næste vagts start) - Internt vikarbureau (bookes af afdelingssygeplejersken i dag tid på hverdage 8-16) - Eget personale (pålagt vagt) Ledsager til patienter der bor i pædagogiske botilbud/har fast hjælperordning/stærkt præget adfærd der forventes at forværres ved indlæggelse: (Sundhedsaftalen Region Hovedstaden) Ledsager fra patientens bosted kan bevilges til at følge patienten under indlæggelse. Dette skal aftales mellem afdelingssygeplejersken og patientens hjemkommune. Kontrakt mellem afdelingen og patientens bosted/kommune udfærdiges og godkendes. Hvor mange timer i døgnet og hvad hjælpen indbefatter. Bosted/kommune stiller med medarbejder, afdelingen betaler. Se under referencer for links til aftalen Vagt/Våge til terminale patienter som en aflastning af pårørende eller hos dem der ikke har pårørende. Vågetjenester påtager ingen plejeopgaver - Røde Kors Vågetjeneste: Røde Kors Hovedstaden: ###TELEFON### Røde Kors vågetjeneste Østerbro: ###TELEFON### (Lisbeth) Beskrivelse af opgaver til eksterne vagter Opgaver der skal udføres af eksterne vagter (FADL m.m.) aftales ved vagtstart mellem primær sygeplejerske og vagten. Opgaverne revurderes løbende. Eksempler på opgaver: Afklaring af vagt typen og dertil hørende forholdsregler EWS: aftal hvor hyppigt og hvilke værdier der skal handles på Hjælp til personlig pleje Hjælp til indtag af sufficient ernærings og væske indtag, samt registrering Hjælp til mobilisering, afledning og opretholdelse af patientens egenomsorgskapacitet Hjælp til tryghed og døgnrytme/virkeligheds fornemmelse Uniformer til eksterne vagter: Låne/gæstekort til uniformsdepoterne hænger på opslagstavlen i personalestuen - Ansvar og organisering Afdelingsledelsen i Afdeling for Øre-Næse-Halskirurgi og Audiologi Referencer, lovgivning og faglig evidens samt links hertil VIP til dobbelt-indlæggelse med tvang https://vip.regionh.dk/VIP/Redaktoer/RH.nsf/XB9C311EFDA212EFFC12579C7003D7028?OpenDocument&ref=internalVIP Ledsager under indlæggelse Grundaftale mellem hospitalerne i Region Hovedstaden.pdf Bilag 2 Standardard kontrakt.pdf (regionh.dk) Bilag

<h1><div id="Afsnit#1699579235911">Fast vagt i Afdeling for Øre-næse-halskirurgi og Audiologi</div></h1><div id="BodyWeb#1699579235911"><p><a name="1699579235911Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579235911Formaal">Formål</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579235911Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579235911Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579235911Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579235911Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579235911Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579235911Bilag">Bilag</a><br> &nbsp;</h3> <div class="collapsible-item" expandedstart="1"><a name="1699579235911Formaal"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Formål</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>At sikre patientsikkerhed og optimal behandling til patienter der har behov for opsyn/fast vagt.</p> <p>At afklare/beskrive retningslinjer i klinikken for anvendelse og bestilling af vagter.</p> <p>At sikre hensigtsmæssig og ensartet arbejdsgang vedr. vurdering af bemanding, bestilling og prioritering af vagt behov.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579235911Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579235911Maalgrupper"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Målgrupper og anvendelsesområde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>Læge og sygeplejefagligt personale i Afdeling for Øre, Næse og Halskirurgi og Audiologi på Rigshospitalet.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579235911Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579235911Definitioner"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Definitioner</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>At være vagt/fast vagt betyder, at man er tildelt en del af plejen hos en patient, der har brug for øget tilsyn i forhold til deres sygdomsbillede. Ud fra patientens sygdomsbillede besluttes hvilken form for vagttype, der vil være til gavn for patienten. Herunder findes eksempler på vagttyper:</p> <p>&nbsp;</p> <ul> <li><strong>Vagt ved akut kritisk sygdom</strong></li> </ul> <p>Uafbrudt observation og pleje af patienten</p> <p>Kan omfatte alle døgnets 24 timer eller dele af døgnet</p> <p>&nbsp;</p> <ul> <li><strong>Opmærksomhedsvagt</strong></li> </ul> <p>Kontinuerligt opsyn og tilstedeværelse af personale</p> <p>Kan i nogle tilfælde dækkes af hyppige tilsyn fra plejepersonale</p> <p>Observation og afledning af uhensigtsmæssig adfærd og patientpleje.</p> <p>&nbsp;</p> <ul> <li><strong>Vagt til suicidal truet/psykiatrisk patient indlagt uden tvang</strong></li> </ul> <p>Uafbrudt observation og pleje af patienten hele døgnet</p> <p>&nbsp;</p> <ul> <li><strong>Vagt til dobbelt indlagt psykiatrisk patient med henblik på tvangsbehandling på somatisk afdeling</strong></li> </ul> <p>Uafbrudt observation og pleje af patienten hele døgnet</p> <p>&nbsp;</p> <p>Hvem der er kvalificeret (hvilken faggruppe/vagtbureau) til at varetage vagten, aftales ud fra sygdomsbillede, behandlingsplan og bemandingssituation. Beslutningen tages mellem stuegangsgående/vagthavende læge og afdelingssygeplejersken/ansvarshavende sygeplejerske.</p> <p>Alle eksterne vagter arbejder under primærsygeplejerskens ansvar.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579235911Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579235911Fremgangsmaade"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Fremgangsmåde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p><strong>Ordination:</strong></p> <p>En vagt ordineres af stuegang/vagthavende læge i samarbejde med afdelingssygeplejersken eller ansvarshavende sygeplejerske. Lægen skriver ordination, indikation og behandlingsplan i et notat i SP.</p> <p>Behandlingsplanen skal indeholde:</p> <p>&nbsp;</p> <ul> <li>Indikation</li> <li>Tidspunkt for revurdering af indikationen</li> <li>Observationshyppighed (eksempler: tilsyn, EWS, halsomfang, indgift/udgift)</li> </ul> <p>&nbsp;</p> <p>Seponering af fastvagt skal også fremgå af patientjournalen og ske i et samarbejde mellem stuegangsgående/vagthavende læge og afdelingssygeplejersken/ansvarshavende sygeplejerske.</p> <p>&nbsp;</p> <p><strong><em>Indikation:</em></strong></p> <p>Generel indikation: Patienter der ikke kan lades uden opsyn, enten på grund af deres sygdomsbillede eller fordi de er ude afstand til at huske eller følge anvisninger fra personale og derfor er til skade for dem selv.</p> <p>Husk at afklare om patientens behov kan afhjælpes ved andre tiltag, inden der bestilles vagter (f.eks. faldplejeplaner, medicinpåvirkning, smerter m.m.).</p> <p>&nbsp;</p> <p>&nbsp;</p> <ul> <li>Ved akut kritisk sygdom (eksempler på indikation): <ul> <li>Uafklaret sygdomsbillede (påvirket ABCDE + EWS)</li> <li>Re-blødninger</li> <li>Patienten kan ikke sikre frie luftveje/suge - eller kalde på hjælp i situationen</li> <li>Sepsis</li> <li>Stor blødningsrisiko - med angstproblematik</li> <li>Delirium</li> <li>Efter længerevarende ITA indlæggelse med multiple problematikker</li> </ul> </li> </ul> <p>&nbsp;</p> <ul> <li>Opmærksomhedsvagt (eksempler på indikation): <ul> <li>Konfusion/delirium/demens</li> <li>Risiko for at patienten forvolder skade på sig selv - seponering af KAD, PVK, Sonde, Dræn</li> <li>Angst - krisereaktioner</li> <li>Adfærd, der er til gene for andre patienter</li> </ul> </li> </ul> <p>&nbsp;</p> <ul> <li>Vagt ved Suicidal truet/psykiatrisk patient indlagt uden tvang.</li> </ul> <p>&nbsp;</p> <ul> <li>Vagt ved dobbelt-indlagt psykiatrisk patient med henblik på tvangsbehandling.</li> </ul> <p>&nbsp;</p> <p>&nbsp;</p> <p>Se den regionale VIP <em>"Tvangsbehandling af patienter på somatisk afdeling – dobbeltindlæggelse og brug af fast vagt" </em></p> <p><a href="https://vip.regionh.dk/VIP/Redaktoer/RH.nsf/XB9C311EFDA212EFFC12579C7003D7028?OpenDocument&amp;ref=internalVIP"><span style="color:#0066cc"><u>https://vip.regionh.dk/VIP/Redaktoer/RH.nsf/XB9C311EFDA212EFFC12579C7003D7028?OpenDocument&amp;ref=internalVIP</u></span></a></p> <p>&nbsp;</p> <p>Obs! der er ingen lokalaftaler mellem RH og de psykiatriske centre i Region Hovedstaden eller Region Sjælland</p> <p>&nbsp;</p> <ul> <li>Ledsager fra patientens bosted - Se under bestilling og afbestilling</li> </ul> <p>&nbsp;</p> <p><strong>Bestilling og afbestilling</strong></p> <p><strong>Hvem skal dække vagten og i hvilken rækkefølge skal de prioriteres: </strong></p> <p>&nbsp;</p> <ol> <li>Eget personale, herunder timelønnet (Se på bemanding og muligheder internt)</li> <li>FADL's vagtbureau (kontaktes på ###TELEFON### hele døgnet. Ved ønske om vagthold kontaktes sygeplejerske på ###TELEFON### i dagtid på hverdage. Afbestilling skal se telefonisk senest 4 timer før næste vagts start)</li> <li>Internt vikarbureau (bookes af afdelingssygeplejersken i dag tid på hverdage 8-16)</li> <li>Eget personale (pålagt vagt)</li> </ol> <p>&nbsp;</p> <p><strong>Ledsager til patienter der bor i pædagogiske botilbud/har fast hjælperordning/stærkt præget adfærd der forventes at forværres ved indlæggelse: </strong>(Sundhedsaftalen Region Hovedstaden)</p> <p>Ledsager fra patientens bosted kan bevilges til at følge patienten under indlæggelse.</p> <p>Dette skal aftales mellem afdelingssygeplejersken og patientens hjemkommune.</p> <p>Kontrakt mellem afdelingen og patientens bosted/kommune udfærdiges og godkendes. Hvor mange timer i døgnet og hvad hjælpen indbefatter. Bosted/kommune stiller med medarbejder, afdelingen betaler.</p> <p>Se under referencer for links til aftalen</p> <p>&nbsp;</p> <p><strong>Vagt/Våge til terminale patienter</strong> som en aflastning af pårørende eller hos dem der ikke har pårørende.</p> <p>Vågetjenester påtager ingen plejeopgaver</p> <ul> <li>Røde Kors Vågetjeneste:</li> </ul> <p>Røde Kors Hovedstaden:<strong> </strong>###TELEFON### Røde Kors vågetjeneste Østerbro: ###TELEFON### (Lisbeth)</p> <p>&nbsp;</p> <p><strong>Beskrivelse af opgaver til eksterne vagter</strong></p> <p>Opgaver der skal udføres af eksterne vagter (FADL m.m.) aftales ved vagtstart mellem primær sygeplejerske og vagten. Opgaverne revurderes løbende.</p> <p>&nbsp;</p> <p>Eksempler på opgaver:</p> <p>Afklaring af vagt typen og dertil hørende forholdsregler</p> <p>EWS: aftal hvor hyppigt og hvilke værdier der skal handles på</p> <p>Hjælp til personlig pleje</p> <p>Hjælp til indtag af sufficient ernærings og væske indtag, samt registrering</p> <p>Hjælp til mobilisering, afledning og opretholdelse af patientens egenomsorgskapacitet</p> <p>Hjælp til tryghed og døgnrytme/virkeligheds fornemmelse</p> <p>&nbsp;</p> <p>Uniformer til eksterne vagter: Låne/gæstekort til uniformsdepoterne hænger på opslagstavlen i personalestuen</p> <p>&nbsp;</p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579235911Top">Tilbage til top</a></p> <ul> </ul> <ul> </ul> <ul> </ul> <ul> </ul> <ul> </ul> <ul> </ul> <ul> </ul> <p>&nbsp;</p> <ul><br> <br> <br> <li>&nbsp;</li> </ul> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579235911Ansvar"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Ansvar og organisering</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>Afdelingsledelsen i Afdeling for Øre-Næse-Halskirurgi og Audiologi</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579235911Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579235911Referencer"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Referencer, lovgivning og faglig evidens samt links hertil</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>VIP til dobbelt-indlæggelse med tvang</p> <p><a href="https://vip.regionh.dk/VIP/Redaktoer/RH.nsf/XB9C311EFDA212EFFC12579C7003D7028?OpenDocument&amp;ref=internalVIP"><span style="color:#0066cc"><u>https://vip.regionh.dk/VIP/Redaktoer/RH.nsf/XB9C311EFDA212EFFC12579C7003D7028?OpenDocument&amp;ref=internalVIP</u></span></a></p> <p>Ledsager under indlæggelse</p> <p><a href="https://www.regionh.dk/Sundhedsaftale/Vaerktoejskasse/Documents/Grundaftale%20mellem%20hospitalerne%20i%20Region%20Hovedstaden.pdf?rhKeywords=grundaftale#search=grundaftale"><span style="color:#0066cc"><u>Grundaftale mellem hospitalerne i Region Hovedstaden.pdf</u></span></a></p> <p><a href="https://www.regionh.dk/Sundhedsaftale/Vaerktoejskasse/Documents/Bilag%202%20Standardard%20kontrakt.pdf?rhKeywords=grundaftale#search=grundaftale"><span style="color:#0066cc"><u>Bilag 2 Standardard kontrakt.pdf (regionh.dk)</u></span></a></p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579235911Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579235911Bilag"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Bilag</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579235911Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_FESS Behandling og pleje af.

FESS, Behandling og pleje af Formål Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Formål Angive retningslinjer for behandling og pleje af patienter der indlægges til FESS operation Målgrupper og anvendelsesområde Læger og plejepersonale ansat i Afdeling for Øre-Næse-Halskirurgi og Audiologi på Rigshospitalet og Gentofte Hospital Definitioner FESS: Functional Endoscopic Sinus Surgery CAS: Computer Aided Surgery Fremgangsmåde Indikation: Akut og kronisk sinuitis, nasal polypose, papillomer og andre benigne neoplasier samt udvalgte maligne lidelser. Visitering: Dagkirurgisk regi eller indlæggelse. Hvis patienten er henvist fra andre afdelinger / afsnit skal journal og CT-fusion rekvireres af sekretæren. Ambulatoriet, 1. besøg: Der optages anamnese og udføres objektiv undersøgelse incl. skopi af næse / bihuler (rigid eller fleksibel). Ved ukendt histologi tages biopsi. Forundersøgelser: Hvis sufficient CT ikke foreligger, skal der bestilles ny CT-fusion af næse og bihuler. Alle patienter som skal have foretaget FESS skal have lavet en CT af bihuler før evt. operation. Man tager ved forundersøgelsen stilling til om der skal laves en ny CT-fusion i det tilfælde at man planlægger CAS-FESS (oftest) Behandlingsplan Stillingtagen til dagkirurgisk regi eller indlæggelse. I ukomplicerede tilfælde blot med åbning til kæbehule og forreste etmoid henvises til dagkirurgisk regi efter gældende regler. De resterende planlægges til indlæggelse. Der tages endvidere stilling til præoperativ steroidinjektion eller peroral prednison , som planlægges til 7 - 14 dage inden operationen. Injektionen kan gives af sygeplejersken i ambulatoriet, alternativt af egen læge. Skal forudgående ordineres i journal og EPM. Ved behov ordineres antibiotika. Patienten informeres om behandlings- og plejeforløb, mulige per- og postoperative komplikationer samt forholdsregler efter udskrivelsen. Endvidere kan udleveres pjecen FESS operatiion til patienten. Indlæggelse: Der skal foreligge relevant journal, incl. CT- fusion og MR-fusion (foretages af sekretær). Ambulatoriet, 2. besøg Der optages indlæggelsesjournal med vægt på ændringer siden sidst. Dog optages fuld journal, hvis patienten ikke tidligere er set i afdelingen. Præoperative prøver Hgb og type skal foreligge (OBS der skal indhentes samtykke til dette!). Der skal tages stilling til rtg. af thorax, EKG, samt evt. andre undersøgelser afhængigt af patientens almentilstand. Operation, fremgangsmåde Operationen udføres i generel anæstesi, suppleret med lokalbedøvelse i næsen. Operationen kan evt. i udvalgte ikke-komplicerede situationer udføres i lokalanæstesi. Der lægges vatstave eller gazemeche fugtet med kokain-adrenalin 2% eller 4% i begge næsekaviteter (meatus-medius). Obs! Ved anvendelse af meche bør enden af denne være synlig (se vedhæftede instruks for fixering af meche i cavum nasi postoperativt) Der kan suppleres med injektion af lidokain-adrenalin 0.5%, svarende til forreste pol af concha media, samt svarende til forkanten proc. uncinatus. Incision langs forkanten af proc. uncinatus, som fjernes. Forreste etmoid ryddes og evt. åbnes der til kæbehule via det naturlige ostie. Bageste etmoid, recessus frontalis og sinus sphenoidalis åbnes, såfremt der er patologi her. Operationen afsluttes. Der kan ved blødning anlægges tamponade, evt. ved brug af gaze med Hydrokortison-Terramycinsalve eller Nasopore. Tamponaden skal fikseres til ydre næse (se vedhæftede instruks for fixering af meche i cavum nasi postoperativt) Der kan ofte være nogen siveblødning umiddelbart efter operationen, men denne standser som regel spontant. Operation, komplikationer peroperativt - Penetration til fossa anterior med rhinoliquorré til følge. - Penetration til orbita med skade på strukturerne i orbita til følge / hæmatomer i orbita med synsnedsættelse til følge - Blødninger, således at indgrebet ikke kan gennemføres. Såfremt der opstår komplikationer, som kirurgen ikke behersker, skal overlæge straks tilkaldes. Efterbehandling Tamponaden i meatus medius fjernes dagen efter operationen, hvorefter patienten bør begynde med saltvandsopsnusninger/skylninger. Patienten må ikke pudse næse de første 3 døgn efter operationen på grund af risiko for subkutant emphysem. Patienten skal undgå varme spiser eller drikke det første døgn. Større fysisk aktivitet bør undgås de første 10 - 14 dage. Patienten medgives ved udskrivelse en ambulant tid hos operatøren efter 10 - 14 dage postoperativt, hvor der oprenses og fjernes skorper i meatus medius. Hos børn kan oprensningerne evt. foregå i general anæstesi. Oprensningen kan gentages efter behov med en uges mellemrum, indtil der er pænt og rent. Herefter kan patienten afsluttes ved 3 - måneders kontrol. Yderligere ambulante kontroller kan aftales efter behov. Ved svær nasal polyposis skal patienten følges indtil tilstanden er stabiliseret. Herefter kan patienten overgå til kontrol hos egen otolog. Intranasal steroidbehandling kan genoptages 4 - 5 dage efter operationen (saltvandsopsnusninger / -skylninger foretages før steroidapplikation). Ved papillomer og andre neoplasier med tendens til recidiv skal patienten følges minimum hvert ½ år op til 5 år uden recidiv. Ansvar og organisering Afdelingsledelsen i Afdeling for Øre-Næse-Halskirurgi og Audiologi Referencer, lovgivning og faglig evidens samt links hertil Steroidbehandling: Injektion af Diprospan im i sygeplejeambulatoriet - gældende for Rigshospitalet Akkrediteringsstandarder Bilag INSTRUKS FOR FIXERING AF MECHE I CAVUM NASI POSTOPERATIVT PÅ 2073.doc

<h1><div id="Afsnit#1699579233733">FESS, Behandling og pleje af</div></h1><div id="BodyWeb#1699579233733"><p><a name="1699579233733Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579233733Formaal">Formål</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579233733Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579233733Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579233733Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579233733Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579233733Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579233733Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579233733Bilag">Bilag</a><br> &nbsp;</h3> <p><a name="1699579233733Formaal"></a></p> <h2>Formål</h2> <p>Angive retningslinjer for behandling og pleje af patienter der indlægges til FESS operation</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579233733Top">Tilbage til top</a></p> <h2><a name="1699579233733Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p>Læger og plejepersonale ansat i Afdeling for Øre-Næse-Halskirurgi og Audiologi på Rigshospitalet og Gentofte Hospital</p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579233733Top">Tilbage til top</a></p> <h2><a name="1699579233733Definitioner"></a><br> Definitioner</h2> <p>FESS: Functional Endoscopic Sinus Surgery</p> <p>CAS: Computer Aided Surgery</p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579233733Top">Tilbage til top</a></p> <h2><a name="1699579233733Fremgangsmaade"></a><br> Fremgangsmåde</h2> <h4><u>Indikation:</u></h4> <p>Akut og kronisk sinuitis, nasal polypose, papillomer og andre benigne neoplasier samt udvalgte maligne lidelser.</p> <h4><u>Visitering:</u></h4> <p>Dagkirurgisk regi eller indlæggelse.</p> <p>Hvis patienten er henvist fra andre afdelinger / afsnit skal journal og CT-fusion rekvireres af sekretæren.</p> <p><strong>Ambulatoriet, 1. besøg:</strong></p> <p>Der optages anamnese og udføres objektiv undersøgelse incl. skopi af næse / bihuler (rigid eller fleksibel).</p> <p>Ved ukendt histologi tages biopsi.</p> <p><strong><u>Forundersøgelser:</u></strong></p> <h4>Hvis sufficient CT <em>ikke</em> foreligger, skal der bestilles ny CT-fusion af næse og bihuler.</h4> <p>Alle patienter som skal have foretaget FESS skal have lavet en CT af bihuler før evt. operation. Man tager ved forundersøgelsen stilling til om der skal laves en ny CT-fusion i det tilfælde at man planlægger CAS-FESS (oftest)</p> <p><strong><u>Behandlingsplan</u></strong></p> <p><strong>Stillingtagen til dagkirurgisk regi eller indlæggelse</strong>.</p> <p>I ukomplicerede tilfælde blot med åbning til kæbehule og forreste etmoid henvises til dagkirurgisk regi efter gældende regler.</p> <p>De resterende planlægges til indlæggelse.</p> <p>Der tages endvidere stilling til præoperativ steroidinjektion&nbsp; eller peroral prednison , som planlægges til 7 - 14 dage inden operationen.&nbsp;Injektionen kan gives af sygeplejersken i ambulatoriet, alternativt af egen læge. Skal forudgående ordineres i journal og EPM.</p> <p>Ved behov ordineres <strong>antibiotika.</strong></p> <p><strong>Patienten informeres om</strong> behandlings- og plejeforløb, mulige per- og postoperative komplikationer samt forholdsregler efter udskrivelsen. Endvidere kan udleveres pjecen FESS operatiion til patienten.</p> <h4><u>Indlæggelse</u>:</h4> <p>Der skal foreligge relevant journal, incl. CT- fusion og MR-fusion (foretages af sekretær).</p> <p><strong><u>Ambulatoriet, 2. besøg</u></strong></p> <p>Der optages indlæggelsesjournal med vægt på ændringer siden sidst. Dog optages fuld journal, hvis patienten ikke tidligere er set i afdelingen.</p> <p><strong><u>Præoperative prøver</u></strong></p> <p>Hgb og type skal foreligge (<strong>OBS der skal indhentes samtykke til dette!)</strong>.</p> <p>Der skal tages stilling til rtg. af thorax, EKG, samt evt. andre undersøgelser afhængigt af patientens almentilstand.</p> <p><strong><u>Operation, fremgangsmåde</u></strong></p> <p>Operationen udføres i generel anæstesi, suppleret med lokalbedøvelse i næsen.</p> <p>Operationen kan evt. i udvalgte <em><u>ikke</u></em>-komplicerede situationer udføres i lokalanæstesi.</p> <p>Der lægges vatstave eller gazemeche fugtet med kokain-adrenalin 2% eller 4% i begge næsekaviteter (meatus-medius). Obs! Ved anvendelse af meche bør enden af denne være synlig (se vedhæftede instruks for fixering af meche i cavum nasi postoperativt)</p> <p>Der kan suppleres med injektion af lidokain-adrenalin 0.5%, svarende til forreste pol af concha media, samt svarende til forkanten proc. uncinatus.</p> <p>Incision langs forkanten af proc. uncinatus, som fjernes.</p> <p>Forreste etmoid ryddes og evt. åbnes der til kæbehule via det naturlige ostie. Bageste etmoid, recessus frontalis og sinus sphenoidalis åbnes, såfremt der er patologi her.&nbsp;</p> <p>Operationen afsluttes. Der kan ved blødning anlægges tamponade, evt. ved brug af gaze med Hydrokortison-Terramycinsalve eller Nasopore.</p> <p>Tamponaden skal fikseres til ydre næse (se vedhæftede instruks for fixering af meche i cavum nasi postoperativt)&nbsp;</p> <p>Der kan ofte være nogen siveblødning umiddelbart efter operationen, men denne standser som regel spontant.</p> <h4><u>Operation, komplikationer peroperativt</u></h4> <ol> <li>Penetration til fossa anterior med rhinoliquorré til følge.</li> <li>Penetration til orbita med skade på strukturerne i orbita til følge / hæmatomer i orbita med synsnedsættelse til følge</li> <li>Blødninger, således at indgrebet ikke kan gennemføres.&nbsp;</li> </ol> <p>Såfremt der opstår komplikationer, som kirurgen ikke behersker, skal overlæge straks tilkaldes.</p> <p><strong><u>Efterbehandling</u></strong></p> <p>Tamponaden i meatus medius fjernes dagen efter operationen, hvorefter patienten bør begynde med saltvandsopsnusninger/skylninger.</p> <p>Patienten må ikke pudse næse de første 3 døgn efter operationen på grund af risiko for subkutant emphysem.&nbsp;</p> <p>Patienten skal undgå varme spiser eller drikke det første døgn.&nbsp;</p> <p>Større fysisk aktivitet bør undgås de første 10 - 14 dage.&nbsp;</p> <p>Patienten medgives ved udskrivelse en ambulant tid hos operatøren efter 10 - 14 dage postoperativt, hvor der oprenses og fjernes skorper i meatus medius.</p> <p>Hos børn kan oprensningerne evt. foregå i general anæstesi.</p> <p>Oprensningen kan gentages efter behov med en uges mellemrum, indtil der er pænt og rent. Herefter kan patienten afsluttes ved 3 - måneders kontrol.</p> <p>Yderligere ambulante kontroller kan aftales efter behov.</p> <p>Ved svær nasal polyposis skal patienten følges indtil tilstanden er stabiliseret. Herefter kan patienten overgå til kontrol hos egen otolog.</p> <p>Intranasal steroidbehandling kan genoptages 4 - 5 dage efter operationen (saltvandsopsnusninger / -skylninger foretages før steroidapplikation).&nbsp;</p> <p>Ved papillomer og andre neoplasier med tendens til recidiv skal patienten følges minimum hvert ½ år op til 5 år uden recidiv.&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579233733Top">Tilbage til top</a></p> <h2><a name="1699579233733Ansvar"></a><br> Ansvar og organisering</h2> <p>Afdelingsledelsen i Afdeling for Øre-Næse-Halskirurgi og Audiologi</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579233733Top">Tilbage til top</a></p> <h2><a name="1699579233733Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p>&nbsp;Steroidbehandling: <a href="###FOLDER###" target="_blank">Injektion af Diprospan im i sygeplejeambulatoriet - gældende for Rigshospitalet</a></p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579233733Top">Tilbage til top</a></p> <h2><a name="1699579233733Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579233733Top">Tilbage til top</a></p> <h2><a name="1699579233733Bilag"></a><br> Bilag</h2> <p>&nbsp;<img src="/icons/vwicn005.gif" onclick="Ext.DMS.util.showImage(this);"><a href="###FOLDER###" target="_blank">INSTRUKS FOR FIXERING AF MECHE I CAVUM NASI POSTOPERATIVT PÅ 2073.doc</a></p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579233733Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Fraktur af kæbe - og ansigtsknogler.

Fraktur af kæbe - og ansigtsknogler, Forløbsbeskrivelse for patienter med Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Målgrupper og anvendelsesområde Klinisk personale i Afdeling for Øre-Næse-Halskirurgi og Audiologi og Afdeling for Kæbekirurgi Definitioner TC: Traumecentret, Rigshospitalet IMF: Intermaxillær fiksation Fremgangsmåde Alment Aktuelle patientforløbsbeskrivelse referer til "Procedurevejledning vedr. patientforløb på Afdeling for Kæbekirurgi Z" og Afdeling for Øre-Næse-Halskirurgi og Audiologi F Patienter med frakturer i kæbe- og ansigtsskelettet fordeler sig i forskellige kategorier m.h.t. anatomisk lokalisation og alvorlighed. Eksempler er anført i nedenstående skema. Patienterne har ofte andre læsioner og de indlægges i den for deres væsentligste problem relevante afdeling. Patientkategorier ###TABEL_1### *naso-fronto-orbito-etmoide frakturer. Patientens veje ind i systemet til stationær eller ambulant behandling - Gennem Traumecentret (TC) fra skadestedet efter præhospital visitation. - Efter henvisning / omvisitation fra andet sygehus i Region H, og Region Sjælland, herunder skadestuerne Region H, eller fra anden regions hospital til (videre) behandling på Rigshospitalet - Efter henvisning fra primærsektoren 1.1 Patienter indbragt i Rigshospitalets Traumecenter (TC) Alle patienter med ansigtslæsioner, som indbringes til TC undersøges og visiteres af TC læge. Ved mistanke om eller påvist kæbe- / ansigtsfraktur tilkaldes vagthavende Øre-næse-halskirurgisk F læge på telefon 5-1249 og vagthavende tandlæge på telefon 5-1280 i dagarbejdstiden, efter vagtliste i vagten. Klinisk undersøgelse og billeddiagnostik. Det forudsættes, at en patient med kæbe-ansigtsfraktur, som a.h.t. cerebral diagnostik eller af anden årsag bliver traumeskannet, også får CT skannet ansigtsskelettet (incl. mandiblen) med tynde snit (1-2 mm), der muliggør evt. senere 3-D rekonstruktion. Konventionel røntgenundersøgelse for kæbe- / ansigtsfraktur omfatter følgende optagelser: Mandibelfraktur: OP (ortopantomogram) (hos vågne patienter, som kan stå op), AP og Towne's projektion. Hos bevidstløse patienter og andre patienter, der ikke kan stå op til røntgenundersøgelse erstattes OP af skrålateral optagelse af begge siders corpus, angulus og ramus mandibulae. Evt. enoral optagelse i bidplan (mundbundsoptagelse). Maxil-/zygomafraktur: Kranieoptagelser i AP-projektion, profiloptagelse og moon-face projektion samt hos ikke bevidstløse patienter uden mistanke om læsioner af halscolumna submento-vertikal projektion (overkippet basisoptagelse). Alle patienter med kæbe- / ansigts fraktur eller mistanke herom undersøges af vagthavende Øre-næse-halskirurgisk F læge (dect 5-1249) og vagthavende tandlæge (dect 5-1218), som tilkaldes til TC ved patientens modtagelse m.h.p. diagnostik af alle relevante forhold og aftrykstagning til fiksationsapparatur. Der træffes beslutning om akut / ikke akut operation. Akut intervention: Kæbe- / ansigtsfrakturer indicerer ikke akut operation (udover akut blødning eller omfattende komplicerede åbne frakturer), men akut operation af andre læsioner i universel anæstesi kan gøre det mest praktisk, at også kæbe-/ansigtsfrakturer behandles i samme anæstesi. Behandlingsplan: Behandlingsplan - eller i det mindste foreløbig plan (dikteret til journalen) - skal foreligge inden 24 timer. Denne plan koordineres med undersøgende læge fra andre aktuelle specialer, der koordinerer en eventuel samlet behandlingsplan sammen med ansvarlig stamafdeling og afstemmes med ansvarshavende overtandlæge/overlæge/bagvagt. 1.2 – ikke Region H patient indbragt til TC - der ikke har behov for overvågning eller akut behandling, omvisiteres til relevant sygehusafdeling i egen region. Vagthavende tandlæge, vagthavende Øre-næse-halskirurgisk læge og/eller TC-læge kontakter vagthavende kollega i region, aftaler forhold vedr. overflytning, skriver skadeseddel, overførselsnotat i journalen, epikrise eller anden skriftlig meddelelse med fornødne oplysninger samt billeddiagnostisk materiale. Ansvar for patientens tilstand under transport påhviler 'afsenderen', almindeligvis TC. Transport af ikke intuberede patienter med IMF (intermaxillær fiksation) skal ledsages af sufficient uddannet fagperson. - der har behov for akut behandling, skal behandling tilstræbes at være afsluttet indenfor 24 timer, hvorefter patienten kan overføres til Øre-næse-halskirurgisk afdeling i egen region, når transport er forsvarlig og praktisk mulig. Indikationen for akut kæbefrakturbehandling vil oftest være dikteret af, at højere prioriterede læsioner skal behandles i universel anæstesi. Blødning kan være en akut indikation for kæbefrakturbehandling - såfremt akut indikation ikke foreligger, og patienten ikke er transportabel, klassificeres patienten som land-landsdels patient, hvis der er indikation for, at behandling foregår på Rigshospitalet. Hjemregionen orienteres om, at behandling foregår her. 1.3 - Region H patient indbragt til TC - visiteres til indlæggelse i relevant afdeling af TC-læge (Traumecenter, Ortopædkirurgisk afd., Afdeling for Øre-Næse-Halskirurgi og Audiologi, Afdeling for Kæbekirurgi, Afdeling for Plastikkirurgi og Brandsårsbehandling etc.) - læge fra ansvarlig afdeling tager initiativ til prioritering og samordning af indsats / operation i samråd med vagthavende ortopædkirurg, ørelæge, tandlæge, plastikkirurg (eller andre) efter behov. 2. Patient som henvender sig/ indbringes til Region H skadestue 2.1 – Region H patient Skadestuelæge stiller henvisningsdiagnosen og transportable patienter overføres til visitation i TC efter ovennævnte retningslinier eller direkte til Afdeling for Øre-Næse-Halskirurgi og Audiologi F eller Afdeling for Kæbekirurgi. Vagthavende Øre-næse-hals-læge F kaldes op 5-1249. Vagthavende tandlæge kaldes på telefon 5-1280 i dagarbejdstid, efter vagtliste i vagten. Så snart vagthavende F læge og tandlæge har orienteret sig om patienten, diagnose og behandlingsbehov, kontaktes sengeafsnit 7054 F eller 7054Z m.h.p. evt. indlæggelse af patienten. Patienter, der kan behandles ambulant får tid hertil på Afdeling for Øre-Næse-Halskirurgi og Audiologi, ambulatoriet 7056, F 7054 eller Afdeling for Kæbekirurgi, ambulatoriet afsnit 2002, operationsgang afsnit 6013eller bliver behandlet i TC's tandklinik. 2.2 - Ikke Region H patient Overføres oftest med primært klarlagte problemstillinger og herunder evt. kæbefrakturer. Skadelæge modtager patienten og kontakter vagthavende Øre-næse-halslæge og tandlæge der stiller diagnosen. Vagthavende Øre-næse-hals F læge kaldes på 5-1249. Vagthavende tandlæge kaldes på telefon 5-1280 i dagarbejdstid, efter vagtliste i vagten. Så snart vagthavende tandlæge og F læge har orienteret sig om patienten, diagnose og behandlingsbehov, kontakte sengeafsnit 7054 Z eller 7054 F m.h.p. evt. indlæggelse af patienten Ved behov for indlæggelse i Righospitalets Traumecenter følges proceduren som beskrevet under 1.1. 3. Patient med kæbe-/ansigtsskade henvist fra primærsektoren ellers Region H patienter fra andre sygehuse - akut/subakut/ikke akut. 3.1 Ikke Region H patient Patienten kan efter aftale med vagthavende Øre-næse-halskirurgisk F læge 5-1249 eller vagthavende tandlæge (dagtid 5-1280, vagt: se liste) modtages på Afdeling for Kæbekirurgi, afsnit 2002 (i vagten i Traumecentret tandklinik) til forundersøgelse og ambulant behandling eller F 7056. Der tages stilling til, om patienten skal behandles på Rigshospitalet. Ved behov for indlæggelse kan patienten indlægges direkte på sengeafsnit 7054 F, 7054Z eller TC efter forudgående telefonisk aftale mellem afsendende afdeling (der har ansvaret under transporten) og vagthavende Øre-næse-halskirurgisk læge og ansvarshavende tandlæge. Inden transporten skal det afklares, om patienten kan modtages, herunder pladsforhold og andre forhold, der betinger særlig pleje/behandling, f.eks. commotio eller andre skader. Når patienten ankommer til sengeafsnit 7054 F, 7054 Z eller TC, kaldes vagthavende øre-næse-hals-læge og vagthavende tandlæge til journaloptagelse, ordination af evt.supplerende røntgenbilleder, præoperative blodprøver og evt. supplerende undersøgelser, røntgen, CT-skanning m.v. Der lægges en foreløbig behandlingsplan. 4. Visitation af patient med kæbe- / ansigtsfraktur af patienter modtaget i TC. Vagthavende Øre-næse-halskirurgisk F læge foretager journaloptagelse (anamnese og objektiv undersøgelse), samt behandlingsplan lægges i samarbejde med afd.Z vagthavende tandlæge Vagthavende tandlæge foretager klinisk undersøgelse for kæbe- / ansigtsfraktur, se procedurevejledning vedr. "Kæbefraktur behandlet i stationært regi (sengeafsnit 7054 Z)." Der skrives journal, tages aftryk til dentale skinner eller andet fiksationsapparatur og ordineres relevante supplerende undersøgelser og blodprøver, jvfr. procedurevejledning. Der oprettes operationsbestilling i Orbit, forventet operationsvarighed, særlige ønsker om intubering (side) eller evt. behov for tracheostomi eller evt. intubering over fiberskop. I dagarbejdstiden aftales operation via koordinatorbordet på operationsgang afsnit 6013 Alle patienter med mandibelfraktur og/eller maxilfraktur LeFort 1 ,2 og 3 visiteres til Afdeling for Kæbekirurgi Z, med mindre konkurrende læsioner tilsiger indlæggelse på anden afdeling. Ved fund eller mistanke om zygomafraktur ulige datoer, orbita blow out, sinus frontal frakturer eller næsefraktur visiteres til Afdeling for Øre-Næse-Halskirurgi og Audiologi F, hvorefter behandling koordineres. Patient med udisloceret mandibelfraktur af (in fraktion, fissur, greenstick) og uden malokklusion. Der informeres om hensigtsmæssig adfærd, tyggefri kost, tidsperspektiv for heling, genoptræning m.v. Patient afsluttes i TC med skadeseddel eller epikrise. Visiteres til ambulant kontrol på Afdeling for Kæbekirurgi Z, ambulatoriet, afsnit 2002 Z. Patient med udisloceret mandibelfraktur og malokklusion. Voksne patienter visiteres til ambulant behandling i lokalanalgesi på Tand-, Mund- og Kæbekirurgisk Klnik Z, ambulatoriet, afnsit 2002 Z eller i Traumecentrets tandklinik eller ved behov for behandling i generel anæstesi. Børn indlægges på sengeafsnit 3082 S, til behandling i universel analgesi. Patient med udisloceret fraktur af collum mandibulae og normal okklusion Der informeres om hensigtsmæssig adfærd, tyggefri kost, tidsperspektiv for heling, genoptræning m.v. Patient afsluttes i Traumecentret med skadeseddel eller epikrise. Visiteres til ambulant kontrol på Afdeling for Kæbekirurgi Z, ambulatoriet, afsnit 2002. Patient med disloceret fraktur af collum mandibulae og malokklusion* Ved isoleret fraktur af collum mandibulae tages stilling til konservativ behandling (dentale skinner og IMF) eller kirurgisk behandling med oteosyntese. Konservativ behandling: Voksne patienter visiteres til ambulant behandling i lokalanalgesi på Afdeling for Kæbekirurgi, ambulatoriet, operationsgang afsnit 6013 eller Traumecentret tandklinik. Voksne, der vurderes til ikke at kunne samarbejde om behandling i lokalanalgesi og børn indlægges på sengeafsnit 6053 Z eller 3082 S til behandling i universel analgesi. Operativ behandling (kun voksne): Indlæggelse afsnit 3061 Z, samtykke til operation, information om behandlingsmål, midler og risici. Operation på akutleje eller på afsnit 3031. Patient med disloceret fraktur af corpus, angulus eller ramus mandibulae og malokklusion: Indlægges på afsnit 3061 Z til anlæg af dentale skinner og kirurgisk behandling med osteosyntese +/- IMF. Operation på akutleje, eller i afsnit 3031 i dagtiden, eller i vagten. Patient med behandlingskrævende maxilfraktur LeFort 1 , LeFort 2, LeFort 3 +/- mandibelfraktur (alle slags): Indlægges afsnit 7054 til anlæg af dentale skinner og kirurgisk behandling af osteosyntese +/- IMF. Operation på akutleje i afsnit 3031 i dagtiden, eller i vagten. Patient med sinus frontale fraktur, zygomafraktur ulige datoer, isoleret orbita blow out fraktur samt isoleret frakturer i det naso-fronto-etmoide kompleks uden involvering okklusion. Indlægges på Øre-næse-halskirurgisk sengeafsnit 7054 F til behandling og operationsplanlægning. Operation på afsnit 2073. Information Alle vågne (ikke bevidstløse) patienter informeres om mål og midler i behandlingen (+/- operation) og relevante risici ved behandling og ved undladelse heraf, så snart der foreligger en sikker diagnose og en konfereret behandlingsplan i overensstemmelse med Rigshospitalets regelsæt for patientrettigheder. Informeret samtykke til behandling indhentes og journalføres. Præmedicinering: Er patienten indlagt i Tand-, Mund- og Kæbekirurgisk regi, skal vagthavende tandlæge orientere operationsgangen (afsnit 6013), ved indlæggesle i Øre-næse-halskirurgisk regi, skal vagthavende Øre-næse-halskirurgisk F læge orientere operationsgangen 2073 og sikre et præmedicinsk anæstesiologisk tilsyn, at orange skema er udfyldt, samt blåt skema om informeret samtykke, hvis patienten er vågen. Relevante præoperative ordinationer skal være i EPM, der udfyldes vedrørende eventuel per-/postoperativ antibiotika, analgetika, dosis, plan m.m. Patientorientering, evt. skriftlig patientinformation vedr. medicinering udleveres og dokumenteres i journalen. 5.1 Antibiotika. Antibiotikaregime for kæbefrakturpatienter: Patienter med åbne frakturer bør gives antibiotika profylaktisk i forbindelse med operation og 24 timer herefter. Førstevalg er Penicillin. Ved penicillinallergi er Zinacef det primære valg, hernæst erytromycin. Patienter med åbne frakturer og klinisk infektion eller frakturer der har været ubehandlet i mere end tre døgn skal have antibiotikabehandling med de nævnte præparater suppleret med metronidazol og behandlingsvarigheden bør være 3-6 dage. 5.2 Analgetika Analgetika-regime postoperativt: Efter udskrivning fra opvågnings- eller intensivafdeling ordineres analgetikabehandling af stamafdelingen. For patienter med velreponerede frakturer vil behandling med NSAID præparater, evt, som suppositorier, som regel være sufficient. Evt. kan der suppleres med paracetamol 1 g x 3 og kodein p.n., og i særtilfælde morfin efter ordination. 6. Behandling/operation. Vågne patienter, som har valgt behandling / operation i lokalanalgesi informeres af operatøren nok en gang om behandingens mål og midler, foreløbige planer for ernæring og genoptræning mv. før anlæg af analgesi. Vågne patienter, som har valgt/er visiteret til behandling i universel anæstesi informeres af operatøren om operationen nok en gang om behandlingens mål og midler, specielt planer om IMF. Patienter for hvem, der er planlagt IMF, bør ikke vågne op fra anæstesi med kæberne bundet sammen med mindre dette er nødvendigt, planlagt og patienten er informeret. 7. Opvågningsafd. Opererede frakturpatienter på opvågningsafdelingen tilses ved aftenstuegang. 8. Sengeafdelingen. - Smertedækning: De fleste patienter med velreponerede og fikserede frakturer vil være sufficient smertedækket med NSAID præparater, evt. suppleret med et centralt virkende analgetikum, eksempelvis kodein, undtagelsesvis morfin. Patienter med IMF behandles mest praktisk med suppositorier efter ordination (f.eks. Ibumetin 600 mg x 3 , evt. suppleret med Kodein stærk , mikstur 8 mg/l.1 ml indeholder 6,6 mg kodein. Patienter uden IMF kan sluge tabletter efter ordination. Patienter med ASA allergi eller ulcusdyspepsi, refluxoesophagit kan gives Paracetamol (eksempelvis Panodil a 500 mg eller Panodil Brus, brusetablettera 500 mg, evt. suppleret med Kodein stærk mikstur 8 mg/ml). Generelt skal der i journalen anføres indikation for smertebehandlingen, herunder smerteniveau før og under behandlingen, af hensyn til vurdering af effekt og seponering af smertebehandlingen. Effekten af den analgetiske behandling skal vurderes med reference til VAS-skala og noteres i KISO én gang i hver vagt. - Kost/ernæring: Alle patienter ernæringsscreenes ved indlæggelse iflg.Underernæring og ernæringsrisiko - Screening, udredning, ernæringsterapi og udskrivelse - voksne eller jvfr.retningslinier for ernæring i Afdeling for Kæbekirurgi. Der foretages løbende kontrol af ernæringstilstand, såfremt patienten er indlagt mere end 3 døgn. - Kostplan ifølge skriftlig kostorientering af kæbefrakturpatienter - På operationsdagen må patienter, der er blevet opereret ved transoral adgang få koldt flydende pr os. - Patienter med IMF får tyndt flydende kost, så længe IMF opretholdes. Patienter uden IMF må grundlæggende ikke tygge i 3 uger, de må få pureret kost (skema, ikke brød). Efter 3 uger må patienterne indtage kost af gradvist stigende konsistens under iagttagelse af smertegrænse og okklusionens stabilitet. Mobilisering Patienter uden konkurrende læsioner eller lidelser bør aktiveres til oppegående så snart dette er praktisk muligt. Kontrolrøntgen Alle patienter skal have taget kontrolrøntgen inden udskrivelse. Patienten informeres om røntgenfund og eventuelle konsekvenser heraf for det resterende behandlingsforløb. Der tages optagelser af reposition i to på hinaden vinkelrette planer. I praksis skal mandibelfrakturer kontrolleres med OP og Towne, og maksilfrakturer kontrolleres med kraniebilleder i Water's prjektion. (PA i mento-occipitla projektion) og profiloprtagelse. Zygomafrakturer med displacering af arcus bør kontrolleres med en "overkippet basisoptagelse" (submento-vertikal projektion).Kombinerede ansigtstraumer kontrolleres med CT scanning af ansigtsskelettet med 3-D rekonstruktion. Udskrivning Patienter med kæbefraktur kan udskrives til fortsat ambulant kontrol På Tand-, Mund- og Kæbekirurgisk Klink Z, afsnit 2002 eller på Afdeling for Øre-Næse-Halskirurgi og Audiologi F 7056eller i hjemregionen så snart almentilstanden tillader dette. Ambulant efterkontrol. Epikrise afsluttes og underskrives samme døgn og skal være egen læge/tandlælge i hænde senest efter 3 døgn. Patienter med fraktur af kæbe- og ansigtsknogler er en meget inhomogen gruppe. Målet med den ambulante efterkontrol er i alle tilfælde sikring af brudheling i korrekt stilling uden infektion og efterfølgende normal funktion. Midlerne er monitorering af brudstilling ved klinisk undersøgelse af tændernes okklusion, evt. røntgen, antibiotikaprofylakse efter frakturer med forbindelse til hud eller slimhinde og individuelt tilpasset genoptagelse af tyggefunktionen. Ved brud sinus frontale, nasoetmoidalt, orbita eller zygoma er målet med den ambulante kontrol sikring af repositionsstillingen, bulbus oculi stilling, tyggefunktion, ventilatonsfunkton og symmetri af ansigtsskellettet samt undersøge for rhinoliquorrhoe. I almindelighed kan et ukompliceret behandlingsforløb fuldt forsvarligt afsluttes endeligt efter 6 uger, hvorefter osteosyntesemateriale kan lades in situ. Behovet for kontrolundersøgelse i tidsrummet mellem udskrivelse og endelig afslutning varierer med kompleksiteten af brud og behandling. Afvigelser fra aftalt behandlingsforløb og eventuelle revurderinger og ændringer i behandlingsplanen forelægges patienten og anføres i journalen. Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag

<h1><div id="Afsnit#1699579253738">Fraktur af kæbe - og ansigtsknogler, Forløbsbeskrivelse for patienter med</div></h1><div id="BodyWeb#1699579253738"><p><a name="1699579253738Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579253738Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579253738Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579253738Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579253738Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579253738Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579253738Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579253738Bilag">Bilag</a><br> &nbsp;</h3> <h2><a name="1699579253738Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p>Klinisk personale i Afdeling for Øre-Næse-Halskirurgi og Audiologi og Afdeling for Kæbekirurgi</p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579253738Top">Tilbage til top</a></p> <h2><a name="1699579253738Definitioner"></a><br> Definitioner</h2> <p><strong>TC:</strong> Traumecentret, Rigshospitalet</p> <p><strong>IMF: </strong>Intermaxillær fiksation&nbsp;</p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579253738Top">Tilbage til top</a></p> <h2><a name="1699579253738Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p><strong>Alment</strong></p> <p>Aktuelle patientforløbsbeskrivelse referer til "Procedurevejledning vedr. patientforløb på Afdeling for Kæbekirurgi Z" og Afdeling for Øre-Næse-Halskirurgi og Audiologi F&nbsp;</p> <p>Patienter med frakturer i kæbe- og ansigtsskelettet fordeler sig i forskellige kategorier m.h.t. anatomisk lokalisation og alvorlighed. Eksempler er anført i nedenstående skema.&nbsp;</p> <p>Patienterne har ofte andre læsioner og de indlægges i den for deres væsentligste problem relevante afdeling.</p> <p><strong>Patientkategorier</strong></p> <p>&nbsp;</p> ###TABEL_1### <p>*naso-fronto-orbito-etmoide frakturer.</p> <p><strong>Patientens veje ind i systemet til stationær eller ambulant behandling</strong></p> <ol> <li>Gennem Traumecentret (TC) fra skadestedet efter præhospital visitation.</li> <li>Efter henvisning / omvisitation fra andet sygehus i Region H, og Region Sjælland, herunder skadestuerne Region H, eller fra anden regions hospital til (videre) behandling på Rigshospitalet</li> <li>Efter henvisning fra primærsektoren&nbsp;</li> </ol> <p><strong><em><u>1.1 Patienter indbragt i Rigshospitalets Traumecenter (TC)</u></em></strong></p> <p>Alle patienter med ansigtslæsioner, som indbringes til TC undersøges og visiteres af TC læge. Ved mistanke om eller påvist kæbe- / ansigtsfraktur tilkaldes vagthavende Øre-næse-halskirurgisk F læge på telefon 5-1249 og vagthavende tandlæge på telefon 5-1280 i dagarbejdstiden, efter vagtliste i vagten.</p> <p><strong><em><u>Klinisk undersøgelse og billeddiagnostik.</u></em></strong></p> <p>Det <em>forudsættes</em>, at en patient med kæbe-ansigtsfraktur, som a.h.t. cerebral diagnostik eller af anden årsag bliver traumeskannet, <em>også får CT skannet ansigtsskelettet</em> (incl. mandiblen) med tynde snit (1-2 mm), der muliggør evt. senere 3-D rekonstruktion.</p> <p>Konventionel røntgenundersøgelse for kæbe- / ansigtsfraktur omfatter følgende optagelser:</p> <p><strong><em><u>Mandibelfraktur:</u></em></strong></p> <p>OP (ortopantomogram) (hos vågne patienter, som kan stå op), AP og Towne's projektion. Hos bevidstløse patienter og andre patienter, der ikke kan stå op til røntgenundersøgelse erstattes OP af skrålateral optagelse af begge siders corpus, angulus og ramus mandibulae. Evt. enoral optagelse i bidplan (mundbundsoptagelse).</p> <p><strong><em><u>Maxil-/zygomafraktur:</u></em></strong></p> <p>Kranieoptagelser i AP-projektion, profiloptagelse og moon-face projektion samt hos ikke bevidstløse patienter uden mistanke om læsioner af halscolumna submento-vertikal projektion (overkippet basisoptagelse).</p> <p>Alle patienter med kæbe- / ansigts fraktur eller mistanke herom undersøges af vagthavende Øre-næse-halskirurgisk F læge (dect 5-1249) og vagthavende tandlæge (dect 5-1218), som tilkaldes til TC ved patientens modtagelse m.h.p. diagnostik af alle relevante forhold og aftrykstagning til fiksationsapparatur. Der træffes beslutning om akut / ikke akut operation.</p> <p><strong><em><u>Akut intervention:</u></em></strong></p> <p>Kæbe- / ansigtsfrakturer indicerer ikke akut operation (udover akut blødning eller omfattende komplicerede åbne frakturer), men akut operation af andre læsioner i universel anæstesi kan gøre det mest praktisk, at også kæbe-/ansigtsfrakturer behandles i samme anæstesi.</p> <p><strong><em><u>Behandlingsplan: </u></em></strong></p> <p>Behandlingsplan - eller i det mindste foreløbig plan (dikteret til journalen) - skal foreligge inden 24 timer. Denne plan koordineres med undersøgende læge fra andre aktuelle specialer, der koordinerer en eventuel samlet behandlingsplan sammen med ansvarlig stamafdeling og afstemmes med ansvarshavende overtandlæge/overlæge/bagvagt.</p> <p><strong><em><u>1.2 – ikke Region H patient indbragt til TC</u></em></strong></p> <ul> <li value="1"><u>der <em>ikke</em> har behov for overvågning</u> eller akut behandling, <em>omvisiteres </em>til relevant sygehusafdeling i egen region. Vagthavende tandlæge, vagthavende Øre-næse-halskirurgisk læge og/eller TC-læge kontakter vagthavende kollega i region, aftaler forhold vedr. overflytning, skriver skadeseddel, overførselsnotat i journalen, epikrise eller anden skriftlig meddelelse med fornødne oplysninger samt billeddiagnostisk materiale. Ansvar for patientens tilstand under transport påhviler 'afsenderen', almindeligvis TC. Transport af ikke intuberede patienter med IMF (intermaxillær fiksation) skal ledsages af sufficient uddannet fagperson.</li> <li value="1"><u>der <em>har behov for akut behandling</em></u>, skal behandling tilstræbes at være afsluttet indenfor 24 timer, hvorefter patienten kan overføres til Øre-næse-halskirurgisk afdeling i egen region, når transport er forsvarlig og praktisk mulig. Indikationen for akut kæbefrakturbehandling vil oftest være dikteret af, at højere prioriterede læsioner skal behandles i universel anæstesi. <em>Blødning</em> kan være en akut indikation for kæbefrakturbehandling</li> <li value="1">såfremt akut indikation ikke foreligger, og patienten ikke er transportabel, klassificeres patienten som land-landsdels patient, hvis der er indikation for, at behandling foregår på Rigshospitalet. Hjemregionen orienteres om, at behandling foregår her.</li> </ul> <p>&nbsp;</p> <p><strong><em><u>1.3 - Region H patient indbragt til TC</u></em></strong></p> <ul> <li>visiteres til indlæggelse i relevant afdeling af TC-læge (Traumecenter, Ortopædkirurgisk afd., Afdeling for Øre-Næse-Halskirurgi og Audiologi, Afdeling for Kæbekirurgi, Afdeling for Plastikkirurgi og Brandsårsbehandling etc.)</li> <li>læge fra ansvarlig afdeling tager initiativ til prioritering og samordning af indsats / operation i samråd med vagthavende ortopædkirurg, ørelæge, tandlæge, plastikkirurg (eller andre) efter behov.&nbsp;</li> </ul> <p><strong><em><u>2. Patient som henvender sig/ indbringes til Region H skadestue</u></em></strong></p> <p><strong><em><u>2.1 – Region H patient</u></em></strong></p> <p>Skadestuelæge stiller henvisningsdiagnosen og transportable patienter overføres til visitation i TC efter ovennævnte retningslinier eller direkte til Afdeling for Øre-Næse-Halskirurgi og Audiologi F eller Afdeling for Kæbekirurgi.</p> <p>Vagthavende Øre-næse-hals-læge F kaldes op 5-1249.</p> <p>Vagthavende tandlæge kaldes på telefon 5-1280 i dagarbejdstid, efter vagtliste i vagten. Så snart vagthavende F læge og tandlæge har orienteret sig om patienten, diagnose og behandlingsbehov, kontaktes sengeafsnit 7054 F eller 7054Z m.h.p. evt. indlæggelse af patienten.&nbsp;</p> <p>Patienter, der kan behandles ambulant får tid hertil på Afdeling for Øre-Næse-Halskirurgi og Audiologi, ambulatoriet 7056, F 7054 eller Afdeling for Kæbekirurgi, ambulatoriet afsnit 2002, operationsgang afsnit 6013eller bliver behandlet i TC's tandklinik.&nbsp;</p> <p><strong><em><u>2.2 - Ikke Region H patient</u></em></strong></p> <p>Overføres oftest med primært klarlagte problemstillinger og herunder evt. kæbefrakturer. Skadelæge modtager patienten og kontakter vagthavende Øre-næse-halslæge og tandlæge der stiller diagnosen.</p> <p>Vagthavende Øre-næse-hals F læge kaldes på 5-1249.</p> <p>Vagthavende tandlæge kaldes på telefon 5-1280 i dagarbejdstid, efter vagtliste i vagten. Så snart vagthavende tandlæge og F læge har orienteret sig om patienten, diagnose og behandlingsbehov, kontakte sengeafsnit 7054 Z eller 7054 F m.h.p. evt. indlæggelse af patienten</p> <p>Ved behov for indlæggelse i Righospitalets Traumecenter følges proceduren som beskrevet under 1.1.&nbsp;</p> <p><strong><em><u>3. Patient med kæbe-/ansigtsskade henvist fra primærsektoren ellers Region H patienter fra andre sygehuse - akut/subakut/ikke akut.</u></em></strong></p> <p><strong><em><u>3.1 Ikke Region H patient</u></em></strong></p> <p>Patienten kan efter aftale med vagthavende Øre-næse-halskirurgisk F læge 5-1249 eller vagthavende tandlæge (dagtid 5-1280, vagt: se liste) modtages på Afdeling for Kæbekirurgi, afsnit 2002 (i vagten i Traumecentret tandklinik) til forundersøgelse og ambulant behandling eller F 7056.</p> <p>Der tages stilling til, om patienten skal behandles på Rigshospitalet.&nbsp;</p> <p>Ved behov for indlæggelse kan patienten indlægges direkte på sengeafsnit 7054 F, 7054Z eller TC efter forudgående telefonisk aftale mellem afsendende afdeling (der har ansvaret under transporten) og vagthavende Øre-næse-halskirurgisk læge og ansvarshavende tandlæge. Inden transporten skal det afklares, om patienten kan modtages, herunder pladsforhold og andre forhold, der betinger særlig pleje/behandling, f.eks. commotio eller andre skader.&nbsp;</p> <p>Når patienten ankommer til sengeafsnit 7054 F, 7054 Z eller TC, kaldes vagthavende øre-næse-hals-læge og vagthavende tandlæge til journaloptagelse, ordination af evt.supplerende røntgenbilleder, præoperative blodprøver og evt. supplerende undersøgelser, røntgen, CT-skanning m.v. Der lægges en foreløbig behandlingsplan.&nbsp;</p> <p><strong><em><u>4. Visitation af patient med kæbe- / ansigtsfraktur af patienter modtaget i TC.</u></em></strong></p> <p>Vagthavende Øre-næse-halskirurgisk F læge foretager journaloptagelse (anamnese og objektiv undersøgelse), samt behandlingsplan lægges i samarbejde med afd.Z vagthavende tandlæge&nbsp;</p> <p>Vagthavende tandlæge foretager klinisk undersøgelse for kæbe- / ansigtsfraktur, se procedurevejledning vedr. "Kæbefraktur behandlet i stationært regi (sengeafsnit 7054 Z)."&nbsp;</p> <p>Der skrives journal, tages aftryk til dentale skinner eller andet fiksationsapparatur og ordineres relevante supplerende undersøgelser og blodprøver, jvfr. procedurevejledning.</p> <p>Der oprettes operationsbestilling i Orbit, forventet operationsvarighed, særlige ønsker om intubering (side) eller evt. behov for tracheostomi eller evt. intubering over fiberskop. I dagarbejdstiden aftales operation via koordinatorbordet på operationsgang afsnit 6013</p> <p>Alle patienter med mandibelfraktur og/eller maxilfraktur LeFort 1 ,2 og 3 visiteres til Afdeling for Kæbekirurgi Z, med mindre konkurrende læsioner tilsiger indlæggelse på anden afdeling.</p> <p>Ved fund eller mistanke om zygomafraktur ulige datoer, orbita blow out, sinus frontal frakturer eller næsefraktur visiteres til Afdeling for Øre-Næse-Halskirurgi og Audiologi F, hvorefter behandling koordineres.&nbsp;</p> <p><strong><em>Patient med udisloceret mandibelfraktur af (in fraktion, fissur, greenstick) og uden malokklusion.</em></strong></p> <p>Der informeres om hensigtsmæssig adfærd, tyggefri kost, tidsperspektiv for heling, genoptræning m.v. Patient afsluttes i TC med skadeseddel eller epikrise. Visiteres til ambulant kontrol på Afdeling for Kæbekirurgi Z, ambulatoriet, afsnit 2002 Z.</p> <p><strong><em>Patient med udisloceret mandibelfraktur og malokklusion.</em></strong></p> <p>Voksne patienter visiteres til ambulant behandling i lokalanalgesi på Tand-, Mund- og Kæbekirurgisk Klnik Z, ambulatoriet, afnsit 2002 Z eller i Traumecentrets tandklinik eller ved behov for behandling i generel anæstesi. Børn indlægges på sengeafsnit 3082 S, til behandling i universel analgesi.&nbsp;</p> <p><strong><em>Patient med udisloceret fraktur af collum mandibulae og normal okklusion</em></strong></p> <p>Der informeres om hensigtsmæssig adfærd, tyggefri kost, tidsperspektiv for heling, genoptræning m.v. Patient afsluttes i Traumecentret med skadeseddel eller epikrise. Visiteres til ambulant kontrol på Afdeling for Kæbekirurgi Z, ambulatoriet, afsnit 2002.&nbsp;</p> <p><strong><em>Patient med disloceret fraktur af collum mandibulae og malokklusion*</em></strong></p> <p>Ved isoleret fraktur af collum mandibulae tages stilling til konservativ behandling (dentale skinner og IMF) eller kirurgisk behandling med oteosyntese.&nbsp;</p> <p><strong><em>Konservativ behandling:</em></strong></p> <p>Voksne patienter visiteres til ambulant behandling i lokalanalgesi på Afdeling for Kæbekirurgi, ambulatoriet, operationsgang afsnit 6013 eller Traumecentret tandklinik. Voksne, der vurderes til ikke at kunne samarbejde om behandling i lokalanalgesi og børn indlægges på sengeafsnit 6053 Z eller 3082 S til behandling i universel analgesi.&nbsp;</p> <p><strong><em>Operativ behandling (kun voksne):</em></strong></p> <p>Indlæggelse afsnit 3061 Z, samtykke til operation, information om behandlingsmål, midler og risici. Operation på akutleje eller på afsnit 3031.&nbsp;</p> <p><strong><em>Patient med disloceret fraktur af corpus, angulus eller ramus mandibulae og malokklusion:</em></strong></p> <p>Indlægges på afsnit 3061 Z til anlæg af dentale skinner og kirurgisk behandling med osteosyntese +/- IMF. Operation på akutleje, eller i afsnit 3031 i dagtiden, eller i vagten.&nbsp;</p> <p><strong><em>Patient med behandlingskrævende maxilfraktur LeFort 1 , LeFort 2, LeFort 3 +/- mandibelfraktur (alle slags):</em></strong></p> <p>Indlægges afsnit 7054 til anlæg af dentale skinner og kirurgisk behandling af osteosyntese +/- IMF. Operation på akutleje i afsnit 3031 i dagtiden, eller i vagten.</p> <p><strong><em>Patient med sinus frontale fraktur, zygomafraktur ulige datoer, isoleret orbita blow out fraktur samt isoleret frakturer i det naso-fronto-etmoide kompleks uden involvering okklusion.</em></strong></p> <p>Indlægges på Øre-næse-halskirurgisk sengeafsnit 7054 F til behandling og operationsplanlægning. Operation på afsnit 2073.&nbsp;</p> <p><strong>Information</strong></p> <p>Alle vågne (ikke bevidstløse) patienter informeres om mål og midler i behandlingen (+/- operation) og relevante risici ved behandling og ved undladelse heraf, så snart der foreligger en sikker diagnose og en konfereret behandlingsplan i overensstemmelse med Rigshospitalets regelsæt for patientrettigheder.</p> <p>Informeret samtykke til behandling indhentes og journalføres.&nbsp;</p> <p><em>Præmedicinering: </em></p> <p>Er patienten indlagt i Tand-, Mund- og Kæbekirurgisk regi, skal vagthavende tandlæge orientere operationsgangen (afsnit 6013), ved indlæggesle i Øre-næse-halskirurgisk regi, skal vagthavende Øre-næse-halskirurgisk F læge orientere operationsgangen 2073 og sikre et præmedicinsk anæstesiologisk tilsyn, at orange skema er udfyldt, samt blåt skema om informeret samtykke, hvis patienten er vågen.</p> <p>Relevante præoperative ordinationer skal være i EPM, der udfyldes vedrørende eventuel per-/postoperativ antibiotika, analgetika, dosis, plan m.m. Patientorientering, evt. skriftlig patientinformation vedr. medicinering udleveres og dokumenteres i journalen.&nbsp;</p> <p><em>5.1 Antibiotika.</em></p> <p>Antibiotikaregime for kæbefrakturpatienter: Patienter med åbne frakturer bør gives antibiotika profylaktisk i forbindelse med operation og 24 timer herefter. Førstevalg er Penicillin. Ved penicillinallergi er Zinacef det primære valg, hernæst erytromycin. Patienter med åbne frakturer og klinisk infektion eller frakturer der har været ubehandlet i mere end tre døgn skal have antibiotikabehandling med de nævnte præparater suppleret med metronidazol og behandlingsvarigheden bør være 3-6 dage.&nbsp;</p> <p><em>5.2 Analgetika</em></p> <p>Analgetika-regime postoperativt: Efter udskrivning fra opvågnings- eller intensivafdeling ordineres analgetikabehandling af stamafdelingen. For patienter med velreponerede frakturer vil behandling med NSAID præparater, evt, som suppositorier, som regel være sufficient. Evt. kan der suppleres med paracetamol 1 g x 3 og kodein p.n., og i særtilfælde morfin efter ordination.&nbsp;</p> <p><em>6. Behandling/operation.</em></p> <p>Vågne patienter, som har valgt behandling / operation i lokalanalgesi informeres af operatøren nok en gang om behandingens mål og midler, foreløbige planer for ernæring og genoptræning mv. før anlæg af analgesi.&nbsp;</p> <p>Vågne patienter, som har valgt/er visiteret til behandling i universel anæstesi informeres af operatøren om operationen nok en gang om behandlingens mål og midler, specielt planer om IMF.</p> <p>Patienter for hvem, der er planlagt IMF, bør ikke vågne op fra anæstesi med kæberne bundet sammen med mindre dette er nødvendigt, planlagt og patienten er informeret.&nbsp;</p> <p><em>7. Opvågningsafd.</em></p> <p>Opererede frakturpatienter på opvågningsafdelingen tilses ved aftenstuegang.&nbsp;</p> <p><em>8. Sengeafdelingen.</em></p> <ol> <li>Smertedækning: De fleste patienter med velreponerede og fikserede frakturer vil være sufficient smertedækket med NSAID præparater, evt. suppleret med et centralt virkende analgetikum, eksempelvis kodein, undtagelsesvis morfin. Patienter med IMF behandles mest praktisk med suppositorier efter ordination (f.eks. Ibumetin 600 mg x 3 , evt. suppleret med <em>Kodein stærk , mikstur 8 mg/l.</em>1 ml indeholder 6,6 mg kodein. Patienter uden IMF kan sluge tabletter efter ordination. Patienter med ASA allergi eller ulcusdyspepsi, refluxoesophagit kan gives Paracetamol (eksempelvis Panodil a 500 mg eller <em>Panodil Brus, brusetabletter</em>a 500 mg, evt. suppleret med Kodein stærk mikstur 8 mg/ml). Generelt skal der i journalen anføres indikation for smertebehandlingen, herunder smerteniveau før og under behandlingen, af hensyn til vurdering af effekt og seponering af smertebehandlingen. Effekten af den analgetiske behandling skal vurderes med reference til VAS-skala og noteres i KISO &nbsp;én gang i hver vagt.&nbsp;</li> </ol> <ol> <li value="2">Kost/ernæring: Alle patienter ernæringsscreenes ved indlæggelse iflg.<a href="###FOLDER###" target="_blank">Underernæring og ernæringsrisiko - Screening, udredning, ernæringsterapi og udskrivelse - voksne</a>&nbsp;eller jvfr.retningslinier for ernæring i Afdeling for Kæbekirurgi. Der foretages løbende kontrol af ernæringstilstand, såfremt patienten er indlagt mere end 3 døgn.&nbsp;</li> </ol> <ol> <li value="3">Kostplan ifølge skriftlig kostorientering af kæbefrakturpatienter - På operationsdagen må patienter, der er blevet opereret ved transoral adgang få koldt flydende pr os. - Patienter med IMF får tyndt flydende kost, så længe IMF opretholdes.&nbsp;</li> </ol> <p><u>Patienter uden IMF <em>må grundlæggende ikke tygge i 3 uger,</em></u> de må få pureret kost (skema, ikke brød). Efter 3 uger må patienterne indtage kost af gradvist stigende konsistens under iagttagelse af smertegrænse og okklusionens stabilitet.&nbsp;</p> <p><em>Mobilisering</em></p> <p>Patienter uden konkurrende læsioner eller lidelser bør aktiveres til oppegående så snart dette er praktisk muligt.</p> <p><em>Kontrolrøntgen</em></p> <p>Alle patienter skal have taget kontrolrøntgen inden udskrivelse. Patienten informeres om røntgenfund og eventuelle konsekvenser heraf for det resterende behandlingsforløb. Der tages optagelser af reposition i to på hinaden vinkelrette planer. I praksis skal mandibelfrakturer kontrolleres med OP og Towne, og maksilfrakturer kontrolleres med kraniebilleder i Water's prjektion. (PA i mento-occipitla projektion) og profiloprtagelse. Zygomafrakturer med displacering af arcus bør kontrolleres med en "overkippet basisoptagelse" (submento-vertikal projektion).Kombinerede ansigtstraumer kontrolleres med CT scanning af ansigtsskelettet med 3-D rekonstruktion.&nbsp;</p> <p><em>Udskrivning</em></p> <p>Patienter med kæbefraktur kan udskrives til fortsat ambulant kontrol På Tand-, Mund- og Kæbekirurgisk Klink Z, afsnit 2002 eller på Afdeling for Øre-Næse-Halskirurgi og Audiologi F 7056eller i hjemregionen så snart almentilstanden tillader dette.&nbsp;</p> <p><em>Ambulant efterkontrol.</em></p> <p>Epikrise afsluttes og underskrives samme døgn og skal være egen læge/tandlælge i hænde senest efter 3 døgn.&nbsp;</p> <p>Patienter med fraktur af kæbe- og ansigtsknogler er en meget inhomogen gruppe. Målet med den ambulante efterkontrol er i alle tilfælde sikring af brudheling i korrekt stilling uden infektion og efterfølgende normal funktion. Midlerne er monitorering af brudstilling ved klinisk undersøgelse af tændernes okklusion, evt. røntgen, antibiotikaprofylakse efter frakturer med forbindelse til hud eller slimhinde og individuelt tilpasset genoptagelse af tyggefunktionen.</p> <p>Ved brud &nbsp;sinus frontale, nasoetmoidalt, orbita eller zygoma er målet med den ambulante kontrol sikring af repositionsstillingen, bulbus oculi stilling, tyggefunktion, ventilatonsfunkton og symmetri af ansigtsskellettet samt undersøge for rhinoliquorrhoe.&nbsp;</p> <p>I almindelighed kan et ukompliceret behandlingsforløb fuldt forsvarligt afsluttes endeligt efter 6 uger, hvorefter osteosyntesemateriale kan lades in situ. Behovet for kontrolundersøgelse i tidsrummet mellem udskrivelse og endelig afslutning varierer med kompleksiteten af brud og behandling.&nbsp;</p> <p>Afvigelser fra aftalt behandlingsforløb og eventuelle revurderinger og ændringer i behandlingsplanen forelægges patienten og anføres i journalen.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579253738Top">Tilbage til top</a></p> <h2><a name="1699579253738Ansvar"></a><br> Ansvar og organisering</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579253738Top">Tilbage til top</a></p> <h2><a name="1699579253738Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579253738Top">Tilbage til top</a></p> <h2><a name="1699579253738Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579253738Top">Tilbage til top</a></p> <h2><a name="1699579253738Bilag"></a><br> Bilag</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579253738Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Fraktur af kæbe - og ansigtsknogler_TABEL_1.

PATIENTKATEGORIER VISITATION, INDLÆGGELSE PRIORITERING Multitraumatiseret, bevidstløs patient, alle kæbe- / ansigtsfrakturer Traumecentrets intensivafsnit (TCI),tilsyn af vagthavende Øre-næse-halskirurgisk F læge og tilsyn af vagthavende tandlæge. Omvisitering til relevant afdeling, når behov for intensiv indsats ikke mere er påkrævet Undersøgelse og behandlingsplanlægning: høj. Behandling: lav Isoleret ansigtstraume, bevidstløs patient alle kæbe- / ansigtsfrakturer TCI intensivafsnit, tilsyn af vagthavende Øre-næse-halskirurgisk F læge og tilsyn af vagthavende tandlæge. Omvisitering til relevant afdeling, når behov for intensiv indsats ikke mere er påkrævet Undersøgelse og behandlingsplanlægning: høj Behandling: lav Isoleret ansigtstraume, cerebralt afklaret / upåvirket patient Le Fort 1, 2,3 TC Øre-næse-halskirurgisk F læge tilsyn og tilsyn af vagthavende tandlæge. Behandlingansvar Afdeling for Kæbekirurgi, samarbejde med Afdeling for Øre-Næse-Halskirurgi og Audiologi F Undersøgelse og behandlingsplanlægning: høj Behandling: høj Isoleret ansigtstraume, cerebralt afklaret/upåvirket patient isoleret zygoma, naso / fronto- eller orbitoetmoid fraktur TC Tilsyn Øre-næse-halskirurgisk F læge. Behandling: Afdeling for Øre-Næse-Halskirurgi og Audiologi. Ingen kæbefraktur Behandling: middel Isoleret ansigtstraume cerebralt afklaret / upåvirket patient med maxilfraktur TC Øre-næse-halskirurgisk F læge tilsyn og tilsyn vagthavende tandlæge. Behandling: Afdeling for Kæbekirurgi Z Undersøgelse og behandlingsplanlægning: høj Behandling: høj Isoleret ansigtstraume cerebralt afklaret / upåvirket patient med Zygoma-maxilfraktur TC Afdeling for Kæbekirurgi og Afdeling for Øre-Næse-Halskirurgi og Audiologi F læge. Behandling: Sammenbidsproblemer og lige datoer Afdeling for Kæbekirurgi Ulige datoer Afdeling for Øre-Næse-Halskirurgi og Audiologi Undersøgelse og behandlingsplanlægning: høj Behandling: høj Isoleret ansigtstraume, cerebralt afklaret / upåvirket patient med mandibelfraktur +/- andre frakturer Afdeling for Kæbekirurgi og tilsyn Afdeling for Øre-Næse-Halskirurgi og Audiologi F læge Behandling: Afdeling for Kæbekirurgi ( i samarbejde med Afdeling for Øre-Næse-Halskirurgi og Audiologi)* Undersøgelse og behandlingsplanlægning: høj Behandling: høj

<table border="0" cellpadding="0" cellspacing="3" style="width:90%"> <tbody> <tr> <td> <p><strong>PATIENTKATEGORIER</strong></p> </td> <td> <p><strong>VISITATION, INDLÆGGELSE</strong></p> </td> <td> <p><strong>PRIORITERING</strong></p> </td> </tr> <tr> <td> <p>Multitraumatiseret, bevidstløs patient,</p> <p><strong>alle kæbe- / ansigtsfrakturer</strong></p> </td> <td> <p>Traumecentrets intensivafsnit (TCI),tilsyn af vagthavende Øre-næse-halskirurgisk F læge og tilsyn af vagthavende tandlæge.</p> <p>Omvisitering til relevant afdeling, når behov for intensiv indsats ikke mere er påkrævet</p> </td> <td> <p>Undersøgelse og behandlingsplanlægning: høj.</p> <p>&nbsp;</p> <p>Behandling: lav</p> </td> </tr> <tr> <td> <p>Isoleret ansigtstraume, bevidstløs patient <strong>alle kæbe- / ansigtsfrakturer</strong></p> </td> <td> <p>TCI intensivafsnit, tilsyn af vagthavende Øre-næse-halskirurgisk F læge og tilsyn af vagthavende tandlæge. Omvisitering til relevant afdeling, når behov for intensiv indsats ikke mere er påkrævet</p> </td> <td> <p>Undersøgelse og behandlingsplanlægning: høj</p> <p>Behandling: lav</p> </td> </tr> <tr> <td> <p>Isoleret ansigtstraume, cerebralt afklaret / upåvirket patient <strong>Le Fort 1, 2,3</strong></p> </td> <td> <p>TC Øre-næse-halskirurgisk F læge tilsyn og tilsyn af vagthavende tandlæge. Behandlingansvar Afdeling for Kæbekirurgi, samarbejde med Afdeling for Øre-Næse-Halskirurgi og Audiologi F</p> </td> <td> <p>Undersøgelse og</p> <p>behandlingsplanlægning: høj</p> <p>Behandling: høj</p> </td> </tr> <tr> <td> <p>Isoleret ansigtstraume, cerebralt afklaret/upåvirket patient</p> <p><strong>isoleret zygoma, naso / fronto- eller orbitoetmoid fraktur</strong></p> </td> <td> <p>TC</p> <p>Tilsyn Øre-næse-halskirurgisk F læge.</p> <p>Behandling: Afdeling for Øre-Næse-Halskirurgi og Audiologi.</p> </td> <td> <p>Ingen kæbefraktur</p> <p>&nbsp;</p> <p>Behandling: middel</p> </td> </tr> <tr> <td> <p>Isoleret ansigtstraume</p> <p>cerebralt afklaret / upåvirket patient med <strong>maxilfraktur</strong></p> </td> <td> <p>TC</p> <p>Øre-næse-halskirurgisk F læge tilsyn og tilsyn vagthavende tandlæge.</p> <p>Behandling:</p> <p>Afdeling for Kæbekirurgi Z</p> </td> <td> <p>Undersøgelse og</p> <p>behandlingsplanlægning: høj</p> <p>&nbsp;</p> <p>Behandling: høj</p> </td> </tr> <tr> <td> <p>Isoleret ansigtstraume</p> <p>cerebralt afklaret / upåvirket patient med Zygoma-<strong>maxilfraktur </strong></p> </td> <td> <p>TC</p> <p>Afdeling for Kæbekirurgi og Afdeling for Øre-Næse-Halskirurgi og Audiologi F læge.</p> <p>Behandling: Sammenbidsproblemer og lige datoer Afdeling for Kæbekirurgi</p> <p>Ulige datoer Afdeling for Øre-Næse-Halskirurgi og Audiologi</p> </td> <td> <p>Undersøgelse og behandlingsplanlægning: høj</p> <p>&nbsp;</p> <p>Behandling: høj</p> </td> </tr> <tr> <td> <p>Isoleret ansigtstraume, cerebralt afklaret / upåvirket patient med</p> <p><strong>mandibelfraktur</strong> +/- andre frakturer</p> </td> <td> <p>Afdeling for Kæbekirurgi og tilsyn Afdeling for Øre-Næse-Halskirurgi og Audiologi F læge</p> <p>Behandling: Afdeling for Kæbekirurgi ( i samarbejde med Afdeling for Øre-Næse-Halskirurgi og Audiologi)*</p> </td> <td> <p>Undersøgelse og</p> <p>behandlingsplanlægning: høj</p> <p>&nbsp;</p> <p>Behandling: høj</p> </td> </tr> </tbody> </table>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Fremmedlegeme i oesophagus.

Fremmedlegeme i oesophagus Målgrupper og anvendelsesområde Lægefagligt personale i Afdeling for Øre-Næse-Halskirurgi og Audiologi Voksne patienter, alder 16 år eller ældre, med fremmedlegemer i oesophagus Definitioner Fremmedlegemer i oesophagus dækker over synkestop efter indtagelse af føde bolus samt fastsiddende objekter såsom legetøj, mønter, ben og lignende. Fremmedlegeme i oesophagus er en akut tilstand idet der potentielt er perforationsrisiko. Fremgangsmåde Forud for speciale afsnit: Patienterne ses typisk på skadestue eller hos vagtlægen og viderevisiteres læge til læge. Anamnesen giver som regel diagnosen, dog kan børn, demente, psykisk syge eller mentalt retarderede ikke altid redegøre for forløbet. Der skal differentieres mellem: Skarpt fremmedlegeme versus uskarpt samt et bud på lokalisation af fremmedlegemet og om der er tale om respirationspåvirkethed. Visitation Fremmedlegemer i oesophagus behandles primært hos Thoraxkirurgerne. Undtagelsen er respirationstruede patienter (voksne, alder 16 år eller ældre), der skal modtages af ØNH. Thoraxkirurgisk Afdeling bør informeres om patienten, idet der ved et mere distalt placeret fremmedlegeme kan blive tale om en samarbejdspatient. Udredning: Ved den respirationstruede patient sidder fremmedlegemet typisk i hypopharynx eller den øverste del af oesophagus. Ved et røntgenfast fremmedlegeme kan man overveje et simpelt røntgen af thorax, dog ikke på bekostning af patientens tilstand. Såfremt der er mistanke om et ikke-røntgenfast fremmedlegeme så som ben eller lignende, kan der udføres røntgen af oesophagus, først med kontrast og derefter skylles med vand, hvorefter fremmedlegemet visualiseres. Journaloptagelse: I journalen anføres / dokumenteres følgende: - Hvorvidt fremmedlegemet er skarpt / uskarpt - Fremmedlegemets / synkestoppets lokalisation - Tidligere synkestop eller nærsynkestop - Vægttab - Dyspepsier - Anvendelse af antacida - Smerter i brystet, retrosternalt, i ryggen, epigastriet Objektiv undersøgelse: Undersøgelsen omfatter: - Febrilia - Spytflod - Hoste - Hæshed - Stridor - Lokaliseret ømhed på halsen - Subkutant emfysem på halsen. Blodprøver: Vanlige præoperative prøver. Det vil sige, at ved en i øvrigt rask patient er der ikke indikation for blodprøver. Anæstesi: Der er ikke indikation for at faste 6 timer. Patienten skal være totalt relaxeret under universiel anæstesi. Behandling: Der skønnes mellem følgende patientkategorier: 1: Skarpt fremmedlegeme: Skarpt fremmedlegeme bør fjernes akut. Der kan indledes med laryngoskop og ofte vil fremmedlegemet være synligt i hypopharynx og kan fjernes med fremmedlegemetang. Der anvendes stift oesophagoskop til fremmedlegemer i øverste og midterste del af oesophagus, mens der distalt anvendes flexibelt skop. Afslutningsvis kan gøres flexibel oesophagoskopi, hvor oesophagus efterses fra ventriklen og kranielt for perforationer, rifter eller øvrig patologi. Såfremt der findes tegn på patologi tages der relevante biopsier og evt. billeder af dette. 2: Synkestop højtsiddende respirationspåvirket pt.: Synkestop højtsiddende bør fjernes akut. Synkestop her passerer sjældent spontant og patienten er ofte med påvirket respiration p.gr.a. kraftigt spytflåd/risiko for aspiration. Man kan evt. i ventetiden på anæstesi anlægge nasalsonde hvor der kan aspireres spyt forsigtigt efter behov. Der må ikke forsøges at skubbe fødeemnet distalt. Postoperativt: Ved ukompliceret fjernelse af fremmedlegeme / fødebolus kan patienten drikke umiddelbart efter opvågning. Ved mistanke om rift eller perforation peroperativt skal der nedlægges nasogastrisk sonde og foretages rtg.af oesophagus med vandigt kontrast. På mistanke om perforation sættes patienten i behandling med: iv Zinacef 1500mg x 3 og iv Metronidazol 500 mg x 3. Patienten skal faste, observeres med VAS, temperatur og for subcutant emfysem. Ved sikker perforation: Tilkald thoraxkirurgierne mhp. thoracotomi/ stent behandling og opstart antibiotisk behandling i henhold til givne thoraxkirurgiske retningslinier ref 4. ( Meropenem 2g x 3 iv., Ciprofloxacin 600mg x 2 iv., Metronidazol 500mg x 3 iv. og Caspofungin 70 mg iv det første døgn. eller Anidulafungin 200mg det første døgn. Behandlingvarighed i op til 6 uger.) Ambulant kontrol: Da op til 80% af patienter med synkestop har en tilgrundliggende patologi såsom dysmotilitet, eosophagit, Schatzki´s ring, tumor, reflux, webdannelse eller andet, er det vigtigt, at patienten bliver fulgt op. Såfremt der er taget biopsier, skal patienten ligeledes komme til svar på disse i ambulatoriet. Ved fund af malignitet skal patienten henvises til videre udredning i henhold til gældende Esophaguscancerpakke. Ved øvrige benigne patologiske tilstande kan patienten henvises til opfølgning og udredning på medicinsk gastroenterologisk afdeling. Kontraindiceret: Der må IKKE anvendes: - Brækmidler - Blind nedføring af tænger, bougier eller sonder Udskrivelse: Ved ukompliceret forløb: kan patienten udskrives efter 6 timers observation. Ved komplicerede forløb: vurderes udskrivelse individuelt Referencer, lovgivning og faglig evidens samt links hertil - Dansk radiologisk selskab: Vejledninger vedrørende radiologiske procedurer, 2. udgave marts 2003 - Loh KS, Tan LK, Smith JD, Yeoh KH, Dong F.: Complications of foreign bodies in the esophagus. Otolaryngol Head Neck Surg. 2000 Nov;123(5):613-6. PMID: 11077351 [PubMed - indexed for MEDLINE] - Lacy PD, Donnelly MJ, McGrath JP, Byrne PJ, Hennessy TP, Timon CV.: Acute food bolus impaction: aetiology and management. J Laryngol Otol. 1997 Dec;111(12):1158-61. PMID: 9509106 [PubMed - indexed for MEDLINE] - Instruks for empirisk antibiotikaterapi, Hjertecentrets intensivterapi, Rigshospitalet 2009. http://www.rh-vejledninger.dk/CMS/PVI/rh-vejledninger.nsf/0/1e9d9cc21c4f6952c12576410059c8e8/$FILE/antibiotikainstruks4141_17.pdf Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag

<h1><div id="Afsnit#1699579282347">Fremmedlegeme i oesophagus</div></h1><div id="BodyWeb#1699579282347"><p><a name="1699579282347Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579282347Maalgrupper">Målgrupper og anvendelsesområde</a></h3> <p>&nbsp;</p> <p>Lægefagligt personale i Afdeling for Øre-Næse-Halskirurgi og Audiologi</p> <p>Voksne patienter,&nbsp;alder 16 år eller ældre,&nbsp;med fremmedlegemer i oesophagus</p> <h3>&nbsp;<a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579282347Definitioner">Definitioner</a></h3> <h3>Fremmedlegemer i oesophagus dækker over synkestop efter indtagelse af føde bolus samt fastsiddende objekter såsom legetøj, mønter, ben og lignende.<br> Fremmedlegeme i oesophagus er en akut tilstand idet der potentielt er perforationsrisiko.<br> <br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579282347Fremgangsmaade">Fremgangsmåde</a></h3> <h3>Forud for speciale afsnit:</h3> <p>Patienterne ses typisk på skadestue eller hos vagtlægen og viderevisiteres læge til læge.</p> <p>Anamnesen giver som regel diagnosen, dog kan børn, demente, psykisk syge eller mentalt retarderede ikke altid redegøre for forløbet.</p> <p>Der skal differentieres mellem: Skarpt fremmedlegeme versus uskarpt samt et bud på lokalisation af fremmedlegemet og om der er tale om respirationspåvirkethed.</p> <p><strong>Visitation</strong></p> <p>Fremmedlegemer i oesophagus behandles primært hos Thoraxkirurgerne.</p> <p>Undtagelsen er respirationstruede patienter (voksne, alder 16 år eller ældre), der skal modtages af ØNH. Thoraxkirurgisk Afdeling bør informeres om patienten, idet der&nbsp;ved et&nbsp;mere distalt placeret fremmedlegeme kan blive tale om en samarbejdspatient.</p> <p><strong>Udredning:</strong></p> <p>Ved den respirationstruede patient sidder fremmedlegemet typisk i hypopharynx eller den øverste del af oesophagus.</p> <p>Ved et røntgenfast fremmedlegeme kan man overveje et simpelt røntgen af thorax, dog ikke på bekostning af patientens tilstand.</p> <p>Såfremt der er mistanke om <u>et ikke-røntgenfast fremmedlegeme</u> så som ben eller lignende, kan der udføres røntgen af oesophagus, først med kontrast og derefter skylles med vand, hvorefter fremmedlegemet visualiseres.</p> <h4>Journaloptagelse:</h4> <h4>I journalen anføres / dokumenteres følgende:</h4> <p>&nbsp;</p> <ul> <li>&nbsp;Hvorvidt fremmedlegemet er skarpt / uskarpt</li> <li>&nbsp;Fremmedlegemets / synkestoppets lokalisation</li> <li>Tidligere synkestop eller nærsynkestop</li> <li>Vægttab</li> <li>Dyspepsier</li> <li>Anvendelse af antacida</li> <li>Smerter i brystet, retrosternalt, i ryggen, epigastriet</li> </ul> <h4>Objektiv undersøgelse:</h4> <p>Undersøgelsen omfatter:</p> <ul> <li>Febrilia</li> <li>Spytflod</li> <li>Hoste</li> <li>Hæshed</li> <li>Stridor</li> <li>Lokaliseret ømhed på halsen</li> <li>Subkutant emfysem på halsen.</li> </ul> <h4>Blodprøver:</h4> <p>Vanlige præoperative prøver. Det vil sige, at ved en i øvrigt rask patient er der ikke indikation for blodprøver.</p> <p>&nbsp;</p> <h4>Anæstesi:</h4> <p>Der er ikke indikation for at faste 6 timer. Patienten skal være totalt relaxeret under universiel anæstesi.</p> <p>&nbsp;</p> <h4>Behandling:</h4> <p>Der skønnes mellem følgende patientkategorier:</p> <p>&nbsp;</p> <h4><u>1: Skarpt fremmedlegeme:</u></h4> <p>Skarpt fremmedlegeme bør fjernes akut.</p> <p>Der kan indledes med laryngoskop og ofte vil fremmedlegemet være synligt i hypopharynx og kan fjernes med fremmedlegemetang.<br> Der anvendes stift oesophagoskop til fremmedlegemer i øverste og midterste del af oesophagus, mens der distalt anvendes flexibelt skop.<br> Afslutningsvis kan gøres flexibel oesophagoskopi, hvor oesophagus efterses fra ventriklen og kranielt for perforationer, rifter eller øvrig patologi. Såfremt der findes tegn på patologi tages der relevante biopsier og evt. billeder af dette.</p> <p>&nbsp;</p> <h4><u>2: Synkestop højtsiddende respirationspåvirket pt.:</u></h4> <p>&nbsp;<br> &nbsp;</p> <p>Synkestop højtsiddende bør fjernes akut.<br> Synkestop her passerer sjældent spontant og patienten er ofte med påvirket respiration p.gr.a. kraftigt spytflåd/risiko for aspiration.<br> Man kan evt. i ventetiden på anæstesi anlægge nasalsonde hvor der kan aspireres spyt forsigtigt efter behov. Der må ikke forsøges at skubbe fødeemnet distalt.</p> <p>&nbsp;</p> <h4>Postoperativt:</h4> <p>&nbsp;</p> <p><strong>Ved ukompliceret fjernelse af fremmedlegeme / fødebolus</strong> kan patienten drikke umiddelbart efter opvågning.</p> <p><strong>Ved mistanke om rift eller perforation peroperativt</strong> skal der nedlægges nasogastrisk sonde og foretages rtg.af oesophagus med vandigt kontrast.<br> På mistanke om perforation sættes patienten i behandling med: iv Zinacef&nbsp; 1500mg&nbsp; x 3 og iv <a href="http://www.lmk.dk/(pv35pyiu4g0hxh45qjzkrt45)/show.aspx">Metronidazol </a>500 mg x 3.<br> Patienten skal faste,&nbsp; observeres med VAS, temperatur og for subcutant emfysem.</p> <p><strong>Ved sikker perforation: </strong>Tilkald thoraxkirurgierne mhp. thoracotomi/ stent behandling og opstart antibiotisk behandling i henhold til givne thoraxkirurgiske retningslinier ref 4. ( Meropenem&nbsp; 2g x 3 iv., Ciprofloxacin 600mg x 2 iv., Metronidazol 500mg x 3 iv. og Caspofungin 70 mg iv det første døgn. eller Anidulafungin 200mg det første døgn. Behandlingvarighed&nbsp; i op til 6 uger.)</p> <h4><br> Ambulant kontrol:</h4> <p>Da op til 80% af patienter med synkestop har en tilgrundliggende patologi såsom dysmotilitet, eosophagit, Schatzki´s ring, tumor, reflux, webdannelse eller andet, er det vigtigt, at patienten bliver fulgt op.</p> <p><strong>Såfremt der er taget biopsier,</strong> skal patienten ligeledes komme til svar på disse i ambulatoriet.<br> Ved fund af malignitet skal patienten henvises til videre udredning i henhold til gældende Esophaguscancerpakke. Ved øvrige benigne patologiske tilstande kan patienten henvises til opfølgning og udredning på medicinsk gastroenterologisk afdeling.</p> <p>&nbsp;</p> <h4>Kontraindiceret:</h4> <p>&nbsp;</p> <p><strong>Der må IKKE anvendes:</strong></p> <ul> <li>&nbsp;Brækmidler</li> <li>&nbsp;Blind nedføring af tænger, bougier eller sonder</li> </ul> <p>&nbsp;</p> <h4>Udskrivelse:</h4> <p>&nbsp;</p> <p>Ved ukompliceret forløb: kan patienten udskrives efter 6 timers observation.<br> <br> Ved komplicerede forløb: vurderes udskrivelse individuelt</p> <h3>&nbsp;</h3> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579282347Ansvar">&nbsp;</a></p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579282347Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> &nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <ol> <li><a href="http://www.drs.dk/guide.htm"><strong>Dansk radiologisk selskab: Vejledninger vedrørende radiologiske procedurer, 2. udgave marts 2003</strong></a></li> <li><strong>Loh KS, Tan LK, Smith JD, Yeoh KH, Dong F.:</strong> Complications of foreign bodies in the esophagus. Otolaryngol Head Neck Surg. 2000 Nov;123(5):613-6. PMID: 11077351 [PubMed - indexed for MEDLINE]</li> <li><strong>Lacy PD, Donnelly MJ, McGrath JP, Byrne PJ, Hennessy TP, Timon CV.:</strong> Acute food bolus impaction: aetiology and management. J Laryngol Otol. 1997 Dec;111(12):1158-61. PMID: 9509106 [PubMed - indexed for MEDLINE]</li> <li>Instruks for empirisk antibiotikaterapi, Hjertecentrets intensivterapi, Rigshospitalet 2009.&nbsp; <a href="http://www.rh-vejledninger.dk/CMS/PVI/rh-vejledninger.nsf/0/1e9d9cc21c4f6952c12576410059c8e8/$FILE/antibiotikainstruks4141_17.pdf">http://www.rh-vejledninger.dk/CMS/PVI/rh-vejledninger.nsf/0/1e9d9cc21c4f6952c12576410059c8e8/$FILE/antibiotikainstruks4141_17.pdf</a></li> </ol> <h3><br> &nbsp;</h3> <h2><a name="1699579282347Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579282347Top">Tilbage til top</a></p> <h2><a name="1699579282347Definitioner"></a><br> Definitioner</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579282347Top">Tilbage til top</a></p> <h2><a name="1699579282347Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579282347Top">Tilbage til top</a></p> <h2><a name="1699579282347Ansvar"></a><br> Ansvar og organisering</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579282347Top">Tilbage til top</a></p> <h2><a name="1699579282347Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579282347Top">Tilbage til top</a></p> <h2><a name="1699579282347Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579282347Top">Tilbage til top</a></p> <h2><a name="1699579282347Bilag"></a><br> Bilag</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579282347Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Godkendelse revision og udgivelse af dokumenter.

Godkendelse, revision og udgivelse af dokumenter i Afdeling for Øre-Næse-Halskirurgi og Audiologi Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Målgrupper og anvendelsesområde Alle ansatte i Afdeling for Øre-Næse-Halskirurgi og Audiologi. Alle VIP og pjecer der udarbejdes i afdelingen og udgives på VIP portalen eller intra- og internet, følger nedenstående retningslinjer. Definitioner Redaktør: medarbejder med ansvar for udgivelsen af færdiggodkendte VIP dokumenter og pjecer samt den tekniske vedligeholdelse. VIP: Vejledning, Instruks, Politik VIP-ansvarlig: Sygeplejespecialist ansvarlig for sygepleje VIPér samt forløbsbeskrivelser. Sektionsansvarlig overlæge: Overlæge ansvarlig for enten otologi (rød søjle), næse-bihuler (blå søjle), cancer (gul søjle) eller audiologien. Fremgangsmåde Udarbejdelse: Ved oprettelsen af nye VIP’er og pjecer udarbejder forfatteren dokumentet i de gældende skabeloner og formater, som findes på vip-portalen (vip.regionh.dk) under ikonet ’Forfattermiljø’ eller for pjecer som Word-dokument. Revision: VIP Redaktøren får besked fra VIP portalen om dokumenter, der skal revideres. Redaktøren sender besked til relevant lægefaglig sektionsansvarlig eller VIP-ansvarlig for sygeplejen, som giver besked til forfatterne. Er dette ikke muligt, udpeger den lægefaglige sektionsansvarlige en ny forfatter. Det endelige dokument sendes som Word-dokument til redaktøren. Pjecer Redaktøren sender besked til den pjece-ansvarlige, der følger samme procedure som for VIP. Fra redaktøren har fremsendt dokumentet til relevant lægefaglig sektionsansvarlig eller sygeplejefaglig ansvarlig, til dokumentet tilbagesendes i revideret tilstand, må højest gå 2 måneder. Godkendelse: Dokumentet (nyt eller revideret) sendes til relevant lægefaglig sektionsansvarlig og sygeplejefaglig godkender. Eventuelle rettelser sendes til forfatterne. Når et dokument er godkendt af relevant lægefaglig sektionsansvarlig og sygeplejefaglig godkender, sendes dette til endelig godkendelse hos afdelingsledelsen. Udgivelse: VIP-redaktør sørger for at det færdige dokument udgives på VIP-portalen. Pjeceansvarlig redaktør udgiver pjecen på intra- og internet. Når dokumentet er udgivet på VIP portalen, giver lægefaglig eller sygeplejefaglig VIP-ansvarlig besked til alle ansatte i afdelingen via mail. Det påhviler de sektionsansvarlige og afsnitsledelserne at lede implementeringen af den ændrede/nye procedure. I forbindelse med implementeringen af større vejledninger og instrukser, både interne, Rigshospitals og regionale, informeres desuden på morgenmøder og i nyhedsbreve. Ansvar og organisering Afdelingsledelsen

<h1><div id="Afsnit#1699579271329">Godkendelse, revision og udgivelse af dokumenter i Afdeling for Øre-Næse-Halskirurgi og Audiologi</div></h1><div id="BodyWeb#1699579271329"><p><a name="1699579271329Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579271329Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579271329Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579271329Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579271329Ansvar">Ansvar og organisering</a><br> &nbsp;</h3> <h2><a name="1699579271329Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p style="margin-left:10pt; margin-right:0cm">Alle ansatte i Afdeling for Øre-Næse-Halskirurgi og Audiologi. Alle VIP og pjecer der udarbejdes i afdelingen og udgives på VIP portalen eller intra- og internet, følger nedenstående retningslinjer.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579271329Top">Tilbage til top</a></p> <h2><a name="1699579271329Definitioner"></a><br> Definitioner</h2> <p><strong>Redaktør</strong>: medarbejder med ansvar for udgivelsen af færdiggodkendte VIP dokumenter og pjecer&nbsp;samt den tekniske vedligeholdelse.</p> <p><strong>VIP</strong>: Vejledning, Instruks, Politik</p> <p><strong>VIP-ansvarlig:&nbsp;</strong>Sygeplejespecialist ansvarlig for sygepleje VIPér samt forløbsbeskrivelser.</p> <p>Sektionsansvarlig overlæge: Overlæge ansvarlig for enten otologi (rød søjle), næse-bihuler (blå søjle),</p> <p>cancer (gul søjle) eller audiologien.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579271329Top">Tilbage til top</a></p> <h2><a name="1699579271329Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p><strong>Udarbejdelse:</strong><br> Ved oprettelsen af nye VIP’er og pjecer udarbejder forfatteren dokumentet i de gældende skabeloner og formater, som findes på vip-portalen (vip.regionh.dk) under ikonet ’Forfattermiljø’ eller for pjecer som Word-dokument.</p> <p><strong>Revision</strong>:</p> <p><strong>VIP</strong><br> Redaktøren får besked fra VIP portalen om dokumenter, der skal revideres. Redaktøren sender besked til relevant lægefaglig sektionsansvarlig eller&nbsp;VIP-ansvarlig for sygeplejen, som giver besked til forfatterne. Er dette ikke muligt, udpeger den lægefaglige sektionsansvarlige en ny forfatter.&nbsp; Det endelige dokument sendes som Word-dokument&nbsp;til redaktøren.</p> <p><strong>Pjecer</strong></p> <p>Redaktøren sender besked til den pjece-ansvarlige, der følger samme procedure som for VIP.</p> <p>Fra redaktøren har fremsendt dokumentet til relevant lægefaglig sektionsansvarlig eller sygeplejefaglig ansvarlig, til dokumentet tilbagesendes i revideret tilstand, må højest gå 2 måneder.</p> <p><strong>Godkendelse:</strong><br> Dokumentet (nyt eller revideret) sendes til relevant lægefaglig sektionsansvarlig og sygeplejefaglig godkender.&nbsp; Eventuelle rettelser sendes til forfatterne.</p> <p>Når et dokument er godkendt af relevant lægefaglig sektionsansvarlig og sygeplejefaglig godkender, sendes dette til endelig godkendelse hos afdelingsledelsen.</p> <p><strong>Udgivelse:</strong></p> <p>VIP-redaktør&nbsp;sørger for at det færdige dokument udgives på VIP-portalen.&nbsp;Pjeceansvarlig redaktør udgiver pjecen på intra- og internet.</p> <p>Når dokumentet er udgivet på VIP portalen, giver lægefaglig eller sygeplejefaglig VIP-ansvarlig&nbsp;besked til alle ansatte i afdelingen&nbsp;via mail. Det påhviler de sektionsansvarlige og afsnitsledelserne at lede implementeringen af den ændrede/nye procedure. I forbindelse med implementeringen af større vejledninger og instrukser, både interne, Rigshospitals og regionale, informeres desuden på morgenmøder og i nyhedsbreve<em>. </em></p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579271329Top">Tilbage til top</a></p> <h2><a name="1699579271329Ansvar"></a><br> Ansvar og organisering</h2> <p>&nbsp;Afdelingsledelsen</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579271329Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Helen-test til voksne CI-klienter.

Helen-test til voksne CI-klienter Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Målgrupper og anvendelsesområde Personale der arbejder med CI-klienter på Hørepædagogisk afsnit Definitioner CI = cochlear implant Fremgangsmåde ###NAVN###-test til voksne med Cochlear Implant Helentesten er en skelneprøve, som foregår med Live Speech, i et roligt rum, hvor støjen kan kontrolleres. Hver test består af en liste med 25 simple spørgsmål. Testen er vejledende og er ikke en sikker skelneprøve. Testens udførelse Testningen udgøres af: 1. Præsentation af testen samt gennemgang af proceduren ved øveliste 00 eller 0. 2. Den Audiovisuelle (AV) test, dvs. testeren sidder en meter foran CI-klienten og læser sætninger fra en oplæsningsliste med ulige nummer. For hver sætning afventes klientens svar. Rigtigt svar markeres med et plus ud for den givne sætning, forkerte eller ingen svar markeres med et minus. Når alle spørgsmål er gennemgået, opgøres antallet af rigtige svar, som noteres på testarkets hoved. 3. Den Auditive (A) test, hvor proceduren er lig med AV-testen, bortset fra, a) at testeren skjuler munden bag et stykke papir eller sørger for på anden vis, at mundaflæsning ikke er muligt, og b) der anvendes en oplæsningsliste med lige nummer. Spørgsmålene må kun læses op én gang. Spørgsmål, der kun kan besvares, såfremt de gentages, noteres som forkert besvaret. Kan klienten ikke besvare de første fem spørgsmål, stoppes test, og der noteres ”0 rigtige” på arkets hoved. Hver test foretages som den første aktivitet i forbindelse med klientens kontrolbesøg af cochlea implant. Testen skal foretages som klienten anvender sin processor bedst og med høreapparat, hvis klienten anvender det. Evt. kan HA eller 1. CI tages af pga. lofteffekt. Forventet tidsforbrug: 20 - 30 minutter. Resultaterne opgøres som antal rigtige ud af 25 og registreres i Cochleaimplant databasen i modulet Helen under Patientdata, samt noteres i den tekniske journal og rapporten, som sendes til klientens Tale- og hørepædagog. Resultatet må ikke omregnes til procent. Testtidspunkter 1. test, en måned efter switch on. Der anvendes liste 1 til AV-testen og liste 2 til A-testen. 2. test ca. et halvt år efter switch on. Der anvendes liste 3 til AV-testen og liste 4 til A-testen. 3. test ca. et år efter switch on. Der anvendes liste 5 til AV-testen og liste 6 til A-testen. 4. test ca. to år efter switch on. Der anvendes liste 7 til AV-testen og liste 8 til A-testdelen. Herefter testes, når der er behov for det. Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag

<h1><div id="Afsnit#1699579389438">Helen-test til voksne CI-klienter</div></h1><div id="BodyWeb#1699579389438"><p><a name="1699579389438Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579389438Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579389438Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579389438Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579389438Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579389438Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579389438Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579389438Bilag">Bilag</a><br> &nbsp;</h3> <h2><a name="1699579389438Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p>Personale der arbejder med CI-klienter på Hørepædagogisk afsnit&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579389438Top">Tilbage til top</a></p> <h2><a name="1699579389438Definitioner"></a><br> Definitioner</h2> <p>CI = cochlear implant&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579389438Top">Tilbage til top</a></p> <h2><a name="1699579389438Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p>&nbsp;</p> <p><strong>###NAVN###-test til voksne med Cochlear Implant</strong></p> <p>Helentesten er en skelneprøve, som foregår med Live Speech, i et roligt rum, hvor støjen kan kontrolleres. Hver test består af en liste med 25 simple spørgsmål. Testen er vejledende og er ikke en sikker skelneprøve.</p> <p><strong>Testens udførelse</strong><br> Testningen udgøres af:</p> <p>1. <u>Præsentation</u> af testen samt gennemgang af proceduren ved øveliste 00 eller 0.</p> <p>2. <u>Den Audiovisuelle (AV) test</u>, dvs. testeren sidder en meter foran CI-klienten og læser sætninger fra en oplæsningsliste med ulige nummer. For hver sætning afventes klientens svar. Rigtigt svar markeres med et plus ud for den givne sætning, forkerte eller ingen svar markeres med et minus. Når alle spørgsmål er gennemgået, opgøres antallet af rigtige svar, som noteres på testarkets hoved.</p> <p>3. <u>Den Auditive (A) test</u>, hvor proceduren er lig med AV-testen, bortset fra,</p> <p>a) at testeren skjuler munden bag et stykke papir eller sørger for på anden vis, at mundaflæsning ikke er muligt, og</p> <p>b) der anvendes en oplæsningsliste med lige nummer.</p> <p>Spørgsmålene må kun læses op én gang. Spørgsmål, der kun kan besvares, såfremt de gentages, noteres som forkert besvaret.<br> <br> <em>Kan klienten ikke besvare de første fem spørgsmål, stoppes test, og der noteres ”0 rigtige” på arkets hoved.</em><br> <br> Hver test foretages som den første aktivitet i forbindelse med klientens kontrolbesøg af cochlea implant.<br> <br> Testen skal foretages som klienten anvender sin processor bedst og med høreapparat, hvis klienten anvender det. Evt. kan HA eller 1. CI tages af pga. lofteffekt.<br> <br> Forventet tidsforbrug: 20 - 30 minutter.<br> <br> Resultaterne opgøres som antal rigtige ud af 25 og registreres i Cochleaimplant databasen i modulet Helen under Patientdata, samt noteres i den tekniske journal og rapporten, som sendes til klientens Tale- og hørepædagog. Resultatet må ikke omregnes til procent.<br> <br> <strong>Testtidspunkter</strong><br> <br> 1. test, en måned efter <em>switch on</em>. Der anvendes liste 1 til AV-testen og liste 2 til A-testen.<br> 2. test ca. et halvt år efter switch on. Der anvendes liste 3 til AV-testen og liste 4 til A-testen.<br> 3. test ca. et år efter switch on. Der anvendes liste 5 til AV-testen og liste 6 til A-testen.<br> 4. test ca. to år efter switch on. Der anvendes liste 7 til AV-testen og liste 8 til A-testdelen.<br> <br> Herefter testes, når der er behov for det.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579389438Top">Tilbage til top</a></p> <h2><a name="1699579389438Ansvar"></a><br> Ansvar og organisering</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579389438Top">Tilbage til top</a></p> <h2><a name="1699579389438Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579389438Top">Tilbage til top</a></p> <h2><a name="1699579389438Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579389438Top">Tilbage til top</a></p> <h2><a name="1699579389438Bilag"></a><br> Bilag</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579389438Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Hoved-halscancer patienter Ambulant sygeplejefaglig opf¢lgning på.

Hoved-halscancer patienter, Ambulant sygeplejefaglig opfølgning på Formål Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Formål At alle nye patienter i kræftpakkeforløb, får en ensartet og samtidigt individuelt tilpasset sygeplejefaglig opfølgning og information i forbindelse med forundersøgelse, histologisvar, forberedelse til operation eller overgang til onkologisk afdeling, idet patienter der henvises til ambulatoriet i kræftpakkeforløb, gennemgår accelererede forløb, der kan medføre usikkerhed hos patienten og tab af informationer. Målgrupper og anvendelsesområde Sygeplejefagligt personale i ambulatoriet Fremgangsmåde Forundersøgelse Sygeplejersken bør være opmærksom på følgende problemområder eller behov hos patienten: Smerter, ernæring, rygning, alkohol, motion. Endvidere psykosocial status: sygeplejersken undersøger om patienten har psykosociale behov/problemer og om evt. pårørende har behov for støtte samt sikrer sig, at patienten har forstået udrednings- og/eller behandlingsplanen. Ved operationsforberedelse forud for operation udleveres kontaktkort med navn på operatør samt kontaktoplysninger til dennes sekretær, forløbskoordinator samt navn på den sygeplejerske, de har talt med. Histologisvar Der skal altid være en sygeplejerske til stede ved samtalen. Lægen informerer patienten om histologisvaret og den videre plan, herunder evt. yderligere undersøgelser. Sygeplejersken sikrer, at patienten har forstået informationen og støtter med supplerende oplysninger. Uddybende patientinformation (se nedenstående) kan foregå i samtalerum eller i sygeplejeambulatorium. Her skal sygeplejersken være opmærksom på patientens behov for omsorg, psykisk støtte, inddragelse af pårørende og sikre at patientens psykiske tilstand er stabil før han/hun forlader afdelingen. Patienten medgives relevante pjecer, herunder ’Information om behandling af kræft i hovedhalsområdet’. Det sikres, at patienten har kontaktoplysninger til operatørens sekretær og til forløbskoordinator. Dokumentation Sygeplejersken udfylder sygeplejejournal ved hjælp af fritekst i et Samtalenotat i Sundhedsplatformen. Sygeplejefaglig opfølgning og patientinformation Patientinformationen baseres på patientens individuelle behov og under hensyntagen til dennes psykiske tilstand efter det maligne svar. Informationen bør omfatte alle nedenstående områder, men det må bero på et individuelt skøn, i hvor stort omfang der skal gås i dybden med hvert område. Den sygeplejefaglige opfølgning baseres på patientens problemer/behov i følge nedenstående retningslinjer. (Retningslinierne omfatter ikke specifik opfølgning eller støtte ifm. alkolholoverforbrug eller –misbrug, samt motion. Det skønnes vanskeligt for patienten at arbejde med for mange områder i relation til egenomsorg på én gang, set i sammenhæng med en nylig malign diagnose. Ifm. patientens behandling er nedenstående områder af større betydning.) Smerter Patienten NRS-scores, og ved behov startes smertebehandling op i samarbejde med lægen. Se VIP: Smertescoring i Afdeling for Øre-Næse-Halskirurgi og Audiologi, Rigshospitalet. Ernæring For at forebygge/minimere behandlingsudløste ernæringsproblemer skal der gennem hele forløbet gøres en indsats for at hjælpe patienten til at holde vægten. Patienten skal informeres om, at sondeernæring kan blive nødvendigt Dette gøres ved at: Patienten ernæringsscreenes jf. afdelingens vejledning om ernæringsscreening (Ernæringsscreening i Afdeling for Øre-Næse-Halskirurgi og Audiologi) og evt. ernæringsmæssige problemer afdækkes. Ved vægttab angives dette og over hvilket tidsrum. Man bør være opmærksom på om patienten kan være i risiko for at udvikle refeeding syndrom (refeeding syndrom, udredning, behandling, pleje og forebyggelse til voksne over 16 år) Patienten informeres om og vejledes i at stabilisere eller øge vægten før operation eller strålebehandling. Patienten informeres om at sondeernæring kan blive nødvendig på et senere tidspunkt i forløbet. Patienten får udleveret relevante pjecer vedrørende ernæring. Ved behov for tværfaglig vurdering og/eller behandling af patienten, kan denne bookes til det tværfaglige ambulatorie. Rygning Det er dokumenteret, at effekten af strålebehandlingen reduceres betragteligt, hvis patienten ryger i strålebehandlingsperioden. Der ses desuden dårligere sårheling samt andre operationskomplikationer hos rygere i forbindelse med operation. Derfor skal patienten opfordres til at holde op med at ryge og informeres om mulige støttemuligheder i den forbindelse. Dette gøres ved at: Patienten orienteres om vigtigheden af rygereduktion eller rygeophør. Det understreges, at effekten af strålebehandlingen øges, samt sårheling og andre operationskomplikationer formindskes, hvis rygning undgås. Patienten får udleveret relevant skriftlig information om rygestop og bliver oplyst om Stoplinien - tlf: ###TELEFON### eller www.stoplinien.dk, samt mulighed for samtale med afdelingens rygestopkonsulent Vær opmærksom på: Center for Kræft og Sundhed i København som tilbyder hjælp til borgere i Københavns Kommune med en kræftdiagnose. Ansvar og organisering Afdelingsledelsen Bilag Pjece: Rygestop og operation

<h1><div id="Afsnit#1699579340584">Hoved-halscancer patienter, Ambulant sygeplejefaglig opfølgning på</div></h1><div id="BodyWeb#1699579340584"><p><a name="1699579340584Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579340584Formaal">Formål</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579340584Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579340584Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579340584Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579340584Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579340584Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579340584Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579340584Bilag">Bilag</a><br> &nbsp;</h3> <p><a name="1699579340584Formaal"></a></p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Formål</span></strong></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">At alle nye patienter i kræftpakkeforløb, får en ensartet og samtidigt individuelt tilpasset sygeplejefaglig opfølgning og information i forbindelse med forundersøgelse, histologisvar, forberedelse til operation eller overgang til onkologisk afdeling, idet patienter der henvises til ambulatoriet i kræftpakkeforløb, gennemgår accelererede forløb, der kan medføre usikkerhed hos patienten og tab af informationer.</span></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#0000ef">Tilbage til top</span></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Målgrupper og anvendelsesområde</span></strong></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#222222">Sygeplejefagligt personale i ambulatoriet</span></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#0000ef">Tilbage til top</span></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong>Fremgangsmåde</strong></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong>Forundersøgelse</strong></p> <p style="margin-left:0cm; margin-right:0cm">Sygeplejersken bør være opmærksom på følgende problemområder eller behov hos patienten:</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm">Smerter, ernæring, rygning, alkohol, motion.</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm">Endvidere psykosocial status: sygeplejersken undersøger om patienten har psykosociale behov/problemer og om evt. pårørende har behov for støtte samt sikrer sig, at patienten har forstået udrednings- og/eller behandlingsplanen.</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm">Ved operationsforberedelse forud for operation udleveres kontaktkort med navn på operatør samt kontaktoplysninger til dennes sekretær, forløbskoordinator samt navn på den sygeplejerske, de har talt med.</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong>Histologisvar</strong></p> <p style="margin-left:0cm; margin-right:0cm">Der skal altid være en sygeplejerske til stede ved samtalen. Lægen informerer patienten om histologisvaret og den videre plan, herunder evt. yderligere undersøgelser. Sygeplejersken sikrer, at patienten har forstået informationen og støtter med supplerende oplysninger.</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm">Uddybende patientinformation (se nedenstående) kan foregå i samtalerum eller i sygeplejeambulatorium. Her skal sygeplejersken være opmærksom på patientens behov for omsorg, psykisk støtte, inddragelse af pårørende og sikre at patientens psykiske tilstand er stabil før han/hun forlader afdelingen.</p> <p style="margin-left:0cm; margin-right:0cm">Patienten medgives relevante pjecer, herunder <a href="https://intranet.regionh.dk/pim/Lists/PDPDocuments/Information-om-behandling-af-kraeft-i-hoved-halsomraadet-30356.pdf" style="color:#0563c1; text-decoration:underline">’Information om behandling af kræft i hovedhalsområdet</a>’.</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm">Det sikres, at patienten har kontaktoplysninger til operatørens sekretær og til forløbskoordinator.</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong>Dokumentation</strong></p> <p style="margin-left:0cm; margin-right:0cm">Sygeplejersken udfylder sygeplejejournal ved hjælp af fritekst i et Samtalenotat i Sundhedsplatformen.</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong>Sygeplejefaglig opfølgning og patientinformation</strong></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm">Patientinformationen baseres på patientens individuelle behov og under hensyntagen til dennes psykiske tilstand efter det maligne svar. Informationen bør omfatte alle nedenstående områder, men det må bero på et individuelt skøn, i hvor stort omfang der skal gås i dybden med hvert område.</p> <p style="margin-left:0cm; margin-right:0cm">Den sygeplejefaglige opfølgning baseres på patientens problemer/behov i følge nedenstående retningslinjer.</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><em>(Retningslinierne omfatter ikke specifik opfølgning eller støtte ifm. alkolholoverforbrug eller –misbrug, samt motion. Det skønnes vanskeligt for patienten at arbejde med for mange områder i relation til egenomsorg på én gang, set i sammenhæng med en nylig malign diagnose. Ifm. patientens behandling er nedenstående områder af større betydning.)</em></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Smerter</span></strong></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Patienten NRS-scores, og ved behov startes smertebehandling op i samarbejde med lægen. Se VIP: </span><a href="https://vip.regionh.dk/VIP/Admin/GUI.nsf/Desktop.html?open&amp;openlink=https://vip.regionh.dk/VIP/Slutbruger/Portal.nsf/Main.html?open&amp;unid=X5F9326C77C279A1FC1257959005CCA0D&amp;level=130126&amp;dbpath=/VIP/Redaktoer/130126.nsf/&amp;windowwidth=1100&amp;windowheight=600&amp;windowtitle=S%F8g" style="color:#0563c1; text-decoration:underline">Smertescoring i Afdeling for Øre-Næse-Halskirurgi og Audiologi, Rigshospitalet</a><span style="color:#0000ef">.</span></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Ernæring</span></strong></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">For at forebygge/minimere behandlingsudløste ernæringsproblemer skal der gennem hele forløbet gøres en indsats for at hjælpe patienten til at holde vægten. Patienten skal informeres om, at sondeernæring kan blive nødvendigt</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Dette gøres ved at: Patienten ernæringsscreenes jf. afdelingens vejledning om ernæringsscreening (</span><span style="color:#0000ef">Ernæringsscreening i Afdeling for Øre-Næse-Halskirurgi og Audiologi) </span><span style="color:black">og evt. ernæringsmæssige problemer afdækkes. Ved vægttab angives dette og over hvilket tidsrum. Man bør være opmærksom på om patienten kan være i risiko for at udvikle refeeding syndrom (</span><span style="color:#0000ef">refeeding syndrom, udredning, behandling, pleje og forebyggelse til</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#0000ef">voksne over 16 år</span><span style="color:black">)</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Patienten informeres om og vejledes i at stabilisere eller øge vægten før operation eller strålebehandling.</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Patienten informeres om at sondeernæring kan blive nødvendig på et senere tidspunkt i forløbet.</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Patienten får udleveret relevante pjecer vedrørende ernæring.</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Ved behov for tværfaglig vurdering og/eller behandling af patienten, kan denne bookes til det tværfaglige ambulatorie. </span></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Rygning</span></strong></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Det er dokumenteret, at effekten af strålebehandlingen reduceres betragteligt, hvis patienten ryger i strålebehandlingsperioden. Der ses desuden dårligere sårheling samt andre operationskomplikationer hos rygere i forbindelse med operation. Derfor skal patienten opfordres til at holde op med at ryge og</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">informeres om mulige støttemuligheder i den forbindelse.</span></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Dette gøres ved at:</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Patienten orienteres om vigtigheden af rygereduktion eller rygeophør. Det understreges, at effekten af strålebehandlingen øges, samt sårheling og andre operationskomplikationer formindskes, hvis rygning undgås.</span></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Patienten får udleveret relevant skriftlig information om rygestop og bliver oplyst om Stoplinien - tlf: ###TELEFON### eller </span><a href="http://www.stoplinien.dk" style="color:#0563c1; text-decoration:underline">www.stoplinien.dk</a><span style="color:black">, samt mulighed for samtale med afdelingens rygestopkonsulent</span></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Vær opmærksom på:</span></strong></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Center for Kræft og Sundhed i København som tilbyder hjælp til borgere i Københavns Kommune med en kræftdiagnose.</span></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#0000ef">Tilbage til top</span></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Ansvar og organisering</span></strong></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Afdelingsledelsen</span></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#0000ef">Tilbage til top</span></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:black">Bilag</span></strong></p> <p style="margin-left:0cm; margin-right:0cm">Pjece: <a href="https://intranet.regionh.dk/pim/Lists/PDPDocuments/Rygestop-og-operation-30325.pdf" style="color:#0563c1; text-decoration:underline">Rygestop og operation</a></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#0000ef">Tilbage til top</span></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_H¢jrisiko områder i ¥re-næse-halskirurgisk og Audiologisk.

Højrisiko områder i Øre-næse-halskirurgisk og Audiologisk Klinik Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Målgrupper og anvendelsesområde Personale i Øre-næse-halskirurgisk og Audiologisk Klinik Fremgangsmåde Følgende højrisiko-områder er gældende i Øre-næse-halskirurgisk Klinik: Område: VIP: Luftvejsobstruktion Trachealkanyle, Skiftning af Stridor, Sygepleje til patienter med Tracheostomi, Pleje af patienter med Trachealkanyle, Skiftning af i ambulatoriet Epiglottitis acuta Epistaxis Epistaxis, Behandling og pleje af patienter med Behandling og pleje af lap patienter Lapkirurgi, Behandling postoperativt Pectoralis major lap, Pleje af patienter med Reblødning efter tonsillectomi Tonsilefterblødning, Behandling og pleje af Modtagelse af akutte patienter aften og nat Vurdering af patienten indlagt i Afdeling for Øre-Næse-Halskirurgi og Audiologi, sengeafsnit Følgende højrisiko områder er gældende i Tand-mund.kæbekirurgisk Klinik: Fractura Colli Mandibulae HØJRISIKO, Fractura colli mandibulae, Kliniske retningslinjer for behandling Efterblødning efter dento-alveolære kirurgiske indgreb HØJRISIKO, Efterblødning efter dento-alveolære kirurgiske indgreb Absces HØJRISIKO, Absces Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag

<h1><div id="Afsnit#1699579322423">Højrisiko områder i Øre-næse-halskirurgisk og Audiologisk Klinik</div></h1><div id="BodyWeb#1699579322423"><p> <a name="1699579322423Top"></a></p> <h3> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579322423Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579322423Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579322423Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579322423Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579322423Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579322423Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579322423Bilag">Bilag</a><br> &nbsp;</h3> <h2> <a name="1699579322423Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p> &nbsp;Personale i Øre-næse-halskirurgisk og Audiologisk Klinik</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579322423Top">Tilbage til top</a></p> <h2> &nbsp;</h2> <h2> <a name="1699579322423Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p> <strong>Følgende højrisiko-områder er gældende i Øre-næse-halskirurgisk Klinik:</strong></p> <p> <strong>Område:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;VIP: </strong></p> <p> <em>Luftvejsobstruktion</em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <a href="###FOLDER###" target="_blank">Trachealkanyle, Skiftning af</a></p> <p> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <a href="###FOLDER###" target="_blank">Stridor, Sygepleje til patienter med</a></p> <p> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <a href="###FOLDER###" target="_blank">Tracheostomi, Pleje af patienter med</a></p> <p> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <a href="###FOLDER###" target="_blank">Trachealkanyle, Skiftning af i ambulatoriet</a></p> <p> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href="###FOLDER###" target="_blank">Epiglottitis acuta</a></p> <p> &nbsp;</p> <p> <em>Epistaxis&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</em> <a href="###FOLDER###" target="_blank">Epistaxis, Behandling og pleje af patienter med</a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p> <p> &nbsp;</p> <p> <em>Behandling og pleje af lap patienter&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><a href="###FOLDER###" target="_blank">Lapkirurgi, Behandling postoperativt</a></p> <p> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <a href="###FOLDER###" target="_blank">Pectoralis major lap, Pleje af patienter med</a></p> <p> &nbsp;</p> <p> <em>Reblødning efter tonsillectomi&nbsp;&nbsp;</em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <a href="###FOLDER###" target="_blank">Tonsilefterblødning, Behandling og pleje af</a></p> <p> &nbsp;</p> <p> <em>Modtagelse af akutte patienter</em></p> <p> <em>aften og nat&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><a href="###FOLDER###" target="_blank">Vurdering af patienten indlagt i Afdeling for Øre-Næse-Halskirurgi og Audiologi, sengeafsnit</a></p> <p> &nbsp;</p> <p> <strong>Følgende højrisiko områder er gældende i Tand-mund.kæbekirurgisk Klinik:</strong></p> <p> <em>Fractura Colli Mandibulae&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><a href="###FOLDER###" target="_blank">HØJRISIKO, Fractura colli mandibulae, Kliniske retningslinjer for behandling</a></p> <p> <em>Efterblødning efter dento-alveolære</em></p> <p> <em>kirurgiske indgreb&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</em><a href="###FOLDER###" target="_blank">HØJRISIKO, Efterblødning efter dento-alveolære kirurgiske indgreb</a><em>&nbsp;</em></p> <p> <em>Absces</em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <a href="###FOLDER###" target="_blank">HØJRISIKO, Absces</a></p> <p> &nbsp;</p> <p> &nbsp;</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579322423Top">Tilbage til top</a></p> <h2> <a name="1699579322423Ansvar"></a><br> Ansvar og organisering</h2> <p> &nbsp;</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579322423Top">Tilbage til top</a></p> <h2> <a name="1699579322423Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p> &nbsp;</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579322423Top">Tilbage til top</a></p> <h2> <a name="1699579322423Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p> &nbsp;</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579322423Top">Tilbage til top</a></p> <h2> <a name="1699579322423Bilag"></a><br> Bilag</h2> <p> &nbsp;</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579322423Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_H¢rescreening af nyf¢dte på f¢destederne i.

Hørescreening af nyfødte på fødestederne i Region Hovedstadens område Midt, Syd, Byen samt Bornholm Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Målgrupper og anvendelsesområde Personale ved Rescreeningsenheden, aud. afd., GeH Definitioner Fremgangsmåde Hørescreeningen udføres med automatiseret måling af transientudløste otoakustiske emissioner (AOAE) eventuelt suppleret med automatiseret hjernestammeaudiometri – auditory brainstem responses (AABR) som en tostadiescreening. Begge ører screenes. Screening skal undgås i første levedøgn på grund af et øget antal falsk positive resultater, og skal gerne vente til barnet er 2 døgn gammelt. Der skal ved hørescreeningen sikres optimale måleomstændigheder: - Tilstrækkelig lav baggrundsstøj. - Den nyfødte skal være i passende ro. - God placering af proben i øret / tilfredsstillende lav elektrodeimpedans. Resultatet af screening af et øre er enten pass (passeret), refer (henvises) eller uafsluttet. Det sidstnævnte er udfaldet, hvis barnet under målingen vågner og bliver uroligt, eller de tilstrækkelige målebetingelser af anden årsag ikke længere er til stede. Den nærmere procedure er afhængig af, hvilken af nedennævnte kategorier, barnet tilhører: - Raske nyfødte. - Nyfødte indlagt mere end 48 timer i neonatalafdeling. - Nyfødte med kraniofaciale misdannelser, herunder misdannelse af ører og ganespalte, og nyfødte med kromosomfejl. - Nyfødte, hvor forælder eller søskende bruger eller har brugt høreapparat. Raske nyfødte screenes med AOAE. Opnås pass for AOAE for begge ører, kan barnet uden videre afsluttes fra hørescreeningen med besked til forældrene om, at hørescreeningen giver god sikkerhed for, at der ikke foreligger en hørenedsættelse. Hvis der ikke kan opnås pass for begge ører, skal screeningen gentages efter mindst 6 timer, men fortrinsvis en anden dag og senest 7 dage efter 1. screening. Hvis der efter denne 2. screening med AOAE stadig ikke er opnået pass for begge ører, skal barnet henvises til rescreeningsenheden i Audiologisk afdeling på Gentofte Hospital. Hvis barnet på grund af et uafsluttet screeningsresultat for et eller begge ører screenes på ny inden for få timer, regnes dette ikke som en 2. screening. Er der ved 1. screening opnået pass for det ene øre, gentages måling på dette øre ikke ved 2. screening. Nyfødte indlagt i neonatalafdeling i mere end 48 timer screenes med både AOAE og AABR. AABR er nødvendig for at identificere børn med auditiv neuropati (AN), og børn indlagt i neonatalafdeling i mere end 48 timer har højere risiko for AN end raske nyfødte. At supplere AABR med AOAE giver større sikkerhed for at identificere også de lette høretab, da AOAE anses for mere følsom end AABR. Har barnet under indlæggelsen i neonatalafdelingen haft meningitis, skal barnet ikke hørescreenes i neonatalafdelingen, men henvises direkte til rescreeningsenheden i Audiologisk afdeling til undersøgelse der, så snart barnets tilstand tillader det. Alle andre børn indlagt i neonatalafdelingen screenes inden udskrivelsen. Overflyttets barnet i forløbet til lokal neonatalafdeling, skal barnet først hørescreenes inden udskrivelse fra den lokale neonatalafdeling. Det er i almindelighed hensigstmæssigt, at hørescreening foregår så tæt på udskrivelsen som muligt. Opnås pass for såvel AOAE og AABR for begge ører, kan barnet uden videre afsluttes fra hørescreeningen med besked til forældrene om, at hørescreeningen giver god sikkerhed for, at der ikke foreligger en hørenedsættelse. Hvis der ikke kan opnås pass for såvel AOAE og AABR for begge ører, kan screeningen afhængigt af situationen enten gentages efter mindst 6 timer, men fortrinsvis en anden dag og senest 7 dage efter 1. screening eller barnet kan henvises til rescreeningsenheden i Audiologisk afdeling. Målinger, der har vist pass ved 1. screening, gentages ikke ved en 2. screening. Hvis der efter en 2. screening stadig ikke er opnået pass for såvel AOAE og AABR for begge ører, skal barnet henvises til rescreeningsenheden i Audiologisk afdeling på Gentofte Hospital. Hvis barnet på grund af et uafsluttet screeningsresultat for et eller begge ører screenes på ny inden for få timer, regnes dette ikke som en 2. screening. Nyfødte med kraniofaciale misdannelser eller kromosomfejl screenes ikke på fødestedet, men henvises direkte til rescreeningsenheden i Audiologisk afdeling. Som nævnt ovenfor henvises også nyfødte fra neonatalafdeling, som har været diagnosticeret med meningitis, direkte til rescreeningsenheden. Nyfødte, hvor en forælder eller en søskende bruger eller har brugt høreapparat eller i barndommen (inden 18 årsalderen) har fået konstateret blivende hørenedsættelse, håndteres screeningsmæssigt efter ovenfor anførte retningslinier, men henvises uanset udfaldet af screeningen altid til rescreeningsenheden i Audiologisk afdeling. Forekomst af hørenedsættelse i barndommen i den nære familie er en risikofaktor for udvikling af hørenedsættelse i løbet af barndommen, og disse nyfødte vil efter en individuel vurdering blive tilbudt opfølgende kontrol i Audiologisk afdeling. Henvisning til rescreeningsenheden i Audiologisk afdeling, Gentofte Hospital: Henvisningsblanket med barnets data, resultatet af hørescreeningen, kontaktinfo på forældre og eventuelle andre oplysninger faxes til rescreeningsenheden på faxnr. ###TELEFON###. I hastetilfælde og ved behov for kontakt i øvrigt kan tlf.nr. ###TELEFON### benyttes. Yderligere information: Audiologisk afdeling, Gentofte hospital, tlf. ###TELEFON###. Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag

<h1><div id="Afsnit#1699579391865">Hørescreening af nyfødte på fødestederne i Region Hovedstadens område Midt, Syd, Byen samt Bornholm</div></h1><div id="BodyWeb#1699579391865"><p><a name="1699579391865Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579391865Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579391865Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579391865Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579391865Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579391865Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579391865Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579391865Bilag">Bilag</a><br> &nbsp;</h3> <h2><a name="1699579391865Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p>Personale ved Rescreeningsenheden,&nbsp;aud. afd., GeH&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579391865Top">Tilbage til top</a></p> <h2><a name="1699579391865Definitioner"></a><br> Definitioner</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579391865Top">Tilbage til top</a></p> <h2><a name="1699579391865Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p><span style="color:black">Hørescreeningen udføres med automatiseret måling af transientudløste otoakustiske emissioner (AOAE) eventuelt suppleret med automatiseret hjernestammeaudiometri – auditory brainstem responses (AABR) som en tostadiescreening. Begge ører screenes. Screening skal undgås i første levedøgn på grund af et øget antal falsk positive resultater, og skal gerne vente til barnet er 2 døgn gammelt. </span></p> <p>&nbsp;</p> <p><span style="color:black">Der skal ved hørescreeningen sikres optimale måleomstændigheder:</span></p> <p><span style="color:black">· </span>Tilstrækkelig lav baggrundsstøj.</p> <p><span style="color:black">· </span>Den nyfødte skal være i passende ro.</p> <p><span style="color:black">· </span>God placering af proben i øret / tilfredsstillende lav elektrodeimpedans.</p> <p><span style="color:black">Resultatet af screening af et øre er enten pass (passeret), refer (henvises) eller uafsluttet. Det sidstnævnte er udfaldet, hvis barnet under målingen vågner og bliver uroligt, eller de tilstrækkelige målebetingelser af anden årsag ikke længere er til stede.</span></p> <p>&nbsp;</p> <p><span style="color:black">Den nærmere procedure er afhængig af, hvilken af nedennævnte kategorier, barnet tilhører:</span></p> <p><span style="color:black">· </span>Raske nyfødte.</p> <p><span style="color:black">· </span>Nyfødte indlagt mere end 48 timer i neonatalafdeling.</p> <p><span style="color:black">· </span>Nyfødte med kraniofaciale misdannelser, herunder misdannelse af ører og ganespalte, og nyfødte med kromosomfejl.</p> <p><span style="color:black">· </span>Nyfødte, hvor forælder eller søskende bruger eller har brugt høreapparat.</p> <p>&nbsp;</p> <p><em><span style="color:black">Raske nyfødte</span></em> screenes med AOAE.</p> <p><span style="color:black">Opnås pass for AOAE for begge ører, kan barnet uden videre afsluttes fra hørescreeningen med besked til forældrene om, at hørescreeningen giver god sikkerhed for, at der ikke foreligger en hørenedsættelse.</span></p> <p><span style="color:black">Hvis der ikke kan opnås pass for begge ører, skal screeningen gentages efter mindst 6 timer, men fortrinsvis en anden dag og senest 7 dage efter 1. screening. Hvis der efter denne 2. screening med AOAE stadig ikke er opnået pass for begge ører, skal barnet henvises til rescreeningsenheden i Audiologisk afdeling på Gentofte Hospital.</span></p> <p><span style="color:black">Hvis barnet på grund af et uafsluttet screeningsresultat for et eller begge ører screenes på ny inden for få timer, regnes dette ikke som en 2. screening. Er der ved 1. screening opnået pass for det ene øre, gentages måling på dette øre ikke ved 2. screening.</span></p> <p>&nbsp;</p> <p><em><span style="color:black">Nyfødte indlagt i neonatalafdeling i mere end 48 timer</span></em> screenes med både AOAE og AABR. AABR er nødvendig for at identificere børn med auditiv neuropati (AN), og børn indlagt i neonatalafdeling i mere end 48 timer har højere risiko for AN end raske nyfødte. At supplere AABR med AOAE giver større sikkerhed for at identificere også de lette høretab, da AOAE anses for mere følsom end AABR.</p> <p><span style="color:black">Har barnet under indlæggelsen i neonatalafdelingen haft <em>meningitis</em>, skal barnet ikke hørescreenes i neonatalafdelingen, men henvises direkte til rescreeningsenheden i Audiologisk afdeling til undersøgelse der, så snart barnets tilstand tillader det. Alle andre børn indlagt i neonatalafdelingen screenes inden udskrivelsen. Overflyttets barnet i forløbet til lokal neonatalafdeling, skal barnet først hørescreenes inden udskrivelse fra den lokale neonatalafdeling. Det er i almindelighed hensigstmæssigt, at hørescreening foregår så tæt på udskrivelsen som muligt.</span></p> <p><span style="color:black">Opnås pass for såvel AOAE og AABR for begge ører, kan barnet uden videre afsluttes fra hørescreeningen med besked til forældrene om, at hørescreeningen giver god sikkerhed for, at der ikke foreligger en hørenedsættelse.</span></p> <p><span style="color:black">Hvis der ikke kan opnås pass for såvel AOAE og AABR for begge ører, kan screeningen afhængigt af situationen enten gentages efter mindst 6 timer, men fortrinsvis en anden dag og senest 7 dage efter 1. screening eller barnet kan henvises til rescreeningsenheden i Audiologisk afdeling. Målinger, der har vist pass ved 1. screening, gentages ikke ved en 2. screening. Hvis der efter en 2. screening stadig ikke er opnået pass for såvel AOAE og AABR for begge ører, skal barnet henvises til rescreeningsenheden i Audiologisk afdeling på Gentofte Hospital. </span></p> <p><span style="color:black">Hvis barnet på grund af et uafsluttet screeningsresultat for et eller begge ører screenes på ny inden for få timer, regnes dette ikke som en 2. screening.</span></p> <p>&nbsp;</p> <p><em><span style="color:black">Nyfødte med kraniofaciale misdannelser eller kromosomfejl</span></em> screenes ikke på fødestedet, men henvises direkte til rescreeningsenheden i Audiologisk afdeling. Som nævnt ovenfor henvises også nyfødte fra neonatalafdeling, som har været diagnosticeret med <em>meningitis</em>, direkte til rescreeningsenheden.</p> <p>&nbsp;</p> <p><em><span style="color:black">Nyfødte, hvor en forælder eller en søskende bruger eller har brugt høreapparat eller i barndommen (inden 18 årsalderen) har fået konstateret blivende hørenedsættelse</span></em>, håndteres screeningsmæssigt efter ovenfor anførte retningslinier, men henvises uanset udfaldet af screeningen altid til rescreeningsenheden i Audiologisk afdeling. Forekomst af hørenedsættelse i barndommen i den nære familie er en risikofaktor for udvikling af hørenedsættelse i løbet af barndommen, og disse nyfødte vil efter en individuel vurdering blive tilbudt opfølgende kontrol i Audiologisk afdeling.</p> <p>&nbsp;</p> <p><em><span style="color:black">Henvisning til rescreeningsenheden i Audiologisk afdeling, Gentofte Hospital:</span></em></p> <p><strong>Henvisningsblanket med barnets data, resultatet af hørescreeningen, kontaktinfo på forældre og eventuelle andre oplysninger faxes til rescreeningsenheden på faxnr. ###TELEFON###.</strong></p> <p><strong>I hastetilfælde og ved behov for kontakt i øvrigt kan tlf.nr. ###TELEFON### benyttes.</strong></p> <p>&nbsp;</p> <p><span style="color:black">Yderligere information: Audiologisk afdeling, Gentofte hospital, tlf. ###TELEFON###.</span></p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579391865Top">Tilbage til top</a></p> <h2><a name="1699579391865Ansvar"></a><br> Ansvar og organisering</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579391865Top">Tilbage til top</a></p> <h2><a name="1699579391865Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579391865Top">Tilbage til top</a></p> <h2><a name="1699579391865Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579391865Top">Tilbage til top</a></p> <h2><a name="1699579391865Bilag"></a><br> Bilag</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579391865Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Incision og skiftning af absces.

Incision og skiftning af absces Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Målgrupper og anvendelsesområde Klinisk personale i Afdeling for Øre-Næse-Halskirurgi og Audiologi Incision og skift af abscesser i hoved-halsområdet Definitioner Absces: Byld, pusansamling i et ikke-præformet hulrum. Hulrummet dannes ved nekrose og afgrænsningen udgøres af beskadiget ,men levedygtigt væv med inflammation Fremgangsmåde Modtagelse af patient i sygeplejeambulatoriet: Patienten vil ofte være henvist til sygeplejeambulatoriet af afdelingens læger, efter at abscessen er incideret. P Patienten kan have smerter og være alment svækket. Patienten observeres for smerter og VAS/NRS-scores Remedier Afhængigt af abscessens beskaffenhed fremlægges de nødvendige remedier Ved alle skiftninger bruges: - Rullebord med afdækningstykke - Skiftesæt - Handsker - Cellestof - Kapsel - 20 ml sprøjte - Lyserød venflon 1,1 mm/brunt øresug - Gazeswabs (non-wowen) - Hydrofiberprodukt eller gel afhængigt af sekretion - Bandagerings/forbindsmateriale Til skylning af sår anvendes vandhanevand eller Nacl/sterilt vand, afhængigt af vandkvaliteten, som skal være af en kvalitet så det kan drikkes. Vandet bør ikke være for koldt. Se bilag: Rensning af akutte og kroniske sår: Skyllevæsker og skylletryk Sårpleje - Forbindingen inspiceres og fjernes - Sår og omliggende hud inspiceres. Ved forværring eller anden usikkerhed konfereres med lægen - Caviteten skylles med vandhanevand eller NaCl/sterilt vand - Ved kraftig til moderat sekretion bruges et alginat eller hydrofiberprodukt (10 ml per cm3) og derover tør forbinding - Ved minimal eller ingen sekretion bruges ved de efterfølgende skiftninger gel, semipermeabel film og afhængigt af sekretionen, evt. skumbandage Se bilag Bandageoversigt mhp valg af sårplejemateriale. Information af patienten ved hjemsendelse Patienten informeres om - Proceduren - At henvende sig ved temperaturstigning, rødme, hævelse og tiltagende smerter Ambulant kontrol Patienten ses jævnligt (typisk hver 2. og 3. dag) i sygeplejeambulatoriet. Dette indtil det vurderes af sygeplejersken og lægen, at patienten enten kan afsluttes eller overgå til skiftning hos egen læge/hjemmesygeplejerske Ansvar og organisering Afdelingsledelsen i Afdeling for Øre-Næse-Halskirurgi og Audiologi Referencer, lovgivning og faglig evidens samt links hertil Region Hovedstadens Sårbog (findes under dokumentsamlinger) Akkrediteringsstandarder Bilag Bandageoversigt - RegionH - 2013 - 2015.pdf RegH - Rensning af akutte og kroniske sår.pdf

<h1><div id="Afsnit#1699579424789">Incision og skiftning af absces</div></h1><div id="BodyWeb#1699579424789"><p><a name="1699579424789Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579424789Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579424789Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579424789Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579424789Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579424789Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579424789Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579424789Bilag">Bilag</a><br> &nbsp;</h3> <h2><a name="1699579424789Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p>Klinisk personale i Afdeling for Øre-Næse-Halskirurgi og Audiologi</p> <p>Incision og skift af abscesser i hoved-halsområdet</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579424789Top">Tilbage til top</a></p> <h2><a name="1699579424789Definitioner"></a><br> Definitioner</h2> <p>Absces: Byld, pusansamling i et ikke-præformet hulrum. Hulrummet dannes ved nekrose og afgrænsningen udgøres af beskadiget ,men levedygtigt væv med inflammation&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579424789Top">Tilbage til top</a></p> <h2><a name="1699579424789Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p><strong>Modtagelse af patient i sygeplejeambulatoriet:</strong></p> <p>Patienten vil ofte være henvist til sygeplejeambulatoriet af afdelingens læger, efter at abscessen er incideret. P</p> <p>Patienten kan have smerter og være alment svækket. Patienten observeres for smerter og VAS/NRS-scores</p> <p><strong>Remedier</strong></p> <p>Afhængigt af abscessens beskaffenhed fremlægges de nødvendige remedier</p> <p>Ved alle skiftninger bruges:</p> <ul> <li>Rullebord med afdækningstykke</li> <li>Skiftesæt</li> <li>Handsker</li> <li>Cellestof</li> <li>Kapsel</li> <li>20 ml sprøjte</li> <li>Lyserød venflon 1,1 mm/brunt øresug</li> <li>Gazeswabs (non-wowen)</li> <li>Hydrofiberprodukt eller gel afhængigt af sekretion</li> <li>Bandagerings/forbindsmateriale</li> </ul> <p>Til skylning af sår anvendes vandhanevand eller Nacl/sterilt vand, afhængigt af vandkvaliteten, som skal være af en kvalitet så det kan drikkes. Vandet bør ikke være for koldt. Se bilag: <u>Rensning af akutte og kroniske sår: Skyllevæsker og skylletryk</u></p> <p><strong>Sårpleje</strong></p> <ol> <li>Forbindingen inspiceres og fjernes</li> <li>Sår og omliggende hud inspiceres. Ved forværring eller anden usikkerhed konfereres med lægen</li> <li>Caviteten skylles med vandhanevand&nbsp;eller NaCl/sterilt vand</li> <li>Ved kraftig til moderat sekretion bruges et alginat eller hydrofiberprodukt (10 ml per cm³)&nbsp;og derover tør forbinding</li> <li>Ved minimal eller ingen sekretion bruges ved de efterfølgende skiftninger gel, semipermeabel film og afhængigt af sekretionen, evt. skumbandage</li> </ol> <p>Se bilag <u>Bandageoversigt </u>mhp valg af sårplejemateriale.</p> <p style="margin-left:18pt"><strong>Information af patienten ved hjemsendelse</strong></p> <p style="margin-left:18pt">Patienten informeres om</p> <ul> <li>Proceduren</li> <li>At henvende sig ved temperaturstigning, rødme, hævelse og tiltagende smerter</li> </ul> <p><strong>Ambulant kontrol</strong></p> <p>Patienten ses jævnligt (typisk hver 2. og 3. dag) i sygeplejeambulatoriet. Dette indtil det vurderes af sygeplejersken og lægen, at patienten enten kan afsluttes eller overgå til skiftning hos egen læge/hjemmesygeplejerske</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579424789Top">Tilbage til top</a></p> <h2><a name="1699579424789Ansvar"></a><br> Ansvar og organisering</h2> <p>Afdelingsledelsen i Afdeling for Øre-Næse-Halskirurgi og Audiologi</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579424789Top">Tilbage til top</a></p> <h2><a name="1699579424789Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p>Region Hovedstadens Sårbog (findes under dokumentsamlinger)</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579424789Top">Tilbage til top</a></p> <h2><a name="1699579424789Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579424789Top">Tilbage til top</a></p> <h2><a name="1699579424789Bilag"></a><br> Bilag</h2> <p>&nbsp;<img src="/icons/vwicn005.gif" onclick="Ext.DMS.util.showImage(this);"><a href="###FOLDER###" target="_blank">Bandageoversigt - RegionH - 2013 - 2015.pdf</a></p> <p><img src="/icons/vwicn005.gif" onclick="Ext.DMS.util.showImage(this);"><a href="###FOLDER###" target="_blank">RegH - Rensning af akutte og kroniske sår.pdf</a></p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579424789Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Injektion af Betamethason (Diprospan) im i.

Injektion af Betamethason (Diprospan) im i sygeplejeambulatoriet Målgrupper og anvendelsesområde Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Målgrupper og anvendelsesområde Klinisk personale i Afdeling for Øre-Næse-Halskirurgi og Audiologi Fremgangsmåde Indikation: Injektion af Betamethason gives: - Som præoperativ injektion for at reducere polypper inden kirurgisk indgreb. - Som generel forebyggelse / afhjælpning af polypper i næseslimhinden. Dosis: Sygeplejersken giver 2 ml Betamethason i.m., medmindre andet er ordineret. Injektionen bør gives dybt i glutealmusklen, for at undgå vævsatrofi Der må max gives Betamethason 4 x årligt eller hver tredje måned Ved hver injektion anbefales patienten at tage 1 tbl. Unikalk Mega i 3 uger (kan købes på apotek i håndkøb) Dokumentation: Evt. observationer i forbindelse med injektionen, samt Sundhedsplatformen/journalen. Dispensering og administration af injektionen, dokumenteres i EPM. Kontraindikation: - Osteoporose - Hypertension - Diabetes Mellitus - Hjerteinsufficiens - Uræmi - Levercirrose - Psykiske lidelser - Tidligere injektioner af Bethametason har givet kløe eller udslæt. (Patienten skal i stedet behandles med steroid i tabletform). I så tilfælde orienteres læge og tager stilling til om injektionen kan gives. Procedure: Før injektionen informeres patienten om mulige bivirkninger: - Søvnløshed - Uro - Øget appetit Efter injektionen observeres patienten i 30 min. for anafylaktisk reaktion (meget sjælden) Se RH vejledning: Anafylaktisk shock Ansvar og organisering Afdeling - og afsnitledelser er ansvarlige for at instruksen følges Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag

<h1><div id="Afsnit#1699579448955">Injektion af Betamethason (Diprospan) im i sygeplejeambulatoriet</div></h1><div id="BodyWeb#1699579448955"><p><a name="1699579448955Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579448955Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579448955Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579448955Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579448955Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579448955Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579448955Bilag">Bilag</a><br> &nbsp;</h3> <h2><a name="1699579448955Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p>Klinisk personale i Afdeling for Øre-Næse-Halskirurgi og Audiologi&nbsp;</p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579448955Top">Tilbage til top</a></p> <h2><a name="1699579448955Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p><strong>Indikation:</strong></p> <p>Injektion af Betamethason &nbsp;gives:</p> <ol> <li>Som præoperativ injektion for at reducere polypper inden kirurgisk indgreb.</li> <li value="2">Som generel forebyggelse / afhjælpning af polypper i næseslimhinden.</li> </ol> <p><strong>Dosis:</strong></p> <p>Sygeplejersken giver 2 ml&nbsp;Betamethason i.m., medmindre andet er ordineret. Injektionen bør gives dybt i glutealmusklen, for at undgå vævsatrofi</p> <p>Der må max gives Betamethason &nbsp;4 x årligt eller hver tredje måned</p> <p>Ved hver injektion anbefales patienten at tage 1 tbl. Unikalk Mega i 3 uger (kan købes på apotek i håndkøb)</p> <p><strong>Dokumentation:</strong></p> <p>Evt. observationer i forbindelse med injektionen,&nbsp;samt Sundhedsplatformen/journalen. &nbsp;Dispensering og administration af injektionen, dokumenteres i EPM.</p> <p><strong>Kontraindikation:</strong></p> <ul> <li>Osteoporose</li> <li>Hypertension</li> <li>Diabetes Mellitus</li> <li>Hjerteinsufficiens</li> <li>Uræmi</li> <li>Levercirrose</li> <li>Psykiske lidelser</li> <li>Tidligere injektioner af Bethametason &nbsp;har givet kløe eller udslæt. (Patienten skal i stedet behandles med steroid i tabletform).</li> </ul> <p><strong>I så tilfælde orienteres læge og tager stilling til om injektionen kan gives.</strong></p> <p><strong>Procedure:</strong></p> <p>Før injektionen informeres patienten om mulige bivirkninger:</p> <ul> <li>Søvnløshed</li> <li>Uro</li> <li>Øget appetit</li> </ul> <p>Efter injektionen observeres patienten<u> i 30 min</u>. for &nbsp;anafylaktisk reaktion (meget sjælden) Se&nbsp;RH vejledning: <a href="###FOLDER###" target="_blank">Anafylaktisk shock</a></p> <p>&nbsp;&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579448955Top">Tilbage til top</a></p> <h2><a name="1699579448955Ansvar"></a><br> Ansvar og organisering</h2> <p>Afdeling - og afsnitledelser er ansvarlige for at instruksen følges</p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579448955Top">Tilbage til top</a></p> <h2><a name="1699579448955Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579448955Top">Tilbage til top</a></p> <h2><a name="1699579448955Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579448955Top">Tilbage til top</a></p> <h2><a name="1699579448955Bilag"></a><br> Bilag</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579448955Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Injektion fluorescein og rhinoliquorrhoe.

Injektion fluorescein og rhinoliquorrhoe Målgrupper og anvendelsesområde Fremgangsmåde Ansvar og organisering Målgrupper og anvendelsesområde Klinisk personale i Afdeling for Øre-Næse-Halskirurgi og Audiologi, samt anæstesi- og OMO personale. Fremgangsmåde Indikation: Begrundet mistanke om persisterende lækage af CSV (cerebrospinal væske)til næse-bihuler, hvor skopi af næsen og CT af basis cranii og bihuler med tynde snit ikke med sikkerhed har kunnet lokalisere udgangspunktet for lækagen. Information af patient: Informeres om risiko for universelle kramper i forbindelse med injektionen. Risikoen opvejes af den endnu større risiko for bakteriel meningitis ved persisterende fistel. Andre bivirkninger: forbigående andre neurologiske symptomer som svaghed i benene, følelsesløshed, opistotonus, hjernenervepareser. Patienten skal ikke være fastende. (Med mindre der er kontraindikation skal patienten skal have tilbud om pneumokok-vaccination) Forberedelse - kirurg: - Kontakt anæstesiafdelingen på 5-1696 senest to dage inden operationen og anmod om engangsindgift af Fluorescein. - SP: Lav først operationscase på ”CSF-LEAK, næse-bihule” og træk den op i SP’s snapboard. Vælg derefter indlagte behandlingskontakt, vælg ”best-ord-sæt”, vælg ”anæstesi, eksterne ydelser”, vælg ”ydelser til udførelse på operationsgang”, vælg ”lumbal punktur”. - Lav gul note på ledigt leje i snapboard om formiddagen dagen inden FESS-operation og angiv- ”Flourescein injektion ved anæstesi- ekstern ydelse”. - Følgende Noteres i SP af ordinerende ØNH-kirurg senest dagen før fluorescein indgiften: - Information af patienten og accept - Ordinere engangsindgift af fluorescein - Angive præcis dosering og koncentration af fluorescein: 10 ml Fluorescein af 5 mg/ml til standard voksen - Skriv at ”Der er indikation for intratekal injektion af Fluorescein på trods af Lægemiddelstyrelsens vejledning om at Fluorescein kun må gives intravenøst”. - Arranger præindlæggelse på ØNH sengeafd. på dagen til fluorescein injektion (dvs. dagen inden FESS), ved at kontakte ansvarshavende på sengeafd. Patienten informeres om at møde i sengeafsnit til indlæggelse inden injektionen. NB. Øre-næse-hals-afdelingen sørger for at der er indkøbt Fluorescein til operationsgangen. Praktisk udførelse - anæstesilæge: - Træk ekstern ydelse op på snapboard. - Kald patienten til ledigt operationsleje. Procedure kan foretages med anæstesisygeplejerske. - Fluorescein hentes i køleskabet på afsnit 6023 - Spinalsæt og nåle (25G) hentes på ”U-op”. Dæk op og brug værnemidler som til steril spinal bedøvelse. - Standard monitorering, i.v.-adgang. - Klargør fluorescein brugsopløsning: Fra fluorescein hætteglas (100 mg/ml) optrækkes 0,5 ml i 1 ml sprøjte 0,5 ml fluorescein (50 mg) iblandes isoton NaCl 9,5 ml Resultatet er 10 ml fluorescein brugsopløsning (5 mg/ml) - Anlæg Lokal bedøvelse Lidocain 20mg/ml (med eller uden adrenalin) - 10 ml Fluorescein brugsopløsning (i alt 50 mg) injiceres herefter langsomt i spinalkanalen L2-L4 via spinalnål eller lumbaldræn - Patienten meldes til OMO og skal her observeres i 2 timer for tegn på allergisk reaktion, generaliserede kramper, svaghed i underekstremiteter, følelsesløshed, opistotonus, kranienerveparese. - Udskrives fra OMO til ØNH sengeafsnit. Pt. tilses til aftenstuegang af ØNH læge, hvor det vurderes om patienten kan gå på orlov til dagen efter. Pleje i sengeafsnit: Generelt ved Fluorescein injektion: - Patienten skal have målt vitale værdier (EWS), 1 time efter ankomst i sengeafsnittet som vanligt - Der observeres for allergisk reaktion (generaliserede kramper, svaghed i underekstremiteter, følelsesløshed, opistotonus, kranienerveparese). - I tilfælde af komplikationer tilkaldes vagthavende læge og der ABCDE – optimeres - Early Warning Score i Afdeling for Øre-Næse-Halskirurgi og Audiologi. Derefter måles vitale værdier efter vanlig EWS handlings algoritme. Ansvar og organisering Afdelingsledelsen

<h1><div id="Afsnit#1699579418188">Injektion fluorescein og rhinoliquorrhoe</div></h1><div id="BodyWeb#1699579418188"><p><a name="1699579418188Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579418188Maalgrupper">Målgrupper og anvendelsesområde</a></h3> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579418188Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579418188Ansvar">Ansvar og organisering</a><br> &nbsp;</h3> <h2><a name="1699579418188Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#222222">Klinisk personale i Afdeling for Øre-Næse-Halskirurgi og Audiologi, samt anæstesi- og OMO personale.</span></p> <p>&nbsp;<a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579418188Top">Tilbage til top</a></p> <h2><a name="1699579418188Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p style="margin-left:0cm; margin-right:0cm"><u><span style="color:#222222">Indikation</span></u><span style="color:#222222">:</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#222222">Begrundet mistanke om persisterende lækage af CSV (cerebrospinal væske)til næse-bihuler, hvor skopi af næsen og CT af basis cranii og bihuler med tynde snit ikke med sikkerhed har kunnet lokalisere udgangspunktet for lækagen.&nbsp;</span></p> <p style="margin-left:0cm; margin-right:0cm"><u><span style="color:#222222">Information af patient</span></u><span style="color:#222222">:</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#222222">Informeres om risiko for universelle kramper i forbindelse med injektionen.</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#222222">Risikoen opvejes af den endnu større risiko for bakteriel meningitis ved persisterende fistel.</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#222222">Andre bivirkninger: forbigående andre neurologiske symptomer som svaghed i benene, følelsesløshed, opistotonus, hjernenervepareser.</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#222222">Patienten skal ikke være fastende.&nbsp;</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#222222">(Med mindre der er kontraindikation skal patienten skal have tilbud om pneumokok-vaccination)</span></p> <p style="margin-left:0cm; margin-right:0cm"><u><span style="color:#222222">Forberedelse - kirurg</span></u><span style="color:#222222">:</span></p> <ol> <li><span style="color:#222222">Kontakt anæstesiafdelingen på 5-1696 senest to dage inden operationen og anmod om engangsindgift af Fluorescein. </span></li> </ol> <p style="margin-left:36pt; margin-right:0cm">&nbsp;</p> <ol start="2"> <li><span style="color:#222222">SP: Lav først operationscase på ”CSF-LEAK, næse-bihule” &nbsp;og træk den op i SP’s snapboard. Vælg derefter indlagte behandlingskontakt, vælg ”best-ord-sæt”, vælg ”anæstesi, eksterne ydelser”, vælg ”ydelser til udførelse på operationsgang”, vælg ”lumbal punktur”. </span></li> </ol> <p style="margin-left:36pt; margin-right:0cm">&nbsp;</p> <ol start="3"> <li><span style="color:#222222">Lav gul note på ledigt leje i snapboard om formiddagen dagen inden FESS-operation og angiv- ”Flourescein injektion ved anæstesi- ekstern ydelse”.</span></li> </ol> <p style="margin-left:36pt; margin-right:0cm">&nbsp;</p> <ol start="4"> <li><span style="color:#222222">Følgende Noteres i SP af ordinerende ØNH-kirurg senest dagen før fluorescein indgiften:</span> <ol style="list-style-type:lower-alpha"> <li><span style="color:#222222">Information af patienten og accept</span></li> <li><span style="color:#222222">Ordinere engangsindgift af fluorescein </span></li> <li><span style="color:#222222">Angive præcis dosering og koncentration af fluorescein: 10 ml Fluorescein af 5 mg/ml til standard voksen</span></li> <li><span style="color:#222222">Skriv at ”Der er indikation for intratekal injektion af Fluorescein på trods af Lægemiddelstyrelsens vejledning om at Fluorescein kun må gives intravenøst”.&nbsp;</span></li> </ol> </li> </ol> <p style="margin-left:36pt; margin-right:0cm">&nbsp;</p> <ol start="5"> <li><span style="color:#222222">Arranger præindlæggelse <strong>på ØNH sengeafd. på dagen til fluorescein injektion </strong>(dvs. dagen inden FESS), ved at kontakte ansvarshavende på sengeafd. Patienten informeres om at møde i sengeafsnit til indlæggelse inden injektionen. </span></li> </ol> <p style="margin-left:36pt; margin-right:0cm"><span style="color:#222222">NB. Øre-næse-hals-afdelingen sørger for at der er indkøbt Fluorescein til operationsgangen.</span></p> <p style="margin-left:36pt; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><u><span style="color:#222222">Praktisk udførelse - anæstesilæge</span></u><span style="color:#222222">:</span></p> <ol> <li><span style="color:#222222">Træk ekstern ydelse op på snapboard. </span></li> <li><span style="color:#222222">Kald patienten til ledigt operationsleje. Procedure kan foretages med anæstesisygeplejerske. </span></li> <li><span style="color:#222222">Fluorescein hentes i køleskabet på afsnit 6023</span></li> <li><span style="color:#222222">Spinalsæt og nåle (25G) hentes på ”U-op”. Dæk op og brug værnemidler som til steril spinal bedøvelse.</span></li> <li><span style="color:#222222">Standard monitorering, i.v.-adgang.</span></li> <li>Klargør <strong>fluorescein brugsopløsning</strong>:</li> </ol> <p style="margin-left:36pt; margin-right:0cm">&nbsp;</p> <p style="margin-left:36pt; margin-right:0cm">Fra fluorescein <em>hætteglas</em> (100 mg/ml) optrækkes 0,5 ml i 1 ml sprøjte</p> <p style="margin-left:36pt; margin-right:0cm">0,5 ml fluorescein (50 mg) iblandes isoton NaCl 9,5 ml</p> <p style="margin-left:36pt; margin-right:0cm">Resultatet er 10 ml fluorescein <em>brugsopløsning</em> (5 mg/ml)</p> <p style="margin-left:36pt; margin-right:0cm">&nbsp;</p> <ol start="7"> <li>Anlæg Lokal bedøvelse Lidocain 20mg/ml (med eller uden adrenalin)</li> <li>10 ml Fluorescein brugsopløsning (i alt 50 mg) injiceres herefter langsomt i spinalkanalen L2-L4 via spinalnål eller lumbaldræn</li> <li><span style="color:#222222">Patienten meldes til OMO og skal her observeres i 2 timer for tegn på allergisk reaktion, generaliserede kramper, svaghed i underekstremiteter, følelsesløshed, opistotonus, kranienerveparese.</span></li> <li><span style="color:#222222">Udskrives fra OMO til ØNH sengeafsnit. Pt. tilses til aftenstuegang af ØNH læge, hvor det vurderes om patienten kan gå på orlov til dagen efter.</span></li> </ol> <p style="margin-left:36pt; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><u><span style="color:#222222">Pleje i sengeafsnit:</span></u></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#222222">Generelt ved Fluorescein injektion: </span></p> <ol> <li><span style="color:#222222">Patienten skal have målt vitale værdier (EWS), 1 time efter ankomst i sengeafsnittet som vanligt</span></li> <li><span style="color:#222222">Der observeres for allergisk reaktion (generaliserede kramper, svaghed i underekstremiteter, følelsesløshed, opistotonus, kranienerveparese). </span></li> <li><span style="color:#222222">I tilfælde af komplikationer tilkaldes vagthavende læge og der ABCDE – optimeres -&nbsp;</span><u><span style="color:blue">Early Warning Score i Afdeling for Øre-Næse-Halskirurgi og Audiologi</span></u><span style="color:#222222">. Derefter måles vitale værdier efter vanlig EWS handlings algoritme.&nbsp;</span></li> </ol> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579418188Top">Tilbage til top</a></p> <h2><a name="1699579418188Ansvar"></a><br> Ansvar og organisering</h2> <p>Afdelingsledelsen&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579418188Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Instruks for udredning og behandling af.

Instruks for udredning og behandling af et tilfældigt fund af fokal øget optagelse i glandula thyroidea ved 18F-FGD PET/CT Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Bilag Målgrupper og anvendelsesområde Læger og klinisk personale i Øre-næse-halskirurgisk Klinik Definitioner Fremgangsmåde Baggrund Fokal øget optagelse i glandula thyroidea ved PET/CT opdaget tilfældigt i forbindelse med udredning af anden sygdom er associeret med en malignitetshypppighed på 24-30 % (1). Derfor kræver ethvert PET/CT thyroideaincidentalom stillingtagen til udrednings- og behandlingsbehov ud fra den enkelte patients comorbiditet og prognose. Den hyppigste form for primær thyroideacancer i et 18F-FGD PET/CT thyroideaincidentalom er papillært adenokarcinom (1), som har en god prognose (2). Eftersom fund af øget fokal FDG optagelse oftest er en konsekvens af behandling eller udredning af en verificeret malign lidelse, opstår en diagnostisk udfordring, idet patienten muligvis har to maligne sygdomme. Dette medfører et behov for aktiv stillingtagen hos både patient og læge til, hvorvidt udredning er nødvendig og i så fald, hvornår udredning, som ofte indbefatter diagnostisk hemithyroidektomi, skal planlægges mest hensigtsmæssigt i forhold til patientens anden maligne sygdom og dennes prognose. Modtagelse af henvisning af patient med et PET/CT thyroideaincidentalom: Det er hensigtsmæssigt at henvisende læge i sit oplæg beskriver indikation for PET/CT skanning og status på anden malign eller ikke malign sygdom med en estimering af patientens forventede restlevetid (restlevetid <1 år, restlevetid 1-5 år og restlevetid >5 år). Alternativt må den patientansvarlige læge fra den henvisende afdeling kontaktes med henblik på en status på patientens anden sygdom inden evt. operationsindikation stilles. Hvis forventet restlevetid <1 år er der ikke indikation for udredning af den PET-positive knude i thyroidea Indikation for ultralydsvejledt FNA af et PET/CT thyroideaincidentalom: Ved første fremmøde i pakkeforløb udredes alle patienter med ultralydsundersøgelse af thyroidea og hals, og herefter tages stilling til, hvorvidt der skal foretages ultralydsvejledt finnålsaspiration (FNA) eller evt. grovnålsprøve. Det er hensigtsmæssigt, at der foreligger TSH, T3 og T4 fra de seneste tre måneder. Såfremt patientens thyroideastatus er ukendt, rekvireres blodprøver, som ses samme eftermiddag. Patienter, med et PET-positivt adenom >1 cm informeres om tilbud om FNA i pakkeforløb pga. 30 % risiko for malignitet (3). Patienten skal ligeledes informeres om mulighed for at træde ud af pakkeforløb uden FNA efter vurdering af symptomer, EUTIRADS score og patientønske og blive henvist til endokrinologisk ambulatorium mhp. skintigrafi og kontrol efter otte uger. Således vil udredningen blive forlænget, men FNA fra et varmt adenom forhindres. Ved et adenom <1 cm skal der som udgangspunkt ikke foretages FNA, dog kan det overvejes ved høj EUTIRADS score (5) eller hvis det klinisk vurderes at være relevant. Alle beslutninger om ikke at foretage FNA enten ud fra patientens ønske eller efter klinisk vurdering skal konfereres med den hoved/hals-kirurgiske (gule) ansvarshavende speciallæge. Ligeledes skal den hoved/hals-kirurgiske ansvarshavende involveres, hvis patienten afsluttes, og når der oprettes casebestilling til operation. Se flowchart for udredning og behandling af et 18F-FGD PET/CT thyroideaincidentalom. Diagnostisk operation af et PET/CT thyroideaincidentalom: Hemithyroidektomi og evt. dissektion af level VI ipsilateralt. I nogle tilfælde hemithyroidektomi med frys og evt. total thyroidektomi. Figur 1: oversigt over udredning og behandling af et 18F-FGD PET/CT thyroideaincidentalom Ansvar og organisering Medlemmer af arbejdsgruppen: ###NAVN###, ###NAVN###, ###NAVN###, ###NAVN###, ###NAVN### (tovholder) Referencer, lovgivning og faglig evidens samt links hertil Referencer: 1. Soelberg KK, Bonnema SJ, Brix TH, Hegedus L. Risk of malignancy in thyroid incidentalomas detected by 18F-fluorodeoxyglucose positron emission tomography: a systematic review. Thyroid. 2012;22(9):918-25. 2. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133. 3. Abdel-Halim CN, Rosenberg T, Bjorndal K, Madsen AR, Jakobsen J, Dossing H, et al. Risk of Malignancy in FDG-Avid Thyroid Incidentalomas on PET/CT: A Prospective Study. World J Surg. 2019;43(10):2454-8. 4. Danish Thyroid Cancer GD. National vejledning for behandling af thyroideacancer i Danmanrk 2015. 5. Russ G, Bonnema SJ, Erdogan MF, Durante C, Ngu R, Leenhardt L. European Thyroid Association Guidelines for Ultrasound Malignancy Risk Stratification of Thyroid Nodules in Adults: The EU-TIRADS. Eur Thyroid J. 2017;6(5):225-37. 6. Cibas ES, Ali SZ. The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2017;27(11):1341-6. 7. Sundhedsstyrelsen. Pakkeforløb for hoved- og halskræft - For fagfolk 2020. Bilag

<h1><div id="Afsnit#1699579246929">Instruks for udredning og behandling af et tilfældigt fund af fokal øget optagelse i glandula thyroidea ved 18F-FGD PET/CT</div></h1><div id="BodyWeb#1699579246929"><p><a name="1699579246929Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579246929Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579246929Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579246929Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579246929Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579246929Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579246929Bilag">Bilag</a><br> &nbsp;</h3> <h2>&nbsp;</h2> <div class="collapsible-item" expandedstart="1"><a name="1699579246929Maalgrupper"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Målgrupper og anvendelsesområde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>Læger og klinisk personale i Øre-næse-halskirurgisk Klinik</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579246929Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579246929Definitioner"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Definitioner</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579246929Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579246929Fremgangsmaade"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Fremgangsmåde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:#1f3864">Baggrund</span></strong></p> <p style="margin-left:0cm; margin-right:0cm">Fokal øget optagelse i glandula thyroidea ved PET/CT opdaget tilfældigt i forbindelse med udredning af anden sygdom er associeret med en malignitetshypppighed på 24-30 % (1). Derfor kræver ethvert PET/CT thyroideaincidentalom stillingtagen til udrednings- og behandlingsbehov ud fra den enkelte patients comorbiditet og prognose. Den hyppigste form for primær thyroideacancer i et ¹⁸F-FGD PET/CT thyroideaincidentalom er papillært adenokarcinom (1), som har en god prognose (2). Eftersom fund af øget fokal FDG optagelse oftest er en konsekvens af behandling eller udredning af en verificeret malign lidelse, opstår en diagnostisk udfordring, idet patienten muligvis har to maligne sygdomme. Dette medfører et behov for aktiv stillingtagen hos både patient og læge til, hvorvidt udredning er nødvendig og i så fald, hvornår udredning, som ofte indbefatter diagnostisk hemithyroidektomi, skal planlægges mest hensigtsmæssigt i forhold til patientens anden maligne sygdom og dennes prognose.</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:#1f3864">Modtagelse af henvisning af patient med et PET/CT thyroideaincidentalom:</span></strong></p> <p style="margin-left:0cm; margin-right:0cm">Det er hensigtsmæssigt at henvisende læge i sit oplæg beskriver indikation for PET/CT skanning og status på anden malign eller ikke malign sygdom med en estimering af patientens forventede restlevetid (restlevetid &lt;1 år, restlevetid 1-5 år og restlevetid &gt;5 år). Alternativt må den patientansvarlige læge fra den henvisende afdeling kontaktes med henblik på en status på patientens anden sygdom inden evt. operationsindikation stilles. Hvis forventet restlevetid &lt;1 år er der ikke indikation for udredning af den PET-positive knude i thyroidea</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:#1f3864">Indikation for ultralydsvejledt FNA af et PET/CT thyroideaincidentalom:</span></strong></p> <p style="margin-left:0cm; margin-right:0cm">Ved første fremmøde i pakkeforløb udredes alle patienter med ultralydsundersøgelse af thyroidea og hals, og herefter tages stilling til, hvorvidt der skal foretages ultralydsvejledt finnålsaspiration (FNA) eller evt. grovnålsprøve<em>. </em>Det er hensigtsmæssigt, at der foreligger TSH, T3 og T4 fra de seneste tre måneder. Såfremt patientens thyroideastatus er ukendt, rekvireres blodprøver, som ses samme eftermiddag. Patienter, med et PET-positivt adenom &gt;1 cm informeres om tilbud om FNA i pakkeforløb pga. 30 % risiko for malignitet (3). Patienten skal ligeledes informeres om mulighed for at træde ud af pakkeforløb uden FNA efter vurdering af symptomer, EUTIRADS score og patientønske og blive henvist til endokrinologisk ambulatorium mhp. skintigrafi og kontrol efter otte uger. Således vil udredningen blive forlænget, men FNA fra et varmt adenom forhindres. Ved et adenom &lt;1 cm skal der som udgangspunkt ikke foretages FNA, dog kan det overvejes ved høj EUTIRADS score (5) eller hvis det klinisk vurderes at være relevant. Alle beslutninger om ikke at foretage FNA enten ud fra patientens ønske eller efter klinisk vurdering skal konfereres med den hoved/hals-kirurgiske (gule) ansvarshavende speciallæge. Ligeledes skal den hoved/hals-kirurgiske ansvarshavende involveres, hvis patienten afsluttes, og når der oprettes casebestilling til operation. Se flowchart for udredning og behandling af et ¹⁸F-FGD PET/CT thyroideaincidentalom.</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:#1f3864">Diagnostisk operation af et PET/CT thyroideaincidentalom:</span></strong></p> <p style="margin-left:0cm; margin-right:0cm">Hemithyroidektomi og evt. dissektion af level VI ipsilateralt.&nbsp; I nogle tilfælde hemithyroidektomi med frys og evt. total thyroidektomi.</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm">Figur 1: oversigt over udredning og behandling af et ¹⁸F-FGD PET/CT thyroideaincidentalom</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><img id="Billede_x0020_1" src="data:image/png;base64,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" style="height:279pt; width:482.25pt" onclick="Ext.DMS.util.showImage(this);"></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579246929Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579246929Ansvar"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Ansvar og organisering</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm">Medlemmer af arbejdsgruppen: ###NAVN###, ###NAVN###, ###NAVN###, ###NAVN###, ###NAVN### (tovholder)</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579246929Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579246929Referencer"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Referencer, lovgivning og faglig evidens samt links hertil</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm">Referencer:</p> <p style="margin-left:0cm; margin-right:0cm">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Soelberg KK, Bonnema SJ, Brix TH, Hegedus L. Risk of malignancy in thyroid incidentalomas detected by 18F-fluorodeoxyglucose positron emission tomography: a systematic review. Thyroid. 2012;22(9):918-25.</p> <p style="margin-left:0cm; margin-right:0cm">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133.</p> <p style="margin-left:0cm; margin-right:0cm">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abdel-Halim CN, Rosenberg T, Bjorndal K, Madsen AR, Jakobsen J, Dossing H, et al. Risk of Malignancy in FDG-Avid Thyroid Incidentalomas on PET/CT: A Prospective Study. World J Surg. 2019;43(10):2454-8.</p> <p style="margin-left:0cm; margin-right:0cm">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Danish Thyroid Cancer GD. National vejledning for behandling af thyroideacancer i Danmanrk 2015.</p> <p style="margin-left:0cm; margin-right:0cm">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russ G, Bonnema SJ, Erdogan MF, Durante C, Ngu R, Leenhardt L. European Thyroid Association Guidelines for Ultrasound Malignancy Risk Stratification of Thyroid Nodules in Adults: The EU-TIRADS. Eur Thyroid J. 2017;6(5):225-37.</p> <p style="margin-left:0cm; margin-right:0cm">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cibas ES, Ali SZ. The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2017;27(11):1341-6.</p> <p style="margin-left:0cm; margin-right:0cm">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sundhedsstyrelsen. Pakkeforløb for hoved- og halskræft - For fagfolk 2020.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579246929Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579246929Bilag"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Bilag</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579246929Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Instruktion i NaCl skylning.

Instruktion i NaCl skylning Målgrupper og anvendelsesområdeDefinitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Målgrupper og anvendelsesområde Til læger, sygeplejersker og social og sundhedsassistenter i ØNH kirurgisk og audiologisk afdeling. Anvendes til patienter med næse- bihuleproblemer før og efter operation. Formålet er at fjerne skorper, pus, allergener og størknet blod fra slimhinderne på en skånsom måde. Definitioner NaCl: Saltvandsopløsning, der enten kan købes på apoteket eller patienten kan opløse 9 gram salt i en liter kogt vand. Næseskylleflaske: flaske, der er udformet, så man kan bruge den til næseskylning. Fremgangsmåde Materialer: næseskylleflaske, servietter, plastikkrus, NaCl i harmonikaflaske, blåt stykke eller forklæde til patientens tøj. Patienten instrueres og afprøver ved håndvasken i at sprøjte saltvand ind gennem det ene næsebor og ud gennem det andet. Saltvandet skal lige akkurat kunne smages i svælget. Patienten kan evt. snuse ind samtidig. Det er nødvendigt at øve sig. De fleste får for meget saltvand op i næsen i starten, så de hoster. Til at starte med vil det for mange føles ubehageligt, men efter tilvænning vil det give en følelse af renhed og velbefindende. Hvis det er for svært for patienten at få vandet ind gennem det ene og ud gennem det andet, kan man snuse ind med begge næsebor på en gang fra et plastikkrus og puste ud fra begge næsebor samtidig. Patienten informeres om: - at skylle dagen efter operationen (evt.starte inden) - at skylle 2 gange dagligt med 100-150 ml saltvand (gerne flere gange ved behov). - muligheden for at købe et næsehorn/saltvand/næseskylleflaske på apotek - blandingsforhold til saltvand (udlevér pjece) - ved skylning inden næsespray informeres patienten om, at der skal gå en halv time efter skylning, før sprayen må anvendes Ansvar og organisering Afdelingsledelsen Referencer, lovgivning og faglig evidens samt links hertil FESS, Behandling og pleje af Akkrediteringsstandarder Bilag

<h1><div id="Afsnit#1699579244725">Instruktion i NaCl skylning</div></h1><div id="BodyWeb#1699579244725"><p><a name="1699579244725Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579244725Maalgrupper">Målgrupper og anvendelsesområde</a><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579244725Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579244725Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579244725Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579244725Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579244725Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579244725Bilag">Bilag</a><br> &nbsp;</h3> <h2><a name="1699579244725Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p>Til læger, sygeplejersker og social og sundhedsassistenter i ØNH kirurgisk og audiologisk afdeling. Anvendes til patienter med næse- bihuleproblemer før og efter operation. Formålet er at fjerne skorper, pus, allergener og størknet blod fra slimhinderne på en skånsom måde.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579244725Top">Tilbage til top</a></p> <h2><a name="1699579244725Definitioner"></a><br> Definitioner</h2> <p>NaCl: Saltvandsopløsning, der enten kan købes på apoteket eller patienten kan opløse 9 gram salt i en liter kogt vand. Næseskylleflaske: flaske, der er udformet, så man kan bruge den til næseskylning.</p> <p>&nbsp;<a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579244725Top">Tilbage til top</a></p> <h2><a name="1699579244725Fremgangsmaade"></a><br> Fremgangsmåde&nbsp;</h2> <p>Materialer: næseskylleflaske, servietter, plastikkrus, NaCl i harmonikaflaske, blåt stykke eller forklæde til patientens tøj.</p> <p>Patienten instrueres og afprøver ved håndvasken i at sprøjte saltvand ind gennem det ene næsebor og ud gennem det andet. Saltvandet skal lige akkurat kunne smages i svælget. Patienten kan evt. snuse ind samtidig. Det er nødvendigt at øve sig. De fleste får for meget saltvand op i næsen i starten, så de hoster. Til at starte med vil det for mange føles ubehageligt, men efter tilvænning vil det give en følelse af renhed og velbefindende. Hvis det er for svært for patienten at få vandet ind gennem det ene og ud gennem det andet, kan man snuse ind med begge næsebor på en gang fra et plastikkrus og puste ud fra begge næsebor samtidig.</p> <p>Patienten informeres om:</p> <ul> <li>at skylle dagen efter operationen (evt.starte inden)</li> <li>at skylle 2 gange dagligt med 100-150 ml saltvand (gerne flere gange ved behov).</li> <li>muligheden for at købe et næsehorn/saltvand/næseskylleflaske på apotek</li> <li>blandingsforhold til saltvand (udlevér pjece)</li> <li>ved skylning inden næsespray informeres patienten om, at der skal gå en halv time efter skylning, før sprayen må anvendes</li> </ul> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579244725Top">Tilbage til top</a></p> <h2><a name="1699579244725Ansvar"></a><br> Ansvar og organisering</h2> <p>Afdelingsledelsen</p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579244725Top">Tilbage til top</a></p> <h2><a name="1699579244725Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p><a href="###FOLDER###" target="_blank">FESS, Behandling og pleje af</a></p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579244725Top">Tilbage til top</a></p> <h2><a name="1699579244725Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579244725Top">Tilbage til top</a></p> <h2><a name="1699579244725Bilag"></a><br> Bilag</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579244725Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Kirurgisk behandling af kort tungebånd (frenectomi).

Kirurgisk behandling af kort tungebånd (frenectomi) ved problemer med amning Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Bilag Målgrupper og anvendelsesområde Formål Korrekt diagnostik og behandling af spædbørn med ammeproblemer som skyldes stramt tungebånd (ankyloglossi). Definition Definitionen af ankyloglossi er omdiskuteret. Ved klassisk anatomisk ankyloglossi hæfter det linguale frenulum fortil på apex lingua (kaldes nu anterior ankyloglossi af nogle). Der kan være tunge mobilitets problemer relateret til ankyloglossi, selvom frenulum ikke hæfter på apex lingua. Hvis frenulum hæfter midt på tungens underside eller bagud mod mundbunden kaldes det posterior ankyloglossi af nogle. Det er god praksis at anvende en systematisk vurderingsmetode til at vurdere tungebåndets udseende og mobilitet hos de børn, der har ammeproblemer, og hvor der er mistanke om ankyloglossi. Det anbefales, at anvende Tongue-tie and Breastfed Babies Assessment Tool (TABBY). Der henvises endvidere til dette link for mere information og instruktionsvideoer vejledningsfilm i vurdering af barnets tunge. Der er lavet en national klinisk retningslinje for behandling af kort tungebånd, se bilag. Fremgangsmåde - Ætiologi: Ankyloglossi er en medfødt anomali, der kan begrænse mobiliteten af tungen. Ankyloglossier oftest asymptomatisk. Ankyloglossikan dog medføre ammeproblemer hvor spædbarnet ikke få godt fat om brystet og svøbe brystvorten og det kan give moderen ømme brystvorter. Der er ikke påvist en sikker sammenhæng mellem ankyloglossiog dårlig trivsel (manglende vægtøgning), gastrooesophageal refluks eller udvikling af udtaleproblemer senere i livet. Kirurgisk behandling af ankyloglossikan bedrer ammeproblemer på kort sigt. Derimod er effekten af indgrebet på længere sigt ukendt. Det er derfor uvist, om ammeproblemerne spontant ville svinde uden behandling som følge af ammetræning, spontant træk på tungebåndet mm. - Forekomst: Prævalensen af ankyloglossier opgivet fra 0,1-12% af spædbørn. Den store forskel tilskrives forskelle i definition af ankyloglossi. Figur 1 Coryllos klassifikation, Walsh et al, JAMA Otolar, 2017 - Visitation: Vurdering og behandling af spædbørn med ammeproblemer på grund af ankyloglossi gøres hos privatpraktiserende øre-næse-hals specialister. Tvivlstilfælde eller behandlingsrefraktære tilfælde kan vurderes på hospital. Vi tilråder at nedenstående punkter er opfyldt inden henvisning: - - Familien har modtaget grundig ammevejledning - Begrundet mistanke om at ammeproblemet kan relateres til ankyloglossi - Forældre ønsker kirurgisk behandling af ankyloglossi Fremgangsmåde Anamnese: Ammeproblem består trods relevant vejledning og henvisende sundhedsfaglige (jordemoder, sundhedsplejerske, egen læge, pædiater) har mistanke om ankyloglossi som årsagsforklaring. Objektiv undersøgelse: Cavum oris inspiceres bedst når spædbarnet ligger på mors skød, med hovedet vendt mod undersøgeren og benene mod mor, en hjerteformet tungeretraktor kan anvendes. Anatomi og mobilitet af tungen vurderes. Med finger palperes fortil i mundhulen for eventuel stramning, hvor et summukøst fibrøst stræg også vil kunne erkendes. Kontraindikationer: Komorbiditet (ASA ³3), kraniofacial misdannelse, neurologisk sygdom eller blødningsforstyrrelse. Kirurgisk behandling: Frenektomi af ankyloglossi hos spædbørn kan gøres ambulant. Frenulum lingua fremstilles og gennemklippes midt mellem tungespids og mundgulv. Der kan anvendes saks eller monopolær brændespids. Der klippes indtil stramning er gennemklippet, hos nogle også mubmukøst igennem til muskulaturen. Smertebehandling: Der kan gives sukker-vand (2ml per gang af 24% sukkeropløsning) som smertebehandling. Der kan evt. suppleres med lokal overfladeanalgesi (lidokain/adenalin på meche). Postoperativ plan: Amming kan straks genoptages, og virker smertelindrende. Betydningen af tungemobilitets øvelser efter frenektomi er ukendt, men anbefales i nogle centre. Der er ikke behov for ambulant opfølgning. Komplikationer: Blødning, infektion og arvævsdannelse kan sjældent forekomme. Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil 1. Diagnosis and Treatment of Ankyloglossia in Newborns and Infants: A Review; Jonathan Walsh, MD; David Tunkel, MD; JAMA Otolaryngology–Head & Neck Surgery; October 2017 Volume 143, Number 10; 1032-1039 2. Frenotomy for tongue-tie in newborn infants (Review); O’Shea JE, Foster JP, O’Donnell CPF, Breathnach D, Jacobs SE, Todd DA, Davis PG; Cochrane Database of Systematic Reviews 2017, Issue 3. Art. No.: CD011065 3. Division of ankyloglossia (tongue-tie) for breastfeeding, National Institute for Health and Care Excellence, 14 December 2005. nice.org.uk/guidance/ipg149 4. Frenectomy for the Correction of Ankyloglossia: A Review of Clinical Effectiveness and Guidelines; Canadian Agency for Drugs and Technologies in Health, 15 June 2016. 5. Treatment of Ankyloglossia and Breastfeeding Outcomes: A Systematic Review; David O. Francis et al; Pediatrics; 2015:135, Bilag

<h1><div id="Afsnit#1699579298196">Kirurgisk behandling af kort tungebånd (frenectomi) ved problemer med amning</div></h1><div id="BodyWeb#1699579298196"><p>&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><a name="16995792981961668682464719Top"></a><strong><span style="color:#222222"><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#16995792981961668682464719Maalgrupper" style="color:blue; text-decoration:underline">Målgrupper og anvendelsesområde</a></span></strong><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#16995792981961668682464719Definitioner" style="color:blue; text-decoration:underline"><strong>Definitioner</strong></a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#16995792981961668682464719Fremgangsmaade" style="color:blue; text-decoration:underline"><strong>Fremgangsmåde</strong></a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#16995792981961668682464719Ansvar" style="color:blue; text-decoration:underline"><strong>Ansvar og organisering</strong></a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#16995792981961668682464719Referencer" style="color:blue; text-decoration:underline"><strong>Referencer, lovgivning og faglig evidens samt links hertil</strong></a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#16995792981961668682464719Bilag" style="color:blue; text-decoration:underline"><strong>Bilag</strong></a><br> <strong>&nbsp;</strong></p> <p style="margin-left:0cm; margin-right:0cm"><a name="16995792981961668682464719Maalgrupper"></a><br> <strong><span style="color:#222222">Målgrupper og anvendelsesområde</span></strong></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><a href="https://vip.regionh.dk/vip/slutbruger/Portal.nsf/mainEnterprise.html?OpenPage#1668682464719Top" style="color:blue; text-decoration:underline">Tilbage til top</a></p> <p style="margin-left:0cm; margin-right:0cm"><a name="16995792981961668682464719Definitioner"></a><br> &nbsp;</p> <h3 style="margin-left:0cm; margin-right:0cm">Formål</h3> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#222222">Korrekt diagnostik og behandling af spædbørn med ammeproblemer som skyldes stramt tungebånd (ankyloglossi).</span></p> <h3 style="margin-left:0cm; margin-right:0cm">Definition</h3> <p style="margin-left:0cm; margin-right:0cm">Definitionen af ankyloglossi er omdiskuteret. Ved klassisk anatomisk ankyloglossi hæfter det linguale frenulum fortil på apex lingua (kaldes nu anterior ankyloglossi af nogle). Der kan være tunge mobilitets problemer relateret til ankyloglossi, selvom frenulum ikke hæfter på apex lingua. Hvis frenulum hæfter midt på tungens underside eller bagud mod mundbunden kaldes det posterior ankyloglossi af nogle. Det er god praksis at anvende en systematisk vurderingsmetode til at vurdere tungebåndets udseende og mobilitet hos de børn, der har ammeproblemer, og hvor der er mistanke om ankyloglossi. Det anbefales, at anvende Tongue-tie and Breastfed Babies Assessment Tool (TABBY). Der henvises endvidere til dette link for mere information og instruktionsvideoer <a href="http://kompetencecenterforamning.dk/projekter/national-klinisk-retningslinje-for-stramt-tungebaand/vejledningsfilm-i-vurdering-af-barnets-tunge.aspx" style="color:blue; text-decoration:underline">vejledningsfilm i vurdering af barnets tunge</a>. Der er lavet en national klinisk retningslinje for behandling af kort tungebånd, se bilag.</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <h3 style="margin-left:0cm; margin-right:0cm"><img alt="Et billede, der indeholder pil Automatisk genereret beskrivelse" src="data:image/png;base64,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" style="height:465px; width:642px" onclick="Ext.DMS.util.showImage(this);"></h3> <p style="margin-left:0cm; margin-right:0cm"><a href="https://vip.regionh.dk/vip/slutbruger/Portal.nsf/mainEnterprise.html?OpenPage#1668682464719Top" style="color:blue; text-decoration:underline">Tilbage til top</a></p> <p style="margin-left:0cm; margin-right:0cm"><a name="16995792981961668682464719Fremgangsmaade"></a><br> <strong><span style="color:#222222">Fremgangsmåde</span></strong></p> <ol> <li>Ætiologi: Ankyloglossi er en medfødt anomali, der kan begrænse mobiliteten af tungen. Ankyloglossier oftest asymptomatisk. Ankyloglossikan dog medføre ammeproblemer hvor spædbarnet ikke få godt fat om brystet og svøbe brystvorten og det kan give moderen ømme brystvorter. Der er ikke påvist en sikker sammenhæng mellem ankyloglossiog dårlig trivsel (manglende vægtøgning), gastrooesophageal refluks eller udvikling af udtaleproblemer senere i livet. Kirurgisk behandling af ankyloglossikan bedrer ammeproblemer på kort sigt. Derimod er effekten af indgrebet på længere sigt ukendt. Det er derfor uvist, om ammeproblemerne spontant ville svinde uden behandling som følge af ammetræning, spontant træk på tungebåndet mm.</li> </ol> <p style="margin-left:36pt; margin-right:0cm">&nbsp;</p> <ol start="2"> <li>Forekomst: Prævalensen af ankyloglossier opgivet fra 0,1-12% af spædbørn. Den store forskel tilskrives forskelle i definition af ankyloglossi. Figur 1 Coryllos klassifikation, Walsh et al, JAMA Otolar, 2017</li> </ol> <p style="margin-left:36pt; margin-right:0cm">&nbsp;</p> <ol start="3"> <li>Visitation: Vurdering og behandling af spædbørn med ammeproblemer på grund af ankyloglossi gøres hos privatpraktiserende øre-næse-hals specialister. Tvivlstilfælde eller behandlingsrefraktære tilfælde kan vurderes på hospital. Vi tilråder at nedenstående punkter er opfyldt inden henvisning:</li> </ol> <p style="margin-left:36pt; margin-right:0cm">&nbsp;</p> <ol> <li style="list-style-type:none"> <ol style="list-style-type:lower-alpha"> <li>Familien har modtaget grundig ammevejledning</li> <li>Begrundet mistanke om at ammeproblemet kan relateres til ankyloglossi</li> <li>Forældre ønsker kirurgisk behandling af ankyloglossi</li> </ol> </li> </ol> <h3 style="margin-left:0cm; margin-right:0cm">Fremgangsmåde</h3> <p style="margin-left:0cm; margin-right:0cm">Anamnese: Ammeproblem består trods relevant vejledning og henvisende sundhedsfaglige (jordemoder, sundhedsplejerske, egen læge, pædiater) har mistanke om ankyloglossi som årsagsforklaring.</p> <p style="margin-left:0cm; margin-right:0cm">Objektiv undersøgelse: Cavum oris inspiceres bedst når spædbarnet ligger på mors skød, med hovedet vendt mod undersøgeren og benene mod mor, en hjerteformet tungeretraktor kan anvendes. Anatomi og mobilitet af tungen vurderes. Med finger palperes fortil i mundhulen for eventuel stramning, hvor et summukøst fibrøst stræg også vil kunne erkendes.</p> <p style="margin-left:0cm; margin-right:0cm">Kontraindikationer: Komorbiditet (ASA ³3), kraniofacial misdannelse, neurologisk sygdom eller blødningsforstyrrelse.</p> <p style="margin-left:0cm; margin-right:0cm">Kirurgisk behandling: Frenektomi af ankyloglossi hos spædbørn kan gøres ambulant. Frenulum lingua fremstilles og gennemklippes midt mellem tungespids og mundgulv. Der kan anvendes saks eller monopolær brændespids. Der klippes indtil stramning er gennemklippet, hos nogle også mubmukøst igennem til muskulaturen.</p> <p style="margin-left:0cm; margin-right:0cm">Smertebehandling: Der kan gives sukker-vand (2ml per gang af 24% sukkeropløsning) som smertebehandling. Der kan evt. suppleres med lokal overfladeanalgesi (lidokain/adenalin på meche).</p> <p style="margin-left:0cm; margin-right:0cm">Postoperativ plan: Amming kan straks genoptages, og virker smertelindrende. Betydningen af tungemobilitets øvelser efter frenektomi er ukendt, men anbefales i nogle centre. Der er ikke behov for ambulant opfølgning.</p> <p style="margin-left:0cm; margin-right:0cm">Komplikationer: Blødning, infektion og arvævsdannelse kan sjældent forekomme.</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><a name="16995792981961668682464719Ansvar"></a><br> <strong><span style="color:#222222">Ansvar og organisering</span></strong></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><a href="https://vip.regionh.dk/vip/slutbruger/Portal.nsf/mainEnterprise.html?OpenPage#1668682464719Top" style="color:blue; text-decoration:underline">Tilbage til top</a></p> <p style="margin-left:0cm; margin-right:0cm"><a name="16995792981961668682464719Referencer"></a><br> <strong><span style="color:#222222">Referencer, lovgivning og faglig evidens samt links hertil</span></strong></p> <p style="margin-left:0cm; margin-right:0cm">1. Diagnosis and Treatment of Ankyloglossia in Newborns and Infants: A Review; Jonathan Walsh, MD; David Tunkel, MD; JAMA Otolaryngology–Head &amp; Neck Surgery; October 2017 Volume 143, Number 10; 1032-1039</p> <p style="margin-left:0cm; margin-right:0cm">2. Frenotomy for tongue-tie in newborn infants (Review); O’Shea JE, Foster JP, O’Donnell CPF, Breathnach D, Jacobs SE, Todd DA, Davis PG; Cochrane Database of Systematic Reviews 2017, Issue</p> <p style="margin-left:0cm; margin-right:0cm">3. Art. No.: CD011065 3. Division of ankyloglossia (tongue-tie) for breastfeeding, National Institute for Health and Care Excellence, 14 December 2005. nice.org.uk/guidance/ipg149</p> <p style="margin-left:0cm; margin-right:0cm">4. Frenectomy for the Correction of Ankyloglossia: A Review of Clinical Effectiveness and Guidelines; Canadian Agency for Drugs and Technologies in Health, 15 June 2016.</p> <p style="margin-left:0cm; margin-right:0cm">5. Treatment of Ankyloglossia and Breastfeeding Outcomes: A Systematic Review; David O. Francis et al; Pediatrics; 2015:135,</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><a href="https://vip.regionh.dk/vip/slutbruger/Portal.nsf/mainEnterprise.html?OpenPage#1668682464719Top" style="color:blue; text-decoration:underline">Tilbage til top</a></p> <p style="margin-left:0cm; margin-right:0cm"><a name="16995792981961668682464719Bilag"></a><br> <strong><span style="color:#222222">Bilag</span></strong></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><a href="https://vip.regionh.dk/vip/slutbruger/Portal.nsf/mainEnterprise.html?OpenPage#1668682464719Top" style="color:blue; text-decoration:underline">Tilbage til top</a></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <h2>&nbsp;</h2> <p>&nbsp;</p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Klarg¢ring af brugte udleveringsh¢reapparater.

Klargøring af brugte udleveringshøreapparater Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Målgrupper og anvendelsesområde Personale på Hørepædagogisk afsnit, GeH Definitioner Fremgangsmåde Hvis der stadig er garanti på et brugt høreapparat, sendes det til det pågældende firma, hvorefter det genoptages på lager. Hos firmaet vil de gennemgå rengøring og teknisk kontrol samt klargøres til udlevering, hvilket for eksempel vil sige få nyt hus, hook, batteriskuffe osv. På følgesedlen skal noteres: almindelig rens og eftersyn m.h.p. genudlevering (lagerapp.) Når apparatet lægges tilbage på lager, tages stilling til, om det skal lægges på primærlager eller sekundærlager. Hvis apparatet har været udleveret i mindre end seks måneder, lægges det på primærlager. Hvis det har været udleveret mere end seks måneder lægges det på sekundærlager. For alle apparater gælder, at der skal være to år tilbage af garantiperioden, når de udleveres. Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag

<h1><div id="Afsnit#1699579387249">Klargøring af brugte udleveringshøreapparater</div></h1><div id="BodyWeb#1699579387249"><p><a name="1699579387249Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579387249Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579387249Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579387249Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579387249Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579387249Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579387249Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579387249Bilag">Bilag</a><br> &nbsp;</h3> <h2><a name="1699579387249Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p>Personale på Hørepædagogisk afsnit, GeH&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579387249Top">Tilbage til top</a></p> <h2><a name="1699579387249Definitioner"></a><br> Definitioner</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579387249Top">Tilbage til top</a></p> <h2><a name="1699579387249Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p><span style="color:#000000">Hvis der stadig er garanti på et brugt høreapparat, sendes det til det pågældende firma, hvorefter det genoptages på lager. Hos firmaet vil de gennemgå rengøring og teknisk kontrol samt klargøres til udlevering, hvilket for eksempel vil sige få nyt hus, hook, batteriskuffe osv. </span></p> <p><span style="color:#000000">På følgesedlen skal noteres: <em>almindelig rens og eftersyn m.h.p. genudlevering (lagerapp.)</em><br> <br> Når apparatet lægges tilbage på lager, tages stilling til, om det skal lægges på primærlager eller sekundærlager. Hvis apparatet har været udleveret i mindre end seks måneder, lægges det på primærlager. Hvis det har været udleveret mere end seks måneder lægges det på sekundærlager. For alle apparater gælder, at der skal være to år tilbage af garantiperioden, når de udleveres.</span></p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579387249Top">Tilbage til top</a></p> <h2><a name="1699579387249Ansvar"></a><br> Ansvar og organisering</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579387249Top">Tilbage til top</a></p> <h2><a name="1699579387249Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579387249Top">Tilbage til top</a></p> <h2><a name="1699579387249Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579387249Top">Tilbage til top</a></p> <h2><a name="1699579387249Bilag"></a><br> Bilag</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579387249Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Kostformer retningslinjer for ordination af.

Kostformer, retningslinjer for ordination af Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Målgrupper og anvendelsesområde Klinisk personale i Øre-næse-halskirurgisk og Audiologisk Klinik Fremgangsmåde Retningslinier for ordination af kostform i forbindelse med operative indgreb i Øre-næse-halskirurgisk og Audiologisk Klinik ###TABEL_1### Ansvar og organisering Klinikledelse Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag

<h1><div id="Afsnit#1699579317979">Kostformer, retningslinjer for ordination af</div></h1><div id="BodyWeb#1699579317979"><p> <a name="1699579317979Top"></a></p> <h3> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579317979Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579317979Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579317979Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579317979Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579317979Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579317979Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579317979Bilag">Bilag</a><br> &nbsp;</h3> <h2> <a name="1699579317979Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p> Klinisk personale i Øre-næse-halskirurgisk og Audiologisk Klinik</p> <p> &nbsp;</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579317979Top">Tilbage til top</a></p> <h2> <a name="1699579317979Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p> <strong>Retningslinier for ordination af kostform i forbindelse med operative indgreb i Øre-næse-halskirurgisk og Audiologisk Klinik </strong></p> <p> &nbsp;</p> ###TABEL_1### <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579317979Top">Tilbage til top</a></p> <h2> <a name="1699579317979Ansvar"></a><br> Ansvar og organisering</h2> <p> Klinikledelse&nbsp;</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579317979Top">Tilbage til top</a></p> <h2> <a name="1699579317979Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p> &nbsp;</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579317979Top">Tilbage til top</a></p> <h2> <a name="1699579317979Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p> &nbsp;</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579317979Top">Tilbage til top</a></p> <h2> <a name="1699579317979Bilag"></a><br> Bilag</h2> <p> &nbsp;</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579317979Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Kostformer retningslinjer for ordination af_TABEL_1.

Operation/behandling Kostform Næse, bihuler og frakturer Epistaxis Ispiller. Gerne kolde drikke og spiser. Alkohol (og tobak) frarådes. Septum Næsefrakturer FESS Efter evne Zygomafrakturer Mandibel -og maxilfrakturer Blød kost i 14 dage eller efter ordination Hoved/hals Tonsillectomi Peritonsillær absces Direkte laryngoscopi Fuldkost. Gerne /bedst blød kost . Laryngectomi Er minus per os 10 -12 dage som angivet i operationsnotatet. Sondemad iflg VIP Drikkeprøve foretages ved stuegangsgående læge Holder det tørt, må der resten af døgnet indtages koldt, klart flydende - herefter ét døgn med flydende kost, - efterfulgt af én uge med blød kost, - hvorefter patienten kan stige til kost efter evne. Oesophagoskopi Intet per os i 4 timer (obs. blødning, perforation) Klart, flydende første døgn, herefter efter evne. Zenckers divertikel Intet per os i 6 timer, derefter flydende i første døgn Blød kost i én uge Parotidectomi Halsglandel dissektion Fuldkost Hemithyreoidectomi Fuldkost. Mundhuleopererede Lap-opererede Intet per os i 7 dage, sondekost. Herefter individuel ordination Mindre lapper, f.eks. FAMM-lap, Flydende kost eller iht operatørnotat. Resektion, åbne sårflader Flydende/blød kost p.gr.a. smerter Resektion, suturerede sårflader Flydende til blød kost eller efter ordination. Gerne mundskylle med vand Øreoperationer Alle typer øreoperationer Fuldkost. Ingen restriktioner.

<table border="1" cellpadding="1" cellspacing="1" style="width: 500px"> <tbody> <tr> <td> <strong>Operation/behandling </strong></td> <td> <strong>Kostform </strong></td> </tr> <tr> <td> <strong>Næse, bihuler og frakturer </strong></td> <td> &nbsp;</td> </tr> <tr> <td> Epistaxis</td> <td> <p> Ispiller. Gerne kolde drikke og spiser.</p> <p> Alkohol (og tobak) frarådes.</p> </td> </tr> <tr> <td> <p> Septum</p> <p> Næsefrakturer</p> <p> FESS</p> </td> <td> Efter evne</td> </tr> <tr> <td> <p> Zygomafrakturer</p> <p> Mandibel -og maxilfrakturer</p> </td> <td> Blød kost i 14 dage eller efter ordination</td> </tr> <tr> <td> <strong>Hoved/hals </strong></td> <td> &nbsp;</td> </tr> <tr> <td> <p> Tonsillectomi</p> <p> Peritonsillær absces</p> <p> Direkte laryngoscopi</p> </td> <td> Fuldkost. Gerne /bedst blød kost .</td> </tr> <tr> <td> Laryngectomi</td> <td> <p> Er minus per os 10 -12 dage som angivet i operationsnotatet.</p> <p> Sondemad&nbsp;iflg VIP</p> <p> Drikkeprøve foretages ved stuegangsgående læge</p> <p> Holder det tørt, må der resten af døgnet indtages koldt, klart flydende -</p> <p> herefter ét døgn med flydende kost, -</p> <p> efterfulgt af én uge med blød kost, -</p> <p> hvorefter patienten kan stige til kost efter evne.</p> </td> </tr> <tr> <td> Oesophagoskopi</td> <td> Intet per os i 4 timer (obs. blødning, perforation) Klart, flydende første døgn, herefter efter evne.</td> </tr> <tr> <td> Zenckers divertikel</td> <td> Intet per os i 6 timer, derefter flydende i første døgn Blød kost i én uge</td> </tr> <tr> <td> <p> Parotidectomi</p> <p> Halsglandel dissektion</p> </td> <td> Fuldkost</td> </tr> <tr> <td> Hemithyreoidectomi</td> <td> Fuldkost.</td> </tr> <tr> <td> <strong>Mundhuleopererede </strong></td> <td> &nbsp;</td> </tr> <tr> <td> Lap-opererede</td> <td> <p> Intet per os i 7 dage, sondekost.</p> <p> Herefter individuel ordination</p> </td> </tr> <tr> <td> Mindre lapper,&nbsp;f.eks. FAMM-lap,</td> <td> <p> Flydende kost eller iht operatørnotat.</p> </td> </tr> <tr> <td> Resektion, åbne sårflader</td> <td> Flydende/blød kost p.gr.a. smerter</td> </tr> <tr> <td> Resektion, suturerede sårflader</td> <td> <p> Flydende til blød kost eller efter ordination.</p> <p> Gerne mundskylle med vand</p> </td> </tr> <tr> <td> <strong>Øreoperationer </strong></td> <td> &nbsp;</td> </tr> <tr> <td> Alle typer øreoperationer</td> <td> Fuldkost. Ingen restriktioner.</td> </tr> </tbody> </table>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Kronisk otitis media Behandling af.

Kronisk otitis media, Behandling af Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Målgrupper og anvendelsesområde Læger og sygeplejersker Definitioner Fremgangsmåde Forberedelse til operation: Konferér med ørekirurg, når indlæggelse planlægges. Øret skal så vidt muligt tørlægges konservativt før operationen ved at: - Fraråde svømmebadning - Kradsning - Brug af høreapparat - Lokalbehandle med oprensning under mikroskop og skylning med 50% eddikevand eller drypning med øredråber m. antibiotika og/eller hydrocortison (f.eks. Ciflox, Cilodex, Diproderm, Elocon) - Ørerne kan ikke altid blive helt tørre før operation. Svampeinfektioner bør dog nedkæmpes med methylrosanilin pensling og evt. brentan mecher (ofte langvarig behandling) før operation. - Der skal foreligge en komplet, aktuel audiologisk undersøgelse før operation. - Patienten skal ses og orienteres af operatøren før operation. Operationstyper: Resectio processus mastoidei: Opboring af processus mastoideus. Anvendes ved mastoiditis og cholesteatoma. Myringoplastik: Lukning af trommehindeperforation uden indgreb i mellemøret. Tympanoplastik type I: Operation på mellemøret. Knoglekæden intakt. Tympanoplastik type II: Operation på mellemøret. Knoglekæden er brudt, men stapes er intakt. Lydledningen forsøges genoprettet ved interponering af protese (oftest egen incus) mellem stapes, hammer og trommehinde. Tympanoplastik type III: Operation på mellemøret. Knoglekæden er brudt og stapesbuen defekt. Lydledning forsøges genoprettet ved interponering af protese mellem fodpladen og trommehinden. Radikaloperation: Opboring af processus mastoideus og fjernelse af øregangens bagvæg og udvidelse af øregangen. Foretages ved cholesteatom. Tympanotomi: Diagnostisk åbning af mellemøret. Efterkontrol: - Normalt kan patienten udskrives til hjemmet dagen efter operationen. - En eventuel hovedforbinding fjernes forinden og erstattes af vat og plaster, som sammen med et evt. mastoidal-dræn skal sidde tørt og urørt indtil mechefjernelse 3 uger postoperativt (så vidt muligt hos operatøren). Har patienten ikke dræn efter mastoidektomi, skal næsepudsning undgåes. - Vejledende tidsskema for kontroller: Tidsskema for kontroller.doc. Relevante links: Der findes instruks: Akut mastoiditis, Behandling af Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag

<h1><div id="Afsnit#1699579291154">Kronisk otitis media, Behandling af</div></h1><div id="BodyWeb#1699579291154"><p> <a name="1699579291154Top"></a></p> <h3> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579291154Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579291154Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579291154Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579291154Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579291154Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579291154Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579291154Bilag">Bilag</a><br> &nbsp;</h3> <h2> <a name="1699579291154Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p> Læger og sygeplejersker&nbsp;</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579291154Top">Tilbage til top</a></p> <h2> <a name="1699579291154Definitioner"></a><br> Definitioner</h2> <p> &nbsp;</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579291154Top">Tilbage til top</a></p> <h2> <a name="1699579291154Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p> F<strong>orberedelse til operation:</strong></p> <p> Konferér med ørekirurg, når indlæggelse planlægges.</p> <p> Øret skal så vidt muligt tørlægges konservativt før operationen ved at:</p> <ul> <li> Fraråde svømmebadning</li> <li> Kradsning</li> <li> Brug af høreapparat</li> <li> Lokalbehandle med oprensning under mikroskop og skylning med 50% eddikevand eller drypning med&nbsp;øredråber m. antibiotika og/eller hydrocortison (f.eks. Ciflox, Cilodex, Diproderm, Elocon)</li> <li> Ørerne kan ikke altid blive helt tørre før operation. Svampeinfektioner bør dog nedkæmpes med <a href="http://www.lk-online.dk/" target="_blank">methylrosanilin pensling og evt. brentan mecher</a> (ofte langvarig behandling) før operation.</li> <li> Der skal foreligge en komplet, aktuel audiologisk undersøgelse før operation.</li> <li> Patienten skal ses og orienteres af operatøren før operation.</li> </ul> <p> &nbsp;<strong>Operationstyper:</strong></p> <p> <b><u><span style="line-height: 140%; font-family: 'Tahoma','sans-serif'; color: black; font-size: 10pt">Resectio processus mastoidei:</span></u></b><br> <span style="line-height: 140%; font-family: 'Tahoma','sans-serif'; color: black; font-size: 10pt">Opboring af processus mastoideus. Anvendes ved mastoiditis og cholesteatoma.<o:p></o:p></span></p> <p> <span style="line-height: 140%; font-family: 'Tahoma','sans-serif'; color: black; font-size: 10pt"><o:p></o:p></span></p> <p> <b><u><span style="line-height: 140%; font-family: 'Tahoma','sans-serif'; color: black; font-size: 10pt">Myringoplastik:</span></u></b><br> <span style="line-height: 140%; font-family: 'Tahoma','sans-serif'; color: black; font-size: 10pt">Lukning af trommehindeperforation uden indgreb i mellemøret.</span><span style="line-height: 140%; font-family: 'Tahoma','sans-serif'; color: black; font-size: 10pt">&nbsp;<o:p></o:p></span></p> <p> <b><u><span style="line-height: 140%; font-family: 'Tahoma','sans-serif'; color: black; font-size: 10pt">Tympanoplastik type I:</span></u></b><br> <span style="line-height: 140%; font-family: 'Tahoma','sans-serif'; color: black; font-size: 10pt">Operation på mellemøret. Knoglekæden intakt.<o:p></o:p></span></p> <p> <span style="line-height: 140%; font-family: 'Tahoma','sans-serif'; color: black; font-size: 10pt"><o:p></o:p></span></p> <p> <b><u><span style="line-height: 140%; font-family: 'Tahoma','sans-serif'; color: black; font-size: 10pt">Tympanoplastik type II:</span></u></b><br> <span style="line-height: 140%; font-family: 'Tahoma','sans-serif'; color: black; font-size: 10pt">Operation på mellemøret. Knoglekæden er brudt, men stapes er intakt. Lydledningen forsøges genoprettet ved interponering af protese (oftest egen incus) mellem stapes, hammer og trommehinde.</span><span style="line-height: 140%; font-family: 'Tahoma','sans-serif'; color: black; font-size: 10pt">&nbsp;<o:p></o:p></span></p> <p> <b><u><span style="line-height: 140%; font-family: 'Tahoma','sans-serif'; color: black; font-size: 10pt">Tympanoplastik type III:</span></u></b><br> <span style="line-height: 140%; font-family: 'Tahoma','sans-serif'; color: black; font-size: 10pt">Operation på mellemøret. Knoglekæden er brudt og stapesbuen defekt. Lydledning forsøges genoprettet ved interponering af protese mellem fodpladen og trommehinden.</span><span style="line-height: 140%; font-family: 'Tahoma','sans-serif'; color: black; font-size: 10pt">&nbsp;<o:p></o:p></span></p> <p> <b><u><span style="line-height: 140%; font-family: 'Tahoma','sans-serif'; color: black; font-size: 10pt">Radikaloperation:</span></u></b><br> <span style="line-height: 140%; font-family: 'Tahoma','sans-serif'; color: black; font-size: 10pt">Opboring af processus mastoideus og fjernelse af øregangens bagvæg og udvidelse af øregangen. Foretages ved cholesteatom.<o:p></o:p></span></p> <p> <span style="line-height: 140%; font-family: 'Tahoma','sans-serif'; color: black; font-size: 10pt"><o:p></o:p></span></p> <p> <b><u><span style="line-height: 140%; font-family: 'Tahoma','sans-serif'; color: black; font-size: 10pt">Tympanotomi:</span></u></b><br> <span style="line-height: 140%; font-family: 'Tahoma','sans-serif'; color: black; font-size: 10pt">Diagnostisk åbning af mellemøret.</span></p> <p> <span style="line-height: 140%; font-family: 'Tahoma','sans-serif'; color: black; font-size: 10pt"><o:p></o:p></span></p> <p> <strong>Efterkontrol:</strong></p> <ul> <li> Normalt kan patienten <u>udskrives</u> til hjemmet dagen efter operationen.</li> <li> En eventuel <u>hovedforbinding</u> fjernes forinden og erstattes af vat og plaster, som sammen med et evt. mastoidal-dræn skal sidde tørt og urørt indtil mechefjernelse 3 uger postoperativt (så vidt muligt hos operatøren). Har patienten ikke dræn efter mastoidektomi, skal næsepudsning undgåes.</li> <li> <u>Vejledende tidsskema</u> for kontroller:&nbsp;<strong> <a href="http://vip.regionh.dk/VIP/Redaktoer/130126.nsf/vLookupUpload/RHAP8M26Y62/$File/Tidsskema%20for%20kontroller.doc" target="_blank"><img src="http://vip.regionh.dk/icons/vwicn005.gif">Tidsskema for kontroller.doc</a>.</strong></li> </ul> <p> <strong>Relevante links:</strong></p> <p> <strong>Der findes instruks: </strong><strong><a href="###FOLDER###" target="_blank">Akut mastoiditis, Behandling af</a></strong></p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579291154Top">Tilbage til top</a></p> <p> &nbsp;</p> <h2> <a name="1699579291154Ansvar"></a><br> Ansvar og organisering</h2> <p> &nbsp;</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579291154Top">Tilbage til top</a></p> <h2> <a name="1699579291154Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p> &nbsp;</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579291154Top">Tilbage til top</a></p> <h2> <a name="1699579291154Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p> &nbsp;</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579291154Top">Tilbage til top</a></p> <h2> <a name="1699579291154Bilag"></a><br> Bilag</h2> <p> &nbsp;</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579291154Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Kæbehulepunktur Pleje og behandling af patienter.

Kæbehulepunktur, Pleje og behandling af patienter Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Målgrupper og anvendelsesområde Klinisk personale i Afdeling for Øre-Næse-Halskirurgi og Audiologi Fremgangsmåde Baggrund: - Ved bihulebetændelse (sinuitis acuta) kan det være nødvendigt at foretage kæbehulepunktur. - De fleste bihulebetændelser optræder i tilslutning til en almindelig forkølelse eller influenza. - Symptomerne kan være smerter (hyppigst i panden), purulent sekretion, nasalstenose og feber. - Formålet er at aflaste kæbehulen ved gennemskylning med fjernelse af sekret. - For at undgå gentagne kæbehulepunkturer, kan lægen for en tid indlægge et tyndt dræn (sinoject) i kæbehulen. Kæbehulepunktur med kanyle: Nedenfor er beskrevet, procedure, behandling og pleje, når kæbehulepunkturen foretages uden indlæggelse af dræn. Remedier: Der anvendes og klargøres følgende remedier: - Sterilt afdækningsstykke - Vinkelpincet eller bajonetpincet - Vat - Lidokain-adrenalin 2 % til lokalbedøvelse - 2 stk. sterile kæbehulepunkturkanyler. - Varmt NaCl (hav minimum 4 - 5 x 150 ml klar), - Plastikfad med skylleapparatur, hvorpå der monteres studs passende til kæbepunkturkanyle. Evt. kan 20 ml sprøjte også bruges Behandling/pleje: - Lægen lægger lokalbedøvelsen med vat og Lidokain adrenalin 2 % under concha inferior (gennem næsen). Dette skal virke minimum 10 minutter. - Det varme vand hældes i det blå fad, skylleapparaturet påmonteres og der skylles. - Det er hensigtsmæssigt, at patienten sidder let foroverbøjet med kapslen foran sig, idet skyllevæsken løber ud gennem næse og mund. Kæbehulepunktur med Sinoject: Nedenfor er beskrevet, procedure, behandling og pleje, når kæbehulepunkturen udføres med Sinoject (med indlæggelse af dræn). Remedier: Der anvendes og klargøres følgende remedier: - Sterilt afdækningsstykke - Vinkelpincet eller bajonetpincet - Vat - Lidokain-adrenalin 2 % til lokalbedøvelse - Sinoject "pistol" - Sinojectdræn - Sinoject-connection - Varmt NaCl (hav minimum 4 - 5 x 150 ml klar), - Sterilkapsel til NaCl - 50 ml engangssprøjte som passer til sinoject-connection Behandling/pleje: - Lægen lægger lokalbedøvelsen med vat og Lidokain-adrenalin 2 % under concha inferior (gennem næsen). Dette skal virke minimum 10 minutter. - Lægen "skyder" sinoject-drænet på plads, imens støtter sygeplejersken patientens hoved. - Sinoject-connectionen placeres herefter. - Det varme NaCl hældes i steril kapsel, og lægen skyller med 50 ml sprøjten. - Det er hensigtsmæssigt, at patienten sidder let foroverbøjet med kapslen foran sig, idet skyllevæsken løber ud gennem næse og mund. - Lægen vurderer, hvornår patienten næste gang skal komme til skylning, samt hvor længe drænet skal blive siddende. Skylningen foretages i begyndelsen af forløbet 2-3 gange ugentligt. Efterhånden som sekretmængden aftager kan intervallet øges til f.eks. 1 x om ugen. Når skyllevæsken er helt klar, kan skylningerne ophøre. - Evt. bedes patienten om at medbringe den anvendte 50 ml sprøjte samt den rengjorte sinojectconnection ved næste ambulante besøg. - Lægen tager stilling til opstart af evt. systemisk antibiotikabehandling samt til smertestillende medicin. Information til patienten: Sygeplejersken informerer (evt. i samarbejde med lægen) om kæbehulepunkturen og skylningen. Ansvar og organisering Afdelingsledelsen Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag

<h1><div id="Afsnit#1699579309205">Kæbehulepunktur, Pleje og behandling af patienter</div></h1><div id="BodyWeb#1699579309205"><p><a name="1699579309205Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579309205Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579309205Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579309205Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579309205Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579309205Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579309205Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579309205Bilag">Bilag</a><br> &nbsp;</h3> <h2><a name="1699579309205Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p>Klinisk personale i Afdeling for Øre-Næse-Halskirurgi og Audiologi</p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579309205Top">Tilbage til top</a></p> <h2><a name="1699579309205Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p><strong>Baggrund:</strong></p> <ul> <li>Ved bihulebetændelse (sinuitis acuta) kan det være nødvendigt at foretage kæbehulepunktur.</li> <li>De fleste bihulebetændelser optræder i tilslutning til en almindelig forkølelse eller influenza.</li> <li>Symptomerne kan være smerter (hyppigst i panden), purulent sekretion, nasalstenose og feber.</li> <li>Formålet er at aflaste kæbehulen ved gennemskylning med fjernelse af sekret.</li> <li>For at undgå gentagne kæbehulepunkturer, kan lægen for en tid indlægge et tyndt dræn (sinoject) i kæbehulen.</li> </ul> <p><strong>Kæbehulepunktur med kanyle:</strong></p> <p>Nedenfor er beskrevet, procedure, behandling og pleje, når kæbehulepunkturen foretages <strong><em>uden</em></strong> indlæggelse af dræn.</p> <p><strong>Remedier:</strong></p> <p>Der anvendes og klargøres følgende remedier:</p> <ul> <li>Sterilt afdækningsstykke</li> <li>Vinkelpincet eller bajonetpincet</li> <li>Vat</li> <li>Lidokain-adrenalin 2&nbsp;% til lokalbedøvelse</li> <li>2 stk. sterile kæbehulepunkturkanyler.</li> <li><u>Varmt</u> NaCl (hav minimum 4 - 5 x 150 ml klar),</li> <li>Plastikfad med skylleapparatur, hvorpå der monteres studs passende til kæbepunkturkanyle.</li> </ul> <p style="margin-left:36pt">Evt. kan 20 ml sprøjte også bruges</p> <p><strong>Behandling/pleje:</strong></p> <ul> <li>Lægen lægger lokalbedøvelsen med vat og Lidokain adrenalin 2 % under concha inferior (gennem næsen). Dette skal virke minimum 10 minutter.</li> <li>Det varme vand hældes i det blå fad, skylleapparaturet påmonteres og der skylles.</li> <li>Det er hensigtsmæssigt, at patienten sidder let foroverbøjet med kapslen foran sig, idet skyllevæsken løber ud gennem næse og mund.</li> </ul> <p><strong>Kæbehulepunktur med Sinoject:</strong></p> <p>Nedenfor er beskrevet, procedure, behandling og pleje, når kæbehulepunkturen udføres <strong><em>med</em></strong> Sinoject (med indlæggelse af dræn).</p> <p><strong>Remedier:</strong></p> <p>Der anvendes og klargøres følgende remedier:</p> <ul> <li>Sterilt afdækningsstykke</li> <li>Vinkelpincet eller bajonetpincet</li> <li>Vat</li> <li>Lidokain-adrenalin 2&nbsp;% til lokalbedøvelse</li> <li>Sinoject "pistol"</li> <li>Sinojectdræn</li> <li>Sinoject-connection</li> <li><u>Varmt</u> NaCl (hav minimum 4 - 5 x 150 ml klar),</li> <li>Sterilkapsel til NaCl</li> <li>50 ml engangssprøjte som passer til sinoject-connection</li> </ul> <p><strong>Behandling/pleje:</strong></p> <ul> <li>Lægen lægger lokalbedøvelsen med vat og Lidokain-adrenalin 2&nbsp;% under concha inferior (gennem næsen). Dette skal virke minimum 10 minutter.</li> <li>Lægen "skyder" sinoject-drænet på plads, imens støtter sygeplejersken patientens hoved.</li> <li>Sinoject-connectionen placeres herefter.</li> <li>Det varme NaCl hældes i steril kapsel, og lægen skyller med 50 ml sprøjten.</li> <li>Det er hensigtsmæssigt, at patienten sidder let foroverbøjet med kapslen foran sig, idet skyllevæsken løber ud gennem næse og mund.</li> <li>Lægen vurderer, hvornår patienten næste gang skal komme til skylning, samt hvor længe drænet skal blive siddende. Skylningen foretages i begyndelsen af forløbet 2-3 gange ugentligt. Efterhånden som sekretmængden aftager kan intervallet øges til f.eks. 1 x om ugen. Når skyllevæsken er helt klar, kan skylningerne ophøre.</li> <li>Evt. bedes patienten om at medbringe den anvendte 50 ml sprøjte samt den rengjorte sinojectconnection ved næste ambulante besøg.</li> <li>Lægen tager stilling til opstart af evt. systemisk antibiotikabehandling samt til smertestillende medicin.</li> </ul> <p><strong>Information til patienten:</strong></p> <p>Sygeplejersken informerer (evt. i samarbejde med lægen) om kæbehulepunkturen og skylningen.</p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579309205Top">Tilbage til top</a></p> <h2><a name="1699579309205Ansvar"></a><br> Ansvar og organisering</h2> <p>Afdelingsledelsen</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579309205Top">Tilbage til top</a></p> <h2><a name="1699579309205Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579309205Top">Tilbage til top</a></p> <h2><a name="1699579309205Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579309205Top">Tilbage til top</a></p> <h2><a name="1699579309205Bilag"></a><br> Bilag</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579309205Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Lapkirurgi Behandling postoperativt.

Lapkirurgi, Behandling postoperativt Målgrupper og anvendelsesområde Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Målgrupper og anvendelsesområde Klinisk personale i Afdeling for Øre-Næse-Halskirurgi og Audiologi Fremgangsmåde Præoperativt Journaloptagelse Vær opmærksom på: - Huden i såvel operationsområdet på hoved-hals som donorområde - Tidligere bestråling - Type II diabetes - Hypertension - Stillingtagen til tromboseprofylakse - Pulsation i a. dorsalis pedis Blodprøver - Hgb - Na - K - Creatinin - Type - Bas-test Operatør: Samtale med operatør, evt. både øre-næse-halskirurg og plastikkirurg. Anæstesi: Samtale med anæstesilæge. Postoperativt Lappen Kontrolleres hver 2. time de første 2 døgn for: - Farve - Kapillærreaktion og dopplersignal Herefter 2 x i hver vagt. Lokalisation af karstilk er angivet af operatør med tydeligt kryds. En vital lap er fjedrende ved let tryk. Ved stilket lap skal man undgå kompression på stilk, området er tydeligt afmærket af operatør. Ved mistanke om manglende perfusion kan man evt. prikke med kanyle i lappen og se om der kommer kapillærblødning, obs undgå at ramme fødekar. Kontrollér at drænet fungerer og vurder om der er hæmatom. Obs! Ved mistanke om dårlig perfusion, tilkaldes læge (operatør og/eller plastikkirurg) Doppler: Med doppler 5Hz transducer (håndholdt doppler ligger i afsnit 6053/7054) (anvend explorationscreme) eller UL-apparat (står på OP) kontrolleres pulsation i lapstilken. Ved pectoralis major lap kan karstilken fra a. thoracoacromialis findes gående superficielt for clavicula i det af operatøren markerede område. Diureser: Der føres væskeskema og måles timediureser det første døgn, herefter x 1 i vagten. Antiemetika: Der gives præventivt Zofran 8 mg x 3 det første døgn, alternativt 1 mg/time kontinuerlig infusion det første døgn . Dette efterfølges af 8 mg x 2 dagligt i op til 5 døgn. Væskeordination: Der føres væskeskema (+/- balance regnes fra kl. 00.00). Der anvendes tynde væsker (NaCl, basisvæske osv.) Ved behov for plasmasubstitution kan der anvendes Macrodex (dextran), hvorimod der IKKE må anvendes HAES. Der indgives tynde væsker iv. afhængig af: - Hæmatokrit - Per os væskeindtag - Timediureser - BT Ernæring: Såfremt der er udført lapkirurgi i relation til fødevejen anlægges der nasogastrisk sonde. Der må intet gives per os. Der gives relevant sondeernæring i henhold til patientens ernæringstilstand. Mundhygiejne: Intet per os. Kun mundhygiejne i modsat side af lap. Temperatur: Måles x 2 / døgn. BT og puls: Det første døgn måles BT og puls hver 2. time. Herefter x 2 / vagt. Middelblodtrykket skal ligge højt, helst > 130 mmHg systolisk for at sikre perfusion af lap. Mobilisering: Ved operation med frie lapper, skal patienten de første 3 døgn være lejret vandret for at sikre sufficient perfusion af lappen. Der kan maksimalt tillades 30 graders elevation af hovedgærdet. Patienten må ikke mobiliseres i disse tre døgn. Ve operation med stilkede lapper, må patienten, under hensyntagen til den generelle tilstand, mobiliseres fra 1. postoperative døgn. der må dog ikke ske stræk af hand-off området på halsen, ved mobiliseringen. Blodprøver: De første 3 døgn kontrolleres dagligt: - Hgb - NaK - Creatinin - B-erytrocytter volumen fraktion (hæmatokrit) Hæmatokritten må ikke overstige 0.3 (normalværdi: kvinder: 0.35 - 0.47, mænd: 0.40 - 0.52). Ved anæmi overvejes først blodtransfusion ved Hgb under 5.8. Ved hypovolæmi se punktet væskeordination. Ved hgb < 6.5 ordineres tbl. jern-c x 2 dagligt. Tromboseprofylakse: Da patienten er lejret fladt de første 3 døgn gives tromboseprofylakse i 3 døgn. Herefter Magnyl 150 mg dagligt. Se Tromboseprofylakse på Afdeling for Øre-Næse-Halskirurgi og Audiologi Laksantia: Vær opmærksom på Morfin og obstipation. Giv evt. fast de første 3 døgn tbl. Magnesia 1 g dagligt (gives kl. 22). Udskrivelse Fra 3. døgn postoperativt tbl. Magnyl ® 150 mg x 1 i 2 uger. Ansvar og organisering Afdelingsledelsen i Afdeling for Øre-Næse-Halskirurgi og Audiologi Referencer, lovgivning og faglig evidens samt links hertil

<h1><div id="Afsnit#1699579304778">Lapkirurgi, Behandling postoperativt</div></h1><div id="BodyWeb#1699579304778"><p><a name="1699579304778Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579304778Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579304778Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579304778Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579304778Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579304778Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579304778Bilag">Bilag</a><br> &nbsp;</h3> <h2><a name="1699579304778Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p>Klinisk personale i Afdeling for Øre-Næse-Halskirurgi og Audiologi</p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579304778Top">Tilbage til top</a></p> <h2><a name="1699579304778Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p><u><strong>Præoperativt</strong></u></p> <p><strong>Journaloptagelse</strong></p> <p>Vær opmærksom på:</p> <ul> <li>Huden i såvel operationsområdet på hoved-hals som donorområde</li> <li>Tidligere bestråling</li> <li>Type II diabetes</li> <li>Hypertension</li> <li>Stillingtagen til tromboseprofylakse</li> <li>Pulsation i a. dorsalis pedis</li> </ul> <p><strong>Blodprøver</strong></p> <ul> <li>Hgb</li> <li>Na</li> <li>K</li> <li>Creatinin</li> <li>Type</li> <li>Bas-test</li> </ul> <p><strong>Operatør:</strong></p> <p>Samtale med operatør, evt. både øre-næse-halskirurg og plastikkirurg.</p> <p><strong>Anæstesi:</strong></p> <p>Samtale med anæstesilæge.</p> <p><u><strong>Postoperativt</strong></u></p> <p><strong>Lappen</strong></p> <p><u>Kontrolleres hver 2. time de første 2 døgn for:</u></p> <ul> <li>Farve</li> <li>Kapillærreaktion og dopplersignal</li> </ul> <p>Herefter 2 x i hver vagt.</p> <p>Lokalisation af karstilk er angivet af operatør med tydeligt kryds. En vital lap er fjedrende ved let tryk.</p> <p>Ved stilket lap skal man undgå kompression på stilk, området er tydeligt afmærket af operatør.</p> <p>Ved mistanke om manglende perfusion kan man evt. prikke med kanyle i lappen og se om der kommer kapillærblødning, obs undgå at ramme fødekar.</p> <p>Kontrollér at drænet fungerer og vurder om der er hæmatom.</p> <p><strong>Obs! Ved mistanke om dårlig perfusion, </strong>tilkaldes læge (operatør og/eller plastikkirurg)</p> <p><strong>Doppler:</strong></p> <p>Med doppler 5Hz transducer (håndholdt doppler ligger i afsnit 6053/7054) (anvend explorationscreme) <u>eller</u> UL-apparat (står på OP) kontrolleres pulsation i lapstilken.</p> <p>Ved pectoralis major lap kan karstilken fra a. thoracoacromialis findes gående superficielt for clavicula i det af operatøren markerede område.</p> <p><strong>Diureser:</strong></p> <p>Der føres væskeskema og måles timediureser det første døgn, herefter x 1 i vagten.</p> <p><strong>Antiemetika:</strong></p> <p>Der gives præventivt Zofran 8 mg x 3 det første døgn, alternativt 1 mg/time kontinuerlig infusion det første døgn . Dette efterfølges af 8 mg x 2 dagligt i op til 5 døgn.</p> <p><strong>Væskeordination:</strong></p> <p>Der føres væskeskema (+/- balance regnes fra kl. 00.00).</p> <p>Der anvendes tynde væsker (NaCl, basisvæske osv.)</p> <p>Ved behov for plasmasubstitution kan der anvendes Macrodex (dextran), hvorimod der <strong><u>IKKE</u></strong> må anvendes HAES.</p> <p><u>Der indgives tynde væsker iv. afhængig af:</u></p> <ul> <li>Hæmatokrit</li> <li>Per os væskeindtag</li> <li>Timediureser</li> <li>BT</li> </ul> <p><strong>Ernæring:</strong></p> <p>Såfremt der er udført lapkirurgi i relation til fødevejen anlægges der nasogastrisk sonde.</p> <p>Der må intet gives per os.</p> <p>Der gives relevant sondeernæring i henhold til patientens ernæringstilstand.</p> <p><strong>Mundhygiejne:</strong></p> <p>Intet per os.</p> <p>Kun mundhygiejne i modsat side af lap.</p> <p><strong>Temperatur:</strong></p> <p>Måles x 2 / døgn.</p> <p><strong>BT og puls:</strong></p> <p>Det første døgn måles BT og puls hver 2. time.</p> <p>Herefter x 2 / vagt.</p> <p><u>Middelblodtrykket</u> skal ligge højt, helst &gt; 130 mmHg systolisk for at sikre perfusion af lap.</p> <p><strong>Mobilisering:</strong></p> <p>Ved operation med frie lapper, skal patienten de første 3 døgn&nbsp;være lejret vandret for at sikre sufficient perfusion af lappen. Der kan maksimalt tillades 30 graders elevation af hovedgærdet. Patienten må ikke mobiliseres i disse tre døgn.</p> <p>Ve operation med stilkede lapper, må patienten, under hensyntagen til den generelle tilstand, mobiliseres fra 1. postoperative døgn. der må dog ikke ske stræk af hand-off området på halsen, ved mobiliseringen.</p> <p><strong>Blodprøver:</strong></p> <p>De første 3 døgn kontrolleres dagligt:</p> <ul> <li>Hgb</li> <li>NaK</li> <li>Creatinin</li> <li>B-erytrocytter volumen fraktion (hæmatokrit) Hæmatokritten må ikke overstige 0.3 (normalværdi: kvinder: 0.35 - 0.47, mænd: 0.40 - 0.52).</li> </ul> <p><u>Ved anæmi</u> overvejes først blodtransfusion ved Hgb under 5.8.</p> <p><u>Ved hypovolæmi</u> se punktet væskeordination.</p> <p><u>Ved hgb &lt; 6.5</u> ordineres tbl. jern-c x 2 dagligt.</p> <p><strong>Tromboseprofylakse:</strong></p> <p>Da patienten er lejret fladt de første 3 døgn gives tromboseprofylakse i 3 døgn.</p> <p>Herefter Magnyl 150 mg dagligt. Se <a href="###FOLDER###" target="_blank">Tromboseprofylakse på Afdeling for Øre-Næse-Halskirurgi og Audiologi</a></p> <p><strong>Laksantia:</strong></p> <p>Vær opmærksom på Morfin og obstipation.</p> <p>Giv evt. fast de første 3 døgn tbl. Magnesia 1 g dagligt (gives kl. 22).</p> <p><strong>Udskrivelse</strong></p> <p>Fra 3. døgn postoperativt tbl. Magnyl ® 150 mg x 1 i 2 uger.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579304778Top">Tilbage til top</a></p> <p>&nbsp;</p> <h2><a name="1699579304778Ansvar"></a><br> Ansvar og organisering</h2> <p>&nbsp;Afdelingsledelsen i Afdeling for Øre-Næse-Halskirurgi og Audiologi</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579304778Top">Tilbage til top</a></p> <h2><a name="1699579304778Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579304778Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Laryngectomi - forl¢bsbeskrivelse.

Laryngectomi - forløbsbeskrivelse Formål Målgruppe, anvendelsesområde samt afgrænsning af patientgruppe Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Bilag Formål At angive retningslinjer for laryngectomerede patienters behandling og pleje. Målgruppe, anvendelsesområde samt afgrænsning af patientgruppe Målgruppe: Personale i Afdeling for Øre-Næse-Halskirurgi og Audiologi. Patientgruppe: Patienter der gennemgår laryngektomi. Definitioner Larynxteam: En mindre gruppe sygeplejersker i ambulatoriet, der har specialiserede kompetencer til at varetage præoperative sygeplejefaglige opgaver for patienter, der vurderes og evt. planlægges til laryngektomi. Fremgangsmåde Ambulant Forundersøgelse inden indlæggelse foregår ambulant. Patienten, der skal have foretaget en laryngektomi, er af operatøren informeret om operationen og den videre plan. Patienten har fået tildelt en kontaktsygeplejerske, som udfører operationsforberedelsen inden indlæggelsen. Kontaktsygeplejersken vil fremgå af patientens behandlingsteam i SP. Se VIP vejledning Præoperativ forberedelse i ambulatoriet: patienter der skal laryngektomeres for yderligere information om den præoperative forberedelse i ambulant regi. Se i øvrigt VIP vejledning Ambulant sygeplejefaglig opfølgning på Hoved-halscancer patienter for yderligere beskrivelse af relevant patientinformation til hoved-halscancer patienter. Indlæggelse på sengeafsnit Patienten tildeles en kontaktsygeplejerske under indlæggelsen. Denne vil fremgå af patientens behandlingsteam i SP. Postoperative observationer/pleje Værdier: - Der måles vitale værdier (EWS) med følgende ekstra intervaller: 2 x i dagvagt og aftenvagt, 1 x nattevagt det første døgn, hvis patienten er stabil, herefter EWS efter normale retningslinjer. Blodprøver - Der tages følgende blodprøver: ’Postoperative infektionstal-pakke’ på 3. og 7. dagen samt før udskrivelsen. Der tages ’Refeedingpakke Dag 1 og 3’ ved indikation for refeeding syndrom. Se lokal VIP: Refeeding Syndrom, udredning, behandling, pleje og forebyggelse til voksne over 16 år. Medicinering - Der gøres medicinstatus med særlig opmærksomhed på morfica, laxantia og syrehæmmende medicin ved første stuegang efter patienten er retur i sengeafsnittet. Desuden stillingtagen til fortsat antibiotika. Obs at patienten er % pr. os. minimum 10 dage postoperativt og må derfor medicineres via sonde eller intravenøst. Stomapleje Efter endt operation påsættes Provox Life Sensitiv plaster over stoma og Provox Life Lary-Tube klikkes på med tilhørende Provox Life Home HME-kassette. Provox Life Lary-Tube anvendes til at opretholde åbningen i trakeostomaet. Ved 1 måneds kontrol tager operatøren stilling til om brugen af Provox Life Lary-Tube kan nedtrappes. - Kassetter skiftes efter behov, dog minimum 1 gang dagligt. - Hvis der forekommer småblødning, der småsiver umiddelbart postoperativt, kan der være behov for at anlægge cuff’et kanyle, der er ingen kontraindikation for dette. Vagthavende læge vurderer behovet for dette. - Provox Life Sensitiv plaster skiftes dagligt, med mindre det ikke slutter tæt, så skal det skiftes oftere. Plasteret skal slutte helt tæt for at kassettens evne til at fugte kan udnyttes. Slutter plasteret ikke tæt pga. suturer i området, må man forstærke så godt som muligt og evt. fugte med NaCl inhalationer. Der kan være tilfælde pga. halsens anatomi, hvor det er nødvendigt at skifte til et andet plaster, der passer bedre. - Huden soigneres i forbindelse med skift at plaster. Her anvendes gaze-stykker, vand samt renseservietterne; optifahl stoma cleaning wipes. Derudover smøres stoma med parfumefri lotion. Ved rødme og irritation smøres med pantenolcreme. Vigtigt: - De første dage (eller så længe der er stor sekret produktion) SKAL stoma efterses som minimum 2 x hver vagt og renses for skorper. Tidligt i forløbet skal patienten inddrages og oplæres i stomapleje således, at patienten er tryg ved selvstændig varetagelse af pleje og sugning gerne flere dage før udskrivelse. Suturfjernelse - Sutur på hals: Hver anden sutur seponeres på 10. dagen, resten på 12. dagen, hvis huden ellers heler pænt op. Dette vurderes af stuegangsgående læge. - Sutur i stoma: Disse lades urørt indtil ambulant kontrol hos operatør (ca. én måned efter operation). Mundpleje - Der må gerne børstes tænder. Dog vigtigt: Patienten må IKKE sluge vand under mundplejen. - Derudover kan der ved behov udføres mundpleje med lyserøde swabs og danskvand i hele mundhulen fra 1. postoperative døgn. Fugtning - Ved ilt-tilskud skal dette altid gives som fugtet ilt. Provox - Provox-ventilen skal renses mindst 1 x dagligt, begyndende på ugedagen for operationen, medmindre andet er angivet i operationsnotatet. - Patienten skal oplæres i selv at kunne varetage rensning af Provox inden udskrivelsen. Konsulenter - Alle patienter får tilbudt et besøg af deres konsulent under indlæggelsen. Konsulenten er fra Dansk Landsforening for hals- og mundhuleopererede (DLHM). Talefunktion Logopæd på taleinstitut skal informeres om dato for drikkeprøve. Vanligvis kan de påbegynde brug af provoxventil efter ambulant kontrol hos operatør, ca. en måned efter operationen. Lejring/mobilisering Patienten må frit mobiliseres under hensyntagen til almindeligt velbefindende. Patienten skal de første døgn ligge med 30 graders eleveret hovedgærde for at undgå træk i suturer. Patienter med PM-lapper må mobiliseres fra 1. postoperative døgn, under hensyntagen til den generelle tilstand. ’Hands-off’ område på halsen, må ikke strækkes, bøjes eller afklemmes med bændler og bandage. Se i øvrigt VIP vejledning: Pectoralis major lap, Pleje af patienter med. Kost Patienten er minus per os 10 -12 dage som angivet i operationsnotatet. Sondemad opstartes ifl. VIP vejledning: Sondeernæring til voksne i Afdeling for Øre-Næse-Halskirurgi og Audiologi. Drikkeprøve foretages ved stuegangsgående læge. Holder det tørt, må der resten af døgnet indtages koldt, klart flydende. Herefter ét døgn med flydende kost, efterfulgt af én uge med blød kost, hvorefter patienten kan indtage kost efter evne. Udskrivelse Oftest udskrives patienten med en hjemmesygeplejerske til tryghedsbesøg én gang dagligt den første tid, hvis patienten ønsker det. Nødkald Der skal tages individuelt stilling til, hvilket behov for nødkald patienten har. Der er forskellige muligheder såsom App, SMS, nødkald til hjemmesygeplejen og nødkald til alarmcentralen. Se bilag 1 for yderligere information. Ved udskrivelse; - Patienten medgives remedier til 14 dages forbrug. Der medfølger en skriftlig oversigt over remedierne til hjemmesygeplejersken. Konsulenter fra DLHM sørger for at sende ansøgning til patientens kommune efter samtykke fra patienten. Ønsker patienten ikke kontakt til konsulent fra DLHM hjælper rehabiliteringsteamet i stedet med at sende ansøgningen. - Patienten medgives kuffertsug (engangs) + instruks ved udskrivelsen. Patienter der hører til Sjællands Universitetshospital - Køge eller Nordsjællands Hospital - Hillerød, skal fremadrettet have kuffertsug derfra. Patienter fra Bornholm får kuffertsug udleveret af ###NAVN### (tlf: ###TELEFON###). - Evt. medgives nebulisator til saltvandsinhalation. Denne udleveres i sengeafsnittet. - Det sikres, at der er sendt besked til logopæd, hvis patienten ikke har haft kontakt med konsulent fra DLHM. Rehabiliteringsteamet; - Introducerer sig selv til patienten under indlæggelsen. Efter udskrivelsen foregår samtalerne i patientens hjem. Kontaktperson fra Rehabiliteringsteam fremgår af patientens behandlingsteam i SP. - Vurderer om der er behov for genoptræning og sender evt. en GOP til kommunen mhp. fysioterapi eller ergoterapi (synketræning, lymfødem behandling o.a.) – dette kan også gøres ved fire ugers kontrol. - Sørger for at lave aftale med hjemmesygeplejen i patientens kommune om undervisning af de sygeplejersker, der vil være primære hos patienten. Undervisning af hjemmesygeplejersker foregår i patientens hjem på udskrivelsesdagen eller dagen efter. Evt. suppleres med undervisning af en større gruppe i hjemmeplejens egne lokaler. - Følger op på patienten via mail/SMS-kontakt eller besøg ud fra patientens behov. - Giver besked til konsulent fra DLHM, når patienten må begynde taletræning. Efter udskrivelse; - Indkaldes patienten til fire ugers kontrol, som varetages af ambulatoriet. Hvis det vurderes relevant, kan patienten opskrives til tværfagligt ambulatorie ved fire ugers kontrollen. Dette er efter aftale med kirurgen. Ca. to måneder fra operationsdatoen indkaldes patienten til MDT 2 konference. Tværfaglige samarbejdspartnere – opgaver Ergoterapeut - Deltager ved synketest (hvis muligt) 10. postoperative dag. - Udleverer og vejleder i træningsprogram for synkefunktion. - Udarbejder et statusnotat i SP, der af sygeplejerskerne sendes til patientens kommune som genoptræningsplan (GOP). - Deltager ved Tværfagligt Ambulatorie for patienter med komplekse problemstillinger efter kirurgi. - For patienter med fx smerter eller fibrose kan der tilbydes Deep Oscillation behandling. Logopæd - Henvisningen til logopæd sendes af konsulent fra DLHM oftest inden operationen, hvis patienten er bosat i Region Hovedstaden. Hvis patienten bor i Region Sjælland, sendes henvisningen under indlæggelsen. - Hvis muligt møder logopæden patient og pårørende før operationen, hvis patienten er bosiddende i Region Hovedstaden. Her kan logopæden høre og iagttage patientens artikulation, taletempo, gestik, mimik mm. - Når patienten er opereret, sendes operationsnotatet fra Rigshospitalet, hvorefter logopæd skriver en udredningsrapport til patientens kommune, her ansøges om tilsagn til et undervisningsforløb. Tiden fra operation og frem til patienten må opstarte taletræning (fire uger) bruger logopæden til denne sagsbehandling. - Kommunen ansøges om et undervisningsforløb på mellem 8-12 timer. - Undervisningsforløbet er i starten intensivt, men når patienten lærer at kommunikere med Provox-ventil eller kommunikationsvibrator, bliver der længere mellem de enkelte undervisninger. - Der tilbydes kun eneundervisning, hvor pårørende også kan deltage. DLHM-konsulenter - Når konsulent fra DLHM har fået mail fra kontaktsygeplejersken om en patient, der skal gennemgå laryngektomi, tager konsulenten kontakt til patienten og tilbyder et besøg. Konsulenten fortæller om sine erfaringer som laryngektomeret, og tilbyder vejledning ift. forskellige bandage muligheder. - Konsulenten indhenter samtykkeerklæring fra patienten mhp. at tage kontakt til; - Kommune - Logopæd - Konsulenten sender ansøgning til patientens kommune dagen efter operationen, mhp. - Remedier - Hjælpemidler - Konsulenten sender besked til logopæd efter fire ugers kontrol og suturfjernelse, om der må startes taletræning (orienteres af rehabiliteringsteamet). Ansvar og organisering Afdelingsledelsen i Afdeling for Øre-Næse-Halskirurgi og Audiologi, Rigshospitalet. Referencer, lovgivning og faglig evidens samt links hertil Kræft, senfølger og rehabilitering. Red. Christoffer Johansen. Hans Reitzels Forlag, 2013. VIP vejledninger Ambulant sygeplejefaglig opfølgning på Hoved-halscancer patienter Pectoralis major lap, Pleje af patienter med Præoperativ forberedelse i ambulatoriet: patienter der skal laryngektomeres Refeeding Syndrom, udredning, behandling, pleje og forebyggelse til voksne over 16 år. Sondeernæring og anlæggelse og kontrol af sonde (voksne, alder 16 år eller ældre) BILAG 1- Nødkald App til smartphone ”Akut hjælp til døve”: - Appen kan downloades til Iphone og Android. - Man aktiverer app’en på sin smartphone og indtaster personlige oplysninger i felterne – derefter er app’en klar til brug. - Ved aktivering af app’en er der tre muligheder for hjælp - Politi - Brandvæsen - Ambulance Herefter startes en chat funktion, hvor der evt. kan komme uddybende spørgsmål. - GPS (lokation) skal være tændt, så patientens placering bliver sendt, når man åbner en kontakt. SMS fra mobil telefon til alarmcentralen: - Hvis patienten ikke har en smartphone, kan der sendes sms fra mobil direkte til alarmcentralen Tlf. ###TELEFON### - Nummeret indkodes i patientens mobiltelefon. - Der laves en standardtekst med navn, lokation og behov fx: ”Hans Knudsen, Sønder Ringvej 20, 0987 Nørre Snede, jeg kan ikke få luft og har brug for en ambulance”. - Standardteksten gemmes som kladde og kan sendes, hvis patienten får behov for akut hjælp. Nødkald 2 til hjemmesygeplejen: - Patienten får installeret et nødkald 2 til hjemmesygeplejen, hvor det aftales, at når patienten benytter kaldet, rekvirerer hjemmesygeplejersken en ambulance. - Nogle kommuner har også mulighed for, at patienten kan sende en sms til dem. Nødkald 1 til Alarmcentralen: - Hvis ingen af de ovenstående løsninger er mulige, kan der installeres nødkald til kørsel 1. I så fald skal ansøgningen sendes i god tid. - I nogle kommuner kræver et nødkald 1, at patienten har en fastnetforbindelse. Ved opsætning af fastnet er der et oprettelsesgebyr for patienten. Der skal indsættes nøgleboks ved hoveddøren. - Hvis der skal oprettes nødkald 1, skal der sendes Klinisk Korrespondance med bevilling.

<h1><div id="Afsnit#1699579331256">Laryngectomi - forløbsbeskrivelse</div></h1><div id="BodyWeb#1699579331256"><p><a name="1699579331256Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579331256Formaal">Formål</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579331256Maalgrupper">Målgruppe, anvendelsesområde samt afgrænsning af patientgruppe</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579331256Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579331256Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579331256Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579331256Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579331256Bilag">Bilag</a><br> &nbsp;</h3> <p><a name="1699579331256Formaal"></a></p> <h2>Formål</h2> <p>At angive retningslinjer for laryngectomerede patienters behandling og pleje.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579331256Top">Tilbage til top</a></p> <h2><a name="1699579331256Maalgrupper"></a><br> Målgruppe, anvendelsesområde samt afgrænsning af patientgruppe&nbsp;</h2> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#222222">Målgruppe: Personale i Afdeling for Øre-Næse-Halskirurgi og Audiologi.</span></p> <p><span style="color:#222222">Patientgruppe: Patienter der gennemgår laryngektomi.</span></p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579331256Top">Tilbage til top</a></p> <p style="margin-left:0cm; margin-right:0cm"><strong>Definitioner</strong><u> </u></p> <p style="margin-left:0cm; margin-right:0cm"><u><span style="color:#222222">Larynxteam</span></u><span style="color:#222222">: En mindre gruppe sygeplejersker i ambulatoriet, der har specialiserede kompetencer til at varetage præoperative sygeplejefaglige opgaver for patienter, der vurderes og evt. planlægges til laryngektomi.</span></p> <p style="margin-left:0cm; margin-right:0cm"><strong>Fremgangsmåde</strong></p> <p style="margin-left:0cm; margin-right:0cm"><strong><u>Ambulant</u></strong></p> <p style="margin-left:0cm; margin-right:0cm">Forundersøgelse inden indlæggelse foregår ambulant. Patienten, der skal have foretaget en laryngektomi, er af operatøren informeret om operationen og den videre plan. Patienten har fået tildelt en kontaktsygeplejerske, som udfører operationsforberedelsen inden indlæggelsen. Kontaktsygeplejersken vil fremgå af patientens behandlingsteam i SP.</p> <p style="margin-left:0cm; margin-right:0cm">Se VIP vejledning <a href="https://vip.regionh.dk/VIP/Admin/GUI.nsf/Desktop.html?open&amp;openlink=https://vip.regionh.dk/VIP/Slutbruger/Portal.nsf/Main.html?open&amp;unid=X44AB3029CE5EDDC2C125877500448039&amp;level=130126&amp;dbpath=/VIP/Redaktoer/130126.nsf/&amp;windowwidth=1100&amp;windowheight=600&amp;windowtitle=S%F8g" style="color:blue; text-decoration:underline">Præoperativ forberedelse i ambulatoriet: patienter der skal laryngektomeres</a><u> </u>for yderligere information om den præoperative forberedelse i ambulant regi.</p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#222222">Se i øvrigt VIP vejledning </span><a href="https://vip.regionh.dk/VIP/Admin/GUI.nsf/Desktop.html?open&amp;openlink=https://vip.regionh.dk/VIP/Slutbruger/Portal.nsf/Main.html?open&amp;unid=XB15FF8121BF2B9ABC125791500783D8D&amp;level=130126&amp;dbpath=/VIP/Redaktoer/130126.nsf/&amp;windowwidth=1100&amp;windowheight=600&amp;windowtitle=S%F8g" style="color:blue; text-decoration:underline">Ambulant sygeplejefaglig opfølgning på Hoved-halscancer patienter</a><span style="color:#222222"> for yderligere beskrivelse af relevant patientinformation til hoved-halscancer patienter.</span></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong><u>Indlæggelse på sengeafsnit</u></strong></p> <p style="margin-left:0cm; margin-right:0cm">Patienten tildeles en kontaktsygeplejerske under indlæggelsen. Denne vil fremgå af patientens behandlingsteam i SP.</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong><u>Postoperative observationer/pleje</u></strong></p> <p style="margin-left:0cm; margin-right:0cm">Værdier:</p> <ul> <li>Der måles vitale værdier (EWS) med følgende ekstra intervaller:</li> </ul> <p style="margin-left:36pt; margin-right:0cm">2 x i dagvagt og aftenvagt, 1 x nattevagt det første døgn, hvis patienten er stabil, herefter EWS efter normale retningslinjer.</p> <p style="margin-left:36pt; margin-right:0cm">&nbsp;</p> <p style="margin-left:36pt; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm">Blodprøver</p> <ul> <li>Der tages følgende blodprøver: ’Postoperative infektionstal-pakke’ på 3. og 7. dagen samt før udskrivelsen.</li> </ul> <p style="margin-left:36pt; margin-right:0cm">Der tages ’Refeedingpakke Dag 1 og 3’ ved indikation for refeeding syndrom.</p> <p style="margin-left:36pt; margin-right:0cm">Se <span style="background-color:white"><span style="color:#222222">lokal VIP: </span></span><a href="https://vip.regionh.dk/VIP/Admin/GUI.nsf/Desktop.html?open&amp;openlink=https://vip.regionh.dk/VIP/Slutbruger/Portal.nsf/Main.html?open&amp;unid=XBECA65B461C26851C125796E004E8828&amp;level=130126&amp;dbpath=/VIP/Redaktoer/130126.nsf/&amp;windowwidth=1100&amp;windowheight=600&amp;windowtitle=S%F8g" style="color:blue; text-decoration:underline"><span style="background-color:white">Refeeding Syndrom, udredning, behandling, pleje og forebyggelse til voksne over 16 år.</span></a></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm">Medicinering</p> <ul> <li>Der gøres medicinstatus med særlig opmærksomhed på morfica, laxantia og syrehæmmende medicin ved første stuegang efter patienten er retur i sengeafsnittet. Desuden stillingtagen til fortsat antibiotika.</li> </ul> <p style="margin-left:36pt; margin-right:0cm">Obs at patienten er % pr. os. minimum 10 dage postoperativt og må derfor medicineres via sonde eller intravenøst.</p> <p style="margin-left:36pt; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm">Stomapleje</p> <p style="margin-left:36pt; margin-right:0cm">Efter endt operation påsættes Provox Life Sensitiv plaster<strong> </strong>over stoma og Provox Life Lary-Tube klikkes på med tilhørende Provox Life Home HME-kassette. Provox Life Lary-Tube anvendes til at opretholde åbningen i trakeostomaet. Ved 1 måneds kontrol tager operatøren stilling til om brugen af Provox Life Lary-Tube kan nedtrappes.</p> <ul> <li>Kassetter skiftes efter behov, dog minimum 1 gang dagligt.</li> <li>Hvis der forekommer småblødning, der småsiver umiddelbart postoperativt, kan der være behov for at anlægge cuff’et kanyle, der er ingen kontraindikation for dette. Vagthavende læge vurderer behovet for dette.</li> </ul> <ul> <li>Provox Life Sensitiv plaster<strong> </strong>skiftes dagligt, med mindre det ikke slutter tæt, så skal det skiftes oftere. Plasteret skal slutte helt tæt for at kassettens evne til at fugte kan udnyttes. Slutter plasteret ikke tæt pga. suturer i området, må man forstærke så godt som muligt og evt. fugte med NaCl inhalationer. Der kan være tilfælde pga. halsens anatomi, hvor det er nødvendigt at skifte til et andet plaster, der passer bedre.</li> </ul> <ul> <li>Huden soigneres i forbindelse med skift at plaster. Her anvendes gaze-stykker, vand samt renseservietterne; optifahl stoma cleaning wipes. Derudover smøres stoma med parfumefri lotion. Ved rødme og irritation smøres med pantenolcreme.&nbsp;</li> </ul> <p>&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong>Vigtigt: </strong></p> <ul> <li>De første dage (eller så længe der er stor sekret produktion) <strong>SKAL </strong>stoma efterses som minimum 2 x hver vagt og renses for skorper.</li> </ul> <p style="margin-left:0cm; margin-right:0cm">Tidligt i forløbet skal patienten inddrages og oplæres i stomapleje således, at patienten er tryg ved selvstændig varetagelse af pleje og sugning gerne flere dage før udskrivelse.</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <h2 style="margin-left:0cm; margin-right:0cm"><span style="color:#2f5496"><strong>Suturfjernelse</strong></span></h2> <ul> <li>Sutur på hals: Hver anden sutur seponeres på 10. dagen, resten på 12. dagen, hvis huden ellers heler pænt op.</li> </ul> <p style="margin-left:0cm; margin-right:0cm">Dette vurderes af stuegangsgående læge.</p> <ul> <li>Sutur i stoma: Disse lades urørt indtil ambulant kontrol hos operatør (ca. én måned efter operation).</li> </ul> <p style="margin-left:36pt; margin-right:0cm">&nbsp;</p> <h2 style="margin-left:0cm; margin-right:0cm"><span style="color:#2f5496"><strong>Mundpleje</strong></span></h2> <ul> <li>Der må gerne børstes tænder. Dog <strong>vigtigt</strong>:<strong> </strong>Patienten må IKKE sluge vand under mundplejen.</li> <li>Derudover kan der ved behov udføres mundpleje med lyserøde swabs og danskvand i hele mundhulen fra 1. postoperative døgn.</li> </ul> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong>Fugtning</strong></p> <ul> <li>Ved ilt-tilskud skal dette altid gives som fugtet ilt.</li> </ul> <p style="margin-left:36pt; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong>Provox</strong></p> <ul> <li>Provox-ventilen skal renses mindst 1 x dagligt, begyndende på ugedagen for operationen, medmindre andet er angivet i operationsnotatet.</li> <li>Patienten skal oplæres i selv at kunne varetage rensning af Provox inden udskrivelsen.</li> </ul> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong>Konsulenter</strong></p> <ul> <li>Alle patienter får tilbudt et besøg af deres konsulent under indlæggelsen. Konsulenten er fra Dansk Landsforening for hals- og mundhuleopererede (DLHM).</li> </ul> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong>Talefunktion</strong></p> <p style="margin-left:0cm; margin-right:0cm">Logopæd på taleinstitut skal informeres om dato for drikkeprøve. Vanligvis kan de påbegynde brug af provoxventil efter ambulant kontrol hos operatør, ca. en måned efter operationen.</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong>Lejring/mobilisering</strong></p> <p style="margin-left:0cm; margin-right:0cm">Patienten må frit mobiliseres under hensyntagen til almindeligt velbefindende.</p> <p style="margin-left:0cm; margin-right:0cm">Patienten skal de første døgn ligge med 30 graders eleveret hovedgærde for at undgå træk i suturer. Patienter med PM-lapper må mobiliseres fra 1. postoperative døgn, under hensyntagen til den generelle tilstand. ’Hands-off’ område på halsen, må ikke strækkes, bøjes eller afklemmes med bændler og bandage.</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm">Se i øvrigt VIP vejledning: <a href="https://vip.regionh.dk/VIP/Admin/GUI.nsf/Desktop.html?open&amp;openlink=https://vip.regionh.dk/VIP/Slutbruger/Portal.nsf/Main.html?open&amp;unid=X3DE64F024C594419C125791500787132&amp;level=130126&amp;dbpath=/VIP/Redaktoer/130126.nsf/&amp;windowwidth=1100&amp;windowheight=600&amp;windowtitle=S%F8g" style="color:blue; text-decoration:underline">Pectoralis major lap, Pleje af patienter med</a><span style="color:#2f5496">. </span></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong>Kost</strong></p> <p style="margin-left:0cm; margin-right:0cm">Patienten er minus per os 10 -12 dage som angivet i operationsnotatet.</p> <p style="margin-left:0cm; margin-right:0cm">Sondemad opstartes ifl. VIP vejledning: <a href="https://vip.regionh.dk/VIP/Admin/GUI.nsf/Desktop.html?open&amp;openlink=https://vip.regionh.dk/VIP/Slutbruger/Portal.nsf/Main.html?open&amp;unid=X8560868F6D0A0101C1257915007837F5&amp;level=130126&amp;dbpath=/VIP/Redaktoer/130126.nsf/&amp;windowwidth=1100&amp;windowheight=600&amp;windowtitle=S%F8g" style="color:blue; text-decoration:underline"><span style="background-color:white">Sondeernæring til voksne i Afdeling for Øre-Næse-Halskirurgi og Audiologi</span></a><span style="background-color:white"><span style="color:#222222">.</span></span></p> <p style="margin-left:0cm; margin-right:0cm">Drikkeprøve foretages ved stuegangsgående læge.</p> <p style="margin-left:0cm; margin-right:0cm">Holder det tørt, må der resten af døgnet indtages koldt, klart flydende. Herefter ét døgn med flydende kost, efterfulgt af én uge med blød kost, hvorefter patienten kan indtage kost efter evne.</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong><u>Udskrivelse</u></strong></p> <p style="margin-left:0cm; margin-right:0cm">Oftest udskrives patienten med en hjemmesygeplejerske til tryghedsbesøg én gang dagligt den første tid, hvis patienten ønsker det.</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong>Nødkald</strong></p> <p style="margin-left:0cm; margin-right:0cm">Der skal tages individuelt stilling til, hvilket behov for nødkald patienten har. Der er forskellige muligheder såsom App, SMS, nødkald til hjemmesygeplejen og nødkald til alarmcentralen.</p> <p style="margin-left:0cm; margin-right:0cm">Se bilag 1 for yderligere information.</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong>Ved udskrivelse;</strong></p> <ul> <li><span style="color:black">Patienten medgives remedier </span>til 14 dages forbrug. Der medfølger en skriftlig oversigt over remedierne til hjemmesygeplejersken.</li> </ul> <p style="margin-left:36pt; margin-right:0cm"><span style="background-color:white"><span style="color:black">Konsulenter fra DLHM sørger for at sende ansøgning til patientens kommune efter samtykke fra patienten. Ønsker patienten ikke kontakt til konsulent fra DLHM hjælper rehabiliteringsteamet i stedet med at sende ansøgningen.</span></span></p> <ul> <li><span style="background-color:white"><span style="color:black">Patienten medgives kuffertsug (engangs) + instruks ved udskrivelsen. Patienter der hører til </span><span style="color:black">Sjællands Universitetshospital - Køge eller Nordsjællands Hospital - Hillerød, skal fremadrettet have kuffertsug </span><span style="color:black">derfra. Patienter fra Bornholm får kuffertsug udleveret af ###NAVN### (tlf: ###TELEFON###).</span></span></li> <li><span style="background-color:white"><span style="color:black">Evt. medgives nebulisator til saltvandsinhalation. Denne udleveres i sengeafsnittet. </span></span></li> <li><span style="background-color:white"><span style="color:black">Det sikres, at der er sendt besked til logopæd, hvis patienten ikke har haft kontakt med konsulent fra DLHM.</span></span></li> </ul> <p style="margin-left:0cm; margin-right:0cm"><strong>Rehabiliteringsteamet;</strong></p> <ul> <li><span style="background-color:white"><span style="color:black">Introducerer sig selv til patienten under indlæggelsen. Efter udskrivelsen foregår samtalerne i patientens hjem. Kontaktperson fra Rehabiliteringsteam fremgår af patientens behandlingsteam i SP. </span></span></li> </ul> <ul> <li><span style="background-color:white"><span style="color:black">Vurderer om der er behov for genoptræning og sender evt. en GOP til kommunen mhp. fysioterapi eller ergoterapi (synketræning, lymfødem behandling o.a.) – dette kan også gøres ved fire ugers kontrol.</span></span></li> <li><span style="background-color:white"><span style="color:black">Sørger for at lave aftale med hjemmesygeplejen i patientens kommune om undervisning af de sygeplejersker, der vil være primære hos patienten.<br> Undervisning af hjemmesygeplejersker foregår i patientens hjem på</span> <span style="color:black">udskrivelsesdagen eller dagen efter.<br> Evt. suppleres med undervisning af en større gruppe i hjemmeplejens egne lokaler.</span></span></li> <li><span style="background-color:white"><span style="color:black">Følger op på patienten via mail/SMS-kontakt eller besøg ud fra patientens behov.</span></span></li> <li><span style="background-color:white"><span style="color:black">Giver besked til konsulent fra DLHM, når patienten må begynde taletræning.</span></span></li> </ul> <p style="margin-left:0cm; margin-right:0cm"><span style="background-color:white"><strong><span style="color:black">Efter udskrivelse;</span></strong></span></p> <ul> <li><span style="background-color:white"><span style="color:black">Indkaldes patienten til fire ugers kontrol, som varetages af ambulatoriet. Hvis det vurderes relevant, kan patienten opskrives til tværfagligt ambulatorie ved fire ugers kontrollen. Dette er efter aftale med kirurgen.</span></span></li> </ul> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Ca. to måneder fra operationsdatoen indkaldes patienten til MDT 2 konference. </span></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong><u>Tværfaglige samarbejdspartnere – opgaver</u></strong></p> <h2 style="margin-left:0cm; margin-right:0cm"><span style="color:#2f5496"><strong>Ergoterapeut</strong></span></h2> <ul> <li><span style="background-color:white"><span style="color:black">Deltager ved synketest (hvis muligt) 10. postoperative dag.</span></span></li> <li><span style="background-color:white"><span style="color:black">Udleverer og vejleder i træningsprogram for synkefunktion.</span></span></li> <li><span style="background-color:white"><span style="color:black">Udarbejder et statusnotat i SP, der af sygeplejerskerne sendes til patientens kommune som genoptræningsplan (GOP). </span></span></li> <li><span style="background-color:white"><span style="color:black">Deltager ved Tværfagligt Ambulatorie for patienter med komplekse problemstillinger efter kirurgi. </span></span></li> <li><span style="background-color:white"><span style="color:black">For patienter med fx smerter eller fibrose kan der tilbydes Deep Oscillation behandling.</span></span></li> </ul> <h2 style="margin-left:0cm; margin-right:0cm"><span style="color:#2f5496"><strong>Logopæd</strong></span></h2> <ul> <li><span style="color:black">Henvisningen til logopæd sendes af konsulent fra DLHM oftest inden operationen, hvis patienten er bosat i Region Hovedstaden. </span></li> </ul> <p style="margin-left:36pt; margin-right:0cm"><span style="color:black">Hvis patienten bor i Region Sjælland, sendes henvisningen under indlæggelsen.</span></p> <ul> <li><span style="color:black">Hvis muligt møder logopæden patient og pårørende før operationen, hvis patienten er bosiddende i Region Hovedstaden. Her kan logopæden høre og iagttage patientens artikulation, taletempo, gestik, mimik mm. </span></li> <li><span style="color:black">Når patienten er opereret, sendes operationsnotatet fra </span><span style="color:black">Rigshospitalet, </span><span style="color:black">hvorefter logopæd skriver en udredningsrapport til patientens kommune, her ansøges om tilsagn til et undervisningsforløb. Tiden fra operation og frem til patienten må opstarte taletræning (fire uger) bruger logopæden til denne sagsbehandling. </span></li> <li><span style="color:black">Kommunen ansøges om et undervisningsforløb på mellem 8-12 timer. </span></li> <li><span style="color:black">Undervisningsforløbet er i starten intensivt, men når patienten lærer at kommunikere med Provox-ventil eller kommunikationsvibrator, bliver der længere mellem de enkelte undervisninger.</span></li> </ul> <ul> <li>Der tilbydes kun eneundervisning, hvor pårørende også kan deltage.</li> </ul> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <h2 style="margin-left:0cm; margin-right:0cm"><span style="color:#2f5496"><strong>DLHM-konsulenter</strong></span></h2> <ul> <li><span style="background-color:white"><span style="color:black">Når konsulent fra DLHM har fået mail fra kontaktsygeplejersken om en patient, der skal gennemgå laryngektomi, tager konsulenten kontakt til patienten og tilbyder et besøg. Konsulenten fortæller om sine erfaringer som laryngektomeret, og tilbyder vejledning ift. forskellige bandage muligheder.</span></span></li> <li><span style="background-color:white"><span style="color:black">Konsulenten indhenter samtykkeerklæring fra patienten mhp. at tage kontakt til;</span></span> <ul style="list-style-type:circle"> <li><span style="background-color:white"><span style="color:black">Kommune</span></span></li> <li><span style="background-color:white"><span style="color:black">Logopæd</span></span></li> </ul> </li> <li><span style="background-color:white"><span style="color:black">Konsulenten sender ansøgning til patientens kommune dagen efter operationen, mhp.</span></span></li> </ul> <ul style="list-style-type:circle"> <li><span style="background-color:white"><span style="color:black">Remedier</span></span> <ul style="list-style-type:circle"> <li><span style="background-color:white"><span style="color:black">Hjælpemidler </span></span></li> </ul> </li> </ul> <ul> <li><span style="background-color:white"><span style="color:black">Konsulenten sender besked til logopæd efter fire ugers kontrol og suturfjernelse, om der må startes taletræning (orienteres af rehabiliteringsteamet).</span></span></li> </ul> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <h1 style="margin-left:0cm; margin-right:0cm"><span style="color:#2f5496"><strong>Ansvar og organisering </strong></span></h1> <p style="margin-left:0cm; margin-right:0cm">Afdelingsledelsen i Afdeling for Øre-Næse-Halskirurgi og Audiologi, Rigshospitalet.</p> <h1 style="margin-left:0cm; margin-right:0cm"><span style="color:#2f5496"><strong>Referencer, lovgivning og faglig evidens samt links hertil</strong></span></h1> <p style="margin-left:0cm; margin-right:0cm"><span style="color:#222222">Kræft, senfølger og rehabilitering. Red. Christoffer Johansen. Hans Reitzels Forlag, 2013. </span></p> <p style="margin-left:0cm; margin-right:0cm"><strong><span style="color:#222222">VIP vejledninger</span></strong></p> <p style="margin-left:0cm; margin-right:0cm"><a href="https://vip.regionh.dk/VIP/Admin/GUI.nsf/Desktop.html?open&amp;openlink=https://vip.regionh.dk/VIP/Slutbruger/Portal.nsf/Main.html?open&amp;unid=XB15FF8121BF2B9ABC125791500783D8D&amp;level=130126&amp;dbpath=/VIP/Redaktoer/130126.nsf/&amp;windowwidth=1100&amp;windowheight=600&amp;windowtitle=S%F8g" style="color:blue; text-decoration:underline">Ambulant sygeplejefaglig opfølgning på Hoved-halscancer patienter</a></p> <p style="margin-left:0cm; margin-right:0cm"><a href="https://vip.regionh.dk/VIP/Admin/GUI.nsf/Desktop.html?open&amp;openlink=https://vip.regionh.dk/VIP/Slutbruger/Portal.nsf/Main.html?open&amp;unid=X3DE64F024C594419C125791500787132&amp;level=130126&amp;dbpath=/VIP/Redaktoer/130126.nsf/&amp;windowwidth=1100&amp;windowheight=600&amp;windowtitle=S%F8g" style="color:blue; text-decoration:underline">Pectoralis major lap, Pleje af patienter med</a></p> <p style="margin-left:0cm; margin-right:0cm"><a href="https://vip.regionh.dk/VIP/Redaktoer/130126.nsf/X44AB3029CE5EDDC2C125877500448039?OpenDocument&amp;level=130126&amp;ref=internalVIP" style="color:blue; text-decoration:underline">Præoperativ forberedelse i ambulatoriet: patienter der skal laryngektomeres</a></p> <p style="margin-left:0cm; margin-right:0cm"><a href="https://vip.regionh.dk/VIP/Admin/GUI.nsf/Desktop.html?open&amp;openlink=https://vip.regionh.dk/VIP/Slutbruger/Portal.nsf/Main.html?open&amp;unid=XBECA65B461C26851C125796E004E8828&amp;level=130126&amp;dbpath=/VIP/Redaktoer/130126.nsf/&amp;windowwidth=1100&amp;windowheight=600&amp;windowtitle=S%F8g" style="color:blue; text-decoration:underline"><span style="background-color:white">Refeeding Syndrom, udredning, behandling, pleje og forebyggelse til voksne over 16 år.</span></a></p> <p style="margin-left:0cm; margin-right:0cm"><a href="https://vip.regionh.dk/VIP/Admin/GUI.nsf/Desktop.html?open&amp;openlink=https://vip.regionh.dk/VIP/Slutbruger/Portal.nsf/Main.html?open&amp;unid=X18B2DAEFABFB5DFBC12578AA002C7F00&amp;level=130126&amp;dbpath=/VIP/Redaktoer/RH.nsf/&amp;windowwidth=1100&amp;windowheight=600&amp;windowtitle=S%F8g" style="color:blue; text-decoration:underline">Sondeernæring og anlæggelse og kontrol af sonde (voksne, alder 16 år eller ældre)</a></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><strong>BILAG 1- Nødkald </strong></p> <p style="margin-left:0cm; margin-right:0cm"><strong>App til smartphone ”Akut hjælp til døve”:</strong></p> <ul> <li><span style="background-color:white"><span style="color:black">Appen kan downloades til Iphone og Android.</span></span></li> <li><span style="background-color:white"><span style="color:black">Man aktiverer app’en på sin smartphone og indtaster personlige oplysninger i felterne – derefter er app’en klar til brug. </span></span></li> <li><span style="background-color:white"><span style="color:black">Ved aktivering af app’en er der tre muligheder for hjælp</span></span> <ul style="list-style-type:circle"> <li><span style="background-color:white"><span style="color:black">Politi</span></span></li> <li><span style="background-color:white"><span style="color:black">Brandvæsen</span></span></li> <li><span style="background-color:white"><span style="color:black">Ambulance<br> Herefter startes en chat funktion, hvor der evt. kan komme uddybende spørgsmål.</span></span></li> </ul> </li> <li><span style="background-color:white"><span style="color:black">GPS (lokation) skal være tændt, så patientens placering bliver sendt, når man åbner en kontakt.</span></span></li> </ul> <p style="margin-left:0cm; margin-right:0cm"><strong>SMS fra mobil telefon til alarmcentralen:</strong></p> <ul> <li><span style="background-color:white"><span style="color:black">Hvis patienten ikke har en smartphone, kan der sendes sms fra mobil direkte til alarmcentralen<br> Tlf. ###TELEFON###</span></span></li> <li><span style="background-color:white"><span style="color:black">Nummeret indkodes i patientens mobiltelefon.</span></span></li> <li><span style="background-color:white"><span style="color:black">Der laves en standardtekst med navn, lokation og behov fx: <em>”Hans Knudsen, Sønder Ringvej 20, 0987 Nørre Snede, jeg kan ikke få luft og har brug for en ambulance”.</em></span></span></li> <li><span style="background-color:white"><span style="color:black">Standardteksten gemmes som kladde og kan sendes, hvis patienten får behov for akut hjælp.</span></span></li> </ul> <h2 style="margin-left:0cm; margin-right:0cm"><span style="color:#2f5496"><strong>Nødkald 2 til hjemmesygeplejen:</strong></span></h2> <ul> <li><span style="background-color:white"><span style="color:black">Patienten får installeret et nødkald 2 til hjemmesygeplejen, hvor det aftales, at når patienten benytter kaldet, rekvirerer hjemmesygeplejersken en ambulance.</span></span></li> <li><span style="background-color:white"><span style="color:black">Nogle kommuner har også mulighed for, at patienten kan sende en sms til dem.</span></span></li> </ul> <h2 style="margin-left:0cm; margin-right:0cm"><span style="color:#2f5496"><strong>Nødkald 1 til Alarmcentralen:</strong></span></h2> <ul> <li><span style="background-color:white"><span style="color:black">Hvis ingen af de ovenstående løsninger er mulige, kan der installeres nødkald til kørsel 1. I så fald skal ansøgningen sendes i god tid.</span></span></li> <li><span style="background-color:white"><span style="color:black">I nogle kommuner kræver et nødkald 1, at patienten har en fastnetforbindelse. Ved opsætning af fastnet er der et oprettelsesgebyr for patienten. Der skal indsættes nøgleboks ved hoveddøren</span><span style="color:black">.</span></span></li> <li><span style="background-color:white"><span style="color:black">Hvis der skal oprettes nødkald 1, skal der sendes Klinisk Korrespondance med bevilling. </span></span></li> </ul> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:36pt; margin-right:0cm">&nbsp;</p> <p style="margin-left:36pt; margin-right:0cm">&nbsp;</p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Laryngomalaci og vejrtrækningsbesvær - pædiatrisk ¥NH.

Laryngomalaci og vejrtrækningsbesvær - pædiatrisk ØNH Formål Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Bilag Formål Vurdering og behandling af laryngomalaci. Luftvejspatologi hos børn adskiller særligt sig fra den voksne patient grundet kongenitte årsager og dermed tidspunkt for symptomdebut. Symptomerne præsenterer sig ifa stertor (snorken), stridor, anstrengelse/besvær, uro/angst, apnøer og cyanotiske episoder (”blue spells”). Stertor defineres som lyd fra extrapulmonale luftveje, primært posteriort i cavum nasi/oris samt pharynx. Stridor defineres som (højfrekvent) lyd fra øvre luftveje, enten ved inspiration, ekspiration eller bifasisk. Målgrupper og anvendelsesområde Primært ØNH-læger med funktion som vurderende fagperson ved pædiatrisk luftvejsproblemstilling Definitioner Patologi svt. aditus laryngis enten grundet partiel eller komplet kollaps af de supraglottiske strukturer. Laryngomalaci kan inddeles i forskellige typer/klassifikationer delvist afhængig af udløsende komponent. 1. Overskydende mucosa svt. cartilago arytenoidea og posterior laryngeal kollaps ved inspiration 2. Omegaformet el. tubulær epiglottis pga. korte plica aryepiglottica med afsmalning af aditus laryngis og anterior og/eller lateral laryngeal kollaps ved inspiration 3. Retroverteret/-flekteret epiglottis og anterior laryngeal kollaps ved inspiration, benævnes også visse steder som neuromuskulær inkoordination med paradoks kollaps ved inspiration 4. Gastroesophageal reflux – omdiskuteret som udløsende årsag eller som resultat af laryngomalaci! Andre kategoriserer det blot som: anterior, posterior, lateral kollaps eller blanding. Præmaturitet disponerer for kongenit luftvejspatologi og associeret til laryngomalaci, men ej bevist kausalt og ”for blød” brusk er ikke hele forklaringen. Op til 20 % har synkron patologi i luftvejene. Laryngomalaci kan manifestere sig indenfor den første time postnatalt, men debuterer oftest omkring 2 ugers-alderen og topper typisk ved 6-mdr-alderen. Mediantid til spontan remission 9 mdr. Symptomerne aftager gradvist indtil 2 års-alderen. Fremgangsmåde Trives barnet? (Vægtstigning ifht. alder) Ernæring: Forværring af stridor? Amning eller flaske? Varighed? Opkastning? Hoste? Pneumonier? Forværring i liggende stilling, ved agitation, ved gråd? Lindring i bugleje eller hyperekstension i nakken? Indtrækninger? Respirationsstop? Obstruktiv søvnapnø? Cyanotiske tilfælde? Indlæggelseskrævende? Vurdering bør altid foretages med barnet i omsorgspersons/forælders skød, støttende arme, ben og hoved. Barnet bør sidde op og have ansigtet mod undersøger. Man bruger fiberskop eller fleksibelt (video)endoskop, som er påsmurt gel, transnasalt. Behandling: Milde tilfælde: Observation med opfølgning hos e.o om 3 mdr. Ved anamnestisk OSA da CRM via e.o. Råd om ernæringsmæssige optimering (oprejst lejring, pauser, evt. fortykningsmiddel) og soveposition i bugleje. Desuden skal vores laryngomalaci-patientinformationspjece udleveres. Moderate tilfælde: Opstart af PPI (Nexium, ½ brev dgl, vægt over 10 kg da 1 brev dgl.), henvisning til pædiatrisk afd. inkl. børneergoterapeuter samt opfølgning hos os på RH om 3 mdr. Svære tilfælde med dårlig trivsel og flere hospitalskontakter grundet infektioner eller regelret indlagte tilfælde - da booking til MLB i GA (mikrolaryngobronkoskopi = pædiatrisk direkte laryngotracheobronkoskopi). Supraglottoplastik er sjældent nødvendigt og proceduretype er afhængig af patologien. Pædiatrisk tracheostomi er ekstremt sjældent. Ansvar og organisering Afdeling for Øre-Næse-Halskirurgi og Audiologi Inge Lehmanns Vej 8 2100 København Ø Kontorafsnit 6033, opgang 6, 3. sal Referencer, lovgivning og faglig evidens samt links hertil Graham J.M., Scadding G.K. and Bull P.D. (Eds.) Springer (2007) Pediatric ENT Anniko M., Bernal-Sprekelsen M., Bonkowsky V., Bradley P. and Iurato S. (Eds.) Springer (2010) Otorhinolaryngology, Head & Neck Surgery Monnier P. (Ed.) Springer (2011) Pediatric Airway Surgery Lioy J. and Sobol S. (Eds.) Springer (2015) Disorders of the Neonatal Airway https://vula.uct.ac.za/access/content/group/ba5fb1bd-be95-48e5-81be-586fbaeba29d/Supraglottoplasty%20for%20laryngomalacia.pdf https://pubmed.ncbi.nlm.nih.gov/22178204/ https://pubmed.ncbi.nlm.nih.gov/32556789/ Bilag Pædiatrisk ØNH – luftvejspatologi, pdf forefindes på afdelingens P-drev, mappe; Pædiatrisk_ØNH. Det uddybende materiale inkluderer andre årsager inkl. billeder til pæd. luftvejsproblemer herunder; Stertor: AV- og tonsilhypertrofi Rhinosinuit (CRSwNP/CRSsNP) Mikro- og/eller retrognathi med deraf følgende glossoptosis (som fx ved Pierre-Robin ”sekvens”) Neuromuskulær inkoordination (eller hypotonus som fx ved trisomi 21 eller CHARGE) (Choanalstenose/-atresi) Stridor: Laryngomalaci (kan også have grad af stertor) Laryngitis (laryngotracheobronkitis/pseudocroup) N. recurrensparese (fx efter hjertekirurgi) Subglottisk stenose (fx. ved infantil hæmangiom eller postintubation) og regelret trachealstenose Laryngeal papillomatose, cyster og -celer, web og stenose/atresi samt kløft (Ikke kongenit; akut stridor og relevant anamnese - tænk fremmedlegeme!)

<h1><div id="Afsnit#1699579320202">Laryngomalaci og vejrtrækningsbesvær - pædiatrisk ØNH</div></h1><div id="BodyWeb#1699579320202"><p><a name="1699579320202Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579320202Formaal">Formål</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579320202Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579320202Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579320202Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579320202Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579320202Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579320202Bilag">Bilag</a><br> &nbsp;</h3> <div class="collapsible-item" expandedstart="1"><a name="1699579320202Formaal"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Formål</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm">Vurdering og behandling af laryngomalaci.</p> <p style="margin-left:0cm; margin-right:0cm">Luftvejspatologi hos børn adskiller særligt sig fra den voksne patient grundet kongenitte årsager og dermed tidspunkt for symptomdebut. Symptomerne præsenterer sig ifa stertor (snorken), stridor, anstrengelse/besvær, uro/angst, apnøer og cyanotiske episoder (”blue spells”).</p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Stertor defineres som lyd fra extrapulmonale luftveje, primært posteriort i cavum nasi/oris samt pharynx. Stridor defineres som (højfrekvent) lyd fra øvre luftveje, enten ved inspiration, ekspiration eller bifasisk.</span></p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579320202Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579320202Maalgrupper"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Målgrupper og anvendelsesområde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm">Primært ØNH-læger med funktion som vurderende fagperson ved pædiatrisk luftvejsproblemstilling</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579320202Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579320202Definitioner"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Definitioner</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Patologi svt. aditus laryngis enten grundet partiel eller komplet kollaps af de supraglottiske strukturer. Laryngomalaci kan inddeles i forskellige typer/klassifikationer delvist afhængig af udløsende komponent. </span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">1. Overskydende mucosa svt. cartilago arytenoidea og posterior laryngeal kollaps ved inspiration </span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">2. Omegaformet el. tubulær epiglottis pga. korte plica aryepiglottica med afsmalning af aditus laryngis og anterior og/eller lateral laryngeal kollaps ved inspiration </span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">3. Retroverteret/-flekteret epiglottis og anterior laryngeal kollaps ved inspiration, benævnes også visse steder som neuromuskulær inkoordination med paradoks kollaps ved inspiration </span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">4. Gastroesophageal reflux – omdiskuteret som udløsende årsag eller som resultat af laryngomalaci! </span></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><img alt="" src="/VIP/Redaktoer/130126.nsf/vLookupUpload/ATTACH-RHAP-CRGGFX/$FILE/Skærmbillede 2023-05-03 141902.png" style="height:335px; width:655px" onclick="Ext.DMS.util.showImage(this);"></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm">Andre kategoriserer det blot som: anterior, posterior, lateral kollaps eller blanding.</p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Præmaturitet disponerer for kongenit luftvejspatologi og associeret til laryngomalaci, men ej bevist kausalt og ”for blød” brusk er ikke hele forklaringen. Op til 20 % har synkron patologi i luftvejene. </span></p> <p style="margin-left:0cm; margin-right:0cm">Laryngomalaci kan manifestere sig indenfor den første time postnatalt, men debuterer oftest omkring 2 ugers-alderen og topper typisk ved 6-mdr-alderen. Mediantid til spontan remission 9 mdr. Symptomerne aftager gradvist indtil 2 års-alderen.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579320202Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579320202Fremgangsmaade"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Fremgangsmåde</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Trives barnet? (Vægtstigning ifht. alder) </span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Ernæring: Forværring af stridor? Amning eller flaske? Varighed? Opkastning? Hoste? Pneumonier? </span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Forværring i liggende stilling, ved agitation, ved gråd? Lindring i bugleje eller hyperekstension i nakken? Indtrækninger? Respirationsstop? Obstruktiv søvnapnø? Cyanotiske tilfælde? Indlæggelseskrævende?</span></p> <p style="margin-left:0cm; margin-right:0cm">Vurdering bør altid foretages med barnet i omsorgspersons/forælders skød, støttende arme, ben og hoved. Barnet bør sidde op og have ansigtet mod undersøger. Man bruger fiberskop eller fleksibelt (video)endoskop, som er påsmurt gel, transnasalt.</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Behandling: </span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Milde tilfælde: Observation med opfølgning hos e.o om 3 mdr. Ved anamnestisk OSA da CRM via e.o. Råd om ernæringsmæssige optimering (oprejst lejring, pauser, evt. fortykningsmiddel) og soveposition i bugleje. Desuden skal vores laryngomalaci-patientinformationspjece udleveres.</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Moderate tilfælde: Opstart af PPI (Nexium, ½ brev dgl, vægt over 10 kg da 1 brev dgl.), henvisning til pædiatrisk afd. inkl. børneergoterapeuter samt opfølgning hos os på RH om 3 mdr. </span></p> <p style="margin-left:0cm; margin-right:0cm">Svære tilfælde med dårlig trivsel og flere hospitalskontakter grundet infektioner eller regelret indlagte tilfælde - da booking til MLB i GA (mikrolaryngobronkoskopi = pædiatrisk direkte laryngotracheobronkoskopi). Supraglottoplastik er sjældent nødvendigt og proceduretype er afhængig af patologien. Pædiatrisk tracheostomi er ekstremt sjældent.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579320202Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579320202Ansvar"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Ansvar og organisering</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Afdeling for Øre-Næse-Halskirurgi og Audiologi</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Inge Lehmanns Vej 8</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">2100 København Ø</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Kontorafsnit 6033, opgang 6, 3. sal</span></p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579320202Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579320202Referencer"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Referencer, lovgivning og faglig evidens samt links hertil</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm">Graham J.M., Scadding G.K. and Bull P.D. (Eds.) Springer (2007) Pediatric ENT</p> <p style="margin-left:0cm; margin-right:0cm">Anniko M., Bernal-Sprekelsen M., Bonkowsky V., Bradley P. and Iurato S. (Eds.) Springer (2010) Otorhinolaryngology, Head &amp; Neck Surgery</p> <p style="margin-left:0cm; margin-right:0cm">Monnier P. (Ed.) Springer (2011) Pediatric Airway Surgery</p> <p style="margin-left:0cm; margin-right:0cm">Lioy J. and Sobol S. (Eds.) Springer (2015) Disorders of the Neonatal Airway</p> <p style="margin-left:0cm; margin-right:0cm"><a href="https://vula.uct.ac.za/access/content/group/ba5fb1bd-be95-48e5-81be-586fbaeba29d/Supraglottoplasty%20for%20laryngomalacia.pdf" style="color:blue; text-decoration:underline">https://vula.uct.ac.za/access/content/group/ba5fb1bd-be95-48e5-81be-586fbaeba29d/Supraglottoplasty%20for%20laryngomalacia.pdf</a></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:blue"><u>https://pubmed.ncbi.nlm.nih.gov/22178204/</u></span></p> <p style="margin-left:0cm; margin-right:0cm"><a href="https://pubmed.ncbi.nlm.nih.gov/32556789/" style="color:blue; text-decoration:underline">https://pubmed.ncbi.nlm.nih.gov/32556789/</a></p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579320202Top">Tilbage til top</a></p> </div> </div> <div class="collapsible-item" expandedstart="1"><a name="1699579320202Bilag"></a> <div class="collapsible-item-title collapsible-item-active"> <h2>Bilag</h2> </div> <div class="collapsible-item-body" style="display: block;"> <p style="margin-left:0cm; margin-right:0cm">Pædiatrisk ØNH – luftvejspatologi, pdf forefindes på afdelingens P-drev, mappe; Pædiatrisk_ØNH. Det uddybende materiale inkluderer andre årsager inkl. billeder til pæd. luftvejsproblemer herunder;</p> <p style="margin-left:0cm; margin-right:0cm">Stertor:</p> <p style="margin-left:0cm; margin-right:0cm">AV- og tonsilhypertrofi</p> <p style="margin-left:0cm; margin-right:0cm">Rhinosinuit (CRSwNP/CRSsNP)</p> <p style="margin-left:0cm; margin-right:0cm">Mikro- og/eller retrognathi med deraf følgende glossoptosis (som fx ved Pierre-Robin ”sekvens”)</p> <p style="margin-left:0cm; margin-right:0cm">Neuromuskulær inkoordination (eller hypotonus som fx ved trisomi 21 eller CHARGE)</p> <p style="margin-left:0cm; margin-right:0cm">(Choanalstenose/-atresi)</p> <p style="margin-left:0cm; margin-right:0cm">Stridor:</p> <p style="margin-left:0cm; margin-right:0cm"><strong><img src="data:image/jpeg;base64,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" style="height:258px; width:285px" onclick="Ext.DMS.util.showImage(this);"></strong></p> <p style="margin-left:0cm; margin-right:0cm">Laryngomalaci (kan også have grad af stertor)<strong> </strong></p> <p style="margin-left:0cm; margin-right:0cm">Laryngitis (laryngotracheobronkitis/pseudocroup)</p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">N. recurrensparese (fx efter hjertekirurgi)</span></p> <p style="margin-left:0cm; margin-right:0cm">Subglottisk stenose (fx. ved infantil hæmangiom eller postintubation) og regelret trachealstenose</p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">Laryngeal papillomatose, cyster og -celer, web og stenose/atresi samt kløft</span></p> <p style="margin-left:0cm; margin-right:0cm"><span style="color:black">(Ikke kongenit; akut stridor og relevant anamnese - tænk fremmedlegeme!)</span></p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p style="margin-left:0cm; margin-right:0cm">&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579320202Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Lumbal drænage ved ligoursivning efter operation.

Lumbal drænage ved ligoursivning efter operation for Vestibularis schwannom (acusticus neurinom) Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Målgrupper og anvendelsesområde Klinisk personale i Afdeling for Øre-Næse-Halskirurgi og Audiologi Definitioner Klinisk vejledning ang. liqoursivning efter operation for benign tumor udgående fra nervus vestibularis. Fremgangsmåde Lumbal drænage ved liquorsivning efter operation for Vestibularis schwannom (acusticus neurinom) Resume Klinisk vejledning ang. liquorsivning. Fremgangsmåde Baggrund: Liquorsivning efter operation for vestibularis schwannom (acusticus neurinom) kan forekomme gennem cikatricen eller fra mellemøret gennem det eustakiske rør og ud gennem næsen (rhinoliquorrhoea). Den normale døgnproduktion af cerebrospinal væske er ca. 300 – 450 ml. (0,2 – 0,3 ml/min). Ved liquorrhea vil udsivning af denne væske være med til at opretholde liquorfistlen. Formålet med lumbal drænage er at tappe den producerede mængde cerebrospinal væske for herved at aflaste fistlen, der så har mulighed for at hele op. Den planlagte drænage-tid er 3 - 4 døgn. Anlæggelse af lumbaldræn: - Anlæggelse af lumbalt dræn foregår i lokal anæstesi og udføres af anæstesilæge. Patienten behøver ikke at være fastende. - Efter anlæggelse af lumbalt dræn skal patienten lejres fladt i sengen med hovedet eleveret ca. 10 grader. Det intracranielle tryk vil i denne stilling være ca. 10 cm. vand. Tromboseprofylakse: Så længe patienten er immobiliseret gives Innohep 3500 IE x 1 sc og TED-strømper Observationer: Opsætning og observation af dråbe-kammer-pose: se tegning - Der opsættes et drop-stativ ved patientens hovedgærde. Dråbe-kammer-posen ophænges ved hjælp af den monterede snor i drop-stativet og posens højde reguleres ved hjælp af snor-klemmen således at niveaupunktet ”0” er i højde med patientens ydre øregang. Nu vil cerebrospinalvæsken langsomt begynde at dryppe fra dråbestudsen i dråbekammeret ned i opsamlingsposen. Drænet skal dryppe med 4 dråber/min. hele døgnet, svarende til 50 ml over 4 timer med en døgnproduktion på 300 ml. - I starten af hver vagt tjekkes dråbehastighed (dette bør gøres yderligere en gang i hver vagt). - Dråbehastigheden skal svare nogenlunde til den producerede mængde, altså 0,2 – 0,3 ml/min = 4 – 6 dråber/min. - Hvis den observerede dråbehastighed er mindre end 4 – 6 dråber/min, hænger posen for højt (der er ingen risiko forbundet med dette, da posen er lufttom/lufttæt, blot opnås den ønskede drænage ikke). Hvis den observerede dråbehastighed er større end 4 – 6 dråber/min, hænger posen for lavt og patienten vil efter nogen tid klage over hovedpine. Det er almindeligt at patienter der behandles med lumbaldrænage får let hovedpine og hørenedsættelse på det raske øre. Hørenedsættelsen er reversibel og fortager sig efter endt drænage. Opsamlingsposen tømmes en gang i døgnet kl. 24 og den samlede mængde noteres i plejeplanen. Liquor`s farve observeres i hver vagt. - Sættet åbnes ikke og skiftes ikke. Der kan med fordel sættes en aftømningspose nederst på opsamlingsposen. - Hvert døgn patienten behandles, skal posen tømmes. Dette foregår efter at døgnproduktion er noteret, ved at lukke for 3-vejs-ventilen, afklemme tilløbsslangen, og åbne for klemmen på afløbsstudsen. Når posen er tømt (også for evt. luft), lukkes afløbsstudsen med klemmen og 3-vejs-ventilen åbnes. Drænet fjernes først når det har været afklemt og der ingen liquorsivning har været i 24 timer. Sædvanligvis først efter 4 døgn. - Seponering af drænet foretages af en læge efter aftale med en af operatørerne. Drænet er meget langt og seponeres ved langsom udtræk med patienten liggende på siden med ”krummet” ryg. Der lægges Tegaderm på og derover rulles en pølse af to vaskeklude som sættes over med plaster, så patienten komprimerer indstik selv i mindst 2 timer. EWS efter handlingsalgoritme – dog tjekkes temperatur og AVPU i hver vagt - Drænsted observeres kun hvis der er temperatur forhøjelse eller smerter ved indstiks stedet, da patienten helst ikke skal ligge på siden. - Såfremt patienten får temperaturstigning og/eller tiltagende hovedpine skal vagthavende læge tilkaldes og patienten skal undersøges for evt. meningit symptomer (liquor væsken kan undersøges). I tvivlstilfælde kontakt ###NAVN###-###NAVN### eller ###NAVN###. Sygepleje - Patienten er T.L. under hele behandlingen med 10 grader eleveret hovedgærde (også ved måltid) - Patienten må gerne sætte sig på sengekanten i kortere øjeblikke (f.eks. vandladning, afføring/bækkenstol) - Drænet skal afklemmes inden patienten rejser sig (klemme på dræn slangen). Husk at åbne igen!

<h1><div id="Afsnit#1699579431333">Lumbal drænage ved ligoursivning efter operation for Vestibularis schwannom (acusticus neurinom)</div></h1><div id="BodyWeb#1699579431333"><p><a name="1699579431333Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579431333Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579431333Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579431333Fremgangsmaade">Fremgangsmåde</a><br> &nbsp;</h3> <h2><a name="1699579431333Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p>&nbsp;Klinisk personale i Afdeling for Øre-Næse-Halskirurgi og Audiologi</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579431333Top">Tilbage til top</a></p> <h2><a name="1699579431333Definitioner"></a><br> Definitioner</h2> <p>&nbsp;Klinisk vejledning ang. liqoursivning efter operation for benign tumor udgående fra nervus vestibularis.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579431333Top">Tilbage til top</a></p> <h2><a name="1699579431333Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p>&nbsp;&nbsp;</p> <p><strong>Lumbal drænage ved liquorsivning efter operation for </strong><strong>Vestibularis schwannom (acusticus neurinom) </strong></p> <p>&nbsp;</p> <p><strong>Resume</strong></p> <p>Klinisk vejledning ang. liquorsivning.</p> <p><strong>Fremgangsmåde</strong></p> <p><strong>Baggrund:</strong></p> <p>Liquorsivning efter operation for vestibularis schwannom (acusticus neurinom) kan forekomme gennem cikatricen eller fra mellemøret gennem det eustakiske rør og ud gennem næsen (rhinoliquorrhoea).<br> <br> Den normale døgnproduktion af cerebrospinal væske er ca. 300 – 450 ml. (0,2 – 0,3 ml/min). Ved liquorrhea vil udsivning af denne væske være med til at opretholde liquorfistlen. Formålet med lumbal drænage er at tappe den producerede mængde cerebrospinal væske for herved at aflaste fistlen, der så har mulighed for at hele op. Den planlagte drænage-tid er 3 - 4 døgn.</p> <p><strong>Anlæggelse af lumbaldræn:</strong></p> <ul> <li>Anlæggelse af lumbalt dræn foregår i lokal anæstesi og udføres af anæstesilæge. Patienten behøver ikke at være fastende.</li> <li>Efter anlæggelse af lumbalt dræn skal patienten lejres fladt i sengen med hovedet eleveret ca. 10 grader. Det intracranielle tryk vil i denne stilling være ca. 10 cm. vand.</li> </ul> <p>Tromboseprofylakse: Så længe patienten er immobiliseret gives Innohep 3500 IE x 1 sc og TED-strømper</p> <p><strong>Observationer:</strong></p> <p><u>Opsætning og observation af dråbe-kammer-pose: se tegning</u></p> <ul> <li>Der opsættes et drop-stativ ved patientens hovedgærde. Dråbe-kammer-posen ophænges ved hjælp af den monterede snor i drop-stativet og posens højde reguleres ved hjælp af snor-klemmen således at <u>niveaupunktet ”0” er i højde med patientens ydre øregang</u>. Nu vil cerebrospinalvæsken langsomt begynde at dryppe fra dråbestudsen i dråbekammeret ned i opsamlingsposen.</li> </ul> <p style="margin-left:18pt"><u>Drænet skal dryppe med 4 dråber/min. hele døgnet, svarende til 50 ml over 4 timer med en døgnproduktion på 300 ml. </u></p> <ul> <li>I starten af hver vagt tjekkes dråbehastighed (dette bør gøres yderligere en gang i hver vagt).</li> <li>Dråbehastigheden skal svare nogenlunde til den producerede mængde, altså 0,2 – 0,3 ml/min = 4 – 6 dråber/min.</li> <li>Hvis den observerede dråbehastighed er mindre end 4 – 6 dråber/min, hænger posen for højt (der er ingen risiko forbundet med dette, da posen er lufttom/lufttæt, blot opnås den ønskede drænage ikke). Hvis den observerede dråbehastighed er større end 4 – 6 dråber/min, hænger posen for lavt og patienten vil efter nogen tid klage over hovedpine. Det er almindeligt at patienter der behandles med lumbaldrænage får let hovedpine og hørenedsættelse på det raske øre. Hørenedsættelsen er reversibel og fortager sig efter endt drænage.</li> </ul> <p style="margin-left:18pt"><u>Opsamlingsposen tømmes en gang i døgnet kl. 24 og den samlede mængde noteres i plejeplanen. Liquor`s farve observeres i hver vagt.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </u></p> <ul> <li>Sættet åbnes ikke og skiftes ikke. Der kan med fordel sættes en aftømningspose nederst på opsamlingsposen.</li> <li>Hvert døgn patienten behandles, skal posen tømmes. Dette foregår efter at døgnproduktion er noteret, ved at lukke for 3-vejs-ventilen, afklemme tilløbsslangen, og åbne for klemmen på afløbsstudsen. Når posen er tømt (også for evt. luft), lukkes afløbsstudsen med klemmen og 3-vejs-ventilen åbnes.</li> </ul> <p style="margin-left:18pt"><u>Drænet fjernes først når det har været afklemt og der ingen liquorsivning har været i 24 timer. Sædvanligvis først efter 4 døgn</u>.</p> <ul> <li>Seponering af drænet foretages af en læge efter aftale med en af operatørerne. Drænet er meget langt og seponeres ved langsom udtræk med patienten liggende på siden med ”krummet” ryg. Der lægges Tegaderm på og derover rulles en pølse af to vaskeklude som sættes over med plaster, så patienten komprimerer indstik selv i mindst 2 timer.</li> </ul> <p style="margin-left:18pt"><u>EWS efter handlingsalgoritme – dog tjekkes temperatur og AVPU i hver vagt </u></p> <ul> <li>Drænsted observeres kun hvis der er temperatur forhøjelse eller smerter ved indstiks stedet, da patienten helst ikke skal ligge på siden.</li> <li>Såfremt patienten får temperaturstigning og/eller tiltagende hovedpine skal vagthavende læge tilkaldes og patienten skal undersøges for evt. meningit symptomer (liquor væsken kan undersøges). I tvivlstilfælde kontakt ###NAVN###-###NAVN### eller ###NAVN###.</li> </ul> <p><strong>Sygepleje</strong></p> <ul> <li>Patienten er T.L. under hele behandlingen med 10 grader eleveret hovedgærde (også ved måltid)</li> <li>Patienten må gerne sætte sig på sengekanten i kortere øjeblikke (f.eks. vandladning, afføring/bækkenstol)</li> <li><strong>Drænet skal afklemmes inden patienten rejser sig (klemme på dræn slangen). Husk at åbne igen</strong>!</li> </ul> <p style="margin-left:18pt">&nbsp;<img alt="" src="/VIP/Redaktoer/130126.nsf/vLookupUpload/ATTACH-RHAP-9L2LD7/$FILE/tegning.jpg" style="height:487px; width:378px" onclick="Ext.DMS.util.showImage(this);"></p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579431333Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Mistet i-¢ret h¢reapparat udleveret herfra med.

Mistet i-øret høreapparat, udleveret herfra med dækkende garanti Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Målgrupper og anvendelsesområde Personale ved Hørepædagogisk afsnit, GeH Definitioner Fremgangsmåde Mistet i-øret høreapparat, udleveret herfra med dækkende garanti Klienter med CI på det ene øre og IØ apparat på modsatte øre, som mister deres IØ app indenfor garanti, skal kontake Hørepædagogisk afsnit. Herefter kan de møde op til nyt aftryk i Ørepropteknikken opgang 3B eller 3C hver tirsdag og onsdag mellem 9 og 13. Her vil de få taget aftryk af det pågældende øre til et HA magen til det, de har mistet og derefter få sendt apparat hjem til dem. Proceduren er som følger: - Klienten møder op i ØP 3B eller 3C tirsdag og onsdag mellem 9 og 13 + evt. aktuel høreprøve fra e.o. - ØP tager aftryk af det pågældende øre og får klientens navn og CPR-nr. - ØP skriver klientens navn og CPR-nr. samt ”tabt apparat” på aftrykskassen og afleverer den på Hørepædagogisk afsnit. - Sekretærer på hørepæd. registrerer ydelserne samt udfylder bestillingsseddel og sender aftryk til det pågældende firma. OBS! Hvis høreprøven er ældre end ½ år skal der laves en ny. Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag

<h1><div id="Afsnit#1699579394040">Mistet i-øret høreapparat, udleveret herfra med dækkende garanti</div></h1><div id="BodyWeb#1699579394040"><p><a name="1699579394040Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579394040Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579394040Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579394040Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579394040Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579394040Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579394040Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579394040Bilag">Bilag</a><br> &nbsp;</h3> <h2><a name="1699579394040Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p>Personale ved Hørepædagogisk afsnit, GeH&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579394040Top">Tilbage til top</a></p> <h2><a name="1699579394040Definitioner"></a><br> Definitioner</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579394040Top">Tilbage til top</a></p> <h2><a name="1699579394040Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p><strong>Mistet i-øret høreapparat, udleveret herfra med dækkende garanti</strong></p> <p>&nbsp;</p> <p>Klienter med CI på det ene øre og&nbsp;IØ apparat på modsatte øre, som mister deres&nbsp;IØ app&nbsp;indenfor garanti,&nbsp;skal kontake Hørepædagogisk afsnit. Herefter kan de møde op til nyt aftryk i Ørepropteknikken opgang 3B eller 3C hver tirsdag og onsdag mellem 9 og 13. Her vil de få taget aftryk af det pågældende øre til et HA magen til det, de har mistet og derefter få sendt apparat hjem til dem.</p> <p>&nbsp;</p> <p>Proceduren er som følger:</p> <p>&nbsp;</p> <p>· Klienten møder op i ØP 3B eller 3C tirsdag og onsdag mellem 9 og 13 + evt. aktuel høreprøve fra e.o.</p> <p>· ØP tager aftryk af det pågældende øre og får klientens navn og CPR-nr.</p> <p>· ØP skriver klientens navn og CPR-nr. samt ”tabt apparat” på aftrykskassen og afleverer den på Hørepædagogisk afsnit.</p> <p>· Sekretærer på hørepæd. registrerer ydelserne samt udfylder bestillingsseddel og sender aftryk til det pågældende firma.</p> <p>&nbsp;</p> <p>OBS! Hvis høreprøven er ældre end ½ år skal der laves en ny.</p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579394040Top">Tilbage til top</a></p> <h2><a name="1699579394040Ansvar"></a><br> Ansvar og organisering</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579394040Top">Tilbage til top</a></p> <h2><a name="1699579394040Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579394040Top">Tilbage til top</a></p> <h2><a name="1699579394040Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579394040Top">Tilbage til top</a></p> <h2><a name="1699579394040Bilag"></a><br> Bilag</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579394040Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Morbus Ménière.

Morbus Ménière Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Målgrupper og anvendelsesområde Læger og sygeplejersker Definitioner Ménières sygdom er en af de hyppigere årsager til vertigo. Cirka 1 ud af 1000 rammes. Fremgangsmåde Patogenese: Mb. Ménière anses at være forårsaget af en øget mængde væske eller øget væsketryk i endolymferummet, hvilke er observeret på temporalbenspræparater. Hvordan dette hydrops kan forårsage symptomer, eller om den er en årsag eller følge af Ménière sygdom, er der ikke enighed om i litteraturen. Den førende hypotese er dog at et hydrops fører til cochleovestibulært funktionstab, hvilket i sin natur forårsager hørenedsættelse, tinnitus og nedsat funktion af det vestibulære apparat. Generelt rammes patienten af pludselige attacker af triaden: vertigo, tinnitus og hørenedsættelse, hvilke er de karakteristika der kræves for at kunne stille diagnosen. Man mener attackerne kan skyldes at den membranøse labyrint, der omskeder endolymferummet, brister med følgende trykændring heri og lækage af ioner mellem peri- og endolymfe rummene. Symptomer: Anfald kommer i varighed af ½ til nogle timer. Triaden af symptomer er 1. Vertigo som er rotatorisk af karakter, ofte kvalme med opkast 2. Høretab som er anfaldsvis med progressivt ofte med diplakusis, fyldningsfornemmelse (= fullness) i samme øre før og under anfaldene. 3. Tinnitus som er anfaldsvis og progressivt Efterhånden aftager svimmelhedsanfaldene, da den vestibulære funktion forringes. Mellem anfaldene er symptomerne reversible, men som sygdommen skrider frem kommer der permanent sensorineuralt høretab og tinnitus. Bilateral affektion ses hos cirka 40 % og er hyppigst relateret til at patienten har haft sygdommen i lang tid. Diagnose: Diagnosen stilles ved: 1. To eller flere anfald af vertigo af mindst 20 minutters varighed 2. Objektiv sensorineural hørenedsættelse i lavtone område 3. Tinnitus og træthedsfornemmelse i øret 4. Basale og udvidede otoneurologiske tests. Differentialdiagnostik: Et lignende sygdomsbillede ses ved migræne, som ikke giver hørenedsættelse, hvorfor disse patienter altid skal have et audiogram. Vestibulær schvanom kan give hørenedsættelse, men er oftest ikke fulgt at vertigoanfald. Behandling: Disse deles ind i 2 kategorier 1. Konservativ behandling, hvor man bevarer den cochleovestibulære funktion under samtidig forsøg på at korrigere for ætiologiske faktorer. Medicinsk: Patient behandles patient med diuretika, kvalme- og vertigodæmpende medicin. Desuden underkastes patienten saltrestriktion. Kirurgisk: Dræn/Meniet behandling. Shuntoperation, hvilke er et omdiskuteret område. 2. Destruktion af hele eller dele af det indre øre ved hhv. kirurgisk eller medicinsk behandling. Kirurgisk: - Vestibulær neurektomi &n bsp; - Labyrintektomi Medicinsk: - Gentamycin installation i mellemøre Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag

<h1><div id="Afsnit#1699579371847">Morbus Ménière</div></h1><div id="BodyWeb#1699579371847"><p><a name="1699579371847Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579371847Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579371847Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579371847Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579371847Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579371847Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579371847Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579371847Bilag">Bilag</a><br> &nbsp;</h3> <h2><a name="1699579371847Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p>&nbsp;Læger og sygeplejersker</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579371847Top">Tilbage til top</a></p> <h2><a name="1699579371847Definitioner"></a><br> Definitioner</h2> <p>Ménières sygdom er en af de hyppigere årsager til vertigo. Cirka 1 ud af 1000 rammes.&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579371847Top">Tilbage til top</a></p> <h2><a name="1699579371847Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p>&nbsp;</p> <p><strong>Patogenese: </strong></p> <p>Mb. Ménière anses at være forårsaget af en øget mængde væske eller øget væsketryk i endolymferummet, hvilke er observeret på temporalbenspræparater. Hvordan dette hydrops kan forårsage symptomer, eller om den er en årsag eller følge af Ménière sygdom, er der ikke enighed om i litteraturen. Den førende hypotese er dog at et hydrops fører til cochleovestibulært funktionstab, hvilket i sin natur forårsager hørenedsættelse, tinnitus og nedsat funktion af det vestibulære apparat.</p> <p>Generelt rammes patienten af pludselige attacker af triaden: vertigo, tinnitus og hørenedsættelse, hvilke er de karakteristika der kræves for at kunne stille diagnosen. Man mener attackerne kan skyldes at den membranøse labyrint, der omskeder endolymferummet, brister med følgende trykændring heri og lækage af ioner mellem peri- og endolymfe rummene.</p> <p><strong>Symptomer: </strong></p> <p>Anfald kommer i varighed af ½ til nogle timer. Triaden af symptomer er<br> <br> 1. Vertigo som er rotatorisk af karakter, ofte kvalme med opkast</p> <p>2. Høretab som er anfaldsvis med progressivt ofte med diplakusis, fyldningsfornemmelse (= fullness) i samme øre før og under anfaldene.</p> <p>3. Tinnitus som er anfaldsvis og progressivt</p> <p>Efterhånden aftager svimmelhedsanfaldene, da den vestibulære funktion forringes. Mellem anfaldene er symptomerne reversible, men som sygdommen skrider frem kommer der permanent sensorineuralt høretab og tinnitus. Bilateral affektion ses hos cirka 40 % og er hyppigst relateret til at patienten har haft sygdommen i lang tid.</p> <p><strong>Diagnose: </strong></p> <p>Diagnosen stilles ved:<br> &nbsp;</p> <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To eller flere anfald af vertigo af mindst 20 minutters varighed</p> <p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Objektiv sensorineural hørenedsættelse i lavtone område</p> <p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tinnitus og træthedsfornemmelse i øret</p> <p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Basale og udvidede otoneurologiske tests.</p> <p><strong>Differentialdiagnostik:</strong></p> <p>Et lignende sygdomsbillede ses ved migræne, som ikke giver hørenedsættelse, hvorfor disse patienter altid skal have et audiogram. Vestibulær schvanom kan give hørenedsættelse, men er oftest ikke fulgt at vertigoanfald.</p> <p><strong>&nbsp;</strong><strong>&nbsp;</strong></p> <p><strong>Behandling:</strong></p> <p>Disse deles ind i 2 kategorier</p> <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Konservativ behandling, hvor man bevarer den cochleovestibulære funktion under samtidig forsøg på at korrigere for ætiologiske faktorer.</p> <p><u>Medicinsk</u>: Patient behandles patient med diuretika, kvalme- og vertigodæmpende medicin. Desuden underkastes patienten saltrestriktion.</p> <p><u>Kirurgisk</u>: Dræn/Meniet behandling. Shuntoperation, hvilke er et omdiskuteret område.</p> <p>&nbsp;</p> <p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Destruktion af hele eller dele af det indre øre ved hhv. kirurgisk eller medicinsk behandling.</p> <p>Kirurgisk: &nbsp; - Vestibulær neurektomi</p> <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&amp;n bsp;&nbsp;&nbsp;&nbsp; - Labyrintektomi</p> <p>Medicinsk: - Gentamycin installation i mellemøre</p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579371847Top">Tilbage til top</a></p> <h2><a name="1699579371847Ansvar"></a><br> Ansvar og organisering</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579371847Top">Tilbage til top</a></p> <h2><a name="1699579371847Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579371847Top">Tilbage til top</a></p> <h2><a name="1699579371847Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579371847Top">Tilbage til top</a></p> <h2><a name="1699579371847Bilag"></a><br> Bilag</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579371847Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Neuronitis vestibulares.

Neuronitis vestibulares Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Målgrupper og anvendelsesområde Læger og sygeplejersker Definitioner En af de mest hyppige årsager til svimmelhed og kan ramme patienter i alle aldersgrupper. Incidensen er usikker, idet ordet ”virus på balancenerven” bruges i flæng om svimle patienter. Fremgangsmåde Ætiologi: Ukendt. I litteraturen skriver man at virusinfektion med Herpes Simplex er sandsynlig, men man kan også tænke sig andre årsager. Symptomer: Akut, ensidig vestibulær parese bevirker, at der fra det ene vestibulære organ ikke sendes impulser centralt og fra det andet vestibulære organ er der normale impulser. Dette giver vertigo (subjektiv oplevelse af svimmelhed) med forstyrrelser i de vestibulookulære, vestibulospinale og vestibuloretikulære reflekser. Dominerende symptom er akut rotatorisk vertigo som oftest opstår, når patienten står op om morgen. Ofte kvalme med opkast. Patient vil helst ligge helt stille med lukkede øjne, idet visuel fiksation forværre svimmelheden. Diagnose: 1. Svær rotatorisk vertigo mod raske side, varighed dage til en uge. 2. Kvalme og ofte opkastninger. 3. Spontan horisontal-tortionel nystagmus mod raske side, med illusorisk bevægelse af omgivelserne (oscillopsi). Nystagmus forstærkes bag Bartels/Frentzels brille og bliver kraftigere eller svagere ved blikretning mod henholdsvis hurtig eller langsom nystagmusfase. Ved fiksation svækkes nystagmusamplituden, e.g Bartels/Frentzels briller er påkrævet. 4. Gangdeviation og fald mod den syge side ved Rombergs prøve. 5. Ingen andre neurologiske udfald, specielt ingen ved audiologisk undersøgelse. 6. Ipsilateralt udfald af horisontale buegangsfunktion, bedømt ved impuls test og vestibulær asymmetrisk funktion bedømt ved head-shake test eller kalorisk øreskylning (varierende grader af hypo- eller non-reaktivitet). Alle elementer kan ses i den akutte fase inden for 1-3 dage. Forløb: Vestibulær kompensation indtræder inden for dage og patienten får mindre vertigo og kvalme. Generelt skal patient have så lidt sederende medikamenter i kortest mulig tid for at opnå størst og hurtigst kompensation. Unge og fysisk aktive patienter kommer sig hurtigere end ældre og funktionshæmmede. Sygdomsbilledet er præget at træthed i flere måneder efterfølgende. Op til 20 % får BPPV på det syge øre på et senere tid i livet. Behandling: 1. Akut fase (1-3 døgn): Sengeleje, ro, antiemetika (f.eks. supp. Primperan) og svimmelhedsdæmpende medikament (f.eks. tbl. Sepan) i så lille udstrækning som muligt 2. Subakut fase (2-10 døgn): Træningsøvelser (se vejledning om vestibulær rehabilisering) med mobilisering således patienten bliver svimmel, hvilke giver hurtigere habituering. Hold hyppige pauser, men stop ikke træningen. Indgå sederende medicinering. Udskrivning vejledt af samlet klinisk billede, men patient har ofte brug for sygemelding i 2-3 uger. Inaktivitet er kontraindiceret! Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag

<h1><div id="Afsnit#1699579369636">Neuronitis vestibulares</div></h1><div id="BodyWeb#1699579369636"><p><a name="1699579369636Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579369636Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579369636Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579369636Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579369636Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579369636Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579369636Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579369636Bilag">Bilag</a><br> &nbsp;</h3> <h2><a name="1699579369636Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p>&nbsp;Læger og sygeplejersker</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579369636Top">Tilbage til top</a></p> <h2><a name="1699579369636Definitioner"></a><br> Definitioner</h2> <p>En af de mest hyppige årsager til svimmelhed og kan ramme patienter i alle aldersgrupper. Incidensen er usikker, idet ordet ”virus på balancenerven” bruges i flæng om svimle patienter.</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579369636Top">Tilbage til top</a></p> <h2><a name="1699579369636Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p><strong>Ætiologi: </strong></p> <p>Ukendt. I litteraturen skriver man at virusinfektion med Herpes Simplex er sandsynlig, men man kan også tænke sig andre årsager.</p> <p><strong>Symptomer: </strong></p> <p>Akut, ensidig vestibulær parese bevirker, at der fra det ene vestibulære organ ikke sendes impulser centralt og fra det andet vestibulære organ er der normale impulser. Dette giver vertigo (subjektiv oplevelse af svimmelhed) med forstyrrelser i de vestibulookulære, vestibulospinale og vestibuloretikulære reflekser. Dominerende symptom er akut rotatorisk vertigo som oftest opstår, når patienten står op om morgen. Ofte kvalme med opkast. Patient vil helst ligge helt stille med lukkede øjne, idet visuel fiksation forværre svimmelheden.</p> <p><strong>Diagnose: </strong></p> <p>1.&nbsp;&nbsp; Svær rotatorisk vertigo mod raske side, varighed dage til en uge.</p> <p>2.&nbsp;&nbsp; Kvalme og ofte opkastninger.</p> <p>3.&nbsp;&nbsp; Spontan horisontal-tortionel nystagmus mod raske side, med illusorisk bevægelse af omgivelserne (oscillopsi). Nystagmus forstærkes bag Bartels/Frentzels brille og bliver kraftigere eller svagere ved blikretning mod henholdsvis hurtig eller langsom nystagmusfase. Ved fiksation svækkes nystagmusamplituden, e.g Bartels/Frentzels briller er påkrævet.</p> <p>4.&nbsp;&nbsp;&nbsp; Gangdeviation og fald mod den syge side ved Rombergs prøve.</p> <p>5.&nbsp;&nbsp;&nbsp; Ingen andre neurologiske udfald, specielt ingen ved audiologisk undersøgelse.</p> <p>6.&nbsp;&nbsp;&nbsp; Ipsilateralt udfald af horisontale buegangsfunktion, bedømt ved impuls test og vestibulær asymmetrisk funktion bedømt ved head-shake test eller kalorisk øreskylning (varierende grader af hypo- eller non-reaktivitet).</p> <p>Alle elementer kan ses i den akutte fase inden for 1-3 dage.</p> <p><strong>Forløb:</strong></p> <p>Vestibulær kompensation indtræder inden for dage og patienten får mindre vertigo og kvalme. Generelt skal patient have så lidt sederende medikamenter i kortest mulig tid for at opnå størst og hurtigst kompensation. Unge og fysisk aktive patienter kommer sig hurtigere end ældre og funktionshæmmede. Sygdomsbilledet er præget at træthed i flere måneder efterfølgende. Op til 20 % får BPPV på det syge øre på et senere tid i livet.</p> <p><strong>Behandling:</strong></p> <p>1.&nbsp;&nbsp;&nbsp; Akut fase (1-3 døgn): Sengeleje, ro, antiemetika (f.eks. supp. Primperan) og svimmelhedsdæmpende medikament (f.eks. tbl. Sepan) i så lille udstrækning som muligt</p> <p>2.&nbsp;&nbsp;&nbsp; Subakut fase (2-10 døgn): Træningsøvelser (se vejledning om vestibulær rehabilisering) med mobilisering således patienten bliver svimmel, hvilke giver hurtigere habituering. Hold hyppige pauser, men stop ikke træningen. Indgå sederende medicinering. Udskrivning vejledt af samlet klinisk billede, men patient har ofte brug for sygemelding i 2-3 uger. Inaktivitet er kontraindiceret!</p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579369636Top">Tilbage til top</a></p> <h2><a name="1699579369636Ansvar"></a><br> Ansvar og organisering</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579369636Top">Tilbage til top</a></p> <h2><a name="1699579369636Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579369636Top">Tilbage til top</a></p> <h2><a name="1699579369636Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579369636Top">Tilbage til top</a></p> <h2><a name="1699579369636Bilag"></a><br> Bilag</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579369636Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Næsefraktur behandling og pleje ved.

Næsefraktur, behandling og pleje ved Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Målgrupper og anvendelsesområde Klinisk personale i Afdeling for Øre-Næse-Halskirurgi og Audiologi Fremgangsmåde Baggrund: Næsefraktur (brud på næsebenet) opstår hyppigst ved traumer, såsom kontaktsport, ulykker eller vold. Ved bruddet bliver næsebenet trykket ind, hvilket ud over det synsmæssige indtryk også kan give problemer med luftskiftet i næsen. Der kan ses septumhæmatom ved næsefraktur. Patienterne er hyppigst henvist fra skadestue, hvor patienten er blevet orienteret om, at de skal tilses af Øre-Næse-Halslæge efter 3 – 5 dage, da hævelse skal aftage. Pleje/behandling: Det afklares, om næsen er brækket. Er dette tilfældet, må lægen afgøre, hvorvidt næsebenene sidder på plads, eller de skal løftes på plads. Er bruddet nyt bliver næsefrakturen sat på plads i lokalbedøvelse i ambulatoriet. Er bruddet ældre end 7 - 10 dage gammelt / er patienten et barn (under 15 år), eller er der andre ting, der taler for det, indlægges patienten i sengeafsnittet, hvorefter næsefrakturen sættes på plads i GA. Remedier: Sygeplejersken gør et rullebord klar med: - Afdækningsstykke - Elevatorium - Næsespekulum - Vinkelpincet - Næsesug - gøres klar på væggen - Meche 1 cm eller 2 cm - Hydrocortison med terramycin creme - Næseskinne Str. S, M, L - Plaster til fiksering - Spejl - Sutur til meche Bedøvelse: Lægen afgør hvilken lokalanæstesi vedkommende ønsker at anvende. Der anvendes en eller flere af nedenstående metoder: Lidokain Adrenalin 2% på vat eller vatpinde; Lidokain-Noradrenalin 20 mg/ml som injektionsvæske (infiltrationsanæstesi) Procedure/behandling i ambulatoriet: - Der detumeceres med Lidokain Adrenalin 2 % på vat eller meche i begge næsebor, mhp indledning af lokalbedøvelse, samt afhævning af slimhinden. - Herefter anbringes vatpinde med Lidokain Adrenalin i næsen. - Når dette har virket i ca. 20 minutter kan Lidokain Noradrenalin injiceres omkring brudsteddet, enten udefra eller gennem næseborene. Elevatoriet påføres vaseline eller HT-salve og indføres i patientens næse på den side, hvor næsebenet er trykket ind. Når næsebenet er på plads, må det i nogle tilfælde støttes med en meche indsmurt i vaseline eller Hydrocortison med terramycin creme. Enden af en sådan meche fikseres med et plaster på kinden. Alternativt bindes en sutur om mechen, der placeres i næseboret og suturen fæstnes på kinden. Patienten får til sidst en næsebeskytter på eller gips/hexalite Information til patienten ved hjemsendelse/udskrivelse: Patienten informeres ifølge pjece: ’Næse rettet i lokalbedøvelse’ om: - at den eventuelle gaze meche skal trækkes ud efter 3 dage. (ambulant) - at hvis mechen bevæger sig bagud og ned i svælget skal den fjernes med det samme - at næsebeskytteren ikke holder næsebenet på plads, men snarere er der for at minde patienten om, at han/hun skal være varsom med sin næse og undgå stød og slag de næste ca. 3 til 4 uger. Næsebeskytteren fjernes efter 7 dage (ambulant) - at patienten skal snuse saltvand op, for at undgå skorpedannelse Ambulant kontrol: Patienten vil få en tid i ambulatoriet, hvis lægen skønner, det er nødvendigt. Organisering Patienten visiteres via RH-Afdeling for Øre-Næse-Halskirurgi og Audiologi til fast mødetid på GeH-Afdeling for Øre-Næse-Halskirurgi og Audiologi mhp vurdering og evt. reponering Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag

<h1><div id="Afsnit#1699579229308">Næsefraktur, behandling og pleje ved</div></h1><div id="BodyWeb#1699579229308"><p><a name="1699579229308Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579229308Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579229308Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579229308Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579229308Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579229308Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579229308Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579229308Bilag">Bilag</a><br> &nbsp;</h3> <h2><a name="1699579229308Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p>Klinisk personale i Afdeling for Øre-Næse-Halskirurgi og Audiologi</p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579229308Top">Tilbage til top</a></p> <h2><a name="1699579229308Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p><strong>Baggrund:</strong></p> <p>Næsefraktur (brud på næsebenet) opstår hyppigst ved traumer, såsom kontaktsport, ulykker eller vold.&nbsp;</p> <p>Ved bruddet bliver næsebenet trykket ind, hvilket ud over det synsmæssige indtryk også kan give problemer med luftskiftet i næsen. Der kan ses septumhæmatom ved næsefraktur.</p> <p>Patienterne er hyppigst henvist fra skadestue, hvor patienten er blevet orienteret om, at de skal tilses af Øre-Næse-Halslæge efter 3&nbsp;– 5 dage, da hævelse skal aftage.</p> <p><strong>Pleje/behandling:</strong></p> <p>Det afklares, om næsen er brækket. Er dette tilfældet, må lægen afgøre, hvorvidt næsebenene sidder på plads, eller de skal løftes på plads.</p> <p>Er bruddet nyt bliver næsefrakturen sat på plads i lokalbedøvelse i ambulatoriet.</p> <p>Er bruddet ældre end 7 - 10 dage gammelt / er patienten et barn (under 15 år), eller er der andre ting, der taler for det, indlægges patienten i sengeafsnittet, hvorefter næsefrakturen sættes på plads i GA.</p> <p><strong>Remedier:</strong></p> <p>Sygeplejersken gør et rullebord klar med:</p> <ul> <li>Afdækningsstykke</li> <li>Elevatorium</li> <li>Næsespekulum</li> <li>Vinkelpincet</li> <li>Næsesug - gøres klar på væggen</li> <li>Meche 1 cm eller 2 cm</li> <li>Hydrocortison med terramycin creme</li> <li>Næseskinne Str. S, M, L</li> <li>Plaster til fiksering</li> <li>Spejl</li> <li>Sutur til meche</li> </ul> <p><strong>Bedøvelse:</strong></p> <p>Lægen afgør hvilken lokalanæstesi vedkommende ønsker at anvende. Der anvendes en eller flere af nedenstående metoder:</p> <p>Lidokain Adrenalin 2% på vat eller vatpinde; Lidokain-Noradrenalin 20 mg/ml som injektionsvæske (infiltrationsanæstesi)</p> <p>&nbsp;</p> <p><strong>Procedure/behandling i ambulatoriet:</strong></p> <ol> <li>Der detumeceres med Lidokain Adrenalin 2 % på vat eller meche i begge næsebor, mhp indledning af &nbsp;lokalbedøvelse,&nbsp; samt afhævning af slimhinden.</li> <li>Herefter anbringes vatpinde med Lidokain Adrenalin i næsen.&nbsp;</li> <li value="3">Når dette har virket i ca. 20 &nbsp;minutter kan Lidokain Noradrenalin injiceres omkring brudsteddet, enten udefra eller gennem næseborene.</li> </ol> <p>Elevatoriet påføres &nbsp;vaseline eller HT-salve og indføres i patientens næse på den side, hvor næsebenet er trykket ind.&nbsp;</p> <p>Når næsebenet er på plads, må det i nogle tilfælde støttes med en meche indsmurt i vaseline eller Hydrocortison med terramycin creme. Enden af en sådan meche fikseres med et plaster på kinden. Alternativt bindes en sutur om mechen, der placeres i næseboret og suturen fæstnes på kinden.</p> <p>Patienten får til sidst en næsebeskytter på eller gips/hexalite</p> <p><strong>Information til patienten ved hjemsendelse/udskrivelse:</strong></p> <p>Patienten informeres ifølge pjece: ’Næse rettet i lokalbedøvelse’ om:</p> <ul> <li>at den eventuelle gaze meche skal trækkes ud efter 3 dage. (ambulant)</li> <li>at hvis mechen bevæger sig bagud og ned i svælget skal den fjernes med det samme</li> <li>at næsebeskytteren ikke holder næsebenet på plads, men snarere er der for at minde patienten om, at han/hun skal være varsom med sin næse og undgå stød og slag de næste ca. 3 til 4 uger. Næsebeskytteren fjernes efter 7 dage (ambulant)</li> <li>at patienten skal snuse saltvand op, for at undgå skorpedannelse&nbsp;</li> </ul> <p><strong>Ambulant kontrol:</strong></p> <p>Patienten vil få en tid i ambulatoriet, hvis lægen skønner, det er nødvendigt.</p> <p><strong>Organisering</strong></p> <p>Patienten visiteres via RH-Afdeling for Øre-Næse-Halskirurgi og Audiologi til fast mødetid på GeH-Afdeling for Øre-Næse-Halskirurgi og Audiologi mhp vurdering og evt. reponering</p> <p>&nbsp;</p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579229308Top">Tilbage til top</a></p> <h2><a name="1699579229308Ansvar"></a><br> Ansvar og organisering</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579229308Top">Tilbage til top</a></p> <h2><a name="1699579229308Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579229308Top">Tilbage til top</a></p> <h2><a name="1699579229308Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579229308Top">Tilbage til top</a></p> <h2><a name="1699579229308Bilag"></a><br> Bilag</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579229308Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Operation på glandula parathyreoidea.

Operation på glandula parathyreoidea Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Målgrupper og anvendelsesområde Læger, sygeplejersker og sekretærer i Afdeling for Øre-Næse-Halskirurgi og Audiologi Fremgangsmåde Visitation Henvisninger til Rigshospitalet visiteres af overlæge ###NAVN### og ###NAVN### og henvisninger til Gentofte visiteres af overlæge ###NAVN###. Ved fravær visiteres af anden Para-/thyroideakirurg. Patient-flow Langt de fleste patienter henvises fra nefrologiske- eller endokrinologiske afdelinger, hvor den primære udredning foregår. Operationsindikation stilles af de henvisende afdelinger, og endelig stillingtagen til operation foretages på tværfaglige thyroideakonferencer eller af kirurgen. De fleste patienter med primær hyperparathyroidisme opereres på Gentofte matriklen, hvorimod patienter med sekundær/tertiær hyperparathyroidisme, opereres på RH. Ambulant forundersøgelse Ved den ambulante forundersøgelse foretages, hvis det er muligt, fuld journaloptagelse samt anæstesiologisk tilsyn, således at patienten bliver klargjort og kan møde fastende på selve operationsdagen. Patienten informeres om operationen og om risiko for recurrensparese samt om risiko for hypocalcæmi eller vedvarende hypercalcæmi. Præoperative blodprøver: Ioniseret calcium og PTH Alle patienter skal have foretaget præoperativ undersøgelse af stemmelæbernes bevægelighed. Vedrørende eventuel pausering med antitrombotisk medicin samt antitrombotisk behandling generelt henvises til relevante instrukser. Operation Ved primær hyperparathyroidisme, hvor der foreligger positiv billeddiagnostik, tilsigtes focuseret operation. Et muligt adenom søges fjernet gennem et ca. 2,5 cm incision. Der benyttes peroperativ PTH-måling idet et PTH fald på mindst 50%, 10 minutter efter fjernelse af et muligt adenom, giver høj sikkerhed for at alt patologiske væv er fjernet. Såfremt et adenom præoperativt eller ved focuseret operation, ikke kan identificeres, foretages eksploration. Ved sekundær/tertiær hyperparathyroidisme, fortages normalt eksploration, hvor man søger at fjerne 3,5 ud af 4 kirtler alternativt fjerner alle 4 kirtler og reimplantere parathyroidea. Det fjernede parathyroideavæv vejes på mikrovægt, inden det kommer i formalin. Der benyttes nerveregistrering såfremt kirurgen ønsker dette. I de fleste tilfælde vil der yderligere blive benyttet synsforstørrelse i form af lupbriller. Der anlægges sugedræn, hvis det er nødvendigt. Suturvalg afgøres af kirurgen. Ved benyttelse af intrakutane selvopløselige suturer undgås sutur-ar og suturfjernelse. På patologirekvisitionen anføres, hvornår patienten kommer til ambulant kontrol og histologisvar. Kirurgen har ansvaret for udfyldelse af papirversion til Parathyroidea-databasen. Postoperativ observation Patienterne observeres i mindst 1 time på opvågningen for efterblødning. For alle patienter, som har fået foretaget operation for sekundær/tertiær hyperparathyroidisme, tages der blodprøve, for PTH x 1 og ioniseret calcium x 3, på operationsdagen. For patienter med primær hyperparathyroidisme tages kun ioniseret calcium x 1. Dræn observeres med henblik på, at der skal være konstant undertryk. Hypocalcæmi Især for patienter, som har fået foretaget operation for sekundær/tertiær hyperparathyroidisme, er der risiko for udvikling af hypocalcæmi. Disse patienter behandles med Calcium Sandoz 1g gange 3-4 og evt. Etalpha og i tæt samarbejde med den henvisende nefrologiske afdeling. Ved meget lav ioniseret calcium , kan der gives Calcium-Sandoz i.v. som langsom bolus, fx 90 mg (= 10 ml). Patienter opereret for primær hyperparathyroidisme, kan ved postoperativ hypocalcæmi oftest behandles med ”Unikalk med D-vitamin”. Udskrivelse Alle patienter skal have foretaget undersøgelse af larynx inden udskrivelsen. Afhængig af indgrebet kan patienten sygemeldes i 2 uger med mulighed for forlængelse. Patienter med sekundær/tertiær hyperparathyroidisme, overflyttes til den henvisende nefrologiske afdeling, morgenen efter operation og efter fjernelse af et evt. dræn, mhp. behandling af ”hungry bones”. Patienten informeres om at undgå sol på cicatricen og generelt at holde plasteret tørt. Efterkontrol Alle patienter møder til ambulant kontrol og histologisvar, med mindre andet er aftalt med kirurgen. Papirer til Parathyroidea-databasen færdigudfyldes. Der sendes henvisning til den endokrinologiske/nefrologiske afdeling, som har foretaget den primære udredning. Kodning af parathyroideaindgreb BBA30 excision glandula parathyroidectomia. BBA40 Excisio subtotalis glandula parathyroidectomia. Ansvar og organisering Afdelingsledelsen Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag

<h1><div id="Afsnit#1699579277946">Operation på glandula parathyreoidea</div></h1><div id="BodyWeb#1699579277946"><p><a name="1699579277946Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579277946Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579277946Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579277946Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579277946Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579277946Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579277946Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579277946Bilag">Bilag</a><br> &nbsp;</h3> <h2><a name="1699579277946Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p>Læger, sygeplejersker og sekretærer i Afdeling for Øre-Næse-Halskirurgi og Audiologi</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579277946Top">Tilbage til top</a></p> <h2><a name="1699579277946Fremgangsmaade"></a><br> Fremgangsmåde</h2> <h4><strong><u>Visitation</u></strong></h4> <p>Henvisninger til Rigshospitalet visiteres af overlæge ###NAVN### og ###NAVN### og henvisninger til Gentofte visiteres af overlæge ###NAVN###. Ved fravær visiteres af anden Para-/thyroideakirurg.</p> <p><strong><u>Patient-flow</u></strong></p> <p>Langt de fleste patienter henvises fra nefrologiske-&nbsp; eller endokrinologiske afdelinger, hvor den primære udredning foregår. Operationsindikation stilles af de henvisende afdelinger, og endelig stillingtagen til operation foretages på tværfaglige thyroideakonferencer eller af kirurgen. De fleste patienter med primær hyperparathyroidisme opereres på Gentofte matriklen, hvorimod patienter med sekundær/tertiær hyperparathyroidisme, opereres på RH.</p> <p><strong><u>Ambulant forundersøgelse</u></strong></p> <p>Ved den ambulante forundersøgelse foretages, hvis det er muligt, fuld journaloptagelse samt anæstesiologisk tilsyn, således at patienten bliver klargjort og kan møde fastende på selve operationsdagen. Patienten informeres om operationen og om risiko for recurrensparese samt om risiko for hypocalcæmi eller vedvarende hypercalcæmi.</p> <p><em>Præoperative blodprøver:</em></p> <p>Ioniseret calcium og PTH&nbsp;</p> <p>Alle patienter skal have foretaget præoperativ undersøgelse af stemmelæbernes bevægelighed.</p> <p>Vedrørende eventuel pausering med antitrombotisk medicin samt antitrombotisk behandling generelt henvises til relevante instrukser.</p> <p><strong><u>Operation</u></strong></p> <p>Ved primær hyperparathyroidisme, hvor der foreligger positiv billeddiagnostik, tilsigtes focuseret operation. Et muligt adenom søges fjernet gennem et ca. 2,5 cm incision. Der benyttes peroperativ PTH-måling idet et PTH fald på mindst 50%, 10 minutter efter fjernelse af et muligt adenom, giver høj sikkerhed for at alt patologiske væv er fjernet. Såfremt et adenom præoperativt eller ved focuseret operation, ikke kan identificeres, foretages eksploration. Ved sekundær/tertiær hyperparathyroidisme, fortages normalt eksploration, hvor man søger at fjerne 3,5 ud af 4 kirtler alternativt fjerner alle 4 kirtler og reimplantere parathyroidea.</p> <p>Det fjernede parathyroideavæv vejes på mikrovægt, inden det kommer i formalin.</p> <p>Der benyttes nerveregistrering såfremt kirurgen ønsker dette. I de fleste tilfælde vil der yderligere blive benyttet synsforstørrelse i form af lupbriller.</p> <p>Der anlægges sugedræn, hvis det er nødvendigt.</p> <p>Suturvalg afgøres af kirurgen. Ved benyttelse af intrakutane selvopløselige suturer undgås sutur-ar og suturfjernelse.</p> <p>På patologirekvisitionen anføres, hvornår patienten kommer til ambulant kontrol og histologisvar.</p> <p>Kirurgen har ansvaret for udfyldelse af papirversion til Parathyroidea-databasen.&nbsp;</p> <p><strong><u>Postoperativ observation</u></strong></p> <p>Patienterne observeres i mindst 1 time på opvågningen for efterblødning. For alle patienter, som har fået foretaget operation for sekundær/tertiær hyperparathyroidisme, tages der blodprøve, for PTH x 1 og ioniseret calcium x 3, på operationsdagen. For patienter med primær hyperparathyroidisme tages kun ioniseret calcium x 1.</p> <p>Dræn observeres med henblik på, at der skal være konstant undertryk.&nbsp;</p> <h4><strong><u>Hypocalcæmi</u></strong></h4> <p>Især for patienter, som har fået foretaget operation for sekundær/tertiær hyperparathyroidisme, er der risiko for udvikling af hypocalcæmi. Disse patienter behandles med Calcium Sandoz 1g gange 3-4 og&nbsp; evt. Etalpha og i tæt samarbejde med den henvisende nefrologiske afdeling. Ved meget lav ioniseret calcium , kan der gives Calcium-Sandoz i.v. som langsom bolus, fx 90 mg (= 10 ml). Patienter opereret for primær hyperparathyroidisme, kan ved postoperativ hypocalcæmi oftest behandles med ”Unikalk med D-vitamin”.</p> <p><strong><u>Udskrivelse</u></strong></p> <p>Alle patienter skal have foretaget undersøgelse af larynx inden udskrivelsen.</p> <p>Afhængig af indgrebet kan patienten sygemeldes i 2 uger med mulighed for forlængelse.</p> <p>Patienter med sekundær/tertiær hyperparathyroidisme, overflyttes til den henvisende nefrologiske afdeling, morgenen efter operation og efter fjernelse af et evt. dræn, mhp. behandling af ”hungry bones”.</p> <p>Patienten informeres om at undgå sol på cicatricen og generelt at holde plasteret tørt.&nbsp;</p> <p><strong><u>Efterkontrol</u></strong></p> <p>Alle patienter møder til ambulant kontrol og histologisvar, med mindre andet er aftalt med kirurgen. Papirer til Parathyroidea-databasen færdigudfyldes. Der sendes henvisning til den endokrinologiske/nefrologiske afdeling, som har foretaget den primære udredning.</p> <p>&nbsp;<strong><u>Kodning af parathyroideaindgreb</u></strong></p> <p>BBA30 excision glandula parathyroidectomia.</p> <p>BBA40 Excisio subtotalis glandula parathyroidectomia<strong>.</strong></p> <p>&nbsp;<a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579277946Top">Tilbage til top</a></p> <h2><a name="1699579277946Ansvar"></a><br> Ansvar og organisering</h2> <p>Afdelingsledelsen</p> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579277946Top">Tilbage til top</a></p> <h2><a name="1699579277946Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579277946Top">Tilbage til top</a></p> <h2><a name="1699579277946Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579277946Top">Tilbage til top</a></p> <h2><a name="1699579277946Bilag"></a><br> Bilag</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579277946Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Operation på gld. Thyreoidea.

Operation på gld. Thyreoidea Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Bilag Målgrupper og anvendelsesområde Læger i Afdeling for Øre-Næse-Halskirurgi og Audiologi Definitioner Fremgangsmåde Fremgangsmåde Visitation Henvisninger til Rigshospitalet visiteres af overlæge ###NAVN### og ###NAVN###, og henvisninger til Gentofte visiteres af overlæge ###NAVN###. Ved fravær visiteres af anden thyroideakirurg. Patient-flow Langt de fleste patienter henvises fra endokrinologiske afdelinger, hvor den primære udredning foregår. Operationsindikation stilles af de endokrinologiske afdelinger, og endelig stillingtagen til operation foretages på tværfaglige thyroideakonferencer. Enkelte patienter med bestyrket mistanke om thyroideacancer, (fx hurtig voksende hård knude med fiksation til omgivende væv, recurrensparese, stridor), henvises evt. direkte til øre-næse-halsafdelingen uden om de endokrinologiske afdelinger. Ambulant forundersøgelse Ved den ambulante forundersøgelse foretages, hvis det er muligt, fuld journaloptagelse samt anæstesiologisk tilsyn, således at patienten bliver klargjort og kan møde fastende på selve operationsdagen. Patienten informeres om operationen og om risiko for recurrensparese samt om risiko for hypocalcæmi. Der er et lovkrav om at patienter med mistanke om cancer, inklusiv follikulær neoplasi i kold knude, skal ses i ambulatoriet senest 14 dage efter at henvisningen er modtaget. Operation af denne gruppe patienter skal, efter informeret samtykke på den behandlende afdeling, foregå senest 14 dage senere. Der skal tages stilling til evt. ændring i AK-behandlingen og til tromboseprofylakse ud fra gældende instrukser. Diverse præoperative blodprøver og undersøgelser foretages iht. regionens instruks for præoperative undersøgelser. Specifikt ved thyroideakirurgi gælder følgende: - Forud for ukompliceret hemithyroidektomi: Ingen blodprøver. - Hemithyroidektomi på mistanke om papillært thyroideakarcinom og alle totalthyroidektomier: Hæmoglobin, ioniseret kalcium, PTH og type. - Ved stofskiftesygdomme suppleres med TSH, T3 og T4. - Ved intrathorakale strumaer eller ved anden risiko for større blodtab, skal der suppleres med BAS-test. - Ved mistanke om medullært thyroidea carcinom, skal der suppleres med fastende calcitonin og Methoxy- catecholaminer (P) i blodet. Pt skal efter operationen henvises til RH endokrinologisk afdeling, mhp yderligere MEN udredning og genetisk testning. Alle patienter skal have foretaget præoperativ undersøgelse af stemmelæbernes bevægelighed Billeddiagnostik: Såfremt der er mistanke om lymfeknudemetastaser, skal der udføres ultralyd og CT-/MR-scanning. Ved intrathorakale strumaer skal der foreligge CT-scanning/MR-scanning, og disse er ligeledes relevante, hvis det drejer sig om oplagt malignitetssuspekt tumor. CT-scanning skal normalt udføres med kontrast. Ved CT scanning skal der ligge billeder i 3 planer (axiale, coronale og sagitale billeder). Større intrathorakal strumaer, som strækker sig mere end 5 cm intrathorakalt skal opereres på Rigshospitalet. Såfremt der er risiko for sternumsplit, skal thoraxkirurger adviseres. Dette vurderes ved visiterende læge. Ved intrathorakale strumaer, hvor der med overvejende sandsynlighed skal laves sternumsplit, skal der arrangeres overnatning på thoraxkirurgisk opvågning. Operation Der benyttes nerveregistrering såfremt kirurgen ønsker dette. Desuden kan der benyttes synsforstørrende briller samt Ultracision/LigaSure. Glandulae parathyroideae forsøges bevaret med karstilk. Hvis blodforsyningen til glandulae parathyroideae skønnes at være kompromitteret, foretages reimplantation af glandulae parathyroideae i musculus sternocleidomastoideus. Hvis der opereres på malignitetsmistanke foretages som minimum eksploration af level VI i den afficerede side med henblik på undersøgelse for lymfeknudemetastaser. Afhængig af resultatet foretages evt. samtidig neck level VI. Frysemikroskopi kan anvendes ved FNAB, som viser obs. Papillært thyroidea carcinom eller obs maligne tumorceller, men benyttes normalt ikke, hvis der foreligger follikulær neoplasi i et koldt adenom. Der anlægges sugedræn, hvis det er nødvendigt. Suturvalg afgøres af kirurgen. Ved benyttelse af intrakutane selvopløselige suturer undgås sutur-ar og suturfjernelse. Vedrørende behandling af specifikke cancertyper i glandula thyroidea henvises til DAHANCAs nationale retningslinjer for udredning og behandling af thyroideacancer i Danmark: http://www.dahanca.dk/get_media_file.php?mediaid=255 På patologirekvisitionen anføres, hvornår patienten kommer til ambulant kontrol og histologisvar. Kirurgen har ansvaret for hele udfyldelsen af papirversion til thykir-databasen inklusiv de postoperative data. Postoperativ observation Patienterne observeres i mindst 2 timer på opvågningen for efterblødning. Ved hemithyroidektomi kun i 1 time, med mindre andet er anvist af kirurgen. For alle patienter, som har fået foretaget total thyroidektomi, tages der som minimum én blodprøve for ioniseret calcium og PTH på operationsdagen samt én blodprøve for ioniseret calcium næste morgen. Startes medicinsk behandling mod hypocalcæmi, tages der blodprøver for ioniseret calcium x 3. Det er normalt ikke nødvendigt at tage postoperative blodprøver på patienter, som kun har fået foretaget hemithyroidektomi. Dræn observeres med henblik på, at der skal være konstant undertryk. Hypocalcæmi Der henvises til den nationale retningslinje om ”postoperativ hypocalcæmi" (se bilag) For alle patienter, som har fået foretaget total thyroidektomi, er der risiko for udvikling af hypocalcæmi. Såfremt PTH taget postoperativt på operationsdagen, falder over 50% i forhold til patientens præoperative PTH-værdi, eller PTH falder til under nedre grænse for normal området (1,6 pmol/l) , eller såfremt man ud fra andre parametre må forvente postoperativ hypocalcæmi, startes op med Calcium Sandoz 500 mg 2 tabletter gange 3-4 dagligt. Herefter tages der som standard for total thyroidektomerede ioniseret calcium x 3, men ikke flere standardblodprøver for PTH. Hvis ioniseret calcium ved de efterfølgende blodprøver falder til under 1,0 mmol/ltr., suppleres multikalk forte-behandlingen med tabl. Etalpha 1 mikg x 2. Omkring 5-10% af patienterne med hypoparathyroidisme har vanskeligt ved at optage calcium carbonat, derfor skal Multikalk Forte seponeres ved vedvarende hypocalcæmi, og der skal ordineres Calcium Sandoz 1g*4. Patienter med hypocalcæmi (ioniseret calcium under 1,15) kan først udskrives, hvis følgende betingelser er opfyldt: De er i medicinsk behandling med Calcium Sandoz+/- Etalpha, calcium-ion er på mindst 1,05 og de er uden symptomer på hypocalcæmi. Såfremt det har været nødvendigt at supplere med Etalpha, skal der sendes henvisning til ”den henvisende endokrinologisk afdeling” med henblik på hurtig indkaldelse til opfølgende behandling og kontrol. Alle patienter, som er sat i behandling med Calcium Sandoz +/- Etalpha, skal have kontrolleret Ca++ og PTH ved første kontrol i ØNH ambulatoriet, hvor der gives histologi svar. Almindeligvis skal behandlingen fortsætte indtil patienten ses af endokrinologerne. Ved meget lav ioniseret calcium (<0,9 mmol/l), kan der gives Calcium-Sandoz i.v. som langsom bolus, fx 90 mg (= 10 ml), og Calcium Sandoz dosis kan øges til 1g gange 7 p.o. Udskrivelse Alle patienter skal have foretaget fiberlaryngoskopi af larynx inden udskrivelsen. Afhængig af indgrebet kan patienten sygemeldes i 2 uger med mulighed for forlængelse. Patienter, som er totalthyroidektomerede på grund af benign eller malign lidelse, startes op med tabl. Eltroxin 100 mikg x 1 på dag 1 efter operationen. Patienter med fjernmetastaser fra papillære og follikulære thyroidea carcinomer startes derimod op med tabl. Liothyronin 20 mikg x 2 på dag 1 efter operationen. Disse patienter medgives kopi af generel udleveringstilladelse samt recept og ansøgningsskema om enkelttilskud som faxes til lægemiddelstyrelsen. Patienten informeres om at undgå sol på cicatricen og generelt at holde plasteret tørt. Efterkontrol Alle patienter møder til ambulant kontrol og histologisvar med mindre andet er aftalt med kirurgen. Papirer til thy-kir-database færdigudfyldes. Der sendes henvisning til den endokrinologiske afdeling, som har foretaget den primære udredning. I de fleste tilfælde vil det være den endokrinologiske afdeling som ligger tættest på patientens bopæl og ikke RH´s endokrinologiske afdeling, selvom en del af udredningen er foregået på RH. Ved malignt histologisvar sendes henvisning til onkologisk afdeling i Herlev. Kodning af thyreoideaindgreb BAA60 thyroidectomia totalis. Denne kode bruges også om supplerende operationer, fx en hemithyroidektomi, hvor patienten gøres athyroid. BAA60a intrathorakal thyroidectomia totalis. BAA40 hemithyroidectomia. BAA40a intrathorakal hemithyroidektomi BAA30 Isthmus resektion BBA70 ved autotransplantation af parathyroideavæv. PJD51 exairesis lymphonodorum colli. Den samlede DRG-takstudmåling er afhængig af diagnosekoderne, evt. maligne koder er derfor vigtige. Husk også at de intrathorakale operationer takseres højt. Tilbage til top Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Bilag Hypocalc+ªmi.docx

<h1><div id="Afsnit#1699579311394">Operation på gld. Thyreoidea</div></h1><div id="BodyWeb#1699579311394"><p><a name="1699579311394Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579311394Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579311394Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579311394Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579311394Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579311394Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579311394Bilag">Bilag</a><br> &nbsp;</h3> <h2><a name="1699579311394Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p>Læger i Afdeling for Øre-Næse-Halskirurgi og Audiologi</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579311394Top">Tilbage til top</a></p> <h2><a name="1699579311394Definitioner"></a><br> Definitioner</h2> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579311394Top">Tilbage til top</a></p> <h2><a name="1699579311394Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p><strong>Fremgangsmåde</strong></p> <p><strong><u>Visitation</u></strong></p> <p>Henvisninger til Rigshospitalet visiteres af overlæge ###NAVN### og ###NAVN###, og henvisninger til Gentofte visiteres af overlæge ###NAVN###. Ved fravær visiteres af anden thyroideakirurg.</p> <p><strong><u>Patient-flow</u></strong></p> <p>Langt de fleste patienter henvises fra endokrinologiske afdelinger, hvor den primære udredning foregår. Operationsindikation stilles af de endokrinologiske afdelinger, og endelig stillingtagen til operation foretages på tværfaglige thyroideakonferencer. Enkelte patienter med bestyrket mistanke om thyroideacancer, (fx hurtig voksende hård knude med fiksation til omgivende væv, recurrensparese, stridor), henvises evt. direkte til øre-næse-halsafdelingen uden om de endokrinologiske afdelinger.</p> <p><strong><u>Ambulant forundersøgelse</u></strong></p> <p>Ved den ambulante forundersøgelse foretages, hvis det er muligt, fuld journaloptagelse samt anæstesiologisk tilsyn, således at patienten bliver klargjort og kan møde fastende på selve operationsdagen. Patienten informeres om operationen og om risiko for recurrensparese samt om risiko for hypocalcæmi. Der er et lovkrav om at patienter med mistanke om cancer, inklusiv follikulær neoplasi i kold knude, skal ses i ambulatoriet senest 14 dage efter at henvisningen er modtaget. Operation af denne gruppe patienter skal, efter informeret samtykke på den behandlende afdeling, foregå senest 14 dage senere.</p> <p>Der skal tages stilling til evt. ændring i AK-behandlingen og til tromboseprofylakse ud fra gældende instrukser.</p> <p><em>Diverse præoperative blodprøver og undersøgelser foretages iht. regionens instruks for præoperative undersøgelser. Specifikt ved thyroideakirurgi gælder følgende:</em></p> <p>&nbsp;</p> <p>&nbsp;</p> <ol> <li> <p>Forud for ukompliceret hemithyroidektomi: Ingen blodprøver.</p> </li> <li> <p>Hemithyroidektomi på mistanke om papillært thyroideakarcinom og alle totalthyroidektomier: Hæmoglobin, ioniseret kalcium, PTH og type.</p> </li> <li> <p>Ved stofskiftesygdomme suppleres med TSH, T3 og T4.</p> </li> <li> <p>Ved intrathorakale strumaer eller ved anden risiko for større blodtab, skal der suppleres med BAS-test.</p> </li> <li> <p>Ved mistanke om medullært thyroidea carcinom, skal der suppleres med fastende calcitonin og Methoxy- catecholaminer (P) i blodet. Pt skal efter operationen henvises til RH endokrinologisk afdeling, mhp yderligere MEN udredning og genetisk testning.</p> <p>Alle patienter skal have foretaget præoperativ undersøgelse af stemmelæbernes bevægelighed</p> <p><em>Billeddiagnostik:</em></p> <p>Såfremt der er mistanke om lymfeknudemetastaser, skal der udføres ultralyd og CT-/MR-scanning.&nbsp; Ved intrathorakale strumaer skal der foreligge CT-scanning/MR-scanning, og disse er ligeledes relevante, hvis det drejer sig om oplagt malignitetssuspekt tumor. CT-scanning skal normalt udføres med kontrast. Ved CT scanning skal der ligge billeder i 3 planer (axiale, coronale og sagitale billeder).</p> <p>Større intrathorakal strumaer, som strækker sig mere end 5 cm intrathorakalt skal opereres på Rigshospitalet.</p> <p>Såfremt der er risiko for sternumsplit, skal thoraxkirurger adviseres. Dette vurderes ved visiterende læge.</p> <p>Ved intrathorakale strumaer, hvor der med overvejende sandsynlighed skal laves sternumsplit, skal der arrangeres overnatning på thoraxkirurgisk opvågning. &nbsp;</p> <p>&nbsp;</p> <p><strong><u>Operation</u></strong></p> <p>Der benyttes nerveregistrering såfremt kirurgen ønsker dette. Desuden kan der benyttes synsforstørrende briller samt Ultracision/LigaSure. Glandulae parathyroideae forsøges bevaret med karstilk. Hvis blodforsyningen til glandulae parathyroideae skønnes at være kompromitteret, foretages reimplantation af glandulae parathyroideae i musculus sternocleidomastoideus.</p> <p>Hvis der opereres på malignitetsmistanke foretages som minimum eksploration af level VI i den afficerede side med henblik på undersøgelse for lymfeknudemetastaser. Afhængig af resultatet foretages evt. samtidig neck level VI.</p> <p>Frysemikroskopi kan anvendes ved FNAB, som viser obs. Papillært thyroidea carcinom eller obs maligne tumorceller, men benyttes normalt ikke, hvis der foreligger follikulær neoplasi i et koldt adenom.</p> <p>Der anlægges sugedræn, hvis det er nødvendigt.</p> <p>Suturvalg afgøres af kirurgen. Ved benyttelse af intrakutane selvopløselige suturer undgås sutur-ar og suturfjernelse.</p> <p>Vedrørende behandling af specifikke cancertyper i glandula thyroidea henvises til DAHANCAs nationale retningslinjer for udredning og behandling af thyroideacancer i Danmark: <a href="http://www.dahanca.dk/get_media_file.php?mediaid=255"><u>http://www.dahanca.dk/get_media_file.php?mediaid=255</u></a></p> </li> </ol> <p>På patologirekvisitionen anføres, hvornår patienten kommer til ambulant kontrol og histologisvar.</p> <p>Kirurgen har ansvaret for hele udfyldelsen af papirversion til thykir-databasen inklusiv de postoperative data.&nbsp;</p> <p><strong><u>Postoperativ observation</u></strong></p> <p>Patienterne observeres i mindst 2 timer på opvågningen for efterblødning. Ved hemithyroidektomi kun i 1 time, med mindre andet er anvist af kirurgen. For alle patienter, som har fået foretaget total thyroidektomi, tages der som minimum én blodprøve for ioniseret calcium og PTH på operationsdagen samt én blodprøve for ioniseret calcium næste morgen. Startes medicinsk behandling mod hypocalcæmi, tages der blodprøver for ioniseret calcium x 3. Det er normalt ikke nødvendigt at tage postoperative blodprøver på patienter, som kun har fået foretaget hemithyroidektomi.</p> <p>Dræn observeres med henblik på, at der skal være konstant undertryk.</p> <p>&nbsp;<strong><u>Hypocalcæmi</u></strong></p> <p>Der henvises til den nationale retningslinje om ”postoperativ hypocalcæmi" (se bilag)</p> <p>For alle patienter, som har fået foretaget total thyroidektomi, er der risiko for udvikling af hypocalcæmi. Såfremt PTH taget postoperativt på operationsdagen, falder over 50% i forhold til patientens præoperative PTH-værdi, eller PTH falder til under nedre grænse for normal området (1,6 pmol/l) , eller såfremt man ud fra andre parametre må forvente postoperativ hypocalcæmi, startes op med&nbsp;Calcium Sandoz 500 mg&nbsp;&nbsp;2 tabletter gange 3-4 dagligt.</p> <p>Herefter tages der som standard for total thyroidektomerede ioniseret calcium x 3, men ikke flere standardblodprøver for PTH.</p> <p>Hvis ioniseret calcium ved de efterfølgende blodprøver falder til under 1,0 mmol/ltr., suppleres multikalk forte-behandlingen med tabl. <strong>Etalpha 1 mikg x 2</strong>.</p> <p>&nbsp;</p> <p>Omkring 5-10% af patienterne med hypoparathyroidisme har vanskeligt ved at optage calcium carbonat, derfor skal Multikalk Forte seponeres ved vedvarende hypocalcæmi, og der skal ordineres Calcium Sandoz 1g*4.</p> <p>&nbsp;</p> <p>Patienter med hypocalcæmi (ioniseret calcium under 1,15) kan først udskrives, hvis følgende betingelser er opfyldt: De er i medicinsk behandling med Calcium Sandoz+/- Etalpha, calcium-ion er på mindst 1,05 og de er uden symptomer på hypocalcæmi.</p> <p>Såfremt det har været nødvendigt at supplere med Etalpha, skal der sendes henvisning til ”den henvisende endokrinologisk afdeling” med henblik på hurtig indkaldelse til opfølgende behandling og kontrol.&nbsp;</p> <p>Alle patienter, som er sat i behandling med Calcium Sandoz +/- Etalpha, skal have kontrolleret Ca++ og PTH ved første kontrol i ØNH ambulatoriet, hvor der gives histologi svar. Almindeligvis skal behandlingen fortsætte indtil patienten ses af endokrinologerne.</p> <p>Ved meget lav ioniseret calcium (&lt;0,9 mmol/l), kan der gives <strong>Calcium-Sandoz i.v. som langsom bolus, fx 90 mg (= 10 ml), og Calcium Sandoz dosis kan øges til 1g gange 7 p.o.</strong></p> <p><strong><u>Udskrivelse</u></strong></p> <p>Alle patienter skal have foretaget fiberlaryngoskopi af larynx inden udskrivelsen.</p> <p>Afhængig af indgrebet kan patienten sygemeldes i 2 uger med mulighed for forlængelse.</p> <p>Patienter, som er totalthyroidektomerede på grund af benign eller malign lidelse, startes op med tabl. <strong>Eltroxin 100 mikg x 1 på dag 1 efter operationen</strong>.</p> <p>Patienter med fjernmetastaser fra papillære og follikulære thyroidea carcinomer startes derimod &nbsp;op med tabl. <strong>Liothyronin 20 mikg x 2 på dag 1 efter operationen</strong>. Disse patienter medgives kopi af generel udleveringstilladelse samt recept og ansøgningsskema om enkelttilskud som faxes til lægemiddelstyrelsen.</p> <p>Patienten informeres om at undgå sol på cicatricen og generelt at holde plasteret tørt.</p> <p><strong><u>Efterkontrol</u></strong></p> <p>Alle patienter møder til ambulant kontrol og histologisvar med mindre andet er aftalt med kirurgen. Papirer til thy-kir-database færdigudfyldes.</p> <p>Der sendes henvisning til den endokrinologiske afdeling, som har foretaget den primære udredning. I de fleste tilfælde vil det være den endokrinologiske afdeling som ligger tættest på patientens bopæl og ikke RH´s endokrinologiske afdeling, selvom en del af udredningen er foregået på RH. Ved malignt histologisvar sendes henvisning til onkologisk afdeling i Herlev.</p> <p><strong><u>Kodning af thyreoideaindgreb</u></strong></p> <p><strong>BAA60</strong> thyroidectomia totalis. Denne kode bruges også om supplerende operationer, fx en hemithyroidektomi, hvor patienten gøres athyroid.</p> <p><strong>BAA60a</strong> intrathorakal thyroidectomia totalis.</p> <p><strong>BAA40</strong> hemithyroidectomia.</p> <p><strong>BAA40a</strong> intrathorakal hemithyroidektomi</p> <p><strong>BAA30</strong> Isthmus resektion</p> <p><strong>BBA70</strong> ved autotransplantation af parathyroideavæv.</p> <p><strong>PJD51</strong> exairesis lymphonodorum colli.</p> <p>Den samlede DRG-takstudmåling er afhængig af diagnosekoderne, evt. maligne koder er derfor vigtige. Husk også at de intrathorakale operationer takseres højt.&nbsp;</p> <p>&nbsp;</p> <p>T<a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579311394Top">ilbage til top</a></p> <h2><a name="1699579311394Ansvar"></a><br> Ansvar og organisering</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579311394Top">Tilbage til top</a></p> <h2><a name="1699579311394Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579311394Top">Tilbage til top</a></p> <h2><a name="1699579311394Bilag"></a><br> Bilag</h2> <p>&nbsp;<img src="data:image/png;base64,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" style="height:15px; width:17px" onclick="Ext.DMS.util.showImage(this);"><a href="https://vip.regionh.dk/VIP/Redaktoer/130126.nsf/vLookupUpload/ATTACH-RHAP-9STNEY/$FILE/Hypocalc+%C2%AAmi.docx"><u>Hypocalc+ªmi.docx</u></a></p> <p>Tilbage til top</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579311394Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Parotissygdomme behandling og pleje.

Parotissygdomme, behandling og pleje Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag Målgrupper og anvendelsesområde Klinisk personale i Afdeling for Øre-Næse-Halskirurgi og Audiologi Fremgangsmåde Henvisninger: Generelt skal 1 måneders garantien søges overholdt, dvs. at patienten skal udredes indenfor 1 mdr, hvis der ikke er malignitetssuspicio. Alle patienter henvist fra primærsektoren skal som hovedregel ses ambulant, men de kan omvisiteres til praktiserende otolog, hvis det skønnes relevant. Patienter henvist fra andre øre-næse-halsafdelinger kan indlægges direkte til operation efter visitators skøn. Ved mistanke om malignitet skal patienten ses i henhold til kræftpakkeforløb. Hvis der ikke er malignitetsmistanke ses patienten inden for 1 - 2 måneder. Forundersøgelse: Problemorienteret anamnese og objektiv undersøgelse inkl. evt. tumorstørrelse og tegning samt vurdering af n. facialis funktion og halsundersøgelse med henblik på lymfeknuder. Der suppleres med ultralydskanning v. undersøgende læge Mistanke om sialoadenit eller sialolithiasis: Udførselsgange kan sonderes, der kan efter vurdering ordineres røntgenundersøgelse som oversigt, diagnostisk sialoendoskopi (ØNH-Hillerød) eller sialografi. Der podes ved infektion. Relevant behandling iværksættes inklusive spytstimulerende spiser og massage, samt smertestillende behandling Mistanke om vaskulær malformation: Der foretages ultralydskanning samt evt. punktur. Patienten vurderes af læge i teamet vedr. vaskulære malformationer. Der kan suppleres med MR-skanning med angiosekvenser. Skanningen skal visiteres af ###NAVN### ###NAVN### og patienten skal drøftes på vaskulær malformationskonference, tilmelding via ###NAVN### sekretær. Akut parotit: Der podes og patienten sættes i relevant antibiotisk behandling som regel ampicillin. Fremtidig antibiotisk behandling retter sig efter podesvar. Massage og rehydrering anbefales. Evt. indlæggelse. Mistanke om benign eller malign tumor: Hvis der ikke foreligger cytologisk / histologisk undersøgelse udføres finnålsaspiration iht. kræftpakkeforløb. Præparatet sendes som hastecytologi og kan gentages op til 2 gange samme dag, hvis svaret er inkonklusivt.Patienten meddeles svar iht. kræftpakkeforløb. Ved begrundet mistanke om malignitet bestilles MR-scanning af hoved og hals som hasteundersøgelse iht kræftpakkegaranti plus røntgen af thorax. Ved benignt svar opskrives patienten til superficiel parotidektomi over vanlig venteliste, og lægen informerer patienten om sygdommen og indgrebet inkl. evt. sequelae (anæstesi i n. auricularis magnus innervationsområde, Frey's syndrom og spytfistel). Patienten skal endvidere vurderes af parotisoperatør. Ved malignt svar eller usikkert svar opskrives og bookes patienten til parotidektomi påført evt. total parotidektomi og samsidig halsglandeldissektion station II - IV med operation inden for kræftpakkegaranti (indenfor 28 dage efter start på pakkeforløb og indenfor 14 dage fra behandlingsbeslutning) undtagen ved anaplastisk / udifferentieret carcinom som henvises til strålebehandling. Patienten skal operabilitetsvurderes af OPAL eller anden parotisoperatør. Koderne BVAA31 (samtale vedr. behandling) samt AFB02C1 (tilbud om kirurgisk behandling) registreres. Lægen informerer patienten om sygdommen og indgrebet inkl. sequelae herunder risiko for n. facialis, n. aricularis magnus og Frey´s syndrom, samt spytfistel og infektion. Patienten ses om muligt af operatør. Operationsindikation 1. Alle tumorer i gl. parotis undtagen anaplastisk / udifferentieret carcinom (se ovenfor). Behandling: Malignitet: Der forberedes total parotidektomi inkl. samsidig halsglandelsdissektion station II - IV. Benignitet: Der forberedes partiel eller superficiel parotidektomi. Generelt: Patienten bør ultralydskannes af operatøren præoperativt på lejet før steril afvaskning. Der anlægges neurosign før afvaskning, når patienten er bedøvet. Neurosignfunktionen kontrolleres. Afdækning bør være af en type, således at kirurgen kan overse hele aktuelle side af ansigtet under operationen. Ved mistanke om malignitet søges diagnosen bekræftet peroperativt ved frys. Al fjernet væv sendes til histologisk undersøgelse. Koden AFB02F1 (behandlingsstart, kirurgisk) registreres ved malignitetssuspicio. Præoperativt: Klargøring til operation: Journaloptagelse inkl. vurdering af n. facialis funktion, samt hvorvidt patienten er i operabel tilstand (vurderes af journaloptagende læge). Der bestilles hgb, elektrolytter, se-creat. samt type og BAS-test. (Obs der skal indhentes og dokumenteres samtykke fra patienten før der kan tages type / BAS-test). Der ordineres evt. røntgen af thorax og EKG. Der ordineres tromboseprofylakse efter behov Tromboseprofylakse på Afdeling for Øre-Næse-Halskirurgi og Audiologi. Det sikres, at der foreligger svar på finnålsbiopsi og ved malignitet at evt. MR-scanning foreligger på PACS-systemet eller som billeder. Patienten ses af operatør, som informerer om operationen, mulige sequelae, drænanlæggelse samt efterforløb. Anæstesilæge udfører anæstesitilsyn. Postoperativt: Angivne smerteordinationer og andre ordinationer følges. Drænfunktion og operationsområde kontrolleres iht. 'Huskeliste for dræn'. Døgnproduktion måles og noteres af aftenvagt. Dræn tømmes efter behov, men mindst 1 x i døgnet. Ved aftenstuegang vurderes patienten inkl. altid n. facialisfunktion. De følgende dage: Patienten kan spise normalt, være oppegående og bade, såfremt cicatricen beskyttes mod vand. Steristrips skiftes ikke før suturfjernelse. Drænet seponeres vanligvis og efter lægelig ordination ved mindre end 10 - 15 ml døgnproduktion. Smertebehandling ordineres individuelt. Udskrivelse: Ved udskrivelse meddeles patienten tid til suturfjernelse og histologisvar i ambulatoriet 7-10 dage postoperativt. Det tilstræbes, at patienten i ambulatoriet ses af operatør. Ambulant kontrol: Funktion af n. facialis kontrolleres. Der informeres om histologisvar. Suturer fjernes og cicatrice kontrolleres. Ved benigne svar og ukomplicerede forløb kan patienten afsluttes. Ved malignitet er sygeplejersken altid til stede. Patienten skal bookes til MDT konference på RH, hvis patienten onkologisk hører dertil eller henvises til Herlev Onkologisk klinik, hvis patienten hører dertil. Sygeplejersken følger op på patienten i flg. VIP Hoved-halscancer patienter, Ambulant sygeplejefaglig opfølgning på Ved infektionstegn / fistel indledes relevant behandling, og ny ambulant tid aftales til kontrol. Ved facialisparese / paralyse følges patienten i mindst 3 måneder eller til normal funktion. Ansigtstræning påbegyndes, når funktionen er tilstede. Ansvar og organisering Afdelingsledelsen Referencer, lovgivning og faglig evidens samt links hertil Akkrediteringsstandarder Bilag

<h1><div id="Afsnit#1699579429152">Parotissygdomme, behandling og pleje</div></h1><div id="BodyWeb#1699579429152"><p><a name="1699579429152Top"></a></p> <h3><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579429152Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579429152Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579429152Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579429152Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579429152Referencer">Referencer, lovgivning og faglig evidens samt links hertil</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579429152Akkrediteringsstandarder">Akkrediteringsstandarder</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579429152Bilag">Bilag</a><br> &nbsp;</h3> <h2><a name="1699579429152Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p>&nbsp;Klinisk personale i Afdeling for Øre-Næse-Halskirurgi og Audiologi</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579429152Top">Tilbage til top</a></p> <h2><a name="1699579429152Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p><strong>Henvisninger:&nbsp;</strong></p> <p>Generelt skal 1 måneders garantien søges overholdt, dvs. at patienten skal udredes indenfor 1 mdr, hvis der ikke er malignitetssuspicio. Alle patienter henvist fra primærsektoren skal som hovedregel ses ambulant, men de kan omvisiteres til praktiserende otolog, hvis det skønnes relevant. Patienter henvist fra andre øre-næse-halsafdelinger kan indlægges direkte til operation efter visitators skøn.&nbsp;Ved mistanke om malignitet skal patienten ses i henhold til kræftpakkeforløb. Hvis der ikke er malignitetsmistanke ses patienten inden for 1 - 2 måneder.</p> <p>&nbsp;</p> <p>&nbsp;</p> <p><strong>Forundersøgelse:</strong></p> <p>&nbsp;</p> <p>Problemorienteret anamnese og objektiv undersøgelse inkl. evt. tumorstørrelse og tegning samt vurdering af n. facialis funktion og halsundersøgelse med henblik på lymfeknuder. Der suppleres med ultralydskanning v. undersøgende læge</p> <p><em><u>Mistanke om sialoadenit eller sialolithiasis</u></em><strong><em><u>:</u></em></strong></p> <p>Udførselsgange kan sonderes, der kan efter vurdering ordineres røntgenundersøgelse som oversigt, diagnostisk sialoendoskopi (ØNH-Hillerød) eller sialografi.</p> <p>Der podes ved infektion. Relevant behandling iværksættes inklusive spytstimulerende spiser og massage, samt smertestillende behandling</p> <p><em><u>Mistanke om vaskulær malformation:</u></em></p> <p>Der foretages ultralydskanning samt evt. punktur. Patienten vurderes af læge i teamet vedr. vaskulære malformationer. Der kan suppleres med MR-skanning med angiosekvenser. Skanningen skal visiteres af ###NAVN### ###NAVN### og patienten skal drøftes på vaskulær malformationskonference, tilmelding via ###NAVN### sekretær.</p> <p><em><u>Akut parotit:</u></em></p> <p>Der podes og patienten sættes i relevant antibiotisk behandling som regel ampicillin. Fremtidig antibiotisk behandling retter sig efter podesvar. Massage og rehydrering anbefales. Evt. indlæggelse.</p> <p><em><u>Mistanke om benign eller malign tumor:</u></em></p> <p>Hvis der ikke foreligger cytologisk / histologisk undersøgelse udføres finnålsaspiration iht. kræftpakkeforløb. Præparatet sendes som hastecytologi og kan gentages op til 2 gange samme dag, hvis svaret er inkonklusivt.Patienten meddeles svar iht. kræftpakkeforløb.&nbsp;&nbsp;</p> <p>Ved begrundet mistanke om malignitet bestilles MR-scanning af hoved og hals som hasteundersøgelse iht kræftpakkegaranti plus røntgen af thorax.</p> <p>Ved <strong>benignt svar</strong> opskrives patienten til superficiel parotidektomi over vanlig venteliste, og lægen informerer patienten om sygdommen og indgrebet inkl. evt. sequelae (anæstesi i n. auricularis magnus innervationsområde, Frey's syndrom og spytfistel). Patienten skal endvidere vurderes af parotisoperatør.</p> <p>Ved <strong>malignt svar</strong> eller usikkert svar opskrives og bookes patienten til parotidektomi påført evt. total parotidektomi og samsidig halsglandeldissektion station II - IV med operation inden for kræftpakkegaranti (indenfor 28 dage efter start på pakkeforløb og indenfor 14 dage fra behandlingsbeslutning) undtagen ved anaplastisk / udifferentieret carcinom som henvises til strålebehandling. Patienten skal operabilitetsvurderes af OPAL eller anden parotisoperatør.</p> <p>Koderne BVAA31 (samtale vedr. behandling) samt AFB02C1 (tilbud om kirurgisk behandling) &nbsp;registreres.</p> <p>Lægen informerer patienten om sygdommen og indgrebet inkl. sequelae herunder risiko for n. facialis, n. aricularis magnus og Frey´s syndrom, samt spytfistel og infektion. Patienten ses om muligt af operatør.</p> <p><span style="color:black"><strong>Operationsindikation</strong> </span></p> <p><span style="color:black"><span style="color:black">1. Alle tumorer i gl. parotis undtagen anaplastisk / udifferentieret carcinom (se ovenfor).</span></span></p> <p><span style="color:black"><span style="color:black"><strong>Behandling:</strong></span></span></p> <p><span style="color:black"><span style="color:black"><em><u>Malignitet:</u></em></span></span></p> <p><span style="color:black"><span style="color:black">Der forberedes total parotidektomi inkl. samsidig halsglandelsdissektion station II - IV.</span></span></p> <p><span style="color:black"><span style="color:black"><em><u>Benignitet:</u></em></span></span></p> <p><span style="color:black"><span style="color:black">Der forberedes partiel eller superficiel parotidektomi.</span></span></p> <p><span style="color:black"><span style="color:black"><em><u>Generelt:</u></em></span></span></p> <p><span style="color:black"><span style="color:black">Patienten bør ultralydskannes af operatøren præoperativt på lejet før steril afvaskning.&nbsp;Der anlægges neurosign før afvaskning, når patienten er bedøvet. Neurosignfunktionen kontrolleres. Afdækning bør være af en type, således at kirurgen kan overse hele aktuelle side af ansigtet under operationen. Ved mistanke om malignitet søges diagnosen bekræftet peroperativt ved frys. Al fjernet væv sendes til histologisk undersøgelse.</span></span></p> <p><span style="color:black"><span style="color:black">Koden AFB02F1 (behandlingsstart, kirurgisk) registreres ved malignitetssuspicio.</span></span></p> <p><span style="color:black"><span style="color:black"><strong>Præoperativt:</strong>&nbsp;</span></span></p> <p><span style="color:black"><span style="color:black">Klargøring til operation:</span></span></p> <p><span style="color:black"><span style="color:black">Journaloptagelse inkl. vurdering af n. facialis funktion, samt hvorvidt patienten er i operabel tilstand (vurderes af journaloptagende læge).</span></span></p> <p><span style="color:black"><span style="color:black">Der bestilles hgb, elektrolytter, se-creat. samt type og BAS-test. (Obs der skal indhentes og dokumenteres samtykke fra patienten før der kan tages type / BAS-test).</span></span></p> <p><span style="color:black"><span style="color:black">Der ordineres evt. røntgen af thorax og EKG.</span></span></p> <p><span style="color:black"><span style="color:black">Der ordineres tromboseprofylakse efter behov&nbsp;<a href="###FOLDER###" target="_blank">Tromboseprofylakse på Afdeling for Øre-Næse-Halskirurgi og Audiologi</a>.&nbsp;Det sikres, at der foreligger svar på finnålsbiopsi og ved malignitet at evt. MR-scanning foreligger på PACS-systemet eller som billeder.</span></span></p> <p><span style="color:black"><span style="color:black">Patienten ses &nbsp;af operatør, som informerer &nbsp;om operationen, mulige sequelae, drænanlæggelse samt efterforløb. Anæstesilæge udfører anæstesitilsyn.</span></span></p> <p><strong>Postoperativt:</strong></p> <p>Angivne smerteordinationer og andre ordinationer følges.&nbsp;&nbsp;</p> <p>Drænfunktion og operationsområde kontrolleres iht. &nbsp;'Huskeliste for dræn'. Døgnproduktion måles og noteres af aftenvagt. Dræn tømmes efter behov, men mindst 1 x i døgnet.</p> <p>Ved aftenstuegang vurderes patienten inkl. altid n. facialisfunktion.</p> <p><strong><em><u>De følgende dage:</u></em></strong></p> <p>Patienten kan spise normalt, være oppegående og bade, såfremt cicatricen beskyttes mod vand.&nbsp;Steristrips skiftes ikke før suturfjernelse.&nbsp;&nbsp;</p> <p>Drænet seponeres vanligvis og efter lægelig ordination ved mindre end 10 - 15 ml døgnproduktion.</p> <p>Smertebehandling ordineres individuelt.</p> <p><strong><em><u>Udskrivelse:</u></em></strong></p> <p>Ved udskrivelse meddeles patienten &nbsp;tid til suturfjernelse og histologisvar i ambulatoriet 7-10 dage postoperativt. Det tilstræbes, at patienten i ambulatoriet ses af operatør.</p> <p><strong>Ambulant kontrol:</strong></p> <p>Funktion af n. facialis kontrolleres. Der informeres om histologisvar. Suturer fjernes og cicatrice kontrolleres. Ved benigne svar og ukomplicerede forløb kan patienten afsluttes.</p> <p><em><u>Ved malignitet </u></em>er sygeplejersken altid til stede. Patienten skal bookes til MDT konference på RH, hvis patienten onkologisk hører dertil eller henvises &nbsp;til Herlev Onkologisk klinik, hvis patienten hører dertil.</p> <p>Sygeplejersken følger op på patienten i flg. VIP&nbsp; <a href="###FOLDER###" target="_blank">Hoved-halscancer patienter, Ambulant sygeplejefaglig opfølgning på</a></p> <p>&nbsp;<em><u>Ved infektionstegn / fistel</u></em> indledes relevant behandling, og ny ambulant tid aftales til kontrol.</p> <p><em><u><span style="color:black">Ved facialisparese / paralyse</span></u></em><span style="color:black"> følges patienten i mindst 3 måneder eller til normal funktion. Ansigtstræning påbegyndes, når funktionen er tilstede. </span></p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579429152Top">Tilbage til top</a></p> <h2><a name="1699579429152Ansvar"></a><br> Ansvar og organisering</h2> <p>&nbsp;Afdelingsledelsen</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579429152Top">Tilbage til top</a></p> <h2><a name="1699579429152Referencer"></a><br> Referencer, lovgivning og faglig evidens samt links hertil</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579429152Top">Tilbage til top</a></p> <h2><a name="1699579429152Akkrediteringsstandarder"></a><br> Akkrediteringsstandarder</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579429152Top">Tilbage til top</a></p> <h2><a name="1699579429152Bilag"></a><br> Bilag</h2> <p>&nbsp;</p> <p><a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579429152Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Patienter indlagt under 24 timer -.

Patienter indlagt under 24 timer - Indledende Sygeplejevurdering Formål Målgrupper og anvendelsesområde Definitioner Fremgangsmåde Ansvar og organisering Bilag Formål At fastlægge retningslinjer for hvilke områder af den Indledende SygeplejeVurdering (ISV) der skal dokumenters i KISO, for patienter indlagt under 24 timer Målgrupper og anvendelsesområde Sygeplejefagligt personale i Øre-næse-halskirurgisk og Audiologisk Klinik på Rigshospitalet og Gentofte Hospital Definitioner - ASA 1 klassifikation: patient der fraset den planlagte operation er fuldstændig rask - ASA 2 klassifikation: patient der har en let systemisk lidelse, uden begrænsning af funktionsniveau (f.eks, behandlet hypertension, velbehandlet diabetes uden senkomplikationer, velbehandlet astma, ryger KOL uden dyspnøe) Fremgangsmåde Der tages udgangspunkt i en vurdering af hvilken ASA gruppe patienterne tilhører: - For ASA 1 patienter skal der laves Indledende Sygeplejevurdering (ISV) svarende til kriterier i nedenstående tabel. - For ASA 2 patienter skal der laves fuld Indledende Sygeplejevurdering (ISV), dog undtaget screeninger. Forbliver en patient indlagt mere end 24 timer, skal der laves fuld ISV Alle felter skal udfyldes, men i visse felter kan noteres ’ej relevant’. Det er ikke tilladt at skrive i.a eller anvende andre forkortelser. ###TABEL_1### Ansvar og organisering Klinikledelsen og sygeplejefaglige ledelse i Øre-næse-halskirurgisk og Audiologisk Klinik Bilag

<h1><div id="Afsnit#1699579411618">Patienter indlagt under 24 timer - Indledende Sygeplejevurdering</div></h1><div id="BodyWeb#1699579411618"><p> <a name="1699579411618Top"></a></p> <h3> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579411618Formaal">Formål</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579411618Maalgrupper">Målgrupper og anvendelsesområde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579411618Definitioner">Definitioner</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579411618Fremgangsmaade">Fremgangsmåde</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579411618Ansvar">Ansvar og organisering</a><br> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579411618Bilag">Bilag</a><br> &nbsp;</h3> <p> <a name="1699579411618Formaal"></a></p> <h2> Formål</h2> <p> At fastlægge retningslinjer for hvilke områder af den Indledende SygeplejeVurdering&nbsp; (ISV) der skal dokumenters i KISO,&nbsp;for patienter indlagt under 24 timer</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579411618Top">Tilbage til top</a></p> <h2> <a name="1699579411618Maalgrupper"></a><br> Målgrupper og anvendelsesområde</h2> <p> Sygeplejefagligt personale i Øre-næse-halskirurgisk og Audiologisk Klinik på Rigshospitalet og Gentofte Hospital&nbsp;</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579411618Top">Tilbage til top</a></p> <h2> <a name="1699579411618Definitioner"></a><br> Definitioner</h2> <ul> <li> ASA 1 klassifikation: patient der fraset den planlagte operation er fuldstændig rask</li> <li> ASA 2 klassifikation: patient der har en let systemisk lidelse, uden begrænsning af funktionsniveau (f.eks, behandlet hypertension, velbehandlet diabetes uden senkomplikationer, velbehandlet astma, ryger KOL uden dyspnøe)&nbsp;</li> </ul> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579411618Top">Tilbage til top</a></p> <h2> <a name="1699579411618Fremgangsmaade"></a><br> Fremgangsmåde</h2> <p> Der tages udgangspunkt i en vurdering af hvilken ASA gruppe patienterne tilhører:</p> <ul> <li> For ASA 1 patienter skal der laves Indledende Sygeplejevurdering (ISV) svarende til&nbsp;kriterier i nedenstående tabel.</li> <li> For ASA 2 patienter skal der laves fuld Indledende Sygeplejevurdering (ISV), dog undtaget screeninger.</li> </ul> <p> Forbliver en patient indlagt mere end 24 timer, skal der laves fuld ISV</p> <p> Alle felter skal udfyldes, men i visse felter kan noteres ’ej relevant’. Det er ikke tilladt at skrive i.a eller anvende andre forkortelser.</p> ###TABEL_1### <p> &nbsp;</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579411618Top">Tilbage til top</a></p> <h2> <a name="1699579411618Ansvar"></a><br> Ansvar og organisering</h2> <p> Klinikledelsen og sygeplejefaglige ledelse i Øre-næse-halskirurgisk og Audiologisk Klinik</p> <p> &nbsp;</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579411618Top">Tilbage til top</a></p> <h2> <a name="1699579411618Bilag"></a><br> Bilag</h2> <p> &nbsp;</p> <p> <a onclick="Ext.DMS.util.expandCollapsibleSections(this);" href="#1699579411618Top">Tilbage til top</a></p>

Rigshospitalet_¥re-Næse-Halskirurgi og Audiologi (HOC)_Patienter indlagt under 24 timer -_TABEL_1.

Søgeord ASA 1 ASA 2 Kontaktårsag Dokumenteres Dokumenteres Respiration, cirkulation, bevidsthed Dokumenteres Dokumenteres Smerter Dokumenteres Dokumenteres Udskillelser og affaldsstoffer Ej relevent Dokumenteres Kommunikation Dokumenteres Herunder behov for evt. tolk Dokumenteres Herunder behov for evt. tolk Viden og udvikling Dokumenteres Dokumenteres Funktion, fald og aktivitet Dokumenteres minus faldscreening og funktionsvurdering Dokumenteres minus faldscreening og funktionsvurdering Ernæring Dokumenteres Herunder kostform Minus ernæringsscreening Dokumenteres Herunder kostform Minus ernæringsscreening Hud, slimhinder og sår Ej relevant Dokumenteres Minus tryksårsscreening Sociale oplysninger og livsstil Dokumenteres Herunder tobaks - og alkoholforbrug Dokumenteres Herunder tobaks - og alkoholforbrug Psykosocialt Dokumenteres Dokumenteres Søvn og hvile Ej relevant Dokumenteres Åndeligt og kulturelt Ej relevant Dokumenteres Sektualitet Ej relevant Dokumenteres

<table border="1" cellpadding="1" cellspacing="1" style="width: 500px"> <tbody> <tr> <td> <strong>Søgeord</strong></td> <td> <strong>ASA 1</strong></td> <td> <strong>ASA 2</strong></td> </tr> <tr> <td> Kontaktårsag</td> <td> Dokumenteres</td> <td> Dokumenteres</td> </tr> <tr> <td> Respiration, cirkulation, bevidsthed</td> <td> Dokumenteres</td> <td> Dokumenteres</td> </tr> <tr> <td> Smerter</td> <td> Dokumenteres</td> <td> Dokumenteres</td> </tr> <tr> <td> Udskillelser og affaldsstoffer</td> <td> Ej relevent</td> <td> Dokumenteres</td> </tr> <tr> <td> Kommunikation</td> <td> <p> Dokumenteres</p> <p> Herunder behov for evt. tolk</p> </td> <td> <p> Dokumenteres</p> <p> Herunder behov for evt. tolk</p> </td> </tr> <tr> <td> Viden og udvikling</td> <td> Dokumenteres</td> <td> Dokumenteres</td> </tr> <tr> <td> Funktion, fald og aktivitet</td> <td> <p> Dokumenteres</p> <p> minus faldscreening og funktionsvurdering</p> </td> <td> <p> Dokumenteres</p> <p> minus faldscreening og funktionsvurdering</p> </td> </tr> <tr> <td> Ernæring</td> <td> <p> Dokumenteres</p> <p> Herunder kostform</p> <p> Minus ernæringsscreening</p> </td> <td> <p> Dokumenteres</p> <p> Herunder kostform</p> <p> Minus ernæringsscreening</p> </td> </tr> <tr> <td> Hud, slimhinder og sår</td> <td> Ej relevant</td> <td> <p> Dokumenteres</p> <p> Minus tryksårsscreening</p> </td> </tr> <tr> <td> Sociale oplysninger og livsstil</td> <td> <p> Dokumenteres</p> <p> Herunder tobaks - og alkoholforbrug</p> </td> <td> <p> Dokumenteres</p> <p> Herunder tobaks - og alkoholforbrug</p> </td> </tr> <tr> <td> Psykosocialt</td> <td> Dokumenteres</td> <td> Dokumenteres</td> </tr> <tr> <td> Søvn og hvile</td> <td> Ej relevant</td> <td> Dokumenteres</td> </tr> <tr> <td> Åndeligt og kulturelt</td> <td> Ej relevant</td> <td> Dokumenteres</td> </tr> <tr> <td> Sektualitet</td> <td> Ej relevant</td> <td> Dokumenteres</td> </tr> </tbody> </table>